

leptin receptor/LEPR	03 NM_0023	601007	insertion/deletion CA microsatellite repeat in intron 3, IVS16, G-A, +1
leptin receptor/LEPR	03 NM_0023	601007	
leptin receptor/LEPR	03 NM_0023	601007	K109R
leptin receptor/LEPR	03 NM_0023	601007	K656N
leptin receptor/LEPR	03 NM_0023	601007	Ala976Asp
leptin receptor/LEPR	03 NM_0023	601007	Gln223Arg
leptin receptor/LEPR	03 NM_0023	601007	Lys109Arg
leptin receptor/LEPR	03 NM_0023	601007	Lys656Asn
leptin receptor/LEPR	03 NM_0023	601007	Pro1019Pro
leptin receptor/LEPR	03 NM_0023	601007	Ser343Ser
leptin receptor/LEPR	03 NM_0023	601007	Ser492Thr
leptin receptor/LEPR	03 NM_0023	601007	GLN23ARG
Leukocyte integrin alpha-I	Y00796	153370	none found
Leukocyte integrin alpha-x	M81695	151510	none found
Lipoprotein lipase	M15856	238600	INS
Lipoprotein lipase	M15856	238600	(TTTA)n

Lipoprotein lipase	M15856	238600	-39T-C	
Lipoprotein lipase	M15856	238600	-93T-G	
Lipoprotein lipase	M15856	238600	1-BP DEL	frameshift
Lipoprotein lipase	M15856	238600	1-BP DEL, 221G	frameshift
Lipoprotein lipase	M15856	238600	2-KB DUP	
Lipoprotein lipase	M15856	238600	6-KB DEL	
Lipoprotein lipase	M15856	238600	C-->A -3 intron 6	
Lipoprotein lipase	M15856	238600	C-to-T -480	
Lipoprotein lipase	M15856	238600	C1338-->A	Thr361 Thr
Lipoprotein lipase	M15856	238600	C1595-->G	S447X
Lipoprotein lipase	M15856	238600	G579-->A	V108V
Lipoprotein lipase	M15856	238600	HindIII	
Lipoprotein lipase	M15856	238600	IVS1, G-C, +1	
Lipoprotein lipase	M15856	238600	IVS2DS, G-A	
Lipoprotein lipase	M15856	238600	IVS2DS, G-A, +1	
Lipoprotein lipase	M15856	238600		ALA176THR
Lipoprotein lipase	M15856	238600		GLY188GLU
Lipoprotein lipase	M15856	238600		TRP64TER
Lipoprotein lipase	M15856	238600		ARG75SER
Lipoprotein lipase	M15856	238600		TYR73TER
Lipoprotein lipase	M15856	238600		SER172CYS
Lipoprotein lipase	M15856	238600		TRP382TER
Lipoprotein lipase	M15856	238600		TYR61TER
Lipoprotein lipase	M15856	238600		ASP204GLU
Lipoprotein lipase	M15856	238600		GLY142GLU
Lipoprotein lipase	M15856	238600		GLY195GLU
Lipoprotein lipase	M15856	238600		ILE194THR
Lipoprotein lipase	M15856	238600		ARG243HIS
Lipoprotein lipase	M15856	238600		ASP156GLY
Lipoprotein lipase	M15856	238600		SER447TER
Lipoprotein lipase	M15856	238600		Cys239-->stop

SD-144141.1



Lipoprotein lipase	M15856	238600	His183-->Gln
Lipoprotein lipase	M15856	238600	ARG243CYS
Lipoprotein lipase	M15856	238600	ASN291SER
Lipoprotein lipase	M15856	238600	E163G
Lipoprotein lipase	M15856	238600	E410K
Lipoprotein lipase	M15856	238600	ASP180GLU
Lipoprotein lipase	M15856	238600	ASP250ASN
Lipoprotein lipase	M15856	238600	Pro157 Arg
Lipoprotein lipase	M15856	238600	Glu118 Glu
Lipoprotein lipase	M15856	238600	Glu421Lys
Lipoprotein lipase	M15856	238600	CYS418TYR
Lipoprotein lipase	M15856	238600	LEU365VAL
Lipoprotein lipase	M15856	238600	ALA334THR
Lipoprotein lipase	M15856	238600	ASP9ASN
Lipoprotein lipase	M15856	238600	ILE225THR
Lipoprotein lipase	M15856	238600	TRP86ARG
Lipoprotein lipase	M15856	238600	SER244THR
Lipoprotein lipase	M15856	238600	GLN106TER
Lipoprotein lipase	M15856	238600	PRO207LEU
Lipoprotein lipase	M15856	238600	Tyr262-->His
MELANOCORTIN 4 RECEPTOR		4-BP DEL NT631	
MELANOCORTIN 4 RECEPTOR		4-BP INS, NT732	
MELANOCORTIN 4 RECEPTOR			TYR35TER
MELANOCORTIN 4 RECEPTOR			ASP37VAL
MELANOCORTIN 4 RECEPTOR			Thr112Met
MELANOCORTIN 4 RECEPTOR			Ile137Thr

RECEPTOR						
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	1-BP DEL	frameshift at codon 337		
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	1-BP DEL	frameshift at codon 459		
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	760-->G760	Ileu180-- >Val180		
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	A DEL, +3 intron 5			
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	C944-->T944	Ala241-- >Val241		
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983		ARG537TER		
natriuretic peptide receptor B/guanylate cyclase B	L13436	108961	none found			
NEUROMEDIN K RECEPTOR	M89473	162332	none found			
Neuropeptide Y receptor Y5	U94320	602001	none found			
Nicotinic, Cholinergic receptor alpha 2	118502	U62431	none found			
Norepinephrine transporter	M65105	163970	none found			
Opioid Receptor,	U17298	165196	none found			

Kappa-1; Oprk1				
Oxytocin receptor	X64878	167055	C to T exon 3	
Oxytocin receptor	X64878	167055	CA repeat	
PAIRED BOX GENE		167413	none found	
Pancreatic lipase	M93285	246600	C-to-T promoter	
(PNLIP) (Dietary supplement)				Ser267Phe
Pancreatic lipase	M93285	246600		
(PNLIP) (Dietary supplement)				Thr383Met
Pancreatic lipase	M93285	246600		
(PNLIP) (Dietary supplement)				
Parathyroid hormone	V00597	168450	Drall	
Parathyroid hormone	V00597	168450	G-C, +1	EX2DEL
Parathyroid hormone	V00597	168450	(AAAT)n intron 1	
Parathyroid hormone	V00597	168450	BstBI	
Parathyroid hormone	V00597	168450	PstI	
Parathyroid hormone	V00597	168450	TaqI	
Parathyroid hormone	V00597	168450	XmnI	
Parathyroid hormone	V00597	168450		CYS18ARG
Peroxidase (thyoid)	Y00406	274500	1-BP INS	
Peroxidase (thyoid)	Y00406	274500	1-BP INS, 2505C	
Peroxidase (thyoid)	Y00406	274500	20-BP DUP	frameshift
Peroxidase (thyoid)	Y00406	274500	2612 (GTG-->GCG)	Val-->Ala
Peroxidase (thyoid)	Y00406	274500	4-BP INS	frameshift
Peroxidase (thyoid)	Y00406	274500	50 bp repeat in intron 10	
Peroxidase (thyoid)	Y00406	274500	Acyl intron 8	
Peroxidase (thyoid)	Y00406	274500	Eco RI	

Peroxidase (thyroid)	Y00406	274500	ARG648GLN
Peroxidase (thyroid)	Y00406	274500	GLU799LYS
Peroxidase (thyroid)	Y00406	274500	GLY590SER
Peroxidase (thyroid)	Y00406	274500	ILE447PHE
Peroxidase (thyroid)	Y00406	274500	TYR453ASP
Peroxidase (thyroid)	Y00406	274500	ARG540TER
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	1-BP DEL, 472A Frameshift
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	PRO115GLN
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	ARG288HIS
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	GLN286PRO
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	LYS319TER
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	PRO12ALA
phospholipid transfer	NM_0062	172425	TaqIB

SD-144141.1

protein/PLTP	27			
plasma cholesterol	NM_0000	118470	A1503G	
ester transfer	78			
protein/CETP				
plasma cholesterol	NM_0000	118470	G-A splice junction	alternative
ester transfer	78			splice
protein/CETP				
plasma cholesterol	NM_0000	118470	G1696A	
ester transfer	78			
protein/CETP				
plasma cholesterol	NM_0000	118470	C-T transition in	
ester transfer	78		intron 12	
protein/CETP				
plasma cholesterol	NM_0000	118470	EcoNI	
ester transfer	78			
protein/CETP				
plasma cholesterol	NM_0000	118470	G-->A intron 14	
ester transfer	78			
protein/CETP				
plasma cholesterol	NM_0000	118470	G-A transition in	
ester transfer	78		intron 15	
protein/CETP				
plasma cholesterol	NM_0000	118470	G1533A	
ester transfer	78			
protein/CETP				
plasma cholesterol	NM_0000	118470	INS T alternative	
ester transfer	78		(intron/exon14) splice	
protein/CETP				
plasma cholesterol	NM_0000	118470	StuI	
ester transfer	78			
protein/CETP				

plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	T-->G tyr57stop
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	TaqIA
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	TaqIB in intron 1
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	268 Arg-- >STOP
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G181X
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	Asp 442 to Gly
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	I405V
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	Lys309-Stop
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	Val421-Ile
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	R451Q
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	ASP442GLY

SD-144141.1

ester transfer protein/CETP	78			
potassium channel beta subunit	U25138	603951	none found	
POTASSIUM CHANNEL		600937		LEU147PRO
INWARDLY RECTIFYING SUBFAMILY J MEMBER 11; KCNJ11				
Potassium channel Kir3.4	X83582	600734	none found	
PRO-MELANIN- CONCENTRATING HORMONE		176795	none found	
progesterone receptor	M15716	264080	none found	
Prolactin	V00566	176760	Bg/II	
Prolactin receptor	M31661	176761	none found	
protein kinase C beta I	X06318	176970	none found	
Pyridoxine (Pyridoxal Kinase)	U89606	179020	none found	
RAR related orphan receptor A/RORA	NM_0029 43	600825	none found	
RAR related orphan receptor B/RORB	*****	601972	none found	
RAR related orphan receptor C/RORC	NM_0050 60	602943	none found	
REGUCALCIN		300212	none found	
retinoic acid receptor alpha/RARA	NM_0009 64	180240	7-base deletion frameshift	

retinoic acid receptor alpha/RARA	NM_0009 64	180240	codon 411 C to T	
retinoic acid receptor alpha/RARA	NM_0009 64	180240	Arg272Gln	
retinoic acid receptor alpha/RARA	NM_0009 64	180240	Met297Leu	
RETINOIC ACID RECEPTOR BETA-2	X07282	180220	none found	
retinoic acid receptor gamma/RARG	M57707	180190	none found	
Retinoic acid receptor, gamma I	M38258	180190	none found	
retinoid X receptor alpha/RXRA	NM_0029 57	180245	none found	
retinoid X receptor gamma/RXRG	U38480	180247	none found	
Retinoid X receptor- gamma	U38480	180247	none found	
serotonin 5-HT receptors 5-HT1C, G protein-coupled	U49516	312861	2831T > G in the 3'	
serotonin 5-HT receptors 5-HT1C, G protein-coupled	U49516	312861	CYS23SER	
SODIUM-IODIDE SYMPORTER		601843	THR354PRO	
SODIUM-IODIDE SYMPORTER		601843	CYS272TER	
SODIUM-IODIDE SYMPORTER		601843	GLN267GLU	
SODIUM-IODIDE		601843	TYR531TER	

SD-144141.1



SYMPORTER	601843	GLY93ARG
SODIUM-IODIDE SYMPORTER	601843	GLY543GLU
Solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na <sup>+</sup> /H <sup>+</sup> , amiloride sensitive)	600228	2-BP DEL frameshift
Solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na <sup>+</sup> /H <sup>+</sup> , amiloride sensitive)	600228	2-BP DEL ARG508TER
Somatostatin receptor 1/G protein-coupled	182451	(CA) <sub>n</sub> 5' TRP188TER
Somatostatin receptor 2	182452	
Somatostatin receptor 3/adenyl cyclase coupled	182453	none found
Somatostatin receptor 5	182455	2 RFLP's promoter
somatostatin receptor subtype 2	L05521	none found
Steroid 5 alpha reductase 1	184753	none found
STEROID HORMONE	601998	none found
RECEPTOR ERR1		
Steroid receptor coactivator (SRC-1)	602691	none found

Sucrase-isomaltase	X63597	222900	GLN1098PRO
Tachykinin NK1 receptor/TACR1	M81797	162323	none found
thyroid stimulating hormone receptor	NM_000369	603372	18-BP DEL, 4-BP frameshift INS
thyroid stimulating hormone receptor	NM_000369	603372	1953-1957 deletion Asp at 619 deleted
thyroid stimulating hormone receptor	NM_000369	603372	2 bases deleted of codon 655
thyroid stimulating hormone receptor	NM_000369	603372	C253A
thyroid stimulating hormone receptor	NM_000369	603372	duplication of nucleotides -346 to -330
thyroid stimulating hormone receptor	NM_000369	603372	G to C +3 intron 6
thyroid stimulating hormone receptor	NM_000369	603372	G-A -4 intron
thyroid stimulating hormone receptor	NM_000369	603372	TaqI
thyroid stimulating hormone receptor	NM_000369	603372	P52T
thyroid stimulating hormone receptor	NM_000369	603372	leu677val
thyroid stimulating hormone receptor	NM_000369	603372	Asn715Asp
thyroid stimulating hormone receptor	NM_000369	603372	Asp219Glu
thyroid stimulating hormone receptor	NM_000369	603372	Asp727Glu
thyroid stimulating hormone receptor	NM_000369	603372	Lys723 Met

SD-144141.1

hormone receptor	69			
thyroid stimulating hormone receptor	NM_000369	603372	Phe197Ile	
thyroid stimulating hormone receptor	NM_000369	603372	LYS183ARG	
thyroid stimulating hormone receptor	NM_000369	603372	ILE167ASN	
thyroid stimulating hormone receptor	NM_000369	603372	PRO162ALA	
thyroid stimulating hormone receptor	NM_000369	603372	PHE631LEU	
thyroid stimulating hormone receptor	NM_000369	603372	CYS672TYR	
thyroid stimulating hormone receptor	NM_000369	603372	VAL509ALA	
thyroid stimulating hormone receptor	NM_000369	603372	ALA623ILE	
thyroid stimulating hormone receptor	NM_000369	603372	ASP619GLY	
thyroid stimulating hormone receptor	NM_000369	603372	ALA553THR	
thyroid stimulating hormone receptor	NM_000369	603372	SER281ILE	
thyroid stimulating hormone receptor	NM_000369	603372	SER281ASN	
thyroid stimulating hormone receptor	NM_000369	603372	ASP633HIS	
thyroid stimulating hormone receptor	NM_000369	603372	LEU629PHE	
thyroid stimulating hormone receptor	NM_000369	603372	SER505ASN	

SD-144141.1

thyroid stimulating hormone receptor	NM_000369	603372	TRP546TER
thyroid stimulating hormone receptor	NM_000369	603372	MET453THR
thyroid stimulating hormone receptor	NM_000369	603372	ASP36HIS
thyroid stimulating hormone receptor	NM_000369	603372	alanine 623 to valine
thyroid stimulating hormone receptor	NM_000369	603372	asp727glu
thyroid stimulating hormone receptor	NM_000369	603372	CAG
thyroid stimulating hormone receptor	NM_000369	603372	[Glu]227CAT
thyroid stimulating hormone receptor	NM_000369	603372	[His]
thyroid stimulating hormone receptor	NM_000369	603372	GCG
thyroid stimulating hormone receptor	NM_000369	603372	[Ala]460GCA
thyroid stimulating hormone receptor	NM_000369	603372	[Ala]
thyroid stimulating hormone receptor	NM_000369	603372	GGT[Arg]201C
thyroid stimulating hormone receptor	NM_000369	603372	AT [His]
thyroid stimulating hormone receptor	NM_000369	603372	ARG109GLN
thyroid stimulating hormone receptor	NM_000369	603372	CYS41SER
thyroid stimulating hormone receptor	NM_000369	603372	ASP410ASN
thyroid stimulating hormone receptor	NM_000369	603372	CYS390TRP
thyroid stimulating hormone receptor	NM_000369	603372	GLN324TER
thyroid stimulating hormone receptor	NM_000369	603372	PHE525LEU
Transferrin receptor	X01060	190010	BclI

SD-144141.1

(p90, CD71)				
Transferrin receptor	X01060	190010	RsaI	
(p90, CD71)				
Transferrin receptor	X01060	190010		Ser142-->Gly
(p90, CD71)				
transforming growth	M85079	190182	2-BP INS frameshift	
factor, beta receptor II				
(70-80kD)/TGFB2				
transforming growth	M85079	190182	a-4t intron 3	
factor, beta receptor II				
(70-80kD)/TGFB2				
transforming growth	M85079	190182	a7g intron 2	
factor, beta receptor II				
(70-80kD)/TGFB2				
transforming growth	M85079	190182	ACA to GCA Thr to Ala	
factor, beta receptor II				
(70-80kD)/TGFB2				
transforming growth	M85079	190182	base in the	
factor, beta receptor II			polyadenine tract of	
(70-80kD)/TGFB2			exon 3	
transforming growth	M85079	190182	GG to TT Stop codon	
factor, beta receptor II				
(70-80kD)/TGFB2				
transforming growth	M85079	190182	THR315MET	
factor, beta receptor II				
(70-80kD)/TGFB2				
transforming growth	M85079	190182	codon 128	
factor, beta receptor II				
(70-80kD)/TGFB2				
TUBBY, MOUSE,		601197	none found	
HOMOLOG				

SD-144141.1

type I 5 iodothyronine deiodinase [human, mRNA, 2222 nt]	S48220	147892	none found
Type V cyclic nucleotide phosphodiesterase	AJ004865	603310	none found
vitamin D receptor/VDR	NM_0003 76	601769	A(T/C)G putative translation start site
vitamin D receptor/VDR	NM_0003 76	601769	Apal
vitamin D receptor/VDR	NM_0003 76	601769	BsmI
vitamin D receptor/VDR	NM_0003 76	601769	FokI
vitamin D receptor/VDR	NM_0003 76	601769	PvuII
vitamin D receptor/VDR	NM_0003 76	601769	TaqI
vitamin D receptor/VDR	NM_0003 76	601769	XbaI
vitamin D receptor/VDR	NM_0003 76	601769	ARG-GLY
vitamin D receptor/VDR	NM_0003 76	601769	GLY30ASP
vitamin D receptor/VDR	NM_0003 76	601769	TYR292TER
vitamin D receptor/VDR	NM_0003 76	601769	ARG77GLN
vitamin D receptor/VDR	NM_0003 76	601769	ARG391CYS

SD-144141.1

vitamin D receptor/VDR	NM_0003 76	601769	ILE314SER
vitamin D receptor/VDR	NM_0003 76	601769	ARG271LEU
vitamin D receptor/VDR	NM_0003 76	601769	GLN149TER
vitamin D receptor/VDR	NM_0003 76	601769	ARG30TER
vitamin D receptor/VDR	NM_0003 76	601769	GLY46ASP
vitamin D receptor/VDR	NM_0003 76	601769	codon 352
vitamin D receptor/VDR	NM_0003 76	601769	HIS305GLN
vitamin D receptor/VDR	NM_0003 76	601769	ARG47GLN

Table 23. Identified  
Variances in Genes or  
Related Pathways  
involved in  
Cardiovascular and  
Renal Disease

3beta hydroxysteroid dehydrogenase	M27137	109715	none found
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	1027T-G
5,10-	U09806	236250	1084C-T

METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	1298A-C	
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE				
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	1711C-T	
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE				
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	677C-T	ala --> val
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE				
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	983A-G	
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE				
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	exon 7	Ala-->Glu
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE				
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250		A225V
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE				
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250		ARG158GLN

SD-144141.1



5,10-METHYLENETETRAHYDROFOLATE REDUCTASE	U09806	236250	ARG184TER
Adenosine A1 Receptor; Adoral/G protein-coupled	L22214	102775	1777C/A
Adenosine A1 Receptor; Adoral/G protein-coupled	L22214	102775	1827C/T
Adenosine A1 Receptor; Adoral/G protein-coupled	L22214	102775	1904C/T
Adenosine A1 Receptor; Adoral/G protein-coupled	L22214	102775	2126G/T
Adenosine A1 Receptor; Adoral/G protein-coupled	L22214	102775	2294insT
Adenosine A1 Receptor; Adoral/G protein-coupled	L22214	102775	267 + 275C/T
Adenosine A1 Receptor; Adoral/G protein-coupled	L22214	102775	2776C/T
Adenosine A1 Receptor; Adoral/G protein-coupled	L22214	102775	2777del36
Adenosine A1 Receptor; Adoral/G protein-coupled	L22214	102775	2819T/G

SD-144141.1

Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	805T/G	Gly-340-Ser
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	48T/A	
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	716T/G	
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	1083C/T	
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	405C/T	
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	432C/T	
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776		
Adenosine A2b Receptor; Adora2b/G protein-coupled	X68487	600446	none found	
Adenosine A3 Receptor; Adora3/G protein-coupled	L20463	600445	none found	
alpha-1b-adrenergic receptor; ADRA1B	L31773	104220	none found	
alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	-1291	

SD-144141.1

alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	DraI	
alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	HhaI	
alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	MspI promoter	
alpha-2b-adrenergic receptor; ADRA2B	AF005900	104260	none found	
alpha-2c-adrenergic receptor; ADRA2C	J03853	104250	(CA) <sub>n</sub>	
androgen receptor	M20132	313700	Hind III	
androgen receptor	M20132	313700	(CAA) <sub>n</sub>	
androgen receptor	M20132	313700	(CAG) <sub>n</sub>	
androgen receptor	M20132	313700	(GGN) <sub>n</sub>	
androgen receptor	M20132	313700	5-KB DEL, EX F,G	
androgen receptor	M20132	313700	5-KB DEL, EX E	
androgen receptor	M20132	313700	C>T within exon B	silent
androgen receptor	M20132	313700	CAG340TAG	Gln>Ter
androgen receptor	M20132	313700	Del T at 3286	frameshift
androgen receptor	M20132	313700	del1893	frameshift
androgen receptor	M20132	313700	G Codon 210 A	
androgen receptor	M20132	313700	G Codon 211 A	
androgen receptor	M20132	313700	G2314A	ala>thr
androgen receptor	M20132	313700	G2677A	glu629arg
androgen receptor	M20132	313700	HhaI	
androgen receptor	M20132	313700	HpaII	
androgen receptor	M20132	313700	Insert of 69 nucleotides	
androgen receptor	M20132	313700	MaeIII	
androgen receptor	M20132	313700	PARTIAL DEL	
androgen receptor	M20132	313700	Stu I	

androgen receptor	M20132	313700	598 or 599 ter
androgen receptor	M20132	313700	ALA721THR
androgen receptor	M20132	313700	ALA771THR
androgen receptor	M20132	313700	ARG607GLN
androgen receptor	M20132	313700	ARG608LYS
androgen receptor	M20132	313700	Arg615His
androgen receptor	M20132	313700	arg726leu
androgen receptor	M20132	313700	Arg752Gln
androgen receptor	M20132	313700	ARG772CYS
androgen receptor	M20132	313700	ARG773CYS
androgen receptor	M20132	313700	ARG773HIS
androgen receptor	M20132	313700	ARG839CYS
androgen receptor	M20132	313700	ARG839HIS
androgen receptor	M20132	313700	arg840his
androgen receptor	M20132	313700	ARG846HIS
androgen receptor	M20132	313700	ARG855HIS
androgen receptor	M20132	313700	CYS579PHE
androgen receptor	M20132	313700	G214R
androgen receptor	M20132	313700	GLN60TER
androgen receptor	M20132	313700	Gln798Glu
androgen receptor	M20132	313700	GLN902ARG
androgen receptor	M20132	313700	GLU2LYS
androgen receptor	M20132	313700	gly743val
androgen receptor	M20132	313700	HIS874TYR
androgen receptor	M20132	313700	ILE869MET
androgen receptor	M20132	313700	LEU172TER
androgen receptor	M20132	313700	LEU676PRO
androgen receptor	M20132	313700	LEU707ARG
androgen receptor	M20132	313700	LYS588TER
androgen receptor	M20132	313700	LYS882TER
androgen receptor	M20132	313700	MET780ILE

androgen receptor	M20132	313700	MET786VAL
androgen receptor	M20132	313700	PHE582TYR
androgen receptor	M20132	313700	PRO546SER
androgen receptor	M20132	313700	pro892ser
androgen receptor	M20132	313700	SER647ASN
androgen receptor	M20132	313700	THR877ALA
androgen receptor	M20132	313700	THR877SER
androgen receptor	M20132	313700	TRP717TER
androgen receptor	M20132	313700	TRP794TER
androgen receptor	M20132	313700	TYR761CYS
androgen receptor	M20132	313700	val 581 phe
androgen receptor	M20132	313700	VAL730MET
androgen receptor	M20132	313700	VAL865LEU
androgen receptor	M20132	313700	VAL865MET
androgen receptor	M20132	313700	VAL866MET
angiotensin converting enzyme/dipeptidyl carboxypeptidase	NM_000789	106180	250-bp in/del
angiotensin converting enzyme/dipeptidyl carboxypeptidase	NM_000789	106180	3 in the 3' UTR
angiotensin converting enzyme/dipeptidyl carboxypeptidase	NM_000789	106180	5 in the 5' region
angiotensin converting enzyme/dipeptidyl carboxypeptidase	NM_000789	106180	Pst I RFLP
angiotensin receptor	M87290	106165	1166A-C
1/AGTR1A			
Anticoagulant Protein C (inactivator of	X02750	176860	-1641 A/G

coagulation factors Va and VIIIa)					
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	(6376 G/T) in intron 7		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	-1654 C/T		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	1-BP DEL 42AA		frameshift
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	1432 C-->T		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	2-BP INS, TT, NT6139		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	3350insA		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	3351del4		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	40 T-->G		

C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	5-bp deletion nucleotides 3455 to 3459
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	6128 T-->C
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	6216 C-->T
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	6246 G-->A
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	7253 C-->T
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	8589 G-->A
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	8631 C-->T

SD-144141.1

Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	A/G at -641	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	A/T at -1476	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	A/T at -476	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	C insertion: CAT-- >CCAT	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	C/T at -654	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	CCT to CCC	Pro-21Pro
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	deletion of 5 nucleotides (nt) (CCCCG) in the end of exon VI G3079A	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860		

SD-144141.1



Anticoagulant Protein and VIIIa) C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	G8857 deletion	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	IVS G, C-T, +9	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	MspI	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	T-C, -14	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860		230 Arg-Lys
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860		254 Thr-Ile
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860		325 Val-Ala
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860		359 Asp-Asn

coagulation factors Va and VIIIa)	X02750	176860	364 Met-Trp, 378 Stop
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Ala136-->Pro
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ALA259VAL
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ALA267THR
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Arg 157-Stop
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG12TRP
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG169TRP
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG178GLN

C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG178TRP
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG230CYS
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Arg286His
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG306TER
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	arg352try
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Asn102-->Lys
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Asn329-->Thr

SD-144141.1

Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Asp359Asn
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Asp359Asn
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Cys-331 to Arg
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Cys78-->Stop
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	GLN184HIS
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	GLU20ALA
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Gly-376 Asp
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Gly282Ser

SD-144141.1

Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	GLY292SER
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	GLY301SER
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Gly350Arg
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	HIS107PRO
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ILE403MET
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	LEU223PHE
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Lys150 deletion
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Met365Ile

SD-144141.1

coagulation factors Va and VIIIa)	X02750	176860	Phe139Val
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	PRO168LEU
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	PRO247LEU
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Pro279Leu
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Pro327Leu
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Q132X
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Ser270Pro
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Thr298-->Met

SD-144141.1

C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	TRP402CYS
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Tyr399His
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	VAL297MET
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	VAL34MET
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Y124C
Anticoagulant protein S	Y00692	176880	G to T at codon Cys598 IVS11, A-G, -9
Anticoagulant protein S	Y00692	176880	+1 G to A in intron d
Anticoagulant protein S	Y00692	176880	+3 A to C in intron j

Anticoagulant protein S	Y00692	176880	1 nt (T) insertion at codon 265 delete T 635	
Anticoagulant protein S	Y00692	176880		
Anticoagulant protein S	Y00692	176880	G to A at codon Trp465	
Anticoagulant protein S	Y00692	176880	IVS10, G-A, +5	
Anticoagulant protein S	Y00692	176880		Arg410 (CGA)- ->Stop
Anticoagulant protein S	Y00692	176880		Lys368stop
Anticoagulant protein S	Y00692	176880		Ala 484-->Pro
Anticoagulant protein S	Y00692	176880		Arg506-->Gln
Anticoagulant protein S	Y00692	176880		ARG520GLY
Anticoagulant protein S	Y00692	176880		ASN217SER
Anticoagulant protein S	Y00692	176880		Cys145Tyr
Anticoagulant protein S	Y00692	176880		Cys200Ser
Anticoagulant protein S	Y00692	176880		Cys408Ser
Anticoagulant protein S	Y00692	176880		Cys625Arg
Anticoagulant protein S	Y00692	176880		GLN238TER
Anticoagulant protein S	Y00692	176880		Glu26Ala



S	Anticoagulant protein	Y00692	176880	Gly340Asp
S	Anticoagulant protein	Y00692	176880	Gly54Glu
S	Anticoagulant protein	Y00692	176880	LYS155GLU
S	Anticoagulant protein	Y00692	176880	Lys155Glu
S	Anticoagulant protein	Y00692	176880	Lys9Glu
S	Anticoagulant protein	Y00692	176880	Ser283Pro
S	Anticoagulant protein	Y00692	176880	SER406PRO
S	Anticoagulant protein	Y00692	176880	Ser460Pro
S	Anticoagulant protein	Y00692	176880	TER636TYR, 649TER
S	Anticoagulant protein	Y00692	176880	Tyr595stop
S	Apolipoprotein B (including Ag(x) antigen)	J02610	107730	C2316-->A Val703-->Ile
S	Apolipoprotein B (including Ag(x) antigen)	J02610	107730	(TG) <sup>n</sup>
S	Apolipoprotein B (including Ag(x) antigen)	J02610	107730	1-BP DEL frameshift
S	Apolipoprotein B (including Ag(x) antigen)	J02610	107730	1-BP DEL

(including Ag(x) antigen)	J02610	107730	1-BP DEL, FS1425TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	3'-VNTR
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	A----G second intron +722
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	ApaLI
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	AvaII
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	BalI
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	C to T -516
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	C-->T change at nucleotide 7064,
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	CTT3517-->CTG
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	EcoRI

antigen) Apolipoprotein B (including Ag(x) antigen)	J02610	107730	EX21DEL
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GCC3527-->GCT
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	HincII
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	INS AND DEL
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Ins/Del
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	intron 20 Alu repeat
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	MspI
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	PvuII
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	StyI second intron
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	T-to-C 1981

Apolipoprotein B (including Ag(x) antigen)	J02610	107730	XbaI	
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		A3371V
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		Arg---Glu3611
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ARG1306TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ARG2058TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ARG2495TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ARG3500GLN
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ARG3531CYS
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ASN1728THR
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		Asn4311----Ser
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		Cys646-->Tyr

(including Ag(x) antigen)	J02610	107730	Gln 3405 Glu
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GLN1450TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GLN2252TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Glu207-->Lys
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GLU4034ARG
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Glu4154
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Leu 3350 Leu
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Leu-Ala-Leu signal peptide (SP) insertion/deletion
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	LEU3041TER

Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Q3405E
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Ser 3252 Gl
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Ser 3455 Arg
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	SER1729TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Thr71-->Ile
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Trp66-->Gly
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Val 3396 Met
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	VAL1829CYS
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Val591-->Ala
apolipoprotein E/APOE	NM_000041	107741	7 AA insertion; tandem repeat of residues 121-127
apolipoprotein	NM_0000	107741	AI78G Threonine42Ala

E/APOE	41		nine
apolipoprotein	NM_0000	107741	A490C Lysine146Gluta
E/APOE	41		mine
apolipoprotein	NM_0000	107741	A490G Lysine146Gluta
E/APOE	41		mic Acid
apolipoprotein	NM_0000	107741	A940C Serine296Argini
E/APOE	41		ne
apolipoprotein	NM_0000	107741	Aintron3G substitution
E/APOE	41		creates 2
			abnormally
			spliced mRNA
			forms
apolipoprotein	NM_0000	107741	C305G Proline84Argini
E/APOE	41		ne
apolipoprotein	NM_0000	107741	C460A Arginine136Seri
E/APOE	41		ne
apolipoprotein	NM_0000	107741	C478T Arg142142Cysl
E/APOE	41		42
apolipoprotein	NM_0000	107741	C487T Arginine145Cys
E/APOE	41		teine
apolipoprotein	NM_0000	107741	C526T Arginine158Cys
E/APOE	41		teine
apolipoprotein	NM_0000	107741	C736T Arginine228Cys
E/APOE	41		teine
apolipoprotein	NM_0000	107741	C805G Arg251251Gly2
E/APOE	41		51
apolipoprotein	NM_0000	107741	G144deletion Leucine60Termi
E/APOE	41		nation Codon
			(frameshift)
apolipoprotein	NM_0000	107741	G349A Ala9999Thr99
E/APOE	41		

apolipoprotein E/APOE	NM_0000 41	107741	G434A Gly127127Asp1 27
apolipoprotein E/APOE	NM_0000 41	107741	G455A Arginine134Glu tamine
apolipoprotein E/APOE	NM_0000 41	107741	G488A Arginine145His tidine
apolipoprotein E/APOE	NM_0000 41	107741	G568C Ala152Proline
apolipoprotein E/APOE	NM_0000 41	107741	G61A Glutamic Acid13Lysine
apolipoprotein E/APOE	NM_0000 41	107741	G683A Tryptophan210 Termination Codon
apolipoprotein E/APOE	NM_0000 41	107741	G725A Arg224224Gln2 24
apolipoprotein E/APOE	NM_0000 41	107741	G875A Arginine274His tidine
apolipoprotein E/APOE	NM_0000 41	107741	G91A Glutamic Acid13Lysine
apolipoprotein E/APOE	NM_0000 41	107741	GAG-GAG844- Glu244/Glu245 849AAG-AAG 244- 245Lys244/Lys 245
apolipoprotein E/APOE	NM_0000 41	107741	T137C Leucine28Prolin e
apolipoprotein E/APOE	NM_0000 41	107741	T388C Cysteine112Arg inine
apolipoprotein E/APOE	NM_0000 41	107741	T761A Valine236Glu mic Acid
APOLIPOPROTEIN(a ); LPA		152200	-773G, +93T, +121G

SD-144141.1



APOLIPOPROTEIN(a); LPA	152200	C/T(+93)	
APOLIPOPROTEIN(a); LPA	152200	-773A, +93C, +121A	
APOLIPOPROTEIN(a); LPA	152200	C/T at -49	
APOLIPOPROTEIN(a); LPA	152200	G/A at -21	
APOLIPOPROTEIN(a); LPA	152200	G/A at -914	
APOLIPOPROTEIN(a); LPA	152200	IVS K4 TYPE 8 DS, G-A, +1	
APOLIPOPROTEIN(a); LPA	152200	TTTTA repeat	
APOLIPOPROTEIN(a); LPA	152200		Met-->Thr 66
APOLIPOPROTEIN(a); LPA	152200		Met/Thr 4168
APOLIPOPROTEIN(a); LPA	152200		Thr12-->Pro
arachidonate 5-lipoxygenase-activating protein/FLAP/ALOX5 AP	603700	none found	
Arginine Vasopressin Receptor 1B/AVPR1B	600264	none found	
Arginine vasopressin receptor 2	304800	1-BP DEL	
Arginine vasopressin receptor 2	304800	1-BP DEL, 102G	

SD-144141.1

Arginine vasopressin receptor 2	AF030626	304800	1-BP INS frameshift
Arginine vasopressin receptor 2	AF030626	304800	1-BP INS 804 frameshift
Arginine vasopressin receptor 2	AF030626	304800	15delC
Arginine vasopressin receptor 2	AF030626	304800	28-bp del
Arginine vasopressin receptor 2	AF030626	304800	786delG frameshift
Arginine vasopressin receptor 2	AF030626	304800	CpG dinucleotides
Arginine vasopressin receptor 2	AF030626	304800	ALA132ASP
Arginine vasopressin receptor 2	AF030626	304800	ARG181CYS
Arginine vasopressin receptor 2	AF030626	304800	ARG113TRP
Arginine vasopressin receptor 2	AF030626	304800	ARG203CYS
Arginine vasopressin receptor 2	AF030626	304800	ARG337TER
Arginine vasopressin receptor 2	AF030626	304800	ASP85ASN
Arginine vasopressin receptor 2	AF030626	304800	G107E
Arginine vasopressin receptor 2	AF030626	304800	GLY185CYS
Arginine vasopressin receptor 2	AF030626	304800	GLY201ASP
Arginine vasopressin	AF030626	304800	L43P

receptor 2						P322H
Arginine vasopressin receptor 2	AF030626	304800				
Arginine vasopressin receptor 2	AF030626	304800				P322S
Arginine vasopressin receptor 2	AF030626	304800				R137H
Arginine vasopressin receptor 2	AF030626	304800				TRP71TER
Arginine vasopressin receptor 2	AF030626	304800				TYR205CYS
Arginine vasopressin receptor 2	AF030626	304800				TYR280CYS
Arginine vasopressin receptor 2	AF030626	304800				W193X
ATPase, Ca++ transporting, cardiac muscle, fast twitch 1	U96781	108730			437C DEL	
ATPase, Ca++ transporting, cardiac muscle, fast twitch 1	U96781	108730			IVS3DS G-C, -2	
ATPase, Ca++ transporting, cardiac muscle, fast twitch 1	U96781	108730				ARG198TER
ATPase, Ca++ transporting, cardiac muscle, fast twitch 1	U96781	108730				CYS675TER
beta-1-adrenergic receptor; Adrb1	J03019	109630			Bgl I.	
beta-1-adrenergic receptor; Adrb1	J03019	109630			C1165G	ARG389GLY

Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	Fnu4HI	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	A-->G -1343	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	C-->G -468	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	G-->A -1023	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	G-->A -654	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->A -1429	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->C -20	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->C -367	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->C -47	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690		ARG16GLY
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690		GLN27GLU
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690		Thr164Ile
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690		val 34 met
Beta-Adrenergic Receptor Kinase 2; Adrbk2	X69117	109636	none found	
beta-adrenergic receptor kinase	NM_001619	109635	none found	

SD-144141.1

1/BARK1	NM_0007	600337	9-base pair deletion
bradykinin receptor	10		
B1/BDKRB1 G			
protein-coupled			
bradykinin receptor	NM_0007	600337	A1098-->G
B1/BDKRB1 G	10		
protein-coupled			
bradykinin receptor	NM_0007	600337	C181-->T
B1/BDKRB1 G	10		
protein-coupled			
bradykinin receptor	NM_0007	600337	G-699-->C
B1/BDKRB1 G	10		
protein-coupled			
bradykinin receptor	NM_0006	113503	-143C/T
B2/BDKRB2 G	23		
protein-coupled			
bradykinin receptor	NM_0006	113503	-412C/G
B2/BDKRB2 G	23		
protein-coupled			
bradykinin receptor	NM_0006	113503	-536C/T
B2/BDKRB2 G	23		
protein-coupled			
bradykinin receptor	NM_0006	113503	-640T/C
B2/BDKRB2 G	23		
protein-coupled			
bradykinin receptor	NM_0006	113503	-649insG
B2/BDKRB2 G	23		
protein-coupled			
bradykinin receptor	NM_0006	113503	-704C/T
B2/BDKRB2 G	23		
protein-coupled			

SD-144141.1

bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503	-78C/T
bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503	-845C/T
bradykinin receptor B2/BDKRB2 G	NM_0006 23	113503	9 bp de (-)21-29
bradykinin receptor B2/BDKRB2 G	NM_0006 23	113503	C>T promoter 54
bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503	repeat 3'UTR
bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503	tandem repeat near promoter
bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503	R14C
bradykinin receptor B2/BDKRB2 G protein-coupled	NM_0006 23	113503	T21M
Ca2+-dependent phospholipase A2	U03090	601192	none found
Carbonic anhydrase II	J03037	259730	BstNI
Carbonic anhydrase II	J03037	259730	gt->tt splice donor site at the 5' end of intron 6
Carbonic anhydrase II	J03037	259730	IVS2, G-A, +1

SD-144141.1

Carbonic anhydrase II	J03037	259730	IVS5, G-C, -I	TYR40TER
Carbonic anhydrase II	J03037	259730	TAQI	ASN252ASP
Carbonic anhydrase II	J03037	259730		HIS107TYR
Carbonic anhydrase II	J03037	259730		Ile31Val
Carbonic anhydrase II	J03037	259730		LYS17GLU
Carbonic anhydrase II	J03037	259730		PRO237HIS
Carbonic anhydrase IV	M83670	114760	none found	
Chloride channel 5	X91906	300008	1-BP DEL, 2085C	
Chloride channel 5	X91906	300008	tgcag --> tgaag	
Chloride channel 5	X91906	300008		Arg704Stop
Chloride channel 5	X91906	300008		GLY57VAL
Chloride channel 5	X91906	300008		ARG280PRO
Chloride channel 5	X91906	300008		Arg34Stop
Chloride channel 5	X91906	300008		ARG648TER
Chloride channel 5	X91906	300008		ARG704TER
Chloride channel 5	X91906	300008		GLY506GLU
Chloride channel 5	X91906	300008		LEU200ARG
Chloride channel 5	X91906	300008		SER244LEU
Chloride channel 5	X91906	300008		SER520PRO
Chloride channel 5	X91906	300008		TRP279TER
Chloride channel 5	X91906	300008		TRP343TER
Cholecystokinin A receptor/CCKAR	L13605	118444		GLY21ARG
Cholecystokinin A receptor/CCKAR	L13605	118444		VAL365ILE
Cholecystokinin B receptor/CCKBR	L08112	118445	1550 G-->A Val125-->Ile	
Cholecystokinin B receptor/CCKBR	L08112	118445	CAT 207 CAC His207His	

Cholecystokinin B receptor/CCKBR	L08112	118445	Arg215His
Cholecystokinin B receptor/CCKBR	L08112	118445	Val138Met
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1		100690	Hae III
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1		100690	ASN217LYS
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1		100690	GLY153SER
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1		100690	SER269ILE
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1		100690	THR254ILE
CHOLINERGIC RECEPTOR,		100690	VAL156MET

SD-144141.1



NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1	118938	none found	
CHYMASE 1; CMA1	120580	4-BP DEL	
Complement C1S component precursor	J04080		
(C1 esterase)			
Copper Transport Protein HAH1	U70660	602270	none found
CPLA2-GAMMA	603602	none found	
Cytochrome P450, subfamily XIA	M14565	118485	5' UTR
(cholesterol side chain cleavage)			pentanucleotide repeat
dopamine beta hydroxylase	Y00096	223360	
Dopamine Receptor D1	X58987	126449	C/T Isoleucine49
Dopamine Receptor D2	X51362	126450	141 C ins/del
Dopamine Receptor D2	X51362	126450	A241G
Dopamine Receptor D2	X51362	126450	NcoI RFLP
Dopamine Receptor D2	X51362	126450	TaqI A, TaqI B, TaqI D, and (CA)n
Dopamine Receptor D2	X51362	126450	STRP
Dopamine Receptor D2	X51362	126450	Serine 311Cysteine
Endopeptidase	X07166	120520	none found
Endothelin 1	Y00749	131240	A at position 138
Endothelin 1	Y00749	131240	C at position 121
Endothelin 1	Y00749	131240	Dinucleotide repeat
Endothelin 1	Y00749	131240	Lys198Asn
Endothelin 2	M65199	131241	3'UTR
			A985G

Endothelin 3	X52001	131242	1-BP INS	ALA17THR
Endothelin 3	X52001	131242	1-BP INS, 262G	ALA224THR
Endothelin 3	X52001	131242	262GC-T	CYS159PHE
Endothelin 3	X52001	131242		ARG742CYS
Endothelin 3	X52001	131242		
Endothelin 3	X52001	131242		
Endothelin Converting Enzyme 1	Z35307	600423		
Endothelin Receptor Type A	D90348	131243	none found	
Endothelin Receptor Type B	L06623	131244	1-BP INS, 878T	
Endothelin Receptor Type B	L06623	131244		ALA183GLY
Endothelin Receptor Type B	L06623	131244		GLY57SER
Endothelin Receptor Type B	L06623	131244		SER305ASN
Endothelin Receptor Type B	L06623	131244		TRP275TER
Endothelin Receptor Type B	L06623	131244		TRP276CYS
eosinophil peroxidase/EPX		131399	INS G, NT1537	
eosinophil peroxidase/EPX		131399		ARG286HIS
Erythropoietin receptor	M34986	133171	7-BP DEL	frameshift
Erythropoietin receptor	M34986	133171	1-BP INS	FS444TER
Erythropoietin receptor	M34986	133171	1-BP INS, 5967T	frameshift
Erythropoietin receptor	M34986	133171	BamHI	
Erythropoietin receptor	M34986	133171	Bgl II	

Erythropoietin receptor	M34986	133171	C to T	-->435stop
Erythropoietin receptor	M34986	133171	C6148T	
Erythropoietin receptor	M34986	133171	HindIII	
Erythropoietin receptor	M34986	133171	SacI	
Erythropoietin receptor	M34986	133171		ASN487SER
Erythropoietin receptor	M34986	133171		TRP439TER
Erythropoietin receptor	M34986	133171		TYR426TER
estrogen receptor 1	M12674	133430	RFLP (PssI enzyme)	
estrogen receptor 1	M12674	133430	RFLP (PvuII enzyme)	
estrogen receptor 2	X99101	601663	none found	
Estrogen-preferring sulfotransferase/STE	NM_005420	600043	none found	
G protein coupled potassium channel, subfamily J, member 3/KCNJ3/GIRK1	NM_002239	601534	(CA)n	
GAP JUNCTION PROTEIN, ALPHA-5		121013	none found	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE		231200	(39-base pair)n	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE		231200	92-BP DUP	SER399-THR411 DUP
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE		231200	Arg342 (A --> G)	silent
GLYCOPROTEIN Ib,		231200	T --> C 2nd	

PLATELET, ALPHA POLYPEPTIDE			nucleotide exon 2	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200		Tyr492 (TAT-->T)	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200			ALA156VAL
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200			GLY233VAL
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200			LEU57PHE
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200			MET239VAL
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200			TRP126TER
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200			TRP343TER
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200			TRP498TER
Granulocyte colony- stimulating factor	M64592	120420	none found	
Guanine nucleotide binding protein (G protein), alpha	J03004	139360		PHE200LEU

inhibiting activity polypeptide 2	J03004	139360	ARG179CYS
Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2	J03004	139360	ARG179GLY
Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2	J03004	139360	ARG179HIS
Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2	M31328	139130	C825T
Guanine nucleotide binding protein (G protein), beta polypeptide 3	U40038	600998	none found
Guanine nucleotide binding protein (G protein), q polypeptide GUANINE NUCLEOTIDE- BINDING PROTEIN ALPHA- ACTIVATING ACTIVITY POLYPEPTIDE O;		139311	none found

GNAOI				
Guanylate cyclase 1, soluble, alpha 2	X63282	601244	none found	
GUANYLATE CYCLASE 1,		603695	none found	
SOLUBLE, BETA-2				
Guanylate cyclase soluble, alpha-3 chain	X66534	139396	none found	
Guanylate cyclase soluble, beta-1 chain	X66533	139397	none found	
H.sapiens 40 kDa protein kinase related to rat ERK2	Z11695	176948	none found	
H.sapiens 44kDa protein kinase related to rat ERK1	Z11696	601795	none found	
H.sapiens encoding CLA-1 mRNA	Z22555	601040	none found	
H.sapiens gene for antithrombin III	X68793	107300	AAG----AAA transition at Lys 176	
H.sapiens gene for antithrombin III	X68793	107300	DdeI	
H.sapiens gene for antithrombin III	X68793	107300	Hae III	
H.sapiens gene for antithrombin III	X68793	107300	NheI	
H.sapiens gene for antithrombin III	X68793	107300	Pst I	
H.sapiens gene for antithrombin III	X68793	107300	Trinucleotide repeat	
H.sapiens gene for antithrombin III	X68793	107300		GLU245FS

antithrombin III H.sapiens gene for antithrombin III	X68793	107300	ILE7ASN
H.sapiens gene for antithrombin III	X68793	107300	ALA382THR
H.sapiens gene for antithrombin III	X68793	107300	ala382thr
H.sapiens gene for antithrombin III	X68793	107300	ALA384PRO
H.sapiens gene for antithrombin III	X68793	107300	ALA384SER
H.sapiens gene for antithrombin III	X68793	107300	ALA387VAL
H.sapiens gene for antithrombin III	X68793	107300	ALA404THR
H.sapiens gene for antithrombin III	X68793	107300	ARG129TER
H.sapiens gene for antithrombin III	X68793	107300	ARG24CYS
H.sapiens gene for antithrombin III	X68793	107300	ARG393CYS
H.sapiens gene for antithrombin III	X68793	107300	ARG393HIS
H.sapiens gene for antithrombin III	X68793	107300	ARG393PRO
H.sapiens gene for antithrombin III	X68793	107300	arg406met
H.sapiens gene for antithrombin III	X68793	107300	ARG47CYS
H.sapiens gene for antithrombin III	X68793	107300	ARG47HIS

H.sapiens gene for antithrombin III	X68793	107300	ARG47SER
H.sapiens gene for antithrombin III	X68793	107300	ASN208LYS
H.sapiens gene for antithrombin III	X68793	107300	ASP309LYS
H.sapiens gene for antithrombin III	X68793	107300	GLY392ASP
H.sapiens gene for antithrombin III	X68793	107300	His120-->Tyr
H.sapiens gene for antithrombin III	X68793	107300	LEU-10PRO
H.sapiens gene for antithrombin III	X68793	107300	LEU99PHE
H.sapiens gene for antithrombin III	X68793	107300	LYS228FS
H.sapiens gene for antithrombin III	X68793	107300	LYS370ARG
H.sapiens gene for antithrombin III	X68793	107300	PRO407LEU
H.sapiens gene for antithrombin III	X68793	107300	PRO41LEU
H.sapiens gene for antithrombin III	X68793	107300	PRO429LEU
H.sapiens gene for antithrombin III	X68793	107300	Pro80-->Thr
H.sapiens gene for antithrombin III	X68793	107300	SER291PRO
H.sapiens gene for antithrombin III	X68793	107300	SER349PRO
H.sapiens gene for antithrombin III	X68793	107300	SER394LEU



antithrombin III	X68793	107300			Tyr158-->Cys
H.sapiens gene for antithrombin III					
H.sapiens gene for antithrombin III	X68793	107300			VAL-3GLU
H.sapiens gene for antithrombin III	X68793	107300			VAL48CYS
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045		IVS15, G-A, +1	
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045			Arg102Leu
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045			ARG278CYS
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045			ARG92GLN
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045			ILE79ASN
H.sapiens mRNA for adenosine triphosphatase, calcium	Z69881	601929		none found	
H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047		1389 (A/G)	
H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047		dinucleotide repeat introns 12	

H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047	dinucleotide repeat introns 5	
H.sapiens mRNA for delta-sarcoglycan	X95191	601411	I-BP DEL, 656C	
H.sapiens mRNA for delta-sarcoglycan	X95191	601411		ARG165TER
H.sapiens mRNA for delta-sarcoglycan	X95191	601411		GLU262LYS
H.sapiens mRNA for delta-sarcoglycan	X95191	601411		TRP30TER
H.sapiens mRNA for growth factor receptor tyrosine kinase	X61656	191306	none found	
H.sapiens mRNA for nitric oxide synthase	X73029	163730	(CCTTT) <sub>n</sub>	
H.sapiens mRNA for platelet derived growth factor alpha receptor	X76079	173490	none found	
H.sapiens mRNA for ryanodine receptor 2	X98330	180902	none found	
H.sapiens mRNA for thrombospondin-4	Z19585	600715	none found	
H.sapiens tropomyosin isoform mRNA, complete CDS	Z24727	191010		ASP175ASN
H.sapiens tropomyosin isoform mRNA, complete CDS	Z24727	191010		GLU180GLY
Histamine receptor H1	AF026261	600167	none found	
HMGCoA	NM_0008	142910	HgiAI	

SD-144141.1

reductase/HMGCR	59				
HMGCoA	NM_0008	142910	ScrFI polymorphism		
reductase/HMGCR	59		in the 2nd intron		
Homo sapiens (clone H4/H16) gamma-glutamic carboxylase mRNA, complete cds	L17128	137167			LEU394ARG
Homo sapiens ADDL mRNA for adducin-like protein, complete cds	D67031	601568	none found		
Homo sapiens beta-arrestin 1A mRNA, complete cds	AF084040	107940	none found		
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	2.4-KB DEL		
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760			ARG249GLN
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760			ARG403GLN
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760			ARG403LEU
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760			ARG453CYS

myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	ARG719TRP
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	ARG723CYS
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	ASP778GLY
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	GLU924LYS
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	GLU949LYS
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	GLY256GLU
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	GLY584ARG

Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	GLY741ARG
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	LEU908VAL
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	PHE513CYS
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	VAL606MET
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	18-BP INS, IVS2, -12
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	IVS6DS, G-A, +1
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	ASN754 DEL
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	ASN767SER
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	CYS268PHE

Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	CYS560ARG
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	GLN108TER
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	GLY23GLU
Homo sapiens calcium-independent phospholipase A2 mRNA, complete cds	AF064594	603604	none found
Homo sapiens carbonic anhydrase precursor (CA 12) mRNA, complete cds	AF037335	603263	none found
Homo sapiens focal adhesion kinase mRNA, complete cds	L05186	600758	none found
Homo sapiens GATA-4 mRNA, complete cds	L34357	600576	none found
Homo sapiens integrin alpha 8 subunit mRNA, 3' end	L36531	604063	none found
Homo sapiens integrin alpha-7 mRNA, complete cds	AF032108	600536	1-bp frameshift deletion at cDNA nucleotide 1204
Homo sapiens integrin alpha-7 mRNA, complete cds	AF032108	600536	21-BP INS

Homo sapiens integrin alpha-7 mRNA, complete cds	AF032108	600536	98-BP DEL	
Homo sapiens mRNA for ABC transporter 7 protein, complete cds	AB005289	300135		ILE400MET
Homo sapiens mRNA for AMP-activated protein kinase alpha-1, complete cds	AB022017	602739	none found	
Homo sapiens mRNA for AMP-activated protein kinase beta 1	AJ224515	602740	none found	
Homo sapiens mRNA for AMP-activated protein kinase beta 2 subunit	AJ224538	602741	none found	
Homo sapiens mRNA for brain ryanodine receptor, complete cds	AB001025	180903	none found	
Homo sapiens p21- activated kinase 3 (PAK3) mRNA, complete cds	AF068864	300142		ARG419TER
Homo sapiens paraoxonase 2 (PON2) mRNA, complete cds	L48513	602447		ALA148GLY
Homo sapiens paraoxonase 2 (PON2) mRNA, complete cds	L48513	602447		CYS311SER
Homo sapiens	L48516	602720	none found	

paraoxonase 3 (PON3) mRNA, 3' end of cds	M95678	604114	none found	
Homo sapiens phospholipase C-beta-2 mRNA, complete cds	AF033850	602384	none found	
Homo sapiens phospholipase D2 (PLD2) mRNA, complete cds	L06139	600221		ARG849TRP
Homo sapiens receptor protein-tyrosine kinase (TEK) mRNA, complete cds	M55067	233700	1-BP DEL, 502G	frameshift
Human 47-kD autosomal chronic granulomatous disease protein mRNA, complete cds	M55067	233700	2-BP DEL, EX2, -2, GT	
Human 47-kD autosomal chronic granulomatous disease protein mRNA, complete cds	M55067	233700	2-BP INS	frameshift
Human 47-kD autosomal chronic granulomatous disease protein mRNA, complete cds	M55067	233700		ASP161VAL



protein mRNA, complete cds	M55067	233700	LYS160GLU
Human 47-kD autosomal chronic granulomatous disease protein mRNA, complete cds	U42412	602742	none found
Human 5'-AMP-activated protein kinase, gamma-1 subunit mRNA, complete cds	L11695	190181	S387Y
Human activin receptor-like kinase (ALK-5) mRNA, complete cds	L07261	102680	G460W
Human alpha adducin mRNA, partial cds including alternate exons A and B	M27875	107680	1-BP DEL, CODON 202
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	1-BP INS
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	1121 C/T in intron 3
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	12-BP DEL AND 2-BP INS

Human apolipoprotein A-I mRNA, complete cds	M27875	107680	A/G at position 78 bp upstream
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	DELETION OF APOA1/APOC3/AP OA4 GENE COMPLEX EX4/IVS1
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	G-to-A -75 bp
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	IVS2, G-C, +1
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Msp I
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Pst-I
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	SstI
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	XmnI
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Lys-107 deletion

SD-144141.1

Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Ala-95-->Asp
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	ARG10LEU
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	ARG173CYS
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	ARG173PRO
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Asp103----Asn
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLN-2TER
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLN32TER
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLN84TER
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLU136LYS
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLU198LYS

Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLY26ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	LEU60ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	LEU90PRO
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	LYS107DEL
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	PRO143ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Pro165-->Arg
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	PRO165ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	PRO3ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	PRO4ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Trp-108-->Arg
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	TRP50ARG

SD-144141.1

A-I mRNA, complete cds	M27875	107680	VAL156GLU
Human apolipoprotein A-I mRNA, complete cds			
Human ARF-activated phosphatidylcholine-specific phospholipase D1a (hPLD1) mRNA, complete cds	U38545	602382	none found
Human beta 4 adducin mRNA, alternatively spliced partial cds	U43959	102681	none found
Human bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2) mRNA, complete cds	U58130	600839	ASP648ASN
Human bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2) mRNA, complete cds	U58130	600839	TRP625TER
Human bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2) mRNA, complete cds	U58130	600839	VAL272PHE
Human bumetanide-sensitive Na-K-Cl cotransporter (NKCC1) mRNA, complete cds	U30246	600840	none found
Human c-sis/platelet-derived growth factor 2	M12783	190040	135-BP DEL, IVS5

(SIS/PDGF2) mRNA, complete cds	M12783	190040	FUSION WITH COL1A
Human c-sis/platelet- derived growth factor 2 (SIS/PDGF2) mRNA, complete cds	U95301	603603	none found
Human calcium- dependent group X phospholipase A2 mRNA, complete cds	M33336	188830	none found
Human cAMP- dependent protein kinase type I-alpha subunit (PRKAR1A) mRNA, complete cds	L10844	116952	none found
Human cellular growth-regulating protein mRNA, complete cds	M91667	123805	none found
Human cGMP- inhibited cAMP phosphodiesterase mRNA, complete cds	M14058	216950	none found
Human complement C1r mRNA, complete cds	U59167	125660	21-BP DEL
Human desmin mRNA, complete cds	U59167	125660	EcoRV
Human desmin mRNA, complete cds	U59167	125660	ALA337PRO

complete cds				
Human desmin mRNA,	U59167	125660		ALA360PRO
complete cds				
Human desmin mRNA,	U59167	125660		ASN393ILE
complete cds				
Human desmin mRNA,	U59167	125660		ILE451MET
complete cds				
Human DNA sequence	AL023653	300145	none found	
from clone 753P9 on				
chromosome Xq25-				
26.1. Contains the gene				
coding for				
Aminopeptidase P (EC				
3.4.11.9, XAA-Pro/X-				
Pro/Proline/Aminoacyl				
proline				
Aminopeptidase) and a				
novel gene. Contains				
ESTs, STSs, GSSs and				
a gaaa repeat				
polymorphism				
Human ERK5 mRNA,	U25278	602521	none found	
complete cds				
Human ferritin H chain	M11146	134770	none found	
mRNA, complete cds				
Human ferritin L chain	M11147	134790	22T-G	
mRNA, complete cds				
Human ferritin L chain	M11147	134790	146A-G	
mRNA, complete cds				
Human ferritin L chain	M11147	134790	147G-C	
mRNA, complete cds				

SD-144141.1

Human ferritin L chain mRNA, complete cds	M11147	134790	18C-T	
Human ferritin L chain mRNA, complete cds	M11147	134790	29-BP DEL	IRE DEL
Human ferritin L chain mRNA, complete cds	M11147	134790	32G-A	
Human ferritin L chain mRNA, complete cds	M11147	134790	32G-T	
Human ferritin L chain mRNA, complete cds	M11147	134790	36C-A	
Human ferritin L chain mRNA, complete cds	M11147	134790	39C-T	
Human flt mRNA for receptor-related tyrosine kinase	X51602	165070	Dinucleotide repeat	
Human heparin-binding vascular endothelial growth factor (VEGF) mRNA, complete cds	M32977	192240	none found	
Human hepatic lipase mRNA, complete cds	J03540	151670		SER267PHE
Human hepatic lipase mRNA, complete cds	J03540	151670		THR383MET
Human hormone-sensitive lipase testicular isoform mRNA, complete cds	U40002	151750	dinucleotide repeat	
Human hormone-sensitive lipase testicular isoform	U40002	151750		Arg309Cys



mRNA, complete cds				
Human integrin alpha 9 protein mRNA, 3'end	L24158	603963	none found	
Human IP gene for prostacyclin receptor, exon 3	D38128	600022	none found	
Human kidney mRNA fragment for renin (aa 105-401)	X00063	179820		ARG387TER
Human lipid-activated, protein kinase PRK2 mRNA, complete cds	U33052	602549	none found	
Human mRNA for adrenomedullin, complete cds	D14874	103275	none found	
Human mRNA for cardiac gap junction protein	X52947	121014	GCG-->GTG	Ala253Val
Human mRNA for LIMK (LIM kinase), complete cds	D26309	601329	none found	
Human mRNA for LIMK-2, complete cds	D45906	601988	none found	
Human mRNA for natriuretic peptide receptor (ANP-A receptor)	X15357	108960	none found	
Human mRNA for plasminogen	X05199	173350	IVS17, 1-BP DEL, G, +1 TaqI	
Human mRNA for plasminogen	X05199	173350		

Human mRNA for plasminogen	X05199	173350	GLU460TER
Human mRNA for plasminogen	X05199	173350	ALA600THR
Human mRNA for plasminogen	X05199	173350	Ala675Thr
Human mRNA for plasminogen	X05199	173350	ARG216HIS
Human mRNA for plasminogen	X05199	173350	D676N
Human mRNA for plasminogen	X05199	173350	GLY732ARG
Human mRNA for plasminogen	X05199	173350	LYS19GLU
Human mRNA for plasminogen	X05199	173350	LYS212DEL
Human mRNA for plasminogen	X05199	173350	SER572PRO
Human mRNA for plasminogen	X05199	173350	TRP597TER
Human mRNA for plasminogen	X05199	173350	VAL355PHE
Human mRNA for platelet-derived growth factor PDGF-A	X06374	173430	none found
Human mRNA for thrombospondin	X04665	188060	none found
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	72
Human mRNA for	X02812	190180	-509

transforming growth factor-beta (TGF-beta)	X02812	190180	-800	
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	-988	
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	713-8delC intron 4	
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	C788-T	thr263iso
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180		Arg25-->Pro
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180		Leu10-->Pro
Human mRNA for type I beta cGMP-dependent protein kinase (EC 2.7.1.37)	Y07512	176894	none found	
Human myoadenylate deaminase (AMPD1) mRNA, complete cds	M60092	102770	C143-->T	PRO48LEU
Human myoadenylate deaminase (AMPD1) mRNA, complete cds	M60092	102770	C34-T	Gln-->Stop
Human neuronal nitric	U17327	163731	none found	

SD-144141.1

oxide synthase (NOS1) mRNA, complete cds	M21186	233690	1-BP DEL, 272C	
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690	10-KB DEL	
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690	IVS4DS, G-A, +1	
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690		ARG90GLN
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690		HIS72TYR
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690		HIS94ARG

complete cds				
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690		PRO156GLN
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690		SER118ARG
Human neutrophil oxidase factor (p67- phox) mRNA, complete cds	M32011	233710	5-nucleotide del nts 1169-1173	
Human neutrophil oxidase factor (p67- phox) mRNA, complete cds	M32011	233710	9-nt in-frame deletion in exon 2 (nts 55-63)	
Human neutrophil oxidase factor (p67- phox) mRNA, complete cds	M32011	233710	C(304) --> T	
Human neutrophil oxidase factor (p67- phox) mRNA, complete cds	M32011	233710	del A(728)	
Human neutrophil oxidase factor (p67- phox) mRNA, complete cds	M32011	233710	intron 4 (G --> A)	

Human p21-activated protein kinase (Pak1) gene, complete cds	U24152	602590	none found	
Human phospholamban mRNA, complete cds	M63603	172405	none found	
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515		Ala139(ACC)-- >Thr(GCC)
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515		ASN45SER
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515		ASP21GLY
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515		LEU40PRO
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515		PHE55SER
Human platelet-derived growth factor (PDGF) receptor mRNA, complete cds	M21616	173410	none found	
Human protein kinase C iota isoform (PRKCI) mRNA, complete cds	L18964	300094	none found	
Human RAS-F-A PLA2 mRNA, complete cds	M22430	172411	2-BP DEL	frameshift

Human receptor for advanced glycosylation end products (RAGE) mRNA, partial cds	M91211	600214	none found	
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	1-BP DEL	PRO251DEL
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	null allele	
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		GLY196SER
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		LEU55GLN
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		ARG227TER
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		ARG246TRP
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		GLY115ASP
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		GLY183SER
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		HIS231ARG

Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	MET157DEL
Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	THR228ALA
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	840delA
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	IVS4AS, T-A, -11
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	IVS2, 1-BP INS, T, +3
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	1-BP DEL, 261T
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	ARG182LEU
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	D203A
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	GLN258TER



acute regulatory protein (StAR) mRNA, complete cds	M85079	190182	2-BP INS	Frameshift
Human TGF-beta type II receptor mRNA, complete cds	M85079	190182		THR315MET
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	3-BP DEL	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	119-bp insertion between exons 3 and 4	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	exon 24 was deleted	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	intron 24, GGT --> GTT	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	intron 3, CAG --> CAA	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	IVS15AS, G-T, -I	

cotransporter (hTSC) mRNA, complete cds Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	IVS23DS, G-T, +1	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		ALA588VAL
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		ARG209TRP
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		ARG653LEU
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		ARG655HIS
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		CYS421ARG
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		GLY630VAL
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		LEU623PRO

sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	LEU850PRO
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	PRO349LEU
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U68162	159530	none found
Human thrombopoietin receptor (MPL) gene	M81339	188061	none found
Human thrombospondin mRNA	X60957	600222	none found
Human tie mRNA for putative receptor tyrosine kinase	M12530	190000	AvaI
Human transferrin mRNA, complete cds	M12530	190000	ASP277GLY
Human transferrin mRNA, complete cds	M12530	190000	GLY652GLU
Human transferrin mRNA, complete cds	M12530	190000	HIS300ARG
Human transferrin mRNA, complete cds	M12530	190000	LYS627GLU
Human transferrin mRNA, complete cds	M12530	190000	PRO570SER

Human transforming growth factor-beta type III receptor (TGF-beta) mRNA, complete cds	L07594	600742	none found	
Human urokinase gene, 3' end	K02286	191840	BamHI	
Human urokinase gene, 3' end	K02286	191840	C to T change near the beginning of exon 8	
Human urokinase gene, 3' end	K02286	191840		Leu residue by a Pro, in the kringle domain
Human vascular endothelial growth factor related protein VRP mRNA, complete cds	U43142	601528	none found	
Human VEGF related factor isoform VRF186 precursor (VRF) mRNA, complete cds	U43368	601398	none found	
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	1-BP INS	
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	Dinucleotide repeat	
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810		ARG249TER

SD-144141.1

3 beta- and steroid delta-isomerase 2	M67466	201810	TRP171TER
Hydroxy-delta-5- steroid dehydrogenase,			
3 beta- and steroid delta-isomerase 2	M67466	201810	VAL248ASN
Hydroxy-delta-5- steroid dehydrogenase,			
3 beta- and steroid delta-isomerase 2	K02770	147720	+5887 C --> T
interleukin 1 beta (IL1b)			
interleukin 1 beta (IL1b)	K02770	147720	exon 5 (position +3953)
interleukin 1 beta (IL1b)	K02770	147720	position -511
interleukin 1 beta (IL1b)	K02770	147720	TaqI
interleukin 1 beta (IL1b)	K02770	147720	Asp106Asn
INTERLEUKIN 1 BETA CONVERTASE PRECURSOR	X65019	147678	none found
interleukin 1 receptor (IL-1R)	M27492	147810	PstI
interleukin 12a (IL12a)	M65271	161560	none found
interleukin 12b (IL12b)	M65272	161561	4.4-KB DEL
interleukin 2 (IL2)	X01586	147680	-330
interleukin 2 (IL2)	X01586	147680	166
interleukin 2 (IL2)	X01586	147680	AUUUA motif deleted

interleukin 2 (IL2)	X01586	147680	Dinucleotide Repeat	
interleukin 2 receptor beta (IL-2Rb)	M26062	146710	CA repeat	
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380	690-691 hotspot	
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380	9-BP DUP	GLN-HIS-TRP INS
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380	G-to-A first position of intron 3	ARG222CYS
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		ARG267TER
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		ARG285GLN
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		CYS115ARG
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		CYS62TER
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		GLY114ASP
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		ILE153ASN
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		LEU271GLN
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		LYS97TER
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		SER286TER
interleukin 4 (IL4)	M13982	147780	-285 C-T	
interleukin 4 (IL4)	M13982	147780	-81 A-G	

interleukin 4 (IL4)	M13982	147780	C-589T	
interleukin 4 (IL4)	M13982	147780	Dinucleotide Repeat intron 2	GLN576ARG
interleukin 4 receptor (IL-4R)	X52425	147781		
interleukin 4 receptor (IL-4R)	X52425	147781		ILE50VAL
interleukin 4 receptor (IL-4R)	X52425	147781		S503P
interleukin 6 (IL6)	M14584	147620	CA repeat	
interleukin 6 (IL6)	M14584	147620	174G-C	
interleukin 6 (IL6)	M14584	147620	AT repeat	
interleukin 6 (IL6)	M14584	147620	BglI	
interleukin 6 (IL6)	M14584	147620	BglII	
interleukin 6 (IL6)	M14584	147620	MspI	
interleukin 6 (IL6)	M14584	147620	NlaIII promoter	
interleukin 6 receptor (IL-6R) (20)	M20566	147880	dinucleotide (CA)	
interleukin receptor 11 alpha (IL-11a)	U32324	600939	none found	
interleukin receptor 12 beta2 (IL-12b2)	U03187	601642	none found	
K+ channel (KvLQT1)	AF000571	192500	7-BP DEL AND 8- BP INS	
K+ channel (KvLQT1)	AF000571	192500	1-BP INS, 282G	
K+ channel (KvLQT1)	AF000571	192500	3-BP DEL	
K+ channel (KvLQT1)	AF000571	192500	9-BP DEL, NT373	
K+ channel (KvLQT1)	AF000571	192500		ALA300THR
K+ channel (KvLQT1)	AF000571	192500		ALA341GLU
K+ channel (KvLQT1)	AF000571	192500		ALA341VAL
K+ channel (KvLQT1)	AF000571	192500		ALA529THR

K+ channel (KvLQT1)	AF000571	192500	ALA83PRO
K+ channel (KvLQT1)	AF000571	192500	ARG518TER
K+ channel (KvLQT1)	AF000571	192500	ARG555CYS
K+ channel (KvLQT1)	AF000571	192500	ARG95GLN
K+ channel (KvLQT1)	AF000571	192500	GLY189ARG
K+ channel (KvLQT1)	AF000571	192500	GLY211ARG
K+ channel (KvLQT1)	AF000571	192500	GLY219SER
K+ channel (KvLQT1)	AF000571	192500	GLY250GLU
K+ channel (KvLQT1)	AF000571	192500	LEU178PHE
K+ channel (KvLQT1)	AF000571	192500	PHE339DEL
K+ channel (KvLQT1)	AF000571	192500	THR217ILE
K+ channel (KvLQT1)	AF000571	192500	TRP305SER
K+ channel (KvLQT1)	AF000571	192500	VAL159MET
L-type voltage dependent calcium channel alpha 1C subunit/CACNA1C	NM_000719	114205	none found
Leukocyte integrin beta-1	U28252	135630	none found
Leukocyte integrin beta-3	M35999	173470	11.2-KB DEL
Leukocyte integrin beta-3	M35999	173470	G-T, EXiDEL
Leukocyte integrin beta-3	M35999	173470	ARG143GLN
Leukocyte integrin beta-3	M35999	173470	ARG214GLN
Leukocyte integrin beta-3	M35999	173470	ARG214TRP
Leukocyte integrin beta-3	M35999	173470	ARG489GLN



Leukocyte integrin	M35999	173470	ARG724TER
beta-3			
Leukocyte integrin	M35999	173470	ASP119TYR
beta-3			
Leukocyte integrin	M35999	173470	CYS374TYR
beta-3			
Leukocyte integrin	M35999	173470	GLU616TER
beta-3			
Leukocyte integrin	M35999	173470	LEU33PRO
beta-3			
Leukocyte integrin	M35999	173470	PRO407ALA
beta-3			
Leukocyte integrin	M35999	173470	SER752PRO
beta-3			
Lipoprotein lipase	M15856	238600	INS
Lipoprotein lipase	M15856	238600	(TTTA)n
Lipoprotein lipase	M15856	238600	-39T-C
Lipoprotein lipase	M15856	238600	-93T-G
Lipoprotein lipase	M15856	238600	1-BP DEL
Lipoprotein lipase	M15856	238600	1-BP DEL, 221G
Lipoprotein lipase	M15856	238600	2-KB DUP
Lipoprotein lipase	M15856	238600	6-KB DEL
Lipoprotein lipase	M15856	238600	C-->A -3 intron 6
Lipoprotein lipase	M15856	238600	C-to-T -480
Lipoprotein lipase	M15856	238600	C1338-->A
Lipoprotein lipase	M15856	238600	C1595-->G
Lipoprotein lipase	M15856	238600	G579-->A
Lipoprotein lipase	M15856	238600	HindIII
Lipoprotein lipase	M15856	238600	IVS1, G-C, +1
Lipoprotein lipase	M15856	238600	IVS2DS, G-A
Lipoprotein lipase	M15856	238600	IVS2DS, G-A, +1

Lipoprotein lipase	M15856	238600	ILE194THR
Lipoprotein lipase	M15856	238600	ILE225THR
Lipoprotein lipase	M15856	238600	TRP382TER
Lipoprotein lipase	M15856	238600	TYR61TER
Lipoprotein lipase	M15856	238600	ALA176THR
Lipoprotein lipase	M15856	238600	ALA334THR
Lipoprotein lipase	M15856	238600	ARG243CYS
Lipoprotein lipase	M15856	238600	ARG243HIS
Lipoprotein lipase	M15856	238600	ARG75SER
Lipoprotein lipase	M15856	238600	ASN291SER
Lipoprotein lipase	M15856	238600	ASP156GLY
Lipoprotein lipase	M15856	238600	ASP180GLU
Lipoprotein lipase	M15856	238600	ASP204GLU
Lipoprotein lipase	M15856	238600	ASP250ASN
Lipoprotein lipase	M15856	238600	ASP9ASN
Lipoprotein lipase	M15856	238600	Cys239-->stop
Lipoprotein lipase	M15856	238600	CYS418TYR
Lipoprotein lipase	M15856	238600	E163G
Lipoprotein lipase	M15856	238600	E410K
Lipoprotein lipase	M15856	238600	GLN106TER
Lipoprotein lipase	M15856	238600	Glu118 Glu
Lipoprotein lipase	M15856	238600	Glu421Lys
Lipoprotein lipase	M15856	238600	GLY142GLU
Lipoprotein lipase	M15856	238600	GLY188GLU
Lipoprotein lipase	M15856	238600	GLY195GLU
Lipoprotein lipase	M15856	238600	His183-->Gln
Lipoprotein lipase	M15856	238600	LEU365VAL
Lipoprotein lipase	M15856	238600	Pro157 Arg
Lipoprotein lipase	M15856	238600	PRO207LEU
Lipoprotein lipase	M15856	238600	SER172CYS
Lipoprotein lipase	M15856	238600	SER244THR

Lipoprotein lipase	M15856	238600		SER447TER
Lipoprotein lipase	M15856	238600		TRP64TER
Lipoprotein lipase	M15856	238600		TRP86ARG
Lipoprotein lipase	M15856	238600		Tyr262-->His
Lipoprotein lipase	M15856	238600		TYR73TER
Lipoxygenases: 5-lipoxygenase (leukocytes)	J03571	152390	none found	
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	1-BP DEL	frameshift at codon 337
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	1-BP DEL	frameshift at codon 459
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	760-->G760	Ileu180-->Val180
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	A DEL, +3 intron 5	
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	C944-->T944	Ala241-->Val241
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983		ARG537TER
myeloperoxidase	X04876	254600	C8089T	ARG569TRP
myeloperoxidase	X04876	254600	Dinucleotide Repeat	
myeloperoxidase	X04876	254600	EcoRV	
myeloperoxidase	X04876	254600	G to A (promoter)	
myeloperoxidase	X04876	254600	KpnI	

myeloperoxidase	X04876	254600	PstI	MET251THR
myeloperoxidase	X04876	254600		TYR173CYS
myeloperoxidase	X04876	254600		
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	5-BP DEL, EX25	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	IVS, G-A, +1	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	12-BP DUP/4-BP DEL	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	18-BP DUP	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	BRANCH POINT, IVS23, A-G, TGAT- TGGT	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	IVS, A-G	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	IVS, G-C, +5	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	IVS23, G-A, +1	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	IVS7, G-A, +5	
MYOSIN-BINDING		600958		Arg654His

PROTEIN C, CARDIAC	600958			Glu1096 termination codon
MYOSIN-BINDING PROTEIN C, CARDIAC	600958			GLU542GLN
MYOSIN-BINDING PROTEIN C, CARDIAC	602716		1-BP INS, 3250G	
	602716		2-BP DEL, 121CT	
	602716		2-BP INS, 1306AC	
	602716			ARG1109TER
Neuropeptide Y receptor Y1/NPY1R	M84755		none found	
Nicotinic, Cholinergic receptor beta 1	X14830	100710		LEU263MET
Nicotinic, Cholinergic receptor beta 1	X14830	100710		VAL266MET
Nicotinic, Cholinergic receptor epsilon polypeptide	X66403	100725		ARG147LEU
Nicotinic, Cholinergic receptor epsilon polypeptide	X66403	100725		ARG64TER
Nicotinic, Cholinergic receptor epsilon polypeptide	X66403	100725		LEU269PHE
Nicotinic, Cholinergic receptor epsilon polypeptide	X66403	100725		PRO121LEU
Nicotinic, Cholinergic receptor epsilon polypeptide	X66403	100725		THR264PRO

receptor epsilon polypeptide	163729	GLU298ASP
NITRIC OXIDE SYNTHASE 3		
NITRIC OXIDE SYNTHASE, MACROPHAGE, TYPE 2B	600719	none found
NITRIC OXIDE SYNTHASE, MACROPHAGE, TYPE 2C; NOS2C		
paraoxonase 1/PON1 (arylesterase)	600720	none found
paraoxonase 1/PON1 (arylesterase)	168820	CA repeat intron 4.
paraoxonase 1/PON1 (arylesterase)	168820	GLN192ARG
paraoxonase 1/PON1 (arylesterase)	168820	Leu55Met
paraoxonase 1/PON1 (arylesterase)	168820	MET54LEU
phenylethanolamine N-methyltransferase/PNMT	171190	BANI
Phospholipase A-2 (PLA-2) lung	172410	none found
Phospholipase A2, group IV	600522	none found
Phospholipase C beta-3	600230	none found
Phospholipase C, beta <sup>4</sup>	600810	none found
plasma cholesterol	118470	A1503G

ester transfer protein/CETP	78			
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G-A splice junction alternative splice	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G1696A	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	C-T transition in intron 12	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	EcoNI	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G-->A intron 14	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G-A transition in intron 15	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G1533A	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	INS T alternative (intron/exon14) splice	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	StuI	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	T-->G tyr57stop	

protein/CETP	NM_0000	118470	TaqIA	
plasma cholesterol	78			
ester transfer				
protein/CETP	NM_0000	118470	TaqIB in intron I	
plasma cholesterol	78			
ester transfer				
protein/CETP	NM_0000	118470		268 Arg-->STOP
plasma cholesterol	78			
ester transfer				
protein/CETP	NM_0000	118470		Asp 442 to Gly
plasma cholesterol	78			
ester transfer				
protein/CETP	NM_0000	118470		ASP442GLY
plasma cholesterol	78			
ester transfer				
protein/CETP	NM_0000	118470		G181X
plasma cholesterol	78			
ester transfer				
protein/CETP	NM_0000	118470		I405V
plasma cholesterol	78			
ester transfer				
protein/CETP	NM_0000	118470		Lys309-Stop
plasma cholesterol	78			
ester transfer				
protein/CETP	NM_0000	118470		R451Q
plasma cholesterol	78			
ester transfer				
protein/CETP	NM_0000	118470		Val421-Ile
plasma cholesterol	78			
ester transfer				
protein/CETP				



Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	11-BP DEL, EX12	
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	13-BP DEL AT INTRON-EXON BOUNDARY OF EXON 4	
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	4.5-KB DEL, EX2-9	
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	IVS15DS, G-A, +1	
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	IVS25AS, C-G, -3	
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800		ARG327HIS
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800		ARG584TER
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800		ASP426DEL
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800		GLU324LYS
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800		GLY273ASP

Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	GLY418ASP
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	ILE565THR
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	ILE843SER
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	LEU214PRO
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	VAL425DEL
Platelet-activating factor receptor	M76674	173393	none found
Potassium channel subunit (h-erg)	U04270	152427	1-BP DEL
Potassium channel subunit (h-erg)	U04270	152427	27-BP DEL
Potassium channel subunit (h-erg)	U04270	152427	IVS3, G-C, +1
Potassium channel subunit (h-erg)	U04270	152427	VAL822MET
Potassium channel subunit (h-erg)	U04270	152427	ALA561VAL
Potassium channel subunit (h-erg)	U04270	152427	ARG582CYS
Potassium channel subunit (h-erg)	U04270	152427	ASN470ASP

SD-144141.1

Potassium channel subunit (h-erg)	U04270	152427	GLY628SER
Potassium channel subunit (h-erg)	U04270	152427	ILE593ARG
POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2		603796	GLN9GLU
POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2		603796	ILE57THR
POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2		603796	MET54THR
progesterone receptor PROTEIN KINASE C, EPSILON	M15716	264080 176975	none found none found
PROTEIN KINASE, AMP-ACTIVATED, CATALYTIC, ALPHA-2		600497	none found
PROTEIN KINASE, AMP-ACTIVATED,		602743	none found

NONCATALYTIC, GAMMA-2; PRKAG2	M61831	180960	none found
S-adenosyl homocysteine hydrolase			
serotonin 5-HT receptors 5-HT1A, G protein-coupled	X57829	109760	Rsal
serotonin 5-HT receptors 5-HT4, G protein-coupled	Y08756	602164	none found
small inducible cytokine subfamily A (Cys-Cys), member 2/monocyte chemotactic protein 1/MCP1/SCYA2	M28226	158105	-2076 (A or T)
small inducible cytokine subfamily A (Cys-Cys), member 2/monocyte chemotactic protein 1/MCP1/SCYA2	M28226	158105	-2518 (G or A)
Solute carrier family 9 (sodium/hydrogen exchanger)	M81768	107310	none found
Steroid 5 alpha reductase 1	M32313	184753	none found
Superoxide dismutase 1 (Cu/Zn)	X02317	147450	
Superoxide Dismutase	NM_0004	147450	T-G, -10, 9-BP INS

1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450	VS4AS, A-G, -11		
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		ALA145THR	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		ALA4THR	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		ALA4VAL	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		ASP90ALA	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		CYS6PHE	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLU100GLY	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLU21LYS	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY16SER	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY37ARG	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY41ASP	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY41SER	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY72SER	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY85ARG	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY93ALA	
1/SOD1 (soluble)	54				

Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	GLY93CYS
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	HIS43ARG
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	HIS46ARG
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	ILE104THE
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	ILE113THR
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	LEU106VAL
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	LEU126TER
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	LEU144SER
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	LEU38VAL
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	LEU84VAL
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	SER134ASN
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	THR151ILE
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	Val7-->Glu
Superoxide Dismutase 2/SOD2 (mitochondrial)	X65965	147460	ALA16VAL
Tafazzin	300069	none found	
Thimet oligopeptidase	Z50115	601117	none found

SD-144141.1

Thrombopoietin	U70136	600044	1-BP DEL, 3252G
Thrombopoietin	U70136	600044	IVS3, G-C, +1
THROMBOSPONDIN		188062	none found
III			
Thromboxane synthase	M80646	274180	(CA)n intron 9
Tissue Plasminogen	M18182	173370	BglII
activator, tissue type (t-PA)			
Tissue Plasminogen	M18182	173370	EcoRI
activator, tissue type (t-PA)			
Tissue Plasminogen	M18182	173370	HincII
activator, tissue type (t-PA)			
Tissue Plasminogen	M18182	173370	polymorphic
activator, tissue type (t-PA)			dinucleotide intron 1
Tissue Plasminogen	M18182	173370	PstI
activator, tissue type (t-PA)			
Tissue Plasminogen	M18182	173370	TaqI
activator, tissue type (t-PA)			
Tissue Plasminogen	M18182	173370	XmnI
activator, tissue type (t-PA)			
Transferrin receptor	X01060	190010	BclI
(p90, CD71)			
Transferrin receptor	X01060	190010	RsaI
(p90, CD71)			
tRNA-LEU,		590050	3243A-G

MITOCHONDRIAL	590050	3250T-C	
trNA-LEU,			
MITOCHONDRIAL	590050	3251A-G	
trNA-LEU,			
MITOCHONDRIAL	590050	3252T-C	
trNA-LEU,			
MITOCHONDRIAL	590050	3256C-T	
trNA-LEU,			
MITOCHONDRIAL	590050	3260A-G	
trNA-LEU,			
MITOCHONDRIAL	590050	3271T-C	
trNA-LEU,			
MITOCHONDRIAL	590050	3303C-T	
trNA-LEU,			
MITOCHONDRIAL	590050	A3288G	
trNA-LEU,			
MITOCHONDRIAL	590050	G--> A 12301	
trNA-LEU,			
MITOCHONDRIAL	603310	none found	
Type V cyclic	AJ004865		
nucleotide			
phosphodiesterase			
type V voltage	NM_0003	600163	1-BP DEL frameshift
dependent sodium	35		
channel alpha			
subunit/SCN5A			
type V voltage	NM_0003	600163	2-BP INS
dependent sodium	35		
channel alpha			
subunit/SCN5A			
type V voltage	NM_0003	600163	



dependent sodium channel alpha subunit/SCN5A	35		LYS1505/PROI 506/GLN1507D EL
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_0003 35	600163	ARG1232TRP
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_0003 35	600163	ARG1623GLN
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_0003 35	600163	ARG1644HIS]
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_0003 35	600163	GLU1784LYS
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_0003 35	600163	THR1620MET
Vascular cell adhesion molecule 1	M60335	192225	none found
vitamin B12 receptor/cubilin/CUBN	NM_0010 81	602997	IVS6, C-G
vitamin B12 receptor/cubilin/CUBN	NM_0010 81	602997	PRO1297LEU

Table 24. Current Candidate Therapeutic Interventions for the Treatment of Cancer

Product Name	Latest Phase	Chemical Name	Action	Indication
2-chloro-2'-fluoro-vidarabine; 2-chloro-2'-fluoro-araA	Phase I			cancer
A 007	Phase I	bis(4-hydroxyphenyl)-(2,4-dinitrophenyl)-methanone, hydrazone		cancer
acemannan derivatives, Carrington	Preclinical			cancer
adozelesin; U 73975; ADOSAR	Phase II	(7bR)-N-[2-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl)carbonyl]-1H-indol-5-yl]-2-benzofurancarboxamide		cancer
AG 7352	Preclinical	(3S-trans)-1,4-dihydro-7-[3-methoxy-4-(methylamino)-1-pyrrolidiny]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid		cancer
aging-related disease therapy, Chiroscience/Geron	Preclinical			atherosclerosis; cancer; osteoporosis; diabetes; eye disease

AK 2123	Phase II	N-(2-methoxyethyl)-3-nitro-1H-1,2,4-triazole-1-acetamide	cancer	
alanosine	Phase II	L-2-amino-3-(hydroxynitrosoamino)-L-alanine	cancer	
alkyltransferase inhibitors, National Institutes of Health	Preclinical		cancer	
altretamine; hexamethylamine; hexamethylmelamine; KB 913; NSC 13875; HEXALEN; HEXASTAT; HEXINAWAS	Marketed	N,N,N',N'',N''',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine	cancer	
amonafide; nafidimide; MFA 142; FA 142	Discontinued	5-amino-2-(2-dimethylamine)ethyl-1H-benz[de]isoquinoline-1,3(2H)-dione	cancer	
amsacrine; CI 880; NSC 249992; NSC 156203; AMSIDYL; AMSIDINE; AMSEDINE; AMEKRIN	Marketed	N-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide	cancer	
ANCER	Marketed		cancer, leukopenia	
annonaceous acetogenins	Preclinical		cancer	
anticancer agent, Gryphon	Preclinical		cancer	

anticancer agent, Kyowa Hakko	Preclinical	[1aS-(1aalpha,8beta,8aalpha,8balpha)]-8-[[[(aminocarbonyl)oxy]methyl]-5-ethyl-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxyazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione]		cancer
anticancer agent, Paracelsian	Preclinical			cancer
anticancer agent, SOAD	Preclinical			cancer
anticancer agent, Xcyte Therapies	Preclinical			cancer
anticancer agents, Millennium	Preclinical			cancer
anticancer, Kitasato University	Preclinical	7,8-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one		cancer
anticancer, New York University	Preclinical	(1-methylethyl)carbamic acid (5,6-dihydro-8-methoxypyrrolo[2,1-a]isoquinoline-1,2-diy)bis(methylene) ester		cancer
anticancer, Sloan Kettering	Preclinical	3-[[bis(2-chloroethyl)-amino]methyl]-1,8-dihydroxy-9,10-anthracenedione		cancer

anticancer, Southern Research Institute	Preclinical	(1-alpha, 3-beta, 4-alpha)-2-amino-1,9-dihydro-9-(3-hydroxy-4-(phosphonomethyl)cylopentyl)-6H-purin-6-one	cancer	cancer
anticancer, Takeda	Discontinued	1-octadecyl-2-acetoacetyl-3-glycerol-omega-trimethylammonidecyl phosphate	cancer	cancer
anticancer, Yale University	Preclinical	1-(2-chloroethyl)-2,2-bis(methylsulfonyl)hydrazide	cancer	cancer
antiproliferative agents, Harvard University/Sheffield Medical	Phase I	methanesulfonic acid	cancer; restenosis; psoriasis; atherosclerosis	
antiproliferative therapy, SIDR	Preclinical		cancer	
AP 633	Discontinued		cancer	
AP 656	Discontinued		cancer	
aplidine	Phase I		cancer	
apoptosis modulators, Devgen	Preclinical		cancer; inflammation	
apoptosis regulators, Apoptosis Technology; apoptosis regulators, ICRF	Preclinical		cancer	

AQ6N	Discontinued	1-[[2-(dimethylamino-N-oxide)ethyl]-amino]-4-[[2(ethylamino)ethyl]amino]-5,8-dihydroxyanthracene-9,10-dione	cancer
arginine deaminase; CX 108	Preclinical		cancer
artificial platelets, Andaris; SYNTHOCYTES	Preclinical		thrombocytopenia; cancer
AT 3510	Preclinical		cancer
atrimustine; bestrabucil; busramustine; KM 2210; KREGAN	Discontinued	(17beta)-estra-1,3,5(10)-triene-3,17-diol 3-benzoate 17-[[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]acetate] ester	cancer

ATX 70	Preclinical	(SP-4-2)-[N,N'-[[[7,12-bis[1-(decyloxy)ethyl]-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-diyl-kappaN21,kappaN22,kappaN23,kappaN24]bis(1-oxo-3,1-propanediyl)]bis[L-aspartato]](6-)]gallate (3-) trihydrogen		depression; cancer
AV 109	Discontinued			cancer
AV 21; PM 92100	Preclinical	Unspecified		cancer
azatyrosine; SF 1346	Discontinued	(S)-alpha-amino-5-hydroxy-2-pyridinepropanoic acid		cancer
azinomycin A	Discontinued	6-(3-acetoxy-4-hydroxy-1,5-methylenepyrrolidin-2-ylidene)-2,2(oxymethylene)-5,8-diaza-4,7,10-trioxo-undecyl-3-methoxy-5-methyl-1-naphthalenesboxylate		cancer
azinomycin B	Discontinued			cancer
BCH 1184	Discontinued			cancer
BCH 1667	Discontinued			cancer
BCH 2050	Discontinued			cancer
BD 95325	Discontinued			cancer

BE 12406B	Discontinued			cancer
BE 18591	Discontinued	N-[[3-methoxy-5-(1H-pyrrrol-2-yl)-2H-pyrrrol-2-ylidene]methyl]-1-dodecanamine		cancer
benzeneacetic acid ester	Phase I	alpha-(benzyloxy)-alpha-cyclopentyl-benzeneacetic acid, 1-methyl-4-piperidinyl ester		cancer
bFGF inhibitor, PharmaGenics	Discontinued			cancer; cardiovascular disease
bistratene A; bistramide A	Preclinical	tetrahydro-N-[2-hydroxy-4-[[[3-[8-(6-hydroxy-3,5-dimethyl-4-heptenyl)-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]propyl]amino]-3-methyl-4-oxobutyl]-3-methyl-6-(2-oxo-3-pentenyl)-2H-pyran-2-acetamide		cancer
BMOV	Preclinical	bis(maltolato)orthovanadate		cancer



BMS 181174; BMY 25067	Discontinued	[[1aS-(1aalfa,8beta,8aalfa,8balfa)]-8-[[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-6-[[2-[(4-nitrophenyl)dithio]ethyl]amino]azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione		cancer
BMS 181175	Discontinued			cancer
BMS 181176	Discontinued			cancer
BMS 185660; BMS 18566002	Discontinued			cancer
BMY 27577	Discontinued			cancer
BN 52205	Discontinued	4-hydroxy-7-(methoxymethyl)-N,N,N,8-tetramethyl-3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium 4-oxide inner salt		cancer
BN 52207	Discontinued	4-hydroxy-6-(methoxymethyl)-N,N,N,8-tetramethyl-3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium 4-oxide inner salt		cancer

BN 52208	Discontinued	8-hydroxy-N,N,N-trimethyl-5-[(methyloctadecylamino)methyl]-3-oxo-4,7,9-trioxa-2-aza-8-phosphaundecan-11-aminium 8-oxide inner salt		cancer
BN 52210	Discontinued			cancer
BN 52211	Discontinued	4-hydroxy-7-methoxy-N,N,N,9-tetramethyl-3,5-dioxa-9-aza-4-phosphaheptacosan-1-aminium 4-oxide inner salt		cancer
BN 52213	Discontinued			cancer
BN 52214	Discontinued			cancer
BNP 7787; dimesna	Phase I	2,2'-dithiobisethanesulfonic acid disodium salt		cancer
brain tumor therapy, John Wayne Cancer Institute	Phase II			cancer
breast and ovarian cancer therapy, Myriad/Lilly	Preclinical			cancer
breast cancer therapy, Affymax/American Home Products	Preclinical			cancer
breast cancer therapy, Taiho/SRI International	Preclinical			cancer

BW 773U82; 773U82	Discontinued	2-[(3-fluorantheny(methyl)amino)-2-methyl-1,3-propanediol]		cancer
C 1006	Preclinical	N-hexyl-N'-(1-nitro-9-acridinyl)-1,3-propanediamine dihydrochloride		cancer
C 1210S	Discontinued			cancer
C 609	Preclinical	N,N-dimethyl-N'-(1-nitro-9-anthracenyl)-1,5-pentanediamine dihydrochloride		cancer
C 835	Preclinical	2,2'-[[2-[(1-nitro-9-acridinyl)amino]ethyl]imino]bis-ethanol		cancer
CA 102	Discontinued			cancer
cancer therapy polymers, Cornell Research Foundation	Preclinical			cancer
cancer therapy, Agouron	Preclinical			cancer
cancer therapy, ASP 05/ASP 07	Preclinical			cancer
cancer therapy, brca 2 gene, Cancer Research Campaign	Preclinical			cancer
cancer therapy, Bristol-Myers Squibb/lxsys	Preclinical			cancer

cancer therapy, Cambridge NeuroScience/Repligen	Preclinical				cancer
cancer therapy, Cell Pathways/Tripos/Panlabs	Preclinical				cancer
cancer therapy, CellPath/Genzyme	Preclinical				cancer
cancer therapy, Chiroscience	Discontinued				cancer
cancer therapy, cytolognans	Phase I				cancer
cancer therapy, Duke University/Targon	Preclinical				cancer
cancer therapy, Galenica/SuperGen	Preclinical				cancer
cancer therapy, GenQuest/ArQule	Preclinical				cancer
cancer therapy, Genzyme	Preclinical				cancer
cancer therapy, Genzyme/Xenova	Preclinical				cancer
cancer therapy, Hughes Institute/Minnesota University	Preclinical				cancer
cancer therapy, ImClone/CombiChem	Preclinical				cancer
cancer therapy, Ku80, Lexicon Genetics	Preclinical				cancer

cancer therapy, Lilly; cancer therapy, Millennium	Preclinical				cancer
cancer therapy, modulators of Rad 51/Brca2 signalling pathway, Lexicon Genetics	Preclinical				cancer
cancer therapy, National Cancer Institute	Preclinical				cancer
cancer therapy, NeoGenesis	Preclinical				cancer
cancer therapy, NOVALON	Preclinical				cancer
cancer therapy, Ontogeny/Brigham & Women's Hospital	Preclinical				cancer
cancer therapy, Ontogeny/University of California San Francisco	Preclinical				cancer
cancer therapy, Pharmacopeia	Preclinical				cancer
cancer therapy, PharmaMar	Preclinical				cancer
cancer therapy, Phytera/Chiron	Preclinical				cancer
cancer therapy, polymeric prodrug	Preclinical				cancer
cancer therapy, Prolifix/BioFocus	Preclinical				cancer

cancer therapy, reovirus, SYNSORB Biotech	Preclinical				cancer
cancer therapy, Shinpoong	Preclinical				cancer
cancer therapy, spiegelmer, Noxxon	Preclinical				cancer
cancer therapy, SUGEN/Zeneca	Preclinical				cancer
cancer therapy, Toyama/Sugen	Preclinical				cancer
CaRest M3	Preclinical				cancer; contraception
CB 10200	Preclinical		5-(aziridin-1-yl)-2,4- dinitro-1- isobutylbenzoate		cancer
CB 10277; CB 10- 277	Phase II		4-(3,3-dimethyl-1- triazenyl)benzoic acid		cancer
CB 7646	Preclinical		[[6-(methylamino)- 1,3,5-triazine-2,4- diyl]]bis(methylimino) ]]bismethanol		cancer
CBT 1	Preclinical				malaria; cancer
CCI 779	Phase I				cancer
CD36 inhibitors, Affymax	Preclinical				cancer
CDC 25	Discontinued				cancer
CDF inhibitor, Prolifix	Preclinical				cancer; psoriasis
cell cycle inhibitors, Cortex	Discontinued				cancer
cell cycle regulators, Janssen/Rigel	Preclinical				cancer

cell cycle regulators, Onyx; cell cycle regulators, Warner Lambert	Preclinical			cancer	
CH 271	Preclinical			cancer	
chloroquinoxaline sulfonamide; chloresulfamoxaline ; NSC 339004; CQS	Phase I	4-amino-N-(5-chloro- 2- quinoxaliny)benzene sulfonamide		cancer	
chronic myelogenous leukemia therapy, OSI/Aston Molecules; CML therapy, OSI/Aston Molecules	Discontinued			cancer	
CHS 828	Phase I	N-[6-(4- chlorophenoxy)hexyl] -N'-cyano-N''-4- pyridiny]guanidine		cancer	
CIDI	Preclinical			cancer	
CL 329753	Discontinued	alpha-(3,4- dimethoxyphenyl)- 3,4-dihydro-6,7- dimethoxy-alpha-[(4- methylphenyl)thio]- 2(1H)- isoquinolineheptanenit rile		cancer	
clanfenur; DU 113901	Discontinued	1-(p-chlorophenyl)-3- (6-fluoro-N,N- dimethylanthraniloyl) urea		cancer	

cloturin; VUFB 15686	Suspended	(2-chloroethyl)carbamot hiolic acid, S-1H- purin-6-yl ester		cancer
colon cancer therapy, Onyx	Preclinical			cancer
combretastatin A4; NSC 817373; CRC 8709; CRC 87-09	Preclinical	(Z)-2-methoxy-5-[2- (3,4,5- trimethoxyphenyl)eth enyl]phenol		cancer
combretastatin A4 prodrug	Phase I			cancer
CP 79328	Preclinical	2- [(aminoiminomethyl) amino]-N-(5-fluoro- 2-benzothiazolyl)-4- thiazolecarboxamide		cancer



crambesidin 816; PM 92105	Preclinical	[2'aS- [2'a.alpha.,4'.alpha.(R *),7'.alpha.(S*),8'.bet a.(R*),8'a.alpha.]]-7- ethyl- 1',2',2'a,3',3",4,4",5",6' ,7,8',8'a- dodecahydro-8'a- hydroxy-6"- methylspiro[oxepin- 2(3H),4'-[4H- 5,6,8b]triazacenaphy nylene-7'(5'H),2"- [2H]pyran-8'- carboxylic acid 16- [(4-amino-2- hydroxybutyl)(3- aminopropyl)amino]- 16-oxohexadecyl ester		cancer
	CT 1537X	Discontinued		cancer
	CT 1595	Discontinued		cancer
	CT 3501	Discontinued		cancer; restenosis
	CTC 119	Preclinical	2,4 dihydroxymethyl- alpha-terthiophene	cancer
curacin A	Preclinical		4,5-dihydro-4-(11- methoxy-8-methyl- 1,5,7,13- tetradecatetraenyl)-2- (2- methylcyclopropyl)- thiazole	cancer
	CYC 300	Preclinical		cancer

cyclin D inhibitor, Prolifix	Preclinical			cancer
cyclopentenylcytosine; CPEC	Preclinical	4-amino-1- [(1R,4R,5S)-4,5- dihydroxy-3- (hydroxymethyl)-2- cyclopent en-1-yl]- 2(1H)-pyrimidinone		cancer
D 20133	Discontinued	octadecyl-(2-(N- methylpiperidino)ethyl- yl)-phosphate		cancer
D 20566	Discontinued			cancer
D 20567	Discontinued			cancer
D 21621	Discontinued			cancer
D 21663	Discontinued			cancer
D 21805	Discontinued	[2- [[[hydroxy(octadecylo xy)phosphinyl]oxy]et hyl]trimethylarsoniu m inner salt		cancer
D 23980	Discontinued			cancer
DA 3030; LEUCOSTIM	Pre- registration			leukopenia; cancer
daniquidone; batracylin; BAY h 2049; NSC 320846	Discontinued	8- aminoisindolo[1,2- b]quinazolin- 12(10H)-one		cancer
datelliptium chloride; SR 95156B; NSC 311152; SR 95156	Discontinued	2-[2- (diethylamino)ethyl]- 9-hydroxy-5,11- dimethyl-6H- pyrido[4,3- b]carbolium chloride		cancer

decitabine; 5-azadeoxycytidine; 5-aza-2'-deoxycytidine; 5-CdR; AZA-DC; DAC; NSC 127716	Phase II	4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2 (1H)-one	cancer	
dexifosfamide; D 4809	Discontinued	N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine, 2-oxide	cancer	
dexverapamil; verapamil, d-; verapamil, R-(+)-; verapamil, (R)-; verapamil, (+)-; LU 33925	Phase II	(R)-alpha-[3-[[[2-(3,4-dimethoxyphenyl)ethyl]methoxymethyl]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile	cancer	
diaziquone; AZQ; CI 904; NSC 182986	Phase III	[2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl]biscarbamic acid diethyl ester	cancer	

diazonomide A	Preclinical	2-amino-N-[1,26-dichloro-17,18,19,20-tetrahydro-12,31-dihydroxy-20-(1-methylethyl)-18-oxo-2H,16H-24,27-epoxy-10a,6,10-(methanoxymethyno)-11,15-metheno-23,21-nitrilo[1,4]oxazacyclotetradecino[14,13-g]pyrrolo[2,3,4-rs][4]benzaazacyclopentadecin-17-yl]-3-methylbutanamide	cancer
differentiation-inducing compounds, Prolifix	Discontinued		cancer, psoriasis; restenosis
dihydro-5-azacytidine; DHAC	Phase II		cancer
DIP C1	Preclinical	N,N,N',N'-tetrakis(2-chloroethyl)-4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diamine	cancer
diphenyl spiromustine	Preclinical	3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione diphenyl derivative	cancer
distamycin A derivatives, Menarini	Discontinued		cancer

DNA binding agent, Proteus International	Discontinued			bacterial infection; viral infection; cancer; cardiovascular disease
DNA methyltransferase modulators	Preclinical			cancer
docosahexaenoic acid, Heliosynthese; docosahexaenoic acid, Scotia	Discontinued			cancer
DPPE	Phase II	N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine		cancer; gastrointestinal ulcer
drug delivery system, albumin microcapsules, cytotoxic drugs; CYTOCAPS	Preclinical			cancer; delivery system
drug delivery system, aphidicolin; aphidicolin SPARTAJECT	Preclinical			cancer
drug delivery system, biodegradable polymer paste BMOV; BMOV biodegradable polymer paste	Preclinical			cancer

drug delivery system, chemotherapeutic drugs, ImaRx; MRX-ONC	Preclinical			cancer
drug delivery system, colonic polyp therapy	Phase I			cancer
drug delivery system, intravenous, SPARTAJECT temozolomide; temozolomide SPARTAJECT	Preclinical			cancer
drug delivery system, mitoxantrone; mitoxantrone delivery system; HYAL CV1282	Phase II			cancer
drug delivery system, PepTrans, cancer therapy	Preclinical			cancer
drug delivery system, Polyfunctional Molecular Modification, etoposide; etoposide Polyfunctional Molecular Modification	Preclinical			cancer
drug delivery system, SPARTAJECT busulfan; busulfan SPARTAJECT	Phase I			cancer

drug delivery system, SPARTAJECT etoposide; etoposide SPARTAJECT	Preclinical			cancer
DT 5461	Discontinued	3-[[2-deoxy-6-O-[2-deoxy-3-O-[[[(1-oxododecyl)amino]acetyl]-2-[(1-oxotetradecyl)amino]-4-O-phosphono-beta-D-glucopyranosyl]-3-O-[[[(1-oxododecyl)amino]acetyl]-2-[(1-oxotetradecyl)amino]alpha-D-glucopyranosyl]oxy]pentanedioic acid		cancer
ecomustine; NSC 609224; CY 233	Preclinical	methyl 3-[3-(2-chloroethyl)-3-mitrosoureido]-2,3-dideoxy-alpha-D-arabinohexapyranoside		cancer

ecteinascidin 722; ET 722	Preclinical	[6R-(6alpha,6beta,7beta,13beta,14beta,16alpha,20R*)]-5-(acetyloxy)-2',3',4',6,6a,7,9',13,14,16-decahydro-8,14-dihydroxy-9-methoxy-4,10-dimethylspiro[6,16-(epithiopropoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquinol-3,2-b][3]benzazocine-20,1'-[1H]pyrido[3,4-b]indol]-19-one		cancer
---------------------------	-------------	--	--	--------



<p>ecteinascidin 729; ET 729; E 729; NSC 638718</p>	<p>Preclinical</p>	<p>[6R-(6alpha,6beta,7beta,13beta,14beta,16alpha,20R*)]-5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10-dimethylspiro[6,16-(epithiopropoxy)methano]-7,13-imino-12H-1,3-dioxolo[7,8]isoquinol[3,2-b][3]benzazocine-20,1'(2H)-isoquinolin]-19-one</p>		<p>cancer</p>
---	--------------------	--	--	---------------

ecteinascidin 743; ecteinascidin 743 monoacetyl; ET 743; E 743	Phase II	[6R-(6alpha,6abeta,7beta,13beta,14beta,16alpha,20R*)]-5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethylspiro[6,16-(epithiopropoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquinol-3,2-b][3]benzazocine-20,1'(2H)-isoquinolin]-19-one	cancer	
ED 749; J 107088	Preclinical		cancer	
eflornithine; eflornithine hydrochloride; DFMO; RMI 71782; MDL 71782; MDL 71782A; ORNIDYL	Marketed	2-(difluoromethyl)-DL-ornithine	cancer; trypanosomiasis; skin disease	
EKI 785	Preclinical		cancer	
EL 532	Phase III		anemia; cancer	
elemene	Registered		cancer	

emitefur; BOF A2; LAST-F	Pre- registration	3-[[3-(ethoxymethyl)- 5-fluoro-3,6-dihydro- 2,6-dioxo-1(2H)- pyrimidinyl]carbonyl] benzoic acid 6- (benzoyloxy)-3- cyano-2-pyridinyl ester		cancer
eupenifeldin	Discontinued			cancer
FA 15	Preclinical	3-trifluoromethyl-9- (4-diethylamino-1- methylbutylamino) acridine		cancer
FCE 26492	Preclinical	4,4'- [carbonylbis[imino(1- methyl-1H-pyrrole- 4,2- diyl)carbonylimino(1- methyl-1H-pyrrole- 4,2- diyl)carbonylimino]]b is-1,5- naphthalenedisulfonic acid		cancer

FCE 26605	Preclinical	8,8'-[carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diy)]carbonylimino(1-methyl-1H-pyrrole-4,2-diy)]carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt		cancer
FCE 26752	Preclinical			cancer
FD 211	Preclinical	3,5,7,7a-tetrahydro-3-hydroxy-5,7-di-1-propenyl-2H-furo[3,4-b]pyran-2-one		cancer
FJ 776	Phase I			cancer
FK 973	Discontinued			cancer
fludarabine + pentostatin; pentostatin + fludarabine	Discontinued			cancer
flurbiprofen, (R)-; E 7869	Phase II			cancer
FO 152	Discontinued	L-valine 5'-ester with 5-fluorouridine monohydrochloride		cancer

FOLLIGEN	Preclinical	6-D-phenylalanine-8-L-glutamine-9-(N-ethyl-L-prolinamide)-10-deglycinamide luteinizing hormone-releasing factor (swine)	cancer
fosquidone; GR 63178A; NSC D 611615	Discontinued	benzyl 5,8,13,14-tetrahydro-14-methyl-8,13,dioxobenz[5,6]isobindolo[2,1-b]isoquinolin-9-yl ester	cancer
galocitabine; neofrutulon; Ro 091390; Ro 91390	Phase III	5'-deoxy-5-fluoro-N-(3,4,5-trimethoxybenzoyl)cytidine	cancer
GAP 31	Preclinical	N-[N-[N-[N-(N-L-lysylglycyl)-L-alanyl]-L-threonyl]-L-tyrosyl]-L-L-isooleucyl]-L-threonine	HIV infection; cancer
GBC 590; NCCG	Phase I		cancer
gene discovery, angiogenesis, Progenitor	Preclinical		cancer; cardiovascular disease; eye disease; skin ulcer
gene discovery, breast & prostate cancer	Preclinical		cancer
gene discovery, breast cancer, Amplicon	Preclinical		cancer

gene discovery, cancer	Preclinical				cancer
gene discovery, cancer	Preclinical				cancer
gene discovery, cancer, AlphaGene	Preclinical				cancer
gene discovery, cancer, Chiron/Hyseq	Preclinical				cancer
gene discovery, cancer, CuraGen	Preclinical				cancer
gene discovery, cancer, deCODE genetics	Preclinical				cancer
gene discovery, cancer, Genaissance/Visible Genetics	Preclinical				cancer
gene discovery, cancer, Genetica/Mitotix	Preclinical				cancer
gene discovery, cancer, Genome Pharmaceuticals	Preclinical				cancer
gene discovery, cancer, Genos Biosciences	Preclinical				cancer
gene discovery, cancer, Genzyme	Preclinical				cancer
gene discovery, cancer, Incyte/OncorMed	Discontinued				cancer
gene discovery, cancer, LifeSpan	Preclinical				cancer

gene discovery, cancer, Micromet	Preclinical				cancer
gene discovery, cancer, Tularik/Amplicon	Preclinical				cancer
gene discovery, colorectal cancer, Myriad	Preclinical				cancer
gene discovery, connective tissue disorders	Preclinical				cancer; diabetes; obesity; autoimmune disease
gene discovery, growth factors, CuraGen	Preclinical				cancer
gene discovery, head and neck cancer	Preclinical				cancer
gene discovery, immunomodulatory genes, asthma, Genelabs	Preclinical				asthma; cancer
gene discovery, liver cancer, GeneCore	Preclinical				cancer
gene discovery, lymphoma, Myriad	Preclinical				cancer
gene discovery, p21 ras signalling pathway, Exelixis	Preclinical				cancer
gene discovery, pancreatic cancer	Preclinical				cancer
gene discovery, prostate and colon cancer, Millennium	Preclinical				cancer

gene discovery, prostate cancer, Amplicon	Preclinical			cancer
gene discovery, prostate cancer, Gene Logic	Preclinical			cancer
gene discovery, prostate cancer, GenSet/Sanofi-Synthelabo	Preclinical			cancer
gene discovery, prostate cancer, Myriad/Schering Plough	Preclinical			cancer
gene discovery, prostate cancer, Progenitor	Preclinical			cancer
genetic suppressor elements, cancer	Preclinical			cancer
GM 1603	Preclinical			cancer
granulocyte colony-stimulating factor mimetic; G-CSF mimetic	Discontinued			cancer
GRB2 antagonists	Preclinical			cancer
growth factor inhibitor, GlycoTech	Preclinical			cancer
growth hormone releasing hormone antagonists; GHRH antagonists	Preclinical			cancer



guanine derivatives, National Cancer Institute	Phase I			cancer	
GW 278884; BW 668W95	Preclinical			cancer	
thalomon; NSC 650893	Suspended	(3S,6R)-6-bromo-3-(bromomethyl)-2,3,7-trichloro-7-methyl-1-octene		cancer	
hatomarubigin A; CE 33A	Preclinical	(S)-3,4-dihydro-6-hydroxy-8-methoxy-3-methylbenz[a]anthracene-1,7,12(2H)-trione		cancer	
hatomarubigin B; CE 33B	Preclinical	(S)-3,4-dihydro-11-hydroxy-8-methoxy-3-methylbenz[a]anthracene-1,7,12(2H)-trione		cancer	
hatomarubigin C; CE 33C	Preclinical	(1S-cis)-1,2,3,4-tetrahydro-1,11-dihydroxy-8-methoxy-3-methylbenz[a]anthracene-7,12-dione		cancer	

thiomarubigin D; CE 33D	Preclinical	[1S-[1alpha,3alpha,10(1'R*,3'R*)]]10,10'-methylenebis[1,2,3,4-tetrahydro-1,11-dihydroxy-8-methoxy-3-methylbenz[a]anthracene-7,12-dione		cancer
heat shock transcription factor modulators, ischemia; heat shock transcription factor modulators, cancer	Preclinical			stroke; ischemia; reperfusion injury; cancer
hepsulfam; NSC 329680	Discontinued	1,7-heptanediol-bis-sulfamate		cancer
HO 221	Discontinued	N-[[[4-[(5-bromo-2-pyrimidinyl)oxy]-3-chlorophenyl]amino]carbonyl]-2-nitrobenzamide		cancer
holmium 166 chitosan; DW 166HC	Phase II			cancer; rheumatoid arthritis
HPV E2 inhibitor, Signal	Preclinical			viral infection; cancer
HPV E6 inhibitors, PharmaGenics	Discontinued			cancer
HRP monomer	Preclinical			cancer
human fetal alpha fetoprotein; alpha fetoprotein; DDS-DEA	Marketed			cancer

human papilloma virus 16 inhibitor, Xenova	Discontinued			cancer; viral infection
ICC 03	Discontinued			cancer
ICI 198583	Suspended	2-desamino-2-methyl-N10-propargyl-5,8-dideazafoolic acid		cancer
ICO 15	Discontinued			cancer
ifosfamide + methylene blue; methylene blue + ifosfamide; D 7991	Discontinued			cancer
IKP 104	Preclinical	1-(2-chloro-3,5-dimethoxyphenyl)-2-(4-fluorophenyl)-3-methyl-6-phenyl-4(1H)-pyridinone		cancer
IL 101	Preclinical			cancer
IL-6 production inhibitors, Signal	Preclinical			osteoporosis; cancer
IndH (RuInd2C14)	Preclinical	trans-indazolium-bisindazoletrachlororuthenate III		cancer
inhibitor of mevalonate incorporation into cholesterol; IMIC	Discontinued			cancer; hyperlipidemia
ipomeanol, 4; 4-ipomeanol; IPO; NSC 349438	Phase I	1-(3-furanyl)-4-hydroxy-1-pentanone		cancer
isobengazole	Discontinued			cancer

isohomohalicondrin B	Discontinued	51-de(carboxymethyl)-12,13-dideoxy-51-(4-hydroxy-2-oxobutyl)norhalicondrin A	cancer	
IZP 94002; PHOSPHONATE	Preclinical		cancer	
JP 7	Preclinical		cancer; surgery; heart ischemia; stroke	
kahalalide F; PM 92102	Preclinical	N-(5-methyl-1-oxohexyl)valylthreonylvalylvalyl-D-prolyl-L-ornithyl-D-alloisoleucylthreonyl-D-alloisoleucylvalyl-L-phenylalanyl-(Z)-2,3-didehydro-2-aminobutanoyl-valine rho-lactone	cancer; viral infection	
Kaposi's sarcoma-associated herpes virus (KSHV) infection therapy	Preclinical		herpes; cancer	
KI 414	Preclinical	5'-O-(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methylneuraminosyl)-5-fluoro-2',3'-O-(1-methylethylidene)uridine	cancer	

kinesin modulator, Cytokinetics	Preclinical			cancer
KNK 41	Preclinical	(all-E)-5-hydroxy-4-(8-phenyl-1,3,5,7-octatetraenyl)-2(5H)-furanone		cancer
KT 6124	Discontinued	(9alpha,10alpha,12alpha)-2-amino-9,10,11,12-tetrahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1,3(2H)-dione		cancer
KW 2149; KT 6149	Phase I	7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C		cancer
KW 2170	Phase I			cancer
KYN 54	Discontinued	5-hydroxy-4-(2-phenyl-(E)-ethenyl)-2(5H)-furanone		cancer
LAC 83	Preclinical			cancer

lamellarin-N triacetate	Discontinued	(+)-3,11- bis(acetyloxy)-14-[3- (acetyloxy)-4- methoxyphenyl]- 2,12-dimethoxy-6H- [1]benzopyrano[4',3': 4,5]pyrrolo[2,1- a]isoquinolin-6-one	cancer
LDI 200	Phase III		cancer
lisoclinamide 7	Preclinical	[3R- (3R*,4S*,7R*,11R*,1 4R*,18R*,21S*,26aS *)]- 6,7,12,13,14,17,18,20 ,21,24,25,26,26a- decahydro-3-methyl- 7-(1-methylethyl)- 16,21- bis(phenylmethyl)- 3H,10H- 4,1:11,8:18:15- trinitrilo-1H- pyrrolo[2,1- c][1,1,18,4,7,14,21]o xadithiatetraazacyclot etracosine- 5,12,19,22(4H,11H)- tetrone	cancer
lombricine	Discontinued	L-serine 2- [(aminoinomethyl) amino]ethyl hydrogen phosphate (ester)	cancer

lonidamine; diclonazolic acid; AF 1890; KN 228; DORADAMINA	Marketed	1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid	cancer
LY 195448	Discontinued	(R)-4-[3-[(2-hydroxy-2-phenylethyl)amino]-3-methylbutyl]benzamide monohydrochloride	cancer
LY 296329; 296329	Preclinical		cancer
LY 320236	Phase I	(4aR-trans)-8-[(4-ethyl-2-benzothiazolyl)thio]-1,4,4a,5,6,10b-hexahydro-4,10b-dimethylbenzo[f]quinolin-3(2H)-one	benign prostate hypertrophy; cancer
lysolecitin; lysolecithin; T 680	Discontinued		cancer
mammasatin	Phase I	Unspecified	cancer

MC 77	Preclinical	[1aS-(1aalfa,8beta,8aalfa,8balfa)]-8-[[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-6-[[4-[(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)oxy]phenyl]amino]azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione		Cancer
MDL 27048	Suspended	(E)-1-(2,5-dimethoxyphenyl)-3-[4-(dimethylamino)phenyl]-2-methyl-2-propen-1-one		cancer
melanoma therapy, Ventana Genetics	Preclinical			cancer
melarsoprol; RP 3854	Marketed	2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiar solane-4-methanol		cough; cancer
MEN 10710	Discontinued			cancer
merbarone; V 1235; NSC 336628; NSC 336028	Phase II	hexahydro-4,6-dioxo-N-phenyl-2-thioxo-5-pyrimidinecarboxamide		cancer
METCYCLOR	Preclinical			cancer



MGI 222	Discontinued			cancer
MGI 650	Discontinued			hyperammonemia; cancer
MIF inhibitor, NIH; macrophage migration inhibitory factor inhibitor, NIH	Preclinical			cancer
mitoflaxone; flavone acetic acid; FAA; LM 975; NSC 347512	Discontinued	4-oxo-2-phenyl-4H-1- benzopyran-8-acetic acid		cancer
mitomycin analogues, Georgetown University	Discontinued			cancer
mitoxantrone; CL 232315; NSC 279836; NSC 301739; DHAQ; DHAD; NOVANTRONE; NOVATRON	Marketed	1,4-dihydroxy-5,8- bis[[2-[(2- hydroxyethyl)amino]e thyl]amino]-9,10- anthracenedione		cancer; multiple sclerosis
MM-COOK	Preclinical	4-(3-methyl-1- triazenyl)benzoic acid, monopotassium salt		cancer
mofarotene; Ro 408757	Discontinued	(E)-4-[2-[4-[2- (5,6,7,8-tetrahydro- 5,5,8,8-tetramethyl-2- naphthalenyl)-1- propenyl]phenoxy]eth yl]morpholine		cancer

monophosphoryl lipid A + trehalose dimycolate; trehalose dimycolade + monophosphoryl lipid A; MPL + THD; OVAMID	Discontinued				cancer
mopidamol; RA 233; OLX 102; AR 102; RAPENTON	Withdrawn	2,2',2''-(4- piperidinopyrimido[5, 4-d]pyrimidine-2,6- diyl)dinitrilo]tetraetha nol			cancer
MPC 467	Preclinical				cancer
MS 247	Preclinical	[3-[[5-[5-[[[4-[bis(2- chloroethyl)amino]phe nyl]amino]carbonyl]- 1H-benzimidazol-2- yl]-1-methyl-1H- pyrrol-3-yl]amino]-3- oxopropyl]dimethylsu lfonium mono(4- methylbenzenesulfon ate) salt with 4- methylbenzene sulfonic acid (1:1)			cancer
MSI 1290	Discontinued				cancer
MSI 130	Discontinued				cancer; gastrointestinal disorder
MSI 1436	Discontinued				viral infection; restenosis; diabetes; cancer
MSI 511	Discontinued				cancer

MSI 58	Discontinued			cancer
MSI 782	Discontinued			cancer
MSI 99	Discontinued			cancer
MT 1	Suspended			cancer
MT 2	Preclinical			cancer
multiple drug resistance gene inhibitor, Immunex	Preclinical			cancer
mustard anticancer agent; NORPRAN	Preclinical			cancer
MX 6; MX6	Phase III			cancer
mycaperoxide B; PM 92104	Discontinued	[1R- [1alpha,1[3S*(S*),6S *],2alpha,4aalpha,8ab eta]]-6-[2- (decahydro-1- hydroxy-2,5,5,8a- tetramethyl-1- naphthalenyl)ethyl]- alpha,6-dimethyl-1,2- dioxane-3-acetic acid		cancer
mycobacterial cell wall extract; MCWE; REGRESSIN	Phase II			cancer
myriaporone	Discontinued			cancer
N 1554	Discontinued	(all-E)- 3,7,11,15,19,23,27,31 ,35,39-decamethyl- 6,10,14,18,22,26,30,3 4,38- tetracontanonaen-1-ol dihydrogen phosphate		cancer

N-acetylalinaline; acetylalinaline; CI 994; GOE 5549; PD 123654	Phase II	4-(acetylalino)-N-(2-aminophenyl)benzamide	cancer
NC 381	Preclinical		cancer
NC 383	Preclinical		cancer
NC 384	Preclinical		cancer
NC 407	Preclinical		cancer
melarabine; melzarabine; 506U78; BW 506U; MAY; 506U	Phase III	9-beta-D-arabinofuranosyl-6-methoxy-9H-purin-2-amine	cancer
NIK 264	Phase I		cancer
NK 242	Preclinical	4-(5,6-dihydro-1,4-dioxin-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid bis[3-(3-pyridinyl)propyl] ester	cancer
NK 250	Preclinical	4-(5,6-dihydro-3-methyl-1,4-dithiin-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid bis(4-pyridinylmethyl) ester	cancer

NK 252	Preclinical	4-(5,6-dihydro-1,4-dioxin-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid bis[(5-ethyl-2-pyridinyl)methyl] ester	cancer	
NM 324	Phase I	2-[[[hydroxy[[12-[3-(iodo-125I)phenyl]dodecyl]oxy]phosphinyl]oxy]-N,N,N-trimethylethanaminium inner salt	cancer	
moscapine; narcosine; methoxyhydrastine; opian; opianine; NSC 5366; COSCOPIN; COSCOTABS; CAPVAL; KEY-TUSSCAPINE; NOSCAPAL; TERBENOL	Marketed		cough; cancer	
notch signalling pathway modulators, Exelixis	Preclinical		stroke; cognitive defect; cancer	
NSC 242557	Preclinical	[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]propanedinitrile	cancer	

NSC 303861	Discontinued	S-(N-methylcarbamate)-L-cysteine, ethyl ester, monohydrochloride	cancer
NSC 361456	Phase I	N-mitosopyrazinamine, sodium salt	cancer
NSC 639829	Preclinical	dimethyl amino benzoylphenylurea	cancer
NSC 650573	Preclinical	(Z)-2-methyl-9-(phenylimino)naphth[2,3-d]oxazol-4(9H)-one	cancer
NSC 686288	Preclinical	5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methyl-4H-1-benzopyran-4-one	cancer
OC 144093	Preclinical		cancer
OCT 1001	Preclinical	6-amino-1,2-benzopyrone	viral infection; cancer
okicenone	Preclinical	3,4-dihydro-4,6,9-trihydroxy-8-methyl-1(2H)-anthracenone	cancer
OLX 516	Discontinued		septic shock; cancer; vascular leakage
ONO FS045	Discontinued		cancer
oracin; VUFB 16956	Phase I	6-[2-[(2-hydroxyethyl)amino]ethyl]-5H-indeno[1,2-c]isoquinoline-5,1(6H)-dione	cancer

oral cytokine inducer, Immunex	Phase I				cancer; leukopenia
P 154	Preclinical				cancer
p185 inhibitors, University of Pennsylvania	Preclinical				cancer
p53 function activators, Genzyme	Preclinical				cancer
p53 mimetic, BioNumerik	Preclinical				cancer
p53/MDM2 interaction inhibitor, Genzyme	Preclinical				cancer
PA 8	Preclinical	2,2'-[(1,1,3,3- tetraethyl-1,3- distannoxanediyl)]bis( oxycarbonyl)]bis[4- methoxyphenol]			cancer
palauamine	Discontinued	[3aalpha,10alpha,11 beta,12beta,13beta(S* ,13aalpha,13bR*)-(- )2,2'-diamino-11- (aminomethyl)-12- chloro- 1,1',3a,5',10a,11,12,1 3a-octahydro-5'- hydroxyspiro[8H- cyclopenta[3,4]pyrrol o[1,2-a]imidazo[4,5- b]pyrrolo[1,2- d]pyrazine- 13(10H),4'- [4H]imidazol]-8-one			cancer

palmitoylthiazoxin; RS1541	Preclinical	2,3,11,12-diepoxy-8,12-dimethyl-7,13-dihydroxy-15[3-methoxy-4,8-dimethyl-9-(2-methyl-4-oxazolyl)octa-4,6-dien-2-yl]-9-pentadecenolide-5-acetic acid gamma-lactone		cancer
panaxytriol	Preclinical	1-heptadecene-4,6-diene-3,9,10-triol		cancer
pazelliptine; BD 40; SR 95225A; SR 95225	Discontinued	N,N-diethyl-N'-(6-methyl-5H-pyrido[3',4':4,5]-pyrrolo[2,3-g]isoquinolin-10-yl)-1,3-propanediamine		cancer
PEPTIDYL MIM	Preclinical			cancer; bacterial infection
PG 2	Phase I			anemia; cancer; leukopenia
PG 266	Preclinical			anemia; cancer; leukopenia
PG 278	Discontinued			cancer
PG 349	Discontinued			cancer; anemia
PG 356	Discontinued			cancer; viral infection
PG 36	Discontinued			cancer; viral infection
PG 4336	Discontinued			cancer; viral infection



PG 488	Discontinued				cancer; anemia
phenethyl isothiocyanate	Phase I				cancer
pibicanil; OK 432; OK 5; PCB 45; PICIBANIL; PICIVANYL	Marketed				cancer
piroxantrone; oxathrazole; oxantrazole; CI 942; PD 111815; NSC 349174; DUP 942	Discontinued	5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]anthra[1,9-cd]pyrazol-6(2H)-one			cancer
PKH 135	Discontinued				cancer; ischemia; reperfusion injury
platinum compounds, BioNumerik	Preclinical				cancer
PM 14	Preclinical	hepta-mu-oxo-mu6-oxodioxo(penta-mu-oxotetraoxotetratungstate)divanadate(4-)tetrapotassium			cancer
PM 24	Preclinical	polyoxotungstate			cancer
PM 40; JM 1490	Preclinical	(aquanickelate)[mu12-[orthosilicato(4-)-O:O:O:O':O':O':O":O':O":O":O":O"]tetraco-sa-mu-oxoundeca-oxoundecatungstate(6-)-hexapotassium			cancer
PM 90001	Preclinical				cancer

PM 91101	Preclinical			cancer
PM 91102	Preclinical			cancer
PM 92127	Preclinical			cancer
PM 92130	Preclinical			cancer
PM 93100	Preclinical			cancer
PM 93107	Discontinued			cancer
PM 93113	Preclinical			cancer
PM 94103	Preclinical			cancer
PM 94127	Preclinical			cancer
PM 94132	Preclinical			cancer
PNU 153429	Phase I	2,2'-[carbonylbis(imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino)]bis-1,5-naphthalenedisulfonic acid tetrasodium salt		cancer
PNU 157911	Preclinical			cancer
PNU 166196	Preclinical			cancer
podophyllotoxin analogues, IGT Pharma	Preclinical			cancer
poly ADP-ribose polymerase inhibitor; PARP inhibitor	Preclinical			cancer
protein kinase RNA-activated based therapeutics, RiboGene	Preclinical			cancer; viral infection

PX 12	Preclinical				cancer
pyrazoloacridine; pyrazoloacridine hydrochloride; PD 115934; NSC 366140	Phase I	9-methoxy-N,N- dimethyl-5- nitropyrazolo[3,4,5- kl]acridine-2(6H)- propanamine			cancer
RA 700; RA VII; TPC-B	Suspended	5-(N-methyl-L- tyrosine)-6-(3- hydroxy-N,O- dimethyl-L- tyrosine)bouvardin			cancer
raf antagonists, SUGEN	Preclinical				cancer
ras geranylgeranylation inhibitors	Preclinical				cancer
ras inhibitors, ProScript	Preclinical				cancer
ras-GAP inhibitor, Xenova	Discontinued				cancer
retelliptine; SR 95325; SR 95325B	Discontinued	1-[[3- (dimethylamino)prop yl]amino]-9-methoxy- 5,11-dimethyl-6H- pyrido[4,3- b]carbazole			cancer
retelliptine demethylated	Discontinued				cancer
rice-bran saccharide; RBS; SPR 901	Discontinued	(1-3),(1-6)-alpha-D- glucan			cancer
RL 344007; NORPRAM	Preclinical				cancer

RSR 4	Preclinical	2-[4-[2-[(3,5-dichlorophenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	cancer; surgery; heart ischemia; stroke
RSR 46	Preclinical	2-[4-[2-[(2,3-dihydro-1H-inden-5-yl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	cancer; surgery; heart ischemia; stroke
salvianolic acid A	Preclinical		cancer
sarcodictyins	Preclinical		cancer
SC 101; SC 101c; EPAKEX	Phase III	1-(Z,Z,Z,Z,Z-eicosa-5,8,11,14,17-pentaenyl)-3-(Z,Z,Z,Z,Z-eicosa-5,8,11,14,17-pentaenyl)propane	cancer; cachexia
SC 101a; GLAMEPA	Preclinical	1-(Z,Z,Z,Z,Z-octadeca-6,9,12-trienyl)-3-(Z,Z,Z,Z,Z-eicosa-5,8,11,14,17-pentaenyl)-3-(Z,Z,Z,Z,Z-eicosa-5,8,11,14,17-pentaenyl)propane	cancer
SC 101g; MEGLUMINE-GLA	Phase I	meglumine-Z,Z,Z-6,9,12-octadecatrienoate	cancer
SC 101i	Preclinical	meglumine-6,9,12-octadecatrienoate	cancer

SCHAL 3	Phase I			skin disease; cancer; psoriasis
Sdi 1 mimetics, SENNES	Discontinued			cancer
SDK 110	Preclinical	3-[[3-(trimethylsilyl)propylthio]-1-propanamine		cancer
SDZ MKT 077; MKT 077; FJ 776	Phase I	1-ethyl-2-[[3-ethyl-5-(3-methyl-2(3H)-benzothiazolylidene)-4-oxo-2-thiazolidinylidene]methyl]pyridinium chloride		cancer
SE 12363	Preclinical			cancer
selenium thiosemicarbazone; NEOSTAT	Preclinical			cancer
SF 2698	Preclinical	(6S)-iminoazacyclohexa-3-ene-6-carboxylic acid		cancer
sialyl transferase inhibitor, Biota	Preclinical			cancer
SJ 3249	Preclinical	4-(3,5-dimethylphenyl)-N-(2-methoxy-5,6-dimethyl-3-pyridinyl)-1-piperazinecarboxamide		cancer
sodium phenylacetate; EL 530	Phase III	sodium phenylacetate		cancer

spirodian 3; diam 3; PE 1001	Discontinued	2,2,4,4,-tetrakis(1-aziridiny)-2,2,4,4-tetrahydro-1,3,5,7,11-pentaaza-2,4,6.lambda.5-triphosphaspiro[5.5]undeca-1,3,5-triene		cancer
spongistatin 1	Discontinued			cancer
SR 26050	Discontinued	(1-(3-diethylaminopropylamino))-9-hydroxyellipticine dihydrochloride		cancer
SR 271425	Phase I			cancer
SR 45023a; SR 45023	Phase I	[2-{3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl}ethylidene]bis-phosphonic acid tetrakis(1-methylethyl) ester		cancer
ST 30	Preclinical	(E)-4-[2-(3,4-diisopropylphenyl)-1-propenyl]benzoic acid		cancer
ST 40	Preclinical	(E)-4-[2-(3-tert-butylphenyl)ethenyl]benzoic acid		cancer

stipiamide; fenalamid A1; phenalamide A1	Preclinical	[12R- [1(S*),2E,4E,6Z,8E,1 0E,12R*,13R*,14E,1 6S*]]-13-hydroxy-N- (2-hydroxy-1- methylethyl)- 2,10,12,14,16- pentamethyl-18- phenyl-2,4,6,8,10,14- octadecaheptaenamide		cancer
SU 201	Discontinued			cancer
SU 65591	Preclinical			cancer
SUN 4599	Discontinued	2-alpha-L- arabinopyranosyl-9- hydroxy-5,11- dimethyl-6H- pyrido[4,3- b]carbazolium bromide		cancer
superfibronectin	Preclinical			cancer
suramin; CI 1003; METARET	Marketed	8,8'- [carbonylbis[imino- 3,1- phenylene]carbonyl]limi no(4-methyl-3,1- phenylene)carbonyli mino]]bis-1,3,5- naphthalenetrisulfonic acid		parasitic infection; cancer

swainsonine; (-)-swainsonine; swainsonine hydrochloride; GD 0039	Phase II	[1S-(1alpha,2alpha,8beta,8abeta)]-octahydro-1,2,8-indolizinetriol	cancer; viral infection
T4GEN	Phase I		HIV infection; cancer
TAC 903	Preclinical	chrome-8-acetic acid	cancer
tamoxifen methiodide; PA 50300	Preclinical		cancer
TBC 1635	Preclinical		retinopathy; cancer
tBCEU	Preclinical	4-tert-butyl-[3-(2-chloroethyl)ureido]benzene	cancer
TER 286	Preclinical	(2R)-L-gamma-glutamyl-3-[[[2-[[bis(bis(2-chloroethyl)amino]phosphinyloxy)ethyl]sulfonyl]-L-alanyl-2-phenyl]-glycine	cancer



thaliblastine; thaliblastine; thalicarpine; (+)- thalicarpine; TBL; thalicarpin; NSC 68075	Phase III	[S-(R*,R*)]-9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinoliny)methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-4H-dibenzo[de,g]quinoline	cancer
thrombopoietin mimetic, Axys	Discontinued		cancer; thrombocytopenia
TJ 14026	Discontinued		cancer
transforming growth factor beta receptor inhibitors, Affymax	Preclinical		cancer
triacetylruridine	Phase I		cancer
tricitiribine; NSC 154020; TCN	Preclinical	1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene-3-amine	HIV infection; cancer
TRIFENS	Preclinical		diarrhea; gastrointestinal disorder; sickle cell anemia; cancer
TT 62	Discontinued	5-fluoro-2'-deoxyuridine 5'-tetradecylphosphate	cancer

tucareol; BWA 589C; BW 589C80; BW 589C; 589C	Phase II	4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid	sickle cell anemia; viral infection; HIV infection; cancer; hepatitis
tumor suppressor genes, oncology, Onyx	Preclinical		cancer
tumor suppressor genes, Onyx	Preclinical		cancer
U 77863	Discontinued	trans-3-(2'-methylphenyl)-2-propene-1-carboxamide	cancer
UBC 10 inhibitors, cancer, ProScript	Preclinical		cancer
UK 21	Preclinical	N-(1-oxo-2-propylpentyl)glycine triester with 5-fluorouridine	cancer
V 489	Phase I		cancer
VA 5	Preclinical	6-(2,5-dimethoxyphenyl)-2,3-dihydroimidazo[2,1-b]thiazole	heart failure; cancer
variolin B	Discontinued		cancer; viral infection
VDacac	Preclinical		cancer; contraception
VDDTC	Preclinical		cancer; contraception
velaresol; BW 12C79; 12C	Suspended	5-(2-formyl-3-hydroxyphenoxy)-pentanoic acid	cancer; sickle cell anemia
VG 18563	Preclinical		anemia; cancer

vitamin B12 growth blockers, Receptagen	Preclinical				cancer
WIN 33377	Discontinued	N-[[1-[2-(diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen-4-yl]methyl]-methanesulfonamide			cancer
XK 469	Preclinical				cancer
Y 25510	Discontinued	(+,-)-3-[4-[2-(dimethylamino)-1-methylethoxy]phenyl]-1H-pyrazolo[3,4-b]pyridine-1-acetic acid			cancer
YM 534	Phase I	6-[4-[[5-(1H-imidazol-1-yl)pentyl]oxy]phenoxy]-2,2-dimethylhexanoic acid ethyl ester monohydrochloride			cancer
YW 200	Preclinical				cancer
YW 213	Preclinical				cancer
ZD 2767P	Phase I	N-[[4-[bis(2-iodoethyl)amino]phenoxy]carbonyl]-L-glutamic acid			cancer
ZD 9063P	Preclinical				cancer
zilascorb; ZOXXOZ	Suspended	5,6-O-((RS)-benzylidene-alpha-L)-L-ascorbic acid			cancer

zinosatin stimalamer; drug delivery system; neocarzinostatin; neocarzinostatin delivery system; YM 881; SMANCS	Marketed	zinosatin stimalamer		cancer
ZK 119010	Preclinical	2-(4-hydroxyphenyl)- 3-methyl-1-[6-(1- pyrrolidinyl)hexyl]- 1H-indol-5-ol		cancer
ZYN 176	Suspended			cancer
ZYN-LINKER conjugated thiocolchicine analogues	Preclinical			cancer
episteride; SKF 105657; ONO 9302	Discontinued	17beta-[[[(1,1- dimethylethyl)amino] carbonyl]androsta- 3,5-diene-3- carboxylic acid	5 alpha reductase inhibitor	benign prostate hypertrophy; cancer; alopecia; acne
finasteride; MK 906; MK 0906; YM 152; PROSCAR; FINASPROS; CHIBRO- PROSCAR; FINASTID; PROSTIDE; EUTIZ; PRODEL; PROPECIA	Marketed	(5alpha,17beta)-N- (1,1-dimethylethyl)- 3-oxo-4-azaandrost-1- ene-17-carboxamide	5 alpha reductase inhibitor	cancer; benign prostate hypertrophy; alopecia; acne
1 23	Discontinued		5 alpha reductase inhibitor	cancer; acne; hirsutism

A 63162	Preclinical	N-hydroxy-N-[1-[4-(phenylmethoxy)phenyl]ethyl]acetamide	5 lipoxygenase inhibitor	cancer
masoprocol; CHX 100; ACTINEX	Marketed	(R*,S*)-4,4'-(2,3-dimethyl-1,4-butanediyl)bis-1,2-benzenediol	5 lipoxygenase inhibitor	skin disease; cancer; psoriasis
SC 41661A	Discontinued		5 lipoxygenase inhibitor	cancer
KBR 8498	Preclinical	(1alpha,2alpha,4beta)-4-[[2-(1-piperazinyl)-4-quinazolinyl]oxy]-1,2-cyclopentanediol	5HT agonist	cancer
EF 7412	Preclinical	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]-1-piperazinyl]phenyl]ethanesulfonamide	5HT antagonist; 5HT1A antagonist; glutamate release inhibitor	neurodegeneration; depression; cancer
adecypenol; OM 3223	Preclinical	5-(7,8-dihydro-8-hydroxyimidazo[4,5-d][1,3]diazepin-3(4H)-yl)-3-(hydroxymethyl)-3-cyclopentene-1,2-diol	adenosine deaminase inhibitor	cancer

pentostatin; 2'-deoxycoformycin; covidarabine; CI 825; NSC 218321; PD 81565; CL 67310465; YK 176; NIPENT; COFORIN	Marketed	(R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol	adenosine deaminase inhibitor	cancer
adenosine allosteric modulators, Medco	Preclinical		adenosine regulating agent	cardiovascular disease; cancer; stroke
OCT 1003	Preclinical	3-nitrosobenzamide	ADPRT ligand	cancer
OCT 1004	Preclinical	6-nitroso-1,2-benzopyrone	ADPRT ligand	cancer
forfenimex; forphenicinol; BF 121	Discontinued	(S)-alpha-amino-3-hydroxy-4-(hydroxymethyl)benzoic acid	alkaline phosphatase inhibitor; immunostimulant	bacterial infection; cancer
ambamustine; PTT 119; BLASTOP	Phase III	N-[3-bis(2-chloroethyl)amino]-N-(4-fluoro-L-phenylalanyl)-L-phenylalanyl-L-methionine, ethyl ester	alkylating agent	cancer
bistriazenes, NIH	Preclinical		alkylating agent	cancer
bizelesin; U 77779; NSC 615291	Phase I	[S-(R*,R*)]-6,6'-[carbonylbis(imino-1H-indole-5,2-diylcarbonyl)]bis[8-(chloromethyl)-3,6,7,8-tetrahydro-1-methylbenzo[1,2-b:4,3-b']dipyrrol-4-ol]	alkylating agent	cancer

carzelesin; U 80244	Phase II	N-[2-[[1-(chloromethyl)-1,6-dihydro-8-methyl-5-[[[(phenylamino)carbo-nyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-6-(diethylamino)-2-benzofurancarboxamide	alkylating agent	cancer
CBS 5	Discontinued	4-[3-(2-chloroethyl)-1-(benzyl)-2-triazenyl]-1,4-dioxobutyl-beta-alanyl-tryptophyl-methionyl-aspartyl-phenylalaninamide	alkylating agent	cancer
DABIS maleate; NSC 262666	Preclinical	1,4-bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane ((Z)-2-butenedioate (1:2)	alkylating agent	cancer

drug delivery system, carnustine biodegradable implant; drug delivery system, sustained release BCNU; BIODEL BCNU implant; carnustine delivery system; prolifepros 20, carnustine implant; GLIADEL; GLIADEL WAFER	Marketed			alkylating agent	cancer
electrophilic alkylating agents, BioNumerik	Preclinical			alkylating agent	cancer
EO 9, NSC 382459	Phase II	(E)-5-(1-aziridiny)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione		alkylating agent	cancer
estramustine analogue	Phase II			alkylating agent	cancer
glufosfamide; D 19575	Phase I	1-[N,N'-bis(2-chloroethyl)phosphorodiamidate]-beta-D-glucopyranose		alkylating agent	cancer
glutathione S-transferase-activated toxins, Telik	Discontinued			alkylating agent	cancer
isopropyl pyrrolizine derivative; IPP	Discontinued			alkylating agent	cancer
KF 22678	Preclinical			alkylating agent	cancer



mafosfamide; mefosfamide; ASTA Z 7557; NSC 345842; ASTA Z 7654; Z 7557	Discontinued	cis-(+,-)-2-[[2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-4-yl]thio]ethansulfonic acid P-oxide	alkylating agent	cancer
melphalan + A-MSH; FIK	Discontinued		alkylating agent	cancer
melphalan + L-amino oxidase	Preclinical		alkylating agent	cancer
OCX 177; OCX 0177	Preclinical		alkylating agent	cancer
porfiromycin; porfiromycine; N- methylmitomycin C; ENT 50825; NSC 56410; U 14743; PROMYCIN	Phase III	[1aS-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-6-amino-8-[[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl-azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione	alkylating agent	cancer
SBR 11170; SBR 170	Preclinical		alkylating agent	cancer
temozolomide; methazolastone; SCH 52365; CCRG 81045; NSC 362856; M&B 39831; TEMODAL	Marketed	3,4-dihydro-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide	alkylating agent	cancer
treosulfan; OVASTAT; TREOSULFAN	Marketed	L-threitol 1,4-dimethanesulfonate	alkylating agent	cancer

PNU 159548	Phase I	(7S-cis)-9-acetyl-7-[[[3-(1-aziridinyl)-2,3,6-trideoxy-4-O-(methylsulfonyl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione	alkylating agent; DNA intercalator	cancer
mitolactol; bromoalcohol; dibromodulcitol; DBD; NSC 104800; MITOLACTOL; METHOLACTOLE; ELOBROMOL	Marketed	1,6-dibromo-1,6-dideoxygalactitol	alkylating agent; peptide	cancer
bisaziridinylspermine; BAS	Preclinical	N,N'-bis[3-(1-aziridinylpropyl)]-1,4-butanediamine	alkylating agent; polyamine analogue	cancer
diarizidinylspermine; DASPM	Preclinical	N,N'-bis[3-(1-aziridinylpropyl)]-1,4-butanediamine	alkylating agent; polyamine analogue	cancer
O6-benzylguanine	Phase I		alkyltransferase inhibitor; chemosensitizer	cancer
samarium 153 Sm lexidronam; Sm 153-EDTMP; samarium 153-EDTMP; samarium EDTMP; CYT 424; QUADRAMET	Marketed	(OC-6-21)-[[[1,2-ethanediy]bis[nitritobis(methylene)]tetakis(phosphonato)](8-)-N,N',OP,OP',OP'',OP''']-samarate(5-)-153Sm	analgesic; NSAID; radiotherapeutic	cancer; pain; rheumatoid arthritis

abiraterone; piraterone; CB 7630; CB 7598	Phase I	(3beta)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol	androgen synthesis inhibitor	cancer
cancer therapy, Institute of Cancer Research	Preclinical		androgen synthesis inhibitor	cancer
cancer therapy, Saarbrücken University	Preclinical		androgen synthesis inhibitor	cancer
GI 111924	Suspended		androgen synthesis inhibitor	cancer
VN 851	Preclinical		androgen synthesis inhibitor	cancer
VN 871	Preclinical		androgen synthesis inhibitor	cancer
YM 116	Phase I	2-(1H-imidazol-4-ylmethyl)-9H-carbazole	androgen synthesis inhibitor	cancer
YM 53789	Preclinical	2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-9H-carbazole	androgen synthesis inhibitor	cancer
YM 55208	Preclinical	2-[1-(1H-imidazol-1-yl)ethyl]-9H-carbazole	androgen synthesis inhibitor	cancer
gene therapy, cancer, Genetix	Preclinical		angiogenesis inducer; biotechnology; gene therapy	cancer
2-methyl-2-phthalimidino-glutaric acid	Preclinical		angiogenesis inhibitor	cancer

9alpha-fluoromethylprogesterone acetate, FMPA	Preclinical	(6-alpha)-17-(acetyloxy)-9-fluoro-6-methyl-pregn-4-ene-3,20-dione	angiogenesis inhibitor	cancer
ANG 453; ZD 6126	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitor, Boston Life Sciences	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitor, Merck KGaA; EMD 121974	Phase I		angiogenesis inhibitor	cancer
angiogenesis inhibitors, AstraZeneca	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitors, Nanodesign	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitors, Novartis/Schering AG	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitors, Repligen	Preclinical		angiogenesis inhibitor	cancer; retinopathy
CT 3577	Discontinued		angiogenesis inhibitor	cancer

FCE 26644; PNU 151484	Preclinical	7,7'-[carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrasodium salt	angiogenesis inhibitor	cancer
FCE 27164; PNU 165897	Preclinical	7,7'-[carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt	angiogenesis inhibitor	cancer
gene discovery, tumor epithelium	Preclinical		angiogenesis inhibitor	cancer
greenstatin	Preclinical		angiogenesis inhibitor	cancer
irsogladine; irsogladine maleate; isaglidole; MN 1695; GASLON; GASLON-N	Marketed	2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine	angiogenesis inhibitor	gastrointestinal ulcer; cancer
RG 8803; RG 8803B11; RG 1009	Preclinical		angiogenesis inhibitor	cancer

squalamine	Phase I	(3beta,5alpha,7alpha,24R)-3-[[3-[(4-aminobutyl)amino]propyl]amino]cholestan-7-ol-24-sulfate (hydrogen sulfate)	angiogenesis inhibitor	viral infection; cancer; retinopathy
SR 25989	Discontinued		angiogenesis inhibitor	cancer
SU 301	Discontinued		angiogenesis inhibitor	cancer
SU 302	Discontinued		angiogenesis inhibitor	cancer
suradista	Phase I		angiogenesis inhibitor	cancer
TAN 1120	Preclinical	8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[[octahydro-5-hydroxy-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxocin-8-yl]oxy]-5,12-naphthacenedione	angiogenesis inhibitor	cancer
TZ 93	Discontinued		angiogenesis inhibitor	cancer
VE-cadherin-2 antagonists, ImClone Systems	Preclinical		angiogenesis inhibitor	cancer
VEGF receptor modulators, Pharmacoceia	Preclinical		angiogenesis inhibitor	cancer
TGN 401	Preclinical		angiogenesis inhibitor; antiproliferative agent	cancer
soluble Tie-2	Preclinical		angiogenesis inhibitor; biotechnology	cancer

angiogenesis inhibitor, Bio-Technology General; plasminogen-related peptide Bio-Technology General	Preclinical			angiogenesis inhibitor; biotechnology; peptide	cancer
SU 6668	Phase I			angiogenesis inhibitor; growth factor modulator	cancer
AE 941; NEOVASTAT; NEORETNA; PSOVASCAR; ARTHROVAS	Phase III			angiogenesis inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; eye disease; retinopathy
FR 111142; WF 2015A	Discontinued	4,5-dihydroxy-2-hexenoic acid 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester		angiogenesis inhibitor; NSAID	cancer; rheumatoid arthritis; retinopathy
heparanase inhibitors, InSight	Preclinical			angiogenesis inhibitor; NSAID	cancer; inflammation
troponin I; cartilage derived inhibitor	Preclinical			angiogenesis inhibitor; NSAID; biotechnology	cancer; rheumatoid arthritis; eye disease
antiangiogenesis agent, Ixsys	Discontinued			angiogenesis inhibitor; peptide	cancer; restenosis
XMP 300	Preclinical			angiogenesis inhibitor; peptide	inflammation; cancer
ENDOSTATIN	Preclinical			angiogenesis inhibitor; peptide; biotechnology	cancer

thrombospondin 1 inhibitor, InKine; TSP-1 inhibitor, InKine	Preclinical		angiogenesis inhibitor; platelet antiaggregant; radiodiagnostic; contrast medium	cancer; diagnosis; thrombosis
tecogalan sodium; DS 4152; SP PG	Phase I	sulfated polysaccharide peptidoglycan	angiogenesis inhibitor; polysaccharide sulfate	cancer
SU 5416	Phase II	3-[(4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one	angiogenesis inhibitor; tyrosine kinase inhibitor; signal transduction inhibitor	cancer
rubiginone B1	Discontinued		angucyclinone; antibiotic	cancer
aclarubicin; aclarubicin hydrochloride; aclacinomycin A; NSC 208734; MA 144A1; JACLACIN; ACLAPLASTIN; ACLACINOMYCIN; ACLACINON	Marketed	methyl(1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-1-naphthacene-1-carboxylate	anthracycline; antibiotic; DNA intercalator	cancer



drug delivery system, liposome anthracycline; anthracycline liposome; AR 522; ANNAMYCIN	Phase II		anthracycline; antibiotic; DNA intercalator	cancer
IT 62B	Discontinued		anthracycline; antibiotic; DNA intercalator	cancer; bacterial infection
SO 075R1	Preclinical		anthracycline; antibiotic; DNA intercalator	bacterial infection; cancer
bisantrone; bisantrene hydrochloride; CL 216942; NSC 337766; ADCA; CYABIN	Phase III	bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]-9,10-anthracenedicarboxaldehyde	anthracycline; DNA intercalator; antibiotic	cancer
daunoform	Preclinical		anthracycline; DNA intercalator; antibiotic	cancer
doxoform	Preclinical		anthracycline; DNA intercalator; antibiotic	cancer
drug delivery system, micellar doxorubicin; doxorubicin micelles	Preclinical		anthracycline; DNA intercalator; antibiotic	cancer
epidoxoform	Preclinical		anthracycline; DNA intercalator; antibiotic	cancer

memorubicin; FCE 23762	Phase II	[8S-[8alfa,10alfa(R*)]]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-(2-methoxy-4-morpholinyl)-alfa-L-lyxohexopyranosyl]oxy]-5,12-naphthacenedione	anthracycline; DNA intercalator; antibiotic	cancer
ZYN 191	Suspended		anthracycline; DNA intercalator; antibiotic	cancer
D 26232; AN 207	Preclinical	(2S-cis)-6-[N6-[5-[2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl)-alpha-L-lyxohexopyranosyl]oxy]-2-naphthaceny]]-2-oxoethoxy]-1,5-dioxopentyl]-D-lysine]-luteinizing hormone-releasing factor (swine)	anthracycline; DNA intercalator; antibiotic; gonadorelin agonist; peptide	cancer
AN 1006	Discontinued		anthraquinone	cancer

anthraquinone prodrugs, De Montfort University	Discontinued		anthraquinone; radiosensitizer	cancer
antiandrogen, prostatic carcinoma	Discontinued		antiandrogen	cancer
bicalutamide; Zeneca 176334; ICI 176334; CASODEX	Marketed	(+,-)-N-[4-cyano-3- (trifluoromethyl)phen yl]-3-[(4- fluorophenyl)sulfony l]-2-hydroxy-2- methylpropanamide	antiandrogen	benign prostate hypertrophy; cancer
ICI 192779	Suspended		antiandrogen	cancer
LGD 1331	Preclinical		antiandrogen	cancer; benign prostate hypertrophy; acne; alopecia
nilutamide; RU 23908; RU 23908-10; ANANDRON; NILANDRON	Marketed	5,5-dimethyl-3-[4- nitro-3- (trifluoromethyl)phen yl]-2,4- imidazolidinedione	antiandrogen	cancer
osaterone; osaterone acetate; TZP 4238; HIPROS	Pre- registration	17-(acetyloxy)-6- chloro-2-oxapregna- 4,6-diene-3,20-dione	antiandrogen	benign prostate hypertrophy; cancer; osteoporosis
zanoterone; WIN 49596	Phase II	(5alpha,7alpha)-1'- (methylsulfonyl)-1'H- pregn-20-yno[3,2- c]pyrazol-17-ol	antiandrogen	benign prostate hypertrophy; cancer
albacarcin; virenomycin M, V	Discontinued		antibiotic	cancer

ankinomycin	Discontinued	2-(4,4-anhydro-1,6-dideoxy- $\alpha$ -L-sorbo-2,3-oxiranosyl)-11-hydroxy-5-methyl-10-[2,3,6-trideoxy-3-(dimethylamino)-3-C-methyl- $\alpha$ -L-lyxohexopyranosyl]-4H-anthra[1,2-b]pyran-4,7,12-trione	antibiotic	cancer
antibiotic, Sagami	Preclinical	(7S-cis)-7-[(2,6-dideoxy- $\alpha$ -L-lyxohexopyranosyl)oxy]-9-(fluoroacetyl)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione	antibiotic	cancer
anticancer, Chugai	Discontinued	3'-deoxytalopiericidin A1 (DTPA)	antibiotic	cancer
AT 2433A1	Discontinued	1-chloro-13-[6-O-[2,4-dideoxy-4-(methylamino)- $\alpha$ -D-threo-pentopyranosyl]-4-O-methyl-beta-D-glucopyranosyl]-12,13-dihydro-6-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione	antibiotic	cancer

azamitosenes	Preclinical		antibiotic	cancer
BE 12406A	Discontinued	12-[(6-deoxy- $\alpha$ -L-mannopyranosyl)oxy]-1-hydroxy-10-methoxy-8-methyl-6H-benzo[d]naphtho[1,2-b]pyran-6-one	antibiotic	cancer
betacclamycin B; BCMA	Preclinical		antibiotic	cancer
CC 1065	Discontinued	(7bR)-7-[[1,6-dihydro-4-hydroxy-5-methoxy-7-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrol-3,2-e]indol-2(1H)-yl)carbonyl]benzo[1,2-b:4,3-b']dopyrrol-3(2H)-yl]cabonyl-1,6-dihydro-4-hydroxy-5-methoxybenzo[1,2-b:4,3-b']dipyrrole-3(2H)-carboxamide	antibiotic	bacterial infection; cancer
collismycin A; SF 2738A	Discontinued	(E)-4-methoxy-5-(methylthio)-[2,2'-bipyridine]-6-carboxaldehyde oxime	antibiotic	cancer

collismycin B; SF 2738B	Discontinued	(Z)-4-methoxy-5-(methylthio)-[2,2'-bipyridine]-6-carboxaldehyde oxime	antibiotic	cancer
collismycin C; SF 2738C	Discontinued		antibiotic	cancer
cypemycin	Discontinued	N,N-dimethyl-L-alanyl-(E)-2,3-didehydro-2-aminobutanoyl-L-prolyl-L-alanyl-(E)-2,3-didehydro-2-aminobutanoyl-L-prolyl-(E)-2,3-didehydro-2-aminobutanoyl-L-valyl-L-alanyl-L-glutamyl-L-phenylalanyl-L-valyl-L-isoleucyl-L-glutamylglycyl-L-seryl-(E)-2,3-didehydro-2-aminobutanoyl-L-isoleucyl-L-cysteinyl-L-leucyl-N-(2-mercaptoethenyl)-L-leucinamide cyclic (19-21)-sulfide	antibiotic	bacterial infection; cancer

dioxamycin; BE 16493	Preclinical	[2alfa,3alfa,4aalfa,9[2R*,3S*[1E(2S*,4S*,5S*),3E,5E],6R*],12ba]fa]-(+)-2,4-dimethyl-5-[7-oxo-7-[[[tetrahydro-2-methyl-6-(1,2,3,4,4a,7,12,12b-octahydro-2,3,4a,8,12b-pentahydroxy-3-methyl-1,7,12-trioxobenz[a]anthracen-9-yl)-2H-pyran-3-yl]oxy]-1,3,5-heptatrienyl]-1,3-dioxolane-2-carboxylic acid	antibiotic	cancer; bacterial infection
eponemycin; BMY 28647; BU 3862T	Discontinued	[2R-[2R*[S*(S*)]]]-N-[1-(hydroxymethyl)-2-[[[1-[2-(hydroxymethyl)oxiranyl]carbonyl]-3-methyl-3-butenyl]amino]-2-oxoethyl]-6-methylheptanamide	antibiotic	cancer
epoxomicin	Discontinued		antibiotic	cancer

esperatrucin; esperamicin A1; esperamycin; esperamicin; BMY 28175; BBM 1675A1; BBM 1675	Discontinued	[1R- (1R*,4Z,8S*,12S*,13 E)]-4,5-dimethoxy-2- [(2-methoxy-1-oxo-2- propenyl)amino]benz oic acid 3'(12)-ester with methyl [8-[[4,6- dideoxy-2-O-[2,4- dideoxy-3-O-methyl- 4-[(1- methylethyl)amino]- alfa-L- threopentopyranosyl]- 4-[[[(2,6-dideoxy-4-S- methyl-4-thio-beta-D- ribo- hexopyranosyl)oxy]a mino]-beta-D- glucopyranosyl]oxy]- 12-[(2,6-dideoxy-alfa- L-lyxo- hexopyranosyl)oxy]- 1-hydroxy-13-[2- (methyltrithio)ethylid ene]-11- oxobicyclo[7.3.1]tride ca-4,9-diene-2,6- diyn-10-yl]carbamate	antibiotic	cancer
--	--------------	--	------------	--------



FCE 21424	Preclinical	8-acetyl-10-[[5-(hexahydro-2,4,6-trioxo-5-pyrimidinyl)octahydro-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxocin-8-yl]oxy]-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer
FCE 24366	Preclinical	8-acetyl-10-[[5-(hexahydro-1,3-dimethyl-2,4,6-trioxo-5-pyrimidinyl)octahydro-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxocin-8-yl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer

FCE 24367	Preclinical	8-acetyl-10-[[5-(hexahydro-4,6-dioxo-2-thioxo-5-pyrimidinyl)octahydro-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxazin-8-yl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer
FK 317	Phase I		antibiotic	cancer
fluorodaunorubicin hydrochloride	Preclinical	10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-8-(fluoroacetyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer

hatomamicin; YL 0358MA	Preclinical	[2R- [2alfa,3alfa,6alfa[1R* (S*),2Z,4E(1alfaS*,7 alfaR*)]]]-6-[[4-(2,3- dihydrocyclopent[b]o xireno[c]pyridin- 7(1aH)-ylidene)-1-(1- hydroxypropyl)-3- methyl-2- butenyl]oxy]tetrahydr o-2-methyl-2H-pyran- 3-ol	antibiotic	cancer
himastatin; BMV 40800	Discontinued		antibiotic	bacterial infection; cancer
hydramycin	Discontinued	[4S- (4alfa,4aalfa,5alfa,5aa lfa,6alfa,12aalfa)]-4- (dimethylamino)- 1,4,4a,5,5a,6,11,12a- octahydro- 3,5,10,12,12a- pentahydroxy-6- methyl-1,11-dioxo-2- naphthacenecarboxam ide	antibiotic	cancer; bacterial infection
K 818B	Discontinued		antibiotic	cancer
kedaricin	Discontinued		antibiotic	bacterial infection; cancer
KT 5432	Discontinued		antibiotic	cancer

KW 2189	Phase II	(S)-8-(bromomethyl)-3,6,7,8-tetrahydro-2-methyl-4-[[[(4-methyl-1-piperazinyl)carbonyl]oxy]-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]benzo[1,2-b:4,3-b']dipyrrole-1-carboxylic acid, methyl ester	antibiotic	cancer; bacterial infection
	Discontinued			
lactimidomycin leinamycin; leinomycin; DC 107	Discontinued	[2'R-[2'R*,6'R*(R*),9'E,11'R*,13'E,15'Z]]-4,11'-dihydroxy-2',4,9'-trimethylspiro[1,2-dithiolane-3,6'-[19]thia[3,20]diazabicyclo[15.2.1]eicosa[1(20),9,13,15,17]pentamethyl-4',5,12'-trione 2-oxide	antibiotic antibiotic	cancer cancer
	Discontinued			
leptolstatin liblomycin; NK 313	Preclinical		antibiotic	cancer
	Discontinued	N1-[3-[[[3-bis[[3,4-bis(phenylmethoxy)phenyl]methyl]amino]propyl]methylamino]propyl]bleomycinamide	antibiotic	cancer; bacterial infection

nisamycin; antibiotic 106B	Preclinical	[1S-[1 $\alpha$ ,2 $\beta$ ,2(2E,4E,6E),4(2E,4E),6 $\alpha$ ]]-7-[4-[(5-cyclohexyl)-1-oxo-2,4-pentadienyl]amino]-2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-2-yl]-2,4,6-heptatrienoic acid	antibiotic	bacterial infection; cancer
oligomycin E; MCI 2225	Discontinued	26-hydroxy-28-oxooligomycin A	antibiotic	cancer
oxaunomycin; D 788; R 20X2	Preclinical	[7R-(7 $\alpha$ ,8 $\beta$ ,10 $\beta$ )]-10-[(3-amino-2,3,6-trideoxy- $\alpha$ -L-lyxohexopyranosyl)oxy]-8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-5,12-naphthacenedione	antibiotic	cancer
phenazinomycin; (-)- phenazinomycin	Preclinical	[R-(E)]-5-[5-(2,2-dimethyl-6-methylenecyclohexyl)-3-methyl-2-pentenyl]-1(5H)-phenazinone	antibiotic	bacterial infection; cancer

pyrindamycin A	Discontinued	(2R-trans)-8-(chloromethyl)-1,2,3,6,7,8-hexahydro-4-hydroxy-2-methyl-1-oxo-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]benzo[1,2-b:4,3-b']dipyrrole-2-carboxylic acid, methyl ester	antibiotic	cancer
pyrindamycin B	Discontinued	8-chloro-2,3,6,7,8,9-hexahydro-4-hydroxy-2-methyl-1-oxo-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]-1H-pyrrolo[3,2-f]quinoline-2-carboxylic acid, methyl ester	antibiotic	cancer
saintopin	Discontinued	1,3,8,10,11-pentahydroxy-5,12-naphthacenedione	antibiotic	bacterial infection; cancer

saptomycin D	Discontinued	[2alpha,3beta(Z)]-10-[4-O-acetyl-2,3,6-trideoxy-3-(dimethylamino)-3-C-methyl-alfa-L-lyxohexopyranosyl]-11-hydroxy-5-methyl-2-[2-methyl-3-(1-propenyl)oxiranyl]-4H-anthra[1,2-b]pyran-4,7,12-trione	antibiotic	cancer; bacterial infection
SPM VIII	Discontinued	4-deoxy-4-[[[(1-oxododecyl)amino]acetyl]amino]-N-1H-purin-6-yl-L-glycero-beta-L-manno-heptopyranosylamine	antibiotic	cancer
tetrazomine; Y 09194L-B	Preclinical	3-hydroxy-N-[2a,3,4,5,6,6a,7,11b-octahydro-5-(hydroxymethyl)-11-methoxy-12-methyl-3,6-imino-1H-2-oxa-11c-azanaphth[1,2,3-cd]azulen-10-yl]-2-piperidinecarboxamide	antibiotic	bacterial infection; cancer
UCA 1064B	Discontinued		antibiotic	cancer
vicenistatin	Discontinued		antibiotic	cancer

Y 05460MA	Preclinical	4-amino-4,5,6-trideoxy-N-[1-(3,4-dihydro-8-hydroxy-1H-2-benzopyran-3-yl)-3-methylbutyl]-5-methylhexonamide	antibiotic	bacterial infection; cancer
drug delivery system, mitomycin; mitomycin Therapeutic Implant; MPI 5016	Discontinued		antibiotic; alkylating agent	cancer
MGI 114; HMAF	Phase II	(R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane-1,5'-[5H]inden]-7'(6'H)-one	antibiotic; alkylating agent; terpene	cancer
AGM 1470; TNP 470	Phase II	[3R-[3alfa, 4alfa (2R*, 3R*), 5beta, 6beta]]-5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl carbamic acid chloroacetyl ester	antibiotic; angiogenesis inhibitor	cancer



AD 143	Preclinical	hexanedioic acid (2S-cis)-mono[2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-alpha-L-lyxohexopyranosyl]oxy]-2-naphthaceny]]-2-oxoethyl ester	antibiotic; anthracycline; DNA intercalator	cancer
AD 198	Preclinical	Pentanoic acid (2S-cis)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(phenylmethyl)amino]-alpha-L-lyxohexopyranosyl]oxy]-2-naphthaceny]]-2-oxoethyl ester	antibiotic; anthracycline; DNA intercalator	cancer
anthracycline analogue, BioChem Pharma	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
B 880308	Suspended	7-O-(3-N-methyl-3-N-(R)-glycidyl-alpha-L-daunosaminy)-beta-rhodomyconone	antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, ATRIGEL sustained release doxorubicin; doxorubicin ATRIGEL	Preclinical		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin drug delivery system; AD 70; ADM OXD; GC 1004	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin drug delivery system	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin-tumor homing peptide; THP-doxorubicin	Preclinical		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin Therapeutic Implant; MPI 5015	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, HPMA polymer-bound doxorubicin; doxorubicin HPMA polymer-bound; PK 1	Phase I		antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, liposome daunorubicin; daunorubicin liposome; VS 103; DaunoXome	Marketed		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome; DOXOME	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome; TLC D99; TLC DOX 99; DOX 99; EVACET; LIPODOX	Pre- registration		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome	Clinicals		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome	Phase III		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, micellar doxorubicin; doxorubicin micelles	Preclinical		antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, Phase I nanosphere doxorubicin; doxorubicin nanosphere		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Discontinued ONCHOLAB aclarubicin; aclarubicin ONCHOLAB		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Discontinued ONCHOLAB AD 32; AD 32 ONCHOLAB		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Marketed STEALTH liposome doxorubicin; doxorubicin STEALTH; DOXIL; DOX-SL; S-DOX; CAELYX		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, Preclinical tetrapeptide doxorubicin; doxorubicin tetrapeptide; Super- Leu-Dox		antibiotic; anthracycline; DNA intercalator	cancer

epirubicin; pidorubicin; 4'-epi- doxorubicin; IMI 28; MSC 256942; F1 7701; PHARMORUBICIN; FARMORUBICIN; FARMORUBICINE	Marketed	(8S-cis)-10-[(3- amino-2,3,6-trideoxy- alfa-L-arabino- hexopyranosyl)oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-8- (hydroxyacetyl)-1- methoxy-5,12- naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer
FCE 27726	Discontinued	(7S-cis)-9-acetyl-7- [[3-[bis(2- chloroethyl)amino]- 2,3,6-trideoxy-4-O- (methylsulfonyl)- alpha-L-lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer
galarubicin; DA 125	Phase II	2-[(2S,4S)-4-[(2,6- dideoxy-2-fluoro- alpha-L-talopyran osyl)oxy]- 1,2,3,4,6,11- hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 2-naphthacenyl]-2- oxoethyl ester beta- alanine hydrochloride	antibiotic; anthracycline; DNA intercalator	cancer

GPX 100	Phase I			antibiotic; anthracycline; DNA intercalator	cancer
I-DOX	Phase I	4'-iodo-4'- deoxydoxorubicin		antibiotic; anthracycline; DNA intercalator	cancer
idarubicin; IMI 30; NSC 256439; IMI 22; ZAVEDOS; ZAVEDOSE; ZAVIDOS; IDAMYCIN; DAUNOBLASTINA; CERUBIDINE	Marketed	9-acetyl-7-[(3-amino- 2,3,6-trideoxy- $\alpha$ -L- lyxo- hexopyranosyl)oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione		antibiotic; anthracycline; DNA intercalator	cancer
iododoxorubicin; FCE 21954; IODODOX	Phase II	[2R- [2 $\alpha$ fa(8S*,10S*),4bet a,5beta,6beta]]-10- [(4-aminotetrahydro- 5-iodo-6-methyl-2H- pyran-2-yl)oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-8- (hydroxyacetyl)-1- methoxy-5,12- naphthacenedione		antibiotic; anthracycline; DNA intercalator	cancer

KRN 8602; MX 2	Phase II	[7R-(7 $\alpha$ ,8 $\beta$ ,10 $\beta$ )]-8-ethyl-7,8,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)- $\alpha$ -L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione hydrochloride	antibiotic; anthracycline; DNA intercalator	cancer
ME 2303; FAD 104	Discontinued	heptanedioic acid, mono[2-[4-[(2,6-dideoxy-2-fluoro- $\alpha$ -L-talopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl] ester, (2S-cis)-	antibiotic; anthracycline; DNA intercalator	cancer

menogaril; 7-OMEN; NSC 269148; TUT 7; U 52047; TOMOSAR; TAMOSAR	Phase III	(2R,3S,4R,5R,6R,11R,13R)-4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-2,6-epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione	antibiotic; anthracycline; DNA intercalator	cancer
pirarubicin; tirarubicin; thepirubicin; THP-doxorubicin; THP-ADM; thepirubicin; THERARUBICIN; PINORUBIN; BERJURUBIN; THEPRUBICINE	Marketed	[8S-[8alfa,10alfa(S*)]]-10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alfa-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer



ruboxyl	Phase II	(2S-cis)-4-[[1-[4[(3-amino-2,3,6-trideoxy- $\alpha$ -L-lyxohexopyranosyl)oxy]1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazono-2,2,6,6-tetramethyl-1-piperidinyloxy]	antibiotic; anthracycline; DNA intercalator	cancer
valrubicin; antibiotic AD 32; NSC 246131; VALSTAR	Marketed	Pentanoic acid, (2S-cis)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]- $\alpha$ -L-lyxohexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester	antibiotic; anthracycline; DNA intercalator	cancer
ZYN 198	Suspended		antibiotic; anthracycline; DNA intercalator	cancer
ZYN-LINKER conjugated doxorubicin	Suspended		antibiotic; anthracycline; DNA intercalator	cancer
doxorubicin + estrone; estrone + doxorubicin; DDS-DEA	Marketed		antibiotic; anthracycline; DNA intercalator; estrogen	cancer

amrubicin; SM 5887	Phase II	(7S-cis)-9-acetyl-9-amino-7-[(2-deoxy-beta-D-erythropentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione hydrochloride	antibiotic; anthracycline; DNA topoisomerase inhibitor	cancer
MEN 10755; BMS 195615	Phase I	(7S-cis)-7-[[4-O-(3-amino-2,3,6-trideoxy-alpha-L-lyxohexopyranosyl)-2,6-dideoxy-alpha-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-5,12-naphthacenedione hydrochloride	antibiotic; anthracycline; DNA topoisomerase inhibitor	cancer
BU 4704	Discontinued	1-(4-methoxyphenyl)-4-(4-hydroxysulfonyloxyphenyl)-2,3-diisocyano-1,3-butadiene	antibiotic; antifungal	mycosis; cancer
NK 860279I	Discontinued	44-homooligomycin B	antibiotic; antifungal	mycosis; cancer
NK 860279II	Discontinued	44-homooligomycin A	antibiotic; antifungal	mycosis; cancer

reveromycin A	Preclinical	10-[9-butyl-8-[4-carboxy-3-methyl-1(E),3(E)-butadienyl]-9-(hydroxysuccinyloxy)-3-methyl-1,7-dioxaspiro-[5.5]undec-2-yl]-5-hydroxy-4,8-dimethyl-2(E),6(E),8(E)-decatrienoic acid	antibiotic; antifungal	bacterial infection; cancer; mycosis
sultricin	Discontinued	5,6-dihydro-5-hydroxy-6-(6-hydroxy-5-methyl-4-hydroxysulfonyloxyheptadec-1,7,9,11-tetraenyl)-2H-pyran-2-one	antibiotic; antifungal	cancer; mycosis
JSM ASB001	Preclinical		antibiotic; antioxidant; cicatrizant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
JSM BCYL001	Preclinical		antibiotic; antioxidant; cicatrizant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
JSM BIAS001	Preclinical		antibiotic; antioxidant; cicatrizant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
beta lactam derivatives, Pliva	Preclinical		antibiotic; beta lactam	cancer

clavalanine; SYN 1931; Ro 22-5417	Preclinical	[3S-[3alpha(R*),5alpha]]-alpha-amino-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-3-propanoic acid	antibiotic; beta lactam	cancer
SYN 1127	Preclinical	3-(hydroxymethyl)-4-oxa-1-azabicyclo[3.2.0]heptan-7-one	antibiotic; beta lactam	cancer
SYN 1932	Preclinical	[3R-[3alpha(alphaS*,beta R*),5alpha]]-alpha-amino-7-oxo-beta-(phenylmethoxy-4-oxa-1-azabicyclo[3.2.0]heptane-3-propanoic acid	antibiotic; beta lactam	cancer
MAB, doxorubicin conjugate	Preclinical		antibiotic; biotechnology; monoclonal antibody; anthracycline; DNA intercalator	cancer
MAB, drug delivery system, liposome doxorubicin conjugate; MAB, STEALTH doxorubicin conjugate; SPI 49	Preclinical		antibiotic; biotechnology; monoclonal antibody; anthracycline; DNA intercalator	cancer
drug delivery system, micellar doxorubicin; doxorubicin micelle	Preclinical		antibiotic; DNA intercalator; anthracycline	cancer

IST 622; A 132; NSC 639830	Phase II	3-ethoxypropanoic acid (S)-10-[[6-deoxy-2-O-(6-deoxy-3-O-methyl-alfa-D-galactopyranosyl)-3,4-O-(phenylmethylene)-beta-D-galactopyranosyl]oxy]-5,12-dihydro-1-methyl-5,12-dioxobenzo[h][1]benzopyrano[5,4,3-cde][1]benzopyran-6-yl ester	antibiotic; DNA topoisomerase inhibitor	cancer
NSC 655649; BMJ 27557	Phase I	1,11-dichloro-6-[2-(diethylamino)ethyl]-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione	antibiotic; DNA topoisomerase inhibitor; DNA intercalator	cancer
WIN 58161	Preclinical	(S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid	antibiotic; DNA topoisomerase inhibitor; quinolone	cancer
MI 4337F11; MI 43	Preclinical		antibiotic; immunostimulant	cancer

gludapcin; FK 565; FK 41565	Discontinued	heptanoyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(D)-alanine	antibiotic; immunostimulant; peptide	cancer; HIV infection
feldamycin; BMY 28565	Discontinued	(S)-N-methyl-L-histidyl-N3-[1-carboxy-2-(1H-imidazol-4-yl)ethyl]-L-threo-2,3-diaminobutanoic acid	antibiotic; melanin synthesis inhibitor	cancer
cordycepin; NSC 63984	Phase I		antibiotic; nucleoside; antimetabolite	cancer
C 1027	Preclinical	Antibiotic C	antibiotic; peptide	cancer; bacterial infection
cecropin B	Discontinued		antibiotic; peptide	bacterial infection; cancer
lytic peptides, Proteus International	Discontinued		antibiotic; peptide	bacterial infection; cancer
verucopeptin; BU 3983T; BMY 28782	Discontinued		antibiotic; peptide	cancer
placetin A	Preclinical		antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
placetin B	Preclinical		antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
MS 073	Preclinical	5-(3-(40(10,11-dihydro-5H-dibenzo(a,d)cycloheptene-5-yl)piperazin-1-yl)2-hydroxypropoxy)quinoline	antibiotic; quinoline	cancer

A 74932	Discontinued	6-[2-[(2-amino-1-oxopentyl)amino]-1-pyrrolidinyl]-5-fluoro-3-oxo-3H-pyrido[3,2,1-k]phenoxazine-2-carboxylic acid monohydrochloride	antibiotic; quinolone	cancer
E 7010	Discontinued	N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide	antibiotic; sulfonamide	cancer
E 7070	Phase I		antibiotic; sulfonamide	cancer
ER 34410	Preclinical	N-(10,11-dihydro-2-fluoro-5H-dibenzo[b,e][1,4]diazepin-6-yl)-4-methoxybenzenesulfonamide	antibiotic; sulfonamide	cancer
ER 35744	Preclinical	N-(3-chloro-1H-indol-7-yl)-1,4-benzene-disulfonamide	antibiotic; sulfonamide	cancer
HMN 214	Preclinical	(E)-N-[(4-methoxyphenyl)sulfonyl]-N-[2-(1-oxido-4-pyridinyl)ethenyl]phenylacetamide	antibiotic; sulfonamide	cancer
andrographolide	Preclinical		antibiotic; terpene	cancer
PN 271; PN 27,1; AndroCar	Phase II		antibiotic; terpene	cancer; restenosis

PN 272	Preclinical		antibiotic; terpene	cancer
PN 273	Preclinical		antibiotic; terpene	cancer
PN 274	Preclinical		antibiotic; terpene	cancer
PN 275	Preclinical		antibiotic; terpene	cancer
giraodazole; giraodazole; giroline; (+)-giroline; RP 49532; RP 49532A; NSC 627434	Discontinued	[S-(R*,R*)]-2-amino- alfa-(2-amino-1- chloroethyl)-1H- imidazole-4-methanol	antibiotic; tRNA synthetase inhibitor	cancer
glycopine; glucosaminylmuramyl di peptide; GMDP; LIKOPID; LIKOPID	Marketed	N2-[N-[N-acetyl-4-O- [2-(acetylamino)-2- deoxy-beta-D- glucopyranosyl]mura- moyl]-L-alanyl]-D- alpha-glutamine	antibiotic; vaccine adjuvant; immunostimulant; glycopeptide	psoriasis; cancer; leukopenia; septic shock; infectious disease; eye disease
antiestrogens, AVAX Technologies	Preclinical		antiestrogen	cancer
antiestrogens, BioNumerik	Preclinical		antiestrogen	cancer
antiestrogens, Ligand	Preclinical		antiestrogen	cancer; endometriosis
clomifene analogues	Suspended		antiestrogen	cancer
droloxifene; droloxifene citrate; 3- hydroxytamoxifen; K 21060E citrate	Pre- registration	(E)-alpha-[p-[2- (dimethylamino)ethox- ylphenyl]-alpha- ethyl]-3-stilbenol	antiestrogen	cancer; osteoporosis
drug delivery system, GEOMATRIX controlled release tamoxifen; tamoxifen GEOMATRIX	Discontinued		antiestrogen	cancer



EM 139	Preclinical	(7alpha,16alpha,17beta)-N-butyl-16-chloro-3,17-dihydroxy-N-methylestra-1,3,5(10)-triene-7-undecanamide	antiestrogen	cancer
EM 170	Preclinical	(7alpha,16alpha,17alpha)-N-butyl-16-chloro-3,17-dihydroxy-N-methylestra-1,3,5(10)-triene-7-undecanamide	antiestrogen	cancer
EM 800	Phase III	2,2-dimethylpropanoic acid (S)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl ester	antiestrogen	cancer
estrogen antagonists, Telik	Discontinued		antiestrogen	cancer
fulvestrant; ZD 182780; ZM 182780; Zeneca 182780; ICI 182780; FASLODEX	Phase III	(7alpha,17beta)-7-[9-[(4,4,5,5-pentafluoropentyl)sulphonyl]nonyl]-estra-1,3,5(10)-triene-3,17-beta-diol	antiestrogen	cancer; gynecological

iproxifene; TAT 59	Phase III	(E)-4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-[4-(1-methylethyl)phenyl]-1-butenyl]phenol dihydrogen phosphate (ester)	antiestrogen	cancer
MDL 103323	Suspended	(E)-4-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylbutanamine	antiestrogen	cancer
panomifene; EGIS 5650; GYKI 13504	Discontinued	(E)-2-[[2-[p-(3,3,3-trifluoro-1,2-diphenylpropenyl)phenoxy]ethyl]amino]ethanol	antiestrogen	cancer
R 1128B	Discontinued	1,3,6-trihydroxy-8-n-butylanthraquinone	antiestrogen	cancer
RU 53637	Discontinued	(11beta,17alpha)-3,17-dihydroxy-N-methyl-N-(methylethyl)-19-norpregna-1,3,5(10)-trien-20-yne-11-undecanamide	antiestrogen	cancer
RU 58668; RU 59428	Discontinued		antiestrogen	cancer
SH 646	Phase I		antiestrogen	cancer
toremifene; tolemifene; FC 1157a; NK 622; FARESTON; TREMIFEN	Marketed	2-(p-(Z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine	antiestrogen	cancer

zindoxifene; D 16726	Discontinued	2-[4-(acetyloxyphenyl)-1-ethyl-3-methyl-1H-indol-5-ol acetate (ester)]	antiestrogen	cancer
arzoxifene; LY 353381	Phase II	2-(4-methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]benzo[b]thiophene-6-ol	antiestrogen; estrogen agonist	cancer
ERA 923	Preclinical		antiestrogen; estrogen agonist	cancer
estrogen receptor modulator, Genaissance; estrogen receptor modulator, Telik	Preclinical		antiestrogen; estrogen agonist	cancer; osteoporosis
estrogen receptor modulators, Nanodesign	Preclinical		antiestrogen; estrogen agonist	cancer; osteoporosis
idoxifene; SB 223030; CB 7432	Phase II	(E)-1-[2-[4-[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]pyrrolidine	antiestrogen; estrogen agonist	cancer
LY 326315	Preclinical	6-(4-hydroxyphenyl)-5-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]-2-naphthalenol hydrochloride	antiestrogen; estrogen agonist	cancer

raloxifene; keoxifene; LY 139481; LY 156758; EVISTA	Marketed	[6-hydroxy-2-(4- hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1- piperidinyl) ethoxy]phenyl]metha none	antiestrogen; estrogen agonist	osteoporosis; hyperlipidemia; myocardial infarction; cancer
aminopterin; aminopterine; pteramina; NSC 739; APGA	Phase II	N-[4-[(2,4-diamino- 6- pteridinyl)methyl]ami no]benzoyl]-L- glutamic acid	antifolate	cancer
anticancer agent, Eisai	Discontinued	N-[4-[3-(2,4-diamino- 6,7-dihydro-5H- cyclopenta[d]pyrimidi n-5- yl)propyl]benzoyl]-L- glutamic acid	antifolate	cancer
edatrexate; aminopterin, O-ethyl- 10-deaza; 10 EDAM; EDAM 10; CGP 30694	Discontinued	N-[p-1-[(2,4- diamino-6- pteridinyl)methyl]pro pyl]benzoyl]-L- glutamic acid	antifolate	cancer
lometrexol; LY 249543; LY 264618	Phase I	(R)-N-[4-[2-(2- amino-1,4,5,6,7,8- hexahydro-4- oxopyrido[2,3- d]pyrimidin-6- yl)ethyl]benzoyl]-L- glutamic acid	antifolate	cancer

LY 254155	Phase I	N-[[5-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl-2-thienyl]carbonyl]-L-glutamic acid	antifolate	cancer
LY 335580	Preclinical	N-((2,4-diamino-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidine-6-yl)ethyl)-2-thienylcarbonyl-L-glutamic acid	antifolate	cancer
PT 523	Preclinical	(S)-2-[[[4-carboxy-4-[[4-[[[(2,4-diamino-6-pteridiny)methyl]amino]butano]benzoyl]amino]benzoyl]amino]carbonyl]benzoic acid	antifolate	cancer
TNP 351	Discontinued	N-[4-[3-(2,4-diamino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid	antifolate; antimetabolite	cancer
piritrexim; BW 301U; NSC 351521	Phase II	6-[(2,5-dimethoxyphenyl)-methyl]-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine	antifolate; dihydrofolate reductase inhibitor	cancer; pneumocystis; toxoplasmosis

translation inhibitor, Trega Biosciences/RiboGen e	Preclinical		antifungal	viral infection; mycosis; cancer
liarazole; liarazole hydrochloride; liarazole fumarate; R 75251; R 85246; LIAZAL	Pre- registration	5-[(3-chlorophenyl)- 1H-imidazol-1- ylmethyl]-1H- benzimidazole	antifungal; androgen synthesis inhibitor; imidazole	cancer; psoriasis
BBR 3438	Preclinical		antifungal; anthrapyrazole	cancer
BBR 3439	Discontinued		antifungal; anthrapyrazole	cancer
DUP 942	Discontinued		antifungal; anthrapyrazole	cancer
losoxantrone; losoxantrone hydrochloride; biantrazole; CI 941; DuP 941; NSC 357885; PD 113785; BIANDA	Phase III	7-hydroxy-2-[2-[(2- hydroxyethyl)amino]e thyl]-5-[[2-[(2- hydroxyethyl)amino]e thyl]amino anthra[1,9- cd]pyrazol-6(2H)- one,	antifungal; anthrapyrazole	cancer
teloxantrone; teloxantrone hydrochloride; moxantrazole; DUP 937; CI 937; PD 113309; NSC 355644	Discontinued	7-10-dihydroxy-2-[2- [(2- hydroxyethyl)amino]e thyl]-5-[[2- (methylamino)ethyl]a mino]anthra[1,9- cd]pyrazol-6(2H)- one, dihydrochloride, monohydrate	antifungal; anthrapyrazole	cancer

cancer therapy, Lorus Therapeutics/Ion	Preclinical		antifungal; imidazole	cancer
clotrimazole; BAY 5097; CUTAMYCON; ENSCHENT; FUNGIZID; HAKUSERIN; LOTRIMIN AF; MYCO-HERMAL; MYKO CORDES; TRIGENTAX; CANESTEN; LOTRIMIN	Marketed		antifungal; imidazole	mycosis; sickle cell anemia; cancer; diarrhea
jasplakinolide; jaspamide	Preclinical	[2S- (2R*,4E,6S*,8R*)]- N-[2-bromo-N-(8- hydroxy-2,4,6- trimethyl-1-oxo-4- nonenyl)-L-alanyl]- N-methyl-D- tryptophyl]-L-3-(4- hydroxyphenyl)-beta- alanine rho-lactone	antifungal; peptide	mycosis; cancer
aminoimidazole carboxamide ribonucleotide formyltransferase inhibitors, Agouron; AICART inhibitors, Agouron	Discontinued		antifungal; ribonucleotide formyltransferase inhibitor; NSAID; imidazole	cancer; inflammation

26-epibryostatin I	Preclinical	(2E,4E)-2,4-octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1S)-1-hydroxyethyl]-5-13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13.7.1.11,15]nonacos-8-en-12-yl ester	antimetabolite	cancer
capecitabine; Ro 091978; XELODA	Marketed	pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate	antimetabolite	cancer
doxifluridine; DFUR; Ro 219738; FURTOLON; FURTULON	Marketed	5-deoxy-5-fluorouridine	antimetabolite	cancer
drug delivery system, ATRIGEL sustained release fluorouracil; fluorouracil ATRIGEL	Preclinical		antimetabolite	cancer



drug delivery system, fluorouracil; fluorouracil Therapeutic Implant; MPI 5003; AccuSite	Marketed		antimetabolite	cancer; psoriasis; viral infection
drug delivery system, fluorouracil; fluorouracil Therapeutic Implant; MPI 5011; INTRADOSE-FU	Discontinued		antimetabolite	cancer
drug delivery system, fluorouracil; fluorouracil Therapeutic Adhesive	Preclinical		antimetabolite	cancer
drug delivery system, methotrexate; methotrexate delivery system; HYAL CV1281	Discontinued		antimetabolite	cancer
drug delivery system, sustained release methotrexate; methotrexate DepoFoam	Discontinued		antimetabolite	cancer
fludarabine; arabinosyl-5-azacytosine; ara-AC; NSC 281272	Phase II	4-amino-1-beta-D-arabinofuranosyl-1,3,5-triazin-2(1H)-one	antimetabolite	cancer
fludarabine + chlorambucil; chlorambucil + fludarabine	Discontinued		antimetabolite	cancer

folic acid analogue, Glaxo Wellcome	Discontinued	N-alpha-(5-deaza-5,6,7,8-tetrahydropteroyl)-L-orithine	antimetabolite	cancer
levamisole + fluorouracil; fluorouracil + levamisole	Registered		antimetabolite	cancer
T 506	Discontinued	mono[2-(trimethylammonio)ethyl ester of 2'-deoxy-5-fluoro-5'-uridylic acid 3'-(9-octadecenoate) hydroxide inner salt	antimetabolite	cancer
TAS 102	Phase I		antimetabolite	cancer
tegafur; BMS 20060401; MJF 12264; NSC 148958; DAIYALOSE; FENTAL; FTORAFUR; FTORALON; FURAFLOL; FUTRAFUL; LAMAR; NEBERK; TORAFURIN; UFT	Marketed	5-fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)pyrimidin edione	antimetabolite	cancer
ZYN-LINKER conjugated fluorouracil	Suspended		antimetabolite	cancer

brequinar; brequinar sodium; DUP 785; NSC 368390	Suspended	6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid	antimetabolite; immunosuppressant	cancer; autoimmune disease; transplant rejection
ZYN-LINKER conjugated methotrexate	Suspended		antimetabolite; NSAID	cancer; rheumatoid arthritis; psoriasis
cytarabine ocfosfate; phosphate sodium; YNK 01; C18PCA; STARASID	Marketed	4-amino-1-[5-O-[hydroxy(octadecyloxy)phosphinyl]-beta-D-arabino furanosyl] 2(1H)-pyrimidinone	antimetabolite; nucleoside analogue	cancer
drug delivery system, DepoFoam	Marketed		antimetabolite; nucleoside analogue	cancer
cytarabine; cytarabine DepoFoam; DTC 101; DepoCyt; SAVEDAR	Marketed		antimetabolite; nucleoside analogue	cancer
nucleotide thio analogues, Oklahoma University	Preclinical		antimetabolite; nucleoside analogue	cancer
LY 207702	Preclinical	2',2'-difluoro-2'-deoxyribofuranosyl-2,6-diaminopurine (dFdAP)	antimetabolite; ribonucleotide reductase inhibitor	cancer
antineoplaston A10	Phase II		antineoplaston; peptide	cancer
antineoplaston AS2-1	Phase II		antineoplaston; peptide	HIV infection; cancer

nitroxide antioxidant, NIH	Preclinical		antioxidant; free radical scavenger; NSAID	respiratory distress syndrome; inflammation; cancer; reperfusion injury
antioxidants, University of California	Preclinical		antioxidant; NSAID	skin disease; inflammation; cancer
naphterpin; CL 190Y2	Preclinical	(4aS-cis)-3,4a,5,12b- tetrahydro-8,10- dihydroxy-2,5,5,9- tetramethyl-4H- benzo[d]naphtho[2,3- b]pyran-7,12-dione	antioxidant; NSAID	diabetes; cardiovascular disease; cancer; inflammation
OS 535	Preclinical		antiplasmin	cancer
LG 1127	Preclinical		antiprogestogen	cancer; endometriosis
LG 1147	Preclinical		antiprogestogen	cancer; endometriosis
LG 1447	Preclinical	1,2-dihydro-2,2,4- trimethyl-6-phenyl- quinoline	antiprogestogen	cancer; endometriosis
mifepristone; RU 486; RU 4866; RU 38486; R 38486; MIFEGYNE	Marketed	(11beta,17beta)-11- [4- (dimethylamino)phen yl]-17-hydroxy-17-(1- propynyl)estra-4,9- dien-3-one	antiprogestogen	abortion; cancer; contraception

onapristone; ZK 98299; SH 549; ZK 299	Discontinued	(11beta,13alpha,17alpha)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)estra-4,9-dien-3-one	antiprogesterone	cancer; contraception
ORG 31710	Discontinued	(6beta,11beta,17beta)-11-[4-(dimethylamino)phenyl]-4',5'-dihydro-6-methyl-spiro[estra-4,9-diene-17,2'(3'H)-furan]-3-one	antiprogesterone	cancer
ORG 31806	Discontinued	(7beta,11beta,17beta)-11-[4-(dimethylamino)phenyl]-4',5'-dihydro-7-methyl-spiro[estra-4,9-diene-17,2'(3'H)-furan]-3-one	antiprogesterone	cancer
ORG 33245	Discontinued		antiprogesterone	cancer; abortion
ORG 33628	Discontinued	(11beta,17alpha)-11-(4-acetylphenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one	antiprogesterone	cancer
ORG 33832	Discontinued		antiprogesterone	cancer; abortion
RU 46556	Discontinued	(11beta,17beta)-11-[4-(methylthio)phenyl]spiro[estra-4,9-diene-17,2'(5'H)-furan]-3-one	antiprogesterone	cancer; endometriosis; labor induction

RU 49295	Discontinued	(11beta,17beta)-11-(4-acetylphenyl)spiro[estra-4,9-diene-17,2'(5H)-furan]-3-one	antiprogesterone	cancer; endometriosis
SH 207	Phase I		antiprogesterone	cancer
ZK 112993	Discontinued	(11beta,17beta)-11-(4-acetylphenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one	antiprogesterone	cancer
ZK 136798	Discontinued	4-[[[11alpha,17beta,17(Z)]-9,11-dihydro-17-hydroxy-17-(3-hydroxy-1-propenyl)-3-oxo-4'Hnaphth[3',2':1',10,9,11]estra-4,9(11)-dien-6'-yl]benzonitrile	antiprogesterone	cancer
21-substituted progesterone derivatives, NIH	Preclinical		antiprogesterone; hormone replacement therapy	endometriosis; labor induction; hormone deficiency; cancer
topsentin; topsentine; topsentin B1; topsentine B1	Preclinical	(6-hydroxy-1H-indol-3-yl)[4-(1H-indol-3-yl)-1H-imidazol-2-yl]methanone	antiproliferative agent	cancer

carboxamidotriazole ; CAI; NSC 609974; L 651582	Phase I	5-amino-1-[[[3,5- dichloro-4-(4- chlorobenzyl)phenyl] methyl]-1H-1,2,3- triazole-4- carboxamide	antiproliferative agent; imidazole	cancer
antisense oligonucleotide, BCL-X	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, c-fos	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, c-jun	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, calcium binding protein in placenta; antisense oligonucleotide, CAPL	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, DNA methyltransferase; MG 98	Phase I		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, Epstein Barr virus; antisense oligonucleotide, EBV	Preclinical		antisense; oligonucleotide; biotechnology	cancer

antisense oligonucleotide, jun kinase-1	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, transforming growth factor beta; antisense oligonucleotide, TGF- beta; antisense oligonucleotide, cancer	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotides, basic fibroblast growth factor	Preclinical		antisense; oligonucleotide; biotechnology	cancer
oligonucleotides, cancer, Children's Hospital of Orange County	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, multiple drug resistance	Preclinical		antisense; oligonucleotide; biotechnology; mRNA translation inhibitor	cancer
anticancer agents, OSI/Pfizer	Preclinical		apoptosis inducer	cancer
apoptosis inhibitors, Oxford Asymmetry/LXR Biotechnology	Preclinical		apoptosis inducer	cancer; cardiac therapy; transplant rejection; gastrointestinal disorder



breast cancer therapy, Temple University; breast cancer therapy, Alliance	Preclinical		apoptosis inducer	cancer
C 857	Preclinical	2-[(1-nitro-9-acridinyl)amino]ethanol monohydrochloride	apoptosis inducer	cancer
cancer therapy, Axiom Biotechnologies/Zaiya	Preclinical		apoptosis inducer	cancer
cancer therapy, BioChem Pharma/ImmunoGen	Preclinical		apoptosis inducer	cancer
cancer therapy, Hitachi; cancer therapy, Nippon Chemiphar	Phase I		apoptosis inducer	cancer
cancer therapy, Idun/Abbott	Preclinical		apoptosis inducer	cancer
cancer therapy, Rigel	Preclinical		apoptosis inducer	cancer
DDE 313	Preclinical		apoptosis inducer	cancer
Fas modulators, Menarini	Preclinical		apoptosis inducer	cancer
K 22175; K22.175	Preclinical		apoptosis inducer	cancer
ONCODON	Preclinical		apoptosis inducer	cancer
small cell lung carcinoma therapy, Cadus	Preclinical		apoptosis inducer	cancer
E2F inhibitors, Prolifix	Preclinical		apoptosis inducer; antiproliferative agent	cancer; psoriasis; viral infection; restenosis

apoptosis inducer, IDUN	Preclinical		apoptosis inducer; caspase inhibitor	cancer
CP 461	Phase I		apoptosis inducer; phosphodiesterase inhibitor	cancer
exisulind; FGN 1; PREVATAC	Phase III	(1Z)-5-fluoro-2- methyl-1-[[4- (methylsulfonyl)phen- yl]methylene]-1H - indene-3-acetic acid	apoptosis inducer; phosphodiesterase inhibitor	cancer
apoptosis inhibitor, Biota	Discontinued		apoptosis inhibitor	cancer
apoptosis modulators, University of Colorado	Preclinical		apoptosis inhibitor; apoptosis inducer	cancer; autoimmune disease; neurodegeneration
anastrozole; ZD 1033; ICI D1033; ARIMIDEX	Marketed	alpha, alpha, alpha', alp ha'-tetramethyl-5- (1H-1,2,4-triazol-1- ylmethyl)-1,3- benzenediacetonitrile	aromatase inhibitor	cancer
aromatase inhibitor, Menarini	Preclinical		aromatase inhibitor	cancer
aromatase inhibitor, Merrell Dow	Discontinued	19-acetylenic- androstenedione	aromatase inhibitor	cancer
aromatase inhibitors, Washington Research Foundation	Preclinical		aromatase inhibitor	cancer
ataamestane; SH 489; ZK 95639	Discontinued	1-methylandrosta-1,4- diene-3,17-dione	aromatase inhibitor	cancer; benign prostate hypertrophy
CGP 47645	Discontinued		aromatase inhibitor	cancer

CGS 18320B; CGS 18320	Discontinued	4,4'-(1H-imidazol-1-ylmethylene)bis(benzonitrile) compound with butanedioic acid (2:1)	aromatase inhibitor	cancer
dexamethasone; D 3967	Phase III	3-(4-aminophenyl)-3-ethyl-2,6-piperidinedione	aromatase inhibitor	cancer
exemestane; FCE 24304; PNU 971; ONC 0028; AROMASIN	Pre-registration	6-methylenandrosta-1,4-diene-3,17-dione	aromatase inhibitor	cancer
fadrozole; CGS 16949A; AFEMA	Marketed	4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile	aromatase inhibitor	cancer
formestane; CGP 32349; AT 0931; LENTARON; LENTARE	Marketed	4-hydroxyandrostene-3,17-dione	aromatase inhibitor	cancer
letrozole; CGS 20267; FEMARA	Marketed	4,4'-(1H-1,2,4-triazol-1-ylmethylene)bisbenzonitrile	aromatase inhibitor	cancer
minamestane; FCE 24928	Discontinued	4-aminoandrost-1,4,6-triene-3,17-dione	aromatase inhibitor	cancer
MPV 2213; MPV 2213ad	Phase I	4-[3-(4-fluorophenyl)-2-hydroxy-1-(1H-1,2,4-triazol-1-yl)propyl]benzonitrile	aromatase inhibitor	cancer; benign prostate hypertrophy

NKS 01	Discontinued	14alpha-hydroxy-4-androstene-3,6,17-trione	aromatase inhibitor	cancer
ORG 30958	Discontinued	19-(ethyldithio)androst-4-ene-3,17-dione	aromatase inhibitor	cancer
ORG 33201	Discontinued	(3alphaR)-trans-1-[(3alpha-ethyl-9-(ethythio)-2,3,3alpha,4,5,6-hexahydro-1H-phenalen-2-yl)-methyl]-1H-imidazole HCl	aromatase inhibitor	cancer; endometriosis
pentrozole; SH 582; ZK 154065	Preclinical	17-[(1-oxohexyloxy)-19-norpregn-4-ene-3,20-dione	aromatase inhibitor	cancer
rogletimide; pyridoglutethimide	Discontinued	(+,-)-3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione	aromatase inhibitor	cancer
RU 54115	Discontinued	10-[2-(methylthio)ethyl]estra-4,9(11)-diene-3,17-dione	aromatase inhibitor	cancer; endometriosis
SAE 9	Discontinued		aromatase inhibitor	cancer
TAN 931	Preclinical	4-(2,6-dihydroxybenzoyl)-3-formyl-5-hydroxybenzoic acid	aromatase inhibitor	cancer

vorozole; R 76713; R 83842; JK 201; RIVIZOR	Phase III	6-[(4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]-1-methyl-1H-benzotriazole	aromatase inhibitor	cancer
YM 511	Phase II	4-[[[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]benzonitrile	aromatase inhibitor	cancer; endometriosis
YM 553	Preclinical	4-[[[(3,5-difluorophenyl)methyl]-5-pyrimidinylamino]benzonitrile	aromatase inhibitor	cancer
sparfosic acid; sparfosate sodium; PALA; platinum complex; CI 882; NSC 224131; Pt 268; NSC 328005	Phase III	N-(phosphonoacetyl)-L-aspartic acid, disodium salt	aspartate transcarbamylase inhibitor	cancer; viral infection
AV 04	Discontinued		azaanthraquinone	cancer
AV 17	Discontinued		azaanthraquinone	cancer
AV 38	Discontinued		azaanthraquinone	cancer
AV 43	Discontinued		azaanthraquinone	cancer
AV 57	Discontinued	6,9-dihydro-4-methyl-6-(2-nitrophenyl)-pyrido[3,2-g]quinoline-2,5,10(1H)-trione	azaanthraquinone	cancer
AV 61	Discontinued		azaanthraquinone	cancer
AV 66	Discontinued		azaanthraquinone	cancer
AV 80	Discontinued		azaanthraquinone	cancer

ImuVert	Discontinued			biological response modifier	cancer
ONO 4005	Discontinued			biological response modifier	cancer
ONO 4007	Phase II	(S)-2-deoxy-2-[[1-oxo-3-[1-oxo-9-phenyl(honyl)oxy]tetradecyl]amino-D-glucose, 3-benzenenonanoate 4-(hydrogensulfate), monosodium salt.		biological response modifier	cancer
VIRULIZIN	Registered			biological response modifier	cancer
RS 83277	Discontinued			biological response modifier; peptide	cancer
adiposin; lipotropin	Preclinical			biotechnology	obesity; cancer
alpha mutein; mutein, alpha; HT 003	Preclinical			biotechnology	cancer
anticancer oligonucleotides, MicroProbe	Preclinical			biotechnology	cancer
ATF HI 8	Preclinical			biotechnology	cancer
B 2036PEG; PEG-B 2036; TROVERT	Phase II			biotechnology	retinopathy; acromegaly; cancer; diabetes; kidney disease
cancer immunotherapy, MedImmune	Discontinued			biotechnology	cancer

cancer therapy, University Technologies International	Preclinical		biotechnology	cancer
cell lysis factor, Texas University	Preclinical		biotechnology	cancer
colon cancer therapy, Axis Genetics	Preclinical		biotechnology	cancer
cytolytic factor; CF	Preclinical		biotechnology	cancer
DCC tumor suppressor gene	Preclinical		biotechnology	cancer
drug delivery system, HIT breast cancer	Preclinical		biotechnology	cancer
drug delivery system, ONYX 015; ONYX 015, viraMASC coating; ONYX 015	Preclinical		biotechnology	cancer
drug delivery system, ONYX 838; ONYX 838, viraMASC coating	Preclinical		biotechnology	cancer
G 207	Phase I		biotechnology	cancer
gene discovery, hereditary glioma, Myriad	Preclinical		biotechnology	cancer
gene discovery, leukemia, Myriad	Preclinical		biotechnology	cancer
gene discovery, lung cancer, Myriad	Preclinical		biotechnology	cancer
gene therapy, anti-erbB-2 single chain	Preclinical		biotechnology	cancer

gene therapy, antisense insulin-like growth factor-1; gene therapy, antisense IGF-1	Phase I		biotechnology	cancer
gene therapy, breast cancer; gene therapy, bcr1, MB 200	Preclinical		biotechnology	cancer
gene therapy, interleukin-2	Preclinical		biotechnology	cancer
HER-2/neu oncogene protein	Discontinued		biotechnology	cancer
HGF/NK1	Preclinical		biotechnology	cancer
hPRL G129R	Preclinical		biotechnology	cancer
HSV 1716	Phase I		biotechnology	cancer
human chorionic gonadotropin; hCG; OVIDREL	Phase III		biotechnology	infertility; cancer
IL-2 analogue; INGN 301; F42K	Preclinical		biotechnology	cancer
tirolact; platelet factor 4; PF4; endostatin B; REPLISTATIN	Phase II		biotechnology	heparin neutralization; psoriasis; HIV infection; cancer; diabetes
mismatched double stranded RNA; poly(1)poly(C(sub12)U); AMPLIGEN	Pre-registration		biotechnology	allergy; viral infection; blood clotting disorder; cancer; chronic fatigue syndrome
neu differentiation factor; NDF	Discontinued		biotechnology	cancer
NV 1020	Preclinical		biotechnology	cancer



ONYX 015	Phase II			biotechnology	cancer
osteoprotegerin; OPG	Phase I			biotechnology	osteoporosis; cancer
p53 gene	Preclinical			biotechnology	cancer
prostate cancer therapy, Axis Genetics	Preclinical			biotechnology	cancer
protein replacement therapy, retinoblastoma protein; protein replacement therapy, Rb protein	Preclinical			biotechnology	cancer
Salmonella typhimurium, mutagenized; mutagenized S typhimurium	Preclinical			biotechnology	cancer
single chain antigen binding protein; SCA	Preclinical			biotechnology	diagnosis; cancer
transcription factor, GM-CSF	Preclinical			biotechnology	cancer
urogenital sinus-derived growth inhibitory factor; UGIF; ps20	Preclinical			biotechnology	cancer; benign prostate hypertrophy
vaccine, beta-human chorionic gonadotrophin, Vaxcel; vaccine, cancer	Preclinical			biotechnology	cancer
vaccine, cancer, Ludwig Institute/SIGA	Preclinical			biotechnology	cancer

vaccine, non-Hodgkin's B cell lymphoma	Preclinical		biotechnology	cancer
verotoxin	Preclinical		biotechnology	cancer
angiogenesis inhibitor, Genzyme	Preclinical		biotechnology; angiogenesis inhibitor	cancer
angiopoietin 2	Preclinical		biotechnology; angiogenesis inhibitor	cancer
ANGIOSTATIN	Preclinical		biotechnology; angiogenesis inhibitor	retinopathy; cancer
BST 2001; ANGIOCOL	Preclinical		biotechnology; angiogenesis inhibitor	cancer
gene therapy, endostatin	Preclinical		biotechnology; angiogenesis inhibitor	cancer
Del-1 angiogenic protein based therapies	Preclinical		biotechnology; angiogenesis inhibitor; angiogenesis inducer	cancer; ischemia; restenosis
drug delivery system, TCS, antisense oligonucleotide, VEGFR; antisense oligonucleotide, VEGFR, TCS	Preclinical		biotechnology; angiogenesis inhibitor; antisense; oligonucleotide	cancer
BST 2002	Preclinical		biotechnology; angiogenesis inhibitor; peptide	cancer
antisense oligonucleotide, -myb; LR 3001; INX 3001	Phase I		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, c-kit	Preclinical		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotide, c- myb	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer, Enzo	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer, INSERM	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, chimeric 2-5A, chronic myelogenous leukemia	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, chronic myelogenous leukemia; RGA 1512	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, epidermal growth factor receptor; antisense oligonucleotide, EGFR	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, insulin-like growth factor-1 receptor; antisense oligonucleotide, IGF- 1R; INX 4437	Phase I		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotide, mdm2	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, multi-drug resistance protein-1; antisense oligonucleotide, MDR-1	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, myelogenous leukemia; GT 1102	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, myelogenous leukemia; GT 1106	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, p120; ISIS 3466	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, phospholipase A2; antisense oligonucleotide, PLA2	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, protein kinase A; GEM 231	Phase II		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotide, protein kinase C- alpha; antisense oligonucleotide, cancer; ISIS 3521; CGP 64128A; ISI 641A	Phase II		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, protein kinase type I; antisense oligonucleotide; pKA-I	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, tumor necrosis factor; AR 797	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, vascular endothelial growth factor; AR 639	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, vascular endothelial growth factor; antisense oligonucleotide, VEGF; GEM 220	Preclinical		biotechnology; antisense; oligonucleotide	retinopathy; cancer; skin disease
antisense oligonucleotides, cancer, Matritech	Discontinued		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotides, human papillomavirus 16/18; antisense oligonucleotides, HPV 16/18	Preclinical		biotechnology; antisense; oligonucleotide	cancer; viral infection
antisense oligonucleotides, multi-drug resistance protein; antisense oligonucleotides, MRP	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, antisense oligonucleotide, erbB-2	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, antisense oligonucleotide, p27	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, TCS antisense oligonucleotide, c- myb; antisense oligonucleotide, TCS c-myb; INX 3000, TCS	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, TCS INX 3280; INX 3280 TCS; INXC 6295	Preclinical		biotechnology; antisense; oligonucleotide	cancer

drug delivery system, TCS, antisense oligonucleotide, IGF-1R; antisense oligonucleotide, IGF-1R, TCS; INX 4437, TCS	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, bcl-2; G 3139	Phase II		biotechnology; antisense; oligonucleotide; chemosensitizer	cancer
antisense oligonucleotide, raf-1, Neopharm; drug delivery system, antisense oligonucleotide, raf-1, Neopharm	Preclinical		biotechnology; antisense; oligonucleotide; radiosensitizer	cancer
antisense oligonucleotide, p65 NF-kappaB	Preclinical		biotechnology; antisense; oligonucleotide; transcription factor regulator	cancer
tumor necrosis factor apoptosis inducing ligand; TRAIL	Preclinical		biotechnology; apoptosis inducer	cancer
secreted apoptosis related proteins; SARPS	Preclinical		biotechnology; apoptosis inducer; apoptosis inhibitor	cancer; myocardial infarction; stroke
keratinocyte growth factor antagonist, NeXstar; KGF antagonist	Preclinical		biotechnology; aptamer; oligonucleotide	cancer

PDGF antagonist, NeXstar	Preclinical		biotechnology; aptamer; oligonucleotide	cancer
TGF-beta antagonist, NeXstar	Preclinical		biotechnology; aptamer; oligonucleotide	cancer
NX 1838	Phase I		biotechnology; aptamer; oligonucleotide; angiogenesis inhibitor	cancer; diabetes; retinopathy
MIG	Preclinical		biotechnology; chemokine; angiogenesis inhibitor	cancer
somatomedin binding protein; insulin-like growth factor binding protein; IGF BP-1	Suspended		biotechnology; cicatrizant	skin ulcer; cancer
interleukin-1 beta; IL- 1 beta	Discontinued		biotechnology; cicatrizant; cytokine; vaccine adjuvant	cancer; infectious disease
avotermin; transforming growth factor beta-3; TGF beta-3; CGP 46614	Phase II	transforming growth factor beta3 (human), dimer	biotechnology; cicatrizant; growth factor	cancer; skin ulcer; mucositis
tumor growth factor- alpha; TGF-alpha	Discontinued		biotechnology; cicatrizant; growth factor	eye disease; cancer; skin ulcer
fibroblast anticollagenase; FIBAC; anticollagenase fibroblast	Suspended		biotechnology; cicatrizant; NSAID	arthritis; cancer; skin ulcer; arthritis



tissue inhibitor of metalloproteinase 2; TIMP-2	Discontinued		biotechnology; collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; gene	cancer
BC 1; AS 122; AngioMab	Phase I		biotechnology; contrast medium; monoclonal antibody; radiotherapeutic; radiodiagnostic; angiogenesis inhibitor	cancer; diagnosis
senescence derived inhibitor 1; Sdi 1	Discontinued		biotechnology; cyclin dependent kinase inhibitor	cancer; psoriasis; eye disease; cancer
multiple tumor suppressor 1-based therapy	Preclinical		biotechnology; cyclin dependent kinase inhibitor; gene	cancer
AR 324	Discontinued		biotechnology; cytokine	cancer
canarypox IL-2; ALVAC-hIL-2	Phase II		biotechnology; cytokine	cancer
drug delivery system, interleukin secreting implant; interleukin secreting implant	Preclinical		biotechnology; cytokine	cancer
IL-2 conjugate, Ajinomoto; Gal3 modified IL-2	Preclinical		biotechnology; cytokine	cancer

interleukin-3/interleukin-6 mutein chimeric molecule; IL-3/IL-6 m chimeric molecule	Suspended		biotechnology; cytokine	cancer; thrombocytopenia
interleukin-6; IL-6	Suspended		biotechnology; cytokine	cancer
interleukin-6; IL-6; SDZ ILS 969; ILS 969	Discontinued		biotechnology; cytokine	cancer; thrombocytopenia; leukopenia
interleukin-6; IL-6; SIGOSIX	Phase II		biotechnology; cytokine	cancer; thrombocytopenia
interleukin-6 mutein; IL-6 mutein; FCE 27809	Phase I		biotechnology; cytokine	cancer; thrombocytopenia
magrestipen; magrestip; BB 10010; MIP-1 alpha	Discontinued	(human clone pAT464 macrophage inflammatory reduced), 26-L-alanine-lymphokine MIP 1 alpha	biotechnology; cytokine	cancer; HIV infection
SC 68420; MPO 1	Discontinued		biotechnology; cytokine	cancer
sonermin; tumor necrosis factor; TNF; PT 050; TIENEF; TINEF	Discontinued	3-157-tumor necrosis factor (human)	biotechnology; cytokine	cancer
sonermin; tumor necrosis factor; TNF; PAC 4D	Pre-registration	3-157-tumor necrosis factor (human)	biotechnology; cytokine	cancer; psoriasis

tasonermin; tumor necrosis factor alpha; TNF-alpha; FK 516; BEROMUN	Registered		biotechnology; cytokine	cancer
tumor necrosis factor; TNF	Discontinued		biotechnology; cytokine	cancer
tumor necrosis factor; TNF	Discontinued		biotechnology; cytokine	cancer
tumor necrosis factor alpha; TNF-alpha	Preclinical		biotechnology; cytokine	cancer
tumor necrosis factor alpha tip mutants; TNF-alpha tip mutants	Discontinued		biotechnology; cytokine	cancer
gene therapy, IL-12; gene therapy, cancer	Preclinical		biotechnology; cytokine; gene therapy; biotechnology; immunostimulant	cancer
gene therapy, interferon-alpha; gene therapy, cancer	Phase II		biotechnology; cytokine; gene therapy; immunostimulant; interferon	cancer

daniplestim; interleukin-3 synthokine; IL-3 synthokine; SC 55494	Discontinued	14-ala-18-ile-25-his- 29-arg-32-asn-37-pro- 42-ser-45-met-51-arg- 55-thr-59-leu-62-val- 67-his-69-glu-73-gly- 76-ala-79-arg-82-gln- 87-ser-93-ser-98-ile- 101-ala-105-gln-109- glu-116-val-120-gln- 123-glu-14-125- interleukin 3 (human clone D11)	biotechnology; cytokine; growth factor	cancer
IL-6/IL-2 fusion protein	Preclinical		biotechnology; cytokine; growth factor; hematopoietic factor	cancer
interleukin-6; IL-6; BETATROPIN	Suspended		biotechnology; cytokine; growth factor; hematopoietic factor	cancer; thrombocytopenia
aldesleukin; interleukin-2; IL-2; PROLEUKIN	Marketed	125-L-serine-2-133- interleukin 2 (human reduced)	biotechnology; cytokine; immunostimulant	cancer; HIV infection
cancer therapy, monkey vero cell line secreting IL-2; vero- IL2	Phase II		biotechnology; cytokine; immunostimulant	cancer

celmoleukin; interleukin-2; IL-2; TAKELEUKIN; CELEUK	Marketed	A-P-T-S-S-S-T-K-K- T-Q-L-Q-L-E-H-L-L- L-D-L-Q-M-I-L-N-G- I-N-N-Y-K-N-P-K-L- T-R-M-L-T-F-K-F-Y- M-P-K-K-A-T-E-L- K-H-L-Q-C-L-E-E-E- L-K-P-L-E-E-V-L-N- L-A-Q-S-K-N-F-H-L- R-P-R-D-L-I-S-N-I- N-V-I-V-L-E-L-K-G- S-E-T-T-F-M-C-E-Y- A-D-E-T-A-T-I-V-E- F-L-N-R-W-I-T-F-C- Q-S-I-S-T-L-T	biotechnology; cytokine; immunostimulant	viral infection; cancer
drug delivery system, aldesleukin; drug delivery system, interleukin-2; aldesleukin DepoFoam	Discontinued		biotechnology; cytokine; immunostimulant	cancer; HIV infection
drug delivery system, interleukin-2; interleukin-2 delivery system; drug delivery system, IL-2	Discontinued		biotechnology; cytokine; immunostimulant	viral infection; cancer
drug delivery system, liposome interleukin- 2; interleukin-2 liposome; OTx 287; OncoLipin-2; OncoLipin	Phase II		biotechnology; cytokine; immunostimulant	cancer

interferon alfa-N1; IFN alfa-N1; WELLFERON; SUMIFERON; HUMOFERON	Marketed		biotechnology; cytokine; immunostimulant	cancer; viral infection
interleukin-1; IL-1	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 alpha; IL-1a	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 alpha derivative; OCT 7000	Suspended		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 beta; IL- 1 beta; OCT 43; OCTIN	Pre- registration		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2	Suspended		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2; NSC 600664; LEUFERON 2	Phase III		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-5; IL-5	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-6; IL-6	Suspended		biotechnology; cytokine; immunostimulant	cancer

interleukin-7; IL-7	Preclinical		biotechnology; cytokine; immunostimulant	cancer
mitoflaxone + interleukin-1; interleukin-1 + mitoflaxone	Discontinued		biotechnology; cytokine; immunostimulant	cancer
oprelvekin; interleukin-11; IL-11; YM 294; NEUMEGA	Marketed		biotechnology; cytokine; immunostimulant	cancer; HIV infection; mucositis; Crohn disease
polyethylene glycol interleukin 2; PEG IL-2; interleukin 2 macrogol	Phase II		biotechnology; cytokine; immunostimulant	HIV infection; cancer
SC 71858; PMP	Phase I		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 beta; IL- 1 beta	Preclinical		biotechnology; cytokine; immunostimulant; cicatrizant	cancer; skin ulcer
interleukin-3; IL-3; ALLEVORIN	Suspended		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer
interleukin-3; IL-3	Discontinued		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer

interleukin-3; IL-3	Phase I		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer; leukopenia
leridistim; SC 70935; MPO	Phase III		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer
muplestim; interleukin-3; IL-3; SDZ ILE964; ILE 964; HEMOKINE	Phase III	human interleukin 3	biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer; thrombocytopenia; leukopenia
drug delivery system, ProLease interferon alfa; interferon alfa ProLease	Discontinued		biotechnology; cytokine; immunostimulant; interferon	viral infection; cancer
MAb, ch14.18-IL-2 fusion protein	Preclinical		biotechnology; cytokine; immunostimulant; monoclonal antibody	cancer
interleukin-4; IL-4; SCH 39400; QUADRAKINE	Phase II		biotechnology; cytokine; immunostimulant; NSAID	cancer; viral infection; rheumatoid arthritis
interleukin-12; IL-12; natural killer cell stimulatory factor; NKSF; YM 01C	Phase II		biotechnology; cytokine; immunostimulant; vaccine adjuvant	viral infection; cancer



interleukin-1 deletion mutants	Preclinical		biotechnology; cytokine; vaccine adjuvant; radioprotectant; immunostimulant	cancer; infectious disease
antisense oligonucleotide, cancer; DNA binding antisense oligonucleotide	Preclinical		biotechnology; DNA transcription inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, epidermal growth factor receptor; triple helix oligonucleotide, EGFR; T 03101	Discontinued		biotechnology; DNA transcription inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, her-2; triple helix oligonucleotide, her-2	Discontinued		biotechnology; DNA transcription inhibitor; antisense; oligonucleotide	cancer
sense oligonucleotide, NF-kappaB decoy	Discontinued		biotechnology; DNA transcription inhibitor; oligonucleotide; transcription factor regulator	cancer; viral infection
methioninase; AC 9301; ONCase	Preclinical		biotechnology; enzyme	cancer

acidic fibroblast growth factor-Pseudomonas exotoxin fusion protein; aFGF-Pseudomonas exotoxin fusion protein	Discontinued		biotechnology; fusion toxin	cancer
DWP 408	Preclinical		biotechnology; fusion toxin	cancer
epidermal growth factor diphtheria toxin chimeric protein; EGF diphtheria toxin chimeric protein; EGF fusion protein; DAB 389-EGF; DAB 389-EGF	Phase II		biotechnology; fusion toxin	cancer; restenosis; psoriasis
fusion toxin, interleukin-13 fusion protein; hIL13.E13K-PE4E	Preclinical		biotechnology; fusion toxin	cancer
GM-CSF diphtheria toxin chimeric protein; DT388 GM-CSF	Discontinued		biotechnology; fusion toxin	cancer
heregulin-Pseudomonas exotoxin fusion protein	Preclinical		biotechnology; fusion toxin	cancer

IL-4 fusion toxin; IL-4(38-37)-PE38KDEL; interleukin-4 fusion toxin; NBI 3001	Phase II		biotechnology; fusion toxin	cancer
IL13-PE38QQR; interleukin-13/pseudomonas exotoxin derivative	Preclinical		biotechnology; fusion toxin	cancer
interleukin-4-pseudomonas exotoxin A; IL-4-PE	Preclinical		biotechnology; fusion toxin	cancer
interleukin-6 diphtheria toxin chimeric protein; IL-6 diphtheria toxin chimeric protein; IL-6 fusion protein	Preclinical		biotechnology; fusion toxin	HIV infection; cancer
interleukin-6-Pseudomonas exotoxin 40 chimeric protein; IL-6-PE40	Preclinical		biotechnology; fusion toxin	cancer
interleukin-6-Pseudomonas exotoxin 66(4Glu) chimeric protein; IL-6-PE66(4Glu)	Preclinical		biotechnology; fusion toxin	cancer
melanocyte stimulating hormone diphtheria toxin chimeric protein; MSH diphtheria toxin chimeric protein; MSH fusion protein	Preclinical		biotechnology; fusion toxin	cancer

mitotoxin fibroblast growth factor-saporin; mitotoxin, FGF-saporin; PANTARIN	Discontinued			biotechnology; fusion toxin	cancer; restenosis; eye disease
TGFalpha-PE38; TGFalpha PE38 fusion toxin	Preclinical			biotechnology; fusion toxin	cancer
transferrin-CRM107; transferrin-toxin; HN 66000	Phase II			biotechnology; fusion toxin	cancer
transforming growth factor alpha-Pseudomonas exotoxin 40 chimeric protein; TGF alpha-PE40; TGFA-PE40	Preclinical			biotechnology; fusion toxin	cancer
interleukin-4 diphtheria toxin chimeric protein; IL-4 diphtheria toxin chimeric protein; IL-4 fusion protein	Preclinical			biotechnology; fusion toxin; immunosuppressant	autoimmune disease; transplant rejection; cancer; HIV infection
denileukin diftitox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL-2; LY 335348; DAB389IL2; ONTAK	Marketed	1-388-toxin (Corynebacterium diphtheriae strain C7), N-L-methionyl-387-L-histidine-388-L-alanine, (388.fwdarw.2')-protein with 2-133-interleukin 2 (human clone pTIL2-21a)		biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer

interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion toxin; IL-2 fusion toxin; DAB 486-IL-2; D-IL-2	Discontinued			biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; cancer
cancer therapy, int6	Preclinical			biotechnology; gene	cancer
cancer therapy, tumor suppressor, University Technologies International	Preclinical			biotechnology; gene	cancer; diagnosis
melastatin	Preclinical			biotechnology; gene	cancer
BRUSH-1 gene based therapy; cancer therapy	Preclinical			biotechnology; gene therapy	cancer
cancer therapy, anti- modified adenovirus, Onyx; ONYX 838	Preclinical			biotechnology; gene therapy	cancer
gene therapy, anti- adenoviral herpes simplex virus thymidine kinase; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer
gene therapy, anti- metastasis technology	Clinicals			biotechnology; gene therapy	cancer
gene therapy, anti- cancer stem cell; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer

gene therapy, anticancer T cell; gene therapy, CC49; CC 49	Phase II		biotechnology; gene therapy	cancer
gene therapy, antisense c-myc; gene therapy, prostate cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, Bcl-xS, cancer, IDUN	Preclinical		biotechnology; gene therapy	cancer
gene therapy, BCR-ABL transcription inhibitor protein	Preclinical		biotechnology; gene therapy	cancer
gene therapy, brca1, Vanderbilt University	Phase II		biotechnology; gene therapy	cancer
gene therapy, breast cancer; gene therapy, brca1, MB 300	Preclinical		biotechnology; gene therapy	cancer
gene therapy, breast cancer, Bavarian Nordic Research Institute; Procon CYP2B1	Preclinical		biotechnology; gene therapy	cancer
gene therapy, c-fos; gene therapy, cancer	Phase I		biotechnology; gene therapy	cancer
gene therapy, cancer; GENECEUTICALS	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer; gene therapy, T-body	Discontinued		biotechnology; gene therapy	cancer
gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer

gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer; gene therapy, cationic lipid vectors	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer; gene therapy, immunostimulatory genes	Phase II		biotechnology; gene therapy	cancer
gene therapy, cancer, Copernicus Gene Systems	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer, Vion	Preclinical		biotechnology; gene therapy	cancer
gene therapy, chronic myelogenous leukemia	Phase I		biotechnology; gene therapy	cancer
gene therapy, CITA; gene therapy, MHC class II deficiency	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cytosine deaminase	Phase I		biotechnology; gene therapy	cancer
gene therapy, cytotoxic T cells; gene therapy, cancer	Suspended		biotechnology; gene therapy	cancer
gene therapy, del-1; gene therapy, vascular disease; del-1	Preclinical		biotechnology; gene therapy	coronary artery disease; peripheral vascular disease; cancer
gene therapy, delta-like protein	Preclinical		biotechnology; gene therapy	cancer
gene therapy, drug activation	Preclinical		biotechnology; gene therapy	cancer

gene therapy, E1A repressor; gene therapy, cancer; RGG 0853; RGA 0853; tgDCC-E1A	Phase II			biotechnology; gene therapy	cancer
gene therapy, Egr-1 + TNF-alpha; gene therapy, Ad5.Egr-TNF; gene therapy, radiation-controlled technology	Preclinical			biotechnology; gene therapy	cancer
gene therapy, ErbB2-R; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer
gene therapy, fas ligand; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer
gene therapy, fasdeltaTM; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer
gene therapy, G156A MGMT; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer
gene therapy, glioblastoma; G207	Preclinical			biotechnology; gene therapy	cancer
gene therapy, glioma	Discontinued			biotechnology; gene therapy	cancer
gene therapy, GM-CSF	Preclinical			biotechnology; gene therapy	cancer
gene therapy, H-Nuc	Preclinical			biotechnology; gene therapy	cancer
gene therapy, H19; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer



gene therapy, herpes simplex thymidine kinase	Phase I		biotechnology; gene therapy	cancer
gene therapy, herpes simplex tyrosine kinase; gene therapy HS-tk	Preclinical		biotechnology; gene therapy	cancer
gene therapy, HLA-B7; gene therapy, melanoma	Preclinical		biotechnology; gene therapy	cancer
gene therapy, human papillomavirus; gene therapy, HPV	Preclinical		biotechnology; gene therapy	cancer
gene therapy, IL-12 fusion protein	Preclinical		biotechnology; gene therapy	cancer; viral infection
gene therapy, interleukin-2; AdCAIL-2	Phase I		biotechnology; gene therapy	cancer
gene therapy, interleukin-7	Discontinued		biotechnology; gene therapy	cancer
gene therapy, LelF	Discontinued		biotechnology; gene therapy	cancer
gene therapy, leukemia, Novartis; GVH 313	Phase I		biotechnology; gene therapy	cancer
gene therapy, macrophage colony-stimulating factor	Preclinical		biotechnology; gene therapy	cancer
gene therapy, mda-7; gene therapy, melanoma	Preclinical		biotechnology; gene therapy	cancer

gene therapy, MDR-1; gene therapy, cancer	Phase I		biotechnology; gene therapy	cancer
gene therapy, men1; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, multi-drug resistance	Preclinical		biotechnology; gene therapy	cancer
gene therapy, multiple drug resistance-1; gene therapy, MDR-1	Discontinued		biotechnology; gene therapy	cancer
gene therapy, p16, Introgen; gene therapy, cancer, Introgen; INGN 221	Preclinical		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer; SCH 58500	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, retroviral p53; INGN 101	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, adenovirus p53; INGN 201	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer; p53 TCS	Preclinical		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, p53/MDM2	Preclinical		biotechnology; gene therapy	cancer

gene therapy, p53/WAF1	Discontinued		biotechnology; gene therapy	cancer
gene therapy, pancreatic cancer, Bavarian Nordic Research Institute; Procon CYP2B1	Phase I		biotechnology; gene therapy	cancer
gene therapy, pRb2/p130; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, pro-drug activation	Preclinical		biotechnology; gene therapy	cancer
gene therapy, prostate cancer, Calydon; CN 706	Phase I		biotechnology; gene therapy	cancer
gene therapy, PTEN; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, RB 94; SG 94; RB 94	Preclinical		biotechnology; gene therapy	cancer
gene therapy, recombinant oncolytic HSV expressing CYP2B1; rRp450	Preclinical		biotechnology; gene therapy	cancer
gene therapy, retinoblastoma gene; gene therapy, Rb gene; ACNRB	Preclinical		biotechnology; gene therapy	cancer

gene therapy, ribozyme, cancer, City of Hope Medical Center; ribozyme, cancer, City of Hope Medical Center	Preclinical		biotechnology; gene therapy	cancer
gene therapy, scFv-RAS; INGN 212	Preclinical		biotechnology; gene therapy	cancer
gene therapy, solid tumors, Oxford BioMedica; MetXia	Preclinical		biotechnology; gene therapy	cancer
gene therapy, T cell chimeric receptor; gene therapy, cancer	Discontinued		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, cancer; gene therapy, HS-tk; SDZ GLI328; GLI 328	Phase III		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, leptomenigeal carcinomatosis; gene therapy, HS-tk gene	Discontinued		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk; gene therapy, mesothelioma	Phase I		biotechnology; gene therapy	cancer

gene therapy, thymidine kinase; gene therapy, HS-tk; gene therapy brain cancer	Phase I		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Discontinued		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Suspended		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Phase I		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, cancer; INXC-gTK	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase, National Institute of Neurological Disorders and Stroke; gene therapy, HS-tk, NINDS	Phase I		biotechnology; gene therapy	cancer

gene therapy, TNF alpha	Preclinical		biotechnology; gene therapy	cancer
gene therapy, tumor necrosis factor alpha; gene therapy, solid tumor	Phase II		biotechnology; gene therapy	cancer
toxigenes	Preclinical		biotechnology; gene therapy	cancer
gene therapy, epithelial cell cancer, Cobra Therapeutics; CTL 302	Preclinical		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, liver cancer, Cobra Therapeutics; CTL 203	Preclinical		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, prostate cancer, Cobra Therapeutics; CTL 401	Preclinical		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, angiogenesis	Preclinical		biotechnology; gene therapy; angiogenesis inhibitor	cancer
gene therapy, antiangiogenesis genes, cancer	Preclinical		biotechnology; gene therapy; angiogenesis inhibitor	cancer
gene therapy, cancer; gene therapy, angiogenesis inhibition	Preclinical		biotechnology; gene therapy; angiogenesis inhibitor	cancer

gene therapy, antisense K-ras; antisense oligonucleotide, K-ras; INGN 111	Preclinical		biotechnology; gene therapy; antisense; oligonucleotide	cancer
gene therapy, chemotherapy-resistance genes; gene therapy, MDR	Preclinical		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, MDR; gene therapy, cancer; gene therapy, MDR-1; MDRx1	Phase I		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, MDR-1; gene therapy, cancer	Phase I		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, gp91phox; gene therapy chronic granulomatous disease	Preclinical		biotechnology; gene therapy; coagulation factor	cancer
gene therapy, Sdi 1; gene therapy, cancer	Discontinued		biotechnology; gene therapy; cyclin dependent kinase inhibitor	cancer
gene therapy, cancer; gene therapy, VV-GM	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, cancer; gene therapy, cytokine; gene therapy, immunostimulatory cell surface molecules	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, consensus interferon; gene therapy, IFN- con1; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, IL-2; gene therapy, cancer; BIWB 2	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, IL-3, IntroGene; gene therapy, cancer, IntroGene	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interferon beta; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-12; gene therapy, cancer	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-12/B7-1; gene therapy, AdIL12.B7-1; gene therapy, cancer; AdIL12.B7-1	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer



gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; AC 9401; MetaGene	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; VCL 1102; LEUVECTIN	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, breast cancer; AVECTIN	Discontinued		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; BIWB 1	Discontinued		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, interleukin-2; gene therapy, neuroblastoma	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, colon cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, IL-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2 + interferon gamma; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2 + thymidine kinase; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2, interferon gamma, thymidine kinase; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-4; gene therapy, melanoma	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-7; gene therapy, IL-7; gene therapy, malignant melanoma	Suspended		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, interleukin-7; gene therapy, IL-7	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, tumor necrosis factor; gene therapy, TNF; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, tumor necrosis factor; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
NV 1030	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant; angiogenesis inhibitor	cancer
gene therapy, granulocyte macrophage-colony stimulating factor, Geniva; gene therapy, cancer, Geniva	Phase I		biotechnology; gene therapy; cytokine; immunostimulant; vaccine	cancer
gene therapy, MDR, GenPak; gene therapy, cancer	Phase II		biotechnology; gene therapy; hematoprotectant; chemoprotectant	cancer
gene therapy, MRP; gene therapy, cancer	Preclinical		biotechnology; gene therapy; hematoprotectant; chemoprotectant	cancer

gene therapy, HLA-B7; gene therapy, cancer; gene therapy, HLA-B7/cytotoxic complex; ALLOVECTIN-7	Phase III		biotechnology; gene therapy; immunostimulant	cancer
gene therapy, IL-2; gene therapy, small cell lung cancer; gene therapy, BPV vector	Phase I		biotechnology; gene therapy; immunostimulant	cancer
gene therapy, suicide gene + immunotherapeutic; gene therapy, cancer	Preclinical		biotechnology; gene therapy; immunostimulant	cancer
gene therapy, gamma interferon; gene therapy, cancer	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, GM-CSF; gene therapy, cancer; vaccine, cancer; GVAX	Phase II		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-10; gene therapy, cancer	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, melanoma; gene therapy, tyrosinase promoter	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer

gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, AdCAIL-2; gene therapy, cancer; AdCAIL-2	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-4; gene therapy, cancer	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-4; gene therapy, melanoma	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, leukemia; gene therapy, immunostimulatory molecules	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine	cancer

gene therapy, interferon alfa	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine; interferon	cancer
gene therapy, interferon gamma; gene therapy, cancer	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine; interferon	cancer
gene therapy, MRP; gene therapy, cancer	Preclinical		biotechnology; gene therapy; MDR inhibitor	cancer
gene therapy, multidrug resistance; gene therapy, MDR	Discontinued		biotechnology; gene therapy; MDR inhibitor	cancer
gene therapy, herpes simplex thymidine kinase gene; gene therapy, cancer	Phase I		biotechnology; gene therapy; NSAID	rheumatoid arthritis; restenosis; cancer
gene therapy, transforming growth factor beta; oligonucleotide, TGF beta	Phase I		biotechnology; gene therapy; oligonucleotide	cancer
gene therapy, hammerhead ribozyme, cancer, Berlex Biosciences; ribozyme, c-erb-B2, Berlex Biosciences	Preclinical		biotechnology; gene therapy; oligonucleotide; ribozyme	cancer

gene therapy, Ad(GV)CD.10; gene therapy, cytosine deaminase; gene therapy, colon cancer	Phase II		biotechnology; gene therapy; radiosensitizer	cancer
gene therapy, p53; vaccine, p53; gene therapy, cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, B cell lymphoma	Phase I		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, carcinoembryonic antigen; vaccine, gene-based, pGT37; vaccine, gene-based, cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, E7; vaccine, gene-based cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, gp100; vaccine, gene-based, melanoma	Phase I		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, gp100 + MART-1; vaccine, gene-based, melanoma	Phase II		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, MART-1; vaccine, gene-based, cancer	Phase I		biotechnology; gene therapy; vaccine	cancer

vaccine, gene-based, melanoma, Bavarian Nordic Research Institute; gene therapy, melanoma, Bavarian Nordic Research Institute; MVA TYR	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, NY-ESO-1; vaccine, gene-based, cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, T cell cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, human papillomavirus antigens; vaccine HPV antigens; vaccine, cervical cancer	Discontinued		biotechnology; gene therapy; vaccine	cancer
anti-dorsalizing morphogenetic protein-1	Preclinical		biotechnology; growth factor	cancer
heregulin; Neu differentiation factor; NDF	Discontinued		biotechnology; growth factor	cancer
megakaryocyte stimulating factor	Discontinued		biotechnology; growth factor	cancer
Red blood cell growth factor	Preclinical		biotechnology; growth factor	cancer
transforming growth factor beta; TGF beta; BMS 196725	Preclinical		biotechnology; growth factor	cancer; mucositis



transforming growth factor beta; TGF-beta	Preclinical		biotechnology; growth factor	mucositis; cancer; musculoskeletal disorder
keratinocyte growth factor 2; KGF 2; HG 03400	Phase II		biotechnology; growth factor; cicatrizing; chemoprotectant; cytoprotectant	cancer; mucositis; skin ulcer; alopecia; kidney disease
granulocyte macrophage colony stimulating factor muteins; GM-CSF muteins	Preclinical		biotechnology; growth factor; hematopoietic factor	cancer
polyethylene glycol hemoglobin; PEG-hemoglobin	Phase I		biotechnology; growth factor; hematopoietic factor	cancer; anemia
polyethylene glycol megakaryocyte growth and development factor; PEG-MGDF	Discontinued		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia
polyethylene granulocyte macrophage colony stimulating factor glycol; PEG-GM-CSF; PolyMASC-GM-CSF	Preclinical		biotechnology; growth factor; hematopoietic factor	cancer
thrombopoietin; TPO; megakaryocyte growth and development factor; MGDF	Phase III		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia

thrombopoietin; TPO	Discontinued		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia
thrombopoietin; TPO	Preclinical		biotechnology; growth factor	cancer; thrombocytopenia
milodistim; granulocyte macrophage colony stimulating factor/interleukin-3 chimeric; GM- CSF/IL-3 chimeric protein; PIXY 321; BMS 185032; PIXYKINE	Discontinued	APARSPSPST QPWEHVNAIQ EALRLLDLRS DTAAEMNEEV EWISEMFDLQ EPTCLQTRLE LYKQGLRGS TKLKGPLTMM ASHYKQHCPP TPETSCATQI ITFESFKENL KDFLLVIPFD CWEPVQEGGG GSGGGGSAD MTQTTPLKTS WVDCSNMIDE IITHLKQPPL PLLDENNNG EDQDILMENN LRRPNLEAFN RAVKSLQDAS AIESILKNLL PCLPLATAAP TRHPIHKDG DWNEFRRLT FYLKTLNAQ AQQTTLSLAIF	biotechnology; growth factor; hematopoietic factor; cytokine; immunostimulant	cancer

cilmostim; macrophage colony stimulating factor; M- CSF; MACSTIM	Discontinued		biotechnology; growth factor; hematopoietic factor; immunostimulant	hyperlipidemia; bacterial infection; cancer
filgrastim; granulocyte colony stimulating factor; G- CSF; neutropoietin; KRN 8601; NEUPOGEN; GRANULOKINE; GRAN; GRIMATIN	Marketed	N-L-methionyl- colony-stimulating factor (human clone 1034)	biotechnology; growth factor; hematopoietic factor; immunostimulant; cicatrizant	cancer; HIV infection; pneumonia; leukopenia; skin ulcer
filgrastim SD01; PEG-granulocyte- colony stimulating factor; PEG-GCSF; SD-NEUPOGEN	Phase II		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; HIV infection; pneumonia; leukopenia
granulocyte macrophage colony stimulating factor; GM-CSF; LEUCOTROPIN	Phase III		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; leukopenia
macrophage inflammatory protein- 1 alpha; MIP-1 alpha	Preclinical		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer

molgramostim; granulocyte macrophage colony stimulating factor; GM-CSF; GMC 89107; SCH 39300; CSF 39300; LEUCOMAX	Marketed	colony stimulating factor 2 (human clone pHG25 protein moiety reduced)	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; leukopenia
martograstim; marograstim; granulocyte colony stimulating factor munein; G-CSF munein; KW 2228; NEU-UP	Marketed	1-(N-L-methionyl-L- alanine)-3-L- threonine-4-L- tyrosine-5-L-arginine- 17-L-serine-colony- stimulating factor (human clone 1034)	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; leukopenia
pegnartograstim; pegylated G-CSF munein; PEG-G; Ro 258315; Ro 25-8315; Ro 25-8315/000	Suspended	Pegnartograstim	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer
polyethylene glycol granulocyte colony stimulating factor; PEG-G-CSF; granulocyte colony stimulating factor macrogol	Discontinued		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer
progenipoietin; progenipoietin G; SD 1091	Preclinical		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer

totipotent stem cell factor; T-SCF	Preclinical		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer
FLT3 ligand, DNAX Research Institute; FLT 3	Preclinical		biotechnology; growth factor; immunostimulant; hematopoietic factor	cancer
Flt3 ligand, Immunex; FLT 3; FLT 003; MOBIST	Phase II		biotechnology; growth factor; immunostimulant; hematopoietic factor; vaccine adjuvant	cancer
stem cell proliferation factor; SCPF	Preclinical		biotechnology; growth factor; immunostimulant; hematopoietic factor	cancer
DWP 404	Preclinical		biotechnology; hematopoietic factor; growth factor	cancer; thrombocytopenia
TPO-Rp	Preclinical		biotechnology; hematopoietic factor; growth factor; peptide	thrombocytopenia; cancer
thyroid stimulating hormone; TSH; THYROGEN	Marketed	thyrotropin (human beta.-subunit) complex with chorionic gonadotropin (human alpha.-subunit)	biotechnology; hormone	cancer; diagnosis; hypothyroidism
polyethylene glycol arginase; PEG-arginase; arginase macrogol	Discontinued		biotechnology; hydrolase; arginase; enzyme	cancer

pegaspargase; polyethylene glycol L-asparaginase; PEG- L-asparaginase; asparaginase macrogol; ONCASPAR	Marketed	pegaspargase	biotechnology; hydrolase; asparaginase; enzyme	cancer
cervical cancer therapy, Transgene	Preclinical		biotechnology; immunostimulant	cancer
immunotherapeutic, cancer, Transgene	Phase II		biotechnology; immunostimulant	cancer
mistletoe lectin; mistlelektin	Preclinical		biotechnology; immunostimulant	cancer
totipotent stem cell receptor; FLK 2	Discontinued		biotechnology; immunostimulant	cancer
gene therapy, macrophage activated killer cells plus bispecific antibody; MAK therapy; MAK	Phase II		biotechnology; immunostimulant; gene therapy	cancer
ancestim; stem cell factor; SCF; STEMGEN	Pre- registration	N-L-methionyl-1- 165-hematopoietic cell growth factor KL (human clone V19.8:hSCF162) dimer	biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
granulocyte colony- stimulating factor; BM 800001	Suspended		biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer

interleukin-9, IL-9	Discontinued			biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
lenograstim; granulocyte colony stimulating factor; G- CSF; pluripoiectin; NEUTROGIN; GRANOCYTE; EUPROTIN; MYELOSTIM	Marketed	133-[O-[O-(N-acetyl- alpha-neuraminosyl)- (2-3)-O-beta-D- galactopyranosyl-(1- 3)-2-(acetylamino)-2- deoxy-beta-D- galactopyranosyl]-L- threonine]-colony stimulating factor (human clone 1034)		biotechnology; immunostimulant; growth factor; hematopoietic factor	anemia; HIV infection; cancer; leukopenia
sargramostim; granulocyte macrophage colony stimulating factor; GM-CSF; BI 61012; rhu GM-CSF; LEUKINE; PROKINE; INTERBERIN	Marketed	23-L-leucine colony- stimulating factor 2 (human clone pHG25 protein moiety)		biotechnology; immunostimulant; growth factor; hematopoietic factor; vaccine adjuvant	cancer; infectious disease; HIV infection; leukopenia
stem cell factor; SCF	Discontinued			biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
ImmTher	Phase II			biotechnology; immunostimulant; peptide	cancer

vaccine, prostate cancer; JT 1001; OncoVax-P; OncoVax-Pr	Phase II		biotechnology; immunostimulant; vaccine	cancer
cytokine cocktail; BC-IL; leukocyte interleukin injection; MULTIKINE	Phase II		biotechnology; immunostimulant; vaccine adjuvant; cytokine	cancer; infectious disease; HIV infection
ZYN-LINKER conjugated superantigens	Suspended		biotechnology; immunosuppressant; immunostimulant; NSAID	rheumatoid arthritis; cancer
MAb, human interleukin-6 receptor; MAb, human IL-6 receptor; hPM-1; MRA	Phase I		biotechnology; immunosuppressant; monoclonal antibody	autoimmune disease; cancer
E 21R	Preclinical		biotechnology; immunosuppressant; NSAID	cancer; inflammation; allergy
G28-5 sFV-PE40	Preclinical		biotechnology; immunotoxin	cancer
immunotoxin, lymphoma	Discontinued		biotechnology; immunotoxin	cancer
MAb, glioma/neuroblastoma-gelonin; GLIOMAB-H	Phase I		biotechnology; immunotoxin	cancer
immunotoxin, cancer; Immunomedics/NCI	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer



MAb, epidermal growth factor receptor-DM1; MAb, EGFR-DM1	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, interleukin-13-PE38QQR; immunotoxin, IL-13-PE38QQR	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, ricin A immunotoxin; MAb, colorectal cancer; ZD 0490; ICI D0490	Discontinued		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, SS(dsFv)-PE38	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, venus flytrap cluster conjugate	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer; diagnosis

nacolomab tafenatox; Phase I MAb, C242- staphylococcal enterotoxin A; FAb, C242-staphylococcal enterotoxin A; PNU 214565; LS 4565; TTMA LS 4585	Phase I	20-244- immunoglobulin G1, anti-(human colorectal tumor antigen C242) Fab fragment (mouse monoclonal r- C242Fab-SEA clone pKP941 gammal- chain) fusion protein with enterotoxin A (Staphylococcus aureus), disulfide with mouse monoclonal r- C242Fab-SEA clone pKP941 kappa-chain	biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, doxorubicin conjugate; MAb, BR 96-doxorubicin; MAb, BR 96-DOX; BMS 182248; BMS 18224801	Phase II		biotechnology; immunotoxin; monoclonal antibody; anthracycline; antibiotic; DNA intercalator	cancer
MAb, B43-genistein; B43-Gen immunoconjugate	Phase I		biotechnology; immunotoxin; monoclonal antibody; tyrosine kinase inhibitor	cancer

drug delivery system, interferon alfa; interferon alfa drug delivery system; SUMIFERON MINIPELLET	Pre-registration		biotechnology; interferon	viral infection; cancer
drug delivery system, interferon beta; interferon beta delivery system; drug delivery system, IFN beta	Discontinued		biotechnology; interferon	cancer; viral infection; cancer; viral infection
drug delivery system, oral interferon alfa-2a; IFN alfa-2a, oral	Suspended		biotechnology; interferon	cancer; viral infection
interferon alfa, natural; IFN-alfa, natural; EGIFERON	Marketed		biotechnology; interferon	cancer; viral infection
interferon alpha, hybrid; hybrid interferon alpha	Preclinical		biotechnology; interferon	viral infection; cancer
interferon alpha, natural; FPI 31	Pre-registration		biotechnology; interferon	viral infection; cancer
interferon beta; IFN-beta; DL 8234; FERON	Marketed		biotechnology; interferon	viral infection; cancer; retinopathy
interferon beta, IFN-beta	Discontinued		biotechnology; interferon	cancer; viral infection
interferon beta-1a; IFN beta; AVONEX	Marketed	interferon beta-1a	biotechnology; interferon	viral infection; multiple sclerosis; cancer

interferon beta-1a; interferon beta; IFN- beta; REBIF	Marketed		biotechnology; interferon	cancer; viral infection; multiple sclerosis; inflammatory bowel disease
interferon beta-1b; interferon beta-serine; SH 579; ZK 157046; BETASERON; BENESERON; BETAFERON	Marketed	2-166-interferon beta 1 (human fibroblast reduced)	biotechnology; interferon	multiple sclerosis; cancer; viral infection
interferon omega; IFN omega	Phase II		biotechnology; interferon	viral infection; cancer
polyethylene glycol interferon alfa-2b; PEG-interferon alfa- 2b; interferon alfa-2b macrogol; PEG- INTRON A	Phase III		biotechnology; interferon; cytokine	viral infection; cancer
interferon alfa-2b; IFN alfa-2b; SCH 30500; YM 1490; INTRON A; CIBIAN; VIRAFERON	Marketed		biotechnology; interferon; cytokine; immunostimulant	cancer; viral infection
tumor necrosis factor + interferon alfa-2a; interferon alfa-2a + tumor necrosis factor; TNF + IFN alfa-2a	Discontinued		biotechnology; interferon; growth factor	cancer

interferon alfa-2a; IFN alfa-2a; Ro 228181; ROFERON A; CANFERON A; ROFERON	Marketed	(human leukocyte protein moiety) interferon alpha A	biotechnology; interferon; immunostimulant	viral infection; cancer
interferon gamma-1a; SUN 4800; BIOGAMMA	Marketed		biotechnology; interferon; immunostimulant	cancer
interferon gamma-1b; interferon gamma; IFN gamma; ACTIMMUNE; IMUKIN; IMUFOR GAMMA	Marketed		biotechnology; interferon; immunostimulant	cancer; bacterial infection; chronic granulomatous disease; tuberculosis
interferon, consensus; consensus interferon; interferon alfacon-1; YM 643; INFERGEN	Marketed	interferon alpha 1 (human lymphoblast reduced), N-L- methionyl-22-L-arg- 76-L-ala-78-L-aspar- 79-L-glu-86-L-tyr-90- L-tyr-156-L-thr-157- L-asn-158-L-leu-	biotechnology; interferon; immunostimulant	viral infection; cancer
3622W94; BW 3622W94	Phase II		biotechnology; monoclonal antibody	cancer
antibodies, Sdi 1	Discontinued		biotechnology; monoclonal antibody	cancer
detumomab; MAbs, idiotype B cell lymphoma; MAbs, B cell lymphoma; B cell lymphoma MAbs; SPECIFID	Discontinued		biotechnology; monoclonal antibody	cancer

drug delivery system, liposome MAb, 273-34A; MAb, 273-34A liposome; liposome, MAb 273-34A	Preclinical			biotechnology; monoclonal antibody	cancer
edrecolomab; MAb, 17-1A; MAb, colorectal cancer; MAb, CO17-1A; 17-1A; C-1; PANOREX	Marketed	immunoglobulin G 2a (mouse monoclonal 17-1A gamma-chain anti-human colon cancer tumour-associated antigen), disulfide with mouse monoclonal 17-1A light chain dimer		biotechnology; monoclonal antibody	cancer
Intuzumab; MAb, humanized M195; MAb, humanized CD33; SMART M195; HuM195	Phase III	immunoglobulin G1 (human-mouse monoclonal HuM195.gamma.1-chain anti-human antigen CD 33), disulfide with human monoclonal HuM195.kappa.-chain, dimer		biotechnology; monoclonal antibody	cancer
Intuzumab-bismuth-213; MAb, humanized M195-213Bi	Phase I			biotechnology; monoclonal antibody	cancer
LYM 2	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, 12G5	Preclinical			biotechnology; monoclonal antibody	cancer

MAb, 2A11; MAb, gastrin releasing peptide	Phase II		biotechnology; monoclonal antibody	cancer
MAb, 323A3; 323A3	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, 3F8; IgG3 anti-ganglioside GD 2; MAb, neuroblastoma	Phase I		biotechnology; monoclonal antibody	cancer
MAb, 42/6; MAb, transferrin receptor	Phase I		biotechnology; monoclonal antibody	cancer
MAb, 88BV59-rhenium 186	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, 977; MAb, bladder cancer	Preclinical		biotechnology; monoclonal antibody	cancer; diagnosis
MAb, 9D9	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, adrenomedullin	Preclinical		biotechnology; monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
MAb, antiganglioside GM2; KM 966	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, antinuclear auto-antibodies; MAb, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, B cell lymphoma; 1D10	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, B-E4; MAb, interleukin-6; MAb, IL-6; B-E4	Phase I		biotechnology; monoclonal antibody	cancer
MAb, B4-DC1	Discontinued		biotechnology; monoclonal antibody	cancer

MAB, B6.2/212 single chain antibody; MAB, B6.2/212 SCA	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, BCD F9- radionuclide; MAB, breast cancer; BCD F9	Phase I		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, bispecific F(ab') <sub>2</sub> OC/TR; OCTR	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, bispecific hu- bsF(ab') <sub>2</sub>	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, bladder carcinoma; RG 355	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, BR 96; BR 96	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, breast cancer antigen; Pro 1.5.3	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, BW 494	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, c-Nd2; c-Nd2	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, C215- staphylococcal enterotoxin; FAb, C215-SEA	Phase II		biotechnology; monoclonal antibody	cancer
MAB, C242; MAB, colonic adenocarcinoma	Discontinued		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, C242-DM I conjugate; huC242- DM1	Preclinical		biotechnology; monoclonal antibody	cancer



MAb, C242-maytansine conjugate	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, cancer	Phase III		biotechnology; monoclonal antibody	cancer
MAb, cancer; MAb, EpCAM	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, cancer; BW 1209W95	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, cancer; hybrid antibody, anti-Her-2, anti-CD3	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, cancer and Fc; bispecific antibody, melanoma, glioma, neuroblastoma; MDX 260	Preclinical		biotechnology; monoclonal antibody	cancer
Mab, cancer, BioInvent	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, cancer, PPL	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, cancer, XTL Biopharmaceuticals; MAb, cancer, Neoprobe	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, carcinoembryonic antigen; MAb, CEA	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, carcinoembryonic antigen; MAb, CEA	Preclinical		biotechnology; monoclonal antibody	cancer

MAb, carcinoma; MAb, SK-1; MAb, cancer; MONOPHARM C	Phase I		biotechnology; monoclonal antibody	cancer
MAb, CC49; MAb, TAG B723; MAb, B723 second generation	Phase II		biotechnology; monoclonal antibody	cancer
MAb, CC49-interleukin-2; fusion protein, CC49-IL-2	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, CC49-lutetium 177; MAb, anti-TAG-72-lutetium 177	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, CC83; MAb, TAG B723; MAB, B723 second generation	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, CD19/CD3; bispecific antibody, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, CD28/CD30; Bi-MoAb	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, CD3/CD30; Bi-MoAb; bispecific antibody, CD3, CD30	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, CD34; anti-CD34	Phase I		biotechnology; monoclonal antibody	cancer
MAb, CD87; MAb, cancer, Willex Biotechnology	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, ch14.18	Phase II		biotechnology; monoclonal antibody	cancer

MAb, chemotherapeutic conjugates, IDEC	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, chimeric CC49; MAb, chimeric TAG B723	Phase I		biotechnology; monoclonal antibody	cancer
MAb, chimeric CC83; MAb, TAG B723	Phase I		biotechnology; monoclonal antibody	cancer
MAb, chimeric IgG1 anti CD20	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, colon-DM1	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, colorectal cancer	Phase I		biotechnology; monoclonal antibody	cancer; diagnosis
MAb, CYT 372 humanized; MAb, C46 humanized; MAb, humanized panadenocarcinoma	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, directed enzyme prodrug therapy; ADEPT, cancer therapy	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, directed enzyme prodrug therapy + CMDA; ADEPT + CMDA; ZD 2767	Phase II		biotechnology; monoclonal antibody	cancer
MAb, EGF-R and Fc; bispecific antibody, cancer; MDX 447; H 447; EMD 82633	Phase II		biotechnology; monoclonal antibody	cancer

MAb, epidermal growth factor receptor; MAb, EGF receptor; EMD 55900	Discontinued		biotechnology; monoclonal antibody	cancer	
MAb, epidermal growth factor receptor; MAb, EGF receptor; MAb, 528; MoAb528	Preclinical		biotechnology; monoclonal antibody	cancer	
MAb, epidermal growth factor receptor; MAb, EGFR; C 225	Phase III		biotechnology; monoclonal antibody	cancer	
MAb, epidermal growth factor receptor; MAb, EGFR; ICR 62	Phase I		biotechnology; monoclonal antibody	cancer	
MAb, epidermal growth factor, humanized; MAb, EGF, humanized; EMD 72000	Phase I		biotechnology; monoclonal antibody	cancer	
MAb, erbB-2; MAb, cancer	Preclinical		biotechnology; monoclonal antibody	cancer	
MAb, erbB2	Preclinical		biotechnology; monoclonal antibody	cancer	
MAb, F(ab)2 NRC002-rhenium 186; MAb, antiCEA	Discontinued		biotechnology; monoclonal antibody	cancer	
MAb, F4	Preclinical		biotechnology; monoclonal antibody	cancer	

MAb, Fab NRLU10-radionuclide; MAb, lung cancer; MAb, prostate cancer	Phase I			biotechnology; monoclonal antibody	cancer; diagnosis
MAb, fas; MAb, bladder cancer	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, FC-2.15	Phase II			biotechnology; monoclonal antibody	cancer
MAb, fibroblast growth factor receptor; MAb, FGFR	Discontinued			biotechnology; monoclonal antibody	cancer
MAb, germ cell cancer; ImmuraID-HCG	Discontinued			biotechnology; monoclonal antibody	cancer
MAb, gp75; MELVAX II	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, heparanase	Preclinical			biotechnology; monoclonal antibody	cancer; diagnosis
MAb, HER-2 immunoliposome	Discontinued			biotechnology; monoclonal antibody	cancer
MAb, HER2/neu20 immunoliposomes, breast cancer; C 6.5	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, Hodgkin's lymphoma	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, human antiganglioside	Phase II			biotechnology; monoclonal antibody	cancer
MAb, human chorionic gonadotropin; MAb, hCG; CTP 103	Preclinical			biotechnology; monoclonal antibody	cancer

MAb, human chorionic gonadotropin, human; MAb, hCG, human	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, human EpCAM; UBS 54	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, humanized LL2; MAb, B cell lymphoma; LymphoCide	Phase II		biotechnology; monoclonal antibody	cancer
MAb, humanized N901-DC1	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, humanized, cancer; MAb, cancer humanized	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, IgG1 fragment	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, IGX	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, ING-1; MAb, carcinoma	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, interleukin-6; MAB, IL-6	Phase I		biotechnology; monoclonal antibody	cancer
MAB, KAI1; MAb, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, KM641; KM 641	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, L 6; L 6	Discontinued		biotechnology; monoclonal antibody	cancer

MAb, L6 alkaline phosphatase conjugate; L6 alkaline phosphatase MAb conjugate; MAb, carcinoma	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, Lewis Y; ABL 364; SDZ ABL 364	Phase I		biotechnology; monoclonal antibody	cancer
MAb, Lewis Y, humanized; HuABL 364; SMART ABL 364; BR 55-2	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, LL2-rhenium 188; Re-188-LL2	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, MAb fragment, REC A33-nuclide	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, mB43-technetium 99m; Tru-Scint OV	Phase II		biotechnology; monoclonal antibody	cancer; diagnosis
MAb, MDX 11; MAb, myeloid leukemia; MAb, CD15; MDX 11; PM 81	Phase II		biotechnology; monoclonal antibody	cancer
MAb, melanoma; MAb, cancer; MONOPHARM M	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, melanoma, Novartis; CGP 62360	Phase I		biotechnology; monoclonal antibody	cancer
MAb, MN-14 carcinoembryonic antigen; MAb, MN-14 CEA; CEA-Cide	Phase II		biotechnology; monoclonal antibody	diagnosis; cancer

MAb, MRK 20; MRK 20	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, multiple myeloma, U-BiSys	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, oncology, Glaxo Wellcome	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, ONS M21; ONS M21	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, P-67; MAb, acute myelogenous leukemia	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, PAM4	Phase I		biotechnology; monoclonal antibody	cancer
MAb, polymorphic epithelial mucin; MAb, PEM; AS 125	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, prostate cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, prostate cancer	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, prostate cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, SM3 phosphorus 32	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, TAG-72	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, TAG-72 and Fc; bispecific antibody, cancer; MDX 220	Phase II		biotechnology; monoclonal antibody	cancer



MAB, TB94, human; MAB, TB94, IgA1k; MAB, small cell lung cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, TH69	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, transcobalamin II; MAB, vitamin B12 carrier protein, Receptagen	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, transferrin receptor targeted immunotoxin; MAB, tfnR targeted immunotoxin; tfnR- CRM107	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, tumor necrosis factor; MAB, TNF; SMA TNF	Preclinical		biotechnology; monoclonal antibody	Crohn disease; cancer; septic shock
MAB, tumor necrosis factor alpha; MAB, TNF-alpha; MAB32	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, U36/E48	Discontinued		biotechnology; monoclonal antibody	cancer
MAbs, cancer, human, Medarex	Preclinical		biotechnology; monoclonal antibody	cancer
MAbs, chimeric, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAbs, pancreaticoma, B-cell tumor; bispecific antibody, cancer	Preclinical		biotechnology; monoclonal antibody	cancer

prostate carcinoma tumor antigens	Discontinued			biotechnology; monoclonal antibody	cancer; diagnosis
rituximab; MAb, CD20; MAb, pan-B; IDEC 2B8; Ro 425294; IDEC 102; RITUXAN; MabThera	Marketed	immunoglobulin G1 (human-mouse monoclonal IDEC- C2B8 gamma 1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC- C2B8 kappa-chain, dimer		biotechnology; monoclonal antibody	cancer
SDZ MMA 383; MMA 383	Phase I			biotechnology; monoclonal antibody	cancer
trastuzumab; HERCEPTIN	Marketed	immunoglobulin G1, anti-(human p185neu receptor) (human- mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer		biotechnology; monoclonal antibody	cancer
MAB, KDR; MAB, vascular endothelial growth factor receptor; DC 101	Preclinical			biotechnology; monoclonal antibody; angiogenesis inhibitor	cancer
MAB, KDR; MAB, vascular endothelial growth factor receptor; CPIC11	Preclinical			biotechnology; monoclonal antibody; angiogenesis inhibitor	cancer

MAB, VNR integrin; LM 609; VITAXIN	Phase II		biotechnology; monoclonal antibody; angiogenesis inhibitor	cancer
MAB, CEA and doxorubicin; MAB, 26-61-10; bispecific antibody, CEA and doxorubicin	Preclinical		biotechnology; monoclonal antibody; anthracycline; DNA intercalator; antibiotic	cancer
MAB, antilaminin gamma2 chain; BST 11004	Preclinical		biotechnology; monoclonal antibody; contrast medium	cancer; diagnosis
MAB, cancer; MAB, tumor necrosis technology; MAB, TNT	Preclinical		biotechnology; monoclonal antibody; contrast medium; radiodiagnostic; radiotherapeutic	cancer
MAB, cancer, radiolabeled; NOVOMAB-G2	Phase I		biotechnology; monoclonal antibody; contrast medium; radiodiagnostic; radiotherapeutic	cancer; diagnosis
MAB, epidermal growth factor receptor; MAB, EGFr; DiaCIM; TheraCIM; RadioTheraCIM	Phase I		biotechnology; monoclonal antibody; contrast medium; radiotherapeutic; radiodiagnostic	cancer; diagnosis
MAB, TC5-Au198	Preclinical		biotechnology; monoclonal antibody; contrast medium; radiotherapeutic; radiodiagnostic	cancer; diagnosis

MAb, B cell-cytokine fusion protein	Preclinical		biotechnology; monoclonal antibody; cytokine	cancer
interleukin-2, antiganglioside chimeric protein; G2-IL2 fusion protein; MAb-G2 IL-2 fusion protein; ch14.18-IL2	Preclinical		biotechnology; monoclonal antibody; cytokine; growth factor	cancer
MAb, L49-sFv-beta-lactamase	Preclinical		biotechnology; monoclonal antibody; enzyme	cancer
MAb, 2C11.F(ab') <sub>2</sub> + microbeads; MAb, anti-CD3 + microbeads; PLATAR construct	Discontinued		biotechnology; monoclonal antibody; immunostimulant	bacterial infection; cancer
MAb, c-erbB-2 and CD16; bispecific antibody, c-erbB-2 and CD16; 2B1	Phase I		biotechnology; monoclonal antibody; immunostimulant	cancer
MAb, c-Mpl; MAb, thrombocytopenia; BAH 1	Preclinical		biotechnology; monoclonal antibody; immunostimulant	thrombocytopenia; cancer
MAb, CD3 F(ab') <sub>2</sub> + microbeads; MAb, CD3 + microbeads; PLATAR construct	Discontinued		biotechnology; monoclonal antibody; immunostimulant	bacterial infection; cancer

MAB, HER-2 and Fc; bispecific antibody, ovarian and breast cancer; bispecific antibody 520C9x22; MDX 210	Phase II			biotechnology; monoclonal antibody; immunostimulant	cancer
daclizumab; dacliximab; MAb, Tac; MAb, humanized Tac; MAb, SMART Tac; Ro 247375; ZENAPAX	Marketed	immunoglobulin G1 (human-mouse monoclonal clone 1H4 gamma chain anti-human antigen Tac), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer		biotechnology; monoclonal antibody; immunosuppressant	transplant rejection; cancer; autoimmune disease; eye disease
MAB, alpha-tubulin	Preclinical			biotechnology; monoclonal antibody; immunosuppressant	cancer; autoimmune disease; diagnosis
MAB, T cell antigen receptor; TM 29	Preclinical			biotechnology; monoclonal antibody; immunosuppressant	cancer; Crohn disease
MAbs, B cells; migis	Discontinued			biotechnology; monoclonal antibody; immunosuppressant	autoimmune disease; cancer
MAB, MHC class II	Preclinical			biotechnology; monoclonal antibody; immunosuppressant; NSAID	autoimmune disease; transplant rejection; graft versus host disease; cancer

MAB, 791T/36-ricin A immunotoxin; immunotoxin- colorectal cancer; XOMAZYME 791	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, A7 mitomycin C-dextran conjugate; MAB, A7-MMCD; MAB, colon cancer mitomycin C-dextran conjugate	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, alpha CD80- gelonin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, alphaCD86- gelonin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, Anti-Tac Pseudomonas exotoxin; immunotoxin, T cell cancers	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, B3- Pseudomonas exotoxin; immunotoxin B3-PE 38; LMB 1	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, B4-blocked ricin; MAB, B4-bR; ONCOLYSIN B	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, B7- immunotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer

MAb, BACH 250-gelonin conjugate; immunotoxin, BACH 250-gelonin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, basic fibroblast growth factor receptor-saporin; MAb, bFGF receptor-SAP; 11A8	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CD33-calicheamicin; CMA 676; CDP 771	Phase III		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CMB 401-calicheamicin; MAb, ovarian cancer; CMB 401; CDP 671	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CYT 103-aminopterin; MAb, B72.3-aminopterin; ONCOTHER 130	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, epidermal growth factor receptor immunotoxin; immunotoxin, EGRF; OLX 103; TP 40; L 691912	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer

MAb, erbB-2-Pseudomonas exotoxin; immunotoxin, single chain erbB-2-Pseudomonas exotoxin; OLX 209; AR 209	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, F(ab') <sub>2</sub> HRS-3 deglycosylated ricin A; MAb, HRS-3 deglycosylated ricin A; MAb, F(ab') <sub>2</sub> HRS-3 dgA; Mab, HRS-3 deglycosylated ricin A; MAb, F(ab') <sub>2</sub> HRS-3 dgA; MAb, IRac dgA	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, F(ab') <sub>2</sub> IRac deglycosylated ricin A; MAb, IRac deglycosylated ricin A; MAb, F(ab') <sub>2</sub> IRac dgA	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, Fv B3-Pseudomonas exotoxin; immunotoxin Fv B3-PE 38; LMB 7; NSC 658931	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer



MAB, FvB1-Pseudomonas exotoxin; immunotoxin FvB1-PE33	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, LL2-Pseudomonas exotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, ME20-Pseudomonas exotoxin; immunotoxin ME20-LysPE40	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, N901-blocked ricin; immunotoxin, N901-bR; ONCOLYSIN S	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, N901-DM1; immunotoxin, N901-DM1	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, OVB3-Pseudomonas exotoxin conjugate; immunotoxin OVB3-PE	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, RFB4(dsFv)-PE38; immunotoxin, RFB4(dsFv)-PE38; BL 22; NSC 691237	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, RFT5-ricin A (CD25) immunotoxin; RFT5.dgA	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer

MAB, ricin A immunoconjugate; immunotoxin melanoma; XOMAZYME-MEL	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, SN7-ricin A; immunotoxin SN7-ricin A; SN7-RA	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, Tac(Fv)-PE38; immunotoxin Tac(Fv)-PE38; LMB 2	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, Tac(Fv)-PE40 immunotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, transferrin receptor targeted immunotoxin; MAB, tfrR targeted immunotoxin; 454A12-rRA	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, tumor immunotoxins, Menarini	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, UV72 immunotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, VEGF receptor/ligand complex-dgA; immunotoxin VEGF receptor/ligand complex-dgA	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	

MABs, CD22-saporin; Phase II immunotoxin, bispecific, cancer; ITF 1265 + ITF 1269			biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, doxorubicin conjugates; MAB, CC49-doxorubicin	Discontinued		biotechnology; monoclonal antibody; immunotoxin; anthracycline; antibiotic; DNA intercalator	cancer
MAB, anthracycline amine derivative	Preclinical		biotechnology; monoclonal antibody; immunotoxin; antibiotic	cancer
MAB, CD5-momordin; immunotoxin CD5-momordin; ITF 1532	Phase II		biotechnology; monoclonal antibody; immunotoxin; immunosuppressant	cancer; transplant rejection
MAB, humanized, MRK 16; MRK 16	Preclinical		biotechnology; monoclonal antibody; MDR inhibitor	cancer
MAB, MRK 17; MRK 17	Discontinued		biotechnology; monoclonal antibody; MDR inhibitor	cancer
MAB, humanized, leukemia; MAB, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	Phase II		biotechnology; monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
iodine 131 tositumomab; MAB, CD20-iodine 131; BEXXAR	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer

MAB, 16.88-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, 35-67Cu; MAB, murine colon carcinoma; MAB, cancer	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, 88BV59-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, B3-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, CC49-yttrium	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, CD20-iodine 131	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, CD20-streptavidin + biotin-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, CEA rhenium-188; MAB, colorectal cancer; IMMURAIT-Rhenium	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, CG250-iodine 131	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, chimeric L6-iodine 131; BMS 180548	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer

MAb, CYT 103- yttrium 90; MAb, B72.3- <sup>90</sup> yttrium 90; ONCORAD OV103; ONCORAD CR103	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
MAb, ERIC1 yttrium 90	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
MAb, F(ab)2 NRLU10-rhenium 186; MAb, F(ab)2 pancarcinoma; RHENEX	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
MAb, G250-iodine 131	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
MAb, humanized MN-14; MAb, humanized carcinoembryonic antigen; MN 14; CEA-Cide	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
MAb, iodine-131, DNA-associated antigens; <sup>131</sup> I- chTNT-1/B; COTARA; Tumor Necrosis Therapy; TNT	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
MAb, LL2-iodine 131; LymphoCide; ImmuRAIT-LL2	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer	

MAB, LYM-1-iodine 131; LYM 1; ONCOLYM	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, MAB fragment, REC A33-TFM-nuclide; CDP 833	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, NRLU13-streptavidin + biotin-yttrium 90; AVICIDIN	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, OKB7-iodine 131; OKB7	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, pan-B-yttrium; MAB, B-cell radiation therapy; IDEC Y2B8	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, PEM-antisense oligonucleotide-radionuclide; AS 102	Preclinical		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, PF1-A; MAB, squamous cell carcinoma; AS 114	Preclinical		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, UJ13A yttrium 90	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer
yttrium Y 90 capromab; MAB, CYT 356-yttrium 90; MAB, 7E11C5-yttrium 90; MAB, prostate cancer; OncoRad PR	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer

MAB, 4B5; MAB, anti-GD2 anti-idiotypic; NOVOVAC-M1	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer
MAB, BEC-2; vaccine, BEC-2; EMD 60205; BEC2	Phase III		biotechnology; monoclonal antibody; vaccine	cancer
MAB, CA 125; vaccine, cancer; B43.13; OvaRex	Phase III		biotechnology; monoclonal antibody; vaccine	cancer
MAB, CA19.9; AR 44.6; GivaRex	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer
MAB, idiotypic CEA; vaccine, cancer; cancer vaccine; CeaVac	Phase II		biotechnology; monoclonal antibody; vaccine	cancer
MAB, idiotypic GD2; vaccine, cancer; cancer vaccine; TriGem	Phase II		biotechnology; monoclonal antibody; vaccine	cancer; psoriasis
MAB, idiotypic, MUC1; vaccine, cancer; cancer vaccine; TriAb	Phase II		biotechnology; monoclonal antibody; vaccine	cancer
MAB, MUC1; vaccine, cancer; AR 20.5; BrevaRex	Phase I		biotechnology; monoclonal antibody; vaccine	cancer
MAB, PSA; ProstaRex	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer

monoclonal antibody, anti-idiotypic, cancer	Clinicals		biotechnology; monoclonal antibody; vaccine	cancer
antisense oligonucleotide, B cell lymphoma	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, c-myc	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer; mRNA translation inhibitor, cancer	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, Ha-ras; ISIS 2503	Phase II		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, Kaposi's sarcoma	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer



antisense oligonucleotide, Philadelphia chromosome; antisense oligonucleotide, chronic myelogenous leukemia; G 1128	Phase II		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotides, K-ras	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
GPs 0193; NAVIN	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	HIV infection; cancer
LR 3523	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
BCG A4	Preclinical		biotechnology; oligonucleotide	cancer
LR 5165	Discontinued		biotechnology; oligonucleotide	cancer
oligonucleotide directed DNA therapy	Discontinued		biotechnology; oligonucleotide	cancer; genetic disorder; viral infection; bacterial infection
oligonucleotide, cancer, Kimeragen	Preclinical		biotechnology; oligonucleotide	cancer
oligonucleotide, chronic myelogenous leukemia, Kimeragen	Preclinical		biotechnology; oligonucleotide	cancer

antisense oligonucleotide, bcl- 2; ODN 2009	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, GeneSense Technologies; GTI 2040	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, GeneSense Technologies; GTI 2501	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, Isis/AstraZeneca	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, raf kinase; antisense oligonucleotide, cancer; ISIS 5132; CGP 69846A; CGP 69846A; ODN 698	Phase II	d(P-thio) (T-C-C-C- G-C-C-T-G-T-G-A- C-A-T-G-C-A-T-T-)	biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, TAG 6; TAG 6	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotides, non- Hodgkins lymphoma, Fox Chase Cancer Center	Preclinical		biotechnology; oligonucleotide; antisense	cancer

oligonucleotides, VimRx	Preclinical			biotechnology; oligonucleotide; ribozyme	cancer; psoriasis
ribozyme, bcl-2, Ribozyme	Preclinical			biotechnology; oligonucleotide; ribozyme	cancer
ribozyme, europium-tetraphyrin, cancer; ribozyme, europium tetraphyrin, viral infection	Preclinical			biotechnology; oligonucleotide; ribozyme	cancer; viral infection
ribozyme, K-ras	Preclinical			biotechnology; oligonucleotide; ribozyme	cancer
sense oligonucleotides, GenSet; transcription factor decoys, GenSet	Discontinued			biotechnology; oligonucleotide; transcription factor regulator	cancer; viral infection
polyethylene glycol uricase; PEG-uricase; uricase macrogol	Discontinued			biotechnology; oxidoreductase; uricase	gout; cancer
class II restricted melanoma antigens, National Institutes of Health	Preclinical			biotechnology; peptide	cancer
urokinase receptor antagonists, Chiron	Preclinical			biotechnology; peptide	cancer; inflammation
interferon-inducible protein-10; IP-10	Preclinical			biotechnology; peptide; chemokine	cancer
interferon-inducible protein-10; IP-10	Preclinical			biotechnology; peptide; chemokine	cancer; eye disease

antibody-derived anticancer peptides, Antisoma	Discontinued		biotechnology; peptide; contrast medium	cancer; diagnosis
RecepTox-GnRH	Preclinical		biotechnology; peptide; fusion toxin	cancer
chimeric peptides, National Institutes of Health	Preclinical		biotechnology; peptide; vaccine	cancer; viral infection
plasminogen activator inhibitor; PAI-2	Phase II		biotechnology; plasminogen activator inhibitor; cicatrizant	cancer; inflammation; skin ulcer
matrix metalloproteinase inhibitor	Discontinued		biotechnology; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	arthritis; cancer; arthritis
maspin; mammary serine proteinase inhibitor; LXR 023; METAREX	Preclinical		biotechnology; proteinase inhibitor; serine proteinase inhibitor	cancer
neutral endopeptidase; NEP	Discontinued		biotechnology; proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
oligonucleotides, acute promyelocytic leukemia	Preclinical		biotechnology; ribozyme; oligonucleotide	cancer
oligonucleotides, multiple drug resistance	Preclinical		biotechnology; ribozyme; oligonucleotide	cancer

ribozyme, BCR-ABL	Preclinical			biotechnology; ribozyme; oligonucleotide	cancer
ribozyme, ras, Ribozyme	Preclinical			biotechnology; ribozyme; oligonucleotide	cancer
ribozyme, vascular endothelial growth factor receptor; ribozyme, VEGF receptor; RPI 4610; ANGIOZYME	Phase I			biotechnology; ribozyme; oligonucleotide	retinopathy; cancer
screening technology, growth regulatory compounds	Preclinical			biotechnology; target based screening	drug design technology; cancer
drug delivery system, verotoxin fusion protein cancer vaccine; vaccine, cancer	Preclinical			biotechnology; vaccine	cancer
epidermal growth factor; EGF	Phase I			biotechnology; vaccine	cancer
MEDI 501	Phase I			biotechnology; vaccine	cancer; viral infection
MEDI 503	Preclinical			biotechnology; vaccine	cancer
MEDI 504	Preclinical			biotechnology; vaccine	cancer
tumor associated antigen; PP4X	Preclinical			biotechnology; vaccine	cancer
tumor associated antigen; CTAA 79 AV1017	Preclinical			biotechnology; vaccine	cancer

vaccine, B cell lymphoma specific idiotype-granulocyte macrophage colony stimulating factor; vaccine, Id/MoGM-CSF	Preclinical		biotechnology; vaccinecancer	
vaccine, breast cancer; immunotherapy, breast cancer; MUVAC	Preclinical		biotechnology; vaccinecancer	
vaccine, breast cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, breast cancer, CelSci	Preclinical		biotechnology; vaccinecancer	
vaccine, canarypox CEA; vaccine, cancer; ALVAC-CEA	Phase I		biotechnology; vaccinecancer	
vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, cancer, MedImmune	Discontinued		biotechnology; vaccinecancer	
vaccine, cervical cancer; vaccine, Hsp65-HPV E7 fusion protein; Hsp65E7; HspE7; ONCOCINE	Phase I		biotechnology; vaccinecancer	
vaccine, colorectal and lung cancers; colorectal and lung cancers vaccine; OncoVax-CL	Phase II		biotechnology; vaccinecancer	

vaccine, colorectal cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, Epstein Barr viral coat protein; vaccine, EBV	Preclinical		biotechnology; vaccineglandular fever; cancer	
vaccine, Epstein-Barr virus gp 220-340; vaccine, EBV	Clinicals		biotechnology; vaccinecancer	
vaccine, gp75 antigen; vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, hepatitis B core antigen fusion proteins, National Institutes of Health; vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, HER/neu-2 oncogene; vaccine, breast cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, human papilloma virus; vaccine, cervical cancer; vaccine, HPV	Phase I		biotechnology; vaccinecancer	
vaccine, human papillomavirus; therapeutic antigen, cervical cancer; vaccine, HPV; TA-HPV	Phase II		biotechnology; vaccinecancer; viral infection	

vaccine, human papillomavirus; therapeutic antigen, genital warts; vaccine, HPV; TA-GW	Phase II		biotechnology; vaccine	viral infection; cancer
vaccine, mage-1; vaccine, melanoma; TBC-Mage-1; MAGEVAC	Discontinued		biotechnology; vaccine	cancer
vaccine, MART-1; vaccine, melanoma	Phase I		biotechnology; vaccine	cancer
vaccine, mutant p53 and ras peptide activated monocytes	Phase I		biotechnology; vaccine	cancer
vaccine, neu; vaccine, breast and ovarian cancer; TBC-NEU	Preclinical		biotechnology; vaccine	cancer
vaccine, papilloma virus HPV 16; vaccine, cervical cancer	Discontinued		biotechnology; vaccine	cancer
vaccine, prostate cancer; immunotherapy, prostate cancer; PROSTVAC	Phase I		biotechnology; vaccine	cancer
vaccine, prostate cancer	Preclinical		biotechnology; vaccine	cancer
vaccine, prostate cancer; prostate cancer vaccine; NORELIN	Phase II		biotechnology; vaccine	cancer



vaccine, prostate cancer, CelSci	Preclinical		biotechnology; vaccine	cancer
vaccine, ras; vaccine, colorectal cancer; TBC-RAS; RASVAC	Discontinued		biotechnology; vaccine	cancer
vaccine, recombinant dendritic cells, Duke University	Phase I		biotechnology; vaccine	cancer
vaccine, TBC-CEA; vaccine, cancer; TBC-CEA	Phase II		biotechnology; vaccine	cancer
vaccine, tumor; tumor vaccine	Discontinued		biotechnology; vaccine	cancer
virus derived particles, human papillomavirus; VDPs, HPV	Discontinued		biotechnology; vaccine	cancer
thymalfasin; thymosin alpha-1; T-1; ZADAXIN	Marketed	(N-acetyl)-ser-asp-ala-ala-val-asp-thr-ser-ser-glu-ile-thr-thr-lys-asp-leu-lys-glu-lys-lys-glu-val-val-glu-glu-ala-glu-asn-OH	biotechnology; vaccine; adjuvant; immunostimulant; peptide	cancer; viral infection
vaccine, human papilloma E7 antigen; vaccine, HPV; vaccine, cervical cancer	Preclinical		biotechnology; vaccine; biotechnology	cancer
vaccine, gene-based, cancer	Preclinical		biotechnology; vaccine; gene therapy	cancer

vaccine, gene-based, non-Hodgkin's B cell lymphoma; VAXID	Phase II		biotechnology; vaccine; gene therapy	cancer
vaccine, gene-based, T cell lymphoma; APL 400020; GENEVAX	Preclinical		biotechnology; vaccine; gene therapy	cancer
vaccine, ALVAC-hB7.1; vaccine, ovarian carcinoma; AUT-OV-ALVAC-hB7.1	Phase I		biotechnology; vaccine; immunostimulant	cancer
vaccine, cervical intraepithelial neoplasia; TA-CIN; TA-CIN	Preclinical		biotechnology; vaccine; immunostimulant	cancer
MAb, I-Mel-1; I-Mel-1; MELIMMUNE-1	Discontinued		biotechnology; vaccine; monoclonal antibody	cancer
MAb, I-Mel-1 + MAb, I-Mel-2; MAb, I-Mel-2 + MAb, I-Mel-1; MELIMMUNE	Discontinued		biotechnology; vaccine; monoclonal antibody	cancer
MAb, idiotypic 105AD7; MAb, anti-idiotypic gp72; 105AD7	Phase III		biotechnology; vaccine; monoclonal antibody	cancer
MAb, neuroblastoma/glioma; MAb, NG 1; MAb, cancer; NG 1; MONOPHARM G	Preclinical		biotechnology; vaccine; monoclonal antibody	cancer

vaccine, MAb, anti-idiotypic, cancer; vaccine, cancer; MAb, cancer	Preclinical		biotechnology; vaccine; monoclonal antibody	cancer
vaccine, melanoma; MAb, MK2-23	Phase II		biotechnology; vaccine; monoclonal antibody	cancer
etidronate; YM 529; YH 529	Phase II	(1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethylidene)bisphosphonic acid	bisphosphonate	osteoporosis; hypercalcemia; cancer
etidronate; aminohexanediphosphonate; AHDP Na	Discontinued	(6-amino-1-hydroxyhexylidene)diphosphonic acid	bisphosphonate	Paget disease; osteoporosis; cancer
etidronate; pamidronate disodium; APD; CGP 23339AE; AREDIA; OSTEOKIT	Marketed	(3-amino-1-hydroxypropylidene)bisphosphonic acid	bisphosphonate	osteoporosis; cancer
etidronate; ibandronate sodium; BM 210955; BONDRONAT	Marketed	[1-hydroxy-3-(methylpentylamino)propylidene]bisphosphonic acid	bisphosphonate; postmenopausal osteoporosis	osteoporosis; cancer; hypercalcemia

RC 3095	Phase I	(3R)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxyl-L-glutamyl-L-tryptophyl-L-alanyl-L-valylglycyl-N-[(1S)-1-[[[(1S)-1-(aminocarbonyl)-3-methylbutyl]amino]methyl]-3-methylbutyl]-L-histidinamide	bombesin antagonist	cancer
D 22213	Phase I	[1(R),6[S-(R*,R*)]]-N2-[(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl)carbonyl]-L-glutamyl-L-tryptophyl-L-alanyl-L-valylglycyl-N-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]methyl]-3-methylbutyl]-L-histidinamide monoacetate	bombesin antagonist; peptide	cancer

PAK 200	Discontinued	5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-1-[2-(4-morpholinyl)ethyl]-4-(3-nitrophenyl)-3-pyridinecarboxylic acid 2-[phenyl(phenylmethyl)amino]ethyl ester, P-oxide	calcium antagonist	cancer
dilazep; ANGOSIR IS	Marketed	tetrahydro-1H-1,4-diazepine-1,4(5H)-dipropanol 3,4,5-trimethoxybenzoate (diester)	calcium channel blocker; hematoprotectant; chemoprotectant	cancer; cardiac therapy
D 1465	Discontinued		calcium channel blocker; MDR inhibitor	cancer
CP 55940	Preclinical	(1alpha,2beta,5alpha)-(-)-5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol	cannabinoid	cancer
casein kinase inhibitors, ICOS	Preclinical		casein kinase inhibitor; immunosuppressant; NSAID	inflammation; cancer
aragusterol A; YTA 0040	Preclinical		Cdk/cyclin inhibitor	cancer
ONCONEX	Preclinical		chelating agent	cancer

glucarolactam; ND 2001	Discontinued	5-amino-5-deoxy-D- glucosaccharic acid- delta-lactam	chemoprotectant	cancer
myeloid progenitor inhibitory factor; MPIF-1; HG 00300	Phase II		chemoprotectant; biotechnology; hematoprotectant; hematopoiesis inhibitor; stem cell division inhibitor; chemokine	cancer
dexrazoxane; razoxane (+), (S); ICRF 187; NSC 169780; ADR529; ICI 59118; CARDIOXANE; EUCARDION; RAZOXIN; ZINECORE; ZINECARD; ANTRAGARD	Marketed	(+)-(S)-4,4'- propylenedi-2,6- piperazinedione	chemoprotectant; cytoprotectant	cancer; heart failure
gammalinolenic acid + eicosapentaenoic acid; EF 27; AMELORAD; TARAGAM	Discontinued		chemoprotectant; cytoprotectant	cancer
ICRF 197	Preclinical		chemoprotectant; cytoprotectant	cancer; heart failure
MGI 136	Discontinued	diethyldithiocarbamat e	chemoprotectant; cytoprotectant	cancer

WR 151327; NSC 335662	Preclinical	3-[[3-(methylamino)propyl]amino]-1-propanethiol dihydrogen phosphate ester	chemoprotectant; cytoprotectant	cancer; HIV infection
amifostine; ethiofos; gammaphos; WR 2721; NSC 296961; YM 08310; WR 2721C; ETHYOL	Marketed	2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate	chemoprotectant; cytoprotectant; radioprotectant	cancer
hematopoietic growth factor inhibitors, Ligand	Preclinical		chemoprotectant; hematopoiesis inhibitor	cancer
hematopoietic progenitor cell inhibitor, University of Indiana	Preclinical		chemoprotectant; hematoprotectant; hematopoiesis inhibitor; stem cell division inhibitor	cancer
stem-cell division inhibitors, Terry Fox Laboratory	Discontinued		chemoprotectant; stem cell division inhibitor; hematopoiesis inhibitor	cancer
stem cell inhibitory factor, natural; SCIF	Discontinued		chemoprotectant; stem cell division inhibitor; hematoprotectant; hematopoiesis inhibitor	cancer
CRL 1095	Discontinued		chemosensitizer	cancer
CRL 1605	Preclinical		chemosensitizer	cancer
glutathione-S-transferase inhibitors, Telik	Preclinical		chemosensitizer	cancer

mapavin	Preclinical	3-[[[2-[(4-azido-2-nitrophenyl)amino]ethyl]amino]carbonyl]-O4-deacetyl-3-de(methoxycarbonyl)vincal leukoblastine	chemosensitizer	cancer
TER 199	Preclinical	(2R)-L-gamma-glutamyl-S-(phenylmethyl)-L-cysteiny-2-phenylglycine	chemosensitizer	cancer
declopramide; OXI 104	Phase II		chemosensitizer; apoptosis inducer; radiosensitizer	cancer
CMDA; CJS 8	Preclinical	N-[4-[(2-chloroethyl)[2-[methylsulfonyl]oxy]ethyl]amino]benzoyl]-L-glutamic acid	chlormethine derivative; alkylating agent	cancer
galamustine; galactose-6-mustard; C6 GLM; G 6 M	Discontinued	6-[bis(2-chloroethyl)amino]-6-deoxy-D-galactopyranose	chlormethine derivative; alkylating agent	cancer
SN 23862	Preclinical	5-[bis(2-chloroethyl)amino]-2,4-dinitrobenzamide	chlormethine derivative; alkylating agent	cancer
spiromustine; spirohydantoin mustard; SHM; speratine; NSC 172112	Phase II	3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione	chlormethine derivative; alkylating agent	cancer



talimustine; FCE 24517	Discontinued	N-[5-[[[(3-amino-3- iminopropyl)amino]car- bonyl]-1-methyl-4- 1H-pyrrol-3-yl]-4- [[[4-[[4-bis(2- chloroethyl)amino]be- nzoyl]amino]-1- methyl-1H-pyrrol-2- yl]carbonyl]amino]-1- methyl-1H-pyrrole-2- carboxamide	chlormethine derivative; alkylating agent	cancer
veramine; RL 0017	Preclinical	(3beta,16beta,17beta, 22S,25S)-17-methyl- 18-norspirosola-5,12- dien-3-ol	chlormethine derivative; alkylating agent	cancer
flintript; SR 27897; SR 27897B	Phase II	2-[[[4-(2- chlorophenyl)-2- thiazolyl]amino]carbo- nyl]-1H-indole-1- acetic acid	cholecystokinin A antagonist; cholecystokinin antagonist	eating disorder; cancer
docosanol, n-; docosanol, 1-; behenyl alcohol; LIDAKOL	Pre- registration	1-docosanol	cicatrizant	viral infection; skin ulcer; cancer
Myc/Max inhibitors, Apoptosis Technology; Myc/Max inhibitors, ICRF	Discontinued		cicatrizant	cancer; skin ulcer
OLX 501	Discontinued		collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	septic shock; cancer; vascular leakage

OLX 514	Discontinued			collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	septic shock; cancer
MAB, carcinoembryonic antigen; PR1A3	Phase I			contrast medium; monoclonal antibody; biotechnology; radiotherapeutic; radiodiagnostic	cancer; diagnosis
NLCQ 1	Preclinical	4-[3-(2-nitroimidazolyl)propylamino]-7-trifluoromethylquinoline hydrochloride		contrast medium; MRI agent; imidazole	diagnosis; cancer
vasoactive intestinal peptide-iodine 123; VIP-I 123	Phase II			contrast medium; peptide	diagnosis; cancer
cancer therapy, Angstrom/Diatide	Preclinical			contrast medium; radiotherapeutic; radiodiagnostic	cancer
fludarabine + prednisone; prednisone + fludarabine	Discontinued			corticosteroid	cancer
ORG 6632	Discontinued	21-chloro-9alpha-fluoro-11beta-hydroxy-16alpha,17alpha-dimethylpregna-1,4-diene-3,20-dione		corticosteroid; immunosuppressant	cancer; rheumatoid arthritis

HX 0836	Preclinical	(E)-3-(3,4-dihydroxyphenyl)-1-(2,5-dimethoxyphenyl)-2-propen-1-one	COX inhibitor; 5-lipoxygenase inhibitor	cancer
celecoxib; SC 58635; YM 177; CELEBREX; CELEBRA	Marketed	4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain; cancer
cyclocreatine; AM 285	Discontinued	2-amino-4,5-dihydro-1H-imidazole-1-acetic acid	creatine kinase modulator	cancer; viral infection
cdk2 inhibitors, Molecumetics	Preclinical		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase inhibitor, Agouron; cancer therapy, Agouron	Preclinical		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase/cyclin inhibitors, Mitotix; Cdk/cyclin inhibitors, Mitotix	Preclinical		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase4 modulators, Pharmacopeia; cdk4 modulator, Pharmacopeia	Preclinical		cyclin dependent kinase inhibitor	cancer

flavopiridol; NSC 649890; HMR 1275	Phase II	cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidyl)-4H-1-benzopyran-4-one hydrochloride	cyclin dependent kinase inhibitor	cancer
CYC 202	Preclinical		cyclin dependent kinase inhibitor; apoptosis inducer	cancer
tumor necrosis factor alpha, natural; TNF alpha, natural; tonermin; MHR 24	Pre-registration		cytokine	cancer
granulocyte-colony stimulating factor agonists, Pharmacopeia; granulocyte-colony stimulating factor agonists, Regeneron	Preclinical		cytokine agonist	cancer
interferon agonists, Ligand	Preclinical		cytokine agonist; NSAID	cancer; viral infection; infectious disease; multiple sclerosis
cytokine trap, Regeneron	Preclinical		cytokine antagonist	cancer; asthma; rheumatoid arthritis; allergy
IL-6 receptor antagonist, Peptor	Preclinical		cytokine antagonist; peptide; NSAID	cancer

CNI 1493	Phase I	N,N'-bis[3,5-bis[1-[(aminoinimomethyl)hydrazono]ethyl]phenyl]-decanediamide tetrahydrochloride	cytokine synthesis inhibitor	cancer
drug delivery system, IL-2, Biovector Therapeutics	Preclinical		cytokine; biotechnology	cancer
delivery system, gene therapy, IL-2, Biovector Therapeutics; gene therapy, IL-2, Biovector Therapeutics	Preclinical		cytokine; biotechnology; gene therapy; immunostimulant	cancer
cytotoxic lymphocyte maturation factor; CLMF	Discontinued		cytokine; immunostimulant	cancer
LY 295501; ILX 295501	Phase I	N-[[[(3,4-dichlorophenyl)amino]carbonyl]-2,3-dihydro-5-benzofuran-sulfonamide]	diaryl/sulfonylurea	cancer
sulofenur; LY 186641	Discontinued	N-[[[(4-chlorophenyl)amino]carbonyl]-2,3-dihydro-5-1H-indene-5-sulfonamide]	diaryl/sulfonylurea	cancer
AN 9; PIVANEX	Phase II	butanoic acid (2,2-dimethyl-1-oxopropoxy)methyl ester	differentiation inducer	cancer

CBHA	Preclinical	N-hydroxy-3-[3-(hydroxyamino)-3-oxo-1-propenyl]-benzamide	differentiation inducer	cancer
EMBA	Preclinical	diethyl bis-(pentamethylene-N,N-dimethylcarboxamide)malonate	differentiation inducer	cancer
hexamethylene bisacetamide; HMBA; NSC 95580; HEXABID	Phase II	N,N'-1,6-hexanediybisacetamide	differentiation inducer	cancer
NF 036	Preclinical	8-[(7-chloro-4-quinolinyl)amino]-1,3,5-naphthalenetrisulfonic acid trisodium salt	differentiation inducer	cancer
SAHA; SW 064652	Preclinical	suberoylanilide hydroxamic acid	differentiation inducer	cancer
TI 66	Preclinical	6-fluoro-7,7,8,8-tetramethyl-2,4-bis(phenylmethyl)-2,4-diazabicyclo[4.2.0]octane-3,5-dione	differentiation inducer	cancer
CDDO	Preclinical	2-cyano-3,12-dioxoooleana-1,9(11)-dien-28-oic acid	differentiation inducer; antiproliferative agent	cancer

alitretinoin; LGD 1057; LG 1057; LGN 1057; ALRT 1057; NSC 659772; PANRETIN	Marketed	9-cis-retinoic acid	differentiation inducer; retinoid agonist; RXR agonist	cancer; psoriasis
AG 187	Discontinued	2,4-diamino-6-(N-(4-(phenylsulfonyl)benzyl)methylamino)quinazoline	dihydrofolate reductase inhibitor	cancer
LY 298207	Preclinical	N-[4-[4-(2,4-diamino-5-pyrimidinyl)butyl]benzoyl]-L-glutamic acid	dihydrofolate reductase inhibitor	cancer
LY 316373	Preclinical	N-[4-[3-(2,4-diamino-5-pyrimidinyl)propyl]benzoyl]-L-glutamic acid	dihydrofolate reductase inhibitor	cancer
trimetrexate; trimetrexate glucuronate; TMQ; NSC 249008; CI 898; NeuTrexin	Marketed	5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolin-6-yl]carbamate	dihydrofolate reductase inhibitor; antifolate; NSAID	cancer; psoriasis; rheumatoid arthritis; pneumocystis
drug delivery system, methotrexate; methotrexate Therapeutic Implant; MPI 5004; IntraDose-MTX; INTRADOSE-MTX	Discontinued		dihydrofolate reductase inhibitor; antimetabolite	cancer

MDAM	Phase I	N-[4-[2-(2,4-diamino-6-pteridiny)ethyl]benzoyl]-4-methylene-DL-glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma
eniluracil; 5-ethynyluracil; 5-EU; 776C85; BW 776C85	Phase III	5-ethynyl-2,4(1H,3H)-pyrimidinedione	dihydropyrimidine dehydrogenase inhibitor; antimetabolite	cancer
spirogermanium; NSC 192965; SPIRO-32	Discontinued	8,8-diethyl-N,N-dimethyl-2-aza-8-germaspiro[4.5]decan-2-propanamine	DMARD; NSAID	malaria; multiple sclerosis; rheumatoid arthritis; cancer
acidine-derived bisintercalators, NIH	Preclinical		DNA intercalator	cancer
anticancer agents, Kyowa Hakko	Discontinued		DNA intercalator	cancer
BBR 2778	Phase I	6,9-bis[(2-aminoethyl)amino]benzyl[isoquinoline-5,10-dione (Z)-2-butenedioate (1:2)]	DNA intercalator	cancer
bisnafide; DMP 840	Phase II	[R-(R*,R*)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)dione]dimethanesulfonate	DNA intercalator	cancer
BW 7U85	Discontinued		DNA intercalator	cancer
BW A502U; BW 502U83	Discontinued		DNA intercalator	cancer



crisnatol; crisnatol mesilate; BW 770U82; BWA 770U	Discontinued	2-[(6-chrysenylmethyl)amino]-2-methyl-1,3-propanediol	DNA intercalator	cancer
D 1411	Discontinued		DNA intercalator	cancer
DMP 315	Preclinical	[R-(R*,R*)]-5-[1-methyl-2-[[2-[(5-nitro-1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)propyl]amino]ethyl]amino]ethyl-4H-benzol[de]pyrido[3,4-g]isoquinoline-4,6(5H)dione dimethanesulfonate	DNA intercalator	cancer
Iedoxantrone; CI 958 isomer; PD 121373	Phase II	5-[(2-aminoethyl)amino]-2-[2-(diethylamino)ethyl]-2H-[1]benzothiopyrano[4,3,2-cd]indazol-8-ol	DNA intercalator	cancer
mitonafide; NSC 3002888	Phase II	2-[2-(dimethylamino)ethyl]-5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione	DNA intercalator	cancer

S 160202; S 16020-2; S 16020; NSC 659687; NSC D659687	Phase II	N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide dihydrochloride	DNA intercalator	cancer
cyclopentantraquinones, Sloan Kettering Institute	Preclinical		DNA intercalator; anthraquinone	cancer
OC 4845	Preclinical	1,1a,2,2a,5,10-hexahydro-3[[[[(methylamino)carbonyl]oxy]methyl]-azirino[2',3':3,4]cyclopenta[1,2-a]anthracene-5,10-dione	DNA intercalator; anthraquinone	cancer
C 1311	Phase I	5-[[2-(diethylamino)ethyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one	DNA intercalator; DNA topoisomerase inhibitor	cancer
NLP 1	Preclinical	5-[3-(2-nitro-1H-imidazol-1-yl)propyl]phenanthridinium bromide	DNA intercalator; radiosensitizer	cancer

aphidicolin glycinate; NSC 303812	Preclinical	glycine, (3 $\alpha$ ,4 $\alpha$ ,5 $\alpha$ ,17 $\alpha$ ) -3,17-dihydroxy-4- methyl-9,15-cyclo- C,18-dinor-14,15- secoandrostane-4,17- dimethanol ester hydrochloride	DNA polymerase inhibitor	cancer
DNA polymerase beta inhibitors, Agouron	Discontinued		DNA polymerase inhibitor; radiosensitizer; chemosensitizer	cancer
NU/ICRF 505	Discontinued		DNA topoisomerase inducer	cancer
UCT 4B; UCTB 4	Discontinued	2-[1-hydroxy-2- [1,2,3,4,4a,7,8,8a- octahydro-3-hydroxy- 5-(hydroxymethyl)- 1,2,4a-trimethyl-4- oxo-1- naphthalenyl]ethyl]- alpha-oxo- oxiraneacetaldehyde	DNA topoisomerase inducer; antibiotic	bacterial infection; cancer
9- aminocamptothecin; 9-AC; NSC 603071 (S); NSC 629971 (+, -); FCE 28044	Phase II	(S)-10-amino-4-ethyl-1- 4-hydroxy-1H- pyrano[3',4':6,7]indoli- zino[1,2-b]quinoline- 3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
AMP 53; azonafide 53	Discontinued		DNA topoisomerase inhibitor	cancer

asulacrine; amsalog; CI 921; NSC 343499; SN 21407	Phase I	9-[[2-methoxy-4- [(methylsulfonyl)ami no]phenyl]amino]- N,5-dimethyl-4- acridinecarboxamide	DNA topoisomerase inhibitor	cancer
azatoxin; NSC 640737	Preclinical	(5R-cis)-5,6,11,11a- tetrahydro-5-(4- hydroxy-3,5- dimethoxyphenyl)- 1H,3H- oxazolo[3',4':1,6]pyri do[3,4-b]indol-3-one	DNA topoisomerase inhibitor	cancer
BE 10988	Discontinued	2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide	DNA topoisomerase inhibitor	cancer
BE 13793C	Discontinued	12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione	DNA topoisomerase inhibitor	cancer
BE 22179	Discontinued		DNA topoisomerase inhibitor	cancer
BN 80915	Phase I		DNA topoisomerase inhibitor	cancer
BNP 1350	Phase I		DNA topoisomerase inhibitor	cancer
BNPI 1100	Preclinical		DNA topoisomerase inhibitor	cancer

BO 2367	Discontinued	(-)-7-[1R*,2R*,6R*)-2-amino-8-azabicyclo[4.3.0.]non-3-en-8-yl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid	DNA topoisomerase inhibitor	cancer
camptothecin analogues, Research Triangle Institute	Preclinical		DNA topoisomerase inhibitor	cancer
camptothecin derivatives, Daiichi	Discontinued		DNA topoisomerase inhibitor	cancer
CKD 602	Phase I	4-ethyl-4-hydroxy-11-[2-[(1-methylethyl)amino]ethyl]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
DM II 33	Preclinical		DNA topoisomerase inhibitor	cancer
DNA topoisomerase inhibitor, second generation, Xenova; XR 5942 series; XR 5942	Preclinical		DNA topoisomerase inhibitor	cancer
DRF 1042	Preclinical		DNA topoisomerase inhibitor	cancer

drug delivery system, camptothecin; camptothecin delivery system; MPI 5019	Preclinical		DNA topoisomerase inhibitor	cancer
drug delivery system, liposome lurtotecan; lurtotecan liposome; NX 211	Phase I		DNA topoisomerase inhibitor	cancer
drug delivery system, microsphere 10-hydroxycamptothecin; 10-hydroxycamptothecin microsphere	Preclinical		DNA topoisomerase inhibitor	cancer
DX 8951; DX 8951f	Phase II	(1S-trans)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione monomethanesulfonate	DNA topoisomerase inhibitor	cancer

ED 110	Discontinued	12-beta-D-glucopyranosyl-12,13-dihydro-1,11-dihydroxy-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione	DNA topoisomerase inhibitor	cancer
ER 37328	Preclinical	12,13-dihydro-5-[2-(dimethylamino)ethyl]-4H-benzo[c]pyrimido[5,6,1-jk]carbazole-4,6,10(5H,11H)-trione	DNA topoisomerase inhibitor	cancer
F 11782; F 1267; L 0084	Preclinical	[5R-[5alpha,5abeta,8aalpha,9beta(R*)]]-5-[3,5-dimethoxy-4-(phosphonoxy)phenyl]-9-[[4,6-O-ethylidene-2,3-bis-O-[(pentafluorophenoxy)acetyl]-beta-D-glucopyranosyl]oxy]-5,8,8a9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	DNA topoisomerase inhibitor	cancer

fofotriecin; NSC 339638; CI 920; CL 1565A	Phase I	5,6-dihydro-6- [3,6,13-trihydroxy-3- methyl-4- (phosphonoxy)- 1,7,9,11- tridecatetraenyl]-2H- pyran-2-one monosodium salt	DNA topoisomerase inhibitor	cancer
HAR 7	Preclinical		DNA topoisomerase inhibitor	cancer
intoplicine; RP 60475; NSC D645008	Phase I	11-[[3- (dimethylamino)prop yl]amino]-8-methyl- 7H- benzo[e]pyrido[4,3- b]indol-3-ol	DNA topoisomerase inhibitor	cancer
irinotecan; irinotecan hydrochloride; camptothecin 11; CPT 11; DQ 2805; SN 3811; U 101440E; CPT 11; CAMPTO; TOPOTECIN; CAMPTOSAR; IRKAN	Marketed	(1,4'-bipiperidine)-1'- carboxylic acid (S)- 4,11-diethyl- 3,4,12,14-tetrahydro- 4-hydroxy-3,14- dioxo-1H- pyrano(3',4':6,7)indoli zino(1,2-b)quinolin- 9-yl ester, monohydrochloride	DNA topoisomerase inhibitor	cancer



lurtotecan; lurtotecan dihydrochloride; GG 211; GI 147211; GI 147211A; GI 147211C	Suspended	(S)-8-ethyl-2,3-dihydro-8-hydroxy-15-[(4-methyl-1-piperazinyl)methyl]-11H-1,4-dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12(8H,14H)-dione	DNA topoisomerase inhibitor	cancer
MPI 6003	Discontinued		DNA topoisomerase inhibitor	cancer
NB 506	Phase I	N-(12-beta-D-glucopyranosyl-5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-yl)-formamide	DNA topoisomerase inhibitor	cancer
NC 190; NCU 190	Discontinued	6-[[[2-(dimethylamino)ethyl]amino]carbonyl]-5-hydroxy-10-methoxybenzo[a]phenazine-9-carboxylic acid monosodium salt	DNA topoisomerase inhibitor	cancer
NCA 0465	Preclinical		DNA topoisomerase inhibitor	cancer
NK 109; NK 106	Phase I	1-Hydroxy-2-methoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridinium, sulfate (1:1) (salt)	DNA topoisomerase inhibitor	cancer

NU/ICRF 500	Discontinued		DNA topoisomerase inhibitor	cancer
NU/ICRF 506	Discontinued		DNA topoisomerase inhibitor	cancer
polyethylene glycol-camptothecin; PEG-camptothecin; camptothecin macrogol; PROTHECAN	Preclinical		DNA topoisomerase inhibitor	cancer
rubitecan; 9-nitrocarnptothecin; RFS 2000	Phase III		DNA topoisomerase inhibitor	cancer
sobuzoxane; MST 16; PERAZOLIN	Marketed	1,2-ethanedithylbis[(2,6-dioxo-4,1-piperazinediyl)methyl]ene]bis(2-methylpropyl) carbonic acid ester	DNA topoisomerase inhibitor	cancer
TAN 1496	Discontinued		DNA topoisomerase inhibitor	cancer

TAN 1518A	Discontinued	2-hydroxybenzoic acid 3-(aminocarbonyl)-8-[2,6-dideoxy-4-O-(2-methyl-1-oxo-2-butenyl)hexopyranosyl]-1,4,4a,6,11,11a,12,12a-octahydro-2,4a,5,7-tetrahydroxy-11-methoxy-11-methyl-4,6-dioxo-1-naphthaceny] ester	DNA topoisomerase inhibitor	cancer
TAS 103	Phase I	6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one	DNA topoisomerase inhibitor	cancer
teniposide; VM 26; NSC 122819; VUMON; BEKNOS; VEHM SANDOZ	Marketed	[5R-[5-alpha,5abeta,8aalpha,9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]naphthol[2,3-d]-1,3-dioxol-6(5aH)-one	DNA topoisomerase inhibitor	cancer

TOP 53	Phase I	[5R-(5alpha,5beta,8alpha,9beta)]-9-[2-[[2-(dimethylamino)ethyl]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one]	DNA topoisomerase inhibitor	cancer
topoisomerase inhibitor, Biota	Preclinical		DNA topoisomerase inhibitor	cancer
topotecan; hycamtamine; SKF 104864; SKF 104864A; HYCMTIN	Marketed	(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
WIN 63320	Discontinued		DNA topoisomerase inhibitor	cancer
WIN 64593	Discontinued		DNA topoisomerase inhibitor	cancer
XR 5000; NSC 601316; DACA	Phase I	N-[2-(dimethylamino)ethyl]-4-acridinecarboxamide	DNA topoisomerase inhibitor	cancer

AD 312	Preclinical	(8S-cis)-8-acetyl-10-[[3-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2,3,6-trideoxy- $\alpha$ -L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	DNA topoisomerase inhibitor; anthracycline; alkylating agent; antibiotic	cancer
elsamitrucin; elsamycin A; BMY 28090; NSC 369327; BMS 181171	Discontinued	10-[[2-O-(2-amino-2,6-dideoxy-3-O-methyl- $\alpha$ -D-galactopyranosyl)-6-deoxy-3-C-methyl-beta-D-galactopyranosyl]oxy]-6-hydroxy-1-methylbenzo[h][1]benzopyrano[5,4,3-cde][1]benzopyran-5,12-dione	DNA topoisomerase inhibitor; antibiotic	cancer
DNA topoisomerase inhibitors, AVAX Technologies	Preclinical		DNA topoisomerase inhibitor; antifungal	cancer; mycosis; parasitic infection
elinafide; LU 79553	Phase I	2,2'-[1,3-propanediylbis(imino-2,1-ethanediyl)]bis-1H-benz[de]isoquinolone-1,3(2H)-dione	DNA topoisomerase inhibitor; DNA intercalator	cancer

LU 55446	Discontinued			DNA topoisomerase inhibitor; DNA intercalator	cancer
dosergoside; AF 1	Discontinued		[8beta(1S,2R,3E)]-N-[2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-6-methylergoline-8-carboxamide	dopamine agonist	cancer; infertility
drug delivery system, bromocriptine; bromocriptine delivery system; ERGOSET	Pre-registration			dopamine agonist	diabetes; obesity; cancer
ST 557	Discontinued			dopamine agonist; immunostimulant	cancer
ST 570	Discontinued			dopamine agonist; immunostimulant	cancer
Pan-Her inhibitors, SUGEN; Her2 inhibitors, SUGEN	Preclinical			EGF receptor inhibitor	cancer
LFM A12	Preclinical		(Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethoxy)phenyl]-2-butenamide	EGF receptor inhibitor; tyrosine kinase inhibitor	cancer

ABT 627; A 127722; A 147627	Phase II	[2S-(2alpha,3beta,4alpha)]-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid	endothelin antagonist; endothelin A antagonist	cancer; restenosis; myocardial infarction
BE 14348B	Discontinued	2(S),3(S)-3-methyl-4',5,7-trihydroxy-flavanone	estrogen agonist	cancer
GW 5638	Preclinical	(E,Z)-3-[4-(1,2-diphenyl-1-butenyl)phenyl]-2-propenoic acid	estrogen agonist; antiestrogen	osteoporosis; cancer; coronary artery disease
CP 336156	Phase II	(5R,6S)-5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyloxy)phenyl]-2-naphthalenol (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt)	estrogen partial agonist	osteoporosis; cancer
2-methoxyestradiol; 2-ME	Preclinical		estrogen; angiogenesis inhibitor	cancer
estrogen receptor therapy, Ligand/Wyeth Ayerst	Preclinical		estrogen; hormone replacement therapy	hormone deficiency; contraception; cancer; osteoporosis
EMATE	Discontinued	3-[(aminosulfonyloxy]estra-1,3,5(10)trien-17-one	estrogen sulfatase inhibitor	cancer

ara-CDP-DL-PTBA; CYTOROS	Preclinical	4-amino-1-[5-O-[1,3-dihydroxy-6-[(1-oxohexyadecyl)oxy]-2,4-dioxo-8-thia-1,3-diphosphahexacos-1-yl]-beta-D-arabinofuranosyl]-2(1H)-pyrimidinone P,P'-dioxide	ether lipid	cancer
edelfosine; ET 18-OCH <sub>3</sub> ; ALP	Pre-registration	(+,-)-4-hydroxy-7-methoxy-N,N,N-trimethyl-3,5,9-trioxo-4-phosphahaptacosan-1-aminium hydroxide inner salt, 4-oxide	ether lipid	cancer
EG 6	Preclinical	1-[4-[2-[2-(octadecyloxy)ethoxy]ethoxy]butyl]pyridinium methanesulfonate	ether lipid	cancer
ether lipid, Roswell Park	Preclinical	ara-CDP-rac-1-S-tetradecyl-2-O-palmitoyl-1-thioglycerol	ether lipid	cancer
ether lipid, Vancouver University	Preclinical	4-(hexadecyloxy)-3-(S)-methoxybutyl phosphonylcholine	ether lipid	cancer



ilmofosine; BM 41440; BM 21440	Discontinued	4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-3,5-dioxa-9-thia-4-phosphapentacosan-1-aminium hydroxide, inner salt, 4-oxide	ether lipid	cancer
miltefosine; hexadecylphonylcholine; HPC; D 18506; MILTEX	Marketed	2-[[[(hexadecyloxy)hydroxyphosphinyloxy]-N,N,N-trimethyl)ethanaminium, hydroxide, inner salt	ether lipid	cancer; leishmaniasis
perifosine; D 21266; NKA 17	Phase I	4-[[[hydroxy(octadecyloxy)phosphinyloxy]-1,1-dimethylpiperidinium inner salt	ether lipid	cancer
SRI 34234	Discontinued		ether lipid	cancer
SRI 62834	Discontinued	(+,-)-2-[[[hydroxy[[tetrahydro-2-[(octadecyloxy)methyl]-2-furanyl]methoxy]phosphinyloxy]-N,N,N-trimethyl-ethanaminium, inner salt.	ether lipid	cancer; multiple sclerosis
TLC ELL 12; ELL 12	Phase I		ether lipid	cancer

SDZ 62826	Discontinued		ether lipid; immunostimulant	cancer
etoposide phosphate; BMY 40481; ETOPOPHOS	Marketed	(5R,5aR,8aR,9S)-5-[3,5-dimethoxy-4-(phosphonoxy)phenyl]-9-[(4,6-O-(1R)-ethylidene-beta-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	etoposide analogue	cancer
IGT 13	Preclinical		etoposide analogue	cancer
NK 611; VP 19; 2'-(dimethylamino)etoposide	Phase II	[5R-[5alpha,5a-beta,8a-alpha,9beta(R*)]]-9-[[2-deoxy-2-(dimethylamino)-4,6-O-ethylidene-beta-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one hydrochloride	etoposide analogue	cancer

GL 331	Phase II	[5R-(5alpha,5beta,8alpha,9beta)]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-mitrophenyl)amino]furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	etoposide analogue; DNA topoisomerase inhibitor	cancer
ARGLABIN	Registered		farnesyl protein transferase inhibitor	cancer
B 956	Preclinical	[2S-(2R*,3Z,5R*,6E,8S*)]-N-[8-amino-9-mercapto-5-(1-methylethyl)-1-oxo-2-(phenylmethyl)-3,6-nonadienyl]-L-methionine	farnesyl protein transferase inhibitor	cancer
farnesyl transferase inhibitors	Discontinued		farnesyl protein transferase inhibitor	cancer
L 639749	Preclinical		farnesyl protein transferase inhibitor	cancer

L 744832	Preclinical	[2S-[1[R*(R*),2R*(S),3R*]]-2-[[2-[[2-amino-3-mercaptopropyl]amino]oxy]-1-methylpentyl]oxy]-1-oxo-3-phenylpropyl]amino]-4-(methylsulfonyl)-butanoic acid, 1-methylethyl ester	farnesyl protein transferase inhibitor	cancer
L 778123	Phase I		farnesyl protein transferase inhibitor	cancer
PD 169451	Preclinical		farnesyl protein transferase inhibitor	cancer
perillyl alcohol; NSC 641066	Phase II	4-(1-methylethenyl)-1-cyclohexene-1-methanol	farnesyl protein transferase inhibitor	cancer
ras farnesyl protein transferase inhibitors, Parke Davis	Preclinical		farnesyl protein transferase inhibitor	cancer
ras farnesyl protein transferase inhibitors, University of Pittsburgh	Preclinical		farnesyl protein transferase inhibitor	cancer
RPR 115135	Preclinical		farnesyl protein transferase inhibitor	cancer

SCH 59228	Preclinical	1-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-4-[(1-oxido-4-pyridinyl)acetyl]piperazine	farnesyl protein transferase inhibitor	cancer
L 731734	Discontinued	[3S-[3R*[2R*(S*),3S*,3R*]]]-2-[[2-(2-amino-3-mercaptopropyl)amino]-3-methylpentyl]amino]-3-methyl-N-(tetrahydro-2-oxo-3-furanyl)pentanamide	farnesyl protein transferase inhibitor; peptide	cancer
L 731735	Discontinued	[2S-[2R*(S*),3S*]]-N-[N-{2-[(2-amino-3-mercaptopropyl)amino]-3-methylpentyl]-L-isoleucyl]-L-homoserine	farnesyl protein transferase inhibitor; peptide	cancer
R 115777	Phase II		farnesyl protein transferase inhibitor; signal transduction inhibitor	cancer
SCH 66336	Phase II		farnesyl protein transferase inhibitor; signal transduction inhibitor	cancer

TOP 53	Phase I	[5R-(5alpha,5abeta,8aalpha,9beta)]-9-[2-[[2-(dimethylamino)ethyl]-[methylethylamino]ethyl]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	DNA topoisomerase inhibitor	cancer
topoisomerase inhibitor, Biota	Preclinical		DNA topoisomerase inhibitor	cancer
topotecan; hycamtamine; SKF 104864; SKF 104864A; HYCAMTIN	Marketed	(S)-10-[[[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
WIN 63320	Discontinued		DNA topoisomerase inhibitor	cancer
WIN 64593	Discontinued		DNA topoisomerase inhibitor	cancer
XR 5000; NSC 601316; DACA	Phase I	N-[2-(dimethylamino)ethyl]-4-acridinecarboxamide	DNA topoisomerase inhibitor	cancer

BIM 26028	Discontinued			gastrin antagonist; bombesin antagonist	cancer; cachexia; respiratory disease
CDP 845	Discontinued			gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; angiogenesis inhibitor	cancer
CT 1746	Discontinued			gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
gelatinase inhibitors, Celltech	Preclinical			gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
basal cell carcinoma therapy, Ontogeny; patched gene; ptc gene	Preclinical			gene	cancer; skin disease
bcl-6-based non- Hodgkin's lymphoma therapy	Preclinical			gene	cancer
cancer therapy, cancer cell growth genes	Preclinical			gene	cancer
CDK4 based therapy, Axs; melanoma therapy, Axs	Preclinical			gene	cancer
HFE-based therapies, Progenitor	Preclinical			gene	iron overload; cancer

immune system modulators, Chiroscience	Preclinical		gene	autoimmune disease; rheumatoid arthritis; cancer; HIV infection
melanoma differentiation-associated genes	Discontinued		gene	cancer
MMAC1 based therapy, Myriad	Preclinical		gene	cancer
MTS2 based therapy, Myriad	Preclinical		gene	cancer
MTS3 based therapy, Myriad; cancer therapy, Myriad	Preclinical		gene	cancer
num-1-based cancer therapy	Preclinical		gene	cancer
P-TEN-based cancer therapy, Amplicon	Preclinical		gene	cancer
prostate tumor-inducing genes	Discontinued		gene	cancer; diagnosis
gene therapy, ATase	Preclinical		gene therapy; biotechnology	cancer
gene therapy, C-CAM, Introgen; adenoviral C-CAM, Introgen; INGN 231	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer; SMART GENETIC CONSTRUCTS	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer



gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer, Cobra Therapeutics; CTL 102; TXS 0202	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer, pulmonary disease	Preclinical		gene therapy; biotechnology	cancer; respiratory disease
gene therapy, hepatocellular carcinoma; HepXia	Preclinical		gene therapy; biotechnology	cancer
gene therapy, ovarian and pancreatic cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, ovarian cancer; gene therapy, brca1, MB 700	Preclinical		gene therapy; biotechnology	cancer
gene therapy, p16, p27; gene therapy, restenosis; gene therapy, cancer	Preclinical		gene therapy; biotechnology	restenosis; cancer
gene therapy, p53; gene therapy, cancer	Phase I		gene therapy; biotechnology	cancer
gene therapy, scFV/gamma G250; gene therapy, renal carcinoma	Preclinical		gene therapy; biotechnology	cancer
gene therapy, stress proteins	Preclinical		gene therapy; biotechnology	cancer
gene therapy, thymidine kinase; gene therapy, cancer; gene therapy, HS-tk	Phase I		gene therapy; biotechnology	cancer

gene therapy, thymidine kinase; gene therapy, glioma	Preclinical		gene therapy; biotechnology	cancer
gene therapy, tumor antigens; gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, ATF BTPI; gene therapy, cancer	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, colorectal cancer, Oxford BioMedica; CoRectoGen	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, glioma, Oxford Biomedica; GlioStat	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, ovarian cancer, Oxford BioMedica; BetOvaC	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, prostate cancer; ProCaStat	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, interleukin-2, Transgene; gene therapy, cancer	Phase I		gene therapy; biotechnology; cytokine; immunostimulant	cancer
gene therapy, wt p53; gene therapy, cancer	Preclinical		gene therapy; biotechnology; radiosensitizer; chemosensitizer	cancer

vaccine, gene-based, colorectal cancer; vaccine, gene-based, CO17-A/GA733; AV GA 7332	Phase I			gene therapy; biotechnology; vaccine	cancer
vaccine, gene-based, human papilloma virus	Preclinical			gene therapy; biotechnology; vaccine	cancer
progression elevated genes	Discontinued			gene; angiogenesis inhibitor	cancer
glutathione inhibitors, Telik	Discontinued			glutathione inhibitor	cancer
AG 2026	Discontinued			glycinamide ribotide formyltransferase inhibitor	cancer
AG 2032	Discontinued			glycinamide ribotide formyltransferase inhibitor	cancer
AG 2034	Phase I	(S)-N-[[5-[2-(2-amino-4,6,7,8-tetrahydro-4-oxo-1H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]-2-thienyl]carbonyl]-L-glutamic acid		glycinamide ribotide formyltransferase inhibitor	cancer
AG 2037	Preclinical			glycinamide ribotide formyltransferase inhibitor	cancer
contortrostatin; CN	Preclinical			glycoprotein IIb/IIIa antagonist; platelet antiaggregant; biotechnology	cancer; thrombosis

mannostatin A	Preclinical	[1R-(1 $\alpha$ ,2 $\alpha$ ,3 $\alpha$ ,4 $\alpha$ ,5 $\beta$ )-4-amino-5-(methylthio)-1,2,3-cyclopentanetriol	glycosidase inhibitor	cancer
glycosidase inhibitor, Oxford GlycoSciences	Preclinical		glycosidase inhibitor; NSAID	cancer; rheumatoid arthritis
drug delivery system, ATRIGEL sustained release leuporelin; leuporelin ATRIGEL	Preclinical		gonadorelin agonist	cancer
drug delivery system, microparticle buserelin; buserelin microparticle delivery system	Phase III		gonadorelin agonist	cancer; endometriosis
drug delivery system, sustained release LHRH analogue; LHRH analogue delivery system; ProMaxx, LHRH analogue; ProMaxx 100	Clinicals		gonadorelin agonist	cancer

goserelin; goserelin acetate; ICI 118630; ZOLADEX	Marketed	6-[O-(1,1-dimethylethyl)-D-serine]-1-9-luteinizing hormone-releasing factor (swine) 2-(aminocarbonyl)hydrazide	gonadorelin agonist	cancer; endometriosis; infertility
leuprorelin; leuprorelin acetate; leuprolide; TAP 144; TAP 144SR; ABBOTT 43818; LUPRON; CARCIN; LEUPLIN; LUPRON DEPOT; PROSTAP ST; PROSTAP SR; ENANTONE	Marketed	6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide luteinizing hormone-releasing factor (swine)	gonadorelin agonist	cancer; endometriosis
nafarelin; nafarelin acetate; D-Nal(2)6 LHRH; RS 94991; RS 94991 298; SAMYNAREL; SYNAREL; NASANYL	Marketed	6-[3-(2-naphthalenyl)-D-alanine]-luteinizing hormone-releasing factor (swine)	gonadorelin agonist	cancer; endometriosis; infertility
RL 0903	Phase II		gonadorelin agonist	cancer
triptorelin; BN 52014; BIM 21003; AY 25650; CL 118532; WY 42462; ARVECAP; DECAPEPTYL	Marketed	6-D-tryptophan-luteinizing hormone-releasing factor (swine)	gonadorelin agonist	cancer; precocious puberty; endometriosis

leuprolide + estrogen + progesterone	Phase I		gonadorelin agonist; estrogen; progesterone	contraception; cancer
gonadotropin releasing hormone analogue, conjugated; GnRH analogue copolymer conjugate	Preclinical		gonadorelin agonist; gonadorelin antagonist	cancer
avorelin	Phase II	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-2-methyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide	gonadorelin agonist; peptide	cancer; precocious puberty; endometriosis
drug delivery system, histrelin hydrogel implant; histrelin hydrogel implant	Phase I		gonadorelin agonist; peptide	precocious puberty; cancer
A 84861	Phase I		gonadorelin antagonist	cancer
abarelix; PPI 149; R 3827	Phase III	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparagyl-L-N <sup>6</sup> -(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	gonadorelin antagonist cancer; benign prostate hypertrophy; endometriosis	

cetorelix; SB 75; SB 075; CETROTIDE	Registered	N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-oromethyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	infertility; cancer; endometriosis; benign prostate hypertrophy; contraception
D 20453	Discontinued		gonadorelin antagonist	cancer
D 21775; T 148	Discontinued	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[N-acetyl-3-(acetylamino)-L-alanyl]-D-lysyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	cancer
D 23487	Discontinued	Unspecified	gonadorelin antagonist	cancer
D 26344	Preclinical		gonadorelin antagonist	cancer; infertility

detirelix; RS 68439	Discontinued	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	contraception; cancer
drug delivery system, ATRIGEL sustained release ganirelix; ganirelix ATRIGEL	Discontinued		gonadorelin antagonist	cancer; endometriosis
drug delivery system, ATRIGEL sustained release GnRH antagonists	Discontinued		gonadorelin antagonist	endometriosis; cancer
drug delivery system, microcapsule SB 75; SB 75 microcapsule	Preclinical		gonadorelin antagonist	cancer; contraception
gonadotropin releasing hormone antagonists, Alanex	Preclinical		gonadorelin antagonist	contraception; cancer
gonadotropin-releasing hormone antagonist, Agouron; GnRH antagonist, Agouron	Preclinical		gonadorelin antagonist	cancer
HOE 2013	Suspended		gonadorelin antagonist	cancer; endometriosis



ramorelix; HOE 013	Phase II	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-O-(6-deoxy-alpha-L-mannopyranosyl)-D-seryl-L-leucyl-L-arginyl-L-proline, 2-(aminocarbonyl)hydrazide	gonadorelin antagonist	cancer
A 76154	Preclinical	N-[3-(4-fluorophenyl)-1-oxopropyl]-3-(1-naphthalenyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	gonadorelin antagonist; peptide	cancer; endometriosis; precocious puberty

teverelix; ANTARELIX	Phase I	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-L-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	gonadorelin antagonist; peptide	cancer; endometriosis; infertility
deslorelin; BACHEM 9022; SOMAGARD	Marketed	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide	gonadorelin superagonist	cancer; precocious puberty
drug delivery system, deslorelin implant; deslorelin implant	Preclinical		gonadorelin superagonist	cancer; gynecological; infertility
hematology cytokines, AMRAD; hematology cytokines, Chugai	Discontinued		growth factor	cancer
hematopoietic growth factor mimetics, Ligand	Preclinical		growth factor	cancer; bacterial infection; anemia
GM 1306	Preclinical		growth factor modulator	diabetes; retinopathy; cancer
GM 1474	Preclinical	Unspecified	growth factor modulator	cancer
keratinocyte growth factor antagonist	Preclinical		growth factor modulator; peptide	cancer

hepatocyte growth factor related proteins; HGF-related proteins	Preclinical		growth factor; biotechnology; chemoprotectant; cytoprotectant	cancer
CMI SAF9	Preclinical		growth factor; hematopoietic factor	cancer
thrombopoietin; TPO	Phase II		growth factor; hematopoietic factor; biotechnology	cancer; thrombocytopenia
Tie-2 ligands, Regeneron; angiogenesis ligands, Regeneron	Preclinical		growth factor; hematopoietic factor; cicatrizant; angiogenesis inhibitor; angiogenesis inducer	cancer; restenosis; retinopathy; skin ulcer; atherosclerosis; peripheral vascular disease
SB 251353	Preclinical		growth factor; hematopoietic factor; immunostimulant	cancer
goralate; seraspenside; BN 52040; BIM 32001	Phase II	1-[N2-[N-(N-acetyl-L-seryl)-L-alpha-aspartyl]-L-lysyl]-L-proline	hematoprotectant; chemoprotectant; peptide	cancer
pentosan polysulfate sodium; SP 54; PZ 68; CARTROPHEN; LASONIL; ELMIRON; LELONG MOUSSE	Marketed	(1-4)-beta-D-xylan 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis
MAXAMINE	Phase III		histamine agonist; histamine H2 agonist	cancer; viral infection; hepatitis

MAP 30	Preclinical	N2-[N-[N-[N-(N2-(N-L-threonyl)-L-isoleucyl)-L-lysyl]-L-threonyl]-L-threonyl]-L-lysine	HIV integrase inhibitor	HIV infection; cancer
lovastatin; mevinoлин; monakolin K; MK 803; MSD 803; MB 530B; L 154803; MEVACOR; MEVLOR; LOVACOL; HIPOVASTIN; DISLIPIN; LOVASTEROL; LINCIL	Marketed	(S)-2-methylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia; cancer
cancer therapy, Oxis	Preclinical		hormone	cancer
drug delivery system, PEPTITROL	Preclinical		hormone	osteoporosis; Paget disease; cancer
calcitonin; calcitonin PEPTITROL				
drug delivery system, subcutaneous gonadotropin releasing hormone; gonadotropin releasing hormone subcutaneous implant; GnRH	Preclinical		hormone	precocious puberty; endometriosis; cancer; contraception
subcutaneous implant				
glycoprotein hormone superagonists, NIH	Preclinical		hormone	infertility; cancer

human chorionic gonadotropin beta; beta hCG	Preclinical		hormone	cancer
NV 06	Preclinical		hormone; apoptosis inhibitor; antiproliferative agent; differentiation inducer	cancer
gallium nitrate; NSC 15200; CALSTAT; GANITE	Marketed	gallium nitrate monohydrate	hypocalcemic; nitric oxide synthase inhibitor	hypercalcemia; cancer
AS 101; IVXQ 101; OSSIRENE	Phase II	(SP-5-22)-ammonium trichloro(1,2-ethanedioato(2-)-0,0')-tellurate	immunostimulant	HIV infection; cancer
BCH 1393	Suspended	N2-[[[5-[6-(dimethylamino)-9H-purin-9-yl]pentyl]oxy]carbon yl]-D-arginine	immunostimulant	cancer
beta-alethine; BETATHINE	Phase II	3-amino-N-(2-mercaptoethyl)-propanamide	immunostimulant	cancer
propiramine; ABPP; U 54461; U 54461S; NSC 149027; REMISAR	Pre-registration	2-amino-5-bromo-6-phenyl-4(1H)-pyrimidinone	immunostimulant	cancer; viral infection
CL 246738	Phase II	3,6-bis(2-piperidinoethoxy)acridine trihydrochloride	immunostimulant	viral infection; HIV infection; cancer
CL 870420	Discontinued		immunostimulant	cancer
conagenin	Preclinical	N-(3,5-dideoxy-3-methyl-D-xyloonyl)-2-methyl-L-serine	immunostimulant	cancer

DNA repair enhancers, OXiGENE	Preclinical		immunostimulant	cancer
drug delivery system, liposome muramyl tripeptide-phosphatidylethanolamine; drug delivery system, liposome MTP-PE; MTP-PE liposome	Phase III		immunostimulant	cancer
FCE 24578	Discontinued	alpha-cyano-1,4-dihydro-beta-oxo-N,1-diphenyl[1]benzothio pyrano[4,3-c]pyrazole-3-propanamide	immunostimulant	cancer; bacterial infection
FCE 25276	Suspended		immunostimulant	cancer; bacterial infection
FCE 25648	Suspended		immunostimulant	cancer; bacterial infection
FCE 25651	Suspended		immunostimulant	cancer; bacterial infection
FR 901235	Discontinued	(-)-2,4,9-trihydroxy-6-methoxy-7-methyl-2-(2-oxopropyl)-1H-phenalene-1,3(2H)-dione	immunostimulant	cancer
HAB 439	Discontinued	(4,5-dihydro-3-phenyl-5-isoxazolyl)phosphonic acid	immunostimulant	cancer; bacterial infection

icadamines, Cornell Research Foundation	Preclinical			immunostimulant	viral infection; cancer
idramantone; kemantane	Phase I	5-hydroxytricyclo[3.3.1.1(3,7)]decanone		immunostimulant	cancer
imiquimod; R 837; S 26308; DZ 2636; ALDARA; ZARTRA	Marketed	1-(2-methylpropyl)-1H-imadazo[4,5-c]quinolin-4-amine		immunostimulant	viral infection; cancer
immunostimulant, Repligen; immunostimulant, Pfizer	Preclinical			immunostimulant	cancer; infectious disease
immunostimulants, Massachusetts General Hospital	Preclinical			immunostimulant	cancer; autoimmune disease
JT 3002; CGP 40774	Preclinical			immunostimulant	cancer
KRN 7000	Phase I	[1S-(1R*,2R*,3S*)]-N-[1-[(alpha-D-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]hexacosanamide		immunostimulant	cancer
large multivalent immunogen; LMI	Preclinical			immunostimulant	cancer
LC 9018; YIT 9018; DP 2202; PS PG; LIMONAL; LEMONAL	Pre-registration			immunostimulant	cancer; HIV infection
lentinan sulfate; lentinan; LENTINAN	Marketed			immunostimulant	HIV infection; cancer
LK 409	Preclinical	N-(1,7-dioxooctyl)-L-alanyl-D-alpha-glutamine		immunostimulant	cancer

loxoribine; RWJ 21757	Discontinued	7-allyl-8-oxoguanosine	immunostimulant	cancer
mirimostim; human urine derived stimulating factor inducer; CSF-HU; P 100; LEUKOPROL; COSTILATE	Marketed	1-214-colony-stimulating factor 1 (human clone p3ACSF-69 protein moiety reduced)	immunostimulant	cancer
MMS 2	Preclinical		immunostimulant	cancer
Nocardia-CWS; N-CWS; rubratine; RUBRATIN	Discontinued		immunostimulant	cancer
OM 163	Preclinical	Unspecified	immunostimulant	cancer
OM 174	Phase I		immunostimulant	cancer
RG 003; RG 136	Discontinued		immunostimulant	HIV infection; cancer
RM 06	Discontinued	N-[N-[[[5-(1,6-dihydro-6-oxo-9H-purin-9-yl)pentyl]oxy]carbon yl]-L-leucyl]-L-methionine	immunostimulant	cancer; transplant rejection
romurtide; muuroctasin; MDP-Lys (L18); MDP-Lys; DJ 7041; NOPIA	Marketed	2-acetamido-3-O-[(R)-1-[[[(S)-1-[[[(R)-1-carbamoyl-3-[[[(S)-1-carboxy-5-stearamidopentyl]carbamoylethyl]carbamoylethyl]-2-deoxy-D-glucopyranose	immunostimulant	cancer; bacterial infection



RS 0481; S 0481	Discontinued	[R-(R*,R*)]-3-benzoyl-N-(1-phenylethyl)-4-thiazolidinecarboxamide	immunostimulant	cancer
S 27609	Discontinued	4-amino- $\alpha$ , $\alpha$ ,2-trimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol	immunostimulant	cancer
SRL 172	Phase III		immunostimulant	tuberculosis; cancer; asthma; bacterial infection; leprosy; rhinitis
ST 789; PCF 39	Phase I	N-[5-(hypoxanthin-9-yl)pentoxycarbonyl]-L-arginine	immunostimulant	cancer; bacterial infection
thymotrinan; thymopoietin 32-34; RGH 0205; TP3	Suspended	N-(N2-L-arginyl-L-lysyl)-L-aspartic acid	immunostimulant	cancer
vaccine, malignant melanoma; LP 2307	Phase II		immunostimulant	cancer
vaccine, Maruyama; Maruyama vaccine; SSM	Pre-registration		immunostimulant	cancer
vaccine, melanoma, University of Pittsburgh; melanoma vaccine	Phase I		immunostimulant	cancer
tiprotimod; HBW 538	Discontinued	2-[(3-carboxypropyl)thio]-4-methyl-5-thiazoleacetic acid	immunostimulant; antifungal	mycosis; cancer

MGN 3	Phase I	Unspecified	immunostimulant; biological response modifier	cancer
NSC 631570; E 09/029; NSC B238865; UKSR 222; W 122; UKRAIN	Pre- registration	5,5',5"- [[phosphinothioylidyn etris(imino-2,1- ethanediyl)tris[5- methylchelidoninium]] ] trihydroxide	immunostimulant; biological response modifier	cancer
CD40 ligand, Immunex; CD40LT	Phase I		immunostimulant; biotechnology	cancer
prolactin	Preclinical		immunostimulant; biotechnology; hormone; vaccine adjuvant	cancer; infectious disease
pentoxifylline : ciprofloxacin; ciprofloxacin : pentoxifylline; CT 1500	Discontinued		immunostimulant; chemoprotectant; cytoprotectant	cancer
acemannan; CARN 1000; CARN 750; CARRASYN; ALIMINASE; VORALEX; CARRAVEX	Marketed	(1->4),(1->6)-alpha- D-galacto-beta-D- mannan acetate	immunostimulant; cicatrizant	inflammatory bowel disease; skin ulcer; inflammation; cancer
tetrachlorodecaoxide; TCDO; WF 10; OXOFERIN	Marketed		immunostimulant; cicatrizant	skin ulcer; HIV infection; cancer

granulocyte colony stimulating factor mimetic, Ligand/SmithKline Beecham; G-CSF mimetic, Ligand/SmithKline Beecham	Preclinical			immunostimulant; cytokine agonist	cancer; viral infection; bacterial infection
thiethazole	Preclinical	2-[1-(1,1-dioxothiethanyl-3)benzimidazolyl-2-thio] acetic acid		immunostimulant; immunosuppressant; antioxidant	cancer; rheumatoid arthritis; infectious disease; transplant rejection
tabilautide; RP 56142	Discontinued	threo-6-carbamoyl-N2-[N-(N-lauroyl-L-alanyl)-D-gamma-glutamyl]-L-lysine		immunostimulant; lipopeptide	bacterial infection; cancer
hemoregulatory peptide, Nycomed	Preclinical			immunostimulant; peptide	bacterial infection; cancer
immunostimulant peptides, BioChem Pharma	Discontinued			immunostimulant; peptide	cancer; viral infection
interleukin-2 receptor agonist; IL-2R agonist	Preclinical			immunostimulant; peptide	cancer; HIV infection
SUIS-gonadorelin; SUIIS-LHRH	Phase I			immunostimulant; peptide	cancer
thymopoietin receptor agonist	Preclinical			immunostimulant; peptide	cancer; HIV infection
tubenimex; bestatin; NK 421; BESTATIN	Marketed	(-)-N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl)]-L-leucine		immunostimulant; peptide	cancer

ETHERAMIDE	Suspended		immunostimulant; peptide; oligosaccharide	cancer; infectious disease
monophosphoryl lipid A + myobacterium cell wall sk; myobacterium cell wall skeleton + monophosphoryl I; MPL + CWS; DETOX	Phase III		immunostimulant; vaccine adjuvant	cancer
D5; PM 92114	Discontinued		immunosuppressant	cancer
dehydrodidemnin B; DDB	Preclinical	N-[1-(1,2- dioxopropyl)-L- prolyl]didemnin A	immunosuppressant	viral infection; cancer
dinaline; GOE 1734; NSC 328786; AAPBA	Discontinued	4-amino-N-(2- aminophenyl)benzami de	immunosuppressant	cancer
fluasterone	Phase I		immunosuppressant	cancer; diabetes; systemic lupus erythematosus
gusperimus; gusperimus hydrochloride; deoxyspergualin, 15-; desoxyspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215- 1; SPANIDIN; SUPANIDIN	Marketed	(+,-)-7- [(aminoininomethyl) amino]-N-[2-[[4-[(3- aminopropyl)amino]b uty]lamino]-1- hydroxy-2- oxoethyl]heptanamide	immunosuppressant	transplant rejection; multiple sclerosis; cancer
promedulan; TERICIMUS	Discontinued		immunosuppressant	cancer

XENOJECT	Preclinical		immunosuppressant	cancer; autoimmune disease
protein A-based immune modulator	Preclinical		immunosuppressant; immunostimulant	autoimmune disease; cancer
signal transduction modulators, National Jewish Center for Immunology and Respiratory Medicine	Preclinical		immunosuppressant; immunostimulant; NSAID	autoimmune disease; cancer; inflammation
CI 972	Discontinued	2,6-diamino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; cancer; psoriasis
cladribine; 2-CdA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	Marketed	2-chloro-2'-deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
T cell peptide, University of Illinois	Preclinical		immunosuppressant; peptide	autoimmune disease; cancer; bacterial infection
MAb, BR96 sFv-PE40; SGN 10; BMS 191352	Phase I		immunotoxin; biotechnology	cancer
MAb, TES-23-neocarzinostatin; TES-23-NCS	Discontinued		immunotoxin; biotechnology	cancer

MAb, TP3-pokeweed viral protein conjugate; immunotoxin, TP3- pokeweed viral protein conjugate; TP3-PAP	Preclinical		immunotoxin; biotechnology; monoclonal antibody	cancer
MAb, doxorubicin- CEA; DOX-CEA	Preclinical		immunotoxin; biotechnology; monoclonal antibody; anthracycline; antibiotic; DNA intercalator	cancer
drug delivery system, ANCHOR angiostatic agent	Preclinical		integrin antagonist; angiogenesis inhibitor; cell adhesion inhibitor	cancer
S 836	Discontinued		integrin antagonist; angiogenesis inhibitor; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	cancer
CDP 850	Preclinical		integrin antagonist; biotechnology; cell adhesion inhibitor; immunosuppressant; monoclonal antibody; E selectin antagonist	cancer

cytostatin; MJ 654NF4	Preclinical	5,6-dihydro-6-[6-hydroxy-1,5-dimethyl-4-(phosphonoxy)-7,9,11-tridecatrienyl]-5-methyl-2H-pyran-2-one	integrin antagonist; cell adhesion inhibitor	cancer
SB 223245	Preclinical	(S)-7-[[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid	integrin antagonist; cell adhesion inhibitor	osteoporosis; restenosis; cancer
vitronectin receptor antagonists, DuPont	Preclinical		integrin antagonist; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	osteoporosis; cancer; restenosis

IC 101	Preclinical	(alphaS,2R,5S,6R)-6-ethyltetrahydro-alpha-2-dihydroxy-alpha-methyl-5-(3-methylbutyl)-2H-pyran-2-acetyl-(3S)-3-hydroxy-L-leucyl-hexahydro-3-pyridazinecarbonyl-N-hydroxy-L-alanylglycyl-(3S)-hexahydro-3-pyridazinecarbonyl-N-hydroxy-D-Alanine (7->2)-lactone	integrin antagonist; cell adhesion inhibitor; immunostimulant; peptide; antibiotic	cancer; bacterial infection
anti-inflammatory agents, Chiroscience/Trega	Preclinical		integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
cell adhesion inhibitor, GlycoTech/Novartis	Preclinical		integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
drug delivery system, STEALTH cell adhesion inhibitors	Preclinical		integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
GM 7050	Discontinued		integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
RGD-based angiogenesis antagonists	Preclinical		integrin antagonist; NSAID; cell adhesion inhibitor	cancer; rheumatoid arthritis; eye disease



drug delivery system, interferon alfa; interferon alfa depot delivery; MPI 7057	Discontinued		interferon	cancer
drug delivery system, transdermal BIPHASIX interferon alfa; interferon alfa transdermal	Preclinical		interferon	cancer; viral infection
interferon alfa; BALL-1; MR 22; BALL 1; OIF; IFN ALPHA MOCHIDA	Marketed		interferon	cancer; viral infection; mucositis; musculoskeletal disorder
interferon alfa; Interferon Alfa native	Marketed		interferon	cancer; viral infection
interferon alfa-n3; KEMRON; ALFERON; ALFERON N; ALFERON LDO; ALTEMOL; REFERON	Marketed		interferon	viral infection; cancer
interferon beta; FRONE	Marketed		interferon	multiple sclerosis; cancer; eye disease
interferon gamma, natural; IFN gamma, natural; OH 6000; OGAMMA 100	Marketed		interferon	cancer
interferon-alpha; IFN-alpha	Preclinical		interferon; biotechnology	cancer; viral infection
interferon, modified, Tanox	Preclinical		interferon; biotechnology; immunosuppressant	cancer

leukocyte alpha interferon; ALFAFERONE; CILJIFERON	Marketed			interferon; immunostimulant	viral infection; cancer
doretinel; BASF 47011; RWJ 20257; ORF 20257	Discontinued	(E)-1,2,3,4-tetrahydro-7-[2-[4-(hydroxymethyl)phenyl]-1-methylethenyl]-1,1,4,4-tetramethylnaphthalenol		keratolytic	cancer
U 74389	Preclinical	Unspecified		lazaroid	cancer
U 74500A	Preclinical	21-[4-[3,6-bis(diethylamino)-2-pyrindinyl]-1-piperazinyl]-16-methylpregna-1,4,9(11)-triene-3,20-dione hydrochloride		lazaroid	cerebrovascular disease; cancer
lysofylline; lisofylline; CT 1501R; ProTec	Phase III	(R)-1-(5-hydroxyhexyl)-3,7-dimethylxanthine		lysophosphatidate acyltransferase inhibitor; xanthine	cancer; cardiovascular disease; respiratory disease; mucositis
breflate; NSC 656202; NAS 656202	Preclinical	N,N-dimethylglycine, [1R-(1R*,2E,6S*,10E,11aS*,13S*,14aR*)]-1,6,7,8,11a,12,13,14,14a-decahydro-1-hydroxy-6-methyl-4-oxo-4H-cyclopent[f]oxacyclotridecin-13-yl ester		macrolide; antibiotic	cancer

duocarmycin SA; DC 113	Discontinued	(7bR)-1,2,4,5,8,8a-hexahydro-4-oxo-2-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]cyclopropa[c]pyrrolo[3,2-e]indole-6-carboxylic acid methyl ester	macrolide; antibiotic	bacterial infection; cancer
rhizoxin; lizoxine	Phase II		macrolide; antibiotic	cancer
drug delivery system, liposome CGP 31362; CGP 31362 liposome; MLV-CGP 31362	Discontinued		macrophage stimulator; immunostimulant	cancer
GPX 325	Preclinical		MAO inhibitor; chemoprotectant; cytoprotectant; radioprotectant	cancer
matrilysin inhibitors, Affymax	Preclinical		matrilysin inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
matrix metalloproteinase inhibitors, OsteoArthritis; cartilage degrading enzyme inhibitors, OsteoArthritis; CHONDROPROTECTORS	Discontinued		matrix metalloproteinase inhibitor; cicatrizant; proteinase inhibitor; NSAID	arthritis; periodontal disease; skin ulcer; cancer

anticancer matrix metalloproteinase inhibitors	Preclinical		matrix metalloproteinase inhibitor	cancer
CMT 3; COL 3; NSC 683551; METASTAT	Phase I	(4aS,5aR,12aS)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-9-carboxamide	matrix metalloproteinase inhibitor	cancer
D 1927	Preclinical		matrix metalloproteinase inhibitor	cancer
D 2163	Phase I		matrix metalloproteinase inhibitor	cancer
ilomastat; GM 6001; CS 610; GALARDIN; GALARDIN MPI	Phase III	N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methoxymethyl)-2-(2-methylpropyl)-butanediamide]	matrix metalloproteinase inhibitor	retinopathy; diabetes; cancer

marimastat; BB 2516; Phase III TA 2516	(2S,3R)-N4-[(1R)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N1,,2-dihydroxy-3-(2-methylpropyl)butanamide	matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
matrix metalloproteinase inhibitors, Agouron	Preclinical	matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
S 3304	Phase I	matrix metalloproteinase inhibitor; proteinase inhibitor	cancer; inflammation
prinomastat; AG 3340	Phase III	matrix metalloproteinase inhibitor; proteinase inhibitor; angiogenesis inhibitor	cancer; retinopathy
CH 104	Discontinued	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; inflammation
CH 715	Discontinued	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; inflammation
matrix metalloproteinase inhibitor, State University of New York	Preclinical	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis

matrix metalloproteinase inhibitors, ProScript	Preclinical			matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; arthritis
PI 88	Phase I			matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	inflammation; cancer
solimastat; BB 3644	Phase I	(2S,3R)-3-[(1S)-2,2-dimethyl-1-(2-pyridylcarbamoyl)propyl]carbamoyl]-2-methoxy-5-methylhexanoic acid		matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor	multiple sclerosis; rheumatoid arthritis; inflammatory bowel disease; cancer
BIBW 22; BIBW 22BS	Discontinued			MDR inhibitor	cancer
biricodar dicitrate; VX 710; INCEL	Phase II	(S)-1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-2-piperidinecarboxylic acid 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester		MDR inhibitor	cancer
buthionine sulfoximine; BSO; NSC 326231	Phase I	(2S)-2-amino-4-(S-butylsulfonimidoyl)butanoic acid		MDR inhibitor	cancer

dexniguldipine; (+)-niguldipine; (R)-niguldipine; niguldipine; niguldipine, (R)-; B 8509035; B Y 935	Discontinued	(R)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylic acid 3-(4,4-diphenyl-1-piperidiny)propyl methyl ester	MDR inhibitor	cancer
drug delivery system, liposome ciclosporin; ciclosporin liposome; CYCLOXOME	Discontinued		MDR inhibitor	cancer
flezelastine; D 18024	Preclinical	4-((4-fluorophenyl)methyl)-2-(hexahydro-1-(phenylethyl)-1H-azepin-4-yl)-1(2H)-phthalazinone monohydrochloride	MDR inhibitor	cancer
H 85	Preclinical	N-[2-[[3-(4-chlorophenyl)-2-propenyl]formylamino]ethyl]-5-isoquinolinesulfonamide	MDR inhibitor	cancer
LU 49667	Discontinued		MDR inhibitor	cancer
LU 51903	Discontinued		MDR inhibitor	cancer
MDR inhibitor, BioNumerik	Preclinical		MDR inhibitor	cancer
MDR inhibitor, Xenova	Preclinical		MDR inhibitor	cancer
MDR inhibitors, Fox Chase Cancer Center	Preclinical		MDR inhibitor	cancer

MS 209	Phase II	4-(diphenylacetyl)- alpha-[(5- quinolinylloxy)methyl ]-1-piperazineethanol, (E)-2-butenedioate (2:3)	MDR inhibitor	cancer
NA 382	Preclinical	N-(ethoxycarbonyl)- 7-oxostaurosporine	MDR inhibitor	cancer
PAK 104P	Preclinical	trans-5-(4,6-dimethyl- 2-oxido-1,3,2- dioxaphosphorinan-2- yl)-2,6-dimethyl-4-(3- nitrophenyl)-3- pyridinecarboxylic acid 2-[4- (diphenylmethyl)-1- piperazinyl]ethyl ester trihydrochloride	MDR inhibitor	cancer
propyl bis-acridone	Preclinical	1,3-bis(9-oxoacridin- 10-yl)propane	MDR inhibitor	cancer
R 101933	Phase I		MDR inhibitor	cancer
Ro 112933	Discontinued	N-[2-(3,4- dimethoxyphenyl)eth yl]-N-methyl-2-(2- naphthalenyl)-1,3- dithiane-2- propanamine hydrochloride	MDR inhibitor	cancer



S 16209	Preclinical	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-[2-[[4-nitrophenyl)methyl]amino]ethoxy]ethoxy]-3,5-methylpyridinecarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer
S 16317	Preclinical	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-[2-[[4-pyridinyl)methyl]amino]ethoxy]ethoxy]methyl]-3,5-pyridinecarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer
S 16324	Preclinical	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-[2-[[3-thienyl)methyl]amino]ethoxy]ethoxy]methyl]-3,5-pyridinecarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer

S 9788	Discontinued	6-[4-[[2,2-bis(4-fluorophenyl)ethyl]amino]-1-piperidinyl]-N,N'-di-2-propenyl-1,3,5-triazine-2,4-diamine	MDR inhibitor	cancer
SB RA 31012	Preclinical		MDR inhibitor	cancer
SDZ 214103	Discontinued	2-(3-methyl-D-2-hydroxybutanoic acid)-4-L-leucine-7-L-threonine-10-L-leucine cyclosporin A	MDR inhibitor	cancer
XR 1500	Suspended		MDR inhibitor	cancer
CRL 1336	Discontinued		MDR inhibitor; chemosensitizer	cancer
valsopodar; SDZ PSC833; PSC 833; SDZ PSC 833; AMDRAY	Phase III	6-[[R-(E)]-6,7-didehydro-N,4-dimethyl-3-oxo-L-2-aminooctanoic acid]-7-L-valine-cyclosporin A	MDR inhibitor; chemosensitizer; P glycoprotein inhibitor	cancer
elacridar; GF 120918; GG 918	Suspended	N-[4-{2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)ethyl}p-phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide	MDR inhibitor; P glycoprotein inhibitor	cancer

timcodar dimesylate; VX 853	Phase II	(alphaS)-4-chloro-alpha-[methyl[oxo(3,4,5-trimethoxyphenyl)acetyl]amino]-N-(phenylmethyl)-N-[3-(4-pyridinyl)-1-[2-(4-pyridinyl)ethyl]propyl]benzenepropanamide	MDR inhibitor; P-glycoprotein inhibitor	cancer; neuropathy
XR 9051	Suspended	(Z,Z)-N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-4-[[[4-methyl-3,6-dioxo-5-(phenylmethylene)piperazinyldene]methyl]benzamide	MDR inhibitor; P-glycoprotein inhibitor	cancer
SDZ 280446	Discontinued	cyclo[N-methyl-L-alpha-Asp-N-methyl-L-Ile-N-methyl-L-Ile-Gly-N-methyl-L-Val-O-methyl-L-Tyr-(2S)-2-hydroxypropanoyl-(2S)-2-piperidinecarbonyl-N-methyl-L-Val-L-Val], 1,1-dimethylethylester	MDR inhibitor; peptide	cancer

melanostatin; BMY 28566; BU 3619E	Discontinued	(S)-3-[[1-carboxy-2-(1H-imidazol-4-yl)ethyl]amino]-N-(N-methyl-L-phenylalanyl)-L-alanine	melanin synthesis inhibitor	cancer
lithium gammalinolenate; EF 13; GLAMOLEC	Discontinued		metalloproteinase inhibitor; proteinase inhibitor	cancer; HIV infection
PGE 2946979	Preclinical	3-[[[(hydroxyamino)carbonyl]-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinecarboxylic acid phenylmethyl ester	metalloproteinase inhibitor; proteinase inhibitor	inflammation; cancer
metalloproteinase inhibitors, Syntem	Preclinical		metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; arthritis
BW 1069C85	Suspended		microtubule assembly inhibitor	cancer
cryptophycin 52; LY 355703	Phase I	(2S)-3-chloro-N-[(2E,5S,6S)-5-hydroxy-1-oxo-6-[(2R,3R)-3-phenyloxiranyl]-2-heptenyl]-O-methyl-tyrosyl-2,2-dimethyl-beta-alanyl-2-hydroxy-4-methyl-pentanoic acid (3fwdarw1)-lactone	microtubule assembly inhibitor	cancer

cryptophycin 8	Preclinical	(2S)-3-chloro-N- [(2E,5S,6R,7R,8S)-8- chloro-5,7-dihydroxy- 6-methyl-1-oxo-8- phenyl-2-octenyl]-O- methyl-D-tyrosyl- (2R)-2-methyl-beta- alanine-2-hydroxy-4- methylpentanoic acid (3->15)-lactone	microtubule assembly inhibitor	cancer
cryptophycin A derivatives, Wayne State University D 24851	Preclinical		microtubule assembly inhibitor	cancer
	Preclinical	1-[(4- chlorophenyl)methyl]- alpha-oxo-N-4- pyridinyl-1H-indole- 3-acetamide	microtubule assembly inhibitor	cancer
epothilone	Preclinical		microtubule assembly inhibitor	cancer

maitansine; maytansine; NSC 153858	Preclinical	N-acetyl-L-N-methyl-L-alanine [1S-(1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*)]-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxo-9,22-diazatetracyclo[19.3.1.110,14.03.5]hexacos-10,12,14(26),16,18-pentaen-6-yl ester	microtubule assembly inhibitor	cancer
T 138067	Phase I	2-fluoro-1-methyl-4-pentafluorophenylsulfonamidobenzene	microtubule assembly inhibitor	cancer
T 900607	Preclinical		microtubule assembly inhibitor	cancer
AC 7700	Preclinical		microtubule assembly inhibitor; angiogenesis inhibitor	cancer
epothilones, Society for Biotechnology Research	Preclinical		microtubule assembly inhibitor; antibiotic	cancer
cemadotin; LU 103793	Phase II	N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-N-(phenylmethyl)-L-prolinamide	microtubule assembly inhibitor; peptide	cancer

LU 223651	Preclinical	N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-prolin-Tert-butylamide	microtubule assembly inhibitor; peptide	cancer
epothilones	Preclinical	[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (B is [1S-, 16-methyl])	microtubule assembly promoter	cancer
antimitotics, Nanodesign	Preclinical		mitosis inhibitor	cancer
TZT 1027	Phase I	[2S-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidiny]]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-L-valinamide	mitosis inhibitor	cancer
mivobulin; CI 980; NSC 613862(-)	Phase II	(S)-(5-amino-1,2-dihydro-2-methyl-3-phenylpyrido(3,4-b)pyrazin-7-yl)carbamic acid ethyl ester	mitosis inhibitor; tubulin polymerase inhibitor	cancer

MAb, 81C6; MAb, cancer	Phase II		monoclonal antibody; biotechnology	cancer
MAb, alpha5 beta3 integrin	Discontinued		monoclonal antibody; biotechnology	cancer
MAb, boron complex, Strathclyde Institute for Drug Research	Preclinical		monoclonal antibody; biotechnology	cancer
MAb, cancer-beta glucosidase; AGENT	Preclinical		monoclonal antibody; biotechnology	cancer
MAb, epidermal growth factor receptor; MAb, EGFr; MAb, E7.6.3; ABX EGFr	Preclinical		monoclonal antibody; biotechnology	cancer
MAb, HMFg-1	Phase I		monoclonal antibody; biotechnology	cancer
MAb, platelet derived growth factor/basic fibroblast growth factor; MAb PDGF/bFGF; SMA PDGF/bFGF	Preclinical		monoclonal antibody; biotechnology	cancer; restenosis
MAb, tissue factor/factor VII; MAb, TF/factor VII; SMA TF/factor VII	Preclinical		monoclonal antibody; biotechnology	cancer
MAbs, folate receptors & immune effector cells; bispecific monoclonal antibodies, folate receptors & immune effector cells	Preclinical		monoclonal antibody; biotechnology	cancer



tumor stroma specific antibody	Preclinical		monoclonal antibody; biotechnology	cancer	
MAB, vascular endothelium growth factor; MAB, vEGF; SMA vEGF	Preclinical		monoclonal antibody; biotechnology; angiogenesis inhibitor	cancer	
MAB, VEGF; MAB, vascular epithelial growth factor	Phase II		monoclonal antibody; biotechnology; angiogenesis inhibitor	cancer; retinopathy	
MAB, endoglin-tTF; immunotoxin, endoglin-tTF	Preclinical		monoclonal antibody; biotechnology; coagulation factor; immunotoxin	cancer	
MAB, endoglin-dgA; immunotoxin endoglin-dgA	Preclinical		monoclonal antibody; biotechnology; immunotoxin	cancer	
MAB, HMFG-1 fragment-yttrium 90; TheraFab	Preclinical		monoclonal antibody; biotechnology; radiotherapeutic	cancer	
MAB, LL2-yttrium-90; yttrium-90-LL2; LymphoCide	Phase I		monoclonal antibody; biotechnology; radiotherapeutic	cancer	
MAB, polymorphic epithelial mucin-yttrium 90; MAB, human-milk fat globulin-1 (HMFG1); THERAGYN	Phase III		monoclonal antibody; biotechnology; radiotherapeutic	cancer	

N 3554S; N 1554	Preclinical	[S-(all-E)]-3,7,11,15,19,23,27,31,35,39-decamethyl-6,10,14,18,22,26,30,34,38-tetracontanonaen-1-ol, dihydrogen phosphate	N glycosylation stimulator	cancer
SR 48692	Phase II	2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.1.3,7]decane-2-carboxylic acid	neurotensin antagonist	schizophrenia; cancer
NS 521	Discontinued		neurotrophic factor; growth factor	Alzheimer disease; neuropathy; cancer; diabetes
sodium borocaptate 10B; borocaptate sodium B 10; NASH; BSH; BOROLIFE	Suspended	1,2,3,4,5,6,7,8,9,10,11-undecahydro-12-mercaptododecaborate(2-)-10B12 disodium	neutron capture agent	cancer
nitric oxide-releasing anticancer agents, National Institutes of Health	Preclinical		nitric oxide donor	cancer
NCX 1101	Preclinical		nitric oxide donor; NSAID	cancer
hemoglobin-based scavenger; ENDOGLOBIN-HT; ENDOGLOBIN-CT	Discontinued		nitric oxide scavenger	hypotension; cancer

hemoglobin-based therapy, Apex	Preclinical		nitric oxide scavenger	cancer; hypotension; septic shock
NOX 100	Preclinical		nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 101	Discontinued	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 51	Preclinical		nitric oxide scavenger	diabetes; cancer; cardiovascular disease; transplant rejection; septic shock
pyridoxylated hemoglobin polyoxyethylene conjugate; PHP-HT; PHP-CT	Phase II		nitric oxide scavenger	cancer; hypotension; septic shock
fotemustine; S 10036; MUPHORAN	Marketed	(+/-)-diethyl [1-[3-(2- chloroethyl)-3- nitrosoureido]ethyl]p hosphonate	nitrosurea; alkylating agent	cancer
nitrllyn; CRC 7805068	Phase II		nitrosurea; alkylating agent	cancer

SarCNU; NSC 364432	Preclinical	2-[[[(2-chloroethyl)nitrosoamino]carbonyl]methylamino]-acetamide	nitrosurea; alkylating agent	cancer
semustine; methyl CCNU; WR 220076; NSC 95441; ICIG 1110	Phase I	N-(2-chloroethyl)-N'-(4-methylcyclohexyl)-N-nitrosurea	nitrosurea; alkylating agent	cancer
TA 077	Phase III	N-(2-chloroethyl)-N'-(4-O- $\alpha$ -D-glucopyranosyl)-beta-D-glucopyranosyl)-N'-(2-methylpropyl)-N-nitrosurea	nitrosurea; alkylating agent	cancer
taumostine; TCNU; LS 2667; TAURICYT	Phase III	2[[[(2-chloroethyl)nitrosoamino]carbonyl)amino)-N,N-dimethylethanesulfonamide	nitrosurea; alkylating agent	cancer
cell adhesion molecules intracellular inhibitors, ICOS/Abbott	Preclinical		NSAID	cancer; inflammation
drug discovery, Trega Biosciences; drug discovery, Chugai	Preclinical		NSAID	inflammation; diabetes; cardiovascular disease; neurological; cancer; infectious disease
G-protein therapy, Cadus/Bristol-Myers Squibb	Preclinical		NSAID	inflammation; cardiovascular disease; cancer

kinase modulators, ICOS	Preclinical		NSAID	cancer; inflammation
nitric oxide modulators, Duke University	Preclinical		NSAID	hypotension; cancer; rheumatoid arthritis
signal transduction modulators, Cancer Research Campaign	Preclinical		NSAID	cancer; inflammation; neurological
synthetic glycosaminoglycans	Preclinical		NSAID	inflammation; cancer; neuropathy
drug delivery system, HIT diclofenac; diclofenac HIT; HYAL AT2101; HYAL CT1101; HYAL AV2201; HYAL AT1201; HYANALGESE; HYANALGESE-D; SOLARASE; ORALEASE	Registered		NSAID; analgesic	pain; cancer; inflammation; skin disease; mucositis
P 54	Phase II		NSAID; analgesic	osteoarthritis; Crohn disease; cancer
apoptosis modulators, IDUN	Preclinical		NSAID; apoptosis inhibitor; apoptosis inducer; caspase inhibitor	cancer; neuropathy; inflammation
MDR inhibitors, BioResearch Ireland	Preclinical		NSAID; MDR inhibitor	cancer
proteasome inhibitors, inflammation, ProScript	Preclinical		NSAID; transcription factor regulator	inflammation; cancer
EPI 163; EpiCyte	Preclinical		nucleoside analogue	cancer

OGT 719	Phase I	5-fluoro-1-beta-L-galactopyranosyl-2,4(1H,3H)-pyrimidinone	nucleoside analogue	cancer
thio-cytarabine derivatives, Southern Research Institute; thio-araC derivatives, Southern Research Institute	Preclinical		nucleoside analogue	cancer
yunnannmycin	Preclinical		nucleoside analogue	cancer
8-chloro-cAMP; 8-Cl-cyclic adenosine monophosphate; 8-Cl-cAMP	Discontinued	8-chloro-cyclic adenosine 3',5'-monophosphate	nucleoside analogue; antimetabolite	cancer
anticancer, Camerino University	Preclinical	1-beta-D-ribofuranosyl-1H-pyrrolo[3,2-c]pyridine-4,6-diamine	nucleoside analogue; antimetabolite	cancer
CNDAC	Preclinical	4-amino-1-(2-cyano-2-deoxy-beta-D-arabinosylfuranosyl)-2(1H)-pyrimidinone	nucleoside analogue; antimetabolite	cancer
DMDC	Phase II	2'-deoxy-2'-methylene-cytidine	nucleoside analogue; antimetabolite	cancer
drug delivery system, 5 fluoropyrimidinone, 5 fluoropyrimidinone delivery system	Phase I		nucleoside analogue; antimetabolite	cancer; viral infection

fludarabine; F araAMP; fludarabine phosphate; SH 573; SH 584; SH 586; NSC 312887; NSC 328002; 2 F ara AMP; NSC 118218; NSC 118218-H; 2-F- araA; ZK 153851; FLUDARA	Marketed	9-beta-D- arabino-furanosyl-2- fluoroadenine-5'- (dihydrogen phosphate)	nucleoside analogue; antimetabolite	cancer
gemcitabine; dFdC; difluorodeoxycytidine; LY 188011; DDFC; GEMZAR	Marketed	2'-deoxy-2',2'- difluorocytidine	nucleoside analogue; antimetabolite	cancer
RL 0018; CYTOVERT	Preclinical		nucleoside analogue; antimetabolite	cancer
sulfinosine; fin; SULFINOSINE	Preclinical	2-amino-9-beta- ribofuranosyl-9H- purine-6-sulfonamide	nucleoside analogue; antimetabolite	cancer
UK 25	Preclinical	5-fluoro-3,4-dihydro- 2,4-dioxo-N-[6-[[[(1- oxo-2- propylpentyl)amino]a cetyl]amino]hexyl]- 1(2H)- pyrimidinecarboxami de	nucleoside analogue; antimetabolite	cancer
IPdR	Preclinical	5-iodo-pyrimidinone- 2-deoxyribose	nucleoside analogue; antimetabolite; radiosensitizer	cancer

troxacitabine; BCH 4556	Phase II	(2S-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2(1H)-pyrimidinone	nucleoside analogue; DNA polymerase inhibitor	cancer
N 10146	Phase I	5-amino-3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,4H)-dione	nucleoside analogue; immunostimulant; biological response modifier	cancer; viral infection
nucleoside analogues, Nabi; nucleotide analogues, Nabi	Preclinical		nucleoside analogue; nucleotide analogue	viral infection; HIV infection; cancer
TAS 106	Preclinical		nucleoside analogue; RNA polymerase inhibitor; antimetabolite	cancer
FES 12	Preclinical		nucleoside; antimetabolite	cancer
CS 682	Phase I	N-[1-(2-cyano-2-deoxy-beta-D-arabino-furanosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]hexadecanamide	nucleoside; DNA polymerase inhibitor	cancer
adenosine triphosphate; ATP	Discontinued	adenosine 5'-(tetrahydrogen triphosphate)	nucleotide	cancer; cachexia
oligonucleotide, cancer immunotherapy	Preclinical		oligonucleotide; biotechnology; immunostimulant	cancer
ribozyme, dysprosium-tetraphyrin, cancer; Dy-Tex	Preclinical		oligonucleotide; biotechnology; ribozyme	cancer



drug delivery system, sustained release DepoFoam morphine; morphine DepoFoam; C 0401; DepoMorphine	Phase II		opiate agonist; mu agonist; analgesic	pain; cancer
naloxone + pentazocine; pentazocine + naloxone	Pre-registration		opiate agonist; opiate antagonist; analgesic	pain; cancer
CP 100356	Preclinical	4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxy-2-quinazolinamine	P glycoprotein inhibitor	cancer
LY 335979; RS 33295198; RS 33295	Phase II	[6(R)-(1a alpha,6alpha,10b alpha)]-4-(1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl)-alpha-[(5-quinolinylloxy)methyl]-1-piperazineethanol, trihydrochloride	P glycoprotein inhibitor	cancer

N 1379; L 623	Discontinued	hydroxybutanedioic acid compd with N,N'-bis[(3,4-dimethoxyphenyl)methyl]-N-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanoenyl)-1,2-ethanediamine (1:1)	P glycoprotein inhibitor	cancer
XR 9576	Phase II	N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]-3-quinolinecarboxamide	P glycoprotein inhibitor; MDR inhibitor	cancer
rohitukine; L 868275	Preclinical	cis-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-2-methyl-4H-1-benzopyran-4-one	p34 kinase inhibitor	cancer
SDZ 62434; SDZ 62434	Discontinued	2,3-dihydro-5-[4-(1-piperidinylmethyl)phenyl]imidazo[2,1-a]isoquinoline dihydrochloride	PAF antagonist	cancer
plasminogen activator inhibitor antagonists, Corvas	Preclinical		PAI inhibitor	cancer

plasminogen activator inhibitor-1 inhibitor, Xenova; PAI-1 inhibitor, Xenova	Preclinical		PAI inhibitor	cancer
BIM 44002	Phase I		parathyroid hormone antagonist	hypercalcemia; cancer
antifreeze protein, cancer cryosurgery, A F Protein	Preclinical		peptide	cancer
axinastatin 1; malaysiatin; pseudoaxinellin	Preclinical	axinastatin 1	peptide	cancer
axinastatin 2	Preclinical	5-L-leucine-axinastatin 1	peptide	cancer
axinastatin 3	Preclinical	4-L-isoleucine-5-L-leucine-axinastatin 1	peptide	cancer
BST 1002	Preclinical		peptide	cancer
BST 1003; COLLAMER	Preclinical		peptide	cancer
cancer therapy, Aptein	Preclinical		peptide	cancer
cancer therapy, Magainin	Preclinical		peptide	cancer
cancer therapy, PSP 94, Procyon	Preclinical	beta-Inhibin (human reduced)	peptide	cancer
cell permeable peptides	Preclinical		peptide	cancer
corticotropin-releasing factor; corticotropin-releasing hormone; CRF; XERECEPT	Phase II		peptide	cancer; stroke; trauma
CYC 100	Preclinical		peptide	cancer

CYC 101	Preclinical		peptide	cancer
CYC 102	Preclinical		peptide	cancer
CYC 103	Preclinical		peptide	cancer
D 22631	Discontinued		peptide	cancer
drug delivery system, anticancer peptide	Preclinical		peptide	cancer
GPX 200	Phase I		peptide	cancer
GW 395058	Preclinical		peptide	cancer; thrombocytopenia
insulin-like growth factor-1 receptor inhibitor; IGF-1 receptor inhibitor; IGF-1 JB3	Preclinical		peptide	restenosis; cancer
laminin peptides, National Institutes of Health	Preclinical		peptide	cancer
MF 13	Preclinical	L-prolyl-3-[bis(2- chloroethyl)amino]- L-phenylalanyl-L- norvaline ethyl ester monohydrochloride	peptide	cancer
monocyte attracting peptide	Preclinical		peptide	cancer; bacterial infection
MSI 103	Discontinued	Lys Ile Ala Gly Lys Ile Ala Lys Ile Ala Gly Lys Ile Ala Lys Ile Ala Gly Lys Ile Alaninamide	peptide	cancer
MSI 500	Discontinued		peptide	cancer

NA 22598; NA 22598A1	Preclinical	N-[2,3-diamino-8-[2-amino-1-(aminocarbonyl)-4,5-dihydro-1H-imidazol-5-yl]-2,3,4,5,8-pentadeoxyoctonoyl]-L-alanyl-L-valine	peptide	cancer
NSC 630176; FR 901228	Phase I	N-[(3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteiny-(2Z)-2-amino-2-butenoyl-L-valine (4-1)-lactone cyclic (1-2)disulfide	peptide	cancer
p16 analogue	Preclinical		peptide	cancer
prohibitin	Preclinical		peptide	cancer
PTL 03001	Preclinical		peptide	cancer
somatoprim; PTR 3046	Preclinical	cyclo(Phe-N2-Tyr-D-Trp-Lys-Val-Phe-C3)Thr-NH2	peptide	pancreatitis; cancer; restenosis
thiocoraline	Preclinical		peptide	cancer
urokinase receptor antagonist cyclopeptide, Wilex Biotechnology	Preclinical		peptide	cancer
IM 862	Phase II		peptide; angiogenesis inhibitor	cancer
D2AT21	Preclinical		peptide; antibiotic	bacterial infection; trichomoniasis; cancer
breast cancer therapy, Cytoclonal	Preclinical		peptide; antiestrogen	cancer

BRCA1, recombinant	Preclinical			peptide; biotechnology	cancer
transcription factor, vascular endothelial growth factor gene	Preclinical			peptide; biotechnology	cancer; retinopathy
alpha-conopeptides	Preclinical			peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
fibroblast growth factor, basic, antagonists, NIH	Preclinical			peptide; FGF antagonist	cancer
fibroblast growth factor receptor inhibitor; FGF receptor inhibitor	Preclinical			peptide; FGF antagonist; angiogenesis inhibitor	restenosis; cancer
splenopentin; diacetylsplenopentin; berloptentin; DA SP5; DA-Sp 5; BCH 069	Preclinical		N2-acetyl-L-arginyl-N6-acetyl-L-lysyl-L-alpha-glutamyl-L-valyl-L-tyrosine	peptide; immunostimulant	cancer
integrin-specific peptides, Integra LifeSciences	Preclinical			peptide; integrin antagonist; cell adhesion inhibitor; angiogenesis inhibitor	osteoporosis; cancer; restenosis
antagonist D	Preclinical			peptide; substance P antagonist	cancer
auristatin PE	Preclinical			peptide; tubulin polymerase inhibitor	cancer
C3B	Preclinical		Unspecified	phosphatase inhibitor	cancer
Cdc25 inhibitors, Mitotix	Preclinical			phosphatase inhibitor	cardiovascular disease; cancer

CT 2584; APRA	Phase II	1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione	phosphatidic acid inhibitor	cancer	
benzochlorins	Preclinical		photosensitizer	cancer	
benzophenothiazines, Rowland Institute; benzophenothiazines, Ergo Science	Preclinical		photosensitizer	cancer	
benzoporphyrin derivatives, third generation; QLT 0074	Preclinical		photosensitizer	cancer	
boronated porphyrin compounds; BOPP	Phase I		photosensitizer	cancer	
chlorins	Preclinical		photosensitizer	cancer	
cis-porphyrin	Preclinical	cis-meso-bis(N-methyl)-4-pyridinium)diphenyl porphyrin	photosensitizer	cancer	
drug delivery system, liposome zinc phthalocyanine; zinc phthalocyanine liposome; CGP 55847	Discontinued		photosensitizer	cancer	
drug delivery system, RFS aminolevulinic acid; 5-ALA RFS; aminolevulinic acid, RFS	Preclinical		photosensitizer	cancer	

drug delivery system, transdermal 5-aminolevulinic acid; 5-aminolevulinic acid transdermal; drug delivery system, transdermal ALA PDT	Discontinued		photosensitizer	cancer
ER 470	Discontinued		photosensitizer	cancer
HAT D01	Preclinical		photosensitizer	cancer; diagnosis
HPHH	Phase I		photosensitizer	cancer
hypericin; VIMRxyn; CYCLO-WERROL; CYCLOSAN	Phase II	1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione	photosensitizer	psoriasis; cancer
JM 2929	Discontinued	(OC-6-12)-bis[3-(diphenylphosphino-kappaP)benzenesulfonato][29H,31H-phthalocyaninato(2-)-kappaN29,kappaN30,kappaN31,kappaN32]ruthenate(2-), dipotassium	photosensitizer	cancer
lutetium texaphyrin; Lu Tex; PCI 0123; LUTRIN; Lu-TeX; OPTRIN; ANTRIN	Phase II		photosensitizer	cancer; atherosclerosis; eye disease; skin disease



NPc 6; NP e6; ME 2906	Phase II	N-[3-[(2S,3S)-18-carboxy-20-(carboxymethyl)-8-ethenyl-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-21H,23H-porphin-2-yl]-1-oxopropyl]-L-aspartic acid tetrasodium salt	photosensitizer	cancer
photodynamic immunotherapy, Pacific; PDIT	Preclinical		photosensitizer	cancer
photodynamic therapy, Anutech; drug delivery system, photosensitizer	Preclinical		photosensitizer	cancer
photodynamic therapy, plant-derived, Steba Beheer	Preclinical		photosensitizer	cancer; bacterial infection
porfimer sodium; polyporphyrin; CL 184116; PHOTOFRIN; PHOTOFRIN II	Marketed	photofrin porfimer sodium	photosensitizer	cancer
purpurins	Preclinical		photosensitizer	cancer
SC 102	Preclinical		photosensitizer	cancer
SQN 400; SQ 400	Preclinical		photosensitizer	cancer
tellurapyrylium; USB 006	Discontinued		photosensitizer	cancer
temoporfin; m-THPC; EF 9; FOSCAN	Phase III	3,3',3''-(2,3-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetrakis phenol	photosensitizer	cancer

tin ethyl etiopurpurin; SnET2; PURLYTIN	Phase III	tin [ethyl 3,4,20,21-tetrahydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-.kappa.N23,.kappa.N24,.kappa.N25,.kappa.N26]-,(SP-4-2 )-	photosensitizer	cancer; benign prostate hypertrophy; retinopathy
verdins	Preclinical		photosensitizer	cancer
zinc phthalocyanine	Discontinued		photosensitizer	cancer
aminolevulinic acid, photodynamic therapy; 5-ALA PDT; LEVULAN	Pre-registration		photosensitizer; contrast medium	psoriasis; skin disease; endometriosis; cancer; diagnosis
verteporfin; benzoporphyrin derivative; BPD-MA; CL 318952; BPDR; VISUDYNE	Phase III	trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropanoic acid monomethyl ester	photosensitizer; NSAID	cancer; psoriasis; arthritis; retinopathy
anagrelide; anagrelide hydrochloride; BL 4162A; AGRYLIN; AGRELIN	Marketed	6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one	platelet antiaggregant	thrombosis; cancer
AP 5070	Preclinical		platinum complex	cancer

B 850040	Discontinued	1,3-diamino-2-methoxymethyl-2-methyl-propan-N,N-platin (II)-0,0-cyclobutan-1,1-dicarboxylate	platinum complex	cancer
BBR 2207	Discontinued	hydrogen [mu-[benzenepentacarboxylato(5-)-O1,O2:O4,O5]]bis(1,2-cyclohexanediamine-N,N')diplatinate (1-), stereoisomer	platinum complex	cancer
BBR 3464	Phase I		platinum complex	cancer
cisplatin analogue, II Yang	Preclinical		platinum complex	cancer
cycloplatin	Phase I	amine(cyclopentamine)[hydroxybutanedioato(2-)-O1,O4]-platinum	platinum complex	cancer
drug delivery system, ATRIGEL sustained release cisplatin; cisplatin ATRIGEL	Preclinical		platinum complex	cancer
drug delivery system, cisplatin; cisplatin Therapeutic Implant; MPI 5010; IntraDose INJECTABLE GEL; IntraDose-CDDP; INTRADOSE-CDDP; IntraDose	Phase III		platinum complex	cancer

drug delivery system, cisplatin biodegradable polymer implant; cisplatin biodegradable polymer implant	Preclinical		platinum complex	cancer
drug delivery system, liposomal L-NDDP; L-NDDP liposomes; AR 726; PLATAR	Phase II		platinum complex	cancer
drug delivery system, liposome carboplatin; carboplatin liposome	Preclinical		platinum complex	cancer
drug delivery system, liposome carboplatin; carboplatin liposome	Preclinical		platinum complex	cancer
drug delivery system, microsphere cisplatin; cisplatin microsphere	Preclinical		platinum complex	cancer
drug delivery system, NDDP liposome; NDDP liposome	Phase I		platinum complex	cancer
drug delivery system, STEALTH cisplatin; cisplatin STEALTH delivery system; SPI 77; SPI 077	Phase II		platinum complex	cancer
GB 21; W 164; E 92/114	Preclinical	poly-[(trans-1,2-diamino-cyclohexane)platinum]-carboxyamylose	platinum complex	cancer

JM 221	Discontinued	(OC-6-43)- amminebis(butanoato O)dichloro(cyclohexa namine)platinum	platinum complex	cancer
JM 335	Discontinued	(OC-6-12)- amminedichloro(cycl ohexanamine)dihydro xyplatinum	platinum complex	cancer
JM 473	Preclinical	(SP-4-3)- amminedichloro(2- methylpyridine)platin um	platinum complex	cancer
KHPC 001	Phase I	[SP-4-2-(1R-trans)]- (1,2- cyclohexanediamine- kappaN,kappaN')[1,3- propanediylbis[diphe nylphosphine- kappaP]]- platinum(2+),dinitrate	platinum complex	cancer
KHPC 002	Phase I		platinum complex	cancer
KI 30606	Preclinical	poly[[[(+/-)-trans-1,2- diaminocyclohexane]] 1,3- dicarboxylatopropyla mido(nitrido)phospho ric acid]platinum (II)]	platinum complex	cancer

KP 1250	Preclinical	(SP-4-2)-dichloro(5,7,8,10,11,13,14,16,17,19,20,22-dodecahydro[1,4,7,10,13,16]hexaoxacyclodocosaol[19,18-b:20,21-b']dipyridine-N1,N26)platinum	platinum complex	cancer
lipophilic platinum compounds, Aronex	Discontinued		platinum complex	cancer
lobaplatin; D 19466	Registered	cis-(trans-1,2-cyclobutanebis(2-amine N,N')(2-hydroxypropionato(2-O1,O2)platinum	platinum complex	cancer
miboplatin; loboplatin; DWA 2114R; DWA 2114A; NEOPLAT	Discontinued	[SP-4-3-(1R-cis)-[1,1-cyclobutanedicarboxylato(2-)](2-pyrrolidinemethanamine-Nalpa,N1)platinum	platinum complex	cancer
nedaplatin; latoplatin; S 254; 254 S; NSC 375101D; AQUPLA	Marketed	(SP-4-3)-diammine[(hydroxy-kappa.O)acetato(2-)-kappa.O]platinum	platinum complex	cancer
ormaplatin; tetraplatin; TCDCP; NSC 276017; NSC 363812; NSC 363812D; U 77233	Phase I	[OC-6-22-(trans)]-tetrachloro(1,2-cyclohexanediamine-N,N')platinum	platinum complex	cancer

oxaliplatin; oxalatoplatinum; L- OHP; ACT 078; ELOXATINE; L- OHP; TRANSPLATIN; ELOXATIN	Marketed	[SP-4-2-(1R-trans)]-(1,2-cyclohexanediamine)-N,N''[ethanedioato(2-O,O')platinum	platinum complex	cancer
PADP	Phase I	phosphonoacetato-1,2-diaminocyclohexane platinum (II)	platinum complex	cancer
platinum complex, Cancer Research Center	Preclinical	cis-diamine(nitritotris(methylphosphonato)(2-)-O1,N1)platinum II	platinum complex	cancer
platinum compounds, Georgetown University	Discontinued		platinum complex	cancer
platinum-triamine complex; DPR	Preclinical	(SP-4-3)-diamminechloro[2-(diethylamino)ethyl-4-aminobenzoate-N4]platinum(1+)chloride monohydrochloride	platinum complex	cancer
polymer platinate compounds, London School of Pharmacy	Preclinical		platinum complex	cancer

RL 0013; NSC 328005; Pt 268; CYPLATATE	Preclinical	(SP-4-3)-(1,2-cyclohexanediamine-N,N')[(phosphonoacetyl)-L-asparto(4-)-O1,O4]platinate(2-)-dihydrogen	platinum complex	cancer
satraplatin; JM 216; BMS 182751; BMY 45594	Phase III	(OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum	platinum complex	cancer
sebriplatin; NK 121; CI 973; SEVRIPLATIN	Discontinued	[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4-butanediamine-N,N')platinum	platinum complex	cancer
SKI 2034R	Discontinued		platinum complex	cancer
SKI 2053R; SK 12035R	Phase II	[SP-4-2-[4R-(2alpha,4alpha,5beta)]-[2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5]](propanedioato(2-)-kappaO1,kappaO3]platinum	platinum complex	cancer
SM 11355; DACHPM	Discontinued	(trans-cyclohexane-1,2-diamine)bis(myristate)platinum (II)	platinum complex	cancer



TRK 710	Discontinued	[SP-4-3-1(S),3(1R-trans)]-(3-acetyl-5-methyl-2,4(3H,5H)-furanonato-O3,O4)(1,2-cyclohexanediamine-N,N')-platinum(1+), salt with (S)-3-acetyl-5-methyl-2,4(3H,5H)furanone (1:1), tetrahydrate	platinum complex	cancer
ZD 0473; AMD 473	Phase I	(SP-4-3)-aminodichloro(2-methylpyridine)platinum	platinum complex	cancer
zeniplatin; 2,2-bis(aminomethyl)-1,3-propanediol platinum complex; 1,1-cyclobutanedicarboxylic acid platinum complex; CL 286558	Phase II	(SP-4-2)-[2,2-bis(aminomethyl)-1,3-propanediol-N,N'] [1,1-cyclobutanedicarboxylato(2-)]platinum	platinum complex	cancer
PD 128763	Preclinical	3,4-dihydro-5-methyl-1(2H)-isoquinolinone	poly (ADP ribose) polymerase inhibitor	cancer
diethylhomospermine; DEHOP; DE 444	Phase II	N,N'-bis[4-(ethylamino)butyl]-1,4-butanediamine	polyamine analogue	diarrhea; hypertension; cancer; psoriasis; ulcerative colitis
diethylhomospermine; DENSPM; CI 1006; DE 333	Phase II	N1,N11-diethylhomospermine	polyamine analogue	cancer; psoriasis; Alzheimer disease

linear polyamine analogue, SunPharm	Preclinical			polyamine analogue	cancer; Alzheimer disease
MDL 28314	Discontinued	N,N'-bis[3-(ethylamino)propyl]-1,7-heptane diamine		polyamine analogue	cancer
polyamine analogues, National Institutes of Health	Preclinical			polyamine analogue	cancer
mitoguazone; methylglyoxal bisguanyldrazone; MGBG; NSC 32946; ZYRKAMINE	Marketed	1,1'-[(methylethanediyli)di(amine)dinitrilo]diguanidine		polyamine synthesis inhibitor	cancer
polyclonal antibody, complement inhibitor protein; gammaglobulin, complement inhibitor protein; PASS-CaB	Preclinical			polyclonal antibody; immunoglobulin	cancer
actinoplanone A; R 304G	Discontinued	[1S-(1 $\alpha$ ,3 $\alpha$ ,4 $\beta$ ,8 $\alpha$ )-11-chloro-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xantheno[4',3',2':4,5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione		polycyclic xanthone; antibiotic	bacterial infection; cancer

actinoplanone B; R 304H	Discontinued	[1S-(1 $\alpha$ ,3 $\alpha$ ,4 $\beta$ ,8 $\alpha$ )-11-chloro-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xantheno[4',3',2':4,5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione	polycyclic xanthone; antibiotic	bacterial infection; cancer
actinoplanone C; R 304J	Discontinued	[1S-(1 $\alpha$ ,3 $\alpha$ ,4 $\beta$ ,8 $\alpha$ )-13-amino-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xantheno[4',3',2':4,5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione	polycyclic xanthone; antibiotic	bacterial infection; cancer

actinoplanone G; R 304F	Discontinued	[1S-(1 $\alpha$ ,3 $\alpha$ ,4 $\beta$ ,8 $\alpha$ ,13 $\alpha$ )-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-13-[(1-methyl-2-oxopropylidene)amino]-1H-xantheno[4',3',2':4,5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione	polycyclic xanthone; antibiotic	bacterial infection; cancer
CARN 700; CARRAVEX	Phase I	Unspecified	polysaccharide	cancer
CKD 606	Preclinical		polysaccharide	cancer; liver disease
sizofiran; sizofilan; neochizophyllan; SONIFILAN; SONIFIRAN	Marketed	poly[3--(O-beta-D-glucopyranosyl-(1--3)-O-[beta-D-glucopyranosyl-(1--6)]-O-beta-D-glucopyranosyl-(1--3)-O-beta-D-glucopyranosyl)--1]	polysaccharide; immunostimulant	cancer; viral infection
CM 101; ZD 0101	Phase II	Unspecified	polysaccharide; immunostimulant; angiogenesis inhibitor	cancer
AM 5	Discontinued		polysaccharide; radioprotectant	cancer
LG 2527; LG 2716	Preclinical		progestogen; hormone replacement therapy	hormone deficiency; cancer

progesterone receptor therapy, Ligand/Wyeth Ayerst	Preclinical		progestogen; hormone replacement therapy	hormone deficiency; contraception; cancer
prolyl hydroxylase inhibitor, Cornell Research Foundation	Preclinical		prolyl hydroxylase inhibitor; angiogenesis inhibitor	retinopathy; cancer; skin disease; atherosclerosis
TEI 9826	Preclinical		prostaglandin	cancer
OC 3186	Preclinical	(5Z,13E,15S)-15- hydroxy-9-oxo- prosta-5,8(12),13- trien-1-oic acid (acetyloxy)methyl ester homopolymer	prostanoid	cancer
prostaglandin J2; PG J2	Preclinical		prostanoid	cancer; viral infection
YM 11	Preclinical	(5S,6S,7Z,12alpha,14 Z)-5,6-bis(acetyloxy)- 10-chloro-12- hydroxy-9-oxoprost- 7,10,14-trien-1-oic acid methyl ester	prostanoid	cancer
YM 3	Preclinical	(7E,12xi)-10-chloro- 12-hydroxy-9- oxoprost-7,10-dien-1- oic acid methyl ester	prostanoid	cancer

cicaprost; cicaprost clathrate; ZK 114923; SH 574; SH 490	Discontinued	[3aS- [2E,3aalpha,4alpha(3 R*,4R*),5beta,6aalph a]]-[2-[hexahydro-5- hydroxy-4-(3- hydroxy-4-methyl- 1,6-nonadiynyl)- 2(1H)- pentalenylidene]ethox yl]acetic acid	prostanoid; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease; cancer
bryostatin; bryostatin 1; BMY 45618; NSC 339555	Phase II	bryostatin 1	protein kinase activator; protein kinase C activator	cancer
hexamethylene bisacetamide derivative; HMBA derivative	Preclinical		protein kinase activator; protein kinase C activator	cancer
Y 27632	Preclinical	[4(R)-trans]-4-(1- aminoethyl)-N-4- pyridinylcyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
cancer therapy, Kinetix	Preclinical		protein kinase inhibitor; angiogenesis inhibitor	cancer
CP 564959	Preclinical		protein kinase inhibitor; angiogenesis inhibitor	cancer
H 87	Discontinued	N-[2-[[3-(4- bromophenyl)-2- propenyl]ethylamino] ethyl]-5- isquinolinesulfonam ide	protein kinase inhibitor; protein kinase A inhibitor; MDR inhibitor	cancer

BM 41400	Discontinued			protein kinase inhibitor; protein kinase C inhibitor	cancer
calphostin C; calphostin; UCN 1028C; UCN 1028	Discontinued	2-[12-[2-(benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylene]]-1-methylethyl 4-hydroxyphenyl carbonic acid ester		protein kinase inhibitor; protein kinase C inhibitor	cancer
diacylglycerol analogues, National Institutes of Health	Preclinical			protein kinase inhibitor; protein kinase C inhibitor	cancer
midostaurin; benzoylstaurosporine; N-benzoylstaurosporin; CGP 41251; CGP 41231	Phase II	(9alpha,10beta,11beta,13alpha)-N-(2,3,10,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-1m]pyrrolo[3,4-i][1,7]benzodiazonin-11-yl)-N-methylbenzamide		protein kinase inhibitor; protein kinase C inhibitor	cancer
NK 860276	Discontinued			protein kinase inhibitor; protein kinase C inhibitor	cancer

NSC 646958	Preclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer
protein kinase C inhibitor, microalgal, Martek	Preclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer; psoriasis
protein kinase C inhibitor, Xenova	Discontinued		protein kinase inhibitor; protein kinase C inhibitor	cancer
safingol; safingol hydrochloride; SPC 100270; mSPC 100271; KYNAC; KYNACYTE	Phase II	(2S,3S)-2-amino-1,3-octadecanediol	protein kinase inhibitor; protein kinase C inhibitor	psoriasis; dermatitis; cancer
SPC 100221	Preclinical	[R-(R*,S*)]-2-amino-1,3-octadecanediol	protein kinase inhibitor; protein kinase C inhibitor	cancer
SPC 101591	Preclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer; ischemia; reperfusion injury
RK 1409B	Preclinical	[9S-(9alpha,10alpha,11beta,12,13,10,11,12,13-hexahydro-11-hydroxy-10-methoxy-9-methyl-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-b][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor; antibiotic	cancer



CGP 60474	Phase I			protein kinase inhibitor; protein kinase C inhibitor; cyclin dependent kinase inhibitor	cancer
MLR 52; (+)-MLR-52	Discontinued	[9S-(9 $\alpha$ ,10 $\beta$ ,11 $\alpha$ ,12 $\alpha$ ,13 $\alpha$ )]-2,3,10,11,12,13-hexahydro-11,12-dihydroxy-10-methoxy-9-methyl-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one		protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	cancer
balanol; (-)-balanol; azepinostatin; ophiocordin	Preclinical	(3R-trans)-4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxybenzoic acid 1-[hexahydro-3-[(4-hydroxybenzoyl)amino]-1H-azepin-4-yl] ester		protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; psoriasis
SPC 100840	Preclinical			protein kinase inhibitor; protein kinase C inhibitor; NSAID	ischemia; psoriasis; cancer; inflammation; reperfusion injury

UCN 01; UCN 1; KW 2401	Phase I	(3alpha,9beta,10alpha,11alpha,13beta)-(+)-2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-b][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; allergy
MDL 27032	Suspended	4-propyl-5-(4-pyridinyl)-2(3H)oxazolone	protein kinase inhibitor; protein kinase C inhibitor; vasodilator	cancer
BE 23372M	Discontinued	(E)-5-(3,4-dihydroxyphenyl)-3-[[3,4-dihydroxyphenyl)methyl]-2(3H)-furanone	protein kinase inhibitor; tyrosine kinase inhibitor	cancer
CGP 53716	Phase II	N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide	protein kinase inhibitor; tyrosine kinase inhibitor	cancer
CGP 59326B	Preclinical		protein kinase inhibitor; tyrosine kinase inhibitor; EGF receptor inhibitor	cancer

KRN 5500	Phase I	4-deoxy-4-[[[(14-methyl-1-oxopentadecyl)amino]acetyl]amino]-N-1H-purin-6-yl-L-glycero-beta-L-manno-heptoipyranosylamine	protein synthesis inhibitor	cancer
Pseudomonas exotoxin A linked to F(ab') <sub>2</sub> fragment of MAb 1H10-PE; 1H10-PE	Preclinical		protein synthesis inhibitor	cancer
didemnin B; NSC 325319; IND 24505	Phase II	(S)-N-[1-(2-hydroxy-1-oxopropyl)-L-prolyl]didemnin A	protein synthesis inhibitor; antifungal; peptide	cancer; bacterial infection; mycosis; viral infection
B 428	Preclinical	4-iodobenzo[b]thiophene-2-carboximidamide monohydrochloride	proteinase inhibitor	cancer
Bowman Birk inhibitor concentrate; BBIC	Phase II		proteinase inhibitor	benign prostate hypertrophy; cancer
KT 512	Preclinical		proteinase inhibitor	cancer
P 35011	Preclinical		proteinase inhibitor	cancer
urokinase inhibitor, 3 Dimensional Pharmaceuticals	Preclinical		proteinase inhibitor	cancer
urokinase inhibitors, Axys	Preclinical		proteinase inhibitor	cancer
urokinase inhibitors, Corvas	Preclinical		proteinase inhibitor	cancer

PS 341	Phase I	[S-(R*,S*)]-[3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid	proteinase inhibitor; apoptosis inducer	cancer
cathepsin B inhibitors, Axys	Preclinical		proteinase inhibitor; cathepsin B inhibitor	cancer
AG 3433	Preclinical		proteinase inhibitor; matrix metalloproteinase inhibitor	cancer
CGS 27023A	Phase II	(R)-N-hydroxy-2-[[[4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methylbutanamide	proteinase inhibitor; matrix metalloproteinase inhibitor	cancer
CH 4815	Preclinical		proteinase inhibitor; matrix metalloproteinase inhibitor	cancer
metalloproteinase inhibitors, Glycomed	Preclinical		proteinase inhibitor; metalloproteinase inhibitor	cancer
cysteine proteinase inhibitor, SynPhar/British Biotech	Preclinical		proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; cancer; osteoarthritis

peldesine; BCX 34; BCX 34B	Phase II	2-amino-1,5-dihydro- 7-(3- pyridinylmethyl)-4H- pyrrolo[3,2- d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection
CH 799	Discontinued		purine nucleoside phosphorylase inhibitor; NSAID	rheumatoid arthritis; inflammatory bowel disease; cancer
CI 1000; PD 141955	Phase I	2-amino-1,5-dihydro- 7-(3-thienylmethyl)- 4H-pyrrolo[3,2- d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis
purine nucleoside phosphorylase inhibitors, Chiroscience; PNP inhibitors, Chiroscience	Discontinued		purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
Helicobacter pylori therapy, RPMS Technology	Discontinued		quinoline; antibiotic	gastrointestinal ulcer; bacterial infection; cancer
A 84441	Preclinical	6-[3-[(2-amino-1- oxopentyl)amino]-1- pyrrolidinyl]-5- fluoro-3-oxo-3H- pyrido[3,2,1- k]phenoxazine-2- carboxylic acid	quinolone; antibiotic	cancer

KB 5246	Discontinued	6-fluoro-5-(4-methyl-1-piperazinyl)-8-oxo-3H,8H-4-oxa-1-thia-9b-azacyclopenta[cd]phenalene-9-carboxylic acid monohydrochloride	quinolone; antibiotic	cancer; pruritis; hypertension; HIV infection; gastrointestinal ulcer; hyperlipidemia; bacterial infection
quinaldopeptin; BMY 28662; BU 3845T	Discontinued		quinomycin; antibiotic	bacterial infection; cancer
WR 168643; NSC 333839	Preclinical	4,4'-trithiobis-1-butanedisulfonic acid, disodium salt	radioprotectant	cancer
anticancer radiosensitizers, Telik	Preclinical		radiosensitizer	cancer
AQ4N radiation enhancer; AQ4N	Preclinical	1,4-bis[[2-(dimethyloxidoamino)ethyl]amino]-5,8-dihydroxy-9,10-anthracenedione	radiosensitizer	cancer
broxuridine; BuDR; BROXINE; NEOMARK	Pre-registration		radiosensitizer	cancer; diagnosis
CT 2412	Preclinical		radiosensitizer	cancer
cuprinol; RL 5077; CUPRINYL	Discontinued	(2,2'-bipyridine-N,N')[propanedioato(2-)-O,O']copper	radiosensitizer	cancer
etanidazole; SR 2508; NSC 301467; RADINYL	Phase III	N-(2-hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
KIN 804	Preclinical	N-methoxy-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer

KIN 831	Preclinical	N-hydroxy-2-nitro-1H-imidazole-1-propanamide	radiosensitizer	cancer
KU 2285	Preclinical	alpha,alpha-difluoro-N-(2-hydroxyethyl)-2-nitro-1H-imidazole-1-propanamide	radiosensitizer	cancer
metoclopramide; AHR 3070 C; DEL 1267; SENSAMIDE; NEU-SENSAMIDE; AEROFLAT; ANANDA; ANASIN; ANTIMET; BENAGASTRON; PRIMPERAN; DIGENOR; REGLAN	Marketed	4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide	radiosensitizer	emesis; cancer
MPI 5020	Phase II		radiosensitizer	cancer
nimorazole	Discontinued	4-[2-(5-nitroimidazol-1-yl)-ethyl]morpholine	radiosensitizer	cancer
PD 130908	Preclinical	N-(2-bromoethyl)-2-nitro-1H-imidazole-1-propanamine monohydrobromide	radiosensitizer	cancer
radiosensitizer, NCI	Preclinical		radiosensitizer	cancer
RK 28	Discontinued	4-[(2-nitro-1H-imidazol-1-yl)methoxy]-2-buten-1-ol	radiosensitizer	cancer

RP 170	Preclinical	2-[(2-nitro-1H-imidazol-1-yl)methoxy]-1,3-propanediol	radiosensitizer	cancer
RSU 1164	Discontinued	cis-alpha-[(2,3-dimethyl-1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol	radiosensitizer	cancer
RSU 1165	Discontinued	trans-alpha-[(2,3-dimethyl-1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol	radiosensitizer	cancer
SN 24699	Preclinical	N-[2-(2-methyl-5-nitro-1H-imidazolyl)ethyl]-4-(2-nitro-1H-imidazolyl)butanamide	radiosensitizer	cancer
SPI 40	Preclinical		radiosensitizer	cancer
SR 2545	Discontinued	N-[2-(acetyloxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
SR 2555; NSC 314-055	Discontinued	N,N-bis(2-hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
tirapazamine; WIN 59075; SR 4233; TIRAZONE	Phase III	3-amino-1,2,4-benzotriazine-1,4-dioxide	radiosensitizer	cancer



gadolinium texaphyrin; Gd Tex; PCI 0120; Gd-TeX; XCYTRIN	Phase III	(PB-7-11-233'2'4)- bis(acetato-O)[9,10- diethyl-20,21-bis[2- [2-(2- methoxyethoxy)ethox y]ethoxy]-4,15- dimethyl-8,11-imino- 3,6:16,13-dinitrilo- 1,18- benzodiazacycloicos ine-5,14- dipropanolato- N1,N18,N23,N24,N2 5]-gadolinium	radiosensitizer; chemosensitizer	cancer
tiobenguane; tiobenguane sulfate I123; MIBG; MIBG-I 123	Marketed	[[3-(iodo- 131I)phenyl]methyl]g uanidine	radiosensitizer; contrast medium; radiodiagnostic; radiotherapeutic	cancer; diagnosis
PK 110	Preclinical	N-[(4- fluorophenyl)methyl]- 2-nitro-1H-imidazole- 1-acetamide	radiosensitizer; imidazole	cancer
PK 130	Preclinical	N-[(2-nitro-1H- imidazol-1-yl)acetyl]- L-phenylalanine, methyl ester	radiosensitizer; imidazole	cancer
RB 6145; PD 144872; PD 144871; PD 130571; CI 1010	Phase I	alpha-[(2- bromoethyl)amino]m ethyl]-2-nitro-1H- imidazole-1- ethanolmonohydrobro mide	radiosensitizer; imidazole	cancer

nitric oxide-releasing radiosensitizer, National Institutes of Health	Preclinical			radiosensitizer; nitric oxide donor	cancer
cytochlor	Preclinical	5-chloro-2'-deoxycytidine		radiosensitizer; nucleoside analogue	cancer
doranidazole; RP 343; PR 350	Phase I	(R*,S*)-3-[(2-nitro-1H-imidazol-1-yl)methoxy]-1,2,4-butanetriol		radiosensitizer; nucleoside analogue; antimetabolite	cancer
117m Sn DTPA; pentetate 117m Sn	Phase II			radiotherapeutic; analgesic	cancer; pain
thorium Re 186 etidronate; 186-Re HEDP; 186-Re HEDP; BETAMET	Pre-registration			radiotherapeutic; analgesic	pain; cancer
strontium-89 chloride; METASTRON	Marketed	strontium chloride (89SrCl2)		radiotherapeutic; analgesic	pain; cancer
ALRT 1455	Preclinical			RAR agonist; retinoid agonist	cancer
AGN 192792; LG 100382	Preclinical			RAR agonist; RXR agonist; retinoid; retinoid agonist	cancer
CP 609754	Preclinical			RAS inhibitor	cancer
ras inhibitors, Agouron	Suspended			RAS inhibitor	cancer
Ras inhibitors, Bristol-Myers Squibb	Preclinical			RAS inhibitor	cancer
ras farnesyl transferase inhibitor, Xenova; XR 3005 series	Discontinued			RAS inhibitor; farnesyl protein transferase inhibitor	cancer

ras FT inhibitor, Genentech	Discontinued			RAS inhibitor; farnesyl protein transferase inhibitor	cancer
ras inhibitors, Onyx/Bayer	Preclinical			RAS inhibitor, signal transduction inhibitor	cancer
cancer therapy, retinoids, Cornell Research Foundation	Preclinical			retinoid	cancer, psoriasis
drug delivery system, liposome tretinoin; tretinoin liposome; AR 623; ATRAGEN	Pre- registration			retinoid	cancer
NIK 333	Preclinical			retinoid	cancer
polyprenic acid; E 5166	Discontinued	(all-E)-3,7,11,15- tetramethyl- 2,4,6,10,14- hexadecapentaenoic acid		retinoid	cancer
R11 retinamide	Marketed			retinoid	cancer
tazarotene; AGN 190168; ZORAC; TAZORAC	Marketed	6-[(3,4-dihydro-4,4- dimethyl-2H-1- benzothiopyran-6- yl)ethynyl]-3-pyrid inecarboxylic acid ethyl ester		retinoid	acne; cancer; psoriasis
tretinoin; Ro 015488/115; NSC 122758; VESANOID	Marketed	(all-E)-3,7-dimethyl- 9-(2,6,6-trimethyl-1- cyclohexen-1-yl)- 2,4,6,8- nonatetraenoic acid		retinoid	acne; cancer

AM 580	Discontinued	4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]amino]benzoic acid	retinoid agonist	psoriasis; cancer
MX 33511; MX33511; MX 33501	Preclinical	6-(7-tricyclo[3.3.1.1 <sup>3,7</sup> ]dec-1-yl-1,3-benzodioxol-5-yl)-2-naphthalenecarboxylic acid	retinoid agonist	cancer
tamibarotene; AM 80	Discontinued	4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]benzoic acid	retinoid agonist	psoriasis; cancer
LGD 1550; ALRT 1550; LG 100550; AGN 193101; LG 1550; ALRT 550	Phase II	(all-E)-7-[3,5-bis(1,1-dimethylethyl)phenyl]-3-methyl-2,4,6-octatrienoic acid	retinoid agonist; RAR agonist	cancer; skin disease
AGN 190521; LG 030106	Preclinical	5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenecarboxylic acid 4-carboxyphenyl ester	retinoid agonist; RAR agonist; retinoid	cancer; skin disease
ER 38925	Preclinical	4-[5-(4,7-dimethyl-2-benzofuranyl)-1H-pyrrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis

ER 65250	Preclinical	4-[5-(7-ethyl-4-methyl-2-benzofuranyl)-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
ER 69029	Preclinical	4-[5-[7-fluoro-4-(trifluoromethyl)-2-benzofuranyl]-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
AGN 190121; LG 030042	Preclinical	(E)-4-[4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-1-ynyl]benzoic acid	retinoid agonist; RARbeta agonist; RARgamma agonist; retinoid	cancer; viral infection
AGN 191379; LG 030053	Preclinical	4-[(3,4-dihydro-2,2,4,4-tetramethyl-2H-1-benzopyran-6-yl)ethynyl]benzoic acid	retinoid agonist; RARbeta agonist; RARgamma agonist; retinoid	cancer; skin disease
bexarotene; LGD 1069; LG 100069; LG 1069; LDG 1069; TARGRETIN	Phase III	4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthenyl)-1-ethenyl]-benzoic acid	retinoid agonist; retinoid; differentiation inducer; RXR agonist	cancer; diabetes; psoriasis; skin disease
LGD 1324; ALRT 324	Preclinical		retinoid agonist; RXR agonist	diabetes; cancer
AGN 4310; ALRT 4310	Preclinical		retinoid antagonist	psoriasis; cancer
TAC 101; AM 555s	Phase I	4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid	retinoid antagonist	cancer

fenretinide; HPR, 4; 4HPR; RAHA; McN R1967	Phase III	N-(4- hydroxyphenyl)retina mide	retinoid; NSAID	rheumatoid arthritis; cancer
apurinic acid	Preclinical		reverse transcriptase inhibitor	HIV infection; cancer
P 30 protein; P 30; ONCONASE	Phase III	ribonuclease (Rana pipiens reduced)	ribonuclease	cancer
LY 309887	Phase I	(R)-N-[[5-[2-(2- amino-1,4,5,6,7,8- hexahydro-4- oxopyrido[2,3- d]pyrimidin-6- yl)ethyl]-2- thienyl]carbonyl]-L- glutamic acid	ribonucleotide formyltransferase inhibitor; antifolate; antimetabolite	cancer
amidox; VF 236	Preclinical	N,3,4- trihydroxybenzenecar boximidamide	ribonucleotide reductase inhibitor	cancer
didox; VF 147; NSC 324360	Phase II	N,3,4- trihydroxybenzamide	ribonucleotide reductase inhibitor	cancer; HIV infection
OCX 189; OCX 0189	Discontinued		ribonucleotide reductase inhibitor	cancer
OCX 191; OCX 0191; 3AP; TRIAPINE	Phase I	2-[(3-amino-4- methyl-2- pyridinyl)methylene] hydrazinecarbothioam ide	ribonucleotide reductase inhibitor	cancer
OCX 191 prodrugs, Vion	Preclinical		ribonucleotide reductase inhibitor	cancer
trimidox	Preclinical		ribonucleotide reductase inhibitor	HIV infection; cancer

FMdC; MDL 101731; Phase II KW 2331		(E)-2'- fluoromethylene-2'- deoxycytidine (FMdC)	ribonucleotide reductase inhibitor; nucleoside analogue	cancer
parabactin	Preclinical		ribonucleotide reductase inhibitor; polyamine analogue	cancer
LGD 1268; ALRT 268	Preclinical		RXR agonist; retinoid agonist	diabetes; cancer
ALRT 620; AGN 192620; LG 100268	Preclinical	6-[1-(5,6,7,8- tetrahydro-3,5,5,8,8- pentamethyl-2- naphthalenyl)cyclopr opyl]-3- pyridinecarboxylic acid	RXR agonist; retinoid; retinoid agonist	cancer
CGP 35753	Discontinued	2-[[3- (aminoiminomethyl)p henyl]methylene]-N- hydroxyhydrazinecar boximidamide	S adenosylmethionine decarboxylase inhibitor	cancer
CGP 39937	Discontinued	[2,2'-bipyridine]-6,6'- dicarboximidamide	S adenosylmethionine decarboxylase inhibitor	cancer
sardomozide; CGP 48664; SAM 486	Phase II	2-[4- (aminoiminomethyl)- 2,3-dihydro-1H- inden-1- ylidene]hydrazinecarb oximidamide	S adenosylmethionine decarboxylase inhibitor	cancer
cancer therapy, Cortecs	Preclinical		signal transduction inhibitor	cancer

GW 7072	Preclinical		signal transduction inhibitor	cancer
signal transduction inhibitor, National Academy of Science	Preclinical		signal transduction inhibitor	cancer
signal transduction inhibitors, NCI	Preclinical		signal transduction inhibitor	cancer
signal transduction inhibitor, SUGEN/ArQule	Preclinical		signal transduction inhibitor; immunosuppressant	cancer; diabetes; neurological; autoimmune disease
BIBX 1382	Phase II		signal transduction inhibitor; tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
lanreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSTYL	Marketed	3-(2-naphthalenyl)-D-alanyl-L-cysteiny-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteiny-L-threoninamide cyclic (2,7)-disulfide	somatostatin analogue	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
TT 232; TT 2-32	Preclinical	D-phenylalanyl-L-cysteiny-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteiny-L-threoninamide cyclic (2->6)-disulfide	somatostatin analogue	cancer



TT 250; TT 2-50	Preclinical	D-Phenylalanyl-L-cysteiny-L-tyrosyl-L-tryptophyl-L-lysyl-L-leucyl-L-cysteiny-L-threoninamide cyclic (2->7)-disulfide	somatostatin analogue	cancer
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	Marketed	[R-(R*,R*)]-D-phenylalanyl-L-cysteiny-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
vapreotide; octastatin; RC 160; BMY 41606	Phase II	D-Phe-Cys-Trp-D-Trp-Lys-Val-Cys-Trp-NH <sub>2</sub>	somatostatin analogue; analgesic	cancer; pain
stem cell inhibitor	Preclinical		stem cell division inhibitor; hematopoiesis inhibitor; hematoprotectant; chemoprotectant	cancer
BAY 129566	Phase III	(S)-4'-chloro-gamma-oxo-alpha-[(phenylthio)methyl][1,1'-biphenyl]-4-butanoic acid	stromelysin inhibitor; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	osteoarthritis; cancer

stromelysin inhibitors, Agouron	Preclinical		stromelysin inhibitor; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	cancer; arthritis
antagonist G; PTL 68300B	Phase I	Arg-DTrp-NMePhe-DTrp-Leu-Met-NH2	substance P antagonist; peptide; growth factor modulator	cancer
DW 2282	Preclinical		sulfonylurea; antineoplastic	cancer
LaneBase	Preclinical		target based screening	drug design technology; cancer
screening technology, cancer, Cellomics	Preclinical		target based screening	drug design technology; cancer
screening technology, granulocyte colony-stimulating factor mimetic	Discontinued		target based screening	drug design technology; cancer
screening technology, human papillomavirus therapy, Harvard Medical School	Preclinical		target based screening	drug design technology; viral infection; cancer
screening technology, NuMA	Preclinical		target based screening	drug design technology; cancer
screening technology, thrombopoietin mimetic	Discontinued		target based screening	drug design technology; cancer; thrombocytopenia
screening technology, cox-2 gene suppression	Preclinical		target based screening; biotechnology	drug design technology; inflammation; cancer

screening technology, MDR inhibitors	Preclinical		target based screening, MDR inhibitor	drug design technology; cancer
baccatin III derivatives, Indena	Preclinical	[2aR-(2 $\alpha$ alpha,4beta,4alpha,6beta,9alpha,10beta,11alpha,12alpha,12alpha,12beta)-(acetyloxy)-12-(benzoyloxy)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahydro-4,6,9,10,11-pentahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca[3,4]benz[1,2-b]oxet-5-one	taxane	cancer
BMS 184476	Phase I		taxane	cancer

BP 179	Preclinical	[2aR- [2aalpha,4beta,4beta, 6beta,9alpha(alphaR*, betaS*),11alpha,12al pha,12aalpha,12balph a]]-[partial]-beta- (benzoylamino)- alpha- hydroxybenzenepropa noic acid, 6,12b- bis(acetyloxy)-12- (benzoyloxy)-4- [[[(2,3- dihydroxypropoxy)ca rbonyl]oxy]- 2a,3,4,4a,5,6,9,10,11, 12,12a,12b- dodecahydro-11- hydroxy-4a,8,13,13- tetramethyl-5-oxo- 7,11-methano-1H- cyclodeca[3,4]benz[1, 2-b]oxet-9-yl ester	taxane	cancer
--------	-------------	--	--------	--------

dihydrotaxol, 9-; 9- dihydrotaxol; TAXAN	Preclinical	[2aR- [2aalpha,4beta,4alpha, 5alpha,6beta,9alpha(a lphaR*,betaS*),11alp ha,12alpha,12aalpha, 12balpha]]-beta- benzoylamino)-alpha- hydroxy- benzenepropanoic acid, 6,12b- bis(acetyloxy)-12- (benzoyloxy)-12- 2a,3,4,4a,5,6,9,10,11, 12,12a,12b- dodecahydro-4,5,11- trihydroxy- 4a,8,13,13- tetramethyl-7,11- methano-1H- cyclodeca[3,4]benz[1, 2-b]oxet-9-yl ester	taxane	cancer
drug delivery system, LDS microemulsion paclitaxel; paclitaxel LDS microemulsion	Preclinical		taxane	cancer
drug delivery system, liposome paclitaxel; paclitaxel liposome	Phase I		taxane	cancer
IDN 5109; SB T101131	Preclinical		taxane	cancer
paclitaxel analogues, Virginia Tech	Preclinical		taxane	cancer
RPR 109881	Phase I		taxane	cancer

TAXOPREXIN	Phase II		taxane	cancer
TDX 258	Phase I		taxane	cancer
bromotaxol	Preclinical		taxane; microtubule assembly promoter	cancer
docetaxel; RP 56976; NSC 628503; TAXOTERE	Marketed	beta-[[[(1,1-dimethylethoxy)carbo- nyl]amino]-alpha- hydroxybenzenepro- panoic acid [2aR- [2aalpha,4beta,4abeta, 6beta,9alpha(alphaR*, betaS*)- 11alpha,12alpha,12aa lpha,12balpha]]-12b- (acetyloxy)-12- (benzoyloxy)- 2a,3,4,4a,5,6,9,10,11, 12,12a,12b-dodeca- hydro-4,6,11- trihydroxy- 4a,8,13,13- tetramethyl-5-oxo- 7,11-methano-1H- cyclodec a[3,4]benz[1,2- b]oxet-9-yl ester	taxane; microtubule assembly promoter	cancer; malaria
drug delivery system, biodegradable polymer paste paclitaxel; paclitaxel biodegradable polymer paste	Preclinical		taxane; microtubule assembly promoter	cancer

drug delivery system, CYTOPORTER paclitaxel	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, intralesional paclitaxel; paclitaxel anhydrous delivery vehicle; ADV paclitaxel; MPI 5018	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, liposome paclitaxel; paclitaxel liposome	Discontinued		taxane; microtubule assembly promoter	cancer
drug delivery system, liposome paclitaxel; paclitaxel liposome	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, ONCHOLAB paclitaxel; paclitaxel ONCHOLAB	Discontinued		taxane; microtubule assembly promoter	cancer
drug delivery system, polyglutamic acid paclitaxel; paclitaxel polyglutamic acid; PG-TXL	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, polymer-bound paclitaxel; paclitaxel polymer-bound; PNU 166945	Phase I		taxane; microtubule assembly promoter	cancer
drug delivery system, polymeric micelle paclitaxel; paclitaxel polymeric micelle	Preclinical		taxane; microtubule assembly promoter	cancer

drug delivery system, PROCYTE microsphere paclitaxel; paclitaxel PROCYTE	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, ReGel paclitaxel; GENEXOL	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, vascular stent paclitaxel; paclitaxel vascular stent	Preclinical		taxane; microtubule assembly promoter	restenosis; cancer
paclitaxel; NSC 125973; BMS 181339; TAXOL; ANZATAX; YEW TAXAN	Marketed	[2aR[2aalpha,4beta,4 abeta,6beta,9alpha(al phaR*,betaS*),11beta ,12alpha,12aalpha,12 balpha]]-beta- (benzoylamino)- alpha- hydroxybenzenepropan oic acid 6,12b- bis(acetyloxy)-12- (benzoyloxy)- 2a,3,4,4a,5,6,9,10,11, 12,12a,12b- dodecahydro-4,11- dihydroxy- 4a,8,13,13- tetramethyl-5-oxo- 7,11-methano-1H- cyclodeca[3,4]benz[1, 2-b]oxet-9-yl ester	taxane; microtubule assembly promoter	cancer



paclitaxel analogue, Reading University	Preclinical		taxane; microtubule assembly promoter	cancer
paclitaxel derivatives, EnzyMed	Preclinical		taxane; microtubule assembly promoter	cancer
polyethylene glycol paclitaxel; PEG- paclitaxel; paclitaxel macrogol	Preclinical		taxane; microtubule assembly promoter	cancer
ZYN-LINKER conjugated paclitaxel	Suspended		taxane; microtubule assembly promoter	restenosis; cancer
drug delivery system, anticancer agents	Preclinical		taxane; microtubule assembly promoter; DNA topoisomerase inhibitor	cancer
telomerase inhibitor, Telik	Preclinical		telomerase inhibitor	cancer
telomerase inhibitors, Geron	Preclinical		telomerase inhibitor	cancer
telomerase inhibitors, University of Texas	Preclinical		telomerase inhibitor	cancer
telomerase inhibitors, Whitehead Institute for Biomedical Research	Preclinical		telomerase inhibitor	cancer
cancer therapy, Viscount Pharma	Preclinical		telomerase inhibitor; nucleoside analogue	cancer
acylfulvene, MGI Pharma/Dainippon	Phase I		terpene	cancer
betulinic acid; betulinic acid	Preclinical	(3.beta.)-3-hydroxy- lup-20(29)-en-28-oic acid	terpene	cancer
caulerpenyne	Suspended		terpene	cancer

monoterpenes, Endorex	Preclinical		terpene	cancer
TGF beta antagonists, GLYCODesign; transforming growth factor beta antagonists	Preclinical		TGF beta antagonist; cicatrizant	cancer; viral infection; inflammation; skin ulcer
thrombospondin inhibitor, Allelix	Discontinued		thrombospondin inhibitor; peptide; NSAID	inflammation; cancer; sickle cell anemia
CV 6504	Preclinical	2,3,5-trimethyl-6-(3- pyridinylmethyl)-2,5- cyclohexadiene-1,4- dione	thromboxane antagonist; 5- lipoxigenase inhibitor	cancer
ICI D8322; ZD 8322	Discontinued		thymidylate synthase inhibitor	cancer
raltitrexed; paltitrexid; ZD 1694; ICI D1694; TOMUDEX	Marketed	N-[[5-[[[(1,4-dihydro- 2-methyl-4-oxo-6- quinazolinyl)methyl] methylamino]-2- thienyl]carbonyl]-L- glutamic acid	thymidylate synthase inhibitor; antifolate; antimetabolite	cancer
AG 250	Discontinued		thymidylate synthase inhibitor; antimetabolite	cancer
AG 341	Discontinued		thymidylate synthase inhibitor; antimetabolite	cancer
AG 394	Discontinued		thymidylate synthase inhibitor; antimetabolite	cancer

BW 1843U89	Suspended	(S)-2-(5-(((1,2-Dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl)amino)-1-oxo-2-isoindolinyloxy)glutaric Acid	thymidylate synthase inhibitor; antimetabolite	cancer
FTC 092	Discontinued	alpha, alpha, alpha-trifluoro-3'-O-(phenylmethyl)thymidine	thymidylate synthase inhibitor; antimetabolite	cancer
metesind; AG 331	Suspended	4-[[4-[[[(2-aminobenz[cd]indol-6-yl)methylamino]methyl]phenyl]sulfonyl]morpholine	thymidylate synthase inhibitor; antimetabolite	cancer
nolatrexed; nolatrexed dihydrochloride; AG 337; THYMITAQ	Discontinued	2-amino-6-methyl-5-(4-pyridinylthio)-4(1H)-quinazolinone	thymidylate synthase inhibitor; antimetabolite	cancer
pemetrexed; pemetrexed disodium; LY 231514; MTA	Phase III	N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrazolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid	thymidylate synthase inhibitor; antimetabolite	cancer

ZD 9331	Phase II	(2S)-[4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(2-propynyl)amino]-2-fluorobenzamido]-4-(1H-tetrazol-5-yl)butyric acid	thymidylate synthase inhibitor; antimetabolite	cancer
titanocene dichloride	Phase II	CpTiCl <sub>2</sub>	titanium complex	cancer
budotitane	Discontinued	diethoxybis(1-phenyl-1,3-butanedionato-O,O')-titanium	titanium complex; alkylating agent	cancer
CC 1080	Preclinical		TNF inhibitor; NSAID	arthritis; cancer; multiple sclerosis
thalidomide; BMS 205935	Phase II	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; angiogenesis inhibitor	retinopathy; cancer
thalidomide; SYNOVIR; THALOMID	Marketed	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
CC 1069	Preclinical	beta-(3,4-dimethoxyphenyl)-1,3-dihydro-1,3-dioxo-2H-isoindole-2-propanamide	TNF modulator; NSAID	cachexia; arthritis; cancer
FRK inhibitor, Signal; fos regulating kinase inhibitor, Signal	Discontinued		transcription factor regulator; MAP kinase inhibitor	cancer; hypothyroidism; Paget disease; periodontal disease
NF-kappaB inhibitor, Signal	Preclinical		transcription factor regulator; NSAID	inflammation; ischemia; cancer; autoimmune disease

AP-1 inhibitor, Signal; JNK inhibitor, Signal	Preclinical		transcription factor regulator; NSAID; immunosuppressant	inflammation; autoimmune disease; cancer
SC 104	Discontinued		triglyceride	cancer
halichondrin B	Preclinical	halichondrin B	tubulin polymerase inhibitor	cancer
NSC 654261	Preclinical		tubulin polymerase inhibitor	cancer
spongistatin 1 analogues, Hughes Institute	Preclinical		tubulin polymerase inhibitor	cancer
combretastatin analogue	Preclinical	3,4,5-trimethoxy-N- (4-methylphenyl)benzen emethanamine	tubulin polymerase inhibitor; microtubule assembly inhibitor	cancer
DDE 261	Preclinical		tubulin polymerase inhibitor; microtubule assembly inhibitor	cancer
dolastatin 10; NSC 376128	Phase I	N,N-dimethyl-L- valyl-N-[(1S,2R)-2- methoxy-4-[(2S)-2- [(1R,2R)-1-methoxy- 2-methyl-3-oxo-3- [[[(1S)-2-phenyl-1-(2- thiazolyl)ethyl]amino ]propyl]-1- pyrrolidinyl]-1-[(1S)- 1-methylpropyl]-4- oxobutyl]-N-methyl- L-valinamide	tubulin polymerase inhibitor; peptide	cancer

ALL-TK antagonists; acute lymphoblastic leukemia tyrosine kinase antagonists	Suspended		tyrosine kinase inhibitor	cancer
angelmicin B	Discontinued		tyrosine kinase inhibitor	cancer
BCR/ABL antagonists	Discontinued		tyrosine kinase inhibitor	cancer
CEP 2563; KT 8391	Phase I		tyrosine kinase inhibitor	cancer
CEP 701; KR 5555	Phase I		tyrosine kinase inhibitor	cancer
CEP 751; KT 6587	Suspended		tyrosine kinase inhibitor	cancer
CGP 52411	Discontinued	5,6- bis(phenylamino)-1H- isoindole-1,3(2H)- dione	tyrosine kinase inhibitor	cancer
CGP 53353	Discontinued	5,6-bis[(4- fluorophenyl)amino]- 1H-isoindole- 1,3(2H)-dione	tyrosine kinase inhibitor	cancer
CGP 57148; CGP 57148B	Phase I	4-[(4-methyl-1- piperazinyl)methyl]- N-[4-methyl-3-[[4-(3- pyridinyl)-2- pyrimidinyl]amino]ph enyl]-benzamide	tyrosine kinase inhibitor	cancer
FGF-1 receptor inhibitors, Parke Davis/Auckland University	Preclinical		tyrosine kinase inhibitor	cancer

GW 282974; GW 974	Preclinical	N6,N6-dimethyl-N4-[1-(phenylmethyl)-1H-indazol-5-yl]pyrido[3,4-d]pyrimidine-4,6-diamine monohydrochloride	tyrosine kinase inhibitor	cancer
LFM A13	Preclinical		tyrosine kinase inhibitor	cancer
Met tyrosine kinase antagonist	Preclinical		tyrosine kinase inhibitor	cancer
PD 157655	Preclinical		tyrosine kinase inhibitor	cancer
PD 158294	Preclinical		tyrosine kinase inhibitor	cancer
PD 158780	Preclinical	N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine	tyrosine kinase inhibitor	cancer
PD 164199	Preclinical	6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 164771	Preclinical	6-(2,6-dichlorophenyl)-8-methyl-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis

PD 166285	Preclinical	6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 167978	Preclinical		tyrosine kinase inhibitor	cancer
PD 173956	Preclinical		tyrosine kinase inhibitor	cancer
SU 101	Phase III	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	tyrosine kinase inhibitor	cancer
SU 101 analogues	Preclinical		tyrosine kinase inhibitor	cancer
SU 102	Preclinical		tyrosine kinase inhibitor	cancer
SU 65847	Preclinical		tyrosine kinase inhibitor	cancer
tyrosine kinase inhibitors, Cephalon	Discontinued		tyrosine kinase inhibitor	benign prostate hypertrophy; cancer
tyrosine kinase inhibitors, Novartis	Preclinical		tyrosine kinase inhibitor	cancer
tyrosine kinase inhibitors, Xenova	Discontinued		tyrosine kinase inhibitor	cancer
ZD 4190	Preclinical		tyrosine kinase inhibitor	cancer



SU 1433	Discontinued	4-(6,7-dimethyl-2-quinoxaliny)-1,2-benzenediol	tyrosine kinase inhibitor; angiogenesis inhibitor; signal transduction inhibitor	cancer; retinopathy
SU 1498	Discontinued	(E)-2-cyano-3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]-N-(3-phenylpropyl)-2-propenamide	tyrosine kinase inhibitor; angiogenesis inhibitor; signal transduction inhibitor	cancer; retinopathy
CGP 59326A	Phase I	N-(3-chlorophenyl)-5,6-dimethyl-1H-pyrrolo[2,3-d]pyrimidin-4-amine monohydrochloride	tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
CP 358774	Phase II	N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine	tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
PD 153035	Preclinical	N-(3-bromophenyl)-6,7-dimethoxy-4-quinazolinamine	tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
PD 183805; CI 1033	Preclinical		tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
ZD 1839	Phase I		tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
tyrosine kinase inhibitors, AstraZeneca	Discontinued		tyrosine kinase inhibitor; signal transduction inhibitor	cancer
WHI P131	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor	cancer

WHI P154	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor	cancer
DAB 720	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor; EGF receptor inhibitor	cancer
PD 169540	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor; EGF receptor inhibitor	cancer
BMLOV	Discontinued	bis(maltolato) oxovanadium	tyrosine phosphatase inhibitor	cancer
cancer-associated protein tyrosine phosphatase inhibitor, Ontogen	Discontinued		tyrosine phosphatase inhibitor	cancer
AG 213; RG 50964; tyrphostin AG 213; RG 50864 (no stereo)	Phase I	(E)-2-cyano-3-(3,4-dihydroxyphenyl)-2-propenethioamide	tyrphostin	psoriasis; cancer; atherosclerosis
AG 555	Preclinical	(2E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(3-phenylpropyl)-2-propenamide	tyrphostin	psoriasis; cancer; atherosclerosis
tyrphostins	Preclinical		tyrphostin	psoriasis; cancer; atherosclerosis; septic shock
AG 490	Discontinued	(E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenamide	tyrphostin; tyrosine kinase inhibitor	cancer

UBC inhibitors, Mitotix; ubiquitin conjugating enzyme inhibitors	Preclinical		ubiquitin conjugating enzyme inhibitor; NSAID	cancer; inflammation
urate oxidase; SR 29142	Phase III		urate oxidase; biotechnology; enzyme	gout; cancer
epitaloprost; eptaprost; ZK 97959	Discontinued	3aS- [2E,3aalfa,4alfa(3R*, 4R*)5beta,6aalfa]-4- (2-hexahydro-5- hydroxy-4-(3- hydroxy-4-methyl- 1,6-nonadiynyl)- 2(1H))- pentalenylidene)ethox y-butanedioic acid	vasodilator; prostanoid	thrombosis; peripheral vascular disease; cancer
SR 49059	Phase II	[2R- [2alfa(S*),3beta]]-1- [[5-chloro-3-(2- chlorophenyl)-1- [(3,4- dimethoxyphenyl)sulf onyl]-2,3-dihydro-3- hydroxy-1H-indol-2- yl]carbonyl]-2- pyrrolidinecarboxami de	vasopressin antagonist; diuretic	gynecological; cancer; hypertension; heart failure; emesis
VRCTC 310	Preclinical	Unspecified	venom	cancer
anhydrovinblastine	Phase I	3',4'-didehydro-4'- deoxyvincal leukoblast ine	vinca alkaloid	cancer

drug delivery system, liposome vincristine; vincristine liposome; VincaXome	Preclinical		vinca alkaloid	cancer
drug delivery system, ONCHOLAB vincristine; vincristine ONCHOLAB	Discontinued		vinca alkaloid	cancer
drug delivery system, STEALTH liposome vincristine; vincristine STEALTH	Preclinical		vinca alkaloid	cancer
drug delivery system, vinblastine; vinblastine Therapeutic Implant; MPI 5017	Discontinued		vinca alkaloid	cancer
drug delivery system, vincristine; vincristine drug delivery system; Onco TCS	Phase II		vinca alkaloid	cancer
vinflunine; F 12158; L 0070	Phase I	4'-deoxy-20',20'-difluoro-C'-norvincal leukoblastine	vinca alkaloid	cancer
vinorelbine; vinorelbine tartrate; PM 259; DC 1; KW 2307; BW 7Y89; KW 3407; NAVELBINE; EUNADES; NABELBIN	Marketed	3',4'-didehydro-4'deoxy-C'-norvincal leukoblastine	vinca alkaloid	cancer

vinxaltine; S 12363	Phase I	[3(S)]-O4-deacetyl-3-de(methoxycarbonyl)-3-[[[1-(diethoxyphosphiny)]-2-methylpropyl]amino]carbonyl]vincalculastine	vinca alkaloid; microtubule assembly inhibitor	cancer
superactive vasoactive intestinal peptide antagonist, NCI	Preclinical		VIP antagonist	cancer
LR 103	Preclinical		vitamin D analogue	cancer
1alpha-hydroxyvitamin D2; 1alpha-D2; one-alpha D2; TSA 870; HECTOROL	Pre-registration		vitamin D2 analogue	osteoporosis; hyperparathyroidism; cancer
CB 1267	Discontinued	[[1R-[1alpha(R*),3abeta,4E(1R*,3S*,5Z),7aalp ha]]-4-methylene-5-[[octahydro-7a-methyl-1-[1-methyl-2-[[5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentynyl]oxy]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	vitamin D3 analogue	cancer

ILX 237553; ILX 23-7553	Preclinical	1,25(OH) <sub>2</sub> -16ene-23yne-26,27 hexafluorovitamin D3	vitamin D3 analogue	cancer
seocalcitol; EB 1089	Phase II	1(S),3(R)-dihydroxy-20(R)-(5'-ethyl-5'-hydroxy-hepta-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene	vitamin D3 analogue	cancer
solverol; PRI 1901	Phase I	(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-1-[(1R,5E)-7-hydroxy-1,7-dimethyl-5-octenyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	vitamin D3 analogue; differentiation inducer	cancer; psoriasis

Table 25. Current Candidate Therapeutic Interventions for the Treatment of ALS

Product Name	Chemical Name	Action	Indication
EF 7412	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]-1-piperazinyl]phenyl]ethanesulfonamide	5HT antagonist; 5HT1A antagonist; glutamate release inhibitor	Neurodegeneration; depression; cancer
AMPA antagonists	Unspecified	AMPA antagonist; glutamate antagonist	Neurodegeneration; eye disease
SPD 502; NS 1209	2-[[[5-[4-[(dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxybutanoic acid monosodium salt	AMPA antagonist; glutamate antagonist	stroke; neurodegeneration
pirfenidone; MAR 01; AMR 69; DESKAR	5-methyl-1-phenyl-2(1H)-pyridinone	antifibrotic	skin disease; pulmonary fibrosis; neurodegeneration
dehydroascorbic acid	Unspecified	antioxidant	neurodegeneration; neurological
U 101033E	6,7,8,9-tetrahydro-9-[2-(4-morpholinyl)ethyl]-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole dihydrochloride	antioxidant	stroke; neurodegeneration; brain ischemia
MDL 101002	3,4-dihydro-3,3-dimethylisoquinoline 2-oxide	antioxidant; free radical scavenger	stroke; neurodegeneration; septic shock
synthetic catalytic scavenger analogues; SCS analogues	Unspecified	antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
neurodegenerative disease therapy	Unspecified	apoptosis inhibitor	neurodegeneration

neurodegeneration therapy	unspecified	apoptosis inhibitor	neurodegeneration; amyotrophic lateral sclerosis
apoptosis modulators	Unspecified	apoptosis inhibitor; apoptosis inducer	cancer; autoimmune disease; neurodegeneration
apoptosis inhibitors	Unspecified	apoptosis inhibitor; peptide	neurodegeneration
BAY Z 4406	Unspecified	calcium channel blocker	neurodegeneration; Alzheimer disease
cardiotrophin-1 secreting implant	Unspecified	Cardiotrophin-1 agonist	amyotrophic lateral sclerosis; neurodegeneration
caspase inhibitors	Unspecified	caspase inhibitor	neurodegeneration; myocardial infarction; rheumatoid arthritis; septic shock
CPP32 inhibitors, caspase 3 inhibitors,	unspecified	caspase inhibitor; apoptosis inhibitor	neurodegeneration
creb gene transcription modulators, CNS disorders	Unspecified	Creb gene transcription modulation	neurodegeneration; Alzheimer disease
Neurotransmitter transporter modulators	Unspecified	Excitatory amino acids transporter function	neurodegeneration
batyl alcohol; CPR 4001	Unspecified	free radical scavenger; ether lipid	skin disease; neurodegeneration
chimyl alcohol; CPR 4004	Unspecified	free radical scavenger; ether lipid	skin disease; neurodegeneration
free radical scavengers	Unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301	Unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
growth and differentiation factor-1; GDF-1	Unspecified	GDF-1 agonist	neurodegeneration
LY 379268	(1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid	glutamate agonist; mGluR agonist; analgesic	neurodegeneration; pain



Excitatory amino acid antagonists	unspecified	glutamate antagonist; excitatory amino acid antagonist; NMDA antagonist	epilepsy; neurodegeneration
SIB 1757	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
SIB 1893	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
2-PMPA; GPI 5000	Unspecified	glutamate release inhibitor	stroke; neurodegeneration
NZ 093	Unspecified	IGF-1	brain ischemia; trauma; stroke; neurodegeneration
insulin-like growth factor-1; IGF-1	Unspecified	IGF-1 agonist	brain ischemia; trauma; stroke; neurodegeneration
insulin-like growth factor binding protein ligand inhibitors	Unspecified	IGFBP ligand inhibitors	stroke; neurodegeneration
ICE inhibitors	Unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor	neurodegeneration
Neurodegenerative disease therapy	Unspecified	Immunomodulation, peptide mediated	neurodegeneration
MKK4 modulators	Unspecified	MAP kinase inhibitor; signal transduction inhibitor, NSAID	inflammation; neurodegeneration
Melatonin analogue	Unspecified	Melatonin agonist	neurodegeneration
Neurodegenerative disease therapy	Unspecified	monoclonal antibody immunomodulation	neurodegeneration; Alzheimer disease
neural progenitor regulatory factor	Unspecified	Neural progenitor regulation, growth factor; peptide; neurotrophic factor	multiple sclerosis; trauma; neurodegeneration
Neuroimmunophilin ligands	Unspecified	Neuroimmunophilins, growth factor; neurotrophic factor	neurodegeneration
Neuroimmunophilins	Unspecified	neurotrophic factor	neurodegeneration
nerve growth factor secreting implant	Unspecified	NGF agonist	neurodegeneration; neuropathy
nerve growth factor mimetics	Unspecified	NGF mimetics	neurodegeneration

CP 101606	[S-(R*,R*)]-4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-1-piperidineethanol	NMDA antagonist; glutamate antagonist	stroke; trauma; neurodegeneration
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
Telomerase activators	Unspecified	NSAID	neurodegeneration; atherosclerosis; arthritis
Neurotrophin-4/5 secreting implant; NT-4/5 implant	Unspecified	NT-4/5 agonist	neurodegeneration; neuropathy; amyotrophic lateral sclerosis; eye disease
Synthetic opioid alkaloids	Unspecified	Opioid agonists	neurodegeneration
prion inhibiting peptides	Unspecified	Prion inhibition	neurodegeneration
taltirelin; TA 0910; CEREDIST	(S)-N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-L-prolinamide	Protirelin analogue	neurodegeneration
telomere modulators	Unspecified	Telomere modulation	neurodegeneration; atherosclerosis; arthritis
NZ 097	Unspecified	TGF-b agonist	brain ischemia; trauma; stroke; neurodegeneration
Transforming growth factor beta; TGFbeta	Unspecified	TGF-b agonist	brain ischemia; trauma; stroke; neurodegeneration
CEP 3265; CB 1093	5-[[1-(2-ethoxy-6-ethyl-6-hydroxy-1-methyl-3-octynyl)octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol	transcription activator	neurodegeneration; Alzheimer disease

Table 26. Current Candidate Therapeutic Interventions for the Treatment of Anxiety

Product Name	Chemical Name	Action	Indication
CGS 12066	4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline	5HT agonist	anxiety
umespirone; KC 7218; KC 9172	3-butyl-7-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetrone	5HT agonist	anxiety
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
alnespirone; S 20499	(+)-8-[4-[(3,4-dihydro-5-methoxy-2H-1-benzopyran-3-yl)propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione	5HT agonist; 5HT1A agonist	anxiety
EMD 67478		5HT agonist; 5HT1A agonist	anxiety
F 12439		5HT agonist; 5HT1A agonist	depression; anxiety
flesinoxan; DU 29373	(+)-N-[2-[4-[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl]-1-piperazinyl]ethyl]-4-fluorobenzamide	5HT agonist; 5HT1A agonist	anxiety; depression
gepirone; gepirone hydrochloride; MJ 13805; BMJ 13805; BMJ 138051	4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione	5HT agonist; 5HT1A agonist	anxiety; depression

ipsapirone; BAY q 7821; TVX q 7821	2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	5HT agonist; 5HT1A agonist	depression; anxiety
lesopitron; E 4424	2-[4-[4-(4-chloro-1H-pyrazol-1-yl)butyl]-1-piperazinyl]pyrimidine dihydrochloride	5HT agonist; 5HT1A agonist	anxiety
LY 228729	4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
MKC 242	(S)-N-[3-(1,3-benzodioxol-5-yl)oxy]propyl]-2,3-dihydro-1,4-benzodioxin-2-methanamine, hydrochloride	5HT agonist; 5HT1A agonist	anxiety
S 14506	4-fluoro-N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]benzamide hydrochloride	5HT agonist; 5HT1A agonist	anxiety
S 14671	N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-2-thiophenecarboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
SUN 8399	2,3,4,5-tetrahydro-4-(4-(4-(2-pyrimidinyl)piperazin-1-yl)butyl)-1,4-benzoxazepine-3,5-dione hydrochloride	5HT agonist; 5HT1A agonist	anxiety; emesis
Tandospirone; metanopirone; SM 3997; SEDIEL	3aalfa,4beta,7beta,7aalfa-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-methano-1H-isoindole-1,3(2H)-dione	5HT agonist; 5HT1A agonist	anxiety
U 92016A		5HT agonist; 5HT1A agonist	anxiety; depression

U 93385; U 93385E	(3aR-cis)-2,3,3a,4,5,9b-hexahydro-3-propyl-1H-benz[e]indole-9-carboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
SL 870765		5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT1D antagonist	anxiety; depression
adatanserin; adatanserin hydrochloride; WY 50324; WAY SEB 324; SEB 324	N-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1(3,7)]decane-1-carboxamide	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5865	2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide monohydrochloride	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5893; FG 5974	(2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester)	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
S 213571; S 21357-1	3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-6-[4-[4-(2-methoxyphenyl)-1-piperazinyl]-butyl]-2(3H)-benzothiazolone trihydrochloride	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety
sunepitron; CP 93393; CP 93393-1	(7S-trans)-1-[[octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2,5-pyrrolidinedione	5HT agonist; 5HT1A agonist; alpha adrenergic antagonist; alpha2 adrenergic agonist	depression; anxiety
SB 236057		5HT agonist; 5HT1B agonist	anxiety
LY 293284	(R)-1-[4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indol-6-yl]ethanone	5HT agonist; 5HT1D agonist	anxiety

ICI 190622	4-amino-1-(3-pentynyl)-N-2-propenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide	5HT antagonist	anxiety
5HT1B antagonists		5HT antagonist	depression; anxiety
BMY 7378	8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride	5HT antagonist	anxiety
DU 123015		5HT antagonist	anxiety; depression
DU 125530		5HT antagonist	depression; anxiety; psychosis
ICI 170809	N,N,2-trimethyl-1-[(3-phenyl-2-quinoliny)thio]-2-propanamine monohydrochloride	5HT antagonist	anxiety
RS 42358; RS 42358197	(S)-2-(1-azabicyclo[2.2.2]oct-3-yl)-2,4,5,6-tetrahydro-1-H-benz[de]isoquinolin-1-one monohydrochloride	5HT antagonist	anxiety; emesis
seganserin; R 56413	3-[2-[4-[bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one	5HT antagonist	anxiety
serazapine; CGS 15040A	1,3,4,16b-tetrahydro-2-methyl-2H,10H-indolo[2,1-c]pyrazino[1,2-a][1,4]benzodiazepine-16-carboxylic acid methyl ester	5HT antagonist	anxiety

5-HT antagonist; pindobind	2-bromo-N-[4-[1-[[2-hydroxy-3-(1H-indol-4-ylloxy)propyl]amino]-1-methylethyl]-1-methylcyclohexyl]acetamide	5HT antagonist; 5HT1A antagonist	anxiety; depression
Anxiolytic	(S)-5,6,6a,7-tetrahydro-6,10-dimethyl-4H-dibenzo[de,g]quinolin-11-ol	5HT antagonist; 5HT1A antagonist	anxiety
Binospirone; binospirone mesylate; MDL 73005EF	8-[2-[[[(2,3-dihydro-1,4-benzodioxan-2-yl)methyl]amino]ethyl]-8-azaspiro[4.5]decan-7,9-dione	5HT antagonist; 5HT1A antagonist	anxiety
F 8910RS		5HT antagonist; 5HT1A antagonist	anxiety
Robalzotan; NAD 299	(3R)-3-(dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (1:1)	5HT antagonist; 5HT1A antagonist	anxiety; depression
S 15535	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine	5HT antagonist; 5HT1A antagonist	anxiety; depression
SDZ 216525; SDZ 216-525	methyl 4-[4-[4-(1,1,3-trioxo-2H-1,2-benzisothiazol-2-yl)butyl]-1-piperazinyl]-1H-indole-2-carboxylate	5HT antagonist; 5HT1A antagonist	anxiety
UH 301	(+,-)-7-(dipropylamino)-4-fluoro-5,6,7,8-tetrahydro-1-naphthalenol	5HT antagonist; 5HT1A antagonist	anxiety

WAY 100135	N-(1,1-dimethylethyl)-4-(2-methoxyphenyl)-alpha-phenyl-1-piperazinepropanamide	5HT antagonist; 5HT1A antagonist	anxiety
WAY 100635	N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide trihydrochloride	5HT antagonist; 5HT1A antagonist	anxiety
Buspirone hydrochloride; MJ 40221; MJ 9022; BESPAR; BUSPAR; NORMATON; TUTRAN; NAROL; ANSIENON; ANSITEN; TRANBUS; SIMPLESS	8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4,5]decane-7,9-dione hydrochloride	5HT antagonist; 5HT1A antagonist; dopamine agonist	anxiety; depression; dermatitis
drug delivery system, transdermal buspirone; buspirone transdermal		5HT antagonist; 5HT1A antagonist; dopamine agonist	anxiety; depression; attention deficit disorder
CR 1909		5HT antagonist; 5HT2 antagonist	anxiety
Glemanserin; MDL 11939	(+,-)-alpha-phenyl-1-(2-phenylethyl)-4-piperidinemethanol	5HT antagonist; 5HT2 antagonist	anxiety
ritanserin; R 55667	6-[2-[4-[bis(4-fluorophenyl)methylene]piperidino]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	5HT antagonist; 5HT2 antagonist	addiction; anxiety; schizophrenia
CGS 18102	trans-10-methoxy-4-propyl-1,3,4,4a,5,10b-hexahydro-2H-(1)benzopyrano(3,4-b)pyridine	5HT antagonist; 5HT2 antagonist; 5HT agonist; 5HT1A agonist	anxiety



HT 90B	(-)-N-[2-[[[(2,3-dihydro-8-methyl-1,4-benzodioxin-2-yl)methyl]amino]ethyl]tricyclo[3.3.1.1 <sup>3,7</sup> ]decane-1-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT agonist; 5HT1A agonist	anxiety; depression
Amesergide; amerserzide; LY 237733	8beta-N-cyclohexyl-6-methyl-1-(1-methylethyl)ergoline-8-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist	sexual dysfunction; depression; anxiety
Deramciclane; EGIS 3886; EGYT 3886	(1R-exo)-N,N-dimethyl-2-[(1,7,7-trimethyl-2-phenylbicyclo[2.2.1]hept-2-yl)oxy]-ethanamine	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist	anxiety
Ziprasidone; ziprasidone hydrochloride; CP 88059; CP 880591; CP 8805901; ZELDOX	5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist; dopamine antagonist; dopamine D2 antagonist; 5HT1A agonist; 5HT agonist	schizophrenia; anxiety
EGIS 8465		5HT antagonist; 5HT2C antagonist	anxiety
ORG 37415		5HT antagonist; 5HT2C antagonist	depression; anxiety
SB 200646A	N-(1-methyl-1H-indol-5-yl)-N'-(3-pyridinyl)urea monohydrochloride	5HT antagonist; 5HT2C antagonist	anxiety
SB 228357	N-[3-fluoro-5-(3-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide	5HT antagonist; 5HT2C antagonist	anxiety; depression
ADR 851	(S)-4-amino-5-chloro-2,3-dihydro-N-(2-pyrrolidinylmethyl)-7-benzofurancarboxamide monohydrochloride	5HT antagonist; 5HT3 antagonist	anxiety; emesis

Antidepressant		5HT antagonist; 5HT3 antagonist	depression; anxiety
itasetron; DAU 6215; DAU 6215CL; DA 6215; U 98079; U 98079A	endo-2,3-dihydro-N- (8-methyl-8- azabicyclo[3.2.1]oct- 3-yl)-2-oxo-1H- benzimidazole-1- carboxamide	5HT antagonist; 5HT3 antagonist	emesis; anxiety
ricasetron; BRL 46470; BRL 46470A	endo-2,3-dihydro-3,3- dimethyl-N-(8- methyl-8- azabicyclo[3.2.1]oct- 3-yl)-1H-indole-1- carboxamide	5HT antagonist; 5HT3 antagonist	anxiety; schizophrenia; emesis
tropisetron; ICS 205930; NAVOBAN	1H-indole-3- carboxylic acid endo- 8-methyl-8- azabicyclo[3.2.1]oct- 3-yl ester	5HT antagonist; 5HT3 antagonist	emesis; anxiety
VA 21B7	2-[(4-piperonyl)-1- piperazinyl]-3- indolecarboxaldehyde	5HT antagonist; 5HT3 antagonist	anxiety
WAY 100289; WY 100289	(endo)-N-[[[(8-aza-8- methylbicyclo[3,2,1]o ctan-3- yl)amino]carbonyl]- 2- (cyclopropylmethoxy )benzamide	5HT antagonist; 5HT3 antagonist	anxiety
WAY 100579; SEC 579	endo-1-cyclohexyl- 1,4-dihydro-N-(8- methyl-8- azabicyclo[3.2.1]oct- 3-yl)-4-oxo-3- quinolinecarboxamid e (Z)-2-butenedioate	5HT antagonist; 5HT3 antagonist	anxiety
zacopride; zacopride hydrochloride; ZAP; AHR 11190B; AHR 11190; MD 78027	4-amino-N-1- azabicyclo[2.2.2]oct- 3-yl-5-chloro-2- methoxy-benzamide	5HT antagonist; 5HT3 antagonist	anxiety; emesis

zatosetron; LY 277359	endo-5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide	5HT antagonist; 5HT3 antagonist	emesis; anxiety
SB 204070	8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylic acid (1-butyl-4-piperidinyloxy)methyl ester	5HT antagonist; 5HT4 antagonist	anxiety; irritable bowel syndrome
SC 56184		5HT antagonist; 5HT4 antagonist	anxiety
THE JL3; JL 3	10-(4-methyl-1-piperazinyl)-pyrido[4,3-b][1,4]benzothiazepine	5HT antagonist; dopamine antagonist	anxiety; depression
fluvoxamine; fluvoxamine maleate; DU 23000; MK 264; SME 3110; FEVARIN; FLOXYFRAL; LUVOX; DUMYROX; DUMIROX; FLAVOXYL; FAVERIN; DEPROMEL	5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone (E)-O-(2-aminoethyl)oxime	5HT reuptake inhibitor	depression; anxiety; obsessive compulsive disorder
paroxetine hydrochloride; FR 7051; BRL 29060; BRL 29060A; SI 211103; SEROXAT; AROPAX; PAXIL; TAGONIS; FROSINOR; DEROXAT; SEREUPIN; MOTIVAN	(3S-trans)-3-[(1,3-benzodioxol-5-yl)oxy)methyl]-4-(4-fluorophenyl)piperidine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety

sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
venlafaxine; WY 45030; EFFEXOR; EFEXOR; EFFEXOR XR; EFFEXOR XL	(+,-)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol	5HT reuptake inhibitor; noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	depression; anxiety
ST 1112	2-acetyl-5-(4-methoxyphenyl)-3-oxo-1,2,4-triazine	5HT1/5HT2 ligand	anxiety
L 0068; F 11440	4-methyl-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2,4-triazine-3,5(2H,4H)-dione	5HT1A agonist; 5HT agonist	anxiety; depression
OPC 14523	1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone	5HT1A agonist; sigma agonist; 5HT agonist	depression; anxiety; obsessive compulsive disorder
F 92502CN	Unspecified	5HT1A ligand	anxiety
EGIS 9933	2-(2-[N-(3-trifluoromethyl-benzyl)-N-piperazinyl]ethyl)mercapto-4,6-diamino-5-(2-methoxy-benzyl)-pyrimidine hydrochloride	5HT2C antagonist; 5HT antagonist	anxiety
SB 243213	2,3-dihydro-5-methyl-N-[(6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl)-6-(trifluoromethyl)-1H-indole-1-carboxamide	5HT2C antagonist; 5HT antagonist	depression; anxiety

zalospirone; WY 47846	(3aalfa,4beta,4aalfa,6aalfa,7beta,7aalfa)-3a,4,4a,6a,7,7a-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione	5HT3 antagonist	anxiety; depression
ceronapril; ceranapril; SQ 29852	(S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phospinyl]oxy]-1-oxohexyl]-L-proline	ACE inhibitor	cognitive defect; hypertension; anxiety
drug delivery system, adenosine; adenosine drug delivery system; adenosine prodrug	adenosine 5'-(1,4-dihydrotrigonellinate)-2',3'-O-bis-benzoate	adenosine agonist	anxiety; depression
atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety
SNAP 5114	1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-3-piperidinecarboxylic acid	amine uptake inhibitor	epilepsy; anxiety; insomnia
gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
AIT 084		antispasmodic	anxiety
alpidem; SL 80034200; ANANXYL	6-chloro-2-(4-chlorophenyl)-N,N-dipropylimidazo[1,2-a]pyridine-3-acetamide (imidazopyridine)	Anxiolytic activity with unspecified mechanism of action	anxiety

Anxiolytic	Ketoisoxalidine derivative	Anxiolytic activity with unspecified mechanism of action	anxiety
AP 521	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
BMS 181100	alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine-butanol	Anxiolytic activity with unspecified mechanism of action	anxiety
BMS 184111	Unspecified	Anxiolytic activity with unspecified mechanism of action	Anxiety
CEB 1128	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CEB 1342	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CEB 1459	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CGS 13767	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CL 870704	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CNS 3	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
Co 2-6749; Co 26749	Synthetic epalons	Anxiolytic activity with unspecified mechanism of action	anxiety
transmucosal etomidate	Etomidate derivative	Anxiolytic activity with unspecified mechanism of action	anxiety
transdermal buspirone;	Buspirone	Anxiolytic activity with unspecified mechanism of action	anxiety
dulozafone; dicozafone; F 1933	2-[bis(2-hydroxyethyl)amino]-N-[4-chloro-2-(chlorobenzoyl)phenyl]-N-methylacetamide	Anxiolytic activity with unspecified mechanism of action	anxiety

enciprazine; D 13112; WY 48624	(+,-)-4-(2-methoxyphenyl)- alpha-[(3,4,5- trimethoxyphenoxy) methyl]-1- piperazineethanol	Anxiolytic activity with unspecified mechanism of action	anxiety
etizolam; Y 7131; DEPAS; PASADEN	4-(2-chlorophenyl)-2- ethyl-9-methyl-6H- thieno[3,2- f][1,2,4]triazolo[4,3- a][1,4]diazepine	Anxiolytic activity with unspecified mechanism of action	anxiety
F 2692	3-amino-6-methyl-1- [3- (trifluoromethyl)phen yl]-4(1H)- pyridazinone	Anxiolytic activity with unspecified mechanism of action	anxiety
mexidol	2-ethyl-6-methyl-3- hydroxypyridine succinate	Anxiolytic activity with unspecified mechanism of action	anxiety; cognitive defect
rilapine	(Z)-2-chloro-10-(4- methyl-1- piperazinyl)-5H- dibenzo[a,d]cyclohept ene-delta5,alfa- acetonitrile	Anxiolytic activity with unspecified mechanism of action	anxiety
SC 48274; BTG 1501	3-[3- (dimethylamino)prop yl]-3-(3- methoxyphenyl)-4,4- dimethyl-2,6- piperidinedione hydrochloride	Anxiolytic activity with unspecified mechanism of action	anxiety
sultopride; sultopride hydrochloride; LIN 1418; DAN 2163; BARNETIL	N-[(1-ethyl-2- pyrrolidinyl)methyl]- 5-(ethylsulfonyl)-2- methoxybenzamide	Anxiolytic activity with unspecified mechanism of action	anxiety
suriclone; RP 31264; RP 006; SURIL	4-methyl-1- piperazinecarboxylic acid ester with 6-(7- chloro-1,8- naphthyridin-2-yl)- 2,3,6,7-tetrahydro-7- oxy-5H-1,4- dithiino[2,3- c]pyrrol-5-yl	Anxiolytic activity with unspecified mechanism of action	anxiety

TAS 401	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
NNC 138119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine	Benzodiazepine	epilepsy; anxiety
AD 8152		benzodiazepine	anxiety
adinazolam; adinazolam mesylate; adinazolam mesilate; U 41123F; U 41123; DERACYN	8-chloro-N,N-dimethyl-6-phenyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine	benzodiazepine	anxiety; depression
AHR 14749	5-chloro-N,N-dimethyl-2-(4-methylphenyl)-3H-imidazo[4,5-b]pyridine-3-acetamide	benzodiazepine	anxiety
CGS 20625	5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridine-3(2H)-one	benzodiazepine	anxiety
clobazam; HR 376; H 4723; LM 2717; NH 15; FRISIUM; CLIDIZAN; GRIFOCLOBAM; URBADAM; FRISIN; URBANYL; URBANIL; MYSTAN	7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione	benzodiazepine	anxiety; epilepsy
drug delivery system, intranasal benzodiazepines; benzodiazepine intranasal delivery system		benzodiazepine	anxiety; insomnia



drug delivery system, transdermal alprazolam; alprazolam transdermal		benzodiazepine	anxiety
drug delivery system, transdermal alprazolam; alprazolam transdermal		benzodiazepine	anxiety
EGIS 5278	3-amino-4-ethylthio- 7-chloro-quinolone hydrochloride	benzodiazepine	anxiety
EGIS 8858	5-[2-(4- fluorophenyl)ethenyl] -8-methyl-9H-1,3- dioxolo[4,5- h][2,3]benzodiazepin e	benzodiazepine	anxiety
girisopam; EGIS 5810; GYKI 51189	1-(m-chlorophenyl)- 7,8-dimethoxy-4- methyl-5H-2,3- benzodiazepine	benzodiazepine	anxiety
midazolam; Ro 213981/001; Ro 213981/003; HYPNOVEL; VERSED; DORMICUM	8-chloro-6-(2- fluorophenyl)-1- methyl-4H- imidazo[1,5- a][1,4]benzodiazepine	benzodiazepine	anxiety; epilepsy
nerisopam; EGIS 6775; GYKI 52232	4-(7,8-dimethoxy-4- methyl-5H-2,3- benzodiazepin-1-yl)- benzenamine	benzodiazepine	anxiety
panadiplon; U 78875; FG 10571	3-(5-cyclopropyl- 1,2,4-oxadiazol-3-yl)- 5-(1-methylethyl)- imidazo[1,5a]- quinoxalin-4(5H)-one	benzodiazepine	anxiety
RU 32759	[6-ethyl-5-methyl-7- (methylthio)imidazo[ 1,2-a]pyrimidin-2- yl]phenylmethanone	benzodiazepine	anxiety

tofisopam; EGYT 341; MER 19; MER 1961; GRANDAXIN; SERIEL; ISOTAN	1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine	benzodiazepine	anxiety; skin disease
abecarnil; ZK 112119; FG 7516; NNC 157516; SH 524; LADOTEC	4-(methoxymethyl)-6-(phenylmethoxy)-9H-pyrido[3,4-b]indole-3-carboxylic acid, 1-methylethyl ester	benzodiazepine partial agonist	anxiety
FG 8119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	anxiety
FG 8205; L 663581	7-chloro-4,5-dihydro-5-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	epilepsy; anxiety
ICI D7569		benzodiazepine partial agonist	anxiety
imidazenil; FGIN 2073; FID 02023; Ro 231412	6-(2-bromophenyl)-8-fluoro-4H-imidazol[1,5-a][1,4]benzodiazepine-3-carboxamide	benzodiazepine partial agonist	anxiety
Ro 198022	(R)-1-((10-chloro-4-oxo-3-phenyl-4H-benzo(a)quinolizin-1-yl)carbonyl)-2-pyrrolidine-methanol	benzodiazepine partial agonist	anxiety
saripidem; SL 850274	N-[[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-N-methylbutyramide	benzodiazepine partial agonist	anxiety

Y 23684	2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepine[5,4-c]pyridazin-3(2H)-one 7-oxide	benzodiazepine partial agonist	anxiety
5HT4 human neuroreceptor; neuroreceptor, 5HT4		biotechnology	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
Cholecystokinin B antagonist		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
CR 2622	[R-(R*,S*)]-4-[[5-(8-azaspiro[4.5]dec-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-1,5-dioxopentyl]amino]-5-(1-naphthalenylamino)-5-oxo-pentanoic acid	cholecystokinin antagonist; cholecystokinin B antagonist	anxiety
GV 150013	(R)-N-phenyl-N'-[2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo[3.3.1.1 <sup>3,7</sup> ]dec-1-ylmethyl)-1H-1,5-benzodiazepin-3-yl]urea	cholecystokinin antagonist; cholecystokinin B antagonist	anxiety
LY 288513		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
CR 2345	N-[1-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4-(4-methyl-1-piperazinyl)-4-oxobutyl]-3,5-dichlorobenzamide monohydrochloride	cholecystokinin antagonist; cholecystokinin B antagonist; gastrin antagonist	anxiety; gastrointestinal ulcer; bacterial infection

CR 2945		cholecystokinin antagonist; cholecystokinin B antagonist; gastrin antagonist	gastrointestinal ulcer; anxiety
L 740093	(R)-N-[5-(3-azabicyclo[3.2.2]nonan-3-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)urea monohydrochloride	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
PD 134308; CI 988	[R-(R*,R*)]-4-[[2-[[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[[[(tricyclo[3.3.1.1sup 3,7]dec-2-ylloxy)carbonyl]amino]propyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid compound with 1-deoxy-1-(methylamino)-D-glucitol (1:1)	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
PD 135158	[1S-[1 $\alpha$ ,2 $\beta$ [[S*(S*)],4 $\alpha$ ]]-4-[[2-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[[[(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]oxy]carbonyl]amino]propyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid cmpd with meglumine (1:1)	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety

PD 145942	[2-[(hexahydro-1H-azepin-1-yl)amino]-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl]carbamic acid tricyclo[3.3.1.1 <sup>3,7</sup> ]dec-2-yl ester	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
AXC 2219		CRF antagonist	depression; anxiety
AXC 4007		CRF antagonist	depression; anxiety
CRA 1000	INDEX NAME NOT YET ASSIGNED	CRF antagonist	depression; anxiety
CRA 1001		CRF antagonist	depression; anxiety
CRF antagonist		CRF antagonist	depression; anxiety
CRF antagonists		CRF antagonist	depression; anxiety
CRF2 antagonists		CRF antagonist	depression; anxiety
NBI 27914	5-chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine	CRF antagonist	anxiety
NBI 30545	3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propylpyrazolo[1,5-a]pyrimidin-7-amine	CRF antagonist	anxiety; depression
NBI 30775; R 121919		CRF antagonist	anxiety; depression; addiction
NGD 981; NGD 98-1		CRF antagonist	depression; anxiety
PD 171729	butyl-[3[(2,4-dichloro-phenyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl]-ethyl-amine	CRF antagonist	anxiety; depression
corticotropin releasing factor analogue	Unspecified	CRF ligand	anxiety; depression

DMP 695	N-(2-chloro-4,6-dimethylphenyl)-1-[2-methoxy-1-(methoxymethyl)ethyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine monomethanesulfonate	CRH antagonist	anxiety; depression
SA 627	N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-methyl-6-(4-morpholinyl)-1,3,5-triazin-2-amine	CRH antagonist	depression; anxiety
SC 241		CRH antagonist	anxiety; depression
RP 60503	4-(acetylamino)butanoic acid 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl ester	Cyclic GMP modulation	anxiety
CCD 2034		GABA agonist	anxiety
GABA agonist, XR 368 series	(2aR*,5aR,7E,11E,14aS*,14bS*,14cS*)-2a,5a,6,9,10,13,14,14a,14b,14c-decahydro-4-hydroxy-5a,9,9,12-tetramethyl-1,5-dioxacyclopenta[cd]cycloundec[f]inden-3(2H)-one	GABA agonist	anxiety; epilepsy
RWJ 38293	1,2,3,5-tetrahydro-3-oxo-N-4-pyridinylpyrido[1,2-a]benzimidazole-4-carboxamide	GABA agonist	anxiety
U 91571	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethylimidazo[1,5-a]quinoxaline-5(4H)-carboxamide	GABA antagonist	anxiety
U 94625		GABA antagonist	anxiety

ocinaplon; CL 273547	2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	GABA modulation	anxiety
pazinaclone; DN 2327; A 77000	8-[[2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-1,4-dioxo-8-azaspiro[4.5]decane	GABA modulation	anxiety
Anxiolytics		GABA modulator	anxiety
AWD 131138; AWD 131-138	1-(4-chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one	GABA modulator	epilepsy; anxiety
NGD 911; CP 409092		GABA modulator	anxiety
NGD 912; NGD 91-2		GABA modulator	anxiety
NGD 913; NGD 91-3		GABA modulator	anxiety
NS 2552		GABA modulator	anxiety; epilepsy
NS 2608		GABA modulator	epilepsy; anxiety
NS 2710; ME 3127		GABA modulator	anxiety
pagoclon; IP 456; RP 62955; (+)-RP 59037	(+)-2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-1H-isoindol-1-one	GABA modulator	anxiety
RWJ 53050		GABA partial agonist	anxiety
U 101017; PNU 101017	cis-7-chloro-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]imidazo[1,5-a]quinoline-3-carboxylic acid 1,1-dimethylethyl ester	GABA partial agonist	anxiety
RP 59037	2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-1H-isoindol-1-one	GABA partial agonist; benzodiazepine partial agonist	anxiety
SNAP 5258	Unspecified	GAT1 transporter	epilepsy; anxiety; insomnia
SNAP 5294	Unspecified	GAT2 transporter	epilepsy; anxiety; insomnia

ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
HA 966	3-amino-1-hydroxy-2-pyrrolidone	glutamate antagonist; NMDA antagonist	anxiety
LY 354740	(1alpha,2beta,5alpha,6alpha)-2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid	glutamate release inhibitor	anxiety; nicotine withdrawal
hBGT1 transporter modulator	Unspecified	HBGT1 transporter modulator	epilepsy; anxiety; insomnia
GT 5140		histamine agonist; histamine H3 agonist	insomnia; anxiety
Methylhistamine, R-alpha; BP 2.94		histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 49648	(2S-trans)-4-(2-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 50971	(3R-trans)-4-(4-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
CNS disorder modifiers	Unspecified	Ion channel modification	anxiety; schizophrenia; depression
Befloxatone; MD 370503	(R)-5-(methoxymethyl)-3-(p-((R)-4,4,4-trifluoro-3-hydroxybutoxy)phenyl)-2-oxazolidinone	MAO A inhibitor; MAO inhibitor	depression; anxiety; nicotine withdrawal
BW 1370U87	1-ethylphenoxathiin 10,10-dioxide	MAO A inhibitor; MAO inhibitor	depression; anxiety
Co 6-0549; Co 60549		neuroactive steroid	anxiety
MEN 10376		neurokinin antagonist; bronchodilator; neurokinin 2 antagonist	asthma; anxiety
CGP 60829		neurokinin antagonist; neurokinin 1 antagonist	anxiety



GR 100679	N-(cyclohexylcarbonyl)glycyl-L-alanyl-D-tryptophyl-N,N-dimethyl-L-phenylalaninamide	neurokinin antagonist; neurokinin 2 antagonist	anxiety
MEN 10207		neurokinin antagonist; neurokinin 2 antagonist	anxiety
osanetant; SR 142801	(R)-N-[1-[3-[1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl-4-phenyl-4-piperidinyl]-N-methylacetamide monohydrochloride	neurokinin antagonist; neurokinin 3 antagonist	schizophrenia; anxiety
Neuropeptide Y antagonists		neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
MDL 105519	(E)-3-(2-carboxy-2-phenylethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid	NMDA antagonist; glutamate antagonist	anxiety; epilepsy
oxytocin antagonist		oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
SNAP 1156		peptide	anxiety; hypertension; obesity; addiction
LU 28179	1'-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]butyl]spiro[isobenzofuran-1(3H),4'-piperidine]	Sigma ligand	anxiety
CGP 49823	(2R-trans)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-N-(4-quinolinylmethyl)-4-piperidinamine	substance P antagonist	anxiety; asthma
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis

vasopressin antagonist		vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
------------------------	--	----------------------------------	---

Table 27. Current Candidate Therapeutic Interventions for the Treatment of Dementia

Product Name	Chemical Name	Action	Indication
SR 57746; SR 57746A	1,2,3,6-tetrahydro-1-[2-(1-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]pyridine	5HT agonist; 5HT1A agonist; growth factor modulator	Alzheimer disease; neuropathy
AP 159	N-cyclohexyl-1,2,3,4-tetrahydro-[1]benzothieno[2,3c]pyridine-3-carboxamide monohydrochloride	5HT antagonist; 5HT1A antagonist	cognitive defect
SL 880338		5HT antagonist; 5HT1A antagonist	cognitive defect
GYKI 46903	(1R-endo)-6-(4-fluorophenyl)-1-azabicyclo[3.3.1]non-6-en-4-ol propanoate hydrochloride	5HT antagonist; 5HT3 antagonist	cognitive defect
Ondansetron; GR 38032; GR 38032F; SN 307; ZOFRAN; ZOPHREN; ZOFRON	1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one	5HT antagonist; 5HT3 antagonist	emesis; cognitive defect
FG 7080	trans-(-)-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]piperidine hydrochloride	5HT reuptake inhibitor	cognitive defect
Fluoxetine, (R)-; (R)-fluoxetine	(R)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	5HT reuptake inhibitor	migraine; cognitive defect; depression

Indeloxazine; ideloxazine; YM 08054; CI 874; ELEN; NOIN	(+,-)-2-[(indol-7- yloxy)methyl]morpho line	5HT reuptake inhibitor	cognitive defect
NS 2347		5HT reuptake inhibitor; dopamine reuptake inhibitor	depression; cognitive defect
SM 3163	3-((1,5- diphenylpentyl)oxy)- N,N-dimethyl-1- propanamine citrate	5HT reuptake inhibitor; vasodilator	cognitive defect; cerebrovascular disease
FK 960	N-(4-acetyl-1- piperazinyl)-4- fluorobenzamide	5HT, somatostatin	Alzheimer disease
SL 650102; SL 65.0102	(-)-8-amino-7-chloro- N-(1,4- diazabicyclo[2.2.2]oc t-2-ylmethyl)-2,3- dihydro-1,4- benzodioxin-5- carboxamide dihydrochloride	5HT4 agonist; 5HT agonist	Alzheimer disease
5HT4 human neuroreceptor		5HT4 human neuroreceptor	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
Ceranapril; ceranapril; SQ 29852	(S)-1-[6-amino-2- [[hydroxy(4- phenylbutyl)phospiny l]oxy]-1-oxohexyl]- L-proline	ACE inhibitor	cognitive defect; hypertension; anxiety
Alzheimer's disease therapy	1-[3,4- (methylenedioxy)ben zoyl]-3-[2-(1-benzyl- 4- piperidinyl)ethyl]thio urea	Acetylcholinesterase inhibitor	Alzheimer disease
NBI 117	Extracellular portion of activin receptor (soluble)	Activin soluble portion of receptor	Alzheimer disease
AD7C-NTP modulators, Alzheimer disease		AD7C-NTP modulation	Alzheimer disease

KF 15372	8-(3-dicyclopropylmethyl)-1,3-dipropylxanthine	adenosine antagonist	cognitive defect
KFM 19	3,7-dihydro-8-(3-oxocyclopentyl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	Alzheimer disease
MDL 102234	(R)-3,7-dihydro-8-(1-phenylpropyl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect
MDL 102503	(R)-3,7-dihydro-8-(1-methyl-2-phenylethyl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect
midaxifylline; IRFI 117	8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect; depression; kidney disease
apaxifylline; BIIP 20XX; U 98950; BIIP 20	(S)-3,7-dihydro-8-(3-oxocyclopentyl)-1,3-dipropyl 1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist; xanthine	cognitive defect
MAB, adrenomedullin	Unspecified	adrenomedullin monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
Alzheimer's disease therapy		Alpha 2 macroglobulin inhibitor	Alzheimer disease
RU 49041; RU 49067	(3alpha)-(+,-)-11-methyl-20,21-dinoreburnamenine	alpha adrenergic agonist; alpha2 adrenergic partial agonist	cognitive defect
RU 52583	(3alpha)-11-methyl-20,21-dinoreburnamenine	alpha adrenergic agonist; alpha2 adrenergic partial agonist	cognitive defect
NS 1201		AMPA antagonist; glutamate antagonist	cognitive defect
NS 377	7-ethyl-1,6,7,8-tetrahydro-5-phenylbenzo[2,1-b:3,4-c']dipyrrole-2,3-dione 3-oxime	AMPA antagonist; glutamate antagonist	cognitive defect

NS 420	4-[2,3,6,7,8,9-hexahydro-3-(hydroxyimino)-8-methyl-2-oxo-1H-pyrrolo[3,2-h]isoquinolin-5-yl]-N,N-dimethylbenzenesulfonamide	AMPA antagonist; glutamate antagonist	cognitive defect
S 18986; S 18986-1	(S)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide	AMPA antagonist; glutamate antagonist	cognitive defect
CX 691	Unspecified	AMPA glutaminergic receptor ligand	Alzheimer disease; schizophrenia
amyloid aggregation inhibitors	Unspecified	amyloid aggregation inhibitors	Alzheimer disease
antiamyloid	Unspecified	Amyloid antagonists	Alzheimer disease
GT 4001	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4002	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4003	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4011	Unspecified	Amyloid b destruction	Alzheimer disease
GT 5011	Unspecified	Amyloid b destruction	Alzheimer disease
PTI 00703	Cats claw extract	Amyloid b protein deposition inhibitor	Alzheimer disease
amyloid enzyme inhibitors,	Unspecified	amyloid enzyme inhibitors	Alzheimer disease
amyloid inhibiting peptides	Unspecified	amyloid inhibiting peptides	Alzheimer disease
amyloid neurotoxicity antagonists,	Unspecified	amyloid neurotoxicity antagonists,	Alzheimer disease
CX 423	Unspecified	Amyloid neurotoxicity antagonist	Alzheimer disease
amyloid production inhibitors,	Unspecified	amyloid production inhibitors,	Alzheimer disease
amyloid production inhibitors,	Unspecified	amyloid production inhibitors,	Alzheimer disease; diabetes

FID 072021	3-atropanyl 2-(4-chlorophenoxy) butyrate maleate	analgesic	pain; cognitive defect
galanin modulators	Unspecified	galanin modulators analgesic	obesity; diabetes; cognitive defect; pain
galanin1 antagonists	Unspecified	galanin1 antagonists analgesic	obesity; pain; cognitive defect
metabotropic glutamate receptor modulators	Unspecified	metabotropic glutamate receptor modulators analgesic	pain; cognitive defect; schizophrenia; epilepsy
anatoxin analogue,	Unspecified	Anatoxin	Alzheimer disease
prasterone; dehydroepiandrosterone; DHEA; GL 701; NBI 106; PB 007; ASTENILE; DEANDROS; DIANDRON	(3beta)-3-hydroxyandrost-5-en-17-one	androgen; vaccine adjuvant; hormone replacement therapy; corticosteroid	systemic lupus erythematosus; hormone deficiency; Alzheimer disease; reperfusion injury; ischemia
nootropic,	2-(4-allyl-1-piperazinyl)-4-pentyloxyquinazoline	antihypoxic	cognitive defect
RU 35929	(+,-)-5-ethoxy-1-(phenylsulfonyl)-2-pyrrolidinone	antihypoxic	cognitive defect
tenilsetam; tenimal; PAS 997; CAS 997; HR 029	(+/-)-3-(2-thienyl)-2-piperazinone	antihypoxic	cognitive defect
RGH 5279	(3alpha)-eburnamenine-14-carboxylic acid 2-(acetyloxy)ethyl ester monohydrochloride	anti-ischemic	cognitive defect; brain ischemia
CPG 607	Unspecified	antioxidant	cognitive defect
Neurodegenerative disease therapy,	Unspecified	antioxidant	stroke; Alzheimer disease
antioxidant,	Unspecified	antioxidant; free radical scavenger	Alzheimer disease
VANTOX	Unspecified	antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke

antisense oligonucleotides, amyloid precursor/beta amyloid proteins; antisense oligonucleotides, Alzheimer's disease	Unspecified	antisense; oligonucleotide amyloid precursor/beta amyloid	Alzheimer disease
antisense oligonucleotide, APO-E4; antisense oligonucleotide, Alzheimer's disease	Unspecified	antisense; oligonucleotide APO-E4;	Alzheimer disease
Alzheimer's disease therapy	Unspecified	ApoE	Alzheimer disease
RU 34332	3-(cyclopropylcarbonyl)-7-fluoro-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepine-6-one	benzodiazepine	cognitive defect
S 8510	1,6,7,9-tetrahydro-2-(3-isoxazolyl)imidazo[4,5-d]pyrano[4,3-b]pyridine phosphate (1:1)	benzodiazepine inverse agonist	cognitive defect; Alzheimer disease
SX 3933	5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one monohydrochloride	benzodiazepine inverse agonist	cognitive defect; Alzheimer disease
RU 33965	3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepine-6-one	benzodiazepine partial agonist	cognitive defect
terbequinil; SR 25776	1,4-dihydro-1-(methoxymethyl)-4-oxo-N-propyl-3-quinolinecarboxamide	benzodiazepine partial agonist	cognitive defect

nimodipine; BAY e 9736; BAY N 5248; BAY N 5427; NIMOTOP; NIMOTAP; NIVAS; TROPOCER; EUGERIAL; NIMODILAT; CEBROFORT; KENESIL; GENOVOX	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester	calcium antagonist	migraine; cognitive defect; Alzheimer disease; brain ischemia
RGH 2716; TDN 345	8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-1-oxa-3,8-diazaspiro[4.5]decan-2-one	calcium antagonist	cognitive defect
voltage-dependent calcium channel antagonists, VDCC antagonists	Unspecified	calcium antagonist	Alzheimer disease; neurological
sabeluzole; R 58735; JK 601	(+,-)-4-(2-benzothiazolylmethylamino)-alfa-[(4-fluorophenoxy)methyl]-1-piperidineethanol	calcium antagonist; antihypoxic	Alzheimer disease
Tamolarizine; tamolaridine hydrochloride; NC 1100; ZC 110	(+,-)-alfa-(3,4-dimethoxyphenyl)-2-(4-diphenylmethyl)-1-piperazineethanol	calcium antagonist; vasodilator	cognitive defect; cerebrovascular disease
BAY Z 4406	Unspecified	calcium channel blocker	neurodegeneration; Alzheimer disease
NS 649	1-(2,5-dimethoxyphenyl)-5-(trifluoromethyl)-1H-benzimidazol-2-amine	calcium channel blocker	cognitive defect
elziverine; Ro 224839	1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-4-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]isquinoline	calmodulin antagonist; vasodilator	peripheral vascular disease; cognitive defect



drug delivery system, CDS sinnabidol; sinnabidol CDS	Unspecified	cannabinoid; glutamate antagonist; NMDA antagonist	cognitive defect; glaucoma
SK 067	Unspecified	Cerebral metabolic agent	cognitive defect
SNK 882	2-oxo-N-[(tetrahydro- 1H-pyrrolizin- 7a(5H)-yl)methyl]-1- pyrrolidin eacetamide, monohydrochloride	Cerebral metabolic agent	cognitive defect
vinconate; vincantenate; vintenate; OM 853; OC 340; OC 34; BRENAL	(+,-)-methyl 3-ethyl- 2,3,3a,4-tetrahydro- 1H-indolo[3,2,1- de][1,5] naphthyridine-6- carboxylate	Cerebral metabolite enhancer	cognitive defect
SUT 8701	N-[(1,1- dimethylethoxy)carbo nyl]-O- (dimethylphosiny)- L-tyrosyl-L- norleucylglycyl-L- tryptophyl-L- norleucyl-L-alfa- aspartyl-L- phenylalaninamide	cholecystokinin antagonist	Alzheimer disease
sibopirdine; DUP 921; X 9121; EXP 9121; EXP921	5,5-bis(4- pyridinylmethyl)-5H- cyclopenta-[2,1- b:3,4-b']dipyridine	Choline release stimulator	cognitive defect
choline alphoscerate; choline glycerophosphate; GLIATILIN; DELECIT; BREZAL	L-alpha- glycerylphosphorylch oline	Choline releasing agent	cognitive defect
MKC 231	2-oxo-N-(5,6,7,8- tetrahydro-2,3- dimethylfuro[2,3- b]quinolin-4-yl)-1- pyrrolidineacetamide	Choline uptake stimulation	cognitive defect; Alzheimer disease

bifemelane; bifemelane hydrochloride; MCI 2016; E 0687; CELEPORT; ALNERT; NEUROCINE; SURTONIL; CORDINAL	N-methyl-4-[2-(phenylmethyl)phenoxy]-1-butanamine	Cholinergic agent	cognitive defect
ABT 089	(R)-2-methyl-3-(2-pyrrolidinylmethoxy)pyridine	Cholinergic channel modifier	Alzheimer disease
stacofylline; S 9977; S 99772; SE 9977	N,N-diethyl-4-[3-(2,3,6,7-tetrahydro-1,3,7-trimethyl-2,6-dioxo-1H-purin-8-yl)propyl]-1-piperazinecarboxamide monohydrochloride	Cholinergic stimulation, 5HT uptake stimulation	Alzheimer disease
NS 2330	Unspecified	Cholinergic, adrenergic, noradrenergic	cognitive defect
choline derivatives,	Choline derivatives	Cholinomimetic	cognitive defect
HOE 065	[2S-[1[R*(R*)],2alpha,3alpha,6beta]]-1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (Z)-2-butenedioate	Cholinomimetic	cognitive defect
acetyl-L-carnitine; acetylcarnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine	Cholinomimetic, stimulation of neuron growth and repair	Alzheimer disease; stroke; diabetes; neuropathy
Alzheimer's therapy,	Unspecified	Complement activation by b-amyloid	Alzheimer disease

complement activation inhibitors	Unspecified	complement activation inhibitors	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Complex IV cytochrome oxidase function	Alzheimer disease
ebiratide; ACTH (4-9) analogue; corticotropin (4-9) analogue; HOE 427	4-(methylsulfonyl)-L-2-aminobutanoyl-L-alpha-glutamyl-L-histidyl-L-phenylalanyl-D-lysyl-N-alpha-(8-aminooctyl)-L-phenylalaninamide	corticotropin analogue	Alzheimer disease
GR 253035	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain; Alzheimer disease
rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease
creb gene transcription modulators, CNS disorders,	Unspecified	creb gene transcription modulators	neurodegeneration; Alzheimer disease
CRF1 partial agonist	Unspecified	CRF1 partial agonist	Alzheimer disease; Crohn disease
differentiation-inducing factor; DIF	Unspecified	differentiation-inducing factor; DIF; growth factor; neurotrophic factor	cognitive defect
Alzheimer's disease therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's disease therapy	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
NDD 094; SDZ NDD094	Unspecified	Disease specific targets	Alzheimer disease
alaptide; VUFB 15754	8-methyl-6,9-diazaspiro[4.5]decane-7,10-dione	dopamine agonist; cicatrizant; peptide	Alzheimer disease; skin ulcer; gastrointestinal ulcer
dihydrexidine; IP 202	trans-5,6,6a,7,8,12b-hexahydro-benzo[a]phenanthridine-10,11-diol	dopamine agonist; dopamine D1 agonist	Parkinson disease; Alzheimer disease

voxergolide; RU 41656	(8beta)-(+,-)-6-methyl-8-[(methylthio)methyl]-9-oxaergoline	dopamine agonist; dopamine D2 agonist	cognitive defect
estrogens,	Estrogens	estrogen	Alzheimer disease
estrogens,	Estrogens	estrogen	neuropathy; Alzheimer disease
ABPI 124	Unspecified	estrogen agonist	Alzheimer disease
17alpha estradiol	estra-1,3,5(10)-triene-3,17alpha-diol	estrogen; hormone replacement therapy	hormone deficiency; cognitive defect
estrogen,	Estrogen	estrogen; neuroactive steroid	Alzheimer disease
estrogen + medroxyprogesterone acetate; PREMPRO; PREMPHASE; PREMARIN MPA; PREMIQUE:PREMIQUE CYCLE	estrogen + medroxyprogesterone acetate	estrogen; progestogen; hormone replacement therapy	hormone deficiency; Alzheimer disease
excitatory amino acid antagonists,	Unspecified	excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
carboxylated buckminsterfullerenes; carboxyfullerenes	Carboxylated buckminsterfullerenes; carboxyfullerenes	free radical scavenger; apoptosis inhibitor	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
nefiracetam; feniracetam; DM 9384; DMPPA; TRANSLON	N-(2,6-dimethylphenyl)-2-oxo-1-pyrrolidineacetamide	GABA agonist	cognitive defect
ZK 95962; ZK 45962	ethyl 5-isopropoxy-4-methoxymethyl-beta-carboline-3-carboxylate	GABA agonist	epilepsy; cognitive defect
CGP 36742	(3-aminopropyl)butylphosphinic acid	GABA antagonist	epilepsy; Alzheimer disease
cognition enhancer,	Unspecified	GABA inverse agonist	Alzheimer disease
NGD 971; NGD 97-1	Unspecified	GABA inverse agonist	cognitive defect
suritozole; MDL 26479	2,4-dimethyl-5-(3-fluorophenyl)-3H-1,2,4-triazole-3-thione	GABA inverse agonist	depression; cognitive defect

valproate sodium; sodium valproate; NIK 240; SENITA; SELENICA	2-propylpentanoic acid sodium salt	GABA release enhancer	Alzheimer disease; epilepsy
siagoside; AGF 2	[R-[R*,S*-(E)]]-N- [1-[[[O-[1',2- anhydro]-N-acetyl- alpha-neuraminosyl- (2->3)-O-[O-beta-D- galactopyranosyl-(1- >3)-2-(acetylamino)- 2-deoxy-beta-D- galactopyranosyl-(1- >4)-O-beta-D- galactopyranosyl-(1- >4)-beta-D- glucopyranosyl]oxy] methyl]-2-hydroxy-3- heptadecenyl]octadec anamide	ganglioside	cognitive defect; stroke
Dimethylhomospermi ne; DMHSPM	Dimethylhomospermi ne	gastroprokinetic; polyamine analogue	gastrointestinal motility disease; Alzheimer disease
Alzheimer disease therapy,	Unspecified	gene	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Gene transcription based drugs	Alzheimer disease
ALT 766	Unspecified	Glucose derived cross-link breaker	diabetes; cardiovascular disease; Alzheimer disease
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)- 2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
sinnabidol; HU 211; PA 50211; DEXANABINOL	(6aS-trans)-3-(1,1- dimethylheptyl)- 6a,7,10,10a- tetrahydro-1- hydroxy-6,6- dimethyl-6H- dibenzo[b,d]pyran-9- methanol	glutamate antagonist; cannabinoid; NMDA antagonist; free radical scavenger	cognitive defect; stroke; trauma; myocardial infarction; glaucoma

LY 341495	[1S-[1alpha(R*),2beta]]-alpha-amino-alpha-(2-carboxycyclopropyl)-9H-xanthene-9-propanoic acid	glutamate antagonist; mGluR antagonist	psychosis; cognitive defect
PD 129653; SC 46643	(+)-alpha-amino-4-(phosphonomethyl)benzeneacetic acid	glutamate antagonist; NMDA antagonist	cognitive defect
PD 130527	3-(phosphonomethyl)phenylalanine	glutamate antagonist; NMDA antagonist	cognitive defect
dimiracetam; ISF 4185	dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione	Glutamatergic, cholinergic pathways, inhibition of hippocampal serotonergic activity	cognitive defect
glycine transporter modulator,	Unspecified	glycine antagonist	epilepsy; cognitive defect
gene therapy, nerve growth factor	Unspecified	growth factor	Alzheimer disease
BU 4514N	Unspecified	growth factor	cognitive defect
CX 438	Unspecified	growth factor	Alzheimer disease
nerve growth factor inducer, NGF inducer,	Unspecified	growth factor	Alzheimer disease
drug delivery system, polymer pellet nerve growth factor; NGF polymer pellet	NGF polymer pellet	growth factor;	Alzheimer disease
neurodegenerative disease therapy,	Unspecified	growth factor; growth factor modulator	cognitive defect; Alzheimer disease; neuropathy
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
neurotrophin agonist,	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy

drug delivery system, neurotrophin-3 secreting implant; NT-3 implant	NT-3	growth factor; neurotrophic factor; biotechnology	Alzheimer disease; Parkinson disease; neuropathy
ciproxifan; compound 359; BP 2359	Cyclopropyl[4-[3-(1H-imidazol-4-yl)propoxyl]phenyl]methanone	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
compound 421	Unspecified	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
GR 175737	Unspecified	histamine antagonist; histamine H3 antagonist	Alzheimer disease; cognitive defect
GT 2016	1-(5-cyclohexyl-1-oxopentyl)-4-(1H-imidazol-4-yl)piperidine	histamine antagonist; histamine H3 antagonist	cognitive defect; stroke; attention deficit disorder
GT 2227	1-[1H-imidazol-4-yl]-6-cyclohexyl-cis-hex-3-ene	histamine antagonist; histamine H3 antagonist	cognitive defect; attention deficit disorder
GT 2331	4-[(1R,2R)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl]-1H-imidazole	histamine antagonist; histamine H3 antagonist	cognitive defect; attention deficit disorder; Alzheimer disease
thioperamide; MR 12842	N-cyclohexyl-4-(1H-imidazol-4-yl)-1-piperidinecarbothioamide	histamine antagonist; histamine H3 antagonist	cognitive defect
drug delivery system, thyrotropin releasing hormone; TRH-SR; HILTONIN SR	Unspecified	hormone	cognitive defect
ICE inhibitors,	Unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	endotoxic shock; rheumatoid arthritis; Alzheimer disease
AIT 083	Unspecified	immunostimulant	cognitive defect

CEP 1347; KT 7515	[9S-(9alpha,10beta,12alpha)-5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo [1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, methyl ester	Kinase inhibitor, jnk inhibitor	Alzheimer disease
m-NBA	2-amino-3-(3-nitrobenzoyl)propanoic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
Maillard reaction inhibitors	Unspecified	Maillard reaction ; blocks glycated proteins	atherosclerosis; Alzheimer disease
drug delivery system, transdermal selegiline; selegiline transdermal	Selgiline	MAO B inhibitor; MAO inhibitor	Alzheimer disease; depression
lazabemide; Ro 196327; PAKIO; TEMPIUM	N-(2-aminoethyl)-5-chloro-2-pyridine-carboxamide	MAO B inhibitor; MAO inhibitor	Parkinson disease; Alzheimer disease
LU 53439	3,4-dimethyl-7-(2-isopropyl-1,3,4-thiadiazol-5-yl)-methoxy-coumarin	MAO B inhibitor; MAO inhibitor	Parkinson disease; cognitive defect
rasagiline; rasagiline mesylate; TVP 1012; TV 1012	(R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine	MAO inhibitor; MAO B inhibitor	Parkinson disease; Alzheimer disease
SL 251188	Unspecified	MAO inhibitor; MAO B inhibitor	Alzheimer disease; nicotine withdrawal
neurodegenerative disease therapy	Unspecified	monoclonal antibody; biotechnology	neurodegeneration; Alzheimer disease
BY 1949	3-methoxy-11-methyl-dibenz(b,f)(1,4)oxazine-8-carboxylic acid	Na <sup>+</sup> , K <sup>+</sup> ATPase activation	cerebrovascular disease; cognitive defect
SR 57667	Unspecified	Neurodegeneration protection agent	Alzheimer disease; Parkinson disease



memory enhancer,	Unspecified	Neuron enhancement at hippocampus	cognitive defect
neurophilins	Neurophilins	Neurophilin receptor ligand	Alzheimer disease; Parkinson disease; neuropathy
lubeluzole; R 87926; PROSYNAP	(S)-4-(2-benzothiazolylmethylamino)-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol	Neuroprotectant	stroke; Alzheimer disease
CX 417	Unspecified	Neurotransmitter receptro modulator	Alzheimer disease
DMP 543	10,10-bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone	Neurotransmitter release	Alzheimer disease
leteprinin; leteprinin potassium; AIT 082; NEOTROFIN	4-[[3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl]amino]benzoic acid	Neurotrophic factor production stimulation	cognitive defect; Alzheimer disease
CEP 427	Unspecified	neurotrophic factor; growth factor	Alzheimer disease
K 252a derivative	[(9S-(9alpha,10beta,12alpha))-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester	neurotrophic factor; growth factor	neuropathy; Alzheimer disease
NS 506	Unspecified	neurotrophic factor; growth factor	cognitive defect
NS 521	Unspecified	neurotrophic factor; growth factor	Alzheimer disease; neuropathy; cancer; diabetes

ST 857	[R-(R*,S*)]-2-(acetyloxy)-4-[[4-[(aminoiminomethyl)amino]-1-carboxybutyl]amino]-N,N,N-trimethyl-4-oxo-1-butanaminium chloride	neurotrophic factor; growth factor	cognitive defect
eurystatin A; Bu 4164EA	[3S-[3R*,7R*,10R*(E)]]-6-methyl-N-[7-methyl-3-(2-methylpropyl)-2,5,6,9-tetraoxo-1,4,8-triazacyclotridec-10-yl]-2-heptenamide	neutral endopeptidase inhibitor	Alzheimer disease
eurystatin B; Bu 4164EB	[3S-[3R*,7R*,10R*(E)]]-6-methyl-N-[7-methyl-3-(2-methylpropyl)-2,5,6,9-tetraoxo-1,4,8-triazacyclotridec-10-yl]-2-octenamide	neutral endopeptidase inhibitor	Alzheimer disease
Y 29794	[2-[[8-(dimethylamino)octyl]thio]-6-(1-methylethyl)-3-pyridinyl]-2-thienylmethanone	neutral endopeptidase inhibitor	cognitive defect; Alzheimer disease
neurodegeneration therapy	Unspecified	Nicotinic compounds	Alzheimer disease; Parkinson disease
memantine; D 145; NMI 131; AKATINOL	3,5-dimethyl-1-adamantanamine	NMDA antagonist; analgesic; glutamate antagonist	cognitive defect; pain; glaucoma; neuropathy
CR 2249	(S)-4-amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxopentanoic acid	NMDA modulator	Alzheimer disease
GVS 111	1-(phenylacetyl)-L-prolylglycine ethyl ester	NMDA modulator	cognitive defect

adafenoxate; WON 150	4-chlorophenoxyacetic acid 2-(1-adamantylamino)ethyl ester	Nootropic agent	cognitive defect
ALE 26015	Unspecified	Nootropic agent	cognitive defect; Alzheimer disease
aloracetam; CAS 493	N-[2-(3-formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide	Nootropic agent	cognitive defect
Alzheimer's disease therapy,	Unspecified	Nootropic agent	Alzheimer disease
AWD 5239	9,10-dihydrolysergic acid bis-(beta-acetoxyethyl)amide monotartrate	Nootropic agent	cognitive defect
bacoside A	3-[(O-alfa-L-arabinosyl-beta-D-glucosyl)oxy]-19,20-dihydroxydammar-24-en-16-one	Nootropic agent	cognitive defect
bacoside A + bacoside B	Unspecified	Nootropic agent	cognitive defect
bacoside B	3-[(O-L-arabinosyl-D-glucosyl)oxy]-19,20-dihydroxydammar-24-en-16-one	Nootropic agent	cognitive defect
BDP	(11beta,16beta)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione	Nootropic agent	Alzheimer disease
BMY 21502; BMS 181168	1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone	Nootropic agent	cognitive defect
BR 16A	Unspecified	Nootropic agent	cognitive defect
CGP 34735	Unspecified	Nootropic agent	cognitive defect
CGP 50068A	Unspecified	Nootropic agent	cognitive defect

CL 275838	4,5-dihydro-4-((4-(phenylmethyl)-1-piperazinyl)acetyl)-7-(3-(trifluoromethyl)phenyl)pyrazolo(1,5-a)pyrimidine-3-carbonitrile	Nootropic agent	cognitive defect
CX 516; AMPALEX	1-(6-quinoxalinylylcarbonyl)piperidine	Nootropic agent	Alzheimer disease; schizophrenia
cycloserine-D; cycloserine; SC 49088	4-amino-3-isoxazolidinone	Nootropic agent	Alzheimer disease
dabelotine; S 12024; S 120242	(S)-1,2,3,4-tetrahydro-1-methyl-8-(2-morpholinylmethoxy)quinoline monomethanesulfonate	Nootropic agent	Alzheimer disease
exifone; ADLONE	2,3,3',4,4',5'-hexahydroxybenzophenone	Nootropic agent	cognitive defect
fasoracetam; NS 105; LAM 105	(R)-1-[(5-oxo-2-pyrrolidinyl)carbonyl]piperidine	Nootropic agent	cerebrovascular disease; cognitive defect
FR 121196	1-acetyl-4-[[4-(4-fluorophenyl)sulfonylamino]piperazine	Nootropic agent	cognitive defect; sexual dysfunction
gedocarnil; SH 530; ZK 113315	5-(4-chlorophenoxy)-4-(methoxymethyl)-9H-pyrido[3,4-b]indole-3-carboxylic acid 1-methylethyl ester	Nootropic agent	cognitive defect
idebenone; CV 2619; AVAN; LUCEBANOL; GENICERAL; MNESIS; DARUMA; NEMOCEBRAL; KEDANON; ARZKAT; DAYSTROM	2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione	Nootropic agent	cognitive defect

IDRA 21	7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide	Nootropic agent	cognitive defect
KI 711	Sialic acid derivative	Nootropic agent	Alzheimer disease
KW 6055	N-[3-nitro-4-(2-pyridinylmethyl)phenyl]butanamide	Nootropic agent	cognitive defect
mexidol	2-ethyl-6-methyl-3-hydroxypyridine succinate	Nootropic agent	anxiety; cognitive defect
oxiracetam; ISF 2522; CT 848; CGP 21690; NEUROMET; NEURACTIV; SENEX	4-hydroxy-2-oxo-1-pyrrolidineacetamide	Nootropic agent	cognitive defect
P 128	Unspecified	Nootropic agent	cognitive defect
P 58	Unspecified	Nootropic agent	Alzheimer disease; cognitive defect
P 867493	Unspecified	Nootropic agent	cognitive defect
P 878184	Unspecified	Nootropic agent	cognitive defect
PPRT 424	Ginko bilboa extract	Nootropic agent	cognitive defect
pramiracetam; amacetam; CI 879; CNS 1879; ECTAPRAM; NEUPRAMIR; REMEM	N-[2-[bis-(1-methylethyl)amino]ethyl]-2-oxo-1-pyrrolidineacetamide	Nootropic agent	Alzheimer disease
prisinolol; prisotinal; CGS 5649B	(+,-)-6-[2-(isopropylamino)propyl]-3-pyridinol	Nootropic agent	cognitive defect
RU 47067	5-(1-methylethoxy)-1,3-(trifluoromethyl)phenylsulfonyl-2-pyrrolidinone	Nootropic agent	cognitive defect
SC 110	Unspecified	Nootropic agent	Alzheimer disease
SEE 405	Unspecified	Nootropic agent	Alzheimer disease
South American frog toxins	Histrionicotoxin	Nootropic agent	Alzheimer disease
UCB 11056	Unspecified	Nootropic agent	Alzheimer disease
UCB 29427	Unspecified	Nootropic agent	cognitive defect
UCB 29536	Unspecified	Nootropic agent	cognitive defect

Z 4105	N-(3-carboxypropyl)-3-methylisoxazole-5-carboxamide	Nootropic agent	cognitive defect
T 588	(R)-1-alfa-[[2-(diethylamino)ethoxy]methyl]benzo[b]thiophene-5-methanol hydrochloride	Nootropic agent, neurodegeneration protection	cognitive defect
VA 045	(3alpha,16alpha)-eburnamenine-14-carboxylic acid 2-(nitrooxy)ethylester, apovincaminic acid derivative	Nootropic agent, neuroprotective agent	cognitive defect
nebracetam; WEB 1881; WEB 1881FU; MEMOLOG	4-aminomethyl-1-benzylpyrrolidin-2-one hemifumarate	Nootropic agent, unknown mechanism	Alzheimer disease
DQ-CER	des-Gln2-[Leu5,Nle8]-cerulein	Nootropic agent	cognitive defect
MCI 225	4-(2-fluorophenyl)-2-methyl-6-(piperazin-1-yl)-3a,7a-dihydrothieno[2,3-d]pyrimidine	Noradrenergic, serotonergic reuptake inhibitors	cognitive defect; depression
notch signalling pathway modulators	Unspecified	notch signalling pathway modulators	stroke; cognitive defect; cancer
CPH 82; REUMAICON; COMIHOG	Unspecified	NSAID	inflammation; Alzheimer disease
HCT 1026	Unspecified	NSAID; nitric oxide donor	urinary incontinence; Alzheimer disease; osteoporosis
quadazocine; WIN 444413; WIN 44441	(-)-(2R,6S,11S)-1-cyclopentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)-3-pentanone	opiate antagonist; kappa antagonist	cognitive defect
MAb, OX 26-nerve growth factor conjugate; MAb, OX 26-NGF conjugate; OX 26-NGF	Unspecified	OX 26-nerve growth factor conjugate monoclonal antibody	cognitive defect

ACTH (4-10); SEMAX	Unspecified	peptide	cognitive defect; trauma; stroke
Alzheimer disease therapy,	Unspecified	peptide	Alzheimer disease
beta-sheet breaker,	Unspecified	peptide	Alzheimer disease
Transglutaminase inhibitor	Unspecified	peptide; transglutaminase inhibitor	psoriasis; Alzheimer disease
KS 505a	2,3,4,4a,4b,5,6,6a,6b, 7,8,8a,8b,9,10,10a,16, 16a,16b,17,18,18a,18 b,19,2 0,20a,20b,21,22,22a,- triacontahydro- 8a,10a- bis(hydroxymethyl)- 14-(4-methoxy-1,4- dioxobutyl)1,4,4a,6,6 a,16b,18b,20b- octamethyl-2-((2-O - methyl-beta-D- glucopyranuronosyl)o xy)-1H- benzo(9,10)picen o(3,4-a)xanthene- 1,15-dicarboxylic acid	phosphodiesterase inhibitor	cognitive defect
Rolipram; ZK 62711; ME 3167; ADEO	4-[3- (cyclopentyloxy)-4- methoxyphenyl]-2- pyrrolidinone	phosphodiesterase inhibitor	cognitive defect; multiple sclerosis
Propentofylline; HWA 285; HEXTOL; BRAINORM; VIVIQ	3-methyl-1-(5-oxo- hexyl)-7- propylxanthine	phosphodiesterase inhibitor; xanthine	Alzheimer disease
Diethylnorspermine; DENSPM; CI 1006; DE 333	N1,N11- diethylnorspermine	polyamine analogue	cancer; psoriasis; Alzheimer disease
Dipropylnorspermine; DPNSPM	Dipropylnorspermine	polyamine analogue	diarrhea; Alzheimer disease
linear polyamine analogue	linear polyamine analogue	polyamine analogue	cancer; Alzheimer disease
Polymerization inhibitor	Unspecified	polymerization inhibitor	Alzheimer disease

Clausenamide	(3R,4S,5S)-rel-3-hydroxy-5-[(R)-hydroxyphenylmethyl]-1-methyl-4-phenyl-2-pyrrolidinone	potassium channel blocker	cognitive defect
Potassium channel modulators,	Unspecified	potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
Alzheimer's disease therapy	Unspecified	Presenilins	Alzheimer disease
JTP 3399	Unspecified	prolyl endopeptidase inhibitor	cognitive defect
JTP 4819	[S-(R*,R*)]-2-[[2-(hydroxyacetyl)-1-pyrrolidinyl]carbonyl]-N-(phenylmethyl)-1-pyrrolidinecarboxamide	prolyl endopeptidase inhibitor	Alzheimer disease; cognitive defect
ONO 1603	(S)-N-[(4-chlorophenyl)methyl]-2-formyl-gamma-oxo-1-pyrrolidinebutanamide	prolyl endopeptidase inhibitor	Alzheimer disease
S 17092	Unspecified	prolyl endopeptidase inhibitor	Alzheimer disease; cognitive defect
Z 321	(4R)-3-(2-indanyl-2-ylacetyl)-4-(1-pyrrolidinylcarbonyl)-1,3-thiazolidine	prolyl endopeptidase inhibitor	cerebrovascular disease; cognitive defect; Alzheimer disease
CEP 431	Unspecified	proteinase inhibitor	Alzheimer disease
proteinase inhibitors,	Unspecified	proteinase inhibitor	cognitive defect
SIB T1980	Unspecified	proteinase inhibitor	Alzheimer disease
azetirelin; YM 14673	(S)-N-[(4-oxo-2-azetidiny]carbonyl]-L-histidyl-L-prolinamide	protirelin analogue	cognitive defect
JTP 2942	(1S-cis)-N-[(2-methyl-4-oxocyclopentyl)carbonyl]-L-histidyl-L-prolinamide	protirelin analogue	cognitive defect



posatiirelin; RGH 2202	(S)-N-[(6-oxo-2-piperidiny)carbonyl]-L-leucyl-L-prolinamide	protirelin analogue	cognitive defect; obesity
Alzheimer's disease therapy,	Unspecified	Serum amyloid p component	Alzheimer disease
igmesine; igmacine; JO 1784	(+)-N-(1,4-diphenyl-3-butenyl)-N-methylcyclopropane methanamine	sigma agonist	depression; cognitive defect; diarrhea
SA 4503	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	sigma agonist	Alzheimer disease; depression; cognitive defect; stroke
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
NX D2858; NXD 2858	Unspecified	Spherons, inhibition of spherons into plaques	Alzheimer disease
screening technology, ADAP	Unspecified	target based screening	drug design technology; Alzheimer disease
drug delivery system, thyroid stimulating hormone;	Unspecified	thyroid stimulating hormone delivery system	cognitive defect
thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection

CEP 3265; CB 1093	5-[[1-(2-ethoxy-6-ethyl-6-hydroxy-1-methyl-3-octynyl)octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol	transcription activator	neurodegeneration; Alzheimer disease
ademetonine; FO 1561; GUMBARAL; DONAMET; TRANSMETIL; CERITAN; ERGEN; TWIN; SAMY R	(3S)-5'-[(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine hydroxide inner salt	transmethylator; NSAID	inflammation; cognitive defect; cholestasis
AIT 034; AIT 34	1,6-dihydro-6-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]9H-purine-9-propanamide	Unknown	cognitive defect
BTG 1640	Heterocyclic compound	unknown	cognitive defect; Alzheimer disease
cebaracetam; ZY 15119	(+,-)-4-[[4-(p-chlorophenyl)-2-oxo-1-pyrrolidinyl]acetyl]-2-piperazinone	Unknown	cognitive defect
fatty acids, microalgal	Unspecified	Unknown	hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease
NBI 107	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	infectious disease; Alzheimer disease
NBI 108	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	Alzheimer disease; infectious disease; multiple sclerosis
pregnenolone; NBI 113	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	infectious disease; Alzheimer disease

vinpocetine; AY 27255; CAVINTON; CERACTON; AIRPACIL; MEDICHILL; NAIKINOL TEISAN; NAIKINOL IWAKI	(3 $\alpha$ ,16 $\alpha$ )-eburnamenine-14-carboxylic acid ethyl ester	vasodilator	peripheral vascular disease; cognitive defect
vasoactive intestinal peptide analogue; [stearyl norleucine <sup>17</sup> ]VIP; [St-Nle <sup>17</sup> ]VIP	Unspecified	VIP agonist	Alzheimer disease

Table 28. Current Candidate Therapeutic Interventions for the Treatment of Depression

Product Name	Chemical Name	Action	Indication
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
F 12439		5HT agonist; 5HT1A agonist	depression; anxiety
Flesinoxan; DU 29373	(+)-N-[2-[4-[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl]-1-piperazinyl]ethyl]-4-fluorobenzamide	5HT agonist; 5HT1A agonist	anxiety; depression
Gepirone; gepirone hydrochloride; MJ 13805; BMY 13805; BMY 138051	4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione	5HT agonist; 5HT1A agonist	anxiety; depression
Ipsapirone; BAY q 7821; TVX q 7821	2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	5HT agonist; 5HT1A agonist	depression; anxiety

LY 228729	4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
ORG 13011		5HT agonist; 5HT1A agonist	depression
S 14671	N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-2-thiophenecarboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
U 92016A		5HT agonist; 5HT1A agonist	anxiety; depression
U 93385; U 93385E	(3aR-cis)-2,3,3a,4,5,9b-hexahydro-3-propyl-1H-benz[e]indole-9-carboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
WY 48723	octahydro-3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,5-methano-6,7,9-metheno-2H-pentaleno[1,2-a]azepin-2,4(3H,5H)-dione dihydrochloride	5HT agonist; 5HT1A agonist	depression
SL 870765		5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT1D antagonist	anxiety; depression
Adatanserin; adatanserin hydrochloride; WY 50324; WAY SEB 324; SEB 324	N-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1(3,7)]decane-1-carboxamide	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5865	2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide monohydrochloride	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5893; FG 5974	(2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester)	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression

AF 2968	(S)-[R-(R*,R*)]-2,3-2-[3-[4-(3-chlorophenyl)-2-methyl-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one dihydroxybutanedioate (1:1)	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2A antagonist; 5HT2C antagonist	depression
Sunepitron; CP 93393; CP 93393-1	(7S-trans)-1-[[octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2,5-pyrrolidinedione	5HT agonist; 5HT1A agonist; alpha adrenergic antagonist; alpha2 adrenergic agonist	depression; anxiety
Aromatic triflates,		5HT agonist; 5HT1D agonist	depression; migraine
GMC 2020		5HT agonist; 5HT1D agonist	depression; migraine
GMC 2021	trifluoromethanesulfonic acid 3-[2-(dimethylamino)ethyl]-1H-indol-5-yl ester (1:1) ethanedioate	5HT agonist; 5HT1D agonist	depression; migraine
ORG 12962		5HT agonist; 5HT2C agonist	depression
ORG 37684		5HT agonist; 5HT2C agonist	depression
Ro 600175; Ro 60-0175	(alphaS)-6-chloro-5-fluoro-alpha-methyl-1H-indole-1-ethanamine (2E)-2-butenedioate (1:1)	5HT agonist; 5HT2C agonist	depression; obsessive compulsive disorder
SR 57227; CM 57277	1-(6-chloro-2-pyridinyl)-4-piperidinamine	5HT agonist; 5HT3 agonist	depression
5HT1B antagonists,		5HT antagonist	depression; anxiety
BN 50156	3-(4-chlorophenyl)-alpha-[3-(dimethylamino)-1-propenyl]-1,3-dihydro-7-hydroxyfuro[3,4-c]pyridine-6-methanol	5HT antagonist	depression
DU 123015		5HT antagonist	anxiety; depression

DU 125530		5HT antagonist	depression; anxiety; psychosis
Moxyfetin		5HT antagonist	depression
SB 245570		5HT antagonist	depression
5-HT antagonist, pindobind	2-bromo-N-[4-[1-[[2-hydroxy-3-(1H-indol-4-yloxy)propyl]amino]-1-methylethyl]-1-methylcyclohexyl]acetamide	5HT antagonist; 5HT1A antagonist	anxiety; depression
Robalzotan; NAD 299	(3R)-3-(dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (1:1)	5HT antagonist; 5HT1A antagonist	anxiety; depression
S 14063	1-(2-benzothiazolyl)-N-[2-(2-methoxyphenoxy)ethyl]-4-piperidinemethanamine dihydrochloride	5HT antagonist; 5HT1A antagonist	depression
S 15535	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine	5HT antagonist; 5HT1A antagonist	anxiety; depression
Buspirone hydrochloride; MJ 40221; MJ 9022; BESPAR; BUSPAR; NORMATON; TUTRAN; NAROL; ANSIENON; ANSITEN; TRANBUS; SIMPLESS	8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4,5]decane-7,9-dione hydrochloride	5HT antagonist; 5HT1A antagonist; dopamine agonist	anxiety; depression; dermatitis
Drug delivery system, transdermal buspirone; buspirone transdermal		5HT antagonist; 5HT1A antagonist; dopamine agonist	anxiety; depression; attention deficit disorder

EF 7412	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]-1-piperazinyl]phenyl]ethanesulfonamide	5HT antagonist; 5HT1A antagonist; glutamate release inhibitor	neurodegeneration; depression; cancer
L 694247	N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulfonamide	5HT antagonist; 5HT1D antagonist	depression
GR 127935	N-(4-methoxy-3-(4-methyl-1-piperazinyl)phenyl-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-5-yl)-1H-indole-3-yl)ethylamine	5HT antagonist; 5HT1Dbeta antagonist	depression
Flibanserin; BIMT 17	1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one	5HT antagonist; 5HT2 antagonist; 5HT agonist; 5HT1A agonist	depression
HT 90B	(-)-N-[2-[[[(2,3-dihydro-8-methyl-1,4-benzodioxin-2-yl)methyl]amino]ethyl]tricyclo[3.3.1.1 <sup>3,7</sup> ]decane-1-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT agonist; 5HT1A agonist	anxiety; depression
Nefazodone; MJ 13754; MS 13754; BMY 13754; BMY 137541; SERZONE; DUTONIN; RESERIL; NEFADAR; NIFEREL; MENFAZONA; RULIVAN; DEPREFAX; SERZONIL	2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one	5HT antagonist; 5HT2 antagonist; 5HT reuptake inhibitor; alpha adrenergic antagonist; alpha1 adrenergic antagonist	depression

Amesergide; amerserzide; LY 237733	8beta-N-cyclohexyl- 6-methyl-1-(1- methylethyl)ergoline- 8-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist	sexual dysfunction; depression; anxiety
Mirtazapine; mepirzepine; azamianserin; ORG 3770; REMERON; ZISPIN	1,2,3,4,10,14b- hexahydro-2- methylpyrazino[2,1- a]pyrido[2,3- c][2]benzaz epine	5HT antagonist; 5HT2 antagonist; 5HT3 antagonist; alpha2 adrenergic antagonist; alpha adrenergic antagonist	depression
Olanzapine; LY 170053; ZYPREX; ZYPREXA; OLANZEK	2-methyl-4-(4- methyl-1- piperazinyl)-10H- thieno[2,3- b][1,5]benzodiazepi ne	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia; psychosis; depression
ORG 37415		5HT antagonist; 5HT2C antagonist	depression; anxiety
SB 228357	N-[3-fluoro-5-(3- pyridinyl)phenyl]- 2,3-dihydro-5- methoxy-6- (trifluoromethyl)-1H- indole-1-carboxamide	5HT antagonist; 5HT2C antagonist	anxiety; depression
Antidepressant		5HT antagonist; 5HT3 antagonist	depression; anxiety
5HT7 receptor antagonists,		5HT antagonist; 5HT7 antagonist	depression; insomnia; schizophrenia
DR 4004		5HT antagonist; 5HT7 antagonist	depression; insomnia
THE JL3; JL 3	10-(4-methyl-1- piperazinyl)- pyrido[4,3- b][1,4]benzothiazepi e	5HT antagonist; dopamine antagonist	anxiety; depression
BMS 181101; BMY 42569	5-fluoro-3-[3-[4- (1,4,5,6- tetrahydropyrimidin- 4-yl)-2,3- dihydropyrazin-1- yl]propyl]-2,3- dihydro-1H-indole	5HT reuptake inhibitor	depression



Cericlamine; JO 1017(+,-); JO 1239(-); JO 1240(+)	(+,-)-3,4-dichloro-beta-(dimethylamino)-beta-methylbenzenepropanol	5HT reuptake inhibitor	depression
CGP 6085A	4-(5,6-dimethyl-2-benzofuranyl)piperidine hydrochloride	5HT reuptake inhibitor	depression
Citalopram; nitalopram; nitalapram; ZD 211; LU 10171; CIPRAMIL; SEROPRAM; CIPRAM; ELOPRAM; CELEXA	1-[3-(dimethylamino)propyl]-1-4-fluorophenyl)-5-isobenzofurancarbonitrile	5HT reuptake inhibitor	depression
Citalopram, (S); (+)-citalopram	(S)-1-[3-(dimethylamino)propyl]-1-4-fluorophenyl)-5-isobenzofurancarbonitrile	5HT reuptake inhibitor	depression
Dapoxetine; LY 210448	(S)-N,N-dimethyl-alpha-[2-(1-naphthalenyloxy)ethyl]benzenemethanamine	5HT reuptake inhibitor	depression
Depression therapy,		5HT reuptake inhibitor	depression
Dexfenfluramine; dexfenfluramine hydrochloride; S 5614; IP 001; ISOMERIDE; ADIFAX; ARDIX; ISOLIPAN; SIRAN; OBESINE; FLURIL; DISPONDAL; REDUX	(S)-N-ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine	5HT reuptake inhibitor	obesity; depression; nicotine withdrawal

Drug delivery system, controlled release GEOMATRIX paroxetine; paroxetine GEOMATRIX; PAXIL CR		5HT reuptake inhibitor	depression
FCE 25876	(E)-N-methyl-3- phenyl-3-(4- trifluoromethylpheno xy)-2-propen-1-ami ne	5HT reuptake inhibitor	depression
FI 4500		5HT reuptake inhibitor	depression
FI 4501		5HT reuptake inhibitor	depression
FI 4503		5HT reuptake inhibitor	depression
Fluoxetine, (R)-; (R)- fluoxetine	(R)-N-methyl- gamma-[4- (trifluoromethyl)phen oxy]benzenepropana mine	5HT reuptake inhibitor	migraine; cognitive defect; depression
Fluvoxamine; fluvoxamine maleate; DU 23000; MK 264; SME 3110; FEVARIN; FLOXYFRAL; LUVOX; DUMYROX; DUMIROX; FLAVOXYL; FAVERIN; DEPROMEL	5-methoxy-1-[4- (trifluoromethyl)phen yl]-1-pentanone (E)- O-(2- aminoethyl)oxime	5HT reuptake inhibitor	depression; anxiety; obsessive compulsive disorder
Litoxetine; SL 810385	4-(2- naphthalenylmethoxy )piperidine	5HT reuptake inhibitor	depression
LY 280253	Unspecified	5HT reuptake inhibitor	depression
LY 285974	Unspecified	5HT reuptake inhibitor	depression

Paroxetine hydrochloride; FR 7051; BRL 29060; BRL 29060A; SI 211103; SEROXAT; AROPAX; PAXIL; TAGONIS; FROSINOR; DEROXAT; SEREUPIN; MOTIVAN	(3S-trans)-3-[(1,3-benzodioxol-5-yl)oxy)methyl]-4-(4-fluorophenyl)piperidine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety
Sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
Tianeptine; S 1574; STABLON	7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide	5HT reuptake inhibitor	depression
EMD 68843	5-[4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl]benzofuran-2-carboxamide hydrochloride	5HT reuptake inhibitor; 5HT agonist; 5HT1A agonist	depression
YM 992; YM 35992	(S)-2-[[[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxy)methyl]morpholine hydrochloride	5HT reuptake inhibitor; 5HT antagonist; 5HT2A antagonist	depression
A 80426	(R)-N-methyl-N-[(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)methyl]-6-benzofuranethanamine	5HT reuptake inhibitor; alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
Antidepressants		5HT reuptake inhibitor; alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression

NS 2347		5HT reuptake inhibitor; dopamine reuptake inhibitor	depression; cognitive defect
NS 2389		5HT reuptake inhibitor; dopamine reuptake inhibitor; noradrenalin reuptake inhibitor	depression
Drug delivery system, OROS oral controlled release venlafaxine; venlafaxine OROS; EFFEXOR XL		5HT reuptake inhibitor; noradrenalin reuptake inhibitor	depression
Duloxetine; LY 248686	(S)-N-methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine	5HT reuptake inhibitor; noradrenalin reuptake inhibitor	depression; urinary incontinence
Venlafaxine; WY 45030; EFFEXOR; EFEXOR; EFFEXOR XR; EFFEXOR XL	(+,-)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol	5HT reuptake inhibitor; noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	depression; anxiety
Ebalzotan; NAE 086	(R)-3,4-dihydro-N-(1-methylethyl)-3-[(1-methylethyl)propylamino]-2H-1-benzopyran-5-carboxamide	5HT1A agonist; 5HT agonist	depression
L 0068; F 11440	4-methyl-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2,4-triazine-3,5(2H,4H)-dione	5HT1A agonist; 5HT agonist	anxiety; depression
LY 274600	(S)-1,2,3,4-tetrahydro-8-(methylthio)-N,N-dipropyl-2-naphthalenamine hydrochloride	5HT1A agonist; 5HT agonist	sexual dysfunction; depression; irritable bowel syndrome
LY 274601	(R)-1,2,3,4-tetrahydro-8-(methylthio)-N,N-dipropyl-2-naphthalenamine hydrochloride	5HT1A agonist; 5HT agonist	sexual dysfunction; depression; irritable bowel syndrome

OPC 14523	1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone	5HT1A agonist; sigma agonist; 5HT agonist	depression; anxiety; obsessive compulsive disorder
F 12682; F 14258	N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(2-phenylethyl)-1-piperazinecarboxamide	5HT1B/5HT1D inverse agonist	depression
GMC 5036	Mirtazepine analogue	5HT2, 5HT3 antagonist; alpha 2 adrenergic antagonist; histaminergic antagonism;	depression
Levoprotiline; levo-oxaprotiline; oxaprotiline, R-(-) enantiomer; CGP 12103A; CONSONAR	(R)-alpha-[(methylamino)methyl]-9,10-ethanoanthracene-9(10H)-ethanol	5HT2A, 5HT2C 5HT1A agonist alpha adrenergic agonist; 5HT1D and histaminergic antagonist	depression
SB 243213	2,3-dihydro-5-methyl-N-[(6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-6-(trifluoromethyl)-1H-indole-1-carboxamide	5HT2C antagonist; 5HT antagonist	depression; anxiety
Zalospirone; WY 47846	(3aalfa,4beta,4aalfa,6aalfa,7beta,7aalfa)-3a,4,4a,6a,7,7a-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione	5HT3 antagonist	anxiety; depression
Drug delivery system, adenosine; adenosine drug delivery system; adenosine prodrug	adenosine 5'-(1,4-dihydrotrigonellinate)-2',3'-O-bis-benzoate	adenosine agonist	anxiety; depression

Midaxifylline; IRFI 117	8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect; depression; kidney disease
MCI 225	4-(2-fluorophenyl)-2-methyl-6-(piperazin-1-yl)-3a,7a-dihydrothieno[2,3-d]pyrimidine	Adrenergic and serotonergic reuptake inhibitor	cognitive defect; depression
Adrafinil; adrafinal; CRL 40028; OLMIFON	2-[(diphenylmethyl)sulfinyl]-N-hydroxyacetamide	alpha adrenergic agonist	neurological depression
Modafinil; CRL 40476; CEP 1538; MODIODAL; PROVIGIL; ALERTEC; MODASOMIL	2-[(diphenylmethyl)sulfinyl]acetamide	alpha adrenergic agonist	neurological depression
SDZ NVI085	(-)-(4aR,10aR)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-methylthio-2H-naphth[2,3,b]-1,4-oxazine	alpha adrenergic agonist; alpha1 adrenergic agonist	neurological depression; depression
Imiloxan; RS 21361	2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-ethyl-1H-imidazole	alpha adrenergic antagonist	depression
ORG 6906		alpha adrenergic antagonist	depression
Setiptiline; teciptiline; MO 8282; ORG 8282; TECIPUL	2,3,4,9-tetrahydro-2-methyl-1H-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine	alpha adrenergic antagonist	depression
Atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety

CH 38083	[8aS-(8α,11α,12α,13α)]-5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-11-ol hydrochloride	alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
MK 912; L 657743	(2S-trans)-1,3,4,5',6,6',7,12b-octahydro-1',3'-dimethylspiro[2H-benzofuro[2,3-a]quinolizine-2,4'(1'H)-pyrimidin]-2'(3'H)-one monohydrochloride	alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
Idazoxan; RX 781094; RX 781094 A	2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist; antiproliferative agent	Parkinson disease; depression; cardiovascular disease; retinopathy
A 75200	(R*,R*)-(+,-)-3-phenyl-1-[(6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-6-yl)methyl]pyrrolidine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
Napitane; ABT 200; A 75200	(R*,R*)-(+,-)-3-phenyl-1-[(6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-6-yl)methyl]pyrrolidine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
ORG 9768		alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
Reboxetine; FCE 20124; FCE 21684; EDRONAX; PROLIFT	(R*,S*)-2-[(2-ethoxyphenoxy)phenylmethyl]morpholine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
AMPA receptor modulators,		AMPA receptor modulators	schizophrenia; depression

Dehydroepiandrosterone analogues; DHEA analogues,		androgen	atherosclerosis; depression
Drug delivery system, dehydroepiandrosterone; dehydroepiandrosterone delivery system; drug delivery system, DHEA		androgen	atherosclerosis; depression
Adinazolam; adinazolam mesylate; adinazolam mesilate; U 41123F; U 41123; DERACYN	8-chloro-N,N-dimethyl-6-phenyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine	benzodiazepine	anxiety; depression
Flumazenil; flumazepil; flumenazil; Ro 151788; ANEXATE; MAZICON; LANEXAT; ROMAZICON	8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester	benzodiazepine antagonist	neurological depression; liver disease
Flerobuterol	alpha-[[[(1,1-dimethylethyl)amino]methyl]-2-fluorobenzenemethanol	beta adrenergic agonist	depression
SR 56811; SR 58611A; SR 58611; ME 3411	[R-(R*,S*)]-[[7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]acetic acid ethyl ester hydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	irritable bowel syndrome; obesity; depression
KP 840	diethyl 1,4-dihydro 2,6-dimethyl-4-(3-ethynyl phenyl)-3,5-pyridine-dicarboxylic acid	calcium antagonist	ischemia; depression
Topiramate; KW 6485; McN 4853; RWJ 17021; TOPAMAX	2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate	carbonate dehydratase inhibitor; sodium channel blocker; AMPA antagonist; GABA agonist; glutamate antagonist	epilepsy; psychosis; depression



CMI 477	(1S-exo)-2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane	cholinergic agonist; nicotinic agonist; analgesic	obesity; depression; Alzheimer disease; nicotine withdrawal
Corticotropin releasing factor analogue		CRF analogue	anxiety; depression
AXC 2219		CRF antagonist	depression; anxiety
AXC 4007		CRF antagonist	depression; anxiety
CRA 1000	INDEX NAME NOT YET ASSIGNED	CRF antagonist	depression; anxiety
CRA 1001		CRF antagonist	depression; anxiety
CRF antagonist,		CRF antagonist	depression; anxiety
CRF antagonists		CRF antagonist	depression; anxiety
CRF receptor antagonist; corticotropin releasing factor antagonist		CRF antagonist	depression
CRF2 antagonists,		CRF antagonist	depression; anxiety
NBI 103		CRF antagonist	depression; eating disorder
NBI 104		CRF antagonist	depression; stroke
NBI 30545	3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propylpyrazolo[1,5-a]pyrimidin-7-amine	CRF antagonist	anxiety; depression
NBI 30775; R 121919		CRF antagonist	anxiety; depression; addiction
NGD 981; NGD 98-1		CRF antagonist	depression; anxiety
PD 171729	butyl-[3[(2,4-dichloro-phenyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl]-ethyl-amine	CRF antagonist	anxiety; depression
Pivagabine; PG 2; TONERG	4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid	CRF modulation	depression

DMP 695	N-(2-chloro-4,6-dimethylphenyl)-1-[2-methoxy-1-(methoxymethyl)ethyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine monomethanesulfonate	CRH antagonist	anxiety; depression
SA 627	N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-methyl-6-(4-morpholinyl)-1,3,5-triazin-2-amine	CRH antagonist	depression; anxiety
SC 241		CRH antagonist	anxiety; depression
Etrabamine; JL 14839	4,5,6,7-tetrahydro-N-methyl-6-benzothiazolamine	dopamine agonist	depression
MR 708	N-acetyl-DL-phenylalanine with tricyclo[3.3.1.1 <sup>3,7</sup> ]decan-1-amine (1:1)	dopamine agonist	depression
Roxindole; EMD 62100; EMD 49980; EMD 62080	3-(4-(3,6-dihydro-4-phenyl-1(2H)-pyridyl)butyl)indol-5-ol	dopamine agonist; 5HT reuptake inhibitor	depression
Amisulpride; aminosultopride; AST; DAN 2163; SOCIAN; SOLIAN; ENORDEN; DENIBAN; SULAMID	4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy benzamide	dopamine agonist; dopamine antagonist	schizophrenia; depression
Pergolide; pergolide mesylate; LY 141B; LY 127809; PERMAX; CELANCE; PHARKEN; PARKOTIL	(8beta)-8-[(methylthio)methyl]-6-propylergoline	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease; depression

Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQUIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7- tetrahydro-6- (propylamino)- benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
GYKI 52895	4-(8-methyl-9H-1,3- dioxolo[4,5- h][2,3]benzodiazepin- 5-yl)-benzodiazepine	dopamine reuptake inhibitor	depression
HOE 249	(+)-2-[(3- chlorophenyl)-1H- imidazol-1- ylmethyl]tricyclo[3.3. 1.1(3,7)]decan-2-ol	dopamine reuptake inhibitor	depression
NS 2200		dopamine reuptake inhibitor	Parkinson disease; depression; addiction
OPC 14117	N-(2,3-dihydro-7- hydroxy-2,2,4,6- tetramethyl-1H- inden-1-yl)-4-(3- methoxyphenyl)-1- piperazineacetamide	free radical scavenger	neurological depression
GABA-based depression therapy,		GABA agonist	depression
CGP 35348	(3- aminopropyl)(diethox- ymethyl)phosphinic acid	GABA antagonist	depression
Suritozole; MDL 26479	2,4-dimethyl-5-(3- fluorophenyl)-3H- 1,2,4-triazole-3- thione	GABA inverse agonist	depression; cognitive defect
Valproate semisodium; divalproex sodium; semisodium valproate; AB 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA receptor	epilepsy; migraine; schizophrenia; depression

Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	GABA release; analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
BN 50043	N-allyl N-isopropyl (p-chlorophenyl-4- piperidino)-2- acetamide hydrochloride	Imipramine binding site	depression
L 671776	3',4',4'a,5',6',7',8',8'a- octahydro-4,6'- dihydroxy-6- (hydroxymethyl)- 2',5',5',8'a- tetramethylspiro[benz ofuran-2(3H),1'(2'H)- naphthalene]-5- carboxaldehyde	inositol monophosphatase inhibitor	depression
Befloxatone; MD 370503	(R)-5- (methoxymethyl)-3- (p-((R)-4,4,4- trifluoro-3- hydroxybutoxy)phenyl)-2-oxazolidinone	MAO A inhibitor; MAO inhibitor	depression; anxiety; nicotine withdrawal
Brofaromine; CGP 11305A; CONSONAR	4-(7-bromo-5- methoxy-2- benzofuranyl)piperidine	MAO A inhibitor; MAO inhibitor	depression
BW 1370U87	1-ethylphenoxathiin 10,10-dioxide	MAO A inhibitor; MAO inhibitor	depression; anxiety
CS 8359; RS 8359	(+,-)-4-[(6,7-dihydro- 7-hydroxy-5H- cyclopentapyrimidin- 4- yl)amino]benzonitrile	MAO A inhibitor; MAO inhibitor	depression
E 2011	[R-(R*,S*)]-gamma- hydroxy-6-[5- (methoxymethyl)-2- oxo-3-oxazolidinyl]- 2- benzothiazolebutanenitrile	MAO A inhibitor; MAO inhibitor	depression

Esuprone; LU 43839	ethanesulfonic acid 3,4-dimethyl-2-oxo- 2H-1-benzopyran-7- yl ester	MAO A inhibitor; MAO inhibitor	depression
Moclobemide; Ro 111163; Ro 111163/000; AURORIX; MANERIX; ACUILIX; MOCLAMINE	4-chloro-N-[2-(4- morpholinyl)ethyl]be nzamide	MAO A inhibitor; MAO inhibitor	depression
Pirlindole; pyrasidol; pyrazidol; pyrazidole; LIFRIL; PYRAZIDOL; EUTHYM	2,3,3a,4,5,6- hexahydro-8-methyl- 1H-pyrazino[3,2,1- jk]carbazole	MAO A inhibitor; MAO inhibitor	depression
Drug delivery system, controlled release selegiline; selegiline		MAO B inhibitor; MAO inhibitor	depression
Drug delivery system, transdermal selegiline; selegiline transdermal		MAO B inhibitor; MAO inhibitor	Alzheimer disease; depression
MDL 72145	(E)-(beta- fluoromethylene)-3,4- dimethoxybenzeneeth anamine hydrochloride	MAO B inhibitor; MAO inhibitor	depression; Parkinson disease
KP 157		MAO inhibitor; MAO A inhibitor	depression
KP 9		MAO inhibitor; MAO A inhibitor	depression
T 794	(R)-3-[6- (cyclopropylmethoxy )-2-naphthalenyl]-5- (methoxymethyl)-2- oxazolidinone	MAO inhibitor; MAO A inhibitor	depression
SL 650477; SL 65.0477	[R-(R*,R*)]-5- (methoxymethyl)-3- [6-(4,4,4-trifluoro-3- hydroxybutoxy)-3- benzofuranyl]-2- oxazolidinone	MAO inhibitor; MAO A inhibitor; MAO B inhibitor; oxazolidinone	depression; Parkinson disease
Agomelatine; S 20098	N-[2-(7-methoxy-1- naphthalenyl)ethyl]ac etamide	melatonin agonist	depression; insomnia

Melatonin modulators; melatonin analogues		Melatonin analogues	depression; infertility
Neuropeptide Y antagonists		neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypotension; obesity; depression
RB 101	N-[2-[[[2-amino-4-(methylthio)butyl]dit hio]methyl]-1-oxo-3-phenylpropyl]-L-phenylalanine phenylmethyl ester	neutral endopeptidase inhibitor	addiction; depression
EGYT 4201	ethanesulfonic acid compd. with 5-chloro-2-(2-imino-3-thiazolidinyl)benzamine (2:1)	Nonmomoaminergic action	depression
COR 3224	4,5-dihydro-5-((4-phenyl-1-piperazinyl)methyl)-2-oxazamine	Nontricyclic action	depression
Minaprine; minaprine hydrochloride; minaprina; CB 30038; 30038 CB; AGR 1240; CANTOR; KANTOR; ALCAS; NORTIMIC; BRANTUR; ISOPULSAN	4-[2-[(4-methyl-6-phenyl-3-pyridazinyl)amino]ethyl]morpholine	Nontricyclic action	depression
Amfebutamone; bupropion hydrochloride; bupropion; bupropin; BW 323U; WELLBUTRIN; ZYBAN	(+,-)-1-(3-chlorophenyl)-2-[[1,1-dimethylethyl)amino]-1-propanone	noradrenalin reuptake inhibitor	depression; nicotine withdrawal; obesity
Beloxepin; ORG 4428	cis-2,10-dimethyl-1,2,3,4,4a,13b-hexahydrodibenz-[2,3:6,7]oxepino [4,5-c]pyridin-4a-ol	noradrenalin reuptake inhibitor	depression

Dexnafenodone; LU 43706	(S)-2-[2-(dimethylamino)ethyl]-3,4-dihydro-2-phenyl-1(2H)-naphthalenone	noradrenalin reuptake inhibitor	depression
Hydroxynortriptyline	(E)-10-11-dihydro-5-[3-(methylamino)propylidene]-5H-dibenzo-[a,d]cyclohepten-10-ol	noradrenalin reuptake inhibitor	depression
Drug delivery system, sustained release milnacipran; milnacipran sustained release		noradrenalin reuptake inhibitor; 5HT reuptake inhibitor	depression
Milnacipran; midalcipran; midacipran; F 2207; TN 912; DALCIPRAN; IXEL	cis-(+,-)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide	noradrenalin reuptake inhibitor; 5HT reuptake inhibitor	depression
1555; 1555U88; BW 1555U88	[2S-(2alpha,3alpha,5alpha)]-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol hydrochloride	noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	attention deficit disorder; nicotine withdrawal; depression; psychosis
Nalmefene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
Oxytocin antagonist		oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
NS 1546		potassium channel modulator	depression
Potassium channel modulators		potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes

Igmesine; igmacine; JO 1784	(+)-N-(1,4-diphenyl-3-butenyl)-N-methylcyclopropane methanamine	sigma agonist	depression; cognitive defect; diarrhea
SA 4503	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	sigma agonist	Alzheimer disease; depression; cognitive defect; stroke
GW 273293		sodium channel blocker	epilepsy; depression
Lamotrigine; BW 430C; LAMICTAL	6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine	sodium channel blocker	epilepsy; psychosis; depression
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis
Sifaprazine; FI 4303	1-(2-(phenylmethyl)phenyl)-4-methylpiperazine hydrochloride	Tricyclic antidepressant activity	depression
Antidepressant	N'-[5-[(2-chlorophenyl)methylene]-4,5-dihydro-6-methyl-3-pyridazinyl]-N,N-dimethyl-1,2-ethanediamine	Unknown	depression
Antidepressant, PPRT 152	St. John's Wort herbal remedy extract	Unknown	depression
ATX 70	(SP-4-2)-[[N,N'-[[[7,12-bis[1-(decyloxy)ethyl]-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-diyl-kappaN21,kappaN22,kappaN23,kappaN24]bis(1-oxo-3,1-propanediyl)]bis[L-aspartato]](6-)]gallate (3-) trihydrogen	Unknown	depression; cancer
Bipenamol; BW 647U	2-[[2-(aminomethyl)phenyl]thio]benzenemethanol	Unknown	depression



BW 403U76		Unknown	depression
CGP 25454		Unknown	depression
CS 2232		Unknown	depression
Delfaprazine; FI 4310	1-(alpha2-phenyl-2,5-xyl-yl)-piperazine	Unknown	depression
Depression therapy		Unknown	depression
E 5505		Unknown	depression
ORG 12437		Unknown	depression
ORG 20091	5-chloro-4-(1,2,5,6-tetrahydro-1-methyl-3-pyridinyl)-2-thiazolamine (Z)-2-butenedioate (2:1)	Unknown	depression
YKP 10A		Unknown	depression
DGAVP; ORG 5667	8-L-arginine-9-deglycinamidevasopressin	Vasopressin	depression
Vasopressin antagonist,		vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure

Table 29. Current Candidate Therapeutic Interventions for the Treatment of Epilepsy

Product Name	Chemical Name	Action	Indication
MMPQ; SRC 820; SRC 820R	2-methyl-3-(3-methyl-2-pyridinyl)-4(3H)-quinazolinone	5HT neuromodulation	epilepsy
Adenosine regulating agents, epilepsy	Unspecified	adenosine regulating agent	epilepsy
Adenosine utilization inhibitors, epilepsy	Unspecified	adenosine regulating agent	epilepsy
GP 3269; GP 13269	7-(5-deoxy-beta-D-ribofuranosyl)-N-(4-fluorophenyl)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine	adenosine regulating agent	epilepsy
SNAP 5114	1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-3-piperidinecarboxylic acid	amine uptake inhibitor	epilepsy; anxiety; insomnia

LY 215490	(3alpha,4alpha,6beta,8alpha)-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid	AMPA antagonist; glutamate antagonist	epilepsy
LY 293558	[3S-(3alpha,4alpha,6beta,8alpha)]-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid	AMPA antagonist; glutamate antagonist	heart ischemia; epilepsy
SYM 2189	Unspecified	AMPA antagonist; glutamate antagonist	stroke; epilepsy
SYM 2206	8-(4-aminophenyl)-5-methyl-N-propyl-1,3-dioxolo[4,5-g]phthalazine-6(5H)-carboxamide	AMPA antagonist; glutamate antagonist	stroke; epilepsy
Pregabalin; CI 1008; PD 144723	(S)-3-(aminomethyl)-5-methyl-hexanoic acid	analgesic	epilepsy; pain
mu-conopeptides	Unspecified	analgesic; peptide; sodium channel blocker	pain; epilepsy
ADD 196022	4-[(4-chlorophenyl)amino]-6-methyl-2-oxo-3-cyclohexene-1-carboxylic acid methyl ester	Antiepileptic agent with unspecified mechanism of action	epilepsy
ADD 55051	4-chlorobenzenesulfonamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
AHN 649	(9alpha,13alpha,14alpha)-17-methyl-morphinan-3-amine	Antiepileptic agent with unspecified mechanism of action	epilepsy; neuropathy
Ameltolide; LY 201116; ADD 75073	4-amino-N-(2,6-dimethylphenyl)benzamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
Anticonvulsant	(R)-7-[1-(4-chlorophenoxy)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidine	Antiepileptic agent with unspecified mechanism of action	epilepsy

Anticonvulsants	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptic	4-phenoxy-2-(4-propyl-1-piperazinyl)quinazoline	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptic	(S)-2-amino-4,5-dihydro-5-(2-methylpropyl)-4-oxo-1H-imidazole-1-carboxylic acid phenylmethyl ester	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptics	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
B 974	N-(alpha,alpha,alpha-trifluoro-m-tolyl)piperazino-2-acetamido-4-methylthiazole	Antiepileptic agent with unspecified mechanism of action	epilepsy
Benzoidazoxan	6,7-benzoidazoxan	Antiepileptic agent with unspecified mechanism of action	epilepsy
Carabersat; SB 204269; SB 204269EO	(3R-trans)-N-(6-acetyl-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-4-fluorobenzamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
CGS 18416	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
CHF 2993	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
CHF 3381	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
D 20443	[2-amino-4-[[[4-fluorophenyl)methyl]amino]phenyl]carbam ic acid ethyl ester dihydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy

D 2624	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Endixaprine; SR 41378	1-[6-(2,4-dichlorophenyl)-3-pyridazinyl]-4-piperidinol	Antiepileptic agent with unspecified mechanism of action	epilepsy
F 721	5-[4-(trifluoromethyl)phenyl]-3-(diethylamino)-2,2-dimethylpropyl 2-furancarboxylic acid ester hydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy
FCE 23819	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Harkoseride; ADD 234037	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Lodaxaprine; CM 40907	1-(6-(2-chlorophenyl)-3-pyridazinyl)-4-piperidinol	Antiepileptic agent with unspecified mechanism of action	epilepsy
Loreclezole; R 72063	(Z)-1-[2-chloro-2-(2,4-dichlorophenyl)ethenyl]-1H-1,2,4-triazole	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 193453	Amelotide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 228721	Bentamide amelotide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 274959	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
MS 16056	1-(3-phenyl-5-isoxazolyl)-3-(1-imidazolyl)-methyldole hydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy
NPS 1776	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy

Oxcarbazepine; CGP 47680; KIN 493; GP 47680; TRILEPTAL; TOXECAR	10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide	Antiepileptic agent with unspecified mechanism of action	epilepsy; diabetes; neuropathy
Ro 70213	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
RWJ 37868	2-(4-chlorobenzoyl)-4-[(1-piperidiny)acetyl]-1,3,5-trimethylpyrrole	Antiepileptic agent with unspecified mechanism of action	epilepsy
RX 751067	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
SL 900571	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Soretolide; D 2916	2,6-dimethyl-N-(5-methyl-3-isoxazolyl)benzamide; aryl-isoxazole carboxamide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
Stiripentol; BCX 2600	4,4-dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol	Antiepileptic agent with unspecified mechanism of action	epilepsy
TV 141	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
TV 1901	Unspecified	Antiepileptic agent with unspecified mechanism of action	Epilepsy
Clobazam; HR 376; H 4723; LM 2717; NH 15; FRISIUM; CLIDIZAN; GRIFOCLOBAM; URBADAM; FRISIN; URBANYL; URBANIL; MYSTAN	7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione	benzodiazepine	anxiety; epilepsy
GYKI 52466	1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine	benzodiazepine	epilepsy

Midazolam; Ro 213981/001; Ro 213981/003; HYPNOVEL; VERSED; DORMICUM	8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine	benzodiazepine	anxiety; epilepsy
Ro 417812	Unspecified	benzodiazepine	epilepsy
Ro 428773	Unspecified	benzodiazepine	epilepsy
FG 8205; L 663581	7-chloro-4,5-dihydro-5-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	epilepsy; anxiety
CNS 1067	Unspecified	calcium antagonist	epilepsy
U 54494A	cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)cyclohexyl]benzamide monohydrochloride	calcium antagonist	epilepsy
NPS 846	Unspecified	calcium antagonist; analgesic	stroke; epilepsy; pain
Flunarizine; R 14950; FLUZINA; SIBELIUM; ZINASEN; SESNARBO; RIZENA; SINAZINE; HEADACHE; FLORIRATO; DIESPRUDEL	Unspecified	calcium antagonist; vasodilator	peripheral vascular disease; cerebrovascular disease; migraine; epilepsy
CNS 2103	Unspecified	calcium antagonist; venom	epilepsy
CPC 8027	Unspecified	calcium channel blocker	stroke; epilepsy
CPC 8029	Unspecified	calcium channel blocker	stroke; epilepsy
NS 696	Unspecified	calcium channel blocker	epilepsy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia

DP 16	Acylglycerol derivative of BAPTA	Calcium chelation	epilepsy; stroke; heart ischemia
AO 78	Tetronic acid derivative, unspecified	Calcium ion modulator	epilepsy
Topiramate; KW 6485; McN 4853; RWJ 17021; TOPAMAX	2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate	carbonate dehydratase inhibitor; sodium channel blocker; AMPA antagonist; GABA agonist; glutamate antagonist	epilepsy; psychosis; depression
Losigamone; AO 33	5-[(2-chlorophenyl)hydroxymethyl]-4-methoxy-2(5H)-furanon; tetronic acid derivative	Chloride ion influx by GABA sensitive mechanism at a site distant from GABA	epilepsy
Levetiracetam; etiracetam, (S); UCB L059 (S); SIB S1 (S); UCB L060 (R); UCB 6474 (no stereo, etiracetam)	(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide	cholinergic agonist	epilepsy
Dopamine D4 receptor ligands	Unspecified	dopamine antagonist; dopamine D4 antagonist	attention deficit disorder; epilepsy; addiction
ADD 17014	4-[1-(4-chlorophenyl)-4,5-dihydro-1H-1,2,3-triazol-5-yl]pyridine	excitatory amino acid antagonist	epilepsy
Excitatory amino acid antagonists	Unspecified	excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
NPC 18123	Unspecified	excitatory amino acid antagonist; glutamate antagonist	epilepsy; stroke
Dezinamide; AN 051; AHR 11748; ADD 94057	3-[(3-trifluoromethyl)phenoxy]-1-azetidinecarboxamide (desmethyl metabolite of fluzinamide)	Fluzinamide derivative	epilepsy
1-decypyrrolidinone	1-decanoyl-2-pyrrolidinone	GABA agonist	epilepsy
1-dodecypyrrolidinone	1-dodecanoyl-2-pyrrolidinone	GABA agonist	epilepsy

GABA agonist, XR 368 series	(2aR*,5aR,7E,11E,14aS*,14bS*,14cS*)-2a,5a,6,9,10,13,14,14a,14b,14c-decahydro-4-hydroxy-5a,9,9,12-tetramethyl-1,5-dioxacyclopenta[cd]cycloundec[f]inden-3(2H)-one	GABA agonist	anxiety; epilepsy
Ganaxolone; CCD 1042	(3alpha,5alpha)-3-hydroxy-3-methylpregnan-20-one	GABA agonist	epilepsy; migraine
MDL 27192	5-(4-chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one	GABA agonist	epilepsy
PD 144550	(R)-3-(aminomethyl)-5-methylhexanoic acid	GABA agonist	epilepsy
R 7621	N1-(3-trifluoromethylphenyl)N2-nicotinoyl piperazine hydrochloride	GABA agonist	epilepsy
Vigabatrin; gamma vinyl GABA; GVG; RMI 71754; MDL 71754; RMI 71890; RMI 71894; SABRIL; SABRILEX	4-amino-5-hexenoic acid	GABA agonist	epilepsy; addiction
ZK 95962; ZK 45962	ethyl 5-isopropoxy-4-methoxymethyl-beta-carboline-3-carboxylate	GABA agonist	epilepsy; cognitive defect
Milacemide; CP 15525; CP 1552S	2-(pentylamino)acetamide	GABA agonist; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease
CGP 36742	(3-aminopropyl)butylphosphinic acid	GABA antagonist	epilepsy; Alzheimer disease
Rufinamide; CGP 33101; RUF 331	1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide	GABA antagonist	epilepsy



Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	GABA modulation	epilepsy; anxiety; pain; neuropathy; psychosis; depression
NNC 138119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine; benzodiazepine derivative	GABA modulation	epilepsy; anxiety
AWD 131138; AWD 131-138	1-(4-chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one	GABA modulator	epilepsy; anxiety
Co 21068	(3 $\alpha$ ,5 $\beta$ )-3-[(4-acetylphenyl)ethynyl]-21-(3-carboxy-1-oxopropoxy)-3-hydroxypregnan-20-one sodium salt	GABA modulator	epilepsy
NNC 140189	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-5-(4-methyl-1-piperazinyl)-imidazo[1,5-a]quinazoline	GABA modulator	epilepsy
NS 2552	Unspecified	GABA modulator	anxiety; epilepsy
NS 2608	Unspecified	GABA modulator	epilepsy; anxiety
NS 2664	Unspecified	GABA modulator	epilepsy
Retigabine; D 23129; GKE 841	[2-amino-4-[(4-fluorophenyl)methyl]amino]phenyl]carbamic acid ethyl ester	GABA modulator; potassium channel activator	epilepsy
Co 21970	(3 $\alpha$ ,5 $\alpha$ )-3-hydroxy-3-(trifluoromethyl)-pregnan-20-one	GABA partial agonist; neuroactive steroid	epilepsy
Valproate magnesium; magnesium valproate; DEPAMAG; VALPAMAG	2-propylpentanoic acid magnesium salt	GABA release	epilepsy

Valproate semisodium; divalproex sodium; semisodium valproate; ABBOTT 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA release	epilepsy; migraine; schizophrenia; depression
Valproate sodium; sodium valproate; NIK 240; SENITA; SELENICA	2-propylpentanoic acid sodium salt	GABA release	Alzheimer disease; epilepsy
CI 966	1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid	GABA uptake inhibitor	epilepsy
NNC 711	1,2,5,6-tetrahydro-1-[2-[[[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxylic acid monohydrochloride	GABA uptake inhibitor	epilepsy
Tiagabine; tiagabine hydrochloride; NO 050328; A 70569; NO 328; NNC 050328; NNC 328; NN 301; ABT 569; GABITRIL; TIABIX	(R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid	GABA uptake inhibitor	epilepsy
3-isobutyl GABA	3-(aminoethyl)-5-methylhexanoic acid	GAD modulation, L-glutamic acid decarboxylase	Epilepsy
SNAP 5294	Unspecified	GAT1 transporter	epilepsy; anxiety; insomnia
SNAP 5258	Unspecified	GAT3 transporter	epilepsy; anxiety; insomnia
NNC 079202; FG 9202	1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo(f)quinoxaline-7-sulfon amide	glutamate antagonist	epilepsy; stroke

Talampanel; LY 300164	(R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine	glutamate antagonist; AMPA antagonist	epilepsy; amyotrophic lateral sclerosis
Excitatory amino acid antagonists	Unspecified	glutamate antagonist; excitatory amino acid antagonist; NMDA antagonist	epilepsy; neurodegeneration
CNS 2	Unspecified	glutamate antagonist; mGluR antagonist	epilepsy
NPS 2390	Unspecified	glutamate antagonist; mGluR antagonist	pain; epilepsy
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
Dizocilpine; dizocilpine maleate; MK 801	(+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
drug delivery system, felbamate; felbamate drug delivery system	unspecified	glutamate antagonist; NMDA antagonist	epilepsy
Felbamate; W 554; ADD 03055; FELBATOL; FELBAMYL; TALOXIA	2-phenyl-1,3-propanediol dicarbamate	glutamate antagonist; NMDA antagonist	epilepsy
GPI 3000; NPC 17742	[1R-[1alpha(R*),2alpha]]-alpha-amino-2-(2-phosphonoethyl)cyclohexane propanoic acid	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
L 701324	7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-2(1H)-quinolinone	glutamate antagonist; NMDA antagonist	epilepsy; stroke
MDL 27266	5-(4-chlorophenyl)-4-ethyl-2,4-dihydro-2-methyl-3H-1,2,4-triazol-3-one	glutamate antagonist; NMDA antagonist	epilepsy
RPR 118723	Unspecified	glutamate antagonist; NMDA antagonist	epilepsy

YKP 509	Unspecified	glutamate antagonist; NMDA antagonist	epilepsy
Metabotropic glutamate receptor modulators	Unspecified	Glutamate receptor modulation	pain; cognitive defect; schizophrenia; epilepsy
CNS 1145	N,N'-bisacenaphth-5- ylguanidine	glutamate release inhibitor	epilepsy
glycine transporter modulator	Unspecified	glycine antagonist	epilepsy; cognitive defect
MDL 100458	3- (benzoylmethylamino ) -6-chloro-1H-indole- 2-carboxylic acid	glycine antagonist	epilepsy
L 687414	(3R-cis)-3-amino-1- hydroxy-4-methyl-2- pyrrolidone	glycine partial agonist	epilepsy
hBGT1 transporter modulator	Unspecified	hBGT1 transporter modulator	epilepsy; anxiety; insomnia
AQ 0145	4-[1-[(adamant-3- yl)iminomethyl]piperi din-4-yl]imidazole	histamine antagonist; histamine H3 antagonist	epilepsy
m-NBA	2-amino-3-(3- nitrobenzoyl)propano ic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
FCE 26743	(S)-2-[[[4-[(3- fluorophenyl)methox y]phenyl]methyl]ami no]propanamide	MAO B inhibitor; MAO inhibitor	epilepsy
Remacemide, (-); FPL 14145; PR 1032646; PR 1032- 646	(-)-2-amino-N-(1- methyl-1,2- diphenylethyl)acetam ide	NMDA antagonist	epilepsy
NMDA antagonists	Unspecified	NMDA antagonist; analgesic; glutamate antagonist	epilepsy; pain; brain ischemia
ACEA 1011	Unspecified	NMDA antagonist; glutamate antagonist	ischemia; epilepsy
CGP 37849	(E)-(+,-)-2-amino-4- methyl-5-phosphono- 3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy
CGP 39551	(E)-(+,-)-2-amino-4- methyl-5-phosphono- 3-pentenoic acid 1- ethyl ester	NMDA antagonist; glutamate antagonist	epilepsy

CGP 40116	[R-(E)]-2-amino-4-methyl-5-phosphono-3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy; stroke
D-CPP	(R)-4-(3-phosphonopropyl)-2-piperazinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
FR 115427	(+)-1-methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride	NMDA antagonist; glutamate antagonist	epilepsy
L 701252	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy
L 703717	7-chloro-4-hydroxy-3-[3-(4-methoxyphenyl)methyl]phenyl]-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy; stroke
L 708541	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy; stroke
LY 233536	(3R-(3 $\alpha$ ,4 $\alpha$ ,6 $\beta$ ,8 $\alpha$ ))-decahydro-6-(1H-tetrazol-5-ylmethyl)-3-isoquinolinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
LY 235723	(2R-cis)-4-(1H-tetrazol-5-ylmethyl)-2-piperidinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
LY 274614	(3 $\alpha$ ,4 $\alpha$ ,6 $\beta$ ,8 $\alpha$ ))-decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy
MDL 100453	4-oxo-5-phosphono-D-norvaline	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy; stroke
MDL 104653	7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy

MDL 105519	(E)-3-(2-carboxy-2-phenylethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid	NMDA antagonist; glutamate antagonist	anxiety; epilepsy
MDL 29814	5,7 dichlorokynurenic acid	NMDA antagonist; glutamate antagonist	epilepsy
NMDA antagonist	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy; stroke; neuropathy
NPS 1387	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
RPR 104632; RPR 110754	2-[(3-bromophenyl)methyl]-6,8-dichloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-3-carboxylic acid 1,1-dioxide	NMDA antagonist; glutamate antagonist	epilepsy
ACEA 1416; NMCQX	5-nitro-6-methyl-7-chloro-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	epilepsy; pain; brain ischemia
Conantokins	Unspecified	NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia
ADCI; SGB 017; ADCI	10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine-5-carboxamide	NMDA antagonist; glutamate antagonist; sodium channel blocker	epilepsy; stroke
oxytocin antagonist	Unspecified	oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
Conantokin G	Unspecified	peptide; glutamate antagonist; NMDA antagonist	stroke; brain ischemia; epilepsy

Fosphenytoin; fosphenytoin sodium; prophenytoin; ACC 9653; CI 982; PD 135711-15B; CEREBYX; PRO-EPANUTIN	5,5-diphenyl-3-[[ (phosphonooxy)methyl]-2,4-imidazolidinedione	Phenytoin prodrug; fosphenytoin converted to phenytoin by endogenous phosphatases	epilepsy
proline transport inhibitors	Unspecified	Proline transporter inhibitor	epilepsy; stroke
JNK 3 inhibitors	Unspecified	signal transduction inhibitor	epilepsy
Zonisamide; fenisoxine; AD 810; CI 912; PD 110843; EXCEGRAN; EXEGRAN; ZONEGRAN	1,2-benzisoxazole-3-methansulfonamide	Sodium and calcium voltage sensitive channel blockade	epilepsy
534U87; BW 534U87	Unspecified	sodium channel blocker	epilepsy
AWD 140190	4-(4-bromophenyl)-3-(4-morpholinyl)-1H-pyrrole-2-carboxylic acid, methyl ester	sodium channel blocker	epilepsy
Co 102862	2-[[4-(4-fluorophenoxy)phenyl]methylene]hydrazinecarboxamide	sodium channel blocker	epilepsy
GW 273293	Unspecified	sodium channel blocker	epilepsy; depression
Lamotrigine; BW 430C; LAMICTAL	6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine	sodium channel blocker	epilepsy; psychosis; depression
PNU 151774E	(2S)-2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]propanamide monomethanesulfonate	sodium channel blocker; calcium channel blocker; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease; brain ischemia
taurine transporter modulator	Unspecified	Taurine transporter inhibitor	epilepsy; brain ischemia
MDL 27531	4-methyl-3-(methylsulphonyl)-5-phenyl-4H-1,2,4-triazole	triazole	epilepsy

A 76895; ABBOTT 76895	Unspecified	Valproic acid derivative	epilepsy
Anticonvulsants	Unspecified	Valproic acid derivative	epilepsy
Antiepileptics	Unspecified	Valproic acid derivative	epilepsy
CHF 1504	Unspecified	Valproic acid derivative	epilepsy
RAP-valproic acid; DP VPA	Unspecified	Valproic acid derivative	epilepsy
ABS 103; ABS-103R	Unspecified	Valproic acid derivative	epilepsy
CHF 1355	Unspecified	Valproic acid derivative	epilepsy
Vasopressin antagonist	Unspecified	vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure

Table 30. Current Candidate Therapeutic Interventions for the Treatment of Huntington's Disease

Product Name	Chemical Name	Action	Indication
Neurodegenerative disease therapy	Unspecified	apoptosis inhibitor	Neurodegeneration
Brain-derived neurotrophic factor; BDNF;	BDNF, and derivatives	BDNF, growth factor; neurotrophic factor	amyotrophic lateral sclerosis; neuropathy
Dopamine release inhibitor	Unspecified	Calcium antagonist	schizophrenia
Cardiotrophin-1 secreting implant; cardiotrophin-1 secreting implant	Cardiotrophin-1 and derivatives	Cardiotrophin-1; growth factor	amyotrophic lateral sclerosis; neurodegeneration
Tacrine; THA; tetrahydroaminacrine; CI 970; COGNEX	1,2,3,4-tetrahydro-9-acridinamine	cholinesterase inhibitor	Alzheimer disease
AXOKINE	Ciliary neurotrophic factor derivative	CNTF, growth factor	amyotrophic lateral sclerosis; obesity; eye disease
Ciliary neurotrophic factor; CNTF; CNTF delivery system	CNTF and derivatives	CNTF, growth factor	amyotrophic lateral sclerosis; neuropathy



Estrogens	Estrogen and derivatives	estrogen	neuropathy; Alzheimer disease
SYM 2101	Unspecified	glutamate agonist; AMPA partial agonist	neurological
SYM 2250	Unspecified	glutamate agonist; AMPA partial agonist	neurological
SYM 2007	Unspecified	glutamate agonist; kainate partial agonist	neurological
SYM 2192	Unspecified	glutamate agonist; kainate partial agonist	neurological
SYM 1010	Unspecified	glutamate agonist; NMDA partial agonist	neurological
SYM 2315	Unspecified	glutamate agonist; NMDA partial agonist	neurological
Riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
MAB, major histocompatibility complex I; F(ab') <sub>2</sub> , MHC I	Monoclonal antibody fragment	Immunomodulation	transplant rejection
Nerve growth factor secreting implant	NGF and derivatives	NGF, growth factor	Neurodegeneration; neuropathy
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
Idebenone; CV 2619; AVAN; LUCEBANOL; GENICERAL; MNESIS; DARUMA; NEMOCEBRAL; KEDANON; ARZKAT; DAYSTROM	2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione	Nootropic agent	cognitive defect
Neurotrophin-3 secreting implant	NT-3 and derivatives	NT-3, growth factor	Alzheimer disease; Parkinson disease; neuropathy
Neurotrophin-4; NT-4	NT-4 and derivatives	NT-4, growth factor	neuropathy; diabetes

Nalmefene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)- 4,5alpha-epoxy-6- methylenemorphinan- 3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
Synthetic opioid alkaloids	Unspecified	Opioid ligand	Neurodegeneration

Table 31. Current Candidate Therapeutic Interventions for the Treatment of Migraine

Product Name	Chemical Name	Action	Indication
ALX 0646	Unspecified	5HT agonist	migraine
CP 122288	(R)-N-methyl-3-[(1-methyl-2-pyrrolidiny)methyl]-1H-indole-5-methanesulfonamide	5HT agonist	migraine
IS 159	Unspecified	5HT agonist	migraine
avatriptan; avatriptan fumarate; BMS 180048; BMS 18004802	3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-N-methyl-1H-indole-5-methanesulfonamide	5HT agonist; 5HT1 agonist	migraine
BW 324C91	Unspecified	5HT agonist; 5HT1 agonist	migraine
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
D 1997	2-quinolineethanamine	5HT agonist; 5HT1 agonist	migraine
GR 127607	Unspecified	5HT agonist; 5HT1 agonist	migraine
GR 40370	Unspecified	5HT agonist; 5HT1 agonist	migraine

Naratriptan; naratriptan hydrochloride; GR 85548; GR 85548A; GR 85548X; NARAMIG; AMERGE	N-methyl-3-(1- methyl-4- piperidiny)-1H- indole-5- ethanesulfonamide	5HT agonist; 5HT1 agonist	migraine
Sumatriptan; GR 43175; GR 43175X; GR 43175A; GR 43175C; SN 308; GW 102; IMIGRAN; IMITREX; SUMADOL; IMIJECT; ARCOIRAN	3-[2- (dimethylamino)ethyl ]-N-methyl-1H- indole-5- methanesulfonamide	5HT agonist; 5HT1 agonist	migraine
tonabersat; SB 220453	(3S-cis)-N-(6-acetyl- 3,4-dihydro-3- hydroxy-2,2- dimethyl-2H-1-benz pyran-4-yl)-3-chloro- 4-fluorobenzamide	5HT agonist; 5HT1 agonist	migraine
CP 93129	1,4-dihydro-3- (1,2,3,6-tetrahydro-4- pyridinyl)-5H- pyrrolo[3,2-b]pyridin- 5-one	5HT agonist; 5HT1B agonist	migraine
Frovatriptan; VML 251; SB 209509; MIGUARD	(R)-2,3,4,9- tetrahydro-3- (methylamino)-1H- carbazole-6- carboxamide	5HT agonist; 5HT1B agonist; 5HT1D agonist	migraine
rizatriptan; rizatriptan benzoate; rizatriptan sulfate; MK 462; MAXALT	N,N-dimethyl-5-(1H- 1,2,4-triazol-1- ylmethyl)-1H-indole- 3-ethanamine	5HT agonist; 5HT1B agonist; 5HT1D agonist	migraine
Almotriptan; LAS 31416	1-[[[3-[2- (dimethylamino)ethyl ]-1H-indol-5- yl]methyl]sulfonyl]py rrolidine	5HT agonist; 5HT1D agonist	migraine

alniditan; R 91274; PASMIGREN; PASMIGRINE	(R)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine	5HT agonist; 5HT1D agonist	migraine
ALX 1323	Unspecified	5HT agonist; 5HT1D agonist	migraine
aromatic triflates,	Unspecified	5HT agonist; 5HT1D agonist	depression; migraine
eletriptan; UK 116044; RELPAX	(R)-3-[(1-methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole	5HT agonist; 5HT1D agonist	migraine
GMC 2020	Unspecified	5HT agonist; 5HT1D agonist	depression; migraine
GMC 2021	Trifluoromethanesulfonic acid 3-[2-(dimethylamino)ethyl]-1H-indol-5-yl ester (1:1) ethanedioate	5HT agonist; 5HT1D agonist	depression; migraine
L 741519	3-(1-methyl-4-piperidinyl)-5-(4H-1,2,4-triazol-4-yl)-1H-indole	5HT agonist; 5HT1D agonist	migraine
L 741604	N,N-dimethyl-5-(4H-1,2,4-triazol-4-yl)-1H-indole-3-ethanamine	5HT agonist; 5HT1D agonist	migraine
LAS 31727	Unspecified	5HT agonist; 5HT1D agonist	migraine
VS 395	3-[3-[4-(5,6-dimethoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-N-methyl-1H-indole-5-methanesulfonamide	5HT agonist; 5HT1D agonist	migraine

F 11356; L 0076	1-[[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]-4-(4-cyanophenyl)piperazine monohydrochloride	5HT agonist; 5HT1D agonist; 5HT1B agonist	migraine
Zolmitriptan; 311C90; BW 311C90; ZOMIG	(S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone	5HT agonist; 5HT1Dalpha agonist; 5HT1Dbeta agonist; 5HT1B agonist	migraine
LY 334370	4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide	5HT agonist; 5HT1F agonist	migraine
selective serotonin 1F receptor agonists,	Unspecified	5HT agonist; 5HT1F agonist	migraine
Sergolexole; LY281067	trans-4-methoxycyclohexyl 1-isopropyl-6-methylergoline-8beta-carboxylate	5HT antagonist; 5HT2 antagonist	migraine
tropoxin	O-(3,4,5-trimethoxybenzoyl)oxime-8-methyl-8-azabicyclo[3.2.1]octan-3-one monohydrochloride	5HT antagonist; 5HT2 antagonist	migraine
dotarizine; FI 6026	1-(diphenylmethyl)-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist; calcium antagonist	migraine
Bemesetron; MDL 72222	3,5-dichlorobenzoic acid, endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester	5HT antagonist; 5HT3 antagonist	emesis; migraine
LY 53857	(8beta)-6-methyl-1-(1-methylethyl)ergoline-8-carboxylic acid 2-hydroxy-1-methylpropyl ester,(Z)-2-butenedioate (1:1)	5HT antagonist; vasodilator	migraine

fluoxetine, (R)-; (R)-fluoxetine	(R)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	5HT reuptake inhibitor	migraine; cognitive defect; depression
fluoxetine, (S)-; (S)-fluoxetine	(S)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	5HT reuptake inhibitor	migraine
5HT4 human neuroreceptor; neuroreceptor, 5HT4	Unspecified	5HT4 human neuroreceptor;	Irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
drug delivery system, transdermal lidocaine; PAINtrol TW; PAINtrol HM; PAINtrol TV	unspecified	analgesic	pain; migraine
CNS 5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine monohydrochloride	analgesic; NMDA antagonist; glutamate antagonist	pain; migraine; neuropathy
nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET; LOBIVON	[2R*[R*[R*(S*)]]]-alpha,alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator; vasodilator	hypertension; migraine; heart failure
drug delivery system, intranasal propranolol; propranolol intranasal; MIGRASTAT	Unspecified	beta adrenergic antagonist; beta2 adrenergic antagonist	migraine
Bradykinin antagonist/mu agonist,	Unspecified	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	Inflammation; pain; migraine

calcitonin gene-related peptide (CGRP) receptor modulators,	Unspecified	Calcitonin gene related peptide modulation	migraine; diabetes
Nimodipine; BAY e 9736; BAY N 5248; BAY N 5427; NIMOTOP; NIMOTAP; NIVAS; TROPOCER; EUGERIAL; NIMODILAT; CEBROFORT; KENESIL; GENOVOX	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester	calcium antagonist	migraine; cognitive defect; Alzheimer disease; brain ischemia
Flunarizine; R 14950; FLUZINA; SIBELIUM; ZINASEN; SESNARBO; RIZENA; SINAZINE; HEADACHE; FLORIRATO; DIESPRUDEL	Unspecified	calcium antagonist; vasodilator	peripheral vascular disease; cerebrovascular disease; migraine; epilepsy
Lomerizine; KB 2796; TERRANAS TAB; MIGSIS	1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine	calcium antagonist; vasodilator	hypertension; migraine
BIBN 4096	Unspecified	CGRP antagonist	migraine
botulinum toxin type A; Clostridium botulinum toxin type A; OCULINUM; BOTOX	botulin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease; migraine
Ganaxolone; CCD 1042	(3 $\alpha$ ,5 $\alpha$ )-3-hydroxy-3-methylpregnan-20-one	GABA agonist	epilepsy; migraine
valproate semisodium; divalproex sodium; semisodium valproate; ABBOTT 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA releasing agent	epilepsy; migraine; schizophrenia; depression

4991W93	Unspecified	Inflammation inhibitor	migraine
FK 888	trans-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-propyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	neurokinin antagonist	asthma; migraine
lanepitant; LY 303870	(R)-N-[2-acetyl[(2-methoxyphenyl)methyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
GR 205171	(2S-cis)-N-[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist	emesis; migraine
neutral endopeptidase; NEP	Unspecified	neutral endopeptidase; proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
nitric oxide inhibitor,	unspecified	nitric oxide inhibitor	migraine
diclofenac potassium; CGP 45840B; CATAFLAM; CATAFLAN; DICLOFEN; VOLTAREN	potassium (o-(2,6-dichloroanilino)-phenyl)acetate	NSAID	Inflammation; migraine; surgery
dapitant; RPR 100893	[3aS-[2(R*),3aalpha,4beta,7aalpha]]-octahydro-4-(2-methoxyphenyl)-2-[2-(2-methoxyphenyl)-1-oxopropyl]-7,7-diphenyl-1H-isoindol-4-ol	substance P antagonist; NSAID	asthma; inflammation; migraine



BMS 182246	Unspecified	Sumitripan-like activity	migraine
ALX 0625	Unspecified	Unspecified	migraine
BMS 181885	3-[[3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-1H-indol-5-yl]amino]-4-methyl-3-cyclobutene-1,2-dione	Unspecified	migraine
drug delivery system, solid liquid polymer, migraine therapy	Unspecified	Unspecified	migraine
migraine therapy	Unspecified	Unspecified	migraine
Parthenolide	Unspecified	Unspecified	migraine
SB 218842	Unspecified	unspecified	migraine

Table 32. Current Candidate Therapeutic Interventions for the Treatment of Multiple Sclerosis

Product Name	Chemical Name	Action	Indication
RG 13577	(4-hydroxyphenoxy)acetic acid, polymer with formaldehyde monoammoniate	angiogenesis inhibitor; FGF antagonist	restenosis; multiple sclerosis
VLA4 integrin antagonist,	unspecified	cell adhesion inhibitor; integrin antagonist; VLA 4 antagonist; NSAID	asthma; rheumatoid arthritis; multiple sclerosis
drug delivery system, corticotropin; corticotropin delivery system; drug delivery system, ACTH	Unspecified	Corticotropin; hormone	multiple sclerosis
interferon agonists,	Unspecified	cytokine agonist; NSAID	cancer; viral infection; infectious disease; multiple sclerosis
gene therapy, cytokines,	Unspecified	cytokine; immunosuppressant	autoimmune disease; rheumatoid arthritis; diabetes; multiple sclerosis

Interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
Spirogermanium; NSC 192965; SPIRO-32	8,8-diethyl-N,N-dimethyl-2-aza-8-germaspiro[4.5]decan-2-propanamine	DMARD; NSAID	malaria; multiple sclerosis; rheumatoid arthritis; cancer
SRI 62834	(+,-)- 2-[[[hydroxy[[tetrahydro-2-[(octadecyloxy)methyl]-2-furanyl]methoxy]phosphinyl]oxy]-N,N,N-trimethylethanamium, inner salt.	ether lipid	cancer; multiple sclerosis
Transforming growth factor beta 2; TGF beta2; FOVALIN; BetaKine	Unspecified	growth factor; cicatrizant	retinopathy; osteoporosis; skin ulcer; multiple sclerosis
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
neural progenitor regulatory factor	Unspecified	growth factor; peptide; neurotrophic factor	multiple sclerosis; trauma; neurodegeneration
AG 284	MHC molecule with myelin basic protein	Immunomodulation	multiple sclerosis
Multiple sclerosis therapy	Chimeric virus particles	Immunomodulation	multiple sclerosis
Oligodendroglial trophic factor; OTF	Peptide	Immunomodulation	multiple sclerosis
RecepTox-MBP	peptide; fusion toxin	Immunomodulation	multiple sclerosis

MAB, 23F2G; MAB, leukointegrin; Hu 23F2G; LeukArrest	23F2G; MAB, leukointegrin monoclonal antibody	Immunomodulation;	multiple sclerosis; cardiovascular disease; myocardial infarction; stroke
MAB, OX40-ricin A; immunotoxin OX40-ricin A	Immunotoxin monoclonal antibody;	Immunomodulation;	multiple sclerosis
MAB, alpha4beta1 integrin; AN 100226; ANTEGREN	Unspecified	Immunomodulation; monoclonal antibody	multiple sclerosis; Crohn disease; ulcerative colitis
MAB, M1	Unspecified	Immunomodulation; monoclonal antibody	trauma; multiple sclerosis
MAB, humanized, leukemia; MAB, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	Unspecified	Immunomodulation; monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
ABR 215062	Unspecified	Immunomodulator	multiple sclerosis
Glatiramer acetate; copolymer 1; COP 1; COPAXONE	L-glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)	Immunomodulator	multiple sclerosis
PA 1093	Herpes virus 6 protein derivative	Immunomodulator	multiple sclerosis
Roquinimex; LS 2616; FCF 89; LINOMIDE	1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide	immunostimulant	multiple sclerosis
AI 101	Unspecified	immunosuppressant	multiple sclerosis
AI 102	Unspecified	immunosuppressant	multiple sclerosis
Galaptin L-14-1; immunomodulatory lectin-1; IML-1	Unspecified	immunosuppressant	transplant rejection; multiple sclerosis
PEPTIMER	Unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
AI 100; MYLORAL	Unspecified	immunosuppressant	multiple sclerosis

Gusperimus; gusperimus hydrochloride; hydroxyspergualin, 15-; desoxyspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215- 1; SPANIDIN; SUPANIDIN	(+,-)-7- [(aminoiminomethyl) amino]-N-[2-[[4-[(3- aminopropyl)amino]b utyl]amino]-1- hydroxy-2- oxoethyl]heptanamid	immunosuppressant	transplant rejection; multiple sclerosis; cancer
MAb, gamma interferon, humanized; SMART anti-gamma interferon	Unspecified	immunosuppressant monoclonal antibody;	systemic lupus erythematosus; multiple sclerosis
Lymphocyte activation gene 3 protein; LAG 3 protein	Unspecified	immunosuppressant; biotechnology	transplant rejection; multiple sclerosis
MP 4	Unspecified	immunosuppressant; biotechnology; apoptosis inducer	multiple sclerosis
ATP 012; TP 12	Unspecified	immunosuppressant; biotechnology; peptide	multiple sclerosis
MAb, T cell antigen receptor; ATM 027; TM 27	Unspecified	Immunosuppressant; monoclonal antibody;	multiple sclerosis
Priliximab; MAb, humanized CD4; cM- T412; CEN 000029; CENTARA	Immunoglobulin G1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm- T412.kappa.-chain, dimer	immunosuppressant; monoclonal antibody; NSAID	multiple sclerosis; autoimmune disease; rheumatoid arthritis
Lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis

MAb, CD40 ligand; 5C8; ANTOVA	Unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
Autoimmune disease therapy,	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; multiple sclerosis; systemic lupus erythematosus
Cladribine; 2-CdA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	2-chloro-2'- deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
ZAP inhibitors, Ariad	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis
alpha4beta1 integrin antagonist	Unspecified	integrin antagonist; cell adhesion inhibitor; alpha4 beta1 integrin antagonist	multiple sclerosis
VLA-4 antagonists, inflammatory diseases; BIO 1211	N-[[4-[[[(2- methylphenyl)amino] carbonyl]amino]phen yl]acetyl]-L-leucyl-L- alpha-aspartyl-L- valyl-L-proline	integrin antagonist; VLA 4 antagonist	asthma; multiple sclerosis
Interferon beta-1a; IFN beta; AVONEX	interferon beta-1a	interferon	viral infection; multiple sclerosis; cancer
Interferon beta-1a; interferon beta; IFN- beta; REBIF	Unspecified	interferon	cancer; viral infection; multiple sclerosis; inflammatory bowel disease
Interferon beta-1b; interferon beta-serine; SH 579; ZK 157046; BETASERON; BENESERON; BETA FERON	2-166-interferon beta 1 (human fibroblast reduced)	interferon	multiple sclerosis; cancer; viral infection
Interferon tau	Unspecified	interferon	multiple sclerosis

alpha interferon, natural; OMNIFERON	Unspecified	interferon	multiple sclerosis; viral infection
Interferon beta; FRONE	Unspecified	interferon	multiple sclerosis; cancer; eye disease
Solimastat; BB 3644	(2S,3R)-3-[[1S)-2,2-dimethyl-1-(2-pyridylcarbamoyl)propyl]carbamoyl]-2-methoxy-5-methylhexanoic acid	matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor	multiple sclerosis; rheumatoid arthritis; inflammatory bowel disease; cancer
LG 21101	Unspecified	NSAID	inflammation; multiple sclerosis
NBI 116	Unspecified	NSAID	multiple sclerosis; rheumatoid arthritis
PKC-RACK interaction inhibitors,	Unspecified	NSAID, PKC-RACK interaction inhibitors	arthritis; multiple sclerosis; asthma
white blood cell migration inhibitors,	Unspecified	NSAID, white blood cell migration inhibitors,	inflammation; multiple sclerosis
Neurotactin blockers	Unspecified	NSAID; chemokine antagonist; gene	multiple sclerosis; inflammation
Lexipafant; BB 882; DO 6; GR 167089; ZACUTEX	N-methyl-N[[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-L-leucine ethyl ester	PAF antagonist	thrombosis; endotoxic shock; pancreatitis; eye disease; multiple sclerosis
Ginkgolide B; BN 52021	hexacyclic trilactone	PAF antagonist; platelet antiaggregant	thrombosis; dermatitis; asthma; multiple sclerosis; septic shock
CGP 77116	Unspecified	peptide	multiple sclerosis
Multiple sclerosis therapy	Unspecified	peptide	multiple sclerosis
Multiple sclerosis therapy	Unspecified	peptide	multiple sclerosis
Multiple sclerosis therapy	Unspecified	peptide	multiple sclerosis
NBI 114	Unspecified	peptide	multiple sclerosis
NBI 115	Unspecified	peptide	multiple sclerosis

NBI 5788; MSP 771	D-ala-L-lys-L-pro-L-val-L-val-L-his-L-leu-L-phe-L-ala-L-asp-L-ile-L-val-L-thr-L-pro-L-arg-L-thr-L-pro	peptide	multiple sclerosis
rD-mPGPtide	Unspecified	peptide; immunosuppressant	transplant rejection; multiple sclerosis
TNF receptor antagonist; TNF receptor antagonist,	Unspecified	peptide; NSAID	rheumatoid arthritis; multiple sclerosis
rolipram; ZK 62711; ME 3167; ADEO	4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone	phosphodiesterase inhibitor	cognitive defect; multiple sclerosis
SH 636	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	multiple sclerosis
drug delivery system, IPDAS fampridine; fampridine IPDAS	Unspecified	potassium channel blocker	multiple sclerosis; neuropathy
Fampridine; EL 970; AVITROL	4-pyridinamine	potassium channel blocker	multiple sclerosis
adapalene; CD 271; DIFFERINE; DIFFERIN	6-(4-methoxy-3-tricyclo[3.3.1.1(3,7)]dec-1-ylphenyl)-2-naphthalenecarboxylic acid	retinoid agonist; retinoid; RAR agonist; RARbeta agonist	acne; multiple sclerosis
drug delivery system, biodegradable micellar paclitaxel; paclitaxel micellar	Unspecified	Taxane; DMARD; NSAID; microtubule inhibitor	rheumatoid arthritis; multiple sclerosis
CC 1080	Unspecified	TNF inhibitor; NSAID	arthritis; cancer; multiple sclerosis
MNX 160	Unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; diabetes; multiple sclerosis
Thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection

Mitoxantrone; CL 232315; NSC 279836; NSC 301739; DHAQ; DHAD; NOVATRONE; NOVATRON	1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione	Topoisomerase inhibitor	cancer; multiple sclerosis
TCR peptide, multiple sclerosis	Vaccine	vaccine	multiple sclerosis
vaccine, activated T cells; vaccine, multiple sclerosis	Vaccine	vaccine	multiple sclerosis
vaccine, multiple sclerosis; vaccine, Vbeta6.2/6.5 T cell receptor; AI 208; IR 208	Vaccine	vaccine	multiple sclerosis
NBI 108	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	Alzheimer disease; infectious disease; multiple sclerosis
VCAM antagonists	Unspecified	vascular cell adhesion molecule inhibitor; NSAID	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 609	Unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 772	Unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
ZD 7349	Unspecified	VLA 4 antagonist; integrin antagonist; NSAID; cell adhesion inhibitor	multiple sclerosis; arthritis

Table 33. Current Candidate Therapeutic Interventions for the Treatment of Pain

Product Name	Chemical Name	Action	Indication
anpirtoline	4-[(6-chloro-2-pyridyl)thio]piperidine	5HT agonist; 5HT1B agonist; analgesic	pain
5HT antagonists	Unspecified	5HT antagonist; 5HT1A antagonist; analgesic	pain
SP 186	Unspecified	5HT reuptake inhibitor; analgesic	pain



AAL 13	2-[4-(3-chloropropyl)-1-piperazinyl]quinoline	5HT reuptake inhibitor; analgesic; NSAID	inflammation; pain
GR 79236	(1S-trans)-N-(2-hydroxycyclopentyl)adenosine	adenosine agonist; adenosine A1 agonist	pain; coronary artery disease
UP 20232	Unspecified	adenosine agonist; analgesic	pain; neuropathy
adenosine analogues	Unspecified	adenosine analogues analgesic	pain
analgesic adenosine regulating agents	Unspecified	adenosine regulating agent	pain
GP 1683	Unspecified	adenosine regulating agent; analgesic	pain
adrenergic alpha2 human neuroreceptors; neuroreceptors, adrenergic alpha2 human	Unspecified	adrenergic alpha2 human neuroreceptors analgesic	research tool; pain; hypertension; glaucoma
S 18616	8-chloro-3,4-dihydrospiro[naphthalene-2(1H),4'(5'H)-oxazol]-2'-amine	alpha adrenergic agonist; alpha2 adrenergic agonist; analgesic	pain
SNAP 5143	Unspecified	alpha adrenergic agonist; alpha2 adrenergic agonist; analgesic	pain; glaucoma
RWJ 52807	Unspecified	alpha2 adrenergic agonist; alpha adrenergic agonist; analgesic	pain
ABT 594	(R)-2-chloro-5-(2-azetidinylmethoxy)pyridine	analgesic	pain
analben	Unspecified	analgesic	rheumatoid arthritis; pain
analgesic,	2-phenylimidazo[2,1-b]benzothiazole-3-propanoic acid 9,9-dioxide	analgesic	pain
analgesic,	9-phenyl-9H-thioxanthen-9-ol propanoate	analgesic	pain

analgesic	N-[4-(4-methyl-2-thiazolyl)-1-[2-(1H-pyrazol-1-yl)ethyl]-4-piperidiny]N-phenylpropanamide	analgesic	pain; anesthesia
analgesic,	Unspecified	analgesic	pain
analgesic	(R)-3-amino-2,3,4,9-tetrahydrothiopyrano(2,3-b)indole	analgesic	pain
analgesic	(R)-3-methylamino-2,3,4,9-tetrahydrothiopyrano(2,3-b)indole	analgesic	pain
analgesic	(R)-3-dimethylamino-2,3,4,9-tetrahydrothiopyrano(2,3-b)indole	analgesic	pain
analgesic,	Unspecified	analgesic	pain
analgesic	5-(4-methylbenzoyl)-6-(methylthio)-1,2-dihydro-3H-pyrrolo(1,2-a)pyrrole-1-carboxylic acid	analgesic	pain
analgesics	Unspecified	analgesic	pain
Analgesics	Unspecified	analgesic	pain; neuropathy
BCH 1788	Unspecified	analgesic	pain
buprenorphine + naloxone; naloxone + buprenorphine	Unspecified	analgesic	pain
capsaicin; ZOSTRIX; ZOTRIX HP; THERAGEN; THERAGEN HP; CAPSIDOL;	(E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nononamide	analgesic	pain; neuropathy; diabetes
cizolirtine; E 4018	N,N-dimethyl-2-[(1-methyl-1H-pyrazol-5-yl)phenylmethoxy]ethanamine	analgesic	pain
D 20450	Unspecified	analgesic	pain
D 21151	1-phenoxyphthalazine	analgesic	pain
dexpemadolac; PEM 420; WAY PEM 420	(1S-cis)-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyran o[3,4-b]indole-1-acetic acid	analgesic	pain

dezocine; WY 16225; DALGAN	[5R-(5alpha,11alpha,13S*)]-13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-11-methanobenzocyclodecen-3-ol	analgesic	pain
F 9004T	Unspecified	analgesic	pain
FID 072021	3-atropanyl 2-(4-chlorophenoxy)butyrate maleate	analgesic	pain; cognitive defect
filenadol; FI 2024	(R*,S*)-(+,-)-beta-1,3-benzodioxol-5-yl-alpha-methyl-4-morpholineethanol	analgesic	pain
flubichin	Unspecified	analgesic	pain
flupirtine; D 998; W 2964M; KATADOLON	[2-amino-6-[[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]-ethyl ester, carbamic acid	analgesic	pain; neurological
gapxavanyl; DA 5018; DA 50018; KR 25018	4-(2-aminoethoxy)-N-[3-(3,4-dimethylphenyl)propyl]-3-methoxybenzeneacetamide	analgesic	pain
GW 275919	Unspecified	analgesic	pain
JTC 801	Unspecified	analgesic	pain
KR 25018	4-(2-aminoethoxy)-N-[3-(3,4-dimethylphenyl)propyl]-3-methoxybenzeneacetamide	analgesic	pain
pain therapy	Unspecified	analgesic	pain
pain therapy	Unspecified	analgesic	pain
pemedolac; AY 30715	cis-(+,-)-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyran o[3,4-b]indole-1-acetic acid	analgesic	pain
peripheral nervous system therapy	Unspecified	analgesic	pain; urinary tract disorder

phenaridine; fenaridin	N-[2,5-dimethyl-1-(2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide	analgesic	pain
pregabalin; CI 1008; PD 144723	(S)-3-(aminomethyl)-5-methyl-hexanoic acid	analgesic	epilepsy; pain
Ro 158081	Unspecified	analgesic	pain
ruzadolane; UP 2691	3-[[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]thio]-1,2,4-triazolo[4,3-a]pyridine	analgesic	pain
S 01	5,6-dihydro-9,10,14-trimethoxy-8H-1,3-dioxolo[4,5-h]isoindolo[1,2-b][3]benzazepine-8-one	analgesic	pain
S 14080	benzoyl-6 dihydro-2,3-benzothiazole	analgesic	pain
S 8117	Unspecified	analgesic	pain
sameridine; LPB 139	N-ethyl-1-hexyl-N-methyl-4-phenyl-4-piperidinecarboxamide	analgesic	local anesthesia; pain
SJ 2321	Unspecified	analgesic	pain
SYM 2081	(4R)-4-methyl-L-glutamic acid	analgesic	pain
tramadol analogues	Unspecified	analgesic	pain
UP 52204	Unspecified	analgesic	pain
V 2	Unspecified	analgesic	pain
NC 164	Unspecified	analgesic	pain
dynorphin A; dynorphin A (1-13)	Unspecified	analgesic; peptide	pain
bradykinin antagonists	Unspecified	bradykinin antagonist; analgesic; NSAID	pain; inflammation; septic shock
bradykinin antagonist/mu agonist, Cortech	Unspecified	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain; migraine

CP 0880; CP 880	N-[[3-[[1-oxo-3-[4- [(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-3-piperidinyl]propyl]amino]phenyl]acetyl]-beta-alanyl-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-N-cyclohexylglycyl-L-arginine	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain
FR 173657	(E)-3-[6-(acetylamino)-3-pyridinyl]-N-[2-[[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl-2-propenamide	bradykinin antagonist; NSAID; analgesic	asthma; inflammation; pain
NPS 846	Unspecified	calcium antagonist; analgesic	stroke; epilepsy; pain
ziconotide; SNX 111; CI 1009	omega-conotoxin MVIIA	calcium antagonist; analgesic; peptide	stroke; pain; brain ischemia
AM 336	Unspecified	calcium channel blocker; analgesic	pain
calcium channel blockers,	Unspecified	calcium channel blocker; analgesic	pain
SNX 239	Unspecified	calcium channel blocker; analgesic	pain; neuropathy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
NE 21610	(Z)-N-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-9-octadecenamide	capsaicin analogue; analgesic	pain

L 365031	4-bromo-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)benzamide	cholecystokinin A antagonist; cholecystokinin antagonist	pain
L 156586	Unspecified	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156587	14,15-didehydro-14-deoxyvirginiamycin M1	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156588	14-deoxyvirginiamycin M1	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156906	Unspecified	cholecystokinin antagonist	gastrointestinal ulcer; pain
devazepide; L 364718; MK 329	(S)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide	cholecystokinin antagonist; cholecystokinin A antagonist; analgesic	pain
L 365260	(R)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)urea	cholecystokinin B antagonist; cholecystokinin antagonist; analgesic	pain
vedacilidine; NNC 111053; LY 297802	(S)-3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]-1-azabicyclo[2.2.2]octane	cholinergic agonist; muscarinic agonist; analgesic	pain
CMI 980	Unspecified	cholinergic agonist; nicotinic agonist; analgesic	pain
nicotinic agonists	Unspecified	cholinergic agonist; nicotinic agonist; analgesic	cognitive defect; pain; nicotine withdrawal
SIB T1887	Unspecified	cholinergic antagonist; nicotinic antagonist; analgesic	pain
RU 54808	Unspecified	COX inhibitor; 5 lipoxygenase inhibitor	pain

drug delivery system, transdermal ketorolac; ketorolac transdermal	Unspecified	COX inhibitor; analgesic	pain
ketorolac; ketorolac trometamol; BPPC; RS 37619; RS 3761900313; TORADOL; TARASYN; TORATEX; ACULAR; LIDIXOL; TORA DOL; TORA-DO; TONUM; KETRODOL	(+,-)-5-benzoyl-2,3- dihydro-1H- pyrrolizine-1- carboxylic acid	COX inhibitor; analgesic	pain
meloxicam; UH AC62; UH AC26XX; MOBIC; MOBICOX; MOBEC; MOVALIS; MOVATEC	4-hydroxy-2-methyl- N-(5-methyl-2- thiazolyl)-2H-1,2- benzothiazine-3-car boxamide 1,1-dioxide	COX inhibitor; analgesic; COX 2 inhibitor; NSAID	rheumatoid arthritis; inflammation; pain; osteoarthritis
AHR 10037	2-amino-3-(4- chlorobenzoyl)benzen eacetamide	COX inhibitor; analgesic; NSAID	inflammation; pain
D 1367	Unspecified	COX inhibitor; analgesic; NSAID	pain; inflammation
T 614	N-[3-(formylamino)- 4-oxo-6-phenoxy-4H- 1-benzopyran-7-yl]- methanesulfonamide	COX inhibitor; analgesic; NSAID; DMARD	inflammation; pain
GR 253035	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain; Alzheimer disease
L 783003	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain
parecoxib; SC 69124A	N-[[4-(5-methyl-3- phenyl-4- isoxazolyl)phenyl]sul fonyl]propanamide	COX inhibitor; COX 2 inhibitor; analgesic	pain
celecoxib; SC 58635; YM 177	4-[5-(4- methylphenyl)-3- (trifluoromethyl)-1H- pyrazol-1- yl]benzenesulfo namide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain; cancer

CT 3	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
JTE 522	4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
L 745337	N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
L 752860	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
MK 663	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
NS 398	N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
Rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease
Valdecoxib; SC 65872	4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain
COX 2 inhibitors,	Unspecified	COX inhibitor; COX 2 inhibitor; NSAID; analgesic	inflammation; osteoarthritis; pain
Lornoxicam; chlortenoxicam; Ro 139297; TS 110; CTX; SAFEM; XEFO; LORCAM	6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide 1,1-dioxide	COX inhibitor; NSAID; analgesic	inflammation; pain
E 5090	(Z)-3-[4-(acetyloxy)-5-ethyl-3-methoxy-1-naphthalenyl]-2-methyl-2-propenoic acid	cytokine inhibitor; analgesic; NSAID	inflammation; pain



TAN 67	trans-3-(1,3,4,5,12,12a-hexahydro-2-methylpyrido[3,4-b]acridin-4a(2H)-yl)phenol	delta agonist; opiate agonist; analgesic	pain
Prinomide; prinomide tromethamine; CGS 10787; CGS 10787B	alpha-cyano-1-methyl-beta-oxopyrrole-2-propionanilide with 2-amino-2-(hydroxymethyl)-1,3-propanediol	DMARD; analgesic; immunosuppressant; NSAID	inflammation; pain; rheumatoid arthritis
FR 64822	N-(3,6-dihydro-1(2H)-pyridinyl)-N'-4-pyridinylurea	dopamine agonist; dopamine D2 agonist; analgesic	pain
BW 443C	L-tyrosyl-D-arginylglycyl-4-nitro-L-phenylalanyl-L-prolinamide diacetate (salt)	enkephalinase inhibitor; analgesic	asthma; pain; cough
KK 3	[S-(R*,R*)]-alfa-amino-4-hydroxy-N-[4-[[1-(hydroxymethyl)-2-phenylethyl]amino]-4-oxobutyl]-N-methyl-benzenepropanamide	enkephalinase inhibitor; analgesic	pain
ONO 9902	[1S-[1R*[R*(R*)]]]-4-[[2-[[[(1,3-dihydro-3-oxo-1-isobenzofuranyl)thio]methyl]-1-oxo-3-phenylpropyl]amino]-5-oxo-5-(phenylamino)pentanoic acid	enkephalinase inhibitor; analgesic	pain
Excitatory amino acid antagonist	Unspecified	excitatory amino acid antagonist; analgesic	pain
CGP 29030A	1-[2-(4-chlorophenyl)ethyl]-4-(3,5-dimethoxybenzoyl)-piperazine, monohydrochloride	GABA agonist; analgesic	pain

Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexanecarboxylic acid	GABA release analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
galanin1 antagonists,	Unspecified	Galanin 1 antagonists	obesity; pain; cognitive defect
galanin modulators,	Unspecified	Galanin modulation analgesic	obesity; diabetes; cognitive defect; pain
Mipragoside; AGF 44	[R-[R*,S*-(E)]]-N-[1-[[[O-[N-acetyl-1-(1-methylethyl)-alpha-neuraminosyl]-(2-3)-O-[O-beta-D-galactopyranosyl-(1-3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecenyl]octadecanamide	ganglioside analogue; analgesic; NSAID	inflammation; pain
LY 379268	(1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid	glutamate agonist; mGluR agonist; analgesic	neurodegeneration; pain
BW 524C79	Unspecified	glutamate antagonist; analgesic	pain
NPS 2390	Unspecified	glutamate antagonist; mGluR antagonist	pain; epilepsy
SIB 1757	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
SIB 1893	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
GV 196771; GV 196771A	E-4,6-dichloro-3-[(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl]-1H-indole-2-carboxylic acid monosodium salt	glutamate antagonist; NMDA antagonist; analgesic	pain

CP 331; CP 6	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[[2-oxo-2-[[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]ethyl]thio]ethyl ester	histamine antagonist; histamine H2 antagonist; analgesic; NSAID	inflammation; pain
Melanocortin receptor-1 modulators	Unspecified	melanocortin agonist; melanocortin MC1 agonist	asthma; pain; nephritis
Metabotropic glutamate receptor modulators	Unspecified	metabotropic glutamate receptor modulators analgesic	pain; cognitive defect; schizophrenia; epilepsy
remifentanyl; GI 87084; GI 87084B; GI 87084X; ULTIVA	4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic acid methyl ester	mu agonist; opiate agonist; analgesic	pain
trefentanyl; trefentanyl hydrochloride; A 3665	N-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl)-4-phenyl-4-piperidinyl)-N-(2-fluorophenyl)propanamide monohydrochloride	mu agonist; opiate agonist; analgesic	pain
BCH 150	Unspecified	mu agonist; opiate agonist; peptide; analgesic	pain
mirfentanyl; mirfentanyl hydrochloride; A 3508	N-[1-(2-phenethyl)-4-piperidinyl]-N-pyrazinyl-2-furancarboximide	mu antagonist; opiate antagonist; analgesic	anesthesia; pain
Narcotics	Unspecified	Narcotics analgesic	pain; addiction; intoxication
WIN 64821	(2alpha,2'beta,5beta,5'alpha)-2,5:2',5'-dide(epidithio)-3,3'-didemethyl-19,19'-dideoxy-19,19'-diphenylchaetocin	neurokinin antagonist; analgesic	pain

GR 82334	9-deglycine-10-[(5S)-6-oxo-L-alfa--(2-methylpropyl)-1,7-diazaspiro[4.4]nonane-7-acetic acid]-11-L-tryptophanamidephysalemin	neurokinin antagonist; analgesic; neurokinin 1 antagonist	pain
lanepitant; LY 303870	(R)-N-[2-acetyl[(2-methoxyphenyl)methyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
L 733060	(2S-cis)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID	inflammation; pain; asthma
CP 96345	(2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID; substance P antagonist	inflammation; pruritis; pain
saredutant; SR 48968	(S)-N-[4-(4-acetylamino-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl]-N-methyl-benzamide	neurokinin antagonist; analgesic; neurokinin 2 antagonist	asthma; pain; urinary incontinence
neurokinin antagonists	Unspecified	neurokinin antagonist; analgesic; NSAID	pain; inflammation
CP 99994	(2S-cis)-N-[(2-methoxyphenyl)methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist; analgesic	asthma; pain
SR 144190	(R)-4-benzoyl-2-(3,4-difluorophenyl)-2-[2-[4-[[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]ethyl]morpholine	neurokinin antagonist; neurokinin 2 antagonist; analgesic	asthma; urinary incontinence; asthma; pain

neuropeptide Y antagonists	Unspecified	neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
JMV 449	(S)-1-de-L-lysine-2-[N2-(2,6-diaminohexyl)-L-lysine]neuromedin N (pig spinal cord)	neurotensin analogue; analgesic	pain
nitroglycerin; glyceryl trinitrate; trinitrin; ANOGESIC	Unspecified	nitrate; cicatrizant; analgesic	skin ulcer; angina; pain
memantine; D 145; NMI 131; AKATINOL	3,5-dimethyl-1-adamantanamine	NMDA antagonist; analgesic; glutamate antagonist	cognitive defect; pain; glaucoma; neuropathy
NMDA antagonists	Unspecified	NMDA antagonist; analgesic; glutamate antagonist	epilepsy; pain; brain ischemia
CNS 5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine monohydrochloride	NMDA antagonist; glutamate antagonist	pain; migraine; neuropathy
ACEA 1328	5-nitro-6,7-dimethyl-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	pain
ACEA 1416; NMCQX	5-nitro-6-methyl-7-chloro-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	epilepsy; pain; brain ischemia
aptiganel; CNS 1102; CDD 2515A; CERESTAT	N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-guanidine	NMDA antagonist; glutamate antagonist; analgesic	stroke; neuropathy; trauma; Parkinson disease; pain
budipine; budipine hydrochloride; BY 701; PARKINSAN	1-(1,1-dimethylethyl)-4,4-diphenylpiperidine	NMDA antagonist; glutamate antagonist; analgesic	Parkinson disease; pain
NMDA antagonists,	Unspecified	NMDA antagonist; glutamate antagonist; analgesic	pain
conantokins	Unspecified	NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia
nociceptor blockers, NB 1	Unspecified	nociceptor blockers analgesic	pain
non-narcotic analgesic	Unspecified	non-narcotic analgesic analgesic	pain

2-halopyridine	Unspecified	NSAID	inflammation; pain; insomnia
Analgesic	3-methyl-5-oxobenzo(b)thieno(2,3-d)thiazolo(3,2-a)pyrimidine-2-carboxylic acid ethyl ester	NSAID	pain; inflammation; gastrointestinal ulcer
BN 50370	1,3-dihydro-3,6-dimethyl-7-hydroxy-furo(3,4)pyridine hydrochloride	NSAID	inflammation; pain
Diaveridine; EGIS 5645	5-[(3,4-dimethoxyphenyl)methyl]-2,4-pyrimidinediamine	NSAID	inflammation; pain
drug delivery system, hydrogel diclofenac; diclofenac hydrogel; DICLOFENAC HYCORE-R	Unspecified	NSAID	pain; inflammation
drug delivery system, OSAT diclofenac; diclofenac sustained release	Unspecified	NSAID	pain; inflammation
drug delivery system, OSAT ibuprofen; ibuprofen sustained release	Unspecified	NSAID	pain; rheumatoid arthritis; osteoarthritis; inflammation
drug delivery system, sustained release microsphere flurbiprofen; flurbiprofen, sustained release	Unspecified	NSAID	pain; inflammation
DTA	4'-methyl-[1,1':3',1''-terphenyl]-5'-acetic acid	NSAID	inflammation; pain
FA 401	1-(4-fluorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid carboxymethyl ester	NSAID	pain; inflammation

Flurbiprofen axetil; LFP 83; ROPION; LIPFEN	2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid, 1-(acetyloxy)ethyl ester	NSAID	pain; inflammation
HU 239	(6aR-trans)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid	NSAID	inflammation; pain
LA 351	5H-(1)-benzopyrano(2,3-b)pyridin-5-one	NSAID	inflammation; pain; asthma
M 5011; T 3788	alpha-2-[4-(3-methylthienyl)phenyl]propionic acid	NSAID	inflammation; pain
Proglumetacin; protacine; CR 604; IMPETIN; PROXIL; PROXATIL; AFLOXAN; TOLINDOL; BRUXEL; MIRIDACIN	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[4-[3-[[4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl]oxy]propyl]-1-piperazinyl]ethyl ester, (+,-)-	NSAID	inflammation; pain
RP 67580	(3aR-cis)-octahydro-2-[1-imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4H-isoindol-4-one	NSAID	pain; inflammation
SC 107	Unspecified	NSAID	arthritis; pain
TZI 41078	Unspecified	NSAID	inflammation; pain
Aceclofenac; YT 919; AIRTAL; GERBIN; FALCOL; BRISTAFLAM; PRESERVEX; BIOFENAC; BARRACAN	2-[(2,6-dichlorophenyl)amino]benzeneacetic acid, carboxymethyl ester	NSAID; analgesic	pain; inflammation

Amtolmetin guacil; ST 679; MED 15; ARTROMED; EUFANS	N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl]glycine 2-methoxyphenyl ester	NSAID; analgesic	arthritis; rheumatoid arthritis; inflammation; pain
bromfenac; bromfenac sodium; AHR 10282; DURACT	2-amino-3-(4-bromobenzoyl)benzoic acid	NSAID; analgesic	inflammation; pain
CHF 2003	Unspecified	NSAID; analgesic	pain; inflammation
Dexketoprofen trometamol; LM 1158; TRIS; D 1158; ENANTYUM; QUIRALAM; KETESSE	(S)-3-benzoyl-alpha-methylbenzeneacetic acid cpd with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)	NSAID; analgesic	pain; inflammation
Esflurbiprofen; flurbiprofen, (S)-; (S)-flurbiprofen; BTS 24332	(S)-2-fluoro-alpha-methyl-4-biphenylacetic acid	NSAID; analgesic	pain
florifenine; FI 2522	2-(1-pyrrolidinyl)ethyl-N-[7-(trifluoromethyl)-4-quinolyl]anthranilate	NSAID; analgesic	inflammation; pain
flosulide; ZK 38997; CGP 28238; CGS 28238; SH 459	N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	NSAID; analgesic	inflammation; pain
FS 205397	6-ethoxy-2,3-dihydro-3,3-dimethyl-1H-indole methanesulfonate	NSAID; analgesic	pain
HAI 105	6,11-dihydro-2-methoxy-alpha-methyl-11-oxodibenz[b,e]oxepin-3-acetic acid	NSAID; analgesic	pain; inflammation
HN 3392	N-(4-(4-methoxyphenyl)-5-phenylthiazolyl)	NSAID; analgesic	inflammation; pain
mofezolac; N 22; DISOPAIN	3,4-bis(4-methoxyphenyl)-5-isoxazoleacetic acid	NSAID; analgesic	inflammation; pain



Nabumetone; BRL 14777; RELIFEN; RELIFEX; LISTRAN; PRODAG; BALMOX; NABUMETON; RELAFEN	4-(6-methoxy-2-naphthyl)-2-butanone	NSAID; analgesic	pain; inflammation
olvanil; oluvanil; NE 19550	N-vanillyloleamide	NSAID; analgesic	pain; inflammation; viral infection
Pelubiprofen; CS 670; RS 2131	alpha-methyl-4-[(2-oxocyclohexyllidene)methyl]benzeneacetic acid	NSAID; analgesic	inflammation; pain
piroxicam betadex; piroxicam cyclodextrin; CHF 1194; BREXIN; BREXINE; BREXIDOL; CYCLADOL; BREXICAM; BREXINIL	4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound with beta-cyclodextrin	NSAID; analgesic	pain; inflammation
Polyunsaturated fatty acids, PUFA	Unspecified	NSAID; analgesic	inflammation; pain
Tenosal; MR Y134	2-thiophenecarboxylic acid, ester with salicylic acid	NSAID; analgesic	pain
Tifurac; RS 82917; RS 82917030	7-[4-(methylthio)benzoyl]-5-benzofuranacetic acid	NSAID; analgesic	inflammation; pain
Tilnoprofen arbamel; Y 23023	(+/-)-alpha-2-methyl-5H-[1]benzopyran[2,3-b]pyridine-7-acetic acid, 2-(dimethylamino)-2-oxoethyl ester	NSAID; analgesic	inflammation; pain
HCT 3012	Unspecified	NSAID; nitric oxide donor	pain; inflammation
HCT 6015	Unspecified	NSAID; nitric oxide donor	pain

NCX 4016	2-(acetyloxy)benzoic acid, 2-[(nitrooxy)methyl]phenylester	NSAID; nitric oxide donor; platelet antiaggregant; analgesic	thrombosis; pain
HP 228	N-acetyl-Nleu-Gln-His-Phe-Arg-Trp-Gly-amide	NSAID; peptide; melanocortin agonist	pain; inflammation; asthma; cachexia
Samarium 153 Sm lexidronam; Sm 153-EDTMP; samarium 153-EDTMP; samarium EDTMP; CYT 424;	(OC-6-21)-[[[1,2-ethanediylbis[nitrilobis(methylene)]tetrakis(phosphonato)](8-)-N,N',OP,OP',OP'',OP''']-samarate(5-)-153Sm	NSAID; radiotherapeutic	cancer; pain; rheumatoid arthritis
Analgesic, human serum albumin conjugated opioid peptide	Unspecified	opiate agonist	pain
AXC 3742	Unspecified	opiate agonist	pain
AXC 3943	Unspecified	opiate agonist	pain
drug delivery system, hydrogel pethidine; pethidine hydrogel	Unspecified	opiate agonist	pain
Oxycodone + ibuprofen; ibuprofen + oxycodone	Unspecified	opiate agonist	pain
ADL 21294	Unspecified	opiate agonist; analgesic	pain; corneal abrasion
Analgesic	Unspecified	opiate agonist; analgesic	pain
Brifentanil; A 3331	(+,-)-cis-N-[1-[2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-3-methyl-4-piperidyl]-2'-fluoro-2-methoxyacetanilide	opiate agonist; analgesic	pain
drug delivery system, ANCHOR opioid agonist	Unspecified	opiate agonist; analgesic	pain

drug delivery system, transdermal fentanyl; TTS-fentanyl; fentanyl transdermal; KJK 4263; SUBLIMAZE; DURAGESIC; DUROGESIC	Unspecified	opiate agonist; analgesic	pain
LEF 576; BCH 3963	Unspecified	opiate agonist; analgesic	pain
ocfentanil; A 3217	N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]acetamide	opiate agonist; analgesic	pain
TRK 820	(2E)-N-[(5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-2-propenamide monohydrochloride	opiate agonist; analgesic; kappa agonist	pain
BW 373U86	[1(S*),2alpha,5beta]-(+,-)-4-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-hydroxyphenyl)methyl]-N,N-diethylbenzamide	opiate agonist; delta agonist; analgesic	pain
SB 235863	Unspecified	opiate agonist; delta agonist; analgesic	pain
SNF 8912	(H <sub>2</sub> N-(CH <sub>2</sub> ) <sub>7</sub> -CO-NH)Asp-Tyr-(N-Me)Nle-Gly-Trp-(N-Me)Nle-Asp-Phe-NH <sub>2</sub>	opiate agonist; delta agonist; analgesic	pain
SNF 9007	L-alpha-aspartyl-L-tyrosyl-D-phenylalanylglycyl-L-tryptophyl-N-methyl-L-norleucyl-L-alpha-aspartyl-L-phenylalaninamide	opiate agonist; delta agonist; analgesic	pain

opioid mimetic peptides	Unspecified	opiate agonist; delta agonist; analgesic; peptide	pain; addiction
Apadoline; RP 60180; RP 60180A; RPR 60180	(R)-10-[1-methyl-2-(1-pyrrolidiny)ethyl]-N-propyl-10H-phenothiazine-2-carboxamide	opiate agonist; kappa agonist; analgesic	pain
BRL 53001A	(2S)-1-(1-oxo-3,4-dihydro-(2H)-naphth-6-yl)acetyl-2-dimethyl-aminomethyl piperidine hydrochloride	opiate agonist; kappa agonist; analgesic	pain
CL 891601	Unspecified	opiate agonist; kappa agonist; analgesic	pain
DUP 747	trans-(+,-)-3,4-dichloro-N-methyl-N-[1,2,3,4-tetrahydro-5-methoxy-2-(1-pyrrolidiny)-1-naphthalenyl]benzene acetamide	opiate agonist; kappa agonist; analgesic	pain
E 2078; 66A078	N-methyl-L-tyrosylglycylglycyl-L-phenylalanyl-L-leucyl-L-arginyl-N2-methyl-L-arginyl-N-ethyl-D-leucinamide	opiate agonist; kappa agonist; analgesic	pain
EMD 60400	N-methyl-N((1S))-1-phenyl-2-((3S)-3-hydroxypyrrolidine-1-yl)-ethyl-2-amino-phenylacetamide	opiate agonist; kappa agonist; analgesic	pain
GR 102908	Unspecified	opiate agonist; kappa agonist; analgesic	pain
GR 107537	[S-(R*,R*)]-5-[(3,4-dichlorophenyl)acetyl]-4,5,6,7-tetrahydro-4-[(3-hydroxy-1-pyrrolidiny)methyl]furo[3,2-c]pyridine	opiate agonist; kappa agonist; analgesic	pain

ICI 197067	(S)-3,4-dichloro-N-methyl-N-[2-methyl-1-(1-pyrrolidinylmethyl)propyl]benzeneacetamide monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
ICI 204448	(+,-)-[3-[1-[(3,4-dichlorophenyl)acetyl]methylamino]-2-(1-pyrrolidinyl)ethyl]phenoxylacetic acid monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
R 84760	(3R)-4-[[[(1S)-5,6-dichloro-2,3-dihydro-1H-inden-1-yl]carbonyl]-3-(1-pyrrolidinylmethyl)thiomorpholine monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
Asimadoline; EMD 61753	[S-(R*,R*)]-N-[2-(3-hydroxy-1-pyrrolidinyl)-1-phenylethyl]-N-methyl-.alpha.-phenyl-, benzeneacetamide	opiate agonist; kappa agonist; analgesic; NSAID	pain
opiate analgesic,	Unspecified	opiate agonist; mu agonist	pain
BCH 2687; LEF 553	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, hydrogel morphine; morphine hydrogel; MORAXEN; MORPHINE HYCORE-R	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, oral sustained release morphine; morphine sustained release; KAPANOL; KADIAN; MORCAP SR	Unspecified	opiate agonist; mu agonist; analgesic	pain

drug delivery system, oral transmucosal fentanyl; fentanyl OTFC; ACTIQ; FENTANYL ORALET	Unspecified	opiate agonist; mu agonist; analgesic	anesthesia; pain
drug delivery system, OROS oral controlled release hydrocodone; hydrocodone OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OROS oral controlled release hydromorphone; hydromorphone OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OROS oral controlled release morphine; morphine OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OSAT morphine; morphine sustained release	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, subcutaneous hydromorphone; hydromorphone subcutaneous implant	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, sustained release DepoFoam morphine; morphine DepoFoam; C 0401; DepoMorphine	Unspecified	opiate agonist; mu agonist; analgesic	pain; cancer
drug delivery system, transdermal buprenorphine; buprenorphine transdermal	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, transdermal fentanyl; fentanyl transdermal	Unspecified	opiate agonist; mu agonist; analgesic	pain

HP 736	cis-7-bromo-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol (E)-2-butenedioate (1:1) (salt)	opiate agonist; mu agonist; analgesic	pain
morphine-6-glucuronide; CEE 04410; HN 33169; CAP	morphine-6-glucuronide	opiate agonist; mu agonist; analgesic	pain
pentamorphone; RX 77989; A 4492	7,8-didehydro-4,5a-epoxy-3-hydroxy-17-methyl-14-(pentylamino)morphinan-6-one	opiate agonist; mu agonist; analgesic	pain
DPI 3290	[2S-[1(S*),2alpha,5beta]]-3-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide monohydrochloride	opiate agonist; mu agonist; delta agonist; analgesic	pain
OHM 3295; ANQ 3295	Unspecified	opiate agonist; mu agonist; kappa agonist; analgesic	pain
SK 9709	Tyr-D-Ala-Phe-Leu-Arg (CH <sub>2</sub> NH) Arg-NH <sub>2</sub>	opiate agonist; mu agonist; kappa agonist; peptide	pain
naloxone + pentazocine; pentazocine + naloxone	Unspecified	opiate agonist; opiate antagonist; analgesic	pain; cancer
tonazocine; WIN 42156; WIN 42156 2	(+,-)-(2alpha,6alpha,11S*)-1-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)-3-octanone	opiate agonist; opiate antagonist; mu agonist; delta agonist; analgesic	pain

picecadol; LY 150720	trans-(+,-)-3-(1,3-dimethyl-4-propyl-4-piperidinyloxy)phenol	opiate agonist; opiate antagonist; mu agonist; mu antagonist; analgesic	pain
acetylmethadol; levomethadyl acetate hydrochloride; L-alpha acetylmethadol; LAAM; methadyl acetate; LAAM; MK 790; ORLAAM	beta-[2-(dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol acetate (ester)	opiate antagonist; analgesic	pain; addiction
SNC 80	[2S-[1(S*),2alpha,5beta]]-4-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide	opiate antagonist; delta antagonist; analgesic	pain
ibuprofen + propiram; propiram + ibuprofen; DIRATAB	Unspecified	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
propiram; propiram fumarate; BAY 4503; FBA 4503; DIRAME; ALGERIL	N-(1-methyl-2-piperidinoethyl)-N-2-pyridyl-propionamide fumarate	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
propiram + paracetamol; propiram + acetaminophen; paracetamol + propiram; acetaminophen + propiram; DIRAMAX	Unspecified	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
drug delivery system, transdermal buprenorphine; buprenorphine transdermal	Unspecified	opiate partial agonist; analgesic	pain
MR 2264	Unspecified	opiate partial agonist; analgesic	pain
analgesics,	Unspecified	peptide	pain
CEE 04420	Unspecified	peptide	pain
CEE 04421	Unspecified	peptide	pain



drug delivery system, analgesic, oral transmucosal	Unspecified	peptide	pain
drug delivery system, Polyfunctional Molecular Modification, enkephalin; enkephalin Polyfunctional Molecular Modification	Unspecified	peptide; analgesic	pain
MER W8020	Unspecified	peptide; analgesic; NSAID	inflammation; pain
drug delivery system, MICROPUMP oral controlled release aspirin; aspirin MICROPUMP; ASACARD	Unspecified	platelet antiaggregant; thromboxane synthetase inhibitor; analgesic; NSAID	thrombosis; pain; inflammation
ZD 4953	Unspecified	prostaglandin antagonist; prostaglandin endoperoxide 1 antagonist	pain
ZD 6416	Unspecified	prostaglandin endoperoxide 1 antagonist; analgesic	pain
ZD 6804	Unspecified	prostaglandin endoperoxide 1 antagonist; analgesic	pain
limaprost; limeprost; limaprost alfadex; OP 1206; ONO 1206; OPALMON; PRORENAL	(E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-2-heptenoic acid	prostanoid; analgesic	cardiovascular disease; pain
SC 42867	8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[3-(ethylsulfonyl)-1-oxopropyl]hydrazide	prostanoid; analgesic	pain

SCH 34826	N-[N-[2-[(2,2-dimethyl-1-3-dioxolan-4-yl)methoxy]-2-oxo-1-(phenylmethyl)ethyl]-L-phenylalanyl]-beta-alanine	proteinase inhibitor; analgesic	pain; hypertension
<sup>117</sup> m Sn DTPA; pentetate <sup>117</sup> m Sn	Unspecified	radiotherapeutic; analgesic	cancer; pain
rhenium Re 186 etidronate; 186-Re HEDP; 186-Re HEDP; BETAMET	Unspecified	radiotherapeutic; analgesic	pain; cancer
Sm 153 hydroxyapatite; Sm 153 HA; samarium 153 hydroxyapatite	Unspecified	radiotherapeutic; analgesic	pain
strontium-89 chloride; METASTRON	strontium chloride (89SrCl <sub>2</sub> )	radiotherapeutic; analgesic	pain; cancer
PD 144418	1,2,3,6-tetrahydro-5-[3-(4-methylphenyl)-5-isoxazolyl]-1-propylpyridine	sigma antagonist; analgesic	pain
mu-conopeptides	Unspecified	sodium channel blocker	pain; epilepsy
4030W92; BW 4030W92	(5R)-5-(2,3-dichlorophenyl)-6-(fluoromethyl)-2,4-pyrimidinediamine	sodium channel blocker	pain
GW 286103	Unspecified	sodium channel blocker; analgesic	pain
LTA	Unspecified	sodium channel blocker; analgesic	pain
sodium channel blockers	Unspecified	sodium channel blocker; analgesic	pain
sodium channel blockers	Unspecified	sodium channel blocker; analgesic	pain

Octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
Vapreotide; octastatin; RC 160; BMY 41606	D-Phe-Cys-Trp-D-Trp-Lys-Val-Cys-Trp-NH <sub>2</sub>	somatostatin analogue; analgesic	cancer; pain
NKT 343; SDZ NKT 343	1-[[[(2-nitrophenyl)amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	substance P antagonist; analgesic	pain
Etanercept; tumor necrosis factor receptor; TNFr; TNR 001;	Unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease

Table 34: Current Candidate Therapeutic Interventions for the Treatment of Parkinson's Disease

Product Name	Chemical Name	Action	Indication
KF 17837	(E)-8-[2-(3,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist	Parkinson disease
KW 6002	Unspecified	adenosine antagonist	Parkinson disease
Parkinson's disease therapy	Unspecified	adenosine antagonist	Parkinson disease
SCH 58261	2-(2-furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine	adenosine antagonist; adenosine A <sub>2</sub> antagonist	Parkinson disease

Idazoxan; RX 781094; RX 781094 A	2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist; antiproliferative agent	Parkinson disease; depression; cardiovascular disease; retinopathy
alpha2 adrenoceptor antagonists,	Unspecified	alpha2 adrenergic antagonist; alpha adrenergic antagonist	Parkinson disease
SR 57667	Unspecified	Antineurodegenerative	Alzheimer disease; Parkinson disease
Parkinson's disease therapy,	Unspecified	antioxidant	Parkinson disease
VANTOX	Unspecified	antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
CNS therapy, IDUN; CNS therapy	Unspecified	apoptosis inhibitor; caspase inhibitor	stroke; Parkinson disease; amyotrophic lateral sclerosis
CNS 1237	N-5-acenaphthylenyl-N'-(4-methoxy-1-naphthalenyl)-guanidine	Calcium channel blocker; glutamate release inhibitor	brain ischemia; Parkinson disease; neuropathy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
SIB 1508Y	(S)-3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine	cholinergic agonist; nicotinic agonist	Parkinson disease
SIB S1663; S 1663	2,3,3a,4,5,9b-hexahydro-7-methoxy-1-methyl-1H-pyrrolo[3,2-h]isoquinoline	cholinergic agonist; nicotinic agonist	Parkinson disease
CGP 28014	N'-(1,6-dihydro-6-oxo-2-pyridinyl)-N,N-dipropylmethanimidamide	COMT inhibitor	Parkinson disease
Entacapone; OR 611; COMTAN; COMTESS	(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide	COMT inhibitor	Parkinson disease

Tolcapone; Ro 407592; TASMAR	(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone	COMT inhibitor	Parkinson disease
drug delivery system, controlled release carbidopa + levodopa; carbidopa + levodopa	Unspecified	decarboxylase inhibitor; dopamine agonist	Parkinson disease
Dopaminergic neurotrophic factor; DNTF	Unspecified	DNTF growth factor	Parkinson disease
JA 116a; JA 116	1,2,6,7,8,8a-hexahydro-1-acenaphthylenamine hydrochloride	dopamine agonist	Parkinson disease
levodopa methyl; CHF 1301	Unspecified	dopamine agonist	Parkinson disease
levodopa methyl + carbidopa; carbidopa + levodopa methyl; CHF 1512	Unspecified	dopamine agonist	Parkinson disease
Moxiraprime; 4-hydroxyminaprime; CM 30366	p-[5-methyl-6-[(2-morpholinoethyl)amino]-3-pyridazinyl]phenol	dopamine agonist	Parkinson disease
naxagolide; PHNO; dopazinol; MK 458; L 647339	(4aR-trans)-3,4,4a,5,6,10b-hexahydro-4-propyl-2H-naphth[1,2-b]-1,4-oxazin-9-ol	dopamine agonist	Parkinson disease
U 86170F	(R)-5-(dipropylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one monohydrobromide	dopamine agonist	Parkinson disease
WAY 124486	(S)-3-[[[3-(3-aminophenoxy)propyl]amino]methyl]-2,3-dihydro-1,4-benzodioxin-6-ol	dopamine agonist	Parkinson disease

Quinelorane; quinelorane hydrochloride; LY 163502	(5aR-trans)- 5,5a,6,7,8,9,9a,10- octahydro-6- propylpyrido[2,3- g]quinazolin-2-amine	dopamine agonist	Parkinson disease; hyperprolactinemia; hypertension
HW 165	trans-(+/-)- 1,2,3,4,4a,5,6,10b- octahydrobenzo(f)qui nolin-7-ol, hydrobromide	dopamine agonist	Parkinson disease; schizophrenia
Apomorphine; apomorphine hydrochloride; UPRIMA	(R)-5,6,6a,7- tetrahydro-6-methyl- 4H- dibenzo[de,g]quinolin e-10,11- diol hydrochloride hydrate (2:1)	dopamine agonist	sexual dysfunction; Parkinson disease
talipexole; BHT 920; DOMINE; DOMIN	6-allyl-2-amino- 5,6,7,8-tetrahydro- 4H-thiazolo[4,5- d]azepine	dopamine agonist; alpha adrenergic agonist; alpha2 adrenergic agonist	Parkinson disease; glaucoma
drug delivery system, benserazide + levodopa; benserazide + levodopa, levodopa + benserazide; MADOPAR DR	Unspecified	dopamine agonist; decarboxylase inhibitor	Parkinson disease
A 68930	(1R,3S)-1- aminomethyl-5,6- dihydroxy-3- phenylisochroman	dopamine agonist; dopamine D1 agonist	hypertension; Parkinson disease
A 77636	(1R-cis)-1- (aminomethyl)-3,4- dihydro-3- tricyclo[3.3.1.1 <sup>3,7</sup> ]de c-1-yl-1H-2- benzopyran-5,6-diol hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease
A 86929	trans-4,5,5a,6,7,11b- hexahydro-2- propylbenzo[f]thieno[ 2,3-c]quinoline-9,10- diol hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease

ABT 431	(5aR-trans)-4,5,5a,6,7,11b-hexahydro-2-benzo[f]thieno[2,3-c]quinoline-9,10-diol, diacetate (ester), hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease
dopamine agonist	Unspecified	dopamine agonist; dopamine D1 agonist	Parkinson disease
dopamine-D1 agonists, BLSI	Unspecified	dopamine agonist; dopamine D1 agonist	Parkinson disease
dihydropyridine; IP 202	trans-5,6,6a,7,8,12b-hexahydro-benzo[a]phenanthridine-10,11-diol	dopamine agonist; dopamine D1 agonist	Parkinson disease; Alzheimer disease
BAM 1110	(8 beta)-6-methyl-8-(1H-1,2,4-triazol-1-ylmethyl)ergoline (Z)-2-butenedioate	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease
drug delivery system, transdermal pergolide; pergolide transdermal	Unspecified	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease
pergolide; pergolide mesylate; LY 141B; LY 127809; PERMAX; CELANCE; PHARKEN; PARKOTIL	(8beta)-8-[(methylthio)methyl]-6-propylergoline	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease; depression
CQA 206291	Unspecified	dopamine agonist; dopamine D2 agonist	Parkinson disease
drug delivery system, transdermal N 0923; N 0923 transdermal delivery system; N 0923; SPM 962	(S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol	dopamine agonist; dopamine D2 agonist	Parkinson disease
ropinirole; ropinirole hydrochloride; ropinerole; SKF 101468; SKF 101468A;	(4-2(-dipropylamino)ethyl)-1,3-dihydro-2H-indol-2-one monohydrochloride	dopamine agonist; dopamine D2 agonist	Parkinson disease

U 91356A	(R)-5,6-dihydro-5-(propylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one monohydrochloride	dopamine agonist; dopamine D2 agonist	Parkinson disease
Cabergoline; FCE 21336; CG 101; DOSTINEX; SOGILEN; CABASER	(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)ergoline-8-carboxamide	dopamine agonist; dopamine D2 agonist	Parkinson disease; hyperprolactinemia
PNU 95666; U 95666A	(R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one	dopamine agonist; dopamine D2 agonist; 5HT agonist; 5HT1A agonist	Parkinson disease
Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQUIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)-benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
LEK 8829	(8beta)-9,10-didehydro-N,6-dimethyl-N-2-propynylergoline-8-methanamine	dopamine D1 agonist; dopamine D2 antagonist; 5HT antagonist; 5HT2A antagonist; dopamine agonist; dopamine antagonist	schizophrenia; Parkinson disease
Brasofensine; NS 2214; BMS 204756	[1R-[1alpha,2beta(E),3alpha,5alpha]]-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxaldehyde O-methyloxime	dopamine reuptake inhibitor	Parkinson disease
NS 2141	Unspecified	dopamine reuptake inhibitor	Parkinson disease
NS 2200	Unspecified	dopamine reuptake inhibitor	Parkinson disease; depression; addiction



drug delivery system, dopamine secreting implant; dopamine secreting implant; NeuroCRIB	Unspecified	Dopaminergic agonist	Parkinson disease
drug delivery system, dopamine secreting implants, Parkinson's disease; SPHERAMINE	Unspecified	Dopaminergic agonist	Parkinson disease
NB 355	3-hydroxy-L-tyrosine, 4-(2,2,-dimethylpropanoate)	Dopaminergic agonist, L-dopa prodrug	Parkinson disease
epidermal growth factor; EGF	epidermal growth factor	EGF growth factor	eye disease; Parkinson disease
Carboxylated buckminsterfullerenes; carboxyfullerenes	Unspecified	free radical scavenger; apoptosis inhibitor	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
Milacemide; CP 15525; CP 1552S	2-(pentylamino)acetamide	GABA agonist; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease
glial cell line-derived neurotrophic factor; GDNF	Unspecified	GDNF growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
glial-cell-line-derived neurotrophic factor; GDNF	Unspecified	GDNF growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
drug delivery system, neurturin secreting implant; neurturin secreting implant; GDNF secreting implant	Unspecified	GDNF; neurotrophic factor; growth factor	Parkinson disease
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
NS 072	Unspecified	glutamate antagonist	Parkinson disease
MRZ 2579; MRZ 2/579	Unspecified	glutamate antagonist; NMDA antagonist	Parkinson disease; addiction; stroke
CNS 5065	N-(2-chloro-5-ethylphenyl)-N'-(3-ethylphenyl)-N'-methylguanidine	glutamate antagonist; NMDA antagonist	Parkinson disease; neuropathy; brain ischemia

CP 283097	(3R-cis)-3-[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]-3,4-dihydro-2H-1-benzopyran-4,7-diol	glutamate antagonist; NMDA antagonist	Parkinson disease; stroke; trauma
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
Neurotrophin agonist	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; neuropathy
V 10367; VA 10367	Unspecified	growth factor; neurotrophic factor	Parkinson disease
drug delivery system, neurotrophin-3 secreting implant; NT-3 implant	Unspecified	growth factor; neurotrophic factor; biotechnology	Alzheimer disease; Parkinson disease; neuropathy
m-NBA	2-amino-3-(3-nitrobenzoyl)propanoic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
MDL 72145	(E)-(beta-fluoromethylene)-3,4-dimethoxybenzeneethanamine hydrochloride	MAO B inhibitor; MAO inhibitor	depression; Parkinson disease
2 HxMP	N-(2-hexyl)-N-methylpropargylamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
drug delivery system, transdermal selegiline; selegiline transdermal	Unspecified	MAO B inhibitor; MAO inhibitor	Parkinson disease
M 2 PP	N-(2-pentyl)-N-methylpropargylamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
mofegiline; MDL 72974A; MDL 72974	(E)-4-fluoro-beta-(fluoromethylene)benzenebutanamine	MAO B inhibitor; MAO inhibitor	Parkinson disease

selegiline; selegiline hydrochloride; deprenyl; E 250; FPF 1100; ELDEPRYL; DEPRENYL; JULAP; NIAR; SELEDAT; DEPRILAN; SELEPARKIN; KINABIDE; NOVO-SELEGILINE; MOVERDIN	(R)-N,α-dimethyl-N-2-propynylbenzeneethanamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
lazabemide; Ro 196327; PAKIO; TEMPIUM	N-(2-aminoethyl)-5-chloro-2-pyridine-carboxamide	MAO B inhibitor; MAO inhibitor	Parkinson disease; Alzheimer disease
LU 53439	3,4-dimethyl-7-(2-isopropyl-1,3,4-thiadiazol-5-yl)-methoxy-coumarin	MAO B inhibitor; MAO inhibitor	Parkinson disease; cognitive defect
SL 650477; SL 65.0477	[R-(R*,R*)]-5-(methoxymethyl)-3-[6-(4,4,4-trifluoro-3-hydroxybutoxy)-3-benzofuranyl]-2-oxazolidinone	MAO inhibitor; MAO A inhibitor; MAO B inhibitor; oxazolidinone	depression; Parkinson disease
SL 340026; SL 34.0026	3-(2-methoxyethyl)-5-[4-(4,4,4-trifluorobutoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one	MAO inhibitor; MAO B inhibitor	Parkinson disease
rasagiline; rasagiline mesylate; TVP 1012; TV 1012	(R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine	MAO inhibitor; MAO B inhibitor	Parkinson disease; Alzheimer disease
fatty acids, microalgal,	Unspecified	Microalgal extracts	hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease
Neurophilins	Unspecified	Neurophilins	Alzheimer disease; Parkinson disease; neuropathy

LIGA 20; FID 012020	[R-[R*,S*-(E)]-N-[1-[[[O-(N-acetyl- $\alpha$ -neuraminosyl)-(2->3)-O-[O-beta-D-galactopyranosyl-(1->3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1->4)]-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl]oxy)methyl]-2-hydroxy-3-heptadecenyl]-2,2-dichloroacetamide	Neuroprotectant	Parkinson disease
neurturin	Unspecified	Neurturin; growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
SIB 1765F; SIB 1765	3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine, (E)-2-butenedioate (1:1)	nicotinic agonist; cholinergic agonist	Parkinson disease
neurodegeneration therapy	Unspecified	Nicotinic cholinergic receptor ligands	Alzheimer disease; Parkinson disease
nitric oxide synthase inhibitors,	Unspecified	nitric oxide synthase inhibitor	Parkinson disease; stroke
remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
CO 101244	1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]-4-piperidinol hydrochloride	NMDA antagonist; glutamate antagonist	Parkinson disease
PD 158473	3-(1-naphthalenyl)-5-(phosphonomethyl)-L-phenylalanine	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
PD 159913	Unspecified	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
Ro 256981	Unspecified	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke

budipine; budipine hydrochloride; BY 701; PARKINSAN	1-(1,1-dimethylethyl)-4,4-diphenylpiperidine	NMDA antagonist; glutamate antagonist; analgesic	Parkinson disease; pain
aptiganel; CNS 1102; CDD 2515A; CERESTAT	N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-guanidine	NMDA antagonist; glutamate antagonist; analgesic	stroke; neuropathy; trauma; Parkinson disease; pain
antisense oligonucleotide, p75	Unspecified	P75 transcriptional coactivator antisense; oligonucleotide	Parkinson disease
alpha-conopeptides	Unspecified	peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
PNU 151774E	(2S)-2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]propanamide monomethanesulfonate	sodium channel blocker; calcium channel blocker; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease; brain ischemia
CEB 1097	Unspecified	Unknown	Parkinson disease
TV 1203	Unspecified	Unknown	Parkinson disease

Table 35. Current Candidate Therapeutic Interventions for the Treatment of Schizophrenia (and Other Psychoses)

Product Name	Chemical Name	Action	Indication
BW 1192U90; 1192U90	2-amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]benzamide	5HT agonist; 5HT1A agonist; dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
Ritanserlin; R 55667	6-[2-[4-[bis(4-fluorophenyl)methylene]piperidino]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	5HT antagonist; 5HT2 antagonist	addiction; anxiety; schizophrenia

Ziprasidone; ziprasidone hydrochloride; CP 88059; CP 880591; CP 8805901; ZELDOX	5-[2-[4-(1,2- benzisothiazol-3-yl)- 1-piperazinyl]ethyl]- 6-chloro-1,3-dihydro- 2H-indol-2-one	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist; dopamine antagonist; dopamine D2 antagonist; 5HT1A agonist; 5HT agonist	schizophrenia; anxiety
Ocaperidone; R 79598	3-[2-[4-(6-fluoro-1,2- benzisoxazol-3-yl)-1- piperidinyl]ethyl]- 2,9-dimethyl-4H- pyrido[1,2- a]pyrimidin-4-one	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Olanzapine; LY 170053; ZYPREX; ZYPREXA; OLANZEK	2-methyl-4-(4- methyl-1- piperazinyl)-10H- thieno[2,3-b][1,5] benzodiazepine	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia; psychosis; depression
Perospirone; SM 9018; LULLAN	cis-2-[4-[4-(1,2- benzisothiazol-3-yl)- 1-piperazinyl]butyl]- hexahydro-1H-isoin- dole-1,3(2H)-dione	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Risperidone; R 64766; RISPERDAL; BELIVON	3-[2-[4-(6-fluoro-1,2- benzisoxazol-3- yl)piperidinyl]ethyl]- 6,7,8,9-tetrahydro-2- methyl-4H-pyrido[1, 2-a]pyrimidin-4-one	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Eplivanserin; SR 46349; SR 46349B	(1Z,2E)-1-(2- fluorophenyl)-3-(4- hydroxyphenyl)-2- propen-1-one (2E)-2- butenedioate (2:1) salt	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	schizophrenia; insomnia; thrombosis
M 100907; MDL 100907	(R)-alpha-(2,3- dimethoxyphenyl)-1- [2-(4- fluorophenyl)ethyl]- 4-piperidinemethanol	5HT antagonist; 5HT2A antagonist	schizophrenia
Sertindole; LU 23174; S 1991; SERDOLECT	1-[2-[4-[5-chloro-1- (4-fluorophenyl)-1H- indol-3-yl]-1- piperidinyl]ethyl]-2- imidazolidinone	5HT antagonist; 5HT2A antagonist; 5HT2C antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia

AS 5370	N-[hexahydro-1-methyl-4-[(3-methylphenyl)methyl]-1H-1,4-diazepin-6-yl]-1H-indazole-3-carboxamide dihydrochloride	5HT antagonist; 5HT3 antagonist	emesis; schizophrenia
BMY 33426		5HT antagonist; 5HT3 antagonist	schizophrenia
BMY 33462	(4-amino-N-(1-azabicyclo-[2,2,2]oct-3-yl)-2-(butan-2-one-3-yl)oxy-5-chlorobenzamine 1.25 fumerate hydrate	5HT antagonist; 5HT3 antagonist	schizophrenia
Ricasetron; BRL 46470; BRL 46470A	endo-2,3-dihydro-3,3-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indole-1-carboxamide	5HT antagonist; 5HT3 antagonist	anxiety; schizophrenia; emesis
5HT7 receptor antagonists		5HT antagonist; 5HT7 antagonist	depression; insomnia; schizophrenia
BTS 79018		5HT antagonist; dopamine antagonist	schizophrenia
Schizophrenia therapy,		AMPA receptor modulators	schizophrenia; depression
bretazenil; Ro 166028; Ro 166028001	(S)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylic acid 1,1-dimethylethyl ester	benzodiazepine partial agonist	schizophrenia
dopamine release inhibitor,		calcium antagonist; dopamine release inhibitor	schizophrenia
SR 141716; SR 141716A	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide	cannabinoid antagonist	schizophrenia

Cholecystokinin B antagonist		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
LY 288513		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
LY 262691	trans-N-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide	cholecystokinin B antagonist; cholecystokinin antagonist	schizophrenia
Alentemol; alentemol hydrobromide; U 68553B	(+)-2-(dipropylamino)-2,3-dihydrophenalen-5-ol	dopamine agonist	schizophrenia
CGS 15873A	trans-(+,-)-1,3,4,4a,5,10b-hexahydro-4-propyl-2H-[1]benzopyrano[3,4-b]pyridin-7-ol hydrochloride	dopamine agonist	schizophrenia
HW 165	trans-(+/-)-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinolin-7-ol, hydrobromide	dopamine agonist	Parkinson disease; schizophrenia
Amisulpride; aminosultopride; AST; DAN 2163; SOCIAN; SOLIAN; ENORDEN; DENIBAN; SULAMID	4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy benzamide	dopamine agonist; dopamine antagonist	schizophrenia; depression
terguride; TDHL; VUFB 6638; ZK 31224; SH 406; DIRONYL; TELURON; TERULON	1,1-diethyl-3-(6-methylergolin-8alpha-yl)urea	dopamine agonist; dopamine antagonist	schizophrenia; hyperprolactinemia



Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQUIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7- tetrahydro-6- (propylamino)- benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
PD 158771	trans-N-[4-[2-(4- phenyl-1- piperazinyl)ethyl]cyclo- hexyl]-2- pyrimidinamine	dopamine agonist; dopamine D2 partial agonist; 5HT1A partial agonist; 5HT agonist	schizophrenia
CI 1007; PD 143188	(R)-1,2,3,6- tetrahydro-4-phenyl- 1-[(3-phenyl-3- cyclohexen-1-yl)m ethyl]pyridine	dopamine agonist; dopamine D2 partial agonist; dopamine D3 partial agonist	schizophrenia
GYKI 22441; BRENFUMOD	2-(4-chlorophenoxy)- 2-methylpropanoic acid 2-[4-[3-[2- (trifluoromethyl)- 10H-phenothiazin-10- yl]propyl]-1- piperazinyl]ethyl ester	Dopamine antagonist Phenothiazine ester	schizophrenia
Isofloxythepin; VUFB 10662	4-[3-fluoro-10,11- dihydro-8-(1- methylethyl)dibenzo[ b,f]thiepin-10-yl]-1- piperazineethanol	Dopamine antagonist	schizophrenia
Bromperidol; R 11333; IMPROMEN; BRIDOL; IMPROMEN DECANOAS; ERODIUM; LUNAPRON; PRINDRIL; ROPEL	4-[4-(4- bromophenyl)-4- hydroxy-1- piperidinyl]-1-(4- fluorophenyl)-1- butanone	dopamine antagonist	schizophrenia
dopamine D4 antagonists, Taisho		dopamine antagonist	schizophrenia

Nemonapride; emonapride; YM 09151; YM 091512; EMILACE; SEPAN; NEPONID	cis-5-chloro-2- methoxy-4- (methylamino)-N-[2- methyl-1- (phenylmethyl)-3- pyrrolidinyl]benzami de	dopamine antagonist	schizophrenia
Savoxepin; cipazoxapine; CGP 19486	3- (cyclopentylmethyl)- 2,3,4,5-tetrahydro- 1H- dibenz[2,3:6,7]oxepin o[4,5-d]azepine-7- carbonitrile	dopamine antagonist	schizophrenia
NGD 931; NGB 566		dopamine antagonist, 5HT agonist, adrenergic agonist; Atypical neuroleptic,	schizophrenia
Quetiapine; quetiapine fumarate; ZD 5077; Zeneca 204636; ICI 204636; SEROQUEL	2-[2-(4- dibenzo[b,f][1,4]thiaz epin-11-yl-1- piperazinyl)ethoxy]et hanol	dopamine antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
Berupipam; NNC 220010	(S)-8-chloro-5(5- bromo-2,3- dihydrobenzofuran-7- yl)-7-hydroxy-3- methyl-2,3,4,5- tetrahydro-1H-3- benzazepine	dopamine antagonist; dopamine D1 antagonist	schizophrenia
CEE 03310; NNC 010687; NNC 687; NO 687; NNC 01- 0687	(S)-5-(2,3-dihydro-7- benzofuranyl)- 2,3,4,5-tetrahydro-3- methyl-8-nitro-1H-3- benzazepin-7-ol	dopamine antagonist; dopamine D1 antagonist	schizophrenia; insomnia
CEE 03320; NNC 220215	Unspecified	dopamine antagonist; dopamine D1 antagonist	schizophrenia
ecopipam; SCH 39166	(6aS-trans)-11- chloro-6,6a,7,8,9,13b- hexahydro-7-methyl- 5H- benzo[d]naphth[2,1- b]azepin-12-ol	dopamine antagonist; dopamine D1 antagonist	schizophrenia

ZD 3638; M 275562	4-[2-(ethylsulfinyl)-3-pyridinyl]-1-(9,10-methanoanthracen-9(10H)-ylmethyl)-4-piperidinol	dopamine antagonist; dopamine D1 antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
zotepine; LODOPIN; NIOLEPT; ZOLEPTIL; ZOPITE; SETOUS; MAJORPIN	2-[(8-chlorodibenzo[b,f]thi-epin-10-yl)oxy]-N,N-dimethylethylamine	dopamine antagonist; dopamine D1 antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist; noradrenalin reuptake inhibitor	schizophrenia
Mosapramine; clobipramine; Y 516; CREMIN	(+,-)-1'-[3-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]hexahydrospiro[imidazo[1,2-a]pyridine-3(2H),4'-piperidin]-2-one	dopamine antagonist; dopamine D2 antagonist	schizophrenia
Remoxipride; remoxipride hydrochloride; FLA 731; A 33547; ROXIAM	(S)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenzamide	dopamine antagonist; dopamine D2 antagonist	schizophrenia
RWJ 25730	1-[[1-methyl-5-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-1H-pyrrol-2-yl]methyl-2-piperidinone	dopamine antagonist; dopamine D2 antagonist	schizophrenia
DU 29894		dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT1A antagonist	schizophrenia
Blonanserin; AD 5423	2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine	dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia

ORG 5222	trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate (1:1)	dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
Amisulpride, (S); (-)-amisulpride	(S)-4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide	dopamine antagonist; dopamine D2 antagonist; dopamine D3 antagonist	schizophrenia
RGH 1756	6-[4-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butoxy]phenyl]imidazo[2,1-b]thiazole	dopamine antagonist; dopamine D3 antagonist	schizophrenia; psychosis
YM 43611	(S)-5-chloro-4-[(cyclopropylcarbonyl)amino]-2-methoxy-N-[1-(phenylmethyl)-3-pyrrolidinyl]benzamide	dopamine antagonist; dopamine D3 antagonist; dopamine D4 antagonist	schizophrenia
CP 293019	7-[(4-fluorophenoxy)methyl]-2-(5-fluoro-2-pyrimidinyl)octahydro-2H-pyrido[1,2-a]pyrazine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
L 745870	3-[[4-(4-chlorophenyl)-1-piperazinyl)methyl]-1H-pyrrolo[2,3-b]pyridine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
NGD 941	2-[4-[(2-phenyl-1H-imidazol-4-yl)methyl]-1-piperazinyl]pyrimidine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
NGD 944; NGD 94-4		dopamine antagonist; dopamine D4 antagonist	schizophrenia

PD 172760	7-[[4-(4-chlorophenyl)-1-piperazinyl]methyl-2H-1,4-benzoxazin-3(4H)-one	dopamine antagonist; dopamine D4 antagonist	schizophrenia
Sonepiprazole; PNU 101387; U 101387G	(S)-4-[4-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-1-piperazinyl]benzenesulfonamide	dopamine antagonist; dopamine D4 antagonist	schizophrenia
Belaperidone; LU 111995	(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[2-[6-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-2,4(1H,3H)-quinazolinedione	dopamine antagonist; dopamine D4 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
dopamine antagonist		dopamine antagonist; dopamine D4 antagonist; dopamine D2 antagonist	schizophrenia; psychosis
HMR 2934		dopamine antagonist; dopamine D4 antagonist; dopamine D2 antagonist; 5HT antagonist	schizophrenia
LEK 8829	(8 $\beta$ )-9,10-didehydro-N,6-dimethyl-N-2-propynylergoline-8-methanamine	dopamine D1 agonist; dopamine D2 antagonist; 5HT antagonist; 5HT2A antagonist; dopamine agonist; dopamine antagonist	schizophrenia; Parkinson disease
levosulpiride; LEVOPRAID	(S)-5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide	dopamine D2 antagonist; dopamine antagonist	emesis; schizophrenia
LU 201640		dopamine D3 antagonist; dopamine antagonist	schizophrenia

fananserin; RP 62203	2-[3-[4-(4-fluorophenyl)-1-piperazinyl]propyl]-2H-naphth[1,8-cd]isothiazole, 1,1-dioxide	dopamine D4 antagonist; dopamine antagonist; 5HT antagonist; 5HT2A antagonist	schizophrenia
valproate semisodium; divalproex sodium; semisodium valproate; AB 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABAergic agonist	epilepsy; migraine; schizophrenia; depression
glycine reuptake inhibitors,		Glycine reuptake inhibitors, GlyT-1	schizophrenia
ciproxifan; compound 359; BP 2359	cyclopropyl[4-[3-(1H-imidazol-4-yl)propoxyl]phenyl]methanone	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
compound 421		histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
metabotropic glutamate receptor modulators		metabotropic glutamate receptor modulators , analgesic	pain; cognitive defect; schizophrenia; epilepsy
osanetant; SR 142801	(R)-N-[1-[3-[1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl-4-phenyl-4-piperidinyl]-N-methylacetamide monohydrochloride	neurokinin antagonist; neurokinin 3 antagonist	schizophrenia; anxiety
SR 48692	2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.1.3,7]decan-2-carboxylic acid	neurotensin antagonist	schizophrenia; cancer
conantokins		NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia

alpha-conopeptides		peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
lithium gamolenic acid; SC 111	(Z,Z,Z)-6,9,12-octadecatrienoic acid lithium salt	phospholipase inhibitor	schizophrenia
panamesine; EMD 57445	(S)-5-[[4-(1,3-benzodioxol-5-yl)-4-hydroxy-1-piperidinyl]methyl]-3-(4-methoxyphenyl)-2-oxazolidinone	sigma agonist; dopamine antagonist	schizophrenia
BMY 14802; BMY 148021	alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol	sigma antagonist	schizophrenia
CNS 1044		sigma antagonist	schizophrenia
CNS 1169		sigma antagonist	schizophrenia
CNS 1307		sigma antagonist	schizophrenia
CNS 3040		sigma antagonist	schizophrenia
MS 355		sigma antagonist	schizophrenia
NPC 16316		sigma antagonist	schizophrenia
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis
CX 516; AMPALEX	1-(6-quinoxalinylicarbonyl)piperidine	Unknown	Alzheimer disease; schizophrenia
Maroxepine; CGP 13442A	2,3,4,5-tetrahydro-3-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-d]azepine	Unknown	schizophrenia

Table 36. Current Candidate Therapeutic Interventions for the Treatment of Spasticity

Product Name	Chemical Name	Action	Indication
Tizanidine; tizanidine hydrochloride; AN 021A; DS 103 282 CH; SIRDALUD; ZANAFLEX; TEMELIN	5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine	alpha adrenergic agonist; alpha2 adrenergic agonist; antispasmodic; muscle relaxant	muscle spasm

botulinum A toxin; Clostridium botulinum toxin type A; DYSPORT	Botulinum toxin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease
botulinum toxin type A; Clostridium botulinum toxin type A; OCULINUM; BOTOX	Botulin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease; migraine
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
GRI 2	Unspecified	Glycine reuptake inhibitors	muscle spasm
afloqualone; HQ 495; AROFUTO; ALOFT; PLENCO; AFROBARON	6-amino-2-(fluoromethyl)-3-o-tolyl-4(3H)-quinazolinone	muscle relaxant	surgery
lanperisone; lanperisone hydrochloride; NK 433	2-methyl-3-(1-pyrrolidinyl)-1-[4-(trifluoromethyl)phenyl]-1-propa none	muscle relaxant	muscle spasm; urinary incontinence
MS 322	(R)-(+)-3-phenyl-5-(2-(1-pyrrolidinylmethyl)butyryl)isoxazole hydrochloride	muscle relaxant	muscle spasm
threonine, L-; L-threonine; IP 204	L-threonine	unknown	muscle spasm

Table 37. Current Candidate Therapeutic Interventions for the Treatment of Stroke

Product Name	Chemical Name	Action	Indication
repinotan; BAY x 3702	(R)-2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	5HT agonist; 5HT1A agonist	stroke; trauma
Levemopamil; emopamil, (S)	(2S)-2-isopropyl-5-(methylphenethylamino)-2-phenylvaleronitrile	5HT antagonist; 5HT2 antagonist; calcium antagonist; antihypoxic	stroke



5HT4 human neuroreceptor; neuroreceptor, 5HT4		5HT4 human neuroreceptor	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
A3 receptor regulator		Adenosine 3 receptor ligand	stroke
Adenosine A1 agonists		adenosine A1 agonist	stroke
AMP 579		adenosine agonist; adenosine A1 agonist; adenosine A2 agonist	myocardial infarction; stroke
GP 04012		adenosine antagonist; adenosine A1 antagonist	stroke; trauma
Adenosine allosteric modulators		adenosine regulating agent	cardiovascular disease; cancer; stroke
Adenosine regulating agents, stroke		adenosine regulating agent	stroke
CPC 407		adenosine regulating agent	stroke
GP 1668; GP 668	5-amino-1-[beta-D-5-phosphoribofuranosyl]-imidazole-1-N-[(4-nitrophenyl)methyl]carboxamide)	adenosine regulating agent	angina; stroke
NS 257		AMPA antagonist; glutamate antagonist	stroke
NS 479		AMPA antagonist; glutamate antagonist	stroke; neuropathy
S 176252; S 17625	(6,7-dichloro-1,2-dihydro-2-oxo-3-quinolinyl)phosphonic acid	AMPA antagonist; glutamate antagonist	stroke
SH 608		AMPA antagonist; glutamate antagonist	stroke

SPD 502; NS 1209	2-[[[5-[4- [(dimethylamino)sulf onyl]phenyl]- 1,2,6,7,8,9- hexahydro-8-methyl- 2-oxo-3H- pyrrolo[3,2- h]isoquinolin-3- ylidene]amino]oxy]- 4-hydroxybutanoic acid monosodium salt	AMPA antagonist; glutamate antagonist	stroke; neurodegeneration
SYM 2189		AMPA antagonist; glutamate antagonist	stroke; epilepsy
SYM 2206	8-(4-aminophenyl)-5- methyl-N-propyl-1,3- dioxolo[4,5- g]phthalazine-6(5H)- carboxamide	AMPA antagonist; glutamate antagonist	stroke; epilepsy
YM 872	3,4-dihydro-7-(1H- imidazol-1-yl)-6- nitro-2,3-dioxo- 1(2H)- quinoxalineacetic acid	AMPA antagonist; glutamate antagonist	stroke
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1- [[[2'-(1H-tetrazol-5- yl)[1,1'-biphenyl]-4- yl]methyl]-1H- imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
TN 871	1-(6-butyl-6,7- dihydro-5H- indeno[5,6-d]-1,3- dioxol-5-yl)-4-methyl piperazine dihydrochloride	Anoxia protection	stroke
apocuanzine; IDB 1057	(3alfa,16alfa,17alfa)- 17,21-epoxy-12- methoxy- eburnamenine-14- carboxylic acid methyl ester	antihypoxic	stroke
hypoxia therapy		antihypoxic	heart ischemia; stroke
KF 17329		antihypoxic	stroke; brain ischemia
KF 19863		antihypoxic	stroke

MS 153	(-)-1-nicotinoyl-5-methyl-2-pyrazoline	anti-ischemic	stroke
YM 737	N-(N-L-gamma-glutamyl-L-cysteinyl)-glycine, 1-(1-methyl)ester	anti-ischemic	stroke
BXT 51072	3,4-dihydro-4,4-dimethyl-2H-1,2-benzoselenazine	antioxidant	stroke; inflammatory bowel disease
CEB 1370		antioxidant	stroke
LY 231617	2,6-bis(1,1-dimethylethyl)-4-[(ethylamino)methyl]phenol hydrochloride	antioxidant	stroke
Neurodegenerative disease therapy		antioxidant	stroke; Alzheimer disease
U 101033E	6,7,8,9-tetrahydro-9-[2-(4-morpholinyl)ethyl]-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole dihydrochloride	antioxidant	stroke; neurodegeneration; brain ischemia
MDL 101002	3,4-dihydro-3,3-dimethylisoquinoline 2-oxide	antioxidant; free radical scavenger	stroke; neurodegeneration; septic shock
synthetic catalytic scavenger analogues; SCS analogues		antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
VANTOX		antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
secreted apoptosis related proteins; SARPS		apoptosis inducer; apoptosis inhibitor	cancer; myocardial infarction; stroke
CNS therapy, IDUN; CNS therapy		apoptosis inhibitor; caspase inhibitor	stroke; Parkinson disease; amyotrophic lateral sclerosis
VM 201		blood clotting factor IXa inhibitor; proteinase inhibitor	thrombosis; stroke
factor Xa inhibitor		blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis; stroke; myocardial infarction

JTV 803		blood clotting factor Xa inhibitor; proteinase inhibitor	stroke; myocardial infarction; thrombosis
deltibant; CP 0127; SB 238592; BRADYCOR	hexamethylene-bis-(succinimido-Cys(Leu)-Phe-Gly-Hyp-Pro-Arg)	bradykinin antagonist; cicatrizant	trauma; stroke
AJ 3941	11-(4-cinnamyl-1-piperazyl)-3-fluoro-6,11-dihydrodibenzo[6,e]oxepine-2 maleate	calcium antagonist	stroke
calcium antagonist		calcium antagonist	stroke
lifarizine; RS 87476; RS 87476000	1-(diphenylmethyl)-4-[[5-methyl-2-(4-methylphenyl)-1H-imidazol-4-yl]methyl]piperazine	calcium antagonist	stroke; brain ischemia
NCC 161; LY 042826		calcium antagonist	ischemia; stroke
S 830256	3-cyclo-pentyl-5-cyclo-pentyloxyethoxycarbonyl-4,7-dihydro-1,6-di methyl-4-(2-nitro-phenyl)pyrazolo-(3,4-b)pyridine hydrochloride	calcium antagonist	stroke
S 830327	methyl-4,7-dihydro-3-n-butyl-6-methyl-4-(3-nitrophenyl)thieno(2,3-b)pyridine-5-carboxylate	calcium antagonist	stroke
NPS 846		calcium antagonist; analgesic	stroke; epilepsy; pain
ziconotide; SNX 111; CI 1009	omega-conotoxin MVIIA	calcium antagonist; analgesic; peptide	stroke; pain; brain ischemia
rumbrin	(1Z,3E,5E,7E)-6-(8-(3-chloro-1H-pyrrol-2-yl)-1-methyl-1,3,5,7-octatetraenyl)-4-methoxy-3-methyl-2H-pyran-2-one	calcium antagonist; free radical scavenger	stroke

F 0401; D 31D	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenyl-methyl-1,4-dro-2,6-dimethyl-4-(3-nitrophenyl) 3,5-pyridinedicarboxylate	calcium antagonist; PAF antagonist; thromboxane synthetase inhibitor; vasodilator	stroke
S 312; S 312d; S 830312	4,7-dihydro-6-methyl-3-(2-methylpropyl)-4-(3-nitrophenyl)-thieno[2,3-b]pyridine-5-carboxylic acid methyl ester	calcium antagonist; vasodilator	stroke
U 92032	7-[[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl)methyl]-2-[(2-hydroxyethyl)amino]-4-(1-methylethyl)-2,4,6-cycloheptatrien-1-one	calcium antagonist; vasodilator	stroke
calcium channel blocker		calcium channel blocker	stroke
Calcium channel blockers		calcium channel blocker	stroke
calcium channel blockers		calcium channel blocker	stroke
CPC 301		calcium channel blocker	stroke
CPC 304		calcium channel blocker	stroke
CPC 317		calcium channel blocker	stroke
CPC 8027		calcium channel blocker	stroke; epilepsy
CPC 8029		calcium channel blocker	stroke; epilepsy
NS 3034		calcium channel blocker	stroke
NS 638		calcium channel blocker	stroke

SB 201823A	4-[2(3,4-dichlorophenoxy)ethyl]-1-pentyl piperidine hydrochloride	calcium channel blocker	stroke
drug delivery system, conopeptides		calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
DP 16	Acylglycerol derivative of BAPTA	Calcium chelator	epilepsy; stroke; heart ischemia
stroke therapy	N-1-naphthalenyl-1-(3-phenoxypropyl)-4-piperidinamine	Calcium lowering agent	stroke
DY 9760	3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-1-(1H-imidazol-4-ylmethyl)-5,6-dimethoxy-1H-indazole	calmodulin antagonist	brain ischemia; stroke
calpain inhibitors		calpastatin	stroke
calpain inhibitors,		calpastatin; proteinase inhibitor	stroke
caspase antagonists		caspase inhibitor; apoptosis inhibitor	stroke; myocardial infarction
KF 10632; IKY 432	2-methyl-1-[1-oxo-3-[4-(trifluoromethyl)phenyl]-2-propenyl]piperidine	Cerebroprotectant	stroke
acetyl-L-carnitine; acetylcarnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine	Cholinergic agonist stimulation of nerve growth	Alzheimer disease; stroke; diabetes; neuropathy
Aniracetam; Ro 135057; SARPUL; DRAGANON; APAMET; RESET	1-(4-methoxybenzoyl)-2-pyrrolidinone	cholinergic antagonist	cognitive defect; stroke

Citicoline; citicoline sodium; cytidil diphosphocholine; CDP choline; IP 302; NEUROX; ALPHACOLIN; HIPERCOL; NEUREX; SOMAZINA; TRAUSAN	P'-[2-(trimethylammonio)ethyl] citidine 5'-(trihydrogen diphosphate)	cholinesterase inhibitor	stroke
Fibroblast growth factor agonist,		cicatrizant; FGF agonist	skin ulcer; stroke
MAb, C5 single chain; Mab, complement C5; 5G1.1-SC		complement inhibitor; monoclonal antibody; NSAID	inflammation; myocardial infarction; stroke; ischemia
NBI 102		CRF antagonist	stroke
NBI 104		CRF antagonist	depression; stroke
interleukin-8 antagonists; IL-8 antagonists		cytokine antagonist	myocardial infarction; stroke; respiratory distress syndrome
endothelin B antagonist,		endothelin B antagonist; endothelin antagonist	stroke
Endothelium-associated disease therapy,		Endothelin receptor ligand	stroke; asthma
ABPI 126		estrogen agonist	stroke
ABPI 127		estrogen agonist	stroke
excitatory amino acid antagonists		excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
NPC 18123		excitatory amino acid antagonist; glutamate antagonist	epilepsy; stroke
excitatory amino acid receptor modulators		Excitatory amino acid receptor ligand	stroke
APO 99		free radical scavenger	stroke; ischemia; reperfusion injury
K 7259	hexahydro-1,4-bis[4-(3,4,5-trimethoxyphenyl)butyl]-1H-1,4-diazepine dihydrochloride	free radical scavenger	stroke
NXY 059		free radical scavenger	stroke

Pyrrolostatin	4-geranylpyrrole-2-carboxylic acid	free radical scavenger	stroke
resorstatin		free radical scavenger	stroke
stobadine; DH 1101; DP 1031	(4aR,9bS)-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole dihydrochloride	free radical scavenger	ischemia; stroke
TAK 218	(S)-2,3-dihydro-2,4,6,7-tetramethyl-2-[(4-phenyl-1-piperidiny)methyl]-5-benzofuranamine dihydrochloride	free radical scavenger	stroke; trauma
EUK 134	(SP-5-13)-chloro[[2,2'-(1,2-ethanediylbis[(nitrilo-kappaN)methylidyne]]bis[6-methoxyphenolato-kappaO1]]]-manganese	free radical scavenger; antioxidant	stroke
free radical scavengers		free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301		free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
EPC K1; CHX 3107	[2R-[2R*(4R*,8R*)]]-2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl hydrogen phosphate] L-ascorbic acid esters, monopotassium salt	free radical scavenger; phospholipase inhibitor; cytokine antagonist; NSAID	stroke



OC 5186	(5Z,13E,15S)-15-hydroxy-9-oxo-prosta-5,8(12),13-trien-1-oic acid, homopolymer, ester with L-ascorbic acid	free radical scavenger; prostanoid	cancer; stroke; malaria
BMS 183729; BMY 20862	5,6-dihydro-11-methyl-11H-pyrimido[4,5-6][1,4]benzodiazepine	GABA agonist	neuropathy; stroke
clomethiazole; CMZ; HEMINEVRIN; ZENDRA		GABA modulator	insomnia; stroke
GM-1; ganglioside GM-1;	monosialotetrahexosylganglioside	ganglioside	stroke
siagoside; AGF 2	[R-[R*,S*-(E)]]-N-[1-[[[O-[1',2'-anhydro]-N-acetyl-alpha-neuraminosyl-(2->3)-O-[O-beta-D-galactopyranosyl-(1->3)-2-(acetyl-amino)-2-deoxy-beta-D-galactopyranosyl-(1->4)-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecenyl]octadecanamide	ganglioside	cognitive defect; stroke
stroke therapy		glutamate agonist; mGluR agonist	stroke
HF 7		glutamate antagonist	stroke
NNC 079202; FG 9202	1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo(f)quinoxaline-7-sulfon amide	glutamate antagonist	epilepsy; stroke
NS 409; PD 152247; PNQX	1,4,7,8,9,10-hexahydro-9-methyl-6-nitro-pyrido[3,4-f]quinoxaline-2,3-dione	glutamate antagonist	stroke
AMPA antagonist		glutamate antagonist; AMPA antagonist	stroke

CP 465022	3-(2-chlorophenyl)-2-[2-[6-[(diethylamino)methyl]-2-pyridinyl]ethenyl]-6-fluoro-4(3H)-quinazolinone (Z)-2-butenedioate (1:1)	glutamate antagonist; AMPA antagonist	stroke
NNC 070775		glutamate antagonist; AMPA antagonist	stroke
YM 90K; YM 900	1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione monohydrochloride	glutamate antagonist; AMPA antagonist	stroke
sinnabidol; HU 211; PA 50211; DEXANABINOL	(6aS-trans)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol	glutamate antagonist; cannabinoid; NMDA antagonist; free radical scavenger	cognitive defect; stroke; trauma; myocardial infarction; glaucoma
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
CP 283097	(3R-cis)-3-[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]-3,4-dihydro-2H-1-benzopyran-4,7-diol	glutamate antagonist; NMDA antagonist	Parkinson disease; stroke; trauma
dizocilpine; dizocilpine maleate; MK 801	(+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
EAA 090	[2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid	glutamate antagonist; NMDA antagonist	stroke

GPI 3000; NPC 17742	[1R-[1alpha(R*),2alpha]]-alpha-amino-2-(2-phosphonoethyl)cyclohexane propanoic acid	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
L 701324	7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-2(1H)-quinolinone	glutamate antagonist; NMDA antagonist	epilepsy; stroke
MRZ 2579; MRZ 2/579		glutamate antagonist; NMDA antagonist	Parkinson disease; addiction; stroke
2-PMPA; GPI 5000		glutamate release inhibitor	stroke; neurodegeneration
BW 1003C87	Ethanesulfonic acid compd. with 5-(2,3,5-trichlorophenyl)-2,4-pyrimidinediamine (1:1)	glutamate release inhibitor	stroke
sipatrigine; BW 619C89; BW 619C	2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-4-pyrimidinamine	glutamate release inhibitor	stroke
ACEA 1031		glycine antagonist	stroke
gavestinel; GV 150526; GV 150526A; GV 150526X; GG 526; GV 526A	(E)-4,6-dichloro-3-[3-oxo-3-(phenylamino)-1-propenyl]-1H-indole-2-carboxylic acid	glycine antagonist	stroke
HMR 2371		glycine antagonist	stroke
M 241247		glycine antagonist	stroke
M 244249		glycine antagonist	stroke
ZD 9379	7-chloro-3,5-dihydro-2-(4-methoxy-2-methylphenyl)-pyridazino[4,5-b]quinoline-1,4-10(5H)-trione, base and salts	glycine antagonist	stroke
glycoprotein IIb/IIIa antagonist; P246		glycoprotein IIb/IIIa antagonist; peptide; platelet antiaggregant	thrombosis; heart ischemia; stroke
cromafiban		glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke

EMD 122347; YM 028		glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina; stroke
MK 852; L 367073	N-acetyl-L-cysteinyl-L-asparaginyl-(4R)-5,5-dimethyl-4-thiazolidinecarbonyl-4-(aminomethyl)-L-phenylalanylglycyl-L-alpha-aspartyl-L-cysteine, cyclic (1-7)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	stroke; thrombosis
SDZ GPI562	Unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke
pimagedine; pimagedine hydrochloride; aminoguanidine; GER 11; YM 585	aminoguanidine	Glycosylation end-product inhibitor	diabetes; kidney disease; retinopathy; atherosclerosis; neuropathy; stroke
fibroblast growth factor-10		Growth factor, fibroblast growth factor-10	stroke; trauma
insulin-like growth factor-1; IGF-1		Growth factor, IGF-1	brain ischemia; trauma; stroke; neurodegeneration
transforming growth factor beta; TGFbeta		Growth factor, TGF-beta	brain ischemia; trauma; stroke; neurodegeneration
ersofermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; TROFAK	N-(N-glycyl-L-threonyl)-basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced)	growth factor; cicatrizant	stroke
trafermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; trofermin; KCB 1; CAB 2001; FIBLAST	2-155-fibroblast growth factor, basic (human clone lambdaKB7/lambda HFL 1 precursor reduced)	growth factor; cicatrizant	skin ulcer; osteoporosis; stroke; neuropathy; peripheral vascular disease; coronary artery disease

drug delivery system; proteinase inhibitor and trophic factor secreting implant; proteinase inhibitor secreting implant; trophic factor secreting implant		growth factor; neurotrophic factor; proteinase inhibitor	stroke
heat shock transcription factor modulators, ischemia; heat shock transcription factor modulators, cancer		heat shock transcription factor modulators	stroke; ischemia; reperfusion injury; cancer
RSR 13	2-[4-[2-[(3,5- dimethylphenyl)amin o]-2- oxoethyl]phenoxy]-2- methylpropanoic acid	Hemoglobin, allosteric modification	surgery; heart ischemia; stroke
RSR 4	2-[4-[2-[(3,5- dichlorophenyl)amino ]-2- oxoethyl]phenoxy]-2- methylpropanoic acid	Hemoglobin, allosteric modification	cancer; surgery; heart ischemia; stroke
RSR 46	2-[4-[2-[(2,3-dihydro- 1H-inden-5- yl)amino]-2- oxoethyl]phenoxy]-2- methylpropanoic acid	Hemoglobin, allosteric modification	cancer; surgery; heart ischemia; stroke
JP 7		Hemoglobin, synthetic allosteric modifiers of	cancer; surgery; heart ischemia; stroke
enoxaparin sodium; low molecular weight heparin; enoxaparin; enoxaparine; PK 10169; RPY 005; RP 54563; LOVENOX; CLEXAN; CLEXANE	heparin sodium salt	heparinoid	thrombosis; angina; stroke; myocardial infarction
GT 2016	1-(5-cyclohexyl-1- oxopentyl)-4-(1H- imidazol-4- yl)piperidine	histamine antagonist; histamine H3 antagonist	cognitive defect; stroke; attention deficit disorder
MAb, 1A29; MAb, ICAM-1		ICAM monoclonal antibody	stroke

NZ 097		IGF-1 ligand	brain ischemia; trauma; stroke; neurodegeneration
antibody-mediated stroke inhibitor		immunosuppressant; biotechnology	gynecological; stroke; thrombosis; myocardial infarction
insulin-like growth factor binding protein ligand inhibitors, IGFBP ligand inhibitors		insulin-like growth factor binding protein ligand inhibitors	stroke; neurodegeneration
neutrophil inhibitory factor; NIF; CORLEUKIN NIF		integrin antagonist; cell adhesion inhibitor; NSAID	reperfusion injury; inflammation; stroke
AM 36		Ion channel blocker	stroke; trauma
cation channel blocker		Ion channel blocker, cation channel blocker	stroke
Tirilazad; tirilazad mesylate; trilazad; U 74006F; FREDOX	21-[4-(2,6-di-1-pyrrolidiny-4-pyrimidinyl)-1-piperazinyl]-16-alpha-methyl-pregn-1,4,9-(11)-triene-3,20-dione	lazaroid	brain ischemia; stroke; trauma; heart ischemia; kidney disease
MAbs, leukocytes		Leukocytes monoclonal antibody	stroke
MAb, 23F2G; MAb, leukointegrin; Hu 23F2G		leukointegrin monoclonal antibody	multiple sclerosis; cardiovascular disease; myocardial infarction; stroke
stroke and trauma therapy, morphogenic proteins,		morphogenic proteins	trauma; stroke
Lubeluzole; R 87926; PROSYNAP	(S)-4-(2-benzothiazolylmethylamino)-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol	Neuroprotectant	stroke; Alzheimer disease
drug delivery system, neurotrophic peptide; neurotrophic peptide delivery system; TROFEXIN-A	Trofexin-A	Neurotrophic factor	stroke

Neurotrophic peptide; TROFEXIN		neurotrophic factor; peptide; growth factor	stroke
NOX 101	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 151		nitric oxide scavenger	stroke
A 84643	[S-(E)]-N-(4-amino- 5-hydroxy-2- pentenyl)-N'- nitroguanidine	nitric oxide synthase inhibitor	stroke; ischemia
Neuronal nitric oxide synthase inhibitors		nitric oxide synthase inhibitor	stroke; trauma
nitric oxide synthase inhibitors		nitric oxide synthase inhibitor	Parkinson disease; stroke
nitric oxide inhibitors,		nitric oxide synthetase inhibitor; NSAID	stroke; rheumatoid arthritis
ARL 15896; FPL 15896; ARL 15896AR; FPL15896AR	(S)-alpha-phenyl-2- pyridineethanamine	NMDA antagonist; glutamate antagonist	stroke
BIII 277; BIII 277CL	[2R- [2alpha,3(R*),6alpha] [1,2,3,4,5,6- hexahydro-3-(2- methoxypropyl)- 6,11,11-trimethyl-2,6- methano-3- benzazocin-9-ol hydrochloride	NMDA antagonist; glutamate antagonist	stroke
CGP 40116	[R-(E)]-2-amino-4- methyl-5-phosphono- 3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy; stroke
CNS 1118	N,N'-dimethyl-N,N'- bis(1- naphthyl)guanidine	NMDA antagonist; glutamate antagonist	stroke
CNS 1531	(+)-3-fluoro-10,5- iminomethano-10,11- dihydro-5H- dibenzo(a,d)cyclohept ane	NMDA antagonist; glutamate antagonist	stroke

CP 101606	[S-(R*,R*)]-4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-1-piperidineethanol	NMDA antagonist; glutamate antagonist	stroke; trauma; neurodegeneration
eliprodil; SL 820715	(+,-)-alpha-(4-chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol	NMDA antagonist; glutamate antagonist	neuropathy; stroke; trauma
ES 2421		NMDA antagonist; glutamate antagonist	stroke
L 703717	7-chloro-4-hydroxy-3-[3-(4-methoxyphenyl)methyl]phenyl]-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy; stroke
L 708541		NMDA antagonist; glutamate antagonist	epilepsy; stroke
licostinel; ACEA 1021; CGP 63446	6,7-dichloro-5-nitro-1,4-dihydro-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist	stroke; trauma
MDL 100453	4-oxo-5-phosphono-D-norvaline	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy; stroke
NMDA antagonist		NMDA antagonist; glutamate antagonist	epilepsy; stroke; neuropathy
NMDA antagonist, subtype specific, SSNRA		NMDA antagonist; glutamate antagonist	stroke; trauma
NPS 1506		NMDA antagonist; glutamate antagonist	stroke; trauma
P 7189	2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine hydrochloride	NMDA antagonist; glutamate antagonist	stroke; neuropathy
PD 158473	3-(1-naphthalenyl)-5-(phosphonomethyl)-L-phenylalanine	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
PD 159913		NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
Ro 256981		NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
selfotel; CGS 19755	cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid	NMDA antagonist; glutamate antagonist	stroke; trauma



SM 18400		NMDA antagonist; glutamate antagonist	stroke
aptiganel; CNS 1102; CDD 2515A; CERESTAT	N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-guanidine	NMDA antagonist; glutamate antagonist; analgesic	stroke; neuropathy; trauma; Parkinson disease; pain
conantokins		NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia
ADCI; SGB 017; ADCI	10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine-5-carboxamide	NMDA antagonist; glutamate antagonist; sodium channel blocker	epilepsy; stroke
ABS 401		Nonglutaminergic neuromodulators	neuropathy; stroke
notch signalling pathway modulators		notch signalling pathway modulators	stroke; cognitive defect; cancer
PS 519		NSAID; anti- ischemic; proteinase inhibitor	inflammation; stroke
BB 823		PAF antagonist	septic shock; stroke
BN 50739	6-(2-chlorophenyl)-9-[2-[(3,4-dimethoxyphenyl)thio]-1-thioxoethyl]-7,8,9,10-tetrahydro-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist	hypotension; septic shock; stroke
ACTH (4-10); SEMAX		peptide	cognitive defect; trauma; stroke
corticotropin- releasing factor; corticotropin- releasing hormone; CRF; XERECEPT		peptide	cancer; stroke; trauma
pituitary adenylate cyclase activating polypeptide; PACAP	Unspecified	peptide	stroke
conantokin G		peptide; glutamate antagonist; NMDA antagonist	stroke; brain ischemia; epilepsy

denbufylline; BRL 30892	1,3-dibutyl-3,7-dihydro-7-(2-oxopropyl)-1H-purine-2,6-dione	phosphodiesterase inhibitor; vasodilator; xanthine	stroke
coronary artery disease therapy,		platelet antiaggregant	stroke; coronary artery disease
clopidogrel; clopidogrel bisulfate; SR 25990; SR 25990C; DV 7314; PCR 4099; SR 25990B; SR 25990A; SR 25990D; SR 25990E; PLAVIX; ISCOVER	(S)-alfa-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester	platelet antiaggregant	thrombosis; stroke; ischemia
ticlopidine; ticlopidine hydrochloride; 5332 C; 4 C 32; PCR 5332; PICLODIN; PICLONADINE; PROPACALL; TICLID; PANALDINE; ROBETARL; RONDORIN	5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine	platelet antiaggregant; calcium antagonist	stroke; thrombosis
abciximab; abciximab; MAb, F(ab') <sub>2</sub> fragment platelet; MAb, 7E3; c7E3 FAb; c7E3; ReoPro; CENTORX	immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhC.gamma.1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3V.kappa.hc.kappa.alpha.light chain	platelet antiaggregant; monoclonal antibody	thrombosis; restenosis; angina; stroke; myocardial infarction
GPI 6000		poly (ADP ribose) polymerase inhibitor	stroke
GPI 6150		poly (ADP ribose) polymerase inhibitor	stroke; myocardial infarction

KC 399	[N-(2-cyanoethyl)-2,2-bisfluoromethyl-6-nitro-2H-1-benzopyran-4-carbothioamide]	potassium channel activator	angina; stroke
LOE 908	3,4-dihydro-6,7-dimethoxy-alpha-phenyl-N,N-bis[2-(2,3,4-trimethoxyphenyl)ethyl]-1-isoquinolineacetamide	potassium channel blocker	stroke
BMS 204352		potassium channel modulator	stroke
NS 1619	1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one	potassium channel modulator; bronchodilator	stroke; asthma
proline transport inhibitors		Proline transport inhibitor	epilepsy; stroke
drug delivery system, lipid microsphere, clinprost; clinprost lipid microsphere; TTC 909; ARTEON	[3aS-[3aalpha,5beta,6alpha(1E,3R*),6aalpha]]-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-2-pentalenepentanoic acid methyl ester	prostanoid; platelet antiaggregant	thrombosis; stroke
fasudil; fasudil hydrochloride; AT 877; HA 1077; HA 004; ERIL	hexahydro-1-(5-isoquinolylsulfonyl)-1H-1,4-diazepine	protein kinase inhibitor; protein kinase C inhibitor; vasodilator	brain ischemia; stroke; angina; HIV infection
CPC 211; CERESINE		Pyruvate dehydrogenase activation to reduce lactic acid	stroke; trauma
SA 4503	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	sigma agonist	Alzheimer disease; depression; cognitive defect; stroke

BIII 890		sodium channel blocker	stroke
sodium channel blocker		sodium channel blocker	stroke
SL 34082908; SL 34.0829-08; SL 34.0829		sodium channel blocker; calcium channel blocker	stroke; brain ischemia
BIIR 561		sodium channel blocker; glutamate antagonist; AMPA antagonist	stroke
BM 27	4-(cycloheptylamino)-N-[(cycloheptylamino)carbonyl]-3-pyridinesulfonamide	sulfonylurea	stroke
SNO-tissue plasminogen activator; NMI 106		thrombolytic	stroke; myocardial infarction
Tisokinase; tissue plasminogen activator, natural; tPA, natural; AK 124; PLASVATA; HAPASE		thrombolytic	thrombosis; stroke
Prourokinase; PUK; rProUK; A 74187; PROLYSE		thrombolytic; plasminogen activator	thrombosis; stroke
Alteplase; tissue plasminogen activator; tPA; ACTIVASE; ACTILYSE; ACTIVACIN; GRTPA		thrombolytic; plasminogen activator; cicatrizant	thrombosis; skin ulcer; stroke
KT 2962; KT 2-962	3-[4-[(4-chlorophenyl)sulfonylamino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
Isbogrel; CV 4151; A 66900; ANTEXAN	(E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; stroke

Ozagrel; ozagrel sodium; OKY 046; DOMENAN; CATACLOT; XANBON; VEGA	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	stroke; thrombosis; asthma; cough
Y 20811	4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethylbenzoic acid, monosodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; asthma; stroke
NZ 093		Undisclosed receptor ligand	brain ischemia; trauma; stroke; neurodegeneration
CNS 1		Unknown	stroke
EAB 318		Unknown	stroke
ONO 2506		unknown	stroke
SB 221420		Unknown	stroke
SPI 29		Unknown	myocardial infarction; stroke
SPI 42		Unknown	myocardial infarction; stroke
ST 765		Unknown	stroke
stroke therapy		Unknown	stroke; trauma
TV 2711; 2711	Polyamine	Unknown	stroke; trauma
Pentoxifylline; oxpentifylline; EBISANIN; SEVSTAN; TRENTAL; TORENTAL	3,7-dimethyl-1-(5-oxo-hexyl)xanthine	xanthine; vasodilator	peripheral vascular disease; stroke; atherosclerosis

Table 38. Current Candidate Therapeutic Interventions for the Treatment of Arthritis.

Product Name	Chemical Name	Action	Indication
BW 4C; BW A4C; BW 4C86	N-(3-phenoxy-phenyl-2-propenyl)acetoxyhydroxyamic acid	5 lipoxygenase inhibitor; chelating agent; NSAID	arthritis; psoriasis
tenidap; tenidap sodium; CP 66248; CP 6624842; KENIDA; ENABLE; ENABLEX; REUMATEN	(Z)-5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide	5 lipoxygenase inhibitor; COX inhibitor; NSAID	rheumatoid arthritis; arthritis
flobufen; VUFB 16066	2',4'-difluoro-alpha-methyl-gamma-oxo-[1,1'-biphenyl]-4-butanoic acid	5 lipoxygenase inhibitor; COX inhibitor; NSAID	rheumatoid arthritis
ZD 2138; ICI D2138	6-[[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-2(1H)-quinolinone	5 lipoxygenase inhibitor; NSAID	arthritis; asthma
AKI 1	unspecified	adenosine regulating agent; NSAID	inflammation; arthritis
AKI 2	unspecified	adenosine regulating agent; NSAID	inflammation; arthritis
analben	unspecified	analgesic	rheumatoid arthritis; pain
drug delivery system, OSAT ibuprofen; ibuprofen sustained release	unspecified	analgesic; NSAID	pain; rheumatoid arthritis; osteoarthritis; inflammation
SC 107	unspecified	analgesic; NSAID	arthritis; pain
samarium 153 Sm lexidronam; Sm 153-EDTMP; samarium 153-EDTMP; samarium EDTMP; CYT 424; QUADRAMET	(OC-6-21)-[[[1,2-ethanediylbis[nitrilobis(methylene)]tetrakis(phosphonato)](8-)-N,N',OP,OP',OP'',OP''']-samarate(5-)-153Sm	analgesic; NSAID; radiotherapeutic	cancer; pain; rheumatoid arthritis
AE 941; NEOVASTAT; NEORETNA; PSOVASCAR; ARTHROVAS	unspecified	angiogenesis inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; eye disease; retinopathy

FR 111142; WF 2015A	4,5-dihydroxy-2-hexenoic acid 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester	angiogenesis inhibitor; NSAID	cancer; rheumatoid arthritis; retinopathy
troponin I; cartilage derived inhibitor	unspecified	angiogenesis inhibitor; NSAID; biotechnology	cancer; rheumatoid arthritis; eye disease
MHC II peptidomimetic, rheumatoid arthritis	unspecified	Antagonists of MHC	rheumatoid arthritis
SB 226882	4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-N-methyl-2-pyrimidinamine	antifungal; MAP kinase inhibitor; signal transduction inhibitor; imidazole	inflammation; asthma; rheumatoid arthritis
ZYN-LINKER conjugated methotrexate	unspecified	antimetabolite; NSAID	cancer; rheumatoid arthritis; psoriasis
TRK 530	[[[4-(methylthio)phenyl]thio]methylene]bisphosphonic acid disodiumsalt	antioxidant; bisphosphonate	rheumatoid arthritis
LY 221068	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-3-(dimethylamino)-4-thiazolidinone	antioxidant; NSAID	arthritis
LY 269415	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-3-(methylamino)-4-thiazolidinone	antioxidant; NSAID	arthritis
AHR 15010	1-[(2-methoxyphenoxy)methyl]-1,2-ethanediyl ester of sulfamic acid	carbonate dehydratase inhibitor; NSAID	arthritis

caspase inhibitors, Cytovia	unspecified	caspase inhibitor	neurodegeneration; myocardial infarction; rheumatoid arthritis; septic shock
ICE inhibitor, IDUN	unspecified	caspase inhibitor; apoptosis inhibitor; IL-1 beta converting enzyme inhibitor; immunosuppressant	transplant rejection; septic shock; rheumatoid arthritis; inflammatory bowel disease; diabetes
VLA4 integrin antagonist, Cytel	unspecified	cell adhesion inhibitor; integrin antagonist; VLA 4 antagonist; NSAID	asthma; rheumatoid arthritis; multiple sclerosis
drug delivery system, somatomedin C; drug delivery system, insulin-like growth factor-1; somatomedin C DepoFoam; Depo IGF-1	unspecified	cicatrizant; hormone; NSAID; growth factor	rheumatoid arthritis; osteoporosis
fibroblast anticollagenase; FIBAC; anticollagenase fibroblast	unspecified	cicatrizant; NSAID	arthritis; cancer; skin ulcer; arthritis
BB 926	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis; eye disease
collagenase inhibitors, Affymax	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis; inflammation
collagenase inhibitors, Xenova; XR 168 series	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis



Ro 319790	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; arthritis
GR 129574A	(R)-N-[1-carboxy-3-(1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl)propyl]-L-leucyl-N-methyl-L-phenylalaninamide mono(trifluoroacetate)	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis
Ro 323555; TROCADE	beta-(cyclopentylmethyl)-N-hydroxy-gamma-oxo-alfa-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-1-piperidinebutanamide	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis
WY 46135	N-[[[(5-chloro-2-benzothiazolyl)thio]phenylacetyl]-L-cysteine	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis
MAb, C5; MAb, complement C5; 5G1.1	unspecified	complement inhibitor; monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus
hyaluronic acid 6-alpha-methylprednisolone ester; HYC 141	unspecified	corticosteroid	rheumatoid arthritis
MYC 2095	unspecified	corticosteroid	arthritis
rimexolone; trimexolone; ORG 6216; RIMEXEL; VEXOL	(11beta,16alpha,17beta)-11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)androst-1,4-dien-3-one	corticosteroid	rheumatoid arthritis; inflammation; eye disease

deflazacort; azacort; L 5458; MDL 458; AZACORTID; CALCORT; LANTADIN; DEFLAN; FLANTADIN; DEZACOR; ZAMENE; ROSILIN; DEFLAMON; PRANDIN	(11beta,16beta)-21-(acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione	corticosteroid	rheumatoid arthritis; skin disease; asthma
prednisolone farnesylate; PNF 21; FARNESONE; FARNERATE GEL; FARNEZONE GEL	[11beta,21(2E,6E)]-11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrienyl)oxy]-pregna-1,4-diene-3,20-dione	corticosteroid	rheumatoid arthritis; osteoarthritis
ORG 6632	21-chloro-9alpha-fluoro-11beta-hydroxy-16alpha,17alpha-dimethylpregna-1,4-diene-3,20-dione	corticosteroid; immunosuppressant	cancer; rheumatoid arthritis
RU 46057	2-[1,2-bis(1-oxopropoxy)ethyl]-4-hydroxy-N-2-thiazolyl-8-(trifluoromethyl)-3-quinolinecarboxamide	COX inhibitor; 5 lipoygenase inhibitor; NSAID	arthritis; psoriasis
meloxicam; UH AC62; UH AC26XX; MOBIC; MOBICOX; MOBEC; MOVALIS; MOVATEC	4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide	COX inhibitor; analgesic; COX 2 inhibitor; NSAID	rheumatoid arthritis; inflammation; pain; osteoarthritis
SD 8381	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis
SC 57666	1-(4-fluorophenyl)-2-(4-methylsulphonylphenyl)cyclopentene	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis

valdecoxib; SC 65872	4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain
rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease
celecoxib; SC 58635; YM 177; CELEBREX; CELEBRA	4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain; cancer
LAS 33826	unspecified	COX inhibitor; COX 2 inhibitor; NSAID	rheumatoid arthritis
pranoprofen; Y 8004; ITEOPAN; NIEFTOP; NIFLAN; CESFLAN; ELICAPRIL; MABUL; FLANIN; PRAFEN; PRANOX; DIFEN	alpha-methyl-5H[1]benzopyrano[2,3-b]pyridine-7-acetic acid	COX inhibitor; NSAID	rheumatoid arthritis; eye disease
lipophosphoglycan analogue	unspecified	Cytokine antagonist	atherosclerosis; arthritis; septic shock; HIV infection
cytokine trap, Regeneron	unspecified	cytokine antagonist	cancer; asthma; rheumatoid arthritis; allergy
interleukin-12 signal transduction antagonists, Ligand	unspecified	cytokine antagonist; immunosuppressant; NSAID	autoimmune disease; transplant rejection; rheumatoid arthritis
RP 54745	4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinoliny)-3H-1,2-dithiol-3-one	cytokine antagonist; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; psoriasis
interleukin-8 receptor; IL-8r	unspecified	cytokine antagonist; NSAID	psoriasis; rheumatoid arthritis; respiratory distress syndrome; septic shock

interleukin-8 antagonists, Warner Lambert; interleukin-8 antagonists, LeukoSite	unspecified	cytokine antagonist; NSAID	rheumatoid arthritis; psoriasis; atherosclerosis
anakinra; interleukin-1 receptor antagonist; IL-1ra; interleukin-1 inhibitor; ANTRIL	N2-L-methionylinterleukin 1 receptor antagonist (human isoform x reduced)	Cytokine inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; transplant rejection; asthma; septic shock
interleukin-1 receptor ligands, Affymax	unspecified	cytokine inhibitor; NSAID	arthritis; inflammation
SB 242235	unspecified	cytokine inhibitor; NSAID	rheumatoid arthritis
IX 207887	10-methoxy-4H-benzo(4,5)cyclohepta(1,2-b)thiophene-4-yliden)acetic acid	cytokine inhibitor; NSAID	rheumatoid arthritis
ACP	4-[bis(acetyloxy)methyl]-1,2-benzenediol, diacetate	cytokine inhibitor; NSAID	arthritis
interleukin-4; IL-4; SCH 39400; QUADRAKINE	unspecified	cytokine; immunostimulant; NSAID	cancer; viral infection; rheumatoid arthritis
interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
holmium 166 chitosan; DW 166HC	unspecified	Cytotoxic agent; radiation emission at site of injection	cancer; rheumatoid arthritis
CI 959	5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-benzo[b]thiophene-2-carboxamide sodium salt	degranulation inhibitor; immunosuppressant; NSAID	rhinitis; inflammation; asthma; arthritis

trimetrexate; trimetrexate glucuronate; TMQ; NSC 249008; CI 898; NeuTrexin	5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolin-6-ylidene]amino-2,4-diaminopentanoic acid	dihydrofolate reductase inhibitor; antifolate; NSAID	cancer; psoriasis; rheumatoid arthritis; pneumocystis
MDAM	N-[4-[2-(2,4-diamino-6-pteridinyloxy)ethyl]benzoyl]-4-methylene-DL-glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma
prinomide; prinomide tromethamine; CGS 10787; CGS 10787B	alpha-cyano-1-methyl-beta-oxopyrrole-2-propionanilide with 2-amino-2-(hydroxymethyl)-1,3-propanediol	DMARD; analgesic; immunosuppressant; NSAID	inflammation; pain; rheumatoid arthritis
actarit; MS 932; MOVER; ORCL	4-(acetylamino)phenylacetic acid	DMARD; immunosuppressant; NSAID	rheumatoid arthritis
rheumatoid arthritis therapy, Xenova; rheumatoid arthritis therapy, Suntory	unspecified	DMARD; NSAID	rheumatoid arthritis
spirogermanium; NSC 192965; SPIRO-32	8,8-diethyl-N,N-dimethyl-2-aza-8-germaspiro[4.5]decan-2-propanamine	DMARD; NSAID	malaria; multiple sclerosis; rheumatoid arthritis; cancer
elastase inhibitors, Cortech	unspecified	elastase inhibitor; proteinase inhibitor; NSAID	arthritis; inflammatory bowel disease; pulmonary obstructive disease
free radical scavenging estrogens, Jenapharm	unspecified	estrogen; free radical scavenger; NSAID	osteoporosis; arthritis; neurological
TBC 2573	unspecified	FGF antagonist; NSAID	restenosis; rheumatoid arthritis; retinopathy
CGP 39565	unspecified	free radical scavenger; DMARD; NSAID	rheumatoid arthritis; arthritis
superoxide dismutase B, manganese complex; Mn-SOD-B	unspecified	free radical scavenger; NSAID	ischemia; arthritis

free radical scavengers, Strathclyde University	unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301	unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
superoxide dismutase; copper zinc complex; CuZnSOD; OxSODrol	N-acetylsuperoxide dismutase (human clone pS 61-10 copper-zinc subunit protein moiety reduced)	free radical scavenger; NSAID	respiratory disease; ischemia; rheumatoid arthritis; inflammation
superoxide dismutase manganese complex; hMNSOD	unspecified	free radical scavenger; NSAID; immunosuppressant	ischemia; rheumatoid arthritis; inflammation; reperfusion injury
denileukin difitox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL-2; LY 335348; DAB389IL2; ONTAK	1-388-toxin (Corneybacterium diphtheriae strain C7), N-L-methionyl-387-L-histidine-388-L-alanine-, (388.fwdarw.2')-protein with 2-133-interleukin 2 (human clone pTIL2-21a)	fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer
immune system modulators, Chiroscience	unspecified	gene	autoimmune disease; rheumatoid arthritis; cancer; HIV infection
glycosidase inhibitor, Oxford GlycoSciences	unspecified	glycosidase inhibitor; NSAID	cancer; rheumatoid arthritis
pentosan polysulfate sodium; SP 54; PZ 68; CARTROPHEN; LASONIL; ELMIRON; LELONG MOUSSE	(1-4)-beta-D-xylan 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis
ICE inhibitors, BASF/Parke-Davis	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	endotoxic shock; rheumatoid arthritis; Alzheimer disease

VE 19512	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	rheumatoid arthritis; osteoarthritis; inflammation
VX 740; HMR 3480	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	rheumatoid arthritis; osteoarthritis; inflammation
OM 89; OM 8980; SUBREUM; MODIMMUDAL; MUNOLIXOM	Glycoprotein-rich, endotoxin free E. Coli extract	Immunomodulation	rheumatoid arthritis
thiethazole	2-[1-(1,1-dioxothiethanyl-3)benzimidazolyl-2-thio] acetic acid	immunostimulant; immunosuppressant; antioxidant	cancer; rheumatoid arthritis; infectious disease; transplant rejection
FCE 20696	6H-dibenzo[b,d]pyran-6-carboxylic acid 2-(dimethylamino)ethyl ester hydrochloride	immunostimulant; immunosuppressant; NSAID	viral infection; rheumatoid arthritis
IMREG 1	unspecified	immunostimulant; NSAID; peptide	rheumatoid arthritis; HIV infection
PEPTIMER	unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
esonarimod; KE 298	alpha-[(acetylthio)methyl]-4-methyl-gamma-oxobenzenebutanoic acid	immunosuppressant	rheumatoid arthritis
antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) DNA	immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma
apoptosis-inducing antigen, rheumatoid arthritis	unspecified	immunosuppressant; biotechnology; apoptosis inducer; NSAID	rheumatoid arthritis

monocyte colony inhibitory factor-1, Human Genome Sciences	unspecified	immunosuppressant; biotechnology; chemokine	autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus
AI 201	unspecified	immunosuppressant; biotechnology; NSAID	rheumatoid arthritis
AI 202	unspecified	immunosuppressant; biotechnology; peptide; NSAID	rheumatoid arthritis
autoimmune disease-specific MHC blockers, 3 Dimensional Pharmaceuticals	unspecified	immunosuppressant; DMARD; NSAID	rheumatoid arthritis; autoimmune disease
ZYN-LINKER conjugated superantigens	unspecified	immunosuppressant; immunostimulant; NSAID	rheumatoid arthritis; cancer
enlimomab; MAb, intracellular adhesion molecule-1; MAb, ICAM-1; MAb, ICAM; MAb, R65; MAb, CD54; BIRR 0001; BIRR 1	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; autoimmune disease; rheumatoid arthritis
MAb, gp39; MAb, arthritis	unspecified	immunosuppressant; monoclonal antibody; NSAID	rheumatoid arthritis
MAb, R73; MAb, rat alpha/beta T cell receptor	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; rheumatoid arthritis
priliximab; MAb, humanized CD4; cM-T412; CEN 000029; CENTARA	immunoglobulin G1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm-T412.kappa.-chain, dimer	immunosuppressant; monoclonal antibody; NSAID	multiple sclerosis; autoimmune disease; rheumatoid arthritis
IRA 378	(S)-8-chloro-1,2,3,4-tetrahydro-2-(trifluoromethyl)-6-quinolineacetic acid	immunosuppressant; nitric oxide synthase inhibitor; NSAID	rheumatoid arthritis



BMS 188667; CTLA4Ig	unspecified	immunosuppressant; NSAID	transplant rejection; systemic lupus erythematosus; psoriasis; arthritis; allergy
C-Maf based therapy	unspecified	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis
corticotropin releasing factor binding protein; CRF binding protein; NBI 112	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; inflammation
lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis
autoimmune disease therapy, Molecumetics/Bristol -Myers Squibb	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; multiple sclerosis; systemic lupus erythematosus
CD2 binding agents, Procept	unspecified	immunosuppressant; NSAID	rheumatoid arthritis
CT 2576	unspecified	immunosuppressant; NSAID	HIV infection; rheumatoid arthritis
immunoregulators, AVANT Immunotherapeutics; immunoregulators, Repligen	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma
PG 12	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 27	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 2946	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3028	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection

PG 3113	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 94	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PIC 060 analogs	unspecified	immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
PIC 101	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; autoimmune disease; transplant rejection
PIC 102	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
PIC 231	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
VX 10393	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
VX 10428	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
laflunimus; HR 325	(Z)-2-cyano-3- cyclopropyl-3- hydroxy-N-[3-methyl- 4- (trifluoromethyl)phen yl]-2-propenamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; psoriasis
SCH 24937	1-[6-bromo-5-chloro- 3-(2-pyridinyl)-1H- indol-2-yl]-2- (methylsulfinyl)ethan one	immunosuppressant; NSAID	rheumatoid arthritis
KF 20444	10-fluoro-3-(2- fluorophenyl)-6,7- dihydro-5H- benzo[6,7]cyclohepta [1,2-b]quinoline-8- carboxylic acid	immunosuppressant; NSAID	rheumatoid arthritis
KB 2683	2-(4-methylphenyl)-4- benzothiazolol acetate	immunosuppressant; NSAID	rheumatoid arthritis; inflammation; autoimmune disease

CI 972	2,6-diamino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; cancer; psoriasis
MX 68	2-[[[4-[2,4-diamino-6-pteridiny]methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl]amino]hexanedioic acid	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease
baohuoside I; icariside II; B-1	3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one	immunosuppressant; NSAID	systemic lupus erythematosus; rheumatoid arthritis
CL 306293	3-amino-2-[1,1'-biphenyl]-4-yl-6-fluoro-4-quinolinecarboxylic acid	immunosuppressant; NSAID	arthritis; HIV infection
amiprilose; amiprilose hydrochloride; THN; SM 1213; KAP 690; THERAFECTIN	3-O-(3-(dimethylamino)propyl)-1,2-O-isopropylidene-alpha-D-glucofuranose hydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; psoriasis
TAK 603	4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1H-1,2,4-triazol-1-ylmethyl)-3-quinolinecarboxylic acid ethyl ester	immunosuppressant; NSAID	rheumatoid arthritis
mizoribine; HE 69; BREDININ	5-hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; kidney disease
TA 383	cis-2-(4-chlorophenyl)-4,5-dihydro-4,5-diphenyl-1H-imidazole monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis

SKF 105685	N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dihydrochloride	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
AI 200; COLLORAL	trimeric (16-1059)alpha1 (II) collagen	immunosuppressant; NSAID	rheumatoid arthritis
atiprimod; atiprimod dimaleate; SKF 106615	N,N-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine	immunosuppressant; NSAID; macrophage inhibitor	rheumatoid arthritis; autoimmune disease; psoriasis
cladribine; 2-CdA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	2-chloro-2'-deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
PP 14	unspecified	immunosuppressant; peptide; NSAID	autoimmune disease; rheumatoid arthritis
ZAP inhibitors, Ariad	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis
PEGylated p75 TNFR Fc mutein	unspecified	immunosuppressant; TNF inhibitor	rheumatoid arthritis
leflunomide; HWA 486; ARAVA	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	immunosuppressant; tyrosine kinase inhibitor; NSAID; DMARD	rheumatoid arthritis; autoimmune disease
fusion protein, CD5-gelolin; CD5-gelolin T lymphocyte-targeted immunofusion protein; GENIMUNE	unspecified	immunotoxin; NSAID	rheumatoid arthritis; inflammation
alpha d modulator	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	diabetes; atherosclerosis; arthritis; inflammatory bowel disease; respiratory disease

cell adhesion inhibitors, Ligand/Sankyo	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	asthma; rheumatoid arthritis; reperfusion injury
RGD-based angiogenesis antagonists	unspecified	integrin antagonist; NSAID; cell adhesion inhibitor	cancer; rheumatoid arthritis; eye disease
NPC 15669	N-(9H-(2,7-dimethylfluorenyl-9-methoxy)carbonyl)-L-leucine	leukocyte mediator inhibitor; NSAID	arthritis; septic shock; inflammatory bowel disease
CP 105696	(3S-trans)-1-[3-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl]cyclopentanecarboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	rheumatoid arthritis
SC 51146	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; psoriasis; rheumatoid arthritis; inflammatory bowel disease
NPC 16570	4-[[[2-(9H-fluoren-9-yl)ethoxy]carbonyl]amino]benzoic acid	leumedin; NSAID	rheumatoid arthritis
NPC 17923	4-[[3-[(2,7-dichloro-9H-fluoren-9-yl)oxy]-1-oxopropyl]amino]benzoic acid	leumedin; NSAID	rheumatoid arthritis

tacrolimus; tsukubaenolide; fujimycin; FK 506; (-)-FK 506; FR 900506; L 679934; PROGRAF; PROTOPIC	[3S-[3R*[E(1S*,3S*,4S*),4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydro xy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone	macrolide; immunosuppressant; NSAID; antibiotic	transplant rejection; dermatitis; eye disease; rheumatoid arthritis
matrix metalloproteinase inhibitors, OsteoArthritis; cartilage degrading enzyme inhibitors, OsteoArthritis; CHONDROPROTECTORS	unspecified	matrix metalloproteinase inhibitor; cicatrizant; proteinase inhibitor; NSAID	arthritis; periodontal disease; skin ulcer; cancer
anti-arthritic matrix metalloproteinase inhibitors	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis
CH 138	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis
CH 263	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis

matrix metalloproteinase inhibitor, State University of New York	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis
matrix metalloproteinase inhibitors, Bayer	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis
matrix metalloproteinase inhibitors, ProScript	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; arthritis
BE 16627B	N-[N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-seryl]-L-valine	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis
solimastat; BB 3644	(2S,3R)-3-[(1S)-2,2-dimethyl-1-(2-pyridylcarbamoyl)propyl]carbamoyl-2-methoxy-5-methylhexanoic acid	matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor	multiple sclerosis; rheumatoid arthritis; inflammatory bowel disease; cancer
bindarit; AF 2838	2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]-propanoic acid	MCP-1 production inhibitor (reduction of mRNA expression)	rheumatoid arthritis; nephritis
metalloproteinase inhibitors, Syntex	unspecified	metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; arthritis
TNF alpha converting enzyme inhibitors, Immunex; TACE inhibitors, Immunex	unspecified	metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; inflammation
MAb, CD23; GW 353430	unspecified	monoclonal antibody; biotechnology; NSAID	rheumatoid arthritis; asthma
MAb, CD4; 4162W94; BW 4162W94	unspecified	monoclonal antibody; biotechnology; NSAID	rheumatoid arthritis

MAB, chimeric APO1	unspecified	monoclonal antibody; biotechnology; NSAID	rheumatoid arthritis
MAB, interleukin-8; MAB, IL-8; ABX IL8	unspecified	monoclonal antibody; biotechnology; NSAID	respiratory distress syndrome; inflammatory bowel disease; rheumatoid arthritis; inflammation; psoriasis
MAB, tumor necrosis factor; MAB, TNF	unspecified	monoclonal antibody; biotechnology; NSAID	inflammatory bowel disease; rheumatoid arthritis
MAB, Fv, cytokine; CDP 870	unspecified	monoclonal antibody; cytokine inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
MAB, 6G5.1; MAB, autoimmune disease, human, Medarex; MDX CD4	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; rheumatoid arthritis
MAB, T cell receptor; TM 31	unspecified	monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis
MAB, 16H5; MAB, CD4; MAB, rheumatoid arthritis; MAX 16H5	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis
MAB, cytokines; AGT 1	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis
MAB, humanized tumor necrosis factor; MAB, humanized TNF; MAB, CDP571; CDP 571; BAY 103356; B 1351	unspecified	monoclonal antibody; NSAID	septic shock; inflammation; bacterial infection; inflammatory bowel disease; rheumatoid arthritis
MAB, humanized, leukemia; MAB, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
MAB, macrophage migration inhibitory factor, Picower Institute for Medical Research	unspecified	monoclonal antibody; NSAID	arthritis; asthma



MAb, VLA-4, humanized; MAb, very late antigen-4, humanized	unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
clenoliximab; MAb, CD4; MAb, PRIMATIZED CD4; IDEC 151; SB 217969	immunoglobulin G 4 (human-Macaca monoclonal CE9gamma4PE gamma4-chain anti-human antigen CD4), disulfide with human-Macaca monoclonal CE9gamma4PE kappa-chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; psoriasis; asthma
infliximab; MAb, tumor necrosis factor alpha; MAb, TNF-alpha; cA2; TA 650; REMICADE; AVAKINE	immunoglobulin G, anti-(human tumour necrosis factor) (human-mouse monoclonal cA2 heavy chain), disulfide with human-mouse monoclonal cA2 light chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; Crohn disease
keliximab; MAb, CD4; MAb, PRIMATIZED CD4; IDEC CE9.1; SB 210396	immunoglobulin G1 (human-Macaca monoclonal CE9.1.gamma.1-chain anti-human antigen CD 4), disulfide with human-Macaca monoclonal CE9.1.lambda.-chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; asthma
mercaptoethylguanidine; MEG	(2-mercaptoethyl)-guanidine	nitric oxide synthase inhibitor; COX inhibitor; NSAID	cardiovascular disease; arthritis; colitis
l-arginine; 546C88; BW 546C88	N5-[imino(methylamino)methyl]-L-ornithine	nitric oxide synthase inhibitor; NSAID	septic shock; arthritis; kidney disease
nitric oxide inhibitors, Fisons	unspecified	nitric oxide synthetase inhibitor; NSAID	stroke; rheumatoid arthritis

CPR 3005	Lipid analogue	NSAID	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 3014	Lipid analogue	NSAID	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 3016	Lipid analogue	NSAID	skin disease; eye disease; asthma; rheumatoid arthritis
ZD 2315	unspecified	NSAID	rheumatoid arthritis
collagen, human type II	unspecified	NSAID	rheumatoid arthritis
neutrophil degranulation inhibitor; DGI	unspecified	NSAID	asthma; rheumatoid arthritis
recombinant soluble Fc receptor, rheumatoid arthritis; FcgammaRII	unspecified	NSAID	rheumatoid arthritis
telomere modulators, Geron	unspecified	NSAID	neurodegeneration; atherosclerosis; arthritis
anti-inflammatory agents, Phytera/Tsumura	unspecified	NSAID	rheumatoid arthritis; allergy
antiarthritic agent, Proteus	unspecified	NSAID	rheumatoid arthritis
arthritis therapy, OSI/Hoechst Marion Roussel	unspecified	NSAID	arthritis
arthritis therapy, Sumitomo/CombiChem	unspecified	NSAID	arthritis
autoimmune disease therapy, AMRAD/Kaneka	unspecified	NSAID	diabetes; rheumatoid arthritis
CBF BS2	unspecified	NSAID	rheumatoid arthritis
drug delivery system, GEOMATRIX controlled release diclofenac; diclofenac GEOMATRIX; DICLOFENAC-UNO	unspecified	NSAID	arthritis

drug delivery system, GEOMATRIX controlled release naproxen; naproxen GEOMATRIX	unspecified	NSAID	rheumatoid arthritis
drug delivery system, transdermal flurbiprofen; flurbiprofen transdermal	unspecified	NSAID	arthritis
EN 08	unspecified	NSAID	arthritis
FA 31A	unspecified	NSAID	arthritis
gene discovery, arthritis, LifeSpan	unspecified	NSAID	rheumatoid arthritis
gene discovery, immune system disorders, AlphaGene	unspecified	NSAID	arthritis; asthma; allergy
gene discovery, inflammatory diseases, Ariad/Hoechst Marion Roussel	unspecified	NSAID	inflammation; rheumatoid arthritis
glucocorticoid agonists, Ligand	unspecified	NSAID	inflammation; rheumatoid arthritis; inflammatory bowel disease; asthma
GP 44	unspecified	NSAID	arthritis
GW 92527	unspecified	NSAID	rheumatoid arthritis
HP 466	unspecified	NSAID	arthritis
KP 106	unspecified	NSAID	rheumatoid arthritis
lipophosphoglycan analogue	unspecified	NSAID	rheumatoid arthritis; atherosclerosis; HIV infection
lithium gamma-linolenic acid + eicosapentaenoic acid; EF 5	unspecified	NSAID	rheumatoid arthritis
macrophage migration inhibitory factor inhibitors, Picower Institute for Medical Research	unspecified	NSAID	arthritis; asthma
NBI 116	unspecified	NSAID	multiple sclerosis; rheumatoid arthritis

nitric oxide modulators, Duke University	unspecified	NSAID	hypotension; cancer; rheumatoid arthritis
osteoarthritis therapy, Maxia; rheumatoid arthritis therapy, Maxia	unspecified	NSAID	osteoarthritis; rheumatoid arthritis
PKC-RACK interaction inhibitors, Telik	unspecified	NSAID	arthritis; multiple sclerosis; asthma
protein discovery, rheumatoid arthritis, Oxford GlycoSciences; protein discovery, rheumatoid arthritis, Oxford University	unspecified	NSAID	rheumatoid arthritis
pseudopterosin	unspecified	NSAID	arthritis; asthma; psoriasis
rheumatoid arthritis therapy, Corixa; rheumatoid arthritis therapy, Organon; RA-AnergiX	unspecified	NSAID	rheumatoid arthritis
SC 105	unspecified	NSAID	arthritis
telomerase activators, Geron	unspecified	NSAID	neurodegeneration; atherosclerosis; arthritis
fepradinol; DALGEN; FLEXIDOL	(1)-alpha-(((2-hydroxy-1,1-dimethylethyl)amino)methyl)benzyl alcohol	NSAID	rheumatoid arthritis
CTC 23	(OC-6-22)-diammine[[4,4'-(1,2-ethanediyl)dinitrilo]bis[2-pentanonato]](2-)-N,N',O,O']cobalt(1+) chloride	NSAID	viral infection; arthritis
U 91502	[3-(1,6-dihydro-1-methyl-6-oxo-4-phenyl-2-pyrimidinyl)propylidene]bisphosphonic acid tetraethyl ester	NSAID	inflammation; arthritis

sulfasalazine; salazosulfapyridine; azulfide; SI 88; AZULFIDINE; SALAZOPYRIN; SLAMA	2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid	NSAID	ulcerative colitis; rheumatoid arthritis
seprilose; GW 80126	3-O-heptyl-1,2-O-(1-methylethylidene)-alpha-D-glucofuranose	NSAID	rheumatoid arthritis
amtolmetin guacil; ST 679; MED 15; ARTROMED; EUFANS	N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl]glycine 2-methoxyphenyl ester	NSAID; analgesic	arthritis; rheumatoid arthritis; inflammation; pain
monocyte chemoattractant protein-1 antagonists	unspecified	NSAID; chemokine antagonist	rheumatoid arthritis; atherosclerosis
TNF alpha antagonists, Texas Biotechnology	unspecified	NSAID; cytokine antagonist; apoptosis inhibitor	rheumatoid arthritis
S 2474	unspecified	NSAID; DMARD; COX inhibitor; COX 2 inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
rheumatoid arthritis therapy, Birmingham University	unspecified	NSAID; peptide	rheumatoid arthritis
phospholipase A2 inhibitors, La Jolla	unspecified	NSAID; phospholipase inhibitor	rheumatoid arthritis; inflammatory bowel disease; asthma
ZYN-LINKER conjugated yttrium 90	unspecified	NSAID; radiotherapeutic	arthritis
IPL 423; IZP 96001; BISPAN	unspecified	NSAID; transcription factor regulator	arthritis
nalmefene; nalmetrenc; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma

complement inhibitors, Lidak	unspecified	peptide; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease; reperfusion injury; respiratory distress syndrome; transplant rejection
rheumatoid arthritis therapy, Peptide Therapeutics	unspecified	peptide; NSAID	rheumatoid arthritis
rheumatoid arthritis therapy, Peptide Therapeutics	unspecified	peptide; NSAID	rheumatoid arthritis
TNF peptide antagonist, Tocar	unspecified	peptide; NSAID	rheumatoid arthritis
TNF receptor antagonist, Peptor; TNF receptor antagonist, Teva	unspecified	peptide; NSAID	rheumatoid arthritis; multiple sclerosis
type II collagen analogue	unspecified	peptide; NSAID	rheumatoid arthritis
piclamilast; RP 73401; RPR 73401	3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; arthritis
lipocortin; lipomodulin; macrocortin	unspecified	phospholipase inhibitor; NSAID	asthma; arthritis
phospholipase A2 inhibitors, Fisons	unspecified	phospholipase inhibitor; NSAID	asthma; rheumatoid arthritis; psoriasis; inflammatory bowel disease
LM 1228	phosphoric acid mono[2-[(decylsulfonyl)amino]octyl]mono[2-(phenylmethoxy)ethyl] ester	phospholipase inhibitor; NSAID	rheumatoid arthritis

verteporfin; benzoporphyrin derivative; BPD-MA; CL 318952; BPDR; VISUDYNE	trans-18-ethenyl-4,4a- dihydro-3,4- bis(methoxycarbonyl)- 4a,8,14,19- tetramethyl-23H,25H- benzo[b]porphine- 9,13-dipropanoic acid monomethyl ester	photosensitizer; NSAID	cancer; psoriasis; arthritis; retinopathy
polyclonal antibody, tumor necrosis factor alpha; immunoglobulin, TNF-alpha lysate; PASSTNF-alpha	unspecified	polyclonal antibody; immunoglobulin; NSAID	rheumatoid arthritis; inflammatory bowel disease
iloprost; ciloprost; ZK 36374; E 1030; SH 401; ILOMED; ENDOPROST; ILOMEDIN; AIPRO	5-[hexahydro-5- hydroxy-4-(3- hydroxy-4-methyl-1- octen-6-ynyl)-2(1H)- pen talenylidene]pentanoi c acid	prostanoid; platelet antiaggregant; vasodilator; NSAID	peripheral vascular disease; thrombosis; thrombocytopenia; rheumatoid arthritis
Ro 320432; Ro 32- 0432	(S)-3-[8- [(dimethylamino)met hyl]-6,7,8,9- tetrahydropyrido[1,2- a]indol-10-yl]-4-(1- methyl-1H-indol-3- yl)-1H-pyrrole-2,5- dione	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis
proteinase nexin-1 elastase variant; PN-1 elastase variant	unspecified	proteinase inhibitor; biotechnology; cicatrizant	arthritis; skin ulcer
K 11097	unspecified	proteinase inhibitor; cathepsin S inhibitor; NSAID	rheumatoid arthritis
PS 508	unspecified	proteinase inhibitor; matrix metalloproteinase inhibitor	arthritis; inflammatory bowel disease; periodontal disease
matrix metalloproteinase inhibitor	unspecified	proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	arthritis; cancer; arthritis

BB 2983; GI 245402	unspecified	proteinase inhibitor; matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; inflammatory bowel disease
cysteine proteinase inhibitor, SynPhar/British Biotech	unspecified	proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; cancer; osteoarthritis
P 34081	unspecified	proteinase inhibitor; NSAID	arthritis
P 35012	unspecified	proteinase inhibitor; NSAID	arthritis
P 35016	unspecified	proteinase inhibitor; NSAID	arthritis
WY 48989	4-[[2-(7-chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzo nitrile	proteinase inhibitor; NSAID	arthritis
BABIM	bis(5-amidino-2-benzimidazo)methane	proteinase inhibitor; NSAID	arthritis
peldesine; BCX 34; BCX 34B	2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection
CH 799	unspecified	purine nucleoside phosphorylase inhibitor; NSAID	rheumatoid arthritis; inflammatory bowel disease; cancer
purine nucleoside phosphorylase inhibitors, Chiroscience; PNP inhibitors, Chiroscience	unspecified	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
CI 1000; PD 141955	2-amino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis



mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany l)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
fenretinide; HPR, 4; 4HPR; RAHA; McN R1967	N-(4-hydroxyphenyl)retinamide	retinoid; NSAID	rheumatoid arthritis; cancer
rheumatoid arthritis therapy	unspecified	SAIK immunomodulation	rheumatoid arthritis
SR 31747	(Z)-N[3-chloro-4-cyclohexylphenyl)-2-propenyl]-N-ethyl-cyclohexanamine hydrochloride	sigma antagonist; immunosuppressant; NSAID	autoimmune disease; arthritis
stromelysin inhibitors, Affymax	unspecified	stromelysin inhibitor; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	arthritis
stromelysin inhibitors, Agouron	unspecified	stromelysin inhibitor; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	cancer; arthritis
drug delivery system, biodegradable micellar paclitaxel; paclitaxel micellar	unspecified	taxane; DMARD; NSAID	rheumatoid arthritis; multiple sclerosis
etanercept; tumor necrosis factor receptor; TNFr; TNR 001; ENBREL	unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease
soluble tumor necrosis factor- $\alpha$ receptor type 1; sTNFR1	unspecified	TNF inhibitor; NSAID	rheumatoid arthritis
CC 1080	unspecified	TNF inhibitor; NSAID	arthritis; cancer; multiple sclerosis

ITF 1779	unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease
MNX 160	Unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; diabetes; multiple sclerosis
thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3- piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
CC 1069	beta-(3,4- dimethoxyphenyl)- 1,3-dihydro-1,3- dioxo-2H-isoindole- 2-propanamide	TNF modulator; NSAID	cachexia; arthritis; cancer
MHC expression inhibitors, BLSI	unspecified	transcription inhibitor; NSAID	rheumatoid arthritis; systemic lupus erythematosus
SC 106	unspecified	triglyceride; NSAID	rheumatoid arthritis
TCR peptide, rheumatoid arthritis	unspecified	vaccine	rheumatoid arthritis
vaccine, arthritis; vaccine, Vbeta14 T cell receptor; AI 205; IR 205	unspecified	vaccine	rheumatoid arthritis
vaccine, arthritis; vaccine, Vbeta17 T cell receptor; AI 204; IR 204	unspecified	vaccine	rheumatoid arthritis
vaccine, rheumatoid arthritis; IR 501; AI 501	unspecified	vaccine	rheumatoid arthritis
non-ionic surfactant vesicles; NISV	unspecified	vaccine adjuvant; immunosuppressant	rheumatoid arthritis; asthma; inflammation
vaccine, TNF alpha	unspecified	vaccine; cytokine antagonist	rheumatoid arthritis; Crohn disease; cachexia; asthma
MAB, HRF1; vaccine, rheumatoid arthritis	unspecified	vaccine; monoclonal antibody	rheumatoid arthritis
MHC-vaccine, rheumatoid arthritis; AGDR 4/1; AnervaX; RA-AnervaX	unspecified	vaccine; peptide	rheumatoid arthritis

VCAM antagonists, Texas Biotechnology	unspecified	vascular cell adhesion molecule inhibitor; NSAID	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 609	unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 772	unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
20-epi-1,25 dihydroxyvitamin D <sub>3</sub> ; MC 1288; IE	(1 $\alpha$ ,3 $\beta$ ,5Z,7E,20S)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D <sub>3</sub> analogue; immunosuppressant	diabetes; transplant rejection; arthritis
ZD 7349	unspecified	VLA 4 antagonist; integrin antagonist; NSAID; cell adhesion inhibitor	multiple sclerosis; arthritis

Table 39. Current Candidate Therapeutic Interventions for the Treatment of COPD

Product Name	Chemical Name	Action	Indication
3323W	unspecified	5 lipoxygenase inhibitor	asthma
bunaprolast; U 66858	2-butyl-4-methoxy-1-naphthalenol acetate	5 lipoxygenase inhibitor	asthma
BW B70C	N-[3-[3-(4-fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea	5 lipoxygenase inhibitor	asthma
CMI 977	unspecified	5 lipoxygenase inhibitor	asthma
docebenone; AA 861	6-(12-hydroxy-5,10 dodecadienyl)-2,3,5-trimethyl-1,4-benzoquinone	5 lipoxygenase inhibitor	asthma; heart failure
drug delivery system, controlled release zileuton; zileuton	unspecified	5 lipoxygenase inhibitor	asthma
FR 110302	2,2-dibutyl-1,2,3,4-tetrahydro-5-(2-quinolinylmethoxy)-1-naphthalenol	5 lipoxygenase inhibitor	asthma

L 691816	5-[3-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]-2,2-dimethylpropyl]-1H-tetrazole	5 lipoxygenase inhibitor	asthma
L 739010	1,6-anhydro-3-C-[6-[[[7-cyano-5-(3-furanyl)-2-naphthalenyl]oxy]methyl]-2-pyridinyl]-2,4-dideoxy-beta-D-threo-hexopyranose	5 lipoxygenase inhibitor	asthma
linazolast; TMK 688; YM 257	4-[5-[[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]amino]-5-oxo-1,3-pentadienyl]-2-methoxyphenylcarbonic acid ethyl ester	5 lipoxygenase inhibitor	asthma; rhinitis
PF 5901	alpha-pentyl-3-(2-quinolinylmethoxy)-benzenemethanol	5 lipoxygenase inhibitor	asthma
R 85355	Unspecified	5 lipoxygenase inhibitor	asthma; psoriasis; inflammatory bowel disease
SB 202235	(S)-N-(2,3-dihydro-6-phenylmethoxy-3-benzofuranyl)urea	5 lipoxygenase inhibitor	asthma
TZI 41127	4-(5-methoxy-3-methyl-1H-indol-2-yl)-2,6-dimethylphenol	5 lipoxygenase inhibitor	asthma
WY 50295; WY 50295 tromet	(S)-alpha-methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid	5 lipoxygenase inhibitor	asthma; rhinitis

ZD 4407	(2S-trans)-1,3-dihydro-1-methyl-5-[[4-(tetrahydro-4-hydroxy-2-methyl-2H-pyran-4-yl)-2-thienyl]thio]-2H-indol-2-one	5 lipoxygenase inhibitor	asthma
CGS 25997	(2S)-(-)-2-[[N-(aminocarbonyl)-N-hydroxyamino]methyl]-7-(4-fluorophenoxy)-1,4-benzodioxan	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
CHF 1909	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
E 6080	4-[[[(6-hydroxy-4,4,7-trimethyl-2-benzothiazolyl)amino]methyl]benzenesulfonamide monohydrochloride	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
GR 80907	unspecified	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
L 651392	4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one	5 lipoxygenase inhibitor; NSAID	inflammation; bacterial infection; asthma
L 663536; MK 886	1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-alpha,alpha-diethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis
L 699333	2-[2-[1-[(4-chlorophenyl)methyl]-4,5-dihydro-4-methyl-6-[(5-phenyl-2-pyridinyl)methoxy]-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid	5 lipoxygenase inhibitor; NSAID	asthma; inflammation

SC 45662	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis; inflammatory bowel disease
ZD 2138; ICI D2138	6-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-2(1H)-quinolinone	5 lipoxygenase inhibitor; NSAID	arthritis; asthma
ZD 7717; ICI D7717	7-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenyl]thio]-4-methyl-2H-1,4-benzoxazin-3(4H)-one	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
zileuton; A 64077; ZYFLO	N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
GW 328267	unspecified	adenosine agonist; adenosine A2 agonist	asthma
midaglizole; DG 5128	2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine	alpha adrenergic antagonist; alpha2 adrenergic antagonist	asthma; diabetes
melanocortin receptor-1 modulators,	unspecified	analgesic; melanocortin agonist; melanocortin MC1 agonist	asthma; pain; nephritis
LA 351	5H-(1)-benzopyrano(2,3-b)pyridin-5-one	analgesic; NSAID	inflammation; pain; asthma
HP 228	N-acetyl-Nleu-Gln-His-Phe-Arg-Trp-Gly-amide	analgesic; NSAID; peptide; melanocortin agonist	pain; inflammation; asthma; cachexia
L 680833	[S-(R*,S*)]-4-[[[3,3-diethyl-1-[[[1-(4-methylphenyl)butyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]benzenecetic acid	antibiotic; elastase inhibitor; beta lactam; proteinase inhibitor	emphysema
anti-inflammatory macrolide analogues,	unspecified	antibiotic; macrolide	asthma; inflammation

SB 226882	4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-N-methyl-2-pyrimidinamine	antifungal; MAP kinase inhibitor; signal transduction inhibitor; imidazole	inflammation; asthma; rheumatoid arthritis
antioxidants	unspecified	antioxidant	respiratory distress syndrome; stroke; reperfusion injury; asthma
U 74389F	21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]pregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate	antioxidant	emphysema
synthetic catalytic scavenger analogues; SCS analogues	unspecified	antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
VANTOX	unspecified	antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
Z 4003	2-[1-[4-(2-methylpropyl)phenyl]ethyl]-4-thiazolidinecarboxylic acid	antioxidant; NSAID	angina; inflammation; emphysema
antisense oligonucleotide, interleukin-5; antisense oligonucleotide, IL-5	unspecified	antisense; oligonucleotide; ,	asthma
D 2522	unspecified	beta adrenergic agonist	asthma
drug delivery system, liposome terbutaline sulfate; terbutaline sulfate liposome	unspecified	beta adrenergic agonist	asthma

ardeterol; SOM 1122	alpha-[[[3-(1H-benzimidazol-1-yl)-1,1-dimethylpropyl]amino]methyl]-2-fluoro-4-hydroxybenzenemethanol	beta adrenergic agonist	asthma
procaterol; procaterol hydrochloride; OPC 2009; CI 888; MEPTIN; PRO-AIR; ONSUKIL; BRON NOVO; PROMAXOL; MASACIN; PROCADIL; PROPULUM	2(1H)-quinolone, 8-hydroxy-5-(1-hydroxy-2-(1-methylethyl)amino)butyl-, monohydrochloride, (R*S*)(+,-)	beta adrenergic agonist	asthma
RP 58802B	alpha-[[[3-(1H-benzimidazol-1-yl)-1-methylpropyl]amino]methyl]-4-hydroxy-3-methoxy-benzenemethanol	beta adrenergic agonist	asthma
SL 2021	unspecified	beta adrenergic agonist	asthma
CEDO 20433	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, liposome salbutamol sulfate; salbutamol sulfate liposome	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, OROS oral controlled release salbutamol; salbutamol	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, PULSINCAP salbutamol; salbutamol PULSINCAP	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, salbutamol sustained release; salbutamol sustained release	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma



drug delivery system, transdermal salbutamol; salbutamol transdermal	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, transdermal salbutamol; salbutamol transdermal; albuterol transdermal	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
drug delivery system, transdermal TheraDerm-LRS salbutamol; salbutamol TheraDerm-LRS	unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
formoterol, (R,R); (R,R)-formoterol	[R-(R*,R*)-(+,-)-N- [2-hydroxy-5-[1- hydroxy-2-[[2-(4- methoxypheny)-1-m ethylethyl]amino]ethy l]phenyl]formamide	beta adrenergic agonist; beta2 adrenergic agonist	asthma
formoterol; formoterol; formoterol fumarate; YM 08316; BD 40A; CGP 25827; CGP 25827A; ATOCK; FORADIL; ASMATEC; SINASFIX; LEMOTEC; OXIS	(R*,R*)-(+,-)-N-[2- hydroxy-5-[1- hydroxy-2-[[2-(4- methoxypheny)-1- methylethyl]amino]et hyl]phenyl]formamid e	beta adrenergic agonist; beta2 adrenergic agonist	asthma
picumeterol; picumeterol fumarate; GR 114297; GR 114297 X; GR 63411	(-)-(R)-4-amino-3,5- dichloro-alpha-[[[6- [2-(2- pyridinyl)ethoxy]hexy l]amino]methyl]benze nemethanol	beta adrenergic agonist; beta2 adrenergic agonist	asthma
salmeterol, (R)-; (R)- salmeterol	(R)-4-hydroxy- alpha.1-[[[6-(4- phenylbutoxy)hexyl]a mino]methyl-1,3- benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist	asthma

bambuterol; BWD 2183; BAMBEC	dimethylcarbamic acid 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-1,3-phenylene ester	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
broxaterol; Z 1170; SUMMAIR	(+,-)-3-bromo-alpha-[(tert-butylamino)methyl]-5-isoxazolemethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
etanterol	5-amino-alpha-[[p-hydroxy-alpha-methylphenethyl)amino]methyl]-m-xylene-alpha,alpha'-diol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
LAS 32521	unspecified	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
levosalbutamol; levalbuterol; salbutamol, (R)-; (R)-salbutamol; (R)-albuterol; levalbuterol sulfate; XOPENEX	(R)-alpha'-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
salmeterol + fluticasone; fluticasone + salmeterol; SERETIDE; ADVAIR DISKUS; VIANI	unspecified	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator; corticosteroid	asthma
salmeterol; salmeterol; GR 33343X; SN 408; GR 33343G; SEREVENT	4-hydroxy-alpha.1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl-1,3-benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma; pulmonary obstructive disease
TA 2005	[R-(R*,R*)]-8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma

SM 11044	[R-(R*,S*)]-1-[3-(3,4-dihydroxyphenyl)-2-[[3-(4-fluorophenyl)propyl]amino]-3-hydroxy-1-oxopropyl]pyrrolidine monohydrobromide	beta adrenergic agonist; beta3 adrenergic agonist; leukotriene antagonist; leukotriene D4 antagonist	asthma
AR C68397AA; AR-C68397AA; ARL 68397	4-hydroxy-7-[2-[[[3-(2-phenylethoxy)propyl]sulfonyl]ethyl]amino]ethyl-2(3H)-benzothiazolone monohydrochloride	beta adrenergic agonist; bronchodilator	asthma; pulmonary obstructive disease; rhinitis
drug delivery system, transdermal controlled release tulobuterol; tulobuterol transdermal; HOKUNALIN TAPE	unspecified	beta adrenergic agonist; bronchodilator	asthma
tulobuterol; HN 078; C 78; HSR 078A; BRELOMAX; BREMAX; ATENOS; BERACHIN; HOKUNALIN	alpha-[(tert-butylamino)methyl]-o-chlorobenzyl alcohol	beta adrenergic agonist; bronchodilator	asthma
drug delivery system, HALO salbutamol; salbutamol HALO	unspecified	beta2 adrenergic agonist; beta adrenergic agonist	asthma
allergy immunogen, migis epsilon	unspecified	,	allergy; asthma
allergy therapy, E coli enterotoxin B subunit-antigen fusion protein	unspecified	,	rhinitis; asthma
DNase, second generation	unspecified	,	bronchitis; cystic fibrosis
emoctakin; interleukin-8	unspecified	,	asthma
fusion protein, IL-10	unspecified	,	asthma; inflammatory bowel disease

secretory leukocyte proteinase inhibitor, truncated; TEI 7361	unspecified	,	respiratory distress syndrome; emphysema
antisense oligonucleotide, adenosine A1 receptor; antisense oligonucleotide, asthma; EPI 2010; E 2010;	unspecified	,; antisense; oligonucleotide; mRNA translation inhibitor	asthma
interleukin-4 receptor; IL-4r;	unspecified	,; cytokine antagonist	inflammation; asthma
soluble interleukin-5 receptor alpha; IL-5Ra	unspecified	,; cytokine antagonist	asthma
interleukin-1 receptor; IL-1r; HJ 1306	unspecified	,; cytokine inhibitor; immunosuppressant	asthma
anakinra; interleukin-1 receptor antagonist; IL-1ra; interleukin-1 inhibitor; ANTRIL	N2-L-methionylinterleukin 1 receptor antagonist (human isoform x reduced)	,; cytokine inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; transplant rejection; asthma; septic shock
interleukin-12; IL-12; natural killer stimulatory factor; NKSF; edodekin alfa; Ro 247472; Ro 24-7472	unspecified	,; cytokine; immunostimulant	asthma
dornase alfa; deoxyribonuclease; DNase; PULMOZYME	deoxyribonuclease, (human clone 18-1 protein moiety)	,; deoxyribonuclease; enzyme	cystic fibrosis; bronchitis; pulmonary obstructive disease; systemic lupus erythematosus
enkephalinase	unspecified	,; enkephalinase; enzyme	asthma; eye disease
platelet-activating factor acetylhydrolase; PAF-AH; SUN Y7016; PAFASE	unspecified	,; hydrolase	respiratory distress syndrome; asthma; inflammatory bowel disease
IgE receptors, soluble, CorBec	unspecified	,; immunosuppressant	asthma

antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) DNA	;; immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma
lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	unspecified	;; immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis
MAb, AL 901; MAb, IgE; AL 901; CGP 51901; IGE 025A	unspecified	;; monoclonal antibody	allergy; rhinitis; asthma
MAb, CD23; MAb, PRIMATIZED CD23	unspecified	;; monoclonal antibody	asthma; allergy; rhinitis
MAb, IgE; MAb, E25	unspecified	;; monoclonal antibody	asthma; allergy; rhinitis
MAb, interleukin-4; SB 240683	unspecified	;; monoclonal antibody	asthma
MAb, interleukin-5; MAb, IL-5; SCH 55700; CDP 835	unspecified	;; monoclonal antibody; immunosuppressant	asthma
clenoliximab; MAb, CD4; MAb, PRIMATIZED CD4; IDEC 151; SB 217969	immunoglobulin G 4 (human-Macaca monoclonal CE9gamma4PE gamma4-chain anti-human antigen CD4), disulfide with human-Macaca monoclonal CE9gamma4PE kappa-chain, dimer	;; monoclonal antibody; NSAID	rheumatoid arthritis; psoriasis; asthma
keliximab; MAb, CD4; MAb, PRIMATIZED CD4; IDEC CE9.1; SB 210396	immunoglobulin G1 (human-Macaca monoclonal CE9.1.gamma.1-chain anti-human antigen CD 4), disulfide with human-Macaca monoclonal CE9.1.lambda.-chain, dimer	;; monoclonal antibody; NSAID	rheumatoid arthritis; asthma

MAb, macrophage migration inhibitory factor,	unspecified	,; monoclonal antibody; NSAID	arthritis; asthma
MAb, VLA-4, humanized; MAb, very late antigen-4, humanized	unspecified	,; monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
neutrophil degranulation inhibitor; DGI	unspecified	,; NSAID	asthma; rheumatoid arthritis
RecepTox-Fce	unspecified	,; peptide; fusion toxin	asthma; allergy
lipocortin; lipomodulin; macrocortin	unspecified	,; phospholipase inhibitor; NSAID	asthma; arthritis
eglin C	unspecified	,; proteinase inhibitor	septic shock; emphysema
EPI-HNE-1	unspecified	,; proteinase inhibitor	cystic fibrosis; emphysema
alpha-1-antitrypsin; TgAAT; BAY 105233	unspecified	,; proteinase inhibitor; elastase inhibitor	emphysema; cystic fibrosis; genetic disorder
LEX 043	unspecified	,; proteinase inhibitor; serine proteinase inhibitor	inflammation; asthma
neutral endopeptidase; NEP	unspecified	,; proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
ribozymes, asthma	unspecified	,; ribozyme; oligonucleotide	asthma
secretory leukocyte proteinase inhibitor; serine leukocyte proteinase inhibitor; SLPI; serine proteinase inhibitor; SPI; SLPI	unspecified	,; serine proteinase inhibitor; proteinase inhibitor	asthma
vaccine, TNF alpha	unspecified	,; vaccine; cytokine antagonist	rheumatoid arthritis; Crohn disease; cachexia; asthma
bradykinin2 antagonists,	unspecified	bradykinin antagonist	asthma

NOVA 567; NPC 567	N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalaninebradykinin	bradykinin antagonist; cicatrizant; peptide; NSAID	asthma; skin ulcer; inflammation
icatibant; icatibant acetate; HOE 140	D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolincarbonyl-L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl-L-arginine	bradykinin antagonist; NSAID	asthma; inflammation; rhinitis; osteoarthritis
NPC 17731	N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-(trans-4-propoxy-D-proline)-8-[L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carboxylic acid]-bradykinin	bradykinin antagonist; NSAID	inflammation; septic shock; asthma
FR 173657	(E)-3-[6-(acetylamino)-3-pyridinyl]-N-[2-[[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl-2-propenamide	bradykinin antagonist; NSAID; analgesic	asthma; inflammation; pain
dametralast; LA 2851	7-methylpyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine	bronchodilator	asthma
F 3121	1,4-dihydro-3-amino-4-oxo-1-((3-trifluoromethyl)phenyl)pyridazine	bronchodilator	asthma
HOE 058A	unspecified	bronchodilator	asthma

KF 15570	imidazo(4,5-c)quinoline-4-one	bronchodilator	asthma
KF 17625	5-phenyl-(3H)-imidazo(4,5-c)(1,8)-naphthyridine-4-(5H)-one	bronchodilator	asthma
LM 3339	2-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)pyridine 1-oxide	bronchodilator	asthma
PF 904	1-ethyl-6-methyl-1H-pyrazino[2,3-c][1,2,6]thiadiazine-4-amine 2,2-dioxide	bronchodilator	asthma
RU 32210	unspecified	bronchodilator	asthma
S 123701	unspecified	bronchodilator	asthma
SC 109	unspecified	bronchodilator	asthma; pulmonary fibrosis
SDZ MKS492	(R)-8-[[1-(3,4-dimethoxyphenyl)-2-hydroxyethyl]amino]-3,7-dihydro-7-(2-methoxyethyl)-1,3-dimethyl-1H-purine-2,6-dione	bronchodilator	asthma
LY 150310	1-(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-imidazole mononitrate	bronchodilator; imidazole	asthma
fenspiride; KSP 193; PNEUMORAL; ESPIRAN	8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one	bronchodilator; NSAID	inflammation; asthma
Ro 251553; Ro 25-1553	N-acetyl-His-Ser-Asp-Ala-Val-Phe-Thr-Glu-Asn-Tyr-Thr-Lys-Leu-Arg-Lys-Gln-NLeu-Ala-Ala-Lys-Lys-Tyr-Leu-Asn-Asp-Leu-Lys-Lys-Gly-Gly-Thr-amide, cyclic (25->21)-peptide	bronchodilator; VIP agonist	asthma



CD 349	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-(nitrooxy)propyl 3-(nitrooxy)propyl ester	calcium antagonist; bronchodilator	hypertension; asthma; angina
RWJ 22108	4-(2-chloro-6-fluorophenyl)-1,4,6,7,8,9-hexahydro-2-methylthiopyrino[3,2-b]pyridine-3-carboxylic acid 5,5-dioxide 2-[methyl(phenylmethyl)amino]ethyl ester	calcium antagonist; bronchodilator	asthma
MDL 27399	N-[1-[N-[N-(4-methoxy-1,4-dioxobutyl)-L-alanyl]-L-alanyl]-L-prolyl]-L-phenylalanine methyl ester	cathepsin G inhibitor; proteinase inhibitor	emphysema
VLA4 integrin antagonist	unspecified	cell adhesion inhibitor; integrin antagonist; VLA 4 antagonist; NSAID	asthma; rheumatoid arthritis; multiple sclerosis
CCR3 inhibitors	unspecified	chemokine antagonist	asthma
chloride channel blocker	unspecified	chloride channel blocker	asthma; pulmonary obstructive disease
AQRA 721	N-1-azabicyclo[2.2.2]oct-3-yl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepine-11-carboxamide	cholinergic antagonist; bronchodilator	asthma
DAC 5889; DAC 6150	6-oxo-3-phenyl-3-piperidinecarboxylic acid 1-azabicyclo[2.2.2]oct-3-yl ester	cholinergic antagonist; muscarinic antagonist; muscarinic M1 antagonist; bronchodilator	asthma

rispenzepine; ulvenzepine; DF 594	6,11-dihydro-11-[(1-methyl-3-piperidinyl)carbonyl]-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one	cholinergic antagonist; muscarinic antagonist; muscarinic M1 antagonist; muscarinic M3 antagonist; antispasmodic; bronchodilator	asthma; bronchitis
revatropate; UK 112166	(R)-3-quinuclidyl-(2S)-2-hydroxymethyl-4-(R)-methylsulfinyl-2-phenylbutyrate	cholinergic antagonist; muscarinic M3 antagonist; muscarinic antagonist	asthma; pulmonary obstructive disease
chymase inhibitors,	unspecified	chymase inhibitor; NSAID	asthma; inflammation; rhinitis
CMI 903	unspecified	complement inhibitor	asthma
anti-inflammatory corticosteroids	unspecified	corticosteroid	psoriasis; asthma
budesonide; budesonide propionate; S 1320; PREFERID; PULMICORT; RHINOCORT; ENTOCORT; NARICORT; INFLAMMIDE; BETACTIN; ELTAIR; HORACORT; RHINOCORT AQUA	(11beta,16alpha)-16,17-[butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione	corticosteroid	asthma; skin disease; inflammation; rhinitis; ulcerative colitis; Crohn disease
butixocort propionate; JO 1222	(11beta)-11-hydroxy-17-(1-oxobutoxy)-21-[(1-oxopropyl)thio]]pregn-4-ene-3,20-dione	corticosteroid	inflammation; asthma; inflammatory bowel disease

CGP 13774; KSR 592	(+)-methyl 9alpha-chloro- -6alpha-fluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-p ropionyloxy-androsta-1,4-diene-17beta-carboxylate	corticosteroid	asthma; rhinitis
ciclesonide; BY 9010; BTR 15	[11beta,16alfa (R)]-16,17- [(cyclohexylmethylen e)bis(oxy)]-11- hydroxy-21-(2- methyl-1- oxopropoxy)-pregna-1,4-diene-3,20-dione	corticosteroid	asthma
D 5272	unspecified	corticosteroid	asthma
D 5519	unspecified	corticosteroid	asthma
deflazacort; azacort; L 5458; MDL 458; AZACORTID; CALCORT; LANTADIN; DEFLAN; FLANTADIN; DEZACOR; ZAMENE; ROSILIN; DEFLAMON; PRANDIN	(11beta,16beta)-21-(acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-die no[17,16-d]oxazole-3,20-dione	corticosteroid	rheumatoid arthritis; skin disease; asthma
drug delivery system, corticosteroid binding globulin; corticosteroid binding globulin; ALX 25	unspecified	corticosteroid	inflammation; asthma
drug delivery system, LDS microemulsion anti-asthma steroids; anti-asthma steroids LDS microemulsion	unspecified	corticosteroid	asthma

drug delivery system, liposome beclometasone dipropionate; beclometasone dipropionate, liposome	unspecified	corticosteroid	asthma
drug delivery system, liposome rofleponide; rofleponide liposome; rofleponide palmitate	[(6alpha,11beta,16alpha(R)) 16,17- [butylidenebis(oxy)]6,9-difluoro-11,21-dihydroxypregn-4-ene-3,20-dione	corticosteroid	asthma; rhinitis
fluticasone propionate; fluticasone; CCI 18781; SN 410; SN 411MD; FLOVENT; FLIXONASE; FLIXOTIDE; FLONASE; FLUTIVATE; FLUTIDE NASAL; CUTIVATE; RONTILONA; TRIALONA; FLUNASE	(6alpha,11beta,16alpha,17alpha)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-androst-1,4-diene-17-carbothioic acid, S-(fluoromethyl) ester	corticosteroid	dermatitis; rhinitis; asthma; pulmonary obstructive disease; skin disease
GW 215864	unspecified	corticosteroid	asthma
GW 250495	unspecified	corticosteroid	asthma
icometasone enbutate; icomethasone enbutate; icometasone acetate; isomethasone acetate; CL 09	(11beta,16alpha)-21-(acetyloxy)-9-chloro-11-hydroxy-16-methyl-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dione	corticosteroid	asthma; skin disease
mometasone furoate; mometasone; S 2640; SCH 32088; ELOCOM; ELOCON; FULMETA; ECURAL; ERMIL; NASONEX; ASMANEX	(11beta,16alpha)-9,21-dichloro-17-[(2-furanylcarbonyloxy)-11-hydroxy-16-methyl-pregna-1,4-diene-3,20-dione	corticosteroid	dermatitis; asthma; rhinitis; psoriasis; pruritis

rofleponide; D 5522	[6alpha,11beta,16alpha(R)] 16,17-[butylidenebis(oxy)]6,9-difluoro-11,21-dihydroxypregn-4-ene-3,20-dione	corticosteroid	asthma
ST 126; TO 199	unspecified	corticosteroid	asthma
RPR 106541	[6alpha,11beta,16alpha(R),17beta]-16,17-[butylidenebis(oxy)]-6,9-difluoro-11-hydroxy-17-(methylthio)androst-4-en-3-one	corticosteroid; glucocorticoid	asthma
methylprednisolone suleptanate; U 67590A; PROMEDROL	(6alpha,11beta)-11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxooctyl]oxy]pregna-1,4-diene-3,20-dione monosodium salt	corticosteroid; immunosuppressant	inflammation; asthma; anaphylactic shock; transplant rejection
tepoxalin; RWJ 20485; ORF 20485	5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide	COX inhibitor; 5-lipoxygenase inhibitor; NSAID	asthma; inflammation; inflammatory bowel disease
BAY 169996	unspecified	cytokine antagonist	asthma
cytokine trap,	unspecified	cytokine antagonist	cancer; asthma; rheumatoid arthritis; allergy
IL-4 antagonists, Pharmacopeia; IL-4 antagonists	unspecified	cytokine antagonist	asthma
interleukin-4 signal transduction antagonists	unspecified	cytokine antagonist	asthma
interleukin-5 inhibitor	unspecified	cytokine antagonist	asthma
interleukin-4 receptor inhibitors	unspecified	cytokine inhibitor	asthma; diabetes
interleukin-1 inhibitors,	unspecified	cytokine inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease

JTE 711	unspecified	cytokine synthesis inhibitor	dermatitis; asthma; rhinitis
amlexanox; amoxanox; CHX 3673; AA 673; SOLFA; ELICS; APHTHASOL	2-amino-7-(1-methylethyl)-5-oxo-5H-[1]-benzopyrano[2,3-b]pyridine-3-carboxylic acid	degranulation inhibitor	asthma; psoriasis; rhinitis; mucositis; conjunctivitis; allergy
asobamast; Z 1819	2-ethoxyethyl[4-(3-methyl-5-isoxazolyl)-2-thiazolyl]oxamate	degranulation inhibitor	asthma
azelastine; A 5610; W 2979M; E 0659; AZEPTIN; ALLERGODIL; ASTELIN; RADETHAZIN; AFLUONA; AFLUON; AZEPIT; AZECOF; AZERUNART CHOS H; BIFERTIN	4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone	degranulation inhibitor	asthma; rhinitis; skin disease; conjunctivitis
BN 50601	2-[4-(1,1-dimethylethyl)phenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[3,4-b]pyridin-7-ol	degranulation inhibitor	asthma
CGP 25875	unspecified	degranulation inhibitor	asthma
cromoglicate lisetil; AKY 953; KY 556; N 556	2-[[2-(ethoxycarbonyl)-4-oxo-4H-1-benzopyran-5-yl]oxy]-1-[[[2-(ethoxycarbonyl)-4-oxo-4H-1-benzopyran-5-yl]oxy]methyl]ethyl ester, L-lysine dihydrochloride	degranulation inhibitor	asthma; rhinitis; dermatitis; allergy

drug delivery system, oral cromolyn sodium; cromolyn sodium oral delivery system	unspecified	degranulation inhibitor	asthma; allergy; eye disease
nedocromil; FPL 59002; FPL 59002KP; TILADE; TILARIN; TILAVIST; TILAD; NEDREL; DISVEN; IRTEN	9-ethyl-6,9-dihydro- 4,6-dioxo-10-propyl- 4H-pyrano[3,2- g]quinoline-2,8- dicarboxylic acid	degranulation inhibitor	asthma; eye disease; skin disease; rhinitis
pemirolast; pemirolast potassium; BMY 26517; DE 068; BL 5617; PEMILASTON; ALLEGYSAL	9-methyl-3-(1H- tetrazol-5-yl)-4H- pyrido[1,2- a]pyrimidin-4-one	degranulation inhibitor	asthma; conjunctivitis; rhinitis; dermatitis; restenosis
picumast; picumast dihydrochloride; BM 15100	7-[3-[4-(4- chlorobenzyl)-1- piperazinyl]propoxy]- 3,4-dimethylcoumarin	degranulation inhibitor	rhinitis; asthma
quinotolast; quinotolast sodium; FK 021; FR 71021; ASLOCK	4-oxo-1-phenoxy-N- 1H-tetrazol-5-yl-4H- quinolizine-3- carboxamide	degranulation inhibitor	asthma; rhinitis; dermatitis
sulochrin	unspecified	degranulation inhibitor	asthma
suplatast tosilate; IPD 1151T; MPD; IPD	dimethyl-2-[4-(3- ethoxy-2- hydroxypropoxy)phen- ylcarbamoyl]ethylsulf- onium-p-toluene sulfonate	degranulation inhibitor	dermatitis; asthma; allergy; rhinitis
tazanolast; WP 833; TAZANOL; TAZALEST	oxo[[3-(1H-tetrazol- 5- yl)phenyl]amino]aceti- c acid, butyl ester	degranulation inhibitor	asthma; rhinitis
tetrazolast meglumine; tetrazolast; MDL 26024GO	4-(1H-tetrazol-5- yl)tetrazolo[1,5- a]quinoline with 1- deoxy-1- (methylamino)-D- glucitol	degranulation inhibitor	asthma

CI 959	5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-benzo[b]thiophene-2-carboxamide sodium salt	degranulation inhibitor; immunosuppressant; NSAID	rhinitis; inflammation; asthma; arthritis
AP 414	unspecified	degranulation inhibitor; tyrosine kinase inhibitor	asthma; allergy
MDAM	N-[4-[2-(2,4-diamino-6-pteridiny)ethyl]benzo-yl]-4-methylene-DL-glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma
ALP 231	unspecified	elastase inhibitor; proteinase inhibitor	emphysema
ALP 242	unspecified	elastase inhibitor; proteinase inhibitor	asthma; emphysema; psoriasis
DF 1283	tert-butyl (7S) 3-(acetoxymethyl)-7-[(N-benzyloxycarbonyl-L-valyl)amino]-5,5-dioxide-5-thia-1-azabicyclo[4.2.0]oct-2-8-one-2-carboxylate	elastase inhibitor; proteinase inhibitor	emphysema; cystic fibrosis; bronchitis
FK 706	N-[4-[[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-L-prolinamide monosodium salt	elastase inhibitor; proteinase inhibitor	emphysema
FR 134043	unspecified	elastase inhibitor; proteinase inhibitor	emphysema
FR 901277	unspecified	elastase inhibitor; proteinase inhibitor	emphysema



MDL 27324	(S)-N-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-L-alanyl-L-alanyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-L-prolinamide	elastase inhibitor; proteinase inhibitor	emphysema
TEI 5624	(S)-4-[[4-(4-chlorophenyl)sulfonyl]amino]-5-[[5-methyl-2-[(1-methylethyl)amino]-4-oxo-4H-3,1-benzoxazin-7-yl]amino]-5-oxopentanoic acid	elastase inhibitor; proteinase inhibitor	emphysema
TEI 6344	(S)-6-amino-2-[[4-(4-chlorophenyl)sulfonyl]amino]-N-[5-methyl-2-[(1-methylethyl)amino]-4-oxo-4H-3,1-benzoxazin-7-yl]hexanamide	elastase inhibitor; proteinase inhibitor	emphysema
TEI 8362	unspecified	elastase inhibitor; proteinase inhibitor	emphysema; respiratory distress syndrome
SR 26831	5-[(2-chlorophenyl)methyl]-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxythieno[3,2-c]pyridinium	elastase inhibitor; proteinase inhibitor; NSAID	inflammation; emphysema
BQ 153	cyclo(3-sulfo-D-alanyl-L-prolyl-D-valyl-L-leucyl-D-tryptophyl)	endothelin A antagonist; endothelin antagonist	asthma
endothelin antagonist	unspecified	endothelin antagonist	kidney disease; ischemia; inflammatory bowel disease; asthma

BW 443C	L-tyrosyl-D-arginylglycyl-4-nitro-L-phenylalanyl-L-prolinamide diacetate (salt)	enkephalinase inhibitor; analgesic	asthma; pain; cough
BAY x 1005	(R)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)benzeneacetic acid	FLAP antagonist	asthma
VML 530; ABT 080	unspecified	FLAP antagonist	asthma
VB 5122	unspecified	free radical scavenger; xanthine oxidase inhibitor	inflammation; asthma
beta-glucan antagonist	unspecified	glucan antagonist	conjunctivitis; asthma; psoriasis; ulcerative colitis
nitrocinonide	6alpha,9-difluoro-11beta,16alpha,17-trihydroxy-3-oxoandrost-1,4-diene-17beta-carboxylic acid, ester with ethyl(S)-1-hydroxyethyl carbonate, cyclic(R)-16,17-acetal with butyraldehyde	glucocorticoid	asthma
glucocorticoids,	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
methylhistamine, R-alpha; BP 2.94	unspecified	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 49648	(2S-trans)-4-(2-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 50971	(3R-trans)-4-(4-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
HQL 79	4-(diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]piperidine	histamine antagonist; 5HT antagonist	allergy; asthma

asthma therapy	unspecified	histamine antagonist; histamine H1 antagonist	asthma
DF 1111301	1-(2-ethoxyethyl)- N,N-dimethyl-1H- benzimidazole-2- ethanamine dihydrochloride	histamine antagonist; histamine H1 antagonist	allergy; asthma
ebastine; LAS W090; LAS 90; EBASTEL; KESTINE; EVASTEL	1-[4-(1,1- dimethylethyl)phenyl] -4-[4- (diphenylmethoxy)-1- piperidinyl]-1- butanone	histamine antagonist; histamine H1 antagonist	allergy; rhinitis; asthma
epinastine; WAL 801; WAL 801CL; ALESION	9,13b-dihydro-1H- dibenz[c,f]imidazo[1, 5-a]azepin-3-amine	histamine antagonist; histamine H1 antagonist	allergy; asthma; psoriasis; rhinitis
F 9505A	unspecified	histamine antagonist; histamine H1 antagonist	asthma
mizolastine; SL 850324; MKC 431; MIZOLLEN; ZOLIM; MISTAMINE	2-[[1-[1-[(4- fluorophenyl)methyl]- 1H-benzimidazol-2- yl]-4-piperidinyl] methylamino]-4(1H)- pyrimidinone	histamine antagonist; histamine H1 antagonist	asthma; allergy; rhinitis
olopatadine; olopatadine hydrochloride; KW 4679; ALO 4943A; PATANOL	(Z)-11-[3- (dimethylamino)prop ylidene]-6,11- dihydro-dibenz[b,e] oxepin-2-acetic acid	histamine antagonist; histamine H1 antagonist	allergy; rhinitis; asthma; conjunctivitis
selenotifen; BN 52256	4,9-dihydro-4-(1- methyl-4- piperidinylidene)- 10H- benzo[4,5]cyclohepta [1,2-b]selenophen-10- one	histamine antagonist; histamine H1 antagonist	eye disease; asthma; arrhythmia; rhinitis
ZCR 2060	2-[2-[4- (diphenylmethyl)-1- piperazinyl]ethoxy]be nzoic acid maleate	histamine antagonist; histamine H1 antagonist	asthma; allergy

FCC 13	3,4,10,14b-tetrahydrodibenzo[c,f]pyranzino[1,2-a]azepine-2(1H)carboxamide	histamine antagonist; histamine H1 antagonist; 5HT antagonist	asthma
mequitamium iodide; LG 30435	1-methyl-3-(10H-phenothiazin-10-ylmethyl)-1-azoniabicyclo[2.2.2]octane iodide	histamine antagonist; histamine H1 antagonist; muscarinic antagonist; cholinergic antagonist	asthma; rhinitis
KY 234	1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3-(1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid	histamine antagonist; histamine H1 antagonist; thromboxane synthetase inhibitor	asthma
pibaxizine; UCB 20028; UCB J028; J028; J 028	[2-[2-[4-(diphenylmethylene)piperidinyl]ethoxy]ethoxy]acetic acid	histamine antagonist; histamine H2 antagonist	irritable bowel syndrome; asthma
KC 11425	5,6-dihydro-2-methyl-8-(2-methylpropyl)-1-[2-[4-(4-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4H-pyrrolo[3,2,1-ij]quinoline	histamine antagonist; PAF antagonist	asthma; allergy
KC 11404	4-n-butyl-5,6-dihydro-8-hydroxy-2-methyl-1-[2-[4-(4-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4H-pyrrolo[3,2,1-ij]quinoline	histamine antagonist; PAF antagonist; 5 lipoxygenase inhibitor	asthma; allergy
dehydroepiandrosterone sulfate; DHEAS; PB 005	unspecified	hormone; vaccine adjuvant; corticosteroid	inflammation; infectious disease; asthma
pentigetide; IgE pentapeptide human; pentapeptide DSDPR; TA 521; PENTYDE	N2-[1-N-(N-L-alpha-aspartyl-L-seryl)-L-[alpha-aspartyl]-L-prolyl]-L-arginine	immunoglobulin	conjunctivitis; asthma; rhinitis
SRL 172	unspecified	immunostimulant	tuberculosis; cancer; asthma; bacterial infection; leprosy; rhinitis

asthma/allergy therapy,	unspecified	immunosuppressant	asthma; allergy
D 22557	unspecified	immunosuppressant	allergy; asthma
D 7193	unspecified	immunosuppressant	asthma
IgE receptor inhibitors,	unspecified	immunosuppressant	asthma
immunology/inflammation therapy	unspecified	immunosuppressant	inflammation; autoimmune disease; asthma
immunosuppressant	unspecified	immunosuppressant	asthma
immunosuppressants,	unspecified	immunosuppressant	autoimmune disease; asthma
LCB 2183	Unspecified	immunosuppressant	rhinitis; dermatitis; asthma
oxeclosporin; SDZ IMM 125; IMM 125	2-[O-(2-hydroxyethyl)-D-serine]-cyclosporin A	immunosuppressant	asthma
T cell modulators,	unspecified	immunosuppressant	asthma; rhinitis; conjunctivitis; allergy
CBP 1011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; systemic lupus erythematosus; asthma
D 22558	unspecified	immunosuppressant; cytokine inhibitor	asthma; allergy
immunoregulators,	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma
phellodendrine; OB 5	(7S-cis)-5,8,13,13a-tetrahydro-2,11-dihydroxy-3,10-dimethoxy-7-methyl-6H-dibenzo[a,g]quinolizinium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease
alphaE beta7 antagonists,	unspecified	integrin antagonist; cell adhesion inhibitor	asthma; psoriasis; inflammatory bowel disease
cell adhesion inhibitors,	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	asthma; rheumatoid arthritis; reperfusion injury

TBC 1269	3',3'''-(1,6-hexanediyl)bis[6'-(alpha-D-mannopyranosyloxy)-[1,1'-biphenyl]-3-acetic acid	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; asthma
VLA-4 antagonist,	unspecified	integrin antagonist; VLA 4 antagonist	asthma
VLA-4 antagonists, inflammatory diseases; BIO 1211	N-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-leucyl-L-alpha-aspartyl-L-valyl-L-proline	integrin antagonist; VLA 4 antagonist	asthma; multiple sclerosis
VLA4 antagonists	unspecified	integrin antagonist; VLA 4 antagonist; cell adhesion inhibitor	asthma; inflammatory bowel disease
BW A137C	N-hydroxy-N-[[4-(phenylmethoxy)phenyl]methyl]acetamide	leukotriene antagonist	asthma
BW A797C	acetamide, n-hydroxy-n-(3-(5,6,7,8-tetrahydro-2-naphthalenyl)-2-propenyl)-	leukotriene antagonist	asthma
CL 891301	unspecified	leukotriene antagonist	asthma
CS 615	unspecified	leukotriene antagonist	asthma
FK 011	unspecified	leukotriene antagonist	asthma
LF 60361	unspecified	leukotriene antagonist	asthma
RP 12525	unspecified	leukotriene antagonist	asthma
zafirlukast; 204219; ICI 204219; ACCOLATE; VANTICON	[3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic acid, cyclopentyl ester	leukotriene antagonist	asthma; rhinitis
BIIL 284	unspecified	leukotriene antagonist; leukotriene B4 antagonist	asthma; pulmonary obstructive disease

pranlukast; dolukast; ONO 1078; RS 411; ONON; ULTAIR	N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide	leukotriene antagonist; leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene E4 antagonist	asthma; rhinitis
leukotriene D4 antagonists	unspecified	leukotriene antagonist; leukotriene D4 antagonist	asthma
LY 290154	(E)-7-chloro-2-[2-[3-[4-(1H-tetrazol-5-yl)-1-[7-(1H-tetrazol-5-ylmethoxy)-1H-indol-1-yl]butyl]phenyl]ethenyl]quinoline	leukotriene antagonist; leukotriene D4 antagonist	asthma
RG 14524	unspecified	leukotriene antagonist; leukotriene D4 antagonist	asthma
RS 601	4-[5,5,6,6,6-pentafluoro-1-[(4-fluorophenyl)sulfonyl]amino]hexyl]benzenecarboxylic acid	leukotriene antagonist; leukotriene D4 antagonist; thromboxane antagonist	asthma
YM 158; YM 57158	N-[5-[3-[(4-chlorophenyl)sulfonyl]propyl]-2-(1H-tetrazol-5-ylmethoxy)phenyl]-3-[[4-(1,1-dimethylethyl)-2-thiazolyl]methoxy]-benzamide	leukotriene antagonist; leukotriene D4 antagonist; thromboxane antagonist	asthma; rhinitis
ZD 3523; ICI D3523	unspecified	leukotriene antagonist; NSAID	asthma; inflammation

LY 292728	7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-9H-xanthene-4-propanoic acid disodium salt	leukotriene B4 antagonist; leukotriene antagonist	asthma
montazolast; BIRM 270	(S)-N-[2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazoline	leukotriene B4 antagonist; leukotriene antagonist	asthma
RP 69698	5-(1,1-dimethyl-5-((4,6-diphenyl-2-pyridyl)oxy)pentyl)-1H-tetrazole	leukotriene B4 antagonist; leukotriene antagonist	asthma; emphysema
RG 14893	4-(2-(methyl(2-phenethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; inflammation
SC 51146	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; psoriasis; rheumatoid arthritis; inflammatory bowel disease
BAY x 7195	[S-(Z)]-4-[[1-(2-carboxyethyl)-4-[4-(4-phenoxybutoxy)phenyl]-2-butenyl]thio]benzoic acid	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma
cinalukast; Ro 245913	(E)-4-(3-(2-(4-cyclobutyl-2-thiazolyl)ethenyl)phenylamino)-2,2-diethyl-4-oxobutanoic acid	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma



pirodomast; SCH 37224	4-hydroxy-1-phenyl- 3-(1-pyrrolidinyl)- 1,8-naphthyridin- 2(1H)-one	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	rhinitis; asthma
CGP 44044A	(1R,2S)-1-hydroxy-1- (3-trifluoromethyl- phenyl)-8-(4-acetyl-3- hydroxy-2-propyl- phenoxy)-octa- 3(E),5(Z)-dien-2-yl-7- thio-4-oxo-4H-1- benzopyran-2- carboxylic acid sodium salt	leukotriene D4 antagonist; leukotriene antagonist	asthma
DS 4574	6-(2- cyclohexylethyl)- [1,3,4]thiadiazolo[3,2- a]-1,2,3-triazolo[4,5- d]pyrimidin-9(1H)- one	leukotriene D4 antagonist; leukotriene antagonist	gastrointestinal ulcer; asthma
LY 203647	1-[2-hydroxy-3- propyl-4-[4-[2-[4- (1H-tetrazol-5- yl)butyl]-2H-tetrazol- 5- yl]butoxy]phenyl]etha- none	leukotriene D4 antagonist; leukotriene antagonist	hypertension; asthma
LY 287192	(E)-2-[[5-[3-[2-(7- chloro-2- quinolinyl)ethenyl]ph- enyl]-2H-tetrazol-1-2- yl]methyl]-5- fluorobenzoic acid sodium salt	leukotriene D4 antagonist; leukotriene antagonist	asthma
LY 290324	(E)-7-chloro-2-[2-[3- [[7-[2-(1H-tetrazol-5- yl)ethyl]-1H-indol-1- yl]methyl]phenyl]ethe- nyl]quinoline hydrochloride	leukotriene D4 antagonist; leukotriene antagonist	asthma

montelukast; montelukast sodium; MK 476; MK 0476; SINGULAIR	[R-(E)]- 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropanecarboxylic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
NZ 107	4-bromo-5-[[[3-ethoxy-4-methoxyphenyl)methyl]amino]-3(2H)-pyridazinone	leukotriene D4 antagonist; leukotriene antagonist	asthma
pobilukast; pobilukast edamine; SKF 104353; SKF 104353Z2; SKF 104353Q	[R-(R*,S*)]-beta-[(2-carboxyethylthio]-alpha-hydroxy-2-(8-phenyloctyl)benzenepropanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma; rhinitis
RG 12525	2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]quinoline	leukotriene D4 antagonist; leukotriene antagonist	asthma
ritolukast; WY 48252	1,1,1-trifluoro-alpha-2-quinolylmethanesulfonamides	leukotriene D4 antagonist; leukotriene antagonist	asthma
SKF 106203	(S)-beta[(2-carboxyethyl)thio]-2-(8-phenyloctyl)benzenepropanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
verlukast; MK 679; L 660711; MK 571; L 668019	[R-(E)]-3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma

YM 16638	[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
CGP 44826	2-ethenyloxy-N-[4-(5-cyclopentyl-carbonylamino-1-methylindol-3-ylmethyl)-3-methoxy-benzoyl]benzenesulfonylamide	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
FPL 55712	7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid monosodium salt	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
irialukast; CGP 45715A	(1R,2S)-1-hydroxy-1-(3-(trifluoromethylphenyl))-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-deca-3(E),5(Z)-diene-2-yl-7-thio-4-oxo-4H-1-benzopyran-2-carboxylic acid sodium salt	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
MDL 43291	(4a.alpha,7Z,8.beta,8a.beta)-[(octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio]acetic acid	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
sulukast; LY 170680	5-(3-(2(R)-(carboxyethylthio)-1(S)-hydroxypentadeca-3(E),5(Z)-dienyl)phenyl)-1H-tetrazole	leukotriene E4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma

BAY y 1015	unspecified	leukotriene synthesis inhibitor	asthma
MAB, interleukin-5; MAB, IL-5; SB 240563	unspecified	monoclonal antibody;	asthma
MAbs, CCR3	unspecified	monoclonal antibody; ; chemokine antagonist	asthma
MAB, CD4; HumaT4	unspecified	monoclonal antibody; ; immunosuppressant	psoriasis; asthma; rheumatoid arthritis; irritable bowel syndrome; transplant rejection; allergy
MAB, CD23; GW 353430	unspecified	monoclonal antibody; ; NSAID	rheumatoid arthritis; asthma
J 104135	unspecified	muscarinic antagonist; muscarinic M3 antagonist; cholinergic antagonist	urinary incontinence; pulmonary obstructive disease; asthma
FK 888	trans-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-propyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	neurokinin antagonist	asthma; migraine
lanepitant; LY 303870	(R)-N-[2-acetyl[(2-methoxyphenyl)methyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
L 733060	(2S-cis)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID	inflammation; pain; asthma
saredutant; SR 48968	(S)-N-[4-(4-acetylamino-4-phenyl-1-piperidiny)-2-(3,4-dichlorophenyl)butyl]-N-methyl-benzamide	neurokinin antagonist; analgesic; neurokinin 2 antagonist	asthma; pain; urinary incontinence

MEN 10376	unspecified	neurokinin antagonist; bronchodilator; neurokinin 2 antagonist	asthma; anxiety
CP 99994	(2S-cis)-N-[(2-methoxyphenyl)methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist; analgesic	asthma; pain
nolpitantium besilate; SR 140333	(S) 1-[2-[3-(3,4-dichlorophenyl)-1-[[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl]-4-phenyl-1-azoniabicyclo[2.2.2]octane	neurokinin antagonist; neurokinin 1 antagonist; NSAID	asthma; inflammation
NKP 608C	unspecified	neurokinin antagonist; neurokinin 1 antagonist; substance P antagonist	bronchitis
ZD 7944	unspecified	neurokinin antagonist; neurokinin 2 antagonist	asthma
SR 144190	(R)-4-benzoyl-2-(3,4-difluorophenyl)-2-[2-[4-[[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]ethyl]morpholine	neurokinin antagonist; neurokinin 2 antagonist; analgesic	asthma; urinary incontinence; asthma; pain

FK 224; FR 115224	N-[N2-[N-[N-[N-[alfa,beta-didehydro-N-methyl-N-[N-[1-oxo-3-(2-pentylphenyl)propyl]-L-threonyl]tyrosyl]-L-leucyl]-D-phenylalanyl]-L-allothreonyl]-L-asparaginy]-L-serine epsilon-lactone	neurokinin antagonist; neurokinin 2 antagonist; NSAID	asthma; inflammation
NS 2073	unspecified	nitric oxide activator; NSAID	inflammation; glaucoma; gastrointestinal ulcer; asthma
NCX 1005	(11beta,16alpha)-9-fluoro-11,17-dihydroxy-16-methyl-21-[4-(nitrooxy)-1-oxobutoxyl]pregna-1,4-diene-3,20-dione	nitric oxide donor	asthma; inflammatory bowel disease
andolast; CR 2039	N-4-(5-tetrazolyl)-phenyl-4-(5-tetrazolyl)-benzamide	NSAID	asthma; inflammation; allergy
anti-inflammatory agent,	unspecified	NSAID	inflammation; asthma
bamaquimast; F 10126; L 0042	3-[3-[[[(methylamino)carbonyl]oxy]propyl]-1-propyl-2(1H)-quinoxalinone	NSAID	asthma
BTS 71321	N-[1-(4-chlorophenyl)-1-methylethyl]-1H-imidazole-1-propanamine	NSAID	asthma
CD40 receptor signalling pathway inhibitor, CD40 receptor signalling pathway inhibitor,	unspecified	NSAID	allergy; asthma; inflammation
chemokine receptor modulators	unspecified	NSAID	inflammation; asthma; atherosclerosis

contignasterol; IZP 94005	(3alpha,4beta,5alpha,6alpha,7beta,14beta,22S)-22,29-epoxy-3,4,6,7,29-pentahydroxystigmastan-15-one	NSAID	asthma; respiratory disease
glucocorticoid agonists	unspecified	NSAID	inflammation; rheumatoid arthritis; inflammatory bowel disease; asthma
interleukin modulators, IPL 576092	unspecified	NSAID	inflammation; asthma
limazocic; SA 3443	(R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4-carboxylic acid	NSAID	liver disease; inflammation; emphysema; drug overdose
macrophage migration inhibitory factor inhibitors	unspecified	NSAID	arthritis; asthma
PKC-RACK interaction inhibitors	unspecified	NSAID	arthritis; multiple sclerosis; asthma
PNU 142731; PNU 142731A	1-[(2,4-di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)acetyl]pyrrolidine mono hydrochloride	NSAID	asthma
pseudopterosin	unspecified	NSAID	arthritis; asthma; psoriasis
tioxamast; F 1865	[[4-(4-methoxyphenyl)-2-thiazolyl]amino]oxoacetic acid ethyl ester	NSAID	asthma; inflammation; skin disease
Z 1957	ethyl N-((3-methyl-5-isoxazolyl)-2-thiazolyl) oxamate	NSAID	asthma; inflammation
VX 745	unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurological; heart failure; Crohn disease; asthma
NCX 1004	unspecified	NSAID; nitric oxide donor	asthma

phospholipase A2 inhibitors	unspecified	NSAID; phospholipase inhibitor	rheumatoid arthritis; inflammatory bowel disease; asthma
INKP 300	unspecified	NSAID; signal transduction inhibitor	asthma
D 7003	unspecified	nucleoside	bronchitis
oligonucleotide, asthma	unspecified	oligonucleotide; ,; immunostimulant	asthma
sulfated oligosaccharide	unspecified	oligosaccharide	asthma
bepafant; WEB 2170	4-[[6-(2-chlorophenyl)-8,9-dihydro-1-methyl-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazpin-8-yl]carbonyl]morpholine	PAF antagonist	asthma; rhinitis
E 6123	(S)-(+)-6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8,11-dimethyl,2,3,4,5-tetrahydro-8H-pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine	PAF antagonist	asthma
foropafant; SR 27417	N,N-dimethyl-N'-(3-pyridinylmethyl)-N'-[4-[2,4,6-tris(1-methylethyl)phenyl]-2-thiazolyl]-1,2-ethanediamine	PAF antagonist	asthma
ginkgolide A,B,C; BN 52063	(1alpha,7beta)-1,7-dihydroxyginkgolide A mixt with ginkgolide A and (1beta)-1-hydroxyginkgolide A	PAF antagonist	asthma; rhinitis; thrombocytopenia



israpafant; Y 24180; PAFNOI	4-(2-chlorophenyl)- 6,9-dimethyl-2-[2-[4- (2- methylpropyl)phenyl] ethyl]-6H-thieno[3,2- f][1,2,4]triazolo[4,3- a][1,4]diazepine	PAF antagonist	asthma
L 680573; MK 287	(2S-trans)-2-[[3- methoxy-2-propoxy- 5-[tetrahydro-5- (3,4,5- trimethoxyphenyl)-2- furanyl]phenyl]sulfon yl]ethanol	PAF antagonist	asthma; septic shock
Ro 191400	unspecified	PAF antagonist	asthma
Ro 193704; Ro 19- 3704	(R)-3-[4-[2- [(methoxycarbonyl)o xy]-3- [[[(octadecylamino)car bonyl]oxy]propoxy]b utyl]thiazolium iodide	PAF antagonist	asthma
Ro 240238; Ro 24- 0238; Ro 244376	[R-(E,E)]-5-(4- methoxyphenyl)-N- [1-methyl-4-(3- pyridinyl)butyl]-2,4- decadienamide	PAF antagonist	asthma
roceapafant; BN 50730	6-(2-chlorophenyl)- 7,10-dihydro-N-(4- methoxyphenyl)-1- methyl-4H- pyrido[4',3':4,5]thieno [3,2- f][1,2,4]triazolo[4,3- a][1,4]diazepine- 9(8H)-carbothioamide	PAF antagonist	hypotension; cytoprotectant; asthma
tulopafant; RP 59227	(+)-N-(3- benzoylphenyl)-3-(3- pyridinyl)-1H,3H- pyrrolo[1,2- c]thiazole-7- carboxamide	PAF antagonist	asthma

YM 461; YM 46A	1-(3-phenylpropyl)-4-[[2-(3-pyridinyl)-4-thiazolidinyl]carbonyl]piperazine (E)-2-butenedioate (1:1)	PAF antagonist	asthma; pulmonary obstructive disease
SCH 37370	1-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine	PAF antagonist; histamine antagonist; histamine H1 antagonist	asthma; rhinitis
CMI 392	trans-2-[5-(N'-methyl-N'-hydroxyureidylmethyl)-3-methoxy-4-p-chlorophenylthio-ethoxyphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran	PAF antagonist; leukotriene antagonist	psoriasis; dermatitis; asthma
BN 52111	1-(6-((2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy)-6-oxohexyl)-pyridinium bromide	PAF antagonist; NSAID	asthma; inflammation
BN 52115	1-[6-[(2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy]-6-oxohexyl]quinolinium bromide	PAF antagonist; NSAID	asthma; inflammation
SM 10661	cis-(+,-)-3,5-dimethyl-2-(3-pyridinyl)-4-thiazolidinone monohydrochloride	PAF antagonist; NSAID	endotoxic shock; inflammation; asthma
tetrahydrocarbazole	4-(2-chlorophenyl)-9-methyl-2-[3-(1,2,3,4-tetrahydro-9H-carbazol-9-yl)-1-propynyl]-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist; NSAID	inflammation; asthma

tiapafant; PCA 4248	1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid methyl 2-(phenylthio)ethyl ester	PAF antagonist; NSAID	asthma; inflammation
UR 10324	2-(2-acetyl-3,11-dioxo-4,10-dioxo-7-thia-2,12-diazanonacos-1-yl)-1-ethylpyridinium chloride	PAF antagonist; NSAID	inflammation; asthma
UR 12460	4-[[[(diphenylmethyl)amino]acetyl]-alpha-(2-methyl-3-pyridinyl)-1-piperazincacetonitrile	PAF antagonist; NSAID	inflammation; asthma
UR 12510	unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12519	unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12551	unspecified	PAF antagonist; NSAID	inflammation; asthma
AH 21132	cis N-(4-(1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo(c)(1,6)naphthyridin-6-yl)phenyl)-acetamide (Z)-2-butenedioate (1:2)	PAF antagonist; phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
apafant; WEB 2086; WEB 2086BS	4-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo [4,3-a][1,4]diazepin-2-yl]-1-oxopropyl morpholine	PAF antagonist; platelet antiaggregant	asthma; rhinitis; pancreatitis
dacopafant; RP 48740	(3R)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide	PAF antagonist; platelet antiaggregant	asthma; thrombosis

F 1850	unspecified	PAF antagonist; platelet antiaggregant	thrombosis; asthma
ginkgolide B; BN 52021	hexacyclic trilactone	PAF antagonist; platelet antiaggregant	thrombosis; dermatitis; asthma; multiple sclerosis; septic shock
L 659989	trans-(+,-)-tetrahydro- 2-[3-methoxy-5- (methylsulfonyl)-4- propoxyphenyl]-5- (3,4,5- trimethoxyphenyl)furan	PAF antagonist; platelet antiaggregant	asthma; thrombosis
R 74654	3-(6-(0-(2R,2S)-(3- heptadecylcarbamoyl oxytetrahydropyran- 2-yl)methyl)phosphonoxy)hex- ylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis
R 74717	3-(5-(0-(2S,3S)-(3- heptadecylcarbamoyl thiotetrahydropyran-2- yl)methyl)phosphonoxy)pen- tylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis
Ro 244736; Ro 24- 4736	5-[3-[4-(2- chlorophenyl)-9- methyl-6H- thieno[3,2- f][1,2,4]triazolo [4,3- a][1,4]diazepin-2-yl]- 2-propynyl]-6(5H)- phenanthridinone	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
SDZ 64412; SDZ 64- 412	2,3-dihydro-5-[4-[2- (3,4,5- trimethoxyphenyl)eth- yl]phenyl]imidazo[2,1- a]isoquinoline monohydrochloride	PAF antagonist; platelet antiaggregant	asthma; thrombosis

SR 27388	4-[2-[[2-(dimethylamino)ethyl](3-pyridinylmethyl)amino]-4-thiazolyl]-2,6-bis(1,1-dimethylethyl)phenol	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
UK 74505	4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]-5-[(2-pyridinylamino)carbonyl]-3-pyridinecarboxylic acid ethyl ester	PAF antagonist; platelet antiaggregant	thrombosis; asthma
UR 12670	4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-1-(1-oxo-3,3-diphenylpropyl)-piperidine	PAF antagonist; platelet antiaggregant	kidney disease; ischemia; asthma; pancreatitis
WEB 2347	6-(2-chlorophenyl)-8,9-dihydro-1-methyl-N,N-dipropyl-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-8-carboxamide	PAF antagonist; platelet antiaggregant	asthma; anaphylactic shock; thrombosis
YM 264	1-(3-methyl-3-phenylbutyl)-4-[[2-(3-pyridinyl)-4-thiazolidinyl]carbonyl]piperazine (E)-2-butenedioate (1:1)	PAF antagonist; platelet antiaggregant	thrombosis; asthma
SDZ 64619	(+,-)-2-[6-methoxy-2-(methylsulfonyl)-3,9-dioxo-4,8-dioxo-2,10-diazaoctacosan-1-yl]-1-methylpyridinium iodide	PAF antagonist; platelet antiaggregant; bronchodilator	thrombosis; asthma
asthma therapy	unspecified	peptide	asthma

cathepsin S inhibitors, Peptimmune	unspecified	peptide; proteinase inhibitor; cathepsin S inhibitor	asthma
BY 244	unspecified	phosphodiesterase inhibitor	asthma
BY 343	unspecified	phosphodiesterase inhibitor	asthma
phosphodiesterase inhibitor	unspecified	phosphodiesterase inhibitor	asthma
roflumilast; BY 217	3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide	phosphodiesterase inhibitor	asthma
KF 19514	1,5-dihydro-5-phenyl-4H-imidazo[4,5-c][1,8]naphthyridin-4-one	phosphodiesterase inhibitor; bronchodilator	asthma
KP 885	unspecified	phosphodiesterase inhibitor; bronchodilator	asthma
P 1432	3-(cyclopropylmethyl)-xanthine	phosphodiesterase inhibitor; bronchodilator	asthma
WY 123641; PDA 641	unspecified	phosphodiesterase inhibitor; bronchodilator	asthma
arofylline; LAS 31025	3-(4-chlorophenyl)-3,7-dihydro-1-propyl-1H-purine-2,6-dione	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
LAS 31396	unspecified	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
tolafentrine; BY 4070	(-)-4-(cis-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl)-p-toluenesulfonamide	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma

zardaverine; B 84290	6-(4-(difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
AWD 12281	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
BAY 198004	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
CP 220629; CP 220,629	1-cyclopentyl-3-ethyl-1,4,5,6-tetrahydro-6-(2-methylphenyl)-7H-pyrazolo[3,4-c]pyridin-7-one	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
DWP 205297	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
PDE-4 inhibitors	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
YM 976	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
CDP 840	(R)-4-[2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-phenylethyl]pyridine	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; inflammation
flaminalast; WAY PDA 641	1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethanone, (E)-O-(aminocarbonyl)oxime	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma

LAS 32688	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
phosphodiesterase inhibitors	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
piclamilast; RP 73401; RPR 73401	3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; arthritis
SB 207499; ARIFLO	cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylic acid	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; pulmonary obstructive disease
D 4418	N-(3,5-dichloro-4-pyridinyl)-8-methoxy-5-quinolinecarboxamide	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; immunosuppressant; bronchodilator	asthma
D 22888	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; phosphodiesterase V inhibitor; bronchodilator	asthma
SKF 96231	2-(2-propoxyphenyl)-6-purinone	phosphodiesterase inhibitor; phosphodiesterase V inhibitor; bronchodilator	asthma
doxofylline; ABC 12/3; DO 309; MAXIVENT; ANSIMAR	7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione	phosphodiesterase inhibitor; xanthine	asthma



CI 1018	(R)-N-(3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-4-pyridinecarboxamide	phosphodiesterase IV inhibitor	asthma
phospholipase A2 inhibitors	Unspecified	phospholipase inhibitor; NSAID	asthma; rheumatoid arthritis; psoriasis; inflammatory bowel disease
cyclic polyamine analogue	unspecified	polyamine analogue; NSAID	Crohn disease; asthma; inflammation
BIIX 1; RS 91309	unspecified	potassium channel activator	asthma
BRL 55834	(3S,4R)-3,4-dihydro-2,2-dimethyl-4-(2-oxopiperidin-1-yl)-6-pentafluoroethyl-2H-1-benzopyran-3-ol	potassium channel activator; bronchodilator	asthma
CL 891902	unspecified	potassium channel activator; bronchodilator	asthma; hypertension
emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
potassium channel activator	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
Ro 316930	2,2-dimethyl-4-(2-pyridinyl)-2H-1-benzopyran-6-carbonitrile N4-oxide	potassium channel activator; bronchodilator	hypertension; asthma
RP 66471	1S,2R-trans-2-benzoyloxy-1-(pyrid-3-yl)cyclohexane-(N-methyl)-carbthioamide	potassium channel activator; bronchodilator	asthma

SCA 40	6-bromo-8-(methylamino)-imidazo[1,2-a]pyrazine-2-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
SDZ PCO400	(3S-trans)-2,4-dihydro-3-hydroxy-2,2-dimethyl-4-[(3-oxo-1-cyclopenten-1-yl)oxy]-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	asthma
SR 47063	4-(2-cyanoimino-1,2-dihydropyrid-1-yl)-6-nitro-2,2-dimethyl-2H-1-benzopyran	potassium channel activator; bronchodilator	heart ischemia; asthma
symakalim; EMD 57283	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; coronary artery disease; asthma
UR 8225	1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
UR 8308	1,2-dihydro-2,2-dimethyl-4-(N-oxide-2-pyridyl)-1-oxonaphthalen-6-carbonitrile	potassium channel activator; bronchodilator	asthma
UR 8328	1,2-dihydro-2,2-dimethyl-4-(N-oxide-2-pyridyl)-6-pentafluoroethylnaphtalen-1-one	potassium channel activator; bronchodilator	asthma
YM 934	3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-2H-1,4-benzoxazine N-oxide	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence

bimakalim; EMD 52692; SR 44866	2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; vasodilator; bronchodilator	coronary artery disease; asthma; peripheral vascular disease
rilmakalim; HOE 234	(3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxo-1-pyrrolidinyl)-6-phenylsulfonylchroman hemihydrate	potassium channel activator; vasodilator; bronchodilator	asthma
potassium channel modulators	unspecified	potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
NS 1619	1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one	potassium channel modulator; bronchodilator	stroke; asthma
protein kinase activators	unspecified	protein kinase activator; protein kinase A activator	asthma; thrombosis
allergy therapy	unspecified	protein kinase inhibitor	allergy; asthma
Y 27632	[4(R)-trans]-4-(1-aminoethyl)-N-4-pyridinylcyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
Syk inhibitors	unspecified	protein kinase inhibitor; tyrosine kinase inhibitor	asthma; allergy
Der p I inhibitor	unspecified	proteinase inhibitor	asthma
midesteine; MR 889	2-thiophenecarbothioic acid, S-ester with (+,-)-2-mercapto-N-(tetrahydro-2-oxo-3-thienyl)propionamide	proteinase inhibitor	emphysema
alpha-1-antitrypsin	unspecified	proteinase inhibitor; ,	emphysema
alpha-1-antitrypsin	unspecified	proteinase inhibitor; ,	asthma; emphysema; cystic fibrosis; dermatitis; psoriasis

MDL 101146	N-[4-(4-morpholinylcarbonyl)benzoyl]-L-valyl-N-[3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]-L-prolinamide	proteinase inhibitor; neutrophil elastase inhibitor	bronchitis
mycophenolate mofetil; mycophenolate mofetil hydrochloride; RS 61443; RS-61443-190;	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany l)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
NO-SOD mimetics, NitroMed; nitrosylated superoxide dismutase mimetics	unspecified	SOD mimetic; nitric oxide donor	asthma; respiratory distress syndrome; ischemia; reperfusion injury
CGP 49823	(2R-trans)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-N-(4-quinolinylmethyl)-4-piperidinamine	substance P antagonist	anxiety; asthma
FR 113680	N-acetyl-L-threonyl-1-formyl-D-tryptophyl-N-methyl-N-(phenylmethyl)-L-phenylalaninamide	substance P antagonist	asthma
WS 9326A	unspecified	substance P antagonist	asthma
dapitant; RPR 100893	[3aS-[2(R*),3aalpha,4beta,7aalpha]]-octahydro-4-(2-methoxyphenyl)-2-[2-(2-methoxyphenyl)-1-oxopropyl]-7,7-diphenyl-1H-isindol-4-ol	substance P antagonist; NSAID	asthma; inflammation; migraine
MEN 10627	unspecified	tachykinin antagonist; antispasmodic	irritable bowel syndrome; asthma

nepadutant; MEN 11420	Cyclo[3-amino-L-alanyl-L-leucyl-N-[2-(acetyl amino)-2-deoxy-beta-D-glucopyranosyl]-L-asparaginy l-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl], cyclic (4->1)-peptide	tachykinin antagonist; antispasmodic	asthma; irritable bowel syndrome
seratroda st; serabenast; AA 2414; A 73001; ABT 001; BRONICA	(+,-)-zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-benzeneheptanoic acid	thromboxane antagonist	asthma; rhinitis
SKF 88046	N,N'-bis[7-93-chlorobenzene aminosulfonyl)-1,2,3,4-tetrahydroisoquinolyl] disulfonylimide	thromboxane antagonist	asthma
domitroban; S 1452; S 145; ANBOXAN	(+,-)-[1 alfa,2 alfa(Z),3 beta,4 alfa]-7-[3-[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	asthma; rhinitis; thrombosis
ICI 185282	[2 alfa,4 alfa,5 alfa(Z)]-7-[4-(2-hydroxyphenyl)-2-(trifluoromethyl)-1,3-dioxan-5-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ICI 192605	[2 alfa,4 alfa,5 alfa(Z)]-6-[2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
KT 2962; KT 2-962	3-[4-[(4-chlorophenyl)sulfonyl]amino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis

L 670596	(-)-6,8-difluoro-2,3,4,9-tetrahydro-9-[[4-(methylsulfonyl)phenyl]methyl]-1H-carbazole-1-acetic acid	thromboxane antagonist; platelet antiaggregant	asthma; thrombosis
ON 579	4-(2-(4-chlorophenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ONO 8809	[1S-[1 $\alpha$ ,2 $\alpha$ (Z),3 $\beta$ ,4 $\alpha$ ]]-6-[3-[[[(4-bromophenyl)sulfonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-5-hexenoic acid decyl ester	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ramatroban; BAY u 3405; EN 13774	(R)-3-[[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid	thromboxane antagonist; platelet antiaggregant	asthma; rhinitis
SQ 33961	[1S-(exo,exo)]-2-[[3-[4-[[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
KDI 792; FK 070; FR 12170	[2S-[2 $\alpha$ ,4 $\beta$ ]]-6-[4-[[[(4-chlorophenyl)sulfonyl]amino]-1-(3-pyridinylmethyl)-2-pyrrolidinyl]-5-hexenoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma

E 6700	(E)-alpha-[(4-methoxy-2,5-dimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene]-3-pyridineheptanoic acid	thromboxane synthetase inhibitor	asthma
F 1322	N-[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]-3-hydroxy-5-(3-pyridinylmethoxy)-2-naphthalenecarboxamide	thromboxane synthetase inhibitor	asthma
KK 505	2-ethyl-4-(3-pyridyl)-1(2H)-phthalazinone	thromboxane synthetase inhibitor; bronchodilator	asthma
KK 562	2-methyl-4-(5-thiazolyl)-1(2H)-phthalazinone	thromboxane synthetase inhibitor; bronchodilator	asthma
imitrodest; CS 518; RS 5186	4,5-dihydro-2-(1H-imidazol-1-ylmethyl)-benzo[b]thiophene-6-carboxylic acid sodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	asthma
nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis
ozagrel; ozagrel sodium; OKY 046; DOMENAN; CATACLOT; XANBON; VEGA	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	stroke; thrombosis; asthma; cough
Y 20811	4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethyl-benzoic acid, monosodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; asthma; stroke

ZT 386	unspecified	thromboxane synthetase inhibitor; thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
tumor necrosis factor inhibitors	unspecified	TNF inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease
NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	asthma; inflammation; restenosis
BAY 358535; BAY 35-8535; BAY 171998; BAY 17-1998	unspecified	tryptase inhibitor	asthma
BAY 443428	unspecified	tryptase inhibitor	asthma
oral tryptase inhibitors,	unspecified	tryptase inhibitor	inflammatory bowel disease; asthma; psoriasis
tryptase inhibitors	unspecified	tryptase inhibitor	asthma
tryptase inhibitors	unspecified	tryptase inhibitor; NSAID	asthma; inflammation; rhinitis; inflammatory bowel disease; psoriasis
APC 366	N2-[(1-hydroxy-2-naphthalenyl)carbonyl]-L-arginyl-L-prolinamide monohydrochloride	tryptase inhibitor; peptide	asthma
allergy/asthma therapy,	unspecified	Unspecified	asthma; allergy
antiasthma agent	unspecified	unspecified	asthma
AP 0341	5-amino-3-(4-chlorophenyl)-N-methyl-1H-1,2,4-triazole-1-carbothioamide	unspecified	asthma
APO 77	unspecified	unspecified	asthma
ARL 68475; FPL 68475	unspecified	unspecified	asthma
asthma therapy	unspecified	unspecified	asthma
asthma therapy	unspecified	unspecified	asthma
asthma therapy	unspecified	unspecified	asthma



asthma therapy	unspecified	unspecified	asthma
asthma therapy	unspecified	unspecified	asthma
asthma/allergy therapy.	unspecified	unspecified	asthma; allergy
batebulast; batebulast hydrochloride; NCO 650	trans-4-guanidinomethylcyclohexanecarboxylic acid p-tert-butyl-phenyl ester hydrochloride	unspecified	asthma
CCR3 receptor modulators	unspecified	unspecified	asthma
CL 296141	unspecified	unspecified	asthma
CPR 3005	unspecified	unspecified	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 3014	unspecified	unspecified	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 3016	unspecified	unspecified	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 7011	L-alpha-dipalmitoyl-sn-glycero-3-phosphocholine	unspecified	bronchitis; cystic fibrosis; rhinitis; asthma
CT 1441	unspecified	unspecified	asthma; allergy
D 20783	unspecified	unspecified	asthma; rhinitis
D 21247	unspecified	unspecified	asthma; rhinitis
D 24241	unspecified	unspecified	asthma; allergy
D 43787	unspecified	unspecified	asthma; allergy
D 4396	unspecified	unspecified	asthma
DF 1012	endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide	unspecified	cough; bronchitis
drug delivery system, transdermal ketotifen; ketotifen	unspecified	unspecified	asthma
endothelium-associated disease therapy	unspecified	unspecified	stroke; asthma

erdosteine; dithiosteine; RV 144; P 144; KW 9144; EDIREL; TUSSOL	[[2-oxo-2- [(tetrahydro-2-oxo-3- thienyl)amino]ethyl]t hio]acetic acid	unspecified	bronchitis
FPL 68164	unspecified	unspecified	asthma
IgE regulators	unspecified	unspecified	asthma; allergy
INS 365	unspecified	unspecified	cystic fibrosis; bronchitis; eye disease
ion channel modulators,	unspecified	unspecified	arrhythmia; asthma
KCA 757	4-[6-acetyl-3-[3-[(4- acetyl-3-hydroxy-2- propylphenyl)thio]pro poxy]-2- propylphenoxy]butan oic acid	unspecified	asthma
KP 136; AL 136	8-hexyloxy-3-(1H- tetrazol-5-yl)-2H-1- benzopyran-2-one	unspecified	asthma
KSU 2178	unspecified	unspecified	dermatitis; asthma
L 0066; F 11105	unspecified	unspecified	asthma
LAS 30813	unspecified	unspecified	asthma; allergy
LDP 977	unspecified	unspecified	asthma
mast cell activation inhibitors	unspecified	unspecified	asthma; rhinitis
MDL 105212	(R)-1-[2-[3-(3,4- dichlorophenyl)-1- (3,4,5- trimethoxybenzoyl)- 3-pyrrolidinyl]ethyl]- 4-phenyl-4- piperidinecarboxamid e	unspecified	asthma
NIP 502	4-chloro-5-[[3- ethoxy-4- methoxyphenyl)meth yl]amino]-3(2H)- pyridazinone	unspecified	asthma
osthole; osthol	7-methoxy-8-(3- methyl-2-butenyl)- 2H-1-benzopyran-2- one	unspecified	asthma

repirinast; BAY u 2372; MY 5116; ROMET	isopentyl 5,6-dihydro- 7,8-dimethyl-4,5- dioxo-4H-pyrano[3,2- c]quinoline-2- carboxylate	unspecified	asthma
SCA 8801	6-bromo 8- (methylamino)- imidazo[1,2- a]pyrazine-2- carbonitrile	unspecified	asthma
scopinast; KA 398	7-[3-[4-[bis(4- fluorophenyl)hydroxy methyl]-1- piperidinyl]propoxy]- 6-methoxy-2H-1- benzopyran-2-one	unspecified	asthma; allergy
TA 270	N-[1,2-dihydro-4- hydroxy-1-methyl-3- (octyloxy)-2-oxo-7- quinolinyl]-3-(4- hydroxy-3,5- dimethoxyphenyl)-2- propenamide	unspecified	asthma; rhinitis
TAK 661	unspecified	unspecified	dermatitis; asthma
tetrahydrocorynanthei n	17-methoxycorynan- 16-carboxylic acid methyl ester	unspecified	asthma; allergy
Th2 modulators	unspecified	unspecified	asthma; dermatitis
thymosin beta 4; Tbeta4	Thymosin beta 4 (rat clone pROS2 precursor)	unspecified	septic shock; respiratory distress syndrome; asthma
TO 190	unspecified	unspecified	asthma
tranilast; MK 341; AINTERU; BESSARAL; CLANIST; LIZAMONT; RIZALAST; SYNBERNIA; TEIBLOCK; RIZABEN	2-[[3-(3,4- dimethoxyphenyl)-1- oxo-2- propenyl]amino]benz oic acid	unspecified	asthma; allergy; conjunctivitis; rhinitis; restenosis

U 75412E	(16alpha)-21-[4-[3-(ethylamino)-2-pyridinyl]-1-piperazinyl]-16-methylpregna-1,4,9(11)-triene-3,20-dione (2Z)-2-butenedioate (1:1)	unspecified	asthma
doqualast; SM 857	11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid	uricosuric	asthma; gout
vaccine, asthma	unspecified	vaccine	asthma
vaccine, asthma, Proteus International	unspecified	vaccine	asthma
nonionic surfactant vesicles; NISV	unspecified	vaccine adjuvant; immunosuppressant	rheumatoid arthritis; asthma; inflammation
colforsin dapropate; NKH 477; ADEHL	N,N-dimethyl-beta-alanine (3R,4aS,5S,6S,6aS,10S,10aR,10bS)-5-(acetyloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-1H-naphtho[2,1-b]pyran-6-yl ester	vasodilator; bronchodilator	heart failure; asthma; musculoskeletal disorder
ibudilast; KC 404; KETAS; AIVYNAL; EYEVYNIL	3-isobutyl-2-isopropylpyrazolo-(1,5alpha)-pyridine	vasodilator; PAF antagonist	asthma; eye disease
VLA-4 inhibitors, Epimmune	unspecified	VLA 4 antagonist; integrin antagonist; cell adhesion inhibitor	asthma
isbufylline	7-isobutyltheophylline	xanthine	asthma
MX 2120	7-(2,2-dimethyl)propyl-1-methylxanthine	xanthine	asthma
nestifylline; ABC 99	7-(1,3-dithiolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione	xanthine	asthma

MPX	3,7-dihydro-1-methyl-3-(1-methylethyl)-1H-purine-2,6-dione	xanthine; bronchodilator	asthma
-----	--	--------------------------	--------

Table 40. Current Candidate Therapeutic Interventions for the Treatment of Autoimmune Disorders

Product Name	Chemical Name	Action	Indication
brequinar; brequinar sodium; DUP 785; NSC 368390	6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid	antimetabolite; immunosuppressant	cancer; autoimmune disease; transplant rejection
ENZYOX	unspecified	antioxidant	autoimmune disease
antisense oligonucleotide, autoimmune disease	unspecified	antisense; oligonucleotide; immunosuppressant	autoimmune disease
apoptosis modulators	unspecified	apoptosis inhibitor; apoptosis inducer	cancer; autoimmune disease; neurodegeneration
complement inhibitor	unspecified	complement inhibitor; proteinase inhibitor; serine proteinase inhibitor; immunosuppressant	autoimmune disease
interferon gamma antagonists,	unspecified	cytokine antagonist; immunosuppressant	autoimmune disease
interleukin-12 signal transduction antagonists	unspecified	cytokine antagonist; immunosuppressant; NSAID	autoimmune disease; transplant rejection; rheumatoid arthritis
uromodulin	unspecified	cytokine inhibitor; immunosuppressant	autoimmune disease
SelCIDs	unspecified	cytokine inhibitor; NSAID; immunosuppressant; TNF inhibitor; phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	autoimmune disease; inflammation

interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
superoxide dismutase variants; SOD	unspecified	free radical scavenger; NSAID; immunosuppressant	inflammation; autoimmune disease; reperfusion injury
interleukin-4 diphtheria toxin chimeric protein; IL-4 diphtheria toxin chimeric protein; IL-4 fusion protein	unspecified	fusion toxin; immunosuppressant	autoimmune disease; transplant rejection; cancer; HIV infection
glucocorticoids	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
castanospermine	[1S- (1alpha,6beta,7alpha, 8beta,8abeta)]- octahydro-1,6,7,8- indolizine tetrol	glycosidase inhibitor; immunosuppressant	autoimmune disease; viral infection
growth and differentiation factor 3; GDF 3	unspecified	growth factor; differentiation inducer; immunosuppressant	transplant rejection; autoimmune disease
MDL 28842	(Z)-9-(5-deoxy-5- fluoro-beta-D-threo- pent-4-enofuranosyl- 9H-purin-6-one	homocysteine hydrolase inhibitor; immunosuppressant	malaria; autoimmune disease
Hsp70 modulators, autoimmune disease	unspecified	HSP70 inhibition	autoimmune disease
cetraric acid	9-(ethoxymethyl)-4- formyl-3,8- dihydroxy-1,6- dimethyl-11-oxo- 11H- dibenzo[b,e][1,4]diox epin-7-carboxylic acid	immunostimulant	autoimmune disease
immunostimulants	unspecified	immunostimulant	cancer; autoimmune disease

lymphocyte activation inhibitors	unspecified	immunostimulant	autoimmune disease; transplant rejection
T cell modulators,	unspecified	immunostimulant; immunosuppressant	infectious disease; autoimmune disease
B7 molecules; B7-1; B7-2	unspecified	immunosuppressant	autoimmune disease; transplant rejection
cholera toxin subunit B-antigen conjugate	unspecified	immunosuppressant	autoimmune disease
Fc receptors, soluble,	unspecified	immunosuppressant	autoimmune disease
interferon receptor type 1; IFNAR2	unspecified	immunosuppressant	autoimmune disease
MAb, CD45RB	unspecified	immunosuppressant	transplant rejection; autoimmune disease
MAb, humanized B7.1	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MAB, humanized B7.2	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MEDI 507	unspecified	immunosuppressant	autoimmune disease; transplant rejection; psoriasis
PEPTIMER	unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
RG 1046	unspecified	immunosuppressant	autoimmune disease; transplant rejection
T cell antigen receptor technology; TCR technology	unspecified	immunosuppressant	research tool; autoimmune disease
autoimmune disease therapy	unspecified	immunosuppressant	autoimmune disease
bactobolamine	[3S-(3alpha,4alpha,4abeta,5beta,6alpha)]-4-amino-3-(dichloromethyl)-3,4,4a,5,6,7-hexahydro-5,6,8-trihydroxy-3-methyl-1H-2-benzopyran-1-one	immunosuppressant	autoimmune disease
BTS 63155	unspecified	immunosuppressant	autoimmune disease

calcineurin inhibitor	unspecified	immunosuppressant	autoimmune disease; neurological
CT 2544	unspecified	immunosuppressant	autoimmune disease; transplant rejection
drug delivery system, LDS microemulsion ciclosporin; ciclosporin LDS microemulsion	unspecified	immunosuppressant	autoimmune disease; transplant rejection
drug delivery system, microemulsion ciclosporin; ciclosporin microemulsion; SANDIMMUN NEORAL; SANDIMMUN OPTORAL; NEORAL; NEORAL- SANDIMMUN	unspecified	immunosuppressant	autoimmune disease; transplant rejection
FR 901459	4-L-leucine-7-L- threonine-10-L- leucine-cyclosporin A	immunosuppressant	autoimmune disease
FTY 720	2-amino-2-[2-(4- octylphenyl)ethyl]- 1,3-propanediol hydrochloride	immunosuppressant	transplant rejection; autoimmune disease
glycophospholipid, Graves' disease	unspecified	immunosuppressant	autoimmune disease
immunology/inflamm ation therapy	unspecified	immunosuppressant	inflammation; autoimmune disease; asthma
immunophilins,	unspecified	immunosuppressant	autoimmune disease
immunoregulators,	unspecified	immunosuppressant	autoimmune disease
immunoregulatory colostrum isolate	unspecified	immunosuppressant	autoimmune disease
immunosuppressant	unspecified	immunosuppressant	autoimmune disease; transplant rejection
immunosuppressants,	unspecified	immunosuppressant	autoimmune disease; asthma
immunosuppressants	unspecified	immunosuppressant	transplant rejection; autoimmune disease
immunosuppressants,	unspecified	immunosuppressant	autoimmune disease; transplant rejection



immunosuppressants,	unspecified	immunosuppressant	autoimmune disease
immunosuppressants,	unspecified	immunosuppressant	autoimmune disease
immunosuppressants, ZAP70	unspecified	immunosuppressant	autoimmune disease
interferon gamma inhibitor	unspecified	immunosuppressant	septic shock; autoimmune disease
interleukin-2 receptor ligand	unspecified	immunosuppressant	transplant rejection; autoimmune disease
ion channel modulators,	unspecified	immunosuppressant	cardiovascular disease; neurological; autoimmune disease
IR 1116	Unspecified	immunosuppressant	autoimmune disease
leptin antagonists	unspecified	immunosuppressant	autoimmune disease; transplant rejection
LF 150195	unspecified	immunosuppressant	autoimmune disease
LZ 8	unspecified	immunosuppressant	autoimmune disease
microcolins	unspecified	immunosuppressant	autoimmune disease
myriocin; thermozymocidin; ISP-I	[2S- (2R*,3S*,4S*,6E)]-2- amino-3,4-dihydroxy- 2-(hydroxymethyl)- 14-oxo-6-eicosenoic acid	immunosuppressant	autoimmune disease; transplant rejection
PRO 2844	(OC-6-22)- pentaammine(4- methylpyridine)ruthen ium(3+) trichloride	immunosuppressant	psoriasis; autoimmune disease; transplant rejection
prodigiosin 25-C; prodigiosin	4-methoxy-5-[(5- methyl-4-pentyl-2H- pyrrol-2- ylidene)methyl]-2,2'- bi-1H-pyrrole	immunosuppressant	autoimmune disease
rapamycin analogue	unspecified	immunosuppressant	autoimmune disease
Rh toleragens	unspecified	immunosuppressant	autoimmune disease
SKF 106610	2-[3-(1- piperidinyl)propyl]- 8,8-dipropyl-2- azaspiro[4.5]decane dihydrochloride	immunosuppressant	autoimmune disease
SM 8849	4-[1-(2-fluoro-4- biphenyl)ethyl]-2- methylaminothiazole	immunosuppressant	autoimmune disease
Stat4/Stat6 blockers	unspecified	immunosuppressant	autoimmune disease; allergy

TOK 8801	5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)imidazo[2,1-b]thiazole-2-carboxamide	immunosuppressant	autoimmune disease
tresperimus; LF 80299; LF 299	[4-[(3-aminopropyl)amino]butyl]carbamic acid 2-[[6-[(aminoiminomethyl)amino]hexyl]amino]-2-oxoethyl ester	immunosuppressant	autoimmune disease
VE 19613	unspecified	immunosuppressant	autoimmune disease
VX 497	unspecified	immunosuppressant	psoriasis; autoimmune disease; viral infection; hepatitis
XENOJECT	unspecified	immunosuppressant	cancer; autoimmune disease
aldose reductase inhibitors	unspecified	immunosuppressant; aldose reductase inhibitor; NSAID	autoimmune disease; allergy; inflammation
MAB, gp39; BMS 202448	unspecified	immunosuppressant; biotechnology	autoimmune disease
monocyte colony inhibitory factor-1	unspecified	immunosuppressant; biotechnology; chemokine	autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus
chemokine receptor antagonists	unspecified	immunosuppressant; chemokine antagonist; cytokine antagonist	autoimmune disease
CBP 1011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; systemic lupus erythematosus; asthma
CBP 2011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; thrombocytopenia
CBP 2012	unspecified	immunosuppressant; corticosteroid	autoimmune disease; thrombocytopenia
autoimmune disease-specific MHC blockers	unspecified	immunosuppressant; DMARD; NSAID	rheumatoid arthritis; autoimmune disease

Bcl-x gamma-based therapy,	unspecified	immunosuppressant; gene; apoptosis inducer	autoimmune disease
protein A-based immune modulator	unspecified	immunosuppressant; immunostimulant	autoimmune disease; cancer
signal transduction modulators	unspecified	immunosuppressant; immunostimulant; NSAID	autoimmune disease; cancer; inflammation
MAB, H65 humanized Fab'	unspecified	immunosuppressant; monoclonal antibody	autoimmune disease
MAB, human interleukin-6 receptor; MAb, human IL-6 receptor; hPM-1; MRA	unspecified	immunosuppressant; monoclonal antibody	autoimmune disease; cancer
MAB, UCHL1; MAB, CD45RO	unspecified	immunosuppressant; monoclonal antibody	autoimmune disease
MAB, CD3-immunotoxin	unspecified	immunosuppressant; monoclonal antibody; biotechnology; immunotoxin	transplant rejection; autoimmune disease
enlimomab; MAB, intracellular adhesion molecule-1; MAB, ICAM-1; MAB, ICAM; MAB, R65; MAB, CD54; BIRR 0001; BIRR 1	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; autoimmune disease; rheumatoid arthritis
MAB, MHC class II; CDP 855	unspecified	immunosuppressant; monoclonal antibody; NSAID	autoimmune disease; systemic lupus erythematosus
priliximab; MAB, humanized CD4; cM-T412; CEN 000029;	immunoglobulin G1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm-T412.kappa.-chain, dimer	immunosuppressant; monoclonal antibody; NSAID	multiple sclerosis; autoimmune disease; rheumatoid arthritis
C-Maf based therapy	unspecified	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis

leukocyte function associated antigen 3 T cell inhibitor protein; LFA3TIP; LFA3TIP; AMEVIVE	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease; psoriasis
OX40-based immunotherapy	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease
inflammation therapy;	unspecified	immunosuppressant; NSAID	inflammatory bowel disease; inflammation; autoimmune disease
KB 2683	2-(4-methylphenyl)-4-benzothiazolol acetate	immunosuppressant; NSAID	rheumatoid arthritis; inflammation; autoimmune disease
MX 68	2-[[[4-[2,4-diamino-6-pteridiny]methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl]amino]hexanedioic acid	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease
PIC 101	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; autoimmune disease; transplant rejection
PIC 102	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
PIC 231	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
SKF 105685	N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dihydrochloride	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
atiprimod; atiprimod dimaleate; SKF 106615	N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine	immunosuppressant; NSAID; macrophage inhibitor	rheumatoid arthritis; autoimmune disease; psoriasis
calcineurin inhibitory peptides	unspecified	immunosuppressant; peptide	autoimmune disease
immunosuppressant peptides	unspecified	immunosuppressant; peptide	transplant rejection; autoimmune disease
T cell peptide	unspecified	immunosuppressant; peptide	autoimmune disease; cancer; bacterial infection

PP 14	unspecified	immunosuppressant; peptide; NSAID	autoimmune disease; rheumatoid arthritis
potassium channel blocker	unspecified	immunosuppressant; potassium channel blocker	autoimmune disease; allergy; inflammation
autoimmune disease therapy	unspecified	immunosuppressant; proteinase inhibitor	autoimmune disease
leflunomide; HWA 486; ARAVA	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	immunosuppressant; tyrosine kinase inhibitor; NSAID; DMARD	rheumatoid arthritis; autoimmune disease
MAb, ICAM-3; MAb, intracellular adhesion molecule-3; MAb, ICAM-R; ICM3	unspecified	integrin antagonist; biotechnology; cell adhesion inhibitor; immunosuppressant; monoclonal antibody	autoimmune disease; psoriasis
MAb, L-selectin, humanized; SMART anti-L-selectin; HuDREG 200	unspecified	integrin antagonist; biotechnology; monoclonal antibody; cell adhesion inhibitor; immunosuppressant; L selectin antagonist	trauma; respiratory distress syndrome; autoimmune disease; reperfusion injury
microcolin A	N-(2,4-dimethyl-1-oxooctyl)-N-methylleucyl-N-[1-[[2-[(2,5-dihydro-2-methyl-5-oxo-1H-pyrrol-1-yl)carbonyl]-4-hydroxy-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-N-methylthreoninamide, 23-acetate	lipopeptide; immunosuppressant	autoimmune disease

sirolimus; rapamycin; NSC 226080; AY 22989; RAPAMUNE	(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacycloheptriacontine-1,5,11,28,29(4H,6H,31H)-pentone	macrolide; immunosuppressant; antibiotic	transplant rejection; autoimmune disease; restenosis
MAB, red blood cell D antigen; MAB, rhesus D; AM 101	unspecified	monoclonal antibody; biotechnology; immunosuppressant	autoimmune disease
MAB, interleukin-12; MAB, IL-12; J695; C17.15	unspecified	monoclonal antibody; cytokine antagonist; immunosuppressant	autoimmune disease
MAB, Fv, cytokine; CDP 870	unspecified	monoclonal antibody; cytokine inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
MAB, humanized CD3; MAB, SMART CD3; HuM291	unspecified	monoclonal antibody; immunosuppressant	transplant rejection; autoimmune disease; psoriasis
daclizumab; dacliximab; MAB, Tac; MAB, humanized Tac; MAB, SMART Tac; Ro 247375; ZENAPAX	immunoglobulin G1 (human-mouse monoclonal clone 1H4 gamma chain anti-human antigen Tac), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection; cancer; autoimmune disease; eye disease

MAB, 6G5.1; MAb, autoimmune disease, human, Medarex; MDX CD4	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; rheumatoid arthritis
MAB, alpha-tubulin	unspecified	monoclonal antibody; immunosuppressant	cancer; autoimmune disease; diagnosis
MAB, autoimmune disease; MAb, MHC II	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, CD45RB	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, Fc antagonist; MDX 33	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; thrombocytopenia
MAB, gp39; MAB, CD40L; IDEC 131	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection; systemic lupus erythematosus
MAB, H57597	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, inflammation therapy,	unspecified	monoclonal antibody; immunosuppressant	inflammation; autoimmune disease
MAB, L0-CD2a; BTI 322	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, MHC II-CD4; 14-CD4	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; graft versus host disease
MAB, migis-mIgG; Mab, B cell	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, RhCA 61-76; MAB, anti-AChR alpha subunit; TCM 240	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAbs, B cells; migis	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; cancer
MAB, MHC class II	unspecified	monoclonal antibody; immunosuppressant; NSAID	autoimmune disease; transplant rejection; graft versus host disease; cancer
S 2474	unspecified	NSAID; DMARD; COX inhibitor; COX 2 inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
immunosuppressive, ANUTECH	unspecified	peptide; immunosuppressant	autoimmune disease

inflammation therapy, BTG; autoimmune disease therapy, BTG	unspecified	peptide; immunosuppressant	inflammation; autoimmune disease
complement inhibitors,	unspecified	peptide; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease; reperfusion injury; respiratory distress syndrome; transplant rejection
polyclonal antibody, idiopathic thrombocytopenic purpura; polyclonal antibody, ITP; MelGAM	unspecified	polyclonal antibody; immunoglobulin	autoimmune disease
polyclonal antibody, immune thrombocytopenic purpura; polyclonal antibody, ITP; Rho(D) immune globulin; WinRho SD; WinRho SDF	unspecified	polyclonal antibody; immunosuppressant; immunoglobulin	autoimmune disease; HIV infection
ANK 102	Unspecified	polysaccharide; immunosuppressant	autoimmune disease
cathepsin S inhibitors,	unspecified	proteinase inhibitor; cathepsin S inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease
SR 31747	(Z)-N[3-chloro-4-cyclohexylphenyl]-2-propenyl]-N-ethyl-cyclohexanamine hydrochloride	sigma antagonist; immunosuppressant; NSAID	autoimmune disease; arthritis
signal transduction inhibitor, SUGEN/ArQule	unspecified	signal transduction inhibitor; immunosuppressant	cancer; diabetes; neurological; autoimmune disease
SP 100030	Unspecified	signal transduction inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease



tumor necrosis factor binding protein; TBP-1; TBP	unspecified	TNF inhibitor; immunosuppressant	autoimmune disease; reperfusion injury; inflammation; septic shock
etanercept; tumor necrosis factor receptor; TNFr; TNF-001;	unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease
transcription factor inhibitors	unspecified	transcription factor regulator	inflammation; autoimmune disease
NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	inflammation; ischemia; cancer; autoimmune disease
AP-1 inhibitor, JNK inhibitor	unspecified	transcription factor regulator; NSAID; immunosuppressant	inflammation; autoimmune disease; cancer
SC 114	unspecified	triglyceride; immunosuppressant	autoimmune disease; transplant rejection
AP 251	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
p56 lck inhibitors	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
ZAP70 inhibitors	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
Tolerogen, autoimmune disease	unspecified	unspecified	autoimmune disease
Vaccine, gene-based, autoimmune disease	unspecified	vaccine; gene therapy	autoimmune disease; inflammation
vaccine, gene-based, autoimmune disease;	unspecified	vaccine; gene therapy; immunosuppressant	autoimmune disease

Table 41. Current Candidate Therapeutic Interventions for the Treatment of Systemic Lupus Erythematosus

Product Name	Chemical Name	Action	Indication
prasterone; dehydroepiandrosterone; DHEA; GL 701; NBI 106; PB 007; ASTENILE; DEANDROS; DIANDRON	(3beta)-3-hydroxyandrost-5-en-17-one	androgen; vaccine adjuvant; hormone replacement therapy; corticosteroid	systemic lupus erythematosus; hormone deficiency; Alzheimer disease; reperfusion injury; ischemia

FasdeltaTM	unspecified	apoptosis inhibitor	HIV infection
MAb, C5; MAb, complement C5; 5G1.1	unspecified	complement inhibitor; monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus
RP 54745	4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinoliny)-3H-1,2-dithiol-3-one	cytokine antagonist; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; psoriasis
interleukin-1 receptor; IL-1r; HJ 1306	unspecified	cytokine inhibitor; immunosuppressant	asthma
SelCIDs	unspecified	cytokine inhibitor; NSAID; immunosuppressant; TNF inhibitor; phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	autoimmune disease; inflammation
domase alfa; deoxyribonuclease; DNase; PULMOZYME	deoxyribonuclease, (human clone 18-1 protein moiety)	deoxyribonuclease; enzyme	cystic fibrosis; bronchitis; pulmonary obstructive disease; systemic lupus erythematosus
actarit; MS 932; MOVER; ORCL	4-(acetylamino)phenylacetic acid	DMARD; immunosuppressant; NSAID	rheumatoid arthritis
gene therapy, transforming growth factor beta	unspecified	gene therapy; NSAID	rheumatoid arthritis
glucocorticoids, Ligand	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
gallium nitrate; NSC 15200; CALSTAT; GANITE	gallium nitrate nonahydrate	hypocalcemic; nitric oxide synthase inhibitor	hypercalcemia; cancer
geclosporin; ciclosporin G; cyclosporin G; ciclosporin, (NVA)2-; cyclosporin, (NVA)2-; OG 37325	7-L-norvaline cyclosporin A	immunostimulant	transplant rejection

recombinant alpha3 collagen chain; BST 3003	unspecified	immunosuppressant	kidney disease; systemic lupus erythematosus
drug delivery system, microemulsion ciclosporin; ciclosporin microemulsion; SANDIMMUN NEORAL; SANDIMMUN OPTORAL; NEORAL; NEORAL-SANDIMMUN	unspecified	immunosuppressant	autoimmune disease; transplant rejection
fluasterone	unspecified	immunosuppressant	cancer; diabetes; systemic lupus erythematosus
immunosuppressant	unspecified	immunosuppressant	autoimmune disease; transplant rejection
LJP 394	unspecified	immunosuppressant	systemic lupus erythematosus
VX 497	unspecified	immunosuppressant	psoriasis; autoimmune disease; viral infection; hepatitis
SM 8849	4-[1-(2-fluoro-4-biphenyl)ethyl]-2-methylaminothiazole	immunosuppressant	autoimmune disease
monocyte colony inhibitory factor-1	unspecified	immunosuppressant; biotechnology; chemokine	autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus
CBP 1011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; systemic lupus erythematosus; asthma
MAB, MHC class II; CDP 855	unspecified	immunosuppressant; monoclonal antibody; NSAID	autoimmune disease; systemic lupus erythematosus
BMS 188667; CTLA4Ig	unspecified	immunosuppressant; NSAID	transplant rejection; systemic lupus erythematosus; psoriasis; arthritis; allergy

MAb, CD40 ligand; 5C8; ANTOVA	unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
autoimmune disease therapy	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; multiple sclerosis; systemic lupus erythematosus
PG 2946	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3028	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3113	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
MX 68	2-[[[4-[2,4-diamino- 6-pteridiny]methyl]- 3,4-dihydro-2H-1,4- benzothiazin-7- yl]carbonyl]amino]he xanedioic acid	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease
baohuoside 1; icaraside II; B-1	3-[(6-deoxy-alpha-L- mannopyranosyl)oxy]- 5,7-dihydroxy-2-(4- methoxyphenyl)-8-(3- methyl-2-butenyl)- 4H-1-benzopyran-4- one	immunosuppressant; NSAID	systemic lupus erythematosus; rheumatoid arthritis
SKF 105685	N,N-dimethyl-8,8- dipropyl-2- azaspiro[4,5]decane- 2-propanamine dihydrochloride	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
ZAP inhibitors	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis

sirolimus; rapamycin; NSC 226080; AY 22989; RAPAMUNE	(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacycloheptriacontine-1,5,11,28,29(4H,6H,31H)-pentone	macrolide; immunosuppressant; antibiotic	transplant rejection; autoimmune disease; restenosis
bindarit; AF 2838	2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]-propanoic acid	MCP-1 production inhibition; mRNA expression inhibition	rheumatoid arthritis; nephritis
MAB, 1C7; passive immunotherapy, systemic lupus erythematosus	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus
MAB, Fc antagonist; MDX 33	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; thrombocytopenia
MAB, gamma interferon, humanized; SMART anti-gamma interferon	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus; multiple sclerosis
MAB, gp39; MAB, CD40L; IDEC 131	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection; systemic lupus erythematosus
MAB, H57597	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, interleukin-10; MAB, IL-10	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus
MAB, migis-mIgG; Mab, B cell	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease

MAbs, B cells; migis	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; cancer
zolimomab aritox; MAb, H65 RTA; MAb, bone marrow- ricin A conjugate; CD5-T lymphocyte immunotoxin; MAb, CD5; XMMLY H65 RTA; XOMAZYME H65; XOMAZYME CD5+; ORTHOZYME CD5+; CD5 Plus	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	transplant rejection
MAb, cytokines; AGT 1	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis
MAb, VLA-4, humanized; MAb, very late antigen-4, humanized	unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
MAb, B7; MAb, PRIMATIZED B7; IDEC 114	unspecified	monoclonal antibody; NSAID; immunosuppressant	systemic lupus erythematosus; inflammation; transplant rejection; psoriasis
MER W8020	Unspecified	peptide; analgesic; NSAID	inflammation; pain
inflammation therapy, autoimmune disease therapy	unspecified	peptide; immunosuppressant	inflammation; autoimmune disease
complement inhibitors	unspecified	peptide; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease; reperfusion injury; respiratory distress syndrome; transplant rejection
polyclonal antibodies, HIV, anti-70K	unspecified	polyclonal antibody; immunoglobulin	HIV infection

nafamostat; nafamostat mesylate; nafamostat mesilate; FUT 175; FUTHAN TORII; FUTHAN BANYU	6-amidino-2-naphthyl p-guanidinobenzoate	proteinase inhibitor; platelet antiaggregant	thrombosis; pancreatitis; allergy; anaphylactic shock
mycophenolate mofetil; RS 61443	(E)-6-(1,3-dihydro-4- hydroxy-6-methoxy- 7-methyl-3-oxo-5- isobenzofurany l)-4- methyl-4-hexenoic acid 2-(4- morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
rolafagrel; FCE 22178	5,6-dihydro-7-(1H- imidazol-1-yl)-2- naphthalenecarboxyli c acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; kidney disease
thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3- piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
MHC expression inhibitors, BLSI	unspecified	transcription inhibitor; NSAID	rheumatoid arthritis; systemic lupus erythematosus
AP 251	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
vaccine, systemic lupus erythematosus	unspecified	vaccine	systemic lupus erythematosus
MAb, 3E10; vaccine, nephritis	unspecified	vaccine; monoclonal antibody	nephritis

Table 42. Current Candidate Therapeutic Interventions for the Treatment of Immunosuppression

Product Name	Chemical Name	Action	Indication
--------------	---------------	--------	------------

depsidomycin; antibiotic MI 951- 65F2	N-[docosahydro-7- methyl-14-(1- methylethyl)-11,23- bis(2-methylpropyl)- 5,9,12,15,21,24- hexaexo-7H,17H- dipyridazino[6,1- c:6',1'- i][1,4,7,10,13,16]oxa pentaazacyclonadec in-8-yl]-2- (formylamino)-3- methylpentanamide	antibiotic; immunosuppressant; peptide	bacterial infection
brequinar; brequinar sodium; DUP 785; NSC 368390	6-fluoro-2-(2'- fluoro[1,1'-biphenyl]- 4-yl)-3-methyl-4- quinolinecarboxylic acid	antimetabolite; immunosuppressant	cancer; autoimmune disease; transplant rejection
antisense oligonucleotide, interleukin-1; antisense oligonucleotide, IL-1	unspecified	antisense; immunosuppressant; oligonucleotide; NSAID	inflammation
antisense oligonucleotide, NF- kappaB p65 subunit	unspecified	antisense; oligonucleotide; biotechnology; immunosuppressant	Crohn disease
antisense oligonucleotide, autoimmune disease	unspecified	antisense; oligonucleotide; immunosuppressant	autoimmune disease
antisense oligonucleotide, graft versus host disease	unspecified	antisense; oligonucleotide; immunosuppressant; apoptosis inducer	transplant rejection
apoptosis inhibitors, Oxford Asymmetry/LXR Biotechnology	unspecified	apoptosis inducer	cancer; cardiac therapy; transplant rejection; gastrointestinal disorder



L-selectin antagonist, NeXstar	unspecified	aptamer; oligonucleotide; integrin antagonist; L selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation
P-selectin antagonist, NeXstar	unspecified	aptamer; oligonucleotide; integrin antagonist; P selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation
gene therapy, tumor necrosis factor receptor	unspecified	biotechnology; gene therapy; TNF inhibitor; immunosuppressant; NSAID	rheumatoid arthritis
growth and differentiation factor 3; GDF 3	unspecified	biotechnology; growth factor; differentiation inducer; immunosuppressant	transplant rejection; autoimmune disease
growth and differentiation factor- 1; GDF-1	unspecified	biotechnology; growth factor; neurotrophic factor	neurodegeneration
MAB, human interleukin-6 receptor; MAb, human IL-6 receptor; hPM-1; MRA	unspecified	biotechnology; immunosuppressant; monoclonal antibody	autoimmune disease; cancer
LFA-1 alpha subunit; leukocyte function associated antigen-1 alpha subunit; leukocyte cell surface adhesion receptor molecule	unspecified	biotechnology; nosuppressant; NSAID	inflammation

enlimomab; MAb, intracellular adhesion molecule-1; MAb, ICAM-1; MAb, ICAM; MAb, R65; MAb, CD54; BIRR 0001; BIRR 1	unspecified	biotechnology;; monoclonal antibody; NSAID	transplant rejection; autoimmune disease; rheumatoid arthritis
OX40-based immunotherapy, Cantab	unspecified	biotechnology;; NSAID	inflammation; autoimmune disease
casein kinase inhibitors, ICOS	unspecified	casein kinase inhibitor; immunosuppressant; NSAID	inflammation; cancer
ICE inhibitor, IDUN	unspecified	caspase inhibitor; apoptosis inhibitor; IL-1 beta converting enzyme inhibitor; immunosuppressant	transplant rejection; septic shock; rheumatoid arthritis; inflammatory bowel disease; diabetes
cell therapy, FCRx	unspecified	cell therapy; immunosuppressant	transplant rejection
MAb, C5; MAb, complement C5; 5G1.1	unspecified	complement inhibitor; monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus
complement inhibitor, BioCryst/3 Dimensional Pharmaceuticals	unspecified	complement inhibitor; proteinase inhibitor; serine proteinase inhibitor; immunosuppressant	autoimmune disease
methylprednisolone suleptanate; U 67590A; PROMEDROL	(6alpha,11beta)-11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxooctyl]oxy]pregna-1,4-diene-3,20-dione monosodium salt	corticosteroid; immunosuppressant	inflammation; asthma; anaphylactic shock; transplant rejection
ORG 6632	21-chloro-9alpha-fluoro-11beta-hydroxy-16alpha,17alpha-dimethylpregna-1,4-diene-3,20-dione	corticosteroid; immunosuppressant	cancer; rheumatoid arthritis

gene therapy, soluble TNF receptor; gene therapy, corneal transplant rejection	unspecified	cytokine antagonist	transplant rejection
interferon gamma antagonists, Pharmacopeia; interferon gamma antagonists, Regeneron	unspecified	cytokine antagonist; immunosuppressant	autoimmune disease
interleukin-12 signal transduction antagonists, Ligand	unspecified	cytokine antagonist; immunosuppressant; NSAID	autoimmune disease; transplant rejection; rheumatoid arthritis
RP 54745	4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinoliny)-3H-1,2-dithiol-3-one	cytokine antagonist; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; psoriasis
interleukin-8 receptor; IL-8r	unspecified	cytokine antagonist; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
interleukin-1 receptor; IL-1r; HJ 1306	unspecified	cytokine inhibitor; immunosuppressant	asthma
uromodulin	unspecified	cytokine inhibitor; immunosuppressant	autoimmune disease
anakinra; interleukin-1 receptor antagonist; IL-1ra; interleukin-1 inhibitor; ANTRIL	N2-L-methionylinterleukin 1 receptor antagonist (human isoform x reduced)	cytokine inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; transplant rejection; asthma; septic shock
interleukin-7 receptor; IL-7r	unspecified	cytokine inhibitor; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
ScICIDs	unspecified	cytokine inhibitor; NSAID; immunosuppressant; TNF inhibitor; phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	autoimmune disease; inflammation

interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
CI 959	5-methoxy-3-(1- methylethoxy)-N-1H- tetrazol-5-yl- benzo[b]thiophene-2- carboxamide sodium salt	degranulation inhibitor; immunosuppressant; NSAID	rhinitis; inflammation; asthma; arthritis
MDAM	N-[4-[2-(2,4-diamino- 6- pteridinyl)ethyl]benzo yl]-4-methylene-DL- glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma
prinomide; prinomide tromethamine; CGS 10787; CGS 10787B	alpha-cyano-1- methyl-beta- oxopyrrole-2- propionanilide with 2- amino- 2- (hydroxymethyl)-1,3- propanediol	DMARD; analgesic; immunosuppressant; NSAID	inflammation; pain; rheumatoid arthritis
actarit; MS 932; MOVER; ORCL	4- (acetylamino)phenyla cetic acid	DMARD; immunosuppressant; NSAID	rheumatoid arthritis
superoxide dismutase manganese complex; hMNSOD	unspecified	free radical scavenger; NSAID; immunosuppressant	ischemia; rheumatoid arthritis; inflammation; reperfusion injury
superoxide dismutase variants; SOD	unspecified	free radical scavenger; NSAID; immunosuppressant	inflammation; autoimmune disease; reperfusion injury
interleukin-4 diphtheria toxin chimeric protein; IL-4 diphtheria toxin chimeric protein; IL-4 fusion protein	unspecified	fusion toxin; immunosuppressant	autoimmune disease; transplant rejection; cancer; HIV infection
gene therapy, transplant rejection	unspecified	gene therapy; biotechnology; immunosuppressant	transplant rejection

gene cytokines therapy	unspecified	gene therapy; cytokine; immunosuppressant	autoimmune disease; rheumatoid arthritis; diabetes; multiple sclerosis
gene expression regulation technology,	unspecified	gene therapy; genomics; immunosuppressant	delivery system; drug design technology; graft versus host disease; transplant rejection
herpes simplex thymidine kinase; gene therapy, HS-tk	unspecified	gene therapy; immunosuppressant	transplant rejection
herpes simplex thymidine kinase; gene therapy, HS tk; gene therapy, graft versus host disease	unspecified	gene therapy; immunosuppressant	transplant rejection
glucocorticoids, Hoechst Marion Roussel	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation
glucocorticoids, Ligand	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
castanospermine	[1S-(1alpha,6beta,7alpha,8beta,8abeta)]-octahydro-1,6,7,8-indolizine tetrol	glycosidase inhibitor; immunosuppressant	autoimmune disease; viral infection
MDL 28842	(Z)-9-(5-deoxy-5-fluoro-beta-D-threo-pent-4enofuranosyl-9H-purin-6-one	homocysteine hydrolase inhibitor; immunosuppressant	malaria; autoimmune disease
lymphocyte activation inhibitors, Celltech	unspecified	immunostimulant	autoimmune disease; transplant rejection
geclosporin; ciclosporin G; cyclosporin G; ciclosporin, (NVA)2-; cyclosporin, (NVA)2-; OG 37325	7-L-norvaline cyclosporin A	immunostimulant	transplant rejection

RM 06	N-[N-[[[5-(1,6-dihydro-6-oxo-9H-purin-9-yl)pentyl]oxy]carbonyl]-L-leucyl]-L-methionine	immunostimulant	cancer; transplant rejection
T cell modulators, ArQule; T cell modulators, T Cell Sciences	unspecified	immunostimulant; immunosuppressant	infectious disease; autoimmune disease
thiethazole	2-[1-(1,1-dioxothiethanyl-3)benzimidazolyl-2-thio] acetic acid	immunostimulant; immunosuppressant; antioxidant	cancer; rheumatoid arthritis; infectious disease; transplant rejection
FCE 20696	6H-dibenzo[b,d]pyran-6-carboxylic acid 2-(dimethylamino)ethyl ester hydrochloride	immunostimulant; immunosuppressant; NSAID	viral infection; rheumatoid arthritis
thymidine kinase; gene therapy, HS-tk	unspecified	immunosuppressant	transplant rejection; eye disease
AI 101	unspecified	immunosuppressant	multiple sclerosis
AI 301	unspecified	immunosuppressant	eye disease
B7 molecules; B7-1; B7-2	unspecified	immunosuppressant	autoimmune disease; transplant rejection
cholera toxin subunit B-antigen conjugate	unspecified	immunosuppressant	autoimmune disease
Fc receptors, soluble, InKine	unspecified	immunosuppressant	autoimmune disease
galactin L-14-1; immunomodulatory lectin-1; IML-1	unspecified	immunosuppressant	transplant rejection; multiple sclerosis
IgE receptors, soluble, CorBec	unspecified	immunosuppressant	asthma
interferon receptor type 1; IFNAR2	unspecified	immunosuppressant	autoimmune disease
MAb, CD45RB	unspecified	immunosuppressant	transplant rejection; autoimmune disease
MAb, humanized B7.1	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MAb, humanized B7.2	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease

MEDI 507	unspecified	immunosuppressant	autoimmune disease; transplant rejection; psoriasis
OX40-IgG fusion protein	unspecified	immunosuppressant	inflammatory bowel disease
PEPTIMER	unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
recombinant alpha3 collagen chain; BST 3002	unspecified	immunosuppressant	kidney disease
recombinant alpha3 collagen chain; BST 3003	unspecified	immunosuppressant	kidney disease; systemic lupus erythematosus
RG 1046	unspecified	immunosuppressant	autoimmune disease; transplant rejection
T cell antigen receptor technology; TCAR technology	unspecified	immunosuppressant	research tool; autoimmune disease
AI 100; MYLORAL	unspecified	immunosuppressant	multiple sclerosis
AI 102	unspecified	immunosuppressant	multiple sclerosis
AI 300	unspecified	immunosuppressant	eye disease
asthma/allergy therapy, Rigel	unspecified	immunosuppressant	asthma; allergy
autoimmune disease therapy, Genome Pharmaceuticals	unspecified	immunosuppressant	autoimmune disease
BCH 1200	unspecified	immunosuppressant	HIV infection
BTS 63155	unspecified	immunosuppressant	autoimmune disease
calcineurin inhibitor, Agouron	unspecified	immunosuppressant	autoimmune disease; neurological
CI 0694; SULFASIM	unspecified	immunosuppressant	HIV infection
CT 2544	unspecified	immunosuppressant	autoimmune disease; transplant rejection
CT 3578	unspecified	immunosuppressant	transplant rejection
cytomuline	unspecified	immunosuppressant	transplant rejection
D 22557	unspecified	immunosuppressant	allergy; asthma
D 7193	unspecified	immunosuppressant	asthma
D5; PM 92114	unspecified	immunosuppressant	cancer
drug delivery system, CYTOPORTER ciclosporin	unspecified	immunosuppressant	transplant rejection

drug delivery system, HILT, ciclosporin; ciclosporin, HILT, psoriasis; CYCLOPS	unspecified	immunosuppressant	psoriasis
drug delivery system, LDS microemulsion ciclosporin; ciclosporin LDS microemulsion	unspecified	immunosuppressant	autoimmune disease; transplant rejection
drug delivery system, liposome ciclosporin; ciclosporin liposome	unspecified	immunosuppressant	transplant rejection
drug delivery system, liposome ciclosporin; ciclosporin liposome; LipoSPOR	unspecified	immunosuppressant	psoriasis
drug delivery system, microemulsion ciclosporin; ciclosporin microemulsion; SANDIMMUN NEORAL; SANDIMMUN OPTORAL; NEORAL; NEORAL-SANDIMMUN	unspecified	immunosuppressant	autoimmune disease; transplant rejection
fluasterone	unspecified	immunosuppressant	cancer; diabetes; systemic lupus erythematosus
gene discovery, autoimmune disease, deCODE genetics	unspecified	immunosuppressant	autoimmune disease
gliotoxin	unspecified	immunosuppressant	transplant rejection
glycophospholipid, Graves' disease, City of Hope	unspecified	immunosuppressant	autoimmune disease
IgE receptor inhibitors, InKine	unspecified	immunosuppressant	asthma
immunology/inflammation therapy, Rigel	unspecified	immunosuppressant	inflammation; autoimmune disease; asthma



immunophilins, Vertex; immunophilins, Chugai	unspecified	immunosuppressant	autoimmune disease
immunoregulators, T Cell Sciences; immunoregulators, MYCOsearch	unspecified	immunosuppressant	autoimmune disease
immunoregulatory colostrum isolate	unspecified	immunosuppressant	autoimmune disease
immunosuppressant, Hollis Eden	unspecified	immunosuppressant	autoimmune disease; transplant rejection
immunosuppressant, Rhone-Poulenc Rorer	unspecified	immunosuppressant	asthma
immunosuppressants, Agouron	unspecified	immunosuppressant	autoimmune disease; asthma
immunosuppressants, AstraZeneca; immunosuppressants, University of California	unspecified	immunosuppressant	transplant rejection; autoimmune disease
immunosuppressants, Kinetix	Unspecified	immunosuppressant	autoimmune disease; transplant rejection
immunosuppressants, Millennium	unspecified	immunosuppressant	autoimmune disease
immunosuppressants, Nanodesign	unspecified	immunosuppressant	autoimmune disease
immunosuppressants, ZAP70, Roche; immunosuppressants, ZAP70, BioFocus	unspecified	immunosuppressant	autoimmune disease
insulin-dependent diabetes therapy, Procept	unspecified	immunosuppressant	diabetes
interferon gamma inhibitor, PharmaGenics	unspecified	immunosuppressant	septic shock; autoimmune disease
interleukin-2 receptor ligand, Affymax	unspecified	immunosuppressant	transplant rejection; autoimmune disease
ion channel modulators, ArQule; ion channel modulators, ICAgen	unspecified	immunosuppressant	cardiovascular disease; neurological; autoimmune disease

leptin antagonists, Imperial College	unspecified	immunosuppressant	autoimmune disease; transplant rejection
LF 150195	unspecified	immunosuppressant	autoimmune disease
LJP 394	unspecified	immunosuppressant	systemic lupus erythematosus
LJP 920	unspecified	immunosuppressant	transplant rejection
LZ 8	unspecified	immunosuppressant	autoimmune disease
microcolins	unspecified	immunosuppressant	autoimmune disease
NE 501	unspecified	immunosuppressant	transplant rejection
promedulan; TERICIMUS	unspecified	immunosuppressant	cancer
rapamycin analogue, Reading University	unspecified	immunosuppressant	autoimmune disease
Rh toleragens	unspecified	immunosuppressant	autoimmune disease
RWJ 60475	unspecified	immunosuppressant	transplant rejection
spiperone analogues, Arcturus	unspecified	immunosuppressant	skin disease
Stat4/Stat6 blockers, Tularik	unspecified	immunosuppressant	autoimmune disease; allergy
T cell modulators, Fisons	unspecified	immunosuppressant	asthma; rhinitis; conjunctivitis; allergy
VE 19613	unspecified	immunosuppressant	autoimmune disease
VX 10367	unspecified	immunosuppressant	transplant rejection
VX 497	unspecified	immunosuppressant	psoriasis; autoimmune disease; viral infection; hepatitis
Xe 9	unspecified	immunosuppressant	transplant rejection
XENOJECT	unspecified	immunosuppressant	cancer; autoimmune disease
ZAP 70 modulators, Pharmacopeia	unspecified	immunosuppressant	transplant rejection
oxamisole; PR 879317A	(+,-)-2,3,5,6,7,8- hexahydro-8,8- dimethoxy-2-phenyl- imidazo(1,2-a)- pyridine	immunosuppressant	viral infection

gusperimus; gusperimus hydrochloride; deoxyspergualin, 15-; desoxyspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215- 1; SPANIDIN; SUPANIDIN	(+,-)-7- [(aminoiminomethyl) amino]-N-[2-[[4-[(3- aminopropyl)amino]b utyl]amino]-1- hydroxy-2- oxoethyl]heptanamide	immunosuppressant	transplant rejection; multiple sclerosis; cancer
FR 901483	(2 alpha,5 beta, 6 beta, 7 beta, 8 beta, 10a beta)-octahydro- 5-[(4- methoxyphenyl)meth yl]-2-(methylamino)- 1H-7,10a- methanopyrrolo[1,2- a]azocine-6,8-diol, 8- (dihydrogen phosphate)	immunosuppressant	transplant rejection
PRO 1556	(OC-6-11)- hexakis(1H- imidazole- kappaN3)ruthenium(2 +) dichloride	immunosuppressant	transplant rejection
PRO 2844	(OC-6-22)- pentaammine(4- methylpyridine)ruthen ium(3+) trichloride	immunosuppressant	psoriasis; autoimmune disease; transplant rejection
myriocin; thermozymocidin; ISP-1	[2S- (2R*,3S*,4S*,6E)]-2- amino-3,4-dihydroxy- 2-(hydroxymethyl)- 14-oxo-6-eicosenoic acid	immunosuppressant	autoimmune disease; transplant rejection

bactobolamine	[3S-(3alpha,4alpha,4abeta,5beta,6alpha)]-4-amino-3-(dichloromethyl)-3,4,4a,5,6,7-hexahydro-5,6,8-trihydroxy-3-methyl-1H-2-benzopyran-1-one	immunosuppressant	autoimmune disease
discodermolide	[3S-[3alpha,4beta,5beta,6alpha(2R*,3Z,5R*,6R*,7S*,8Z,11R*,12S*,13S*,14S*,15R*,16E)]]-6-[14-[(aminocarbonyl)oxy]-2,6,12-trihydroxy-5,7,9,11,13,15-hexamethyl-3,8,16,18-nonadecatetraenyl]tetrahydro-4-hydroxy-3,5-dimethyl-2H-pyran-2-one	immunosuppressant	transplant rejection
tresperimus; LF 80299; LF 299	[4-[(3-aminopropyl)amino]butyl]carbamic acid 2-[[6-[(aminoiminomethyl)amino]hexyl]amino]-2-oxoethyl ester	immunosuppressant	autoimmune disease
SKF 106610	2-[3-(1-piperidinyl)propyl]-8,8-dipropyl-2-azaspiro[4.5]decane dihydrochloride	immunosuppressant	autoimmune disease
oxeclosporin; SDZ IMM 125; IMM 125	2-[O-(2-hydroxyethyl)-D-serine]-cyclosporin A	immunosuppressant	asthma
FTY 720	2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride	immunosuppressant	transplant rejection; autoimmune disease

HMR 1715	2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-6-heptynamide	immunosuppressant	transplant rejection
SM 8849	4-[1-(2-fluoro-4-biphenyl)ethyl]-2-methylaminothiazole	immunosuppressant	autoimmune disease
SDZ RAD	42-O-(2-hydroxyethyl)rapamycin	immunosuppressant	transplant rejection
dinaline; GOE 1734; NSC 328786; AAPBA	4-amino-N-(2-aminophenyl)benzamide	immunosuppressant	cancer
FR 901459	4-L-leucine-7-L-threonine-10-L-leucine-cyclosporin A	immunosuppressant	autoimmune disease
prodigiosin 25-C; prodigiosin	4-methoxy-5-[(5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl]-2,2'-bi-1H-pyrrole	immunosuppressant	autoimmune disease
TOK 8801	5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)imidazo[2,1-b]thiazole-2-carboxamide	immunosuppressant	autoimmune disease
esonarimod; KE 298	alpha-[(acetylthio)methyl]-4-methyl-gamma-oxobenzenebutanoic acid	immunosuppressant	rheumatoid arthritis
HMR 1279	alpha-cyano-N-(4-cyanophenyl)-beta-oxocyclopropanepropanamide	immunosuppressant	transplant rejection
dehydrodidemnin B; DDB	N-[1-(1,2-dioxopropyl)-L-propyl]didemnin A	immunosuppressant	viral infection; cancer
YM 13650	propanedioic acid, mono(3-imidazo[2,1-b]benzothiazol-2-ylphenyl) ester	immunosuppressant	transplant rejection
IR 1116	Unspecified	immunosuppressant	autoimmune disease
LCB 2183	Unspecified	immunosuppressant	rhinitis; dermatitis; asthma

aldose reductase inhibitors, Washington Research Foundation	unspecified	immunosuppressant; aldose reductase inhibitor; NSAID	autoimmune disease; allergy; inflammation
rapamycin analogues	unspecified	immunosuppressant; antifungal	transplant rejection; mycosis
antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) DNA	immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma
antibody-mediated stroke inhibitor	unspecified	immunosuppressant; biotechnology	gynecological; stroke; thrombosis; myocardial infarction
lymphocyte activation gene 3 protein; LAG 3 protein	unspecified	immunosuppressant; biotechnology	transplant rejection; multiple sclerosis
MAB, gp39; BMS 202448	unspecified	immunosuppressant; biotechnology	autoimmune disease
MAB, interleukin-2 receptor; MAB, IL-2R	unspecified	immunosuppressant; biotechnology	transplant rejection
apoptosis-inducing antigen, diabetes; IG 2; IG2	unspecified	immunosuppressant; biotechnology; apoptosis inducer	diabetes
MP 4	unspecified	immunosuppressant; biotechnology; apoptosis inducer	multiple sclerosis
apoptosis-inducing antigen, rheumatoid arthritis	unspecified	immunosuppressant; biotechnology; apoptosis inducer; NSAID	rheumatoid arthritis
monocyte colony inhibitory factor-1, Human Genome Sciences	unspecified	immunosuppressant; biotechnology; chemokine	autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus
AI 401	unspecified	immunosuppressant; biotechnology; hormone	diabetes
AI 201	unspecified	immunosuppressant; biotechnology; NSAID	rheumatoid arthritis

AI 402	unspecified	immunosuppressant; biotechnology; peptide	diabetes
AI 502	unspecified	immunosuppressant; biotechnology; peptide	transplant rejection
ATP 012; TP 12	unspecified	immunosuppressant; biotechnology; peptide	multiple sclerosis
AI 202	unspecified	immunosuppressant; biotechnology; peptide; NSAID	rheumatoid arthritis
chemokine receptor antagonists, ICOS	unspecified	immunosuppressant; chemokine antagonist; cytokine antagonist	autoimmune disease
soluble complement receptor type 1; sCR1; TP 10; TP 10HD; BRL 55730; YM 55730	unspecified	immunosuppressant; complement inhibitor	respiratory distress syndrome; heart ischemia; transplant rejection
CBP 1011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; systemic lupus erythematosus; asthma
CBP 2011	unspecified	immunosuppressant; corticosteroid	autoimmune disease; thrombocytopenia
CBP 2012	unspecified	immunosuppressant; corticosteroid	autoimmune disease; thrombocytopenia
D 22558	unspecified	immunosuppressant; cytokine inhibitor	asthma; allergy
autoimmune disease- specific MHC blockers, 3 Dimensional Pharmaceuticals	unspecified	immunosuppressant; DMARD; NSAID	rheumatoid arthritis; autoimmune disease
Bcl-x gamma-based therapy, Boston Life Sciences; autoimmune disease therapy, Boston Life Sciences	unspecified	immunosuppressant; gene; apoptosis inducer	autoimmune disease

polyclonal antibody, rabbit antithymocyte; immunoglobulin, rabbit antithymocyte; rabbit antithymocyte immunoglobulin; THYMOGLOBULIN	unspecified	immunosuppressant; immunoglobulin; polyclonal antibody	transplant rejection; aplastic anemia
protein A-based immune modulator	unspecified	immunosuppressant; immunostimulant	autoimmune disease; cancer
ZYN-LINKER conjugated superantigens	unspecified	immunosuppressant; immunostimulant; NSAID	rheumatoid arthritis; cancer
signal transduction modulators, National Jewish Center for Immunology and Respiratory Medicine	unspecified	immunosuppressant; immunostimulant; NSAID	autoimmune disease; cancer; inflammation
SDZ 281240	unspecified	immunosuppressant; macrolide; antibiotic	psoriasis
MAb, 33B3.1; MAb, anti-interleukin-2 receptor	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAb, B7.1; MAb, M24; M 24	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAb, CD3 humanized	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAb, H65 humanized Fab'	unspecified	immunosuppressant; monoclonal antibody	autoimmune disease
MAb, T10B9; T10B9.1A-31; MEDI 500	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAb, UCHL1; MAb, CD45RO	unspecified	immunosuppressant; monoclonal antibody	autoimmune disease
MABs, organ transplantation; TOLERIMAB	unspecified	immunosuppressant; monoclonal antibody	transplant rejection



inolimomab; MAb, IL-2 receptor CD25; MAb, interleukin-2 receptor CD25; BT 563; LEUKOTAC	immunoglobulin G 1 (mouse monoclonal B-B10.gamma.-chain anti-human interleukin 2 receptor.alpha.-chain), disulfide with mouse monoclonal B-B10.kappa.-chain, dimer	immunosuppressant; monoclonal antibody	transplant rejection
MAb, BC3	unspecified	immunosuppressant; monoclonal antibody; biotechnology	transplant rejection
MAb, CD3-immunotoxin	unspecified	immunosuppressant; monoclonal antibody; biotechnology; immunotoxin	transplant rejection; autoimmune disease
MAb, gp39; MAb, arthritis	unspecified	immunosuppressant; monoclonal antibody; NSAID	rheumatoid arthritis
MAb, MHC class II; CDP 855	unspecified	immunosuppressant; monoclonal antibody; NSAID	autoimmune disease; systemic lupus erythematosus
MAb, R73; MAb, rat alpha/beta T cell receptor	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; rheumatoid arthritis
priliximab; MAb, humanized CD4; cM-T412; CEN 000029; CENTARA	immunoglobulin G1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm-T412.kappa.-chain, dimer	immunosuppressant; monoclonal antibody; NSAID	multiple sclerosis; autoimmune disease; rheumatoid arthritis
IRA 378	(S)-8-chloro-1,2,3,4-tetrahydro-2-(trifluoromethyl)-6-quinolineacetic acid	immunosuppressant; nitric oxide synthase inhibitor; NSAID	rheumatoid arthritis
BMS 188667; CTLA4Ig	unspecified	immunosuppressant; NSAID	transplant rejection; systemic lupus erythematosus; psoriasis; arthritis; allergy

C-Maf based therapy	unspecified	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis
corticotropin releasing factor binding protein; CRF binding protein; NBI 112	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; inflammation
E 21R	unspecified	immunosuppressant; NSAID	cancer; inflammation; allergy
lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis
leukocyte function associated antigen 3 T cell inhibitor protein; LFA3TIP; LFA3TIP; AMEVIVE	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease; psoriasis
MAB, CD40 ligand; 5C8; ANTOVA	unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
autoimmune disease therapy, Molecumetics/Bristol -Myers Squibb	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; multiple sclerosis; systemic lupus erythematosus
BN 58705	unspecified	immunosuppressant; NSAID	septic shock; inflammation
BW 91Y78	unspecified	immunosuppressant; NSAID	inflammation
CD2 binding agents, Procept	unspecified	immunosuppressant; NSAID	rheumatoid arthritis
CD4 inhibitors, Procept; CD4 inhibitors, Novartis	unspecified	immunosuppressant; NSAID	inflammation
CT 2576	unspecified	immunosuppressant; NSAID	HIV infection; rheumatoid arthritis
immunoregulators, AVANT Immunotherapeutics; immunoregulators, Repligen	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma

inflammation therapy, Genzyme/LeukoSite	unspecified	immunosuppressant; NSAID	inflammatory bowel disease; inflammation; autoimmune disease
PG 12	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 27	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 2946	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3028	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3113	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 94	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PIC 060 analogs	unspecified	immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
PIC 101	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; autoimmune disease; transplant rejection
PIC 102	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
PIC 231	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
Ro 236457	unspecified	immunosuppressant; NSAID	inflammation
VX 10393	Unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
VX 10428	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes

phellodendrine; OB 5	(7S-cis)-5,8,13,13a-tetrahydro-2,11-dihydroxy-3,10-dimethoxy-7-methyl-6H-dibenzo[a,g]quinolizinium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease
TEI 1338	(E)-N-(2-methoxycarbonylphenyl)-8-(2-naphthyl)-5,6-trans-5,6-methano-7-octenamide	immunosuppressant; NSAID	allergy; inflammation
laflunimus; HR 325	(Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl]-2-propenamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; psoriasis
TEI 3332	[(6,7-dihydroxy-2-naphthalenyl)thio]acetic acid methyl ester	immunosuppressant; NSAID	allergy; inflammation
SCH 24937	1-[6-bromo-5-chloro-3-(2-pyridinyl)-1H-indol-2-yl]-2-(methylsulfinyl)ethanone	immunosuppressant; NSAID	rheumatoid arthritis
KF 20444	10-fluoro-3-(2-fluorophenyl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-b]quinoline-8-carboxylic acid	immunosuppressant; NSAID	rheumatoid arthritis
KB 2683	2-(4-methylphenyl)-4-benzothiazolol acetate	immunosuppressant; NSAID	rheumatoid arthritis; inflammation; autoimmune disease
CI 972	2,6-diamino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; cancer; psoriasis

MX 68	2-[[[4-[2,4-diamino-6-pteridiny]methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl]amino]hexanedioic acid	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease
albifylline; HWA 138	3,7-dihydro-1-(5-hydroxy-5-methylhexyl)-3-methyl-1H-purine-2,6-dione	immunosuppressant; NSAID	septic shock; inflammation
baohuoside I; icariside II; B-1	3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one	immunosuppressant; NSAID	systemic lupus erythematosus; rheumatoid arthritis
CL 306293	3-amino-2-[1,1'-biphenyl]-4-yl-6-fluoro-4-quinolinecarboxylic acid	immunosuppressant; NSAID	arthritis; HIV infection
amiprilose; amiprilose hydrochloride; THN; SM 1213; KAP 690; THERAFECTIN	3-O-(3-(dimethylamino)propyl)-1,2-O-isopropylidene-alpha-D-glucofuranose hydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; psoriasis
TAK 603	4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1H-1,2,4-triazol-1-ylmethyl)-3-quinolinecarboxylic acid ethyl ester	immunosuppressant; NSAID	rheumatoid arthritis
mizoribine; HE 69; BREDININ	5-hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; kidney disease
TA 383	cis-2-(4-chlorophenyl)-4,5-dihydro-4,5-diphenyl-1H-imidazole monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis

SKF 105685	N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dihydrochloride	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
AI 200; COLLORAL	trimeric (16-1059)alpha1 (II) collagen	immunosuppressant; NSAID	rheumatoid arthritis
atiprimod; atiprimod dimaleate; SKF 106615	N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine	immunosuppressant; NSAID; macrophage inhibitor	rheumatoid arthritis; autoimmune disease; psoriasis
celastrol	unspecified	immunosuppressant; NSAID; terpene	inflammation
CD45 inhibitors, Ontogen	unspecified	immunosuppressant; NSAID; tyrosine phosphatase inhibitor	transplant rejection; inflammation
cladribine; 2-CdA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	2-chloro-2'-deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
calcineurin inhibitory peptides, Oregon Health Sciences University	unspecified	immunosuppressant; peptide	autoimmune disease
human leukocyte antigen-derived protein; HLA-derived protein; ALLOTRAP 2702	unspecified	immunosuppressant; peptide	transplant rejection
immunosuppressant peptides, SangStat; immunosuppressant peptides, Syntem	unspecified	immunosuppressant; peptide	transplant rejection; autoimmune disease
T cell peptide, University of Illinois	unspecified	immunosuppressant; peptide	autoimmune disease; cancer; bacterial infection
PP 14	unspecified	immunosuppressant; peptide; NSAID	autoimmune disease; rheumatoid arthritis
potassium channel blocker, Merck & Co	unspecified	immunosuppressant; potassium channel blocker	autoimmune disease; allergy; inflammation

ZAP inhibitors, Ariad	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis
autoimmune disease therapy, Peptimmune	unspecified	immunosuppressant; proteinase inhibitor	autoimmune disease
PEGylated p75 TNFR Fc mutein	unspecified	immunosuppressant; TNF inhibitor	rheumatoid arthritis
leflunomide; HWA 486; ARAVA	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	immunosuppressant; tyrosine kinase inhibitor; NSAID; DMARD	rheumatoid arthritis; autoimmune disease
alpha4 beta7 antagonists, LeukoSite/Warner Lambert	unspecified	integrin antagonist; alpha4 beta7 integrin antagonist; cell adhesion inhibitor	Crohn disease; inflammatory bowel disease
CDP 850	unspecified	integrin antagonist; biotechnology; cell adhesion inhibitor; immunosuppressant; monoclonal antibody; E selectin antagonist	cancer
MAb, ICAM-3; MAb, intracellular adhesion molecule-3; MAb, ICAM-R; ICM3	unspecified	integrin antagonist; biotechnology; cell adhesion inhibitor; immunosuppressant; monoclonal antibody	autoimmune disease; psoriasis
MAb, B11; MAb, E-selectin; MAb, endothelium leukocyte adhesion molecule	unspecified	integrin antagonist; biotechnology; immunosuppressant; monoclonal antibody; E selectin antagonist; cell adhesion inhibitor; NSAID	inflammation
MAb, L-selectin, humanized; SMART anti-L-selectin; HuDREG 200	unspecified	integrin antagonist; biotechnology; monoclonal antibody; cell adhesion inhibitor; immunosuppressant; L selectin antagonist	trauma; respiratory distress syndrome; autoimmune disease; reperfusion injury

GM 1676	unspecified	integrin antagonist; cell adhesion inhibitor; immunosuppressant; NSAID	inflammation
selectin antagonists, Oxford GlycoSciences	unspecified	integrin antagonist; P selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation
low molecular weight selectin inhibitors, Kanebo/Ontogen	Unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; allergy
TBC 427	unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor	ischemia; psoriasis; respiratory distress syndrome; transplant rejection; reperfusion injury
TBC 1269	3',3'''-(1,6- hexanediyl)bis[6'- (alpha-D- mannopyranosyloxy)- [1,1'-biphenyl]-3- acetic acid	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; asthma
interferon, modified, Tanox	unspecified	interferon; biotechnology; immunosuppressant	cancer
microcolin A	N-(2,4-dimethyl-1- oxooctyl)-N- methylleucyl-N-[1- [[2-[(2,5-dihydro-2- methyl-5-oxo-1H- pyrrol-1-yl)carbonyl]- 4-hydroxy-1- pyrrolidiny]carbonyl] -2-methylpropyl]-N- methylthreoninamide, 23-acetate	lipopeptide; immunosuppressant	autoimmune disease
drug delivery system, NanoCrystal sirolimus; sirolimus NanoCrystal	unspecified	macrolide; antibiotic; immunosuppressant	transplant rejection



sirolimus; rapamycin; NSC 226080; AY 22989; RAPAMUNE	(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacycloheptriacontine-1,5,11,28,29(4H,6H,31H)-pentone	macrolide; immunosuppressant; antibiotic	transplant rejection; autoimmune disease; restenosis
tacrolimus; tsukubaenolide; fujimycin; FK 506; (-)-FK 506; FR 900506; L 679934; PROGRAF; PROTOPIC	[3S-[3R*[E(1S*,3S*,4S*),4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotriacotene-1,7,20,21(4H,23H)-tetrone	macrolide; immunosuppressant; NSAID; antibiotic	transplant rejection; dermatitis; eye disease; rheumatoid arthritis
MAb, red blood cell D antigen; MAb, rhesus D; AM 101	unspecified	monoclonal antibody; biotechnology; immunosuppressant	autoimmune disease

MAB, interleukin-12; MAB, IL-12; J695; C17.15	unspecified	monoclonal antibody; cytokine antagonist; immunosuppressant	autoimmune disease
MAB, Fv, cytokine; CDP 870	unspecified	monoclonal antibody; cytokine inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
MAB 2E1; MAB, effector cell proteinase receptor-1	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, 1C7; passive immunotherapy, systemic lupus erythematosus	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus
MAB, 6G5.1; MAB, autoimmune disease, human, Medarex; MDX CD4	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; rheumatoid arthritis
MAB, alpha-tubulin	unspecified	monoclonal antibody; immunosuppressant	cancer; autoimmune disease; diagnosis
MAB, autoimmune disease; MAB, MHC II	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, BMA 031	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD11a; hu 1124	unspecified	monoclonal antibody; immunosuppressant	psoriasis; transplant rejection
MAB, CD45; LM CD45	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD45RB	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, CD7; SDZ CHH 380	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, Fc antagonist; MDX 33	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; thrombocytopenia
MAB, gamma interferon, humanized; SMART anti-gamma interferon	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus; multiple sclerosis
MAB, gp39; MAB, CD40L; IDEC 131	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection; systemic lupus erythematosus
MAB, H57597	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease

MAB, humanized CD3; MAb, SMART CD3; HuM291	unspecified	monoclonal antibody; immunosuppressant	transplant rejection; autoimmune disease; psoriasis
MAB, inflammation therapy, LeukoSite/MorphoSy	unspecified	monoclonal antibody; immunosuppressant	inflammation; autoimmune disease
MAB, interleukin-10; MAB, IL-10	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus
MAB, interleukin-5; MAB, IL-5; SCH 55700; CDP 835	unspecified	monoclonal antibody; immunosuppressant	asthma
MAB, L0-CD2a; BTI 322	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, major histocompatibility complex I; F(ab') <sub>2</sub> , MHC I	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, MHC II-CD4; 14-CD4	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; graft versus host disease
MAB, MHCII-CD8	unspecified	monoclonal antibody; immunosuppressant	transplant rejection; graft versus host disease
MAB, migis-mIgG; Mab, B cell	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, RhCA 61-76; MAB, anti-AChR alpha subunit; TCM 240	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease
MAB, T cell antigen receptor; ATM 027; TM 27	unspecified	monoclonal antibody; immunosuppressant	multiple sclerosis
MAB, T cell antigen receptor; TM 29	unspecified	monoclonal antibody; immunosuppressant	cancer; Crohn disease
MAB, transplant rejection; CBL1; ABX CBL	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAbs, B cells; migis	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; cancer

daclizumab; dacliximab; MAb, Tac; MAb, humanized Tac; MAb, SMART Tac; Ro 247375; ZENAPAX	immunoglobulin G1 (human-mouse monoclonal clone 1H4 gamma chain anti-human antigen Tac), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection; cancer; autoimmune disease; eye disease
odulimomab; MAb, LFA-1 alpha subunit	immunoglobulin G1, anti-(human CD11 (antigen).alpha.- chain)(mouse monoclonal 25.3.gamma.1-chain), disulfide with mouse monoclonal 25. 3 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection
basiliximab; SDZ CHI621; CHI 621; SIMULECT	Immunoglobulin G1, anti-(human interleukin 2 receptor) (human-mouse monoclonal CHI621 .gamma.1- chain),disulfide with human-mouse mo noclonal CHI621 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection
MAb, CD6 blocked ricin; MAb, T12-bR; ONCOLYSIN CD6	unspecified	monoclonal antibody; immunosuppressant; immunotoxin	transplant rejection
MAb, MHC class II	unspecified	monoclonal antibody; immunosuppressant; NSAID	autoimmune disease; transplant rejection; graft versus host disease; cancer
MAb, T cell receptor; TM 31	unspecified	monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis
MAb, CD5- momordin; immunotoxin CD5- momordin; ITF 1532	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	cancer; transplant rejection

zolimomab aritox; MAb, H65 RTA; MAb, bone marrow- ricin A conjugate; CD5-T lymphocyte immunotoxin; MAb, CD5; XMMLY H65 RTA; XOMAZYME H65; XOMAZYME CD5+; ORTHOZYME CD5+; CD5 Plus	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	transplant rejection
MAb, humanized, leukemia; MAb, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
MAb, B7; MAb, PRIMATIZED B7; IDEC 114	unspecified	monoclonal antibody; NSAID; immunosuppressant	systemic lupus erythematosus; inflammation; transplant rejection; psoriasis
neuroimmunophilins, KOSAN	unspecified	neurotrophic factor	neurodegeneration
NOX 100	unspecified	nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 51	unspecified	nitric oxide scavenger	diabetes; cancer; cardiovascular disease; transplant rejection; septic shock
NOX 101	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
S 2474	unspecified	NSAID; DMARD; COX inhibitor; COX 2 inhibitor; immunosuppressant	rheumatoid arthritis; autoimmune disease
immune system modulators, OSI	unspecified	NSAID; immunosuppressant	inflammation
NE 0501	unspecified	oligosaccharide	transplant rejection

opioid antagonists, NIH	unspecified	opiate antagonist; peptide; immunosuppressant	addiction; alcoholism; obesity; transplant rejection
recombinant PSGL 1, Genetics Institute; PSGL 1	unspecified	P selectin antagonist; E selectin antagonist; L selectin antagonist; selectin antagonist; NSAID	inflammation; transplant rejection; ischemia; reperfusion injury
AH 21132	cis N-(4-(1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo(c)(1,6)naphthyridin-6-yl)phenyl)-acetamide (Z)-2-butenedioate (1:2)	PAF antagonist; phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
immunosuppressive, ANUTECH	unspecified	peptide; immunosuppressant	autoimmune disease
inflammation therapy, BTG; autoimmune disease therapy, BTG	unspecified	peptide; immunosuppressant	inflammation; autoimmune disease
rD-mPGPtide	unspecified	peptide; immunosuppressant	transplant rejection; multiple sclerosis
transplantation therapy, SangStat	unspecified	peptide; immunosuppressant	transplant rejection
CD4 peptide antagonist, Tocor	unspecified	peptide; immunosuppressant; NSAID	inflammation
complement inhibitors, Lidak	unspecified	peptide; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease; reperfusion injury; respiratory distress syndrome; transplant rejection
D 4418	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; immunosuppressant; bronchodilator	asthma

B669	3-(cyclohexylimino)-3,5-dihydro-N,5-diphenyl-2-phenazinamine	phospholipase activator; immunosuppressant; NSAID	inflammation
polyclonal antibody, tumor necrosis factor alpha; polyclonal antibody, TNFalpha; CytoTAb	unspecified	polyclonal antibody; immunoglobulin; immunosuppressant	septic shock; malaria; restenosis; Crohn disease; graft versus host disease
polyclonal antibody, immune thrombocytopenic purpura; polyclonal antibody, ITP; Rho(D) immune globulin; WinRho SD; WinRho SDF	unspecified	polyclonal antibody; immunosuppressant; immunoglobulin	autoimmune disease; HIV infection
polysaccharide A immunomodulator	unspecified	polysaccharide; immunosuppressant	surgery
ANK 102	Unspecified	polysaccharide; immunosuppressant	autoimmune disease
SPC 100270	unspecified	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	ischemia; transplant rejection; reperfusion injury
Ro 320432; Ro 32-0432	(S)-3-[8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis

MLR 52; (+)-MLR-52	[9S-(9 $\alpha$ ,10 $\beta$ ,11 $\alpha$ ,12 $\alpha$ ,13 $\alpha$ )]-2,3,10,11,12,13-hexahydro-11,12-dihydroxy-10-methoxy-9-methyl-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-1m]pyrrolo[3,4-j][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	cancer
cathepsin S inhibitors, Axys/Rhone-Poulenc Rorer	unspecified	proteinase inhibitor; cathepsin S inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease
aloxistatin; trexostatine; EP 4S3; E 64d; E 64; EST	[S-[2 $\alpha$ ,3 $\beta$ (R*)]]-3-[[[3-methyl-1-[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]oxiranecarboxylic acid ethyl ester	proteinase inhibitor; immunosuppressant	muscular dystrophy
peldesine; BCX 34; BCX 34B	2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection
purine nucleoside phosphorylase inhibitors, Chiroscience; PNP inhibitors, Chiroscience	unspecified	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany-1)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus



ribozymes, organ transplantation	unspecified	ribozyme; oligonucleotide; immunosuppressant	transplant rejection
SR 31747	(Z)-N[3-chloro-4-cyclohexylphenyl]-2-propenyl]-N-ethyl-cyclohexanamine hydrochloride	sigma antagonist; immunosuppressant; NSAID	autoimmune disease; arthritis
signal transduction inhibitor, SUGEN/ArQule	unspecified	signal transduction inhibitor; immunosuppressant	cancer; diabetes; neurological; autoimmune disease
SP 100030	Unspecified	signal transduction inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease
ABT 281; A 86281	unspecified	Tacrolimus-like; no immunosuppression	psoriasis
CGS 12970	3-methyl-2-(3-pyridinyl)-1-octanoic acid	thromboxane synthase inhibitor; immunosuppressant	transplant rejection
pirmagrel; CGS 13080	imidazo(1,5-a)pyridine-5-hexanoic acid	thromboxane synthetase inhibitor; immunosuppressant	transplant rejection
tumor necrosis factor binding protein; TBP-1; TBP	unspecified	TNF inhibitor; immunosuppressant	autoimmune disease; reperfusion injury; inflammation; septic shock
etanercept; tumor necrosis factor receptor; TNFr; TNR 001; ENBREL	unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease
thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection
AP-1 inhibitor, Signal; JNK inhibitor, Signal	unspecified	transcription factor regulator; NSAID; immunosuppressant	inflammation; autoimmune disease; cancer
SC 114	unspecified	triglyceride; immunosuppressant	autoimmune disease; transplant rejection

AP 251	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
p56 lck inhibitors, Celltech	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
ZAP70 inhibitors, Celltech	unspecified	tyrosine kinase inhibitor; immunosuppressant	autoimmune disease
immunosuppressant, Xcyte Therapies	unspecified	Unspecified	psoriasis
LSL 90202	L-lysine monoeicosapentaenoate (1:1)	unspecified	kidney disease
non-ionic surfactant vesicles; NISV	unspecified	vaccine adjuvant; immunosuppressant	rheumatoid arthritis; asthma; inflammation
vaccine, gene-based, autoimmune disease; GENEVAX	unspecified	vaccine; gene therapy; immunosuppressant	autoimmune disease
20-epi-1,25 dihydroxyvitamin D <sub>3</sub> ; MC 1288; IE	(1alpha,3beta,5Z,7E,20S)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D <sub>3</sub> analogue; immunosuppressant	diabetes; transplant rejection; arthritis

Table 43. Current Candidate Therapeutic Interventions for the Treatment of Transplant Rejection

Product Name	Chemical Name	Action	Indication
brequinar; brequinar sodium; DUP 785; NSC 368390	6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid	antimetabolite; immunosuppressant	cancer; autoimmune disease; transplant rejection
antisense oligonucleotide, graft versus host disease	unspecified	antisense; oligonucleotide; immunosuppressant; apoptosis inducer	transplant rejection
apoptosis inhibitors	unspecified	apoptosis inducer	cancer; cardiac therapy; transplant rejection; gastrointestinal disorder

ICE inhibitor, IDUN	unspecified	caspase inhibitor; apoptosis inhibitor; IL-1 beta converting enzyme inhibitor; immunosuppressant	transplant rejection; septic shock; rheumatoid arthritis; inflammatory bowel disease; diabetes
APT 070; APT 070C; APT070C	unspecified	complement inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
methylprednisolone suleptanate; U 67590A; PROMEDROL	(6alpha,11beta)-11,17- dihydroxy-6-methyl- 21-[[8-[methyl(2- sulfoethyl)amino]- 1,8- dioxooctyl]oxy]pregn- a-1,4-diene-3,20- dione monosodium salt	corticosteroid; immunosuppressant	inflammation; asthma; anaphylactic shock; transplant rejection
gene therapy, soluble TNF receptor; gene therapy, corneal transplant rejection	unspecified	cytokine antagonist	transplant rejection
interleukin-12 signal transduction antagonists, Ligand	unspecified	cytokine antagonist; immunosuppressant; NSAID	autoimmune disease; transplant rejection; rheumatoid arthritis
interleukin-8 receptor; IL-8r	unspecified	cytokine antagonist; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
anakinra; interleukin- 1 receptor antagonist; IL-1ra; interleukin-1 inhibitor; ANTRIL	N2-L- methionylinterleukin 1 receptor antagonist (human isoform x reduced)	cytokine inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; transplant rejection; asthma; septic shock
interleukin-7 receptor; IL-7r	unspecified	cytokine inhibitor; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
MDAM	N-[4-[2-(2,4-diamino- 6- pteridiny)ethyl]benzo- yl]-4-methylene-DL- glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma

interleukin-4 diphtheria toxin chimeric protein; IL-4 diphtheria toxin chimeric protein; IL-4 fusion protein	unspecified	fusion toxin; immunosuppressant	autoimmune disease; transplant rejection; cancer; HIV infection
growth and differentiation factor 3; GDF 3	unspecified	growth factor; differentiation inducer; immunosuppressant	transplant rejection; autoimmune disease
lymphocyte activation inhibitors, Celltech	unspecified	immunostimulant	autoimmune disease; transplant rejection
gecsporin; ciclosporin G; cyclosporin G; ciclosporin, (NVA)2-; cyclosporin, (NVA)2-; OG 37325	7-L-norvaline cyclosporin A	immunostimulant	transplant rejection
RM 06	N-[N-[[[5-(1,6- dihydro-6-oxo-9H- purin-9- yl)pentyl]oxy]carbonyl]-L-leucyl]-L-methionine	immunostimulant	cancer; transplant rejection
thiethazole	2-[1-(1,1- dioxothiethanyl- 3)benzimidazolyl-2- thio] acetic acid	immunostimulant; immunosuppressant; antioxidant	cancer; rheumatoid arthritis; infectious disease; transplant rejection
T-cell modulators	unspecified	Immunosuppressant	transplant rejection
B7 molecules; B7-1; B7-2	unspecified	immunosuppressant	autoimmune disease; transplant rejection
galaptin L-14-1; immunomodulatory lectin-1; IML-1	unspecified	immunosuppressant	transplant rejection; multiple sclerosis
MAb, CD45RB	unspecified	immunosuppressant	transplant rejection; autoimmune disease
MAb, humanized B7.1	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MAb, humanized B7.2	unspecified	immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MEDI 507	unspecified	immunosuppressant	autoimmune disease; transplant rejection; psoriasis

RG 1046	unspecified	immunosuppressant	autoimmune disease; transplant rejection
CT 2544	unspecified	immunosuppressant	autoimmune disease; transplant rejection
CT 3578	unspecified	immunosuppressant	transplant rejection
cytomuline	unspecified	immunosuppressant	transplant rejection
drug delivery system, CYTOPORTER ciclosporin	unspecified	immunosuppressant	transplant rejection
drug delivery system, LDS microemulsion ciclosporin; ciclosporin LDS microemulsion	unspecified	immunosuppressant	autoimmune disease; transplant rejection
drug delivery system, liposome ciclosporin; ciclosporin liposome	unspecified	immunosuppressant	transplant rejection
drug delivery system, microemulsion ciclosporin; ciclosporin microemulsion; SANDIMMUN NEORAL; SANDIMMUN OPTORAL; NEORAL; NEORAL- SANDIMMUN	unspecified	immunosuppressant	autoimmune disease; transplant rejection
gliotoxin	unspecified	immunosuppressant	transplant rejection
immunosuppressant, Hollis Eden	unspecified	immunosuppressant	autoimmune disease; transplant rejection
immunosuppressants, AstraZeneca; immunosuppressants, University of California	unspecified	immunosuppressant	transplant rejection; autoimmune disease
immunosuppressants, Fujisawa/Hoechst Marion Roussel	unspecified	immunosuppressant	transplant rejection
immunosuppressants, Kinetix	unspecified	immunosuppressant	autoimmune disease; transplant rejection
interleukin-2 receptor ligand, Affymax	unspecified	immunosuppressant	transplant rejection; autoimmune disease
ISAtx 247	unspecified	immunosuppressant	transplant rejection

leptin antagonists, Imperial College	unspecified	immunosuppressant	autoimmune disease; transplant rejection
LJP 920	unspecified	immunosuppressant	transplant rejection
NE 501	unspecified	immunosuppressant	transplant rejection
RWJ 60475	unspecified	immunosuppressant	transplant rejection
VX 10367	unspecified	immunosuppressant	transplant rejection
Xe 9	unspecified	immunosuppressant	transplant rejection
ZAP 70 modulators, Pharmacopeia	unspecified	immunosuppressant	transplant rejection
gusperimus; gusperimus hydrochloride; deoxyspergualin, 15-; desoxyspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215- 1; SPANIDIN; SUPANIDIN	(+,-)-7 [(aminoiminomethyl) amino]-N-[2-[[4-[(3- aminopropyl)amino]b utyl]amino]-1- hydroxy-2- oxoethyl]heptanamide	immunosuppressant	transplant rejection; multiple sclerosis; cancer
FR 901483	(2 alpha,5 beta, 6 beta, 7 beta, 8 beta, 10a beta)-octahydro- 5-[(4- methoxyphenyl)meth yl]-2-(methylamino)- 1H-7,10a- methanopyrrolo[1,2- a]azocine-6,8-diol, 8- (dihydrogen phosphate)	immunosuppressant	transplant rejection
PRO 1556	(OC-6-11)- hexakis(1H- imidazole- kappaN3)ruthenium(2 +) dichloride	immunosuppressant	transplant rejection
PRO 2844	(OC-6-22)- pentaammine(4- methylpyridine)ruthen ium(3+) trichloride	immunosuppressant	psoriasis; autoimmune disease; transplant rejection
myriocin; thermozymocidin; ISP-I	[2S- (2R*,3S*,4S*,6E)]-2- amino-3,4-dihydroxy- 2-(hydroxymethyl)- 14-oxo-6-eicosenoic acid	immunosuppressant	autoimmune disease; transplant rejection

discodermolide	[3S-[3 $\alpha$ ,4 $\beta$ ,5 $\beta$ ,6 $\alpha$ ,7 $\alpha$ (2R*,3Z,5R*,6R*,7S*,8Z,11R*,12S*,13S*,14S*,15R*,16E)]]-6-[14-[(aminocarbonyl)oxy]-2,6,12-trihydroxy-5,7,9,11,13,15-hexamethyl-3,8,16,18-nonadecatetraenyl]tetrahydro-4-hydroxy-3,5-dimethyl-2H-pyran-2-one	immunosuppressant	transplant rejection
FTY 720	2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride	immunosuppressant	transplant rejection; autoimmune disease
HMR 1715	2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-6-heptynamide	immunosuppressant	transplant rejection
RAD 001; SDZ RAD	42-O-(2-hydroxyethyl)rapamycin	immunosuppressant	transplant rejection
HMR 1279	alpha-cyano-N-(4-cyanophenyl)-beta-oxocyclopropanepropanamide	immunosuppressant	transplant rejection
YM 13650	propanedioic acid, mono(3-imidazo[2,1-b]benzothiazol-2-ylphenyl) ester	immunosuppressant	transplant rejection
rapamycin analogues	unspecified	immunosuppressant; antifungal	transplant rejection; mycosis
lymphocyte activation gene 3 protein; LAG 3 protein	unspecified	immunosuppressant; biotechnology	transplant rejection; multiple sclerosis
MAb, interleukin-2 receptor; MAb, IL-2R	unspecified	immunosuppressant; biotechnology	transplant rejection
AI 502	unspecified	immunosuppressant; biotechnology; peptide	transplant rejection

soluble complement receptor type 1; sCR1; TP 10; TP 10HD; BRL 55730; YM 55730	unspecified	immunosuppressant; complement inhibitor	respiratory distress syndrome; heart ischemia; transplant rejection
polyclonal antibody, rabbit antithymocyte; immunoglobulin, rabbit antithymocyte; rabbit antithymocyte immunoglobulin; THYMOGLOBULIN	unspecified	immunosuppressant; immunoglobulin; polyclonal antibody	transplant rejection; aplastic anemia
MAB, 33B3.1; MAb, anti-interleukin-2 receptor	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAB, B7.1; MAb, M24; M 24	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAB, CD3 humanized	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAB, T10B9; T10B9.1A-31; MEDI 500	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
MAbs, organ transplantation; TOLERIMAB	unspecified	immunosuppressant; monoclonal antibody	transplant rejection
inolimomab; MAb, IL-2 receptor CD25; MAb, interleukin-2 receptor CD25; BT 563; LEUKOTAC	immunoglobulin G 1 (mouse monoclonal B-B10.gamma.-chain anti-human interleukin 2 receptor.alpha.-chain), disulfide with mouse monoclonal B-B10.kappa.-chain, dimer	immunosuppressant; monoclonal antibody	transplant rejection
MAB, BC3	unspecified	immunosuppressant; monoclonal antibody; biotechnology	transplant rejection
MAB, CD3-immunotoxin	unspecified	immunosuppressant; monoclonal antibody; biotechnology; immunotoxin	transplant rejection; autoimmune disease



enlimomab; MAb, intracellular adhesion molecule-1; MAb, ICAM-1; MAb, ICAM; MAb, R65; MAb, CD54; BIRR 0001; BIRR 1	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; autoimmune disease; rheumatoid arthritis
MAb, R73; MAb, rat alpha/beta T cell receptor	unspecified	immunosuppressant; monoclonal antibody; NSAID	transplant rejection; rheumatoid arthritis
BMS 188667; CTLA4Ig	unspecified	immunosuppressant; NSAID	transplant rejection; systemic lupus erythematosus; psoriasis; arthritis; allergy
immunoregulators, AVANT Immunotherapeutics; immunoregulators, Repligen	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma
PG 12	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 27	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PG 2946	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3028	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 3113	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; transplant rejection
PG 94	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection
PIC 060 analogs	unspecified	immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
PIC 101	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; autoimmune disease; transplant rejection

PIC 102	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
PIC 231	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; autoimmune disease
VX 10393	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
VX 10428	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
phellodendrine; OB 5	(7S-cis)-5,8,13,13a-tetrahydro-2,11-dihydroxy-3,10-dimethoxy-7-methyl-6H-dibenzo[a,g]quinolizinium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease
laflunimus; HR 325	(Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl]-2-propenamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; psoriasis
mizoribine; HE 69; BREDININ	5-hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; kidney disease
CD45 inhibitors, Ontogen	unspecified	immunosuppressant; NSAID; tyrosine phosphatase inhibitor	transplant rejection; inflammation
human leukocyte antigen-derived protein; HLA-derived protein; ALLOTAP 2702	unspecified	immunosuppressant; peptide	transplant rejection
immunosuppressant peptides, SangStat; immunosuppressant peptides, Syntem	unspecified	immunosuppressant; peptide	transplant rejection; autoimmune disease

ZAP inhibitors, Ariad	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis
TBC 427	unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor	ischemia; psoriasis; respiratory distress syndrome; transplant rejection; reperfusion injury
drug delivery system, NanoCrystal sirolimus; sirolimus NanoCrystal	unspecified	macrolide; antibiotic; immunosuppressant	transplant rejection
sirolimus; rapamycin; NSC 226080; AY 22989; RAPAMUNE	(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacycloheptriacontine-1,5,11,28,29(4H,6H,31H)-pentone	macrolide; immunosuppressant; antibiotic	transplant rejection; autoimmune disease; restenosis

tacrolimus; tsukubaenolide; fujimycin; FK 506; (- )-FK 506; FR 900506; L 679934; PROGRAF; PROTOPIC	[3S- [3R*[E(1S*,3S*,4S*) ],4S*,5R*,8S*,9E,12 R*,14R*,15S*,16R*, 18S*,19S*,26aR*]]- 5,6,8,11,12,13,14,15, 16,17,18,19,24,25,26, 26a-hexadecahydro- 5,19-dihydroxy-3- [2-(4-hydroxy-3- methoxycyclohexyl)- 1-methylethenyl]- 14,16-dimethoxy- 4,10,12,18- tetramethyl-8-(2- propenyl)-15,19- epoxy-3H-pyrido[2,1- c][1,4]oxaazacyclotri- c o sine- 1,7,20,21(4H,23H)- tetrone	macrolide; immunosuppressant; NSAID; antibiotic	transplant rejection; dermatitis; eye disease; rheumatoid arthritis
MAb 2E1; MAb, effector cell proteinase receptor-1	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAb, 64G12; Mab, interferon receptor type-1; 64G12	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, BMA 031	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD11a; hu 1124	unspecified	monoclonal antibody; immunosuppressant	psoriasis; transplant rejection
MAB, CD45; LM CD45	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD45RB	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, CD7; SDZ CHH 380	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, gp39; MAB, CD40L; IDEC 131	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection; systemic lupus erythematosus
MAB, humanized CD3; MAB, SMART CD3; HuM291	unspecified	monoclonal antibody; immunosuppressant	transplant rejection; autoimmune disease; psoriasis

MAB, L0-CD2a; BTI 322	unspecified	monoclonal antibody; immunosuppressant	autoimmune disease; transplant rejection
MAB, major histocompatibility complex I; F(ab') <sub>2</sub> , MHC I	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, MHCII-CD8	unspecified	monoclonal antibody; immunosuppressant	transplant rejection; graft versus host disease
MAB, transplant rejection; CBL1; ABX CBL	unspecified	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD4; HumaT4	unspecified	monoclonal antibody; immunosuppressant	psoriasis; asthma; rheumatoid arthritis; irritable bowel syndrome; transplant rejection; allergy
daclizumab; dacliximab; MAB, Tac; MAB, humanized Tac; MAB, SMART Tac; Ro 247375; ZENAPAX	immunoglobulin G1 (human-mouse monoclonal clone 1H4 gamma chain anti-human antigen Tac), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection; cancer; autoimmune disease; eye disease
odulimomab; MAB, LFA-1 alpha subunit; ANTILFA	immunoglobulin G1, anti-(human CD11 (antigen).alpha.-chain)(mouse monoclonal 25.3.gamma.1-chain), disulfide with mouse monoclonal 25.3 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection

basiliximab; SDZ CHI621; CHI 621; SIMULECT	Immunoglobulin G1, anti-(human interleukin 2 receptor) (human-mouse monoclonal CHI621 .gamma.1- chain),disulfide with human-mouse mo noclonal CHI621 light chain, dimer	monoclonal antibody; immunosuppressant	transplant rejection
MAB, CD6 blocked ricin; MAb, T12-bR; ONCOLYSIN CD6	unspecified	monoclonal antibody; immunosuppressant; immunotoxin	transplant rejection
MAB, MHC class II	unspecified	monoclonal antibody; immunosuppressant; NSAID	autoimmune disease; transplant rejection; graft versus host disease; cancer
MAB, CD5- momordin; immunotoxin CD5- momordin; ITF 1532	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	cancer; transplant rejection
zolimomab aritox; MAB, H65 RTA; MAB, bone marrow- ricin A conjugate; CD5-T lymphocyte immunotoxin; MAB, CD5; XMMLY H65 RTA; XOMAZYME H65; XOMAZYME CD5+; ORTHOZYME CD5+; CD5 Plus	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	transplant rejection
MAB, humanized, leukemia; MAB, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	unspecified	monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
MAB, B7; MAB, PRIMATIZED B7; IDEC 114	unspecified	monoclonal antibody; NSAID; immunosuppressant	systemic lupus erythematosus; inflammation; transplant rejection; psoriasis

NOX 100	unspecified	nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; hemorrhagic shock
NOX 51	unspecified	nitric oxide scavenger	diabetes; cancer; hemorrhagic shock; transplant rejection; septic shock
NOX 101	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; hemorrhagic shock
NE 0501	unspecified	oligosaccharide	transplant rejection
opioid antagonists, NIH	unspecified	opiate antagonist; peptide; immunosuppressant	drug addiction; alcoholism; obesity; transplant rejection
recombinant PSGL 1, Genetics Institute; PSGL 1	unspecified	P selectin antagonist; E selectin antagonist; L selectin antagonist; selectin antagonist; NSAID	inflammation; transplant rejection; ischemia; reperfusion injury
rD-mPGPtide	unspecified	peptide; immunosuppressant	transplant rejection; multiple sclerosis
transplantation therapy, SangStat	unspecified	peptide; immunosuppressant	transplant rejection
complement inhibitors, Lidak	unspecified	peptide; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus; autoimmune disease; reperfusion injury; respiratory distress syndrome; transplant rejection
SPC 100270	unspecified	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	ischemia; transplant rejection; reperfusion injury

Ro 320432; Ro 32-0432	(S)-3-[8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis
peldesine; BCX 34; BCX 34B	2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection
purine nucleoside phosphorylase inhibitors, Chiroscience; PNP inhibitors, Chiroscience	unspecified	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
mycophenolate mofetil; mycophenolate mofetil hydrochloride; RS 61443; RS-61443-190; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
ribozymes, organ transplantation	unspecified	ribozyme; oligonucleotide; immunosuppressant	transplant rejection
CGS 12970	3-methyl-2-(3-pyridinyl)-1H-indole-1-octanoic acid	thromboxane synthase inhibitor; immunosuppressant	transplant rejection
pirmagrel; CGS 13080	imidazo(1,5-a)pyridine-5-hexanoic acid	thromboxane synthetase inhibitor; immunosuppressant	transplant rejection
thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease



thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection
SC 114	unspecified	triglyceride; immunosuppressant	autoimmune disease; transplant rejection
20-epi-1,25 dihydroxyvitamin D3; MC 1288; IE	(1 $\alpha$ ,3 $\beta$ ,5Z,7E,20S)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue; immunosuppressant	diabetes; transplant rejection; arthritis

Table 44. Current Candidate Therapeutic Interventions for the Treatment of Pain Related to Inflammation

Product Name	Chemical Name	Action	Indication
anti-inflammatory	4,5-dihydro-3-(1-pyrrolyl)-1-(3-trifluoromethylphenyl)-1H pyrazole	15 lipoxigenase, cyclooxygenase, and thromboxane synthetase inhibitor	inflammation
CO 1828	4-methoxy-2-(3-phenyl-2-propynyl)phenol	5 lipoxigenase and cyclooxygenase inhibitor	inflammation
darbufelone; CI 1004	(Z)-2-amino-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-4(5H)-thiazolone	5 lipoxigenase inhibitor; COX inhibitor; COX 2 inhibitor; NSAID	inflammation
P 8892	2-[2-(ethylhydroxyamino)ethyl]dibenz[b,e]oxepin-11(6H)-one	5 lipoxigenase inhibitor; COX inhibitor; NSAID	inflammation
CI 986	2-hydroxy-N,N,N-trimethylethanaminium salt with 5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione (1:1)	5 lipoxigenase inhibitor; COX inhibitor; NSAID	inflammation

P 8977	3-(6,11-dihydro-11-oxo-dibenz[b,e]oxepin-2-yl)-N-methylpropanamide	5 lipoxygenase inhibitor; COX inhibitor; NSAID	inflammation
CI 987	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylidene]-2,4-thiazolidinedione	5 lipoxygenase inhibitor; COX inhibitor; NSAID	inflammation
BIL 226XX	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation
CGS 23885	unspecified	5 lipoxygenase inhibitor; NSAID	psoriasis; inflammation
CGS 24891	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation
CHF 1909	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
GR 80907	unspecified	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
lagunamycin	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation
SC 45662	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis; inflammatory bowel disease
DUP 654	(2-phenylmethyl)-1-naphthalenol	5 lipoxygenase inhibitor; NSAID	psoriasis; inflammation
CGS 25997	(2S)-(-)-2-[[N-(aminocarbonyl)-N-hydroxyamino]methyl]-7-(4-fluorophenoxy)-1,4-benzodioxan	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
A 121798	(E)-1-methyl-6-[[[3-(tetrahydro-4-methoxy-2-methyl-2H-pyran-4-yl)-2-propenyl]oxy]methyl]-2(1H)-quinolinone	5 lipoxygenase inhibitor; NSAID	inflammation
enofelast; BIL 239X	(E)-4-[2-(4-fluorophenyl)ethenyl]-2,6-dimethylphenol	5 lipoxygenase inhibitor; NSAID	inflammation

T 0757; T 757	(E)-N-(4-hydroxy-3,5-dimethylphenyl)-3,7-dimethyl-2,6-octadienamide	5 lipoxygenase inhibitor; NSAID	inflammation
L 663536; MK 886	1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-alfa,alfa-diethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis
SCH 40120	10-(3-chlorophenyl)-6,8,9,10-tetrahydrobenzo[b][1,8]naphthyridin-5(7H)-one	5 lipoxygenase inhibitor; NSAID	inflammation; psoriasis
ICI 211965	2-[1-methoxy-1-[3-(2-naphthalenylmethoxy)phenyl]propyl]thiazole	5 lipoxygenase inhibitor; NSAID	inflammation
L 699333	2-[2-[1-[(4-chlorophenyl)methyl]-4,5-dihydro-4-methyl-6-[(5-phenyl-2-pyridinyl)methoxy]-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
carbázomycin C	3,6-dimethoxy-1,2-dimethyl-9H-carbazol-4-ol	5 lipoxygenase inhibitor; NSAID	inflammation
carbázomycin B	3-methoxy-1,2-dimethyl-9H-carbazol-4-ol	5 lipoxygenase inhibitor; NSAID	inflammation
E 6080	4-[[[(6-hydroxy-4,4,7-trimethyl-2-benzothiazolyl)amino]methyl]benzenesulfonamide monohydrochloride	5 lipoxygenase inhibitor; NSAID	asthma; inflammation

L 651392	4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one	5 lipoxygenase inhibitor; NSAID	inflammation; bacterial infection; asthma
ZD 7717; ICI D7717	7-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenyl]thio]-4-methyl-2H-1,4-benzoxazin-3(4H)-one	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
zileuton; A 64077; ABBOTT 64077; ZYFLO	N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
T 0799; T 799	N-(4-hydroxy-3,5-dimethylphenyl)-3-thiophenecarboxamide	5 lipoxygenase inhibitor; NSAID	inflammation
A 69412	N-[1-(3-furanyl)ethyl]-N-hydroxyurea	5 lipoxygenase inhibitor; NSAID	inflammation
A 78773; A 79175	N-[3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-propynyl]-N-hydroxyurea	5 lipoxygenase inhibitor; NSAID	allergy; inflammation
atreleuton; atreluton; ABT 761; A 85761.0; ABT 85761	N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxy-urea	5 lipoxygenase inhibitor; NSAID	inflammation
A 72694; ABT72694	N-2,2-dimethyl-3-((1-(4-chlorophenylmethyl)-3-(1,1-dimethylethylthio)-5-(1-methylethyl)indol-2-yl))-propyl-n-hydrourea	5 lipoxygenase inhibitor; NSAID	inflammation
lipoxygenase inhibitor	N-hydroxy-N-[1-(2-phenyl-5-benzofuranyl)ethyl]urea	5 lipoxygenase inhibitor; NSAID	inflammation

lurosetron; lurosetron mesylate; GR 87442; GR 87442N; GR 87442X	6-fluoro-2,3,4,5-tetrahydro-5-methyl-2-[(5-methylimidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one	5HT antagonist; 5HT3 antagonist; NSAID	inflammation; emesis
AAL 13	2-[4-(3-chloropropyl)-1-piperazinyl]quinoline	5HT reuptake inhibitor; analgesic; NSAID	inflammation; pain
AKI 1	unspecified	adenosine regulating agent; NSAID	inflammation; arthritis
AKI 2	unspecified	adenosine regulating agent; NSAID	inflammation; arthritis
GP 1515	1-(5-amino-5-deoxy-beta-D-ribofuranosyl)-3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-amine	adenosine regulating agent; NSAID	inflammation
drug delivery system, hydrogel diclofenac; diclofenac hydrogel; DICLOFENAC HYCORE-R	unspecified	analgesic; NSAID	pain; inflammation
drug delivery system, OSAT diclofenac; diclofenac sustained release	unspecified	analgesic; NSAID	pain; inflammation
drug delivery system, OSAT ibuprofen; ibuprofen sustained release	unspecified	analgesic; NSAID	pain; rheumatoid arthritis; osteoarthritis; inflammation
drug delivery system, sustained release microsphere flurbiprofen; flurbiprofen, sustained release	unspecified	analgesic; NSAID	pain; inflammation
TZI 41078	unspecified	analgesic; NSAID	inflammation; pain
RP 67580	(3aR-cis)-octahydro-2-[1-imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4H-isoindol-4-one	analgesic; NSAID	pain; inflammation

HU 239	(6aR-trans)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid	analgesic; NSAID	inflammation; pain
proglumetacin; protacine; CR 604; IMPETIN; PROXIL; PROXATIL; AFLOXAN; TOLINDOL; BRUXEL; MIRIDACIN	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[4-[3-[[4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl]oxy]propyl]-1-piperazinyl]ethyl ester, (+,-)-	analgesic; NSAID	inflammation; pain
FA 401	1-(4-fluorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid carboxymethyl ester	analgesic; NSAID	pain; inflammation
BN 50370	1,3-dihydro-3,6-dimethyl-7-hydroxy-furo(3,4)pyridine hydrochloride	analgesic; NSAID	inflammation; pain
flurbiprofen axetil; LFP 83; ROPION; LIPFEN	2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid, 1-(acetyloxy)ethyl ester	analgesic; NSAID	pain; inflammation
analgesic	3-methyl-5-oxobenzo(b)thieno(2,3-d)thiazolo(3,2-a)pyrimidine-2-carboxylic acid ethyl ester	analgesic; NSAID	pain; inflammation; gastrointestinal ulcer
DTA	4'-methyl-[1,1':3',1''-terphenyl]-5'-acetic acid	analgesic; NSAID	inflammation; pain
diaveridine; EGIS 5645	5-[(3,4-dimethoxyphenyl)methyl]-2,4-pyrimidinediamine	analgesic; NSAID	inflammation; pain

LA 351	5H-(1)-benzopyrano(2,3-b)pyridin-5-one	analgesic; NSAID	inflammation; pain; asthma
M 5011; T 3788	alpha-2-[4-(3-methylthienyl)phenyl]propionic acid	analgesic; NSAID	inflammation; pain
2-halopyridines	unspecified	analgesic; NSAID	inflammation; pain; insomnia
HCT 3012	unspecified	analgesic; NSAID; nitric oxide donor	pain; inflammation
HP 228	N-acetyl-Nleu-Gln-His-Phe-Arg-Trp-Gly-amide	analgesic; NSAID; peptide; melanocortin agonist	pain; inflammation; asthma; cachexia
heparanase inhibitors	unspecified	angiogenesis inhibitor; NSAID	cancer; inflammation
XMP 300	unspecified	angiogenesis inhibitor; peptide	inflammation; cancer
AGN 190383	4-[1-(acetyloxy)tridecyl]-5-hydroxy-2(5H)-furanone	Antagonist prior to 5-lipoxygenase and cyclooxygenase	inflammation
loteprednol + tobramycin; tobramycin + loteprednol	unspecified	antibiotic	inflammation; bacterial infection
anti-inflammatory macrolide analogues, KOSAN	unspecified	antibiotic; macrolide	asthma; inflammation
drug delivery system, ATRIGEL sustained release sanguinarine chloride; sanguinarine chloride ATRIGEL	unspecified	antibiotic; NSAID; antifungal	bacterial infection; mycosis; inflammation; periodontal disease
SB 226882	4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-N-methyl-2-pyrimidinamine	antifungal; MAP kinase inhibitor; signal transduction inhibitor; imidazole	inflammation; asthma; rheumatoid arthritis
aminoimidazole carboxamide ribonucleotide formyltransferase inhibitors, AICART inhibitors	unspecified	antifungal; ribonucleotide formyltransferase inhibitor; NSAID; imidazole	cancer; inflammation

drug delivery system, anti-inflammatory;	intraocular biodegradable polymer	anti-inflammatory intraocular	inflammation
ibuprofen piconol; U 75630; BE 100; OU 75630; STADERM; VESICUM	alpha-methyl-4-(2-methylpropyl)benzeneacetic acid 2-pyridinylmethyl ester	Antiinflammatory with ibuprofen mechanism, topical cream	inflammation
EN 07	Medicinal herbal extract	Antiinflammatory; dermatologic antiinflammatory	inflammation
nitroxide antioxidant	unspecified	antioxidant; free radical scavenger; NSAID	respiratory distress syndrome; inflammation; cancer; reperfusion injury
antioxidants	unspecified	antioxidant; NSAID	inflammation; atherosclerosis
antioxidants	unspecified	antioxidant; NSAID	skin disease; inflammation; cancer
naphterpin; CL 190Y2	(4aS-cis)-3,4a,5,12b-tetrahydro-8,10-dihydroxy-2,5,5,9-tetramethyl-4H-benzo[d]naphtho[2,3-b]pyran-7,12-dione	antioxidant; NSAID	diabetes; cardiovascular disease; cancer; inflammation
boldine	(S)-5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-4H-dibenzo[de,g]quinoline-2,9-diol	antioxidant; NSAID	inflammation
AD 0261	2-[[3-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]propyl]amino]-4-methylphenol	antioxidant; NSAID	inflammation; allergy; skin disease
Z 4003	2-[1-[4-(2-methylpropyl)phenyl]ethyl]-4-thiazolidinecarboxylic acid	antioxidant; NSAID	angina; inflammation; emphysema
antisense oligonucleotide, IL-1 receptor (type 1)	unspecified	antisense; biotechnology; oligonucleotide; NSAID	inflammation



antisense oligonucleotide, interleukin-1; antisense oligonucleotide, IL-1	unspecified	antisense; immunosuppressant; oligonucleotide; NSAID	inflammation
antisense oligonucleotide, B7-1	unspecified	antisense; oligonucleotide; biotechnology; NSAID	inflammation
antisense oligonucleotide, B7-2	unspecified	antisense; oligonucleotide; biotechnology; NSAID	inflammation
antisense oligonucleotide, ELAM; ISIS 4730	unspecified	antisense; oligonucleotide; NSAID	inflammation
antisense oligonucleotide, PECAM-1	unspecified	antisense; oligonucleotide; NSAID	inflammation
antisense oligonucleotides, VCAM-1	unspecified	antisense; oligonucleotide; NSAID	inflammation
drug delivery system, antisense oligonucleotide, ICAM-1; antisense oligonucleotide, ICAM-1 delivery system; Oligo TCS	unspecified	antisense; oligonucleotide; NSAID	inflammation
drug delivery system, oral, antisense oligonucleotide, TNF-alpha; antisense oligonucleotide, TNF-alpha delivery system	unspecified	antisense; oligonucleotide; NSAID	inflammation
anti-inflammatory aptamers	unspecified	aptamer; NSAID	inflammation
L-selectin antagonist	unspecified	aptamer; oligonucleotide; integrin antagonist; L selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation

P-selectin antagonist	unspecified	aptamer; oligonucleotide; integrin antagonist; P selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation
neutrophil elastase inhibitor, NeXstar	unspecified	aptamer; oligonucleotide; NSAID; elastase inhibitor; proteinase inhibitor	inflammation; respiratory disease
bradykinin antagonists	unspecified	bradykinin antagonist; analgesic; NSAID	pain; inflammation; septic shock
NOVA 567; NPC 567	N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalaninebradykinin	bradykinin antagonist; cicatrizant; peptide; NSAID	asthma; skin ulcer; inflammation
bradykinin antagonist/mu agonist	unspecified	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain; migraine
CP 0880; CP 880	N-[[3-[[1-oxo-3-[4-[(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-3-piperidinyl]propyl]amino]phenyl]acetyl]-beta-alanyl-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-N-cyclohexylglycyl-L-arginine	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain
CP 0364	unspecified	bradykinin antagonist; NSAID	hypertension; inflammation
CP 0494	unspecified	bradykinin antagonist; NSAID	septic shock; inflammation

FR 172357	unspecified	bradykinin antagonist; NSAID	inflammation
non-peptide bradykinin antagonist	unspecified	bradykinin antagonist; NSAID	inflammation
icatibant; icatibant acetate; HOE 140	D-arginyl-L-arginyl- L-prolyl-trans-4- hydroxy-L- prolylglycyl-3-(2- thienyl)-L-alanyl-L- seryl-D-1,2,3,4- tetrahydro-3- isoquinolincarbonyl- L- (2 $\alpha$ ,3 $\beta$ ,7 $\beta$ )- octahydro-1H-indole- 2-carbonyl-L-arginine	bradykinin antagonist; NSAID	asthma; inflammation; rhinitis; osteoarthritis
NPC 17731	N2-D-arginyl-3- (trans-4-hydroxy-L- proline)-7-(trans-4- propoxy-D-proline)- 8-[L- (2 $\alpha$ ,3 $\beta$ ,7 $\beta$ )- octahydro-1H- indole-2-carboxylic acid]-bradykinin	bradykinin antagonist; NSAID	inflammation; septic shock; asthma
FR 173657	(E)-3-[6- (acetylamino)-3- pyridinyl]-N-[2-[[2,4- dichloro-3-[[2- methyl-8- quinolinyl)oxy]methy l]phenyl]methylamino ]-2-oxoethyl-2- propenamide	bradykinin antagonist; NSAID; analgesic	asthma; inflammation; pain
CP 9430	unspecified	bradykinin antagonist; NSAID; peptide	inflammation

CP 0597	D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-N-cyclohexylglycyl-L-arginine	bradykinin antagonist; NSAID; peptide	inflammation
fenspiride; KSP 193; PNEUMORAL; ESPIRAN	8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one	bronchodilator; NSAID	inflammation; asthma
C5A antagonists, SKF 96365	unspecified	C5A antagonists	inflammation
	1-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]-1H-imidazole	calcium antagonist; NSAID	inflammation
NE 28345	(Z)-4-hydroxy-3-methoxy-N-9-octadecenylbenzeneacetamide	capsaicin analogue; NSAID	inflammation
casein kinase inhibitors	unspecified	casein kinase inhibitor; immunosuppressant; NSAID	inflammation; cancer
CD11b/CD18 inhibitors, Corvas; CORLEUKIN	unspecified	CD11b/CD18 receptor inhibitor; NSAID	inflammation
atrinisitol; PP 56	D-myo-inositol 1,2,6-tris(dihydrogen phosphate)	chelating agent; NSAID	inflammation; hyperlipidemia
chemoattractant antagonists	unspecified	chemokine antagonist	inflammation
chemokine antagonists	unspecified	chemokine antagonist	inflammation
CHEMOTIDES	unspecified	chemokine antagonist; NSAID	inflammation
chymase inhibitors, Axys	unspecified	chymase inhibitor; NSAID	asthma; inflammation; rhinitis
MDS 004	unspecified	cicatrizant; NSAID	skin ulcer; inflammation

malotilate; NND 105; NKK 105; DA 3857; KANTEC; KANTECS; TRACTAL	1,3-dithiol-2-ylidenepropanedioic acid bis(1-methylethyl) ester	cicatrizant; NSAID	liver disease; inflammation; skin ulcer
collagenase inhibitors	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis; inflammation
complement factor inhibitors	unspecified	Complement factor inhibitors	inflammation; respiratory distress syndrome
CMI CAB2	unspecified	complement inhibitor; biotechnology; NSAID	inflammation; respiratory distress syndrome
inflammation therapy, complement regulatory protein	unspecified	complement inhibitor; biotechnology; NSAID	inflammation
MAB, C5 single chain; MAB, complement C5; 5G1.1-SC	unspecified	complement inhibitor; monoclonal antibody; NSAID	inflammation; myocardial infarction; stroke; ischemia
sCR1sLex; TP 20	unspecified	complement inhibitor; neutrophil adhesion inhibitor; NSAID	respiratory distress syndrome; inflammation
TP 16	unspecified	complement inhibitor; NSAID	inflammation
kallikrein inhibitors	unspecified	complement inhibitor; NSAID	inflammation
TK 9C	unspecified	complement inhibitor; NSAID	inflammation
CSK 802	unspecified	corticosteroid	inflammation
DM V; DM 5	unspecified	corticosteroid	inflammation
ORG 7258	unspecified	corticosteroid	inflammation
P16CM analogues	unspecified	corticosteroid	inflammation
butixocort propionate; JO 1222	(11beta)-11-hydroxy-17-(1-oxobutoxy)-21-[(1-oxopropyl)thio]]pregn-4-ene-3,20-dione	corticosteroid	inflammation; asthma; inflammatory bowel disease

budesonide; budesonide propionate; S 1320; PREFERID; PULMICORT; RHINOCORT; ENTOCORT; NARICORT; INFLAMMIDE; BETACTIN; ELTAIR; HORACORT; RHINOCORT AQUA	(11beta,16alpha)- 16,17- [butylidenebis(oxy)]- 11,21- dihydroxypregna-1,4- diene-3,20-dione	corticosteroid	asthma; skin disease; inflammation; rhinitis; ulcerative colitis; Crohn disease
rimexolone; trimexolone; ORG 6216; RIMEXEL; VEXOL	(11beta,16alpha,17beta)-11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)androst-1,4-dien-3-one	corticosteroid	rheumatoid arthritis; inflammation; eye disease
prednisolone analogue	(11beta,16beta)-11,21-dihydroxy-3,20-dioxo-4'H-pregna-1,4-dieno[16,17-d]isoxazole-3'-carboxylic acid	corticosteroid	inflammation
amelometasone; TS 410; CS 830; REONA	(11beta,16beta)-9-fluoro-11-hydroxy-21-methoxy-16-methyl-17-(1-oxopropoxy)pregna-1,4-diene-3,20-dione	corticosteroid	inflammation
tipredane; SQ 27239	(11beta,17alpha)-17-(ethylthio)-9-fluoro-11-hydroxy-17-(methylthio)androst-1,4-diene-3-one	corticosteroid	inflammation; psoriasis

clobetasone butyrate; clobetasone; DE 049; CCI 5537; GR 2/1214; SN 203; CLOBETRON; EUMOVATE; EUMOVATE N; KINDABATE; KINDALONE; BUTIDEX	(16beta)-21-chloro-9- fluoro-16-methyl-17- (1-oxobutoxy)pregna- 1,4-diene-3,11,20- trione	corticosteroid	eye disease; inflammation
16-epiestriol; epiestriol	(16beta,17.beta)estra- 1,3,5(10)-triene- 3,16,17-triol	corticosteroid	inflammation
ulobetasol propionate; halobetasol propionate; CGP 14458; BMY 30056; ULTRAVATE	(6alpha,11beta,16beta)- 21-chloro-6,9- difluoro-11-hydroxy- 16-methyl-17-(1- oxopropoxy)-pregna- 1,4-diene-3,20-dione	corticosteroid	skin disease; inflammation; psoriasis
methylprednisolone aceponate; MPA; SH 440; ZK 91588; ADVANTAN	(6alpha,11beta)-21- (acetyloxy)-11- hydroxy-6-methyl-17- (1-oxopropoxy)pr egna-1,4-diene-3,20- dione	corticosteroid	inflammation
P16CM	16alpha- methoxycarbonylpred nisolone	corticosteroid	inflammation
halopredone; THS 20; THS 201; F2; HALOART; HALOART S	17alfa,21-diacetoxy- 2-bromo-6beta,9alfa- difluoro-11beta- hydroxy-1,4- pregnadiene-3,20- dione	corticosteroid	inflammation
prednisolone analogue	21-(acetyloxy)-11- hydroxy-3,20-dioxo- 4'H-pregna-1,4- dieno[16,17-d ]isoxazole-3'- carboxylic acid ethyl ester	corticosteroid	inflammation

compound 3Ae	21-ethylthio-6alpha,9alpha-difluoro-11beta-hydroxy-16alpha,17alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione	corticosteroid	inflammation; skin disease
methylprednisolone suleptanate; U 67590A; PROMEDROL	(6alpha,11beta)-11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxooctyl]oxy]pregna-1,4-diene-3,20-dione monosodium salt	corticosteroid; immunosuppressant	inflammation; asthma; anaphylactic shock; transplant rejection
BIL 93BS; BIL 0093BS	unspecified	COX inhibitor; 5 lipoxxygenase inhibitor; NSAID	inflammation
anti-inflammatory	1,2-dihydro-1-oxo-N-2-thiazolylpyrrolo[3,2,1-kl]phenothiazine-2-carboxamide	COX inhibitor; 5 lipoxxygenase inhibitor; NSAID	inflammation
E 5110	3-[[3,5-bis-(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-1-methoxy-2-pyrrolidinone	COX inhibitor; 5 lipoxxygenase inhibitor; NSAID	inflammation
tepoxalin; RWJ 20485; ORF 20485	5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide	COX inhibitor; 5 lipoxxygenase inhibitor; NSAID	asthma; inflammation; inflammatory bowel disease
LY 178002	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-4-thiazolidinone	COX inhibitor; 5 lipoxxygenase inhibitor; NSAID	inflammation; ischemia
ML 3000	6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid	COX inhibitor; 5 lipoxxygenase inhibitor; NSAID	inflammation



meloxicam; UH AC62; UH AC26XX; MOBIC; MOBICOX; MOBEC; MOVALIS; MOVATEC	4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide	COX inhibitor; analgesic; COX 2 inhibitor; NSAID	rheumatoid arthritis; inflammation; pain; osteoarthritis
D 1367	unspecified	COX inhibitor; analgesic; NSAID	pain; inflammation
AHR 10037	2-amino-3-(4-chlorobenzoyl)benzoic acid	COX inhibitor; analgesic; NSAID	inflammation; pain
T 614	N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-methanesulfonamide	COX inhibitor; analgesic; NSAID; DMARD	inflammation; pain
cyclooxygenase inhibitor, Oxis	unspecified	COX inhibitor; antioxidant; NSAID	inflammation
BF 389; biofor 389	4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]dihydro-2-methyl-2H-1,2-oxazin-3(4H)-one	COX inhibitor; COX 2 inhibitor; 5 lipooxygenase inhibitor; NSAID	inflammation
RWJ 63556	N-[5-[(4-fluorophenoxy)-2-thienyl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; 5 lipooxygenase inhibitor; NSAID	inflammation
CT 3	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
L 748731	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation
MK 663	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
JTE 522	4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease

NS 398	N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
L 745337	N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
L 752860	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
COX 2 inhibitors	unspecified	COX inhibitor; COX 2 inhibitor; NSAID	inflammation
L 761066	(R)-1-[(4-bromophenyl)methyl]-5-methoxy-beta,2-dimethyl-1H-indole-3-butanoic acid	COX inhibitor; COX 2 inhibitor; NSAID	inflammation
L 768277	5-[4-(methylsulfonyl)phenyl]-6-phenylthiazolo[3,2-b][1,2,4]triazole	COX inhibitor; COX 2 inhibitor; NSAID	inflammation
BIRL 790	6-chloro-4-[(1-methylethyl)sulfonyl]-2-(phenylmethyl)-1,3(2H,4H)-isoquinolinedione	COX inhibitor; COX 2 inhibitor; NSAID	inflammation
COX 2 inhibitors	unspecified	COX inhibitor; COX 2 inhibitor; NSAID; analgesic	inflammation; osteoarthritis; pain
CGP 31081	unspecified	COX inhibitor; NSAID	inflammation
lornoxicam; chlortenoxicam; Ro 139297; TS 110; CTX; SAFEM; XEFO; LORCAM	6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide 1,1-dioxide	COX inhibitor; NSAID; analgesic	inflammation; pain
COX 2 inhibitors, SALVAT	unspecified	COX inhibitor; NSAID; COX 2 inhibitor	inflammation

trifenagrel; BW 325U	2-[2-(4,5-diphenyl-1H-imidazole-2-yl)phenoxy]-N,N-dimethylethanamine	COX inhibitor; platelet antiaggregant; NSAID	inflammation; thrombosis
nimesulide; R 805; NIM 03; MESULID; AULIN; NIMED; AINEX; NISULID; ESKAFLAM; SCAFLAN; OXETIAN; ANTIFLOXIL; ARLAGIN	N-(4-nitro-2-phenoxyphenyl)methanesulfonamide	COX inhibitor; prostaglandin synthetase inhibitor; COX 2 inhibitor; NSAID	inflammation
interleukin-4 receptor; IL-4r; NUVANCE	unspecified	cytokine antagonist	inflammation; asthma
DoB 0041	unspecified	cytokine antagonist; biotechnology; NSAID	inflammation
DoB 0039	unspecified	cytokine antagonist; NSAID	inflammation
interleukin-1 antagonist; IRAP	unspecified	cytokine antagonist; NSAID	inflammation
interferon antagonists; interferon antagonists	unspecified	cytokine antagonist; NSAID	inflammation
interleukin-1 antagonist	unspecified	cytokine antagonist; NSAID	inflammation
interleukin-6 antagonist	unspecified	cytokine antagonist; NSAID	cachexia; inflammation
interleukin-8 receptor; IL-8r	unspecified	cytokine antagonist; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
E 5090	(Z)-3-[4-(acetyloxy)-5-ethyl-3-methoxy-1-naphthalenyl]-2-methyl-2-propenoic acid	cytokine inhibitor; analgesic; NSAID	inflammation; pain
interleukin-8 inactivating proteinase; CT 8	unspecified	cytokine inhibitor; biotechnology; NSAID	respiratory disease; inflammation
interleukin-1 inhibitor; IL-1 inhibitor; SEPTANIL	unspecified	cytokine inhibitor; NSAID	inflammation; septic shock
CGP 47969A	unspecified	cytokine inhibitor; NSAID	inflammation

immunomodulatory cytokine modulator	unspecified	cytokine inhibitor; NSAID	inflammation
interleukin-1 inhibitors	unspecified	cytokine inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease
interleukin-1 receptor ligands	unspecified	cytokine inhibitor; NSAID	arthritis; inflammation
interleukin-8 inhibitors	unspecified	cytokine inhibitor; NSAID	inflammation; cardiovascular disease
interleukin-7 receptor; IL-7r	unspecified	cytokine inhibitor; NSAID; immunosuppressant	allergy; inflammation; transplant rejection
SelCIDs	unspecified	cytokine inhibitor; NSAID; immunosuppressant; TNF inhibitor; phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	autoimmune disease; inflammation
cytokine regulators	unspecified	cytokine synthesis inhibitor; NSAID	inflammation; pigmentation disorder
JTE 607	unspecified	cytokine synthesis inhibitor; NSAID	inflammation
SKF 104351	2-(4-fluorophenyl)- 6,7-dihydro-3-(4- pyridinyl)-5H- pyrrolo[1,2- a]imidazole	cytokine synthesis inhibitor; NSAID	inflammation
SKF 86002	6-(4-fluorophenyl)- 2,3-dihydro-5-(4- pyridinyl)imidazo[2,1- b]thiazole	cytokine synthesis inhibitor; NSAID	inflammation
SKF 105809	6,7-dihydro-2-[4- (methylsulfinyl)phenyl]- 3-(4-pyridinyl)-5H- pyrrolo[1,2- a]imidazole	cytokine synthesis inhibitor; NSAID	inflammation
BMY 30094	N- hydroxybenzenenona namide	cytokine synthesis inhibitor; NSAID	inflammation; psoriasis

CI 959	5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-benzo[b]thiophene-2-carboxamide sodium salt	degranulation inhibitor; immunosuppressant; NSAID	rhinitis; inflammation; asthma; arthritis
eclazolast; RG 2871; REV 2871; RHC 2871	2-ethoxyethyl-5-chloro-2-benzoxazolecarboxylate	degranulation inhibitor; NSAID	inflammation
prinomide; prinomide tromethamine; CGS 10787; CGS 10787B	alpha-cyano-1-methyl-beta-oxopyrrole-2-propionanilide with 2-amino-2-(hydroxymethyl)-1,3-propanediol	DMARD; analgesic; immunosuppressant; NSAID	inflammation; pain; rheumatoid arthritis
LY 243062	D-1-isopropyl-6-n-propyl-8-beta-methylthiomethylergoline	dopamine agonist; dopamine D2 agonist; NSAID	inflammation
MAB, E-selectin	unspecified	E selectin antagonist; monoclonal antibody; NSAID	inflammation
neutrophil elastase/matrix metalloproteinase inhibitor	unspecified	elastase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	inflammation
SR 26831	5-[(2-chlorophenyl)methyl]-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxythieno[3,2-c]pyridinium	elastase inhibitor; proteinase inhibitor; NSAID	inflammation; emphysema
superoxide dismutase manganese complex; Mn-SOD	unspecified	free radical scavenger; NSAID	respiratory disease; inflammation
superoxide dismutase, modified; SI 3501	unspecified	free radical scavenger; NSAID	inflammation

superoxide dismutase; superoxide dismutase copper zinc complex; CuZnSOD; OxSODrol	N-acetylsuperoxide dismutase (human clone pS 61-10 copper-zinc subunit protein moiety reduced)	free radical scavenger; NSAID	respiratory disease; ischemia; rheumatoid arthritis; inflammation
OPC 15161; NF 1616904	6-(1H-indol-3- ylmethyl)-5-methoxy- 3-(2-methylpropyl)-2- (1H)-pyrazinone, 4- oxide	free radical scavenger; NSAID	inflammation; kidney disease
superoxide dismutase manganese complex; hMNSOD	unspecified	free radical scavenger; NSAID; immunosuppressant	ischemia; rheumatoid arthritis; inflammation; reperfusion injury
superoxide dismutase variants; SOD	unspecified	free radical scavenger; NSAID; immunosuppressant	inflammation; autoimmune disease; reperfusion injury
VB 5122	unspecified	free radical scavenger; xanthine oxidase inhibitor	inflammation; asthma
mipragoside; AGF 44	[R-[R*,S*-(E)]]-N- [1-[[[O-[N-acetyl-1- (1-methylethyl)-alfa- neuraminosyl]-(2-3)- O-[O-beta-D- galactopyranosyl-(1- 3)-2-(acetyl-amino)-2- deoxy-beta-D- galactopyranosyl-(1- 4)-O-beta-D- galactopyranosyl-(1- 4)-beta-D- glucopyranosyl]oxy] methyl]-2-hydroxy-3- heptadecenyl]octadec anamide	ganglioside analogue; analgesic; NSAID	inflammation; pain
gene therapy, glucocorticomimetic receptor; gene therapy, asthma	unspecified	gene therapy; NSAID	inflammation; asthma
inflammatory disease therapy, IL-1Hy273	unspecified	gene; biotechnology	inflammation

genetic suppressor elements, inflammation	unspecified	Genetic suppression of inflammation	inflammation
glucocorticoids	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation
glucocorticoids	unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
loteprednol etabonate; loteprednol; P 5604; HGP 1; CDDD 5604; LOTEMAX; ALREX; LENOXIN	(11beta,17alpha)-17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid chloromethyl ester	glucocorticoid; NSAID	inflammation; conjunctivitis; rhinitis
MY 1250	5,6-dihydro-7,8-dimethyl-4,5-dioxo-4H-pyrano[3,2-c]quinoline-2-carboxylic acid	histamine antagonist; histamine H1 antagonist; NSAID	inflammation; allergy
CP 331; CP 6	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[[2-oxo-2-[[3-[[3-(1-piperidinylmethyl)phenoxy]propyl]amino]ethyl]thio]ethyl ester	histamine antagonist; histamine H2 antagonist; analgesic; NSAID	inflammation; pain
dehydroepiandrosterone sulfate; DHEAS; PB 005	unspecified	hormone; vaccine adjuvant; corticosteroid	inflammation; infectious disease; asthma
ICE inhibitors	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	inflammation
interleukin-1 beta converting enzyme inhibitors, ICE inhibitors	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	inflammation
interleukin-1 converting enzyme inhibitor; ICE-1 inhibitor	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	inflammation; inflammatory bowel disease

VE 19512	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	rheumatoid arthritis; osteoarthritis; inflammation
VX 740; HMR 3480	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	rheumatoid arthritis; osteoarthritis; inflammation
GYKI 66114	N-(ethoxycarbonyl)-L-alanyl-L-tyrosyl-L-valyl-N-[(1S)-2-carboxy-1-formylethyl]-L-alaninamide	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID; peptide	inflammation
GYKI 66115	N-(ethoxycarbonyl)-L-alanyl-L-tyrosyl-L-valyl-N-[(1S)-2-carboxy-1-formylethyl]glycinamide	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID; peptide	inflammation
clotrimazole + mometasone; mometasone + clotrimazole; SCH 458	unspecified	imidazole; corticosteroid; antifungal	mycosis; inflammation
anti-inflammatory agents	Unspecified bacterial proteins	Immunomodulation	inflammation
acemannan; CARN 1000; CARN 750; CARRASYN; ALIMINASE; VORALEX; CARRAVEX	(1->4),(1->6)-alpha-D-galacto-beta-D-mannan acetate	immunostimulant; cicatrizant	inflammatory bowel disease; skin ulcer; inflammation; cancer
immunology/inflammation therapy, Rigel	unspecified	immunosuppressant	inflammation; autoimmune disease; asthma
aldose reductase inhibitors	unspecified	immunosuppressant; aldose reductase inhibitor; NSAID	autoimmune disease; allergy; inflammation
signal transduction modulators	unspecified	immunosuppressant; immunostimulant; NSAID	autoimmune disease; cancer; inflammation



corticotropin releasing factor binding protein; CRF binding protein; NBI 112	unspecified	immunosuppressant; NSAID	rheumatoid arthritis; inflammation
E 21R	unspecified	immunosuppressant; NSAID	cancer; inflammation; allergy
leukocyte function associated antigen 3 T cell inhibitor protein; LFA3TIP; LFA3TIP; AMEVIVE	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease; psoriasis
LFA-1 alpha subunit; leukocyte function associated antigen-1 alpha subunit; leukocyte cell surface adhesion receptor molecule	unspecified	immunosuppressant; NSAID	inflammation
MAb, CD40 ligand; 5C8; ANTOVA	unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
OX40-based immunotherapy, Cantab	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease
BN 58705	unspecified	immunosuppressant; NSAID	septic shock; inflammation
BW 91Y78	unspecified	immunosuppressant; NSAID	inflammation
CD4 inhibitors	unspecified	immunosuppressant; NSAID	inflammation
inflammation therapy	unspecified	immunosuppressant; NSAID	inflammatory bowel disease; inflammation; autoimmune disease
Ro 236457	unspecified	immunosuppressant; NSAID	inflammation
phellodendrine; OB 5	(7S-cis)-5,8,13,13a-tetrahydro-2,11-dihydroxy-3,10-dimethoxy-7-methyl-6H-dibenzo[a,g]quinolizinium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease

TEI 1338	(E)-N-(2-methoxycarbonylphenyl)-8-(2-naphthyl)-5,6-trans-5,6-methano-7-octenamide	immunosuppressant; NSAID	allergy; inflammation
TEI 3332	[(6,7-dihydroxy-2-naphthalenyl)thio]acetic acid methyl ester	immunosuppressant; NSAID	allergy; inflammation
KB 2683	2-(4-methylphenyl)-4-benzothiazolol acetate	immunosuppressant; NSAID	rheumatoid arthritis; inflammation; autoimmune disease
albifylline; HWA 138	3,7-dihydro-1-(5-hydroxy-5-methylhexyl)-3-methyl-1H-purine-2,6-dione	immunosuppressant; NSAID	septic shock; inflammation
celastrol	unspecified	immunosuppressant; NSAID; terpene	inflammation
CD45 inhibitors	unspecified	immunosuppressant; NSAID; tyrosine phosphatase inhibitor	transplant rejection; inflammation
potassium channel blocker	unspecified	immunosuppressant; potassium channel blocker	autoimmune disease; allergy; inflammation
fusion protein, CD5-gelonin; CD5-gelonin T lymphocyte-targeted immunofusion protein; GENIMUNE	unspecified	immunotoxin; NSAID	rheumatoid arthritis; inflammation
MAB, B11; MAB, E-selectin; MAB, endothelium leukocyte adhesion molecule	unspecified	integrin antagonist; biotechnology; immunosuppressant; monoclonal antibody; E selectin antagonist; cell adhesion inhibitor; NSAID	inflammation
MAB, selectin; CY 1788; CY 1787	Unspecified	integrin antagonist; biotechnology; monoclonal antibody; E selectin antagonist; cell adhesion inhibitor; NSAID	inflammation; septic shock; rhinitis

MAb, L-selectin, human	unspecified	integrin antagonist; biotechnology; monoclonal antibody; L selectin antagonist; cell adhesion inhibitor; NSAID	inflammation; anaphylactic shock
GM 1676	unspecified	integrin antagonist; cell adhesion inhibitor; immunosuppressant; NSAID	inflammation
neutrophil inhibitory factor; NIF; CORLEUKIN NIF	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	reperfusion injury; inflammation; stroke
anti-inflammatory agents	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
cell adhesion antagonist, cell adhesion antagonist,	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation
cell adhesion inhibitor	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; allergy
cell adhesion inhibitor	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
drug delivery system, STEALTH cell adhesion inhibitors	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
E-selectin inhibitors	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation
GM 1606	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation
GM 1925	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation
GM 1986	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation

GM 1998	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; respiratory distress syndrome; heart ischemia; reperfusion injury
GM 2296	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; respiratory distress syndrome
GM 7050	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
VCAM-1 inhibitors	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation
cell adhesion inhibitors	unspecified	integrin antagonist; cell adhesion inhibitor; selectin antagonist; NSAID	inflammation
L-selectin inhibitors	unspecified	integrin antagonist; L selectin antagonist; cell adhesion inhibitor; NSAID	inflammation
NE 1704	unspecified	integrin antagonist; oligosaccharide; E selectin antagonist; cell adhesion inhibitor; NSAID	inflammation
P-selectin inhibitors	unspecified	integrin antagonist; P selectin antagonist; cell adhesion inhibitor; NSAID	inflammation
selectin antagonists	unspecified	integrin antagonist; P selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation
CEN 100	unspecified	integrin antagonist; peptide; P selectin antagonist; cell adhesion inhibitor; NSAID	ischemia; inflammation; reperfusion injury

low molecular weight selectin inhibitors	unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; allergy
TBC 1269	3',3''-(1,6- hexanediyl)bis[6'- (alpha-D- mannopyranosyloxy)- [1,1'-biphenyl]-3- acetic acid	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; asthma
EPI KAL2	unspecified	kallikrein inhibitor; biotechnology	inflammation
PKSI 527	[1(S)-trans]-4-[[2- [[[4- (aminomethyl)cyclohexyl]carbonyl]amino]- 1-oxo-3- phenylpropyl]amino] benzeneacetic acid monohydrochloride	kallikrein inhibitor; NSAID	septic shock; inflammation; thrombosis
leukocyte adhesion inhibitors	unspecified	leukocyte adhesion inhibitor; NSAID	inflammation; cardiac therapy
moxilubant; CGS 25019; CGS 25019C	4-[5-[4- (aminoiminomethyl)phenoxy]pentyl]oxy]- 3-methoxy-N,N- bis(1- methylethyl)benzamide	leukotriene antagonist; leukotriene B4 antagonist; NSAID	inflammation
ZD 3523; ICI D3523	unspecified	leukotriene antagonist; NSAID	asthma; inflammation
RP 66153	unspecified	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation

WF 11605	(1S,1R,4aS,6aR,8R,9R,10aS,12aS)-9-acetoxy-2-((R)-1,2dimethylpropyl)-8-(beta-D-glucopyranosyl)oxy-1,2,3,4,4a,5,6,6a,7,8,9,10,10a,11,12,12a-hexadecahydro-2,4a,7,7,10a,12a,hexamethyl-3-oxochrysene-1-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	hepatitis; inflammation; psoriasis
SB 201993	(E)-3-[[[6-(2-carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	psoriasis; inflammation
SB 201146	(E)-3-[6-[[3-aminophenyl)sulfinyl]methyl]-3-[[8-(4-methoxyphenyl)octyl]oxy]-2-pyridinyl]-2-propenoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation
ticolubant; SB 209247	(E)-3-[6-[[2,6-dichlorophenyl]thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation; psoriasis
LY 255283	1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]ethanone	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation
PF 10042	1-[5-hydroxy-5-[8-(1-hydroxy-2-phenylethyl)-2-dibenzofuranyl]-1-oxopentyl]pyrrolidine	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation

RP 64966	2-((4-(5-(3-phenylpropyl)-2-thienyl)butyl)oxy)acetic acid (sodium salt)	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation; psoriasis; inflammatory bowel disease
RG 14893	4-(2-(methyl(2-phenethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; inflammation
LY 213024	5-(3-carboxybenzoyl)-2-(decyloxy)benzenepropanoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation
SC 50605	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	psoriasis; inflammation
LY 264086	7-carboxy-3-(decyloxy)-9-oxo-9H-xanthene-4-propanoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation
LY 210073	Unspecified	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation
WAY 121006 trom	3-fluoro-4'-(2-quinolinylmethoxy)-[1,1'-biphenyl]-4-acetic acid	leukotriene B4 antagonist; leukotriene D4 antagonist; leukotriene antagonist; NSAID	inflammation
macrophage chemotaxin inhibitor	unspecified	macrophage inhibitor; NSAID	inflammation; cardiovascular disease
S 3304	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor	cancer; inflammation

CH 104	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; inflammation
CH 715	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; inflammation
PI 88	unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	inflammation; cancer
PGE 2946979	3-[(hydroxyamino)carbonyl]-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinecarboxylic acid phenylmethyl ester	metalloproteinase inhibitor; proteinase inhibitor	inflammation; cancer
TNF alpha converting enzyme inhibitors, TACE inhibitors	unspecified	metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; inflammation
MAB, inflammation	unspecified	monoclonal antibody	inflammation
MAB, interleukin-8; MAB, IL-8; ABX IL8	unspecified	monoclonal antibody; biotechnology; NSAID	respiratory distress syndrome; inflammatory bowel disease; rheumatoid arthritis; inflammation; psoriasis
MAB, inflammation therapy, LeukoSite/MorphoSy	unspecified	monoclonal antibody; immunosuppressant	inflammation; autoimmune disease
MAB, cadherin	unspecified	monoclonal antibody; NSAID	inflammation
MAB, CD11a	unspecified	monoclonal antibody; NSAID	inflammation
MAB, CD11b; MAB, m60.1; m60.1; LY 303932	unspecified	monoclonal antibody; NSAID	inflammation; heart ischemia; reperfusion injury
MAB, CD11b	unspecified	monoclonal antibody; NSAID	inflammation



MAB, CD18	unspecified	monoclonal antibody; NSAID	inflammation
MAB, CD18, humanized; SMART anti-CD18	unspecified	monoclonal antibody; NSAID	inflammation
MAB, humanized tumor necrosis factor; MAB, humanized TNF; MAB, CDP571; CDP 571; BAY 103356; B 1351	unspecified	monoclonal antibody; NSAID	septic shock; inflammation; bacterial infection; inflammatory bowel disease; rheumatoid arthritis
MAB, interferon alfa; MAB, IFN-alfa	unspecified	monoclonal antibody; NSAID	inflammation
MAB, interleukin-8, Medarex	unspecified	monoclonal antibody; NSAID	inflammation
MAB, T cells; MAB, rheumatoid arthritis	unspecified	monoclonal antibody; NSAID	inflammation
MAB, tumor necrosis factor-alpha, human; D2E7; LU 200134	unspecified	monoclonal antibody; NSAID	inflammation
MAB, VLA-4, humanized; MAB, very late antigen-4, humanized	unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
MAB, monocyte chemoattractant protein-1 receptor; MAbs, MCP-1 receptor	unspecified	monoclonal antibody; NSAID; chemokine antagonist	inflammation
MAB, B7; MAB, PRIMATIZED B7; IDEC 114	unspecified	monoclonal antibody; NSAID; immunosuppressant	systemic lupus erythematosus; inflammation; transplant rejection; psoriasis
leishmania lipophosphoglycan	leishmania lipophosphoglycan	Monocyte recruitment blockade	inflammation; restenosis
antisense oligonucleotide, interleukin-1 beta; antisense oligonucleotide, IL-1 beta	unspecified	mRNA translation inhibitor; antisense; oligonucleotide	inflammation

L 733060	(2S-cis)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID	inflammation; pain; asthma
CP 96345	(2S,3S)-cis-2-(diphenylmethyl)-N-[[2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID; substance P antagonist	inflammation; pruritis; pain
neurokinin antagonists	unspecified	neurokinin antagonist; analgesic; NSAID	pain; inflammation
nolpitantium besilate; SR 140333	(S) 1-[2-[3-(3,4-dichlorophenyl)-1-[[3-(1-methylethoxy)phenyl]acetate]-3-piperidinyl]ethyl]-4-phenyl-1-azoniabicyclo[2.2.2]octane	neurokinin antagonist; neurokinin 1 antagonist; NSAID	asthma; inflammation
L 737488	(S)-N-[4-[3,5-bis(trifluoromethyl)phenyl]-1-(1H-indol-3-ylmethyl)-2-oxobutyl]-1-azabicyclo[2.2.2]octane-4-carboxamide monohydrochloride	neurokinin antagonist; neurokinin 1 antagonist; NSAID	inflammation
FK 224; FR 115224	N-[N2-[N-[N-[N-[alpha,beta-didehydro-N-methyl-N-[N-[1-oxo-3-(2-pentylphenyl)propyl]-L-threonyl]tyrosyl]-L-leucyl]-D-phenylalanyl]-L-allothreonyl]-L-asparaginyl]-L-serine epsilon-lactone	neurokinin antagonist; neurokinin 2 antagonist; NSAID	asthma; inflammation

NS 2073	unspecified	nitric oxide activator; NSAID	inflammation; glaucoma; gastrointestinal ulcer; asthma
NS 2028	unspecified	nitric oxide inhibitor; NSAID	inflammation
NOS inhibitor	unspecified	nitric oxide synthase inhibitor; NSAID	neurological; inflammation
inflammatory disease therapy,	unspecified	NSAID	inflammation
compinact A	unspecified	NSAID	inflammation
compinact C	unspecified	NSAID	inflammation
GELIN	unspecified	NSAID	inflammation
TSG 6	unspecified	NSAID	inflammation
acute inflammation therapy	unspecified	NSAID	inflammation
adenosine kinase inhibitors, inflammation	unspecified	NSAID	inflammation
anchoring protein modulators	unspecified	NSAID	inflammation
anti-inflammatory agent	unspecified	NSAID	inflammation; asthma
anti-inflammatory agents	unspecified	NSAID	inflammation
anti-inflammatory agents	unspecified	NSAID	inflammation
anti-inflammatory agents	unspecified	NSAID	inflammation
anti-inflammatory agents	unspecified	NSAID	inflammation
anti-inflammatory agents	unspecified	NSAID	inflammation
anti-inflammatory, Pharmacopeia; anti- inflammatory	unspecified	NSAID	inflammation
anti-inflammatory, anti-inflammatory	unspecified	NSAID	inflammation
anti-inflammatory, transcription factors	unspecified	NSAID	inflammation
anti-inflammatory	unspecified	NSAID	inflammation
APC 1024	unspecified	NSAID	inflammation

APC 1070	unspecified	NSAID	inflammation
APC 1132	unspecified	NSAID	inflammation
APC 1134	unspecified	NSAID	inflammation
APC 1390	unspecified	NSAID	inflammation
bradykinin receptor modulators, Pharmacopeia	unspecified	NSAID	inflammation
C5a inhibitors	unspecified	NSAID	inflammation; cardiovascular disease
CD40 receptor signalling pathway inhibitor; CD40 receptor signalling pathway inhibitor	unspecified	NSAID	allergy; asthma; inflammation
cell adhesion molecules intracellular inhibitors	unspecified	NSAID	cancer; inflammation
chemokine receptor modulators	unspecified	NSAID	inflammation; asthma; atherosclerosis
CPH 82; REUMACON; COMIHOG	unspecified	NSAID	inflammation; Alzheimer disease
D 20207	unspecified	NSAID	inflammation; respiratory disease
diclofenac digolil; F 5402M	unspecified	NSAID	inflammation
drug delivery system, diclofenac; diclofenac PULSINCAP	unspecified	NSAID	inflammation
drug delivery system, DIFFUCAP diclofenac; diclofenac DIFFUCAP; DICLOMAX	unspecified	NSAID	inflammation
drug delivery system, diclofenac; diclofenac; ISV 205	unspecified	NSAID	glaucoma; inflammation
drug delivery system, GEOMATRIX controlled release ketoprofen; ketoprofen GEOMATRIX	unspecified	NSAID	inflammation

drug delivery system, NSAIDs; ENTEROTEC	unspecified	NSAID	inflammation
drug delivery system, submicron emulsion diclofenac; diclofenac SME	unspecified	NSAID	inflammation
drug discovery	unspecified	NSAID	inflammation; diabetes; cardiovascular disease; neurological; cancer; infectious disease
EN 03	unspecified	NSAID	inflammation
G-protein antagonist	unspecified	NSAID	inflammation; cardiovascular disease; neurological
G-protein therapy	unspecified	NSAID	inflammation; cardiovascular disease; cancer
gene discovery, inflammatory diseases	unspecified	NSAID	inflammation; rheumatoid arthritis
gene discovery, oxidative stress pathways	unspecified	NSAID	neurological; inflammation
glucocorticoid agonists	unspecified	NSAID	inflammation; rheumatoid arthritis; inflammatory bowel disease; asthma
GM 7072	unspecified	NSAID	inflammation
ICAM-1 inhibitors, intracellular adhesion molecule-1 inhibitors	unspecified	NSAID	inflammation
ICR 18	unspecified	NSAID	inflammation
IL-8 receptor modulators	unspecified	NSAID	inflammation
inflammatory disease therapy	unspecified	NSAID	inflammation
interleukin modulators	unspecified	NSAID	inflammation; asthma
interleukin-8 receptor antagonists	unspecified	NSAID	inflammation
IPL 576; IZP 94005	unspecified	NSAID	psoriasis; allergy; inflammation

kinase modulators	unspecified	NSAID	cancer; inflammation
leucomyzin	unspecified	NSAID	inflammation; hyperlipidemia
LG 21101	unspecified	NSAID	inflammation; multiple sclerosis
major histocompatibility complex II, ligand, MHC II ligand	unspecified	NSAID	allergy; inflammation
MN 10021	unspecified	NSAID	inflammation
p38 kinase modulators	unspecified	NSAID	inflammation
PG CC8	unspecified	NSAID	eye disease; inflammation
phosphosugar anti-inflammatory agent	unspecified	NSAID	inflammation
sialophorin chimeric molecules	unspecified	NSAID	inflammation
signal transduction modulators	unspecified	NSAID	cancer; inflammation; neurological
SR 129	unspecified	NSAID	inflammation
SR 318B; SR 318	unspecified	NSAID	inflammation
synthetic glycosaminoglycans	unspecified	NSAID	inflammation; cancer; neuropathy
TNF alpha proteinase inhibitor; TAPI	unspecified	NSAID	inflammation
white blood cell migration inhibitors	unspecified	NSAID	inflammation; multiple sclerosis
ketoprofen, (R)-; (R)-ketoprofen	(R)-3-benzoyl-alpha-methylbenzeneacetic acid	NSAID	inflammation
limazocic; SA 3443	(R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4-carboxylic acid	NSAID	liver disease; inflammation; emphysema; intoxication
dexketoprofen; ketoprofen, (S)-; (S)-ketoprofen	(S)-3-benzoyl-alpha-methylbenzeneacetic acid	NSAID	inflammation
tioxamast; F 1865	[[4-(4-methoxyphenyl)-2-thiazolyl]amino]oxoacetic acid ethyl ester	NSAID	asthma; inflammation; skin disease

U 91502	[3-(1,6-dihydro-1-methyl-6-oxo-4-phenyl-2-pyrimidinyl)propylidene]bisphosphonic acid tetraethyl ester	NSAID	inflammation; arthritis
AO 1535	[R-[R*,S*-(E)]]-N-[1-[(beta-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecenyl]-3-pyridinecarboxamide	NSAID	skin disease; inflammation
DUP 983	1-(4-(4-pyridyl)phenyl)-1-(4-fluorophenyl)-2-imidazolyl-1-ethanol	NSAID	inflammation
acemetacin; TV 1322; TVX 1322; K 708; BAY F 4975; ANAGEL; FLAMARION; MOSTANOL; OLDAN; RANTUDIL; RANTUDAL; RUCATEN; SPORTIX; TILUR	1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid ester with glycolic acid	NSAID	inflammation
tropesin; indometacin tropine ester; tropine indometacinate; VUFB 12018; REPANIDAL	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-carboxy-2-phenylethyl ester	NSAID	inflammation
indometacin farnesil; indomethacin farnesyl; IM-F; E 0710; E 710; INFREE	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid, 3,7,11-trimethyl-2,6,10-dodecatrienyl ester	NSAID	inflammation
anti-inflammatory	1-(4-chlorophenyl)-1,3-dihydro-3,3-dimethyl-2H-pyrrolo(2,3-b)pyridine-2-one	NSAID	inflammation

tebufelone; NE 11740	1-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-5-hexyn-1-one	NSAID	inflammation
ibuprofen; AD 1590; DIBENON	10,11-dihydro- $\alpha$ ,8-dimethyl-11-oxodibenz[b,f]oxepin-2-acetic acid	NSAID	inflammation
zaltoprofen; CN 100; ZC 102; SOLETON; PEON	10,11-dihydro- $\alpha$ -methyl-10-oxodibenzo[b,f]thiepin-2-acetic acid	NSAID	inflammation; respiratory disease
YT 1	2-phenyl-4(1H)-quinolone	NSAID	inflammation
lonazolac; SNK 874; ARTHROAKUT; IRRITREN	3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-acetic acid	NSAID	inflammation
HWA 131	3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-7H-thiazolo[3,2-b][1,2,4]triazin-7-one	NSAID	inflammation
KF 18280	3-benzyl-5-phenyl-3H-imidazo(4,5-c)(1,8)naphthyridin-4(5H)-one	NSAID	inflammation
piroxicam cinnamate; SPA A510; SPA S510; CINNOXICAM; SINARTROL	3-phenyl-propenoic acid, 2-methyl-3-[(2-pyridinylamino)-carbonyl]-2 H-1,2-benzothiazin-4-yl ester, S,S-dioxide	NSAID	inflammation
eltenac; B 78820	4-(2,6-dichloroanilino)-3-thiopheneacetic acid	NSAID	inflammation
oxaprozin; WY 21743; DAYPRO; ACTIRIN; DURAPRO; DURAPROX; DAXPROZIN	4,5-diphenyl-2-oxazolepropanoic acid	NSAID	inflammation
anti-inflammatory	4-[(2-aminoethyl)amino]-1-(2-thienyl)-1-butanone	NSAID	inflammation



ximoprofen; XIFAM	4-[3-(hydroxyimino)cyclohexyl]-alpha-methylbenzenecetic acid	NSAID	inflammation
FK 3311	4'acetyl-2'-[2,4-difluorophenoxy]methanesulfonanilide	NSAID	inflammation
tenoxicam; Ro 12 0068; LIMAN; MITROTIL; TILCOTIL	4-hydroxy-2-methyl-N-2-pyridyl-2H-thieno[2,3-c]-1,2-thiazine-3-carboxamide 1,1-dioxide	NSAID	inflammation
anti-inflammatory	4-propylthio-o-anisidine	NSAID	inflammation
DUP 697	5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]thiophene	NSAID	inflammation
PD 144795	5-methoxy-3-(1-methylethoxy)-benzo[b]thiophene-2-carboxamide 1-oxide	NSAID	inflammation
droxicam; E 3128; OMBOLAN; FERPAN; DROGELON; PRECAM; DROBENAM; DROXAR	5-methyl-3-(2-pyridyl)-2H,5H-1,3-oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione-6,6-dioxide	NSAID	inflammation
decasilate	8-(2-phenylethyl)-1-oxa-diazaspiro[4.5]decan-2-one compound with 2-thiophenecarboxylic acid (1:1)	NSAID	allergy; inflammation
ibuprofen guaiacol; methoxybutropate; metoxybutropate; AF 2259; BENFLOGIN; BELEP	alpha-methyl-4-(2-methylpropyl)benzeneacetic acid 2-methoxyphenyl ester	NSAID	inflammation

amproxicam; CP 65703; FLUCAM; NACYL	ethyl 1-[[2-methyl-3-[(2-pyridinylamino)carbonyl]-2H-1,2-benzothiazin-4-yl]oxy] ethyl ester S,S-dioxide carbonic acid	NSAID	inflammation
Z 1957	ethyl N-((3-methyl-5-isoxazolyl)-2-thiazolyl) oxamate	NSAID	asthma; inflammation
adelmidrol; LG 21301	N,N'-bis(2-hydroxyethyl)nonane diamide	NSAID	inflammation; acne
andolast; CR 2039	N-4-(5-tetrazolyl)-phenyl-4-(5-tetrazolyl)-benzamide	NSAID	asthma; inflammation; allergy
salnacedin; G 201; SCY	N-acetyl-L-cysteine 2-hydroxybenzoate	NSAID	inflammation; skin disease
diclofenac potassium; CGP 45840B; CATAFLAM; CATAFLAN; DICLOFEN; VOLTAREN	potassium (o-(2,6-dichloroanilino)-phenyl)acetate	NSAID	inflammation; migraine; surgery
glucocorticoid receptor agonists,	unspecified	NSAID, glucocorticoid agonists	inflammation
CHF 2003	unspecified	NSAID; analgesic	pain; inflammation
drug delivery system, HIT diclofenac; diclofenac HIT; HYAL AT2101; HYAL CT1101; HYAL AV2201; HYAL AT1201; HYANALGESE; HYANALGESE-D; SOLARASE; ORALEASE	unspecified	NSAID; analgesic	pain; cancer; inflammation; skin disease; mucositis
drug delivery system, HIT ibuprofen; ibuprofen HIT; HYAL AT2102	unspecified	NSAID; analgesic	inflammation; pain

drug delivery system, HIT piroxicam; piroxicam HIT; HYAL AT2103	unspecified	NSAID; analgesic	inflammation; pain
drug delivery system, IPDAS ketoprofen; ketoprofen IPDAS; KETELAN	unspecified	NSAID; analgesic	inflammation; pain
drug delivery system, naproxen; naproxen, sustained release; IPDAS naproxen; NAPROLEN; NAPRELAN	unspecified	NSAID; analgesic	inflammation; pain
drug delivery system, oral transmucosal piroxicam; piroxicam oral transmucosal	unspecified	NSAID; analgesic	inflammation; pain
drug delivery system, transdermal diclofenac	unspecified	NSAID; analgesic	pain; inflammation
drug delivery system, transdermal fenoprofen; fenoprofen transdermal	unspecified	NSAID; analgesic	pain; inflammation
drug delivery system, transdermal flurbiprofen	unspecified	NSAID; analgesic	pain; inflammation
drug delivery system, transdermal ketoprofen	unspecified	NSAID; analgesic	inflammation; pain
drug delivery system, transdermal piroxicam; piroxicam transdermal	unspecified	NSAID; analgesic	pain; inflammation
polyunsaturated fatty acids, PUFA	unspecified	NSAID; analgesic	inflammation; pain
tilnoprofen arbamel; Y 23023	(+/-)-alpha-2-methyl- 5H- [1]benzopyran[2,3- b]pyridine-7-acetic acid, 2- (dimethylamino)-2- oxoethyl ester	NSAID; analgesic	inflammation; pain

dexketoprofen trometamol; LM 1158; TRIS; D 1158; ENANTYUM; QUIRALAM; KETESSE	(S)-3-benzoyl-alpha-methylbenzeneacetic acid cpd with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)	NSAID; analgesic	pain; inflammation
florifenine; FI 2522	2-(1-pyrrolidinyl)ethyl-N-[7-(trifluoromethyl)-4-quinolyl]anthranilate	NSAID; analgesic	inflammation; pain
aceclofenac; YT 919; AIRTAL; GERBIN; FALCOL; BRISTAFLAM; PRESERVEX; BIOFENAC; BARRACAN	2-[(2,6-dichlorophenyl)amino]benzeneacetic acid, carboxymethyl ester	NSAID; analgesic	pain; inflammation
bromfenac; bromfenac sodium; AHR 10282; DURACT	2-amino-3-(4-bromobenzoyl)benzeneacetic acid	NSAID; analgesic	inflammation; pain
mofezolac; N 22; DISOPAIN	3,4-bis(4-methoxyphenyl)-5-isoxazoleacetic acid	NSAID; analgesic	inflammation; pain
nabumetone; BRL 14777; RELIFEN; RELIFEX; LISTRAN; PRODAG; BALMOX; NABUMETON; RELAFEN	4-(6-methoxy-2-naphthyl)-2-butanone	NSAID; analgesic	pain; inflammation
piroxicam betadex; piroxicam cyclodextrin; CHF 1194; BREXIN; BREXINE; BREXIDOL; CYCLADOL; BREXICAM; BREXINIL	4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound with beta-cyclodextrin	NSAID; analgesic	pain; inflammation

HAI 105	6,11-dihydro-2-methoxy-alpha-methyl-11-oxodibenz[b,e]oxepin-3-acetic acid	NSAID; analgesic	pain; inflammation
tifurac; RS 82917; RS 82917030	7-[4-(methylthio)benzoyl]-5-benzofuranacetic acid	NSAID; analgesic	inflammation; pain
pelubiprofen; CS 670; RS 2131	alpha-methyl-4-[(2-oxocyclohexyllidene)methyl]benzeneacetic acid	NSAID; analgesic	inflammation; pain
HN 3392	N-(4-(4-methoxyphenyl)-5-phenylthiazolyl)	NSAID; analgesic	inflammation; pain
amtolmetin guacil; ST 679; MED 15; ARTROMED; EUFANS	N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl]glycine 2-methoxyphenyl ester	NSAID; analgesic	arthritis; rheumatoid arthritis; inflammation; pain
flosulide; ZK 38997; CGP 28238; CGS 28238; SH 459	N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	NSAID; analgesic	inflammation; pain
olvanil; oluvanil; NE 19550	N-vanillyloleamide	NSAID; analgesic	pain; inflammation; viral infection
AF 150	N,N,-dimethyl-N-[2-[2-[4-(2-methylpropyl)phenyl]-1-oxopropoxy]ethyl]-1-octanaminium bromide	NSAID; antibacterial	bacterial infection; inflammation
PS 519	unspecified	NSAID; anti-ischemic; proteinase inhibitor	inflammation; stroke
apoptosis modulators	unspecified	NSAID; apoptosis inhibitor; apoptosis inducer; caspase inhibitor	cancer; neuropathy; inflammation
CCR1 antagonists	unspecified	NSAID; chemokine antagonist	inflammation

CCR5 antagonists	unspecified	NSAID; chemokine antagonist	HIV infection; inflammation
CXCR3 antagonists	unspecified	NSAID; chemokine antagonist	inflammation
neurotactin blockers	unspecified	NSAID; chemokine antagonist; gene	multiple sclerosis; inflammation
complement C3a receptor modulators	unspecified	NSAID; complement inhibitor	inflammation
etodolac; RAK 591; AY 24236; NIH 9918; RAK 593; RAK 592; HYPEN; LODINE; ULTRADOL; ARFLOGIN; TEDOLAN; ETANAL; ANTILAK; EDINE; LODIO; OSTELUC	1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid	NSAID; COX inhibitor; COX 2 inhibitor	inflammation
immune system modulators,	unspecified	NSAID; immunosuppressant	inflammation
MKK3 modulators	unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation
MKK4 modulators	unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurodegeneration
VX 745	unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurological; heart failure; Crohn disease; asthma
isalsteine; TF 914	(+,-)-N-(2-((2-methyl-4-oxo-1,3-benzodioxan-2-yl)thio)propionyl)glycine	NSAID; mucolytic	respiratory disease; inflammation
NCX 284	unspecified	NSAID; nitric oxide donor	inflammation
nitrosylated nonsteroidal anti-inflammatory agent; NO-NSAIDs	unspecified	NSAID; nitric oxide donor	inflammation

ITF 1697	Unspecified	NSAID; peptide	septic shock; inflammation; heart ischemia; inflammatory bowel disease
misoprostol + diclofenac; diclofenac + misoprostol; ARTHROTEC	unspecified	NSAID; prostaglandin	inflammation
proteasome inhibitors, inflammation	unspecified	NSAID; transcription factor regulator	inflammation; cancer
recombinant PSGL 1, PSGL 1	unspecified	P selectin antagonist; E selectin antagonist; L selectin antagonist; selectin antagonist; NSAID	inflammation; transplant rejection; ischemia; reperfusion injury
BN 54068	unspecified	PAF antagonist; NSAID	inflammation
UR 12510	unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12519	unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12551	unspecified	PAF antagonist; NSAID	inflammation; asthma
BN 52111	1-(6-((2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy)-6-oxohexyl)-pyridinium bromide	PAF antagonist; NSAID	asthma; inflammation
tiapafant; PCA 4248	1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid methyl 2-(phenylthio)ethyl ester	PAF antagonist; NSAID	asthma; inflammation
BN 52115	1-[6-[(2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy]-6-oxohexyl]quinolinium bromide	PAF antagonist; NSAID	asthma; inflammation

UR 10324	2-(2-acetyl-3,11-dioxo-4,10-dioxo-7-thia-2,12-diazanonacos-1-yl)-1-ethylpyridinium chloride	PAF antagonist; NSAID	inflammation; asthma
tetrahydrocarbazole	4-(2-chlorophenyl)-9-methyl-2-[3-(1,2,3,4-tetrahydro-9H-carbazol-9-yl)-1-propynyl]-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist; NSAID	inflammation; asthma
UR 12460	4-[[[(diphenylmethyl)amino]acetyl]-alpha-(2-methyl-3-pyridinyl)-1-piperazineacetonitrile	PAF antagonist; NSAID	inflammation; asthma
SM 10661	cis-(+,-)-3,5-dimethyl-2-(3-pyridinyl)-4-thiazolidinone monohydrochloride	PAF antagonist; NSAID	endotoxic shock; inflammation; asthma
CV 6209	2-(2-acetyl-6-methoxy-3,9-dioxo-4,8-dioxo-2,10-diazaoctacos-1-yl)-1-ethylpyridinium chloride	PAF antagonist; platelet antiaggregant; NSAID	thrombosis; inflammation
UR 11353	2-[[[acetyl][[tetrahydro-5-(octadecyloxy)-3-furanyl]methoxy]carbonyl]amino]methyl]-1-ethylpyridinium chloride	PAF antagonist; platelet antiaggregant; NSAID	thrombosis; inflammation
urokinase receptor antagonists	unspecified	peptide	cancer; inflammation
MER W8020	Unspecified	peptide; analgesic; NSAID	inflammation; pain
inflammation therapy, autoimmune disease therapy,	Unspecified	peptide; immunosuppressant	inflammation; autoimmune disease



CD4 peptide antagonist,	unspecified	peptide; immunosuppressant; NSAID	inflammation
cytochrome b558 derived peptide, anti-inflammatory peptide	unspecified	peptide; NSAID	inflammation
CEN 294	unspecified	peptide; NSAID	inflammation; ischemia; reperfusion injury
corticotropin releasing factor analogue, CRF analogue	unspecified	peptide; NSAID	inflammation
inflammation therapy	unspecified	peptide; NSAID	inflammation
mystixins	unspecified	peptide; NSAID	inflammation
LAS 31396	unspecified	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
arofylline; LAS 31025	3-(4-chlorophenyl)-3,7-dihydro-1-propyl-1H-purine-2,6-dione	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
CDP 840	(R)-4-[2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-phenylethyl]pyridine	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; inflammation
phosphodiesterase IV inhibitor	unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; NSAID	inflammation
B669	3-(cyclohexylimino)-3,5-dihydro-N,5-diphenyl-2-phenazinamine	phospholipase activator; immunosuppressant; NSAID	inflammation
phospholipase C inhibitors	unspecified	phospholipase inhibitor; NSAID	inflammation
WAY 121520	1-[(4-chlorophenyl)methyl]-2-methyl-5-(2-quinolinylmethoxy)-1H-indole-3-acetic acid	phospholipase inhibitor; NSAID	inflammation

BMS 188184	3-[(1Z,2Z)-3-carboxy-2-methyl-1-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)methylene]-2-propenyl]benzoic acid	phospholipase inhibitor; NSAID	psoriasis; dermatitis; inflammation
YM 26734	4-(3,5-didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman	phospholipase inhibitor; NSAID	inflammation
YM 265671; YM 26567-1	trans-(+)-1-[3-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxyphenyl]-1-dodecanone	phospholipase inhibitor; NSAID	inflammation
U 73122	1-[6-[[[(17 beta)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]	phospholipase inhibitor; platelet antiaggregant; NSAID	inflammation; thrombosis
plasminogen activator inhibitor; PAI-2	unspecified	plasminogen activator inhibitor; cicatrizant	cancer; inflammation; skin ulcer
drug delivery system, MICROPUMP oral controlled release aspirin; aspirin MICROPUMP; ASACARD	unspecified	platelet antiaggregant; thromboxane synthetase inhibitor; analgesic; NSAID	thrombosis; pain; inflammation
cyclic polyamine analogue	unspecified	polyamine analogue; NSAID	Crohn disease; asthma; inflammation
anti-inflammatory agents	unspecified	protein kinase inhibitor; cytokine inhibitor; TNF inhibitor	inflammation
Ro 318830	unspecified	protein kinase inhibitor; protein kinase C inhibitor; NSAID	inflammation

SPC 100840	unspecified	protein kinase inhibitor; protein kinase C inhibitor; NSAID	ischemia; psoriasis; cancer; inflammation; reperfusion injury
UCN 01; UCN 1; KW 2401	(3 $\alpha$ ,9 $\beta$ ,10 $\alpha$ ,11 $\alpha$ ,13 $\beta$ )-(+)-2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; allergy
balanol; (-)-balanol; azepinostatin; ophiocordin	(3R-trans)-4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxybenzoic acid 1-[hexahydro-3-[(4-hydroxybenzoyl)amino]-1H-azepin-4-yl] ester	protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; psoriasis
GF 109203X; Go 6850	3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione	protein kinase inhibitor; protein kinase C inhibitor; NSAID	inflammation
LEX 028	unspecified	proteinase inhibitor; cathepsin G inhibitor; NSAID	inflammation
cathepsin S inhibitors	unspecified	proteinase inhibitor; cathepsin S inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease
APC 1403	unspecified	proteinase inhibitor; NSAID	inflammation
LEX 026	unspecified	proteinase inhibitor; serine proteinase inhibitor	thrombosis; inflammation

LEX 043	unspecified	proteinase inhibitor; serine proteinase inhibitor	inflammation; asthma
BCX 1170	unspecified	proteinase inhibitor; serine proteinase inhibitor; complement inhibitor; NSAID	cardiovascular disease; inflammation
neutral endopeptidase; NEP	unspecified	proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
anti-inflammatory	unspecified	rac inhibitor; RAS inhibitor; signal transduction inhibitor; NSAID	inflammation
secretory cell inhibitors, CAMR	unspecified	secretory cell inhibitors	allergy; inflammation; respiratory disease
BCX 1470	unspecified	serine proteinase inhibitor; complement inhibitor; NSAID; proteinase inhibitor	cardiovascular disease; inflammation
complement inhibitors	unspecified	serine proteinase inhibitor; NSAID; complement inhibitor; proteinase inhibitor	inflammation; myocardial infarction; reperfusion injury; respiratory distress syndrome
p-38-2 inhibitor	unspecified	signal transduction inhibitor; NSAID	inflammation; ischemia
SP 100030	Unspecified	signal transduction inhibitor; NSAID; immunosuppressant	inflammation; autoimmune disease
dapitant; RPR 100893	[3aS-[2(R*),3aalpha,4beta,7aalpha]]-octahydro-4-(2-methoxyphenyl)-2-[2-(2-methoxyphenyl)-1-oxopropyl]-7,7-diphenyl-1H-isoindol-4-ol	substance P antagonist; NSAID	asthma; inflammation; migraine
screening technology, cox-2 gene suppression	unspecified	target based screening; biotechnology	drug design technology; inflammation; cancer

TGF beta antagonists; transforming growth factor beta antagonists	unspecified	TGF beta antagonist; cicatrizant	cancer; viral infection; inflammation; skin ulcer
thrombospondin inhibitor	unspecified	thrombospondin inhibitor; peptide; NSAID	inflammation; cancer; sickle cell anemia
tumor necrosis factor binding protein; TBP-1; TBP	unspecified	TNF inhibitor; immunosuppressant	autoimmune disease; reperfusion injury; inflammation; septic shock
tumor necrosis factor binding protein; TNFbp	unspecified	TNF inhibitor; NSAID	septic shock; inflammation
tumor necrosis factor inhibitors	unspecified	TNF inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease
tumor necrosis factor receptor inhibitors	unspecified	TNF inhibitor; NSAID	septic shock; inflammation
A 802715	3,7-dihydro-1-(5-hydroxy-5-methylhexyl)-3-methyl-7-propyl-1H-purine-2,6-dione	TNF inhibitor; NSAID	inflammation; septic shock
peptide T, natural; peptide T	N-[N-[N2-[N-[N-(N-L-alanyl-L-seryl)-L-threonyl]-L-threonyl]-L-threonyl]-L-asparaginy]-L-tyrosyl]-L-threonine	TNF inhibitor; peptide; NSAID	HIV infection; psoriasis; inflammation
transcription factor inhibitors	unspecified	transcription factor regulator	inflammation; autoimmune disease
NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	asthma; inflammation; restenosis
NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	inflammation; ischemia; cancer; autoimmune disease
AP-1 inhibitor; JNK inhibitor	unspecified	transcription factor regulator; NSAID; immunosuppressant	inflammation; autoimmune disease; cancer

ademetionine; FO 1561; GUMBARAL; DONAMET; TRANSMETIL; CERITAN; ERGEN; TWIN; SAMY R	(3S)-5'-[(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine hydroxide inner salt	transmethylator; NSAID	inflammation; cognitive defect; cholestasis
tryptase inhibitors	unspecified	tryptase inhibitor; NSAID	asthma; inflammation; rhinitis; inflammatory bowel disease; psoriasis
UBC inhibitors; ubiquitin conjugating enzyme inhibitors	unspecified	ubiquitin conjugating enzyme inhibitor; NSAID	cancer; inflammation
non-ionic surfactant vesicles; NISV	unspecified	vaccine adjuvant; immunosuppressant	rheumatoid arthritis; asthma; inflammation
vaccine, gene-based, autoimmune disease	unspecified	vaccine; gene therapy	autoimmune disease; inflammation

Table 45. Current Candidate Therapeutic Interventions for the Treatment of Psoriasis

Product Name	Chemical Name	Action	Indication
masoprocol; CHX 100; ACTINEX	(R*,S*)-4,4'-(2,3-dimethyl-1,4-butanediyl)bis-1,2-benzenediol	5 lipoxygenase inhibitor	skin disease; cancer; psoriasis
WY 47288	2-[(1-naphthalenyloxy)methyl]quinoline	5 lipoxygenase inhibitor	psoriasis
enazadrem; enazadrem phosphate; CP 70490; CP 7049009	4,6-dimethyl-2-[(6-phenylhexyl)amino]-5-pyrimidinol	5 lipoxygenase inhibitor	psoriasis
lonapalene; RS 43179	6-chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate	5 lipoxygenase inhibitor	psoriasis
R 85355	Unspecified	5 lipoxygenase inhibitor	asthma; psoriasis; inflammatory bowel disease
BW 4C; BW A4C; BW 4C86	N-(3-phenoxy-phenyl-2-propenyl)acetohydroxamic acid	5 lipoxygenase inhibitor; chelating agent; NSAID	arthritis; psoriasis

CGS 23885	unspecified	5 lipoxygenase inhibitor; NSAID	psoriasis; inflammation
SC 45662	unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis; inflammatory bowel disease
DUP 654	(2-phenylmethyl)-1-naphthalenol	5 lipoxygenase inhibitor; NSAID	psoriasis; inflammation
L 663536; MK 886	1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-alfa,alfa-diethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis
SCH 40120	10-(3-chlorophenyl)-6,8,9,10-tetrahydrobenzo[b][1,8]naphthyridin-5(7H)-one	5 lipoxygenase inhibitor; NSAID	inflammation; psoriasis
AE 941; NEOVASTAT; NEORETNA; PSOVASCAR; ARTHROVAS	unspecified	angiogenesis inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; eye disease; retinopathy
glycopine; glucosaminylmuramyl dipeptide; GMDP; LICOPID; LIKOPID	N2-[N-[N-acetyl-4-O-[2-(acetilamino)-2-deoxy-beta-D-glucopyranosyl]muramoyl]-L-alanyl]-D-alpha-glutaminc	antibiotic; vaccine adjuvant; immunostimulant; glycopeptide	psoriasis; cancer; leukopenia; septic shock; infectious disease; eye disease
liarozole; liarozole hydrochloride; liarozole fumarate; R 75251; R 85246; LIAZAL	5-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-1H-benzimidazole	antifungal; androgen synthesis inhibitor; imidazole	cancer; psoriasis
taxoids	unspecified	Antihyperproliferative agent	psoriasis
drug delivery system, psoriasis therapy, P 37	unspecified	Antikeratinocyte activity	psoriasis

drug delivery system, fluorouracil; fluorouracil Therapeutic Implant; MPI 5003	unspecified	antimetabolite	cancer; psoriasis; viral infection
drug delivery system, topical methotrexate; methotrexate topical	unspecified	antimetabolite	psoriasis
ZYN-LINKER conjugated methotrexate	unspecified	antimetabolite; NSAID	cancer; rheumatoid arthritis; psoriasis
drug delivery system, stabilized lipid dithranol; dithranol stabilized lipid; MICANOL	unspecified	Antimitotic	psoriasis
TV 2801	Anthralin derivative	antimitotic	psoriasis
TV 2802	Anthralin derivative	antimitotic	psoriasis
trimethylangelicin; TMA; 4,4',6-trimethylangelicin; 4,6,4'-trimethylangelicin	4,6,9-trimethyl-2H-furo[2,3-h]-1-benzopyran-2-one	Antiporliferative agent	psoriasis
topical antiproliferative agents	unspecified	antiproliferative agent	psoriasis
SDZ LAP977	5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxybenzoic acid methyl ester	antiproliferative agent	psoriasis
maxacalcitol; 22-oxacalcitriol; oxacalcitriol; OCT; MC 1275	[1S-[1alfa(R*),3abeta,4E(1S*,3R*,5Z),7aalfa]]-4-methylene-5-[2-octahydro-1-[1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	antiproliferative agent; vitamin D3 analogue	hyperparathyroidism; psoriasis
drug delivery system, NOVASOME topical anthralin; anthralin, topical NOVASOME	unspecified	Antimitotic; DNA syntesis inhibition; topical agent	psoriasis



E2F inhibitors	unspecified	apoptosis inducer; antiproliferative agent	cancer; psoriasis; viral infection; restenosis
iroplact; platelet factor 4; PF4; endostatin B; REPLISTATIN	unspecified	biotechnology	heparin neutralization; psoriasis; HIV infection; cancer; diabetes
senescence derived inhibitor 1; Sdi 1	unspecified	biotechnology; cyclin dependent kinase inhibitor	cancer; psoriasis; eye disease; cancer
sonermin; tumor necrosis factor; TNF; PAC 4D	3-157-tumor necrosis factor (human)	biotechnology; cytokine	cancer; psoriasis
interleukin-8 receptor; IL-8r	unspecified	biotechnology; cytokine antagonist; NSAID	psoriasis; rheumatoid arthritis; respiratory distress syndrome; septic shock
interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	biotechnology; cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
epidermal growth factor diphtheria toxin chimeric protein; EGF diphtheria toxin chimeric protein; EGF fusion protein; DAB 389-EGF; DAB 389-EGF	unspecified	biotechnology; fusion toxin	cancer; restenosis; psoriasis
denileukin diftotox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL- 2; LY 335348; DAB389IL2; ONTAK	1-388-toxin (Corneybacterium diphtheriae strain C7), N-L-methionyl- 387-L-histidine-388- L-alanine-, (388.fwdarw.2')- protein with 2-133- interleukin 2 (human clone pTIL2-21a)	biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer

polyethylene glycol transforming growth factor beta2; PEG-TGF beta2; transforming growth factor beta2 macrogol	unspecified	biotechnology; growth factor	osteoporosis; psoriasis; eye disease
MAB, humanized B7.1	unspecified	biotechnology; immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MAB, humanized B7.2	unspecified	biotechnology; immunosuppressant	psoriasis; transplant rejection; autoimmune disease
MEDI 507	unspecified	biotechnology; immunosuppressant	autoimmune disease; transplant rejection; psoriasis
antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) DNA	biotechnology; immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma
BMS 188667; CTLA4Ig	unspecified	biotechnology; immunosuppressant; NSAID	transplant rejection; systemic lupus erythematosus; psoriasis; arthritis; allergy
leukocyte function associated antigen 3 T cell inhibitor protein; LFA3TIP; LFA3TIP; AMEIVE	unspecified	biotechnology; immunosuppressant; NSAID	inflammation; autoimmune disease; psoriasis
MAB, CD11a; hu 1124	unspecified	biotechnology; monoclonal antibody; immunosuppressant	psoriasis; transplant rejection
MAB, humanized CD3; MAB, SMART CD3; HuM291	unspecified	biotechnology; monoclonal antibody; immunosuppressant	transplant rejection; autoimmune disease; psoriasis

clenoliximab; MAb, CD4; MAb, PRIMATIZED CD4; IDEC 151; SB 217969	immunoglobulin G 4 (human-Macaca monoclonal CE9gamma4PE gamma4-chain anti-human antigen CD4), disulfide with human-Macaca monoclonal CE9gamma4PE kappa-chain, dimer	biotechnology; monoclonal antibody; NSAID	rheumatoid arthritis; psoriasis; asthma
MAb, B7; MAb, PRIMATIZED B7; IDEC 114	unspecified	biotechnology; monoclonal antibody; NSAID; immunosuppressant	systemic lupus erythematosus; inflammation; transplant rejection; psoriasis
MAb, idiotypic GD2; vaccine, cancer; cancer vaccine	unspecified	biotechnology; monoclonal antibody; vaccine	cancer; psoriasis
oligonucleotides, psoriasis	unspecified	biotechnology; oligonucleotide	psoriasis
oligonucleotides,	unspecified	biotechnology; oligonucleotide; ribozyme	cancer; psoriasis
vaccine, psoriasis; vaccine, T cell receptor; IR 502	unspecified	biotechnology; vaccine	psoriasis
CDF inhibitor	unspecified	CDF inhibition; inhibition of cdc25C	cancer; psoriasis
SPC 101210	unspecified	ceramide	psoriasis
SPC 103600	unspecified	ceramide regulator	psoriasis
differentiation-inducing compounds	unspecified	Control of cell differentiation	cancer; psoriasis; restenosis
AGN 191743	unspecified	corticosteroid	psoriasis
anti-inflammatory corticosteroids	unspecified	corticosteroid	psoriasis; asthma
auranofin + betamethasone dipropionate; betamethasone dipropionate + auranofin	unspecified	corticosteroid	psoriasis

drug delivery system, betamethasone ViaFoam mousse; betamethasone ViaFoam mousse; BETAMOUSSE; LUXIQ	unspecified	corticosteroid	psoriasis; dermatitis
drug delivery system, clobetasol ViaFoam mousse; clobetasol ViaFoam mousse; OLUX	unspecified	corticosteroid	psoriasis
drug delivery system, liposome clobetasol; clobetasol liposome; LipoFORT	unspecified	corticosteroid	psoriasis
drug delivery system, topical DermaStick betamethasone dipropionate; betamethasone propionate DermaStick; DermaStick	unspecified	corticosteroid	psoriasis
mometasone furoate + salicylic acid; COMBISOR	unspecified	corticosteroid	psoriasis
prednicarbate; HOE 777; S 770777; DERMATOP; PREDNITOP	(11beta)-17- [(ethoxycarbonyl)oxy ]-11-hydroxy-21-(1- oxopropoxy)-pregna- 1,4-diene-3,20-dione	corticosteroid	psoriasis
mometasone furoate; mometasone; S 2640; SCH 32088; ELOCOM; ELOCON; FULMETA; ECURAL; ERMIL; NASONEX; ASMANEX	(11beta,16alpha)- 9,21-dichloro-17-[(2- furanylcarbonyl)oxy]- 11-hydroxy-16- methyl-pregna-1,4- diene-3,20-dione	corticosteroid	dermatitis; asthma; rhinitis; psoriasis; pruritis

tipredane; SQ 27239	(11beta,17alpha)-17-(ethylthio)-9-fluoro-11-hydroxy-17-(methylthio)androst-1,4-diene-3-one	corticosteroid	inflammation; psoriasis
ulobetasol propionate; halobetasol propionate; CGP 14458; BMY 30056; ULTRAVATE	(6alpha,11beta,16beta)-21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione	corticosteroid	skin disease; inflammation; psoriasis
FPL 62064	N-(4-methoxyphenyl)-1-phenyl-1H-pyrazole-3-amine	COX inhibitor; 5 lipoxygenase inhibitor	inflammatory bowel disease; psoriasis
RU 46057	2-[1,2-bis(1-oxopropoxy)ethyl]-4-hydroxy-N-2-thiazolyl-8-(trifluoromethyl)-3-quinolinecarboxamide	COX inhibitor; 5 lipoxygenase inhibitor; NSAID	arthritis; psoriasis
RP 54745	4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinoliny)-3H-1,2-dithiol-3-one	cytokine antagonist; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; psoriasis
interleukin-8 antagonists	unspecified	cytokine antagonist; NSAID	rheumatoid arthritis; psoriasis; atherosclerosis
ETH 615	4-[[[(3-fluorophenyl)methyl]-4-(2-quinolinylmethoxy)phenyl]amino]methylbenzoic acid	cytokine synthesis inhibitor	psoriasis
BMY 30094	N-hydroxybenzenenonamide	cytokine synthesis inhibitor; NSAID	inflammation; psoriasis
amlexanox; amoxanox; CHX 3673; AA 673; SOLFA; ELICS; APHTHASOL	2-amino-7-(1-methylethyl)-5-oxo-5H-[1]-benzopyrano[2,3-b]pyridine-3-carboxylic acid	degranulation inhibitor	asthma; psoriasis; rhinitis; mucositis; conjunctivitis; allergy

alitretinoin; LGD 1057; LG 1057; LGN 1057; ALRT 1057; NSC 659772; PANRETIN	9-cis-retinoic acid	differentiation inducer; retinoid agonist; RAR agonist; RXR agonist	cancer; psoriasis
psoriasis therapy	unspecified	dihydrofolate reductase inhibitor	psoriasis
dihydrofolate reductase inhibitor, psoriasis	unspecified	dihydrofolate reductase inhibitor; antifolate	psoriasis
trimetrexate; trimetrexate glucuronate; TMQ; NSC 249008; CI 898	5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolin-2-ylidene	dihydrofolate reductase inhibitor; antifolate; NSAID	cancer; psoriasis; rheumatoid arthritis; pneumocystis
drug delivery system, methotrexate; methotrexate delivery system; G 301	unspecified	Dihydrofolic acid reductase inhibition; cytotoxic	psoriasis
drug delivery system, topical methotrexate; methotrexate, topical; CHX 150	unspecified	Dihydrofolic acid reductase inhibition; cytotoxic	psoriasis
psoriasis therapy	unspecified	EGF receptor inhibitor	psoriasis
ALP 242	unspecified	elastase inhibitor; proteinase inhibitor	asthma; emphysema; psoriasis
efomycines	unspecified	Endothelium mediated antiadhesive properties	psoriasis
psoriasis enzyme therapy	unspecified	enzyme	psoriasis
fibroblast growth factor antagonist	unspecified	FGF antagonist; angiogenesis inhibitor	cancer; retinopathy; psoriasis
free radical scavengers	unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301	unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
beta-glucan antagonist	unspecified	glucan antagonist	conjunctivitis; asthma; psoriasis; ulcerative colitis

SU 5271	unspecified	growth factor modulator; signal transduction inhibitor; EGF receptor inhibitor	psoriasis
epinastine; WAL 801; WAL 801CL; ALESION	9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepin-3-amine	histamine antagonist; histamine H1 antagonist	allergy; asthma; psoriasis; rhinitis
psoriasis therapy	unspecified	Immunomodulation	psoriasis
drug delivery system, HILT, ciclosporin; ciclosporin, HILT, psoriasis; CYCLOPS	unspecified	immunosuppressant	psoriasis
drug delivery system, liposome ciclosporin; ciclosporin liposome; LipoSPOR	unspecified	immunosuppressant	psoriasis
VX 497	unspecified	immunosuppressant	psoriasis; autoimmune disease; viral infection; hepatitis
PRO 2844	(OC-6-22)-pentaamine(4-methylpyridine)ruthenium(3+) trichloride	immunosuppressant	psoriasis; autoimmune disease; transplant rejection
SDZ 281240	unspecified	immunosuppressant; macrolide; antibiotic	psoriasis
PIC 060 analogs	unspecified	immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
VX 10393	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
VX 10428	unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
laflunimus; HR 325	(Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl]-2-propenamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; psoriasis

CI 972	2,6-diamino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; cancer; psoriasis
amiprilose; amiprilose hydrochloride; THN; SM 1213; KAP 690; THERAFECTIN	3-O-(3-(dimethylamino)propyl)-1,2-O-isopropylidene- $\alpha$ -D-glucofuranose hydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; psoriasis
atiprimod; atiprimod dimaleate; SKF 106615	N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine	immunosuppressant; NSAID; macrophage inhibitor	rheumatoid arthritis; autoimmune disease; psoriasis
ABT 281; A 86281	unspecified	Immunosuppression like tacrolimus ; ao systemic side effects	psoriasis
MAB, ICAM-3; MAB, intracellular adhesion molecule-3; MAB, ICAM-R; ICM3	unspecified	integrin antagonist; biotechnology; cell adhesion inhibitor; immunosuppressant; monoclonal antibody	autoimmune disease; psoriasis
alphaE beta7 antagonists	unspecified	integrin antagonist; cell adhesion inhibitor	asthma; psoriasis; inflammatory bowel disease
TBC 427	unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor	ischemia; psoriasis; respiratory distress syndrome; transplant rejection; reperfusion injury
SCHAL 3	unspecified	Ion transport modulation	skin disease; cancer; psoriasis
antiproliferative agents	unspecified	Ion transport modulation; antiproliferative	Cancer; psoriasis
sumarotene; Ro 149706	(E)-1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-[1-methyl-2-[4-(methylsulfonyl)phenyl]ethenyl]naphthalene	keratolytic	psoriasis



VML 262	unspecified	Leukotriene B4 antagonist	psoriasis
SC 52798	(+)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis; ulcerative colitis
SC 53228; (+)-SC 51146	(S)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-[(methylamino)carbonyl]phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis
LY 293111; VML 295	2-[3-[3-[(5-ethyl-4-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]2-propylphenoxy]-benzoic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis
SM 15178	3-[[[2-[[[2-ethyl-4-(1-oxoethyl)-5-hydroxyphenyl]oxy]methyl]pyridin-6-yl]carbonyl]ethylamino]propanoic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis; inflammatory bowel disease
SC 41930	7-[3-(-4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis

WF 11605	(1S,1R,4aS,6aR,8R,9R,10aS,12aS)-9-acetoxy-2-((R)-1,2dimethylpropyl)-8-(beta-D-glucopyranosyl)oxy-1,2,3,4,4a,5,6,6a,7,8,9,10,10a,11,12,12a-hexadecahydro-2,4a,7,7,10a,12a,hexamethyl-3-oxochrysene-1-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	hepatitis; inflammation; psoriasis
SB 201993	(E)-3-[[[6-(2-carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	psoriasis; inflammation
tiolubant; SB 209247	(E)-3-[6-[[2,6-dichlorophenyl]thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenoic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation; psoriasis
RP 64966	2-((4-(5-(3-phenylpropyl)-2-thienyl)butyl)oxy)acetic acid (sodium salt)	leukotriene B4 antagonist; leukotriene antagonist; NSAID	inflammation; psoriasis; inflammatory bowel disease
SC 50605	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	psoriasis; inflammation

SC 51146	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; psoriasis; rheumatoid arthritis; inflammatory bowel disease
immunosuppressant	Monoclonal antibody	Monoclonal antibody to complement	psoriasis
MAb, interleukin-8; MAb, IL-8; ABX IL8	unspecified	monoclonal antibody; biotechnology; NSAID	respiratory distress syndrome; inflammatory bowel disease; rheumatoid arthritis; inflammation; psoriasis
IPL 400; SORTAC	unspecified	NSAID	psoriasis
IPL 576; IZP 94005	unspecified	NSAID	psoriasis; allergy; inflammation
pseudopterosin	unspecified	NSAID	arthritis; asthma; psoriasis
2-CdAP	2-chloro-2'-deoxy-5'-adenylic acid disodium salt	nucleoside analogue	psoriasis
CMI 392	trans-2-[5-(N'-methyl-N'-hydroxyureidylmethyl)-3-methoxy-4-p-chlorophenylthioethoxyphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran	PAF antagonist; leukotriene antagonist	psoriasis; dermatitis; asthma
drug delivery system, SEPA peptide T; peptide T SEPA	unspecified	peptide; TNF inhibitor	psoriasis
transglutaminase inhibitor	unspecified	peptide; transglutaminase inhibitor	psoriasis; Alzheimer disease
IC 351; GF 196960; GG 960	unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	heart failure; angina; sexual dysfunction; psoriasis

BMS 181162	(Z,E,Z,E)-3-[1-(2-carboxy-1-methylethenyl)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3,5-hexatrienyl]benzoic acid	phospholipase inhibitor	psoriasis; dermatitis
phospholipase A2 inhibitors	unspecified	phospholipase inhibitor; NSAID	asthma; rheumatoid arthritis; psoriasis; inflammatory bowel disease
BMS 188184	3-[(1Z,2Z)-3-carboxy-2-methyl-1-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)methylene]-2-propenyl]benzoic acid	phospholipase inhibitor; NSAID	psoriasis; dermatitis; inflammation
bergapten; 5-methoxypsoralen; 5-MOP; GERALEN; PSORADERM 5; GEROXALEN	unspecified	photosensitizer	psoriasis
hypericin; VIMRxyn; CYCLO-WERROL; CYCLOSAN	1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione	photosensitizer	psoriasis; cancer
aminolevulinic acid, photodynamic therapy; 5-ALA PDT; LEVULAN	unspecified	photosensitizer; contrast medium	psoriasis; skin disease; endometriosis; cancer; diagnosis
verteporfin; benzoporphyrin derivative; BPD-MA; CL 318952; BPDR; VISUDYNE	trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropionic acid monomethyl ester	photosensitizer; NSAID	cancer; psoriasis; arthritis; retinopathy

diethylhomospermine; DEHOP; DE 444	N,N'-bis[4-(ethylamino)butyl]-1,4-butanediamine	polyamine analogue	diarrhea; hypertension; cancer; psoriasis; ulcerative colitis
diethylnorspermine; DENSPM; CI 1006; DE 333	N1,N11-diethylnorspermine	polyamine analogue	cancer; psoriasis; Alzheimer disease
protein kinase C inhibitor, microalgal	unspecified	protein kinase inhibitor; protein kinase C inhibitor	cancer; psoriasis
safingol; safingol hydrochloride; SPC 100270; mSPC 100271; KYNAC; KYNACYTE	(2S,3S)-2-amino-1,3-octadecanediol	protein kinase inhibitor; protein kinase C inhibitor	psoriasis; dermatitis; cancer
CPR 1006	4-hydroxy-7-(1H-imidazol-1-yl)-N,N,N-trimethyl-3,5,9-trioxa-4-phosphaheptacosan-1-aminium, 4-oxide, inner salt	protein kinase inhibitor; protein kinase C inhibitor; ether lipid	psoriasis
SPC 100840	unspecified	protein kinase inhibitor; protein kinase C inhibitor; NSAID	ischemia; psoriasis; cancer; inflammation; reperfusion injury
balanol; (-)-balanol; azepinostat;in; ophiocordin	(3R-trans)-4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxybenzoic acid 1-[hexahydro-3-[(4-hydroxybenzoyl)amino]-1H-azepin-4-yl] ester	protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; psoriasis
alpha-1-antitrypsin	unspecified	proteinase inhibitor; biotechnology	asthma; emphysema; cystic fibrosis; dermatitis; psoriasis
peldesine; BCX 34; BCX 34B	2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection

purine nucleoside phosphorylase inhibitors, PNP inhibitors, Chiroscience	unspecified	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
CI 1000; PD 141955	2-amino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis
cancer therapy, retinoids	unspecified	retinoid	cancer; psoriasis
retinoids	unspecified	retinoid	psoriasis; acne
acitretin; etretin; etretinate free acid; Ro 101670; Ro 101670000; NEOTIGASON; SORIATANE	(all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid	retinoid	psoriasis
tazarotene; AGN 190168; ZORAC; TAZORAC	6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester	retinoid	acne; cancer; psoriasis
tamibarotene; AM 80	4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]benzoic acid	retinoid agonist	psoriasis; cancer
AM 580	4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]amino]benzoic acid	retinoid agonist	psoriasis; cancer
ER 38925	4-[5-(4,7-dimethyl-2-benzofuranyl)-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
ER 65250	4-[5-(7-ethyl-4-methyl-2-benzofuranyl)-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis

ER 69029	4-[5-[7-fluoro-4-(trifluoromethyl)-2-benzofuranyl]-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
bexarotene; LGD 1069; LG 100069; LG 1069; LDG 1069; TARGRETIN	4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthenyl)-1-ethenyl]-benzoic acid	retinoid agonist; retinoid; differentiation inducer; RXR agonist	cancer; diabetes; psoriasis; skin disease
AGN 4310; ALRT 4310	unspecified	retinoid antagonist	psoriasis; cancer
ALRT 1109	unspecified	retinoid antagonist; RAR antagonist	psoriasis
lanreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSTYL	3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2,7)-disulfide	somatostatin analogue	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
AG 85	1-[[4-[[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-propynylamino]phenyl]sulfonyl]-1H-indole	thymidylate synthase inhibitor	psoriasis
ITF 1779	unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease

peptide T, natural; peptide T	N-[N-[N2-[N-[N-[N- (N-L-alanyl-L-seryl)- L-threonyl]-L- threonyl]-L-threonyl]- L-asparaginy]-L- tyrosyl]-L-threonine	TNF inhibitor; peptide; NSAID	HIV infection; psoriasis; inflammation
APC 2059	unspecified	tryptase inhibitor	inflammatory bowel disease; psoriasis
oral tryptase inhibitors	unspecified	tryptase inhibitor	inflammatory bowel disease; asthma; psoriasis
tryptase inhibitors	unspecified	tryptase inhibitor; NSAID	asthma; inflammation; rhinitis; inflammatory bowel disease; psoriasis
tyrphostins	unspecified	tyrphostin	psoriasis; cancer; atherosclerosis; septic shock
AG 555	(2E)-2-cyano-3-(3,4- dihydroxyphenyl)-N- (3-phenylpropyl)-2- propena mide	tyrphostin	psoriasis; cancer; atherosclerosis
AG 213; RG 50964; tyrphostin AG 213; RG 50864 (no stereo)	(E)-2-cyano-3-(3,4- dihydroxyphenyl)-2- propenethioamide	tyrphostin	psoriasis; cancer; atherosclerosis
CHX 108	unspecified	Unspecified	psoriasis
P 53	unspecified	Unspecified	psoriasis; pruritis
SM 10193	unspecified	Unspecified	psoriasis
T 511	Azelaic acid analogue	unspecified	psoriasis
vaccine, PVAC, psoriasis; psoriasis vaccine	unspecified	vaccine	psoriasis
CPR 2005	unspecified	vitamin D analogue	psoriasis
drug delivery system, vitamin D derivatives	unspecified	vitamin D analogue	psoriasis
SH 597	unspecified	vitamin D analogue	psoriasis
calcipotriol; calcipotriene; MC 903; BMS 181161; DAIVONEX; DOVONEX; PSORCUTAN	(1alfa,3beta,5Z,7E,22 E,24S)-24- cyclopropyl-9,10- secochola- 5,7,10(19),22- tetraene-1,3,24-triol	vitamin D analogue	psoriasis



EL 715	unspecified	vitamin D2 analogue	psoriasis; osteoporosis; osteodystrophy
1-alpha-D-hydroxycholecalciferol	unspecified	vitamin D3 analogue	psoriasis
drug delivery system, polymer, ST 630; ST 630 polymer	unspecified	vitamin D3 analogue	psoriasis
tacalcitol; 1 alpha,24(R)-dihydrocholecalciferol; 1,24(R)-dihydroxyvitamin D3; TV 02; BONALFA; CURATODERM	(+)-(5Z,7E,24R)9,10-secocholesta-5,7,10(19)-triene-1 alpha,3beta,24-triol	vitamin D3 analogue	psoriasis
falecalcitriol; flocalcitriol; ST 630; FULSTAN; HORNEL	(1alpha,3beta,5Z,7E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue	osteoporosis; kidney disease; hyperparathyroidism; psoriasis
solverol; PRI 1901	(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-1-[(1R,5E)-7-hydroxy-1,7-dimethyl-5-octenyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	vitamin D3 analogue; differentiation inducer	cancer; psoriasis

Table 46. Current Candidate Therapeutic Interventions for the Treatment of Atherosclerosis

Product Name	Chemical Name	Action	Indication
AGR 529	N-(4-amino-4-oxobutyl)adenosine hydrochloride	A1 fat cell receptor antagonist	hypertension; hyperlipidemia
AGR 540	N-(4-amino-4-oxobutyl)adenosine 2',3',5'-tripropionate	A1 fat cell receptor antagonist; AGR 529 prodrug	hypertension; hyperlipidemia
ACAT inhibitor	unspecified	ACAT inhibitor	hyperlipidemia
BW 2164U90; BW 2164	unspecified	ACAT inhibitor	hyperlipidemia
FR 129169	unspecified	ACAT inhibitor	hyperlipidemia

NTE 122	unspecified	ACAT inhibitor	hyperlipidemia; atherosclerosis
SKF 98016	unspecified	ACAT inhibitor	hyperlipidemia
terpendole C	unspecified	ACAT inhibitor	hyperlipidemia
terpendole D	unspecified	ACAT inhibitor	hyperlipidemia
CP 113818	(S)-(2)-(hexylthio)-N-[6-methyl-2,4-bis(methylthio)-3-pyridinyl]decanamide	ACAT inhibitor	hyperlipidemia
CP 105191	(S)-2-(hexylthio)-N-[6-(methylthio)-5-quinolinyl]decanamide	ACAT inhibitor	hyperlipidemia
CI 999	[[2,6-bis(1-methylethyl)phenoxy]sulfonyl]carbamic acid 2,6-bis(1-methylethyl)phenyl ester sodium salt	ACAT inhibitor	hyperlipidemia
gypsetin	[5aR-(5aalpha,7aalpha,8abeta,13abeta,15aalpha,16aalpha)]-5a,13a-bis(1,1-dimethyl-2-propenyl)-5a,8,8a,13,13a,15a,16a-octahydro-8a,16a-dihydroxypyrazino[1'',2'':1,5,4'',5'':1',5']dipyrrolo[2,3-b:2',3'-b']diindole-7,15(5H,7aH)-dione	ACAT inhibitor	hyperlipidemia
YM 750	1-cycloheptyl-1-(9H-fluoren-2-ylmethyl)-3-(2,4,6-trimethylphenyl) urea	ACAT inhibitor	hyperlipidemia
CI 976	2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide	ACAT inhibitor	hyperlipidemia
AS 183	2,4-dimethyl-2-hydroxy-5-(1,3,5,7-tetramethyl-nonyl)-3(2H)-fluronone	ACAT inhibitor	hyperlipidemia

RP 64477	3-(4-decylcloxybenzamido)-4-methylthio-N-methylthio-N-butylbenzamide	ACAT inhibitor	hyperlipidemia
P 06139	4-[3-[(4,5-diphenyl-1H-imidazol-2-yl)thio]-2-hydroxypropoxy]-benzoic acid 2-methylpropyl ester	ACAT inhibitor	hyperlipidemia
lateritin	4-methyl-6-(1-methylethyl)-3-phenylmethyl-1,4-perhydrooxazine-2,5-dione	ACAT inhibitor	hyperlipidemia
eldacimibe; WAY 125147; ACA 147; ANA 147; WAY-ACA 147	5-[[[3,5-bis(1,1-dimethyl-ethyl)-4-hydroxyphenyl]amino][[[4-(2,2-dimethylpropyl)phenyl]methyl]hexylamino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione	ACAT inhibitor	hyperlipidemia
U 73482	7,7'-[1,2-ethanediylbis(4,1-piperidinediylmethylethyl)]-bis[4,9-dimethoxy-5H-furo[3,2-g][1]benzopyran-5-one	ACAT inhibitor	hyperlipidemia
lecimibide; DUP 128	N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea	ACAT inhibitor	hyperlipidemia
HL 004; TS 962	N-(2,6-diisopropylphenyl)-2-(tetradecylthio)acetamide	ACAT inhibitor	atherosclerosis; hyperlipidemia

YM 17E	N,N'-[1,3-phenylenebis(methylene)]bis[N-cycloheptyl-N'-[4-(dimethylamino)phenyl]urea dihydrochloride	ACAT inhibitor	hyperlipidemia
F 1394	N-[(2,2,5,5-tetramethyl-1,3-dioxan-4-yl)carbonyl]-beta-alanine, 2-[[[2,2-dimethylpropyl)nonyl amino]carbonyl]aminocyclohexyl ester	ACAT inhibitor	atherosclerosis; hyperlipidemia
avasimibe; CI 1011; PD 148515; AVASIMIBE	N-[[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-2,4,6-tris(1-methylethyl)benzeneacetamide	ACAT inhibitor	hyperlipidemia
KW 3033	N-[2,6-bis(1-methylethyl)phenyl]-2-bromo-6,11-dihydrodibenz[b,e]oxepin-11-carboxamide	ACAT inhibitor	hyperlipidemia
PD 129337	N-[2,6-bis(1-methylethyl)phenyl]-N'-[(1-phenylcyclopentyl)methyl]urea	ACAT inhibitor	hyperlipidemia
PD 1323012; PD 132301-2	N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea monohydrochloride	ACAT inhibitor	hyperlipidemia
TMP 153	N-[4-(2-chlorophenyl)-6,7-dimethyl-3-quinolinyl]-N'-(2,4-difluorophenyl)urea	ACAT inhibitor	hyperlipidemia
ACAT inhibitor	N-butyl-N'-(2,4-dimethylphenyl)-N-(phenylmethyl)urea	ACAT inhibitor	hyperlipidemia

E 5324	N-butyl-N'-[2-[3-(5-ethyl-4-phenyl-1H-imidazol-1-yl)propoxy]-6-methyl-phenyl]-urea	ACAT inhibitor	hyperlipidemia
BW 447C88	N-heptyl-N'-(2(4-(2,2-dimethylpropyl)phenyl)ethyl)phenyl)urea	ACAT inhibitor	hyperlipidemia
ACAT inhibitors	unspecified	ACAT inhibitor; imidazole	hyperlipidemia
beauvericin	1,7,13-trioxa-4,10,16-triazacyclooctadecane cyclic peptide derivative	ACAT inhibitor; peptide	bacterial infection; hyperlipidemia
RPR 100579	unspecified	adenosine agonist	hypertension; heart failure; hyperlipidemia
SDZ WAG994; SDZ WAG 994	N-cyclohexyl-2'-O-methyladenosine	adenosine agonist; adenosine A1 agonist	heart failure; hyperlipidemia
SNAP 5150	N-[3-(4,4-diphenyl-1-piperidinyl)propyl]-1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinecarboxamide	alpha adrenergic antagonist; alpha adrenergic antagonist	benign prostate hypertrophy; hyperlipidemia; hypertension
colestilan; colestimide; MCI 196; BMS 180543; CHOLEBINE	1H-imidazole-2-methyl polymer with (chloromethyl)oxirane	anion exchange resin	hyperlipidemia
LY 335124	unspecified	antiestrogen; estrogen agonist	hyperlipidemia
raloxifene; keoxifene; LY 139481; LY 156758; EVISTA	[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone	antiestrogen; estrogen agonist	osteoporosis; hyperlipidemia; myocardial infarction; cancer
atpenin B	[S-(R*,S*)]-3-(2,4-dimethyl-1-oxohexyl)-4-hydroxy-5,6-dimethoxy-2(1H)-pyridinone	antifungal	hyperlipidemia; mycosis

probucol; DH 581; DE 3872; LORELCO; PANAVIR; SINLESTAL	4,4'- isopropylidenedithio- bis-2,6-di-t- butylphenol	antioxidant	HIV infection; hyperlipidemia; restenosis
L 551369	N,N'-diphenyl- phenylenediamine	antioxidant	hyperlipidemia
CK 3363; CK 3368	unspecified	bile acid sequestrant	hyperlipidemia
GT 102279	unspecified	bile acid sequestrant	hyperlipidemia
ICI 245991	unspecified	bile acid sequestrant	hyperlipidemia
SKF 97426	unspecified	bile acid sequestrant	hyperlipidemia
KF 17828	2-bromo-N-(2,6- diisopropylphenyl)- 6,11- dihydrodibenz(b,e)ox epin-11-carboxamide	bile acid sequestrant	hyperlipidemia
colesevelam hydrochloride; GT 31-104HB; GT 31- 104; CholestaGel	N,N,N-trimethyl-6- (2-propenylamino)-1- hexanaminium chloride polymer with (chloromethyl)oxiran e, 2-propen-1-amine and N-2-propenyl-1- decanamine hydrochloride	bile acid sequestrant	hyperlipidemia
CP 88488	N-[2-hydroxy-3- (trimethylammonio)pr opyl] chitosan chloride	bile acid sequestrant	hyperlipidemia
DMP 504	Unspecified	bile acid sequestrant	hyperlipidemia
macrophage colony stimulating factor; M- CSF; MACROLIN	unspecified	biotechnology; growth factor; hematopoietic factor; immunostimulant; cicatrizant; antifungal	mycosis; hyperlipidemia; skin ulcer; bacterial infection
BN 50394	unspecified	calcium antagonist	hyperlipidemia; hypertension
anipamil; LU 42668	alpha-dodecyl-3- methoxy-alpha-[3- [[2-(3- methoxyphenyl)ethyl] methylamino]propyl] benzeneacetonitrile	calcium antagonist	hyperlipidemia

monatepil; monatepil maleate; monasedin maleate; AJ 2615; AD 2615	(+,-)-N-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)-4-(4-fluorophenyl)-1-piperazinebutanamide	calcium antagonist; alpha adrenergic antagonist; alpha adrenergic antagonist	hypertension; angina; hyperlipidemia
BAY 194798	unspecified	CETP inhibitor	atherosclerosis; hyperlipidemia
BNP 9010	unspecified	CETP inhibitor	hyperlipidemia
cholesteryl ester transfer protein inhibitor, CETP inhibitor	unspecified	CETP inhibitor	hyperlipidemia
JTT 705	unspecified	CETP inhibitor	hyperlipidemia
atrinositol; PP 56	D-myo-inositol 1,2,6-tris(dihydrogen phosphate)	chelating agent; NSAID	inflammation; hyperlipidemia
NIP 200	3,5-dimethyl-4,6-diphenyl-tetrahydro-2H-1,3,5-thiadiazine-2-thione	Cholesterol 7-alpha hydroxylase inhibitor	hyperlipidemia
tiqueside; beta-tigogenin cellobioside; CP 88818	(3beta,5alpha,25R)-spirostan-3-yl-4-O-beta-D-glucopyranosyl-beta-D-glucopyranoside	cholesterol absorption inhibitor	hyperlipidemia
SCH 48461	(3R-trans)-1,4-bis(4-methoxyphenyl)-3-(3-phenylpropyl)-2-azetidinone	cholesterol absorption inhibitor	hyperlipidemia
CVT 1	unspecified	cholesterol absorption inhibitor; polysaccharide sulfate	hyperlipidemia
CEB 925	unspecified	cholesterol hydrolase inhibitor	hyperlipidemia
WAY 121751	unspecified	cholesterol hydrolase inhibitor	hyperlipidemia
WAY 121898	unspecified	cholesterol hydrolase inhibitor	hyperlipidemia
policosanol; ATEROMIXOL	unspecified	Cholesterol lowering	hyperlipidemia
fatty acids, microalgal	unspecified	Cholesterol lowering agent	hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease

hyperlipidemia therapy	unspecified	Cholesterol reduction	hyperlipidemia
MC 031	unspecified	cholesterol synthesis inhibitor	hyperlipidemia
MC 032	unspecified	cholesterol synthesis inhibitor	hyperlipidemia
MC 033	unspecified	cholesterol synthesis inhibitor	hyperlipidemia
MC 034	unspecified	cholesterol synthesis inhibitor	hyperlipidemia
SQ 34919	unspecified	cholesterol synthesis inhibitor	hyperlipidemia
azalanstat; azalanstat dihydrochloride; RS 21607; RS 21607-197	(2S-cis)-4-[[[2-[2-(4-chlorophenyl)ethyl]-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl]thio]benzenamine	cholesterol synthesis inhibitor	hyperlipidemia
lilifibrol; K 12148	4-[4-[4-(1,1-dimethylethyl)phenyl]-2-hydroxybutoxy]benzoic acid	cholesterol synthesis inhibitor	hyperlipidemia
MEDICA 16	beta, beta-tetramethyl hexadecanedioic acid	cholesterol synthesis inhibitor	hyperlipidemia
MDL 28815	N-[(1,5,9)-trimethyldecyl]-4alpha,10dimethyl-8-aza-trans-decal-3beta-ol	cholesterol synthesis inhibitor	hyperlipidemia
acipimox; K 9321; OLBETAM; OLBEMOX; ACIPIMOX; NEDIOS	5-methylpyrazinecarboxylic acid 4-oxide	Cyclic AMP inhibition; hormone sensitive lipase inhibitor	hyperlipidemia
AHL 157	unspecified	fibrate	hyperlipidemia
drug delivery system, gemfibrozil; gemfibrozil sustained release; LOPID PUSH-PILL OROS	unspecified	fibrate	hyperlipidemia



drug delivery system, gemfibrozil; gemfibrozil sustained release; LOPID SR	unspecified	fibrate	hyperlipidemia
ciprofibrate; WIN 35833; LIPANOR; HYPERLIPEN; MODALIM; ESTAPROL	2-(p-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropionic acid	fibrate	hyperlipidemia
fenofibrate; fenofibrato; procetofene; LF 178; LIPANTHYL; LIPANTIL; LIPIDIL; LIPSIN; NORMALIP; BISTEROL; NORMOLIP; PROMERAL; LIPCOR; TRICOR	2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester	fibrate	hyperlipidemia
gemfibrozil; CI 719; CS 719; LOPID; ZILOP; IPOLIPID; MARISTON; DELIPID; SCANTIPID	5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid	fibrate	hyperlipidemia
F 2875	[2'-chloro-4-(1,1'-biphenyl)methyl-1-(imidazolyl)acetate	free radical scavenger	hyperlipidemia
cilmostim; macrophage colony stimulating factor; M-CSF; MACSTIM	unspecified	growth factor; hematopoietic factor; immunostimulant	hyperlipidemia; bacterial infection; cancer
high-density lipoproteins	HDL synthetic particles	HDL stimulation	hyperlipidemia; atherosclerosis
BRL 39924A	1-[3-[[[(3 $\alpha$ ,5 $\beta$ )-3-hydroxy-24-oxocholestan-24-yl]amino]propyl]-1,4,4-trimethylpiperazinium diiodide	HDL stimulator	hyperlipidemia
supersulfated low molecular weight heparin; ssLMWH	unspecified	heparinoid	thrombosis; hyperlipidemia

pentosan polysulfate sodium; SP 54; PZ 68; CARTROPHEN; LASONIL; ELMIRON; LELONG MOUSSE	(1-4)-beta-D-xylan 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis
BAY 102987	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
BAY w 9533	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
BB 476	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
BMS 180436	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
BMV 22566	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
DMP 565	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
GR 95030	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
S 853758A	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
S 861006A	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
ZD 4522; S 4522; VISACOR	unspecified	HMG CoA reductase inhibitor	hyperlipidemia
glenvastatin; HR 780; HOE 780	(E)-6(S)-2-[4-(fluorophenyl)-2-(2-methylethyl)-6-phenylpyridin-3-yl]ethenyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
lovastatin; mevinolin; monakolin K; MK 803; MSD 803; MB 530B; L 154803; MEVACOR; MEVLOR; LOVACOL; HIPOVASTIN; DISLIPIN; LOVASTEROL; LINCIL	(S)-2-methylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia; cancer

SQ 33600	(S)-4-[[[1-(4-fluorophenyl)-3-(1-methylethyl)-1H-indol-2-yl]ethynyl]hydroxyphosphinyl]-3-hydroxybutanoic acid	HMG CoA reductase inhibitor	hyperlipidemia
U 88156	[1alpha(E),4beta]-3-[2-(4-hydroxy-1-methylcyclohexyl)ethenyl]-alpha,alpha-dimethylbenzenepentanol	HMG CoA reductase inhibitor	hyperlipidemia
pravastatin; eptastatin; epastatin; CS 514; SQ 31000; RMS 431; LIPOSTAT; MEVALOTIN; PRAVACHOL; PRAVASTATIN; SELECTIN; LIPREVIL; PREVACOL; PRAVASIN; APLACTIN; BRISTACOL	[1S-[1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalfa]]-1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic acid	HMG CoA reductase inhibitor	hyperlipidemia; myocardial infarction
L 669262	[1S-[1alpha,7beta,8beta(2S*,4S*),8abeta]]-1,2,6,7,8,8a-hexahydro-3,7-dimethyl-6-oxo-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester of 2,2-dimethylbutanoic acid	HMG CoA reductase inhibitor	hyperlipidemia

RP 61969	[2S-[2 $\alpha$ (E),4 $\beta$ ]]-4-(4-fluorophenyl)-2-(1-methylethyl)-3-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethenyl]-1(2H)-isoquinolinone	HMG CoA reductase inhibitor	hyperlipidemia
dalvastatin; RG 12561	[4 $\alpha$ ,6 $\beta$ (E)]-(+,-)-6-[2-2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethyl-1-cyclohexen-1-yl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
nisbastatin; NK 104	[4R-[4 $\alpha$ ,6 $\beta$ (E)]]-6-[2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
atorvastatin; atorvastatin calcium; CI 981; PD 1342 98; YM 548; LIPITOR; SORTIS	[R-(R*,R*)]-2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid	HMG CoA reductase inhibitor	hyperlipidemia
CP 83101	[R*,S*-(E)]-(+,-)-3,5-dihydroxy-9,9-diphenyl-6,8-nonadienoic acid methyl ester	HMG CoA reductase inhibitor	hyperlipidemia
fluvastatin; fluindostatin; XU 62320; LESCOL; LOCOL; LOCHOL; FRACTAL	[R*,S*-(E)]-(+,-)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid	HMG CoA reductase inhibitor	hyperlipidemia

BMS 180431; BMS 18043109; BMY 21950	[R*,S*-(E)]-(+,-)-9,9-bis(4-fluorophenyl)-3,5-dihydroxy-8-(1-methyl-1H-tetrazol-5-yl)-6,8-nonadienoic acid	HMG CoA reductase inhibitor	hyperlipidemia
cerivastatin; rivastatin; BAY w 6228; LIPOBAY; BAYCOL; LIPOSTEROL; CERVASTA; VASLIP; SELTA; CERTA	[S-[R*,S*-(E)]]-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid	HMG CoA reductase inhibitor	hyperlipidemia
simvastatin analogue	2,2-dimethylbutanoic acid octahydro-3,7-dimethyl-4-hydroxy-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2yl)ethyl)-1-naphthaleny ester	HMG CoA reductase inhibitor	hyperlipidemia
pannorin	4,8,10-trihydroxy-5-methyl-2H-naphtho[1,2-b]pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
simvastatin analogue; L 679336	6(R)-(2-(8(S)-(2,2-dimethylbutyryl)oxy)-2(S),6(R)-dimethyl-5(R)-hydroxy-1,2,3,4,4a(R),5,6,7,8,8a(R)-decahydronaphthyl-1(S))ethyl)-4-(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
hypolipemic AMMCA	6-amino-1,2-dihydro-5-methyl-2-thioxo-4-pyrimidinecarboxylic acid	HMG CoA reductase inhibitor	hyperlipidemia
BAY x 2678	unspecified	HMG CoA reductase inhibitor; cholesterol synthesis inhibitor	hyperlipidemia

simvastatin; epistatin; synvinolin; velostatin; MK 733; L 654; L 644128; 590328; ZOCOR; DENAN; MEDIPO; SIMOVIL; COLEDIS	2,2-dimethylbutanoic acid [1S- [1 $\alpha$ ,3 $\alpha$ ,7 $\beta$ ,8 $\beta$ - ta(2S*,4S*)8 $\beta$ ]]- 1,2,3,7,8,8a- hexahydro-3,7- dimethyl-8-[2- (tetrahydro-4- hydroxy-6-oxo-2H- pyran-2-yl)ethyl]-1- naphthalenyl ester	HMG CoA reductase inhibitor; osteoporosis	hyperlipidemia; osteoporosis
A 1233; 1233 A	unspecified	HMG CoA synthase inhibitor	hyperlipidemia
L 659699; F 244	[2R- [2 $\alpha$ (2E,4E,7R*),3 $\beta$ - eta]]-11-[3- (hydroxymethyl)-4- oxo-2-oxetanyl]- 3,5,7-trimethyl-2,4- undecadienoic acid	HMG CoA synthase inhibitor	hyperlipidemia
CHOLESS	unspecified	immunostimulant	hyperlipidemia
inhibitor of mevalonate incorporation into cholesterol; IMIC	unspecified	inhibitor of mevalonate incorporation into cholesterol	cancer; hyperlipidemia
DRF 2725	unspecified	insulin sensitizer	diabetes; hyperlipidemia
englitazone; englitazone sodium; CP 68722; CP 72466; CP 72467; CP 724672	(-)-5-[[[(2R)-2-benzyl- 6-chromanyl]methyl]- 2,4-thiazolidinedione	insulin sensitizer	diabetes; hyperlipidemia
TA 1801	ethyl 2-(4- chlorophenyl)-5-(2- furyl)-4- oxazoleacetate	Intestinal cholesterol absorption inhibitor	hyperlipidemia
AJ 814	unspecified	Intestinal lipid absorption inhibitor	hyperlipidemia
LF 70165c	N-methyl-N,N-bis(2- hydroxyethyl)-N-[3- [(3 $\beta$ ,5 $\alpha$ ,25R)- spirostan-3- yloxy]propyl]ammoni- um chloride	Intestinal lipid absorption inhibitor	hyperlipidemia
hypolipidemic, Sam II	unspecified	LDL lowering agent	hyperlipidemia

S 12340	8-[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]propyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one	LDL peroxidation inhibition	hyperlipidemia
LY 295427	(3A,4A,5A)-4-(2-propenylcholestan-3-ol	LDL receptor upregulator	hyperlipidemia
BAY 139952	unspecified	LDL reduction	hyperlipidemia
CGP 26214	unspecified	LDL regulator	hyperlipidemia; atherosclerosis
E 5050	4-(2,6-dimethylheptyl)-N-(2-hydroxyethyl)-beta-methyl-benzenepropanamide	LDL uptake stimulator	hyperlipidemia
cilvastatin; PMD 387	5-oxo-proline, (+,-)-cis-3,3,5-trimethylcyclohexyl ester	LDL-cholesterol stimulate uptake; potent ACAT inhibition	hyperlipidemia
FL 386	trans-1-[4-(2-methylpropyl)cyclohexyl]-2-[(phenylsulfonyl)oxy]ethanone	lipase inhibitor	hyperlipidemia
K 85; OMACOR	Omega 3 fatty acids	Lipid lowering	hyperlipidemia; restenosis
apolipoprotein E	unspecified	lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
pro-apolipoprotein A1	unspecified	lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
yeast-derived dietary fiber; FIBERCEL; CHOLESTRAN; CHOLAZOL	unspecified	lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
NO 1886	[[4-[4-bromo-2-cyanophenyl]amino]carbonyl]phenyl]methyl]-phosphonic acid, diethyl ether	lipoprotein lipase activator	hyperlipidemia

imanixil; HOE 402	4-amino-2-(4,4-dimethyl-2-oxo-1-imidazolidinyl)-alpha,alpha,alpha-trifluoro-5-pyrimidinecarboxym-tolidide	lipoprotein regulator	hyperlipidemia
BMS 212122	unspecified	microsomal transfer protein inhibitor	hyperlipidemia
GW 328713; GR 328713	unspecified	microsomal transfer protein inhibitor	hyperlipidemia
JTT 722	unspecified	microsomal transfer protein inhibitor	hyperlipidemia; obesity
BMS 201038	Unspecified	microsomal transfer protein inhibitor	hyperlipidemia
MAB, LDL and Fc; bispecific antibody, low density lipoprotein	unspecified	monoclonal antibody	hyperlipidemia
drug delivery system, sustained release niacin; niacin sustained release; NIASPAN	unspecified	Niacin sustained release	hyperlipidemia
leucomyzin	unspecified	NSAID	inflammation; hyperlipidemia
orlistat; orlipastat; tetrahydrolipistatin; THL; Ro 180647; XENICAL	N-formyl-L-leucine [2S-[2alpha(R*),3beta]]-1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester	pancreatic lipase inhibitor	obesity; hyperlipidemia; diabetes
LA 230	unspecified	peptide	hypertension; hyperlipidemia
ethyl eicosapentaenoate; ethyl icosapentate; EPA-E; MND 21; EPADEL	ethyl all-cis-5,8,11,14,17-eicosapentaenoate	platelet antiaggregant	thrombosis; hyperlipidemia
AL 0671	(1S-endo)-N-(6-amino-3-pyridinyl)-N'-bicyclo[2.2.1]hept-2-yl-N"-cyanoguanidine	potassium channel activator	hyperlipidemia; hypertension



MDL 29311	4,4'-(methylenebis[thio])bis(2,6-bis[1,1-dimethylethyl]phenol	Probucol analogue antioxidant; LDL inhibitor	diabetes; hyperlipidemia
BMY 42393	2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy] acetic acid	prostaglandin agonist; platelet antiaggregant	hyperlipidemia; thrombosis
KB 5246	6-fluoro-5-(4-methyl-1-piperazinyl)-8-oxo-3H,8H-4-oxa-1-thia-9b-azacyclopenta[cd]phenalene-9-carboxylic acid monohydrochloride	quinolone; antibiotic	cancer; pruritis; hypertension; HIV infection; gastrointestinal ulcer; hyperlipidemia; bacterial infection
BIBX 245	unspecified	Squalene cyclase inhibitor	hyperlipidemia
NB 598	(E)-3-([3,3'-bithiophen]-5-ylmethoxy)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-ethyl-benzenemethanamine	squalene epoxidase inhibitor	hyperlipidemia
RPR 107393	3-hydroxy-3-[4-(quinolin-6-yl)phenyl]-1-azabicyclo[2.2.2]octane dihydrochloride	squalene synthase inhibitor	hyperlipidemia
RPR 101821	trans-2-[4-(benzoxazol-2-yl)-phenylmethoxy] amino cyclohexane HCl	squalene synthase inhibitor	hyperlipidemia
GR 105155	unspecified	squalene synthetase inhibitor	hyperlipidemia
squalestatins	unspecified	squalene synthetase inhibitor	hyperlipidemia

squalestatin 1; zaragozic acid A; L 694599	[5(2E,4S,6S),7S]-2,7- anhydro-3,4-di-C- carboxy-8,9,10,12,13- pentadeoxy-10- methylene-12- (phenylmethyl)-L- erythro-L-glycero-D- altro-7-trideculo-7,4- furanosonic acid 11- acetate 5-(4,6- dimethyl-2-octenoate)	squalene synthetase inhibitor	hyperlipidemia
BMS 188494	2,2- dimethylpropanoic acid [[4-(3- phenoxyphenyl)-1- sulfoethyl]phosphinyl idene]bis(oxymethyle ne) ester	squalene synthetase inhibitor	hyperlipidemia
thyroid hormone receptor beta agonist, thyroid hormone receptor beta agonist	unspecified	thyroid hormone agonist	obesity; hyperlipidemia
transcription factor regulators, antihypercholesterole mia	unspecified	transcription factor regulator	hyperlipidemia
antiatherosclerotic agents	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	atherosclerosis; hyperlipidemia
BOF 6721	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
BOF 6766	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
CDRI 80574	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia

CR 2083	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
diabetes therapy	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	diabetes; obesity; hyperlipidemia
FCP 3P1	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	atherosclerosis; hyperlipidemia
N 1197	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
SRI 62320; SRI 6230	unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
CGS 23425	[[[4-[4-hydroxy-3-(1-methylethyl)phenoxy]-3,5-dimethylphenyl]amino]oxoacetic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
compound 10	2-acetylthio-3-[4-(phenylthio)benzoyl]propionic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
F 2833	2'-chloro-alpha,alpha-dimethyl-[1,1'-biphenyl]-4-methanol	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
LM 1554	2-chloromethyl-5,6,7,8-tetrahydrobenzo(b)thieno(2,3-d)pyrimidin-4(3H)-one	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
RP 54275	2-n-octadecylindole-5-carboxylic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia

fenofibrate; BW 207U; BW 207	4'-(trifluoromethyl)-2-biphenylcarboxylic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
fenofibrate; AY 25712; REDUCTOL	4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furancarboxylic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
P 06103	4-[3-[(6-amino-9-beta-D-ribofuranosyl-9H-purin-8-yl)thio]-2-oxopropoxy]-benzoic acid 2-methylpropyl ester	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
MKC 121	4-tridecylpyrrole-2-carboxylic acid	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
P 0654	8-[3-[4-(2-methylpropyloxycarbonyl)phenoxy]-2-(R)-hydroxypropyl]adenosine	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
hypolipemic	8-O,N-dipivaloyl-3-(N'-(2,4,6-trimethylbenzyl)-N-piperazinyl)rifamycin S	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
CGS 24565	N,15-didehydro-11,15-dideoxy-1-deoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-[4-[(2,4,6-trimethylphenyl)methyl]-1-piperazinyl]rifamycin 8-(2,2-dimethylpropanoate)	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia

CGP 43371	N,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-3-[4-[(2,4,6-trimethylphenyl)methyl]-1-piperazinyl]rifamycin 8-(2,2-dimethylpropanoate)	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
LS 2904	Unspecified	Unspecified lipid, cholesterol, triglyceride lowering agent	hyperlipidemia
NIP 261	unspecified	VLDL catabolism stimulator; HDL synthesis stimulator	hyperlipidemia
S 2E	(S)-(+)-4-[[1-[4-(1,1-dimethylethyl)phenyl]-5-oxo-3-pyrrolidinyl]methoxy]benzoic acid	VLDL formation inhibitor	hyperlipidemia; atherosclerosis

Table 47. Current Candidate Therapeutic Interventions for the Treatment of Asthma

Product Name	Chemical Name	Action	Indication
3323W	unspecified	5 lipoxygenase inhibitor	asthma
CMI 977	Unspecified	5 lipoxygenase inhibitor	asthma
ZD 4407	(2S-trans)-1,3-dihydro-1-methyl-5-[[4-(tetrahydro-4-hydroxy-2-methyl-2H-pyran-4-yl)-2-thienyl]thio]-2H-indol-2-one	5 lipoxygenase inhibitor	asthma
WY 50295; WY 50295 tromet	(S)-alpha-methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid	5 lipoxygenase inhibitor	asthma; rhinitis
SB 202235	(S)-N-(2,3-dihydro-6-phenylmethoxy-3-benzofuranyl)urea	5 lipoxygenase inhibitor	asthma

L 739010	1,6-anhydro-3-C-[6-[[[7-cyano-5-(3-furanyl)-2-naphthalenyl]oxy]methyl]-2-pyridinyl]-2,4-dideoxy-beta-D-threo-hexopyranose	5 lipoxygenase inhibitor	asthma
FR 110302	2,2-dibutyl-1,2,3,4-tetrahydro-5-(2-quinolinylmethoxy)-1-naphthalenol	5 lipoxygenase inhibitor	asthma
bunaprolast; U 66858	2-butyl-4-methoxy-1-naphthalenol acetate	5 lipoxygenase inhibitor	asthma
TDI 41127	4-(5-methoxy-3-methyl-1H-indol-2-yl)-2,6-dimethylphenol	5 lipoxygenase inhibitor	asthma
linazolast; TMK 688; YM 257	4-[5-[[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]amino]-5-oxo-1,3-pentadienyl]-2-methoxyphenylcarbonic acid ethyl ester	5 lipoxygenase inhibitor	asthma; rhinitis
L 691816	5-[3-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]-2,2-dimethylpropyl]-1H-tetrazole	5 lipoxygenase inhibitor	asthma
docebenone; AA 861	6-(12-hydroxy-5,10-dodecadiynyl)-2,3,5-trimethyl-1,4-benzoquinone	5 lipoxygenase inhibitor	asthma; heart failure
PF 5901	alpha-pentyl-3-(2-quinolinylmethoxy)-benzenemethanol	5 lipoxygenase inhibitor	asthma

BW B70C	N-[3-[3-(4-fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea	5 lipoxygenase inhibitor	asthma
R 85355	Unspecified	5 lipoxygenase inhibitor	asthma; psoriasis; inflammatory bowel disease
CHF 1909	Unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
GR 80907	Unspecified	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
SC 45662	Unspecified	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis; inflammatory bowel disease
CGS 25997	(2S)-(-)-2-[[N-(aminocarbonyl)-N-hydroxyamino]methyl]-7-(4-fluorophenoxy)-1,4-benzodioxan	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
L 663536; MK 886	1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-alfa,alfa-diethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid	5 lipoxygenase inhibitor; NSAID	inflammation; asthma; psoriasis
L 699333	2-[2-[1-[(4-chlorophenyl)methyl]-4,5-dihydro-4-methyl-6-[(5-phenyl-2-pyridinyl)methoxy]-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
E 6080	4-[[[(6-hydroxy-4,4,7-trimethyl-2-benzothiazolyl)amino]methyl]benzenesulfonamide monohydrochloride	5 lipoxygenase inhibitor; NSAID	asthma; inflammation

L 651392	4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one	5 lipoxygenase inhibitor; NSAID	inflammation; bacterial infection; asthma
ZD 2138; ICI D2138	6-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-2(1H)-quinolinone	5 lipoxygenase inhibitor; NSAID	arthritis; asthma
ZD 7717; ICI D7717	7-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenyl]thio]-4-methyl-2H-1,4-benzoxazin-3(4H)-one	5 lipoxygenase inhibitor; NSAID	asthma; inflammation
zileuton; A 64077; ABBOTT 64077; ZYFLO	N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea	5 lipoxygenase inhibitor; NSAID	inflammation; asthma
TA 270	N-[1,2-dihydro-4-hydroxy-1-methyl-3-(octyloxy)-2-oxo-7-quinolinyl]-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenamide	5-lipoxygenase inhibitor	asthma; rhinitis
GW 328267	Unspecified	adenosine antagonist; adenosine A2 antagonist	asthma
midaglizole; DG 5128	2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine	alpha adrenergic antagonist; alpha2 adrenergic antagonist	asthma; diabetes
melanocortin receptor-1 modulators, Trega Biosciences	Unspecified	analgesic; melanocortin agonist; melanocortin MC1 agonist	asthma; pain; nephritis
LA 351	5H-(1)-benzopyrano(2,3-b)pyridin-5-one	analgesic; NSAID	inflammation; pain; asthma
HP 228	N-acetyl-Nleu-Gln-His-Phe-Arg-Trp-Gly-amide	analgesic; NSAID; peptide; melanocortin agonist	pain; inflammation; asthma; cachexia
anti-inflammatory macrolide analogues, KOSAN	Unspecified	antibiotic; macrolide	asthma; inflammation



SB 226882	4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-N-methyl-2-pyrimidinamine	antifungal; MAP kinase inhibitor; signal transduction inhibitor; imidazole	inflammation; asthma; rheumatoid arthritis
U 75412E	(16alpha)-21-[4-[3-(ethylamino)-2-pyridinyl]-1-piperazinyl]-16-methylpregna-1,4,9(11)-triene-3,20-dione (2Z)-2-butenedioate (1:1)	Antigen induced bronchopulmonary eosinophilia inhibition, no glucocorticoid activity	asthma
CPR 3005	Lipid analogue	Antiinflammatory	skin disease; eye disease; asthma; rheumatoid arthritis
CPR 3014	Lipid analogue	Antiinflammatory	skin disease; eye disease; asthma; rheumatoid arthritis
CT 1441	Unspecified	Antiinflammatory	asthma; allergy
CPR 3016	Lipid analogue	antiinflammtry	skin disease; eye disease; asthma; rheumatoid arthritis
synthetic catalytic scavenger analogues; SCS analogues	Unspecified	antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
VANTOX	Unspecified	antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
antisense oligonucleotide, interleukin-5; antisense oligonucleotide, IL-5	Unspecified	antisense; oligonucleotide; biotechnology	asthma
D 2522	Unspecified	beta adrenergic agonist	asthma
SL 2021	Unspecified	beta adrenergic agonist	asthma

procaterol; procaterol hydrochloride; OPC 2009; CI 888; MEPTIN; PRO-AIR; ONSUKIL; BRON NOVO; PROMAXOL; MASACIN; PROCADIL; PROPULUM	2(1H)-quinolone, 8-hydroxy-5-(1-hydroxy-2-(1-methylethyl)amino)butyl-, monohydrochloride, (R*S*)(+,-)	beta adrenergic agonist	asthma
nardeterol; SOM 1122	alpha-[[[3-(1H-benzimidazol-1-yl)-1,1-dimethylpropyl]amino]methyl]-2-fluoro-4-hydroxybenzenemethanol	beta adrenergic agonist	asthma
RP 58802B	alpha-[[[3-(1H-benzimidazol-1-yl)-1-methylpropyl]amino]methyl]-4-hydroxy-3-methoxybenzenemethanol	beta adrenergic agonist	asthma
CEDO 20433	Unspecified	beta adrenergic agonist; beta2 adrenergic agonist	asthma
picumeterol; picumeterol fumarate; GR 114297; GR 114297 X; GR 63411	(-)-(R)-4-amino-3,5-dichloro-alpha-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzenemethanol	beta adrenergic agonist; beta2 adrenergic agonist	asthma
salmeterol, (R)-; (R)-salmeterol	(R)-4-hydroxy-alpha.1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist	asthma

formoterol; eformoterol; formoterol fumarate; YM 08316; BD 40A; CGP 25827; CGP 25827A; ATOCK; FORADIL; ASMATEC; SINASFIX; LEMOTEC; OXIS	(R*,R*)-(+,-)-N-[2- hydroxy-5-[1- hydroxy-2-[[2-(4- methoxyphenyl)-1- methylethyl]amino]et hyl]phenyl]formamid e	beta adrenergic agonist; beta2 adrenergic agonist	asthma
formoterol, (R,R); (R,R)-formoterol	[R-(R*,R*)-(+,-)-N- [2-hydroxy-5-[1- hydroxy-2-[[2-(4- methoxyphenyl)-1-m ethylethyl]amino]ethy l]phenyl]formamide	beta adrenergic agonist; beta2 adrenergic agonist	asthma
LAS 32521	Unspecified	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
salmeterol + fluticasone; fluticasone + salmeterol; SERETIDE; ADVAIR DISKUS	Unspecified	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator; corticosteroid	asthma
broxaterol; Z 1170; SUMMAIR	(+,-)-3-bromo-alpha- [(tert- butylamino)methyl]- 5-isoxazolemethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
levosalbutamol; levalbuterol; salbutamol, (R)-; (R)- salbutamol; (R)- albuterol; levalbuterol sulfate; XOPENEX	(R)-alpha'-[[[(1,1- dimethylethyl)amino] methyl]-4-hydroxy- 1,3- benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
TA 2005	[R-(R*,R*)]-8- hydroxy-5-[1- hydroxy-2-[[2-(4- methoxyphenyl)-1- methylethyl]amino]et hyl]-2(1H)- quinolinone monohydrochloride	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma

salmeterol; salmaterol; GR 33343X; SN 408; GR 33343G; SEREVENT	4-hydroxy-alpha.1- [[[6-(4- phenylbutoxy)hexyl]a mino]methyl-1,3- benzenedimethanol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma; pulmonary obstructive disease
etanterol	5-amino-alpha-[[[p- hydroxy-alpha- methylphenethyl)ami no]methyl]-m-xylene- alpha,alpha'-diol	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
bambuterol; BWD 2183; BAMBEC	dimethylcarbamic acid 5-[2-[(1,1- dimethylethyl)amino] -1-hydroxyethyl]-1,3- phenylene ester	beta adrenergic agonist; beta2 adrenergic agonist; bronchodilator	asthma
SM 11044	[R-(R*,S*)]-1-[3- (3,4- dihydroxypheny)-2- [[3-(4- fluorophenyl)propyl]a mino]-3-hydroxy-1- oxopropyl]pyrrolidine monohydrobromide	beta adrenergic agonist; beta3 adrenergic agonist; leukotriene antagonist; leukotriene D4 antagonist	asthma
AR C68397AA; AR- C68397AA; ARL 68397	4-hydroxy-7-[2-[[2- [[3-(2- phenylethoxy)propyl] sulfonyl]ethyl]amino] ethyl-2(3H)- benzothiazolone monohydrochloride	beta adrenergic agonist; bronchodilator	asthma; pulmonary obstructive disease; rhinitis
tulobuterol; HN 078; C 78; HSR 078A; BRELOMAX; BREMAX; ATENOS; BERACHIN; HOKUNALIN	alpha-[(tert- butylamino)methyl]- o-chlorobenzyl alcohol	beta adrenergic agonist; bronchodilator	asthma
allergy immunogen, migis epsilon, Tanox	Unspecified	Immunomodulation	allergy; asthma
allergy therapy, E coli enterotoxin B subunit-antigen fusion protein	Unspecified	Immunomodulation	rhinitis; asthma
emoctakin; interleukin-8	Unspecified	Immunomodulation	asthma

fusion protein, IL-10	Unspecified	Immunomodulation	asthma; inflammatory bowel disease
antisense oligonucleotide, adenosine A1 receptor; antisense oligonucleotide, asthma; EPI 2010; E 2010; EpiGenRx	Unspecified	antisense; oligonucleotide; mRNA translation inhibitor	asthma
interleukin-4 receptor; IL-4r; NUVANCE	Unspecified	cytokine antagonist	inflammation; asthma
soluble interleukin-5 receptor alpha; IL-5Ra	Unspecified	cytokine antagonist	asthma
interleukin-1 receptor; IL-1r; HJ 1306	Unspecified	cytokine inhibitor; immunosuppressant	asthma
anakinra; interleukin-1 receptor antagonist; IL-1ra; interleukin-1 inhibitor; ANTRIL	N2-L-methionylinterleukin 1 receptor antagonist (human isoform x reduced)	cytokine inhibitor; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; transplant rejection; asthma; septic shock
interleukin-12; IL-12; natural killer stimulatory factor; NKSF; edodekin alfa; Ro 247472; Ro 24-7472	Unspecified	cytokine; immunostimulant	asthma
enkephalinase	Unspecified	enkephalinase; enzyme	asthma; ophthalmological
platelet-activating factor acetylhydrolase; PAF-AH; SUN Y7016; PAFASE	Unspecified	hydrolase	respiratory distress syndrome; asthma; inflammatory bowel disease
IgE receptors, soluble, CorBec	Unspecified	immunosuppressant	asthma
antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) DNA	immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma

lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis
MAB, AL 901; MAB, IgE; AL 901; CGP 51901; IGE 025A	Unspecified	monoclonal antibody	allergy; rhinitis; asthma
MAB, CD23; MAB, PRIMATIZED CD23	Unspecified	monoclonal antibody	asthma; allergy; rhinitis
MAB, IgE; MAB, E25	Unspecified	monoclonal antibody	asthma; allergy; rhinitis
MAB, interleukin-4; SB 240683	Unspecified	monoclonal antibody	asthma
MAB, interleukin-5; MAB, IL-5; SCH 55700; CDP 835	Unspecified	monoclonal antibody; immunosuppressant	asthma
MAB, macrophage migration inhibitory factor, Picower Institute for Medical Research	Unspecified	monoclonal antibody; NSAID	arthritis; asthma
MAB, VLA-4, humanized; MAB, very late antigen-4, humanized	Unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
clenoliximab; MAB, CD4; MAB, PRIMATIZED CD4; IDEC 151; SB 217969	immunoglobulin G 4 (human-Macaca monoclonal CE9gamma4PE gamma4-chain anti-human antigen CD4), disulfide with human-Macaca monoclonal CE9gamma4PE kappa-chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; psoriasis; asthma

keliximab; MAb, CD4; MAb, PRIMATIZED CD4; IDEC CE9.1; SB 210396	immunoglobulin G1 (human-Macaca monoclonal CE9.1.gamma.1-chain anti-human antigen CD 4), disulfide with human-Macaca monoclonal CE9.1.lambda.-chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; asthma
neutrophil degranulation inhibitor; DGI	Unspecified	NSAID	asthma; rheumatoid arthritis
RecepTox-Fce	Unspecified	peptide; fusion toxin	asthma; allergy
lipocortin; lipomodulin; macrocortin	Unspecified	phospholipase inhibitor; NSAID	asthma; arthritis
LEX 043	Unspecified	proteinase inhibitor; serine proteinase inhibitor	inflammation; asthma
neutral endopeptidase; NEP	Unspecified	proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
ribozymes, asthma	Unspecified	ribozyme; oligonucleotide	asthma
secretory leukocyte proteinase inhibitor; serine leukocyte proteinase inhibitor; SLPI; serine proteinase inhibitor; SPI; SLPI	Unspecified	serine proteinase inhibitor; proteinase inhibitor	asthma
vaccine, TNF alpha	Unspecified	Immunomodulation, vaccine; cytokine antagonist	rheumatoid arthritis; Crohn disease; cachexia; asthma
bradykinin2 antagonists, Neurogen	Unspecified	bradykinin antagonist	asthma
NOVA 567; NPC 567	N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalaninebradykinin	bradykinin antagonist; cicatrizant; peptide; NSAID	asthma; skin ulcer; inflammation

icatibant; icatibant acetate; HOE 140	D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolincarbonyl-L-(2 $\alpha$ ,3 $\beta$ ,7 $\beta$ )-octahydro-1H-indole-2-carbonyl-L-arginine	bradykinin antagonist; NSAID	asthma; inflammation; rhinitis; osteoarthritis
NPC 17731	N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-(trans-4-propoxy-D-proline)-8-[L-(2 $\alpha$ ,3 $\beta$ ,7 $\beta$ )-octahydro-1H-indole-2-carboxylic acid]-bradykinin	bradykinin antagonist; NSAID	inflammation; septic shock; asthma
FR 170657	(E)-3-[6-(acetylamino)-3-pyridinyl]-N-[2-[[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl-2-propenamide	bradykinin antagonist; NSAID; analgesic	asthma; inflammation; pain
HOE 058A	Unspecified	bronchodilator	asthma
RU 32210	Unspecified	bronchodilator	asthma
S 123701	Unspecified	bronchodilator	asthma
SC 109	Unspecified	bronchodilator	asthma; pulmonary fibrosis
SDZ MKS492	(R)-8-[[1-(3,4-dimethoxyphenyl)-2-hydroxyethyl]amino]-3,7-dihydro-7-(2-methoxyethyl)-1,3-dimethyl-1H-purine-2,6-dione	bronchodilator	asthma



F 3121	1,4-dihydro-3-amino-4-oxo-1-((3-trifluoromethyl)phenyl)pyridazine	bronchodilator	asthma
PF 904	1-ethyl-6-methyl-1H-pyrazino[2,3-c][1,2,6]thiadiazin-4-amine 2,2-dioxide	bronchodilator	asthma
LM 3339	2-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)pyridine 1-oxide	bronchodilator	asthma
KF 17625	5-phenyl-(3H)-imidazo(4,5-c)(1,8)-naphthyridin-4-(5H)-one	bronchodilator	asthma
dametralast; LA 2851	7-methylpyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine	bronchodilator	asthma
KF 15570	imidazo(4,5-c)quinoline-4-one	bronchodilator	asthma
LY 150310	1-(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-imidazole mononitrate	bronchodilator; imidazole	asthma
fenspiride; KSP 193; PNEUMORAL; ESPIRAN	8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one	bronchodilator; NSAID	inflammation; asthma
Ro 251553; Ro 25-1553	N-acetyl-His-Ser-Asp-Ala-Val-Phe-Thr-Glu-Asn-Tyr-Thr-Lys-Leu-Arg-Lys-Gln-NLeu-Ala-Ala-Lys-Lys-Tyr-Leu-Asn-Asp-Leu-Lys-Lys-Gly-Gly-Thr-amide, cyclic (25->21)-peptide	bronchodilator; VIP agonist	asthma

CD 349	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-(nitrooxy)propyl 3-(nitrooxy)propyl ester	calcium antagonist; bronchodilator	hypertension; asthma; angina
RWJ 22108	4-(2-chloro-6-fluorophenyl)-1,4,6,7,8,9-hexahydro-2-methylthiépino[3,2-b]pyridine-3-carboxylic acid 5,5-dioxide 2-[methyl(phenylmethyl)amino]ethyl ester	calcium antagonist; bronchodilator	asthma
IgE regulators	Unspecified	CD23 increase expression and production	asthma; allergy
VLA4 integrin antagonist, Cytel	Unspecified	cell adhesion inhibitor; integrin antagonist; VLA 4 antagonist; NSAID	asthma; rheumatoid arthritis; multiple sclerosis
CCR3 inhibitors	Unspecified	chemokine antagonist	asthma
CCR3 receptor modulators,	Unspecified	Chemokine receptor, CCR3 modulator	asthma
chloride channel blocker, Bayer	Unspecified	chloride channel blocker	asthma; pulmonary obstructive disease
AQRA 721	N-1-azabicyclo[2.2.2]oct-3-yl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepine-11-carboxamide	cholinergic antagonist; bronchodilator	asthma
tiotropium bromide; BA 679BR	(1-alpha,2beta,4beta,5alpha,7beta)-7-[(hydroxydi-(2-thienyl)acetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0 <sup>2,4</sup> ]nonane bromide	cholinergic antagonist; muscarinic antagonist; muscarinic M1 antagonist; muscarinic M3 antagonist; bronchodilator	asthma

rispenzepine; ulvenzepine; DF 594	6,11-dihydro-11-[(1-methyl-3-piperidinyl)carbonyl]-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one	cholinergic antagonist; muscarinic antagonist; muscarinic M1 antagonist; muscarinic M3 antagonist; antispasmodic; bronchodilator	asthma; bronchitis
DAC 5889; DAC 6150	6-oxo-3-phenyl-3-piperidinecarboxylic acid 1-azabicyclo[2.2.2]oct-3-yl ester	cholinergic antagonist; muscarinic antagonist; muscarinic M1 antagonist; bronchodilator	asthma
revatropate; UK 112166	(R)-3-quinuclidyl-(2S)-2-hydroxymethyl-4-(R)-methylsulfinyl-2-phenylbutyrate	cholinergic antagonist; muscarinic M3 antagonist; muscarinic antagonist	asthma; pulmonary obstructive disease
chymase inhibitors, Axys	Unspecified	chymase inhibitor; NSAID	asthma; inflammation; rhinitis
CMI 903	Unspecified	complement inhibitor	asthma
anti-inflammatory corticosteroids, A&M University	Unspecified	corticosteroid	psoriasis; asthma
D 5272	Unspecified	corticosteroid	asthma
D 5519	Unspecified	corticosteroid	asthma
GW 215864	Unspecified	corticosteroid	asthma
GW 250495	Unspecified	corticosteroid	asthma
ST 126; TO 199	Unspecified	corticosteroid	asthma
CGP 13774; KSR 592	(+)-methyl 9alpha-chloro- -6alpha-fluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-p-ropionyloxy-androsta-1,4-diene-17beta-carboxylate	corticosteroid	asthma; rhinitis

icometasone enbutate; icomethasone enbutate; icometasone acetate; isomethasone acetate; CL 09	(11.beta.,16.alpha.)- 21-(acetyloxy)-9- chloro-11-hydroxy- 16-methyl-17-(1- oxobutoxy)pregna- 1,4-diene-3,20-dione	corticosteroid	asthma; skin disease
butixocort propionate; JO 1222	(11beta)-11-hydroxy- 17-(1-oxobutoxy)-21- [(1- oxopropyl)thio]]pregn- 4-ene-3,20-dione	corticosteroid	inflammation; asthma; inflammatory bowel disease
budesonide; budesonide propionate; S 1320; PREFERID; PULMICORT; RHINOCORT; ENTOCORT; NARICORT; INFLAMMIDE; BETACTIN; ELTAIR; HORACORT; RHINOCORT AQUA	(11beta,16alpha)- 16,17- [butylidenebis(oxy)]- 11,21- dihydroxypregna-1,4- diene-3,20-dione	corticosteroid	asthma; skin disease; inflammation; rhinitis; ulcerative colitis; Crohn disease
mometasone furoate; mometasone; S 2640; SCH 32088; ELOCOM; ELOCON; FULMETA; ECURAL; ERMIL; NASONEX; ASMANEX	(11beta,16alpha)- 9,21-dichloro-17-[(2- furanylcarbonyl)oxy]- 11-hydroxy-16- methyl-pregna-1,4- diene-3,20-dione	corticosteroid	dermatitis; asthma; rhinitis; psoriasis; pruritis
deflazacort; azacort; L 5458; MDL 458; AZACORTID; CALCORT; LANTADIN; DEFLAN; FLANTADIN; DEZACOR; ZAMENE; ROSILIN; DEFLAMON; PRANDIN	(11beta,16beta)-21- (acetyloxy)-11- hydroxy-2'-methyl- 5'H-pregna-1,4-die no[17,16-d]oxazole- 3,20-dione	corticosteroid	rheumatoid arthritis; skin disease; asthma

fluticasone propionate; fluticasone; CCI 18781; SN 410; SN 411MD; FLOVENT; FLIXONASE; FLIXOTIDE; FLONASE; FLUTIVATE; FLUTIDE NASAL; CUTIVATE; RONTILONA; TRIALONA; FLUNASE	(6alpha,11beta,16alpha,17alpha)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-androst-1,4-diene-17-carbothioic acid, S-(fluoromethyl) ester	corticosteroid	dermatitis; rhinitis; asthma; pulmonary obstructive disease; skin disease
ciclesonide; BY 9010	[11beta,16alpha (R)]-16,17-[[cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregn-1,4-diene-3,20-dione	corticosteroid	asthma
drug delivery system, liposome rofleponide; rofleponide liposome; rofleponide palmitate	[6alpha,11beta,16alpha(R)] 16,17-[[butylidenebis(oxy)]6,9-difluoro-11,21-dihydroxypregn-4-ene-3,20-dione	corticosteroid	asthma; rhinitis
rofleponide; D 5522	[6alpha,11beta,16alpha(R)] 16,17-[[butylidenebis(oxy)]6,9-difluoro-11,21-dihydroxypregn-4-ene-3,20-dione	corticosteroid	asthma
RPR 106541	[6alpha,11beta,16alpha(R),17beta]-16,17-[[butylidenebis(oxy)]-6,9-difluoro-11-hydroxy-17-(methylthio)androst-4-en-3-one	corticosteroid; glucocorticoid	asthma

methyprednisolone suleptanate; U 67590A; PROMEDROL	(6alpha,11beta)-11,17- dihydroxy-6-methyl- 21-[[8-[methyl(2- sulfoethyl)amino]- 1,8- dioxooctyl]oxy]pregn- a-1,4-diene-3,20- dione monosodium salt	corticosteroid; immunosuppressant	inflammation; asthma; anaphylactic shock; transplant rejection
tepoxalin; RWJ 20485; ORF 20485	5-(4-chlorophenyl)-N- hydroxy-1-(4- methoxyphenyl)-N- methyl-1H-pyrazole- 3-propanamide	COX inhibitor; 5 lipxygenase inhibitor; NSAID	asthma; inflammation; inflammatory bowel disease
BAY 169996	Unspecified	cytokine antagonist	asthma
cytokine trap, Regeneron	Unspecified	cytokine antagonist	cancer; asthma; rheumatoid arthritis; allergy
IL-4 antagonists, Pharmacoceia; IL-4 antagonists, Regeneron	Unspecified	cytokine antagonist	asthma
interleukin-4 signal transduction antagonists, Ligand	Unspecified	cytokine antagonist	asthma
interleukin-4 receptor inhibitors, Affymax	Unspecified	cytokine inhibitor	asthma; diabetes
interleukin-1 inhibitors, Selectide	Unspecified	cytokine inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease
JTE 711	Unspecified	cytokine synthesis inhibitor	dermatitis; asthma; rhinitis
repirinast; BAY u 2372; MY 5116; ROMET	isopentyl 5,6-dihydro- 7,8-dimethyl-4,5- dioxo-4H-pyrano[3,2- c]quinoline-2- carboxylate	Degranulation inhibitor	asthma
CGP 25875	Unspecified	degranulation inhibitor	asthma
sulochrin	Unspecified	degranulation inhibitor	asthma

cromoglicate lisetil; AKY 953; KY 556; N 556	2-[[2-(ethoxycarbonyl)-4-oxo-4H-1-benzopyran-5-yl]oxy]-1-[[[2-(ethoxycarbonyl)-4-oxo-4H-1-benzopyran-5-yl]oxy]methyl]ethyl ester, L-lysine dihydrochloride	degranulation inhibitor	asthma; rhinitis; dermatitis; allergy
BN 50601	2-[4-(1,1-dimethylethyl)phenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[3,4-b]pyridin-7-ol	degranulation inhibitor	asthma
amlexanox; amoxanox; CHX 3673; AA 673; SOLFA; ELICS; APHTHASOL	2-amino-7-(1-methylethyl)-5-oxo-5H-[1]-benzopyrano[2,3-b]pyridine-3-carboxylic acid	degranulation inhibitor	asthma; psoriasis; rhinitis; mucositis; conjunctivitis; allergy
asobamast; Z 1819	2-ethoxyethyl[4-(3-methyl-5-isoxazolyl)-2-thiazolyl]oxamate	degranulation inhibitor	asthma
tetrazolast meglumine; tetrazolast; MDL 26024GO	4-(1H-tetrazol-5-yl)tetrazolo[1,5-a]quinoline with 1-deoxy-1-(methylamino)-D-glucitol	degranulation inhibitor	asthma
azelastine; A 5610; W 2979M; E 0659; AZEPTIN; ALLERGODIL; ASTELIN; RADETHAZIN; AFLUONA; AFLUON; AZEPIT; AZECOF; AZERUNART CHOS H; BIFERTIN	4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone	degranulation inhibitor	asthma; rhinitis; skin disease; conjunctivitis

quinotolast; quinotolast sodium; FK 021; FR 71021; ASLOCK	4-oxo-1-phenoxy-N- 1H-tetrazol-5-yl-4H- quinolizine-3- carboxamide	degranulation inhibitor	asthma; rhinitis; dermatitis
picumast; picumast dihydrochloride; BM 15100	7-[3-[4-(4- chlorobenzyl)-1- piperazinyl]propoxy]- 3,4-dimethylcoumarin	degranulation inhibitor	rhinitis; asthma
nedocromil; FPL 59002; FPL 59002KP; TILADE; TILARIN; TILAVIST; TILAD; NEDREL; DISVEN; IRTEN	9-ethyl-6,9-dihydro- 4,6-dioxo-10-propyl- 4H-pyrano[3,2- g]quinoline-2,8- dicarboxylic acid	degranulation inhibitor	asthma; eye disease; skin disease; rhinitis
pemirolast; pemirolast potassium; BMY 26517; DE 068; BL 5617; PEMILASTON; ALLEGYSAL	9-methyl-3-(1H- tetrazol-5-yl)-4H- pyrido[1,2- a]pyrimidin-4-one	degranulation inhibitor	asthma; conjunctivitis; rhinitis; dermatitis; restenosis
suplatast tosilate; IPD 1151T; MPD; IPD	dimethyl-2-[4-(3- ethoxy-2- hydroxypropoxy)phen ylcarbamoyl]ethylsulf onium-p-toluene sulfonate	degranulation inhibitor	dermatitis; asthma; allergy; rhinitis
tazanolast; WP 833; TAZANOL; TAZALEST	oxo[[3-(1H-tetrazol- 5- yl)phenyl]amino]aceti c acid, butyl ester	degranulation inhibitor	asthma; rhinitis
CI 959	5-methoxy-3-(1- methylethoxy)-N-1H- tetrazol-5-yl- benzo[b]thiophene-2- carboxamide sodium salt	degranulation inhibitor; immunosuppressant; NSAID	rhinitis; inflammation; asthma; arthritis
AP 414	Unspecified	degranulation inhibitor; tyrosine kinase inhibitor	asthma; allergy
MDAM	N-[4-[2-(2,4-diamino- 6- pteridiny]ethyl]benzo yl]-4-methylene-DL- glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma



ALP 242	Unspecified	elastase inhibitor; proteinase inhibitor	asthma; emphysema; psoriasis
BQ 153	cyclo(3-sulfo-D- alanyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl)	endothelin A antagonist; endothelin antagonist	asthma
endothelin antagonist	Unspecified	endothelin antagonist	kidney disease; ischemia; inflammatory bowel disease; asthma
BW 443C	L-tyrosyl-D- arginylglycyl-4-nitro- L-phenylalanyl-L- prolinamide diacetate (salt)	enkephalinase inhibitor; analgesic	asthma; pain; cough
KCA 757	4-[6-acetyl-3-[3-[(4- acetyl-3-hydroxy-2- propylphenyl)thio]pro- poxy]-2- propylphenoxy]butan- oic acid	Eosinophil inhibitory activity	asthma
VML 530; ABT 080	Unspecified	FLAP antagonist	asthma
BAY x 1005	(R)-alpha- cyclopentyl-4-(2- quinolinylmethoxy)be- nzeneacetic acid	FLAP antagonist	asthma
VB 5122	Unspecified	free radical scavenger; xanthine oxidase inhibitor	inflammation; asthma
beta-glucan antagonist	Unspecified	glucan antagonist	conjunctivitis; asthma; psoriasis; ulcerative colitis
nitrocinnonide	6alpha,9-difluoro- 11beta,16alpha,17- trihydroxy-3- oxoandrost-1,4- diene-17beta- carboxylic acid, ester with ethyl(S)-1- hydroxyethyl carbonate, cyclic(R)- 16,17-acetal with butyraldehyde	glucocorticoid	asthma

glucocorticoids, Ligand	Unspecified	glucocorticoid; immunosuppressant; NSAID	inflammation; asthma; autoimmune disease
L 0066; F 11105	Unspecified	GM-CSF inhibitor	asthma
methylhistamine, R- alpha; BP 2.94	Unspecified	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 49648	(2S-trans)-4-(2- methyl-3- pyrrolidinyl)-1H- imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 50971	(3R-trans)-4-(4- methyl-3- pyrrolidinyl)-1H- imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
HQL 79	Unspecified	histamine antagonist; 5HT antagonist	allergy; asthma
asthma therapy, Esteve	Unspecified	histamine antagonist; histamine H1 antagonist	asthma
F 9505A	Unspecified	histamine antagonist; histamine H1 antagonist	asthma
olopatadine; olopatadine hydrochloride; KW 4679; ALO 4943A; PATANOL	(Z)-11-[3- (dimethylamino)prop ylidene]-6,11- dihydro-dibenz[b,e] oxepin-2-acetic acid	histamine antagonist; histamine H1 antagonist	allergy; rhinitis; asthma; conjunctivitis
DF 1111301	1-(2-ethoxyethyl)- N,N-dimethyl-1H- benzimidazole-2- ethanamine dihydrochloride	histamine antagonist; histamine H1 antagonist	allergy; asthma
ebastine; LAS W090; LAS 90; EBASTEL; KESTINE; EVASTEL	1-[4-(1,1- dimethylethyl)phenyl] -4-[4- (diphenylmethoxy)-1- piperidinyl]-1- butanone	histamine antagonist; histamine H1 antagonist	allergy; rhinitis; asthma
mizolastine; SL 850324; MKC 431; MIZOLLEN; ZOLIM; MISTAMINE	2-[[1-[1-[(4- fluorophenyl)methyl]- 1H-benzimidazol-2- yl]-4-piperidinyl] methylamino]-4(1H)- pyrimidinone	histamine antagonist; histamine H1 antagonist	asthma; allergy; rhinitis

ZCR 2060	2-[2-[4-(diphenylmethyl)-1-piperazinyl]ethoxy]benzoic acid maleate	histamine antagonist; histamine H1 antagonist	asthma; allergy
selenotifen; BN 52256	4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo[4,5]cyclohepta[1,2-b]selenophen-10-one	histamine antagonist; histamine H1 antagonist	eye disease; asthma; arrhythmia; rhinitis
epinastine; WAL 801; WAL 801CL; ALESION	9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepin-3-amine	histamine antagonist; histamine H1 antagonist	allergy; asthma; psoriasis; rhinitis
FCC 13	3,4,10,14b-tetrahydrodibenzo[c,f]pyranzino[1,2-a]azepine-2(1H)carboxamide	histamine antagonist; histamine H1 antagonist; 5HT antagonist	asthma
mequitamium iodide; LG 30435	1-methyl-3-(10H-phenothiazin-10-ylmethyl)-1-azoniabicyclo[2.2.2]octane iodide	histamine antagonist; histamine H1 antagonist; muscarinic antagonist; cholinergic antagonist	asthma; rhinitis
KY 234	1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3-(1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid	histamine antagonist; histamine H1 antagonist; thromboxane synthetase inhibitor	asthma
pibaxizine; UCB 20028; UCB J028; J028; J 028	[2-[2-[4-(diphenylmethylene)piperidinyl]ethoxy]ethoxy]acetic acid	histamine antagonist; histamine H2 antagonist	irritable bowel syndrome; asthma
KC 11425	5,6-dihydro-2-methyl-8-(2-methylpropyl)-1-[2-[4-(4-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4H-pyrrolo[3,2,1-ij]quinoline	histamine antagonist; PAF antagonist	asthma; allergy

KC 11404	4-n-butyl-5,6-dihydro-8-hydroxy-2-methyl-1-[2-[4-(4-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4H-pyrrolo[3,2,1-ij]quinoline	histamine antagonist; PAF antagonist; 5-lipoxygenase inhibitor	asthma; allergy
batebulast; batebulast hydrochloride; NCO 650	trans-4-guanidinomethylcyclohexanecarboxylic acid p-tert-butyl-phenyl ester hydrochloride	Histamine release inhibitor	asthma
dehydroepiandrosterone sulfate; DHEAS; PB 005	Unspecified	hormone; vaccine adjuvant; corticosteroid	inflammation; infectious disease; asthma
pentigetide; IgE pentapeptide human; pentapeptide DSDPR; TA 521; PENTYDE	N2-[1-N-(N-L-alpha-aspartyl-L-seryl)-L-[alpha-aspartyl]-L-prolyl]-L-arginine	immunoglobulin	conjunctivitis; asthma; rhinitis
CL 296141	Unspecified	Immunomodulation	asthma
SRL 172	Unspecified	immunostimulant	tuberculosis; cancer; asthma; bacterial infection; leprosy; rhinitis
asthma/allergy therapy, Rigel	Unspecified	immunosuppressant	asthma; allergy
D 22557	Unspecified	immunosuppressant	allergy; asthma
D 7193	Unspecified	immunosuppressant	asthma
IgE receptor inhibitors, InKine	Unspecified	immunosuppressant	asthma
immunology/inflammation therapy, Rigel	Unspecified	immunosuppressant	inflammation; autoimmune disease; asthma
immunosuppressant, Rhone-Poulenc Rorer	Unspecified	immunosuppressant	asthma
immunosuppressants, Agouron	Unspecified	immunosuppressant	autoimmune disease; asthma
T cell modulators, Fisons	Unspecified	immunosuppressant	asthma; rhinitis; conjunctivitis; allergy
oxeclosporin; SDZ IMM 125; IMM 125	2-[O-(2-hydroxyethyl)-D-serine]-cyclosporin A	immunosuppressant	asthma
LCB 2183	Unspecified	immunosuppressant	rhinitis; dermatitis; asthma

CBP 1011	Unspecified	immunosuppressant; corticosteroid	autoimmune disease; systemic lupus erythematosus; asthma
D 22558	Unspecified	immunosuppressant; cytokine inhibitor	asthma; allergy
immunoregulators, AVANT Immunotherapeutics; immunoregulators, Repligen	Unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma
phellodendrinc; OB 5	(7S-cis)-5,8,13,13a- tetrahydro-2,11- dihydroxy-3,10- dimethoxy-7-methyl- 6H- dibenzo[a,g]quinolizi nium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease
antiasthma agent, s	Unspecified	Inflammatory mediator blockade,	asthma
alphaE beta7 antagonists, LeukoSite/Warner Lambert	Unspecified	integrin antagonist; cell adhesion inhibitor	asthma; psoriasis; inflammatory bowel disease
cell adhesion inhibitors, Ligand/Sankyo	Unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	asthma; rheumatoid arthritis; reperfusion injury
TBC 1269	3',3'''-(1,6- hexanediyl)bis[6'- (alpha-D- mannopyranosyloxy)- [1,1'-biphenyl]-3- acetic acid	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor; NSAID	inflammation; asthma
VLA-4 antagonist, Merck/Biogen	Unspecified	integrin antagonist; VLA 4 antagonist	asthma
VLA-4 antagonists, inflammatory diseases; BIO 1211	N-[[[4-[[[(2- methylphenyl)amino] carbonyl]amino]phen yl]acetyl]-L-leucyl-L- alpha-aspartyl-L- valyl-L-proline	integrin antagonist; VLA 4 antagonist	asthma; multiple sclerosis
VLA4 antagonists, Celltech Therapeutics	Unspecified	integrin antagonist; VLA 4 antagonist; cell adhesion inhibitor	asthma; inflammatory bowel disease
CL 891301	Unspecified	leukotriene antagonist	asthma

CS 615	Unspecified	leukotriene antagonist	asthma
FK 011	Unspecified	leukotriene antagonist	asthma
LF 60361	Unspecified	leukotriene antagonist	asthma
RP 12525	Unspecified	leukotriene antagonist	asthma
zafirlukast; Zeneca 204219; ICI 204219; ACCOLATE; VANTICON	[3-[[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic acid, cyclopentyl ester	leukotriene antagonist	asthma; rhinitis
BW A797C	acetamide, n-hydroxy-n-(3-(5,6,7,8-tetrahydro-2-naphthalenyl)-2-propenyl)-	leukotriene antagonist	asthma
BW A137C	N-hydroxy-N-[[4-(phenylmethoxy)phenyl]methyl]acetamide	leukotriene antagonist	asthma
BIIL 284	Unspecified	leukotriene antagonist; leukotriene B4 antagonist	asthma; pulmonary obstructive disease
pranlukast; dolukast; ONO 1078; RS 411; ONON; ULTAIR	N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide	leukotriene antagonist; leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene E4 antagonist	asthma; rhinitis
leukotriene D4 antagonists, Pfizer	Unspecified	leukotriene antagonist; leukotriene D4 antagonist	asthma
RG 14524	Unspecified	leukotriene antagonist; leukotriene D4 antagonist	asthma

LY 290154	(E)-7-chloro-2-[2-[3-[4-(1H-tetrazol-5-yl)-1-[7-(1H-tetrazol-5-ylmethoxy)-1H-indol-1-yl]butyl]phenyl]ethenyl]quinoline	leukotriene antagonist; leukotriene D4 antagonist	asthma
RS 601	4-[5,5,6,6,6-pentafluoro-1-[[4-(4-fluorophenyl)sulfonyl]amino]hexyl]benzenebutanoic acid	leukotriene antagonist; leukotriene D4 antagonist; thromboxane antagonist	asthma
YM 158; YM 57158	N-[5-[3-[(4-chlorophenyl)sulfonyl]propyl]-2-(1H-tetrazol-5-ylmethoxy)phenyl]-3-[[4-(1,1-dimethylethyl)-2-thiazolyl]methoxy]-benzamide	leukotriene antagonist; leukotriene D4 antagonist; thromboxane antagonist	asthma; rhinitis
ZD 3523; ICI D3523	Unspecified	leukotriene antagonist; NSAID	asthma; inflammation
ontazolast; BIRM 270	(S)-N-[2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazamine	leukotriene B4 antagonist; leukotriene antagonist	asthma
RP 69698	5-(1,1-dimethyl-5-((4,6-diphenyl-2-pyridyl)oxy)pentyl)-1H-tetrazole	leukotriene B4 antagonist; leukotriene antagonist	asthma; emphysema
LY 292728	7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-9H-xanthene-4-propanoic acid disodium salt	leukotriene B4 antagonist; leukotriene antagonist	asthma

RG 14893	4-(2-(methyl(2-phenethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; inflammation
SC 51146	7-[3-[2(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist; NSAID	asthma; psoriasis; rheumatoid arthritis; inflammatory bowel disease
cinalukast; Ro 245913	(E)-4-(3-(2-(4-cyclobutyl-2-thiazolyl)ethenyl)phenylamino)-2,2-diethyl-4-oxobutanoic acid	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma
BAY x 7195	[S-(Z)]-4-[[1-(2-carboxyethyl)-4-[4-(4-phenoxybutoxy)phenyl]-2-butenyl]thio]benzoic acid	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma
pirodomast; SCH 37224	4-hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one	leukotriene C4 antagonist; leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	rhinitis; asthma
CGP 44044A	(1R,2S)-1-hydroxy-1-(3-trifluoromethylphenyl)-8-(4-acetyl-3-hydroxy-2-propylphenoxy)-octa-3(E),5(Z)-dien-2-yl-7-thio-4-oxo-4H-1-benzopyran-2-carboxylic acid sodium salt	leukotriene D4 antagonist; leukotriene antagonist	asthma



LY 287192	(E)-2-[[5-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-2H-tetrazol-5-yl]methyl]-5-fluorobenzoic acid sodium salt	leukotriene D4 antagonist; leukotriene antagonist	asthma
LY 290324	(E)-7-chloro-2-[2-[3-[[7-[2-(1H-tetrazol-5-yl)ethyl]-1H-indol-1-yl]methyl]phenyl]ethenyl]quinoline hydrochloride	leukotriene D4 antagonist; leukotriene antagonist	asthma
SKF 106203	(S)-beta[(2-carboxyethyl)thio]-2-(8-phenyloctyl)benzenepropanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
YM 16638	[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
montelukast; montelukast sodium; MK 476; MK 0476; SINGULAIR	[R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropaneacetic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
verlukast; MK 679; L 660711; MK 571; L 668019	[R-(E)]-3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma
pobilukast; pobilukast edamine; SKF 104353; SKF 104353Z2; SKF 104353Q	[R-(R*,S*)]-beta-[(2-carboxyethylthio)-alpha-hydroxy-2-(8-phenyloctyl)benzenepropanoic acid	leukotriene D4 antagonist; leukotriene antagonist	asthma; rhinitis

ritolukast; WY 48252	1,1,1-trifluoro-alpha-2-quinolylmethanesulfon-m-anisidide	leukotriene D4 antagonist; leukotriene antagonist	asthma
LY 203647	1-[2-hydroxy-3-propyl-4-[4-[2-[4-(1H-tetrazol-5-yl)butyl]-2H-tetrazol-5-yl]butoxy]phenyl]ethanone	leukotriene D4 antagonist; leukotriene antagonist	hypertension; asthma
RG 12525	2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]quinoline	leukotriene D4 antagonist; leukotriene antagonist	asthma
NZ 107	4-bromo-5-[[3-ethoxy-4-methoxyphenyl)methyl]amino]-3(2H)-pyridazinone	leukotriene D4 antagonist; leukotriene antagonist	asthma
DS 4574	6-(2-cyclohexylethyl)-[1,3,4]thiadiazolo[3,2-a]-1,2,3-triazolo[4,5-d]pyrimidin-9(1H)-one	leukotriene D4 antagonist; leukotriene antagonist	gastrointestinal ulcer; asthma
iralukast; CGP 45715A	(1R,2S)-1-hydroxy-1-(3-trifluoromethylphenyl)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-deca-3(E),5(Z)-diene-2-yl-7-thio-4-oxo-4H-1-benzopyran-2-carboxylic acid sodium salt	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
MDL 43291	(4a.alpha,7Z,8.beta,8a.beta)-[(octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio]acetic acid	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma

CGP 44826	2-ethenyloxy-N-[4-(5-cyclopentyl-carbonylamino-1-methylindol-3-ylmethyl)-3-methoxy-benzoyl]benzenesulfonylamide	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
FPL 55712	7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid monosodium salt	leukotriene D4 antagonist; leukotriene E4 antagonist; leukotriene antagonist	asthma
sulukast; LY 170680	5-(3-(2(R)-(carboxyethylthio)-1(S)-hydroxypentadeca-3(E),5(Z)-dienyl)phenyl)-1H-tetrazole	leukotriene E4 antagonist; leukotriene D4 antagonist; leukotriene antagonist	asthma
LDP 977	Unspecified	Leukotriene inhibitor	asthma
BAY y 1015	Unspecified	leukotriene synthesis inhibitor	asthma
CPR 7011	L-alpha-dipalmitoyl-sn-glycero-3-phosphocholine	Lung surfactant	bronchitis; cystic fibrosis; rhinitis; asthma
mast cell activation inhibitors, AstraZeneca	Unspecified	Mast cell degranulation inhibition	asthma; rhinitis
MAb, interleukin-5; MAb, IL-5; SB 240563	Unspecified	monoclonal antibody; biotechnology	asthma
MAbs, CCR3	Unspecified	monoclonal antibody; biotechnology; chemokine antagonist	asthma
MAb, CD23; GW 353430	Unspecified	monoclonal antibody; biotechnology; NSAID	rheumatoid arthritis; asthma

FK 888	trans-4-hydroxy-1- [(1-methyl-1H-indol-3-yl)carbonyl]-L-propyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	neurokinin antagonist	asthma; migraine
lanepitane; LY 303870	(R)-N-[2-acetyl[(2-methoxyphenyl)methyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
L 733060	(2S-cis)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID	inflammation; pain; asthma
sarebutamol; SR 48968	(S)-N-[4-(4-acetylamino-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl]-N-methyl-benzamide	neurokinin antagonist; analgesic; neurokinin 2 antagonist	asthma; pain; urinary incontinence
MEN 10376	Unspecified	neurokinin antagonist; bronchodilator; neurokinin 2 antagonist	asthma; anxiety
CP 99994	(2S-cis)-N-[(2-methoxyphenyl)methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist; analgesic	asthma; pain
nolpitantium besilate; SR 140333	(S) 1-[2-[3-(3,4-dichlorophenyl)-1-[[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl]-4-phenyl-1-azoniabicyclo[2.2.2]octane	neurokinin antagonist; neurokinin 1 antagonist; NSAID	asthma; inflammation

ZD 7944	Unspecified	neurokinin antagonist; neurokinin 2 antagonist	asthma
SR 144190	(R)-4-benzoyl-2-(3,4-difluorophenyl)-2-[2-[4-[[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]ethyl]morpholine	neurokinin antagonist; neurokinin 2 antagonist; analgesic	asthma; urinary incontinence; asthma; pain
FK 224; FR 115224	N-[N2-[N-[N-[N-[alpha,beta-didehydro-N-methyl-N-[N-[1-oxo-3-(2-pentylphenyl)propyl]-L-thrconyl]tyrosyl]-L-leucyl]-D-phenylalanyl]-L-allothreonyl]-L-asparaginy]-L-serine epsilon-lactone	neurokinin antagonist; neurokinin 2 antagonist; NSAID	asthma; inflammation
NS 2073	Unspecified	nitric oxide activator; NSAID	inflammation; glaucoma; gastrointestinal ulcer; asthma
NCX 1005	(11beta,16alpha)-9-fluoro-11,17-dihydroxy-16-methyl-21-[4-(nitrooxy)-1-oxobutoxyl]pregna-1,4-diene-3,20-dione	nitric oxide donor	asthma; inflammatory bowel disease
D 21247	Unspecified	Non-steroid respiratory antiinflammatory agent	asthma; rhinitis
D 24241	Unspecified	Non-steroid respiratory antiinflammatory agent	asthma; allergy
D 43787	Unspecified	Non-steroid respiratory antiinflammatory agent	asthma; allergy

FPL 68164	Unspecified	Non-steroid respiratory antiinflammatory agent	asthma
KSU 2178	Unspecified	Non-steroid respiratory antiinflammatory agent	dermatitis; asthma
LAS 30813	Unspecified	Non-steroid respiratory antiinflammatory agent	asthma; allergy
CI 1018	(R)-N-(3,4,6,7- tetrahydro-9-methyl- 4-oxo-1- phenylpyrrolo[3,2,1- jk][1,4]benzodiazepin -3-yl)-4- pyridinecarboxamide	Non-steroid respiratory antiinflammatory agent	asthma
tetrahydrocorynanthei n	17-methoxycorynan- 16-carboxylic acid methyl ester	Non-steroid respiratory antiinflammatory agent	asthma; allergy
tranilast; MK 341; AINTERU; BESSARAL; CLANIST; LIZAMONT; RIZALAST; SYNBERNIA; TEIBLOCK; RIZABEN	2-[[3-(3,4- dimethoxyphenyl)-1- oxo-2- propenyl]amino]benz oic acid	Non-steroid respiratory antiinflammatory agent	asthma; allergy; conjunctivitis; rhinitis; restenosis
NIP 502	4-chloro-5-[[3- ethoxy-4- methoxyphenyl)meth yl]amino]-3(2H)- pyridazinone	Non-steroid respiratory antiinflammatory agent	asthma
AP 0341	5-amino-3-(4- chlorophenyl)-N- methyl-1H-1,2,4- triazole-1- carbothioamide	Non-steroid respiratory antiinflammatory agent	asthma

SCA 8801	6-bromo 8-(methylamino)-imidazo[1,2-a]pyrazine-2-carbonitrile	Non-steroid respiratory antiinflammatory agent	asthma
scopinast; KA 398	7-[3-[4-[bis(4-fluorophenyl)hydroxy methyl]-1-piperidiny]propoxy]-6-methoxy-2H-1-benzopyran-2-one	Non-steroid respiratory antiinflammatory agent	asthma; allergy
KP 136; AL 136	8-hexyloxy-3-(1H-tetrazol-5-yl)-2H-1-benzopyran-2-one	Non-steroid respiratory antiinflammatory agent	asthma
anti-inflammatory agent, North Carolina University	Unspecified	NSAID	inflammation; asthma
CD40 receptor signalling pathway inhibitor, Axiom Biotechnologies; CD40 receptor signalling pathway inhibitor, Zaiya	Unspecified	NSAID	allergy; asthma; inflammation
chemokine receptor modulators, Pharmacopeia	Unspecified	NSAID	inflammation; asthma; atherosclerosis
gene discovery, immune system disorders, AlphaGene	Unspecified	NSAID	arthritis; asthma; allergy
glucocorticoid agonists, Ligand	Unspecified	NSAID	inflammation; rheumatoid arthritis; inflammatory bowel disease; asthma
interleukin modulators, Receptron	Unspecified	NSAID	inflammation; asthma
IPL 576092	Unspecified	NSAID	asthma; respiratory disease
macrophage migration inhibitory factor inhibitors, Picower Institute for Medical Research	Unspecified	NSAID	arthritis; asthma

PKC-RACK interaction inhibitors, Telik	Unspecified	NSAID	arthritis; multiple sclerosis; asthma
pseudopterosin	Unspecified	NSAID	arthritis; asthma; psoriasis
contignasterol	(3alpha,4beta,5alpha,6alpha,7beta,14beta,22S)-22,29-epoxy-3,4,6,7,29-pentahydroxystigmastan-15-one	NSAID	asthma; respiratory disease
tioxamast; F 1865	[[4-(4-methoxyphenyl)-2-thiazolyl]amino]oxoacetic acid ethyl ester	NSAID	asthma; inflammation; skin disease
PNU 142731; PNU 142731A	1-[(2,4-di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)acetyl]pyrrolidine mono hydrochloride	NSAID	asthma
bamaquimast; F 10126; L 0042	3-[3-[[[(methylamino)carbonyl]oxy]propyl]-1-propyl-2(1H)-quinoxalinone	NSAID	asthma
Z 1957	ethyl N-((3-methyl-5-isoxazolyl)-2-thiazolyl) oxamate	NSAID	asthma; inflammation
BTS 71321	N-[1-(4-chlorophenyl)-1-methylethyl]-1H-imidazole-1-propanamine	NSAID	asthma
andolast; CR 2039	N-4-(5-tetrazolyl)-phenyl-4-(5-tetrazolyl)-benzamide	NSAID	asthma; inflammation; allergy
VX 745	Unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurological; heart failure; Crohn disease; asthma
NCX 1004	Unspecified	NSAID; nitric oxide donor	asthma



phospholipase A2 inhibitors, La Jolla	Unspecified	NSAID; phospholipase inhibitor	rheumatoid arthritis; inflammatory bowel disease; asthma
INKP 300	Unspecified	NSAID; signal transduction inhibitor	asthma
oligonucleotide, asthma	Unspecified	oligonucleotide; biotechnology; immunostimulant	asthma
sulfated oligosaccharide, Progen	Unspecified	oligosaccharide	asthma
Ro 191400	Unspecified	PAF antagonist	asthma
tulopafant; RP 59227	(+)-N-(3-benzoylphenyl)-3-(3-pyridinyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide	PAF antagonist	asthma
ginkgolide A,B,C; BN 52063	(1alpha,7beta)-1,7-dihydroxyginkgolide A mixt with ginkgolide A and (1beta)-1-hydroxyginkgolide A	PAF antagonist	asthma; rhinitis; thrombocytopenia
L 680573; MK 287	(2S-trans)-2-[[3-methoxy-2-propoxy-5-[tetrahydro-5-(3,4,5-trimethoxyphenyl)-2-furanyl]phenyl]sulfonyl]ethanol	PAF antagonist	asthma; septic shock
Ro 193704; Ro 19-3704	(R)-3-[4-[2-[(methoxycarbonyloxy)-3-[[[(octadecylamino)carbonyl]oxy]propoxy]butyl]thiazolium iodide	PAF antagonist	asthma

E 6123	(S)-(+)-6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8,11-dimethyl,2,3,4,5-tetrahydro-8H-pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine	PAF antagonist	asthma
Ro 240238; Ro 240238; Ro 244376	[R-(E,E)]-5-(4-methoxyphenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4-decadienamide	PAF antagonist	asthma
YM 461; YM 46A	1-(3-phenylpropyl)-4-[[2-(3-pyridinyl)-4-thiazolidinyl]carbonyl]piperazine (E)-2-butenedioate (1:1)	PAF antagonist	asthma; pulmonary obstructive disease
israpafant; Y 24180; PAFNOL	4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist	asthma
bepafant; WEB 2170	4-[[6-(2-chlorophenyl)-8,9-dihydro-1-methyl-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazpin-8-yl]carbonyl]morpholine	PAF antagonist	asthma; rhinitis

rocepaftant; BN 50730	6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-9(8H)-carbothioamide	PAF antagonist	hypotension; cytoprotectant; asthma
loropafant; SR 27417	N,N-dimethyl-N'-(3-pyridinylmethyl)-N'-[4-[2,4,6-tris(1-methylethyl)phenyl]-2-thiazolyl]-1,2-ethanediamine	PAF antagonist	asthma
SCH 37370	1-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine	PAF antagonist; histamine antagonist; histamine H1 antagonist	asthma; rhinitis
CMI 392	trans-2-[5-(N'-methyl-N'-hydroxyureidylmethyl)-3-methoxy-4-p-chlorophenylthioethoxyphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran	PAF antagonist; leukotriene antagonist	psoriasis; dermatitis; asthma
UR 12510	Unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12519	Unspecified	PAF antagonist; NSAID	inflammation; asthma
UR 12551	Unspecified	PAF antagonist; NSAID	inflammation; asthma
BN 52111	1-(6-((2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy)-6-oxohexyl)-pyridinium bromide	PAF antagonist; NSAID	asthma; inflammation

tiapafant; PCA 4248	1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid methyl 2-(phenylthio)ethyl ester	PAF antagonist; NSAID	asthma; inflammation
BN 52115	1-[6-[(2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy]-6-oxohexyl]quinolinium bromide	PAF antagonist; NSAID	asthma; inflammation
UR 10324	2-(2-acetyl-3,11-dioxo-4,10-dioxo-7-thia-2,12-diazanonacos-1-yl)-1-ethylpyridinium chloride	PAF antagonist; NSAID	inflammation; asthma
tetrahydrocarbazole	4-(2-chlorophenyl)-9-methyl-2-[3-(1,2,3,4-tetrahydro-9H-carbazol-9-yl)-1-propynyl]-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist; NSAID	inflammation; asthma
UR 12460	4-[[[(diphenylmethyl)amino]acetyl]-alpha-(2-methyl-3-pyridinyl)-1-piperazineacetonitrile	PAF antagonist; NSAID	inflammation; asthma
SM 10661	cis-(+,-)-3,5-dimethyl-2-(3-pyridinyl)-4-thiazolidinone monohydrochloride	PAF antagonist; NSAID	endotoxic shock; inflammation; asthma

AH 21132	cis N-(4-(1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo(c)(1,6)naphthyridin-6-yl)phenyl)-acetamide (Z)-2-butenedioate (1:2)	PAF antagonist; phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
F 1850	Unspecified	PAF antagonist; platelet antiaggregant	thrombosis; asthma
dacopafant; RP 48740	(3R)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide	PAF antagonist; platelet antiaggregant	asthma; thrombosis
YM 264	1-(3-methyl-3-phenylbutyl)-4-[[2-(3-pyridinyl)-4-thiazolidinyl]carbonyl]piperazine (E)-2-butenedioate (1:1)	PAF antagonist; platelet antiaggregant	thrombosis; asthma
SDZ 64412; SDZ 64-412	2,3-dihydro-5-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl]imidazo[2,1-a]isoquinoline monohydrochloride	PAF antagonist; platelet antiaggregant	asthma; thrombosis
R 74717	3-(5-(0-(2S,3S)-(3-heptadecylcarbamoylthiotetrahydropyran-2-yl)methyl)phosphonoxy)pentylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis
R 74654	3-(6-(0-(2R,2S)-(3-heptadecylcarbamoyloxytetrahydropyran-2-yl)methyl)phosphonoxy)hexylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis

UK 74505	4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]-5-[(2-pyridinylamino)carbonyl]-3-pyridinecarboxylic acid ethyl ester	PAF antagonist; platelet antiaggregant	thrombosis; asthma
UR 12670	4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-1-(1-oxo-3,3-diphenylpropyl)-piperidine	PAF antagonist; platelet antiaggregant	kidney disease; ischemia; asthma; pancreatitis
SR 27388	4-[2-[[2-(dimethylamino)ethyl](3-pyridinylmethyl)amino]-4-thiazolyl]-2,6-bis(1,1-dimethylethyl)phenol	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
apafant; WEB 2086; WEB 2086BS	4-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-1-oxopropylmorpholine	PAF antagonist; platelet antiaggregant	asthma; rhinitis; pancreatitis
Ro 244736; Ro 24-4736	5-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-2-propynyl]-6(5H)-phenanthridinone	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock

WEB 2347	6-(2-chlorophenyl)-8,9-dihydro-1-methyl-N,N-dipropyl-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-8-carboxamide	PAF antagonist; platelet antiaggregant	asthma; anaphylactic shock; thrombosis
ginkgolide B; BN 52021	hexacyclic trilactone	PAF antagonist; platelet antiaggregant	thrombosis; dermatitis; asthma; multiple sclerosis; septic shock
L 659989	trans-(+,-)-tetrahydro-2-[3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)furan	PAF antagonist; platelet antiaggregant	asthma; thrombosis
SDZ 64619	(+,-)-2-[6-methoxy-2-(methylsulfonyl)-3,9-dioxo-4,8-dioxo-2,10-diazaoctacosan-1-yl]-1-methylpyridinium iodide	PAF antagonist; platelet antiaggregant; bronchodilator	thrombosis; asthma
asthma therapy, Peptide Therapeutics	Unspecified	peptide	asthma
cathepsin S inhibitors, Peptimmune	Unspecified	peptide; proteinase inhibitor; cathepsin S inhibitor	asthma
BY 217	Unspecified	phosphodiesterase inhibitor	asthma
phosphodiesterase inhibitor, Rhone-Poulenc Rorer	Unspecified	phosphodiesterase inhibitor	asthma
KP 885	Unspecified	phosphodiesterase inhibitor; bronchodilator	asthma
WY 123641; PDA 641	Unspecified	phosphodiesterase inhibitor; bronchodilator	asthma
KF 19514	1,5-dihydro-5-phenyl-4H-imidazo[4,5-c][1,8]naphthyridin-4-one	phosphodiesterase inhibitor; bronchodilator	asthma

P 1432	3-(cyclopropylmethyl)-xanthine	phosphodiesterase inhibitor; bronchodilator	asthma
LAS 31396	Unspecified	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
arofylline; LAS 31025	3-(4-chlorophenyl)-3,7-dihydro-1-propyl-1H-purine-2,6-dione	phosphodiesterase inhibitor; bronchodilator; NSAID	asthma; inflammation
tolafentrine; BY 4070	(-)-4-(cis-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]=naphthyridin-6-yl)-p-toluenesulfonamide	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
zardaverine; B 84290	6-(4-(difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
AWD 12281	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
BAY 198004	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
DWP 205297	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
PDE-4 inhibitors, Zambon	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
YM 976	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma



CP 220629; CP 220,629	1-cyclopentyl-3-ethyl-1,4,5,6-tetrahydro-6-(2-methylphenyl)-7H-pyrazolo[3,4-c]pyridin-7-one	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	asthma
LAS 32688	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
phosphodiesterase inhibitors, Celltech/Merck & Co	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
CDP 840	(R)-4-[2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-phenylethyl]pyridine	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; inflammation
filaminast; WAY PDA 641	1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethanone, (E)-O-(aminocarbonyl)oxime	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator	asthma
piclamilast; RP 73401; RPR 73401	3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; arthritis
SB 207499; ARIFLO	cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylic acid	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; bronchodilator; NSAID	asthma; pulmonary obstructive disease
D 4418	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; immunosuppressant; bronchodilator	asthma

D 22888	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor; phosphodiesterase V inhibitor; bronchodilator	asthma
SKF 96231	2-(2-propoxyphenyl)-6-purinone	phosphodiesterase inhibitor; phosphodiesterase V inhibitor; bronchodilator	asthma
doxofylline; ABC 12/3; DO 309; MAXIVENT; ANSIMAR	7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione	phosphodiesterase inhibitor; xanthine	asthma
phospholipase A2 inhibitors, Fisons	Unspecified	phospholipase inhibitor; NSAID	asthma; rheumatoid arthritis; psoriasis; inflammatory bowel disease
cyclic polyamine analogue, SunPharm	Unspecified	polyamine analogue; NSAID	Crohn disease; asthma; inflammation
thymosin beta 4; Tbeta4	Thymosin beta 4 (rat clone pROS2 precursor)	Polymerization of G-actin to F-actin controlling agent	septic shock; respiratory distress syndrome; asthma
BIIX 1; RS 91309	Unspecified	potassium channel activator	asthma
CL 891902	Unspecified	potassium channel activator; bronchodilator	asthma; hypertension
BRL 55834	(3S,4R)-3,4-dihydro-2,2-dimethyl-4-(2-oxopiperidin-1-yl)-6-pentafluoroethyl-2H-1-benzopyran-3-ol	potassium channel activator; bronchodilator	asthma
SDZ PCO400	(3S-trans)-2,4-dihydro-3-hydroxy-2,2-dimethyl-4-[(3-oxo-1-cyclopenten-1-yl)oxy]-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	asthma

emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
UR 8308	1,2-dihydro-2,2-dimethyl-4-(N-oxide-2-pyridyl)-1-oxonaphthalen-6-carbonitrile	potassium channel activator; bronchodilator	asthma
UR 8328	1,2-dihydro-2,2-dimethyl-4-(N-oxide-2-pyridyl)-6-pentafluoroethylnaphthalen-1-one	potassium channel activator; bronchodilator	asthma
UR 8225	1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
RP 66471	1S,2R-trans-2-benzoyloxy-1-(pyrid-3-yl)cyclohexane-(N-methyl)-carbthioamide	potassium channel activator; bronchodilator	asthma
Ro 316930	2,2-dimethyl-4-(2-pyridinyl)-2H-1-benzopyran-6-carbonitrile N4-oxide	potassium channel activator; bronchodilator	hypertension; asthma
YM 934	3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-2H-1,4-benzoxazine N-oxide	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
SR 47063	4-(2-cyanoimino-1,2-dihydropyrid-1-yl)-6-nitro-2,2-dimethyl-2H-1-benzopyran	potassium channel activator; bronchodilator	heart ischemia; asthma
potassium channel activator, Merck KGaA	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma

symakalim; EMD 57283	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; coronary artery disease; asthma
SCA 40	6-bromo-8-(methylamino)-imidazo[1,2-a]pyrazine-2-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
rilmakalim; HOE 234	(3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxo-1-pyrrolidinyl)-6-phenylsulfonylchroman hemihydrate	potassium channel activator; vasodilator; bronchodilator	asthma
bimakalim; EMD 52692; SR 44866	2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; vasodilator; bronchodilator	coronary artery disease; asthma; peripheral vascular disease
potassium channel modulators, Phytera/NeuroSearch	Unspecified	potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
NS 1619	1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one	potassium channel modulator; bronchodilator	stroke; asthma
protein kinase activators, SmithKline Beecham	Unspecified	protein kinase activator; protein kinase A activator	asthma; thrombosis
allergy therapy, Kinetix	Unspecified	protein kinase inhibitor	allergy; asthma
Y 27632	[4(R)-trans]-4-(1-aminoethyl)-N-4-pyridinylcyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
Syk inhibitors, Ariad	Unspecified	protein kinase inhibitor; tyrosine kinase inhibitor	asthma; allergy
Der p I inhibitor, Peptide Therapeutics	Unspecified	proteinase inhibitor	asthma

alpha-1-antitrypsin	Unspecified	proteinase inhibitor; biotechnology	asthma; emphysema; cystic fibrosis; dermatitis; psoriasis
mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany 1)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
asthma therapy, SAIK,	Unspecified	SAIK immunomodulation	asthma
NO-SOD mimetics, NitroMed; nitrosylated superoxide dismutase mimetics, NitroMed	Unspecified	SOD mimetic; nitric oxide donor	asthma; respiratory distress syndrome; ischemia; reperfusion injury
WS 9326A	Unspecified	substance P antagonist	asthma
CGP 49823	(2R-trans)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-N-(4-quinolinylmethyl)-4-piperidinamine	substance P antagonist	anxiety; asthma
FR 113680	N-acetyl-L-threonyl-1-formyl-D-tryptophyl-N-methyl-N-(phenylmethyl)-L-phenylalaninamide	substance P antagonist	asthma
dapitant; RPR 100893	[3aS-[2(R*),3aalpha,4beta,7aalpha]]-octahydro-4-(2-methoxyphenyl)-2-[2-(2-methoxyphenyl)-1-oxopropyl]-7,7-diphenyl-1H-isoindol-4-ol	substance P antagonist; NSAID	asthma; inflammation; migraine
MEN 10627	Unspecified	tachykinin antagonist; antispasmodic	irritable bowel syndrome; asthma

nepadutant; MEN 11420	Cyclo[3-amino-L-alanyl-L-leucyl-N-[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]-L-asparaginy-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl], cyclic (4->1)-peptide	tachykinin antagonist; antispasmodic	asthma; irritable bowel syndrome
Th2 modulators, AstraZeneca	Unspecified	Th2 modulation	asthma; dermatitis
seratrovast; serabenast; AA 2414; A 73001; ABT 001; BRONICA	(+,-)-zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-benzeneheptanoic acid	thromboxane antagonist	asthma; rhinitis
SKF 88046	N,N'-bis[7-(9-chlorobenzeneaminosulfonyl)-1,2,3,4-tetrahydroisoquinolyl]disulfonylimide	thromboxane antagonist	asthma
L 670596	(-)-6,8-difluoro-2,3,4,9-tetrahydro-9-[[4-(methylsulfonyl)phenyl]methyl]-1H-carbazole-1-acetic acid	thromboxane antagonist; platelet antiaggregant	asthma; thrombosis
domitroban; S 1452; S 145; ANBOXAN	(+,-)-[1alpha,2alpha(Z),3beta,4alpha]-7-[3-[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	asthma; rhinitis; thrombosis
ramatroban; BAY u 3405; EN 137774	(R)-3-[[4-(fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid	thromboxane antagonist; platelet antiaggregant	asthma; rhinitis

SQ 33961	[1S-(exo,exo)]-2-[[3-[4-[[4-(cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
ONO 8809	[1S-[1alfa,2alfa(Z),3beta,4alfa]]-6-[3-[[4-(bromophenyl)sulfonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-5-hexenoic acid decyl ester	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ICI 192605	[2alfa,4alfa,5alfa(Z)]-6-[2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ICI 185282	[2alfa,4alfa,5alfa(Z)]-7-[4-(2-hydroxyphenyl)-2-(trifluoromethyl)-1,3-dioxan-5-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
KT 2962; KT 2-962	3-[4-[[4-(chlorophenyl)sulfonyl]amino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
ON 579	4-(2-(4-chlorophenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma

KDI 792; FK 070; FR 12170	[2S-[2alpha,(Z),4beta]]-6-[4-[(4-chlorophenyl)sulfonylamino]-1-(3-pyridinylmethyl)-2-pyrrolidinyl]-5-hexenoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
E 6700	(E)-alpha-[(4-methoxy-2,5-dimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene]-3-pyridineheptanoic acid	thromboxane synthetase inhibitor	asthma
F 1322	N-[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]-3-hydroxy-5-(3-pyridinylmethoxy)-2-naphthalenecarboxamide	thromboxane synthetase inhibitor	asthma
KK 505	2-ethyl-4-(3-pyridyl)-1(2H)-phthalazinone	thromboxane synthetase inhibitor; bronchodilator	asthma
KK 562	2-methyl-4-(5-thiazolyl)-1(2H)-phthalazinone	thromboxane synthetase inhibitor; bronchodilator	asthma
ozagrel; ozagrel sodium; OKY 046; DOMENAN; CATACLOT; XANBON; VEGA	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	stroke; thrombosis; asthma; cough
Y 20811	4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethyl-benzoic acid, monosodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; asthma; stroke
imitrodast; CS 518; RS 5186	4,5-dihydro-2-(1H-imidazol-1-ylmethyl)-benzo[b]thiophene-6-carboxylic acid sodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	asthma



nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis
ZT 386	Unspecified	thromboxane synthetase inhibitor; thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
tumor necrosis factor inhibitors, Selectide	Unspecified	TNF inhibitor; NSAID	inflammation; asthma; inflammatory bowel disease
NF-kappaB inhibitor, Molecumetics	Unspecified	transcription factor regulator; NSAID	asthma; inflammation; restenosis
asthma therapy, Proteus	Unspecified	tryptase inhibitor	asthma
BAY 358535; BAY 35-8535; BAY 171998; BAY 17-1998	Unspecified	tryptase inhibitor	asthma
BAY 443428	Unspecified	tryptase inhibitor	asthma
oral tryptase inhibitors, Molecumetics	Unspecified	tryptase inhibitor	inflammatory bowel disease; asthma; psoriasis
tryptase inhibitors, Axys	Unspecified	tryptase inhibitor; NSAID	asthma; inflammation; rhinitis; inflammatory bowel disease; psoriasis
APC 366	N2-[(1-hydroxy-2-naphthalenyl)carbonyl]-L-arginyl-L-prolinamide monohydrochloride	tryptase inhibitor; peptide	asthma
allergy/asthma therapy,	Unspecified	Tyrosine kinase stimulator; blocks IgE	asthma; allergy
APO 77	Unspecified	Unspecified	asthma
ARL 68475; FPL 68475	Unspecified	Unspecified	asthma
asthma/allergy therapy,	Purified plant extracts	Unspecified	asthma; allergy
TO 190	Unspecified	Unspecified	asthma

MDL 105212	(R)-1-[2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)-3-pyrrolidinyl]ethyl]-4-phenyl-4-piperidinecarboxamide	Unspecified	asthma
doqualast; SM 857	11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid	uricosuric	asthma; gout
vaccine, asthma	Unspecified	vaccine	asthma
non-ionic surfactant vesicles; NISV	Unspecified	vaccine adjuvant; immunosuppressant	rheumatoid arthritis; asthma; inflammation
colforsin dapropate; NKH 477; ADEHL	6-[3-(dimethylamino)propionyl]forskolin	vasodilator; bronchodilator	heart failure; asthma; musculoskeletal disorder
ibudilast; KC 404; KETAS; AIVYNAL; EYEVYNIL	3-isobutyryl-2-isopropylpyrazolo-(1,5 $\alpha$ )-pyridine	vasodilator; PAF antagonist	asthma; eye disease
VLA-4 inhibitors, Cytel	Unspecified	VLA 4 antagonist; integrin antagonist; cell adhesion inhibitor	asthma
nestifylline; ABC 99	7-(1,3-dithiolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione	xanthine	asthma
MX 2120	7-(2,2-dimethyl)propyl-1-methylxanthine	xanthine	asthma
isbufylline	7-isobutyltheophylline	xanthine	asthma
MPX	3,7-dihydro-1-methyl-3-(1-methylethyl)-1H-purine-2,6-dione	xanthine; bronchodilator	asthma

Table 48. Current Candidate Therapeutic Interventions for the Treatment of Inflammatory Bowel Disease

Product Name	Chemical Name	Action	Indication
E 3040	5,7-dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-6-benzothiazolol	5 lipoxygenase inhibitor; thromboxane synthase inhibitor	ulcerative colitis

FPL 64170	unspecified	Antiinflammatory	ulcerative colitis
antisense oligonucleotide, NF- kappaB p65 subunit	unspecified	antisense; oligonucleotide; immunosuppressant	Crohn disease
balazipone; OR 1364	3-(2-acetyl-3-oxo-1- butenyl)benzonitrile	chemoprotectant; cytoprotectant	Crohn disease; ulcerative colitis
sucralfate; ANTEPSIN; CARAFATE; KEAL; TUNALMIN; ULCAR; ULCERLMIN; ULCERIM; ULCOGENT; ULSANIC	sucrose octakis(hydrogen sulfate), aluminum complex	chemoprotectant; cytoprotectant	gastrointestinal ulcer; ulcerative colitis
CR 1795	(R)-5- (dipentylamino)-4- [(2- naphthalenylcarbonyl) amino-5-oxo- pentanoic acid	cholecystokinin antagonist	ulcerative colitis; pancreatitis
budesonide; budesonide propionate; S 1320; PREFERID; PULMICORT; RHINOCORT; ENTOCORT; NARICORT; INFLAMMIDE; BETACTIN; ELTAIR; HORACORT; RHINOCORT AQUA	(11beta,16alpha)- 16,17- [butylidenebis(oxy)]- 11,21- dihydroxypregna-1,4- diene-3,20-dione	corticosteroid	asthma; skin disease; inflammation; rhinitis; ulcerative colitis; Crohn disease
FPL 62064	N-(4- methoxyphenyl)-1- phenyl-1H-pyrazole- 3-amine	COX inhibitor; 5 lipxygenase inhibitor	inflammatory bowel disease; psoriasis
CRF1 partial agonist,	unspecified	CRF1 receptor agonist	Alzheimer disease; Crohn disease

CDC 801	unspecified	cytokine inhibitor; TNF inhibitor; phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	Crohn disease
oprelvekin; interleukin-11; IL-11; YM 294; NEUMEGA	unspecified	cytokine; immunostimulant	cancer; HIV infection; mucositis; Crohn disease
interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
IxC1-62/47	unspecified	enzyme	kidney disease; inflammatory bowel disease; Crohn disease
interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion toxin; IL-2 fusion toxin; DAB 486-IL-2; D-IL-2	unspecified	fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; cancer
WILD 20	[R-[R*,S*-(E)]]-2- amino-3-hydroxy-4- eicosenyl-O-beta-D- galactopyranosyl-(1- >3)-O-2-amino-2- deoxy-beta-D- galactopyranosyl-(1- >4)-O-[alpha- neuraminosyl-(2- >3)]-O-beta-D- galactopyranosyl-(1- >4)-beta-D- glucopyranoside	ganglioside	inflammatory bowel disease
beta-glucan antagonist	unspecified	glucan antagonist	conjunctivitis; asthma; psoriasis; ulcerative colitis

heparin binding epidermal growth factor-like factor; HB-EGF	unspecified	growth factor	respiratory distress syndrome; ulcerative colitis
glucagon-like peptide-2; GLP-2 ALX 0600	unspecified	growth factor; peptide; hormone	inflammatory bowel disease
	unspecified	hormone; peptide	gastrointestinal disorder
interleukin-1 beta converting enzyme inhibitors,	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	inflammation
VX 740; HMR 3480	unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	rheumatoid arthritis; osteoarthritis; inflammation
antisense oligonucleotide, ICAM-1; antisense oligonucleotide, intracellular adhesion molecule-1; ISIS 2302	d[(R)-P-thio](G-C-C- C-A-A-G-C-T-G-G- C-A-T-C-C-G-T-C- A) DNA	immunosuppressant; antisense; oligonucleotide; NSAID	rheumatoid arthritis; psoriasis; inflammatory bowel disease; asthma
leukocyte function associated antigen 3 T cell inhibitor protein; LFA3TIP; LFA3TIP; AMEVIVE	unspecified	immunosuppressant; NSAID	inflammation; autoimmune disease; psoriasis
alpha4 beta7 antagonists,	unspecified	integrin antagonist; alpha4 beta7 integrin antagonist; cell adhesion inhibitor	Crohn disease; inflammatory bowel disease
interferon alfa-2b; IFN alfa-2b; SCH 30500; YM 1490; INTRON A; CIBIAN; VIRAFERON	unspecified	interferon; cytokine; immunostimulant	cancer; viral infection
secretory cell inhibitors, CAMR	Clostridium botulinum toxin extract	Intracellular trafficking blockade	allergy; inflammation; respiratory disease

SC 52798	(+)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	leukotriene B4 antagonist; leukotriene antagonist	psoriasis; ulcerative colitis
ONO 4057; LB 457	(E)-2-(4-carboxybutoxy)-6-[[6-(4-methoxyphenyl)-5-hexenyl]oxy]benzene propanoic acid	leukotriene B4 antagonist; leukotriene antagonist	ulcerative colitis
MAB, tumor necrosis factor; MAB, TNF; SMA TNF	unspecified	monoclonal antibody	Crohn disease; cancer; septic shock
MAB, IBD1; MAB, inflammatory bowel disease; LM IBD1	unspecified	monoclonal antibody	Crohn disease
MAB, interleukin-12; MAB, IL-12	unspecified	monoclonal antibody	Crohn disease; ulcerative colitis
nerelimomab; MAB, TNF; MAB, tumor necrosis factor; BAY x 1351	immunoglobulin G1 (mouse monoclonal BAY x 1351.gamma.1-chain anti-human tumour necrosis factor.alpha.), disulfide with mouse monoclonal BAY x 1351 light chain, dimer	monoclonal antibody	Crohn disease
MAB, T cell antigen receptor; TM 29	unspecified	monoclonal antibody; immunosuppressant	cancer; Crohn disease
MAB, alpha4 beta7 integrin/mucosal adressin interaction; 86.2/96.1; LDP 02	unspecified	monoclonal antibody; integrin antagonist; alpha4 beta7 integrin antagonist; cell adhesion inhibitor	Crohn disease; inflammatory bowel disease

MAb, humanized tumor necrosis factor; MAb, humanized TNF; MAb, CDP571; CDP 571; BAY 103356; B 1351	unspecified	monoclonal antibody; NSAID	septic shock; inflammation; bacterial infection; inflammatory bowel disease; rheumatoid arthritis
MAb, VLA-4, humanized; MAb, very late antigen-4, humanized	unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
infliximab; MAb, tumor necrosis factor alpha; MAb, TNF-alpha; cA2; TA 650; REMICADE; AVAKINE	immunoglobulin G, anti-(human tumour necrosis factor) (human-mouse monoclonal cA2 heavy chain), disulfide with human-mouse monoclonal cA2 light chain, dimer	monoclonal antibody; NSAID	rheumatoid arthritis; Crohn disease
ruthenium nitric oxide (NO) scavengers,	unspecified	nitric oxide scavenger	inflammatory bowel disease; cardiac therapy
sulfasalazine; salazosulfapyridine; azulfide; SI 88; AZULFIDINE; SALAZOPYRIN; SLAMA	2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid	NSAID	ulcerative colitis; rheumatoid arthritis
P 54	unspecified	NSAID; analgesic	osteoarthritis; Crohn disease; cancer
VX 745	unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurological; heart failure; Crohn disease; asthma
MAb, tumor necrosis factor-alpha, human; D2E7; LU 200134	unspecified	onal antibody; NSAID	inflammation
MAb, alpha4beta1 integrin; AN 100226; ANTEGREN	unspecified	onoclonal antibody	multiple sclerosis; Crohn disease; ulcerative colitis

setipafant; BN 50727	6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-9(8H)-carboxamide	PAF antagonist	gastrointestinal ulcer; cytoprotectant
pentapeptide	unspecified	peptide	inflammatory bowel disease
booly protection compound 15; BPC 15	HOOC-val-leu-gly-ala-asp-asp-ala-pro-lys-gly-pro-pro-pro-glu-gly-NH <sub>2</sub>	peptide	Crohn disease; ulcerative colitis
diethyldihydroxyhomospermine;	DEHOHO	polyamine analogue	ulcerative colitis
diethylhomospermine; DEHOP; DE 444	N,N'-bis[4-(ethylamino)butyl]-1,4-butanediamine	polyamine analogue	diarrhea; hypertension; cancer; psoriasis; ulcerative colitis
cyclic polyamine analogue, SunPharm	unspecified	polyamine analogue; NSAID	Crohn disease; asthma; inflammation
polyclonal antibody, tumor necrosis factor alpha; polyclonal antibody, TNFalpha; CytoTAB	unspecified	polyclonal antibody; immunoglobulin; immunosuppressant	septic shock; malaria; restenosis; Crohn disease; graft versus host disease
polyclonal antibody, tumor necrosis factor alpha; immunoglobulin, TNF-alpha lysate; PASSTNF-alpha	unspecified	polyclonal antibody; immunoglobulin; NSAID	rheumatoid arthritis; inflammatory bowel disease
ridogrel; R 68070	(E)-5-[[[3-pyridinyl[3-(trifluoromethyl)phenyl]methylene]amino]oxy]pentanoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	ulcerative colitis; Crohn disease
etanercept; tumor necrosis factor receptor; TNFr; TNR 001; ENBREL	unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease



thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection
AZM 091	unspecified	Undisclosed	ulcerative colitis
colitis therapy	Strath-1, strath-2	Undisclosed	ulcerative colitis
CPR 2015	unspecified	Undisclosed	ulcerative colitis
ulcerative colitis therapy, LecTec	unspecified	Undisclosed	ulcerative colitis
tazofelone; LY 213829	(+,-)-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-4-thiazolidinone	Undisclosed	inflammatory bowel disease
mesalazine; mesalamine; fisalamine; 5-ASA; N 5-ASA; SALOFALK; ASACOL; ROWASA; PENTASA; LIXACOL	5-amino-2-hydroxybenzoic acid	Undisclosed	inflammatory bowel disease
vaccine, TNF alpha	unspecified	vaccine; cytokine antagonist	rheumatoid arthritis; Crohn disease; cachexia; asthma

Table 49. Current Candidate Therapeutic Interventions for the Treatment of Hepatitis

Product Name	Chemical Name	Action	Indication
NP 77A	Plantain isolate	Antiviral	viral infection; hepatitis
hepatitis C therapy	unspecified	Epsilon RNA and 5'UTR binding	hepatitis
gene therapy, hepatitis B	unspecified	Hepatitis gene therapy	hepatitis
MAXAMINE	unspecified	histamine agonist; histamine H2 agonist	cancer; viral infection; hepatitis

VX 497	unspecified	immunosuppressant	psoriasis; autoimmune disease; viral infection; hepatitis
gene therapy, interferon alpha-2b; gene therapy, viral infection	unspecified	interferon gene therapy	hepatitis
tuvirumab; MAb, human hepatitis B; OST 577; PE 11; OSTAVIR	unspecified	monoclonal antibody	hepatitis
MAbs, hepatitis B; HBV-AB	unspecified	monoclonal antibody	hepatitis
oligonucleotides, hepatitis B virus	unspecified	oligonucleotide	hepatitis
gene therapy, hepatitis B ribozyme; ribozyme, hepatitis B	unspecified	oligonucleotide; ribozyme gene therapy;	hepatitis
polyclonal antibody, hepatitis B; hepatitis B immunoglobulin; H-BIG; NABI-HB	unspecified	polyclonal antibody; immunoglobulin	hepatitis
AM 86	unspecified	reverse transcriptase inhibitor	viral infection; hepatitis
lamivudine; BCH 189; GR 103665; GR 109714X; GG 714; 3TC; EPIVIR; ZEFFIX; EPIVIR- HBV; HEPTODIN; HEPTOVIR	(2R-cis)-4-amino-1- [2-(hydroxymethyl)- 1,3-oxathiolan-5-yl]- 2(1H)-pyrimidinone	reverse transcriptase inhibitor; nucleoside analogue; antimetabolite	viral infection; hepatitis; HIV infection
adefovir dipivoxil; bis- POM PMEA; GS 840; PREVEON	[[[2-(6-amino-9H- purin-9- yl)ethoxy)methyl]pho sphorylidene]bis(oxy methylene)-2,2- dimethylpropanoic acid	reverse transcriptase inhibitor; nucleotide analogue	viral infection; HIV infection; hepatitis
ribozymes, hepatitis C; HEPTAZYME	unspecified	ribozyme; oligonucleotide	hepatitis
gene therapy, ribozyme, hepatitis C; ribozyme, hepatitis C	unspecified	Ribozyme; oligonucleotide gene therapy	hepatitis

gene therapy, hepatitis B, GenSet; ribozyme, hepatitis B, GenSet	unspecified	ribozyme; oligonucleotide gene therapy;	viral infection; hepatitis
tucareol; BWA 589C; BW 589C80; BW 589C; 589C	4-[(2-formyl-3- hydroxyphenoxy)met hyl]benzoic acid	RNA helicase	sickle cell anemia; viral infection; HIV infection; cancer; hepatitis
AM 188	unspecified	undisclosed	viral infection; hepatitis
VP 31593	unspecified	Unspecified	hepatitis
vaccine, hepatitis A; hepatitis A vaccine	unspecified	vaccine	hepatitis
vaccine, hepatitis B; hepatitis B vaccine; Hepa-gene 3; HEPAGENE	unspecified	vaccine	hepatitis
vaccine, hepatitis C; hepatitis C vaccine	unspecified	vaccine	hepatitis
vaccine, hepatitis C	unspecified	vaccine	hepatitis

Table 50. Current Candidate Therapeutic Interventions for the Treatment of Diabetes

Product Name	Chemical Name	Action	Indication
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]-3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid	ACE inhibitor	hypertension; heart failure; diabetes
adenosine agonist	Unspecified	adenosine agonist	diabetes
SC 103a	Unspecified	aldose reductase inhibitor	diabetes; neuropathy
SC 103b	Unspecified	aldose reductase inhibitor	diabetes; sexual dysfunction
SX 3030	Unspecified	aldose reductase inhibitor	diabetes
WF 3681	(+,-)-2,5-dihydro-4-hydroxy-5-oxo-3-phenyl-2-furanpropanoic acid	aldose reductase inhibitor	diabetes; retinopathy
aldose reductase inhibitor	(2'R-cis)-6-chloro-2',3'-dihydro-2'methyl-spiro(imidazolidine-4,4'-(4H)pyrano(2,3-b)pyridine)-2,5-dione	aldose reductase inhibitor	diabetes; neuropathy; retinopathy

methosorbinil; M 79175; E 0772; E 79175	(2R-cis)-6-fluoro-2,3-dihydro-2-methylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-diione	aldose reductase inhibitor	diabetes; retinopathy
fidarestat; SNK 860; SK 860	(2S-cis)-6-fluoro-2,3-dihydro-2',5'-dioxospiro[4H-1-benzopyran-4,4'-imidazolidine]-2-carboxamide	aldose reductase inhibitor	diabetes
isoliquiritigenin; GU 17	(E)-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one	aldose reductase inhibitor	diabetes
epalrestat; ONO 2235; KINEDAK	(Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid	aldose reductase inhibitor	neuropathy; kidney disease; eye disease; diabetes
WP 921; TAT	[5-(3-thienyl)tetrazol-1-yl]acetic acid	aldose reductase inhibitor	diabetes; neuropathy
M 16209; MD 32	1-(3-bromobenzeno[b]furan-2-ylsulfonyl)hydantoin	aldose reductase inhibitor	diabetes; neuropathy
M 16287; MD 32	1-(3-chlorobenzeno(b)furan-2-ylsulfonyl)hydantoin	aldose reductase inhibitor	diabetes; neuropathy
aldose reductase inhibitor	1-[(5-bromo-1-naphthalenyl)sulfonyl]-2-thioxo-4-imidazolidinone	aldose reductase inhibitor	diabetes
AD 5467	2,3-dihydro-2,8-bis(1-methylethyl)-3-thioxo-4H-1,4-benzoxazine-4-acetic acid	aldose reductase inhibitor	diabetes; neuropathy
FR 62765	2,5-dihydro-4-methoxy-5-oxo-3-phenyl-2-furanpropanoic acid ethyl ester	aldose reductase inhibitor	diabetes; neuropathy; retinopathy

imirestat; AL 1576; AL 01576; HOE 843	2,7-difluoro- spiro(9H-fluorene- 9,4'-imidazolidine)- 2,5-dione	aldose reductase inhibitor	diabetes; retinopathy
minalrestat; ARI 509; WAY-ARI 509	2-[(4-bromo-2- fluorophenyl)methyl]- 6- fluorospiro[isoquinoli ne-4(1H),3'- pyrrolidine]- 1,2',3,5'(2H)-tetrone	aldose reductase inhibitor	diabetes
AS 3201	2'-[(4-bromo-2- fluorophenyl)methyl] spiro[pyrrolidine- 3,4'(1'H)-pyrrolo[1,2- a]pyrazine]- 1',2,3',5(2'H)-tetrone	aldose reductase inhibitor	diabetes; neuropathy
AL 01567	2-fluorospiro-[9H- fluorene-9,4'- imidazolidine]-2',5'- dione	aldose reductase inhibitor	diabetes
ponalrestat; MK 438; ICI 128436; PRODIAX; STATIL	3-(4-bromo-2- fluorobenzyl)-3,4- dihydro-4-oxo-1- phthalazineacetic acid	aldose reductase inhibitor	diabetes; neuropathy; retinopathy
SPR 210	3,4-dihydro-3-oxo-4- [(4,5,7-trifluoro-2- benzothiazolyl)methy l]-2H-1,4- benzothiazine-2- acetic acid	aldose reductase inhibitor	diabetes; retinopathy; neuropathy
zopolrestat; CP 73850; ALOND	3,4-dihydro-4-oxo-3- [[5-(trifluoromethyl)- 2- benzothiazolyl]methy l]-1-phthalazineacetic acid	aldose reductase inhibitor	diabetes; neuropathy; kidney disease
NZ 314	3-[(3- Nitrophenyl)methyl]- 2,4,5-trioxo-1- imidazolidineacetic acid	aldose reductase inhibitor	diabetes

zenarestat; FR 74366; FK 366	3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid	aldose reductase inhibitor	diabetes; retinopathy; neuropathy
aldose reductase inhibitor, CT 112	5-(3-thienyl)-1H-tetrazole-1-acetic acid	aldose reductase inhibitor	diabetes
	5-[3-ethoxy-4-(pentyloxy)phenyl]-2,4-thiazolidinedione	aldose reductase inhibitor	diabetes; retinopathy
ascorbyl gamolenate; ascorbyl gammalinolenic acid; SC 103; ASCORBYL-GLA	6-[(6Z,9Z,12Z)-6,9,12-octadecatrienoate] L-ascorbic acid	aldose reductase inhibitor	diabetes; neuropathy; sexual dysfunction
ophthalmological,	6'-chloro-3'-methylspiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-trione	aldose reductase inhibitor	retinopathy; diabetes
BAL ARI8	7-fluoro-2-(N-methyl-N-carboxymethyl)sulfa moyl xanthone	aldose reductase inhibitor	diabetes; retinopathy
tolrestat; AY 27773; ALREDASE; LORESTAT	N-(6-methoxythio-5-(trifluoromethyl)-1-naphthoyl)sarcosine	aldose reductase inhibitor	diabetes; neuropathy
ZD 5522; ICI D5522	N-[3,5-dimethyl-4-[(nitromethyl)sulphonyl]phenyl]-2-methylbenzeneacetamide	aldose reductase inhibitor	diabetes
moxonidine; BE 5895; BDF 5895; LY 326869; CYNT; PHYSIOTENS	4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine	alpha adrenergic agonist; alpha2 adrenergic agonist; imidazoline agonist	hypertension; heart failure; diabetes
deriglidole; SL 860715; SL 840418	(+)-1,2,4,5-tetrahydro-2-(2-imidazolin-2-yl)-2-propylpyrrolo[3,2,1-hi]indole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	diabetes

L 659066; MK 467	(2R-trans)-N-[2-(1,3,4,6,7,12b-hexahydro-2'-oxo-spiro[2H-benzofuro[2,3-a]quinolizine-2,4'-imidazolidin]-3'-yl)ethyl]methanesulfonamide	alpha adrenergic antagonist; alpha2 adrenergic antagonist	diabetes
midaglizole; DG 5128	2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine	alpha adrenergic antagonist; alpha2 adrenergic antagonist	asthma; diabetes
atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety
miglitol; BAY m 1099; DIASTABOL; GLYSET	(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol	alpha glucosidase inhibitor	diabetes
emiglitate; BAY o 1248	[2R-(2alpha,3beta,4alpha,5beta)]-4-[2-[3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]ethoxy]benzoic acid ethyl ester	alpha glucosidase inhibitor	diabetes
voglibose; AO 128; A 71100; GLUSTAT; BASEN	3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-D-epi-inositol	alpha glucosidase inhibitor	diabetes
acarbose; BAY g 5421; GLUCOBAY; PRECOSE; GLUCOR; PRANDASE	O-4,6-dideoxy-4-[[[1S-(1alpha,4alpha,5beta,6alpha)]-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose	alpha glucosidase inhibitor	diabetes; neuropathy; retinopathy



amylin, human; human amylin; AC 001	37-L-tyrosine amylin (human clone lambda h201 reduced)	Amlintide	diabetes
AZM 016	Unspecified	amylase inhibitor	obesity; diabetes
AZM 120	Unspecified	amylase inhibitor	obesity; diabetes
AZM 127	Unspecified	amylase inhibitor	obesity; diabetes
AZM 140	Unspecified	amylase inhibitor	obesity; diabetes
amylin agonists	Unspecified	amylin agonist	diabetes
pramlintide; tripro- amylin; AC 137; SYMLIN; NORMYLIN	lys-cys-asn-thr-ala- thr-cys-ala-thr-gln- arg-leu-ala-asn-phe- leu-val-his-ser-ser- asn-asn-phe-gly-pro- ile-leu-pro-pro-thr- asn-val-gly-ser-asn- thr-tyr-NH <sub>2</sub> , cyclic (2->7)-disulphide	amylin agonist	diabetes
oral amylin receptor antagonists	Unspecified	amylin antagonist	diabetes
antam; AC 253; GI 150747A; GG 747	Unspecified	amylin antagonist; peptide	diabetes
galanin modulators	Unspecified	analgesic	obesity; diabetes; cognitive defect; pain
capsaicin; ZOSTRIX; ZOTRIX HP; THERAGEN; THERAGEN HP; CAPSIDOL; LION PLASTER	(E)-N-[(4-hydroxy-3- methoxyphenyl)meth- yl]-8-methyl-6- nonenamide	analgesic	pain; neuropathy; diabetes
EXO 226	Unspecified	Antiglycation agent	diabetes; kidney disease
ALT 4000	Unspecified	Antiglycemic agent	diabetes
C 8778GO	1-butyl-4,5,6,7- tetrahydro-2,6,6- trimethyl-4-oxo-1H- indole-3-acetic acid	Antihypoglycemic agent	diabetes
C 9001GO	4,5,6,7-tetrahydro- 2,6,6-trimethyl-1-(2- methylpropyl)-4-oxo- 1H-indole-3-acetic acid	Antihypoglycemic agent	diabetes
MDL 29311	4,4'- (methylenebis[thio])b- is(2,6-bis[1,1- dimethylethyl)phenol	Antioxidant	diabetes; hyperlipidemia
diabetes therapy	Unspecified	antioxidant	diabetes

phensuccinal	beta-phenylethylamide-2-hydroxysuccinanylic acid	antioxidant	diabetes; kidney disease; retinopathy
raxofelast; IRFI 016	(+,-)-5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acid	antioxidant; mucolytic	atherosclerosis; diabetes
naphterpin; CL 190Y2	(4aS-cis)-3,4a,5,12b-tetrahydro-8,10-dihydroxy-2,5,5,9-tetramethyl-4H-benzo[d]naphtho[2,3-b]pyran-7,12-dione	antioxidant; NSAID	diabetes; cardiovascular disease; cancer; inflammation
NX 1838	Unspecified	aptamer; oligonucleotide; angiogenesis inhibitor	cancer; diabetes; retinopathy
BMS 194449	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 201620	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
LY 362884	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BRL 35135; BRL 35135A	(R*,R*)-(+,-)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid methyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
CL 314698	(R*,R*)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid dimethyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
ICI D7114; ZD 7114	(S)-2-[4-[2-[(2-hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]-N-(2-methoxyethyl)acetamide	beta adrenergic agonist; beta3 adrenergic agonist	diabetes

AJ 9677; AD 9677	[[[3-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yl]oxy]-acetic acid	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
CL 316243; BTA 243	[R-(R*,R*)]-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid, disodium salt.	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
ZD 2079; ICI D2079	4-[2-[[2-(2R)-2-hydroxy-2-phenylethyl]amino]ethoxy]benzeneacetic acid hydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
AZ 002	L-threo-(3,4-dihydroxyphenyl)-N-methylserine methyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes
BMS 196085	N-[5-[(1R)-2-[[1-(4-(difluoromethoxy)phenyl)-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
NNC 550118	Unspecified	Beta cel selective agent	diabetes
CP 80629	Unspecified	beta3 adrenergic agonist; beta adrenergic agonist	diabetes
metformin; metformin hydrochloride; LA 6023; BMS 207150; GLUCOPHAGE	N,N-dimethylimidodicarbonylimidic diamide	biguanide	diabetes
somatomedin C; insulin-like growth factor-1; IGF-1; MKC 031; MKN 031	Unspecified	biotechnology; cicatrizant; hormone	catabolic disorder; diabetes; skin ulcer
interleukin-1; IL-1	Unspecified	biotechnology; cytokine	diabetes

calcitonin gene-related peptide (CGRP) receptor modulators,	Unspecified	calcitonin gene-related peptide (CGRP) receptor modulators	migraine; diabetes
amyloid production inhibitors	Unspecified	Carbohydrate binding mimetic	Alzheimer disease; diabetes
CMDM	meso-2,6-bis(carboxymethyl)-4,4-dimethylmorpholinium bromide	carnitine acetyltransferase inhibitor	diabetes
emeriamine; emeriamine dihydrochloride; AA 4808	(R)-2-amino-3-carboxy-N,N,N-trimethyl-1-propanaminium inner salt	Carnitine dependent oxidation of long chain fatty acids inhibitor	diabetes
SDZ CPI975; SDZ CPI 975	Unspecified	carnitine O-palmitoyltransferase inhibitor	diabetes
etomoxir; BY 754	ethyl (+)-(R)-2-[6-(p-chlorophenoxy)hexyl] glycidate	Carnitine palmitoyltransferase 1 inhibitor	diabetes
ICE inhibitor, IDUN	Unspecified	caspase inhibitor; apoptosis inhibitor; IL-1 beta converting enzyme inhibitor; immunosuppressant	transplant rejection; septic shock; rheumatoid arthritis; inflammatory bowel disease; diabetes
ORG 2766	4-(methylsulfonyl)-L-2-aminobutanoyl-L-alfa-glutamyl-L-histidyl-L-phenylalanyl-D-lysyl-L-phenylalanine	corticotropin analogue	diabetes; neuropathy
interleukin-4 receptor inhibitors	Unspecified	cytokine inhibitor	asthma; diabetes
drug delivery system, bromocriptine; bromocriptine delivery system; ERGOSET	Unspecified	dopamine agonist	diabetes; obesity; cancer
dopamine D1/D2 agonists	Unspecified	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	obesity; diabetes
NBI 6024	Unspecified	Down regulation of immune mediated process	diabetes

fructose 1,6-bisphosphatase inhibitors	Unspecified non-nucleotide, nonphosphate	fructose 1,6-bisphosphatase inhibitors	diabetes
bovine cerebral ganglioside; E 0704; CRONASSIAL	Unspecified	ganglioside	neuropathy; diabetes
gene therapy, diabetes	Unspecified	gene therapy; biotechnology	diabetes
gene therapy, insulinotropin	Unspecified	gene therapy; biotechnology	diabetes
GLP1 agonists	Unspecified	GLP1 agonists	obesity; diabetes
BAY 279955	Unspecified	glucagon antagonist	diabetes
glucagon antagonists	Unspecified	glucagon antagonist	diabetes
glucagon receptor inhibitors	Unspecified	glucagon antagonist	diabetes
glucagon antagonist	des-His(1)[Nle(9)-Ala(11)-Ala(16)]glucagon	glucagon antagonist; peptide	diabetes
drug delivery system, glucagon intranasal; glucagon, intranasal	Unspecified	Glucagon hormone	diabetes
glucagon; GLUCAGON	Unspecified	Glucagon hormone	diabetes
glucagon; glucagon G; GlucaGen	His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr	Glucagon hormone	diabetes
AZM 134	Unspecified Nonpeptide antagonist	Glucagon-like peptide mimetic	obesity; diabetes
drug delivery system, oral glucagon-like peptide-1	Unspecified	glucagon-like peptide-1	diabetes
glucagon-like peptide-1 mimetic	Unspecified	glucagon-like peptide-1 mimetic	diabetes
glucocorticoid receptor antagonists	Unspecified	glucocorticoid receptor antagonists	diabetes
MDL 25637	2,6-imino-2,6-dideoxy-7-O-(beta-D-glucopyranosyl)-D-glycero-L-gulo-heptitol	Glucohydrolase enzyme inhibitor	diabetes

BM 13677	2-[(3-phenoxypropoxy)iminio]butanoic acid	Gluconeogenesis inhibitor	diabetes
glucose-6-phosphatase inhibitors	Unspecified	glucose 6 phosphatase inhibitor	diabetes
bimoclomol; BRLP 42	N-[2-hydroxy-3-(1-piperidinyl)propoxy]-3-pyridine-carboximidoyl chloride	GLUT4 mRNA expression stimulator	diabetes
glutamic acid decarboxylase, type 1 diabetes therapy,	Unspecified	glutamic acid decarboxylase, type 1 enzyme	diabetes
diabetes therapy	Unspecified	Glycoprotein, novel	diabetes
ALT 711	Unspecified	Glycosylation end points crosslink breaker	diabetes; cardiovascular disease
ALT 766	Unspecified	Glycosylation end points crosslink breaker	diabetes; cardiovascular disease; Alzheimer disease
pimagedine; pimagedine hydrochloride; aminoguanidine; GER 11; YM 585	aminoguanidine	Glycosylation end-product inhibitor	diabetes; kidney disease; retinopathy; atherosclerosis; neuropathy; stroke
GM 1306	Unspecified	growth factor modulator	diabetes; retinopathy; cancer
nerve growth factor; NGF; NEULEZE	Unspecified	growth factor; biotechnology; neurotrophic factor	neuropathy; diabetes
neurotrophic factor-3; NT-3; neurotrophin-3	Unspecified	growth factor; neurotrophic factor; biotechnology	neuropathy; diabetes
diabetes therapy, HNF-4 based	Unspecified	Hepatic nuclear factor 4 receptor agonist	diabetes; cardiovascular disease
diabetes therapy	Unspecified	Hexokinase II regulator	diabetes
drug delivery system, insulin secreting implant; insulin secreting implant	Unspecified	Hormone	diabetes

B 2036PEG; PEG-B 2036; TROVERT	Unspecified	Human Growth Hormone receptor antagonist; pegylated	retinopathy; acromegaly; cancer; diabetes; kidney disease
hypoglycemic	N-(4-acetylamino-phenylsulphonyl)-1,3-dioxepino[5,6-b]aziridine	Hypoglycemic	diabetes
BM 130907	5-(4-(chlorophenyl))-2-(4-methyl-phenylsulfonyl)-4-pentynoic acid	Hypoglycemic agent	diabetes
MTP 3631	7,8-dihydro-4-(3-hydroxypiperidinyl)-2-piperazinyl-6H-thiopyrano[3,2-d]pyrimidine-5,5-dioxide	Hypoglycemic agent	diabetes
hypoglycemic 2-oxiranecarboxylate derivatives	2-[6-(2-thienylmethoxy)hexyl]oxiranecarboxylic acid ethyl ester	Hypoglycemic agents	diabetes
PEPTIMER	Unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
fluasterone	Unspecified	immunosuppressant	cancer; diabetes; systemic lupus erythematosus
insulin-dependent diabetes therapy	Unspecified	immunosuppressant	diabetes
apoptosis-inducing antigen, diabetes; IG 2; IG2	Unspecified	immunosuppressant; apoptosis inducer	diabetes
AI 401	Unspecified	immunosuppressant; hormone	diabetes
PIC 060 analogs	Unspecified	immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
VX 10393	Unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes

VX 10428	Unspecified	immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; psoriasis; diabetes
AI 402	Unspecified	immunosuppressant; peptide	diabetes
HOE 1423	Unspecified	insulin analogue	diabetes
insulin lispro; lys-pro insulin; insulin analogue; LY 275585; HUMALOG	28B-L-lysine-29B-L- proline insulin (human)	insulin analogue	diabetes
insulin glargine; HOE 901	human [A21-glycine, B31-arginine, B32- arginine] insulin	insulin analogue	diabetes
insulin analogue B9AspB27Glu; insulin monomeric analogue	Unspecified	insulin analogue	diabetes
LY 197535	Unspecified	insulin analogue	diabetes
insulin detemir; NN 304	Human 29B-[N6-(1- oxotetradecyl)-L- lysine]-(1A- 21A),(1B-29B)- Insulin	insulin analogue	diabetes
insulin aspart; NovoRapid	insulin (human), 28B- L-aspartic acid	insulin analogue	diabetes
drug delivery system, oral insulin; insulin oral; ORALIN; ORALGEN	Unspecified	Insulin hormone	diabetes
drug delivery system, ORASOME, insulin; insulin oral ORASOME	Unspecified	Insulin hormone	diabetes
drug delivery system, TRANSFERSOMES transdermal insulin; TRANSFERSULIN	Unspecified	Insulin hormone	diabetes
insulin, human, BioTechnology General	Unspecified	Insulin hormone	diabetes



insulin, human; HR 1799; INSUMAN	Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn (chain A) Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr (B chain)	Insulin hormone	diabetes
drug delivery system, BEODAS insulin; insulin BEODAS	Unspecified	Insulin hormone	diabetes
drug delivery system, insulin secreting implant; insulin secreting implant; EndoCRIB	Unspecified	Insulin hormone	diabetes
drug delivery system, insulin secreting implant; insulin secreting implant	Unspecified	Insulin hormone	diabetes
drug delivery system, insulin subcutaneous implant; insulin subcutaneous implant	Unspecified	Insulin hormone	diabetes
drug delivery system, MACROMOL oral insulin; insulin MACROMOL; MACRULIN	Unspecified	Insulin hormone	diabetes
drug delivery system, nasal insulin; insulin nasal formulation; NOVOLIN	Unspecified	Insulin hormone	diabetes
drug delivery system, oral copolymer insulin; insulin oral	Unspecified	Insulin hormone	diabetes
drug delivery system, oral insulin; insulin oral delivery system	Unspecified	Insulin hormone	diabetes

drug delivery system, oral insulin; insulin oral delivery system	Unspecified	Insulin hormone	diabetes
drug delivery system, oral nanosphere insulin; insulin oral	Unspecified	Insulin hormone	diabetes
drug delivery system,	Unspecified	Insulin hormone	diabetes
drug delivery system, transdermal BIPHASIX insulin; insulin transdermal	Unspecified	Insulin hormone	diabetes
drug delivery system, transdermal insulin; insulin transdermal	Unspecified	Insulin Hormone	diabetes
drug delivery system, Zot oral insulin; insulin oral	Unspecified	Insulin Hormone	diabetes
RF 1051	Unspecified	Insulin Hormone	obesity; diabetes
drug delivery system, MEDUSA insulin; insulin MEDUSA; BASULIN	Unspecified	Insulin Hormone	diabetes
insulin mimetics, oral,	Unspecified	insulin mimetic	diabetes
oral insulin mimetics,	Unspecified	insulin mimetic	diabetes
diabetes therapy,	(SP-5-21)-oxobis(1- pyrrolidinecarbodithi oato-S,S')vanadium	insulin mimetic	diabetes
L 783281	2-[2-(1,1-dimethyl-2- propenyl)-1H-indol- 3-yl]-3,6-dihydroxy- 5-[7-(3-methyl-2- butenyl)-1H-indol-3- yl]-2,5- cyclohexadiene-1,4- dione	insulin mimetic	diabetes
repaglinide; AGEE 623; AGEE 623 ZW; NN 623PRANDIN	(S)-2-ethoxy-4-[2-[[3- methyl-1-[2-(1- piperidinyl)phenyl]bu tyl]amino]-2- oxoethyl]benzoic acid	Insulin release stimulator	diabetes
Ro 34563	Unspecified	insulin secretagogue	diabetes
JTT 608	trans-4-methyl- gamma- oxocyclohexanebutan oic acid	insulin secretagogue	diabetes

nateglinide; A 4166; AY 4166; YM 026; FOX 988; DJN 608; SDZ DJN608; STARLIX; STARSIS; FASTIC	trans-N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine	insulin secretagogue	diabetes
glucagon-like peptide1; GLP 1	Unspecified	insulin secretagogue; peptide	diabetes
M&B 39890A	N-(3-imidazol-1-ylpropyl)-2-(3-trifluoromethylbenzenesulfonamido)-benzamide hydrochloride	insulin secretion inhibitor; glucagon secretion inhibitor	diabetes
exendin agonists	Unspecified	Insulin secretion stimulation	diabetes
(R)-alpha lipoic acid; (R)-thioctic acid; dextlipotam	Unspecified	insulin sensitizer	diabetes
AM 454	Unspecified	insulin sensitizer	diabetes
BM 170249	Unspecified	insulin sensitizer	diabetes
diabetes therapy	Unspecified	insulin sensitizer	diabetes
DRF 2725	Unspecified	insulin sensitizer	diabetes; hyperlipidemia
insulin potentiating factor; IPF	Unspecified	insulin sensitizer	diabetes
insulin sensitizer	Unspecified	insulin sensitizer	diabetes
insulin sensitizers	Unspecified	insulin sensitizer	diabetes
insulin sensitizers	Unspecified	insulin sensitizer	diabetes
KP 102	Unspecified	insulin sensitizer	diabetes
NN 2344; DRF 2593	Unspecified	insulin sensitizer	diabetes
PNU 106817	Unspecified	insulin sensitizer	diabetes; obesity
PNU 140975	Unspecified	insulin sensitizer	diabetes; obesity
V 411; DIAB II	Unspecified	insulin sensitizer	diabetes
YM 440	Unspecified	insulin sensitizer	diabetes
englitazone; englitazone sodium; CP 68722; CP 72466; CP 72467; CP 724672	(-)-5-[[[(2R)-2-benzyl-6-chromanyl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes; hyperlipidemia
JTT 501	4-[[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-3,5-isoxazolidinedione	insulin sensitizer	diabetes

troglitazone; CS 045; CI 991; GR 92132X; NOSCAL; ReZulin; ROMOZIN; PRELAY	5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes; gynecological
pioglitazone; pioglitazone hydrochloride; AD 4833; U 72107; U 72107A; U 72107E; ACTOS	5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes
rosiglitazone; rosiglitazone maleate; BRL 49653; BRL 49653c; SB 210232; AVANDIA	5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes
isaglitazone; MCC 555	5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes
diabetes therapy	Unspecified	Insulin sensitizing agent	diabetes
insulin agonists,	Unspecified	Insulin small molecule	diabetes
insulin-associated protein tyrosine phosphatase inhibitors	Unspecified	insulin-associated protein tyrosine phosphatase inhibitors	diabetes
insulinotropin; glucagon-like peptide 1; GLP-1; NNC 901170	Unspecified	insulinotropin; glucagon-like peptide 1	diabetes
drug delivery system, insulin-producing beta cells	Unspecified	Insulin-producing beta cells	diabetes
alpha d modulator	Unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	diabetes; atherosclerosis; arthritis; inflammatory bowel disease; respiratory disease

interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion toxin; IL-2 fusion toxin; DAB 486-IL-2; D-IL-2	Unspecified	interleukin-2 diphtheria toxin chimeric protein; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; cancer
denileukin diftitox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL- 2; LY 335348; DAB389IL2; ONTAK	1-388-toxin (Corneybacterium diphtheriae strain C7), N-L-methionyl- 387-L-histidine-388- L-alanine-, (388.fwdarw.2')- protein with 2-133- interleukin 2 (human clone pTIL2-21a)	interleukin-2 diphtheria toxin chimeric protein; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer
islets of neogenesis- associated protein (INGAP)-based therapy	Unspecified	islets of neogenesis- associated protein (INGAP)-based therapy	diabetes
leptin receptor	Unspecified	Leptin receptor	anemia; obesity; diabetes
leptin	Unspecified	Leptin receptor analogs	obesity; diabetes
type II diabetes therapy	Oxidized lipids	Lipid oxidation pathway	diabetes
ALT 420	Unspecified	macrophage stimulator	diabetes; neuropathy; retinopathy; kidney disease
macrophage stimulators	Unspecified	macrophage stimulator	diabetes; neuropathy; retinopathy; kidney disease
NEPHROSTAT	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor	kidney disease; diabetes
ilomastat; GM 6001; CS 610; GALARDIN; GALARDIN MPI	N4-hydroxy-N1-[1- (1H-indol-3- ylmethyl)-2- (methylamino)-2- oxoethyl]-2-(2- methylpropyl)- butanediamide	matrix metalloproteinase inhibitor; proteinase inhibitor	retinopathy; diabetes; cancer

melanocortin receptor-4 modulators	Unspecified	melanocortin agonist; melanocortin MC1 agonist	obesity; diabetes
obesity therapy, diabetes therapy	Unspecified	melanocortin agonist; melanocortin MC4 agonist	obesity; diabetes
MAB, A1717; MAB A717	Unspecified	monoclonal antibody	diabetes
MAB, adrenomedullin	Unspecified	monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
monoclonal antibody, leptin receptor	Unspecified	monoclonal antibody; biotechnology	diabetes; anemia; obesity
MAB, VLA-4, humanized; MAB, very late antigen-4, humanized	Unspecified	monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
oxcarbazepine; CGP 47680; KIN 493; GP 47680; TRILEPTAL; TOXECAR	10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide	Na <sup>+</sup> channel modulator	epilepsy; diabetes; neuropathy
mexiletine; KO 1173; MEXITIL	1-methyl-2-(2,6-xylyloxy)ethylamine hydrochloride	Na <sup>+</sup> channel open and native open state blockade	neuropathy; arrhythmia; diabetes
MSI 1436	Steroidal compound; dog fish shark isolate	Na <sup>+</sup> /H <sup>+</sup> antiporter modulation	viral infection; restenosis; diabetes; cancer
neurotrophin-4; NT-4	Unspecified	neurotrophic factor; growth factor	neuropathy; diabetes
NS 521	Unspecified	neurotrophic factor; growth factor	Alzheimer disease; neuropathy; cancer; diabetes
NOX 100	Unspecified	nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 51	Unspecified	nitric oxide scavenger	diabetes; cancer; cardiovascular disease; transplant rejection; septic shock
NOX 101	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease

AXC 4047	Unspecified	Nonglucagon receptor antagonist	diabetes
acetyl-L-carnitine; acetylcarnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine	Nootropic, acetylcholine mimetic	Alzheimer disease; stroke; diabetes; neuropathy
autoimmune disease therapy,	Unspecified	NSAID	diabetes; rheumatoid arthritis
nucleoside mimetics,	Unspecified	nucleoside analogue	diabetes
orlistat; orlipastat; tetrahydrolipistatin; THL; Ro 180647; XENICAL	N-formyl-L-leucine [2S-[2alpha(R*),3beta]]-1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester	pancreatic lipase inhibitor	obesity; hyperlipidemia; diabetes
C-peptide analogues	Unspecified	peptide	diabetes; kidney disease
CP 95253	Unspecified	peptide	diabetes
exendin 4; exendin-4; AC 2993	Unspecified	peptide	diabetes
exendin agonists,	Unspecified	peptide	diabetes
glucagon-like peptide; GLP-1	Unspecified	peptide	diabetes
insulin B chain peptide	Unspecified	peptide	diabetes
NBI 115	Unspecified	peptide	diabetes
phosphoenol pyruvate carboxykinase modulators; PEPCK modulators	Unspecified	phosphoenol pyruvate carboxykinase modulators; PEPCK modulators	diabetes
ALFA 366	Unspecified	platelet antiaggregant	kidney disease; diabetes
ALFA 642	Unspecified	platelet antiaggregant	diabetes; kidney disease
iroplact; platelet factor 4; PF4; endostatin B; REPLISTATIN	Unspecified	Platelet factor 4	heparin neutralization; psoriasis; HIV infection; cancer; diabetes
NN 5501	Unspecified	potassium channel activator	diabetes

mitiglinide; mituglimide calcium hydrate; KAD 1229; S 21403	[2(S)-cis]-octahydro- gamma-oxo-alpha- (phenylmethyl)-2H- isoindole-2-butanoic acid, calcium salt.	potassium channel blocker; insulin secretagogue	diabetes
potassium channel modulators	Unspecified	potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
PPAR-gamma agonist SB 219994	Unspecified	PPAR agonist	diabetes
GW 1929	N-(2-benzoylphenyl)- O-[2-(methyl-2- pyridinylamino)ethyl] -L-tyrosine	PPAR agonist	diabetes
GW 9820	Unspecified	PPAR agonist; fibrate	diabetes
GI 262570	Unspecified	PPAR agonist; retinoid agonist	diabetes
PPAR modulators, metabolic diseases S 18277	Unspecified	PPAR modulation	diabetes
SDZ PGU 693	2-[(4- chlorophenoxy)methy l]-7a-(3,4- dichlorophenyl)tetrah ydropyrrolo[2,1- b]oxazol-5(6H)-one	PPAR modulation	diabetes
prohormone convertase 2 inhibitors	Unspecified	Prohormone convertase 2 inhibitors	diabetes
beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro- 2-hydroxy-1-(3- hydroxy-4-methyl-1- octen-6-ynyl)-1H- cyclopenta[b]benzofu ran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
LY 333531	(S)-9- [(dimethylamino)met hyl]-6,7,10,11- tetrahydro-9H,18H- 5,21:12,17- dimethenodibenzo[e,k ]pyrrolo[3,4- h][1,4,13]oxadiazacyc lohexadecine- 18,20(19H)-dione	protein kinase inhibitor; protein kinase C inhibitor	diabetes; retinopathy



RAGE modulators	Unspecified	RAGE modulators	diabetes
diabetes therapy	Unspecified	retinoid	diabetes
bexarotene; LGD 1069; LG 100069; LG 1069; LDG 1069; TARGRETIN	4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthenyl)-1-ethenyl]-benzoic acid	retinoid agonist; retinoid; differentiation inducer; RXR agonist	cancer; diabetes; psoriasis; skin disease
AGN 4326	Unspecified	retinoid agonist; RXR agonist	diabetes
LGD 1324; ALRT 324	Unspecified	retinoid agonist; RXR agonist	diabetes; cancer
RXR agonist, second generation	Unspecified	retinoid agonist; RXR agonist; insulin sensitizer	diabetes
AGN 4204; ALRT 4204	Unspecified	RXR agonist; retinoid agonist	diabetes
ALRT 326	Unspecified	RXR agonist; retinoid agonist	diabetes
LGD 1268; ALRT 268	Unspecified	RXR agonist; retinoid agonist	diabetes; cancer
signal transduction inhibitor, SUGEN/ArQule	Unspecified	signal transduction inhibitor; immunosuppressant	cancer; diabetes; neurological; autoimmune disease
insulin-like growth factor-1 coupled with binding protein; IGF-BP3; SomatoKine	Unspecified	somatomedin C coupled with binding protein hormone; cicatrizant; growth factor	osteoporosis; musculoskeletal disorder; skin ulcer; diabetes
lanreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSTYL	3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2,7)-disulfide	somatostatin analogue	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly

drug delivery system, controlled release GEOMATRIX glibenclamide; glibenclamide GEOMATRIX	Unspecified	sulfonylurea	diabetes
drug delivery system, controlled release glibenclamide; glibenclamide controlled release; Glynase PresTab	Unspecified	sulfonylurea	diabetes
drug delivery system, GEOMATRIX controlled release glipizide; glipizide GEOMATRIX	Unspecified	sulfonylurea	diabetes
drug delivery system, GITS glipizide; glipizide GITS; GLUCOTROL XL; GLUCOTROL GITS	Unspecified	sulfonylurea	diabetes
glibenclamide cyclodextrin; cyclodextrin glibenclamide; CHF 1522	Unspecified	sulfonylurea	diabetes
glimepiride; HOE 490; AMARYL	trans-3-ethyl-2,5- dihydro-4-methyl-N- [2-[4-[[[(4- methylcyclohexyl)am ino]carbonyl]amino]s ulfonyl]phenyl]ethyl]- 2-oxo-1H-pyrrole-1- carboxamide	sulfonylurea	diabetes
ZD 9583	Unspecified	thromboxane antagonist; thromboxane synthetase inhibitor	diabetes
etanercept; tumor necrosis factor receptor; TNFr; TNR 001; ENBREL	Unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease
MNX 160	Unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; diabetes; multiple sclerosis

NEURULIN	Unspecified	Topical diabetic neuropathy	diabetes; neuropathy
diabetes therapy	Unspecified	transcription activator	diabetes
insulin RTP antagonist	Unspecified	tyrosine phosphatase inhibitor	diabetes
ALT 946	Pimagedine derivative	Unspecified	diabetes; neuropathy; retinopathy; kidney disease
AR H039242XX	Unspecified	Unspecified	diabetes; atherosclerosis
BST 4001; PYRIDORIN	Vitamin B6 derivative	unspecified	diabetes; kidney disease
BTS 67587	Unspecified	Unspecified	diabetes
diabetes therapy,	Unspecified	Unspecified	diabetes
diabetes therapy	Unspecified	Unspecified	diabetes; obesity; hyperlipidemia
diabetes therapy	Unspecified	Unspecified	diabetes
diabetes therapy	Unspecified	Unspecified	diabetes
DW 391	Unspecified	Unspecified	diabetes
fagopyritols	Alpha-galactosyl-D-chiro inositols	Unspecified	diabetes
fagopyritols	Alpha-galactosyl-D-chiro inositols	Unspecified	diabetes
gammalinolenic acid; EF 4; TARABETIC	gammalinolenic acid; EF 4; Unspecified	Unspecified	diabetes; neuropathy
INS 1	Unspecified	Unspecified	diabetes; gynecological
LG 1411	Biotin derived, Unspecified	Unspecified	diabetes
metabolic disease therapy,	Unspecified	unspecified	diabetes
metabolic disorder therapy	Unspecified	Unspecified	diabetes; obesity; hyperlipidemia
metabolic disorders,	Unspecified	Unspecified	diabetes; obesity; hyperlipidemia
MGI 197	Unspecified	Unspecified	retinopathy; diabetes
MKC 542	Unspecified	Unspecified	diabetes
MXC 3255; MXC3255	Unspecified	Unspecified	diabetes
NNC 051869	Unspecified	Unspecified	neuropathy; diabetes
P 30	Unspecified	Unspecified	diabetes
PN 401	Unspecified	Unspecified	diabetes; neuropathy
SEROSET	Unspecified	Unspecified	diabetes; obesity
SP 134101	Plant extract	Unspecified	diabetes
TV 2251	Unspecified	Unspecified	diabetes

vanadeine	Vanadyl containing compound	Unspecified	diabetes
AS 6	[1R-[1 alpha(2E,4E)2beta,6beta]]-[2-chloro-4-formyl-5-hydroxy-3-methyl-6-[3-methyl-5-(1,2,6-trimethyl-3-oxocyclohexyl)-2,4-pentadienyl]phenoxy]acetic acid	Unspecified	diabetes
succibun	1-[4-N-butylureasulfonyl(phenyl)]pyrrolidin-2,5-dione	Unspecified	diabetes
AY 31637	5-(2-naphthalenylsulfonyl)-2,4-thiazolidine-dione	Unspecified	diabetes
maglivan	bis(2-amino-3-mercapto-N-octylpropanamido-O,S)oxovanadium	Unspecified	diabetes
BTS 67582	N,N'-dimethyl-N'-[2-(4-morpholinyl)phenyl]-guanidine, (E)-2-butenedioate	Unspecified	diabetes
U 10483	Unspecified	Unspecified NIDDM	diabetes
DiaPep 277	Unspecified	vaccine	diabetes
vaccine, diabetes type 1; diabetes type 1 vaccine	Unspecified	vaccine	diabetes
vaccine, diabetes	Unspecified	vaccine; peptide	diabetes
20-epi-1,25 dihydroxyvitamin D3; MC 1288; IE	(1alpha,3beta,5Z,7E,20S)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue; immunosuppressant	diabetes; transplant rejection; arthritis

Table 51. Current Candidate Therapeutic Interventions for the Treatment of Obesity

Product Name	Chemical Name	Action	Indication
obesity therapy	Unspecified	5HT agonist; 5HT2C agonist	obesity

sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
Dexfenfluramine; dexfenfluramine hydrochloride; S 5614; IP 001; ISOMERIDE; ADIFAX; ARDIX; ISOLIPAN; SIRAN; OBESINE; FLURIL; DISPONDAL; REDUX	(S)-N-ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine	5HT reuptake inhibitor	obesity; depression; nicotine withdrawal
sibutramine; sibutramine hydrochloride monohydrate; BTS 54524; REDUCTIL; MERIDIA	1-(4-chlorophenyl)-N,N-dimethyl-alpha-(2-methylpropyl)cyclobutanemethanamine hydrochloride monohydrate	5HT reuptake inhibitor; noradrenalin reuptake inhibitor	obesity
sibutramine, (S)-; (S)-sibutramine	1-(4-chlorophenyl)-N,N-dimethyl-alpha-(2-methylpropyl)cyclobutanemethanamine	5HT reuptake inhibitor; noradrenalin reuptake inhibitor	obesity
Obesity therapy	Unspecified	5HT1 human neuroreceptor ligands, 5HT1 receptor pathway	obesity; anxiety; depression; migraine; drug design technology
MAB, adipocytes	Unspecified	Adipocyte monoclonal antibody	obesity
adiposin; lipotropin	Unspecified	Adiposin, lipotropin pathways	obesity; cancer
RP 55462	6-chloro-5-methyl-N-(1-methylethyl)-2-(1-piperazinyl)-4-pyrimidinamine	alpha adrenergic antagonist; alpha2 adrenergic antagonist	obesity
AZM 016	Unspecified	amylase inhibitor	obesity; diabetes
AZM 120	Unspecified	amylase inhibitor	obesity; diabetes
AZM 127	Unspecified	amylase inhibitor	obesity; diabetes
AZM 140	Unspecified	amylase inhibitor	obesity; diabetes
galanin modulators	Unspecified	analgesic	obesity; diabetes; cognitive defect; pain

galanin1 antagonists	Unspecified	analgesic	obesity; pain; cognitive defect
SNX 024	Typtoline analogue	Appetite suppressant	obesity
AZM 090	unspecified	Appetite suppressant	obesity
AZM 114	Unspecified	Appetite suppressant	obesity
AZM 115	Unspecified	Appetite suppressant	obesity
AZM 132	Unspecified	Appetite suppressant	obesity
biamine	Unspecified	Appetite suppressant	obesity
BTS 78050	Unspecified	Appetite suppressant	obesity
obesity therapy	Aminosterols	Appetite suppression	obesity
P 57	Plant extract	Appetite suppression	obesity
obesity therapy	Unspecified	Beta 3 adrenergic receptor oligonucleotide	obesity
BRL 26830A	(R,R) (+,-)methyl 4-(2-((2-hydroxy-2-phenylethyl)amino)propyl)benzoate	beta adrenergic agonist	obesity
BMS 194449	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 201620	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 210285	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity
LY 362884	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
ULTG 307	Unspecified	beta adrenergic agonist; beta3 adrenergic agonist	obesity
BRL 35135; BRL 35135A	(R*,R*)-(+,-)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid methyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
BRL 37344	(R*,R*)-(+,-)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid	beta adrenergic agonist; beta3 adrenergic agonist	obesity

CL 314698	(R*,R*)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid dimethyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
ICI 198157	(S)-(-)-(methyl-(4-(2-((2-hydroxy-3-phenoxypropyl)amino)ethoxy)phenoxy)acetate	beta adrenergic agonist; beta3 adrenergic agonist	obesity
LY 377604	(S)-6-[4-[2-[[3-(9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-3-pyridinecarboxamide monohydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	obesity
AJ 9677; AD 9677	[[3-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yl]oxy]-acetic acid	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
CL 316243; BTA 243	[R-(R*,R*)]-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid, disodium salt.	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
SR 56811; SR 58611A; SR 58611; ME 3411	[R-(R*,S*)]-[[7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]acetic acid ethyl ester hydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	irritable bowel syndrome; obesity; depression
ZD 2079; ICI D2079	4-[2-[[2-(2R)-2-hydroxy-2-phenylethyl]amino]ethoxy]benzeneacetic acid hydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity

BMS 196085	N-[5-[(1R)-2-[(1R)-1-[4-(difluoromethoxy)phenyl]-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
beta3 adrenergic receptor agonists	Unspecified	beta3 adrenergic agonist; beta adrenergic agonist	obesity
A 71378	N-[1-oxo-3-[4-(sulfooxy)phenyl]propyl]-L-norleucylglycyl-L-tryptophyl-L-norleucyl-N-methyl-L-alfa-aspartyl-L-phenylalanineamide	Cholecystokinin A agonist; cholecystokinin agonist; peptide	obesity
FPL 15849	Unspecified	cholecystokinin agonist; cholecystokinin A agonist	obesity
GI 248573	Unspecified	cholecystokinin agonist; cholecystokinin A agonist	obesity; cholestasis
SR 146131	Unspecified	cholecystokinin agonist; cholecystokinin A agonist	obesity
FPL 14294	(Hpa(S03H)-Met-Gly-Trp-Met-Asp-MePhe-NH <sub>2</sub> NH <sub>3</sub> )	cholecystokinin agonist; cholecystokinin A agonist	obesity
A 71623	N-[(1,1-dimethylethoxy)carbonyl]-L-tryptophyl-N6-[[[(2-methylphenyl)amino]carbonyl]-L-lysyl-L-alfa-aspartyl-N-alfa-methyl-L-phenylalaninamide	cholecystokinin agonist; peptide	obesity



CMI 477	(1S-exo)-2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane	cholinergic agonist; nicotinic agonist; analgesic	obesity; depression; Alzheimer disease; nicotine withdrawal
corticotrophin releasing factor (CRF) agonists	Unspecified	CRF receptor ligand	obesity
drug delivery system, bromocriptine; bromocriptine delivery system; ERGOSET	Unspecified	dopamine agonist	diabetes; obesity; cancer
dopamine D1/D2 agonists	Unspecified	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	obesity; diabetes
drug delivery system, dopamine; dopamine delivery system; NMI 8739; DOPREXIN	Unspecified	Dopaminergic receptor ligand	obesity; Parkinson disease
Galanin receptor modulators	Unspecified	Galanin receptor modulators	obesity
GLP1 agonists	unspecified	GLP1 agonists pathway	obesity; diabetes
AZM 134	unspecified	Glucagon-like peptide 1	obesity; diabetes
RF 1051	Unspecified	hormone	obesity; diabetes
AOD 9604	Human growth hormone analogue	Human growth hormone receptor ligand	obesity
obesity therapy, Obesys; obesity therapy, BTG	Unspecified	Immunomodulation	obesity
PNU 106817	Unspecified	insulin sensitizer	diabetes; obesity
PNU 140975	Unspecified	insulin sensitizer	diabetes; obesity
leptin	Unspecified	Leptin pathway	obesity; diabetes
leptin receptor	Unspecified	Leptin pathway	anemia; obesity; diabetes
leptin, second generation	Unspecified	Leptin pathway	obesity
obesity therapy	Unspecified	Leptin pathway	obesity
leptin agonists	Unspecified	Leptin receptor pathway	obesity
leptin expression modulators	Unspecified	Leptin receptor pathway	obesity

leptin modulator	Unspecified	Leptin receptor pathway	obesity
leptin signalling pathway modulators	Unspecified	Leptin receptor pathway	obesity
ATL 962	Unspecified	lipase inhibitor	obesity
AZM 008	Unspecified	lipase inhibitor	obesity; atherosclerosis
AZM 097	Unspecified	lipase inhibitor	obesity; atherosclerosis
AZM 108	Unspecified	lipase inhibitor	obesity; atherosclerosis
AZM 119	Unspecified	lipase inhibitor	obesity; atherosclerosis
AZM 131	Unspecified	lipase inhibitor	obesity
natural lipase inhibitor	Unspecified	lipase inhibitor	obesity; atherosclerosis
obesity therapy	Unspecified	lipase inhibitor	obesity
MCR4 modulators	Unspecified	MCR4 receptor pathway	obesity
melanocortin receptor-4 modulators	Unspecified	melanocortin agonist; melanocortin MC1 agonist	obesity; diabetes
Melanocortin-4 receptor agonist	Unspecified	melanocortin agonist; melanocortin MC4 agonist	obesity
Obesity therapy, diabetes therapy	Unspecified	melanocortin agonist; melanocortin MC4 agonist	obesity; diabetes
JTT 722	Unspecified	microsomal transfer protein inhibitor	hyperlipidemia; obesity
monoclonal antibody, leptin receptor	Unspecified	monoclonal antibody; biotechnology	diabetes; anemia; obesity
obesity therapy	Unspecified	Neuropeptide Y and galanin receptor ligands	obesity
AXC 0216	Unspecified	neuropeptide Y antagonist	obesity; hypertension
AXC 1829	Unspecified	neuropeptide Y antagonist	obesity; hypertension
neuropeptide Y antagonist	Unspecified	neuropeptide Y antagonist	obesity; hypertension
NGD 951; NGD 95-1; CP 422935	Unspecified	neuropeptide Y antagonist	obesity; eating disorder

Neuropeptide Y antagonists	Unspecified	neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
Neuropeptide Y1 antagonists	Unspecified	neuropeptide Y antagonist; neuropeptide Y1 antagonist	obesity
BIBP 3226	(R)-N-[4-[(aminoiminomethyl)amino]-1-[[[(4-hydroxyphenyl)methyl]amino]carbonyl]butyl]-alpha-phenylbenzeneacetamide	neuropeptide Y antagonist; neuropeptide Y1 antagonist	obesity
SR 120819A	[alpha R-[N[R*(cis)],alpha R*]]-N-[1-[[4-[[[(dimethylamino)methyl]cyclohexyl)methyl]amino]iminomethyl]phenyl)methyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-alpha-[(2-naphthalenylsulfonyl)amino]benzenepropanamide	neuropeptide Y antagonist; neuropeptide Y1 antagonist	hypertension; obesity; eating disorder
Neuropeptide Y antagonists	Unspecified	neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypotension; obesity; depression
Neuropeptide Y5 antagonist	Unspecified	neuropeptide Y antagonist; neuropeptide Y5 antagonist	obesity
Neuropeptide Y5 antagonists	Unspecified	neuropeptide Y antagonist; neuropeptide Y5 antagonist	obesity
Neuropeptide Y receptor modulators	Unspecified	Neuropeptide Y receptor modulation	obesity
SEROSET	Unspecified	Neurotransmitter modulating agent	diabetes; obesity

AXOKINE	Unspecified	neurotrophic growth factor	amyotrophic lateral sclerosis; obesity; eye disease
Amfebutamone; bupropion hydrochloride; bupropion; bupropin; BW 323U; WELLBUTRIN; ZYBAN	(+,-)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone	noradrenalin reuptake inhibitor	depression; nicotine withdrawal; obesity
drug delivery system, liposome oleoyl-estrone;	oleoyl-estrone liposome	Oleoyl estrone activity	obesity
LY 255582	[3R-[1(S*),3alpha,4alpha]-alpha-cyclohexyl-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanol	opiate antagonist	obesity
nalmeferene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
opioid antagonists	Unspecified	opiate antagonist; peptide; immunosuppressant	addiction; alcoholism; obesity; transplant rejection
orlistat; orlipastat; tetrahydrolipistatin; THL; Ro 180647; XENICAL	N-formyl-L-leucine [2S-[2alpha(R*),3beta]]-1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester	pancreatic lipase inhibitor	obesity; hyperlipidemia; diabetes
A 68552	Unspecified	peptide	obesity
SNAP 1156	Unspecified	peptide	anxiety; hypertension; obesity; addiction
enterostatin; D 3800	N2-[1-[N-(1-L-valyl-L-prolyl)-L-alpha-aspartyl]-L-prolyl]-L-arginine	peptide	obesity
obesity therapy	Unspecified	PPAR gamma	obesity; diabetes

butabindide; UCL 1397	[S-(R*,R*)]-1-(2-Amino-1-oxobutyl)-N-butyl-2,3-dihydro-1H-indole-2-carboxamide	proteinase inhibitor; serine proteinase inhibitor	obesity
posatiirelin; RGH 2202	(S)-N-[(6-oxo-2-piperidinyl)carbonyl]-L-leucyl-L-prolinamide	protirelin analogue	cognitive defect; obesity
orotirelin; CG 3509	N-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-L-prolinamide	protirelin analogue	obesity; neuropathy
PPAR modulators	Unspecified	retinoid	atherosclerosis; obesity
obesity therapy, SIDR	Plant extract	Sustained weight loss partially dissociated from a reduction in food intake	obesity
mazindol; MAZANOR; SANOREX	5-(4-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol	Sympathomimetic	obesity
thyroid hormone receptor beta agonist	Unspecified	thyroid hormone agonist	obesity; hyperlipidemia
diabetes therapy	Unspecified	Unspecified	diabetes; obesity; hyperlipidemia
FPL 69931	Unspecified	Unspecified	obesity

Table 52. Current Candidate Therapeutic Interventions for the Treatment of Contraception

Product Name	Chemical Name	Action	Indication
drug delivery system, MENT implant; MENT implant	7-alpha-methyl-19-nortestosterone	androgen	contraception; hypogonadism
testosterone buciclate; testosterone bucyclate	17[[[(4-butylcyclohexyl)carbonyl]oxy]androst-4-en-3-one	androgen; hormone replacement therapy	hypogonadism; contraception
saralasin; saralasin acetate; aralasin; P 113; P 113 (peptide); SARENIN	1-(N-methylglycine)-5-L-valine-8-L-alanineangiotensin II	angiotensin II antagonist	hypertension; contraception; diagnosis

anordrin; Pill No. 53; vacation pill; ANORDRIN; AF 45	(2beta,5alpha,17alpha)-2-ethynyl-A-norpregn-20-yne-2,17-diol dipropionate	antiestrogen	contraception
CDRI 85287	1-[2-[4-(3-phenyl-2H-1-benzopyran-2-yl)phenoxy]ethyl]piperidine	antiestrogen	contraception
CDB 2914; RTI 3021-012	(11beta)-17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione	antiprogesterone	contraception
onapristone; ZK 98299; SH 549; ZK 299	(11beta,13alpha,17alpha)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)estra-4,9-dien-3-one	antiprogesterone	cancer; contraception
mifepristone; RU 486; RU 4866; RU 38486; R 38486; MIFEGYNE	(11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one	antiprogesterone	abortion; cancer; contraception
ORG 31710	(6beta,11beta,17beta)-11-[4-(dimethylamino)phenyl]-4',5'-dihydro-6-methyl-spiro[estra-4,9-diene-17,2'(3'H)-furan]-3-one	antiprogesterone	cancer
ZK 137316	Unspecified	antiprogesterone	contraception
RTI 4587056	Unspecified	Antispermatozoicidal	contraception
male contraceptive	Sugar analogue and derivatives	B variant of N-acetyl-beta-D-glucosaminidase inhibition (only found in sperm)	contraception
vaccine, human chorionic gonadotropin; vaccine, hCG	Unspecified	biotechnology; vaccine	contraception
vaccine, zona protein A	Unspecified	biotechnology; vaccine	contraception

vaccine, zona protein B	Unspecified	biotechnology; vaccine	contraception
cyproterone + estradiol valerate; estradiol valerate + cyproterone; FEMILAR	Unspecified	estrogen	contraception
ethinylestradiol cyclodiol; SH 580; ZK 4944 + ZK 115194	Unspecified	estrogen	contraception
levormeloxifene; NNC 460020	(3R-trans)-1-[2-[4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine	estrogen partial agonist	osteoporosis
J 995	(17beta)-estra-1,3,5(10)-triene-3,17-diol 3-sulfamate	estrogen; hormone replacement therapy	hormone deficiency; contraception
cyproterone acetate + ethinylestradiol; ethinylestradiol + cyproterone acetate; SH 592; ZK 4944 + ZK 9471	Unspecified	estrogen; progestogen	contraception; acne
dienogest + ethinylestradiol; ethinylestradiol + dienogest; SH 659; VALETTE	Unspecified	estrogen; progestogen	contraception
drospirenone + ethinylestradiol; ethinylestradiol + drospirenone; SH 470; ZK 4944 + ZK 30595	Unspecified	estrogen; progestogen	contraception
drug delivery system, IVR estrogen + progestogen; estrogen + progestogen intravaginal ring; progestogen + estrogen intravaginal ring	Unspecified	estrogen; progestogen	contraception

drug delivery system, IVR norethisterone + ethinylestradiol; norethisterone + ethinylestradiol intravaginal ring	Unspecified	estrogen; progestogen	contraception
ethinylestradiol + gestodene; gestodene + ethinylestradiol; SH 543; ZK 4944 + ZK 67998; MELIANE	Unspecified	estrogen; progestogen	contraception
gestodene + ethinylestradiol; ethinylestradiol + gestodene; SH 575; ZK 4944 + ZK 67998	Unspecified	estrogen; progestogen	contraception
norethindrone acetate + ethinyl estradiol; ethinyl estradiol + norethindrone acetate; CI 376; ESTROSTEP	Unspecified	estrogen; progestogen	contraception
norethindrone acetate + ethinyl estradiol; CI 1001	Unspecified	estrogen; progestogen	contraception
norethindrone enanthate + estradiol valerate; estradiol valerate + norethindrone enanthate; SH 329; ZK 5410 + ZK 5104; MESIGYNA	Unspecified	estrogen; progestogen	contraception
norgestimate + ethinylestradiol; ethinylestradiol + norgestimate; CILEST; ORTHOCYCLEN	Unspecified	estrogen; progestogen	contraception
ethinylestradiol + norethisterone; ME 3501; ORTHO-NOVUM 10/11; ELLIOT	(17alpha)-19-nor-prega-1,3,5(10)-trien-20-yne-3,17-diol and (17alpha)-17-hydroxy-19-norpregna-4-en-20-yn-3-one	estrogen; progestogen	contraception



estradiol + ORG 30659; ORG 30659 + estradiol; ORG 30659	Unspecified	estrogen; progestogen; hormone replacement therapy	contraception; osteoporosis
CaRest M3	Unspecified	Glycoprotein protective coat destruction	cancer; contraception
histrelin; ORF 17070; SUPPRELIN	6-[1-(phenylmethyl)-D-histidine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing hormone releasing factor (pig)	gonadorelin agonist	precocious puberty
leuprolide + estrogen + progesterone	Unspecified	gonadorelin agonist; estrogen; progestogen	contraception; cancer
drug delivery system, histrelin hydrogel implant; histrelin hydrogel implant	Unspecified	gonadorelin agonist; peptide	precocious puberty; cancer
drug delivery system, microcapsule SB 75; SB 75 microcapsule	Unspecified	gonadorelin antagonist	cancer; contraception
cetrorelix; SB 75; SB 075; CETROTIDE	N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	infertility; cancer; endometriosis; benign prostate hypertrophy; contraception
detirelix; RS 68439	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-Phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	contraception; cancer

deslorelin; BACHEM 9022; SOMAGARD	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide	gonadorelin superagonist	cancer; precocious puberty
anteovine	Unspecified	Gonadotropin basal periovulatory secretion inhibitor	contraception
drug delivery system, subcutaneous gonadotropin releasing hormone; gonadotropin releasing hormone subcutaneous implant; GnRH subcutaneous implant	Unspecified	hormone	precocious puberty; endometriosis; cancer; contraception
drug delivery system, intravaginal estradiol; estradiol intravaginal	Unspecified	hormone replacement therapy; estrogen	hormone deficiency
arginine derivative,	Unspecified	nitric oxide synthase inhibitor	contraception
drug delivery system, subcutaneous norethindrone subcutaneous implant; ANNUELLE	norethindrone	Norethindrone; estrogen and progestogen	contraception
vaccine, contraceptive, IMMUCON; contraceptive vaccine, IMMUCON	Unspecified	peptide; vaccine	contraception
drug delivery system, implant etonogestrel; etonogestrel implant; drug delivery system, 3-keto-desogestrel; IMPLANON; DESOPLAN	Unspecified	progestogen	contraception
drug delivery system, IVR levonorgestrel; levonorgestrel intravaginal ring; FEMRING	Unspecified	progestogen	contraception

drug delivery system, IVR NESTORONE; NESTORONE intravaginal ring	Unspecified	progestogen	contraception
drug delivery system, IVR progesterone; progesterone intravaginal ring	Unspecified	progestogen	contraception
drug delivery system, levonorgestrel; levonorgestrel drug delivery system; NORPLANT II; NORPLANT; NORPLANT 2	Unspecified	progestogen	contraception
drug delivery system, NESTORONE subdermal implant; NESTORONE subdermal implant	Unspecified	progestogen	contraception
drug delivery system, transdermal NESTORONE; NESTORONE bracelet	Unspecified	progestogen	contraception
levonorgestrel butanoate	Unspecified	progestogen	contraception
gestrinone; R 2323; RU 2323; A 46745; DIMETROSE; NEMESTRAN; DIMETRIOSE	(17alpha)-13-ethyl- 17-hydroxy-18,19- dinorpregna-4,9,11- trien-20-yn-3-one	progestogen	endometriosis
dienogest; dienogestril; SH 660; STS 557; M 18575; MJR 35; ENDOMETRION	(17alpha)-17- hydroxy-3-oxo-19- norpregna-4,9-diene- 21-nitrile	progestogen	endometriosis; contraception
ST 1435; NESTORONE	17-(acetyloxy)-16- methylene-19- norpregn-4-ene-3,20- dione	progestogen	contraception

drospirenone; ZK 30595	[6R-(6 $\alpha$ ,7 $\alpha$ ,8 $\beta$ ,9 $\alpha$ ,10 $\beta$ ,13 $\beta$ ,14 $\alpha$ ,15 $\alpha$ ,16 $\alpha$ ,17 $\beta$ )]-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione	progestogen; aldosterone antagonist	contraception
drug delivery system, IVR NESTORONE + ethinylestradiol; NESTORONE + estradiol intravaginal ring	Unspecified	progestogen; estrogen	contraception
drug delivery system, intrauterine levonorgestrel; IUD levonorgestrel; levonorgestrel interuterine drug delivery system; LNg 20 IUD; SH 650; LEVONOVA; MIRENA	Unspecified	progestogen; hormone replacement therapy	contraception; hormone deficiency
desogestrel; ORG 2969; DESOGEN; MARVELON; MERCILON; OVIDAL; PLANUM; ORTHO-CEPT; CERAZETTE	(17 $\alpha$ )-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol	progestogen; hormone replacement therapy	contraception; hormone deficiency
C 31G; SAVVY	Unspecified	spermicidal	bacterial infection; contraception; HIV infection
DK 1	Unspecified	Spermicidal, germicidal	contraception
DNM 5	Unspecified	Spermicidal, germicidal	contraception

thalidomide; SYNOVIR; THALOMID	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
USHERCELL	Cullose sulfate	Topical contraceptive	contraception; bacterial infection; HIV infection; viral infection
85/83	6,7-dimethoxy-1H-pyrazolo[3,4-b]quinolin-3-amine	Trophoblast cell development inhibitor	contraception
cucumariosid	Unspecified	Unspecified	contraception
drug delivery system, transdermal contraceptive	Unspecified	Unspecified	contraception
praneem	Unspecified	Unspecified	contraception; bacterial infection
immunocontraceptive , human chorionic gonadotropin; vaccine, hCG	Unspecified	vaccine	contraception
vaccine, antisperm	Unspecified	vaccine	contraception
vaccine, contraceptive; contraceptive vaccine	Unspecified	vaccine	contraception
vaccine, FSH; vaccine, contraceptive	Unspecified	vaccine	contraception
vaccine, gonadotropin releasing hormone; vaccine, GnRH; vaccine, contraceptive	Unspecified	vaccine	contraception
vaccine, human chorionic gonadotropin; vaccine, hCG, vaccine, contraceptive; vaccine, lung cancer	Unspecified	vaccine	contraception; cancer
vaccine, human chorionic gonadotropin; vaccine, hCG; vaccine, contraceptive	Unspecified	vaccine	contraception

vaccine, human chorionic gonadotropin beta subunit fragment	Unspecified	vaccine	contraception
vaccine, PH 20; contraceptive vaccine	Unspecified	vaccine	contraception
vaccine, oral contraceptive, IMMUCON; contraceptive vaccine, oral, IMMUCON	Unspecified	vaccine; peptide	contraception
YAL 198	Unspecified	vaccine; peptide	contraception

Table 53. Current Candidate Therapeutic Interventions for the Treatment of Osteoporosis

Product Name	Chemical Name	Action	Indication
ZM 230487; ICI 230487	1-ethyl-6-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-2(1H)-quinolinone	5 lipoxygenase inhibitor	osteoporosis
3-benzothiepin derivative, osteoporosis	(6R-trans)-[[4-[[[(5,6,8,9-tetrahydro-8-methyl-9-oxothiepin-4-yl)carbonyl]amino]phenyl]methyl]phosphonic acid diethyl ester	Alkaline phosphatase activity stimulator	osteoporosis; musculoskeletal disorder
androgen agonists,	Unspecified	Androgen receptor pathway	hypogonadism; osteoporosis
drug delivery system, transdermal testosterone; testosterone transdermal		androgen; hormone replacement therapy	hypogonadism; osteoporosis

drug delivery system, transdermal TheraDerm-LRS testosterone; testosterone TheraDerm-LRS; ANDRODERM; ATMOS; ANDROPATCH; TANDREXEN; ANDROCNOS; TESTOCLIM		androgen; hormone replacement therapy	hypogonadism; osteoporosis
osaterone; osaterone acetate; TZP 4238; HIPROS	17-(acetyloxy)-6-chloro-2-oxapregna-4,6-diene-3,20-dione	antiandrogen	benign prostate hypertrophy; cancer; osteoporosis
droloxifene; droloxifene citrate; 3-hydroxytamoxifen; K 21060E citrate	(E)-alpha-[p-[2-(dimethylamino)ethoxy]phenyl]-alpha-ethyl-3-stilbenol	antiestrogen	cancer; osteoporosis
estrogen receptor modulator,		antiestrogen; estrogen agonist	cancer; osteoporosis
estrogen receptor modulators		antiestrogen; estrogen agonist	cancer; osteoporosis
HMR 3339		antiestrogen; estrogen agonist	osteoporosis
HMR 3656		antiestrogen; estrogen agonist	osteoporosis
raloxifene; keoxifene; LY 139481; LY 156758; EVISTA	[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone	antiestrogen; estrogen agonist	osteoporosis; hyperlipidemia; myocardial infarction; cancer
osteoblast-specific factor; OSF		biotechnology	osteoporosis
osteopoietin; OPO		biotechnology	osteoporosis
osteoprotegerin; OPG		biotechnology	osteoporosis; cancer

drug delivery system, somatomedin C; drug delivery system, insulin-like growth factor-1; somatomedin C DepoFoam; Depo IGF-1		biotechnology; cicatrizant; hormone; NSAID; growth factor	rheumatoid arthritis; osteoporosis
gene therapy, bone growth factor; gene therapy, osteoporosis		biotechnology; gene therapy	osteoporosis
gene therapy, calcitonin; gene therapy, osteoporosis		biotechnology; gene therapy; hormone	osteoporosis
osteoblast stimulating factor; OSF		biotechnology; growth factor	osteoporosis
polyethylene glycol transforming growth factor beta2; PEG-TGF beta2; transforming growth factor beta2 macrogol		biotechnology; growth factor	osteoporosis; psoriasis; eye disease
TGF-beta growth and differentiation factors		biotechnology; growth factor; cicatrizant	skin ulcer; osteoporosis
trafermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; trofermin; KCB 1; CAB 2001; FIBLAST	2-155-fibroblast growth factor, basic (human clone lambda KB7/lambda HFL 1 precursor reduced)	biotechnology; growth factor; cicatrizant	skin ulcer; osteoporosis; stroke; neuropathy; peripheral vascular disease; coronary artery disease
transforming growth factor beta 2; TGF beta2; FOVALIN; BetaKine		biotechnology; growth factor; cicatrizant	retinopathy; osteoporosis; skin ulcer; multiple sclerosis



somatropin; somatotropin; human growth hormone; hGH; CB 311; GENOTROPIN; NUTROPIN; NUTROPIN AQ; CRESCORMON; GENOTONORM	somatotropin (human)	biotechnology; growth hormone	hormone deficiency; growth disorder; Turner syndrome; osteoporosis
calcitonin, human; human calcitonin; hCT; SUN 8577		biotechnology; hormone	osteoporosis
parathyroid hormone		biotechnology; hormone	osteoporosis
parathyroid hormone fragment; BM 06024		biotechnology; hormone	osteoporosis
parathyroid hormone, human; human parathyroid hormone; ALX 111; ALX 1-11		biotechnology; hormone	osteoporosis
TJN 135		biotechnology; hormone	osteoporosis
somatomedin C coupled with binding protein; insulin-like growth factor-1 coupled with binding protein; IGF-BP3;		biotechnology; hormone; cicatrizant; growth factor	osteoporosis; musculoskeletal disorder; skin ulcer; diabetes
bone inducing protein; BIP; osteogenetic protein 1; OP 1; OP 1; NOVOS		biotechnology; osteoanagenetic	musculoskeletal disorder; osteoporosis; neurological
somatomedin B; insulin-like growth factor-2; IGF-2		biotechnology; osteoanagenetic; growth factor	osteoporosis; hormone deficiency
TAK 726		biotechnology; proteinase inhibitor; cathepsin L inhibitor	osteoporosis
proteinase nexin-1; PN-1		biotechnology; proteinase inhibitor; osteoanagenetic; cicatrizant	osteoporosis; skin ulcer

alendronic acid; alendronate sodium; MK 217; G 704650; L 670452; GTH 42; FOSAMAX; DRONAL; ADRONAT; ALENDROS; BONARON; TEIROC; ONCLAST; FOSALAN; MARVIL	(4-amino-1-hydroxybutylidene)bisphosphonic acid	bisphosphonate	osteoporosis
BM 211182	[3-(1-iminoethylamino)-1-hydroxypropylidene]bisphosphonic acid	bisphosphonate	osteoporosis
clodronic acid; clodronate; CL2 MDP; KCO 692; BONEFOS; OSTAC; CLASTEON; OSSITEN; CLASTOBAN; OSSITEN; DIFOSFONAL; OSTAC; MEBONAT; LORON	(dichloromethylene)bisphosphonic acid	bisphosphonate	osteoporosis; hypercalcemia
EB 1053	[1-hydroxy-3-(1-pyrrolidinyl)propylidene]bisphosphonic acid	bisphosphonate	osteoporosis
incadronic acid; incadronate disodium; YM 175; BISPHONAL	[(cycloheptylamino)methylene]bisphosphonic acid	bisphosphonate	hypercalcemia; osteoporosis
minodronic acid; YM 529; YH 529	(1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethylidene)bisphosphonic acid	bisphosphonate	osteoporosis; hypercalcemia; cancer

neridronic acid; aminohexane diphosphonate; AHDP Na	(6-amino-1- hydroxyhexylidene)di phosphonic acid	bisphosphonate	Paget disease; osteoporosis; cancer
olpadronic acid; olpadronate	[3-(dimethylamino)- 1- hydroxypropylidene]d iphosphonic acid	bisphosphonate	osteoporosis
pamidronic acid; pamidronate disodium; APD; CGP 23339AE; AREDIA; OSTEOKIT	(3-amino-1- hydroxypropylidene)b isphosphonic acid	bisphosphonate	osteoporosis; cancer
risedronic acid; risedronate sodium; NE 58095; HMR 4003; ACTONEL	[1-hydroxy-2-(3- pyridinyl)ethylidene] bisphosphonic acid	bisphosphonate	osteoporosis; Paget disease
tiludronic acid; tiludronate disodium; tiludronate sodium; SR 41319; SR 41319B; SR 41319G; ME 3737; SKELID	[[ (4- chlorophenyl)thio]me thylene]bisphosphoni c acid	bisphosphonate	Paget disease; osteoporosis
WY 47766	2-[[ (3- methoxyphenyl)meth yl]sulfinyl]-1H- imidazo[4,5- c]pyridine	bisphosphonate	osteoporosis
ibandronic acid; ibandronate sodium; BM 210955; BONDRONAT	[1-hydroxy-3- (methylpentylamino)p ropylidene]bisphosph onic acid	bisphosphonate; osteoclast-inhibitory	osteoporosis; cancer; hypercalcemia
zoledronic acid; zoledronate; CGP 42446; ZOL 446	[1-hydroxy-2-(1H- imidazol-1-yl)- ethylidene]bisphosph onic acid	bisphosphonate; osteoclast-inhibitory	osteoporosis; hypercalcemia
KCA 098	dimethylcarbamic acid 5,6-dihydro-6- oxobenzofuro[3,2- c]quinoline-3,9-diyl ester	Bone resorption inhibitor	osteoporosis

menatetrenone; E 0167; KAYTWO; GLAKAY	(E,E,E)-2-methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,4-naphthalenedione	Bone resorption inhibitor	osteoporosis; blood clotting disorder
ranelic acid; strontium ranelate; S 12911	5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-3-thiopheneacetic acid	Bone resorption inhibitor	osteoporosis
ipriflavone; TL 80; TC 80; FL 113; OSTEOCHIN; OSTEOFIX; OSTEN; IPRIOSTEN; TEOBONE; OSTEN; IPRI OSTEN	7-isopropoxyisoflavone	Calcium influx regulated osteoclast differentiation and function	osteoporosis
PAA	polyacrylic acid	carbonate dehydratase inhibitor	osteoporosis
TAE 2		carbonate dehydratase inhibitor	osteoporosis
cathepsin K inhibitors		cathepsin K inhibitor; proteinase inhibitor	osteoporosis
cathepsin K inhibitors, osteoporosis		cathepsin K inhibitor; proteinase inhibitor	osteoporosis
SB 205123		cell adhesion inhibitor; integrin antagonist; alpha5 beta3 integrin antagonist	osteoporosis
IL-6 antagonists		cytokine antagonist	osteoporosis
estrogen agonists		estrogen agonist	osteoporosis
estrogen agonists		estrogen agonist	osteoporosis
GW 5638	(E,Z)-3-[4-(1,2-diphenyl-1-butenyl)phenyl]-2-propenoic acid	estrogen agonist; antiestrogen	osteoporosis; cancer; coronary artery disease
FC 1271	(Z)-2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]ethanol	estrogen agonist; antiestrogen; hormone replacement therapy	osteoporosis; hormone deficiency

IL-6 production inhibitors	Unspecified	Estrogen mimetic	osteoporosis; cancer
interleukin-6 production inhibitors, estrogen receptor-independent	Unspecified	Estrogen mimetic	osteoporosis
CP 336156	(5R,6S)-5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt)	estrogen partial agonist	osteoporosis; cancer
levormeloxifene; NNC 460020	(3R-trans)-1-[2-[4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine	estrogen partial agonist	osteoporosis
free radical scavenging estrogens		estrogen; free radical scavenger; NSAID	osteoporosis; arthritis; neurological
drug delivery system, transdermal 17beta estradiol; 17beta estradiol transdermal; FEMATRIX; FEMAPAK		estrogen; hormone replacement therapy	hormone deficiency; osteoporosis
drug delivery system, transdermal estradiol; estradiol transdermal; SH 577; ZK 5018; CLIMARA; PROGYNOVA TS; PROGYNOVA TS FORTE		estrogen; hormone replacement therapy	hormone deficiency; osteoporosis
estrogen receptor therapy		estrogen; hormone replacement therapy	hormone deficiency; contraception; cancer; osteoporosis
estradiol + ORG 30659; ORG 30659 + estradiol; ORG 30659		estrogen; progestogen; hormone replacement therapy	contraception; osteoporosis

simvastatin; epistatin; synvinolin; velostatin; MK 733; L 654; L 644128; 590328; ZOCOR; DENAN; MEDIPO; SIMOVIL; COLEDIS	2,2-dimethylbutanoic acid [1S- [[1alfa,3alfa,7beta,8bet a(2S*,4S*)8abeta]]- 1,2,3,7,8,8a- hexahydro-3,7- dimethyl-8-[2- (tetrahydro-4- hydroxy-6-oxo-2H- pyran-2-yl)ethyl]-1- naphthalenyl ester	HMG CoA reductase inhibitor; osteoclastogenesis	hyperlipidemia; osteoporosis
avicatonin; MCI 536	1-butanoic acid-2-L- alanine-3-L-serine- 26-L-aspartic acid-27- L-valine-29-L- alanine 1,7- dicarbocalcitonin (salmon)	hormone	osteoporosis
drug delivery system, calcitonin		hormone	osteoporosis
drug delivery system, calcitonin; salmon calcitonin; STH 32		hormone	osteoporosis
drug delivery system, LDS microemulsion calcitonin; calcitonin LIPID DISPERSAL SYSTEMS		hormone	osteoporosis
drug delivery system, oral calcitonin; calcitonin oral delivery system		hormone	osteoporosis
drug delivery system, oral MACROMOL calcitonin; calcitonin MACROMOL; MACRITONIN		hormone	osteoporosis
drug delivery system, oral transmucosal calcitonin; calcitonin transmucosal		hormone	osteoporosis

drug delivery system, PEPTITROL calcitonin; calcitonin PEPTITROL		hormone	osteoporosis; Paget disease; cancer
drug delivery system, salmon calcitonin;		hormone	osteoporosis
drug delivery system, salmon calcitonin; salmon calcitonin drug delivery system		hormone	osteoporosis
drug delivery system, submicron emulsion calcitonin; calcitonin SME		hormone	osteoporosis
elcatonin; HC 581; ELCITONIN; ELCITONIN S; LASKARTON; ELCIMEN; CARBICALCIN; TURBOCALCIN; ELCITONINA; DIATIN	1-butyric acid-7(L-2-aminobutyric acid)-26-L-aspartic acid-27-L-valine-29-L-alaninecalcitonin (salmon)	hormone	osteoporosis
parathyroid hormone analogue		hormone	osteoporosis
semparatide; RS 66271	Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Glu-Lys-Leu-His-Thr-Ala-NH2	hormone	osteoporosis
drug delivery system, oral calcitonin; calcitonin delivery system; FORTICAL		hormone; biotechnology	osteoporosis
parathyroid hormone, human; human parathyroid hormone; rhPTH		hormone; biotechnology	osteoporosis

parathyroid hormone; PTH; SUN E3001		hormone; biotechnology	osteoporosis
NOF 003	Eicosapentaenoic acid	IL-6 production inhibition	osteoporosis
integrin antagonist		integrin antagonist; cell adhesion inhibitor	osteoporosis
SB 223245	(S)-7-[[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid	integrin antagonist; cell adhesion inhibitor	osteoporosis; restenosis; cancer
vitronectin antagonist,		integrin antagonist; cell adhesion inhibitor	osteoporosis
vitronectin receptor antagonists		integrin antagonist; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	osteoporosis; cancer; restenosis
WS 7528	(2S-cis)-2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-3-methyl-4H-1-benzopyran-4-one	isoflavanone	osteoporosis
anti-arthritic matrix metalloproteinase inhibitors		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis
matrix metalloproteinase inhibitor		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis
TEI 3313	5-(4,7-dihydroxy-2-heptenylidene)-4-hydroxy-2-(methylthio)-4-(4-phenoxybutyl)-2-cyclopenten-1-one	Mineralization of osteoclasts stimulator	osteoporosis
indian hedgehog gene-based therapy		NSAID	osteoporosis; osteoarthritis
HCT 1026		NSAID; nitric oxide donor	urinary incontinence; Alzheimer disease; osteoporosis



59-0145; 590145	N,N'-bis[5-(trifluoromethyl)-2-pyridinyl]-1,2-ethanediamine	osteoclast calcimimetic	osteoporosis
S 14292		osteoclast calcimimetic	osteoporosis
TEI 7457		osteoclast calcimimetic	osteoporosis
ED 71	2-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	osteoclast calcimimetic; vitamin D3 analogue	osteoporosis
osteoclast calcimimetic	unspecified	osteoclast calcimimetic	osteoporosis
ACT 15		peptide	osteoporosis
OSA; CT 1		peptide	osteoporosis
OSB 201; CT 2		peptide	osteoporosis
peptide fragments, osteoporosis		peptide	osteoporosis
integrin-specific peptides		peptide; integrin antagonist; cell adhesion inhibitor; angiogenesis inhibitor	osteoporosis; cancer; restenosis
Src inhibitors		protein kinase inhibitor; tyrosine kinase inhibitor	osteoporosis
proteinase inhibitors		proteinase inhibitor	viral infection; osteoporosis; Chagas disease
proteinase inhibitors		proteinase inhibitor	osteoporosis
cathepsin L inhibitors		proteinase inhibitor; cathepsin L inhibitor; NSAID	osteoporosis
cathepsin O2 inhibitors		proteinase inhibitor; cathepsin O2 inhibitor	osteoporosis
K 11017		proteinase inhibitor; cathepsin O2 inhibitor	osteoporosis
BB 2983; GI 245402		proteinase inhibitor; matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; inflammatory bowel disease
cysteine proteinase inhibitor		proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; cancer; osteoarthritis

SB 242784		proton pump inhibitor	osteoporosis
FRK phosphatase inhibitor; fos regulating kinase phosphatase inhibitor		signal transduction inhibitor; MAP kinase inhibitor	osteoporosis; musculoskeletal disorder; periodontal disease
EF 40		triglyceride	osteoporosis
SC 116		triglyceride	osteoporosis
AP 448		tyrosine kinase inhibitor	osteoporosis
N 2749	Unspecified	Unspecified	osteoporosis
ormeloxifene; 67/20	trans-1-[2-[4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine	Unspecified	osteoporosis
1 alpha-hydroxyvitamin D2; 1 alpha-D2; one-alpha D2; TSA 870; HECTOROL		vitamin D2 analogue	osteoporosis; hyperparathyroidism; cancer
EL 715		vitamin D2 analogue	psoriasis; osteoporosis; osteodystrophy
alfacalcidol; ALFA D; PLATIBIT; VITAMILO ALFA; CALFINA; ANTUL; CALCITAMIN; BONDIOL; CALBONE; ALFAROL; ONEALFA	(1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3-diol	vitamin D3 analogue	osteomalacia; osteoporosis
falecalcitriol; flocalcitriol; ST 630; FULSTAN; HORNEL	(1alfa,3beta,5Z,7E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue	osteoporosis; kidney disease; hyperparathyroidism; psoriasis
LR 108		vitamin D3 analogue	osteoporosis
NOF 002		vitamin D3 analogue	osteoporosis

secalciferol; 24,25-dihydroxycholecalciferol; KDR; Ro 215816; OSTEO D	(3beta,5Z,7E,24R)-9,10-secocholesta-5,7,10(19)-triene-3,24,25-triol	vitamin D3 analogue	osteodystrophy; osteoporosis
---	---	---------------------	------------------------------

Table 54. Current Candidate Therapeutic Interventions for the Treatment of Acne

Product Name	Chemical Name	Action	Indication
azelaic acid; AGN 191861; T 150; SH 441; SKINOREN; AZELEX; CUTACELAN; DIOLA; ARZEM	nonanedioic acid; saturated dicarboxylic acid	Topical antiacne preparation	acne; skin disease
MGI 434	Unspecified	Unspecified	acne
SH 570; SH H570; ZK 118372	Unspecified	Unspecified	acne
SYC 201G	Unspecified	unspecified	acne
topical antiacne agents,	Unspecified	unspecified	acne
epristeride; SKF 105657; ONO 9302	17beta-[[[(1,1-dimethylethyl)amino]carbonyl]androst-3,5-diene-3-carboxylic acid	5 alpha reductase inhibitor	benign prostate hypertrophy; cancer; alopecia; acne
finasteride; MK 906; MK 0906; YM 152; PROSCAR; FINASPROS; CHIBRO-PROSCAR; FINASTID; PROSTIDE; EUTIZ; PRODEL; PROPECIA	(5alpha,17beta)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide	5 alpha reductase inhibitor	cancer; benign prostate hypertrophy; alopecia; acne
I 23	Unspecified	5 alpha reductase inhibitor	cancer; acne; hirsutism
L 751788	(5alpha,7beta,16beta)-16-(4-chlorophenoxy)-4,7-dimethyl-4-azaandrost-3-one	5 alpha reductase inhibitor	acne
LY 191704	trans-8-chloro-1,4,4a,5,6,10b-hexahydro-4-methylbenzo[f]quinolin-3(2H)-one	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia

MK 0434; MK 434	(5alpha, 17beta)-17-benzoyl-4-azaandrost-1-en-3-one	5 alpha reductase inhibitor	benign prostate hypertrophy; alopecia; acne
MK 386	(5alpha, 7beta)-4,7-dimethyl-4-azacholestan-3-one	5 alpha reductase inhibitor	acne; alopecia; benign prostate hypertrophy
ONO 3805	sodium (-)-4-(2-(2,3-dimethyl-4(1-(4-isobutylphenyl)ethoxy)benzoylamino)phenoxy)butyrate	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia
turosteride; FCE 26073	(5alpha, 17beta)-4-methyl-N-(1-methylethyl)-N-[[[(1-methylethyl)amino]carbonyl]-3-oxo-4-azaandrostane-17-carboxamide	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia
Antiandrogen; EM 250; SCH 54726	Unspecified	antiandrogen	acne; alopecia
cioterone; cyoctol; X-andron; CPC 10997; CYOCTOL; XANDRON	hexahydro-4-(5-methoxyheptyl)-2(1H)-pentalenone	antiandrogen	acne; alopecia; mycosis; hirsutism; benign prostate hypertrophy
inocoterone; inocoterone acetate; RU 882; RU 38882	[3S-(3alpha, 3aalpha, 9alpha, 9beta)]-3-(acetyloxy)-6-ethyl-1,2,3,3a,4,5,8,9,9a,9b-decahydro-3a-methyl-7H-benz[e]inden-7-one	antiandrogen	acne; hirsutism
L 651580	(5alpha, 17beta)-4-methyl-3-oxo-4-azaandrost-1-ene-17-carboxylic acid methyl ester	antiandrogen	acne; alopecia
LGD 1331	Unspecified	antiandrogen	cancer; benign prostate hypertrophy; acne; alopecia
RU 58841	4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)-benzonitrile	antiandrogen	acne; alopecia

acne therapy	Unspecified	antibacterial; peptide	acne
drug delivery system, CRYSTALIP topical metronidazole; metronidazole CRYSTALIP	Unspecified	antibiotic	acne; bacterial infection
drug delivery system, HIT topical clindamycin; HyClinda	Unspecified	antibiotic	acne
drug delivery system, liposome clindamycin phosphate; clindamycin phosphate liposome; LipoCIN	Unspecified	antibiotic	acne
drug delivery system, liposome metronidazole; metronidazole liposome; LipoZOL	Unspecified	antibiotic	acne; dermatitis
drug delivery system, ResiDerm zinc-based clindamycin; clindamycin ResiDerm; ResiDerm A	Unspecified	antibiotic	acne
antiacne	(E)-3-Tridecen-2-one	antibiotic; antifungal	acne; mycosis
zimidoben; GBR 14095	1H-imidazole-1-ethanol benzoate (ester)	antifungal; imidazole	acne
antisense oligonucleotide, 2-5A chimeric, 5 alpha reductase	Unspecified	biotechnology; antisense; oligonucleotide	acne
cyproterone acetate + ethinylestradiol; ethinylestradiol + cyproterone acetate; SH 592; ZK 4944 + ZK 9471	Unspecified	estrogen; progestogen	contraception; acne
flurithromycin; P 0501A; P 80206; CI 932; FLURIZIC; MIZAR; RITRO	8-fluoroerythromycin	macrolide; antibiotic	bacterial infection; acne

erythromycin salnacedin; G 101; SCY Er; ACTAGEN	Erythromycin, compound with N- acetyl-L-cysteine-2- hydroxybenzoate (ester) (1:1)	macrolide; NSAID; antibiotic	acne
adelmidrol; LG 21301	N,N'-bis(2- hydroxyethyl)nonane diamide	NSAID	inflammation; acne
nadifloxacin; zinoxifloxacin; OPC 7251; ACUATIM; NADIXA	9-fluoro-6,7-dihydro- 8-(4-hydroxy-1- piperidinyl)-5- methyl-1-oxo-1 H,5H- benzo[ij]quinolizine- 2-carboxylic acid	quinolone; antibiotic	bacterial infection; acne
BMS 181163	Unspecified	retinoid	acne
BMV 30047	11-cis- (hydroxymethyl)- retinoic acid deltalactone	retinoid	acne
BMV 30123	retinoic acid 4- (acetylamino)phenyl ester	retinoid	acne
drug delivery system, MICROSPONGE tretinoin; tretinoin MICROSPONGE; RETIN A MICRO	Unspecified	retinoid	acne
retinoids	Unspecified	retinoid	psoriasis; acne
tazarotene; AGN 190168; ZORAC; TAZORAC	6-[(3,4-dihydro-4,4- dimethyl-2H-1- benzothiopyran-6- yl)ethynyl]-3-pyrid inecarboxylic acid ethyl ester	retinoid	acne; cancer; psoriasis
tretinoin; Ro 015488/115; NSC 122758; VESANOID	(all-E)-3,7-dimethyl- 9-(2,6,6-trimethyl-1- cyclohexen-1-yl)- 2,4,6,8- nonatetraenoic acid	retinoid	acne; cancer
adapalene; CD 271; DIFFERINE; DIFFERIN	6-(4-methoxy-3- tricyclo[3.3.1.1(3,7)]d ec-1-ylphenyl)-2- naphthalenecarboxylic acid	retinoid agonist; retinoid; RAR agonist; RARbeta agonist	acne; multiple sclerosis
CPR 2003	Unspecified	retinoid; ether lipid	acne

RS 10025	[S-(R*,R*)]-[2-[[[3-chloro-4,5-dihydro-5-isoxazolyl)methyl]amino]-1-(4-hydroxyphenyl)methyl]-2-oxoethyl]carbamic acid phenylmethyl ester	transglutaminase inhibitor	acne
----------	--	----------------------------	------

Table 55. Current Candidate Therapeutic Interventions for the Treatment of Alopecia

Product Name	Chemical Name	Action	Indication
L 733692	Unspecified	5 alpha reductase inhibitor	alopecia
turosteride; FCE 26073	(5alpha,17beta)-4-methyl-N-(1-methylethyl)-N-[[[1-methylethyl)amino]carbonyl]-3-oxo-4-azaandrostane-17-carboxamide	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia
MK 0434; MK 434	(5alpha, 17beta)-17-benzoyl-4-azaandrost-1-en-3-one	5 alpha reductase inhibitor	benign prostate hypertrophy; alopecia; acne
finasteride; MK 906; MK 0906; YM 152; PROSCAR; FINASPROS; CHIBRO-PROSCAR; FINASTID; PROSTIDE; EUTIZ; PRODEL; PROPECIA	(5alpha,17beta)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide	5 alpha reductase inhibitor	cancer; benign prostate hypertrophy; alopecia; acne
dutasteride; GI 198745; GG 745; GI 198745X	(5alpha,17beta)-N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-1-ene-17-carboxamide	5 alpha reductase inhibitor	benign prostate hypertrophy; alopecia
MK 386	(5alpha,7beta)-4,7-dimethyl-4-azacholestan-3-one	5 alpha reductase inhibitor	acne; alopecia; benign prostate hypertrophy

epristeride; SKF 105657; ONO 9302	17beta-[[[(1,1-dimethylethyl)amino]carbonyl]androst-3,5-diene-3-carboxylic acid	5 alpha reductase inhibitor	benign prostate hypertrophy; cancer; alopecia; acne
ONO 3805	sodium (-)-4-(2-(2,3-dimethyl-4(1-(4-isobutylphenyl)ethoxy)benzoylamino)phenoxy)butyrate	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia
LY 191704	trans-8-chloro-1,4,4a,5,6,10b-hexahydro-4-methylbenzo[f]quinolin-3(2H)-one	5 alpha reductase inhibitor	benign prostate hypertrophy; acne; alopecia
PC 1358; TRICOMIN	Unspecified	Anagen phase activation of follicular growth	alopecia
antiandrogen, antiandrogen, EM 250; SCH 54726	Unspecified	antiandrogen	acne; alopecia
LGD 1331	Unspecified	antiandrogen	cancer; benign prostate hypertrophy; acne; alopecia
L 651580	(5alpha,17beta)-4-methyl-3-oxo-4-azaandrost-1-ene-17-carboxylic acid methyl ester	antiandrogen	acne; alopecia
RU 58841	4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)-benzonitrile	antiandrogen	acne; alopecia
cioterone; cyoctol; X-andron; CPC 10997; CYOCTOL; XANDRON	hexahydro-4-(5-methoxyheptyl)-2(1H)-pentalenone	antiandrogen	acne; alopecia; mycosis; hirsutism; benign prostate hypertrophy
keratinocyte growth factor 2; KGF 2; HG 03400	Unspecified	growth factor; cicatrizant; chemoprotectant; cytoprotectant	cancer; mucositis; skin ulcer; alopecia; kidney disease



drug delivery system, hydrogel topical insulin + growth hormone + thyroxine + MCDB 153; CARIEL; PILIEL	Unspecified	hormone	alopecia
drug delivery system, liposome minoxidil; minoxidil liposome	Unspecified	Minoxidil	alopecia
drug delivery system, minoxidil; minoxidil-SEPA	Unspecified	Minoxidil	sexual dysfunction; alopecia
antisense oligonucleotide, androgen receptor mRNA	Unspecified	mRNA translation inhibitor; antisense; oligonucleotide	alopecia
benign prostatic hypertrophy therapy, PC 1031; TRICOMIN	Unspecified	Overproliferation of cells	benign prostate hypertrophy; alopecia
PC 1332; TRICOMIN	Unspecified	peptide	alopecia
KC 516	Unspecified	peptide	alopecia
P 1075	Unspecified	potassium channel activator	alopecia
AN 10; NOVAHEME	[N-cyano-N'-(1,1-dimethylpropyl)-N"-3-pyridylguanidine]	potassium channel activator; vasodilator	alopecia
P 45	Unspecified Butyric acid derivative	Topical	sickle cell anemia; alopecia
diphencyprone; diphenylcyclopropenone	Unspecified	Unspecified	alopecia
	2,3-diphenyl-2-cyclopropen-1-one	Unspecified	alopecia

Table 56. Current Candidate Therapeutic Interventions for the Treatment of Metabolic Syndrome X (including Hypertension, Obesity, Hyperlipidemia, and Diabetes).

Product Name	Chemical Name	Action	Indication
(R)-alpha lipoic acid; (R)-thioctic acid			diabetes
20-epi-1,25 dihydroxyvitamin D3; MC 1288; IE	(1alpha,3beta,5Z,7E,20S)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue; immunosuppressant	diabetes; transplant rejection; arthritis

5-methylurapidil; 5-MU	6-[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3,5-trimethyl-2,4(1H,3H)-pyrimidinedione	5HT agonist; 5HT1A agonist	hypertension
5HT2A human neuroreceptor; neuroreceptor, 5HT2A human		biotechnology	hypertension; research tool
A 1233; 1233 A		HMG CoA synthase inhibitor	hyperlipidemia
A 65317	[5S-[5R*[1R*[R*(S*)],2S*]]-N1-[2-[[1-(cyclohexylmethyl)-2-(3-ethyl-2-oxo-5-oxazolidinyl)-2-hydroxyethyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]-N4-[2-[(2-methoxyethoxy)methoxy]ethyl]-N4-methyl-2-(phenylmethyl)butane diamide	renin inhibitor	hypertension
A 68552		peptide	obesity
A 68930	(1R,3S)-1-aminomethyl-5,6-dihydroxy-3-phenylisochroman	dopamine agonist; dopamine D1 agonist	hypertension; Parkinson disease
A 81282; ABBOTT 81282	4-[butyl[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-5-pyrimidinecarboxylic acid	angiotensin II antagonist	hypertension

acarbose; BAY g 5421; GLUCOBAY; PRECOSE; GLUCOR; PRANDASE	O-4,6-dideoxy-4-[[[1S-(1 $\alpha$ ,4 $\alpha$ ,5 $\beta$ ,6 $\alpha$ )]-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]- $\alpha$ -D-glucopyranosyl-(1-4)-O- $\alpha$ -D-glucopyranosyl-(1-4)-D-glucose	$\alpha$ glucosidase inhibitor	diabetes; neuropathy; retinopathy
acetyl-L-carnitine; acetylcarnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine		Alzheimer disease; stroke; diabetes; neuropathy
acipimox; K 9321; OLBETAM; OLBEMOX; ACIPIMOX; NEDIOS	5-methylpyrazinecarboxylic acid 4-oxide		hyperlipidemia
adenosine agonist, Glaxo Wellcome		adenosine agonist	diabetes
adiposin; lipotropin		biotechnology	obesity; cancer
adrenergic $\alpha$ 2 human neuroreceptors; neuroreceptors, adrenergic $\alpha$ 2 human		analgesic	research tool; pain; hypertension; glaucoma
aging-related disease therapy, Chiroscience/Geron			atherosclerosis; cancer; osteoporosis; diabetes; eye disease
AGN 4204; ALRT 4204		RXR agonist; retinoid agonist	diabetes
AGN 4326		RXR agonist	diabetes

AGR 529	N-(4-amino-4-oxobutyl)adenosine hydrochloride		hypertension; hyperlipidemia
AGR 540	N-(4-amino-4-oxobutyl)adenosine 2',3',5'-tripropionate		hypertension; hyperlipidemia
AHL 157		fibrate	hyperlipidemia
AHR 12742	4-(bis(4-fluorophenylmethyl)-7-(3-(4-chlorophenoxy)propyl)piperidine (E)-2-butenedioate	calcium antagonist	hypertension
AHR 16303B	1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]phenyl]-2-methyl-1-propanone ethanedioate (1:1)	5HT antagonist; 5HT2 antagonist	hypertension; angina
AHR 16462B	4-[bis(4-fluorophenyl)methyl]-1-(2-naphthalenylmethyl)piperidine hydrochloride	calcium antagonist; vasodilator	hypertension
AI 402		immunosuppressant; biotechnology; peptide	diabetes
AIT 111			angina; arrhythmia; hypertension
AJ 9677; AD 9677	[[3-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yl]oxy]-acetic acid	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity

AL 01567	2-fluorospiro-[9H-fluorene-9,4'-imidazolidine]-2',5'-dione	aldose reductase inhibitor	diabetes
AL 0670	(+)-N-(6-amino-3-pyridyl)-N'-[(1S,2R,4R)-bicyclo-[2.2.1]hept-2-yl]-N"-cyanoguanidine	potassium channel activator	hypertension
AL 0671	(1S-endo)-N-(6-amino-3-pyridinyl)-N'-bicyclo[2.2.1]hept-2-yl-N"-cyanoguanidine	potassium channel activator	hyperlipidemia; hypertension
alacepril; DU 1219; CETAPRIL	(S)-N-[1-[3-(acetylthio)-2-methyl-1-oxopropyl]-L-prolyl]-L-phenylalanine	ACE inhibitor	hypertension
aldose reductase inhibitor, Pfizer	(2'R-cis)-6-chloro-2',3'-dihydro-2'methyl-spiro(imidazolidine-4,4'-(4H)pyrano(2,3-b)pyridine)-2,5-dione	aldose reductase inhibitor	diabetes; neuropathy; retinopathy
aldose reductase inhibitor, Wakamoto; TAT	5-(3-thienyl)-1H-tetrazole-1-acetic acid	aldose reductase inhibitor	diabetes
aldose reductase inhibitor, Wyeth Ayerst	1-[(5-bromo-1-naphthalenyl)sulfonyl]-2-thioxo-4-imidazolidinone	aldose reductase inhibitor	diabetes
ALFA 366		platelet antiaggregant	kidney disease; diabetes
ALFA 642		platelet antiaggregant	diabetes; kidney disease

alfuzosin; alfuzosin hydrochloride; SL 77499; SL 7749910; ALFOTEN; XATRAL; BENESTAN; BENESTAIN; XATRAL-MAG; DILOTEX; URION; UROXATRAL	N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	benign prostate hypertrophy; hypertension
alpha d modulator		cell adhesion inhibitor; NSAID	diabetes; atherosclerosis; arthritis; inflammatory bowel disease; respiratory disease
alprostadil; lipo-prostaglandin E1; lipo-PGE1; U 10136; G 511; CAVERJECT; PROSTANDIN; PROSTAVASIN; PALUX; LIPLE; APISTANDIN; PROMOSTAN; PROSTIN; VASOPROST; EDEX	(11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid	prostanoid; vasodilator; cicatrizant	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss
ALRT 326		RXR agonist; retinoid agonist	diabetes
ALT 4000			diabetes
ALT 711			diabetes; cardiovascular disease
ALT 946			diabetes; neuropathy; retinopathy; kidney disease
AM 454		insulin sensitizer	diabetes
AM 522		cardiac glycoside	hypertension; heart failure

AM 524		cardiac glycoside	heart failure; hypertension
amlodipine + benazepril; benazepril + amlodipine; CGP 24267A; LOTREL		calcium antagonist; ACE inhibitor	hypertension
amlodipine analogue, Pfizer	4-(2,3-dichlorophenyl)-1,4-dihydro-2-[(2-hydroxyethoxy)methyl]-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	hypertension
amlodipine besilate; UK 4834026; NORVASC; ISTIN	2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid, 3-ethyl 5-methyl ester monobenzenesulfonate	calcium antagonist	hypertension
amlodipine, (S)-; (S)-amlodipine; (-)-amlodipine; l-amlodipine	(S)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid, 3-ethyl 5-methyl ester	calcium antagonist	hypertension
amosulalol; YM 09538; LOWGAN	5-[1-hydroxy-2-[(2-methoxyphenoxy)ethyl]amino]ethyl]-2-methylbenzenesulfonamide	alpha adrenergic antagonist; beta adrenergic antagonist	hypertension
amylin agonists, Amylin		amylin agonist	diabetes

amyloid production inhibitors, Neurochem			Alzheimer disease; diabetes
angiotensin II receptor antagonist, Yuhan		angiotensin II antagonist	hypertension
angiotensinogen based therapy, Myriad; AGT gene-based therapy, Myriad; hypertension therapy, Myriad			hypertension
antiatherosclerotic agents, Allelix		biotechnology	atherosclerosis; hyperlipidemia
antihypertensive, Central Drug Research Institute	1-((3-methylphenyl)piperazin-1-yl)-3-(thio(4-acetamido)phenyl)-propane		hypertension
antihypertensive, Georgia Institute of Technology			hypertension
antihypertensive, Uppsala University; ALT 462	4-amino-2,4-dihydro-5-(1-methylethyl)-3H-1,2,4-triazol-3-one hydrazone		hypertension
antihypertensive, Yamasu Shoyu	2-hexynyladenosine (2-H-Ado)	adenosine agonist; adenosine A2 agonist	hypertension
antihypertensive, Yamasu Shoyu	2-octynyladenosine (2-O-Ado)	adenosine agonist; adenosine A2 agonist	hypertension
antisense oligonucleotide, angiotensinogen		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	hypertension
AOD 9604			obesity



apoptosis-inducing antigen, diabetes; IG 2; IG2		immunosuppressant; biotechnology; apoptosis inducer	diabetes
apraclonidine; p-aminoclonidine; aplonidine; ALO 2145; NC 14; IOPIDINE	2,6-dichloro-N'-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine	alpha adrenergic agonist; alpha2 adrenergic agonist	glaucoma; hypertension
AR H039242XX			diabetes; atherosclerosis
aranidipine; MPC 1304; SAPRESTA; BEC BM; BEC MARUKO; BEC	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid, methyl 2-oxopropyl ester	calcium antagonist	hypertension
arotinolol; S 596; ALMARL; ANBROTH; ACEMAIL; ALOCHINON; AMOPSOL; AROTINOIL; ASTONIL; LISTERIA	(+,-)-5-[2-[[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]thio]-4-thiazolyl]-2-thiophenecarboxamide	beta adrenergic antagonist	glaucoma; hypertension
ascorbyl gamolenate; ascorbyl gammalinolenic acid; SC 103		aldose reductase inhibitor	diabetes; neuropathy; sexual dysfunction
AT 112	2,3-dihydro-2-[(4-phenyl-1-piperazinyl)methyl]imidazo[1,2-c]quinazolin-5(6H)-one	alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	thrombosis; hypertension

atorvastatin; atorvastatin calcium; CI 981; PD 1342 98; YM 548; LIPITOR; SORTIS	[R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid	HMG CoA reductase inhibitor	hyperlipidemia
atpenin B	[S-(R*,S*)]-3-(2,4-dimethyl-1-oxohexyl)-4-hydroxy-5,6-dimethoxy-2(1H)-pyridinone	antifungal	hyperlipidemia; mycosis
atrinositol; PP 56	D-myo-inositol 1,2,6-tris(dihydrogen phosphate)	chelating agent; NSAID	inflammation; hyperlipidemia
AXC 0216		neuropeptide Y antagonist	obesity; hypertension
AXC 1829		neuropeptide Y antagonist	obesity; hypertension
AXC 4047			diabetes
AXOKINE		biotechnology; growth factor; neurotrophic factor	amyotrophic lateral sclerosis; obesity; eye disease
AY 31637	5-(2-naphthalenylsulfonyl)-2,4-thiazolidine-dione		diabetes
AZM 090			obesity
AZM 119		lipase inhibitor	obesity; atherosclerosis
AZM 131		lipase inhibitor	obesity
AZM 133			obesity; gastrointestinal disorder
AZM 134			obesity; diabetes
AZM 140		amylase inhibitor	obesity; diabetes

BAL ARI8	7-fluoro-2-(N-methyl-N-carboxymethyl)sulfa moyl xanthone	aldose reductase inhibitor	diabetes; retinopathy
barnidipine; mepirodipine; YM 09730; YM 097305; YM 730; HYPOCA; OLDECA	[S-(R*,R*)]-1,4- dihydro-2,6-dimethyl- 4-(3-nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 1- (phenylmethyl)-3- pyrrolidinyl ester	calcium antagonist; vasodilator	hypertension; ischemia
BAY 102987		HMG CoA reductase inhibitor	hyperlipidemia
BAY 139952			hyperlipidemia
BAY 194798			atherosclerosis; hyperlipidemia
BAY 279955		glucagon antagonist	diabetes
BAY w 9533		HMG CoA reductase inhibitor	hyperlipidemia
BAY x 2678		HMG CoA reductase inhibitor; cholesterol synthesis inhibitor	hyperlipidemia
beauvericin	1,7,13-trioxa-4,10,16- triazacyclooctadecane cyclic peptide derivative	ACAT inhibitor; antibiotic; peptide	bacterial infection; hyperlipidemia
belfosdil; SR 7037; BMY 21891	[2-(2-phenoxyethyl)- 1,3- propanediyl]bisphosp honic acid tetrabutyl ester	calcium antagonist	hypertension
benazepril; benazepril hydrochloride; benazepril; CGS 148247; CIBACEN; LOTENSIN; BRIEM; ZINADRIL; TENSANIL; CIBACENE	[S-(R*,R*)]-3-[[1- (ethoxycarbonyl)-3- phenylpropyl]amino]- 2,3,4,5-tetrahydro-2- oxo-1H-1- benzazepine-1-acetic acid	ACE inhibitor	hypertension

benazepril + hydrochlorothiazide; hydrochlorothiazide + benazepril; CIBADREX; LOTENSIN HCT		ACE inhibitor; diuretic	hypertension
benidipine; nakadipine; nacadipine; KW 3049; CONIEL	(R*,R*)-(+,-)-1,4- dihydro-2,6-dimethyl- 4-(3-nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 1- (phenylmethyl)-3- piperidinyl ester	calcium antagonist; vasodilator	hypertension; angina
beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro- 2-hydroxy-1-(3- hydroxy-4-methyl-1- octen-6-ynyl)-1H- cyclopenta[b]benzofu- ran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
beta3 adrenergic receptor agonists, Pfizer		beta3 adrenergic agonist; beta adrenergic agonist	obesity
betaxolol; betaxolol hydrochloride; SL 75212; MCI 144; ABAXON; KERLONE; BETOPTIC; KERLONG; GLAUTAXOL; BERTOCIL; OPTIPRES; BETASEL; BEOF NICOLICH; LOKREN	1-[4-[2- (cyclopropylmethoxy) ethyl]phenoxy]-3-[(1- methylethyl)amino]- 2-propanol	beta adrenergic antagonist	glaucoma; hypertension; angina
betaxolol + chlortalidone; chlortalidone + betaxolol; KERLEDEX		beta adrenergic antagonist; diuretic	hypertension

bevantolol; bevantolol hydrochloride; CL 775; NC 1400; VANTOL; CALVAN; RANESTOL	(+,-)-1-[(3,4- dimethoxyphenethyl) amino]-3-(m- tolylloxy)-2-propanol	beta adrenergic antagonist	hypertension
bexarotene; LGD 1069; LG 100069; LG 1069; LDG 1069; TARGRETIN	4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8- tetrahydro-2- naphthenyl)-1-eth- enyl]-benzoic acid	retinoid; differentiation inducer; RXR agonist	cancer; diabetes; psoriasis; skin disease
biamine			obesity
BIBX 245			hyperlipidemia
bisoprolol; bisoprolol fumarate; EMD 33512; CL 297939; CONCOR; EMCOR; EMCORE; MONOCOR; ISOTEN; SOPROL; DETENSIEL; MAINTATE; ISOBLOC; ZEBETA	1-[(1- methylethyl)amino]- 3-[4-[[2-(1- methylethoxy)ethoxy] methyl]phenoxy]-2- propanol	beta adrenergic antagonist	hypertension; heart failure
bisoprolol + hydrochlorothiazide; hydrochlorothiazide + bisoprolol; EMD 47378; ZIAC; CONCOR PLUS; EMCORECTIC; FONDRIL; MONOZIDE		beta adrenergic antagonist; diuretic	hypertension
BMS 188494	2,2- dimethylpropanoic acid [[4-(3- phenoxyphenyl)-1- sulfobutyl]phosphinyl idene]bis(oxymethyle- ne) ester	squalene synthetase inhibitor	hyperlipidemia

BMS 189921		ACE inhibitor; matrix metalloproteinase inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
BMS 194449		beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 196085	N-[5-[(1R)-2-[[[(1R)-1-[4-(difluoromethoxy)phenyl]-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide	beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 201038	Unspecified	microsomal transfer protein inhibitor	hyperlipidemia
BMS 201620		beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
BMS 210285		beta adrenergic agonist; beta3 adrenergic agonist	obesity
BMS 212122		microsomal transfer protein inhibitor	hyperlipidemia
BNP 9010			hyperlipidemia
BOF 6721			hyperlipidemia
BOF 6766			hyperlipidemia
bopindolol; LT 31200; SANDONORM	(+,-)-1-[(1,1-dimethylethyl)amino]-3-[(2-methyl-1H-indo-4-yl)oxy]]-2-propanol, benzoate	beta adrenergic antagonist	hypertension
bovine cerebral ganglioside; E 0704; CRONASSIAL		ganglioside	neuropathy; diabetes

BST 4001; PYRIDORIN			diabetes; kidney disease
BTS 78050			obesity
bunazosin; bunazosin hydrochloride; E 643; DE 070; E 1015; DETANTOL; DETANTOL R; ANDANTE	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-butyrylhexahydro-1H-1,4-diazepine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy
butabindide; UCL 1397	[S-(R*,R*)]-1-(2-Amino-1-oxobutyl)-N-butyl-2,3-dihydro-1H-indole-2-carboxamide	serine proteinase inhibitor	obesity
C-peptide analogues		peptide	diabetes; kidney disease
calcitonin gene-related peptide (CGRP) receptor modulators, SKBeecham			migraine; diabetes
candesartan; CV 11974	2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist; imidazole	hypertension
candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMIAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease

candoxatril; UK 79300	4-[[[1-[3-[(2,3-dihydro-1H-inden-5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]-cyclohexanecarboxylic acid	atriopeptidase inhibitor	hypertension; heart failure
capsaicin; ZOSTRIX; ZOTRIX HP; THERAGEN; THERAGEN HP; CAPSIDOL; LION PLASTER	(E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide	analgesic	pain; neuropathy; diabetes
captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
cardiovascular disease therapy, Cytokinetics			hypertension; heart failure
carteolol; OPC 1085; ABBOTT 43326; A 43326; ARTEOPTIC; CARTEOL; CARTROL; ENDAK; MERCATOA; MIKELAN; ORUKALOL; PALSIT; TENALET; TENALIN	5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydroquinolinone	beta adrenergic antagonist; beta adrenergic antagonist	glaucoma; hypertension



carvedilol; karvedilol; BM 14190; DQ 2466; KREDEX; COREG; DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC	1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol	beta adrenergic antagonist	hypertension; angina; heart failure
celiprolol; NPB 582; ST 1396; REV 5320A; SELECTOL; CELECTOL	N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethylurea	beta adrenergic antagonist; beta2 adrenergic partial antagonist; vasodilator	hypertension; nephritis
cerivastatin; rivastatin; BAY w 6228; LIPOBAY; BAYCOL; LIPOSTEROL; CERVASTA; VASLIP	[S-[R*,S*-(E)]]-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid	HMG CoA reductase inhibitor	hyperlipidemia
CGP 26214		LDL regulator	hyperlipidemia; atherosclerosis
CGP 60536B; CGS 60536	[alphaS-(alphaR*,gammaR*,deltaR*,zetaR*)]-delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)benzeneoxtanamide	renin inhibitor	hypertension
CHOLESS		immunostimulant	hyperlipidemia

CI 996	2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
CI 999	[[2,6-bis(1-methylethyl)phenoxy]sulfonyl]carbamic acid 2,6-bis(1-methylethyl)phenyl ester sodium salt	ACAT inhibitor	hyperlipidemia
cicletanine; cycletanide; BN 1270; RU 270; WIN 90000; TENSTATEN; JUSTAR	3-(4-chlorophenyl)-1,3-dihydro-6-methylfuro[3,4-c]pyridin-7-ol	diuretic	hypertension
cilazapril; Ro 312848; Ro 312848 006; INHIBACE; VASCACE; DYNORM	(1S,9S)-9-[[[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid	ACE inhibitor	hypertension
cilnidipine; cinaldipine; FRC 8653; SISCARD; CINALONG; ATELEC	(E)-(+,-)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 3-phenyl-2-propenyl ester	calcium antagonist	hypertension
ciprofibrate; WIN 35833; LIPANOR; HYPERLIPEN; MODALIM; ESTAPROL	2-(p-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropionic acid	fibrate	hyperlipidemia
CK 3363; CK 3368		bile acid sequestrant	hyperlipidemia

CKD 705			hypertension
CL 314698	(R*,R*)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid dimethyl ester	beta adrenergic agonist; beta3 adrenergic agonist	diabetes; obesity
CMDM	meso-2,6-bis(carboxymethyl)-4,4-dimethylmorpholinium bromide	carnitine acetyltransferase inhibitor	diabetes
CMI 477	(1S-exo)-2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane	cholinergic agonist; nicotinic agonist; analgesic	obesity; depression; Alzheimer disease; nicotine withdrawal
colesevelam hydrochloride; GT 31-104HB; GT 31-104; CholestaGel	N,N,N-trimethyl-6-(2-propenylamino)-1-hexanaminium chloride polymer with (chloromethyl) oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine hydrochloride	bile acid sequestrant	hyperlipidemia
corticotrophin releasing factor (CRF) agonists, Neurogen			obesity
CP 105191	(S)-2-(hexylthio)-N-[6-(methylthio)-5-quinolinyl]decanamide	ACAT inhibitor	hyperlipidemia
CP 113818	(S)-(2)-(hexylthio)-N-[6-methyl-2,4-bis(methylthio)-3-pyridinyl]decanamide	ACAT inhibitor	hyperlipidemia

CP 71362	[2R-(2R*,4S*,5S*)]-N-[N2-[6-cyclohexyl-5-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-4-hydroxy-2-(2-methylpropyl)-1-oxohexyl]-L-lysyl]-L-phenylalanine	renin inhibitor	hypertension
CP 80629		beta3 adrenergic agonist; beta adrenergic agonist	diabetes
CP 83101	[R*,S*-(E)]-(+,-)-3,5-dihydroxy-9,9-diphenyl-6,8-nonadienoic acid methyl ester	HMG CoA reductase inhibitor	hyperlipidemia
CP 95253		peptide	diabetes
CR 2991		alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
CV 11194; EP 425921A	2-butyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist; imidazole	hypertension
cyclazosin	Cis-1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)decahydroquinoxaline monohydrochloride	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
cyclothiazomycin	cyclothiazomycin	renin inhibitor; antibiotic	hypertension

delapril; alindapril; CV 3317; REV 6000A; ADECUT; CUPRESSIN; KEDAPRIL; DELAKET	(S)-N-(2,3-dihydro-1H-inden-2-yl)-N-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]glycine	ACE inhibitor	hypertension
delapril + indapamide; indapamide + delapril; CHF 1513; DELAPRIDE		ACE inhibitor; diuretic	hypertension
denileukin diftitox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL-2; LY 335348; DAB389IL2; ONTAK	1-388-toxin (Corneybacterium diphtheriae strain C7), N-L-methionyl-387-L-histidine-388-L-alanine-, (388.fwdarw.2')-protein with 2-133-interleukin 2 (human clone pTIL2-21a)	biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer
dexfenfluramine; dexfenfluramine hydrochloride; S 5614; IP 001; ISOMERIDE; ADIFAX; ARDIX; ISOLIPAN; SIRAN; OBESINE; FLURIL; DISPONDAL; REDUX	(S)-N-ethyl-alfa-methyl-3-(trifluoromethyl)benzeneethanamine	5HT reuptake inhibitor	obesity; depression; nicotine withdrawal
DF 100	4-(3,5-dimethyl-1H-pyrazol-1-yl)-2,5-dihydro-1H-pyridazino[4,5-b]indol-1-one hydrazone monohydrochloride		hypertension
diabetes therapy, Allergan/Parke Davis		retinoid	diabetes

diabetes therapy, Cell Therapeutics/City of Hope National Medical Center		antioxidant	diabetes
diabetes therapy, Cornell Research Foundation			diabetes
diabetes therapy, DeveloGen		transcription activator	diabetes
diabetes therapy, Dr Reddy's Research Foundation/Novo Nordisk			diabetes; obesity; hyperlipidemia
diabetes therapy, HNF-4 based, Ligand/Lilly			diabetes; cardiovascular disease
diabetes therapy, Kyoto University	(SP-5-21)-oxobis(1-pyrrolidinecarbodiithioato-S,S')vanadium	insulin mimetic	diabetes
diabetes therapy, Lipha/Ono			diabetes
diabetes therapy, Metabolex			diabetes
diabetes therapy, Metabolex/Parke Davis			diabetes
diabetes therapy, Novo Nordisk/ACADIA			diabetes
diabetes therapy, Novo Nordisk/Takeda			diabetes
diabetes therapy, Novo Nordisk/Trega Biosciences			diabetes
diabetes therapy, OSI			diabetes

diabetes therapy, Telik/Sanwa Kagaku		insulin sensitizer	diabetes
diabetes therapy, Vita Invest			diabetes
DiavaX; IDDM-AnergiX		biotechnology	diabetes
dicentrine; d-dicentrine; (+)-dicentrine; eximine; O,N-dimethylitseferine	(S)-6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-5H-benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
digitoxigenin-PC		cardiac glycoside	heart failure; hypertension
diltiazem analogue, Tanabe; 1058		calcium antagonist	hypertension
diltiazem malate + enalapril; enalapril + diltiazem malate; TECZEM		calcium antagonist; ACE inhibitor	hypertension
ditekiren; U 71038	[1S-[1R*,2R*,4R*(1R*,2R*)]]-1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-L-phenylalanyl-N-[2-hydroxy-5-methyl-1-(2-methylpropyl)-4-[[[2-methyl-1-[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-N-alfa-methyl-L-histidinamide	renin inhibitor	hypertension
dopamine D1/D2 agonists, Ergo Science		dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	obesity; diabetes

doxazosin; UK 33274; UK 3327427; CARDURA; CARDENALIN; SUPRESSIN; CARDURAN; DIBLOCIN; DOXABEN; NORMOTHEN; DEDRALEN; ALFADIL	1-(4-amino-6,7-dimethoxy-2-quinazoliny)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	benign prostate hypertrophy; hypertension
DRF 2725		insulin sensitizer	diabetes; hyperlipidemia
drug delivery system, alliinase + alliin; alliinase + alliin delivery system		biotechnology	hyperlipidemia
drug delivery system, BEODAS insulin; insulin BEODAS		hormone	diabetes
drug delivery system, COER-24 oral verapamil; verapamil COER-24; OROS verapamil; COER-24 verapamil; COVERA-HS; CHRONOVERA; CRONOVERA		calcium antagonist	hypertension; angina
drug delivery system, controlled release antidiabetic; antidiabetic, GEOMATRIX			diabetes
drug delivery system, controlled release diltiazem; diltiazem controlled release; TIAZAC; VIAZEM		calcium antagonist	hypertension; angina



drug delivery system, controlled release GEOMATRIX glibenclamide; glibenclamide GEOMATRIX		sulfonylurea	diabetes
drug delivery system, controlled release glibenclamide; glibenclamide controlled release; Glynase PresTab		sulfonylurea	diabetes
drug delivery system, dopamine; dopamine delivery system; NMI 8739; DOPREXIN			obesity; Parkinson disease
drug delivery system, GEOMATRIX controlled release glipizide; glipizide GEOMATRIX		sulfonylurea	diabetes
drug delivery system, GEOMATRIX controlled release nifedipine; nifedipine GEOMATRIX		calcium antagonist	hypertension; angina
drug delivery system, GEOMATRIX controlled release verapamil; verapamil GEOMATRIX		calcium antagonist	hypertension
drug delivery system, GITS glipizide; glipizide GITS; GLUCOTROL XL; GLUCOTROL GITS		sulfonylurea	diabetes

drug delivery system, insulin secreting implant; insulin secreting implant; EndoCRIB		hormone	diabetes
drug delivery system, insulin secreting implant; insulin secreting implant		hormone	diabetes
drug delivery system, insulin subcutaneous implant; insulin subcutaneous implant		hormone	diabetes
drug delivery system, insulin-producing beta cells		hormone	diabetes
drug delivery system, liposome oleoyl- estrone; oleoyl- estrone liposome			obesity
drug delivery system, MEDUSA insulin; insulin MEDUSA; BASULIN		hormone; biotechnology	diabetes
drug delivery system, MICROPUMP oral controlled release atenolol; atenolol MICROPUMP; ATENAX		beta adrenergic antagonist	hypertension
drug delivery system, oral copolymer insulin; insulin oral		hormone	diabetes
drug delivery system, oral glucagon-like peptide-1		biotechnology; peptide	diabetes

drug delivery system, oral insulin; insulin oral delivery system		hormone	diabetes
drug delivery system, oral insulin; insulin oral; ORALIN; ORALGEN		biotechnology; hormone	diabetes
drug delivery system, oral nanosphere insulin; insulin oral		hormone	diabetes
drug delivery system, OROS oral controlled release isradipine; isradipine OROS; DynaCirc CR		calcium channel blocker	hypertension
drug delivery system, OROS prazosin; prazosin OROS; CP 122991; MINIPRESS XL; ALPRESS LP		alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
drug delivery system, OSAT nifedipine; nifedipine sustained release		calcium antagonist	hypertension; angina
drug delivery system, phospholipase A2; phospholipase A2 delivery system; drug delivery system, PLA2		enzyme	hyperlipidemia
drug delivery system, PROTEIMER insulin; insulin, PROTEIMER; PROTEIMER insulin		hormone	diabetes
drug delivery system, SODAS captopril; captopril SODAS		ACE inhibitor	heart failure; hypertension

drug delivery system, sustained release diltiazem; diltiazem sustained release; DILACOR XR		calcium antagonist	hypertension
drug delivery system, sustained release diltiazem; diltiazem sustained release; DILTELAN; CARDIZEM CD; HERBESSER R; DILZEM OD; TIAZEM SR		calcium antagonist	hypertension
drug delivery system, sustained release diltiazem malate; diltiazem malate sustained release		calcium antagonist	hypertension
drug delivery system, sustained release niacin; niacin sustained release; NIASPAN			hyperlipidemia
drug delivery system, sustained release nifedipine; nifedipine once daily; INDAS nifedipine; NIFENSAR XL; ADALAT SR; UNIDIPINE; NIFELAN; ADALAT OROS		calcium antagonist	angina; hypertension
drug delivery system, transdermal clonidine; clonidine transdermal; M 5041T		alpha adrenergic agonist	hypertension

drug delivery system, transdermal insulin; insulin transdermal		hormone	diabetes
drug delivery system, TRANSFERSOMES transdermal insulin; TRANSFERSULIN		biotechnology	diabetes
drug delivery system, Zot oral insulin; insulin oral		hormone	diabetes
drug discovery, Trega Biosciences; drug discovery, Chugai		NSAID	inflammation; diabetes; cardiovascular disease; neurological; cancer; infectious disease
DY 9708	[1R-[1 alpha,2(3S*,4R*),6al pha]]-3,4-dihydro-3- hydroxy-2,2-dimethy l-4-[(5-oxo-3,4- diazabicyclo[4.1.0]he pt-2-en-2-yl)oxy]-2H- 1-benzopyran-6- carbonitrile	potassium channel activator; vasodilator	hypertension; angina
E 4010	4-[[[(3-chloro-4- methoxyphenyl)meth yl]amino]-1-(4- hydroxy-1-piperid inyl)-6- phthalazinecarbonitril e monohydrochloride	dopamine agonist; dopamine D1 agonist; phosphodiesterase inhibitor; phosphodiesterase V inhibitor	pulmonary hypertension; sexual dysfunction
efonidipine; selefodipine; NZ 105; LANDEL	5-(5,5-dimethyl- 1,3,2- dioxaphosphorinan-2- yl)-1,4-dihydro-2,6- dim ethyl-4-(3- nitrophenyl)-3- pyridine-carboxylic acid, 2- [phenyl(phenylmethyl )amino] ethyl ester, P- oxide	calcium antagonist	hypertension; angina; cerebrovascular disease

emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
EMD 61650	2-butyl-3,5-dihydro-5-(phenylmethyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4H-imidazo[4,5-c]pyridin-4-one		hypertension
EMD 66684	2-butyl-4,5-dihydro-4-oxo-3[[2'-(1H-tetrazol-5-yl)-4-biphenyl]methyl]-3H-imidazo[4,5-C]pyridine-5-(N,N-dimethylacetamide)		hypertension
EMD 94246	N-2,1,3-benzothiadiazo[5-yl]-5-(dimethylamino)-1-naphthalenesulfonamide, potassium salt	endothelin antagonist	hypertension
enalapril; MK 421; INNOVACE; COVERTEN; ENAPREN; RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE	(S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline	ACE inhibitor	hypertension
endothelin antagonists, Novartis		endothelin antagonist	hypertension

englitazone; englitazone sodium; CP 68722; CP 72466; CP 72467; CP 724672	(-)-5-[[[(2R)-2-benzyl-6-chromanyl]methyl]-2,4-thiazolidinedione	insulin sensitizer	diabetes; hyperlipidemia
epalrestat; ONO 2235; KINEDAK	(Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid	aldose reductase inhibitor	neuropathy; kidney disease; eye disease; diabetes
epoprostenol; epoprostenol sodium; prostacyclin; prostaglandin X; prostaglandin I <sub>2</sub> ; UN 53217A; U 53217; FLOLAN; CYCLO- PROSTIN	(5Z,9 $\alpha$ ,11 $\alpha$ ,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid	platelet antiaggregant; vasodilator; prostanoid	pulmonary hypertension; thrombosis
eprosartan; eprosartan mesylate; SB 108566; SKF 108566; SKF 108566 J; TEVETEN	(E)- $\alpha$ -[[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic acid	angiotensin II antagonist	hypertension; kidney disease; heart failure
ER 3295		ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
erythritol; NIK 242	1,2,3,4-butanetetrol		hypertension

ES 1005	[1S-[1R*(R*),2R*,4[R*(R*)]]-N-[4-[[1-[(5-amino-6-hydroxyhexyl)amino]carbonyl]-3-methylbutyl]amino]-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-alfa-[[3-(1-naphthalenyl)-2-(1-naphthalenylmethyl)-1-oxopropyl]amino]-1H-imidazole-4-propanamide dihydrochloride	renin inhibitor; peptide	hypertension
ES 8891	5-cyclohexyl-2,4,5-trideoxy-N-hexyl-4-[[N-[3-(1-naphthalenyl)-N-(4-morpholinylacetyl)-L-alanyl]-3-(4-thiazolyl)-L-alanyl]amino]-L-threo-pentonamide	renin inhibitor	hypertension
esatenolol; atenolol, (S)-; (S)-atenolol; (-)-atenolol	(S)-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide	beta adrenergic antagonist	hypertension
esmolol; ASL 8052; ASL 8123; BREVIBLOC	4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzenepropanoic acid methyl ester	beta adrenergic antagonist	hypertension; arrhythmia
ethyl eicosapentaenoate; ethyl icosapentate; EPA-E; MND 21; EPADEL	ethyl all-cis-5,8,11,14,17-eicosapentaenoate	platelet antiaggregant	thrombosis; hyperlipidemia
exendin 4; exendin-4; AC 2993		peptide	diabetes
exendin agonists, Amylin		peptide	diabetes



exendin agonists, Amylin			diabetes
EXP 3174; E 3174	2-butyl-4-chloro-1- [[2'-(1H-tetrazol-5- yl)[1,1'-biphenyl]-4- yl)methyl]-1H- imidazole-5- carboxylic acid	angiotensin II antagonist	hypertension
F 1394	N-[(2,2,5,5- tetramethyl-1,3- dioxan-4- yl)carbonyl]-beta- alanine, 2-[[[2,2- dimethylpropyl)nonyl amino]carbonyl]amin ocyclohexyl ester	ACAT inhibitor	atherosclerosis; hyperlipidemia
fagopyritols			diabetes
fagopyritols, Cornell Research Foundation			diabetes
fatty acids, microalgal, Martek			hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease
FCP 3P1			atherosclerosis; hyperlipidemia
felodipine; H 15482; HOE 869; CGH 869; HYDAC; PLENDIL; VASOPINE; SPLENDIL; MUNOBAL; FLODIL	4-(2,3- dichlorophenyl)-1,4- dihydro-2,6-dimethyl- 3,5- pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist; vasodilator; diuretic	hypertension; angina; heart failure; atherosclerosis
felodipine + enalapril; enalapril + felodipine; LEXCEL		calcium antagonist; ACE inhibitor	hypertension

felodipine + metoprolol; metoprolol + felodipine; LOGIMAX		calcium antagonist; beta adrenergic antagonist	hypertension; angina
felodipine + ramipril; ramipril + felodipine; HOE 9869; UNIMAX; TAZKO		calcium antagonist; ACE inhibitor	hypertension
fenofibrate; fenofibrato; procetofene; LF 178; LIPANTHYL; LIPANTIL; LIPIDIL; LIPSIN; NORMALIP; BISTEROL; NORMOLIP; PROMERAL; LIPCOR; TRICOR	2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester	fibrate	hyperlipidemia
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenol)-1H-3-benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
fidarestat; SNK 860; SK 860	(2S-cis)-6-fluoro-2,3-dihydro-2',5'-dioxospiro[4H-1-benzopyran-4,4'-imidazolidine]-2-carboxamide	aldose reductase inhibitor	diabetes
fluasterone		immunosuppressant	cancer; diabetes; systemic lupus erythematosus
fluvastatin; fluindostatin; XU 62320; LESCOL; LOCOL; LOCHOL; FRACTAL	[R*,S*-(E)]-(+,-)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid	HMG CoA reductase inhibitor	hyperlipidemia

fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; FUSINORM; FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC	[1[S*(R*)],2alpha.,4b eta]-4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]acetyl]-L-proline	ACE inhibitor	hypertension
fosinopril + hydrochlorothiazide; hydrochlorothiazide + fosinopril; TENSOZIDE; MONOPRIL-HCT; FOSICOMP		ACE inhibitor; diuretic	hypertension; heart failure
FPL 69931			obesity
fructose 1,6-bisphosphatase inhibitors, Ontogen			diabetes
furmidipine; CRE 319	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl (tetrahydro-2-furanyl)methyl ester	calcium antagonist	hypertension; angina; reperfusion injury
galanin modulators, Synaptic		analgesic	obesity; diabetes; cognitive defect; pain
galanin receptor modulators, Pharmacopeia			obesity
galanin1 antagonists, Neurogen		analgesic	obesity; pain; cognitive defect

gallopamil; D 600; PROCORUM; CORAPAMIL; ALGOCOR	5-[(3,4-dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile	calcium antagonist	hypertension; angina; arrhythmia
gemfibrozil; CI 719; CS 719; LOPID; ZILOP; IPOLIPID; MARISTON; DELIPID; SCANTIPID	5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid	fibrate	hyperlipidemia
gene discovery, cardiovascular disease, GenSet			hypertension
gene discovery, cardiovascular disorders, AlphaGene			heart failure; hypertension; stroke
gene discovery, connective tissue disorders			cancer; diabetes; obesity; autoimmune disease
gene discovery, diabetes			diabetes
gene discovery, diabetes, BioStratum			diabetes; kidney disease
gene discovery, diabetes, Glaxo Wellcome/Axys			diabetes
gene discovery, diabetes, LifeSpan			diabetes
gene discovery, diabetes, Lilly			diabetes
gene discovery, diabetes, Millennium/Roche			diabetes

gene discovery, insulin signalling pathway			diabetes
gene discovery, metabolic disease, deCODE genetics			diabetes
gene discovery, metabolic disorders, AlphaGene			obesity; diabetes; osteoporosis
gene discovery, noninsulin dependent diabetes (NIDDM)			diabetes
gene discovery, obesity			obesity
gene discovery, obesity and diabetes, CuraGen			obesity; diabetes
gene discovery, obesity, Amplicon			obesity
gene discovery, obesity, Axys			obesity
gene discovery, obesity, Exelixis			obesity
gene discovery, obesity, Millennium/Roche			obesity
gene discovery, obesity, Myriad; gene discovery, obesity, Bayer			obesity
gene discovery, type II diabetes, Amplicon			diabetes
gene therapy, adrenomedullin; gene therapy, hypertension		gene therapy; biotechnology	hypertension

gene therapy, antisense, AT1; antisense oligonucleotide, AT1; antisense oligonucleotide, hypertension		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide; gene therapy	hypertension
gene therapy, cytokines, Stanford University; gene therapy, autoimmune disease		biotechnology; gene therapy; cytokine; immunosuppressant	autoimmune disease; rheumatoid arthritis; diabetes; multiple sclerosis
gene therapy, diabetes		gene therapy; biotechnology	diabetes
gene therapy, diabetes, GenEra		biotechnology; gene therapy; hormone	diabetes
gene therapy, diabetes, University of California at San Francisco		biotechnology; gene therapy	diabetes
gene therapy, insulin		biotechnology; gene therapy; hormone	diabetes
gene therapy, insulinotropin		gene therapy; biotechnology	diabetes
gene therapy, LDL receptor; gene therapy, hyperlipidemia		biotechnology; gene therapy	hyperlipidemia
gene therapy, LDL receptor; gene therapy, hypercholesterolemia		biotechnology; gene therapy	hyperlipidemia
gene therapy, LDL receptor; gene therapy, hypercholesterolemia		biotechnology; gene therapy	hyperlipidemia

GI 248573		cholecystokinin A agonist	obesity; cholestasis
glimepiride; HOE 490; AMARYL	trans-3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide	sulfonylurea	diabetes
GLP1 agonists, Neurogen			obesity; diabetes
glucagon; glucagon G; GlucaGen	His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr	biotechnology; hormone	diabetes
glucagon hydrochloride; GLUCAGON		biotechnology; hormone	diabetes
glucagon receptor inhibitors		glucagon antagonist	diabetes
glucagon-like peptide; GLP-1		peptide	diabetes
glucagon-like peptide-1 mimetic			diabetes
glucagon-like peptide1; GLP 1		biotechnology; insulin secretagogue; peptide	diabetes
glucocorticoid receptor antagonists, Karo Bio			diabetes

glutamic acid decarboxylase, Genzyme; type 1 diabetes therapy, Genzyme		biotechnology; enzyme	diabetes
glycopril	N-[(2S)-3-(acetylthio)-2-(1,3-benzodioxol-5-ylmethyl)-1-oxopropyl]glycine phenylmethyl ester	ACE inhibitor; enkephalinase inhibitor	hypertension
GM 1306		growth factor modulator	diabetes; retinopathy; cancer
GR 328713		microsomal transfer protein inhibitor	hyperlipidemia
GW 1929	N-(2-benzoylphenyl)-O-[2-(methyl-2-pyridinylamino)ethyl]-L-tyrosine	PPAR agonist	diabetes
GW 9820		PPAR agonist; fibrate	diabetes
GYKI 46544	Unspecified	calcium antagonist	hypertension
gypsetin	(5aalfa,7aalfa,8abeta,13abeta,15aalfa,16aalfa)-5a,13a-bis(1,1-dimethyl-2-propenyl)-5a,8,8a,13,13a,15a,16,16a-octahydro-8a,16a-dihydroxypyrazino[1",2":1,5;4",5":1',5']dipyrrolo[2,3-b:2',3'-b']diindole-7,15(5H,7aH)-dione	ACAT inhibitor	hyperlipidemia
HL 004; TS 962	N-(2,6-diisopropylphenyl)-2-(tetradecylthio)acetamide	ACAT inhibitor	atherosclerosis; hyperlipidemia



HOE 1423		biotechnology; insulin analogue	diabetes
HSR 175	R-(-)-5-[2[2-(5-fluoro-2-methoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; urinary incontinence
hyperlipidemia therapy, City of Hope National Medical Center			hyperlipidemia
hypoglycemic 2-oxiranecarboxylate derivatives, Seoul University	2-[6-(2-thienylmethoxy)hexyl]oxiranecarboxylic acid ethyl ester		diabetes
hypoglycemic, Pliva	N-(4-acetylamino phenylsulphonyl)-1,3-dioxepino[5,6-b]aziridine		diabetes
hypolipemic, North Carolina University; AMMCA	6-amino-1,2-dihydro-5-methyl-2-thioxo-4-pyrimidinecarboxylic acid	HMG CoA reductase inhibitor	hyperlipidemia
hypolipidemic, Sam Il			hyperlipidemia
ICE inhibitor, IDUN		caspase inhibitor; apoptosis inhibitor; IL-1 beta converting enzyme inhibitor; immunosuppressant	transplant rejection; septic shock; rheumatoid arthritis; inflammatory bowel disease; diabetes
ilomastat; GM 6001; CS 610; GALARDIN; GALARDIN MPI	N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-butanediamide	matrix metalloproteinase inhibitor; proteinase inhibitor	retinopathy; diabetes; cancer

imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]-3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid	ACE inhibitor	hypertension; heart failure; diabetes
indoramin; WY 21901; DORALESE; TILTAB; BARATOL; WYDORA; WYPRESIN; VIDORA	N-[1-[2-(1H-indol-3-yl)ethyl]-4-piperidiny]benzamide	alpha adrenergic antagonist	hypertension; benign prostate hypertrophy
insulin agonists, Neurogen			diabetes
insulin B chain peptide, University of Colorado		peptide	diabetes
insulin glargine; HOE 901	human [A21-glycine, B31-arginine, B32-arginine] insulin	biotechnology; insulin analogue	diabetes
insulin lispro; lys-pro insulin; insulin analogue; LY 275585; HUMALOG	28B-L-lysine-29B-L-proline insulin (human)	biotechnology; insulin analogue	diabetes
insulin mimetics, oral, Biota		insulin mimetic	diabetes
insulin potentiating factor; IPF		insulin sensitizer	diabetes
insulin RTP antagonist, SUGEN		tyrosine phosphatase inhibitor	diabetes
insulin sensitizer, Recepton		insulin sensitizer	diabetes
insulin sensitizers, SmithKline Beecham		insulin sensitizer	diabetes

insulin, human; HR 1799; INSUMAN	Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn (chain A) Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr (B chain)	biotechnology; hormone	diabetes
insulin, human, BioTechnology General		biotechnology; hormone	diabetes
insulin-associated protein tyrosine phosphatase inhibitors, Ontogen			diabetes
insulin-dependent diabetes therapy, Procept		immunosuppressant	diabetes
insulinotropin; glucagon-like peptide 1; GLP-1; NNC 901170		biotechnology; hormone; peptide	diabetes
interleukin-1; IL-1		biotechnology; cytokine	diabetes
interleukin-4 receptor inhibitors, Affymax		cytokine inhibitor	asthma; diabetes
irbesartan; SR 47436; BMS 186295; APROVEL; KARVEA; AVAPRO	2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	angiotensin II antagonist	hypertension; kidney disease; heart failure

irbesartan + hydrochlorothiazide; hydrochlorothiazide + irbesartan; AVALIDE; COAPROVEL; KARVEZIDE		angiotensin II antagonist; diuretic	hypertension; kidney disease
IRLS DR09			hypertension
IRLS DR12			hypertension
IRLS DR33			hypertension
islets of neogenesis- associated protein (INGAP)-based therapy, Lilly		biotechnology; gene	diabetes
isradipine; isrodipine; PN 200110; PN 205033; PN 205034; PRESCAL; LOMIR; DynaCirc; VASCAL; ICAZ	4-(4-benzofurazanyl)- 1,4-dihydro-2,6- dimethyl-3,5- pyridinedicarboxylic acid methyl 1- methylethyl ester	calcium antagonist	hypertension; angina
J 104132; L 753037	[5S-[5alpha, 6beta, 7alpha (R*)]]-2- butyl-5-(1,3- benzeodioxol-5-yl)-7- [(2-carboxy-propyl)- 4-methoxyphenyl]-6,- dihydro-5H- cyclopenta[b]pyrindi ne-6-carboxylic acid	endothelin antagonist	hypertension
JMV 236	N-[(1,1- dimethylethoxy)carbo nyl]-O-sulfo-L- tyrosyl-L- norleucylglycyl-L- tryptophyl-L- norleucyl-L-alpha- aspartyl-L- phenylalaninamide	cholecystokinin agonist	hypertension

K 85; OMACOR			hyperlipidemia; restenosis
ketanserin; R 41468; SEREFREV; SUFREXAL; SEREFREX	3-[2-[4-(4-fluorobenzyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione	5HT antagonist; 5HT2 antagonist	hypertension
KP 102		insulin sensitizer	diabetes
KRN 4884	5-amino-N-[2-(2-chlorophenyl)ethyl]-N'-cyano-3-pyridinecarboximide	potassium channel activator	hypertension
KS 341; RKS 0341		adenosine antagonist	hypertension
L 159689	N-[3,4-dihydro-4-oxo-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-6-quinazolinyl]-N-pentylbenzamide	angiotensin II antagonist	hypertension
L 161177	2-ethyl-5,7-dimethyl-3-[[2'-(2-oxido-3H-1,2,3,5-oxathiadiazol-4-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine	angiotensin II antagonist	hypertension
L 162234	[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulphonyl]carbamic acid 1,1-dimethylethyl ester	angiotensin II antagonist	hypertension

L 659699; F 244	[2R-[2alpha(2E,4E,7R*),3beta]]-11-[3-(hydroxymethyl)-4-oxo-2-oxetanyl]-3,5,7-trimethyl-2,4-undecadienoic acid	HMG CoA synthase inhibitor	hyperlipidemia
L 692429	3-amino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3(R)-yl]-butanamide	angiotensin II antagonist	hypertension
lacidipine; GR 43659; GR 43659X; SN 305; GX 1048; LACIPIL; VIAPRES; LACIREX; MOTENS; CALDINE; MIDOTENS; APONIL; ZASCAL; LACIMEN	(E)-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium channel blocker	hypertension
laennec; human placenta hydrolysate			hypertension; liver disease
lanreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSTYL	3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2,7)-disulfide	somatostatin analogue	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
lateritin	4-methyl-6-(1-methylethyl)-3-phenylmethyl-1,4-perhydrooxazine-2,5-dione	ACAT inhibitor	hyperlipidemia
leptin agonists, Pharmacopeia; leptin agonists, Regeneron			obesity

leptin expression modulators			obesity
leptin modulator, Receptron			obesity
leptin receptor		biotechnology	anemia; obesity; diabetes
leptin signalling pathway modulators, Ligand			obesity
leptin, second generation, Amgen		biotechnology	obesity
lercanidipine; masnidipine; REC 152375; R 75; TJN 324; ZANIDIP; LERDIP; ZANEDIP; LERCADIP; CARDIOVASC; LERZAM	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester	calcium antagonist	hypertension
leucomyzin		NSAID	inflammation; hyperlipidemia
levobunolol; W 7000A; AG 901; BETAGAN; VISTAGEN; GOTENSIN; VISTAGAN; LEVOGAN	(-)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2H)-naphthalenone	beta adrenergic antagonist	hypertension; glaucoma
LG 1411			diabetes
LGD 1268; ALRT 268		RXR agonist; retinoid agonist	diabetes
LGD 1324; ALRT 324		retinoid agonist; RXR agonist	diabetes

lidanserin; ZK 33839	(+,-)-4-[3-[3-[4-(p-fluorobenzoyl)piperidin-2-yl]propoxy]-4-methoxyphenyl]-2-pyrrolidinone	5HT antagonist; 5HT2 antagonist; alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
lisinopril + hydrochlorothiazide; hydrochlorothiazide + lisinopril; PRINZIDE; PRINIVIL PLUS; CARACE; ZESTORETIC; ACECOMB; ACERCOMP		ACE inhibitor; diuretic	hypertension
LM 1554	2-chloromethyl-5,6,7,8-tetrahydrobenzo(b)thieno(2,3-d)pyrimidin-4 (3H)-one		hyperlipidemia
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
losartan + hydrochlorothiazide; HYZAAR; LOSACOR D		angiotensin II antagonist; diuretic	hypertension



lovastatin; mevinolin; monakolin K; MK 803; MSD 803; MB 530B; L 154803; MEVACOR; MEVLOR; LOVACOL; HIPOVASTIN; DISLIPIN; LOVASTEROL; LINCIL	(S)-2-methylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia; cancer
LP 805	8-tert-butyl-6,7-dihydropyrrolo[3,2-e]-5-methylpyrazolo[1,5a]pyrimidine-3-carbonitrile	vasodilator	hypertension; angina
LR B139		angiotensin II antagonist	hypertension; angina
LY 197535		insulin analogue	diabetes
LY 203647	1-[2-hydroxy-3-propyl-4-[4-[2-[4-(1H-tetrazol-5-yl)butyl]-2H-tetrazol-5-yl]butoxy]phenyl]ethanone	leukotriene D4 antagonist; leukotriene antagonist	hypertension; asthma
LY 333531	(S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione	protein kinase inhibitor; protein kinase C inhibitor	diabetes; retinopathy
LY 335124		antiestrogen; estrogen agonist	hyperlipidemia

LY 362884		beta adrenergic agonist; beta3 adrenergic agonist	obesity; diabetes
MAb, A1717; MAb A717		biotechnology; monoclonal antibody	diabetes
MAb, adipocytes		biotechnology; monoclonal antibody	obesity
MAb, adrenomedullin		biotechnology; monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
MAb, LDL and Fc; bispecific antibody, low density lipoprotein		biotechnology; monoclonal antibody	hyperlipidemia
MAb, VLA-4, humanized; MAb, very late antigen-4, humanized		biotechnology; monoclonal antibody; NSAID	inflammation; rheumatoid arthritis; asthma; diabetes
macrophage colony stimulating factor; M-CSF; MACROLIN		biotechnology; growth factor; hematopoietic factor; immunostimulant; cicatrizant; antifungal	mycosis; hyperlipidemia; skin ulcer; bacterial infection
manidipine; manidipine hydrochloride; CV 4093; CALSLOT; MADIPINE; IPERTEN	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[4-(diphenylmethyl)-1-piperazinyl]ethyl 3,5-pyridinedicarboxylic acid methyl ester	calcium antagonist; vasodilator	hypertension
mazindol; MAZANOR; SANOREX	5-(4-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol		obesity
MCC 134	1-[4-(1H-imidazol-1-yl)benzoyl]-N-methylcyclobutanecarbothioamide	diuretic; potassium channel activator	hypertension

MCC 555	5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl-2,4-thiazolidinedione	insulin sensitizer	diabetes
MCR4 modulators, Pharmacopeia			obesity
MD 31; M 17055	N-[7-chloro-2,3-dihydro-1-(2-methylbenzoyl)-4(1H)-quinolinyldene]hydroxylamine-O-sulfonic acid	diuretic	hypertension
MEDICA 16	beta, beta-tetramethyl hexadecanedioic acid	cholesterol synthesis inhibitor	hyperlipidemia
melanocortin receptor-4 modulators, Trega Biosciences			obesity; diabetes
MER A2026A; Mer-A 2026A	2-(10-hydroxy-3,7,9,11,13-pentamethyl-2,5,7,11-tetradecatetraenyl)-6-methoxy-3-methyl-4-pyridinol	vasodilator	hypertension
MER A2026B; Mer-A 2026B	2-(10-hydroxy-3,7,9,11-tetramethyl-2,5,7,11-tridecatetraenyl)-6-methoxy-3-methyl-4-pyridinol	vasodilator	hypertension
metabolic disease therapy, Amylin/SIDDCO			diabetes
metabolic disorder therapy, Amylin			diabetes; obesity; hyperlipidemia
metabolic disorders, Amylin			diabetes; obesity; hyperlipidemia

metazosin; metasozin; metazocin; KENOSIN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy; heart failure
metformin; metformin hydrochloride; LA 6023; BMS 207150; GLUCOPHAGE	N,N-dimethylimidodicarbonylimidic diamide	biguanide	diabetes
metipamide	3-(aminosulfonyl)-4-chlorobenzoic acid 2-methyl-2-phenylhydrazide	vasodilator	hypertension
metoprolol, (S)-; (S)-metoprolol		beta adrenergic antagonist; beta1 adrenergic antagonist	angina; hypertension; arrhythmia
mexiletine; KO 1173; MEXITIL	1-methyl-2-(2,6-xylyloxy)ethylamine hydrochloride		neuropathy; arrhythmia; diabetes
miglitol; BAY m 1099; DIASTABOL; GLYSET	(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol	alpha glucosidase inhibitor	diabetes
millisrol; NK 843H; NK 843L; NK 843			hypertension; diagnosis
mineralocorticoid antagonists, Ligand		mineralocorticoid antagonist	hypertension
mixanpril		ACE inhibitor; neutral endopeptidase inhibitor	hypertension
MKC 121	4-tridecylpyrrole-2-carboxylic acid		hyperlipidemia

moexipril; RS 10085; SPM 925; CI 925; RS 10085197; UNIVASC; FAMPRESS; MOEX; PERDIX; FEMPRESS	[3S-[2[R*(R*),3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid	ACE inhibitor	hypertension
moexipril + hydrochlorothiazide; hydrochlorothiazide + moexipril; UNIRETIC		ACE inhibitor; diuretic	hypertension
monoclonal antibody, leptin receptor		monoclonal antibody; biotechnology	diabetes; anemia; obesity
moxonidine; BE 5895; BDF 5895; LY 326869; CYNT; PHYSIOTENS	4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine	alpha adrenergic agonist; alpha2 adrenergic agonist; imidazoline agonist	hypertension; heart failure; diabetes
MXC 3255; MXC3255			diabetes
nalmefene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
naphterpin; CL 190Y2	(4aS-cis)-3,4a,5,12b-tetrahydro-8,10-dihydroxy-2,5,5,9-tetramethyl-4H-benzo[d]naphtho[2,3-b]pyran-7,12-dione	antioxidant; NSAID	diabetes; cardiovascular disease; cancer; inflammation
natural lipase inhibitor, Yakurigaku Chuo Kenkyusho		lipase inhibitor	obesity; atherosclerosis
NBI 115		peptide	diabetes
NCX 900		nitric oxide donor; NSAID	pulmonary hypertension

nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET	[2R*[R*[R*(S*)]]]- alpha,alpha'- [iminobis(methylene) ]bis[6-fluoro-3,4- dihydro-2H-1- benzopyran-2- methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator; vasodilator	hypertension; migraine; heart failure
NEPHROSTAT		matrix metalloproteinase inhibitor; proteinase inhibitor	kidney disease; diabetes
nerve growth factor; NGF; NEULEZE		growth factor; biotechnology; neurotrophic factor	neuropathy; diabetes
neuropeptide Y antagonist, Alanex		neuropeptide Y antagonist	obesity; hypertension
neuropeptide Y antagonists, Neurogen		neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypotension; obesity; depression
neuropeptide Y antagonists, Synaptic; neuropeptide Y antagonists, Novartis		neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
neuropeptide Y receptor modulators, Allelix			obesity
neuropeptide Y1 antagonists, Neurogen		neuropeptide Y antagonist; neuropeptide Y1 antagonist	obesity
neuropeptide Y5 antagonist, Synaptic; neuropeptide Y5 antagonist, Novartis		neuropeptide Y antagonist; neuropeptide Y5 antagonist	obesity
neuropeptide Y5 antagonists, Neurogen		neuropeptide Y antagonist; neuropeptide Y5 antagonist	obesity

neurotrophin-4; NT-4		biotechnology; neurotrophic factor; growth factor	neuropathy; diabetes
NGD 951; NGD 95-1; CP 422935		neuropeptide Y antagonist	obesity; eating disorder
nilvadipine; nivadipine; FK 235; FR 34235; SKF 102362; CL 287389; NIVADIL; ESCOR	2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl) ester	calcium antagonist	hypertension; angina
nisoldipine; BAY k 5552; SULAR; SYSCOR; BAYMYCARD; CORASOL; CORNEL; NISODIPEN; NISOCOR; ZADIPINA	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2-methylpropyl ester	calcium antagonist	angina; hypertension
nitrendipine; BAY e 5009; BAYOTENSIN; BAYPRESS; NIRAPEL; NITRENDIL; NITRENDIPINA; HYPERDIPINA; HIPERTENOL; PORTIONAL; NELCONIL; RETENCAL	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist	hypertension
nitrendipine, (S)-; (S)-nitrendipine		calcium antagonist	hypertension
NK 104	[4R-[4alpha,6beta(E)]]-6-[2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
NN 2344; DRF 2593		insulin sensitizer	diabetes

NN 5501		potassium channel activator	diabetes
NNC 051869			neuropathy; diabetes
NNC 550118			diabetes
noninsulin dependent diabetes mellitus (NIDDM) therapy, MitoKor			diabetes
NOX 100		nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 51		nitric oxide scavenger	diabetes; cancer; cardiovascular disease; transplant rejection; septic shock
NTE 122		ACAT inhibitor	hyperlipidemia; atherosclerosis
nucleoside mimetics, Gensia		nucleoside analogue	diabetes
NX 1838		aptamer; oligonucleotide; angiogenesis inhibitor	cancer; diabetes; retinopathy
NY 008	3-octyl-1(3H)-isobenzofuranone	vasodilator	hypertension
obesity therapy, Bristol-Myers Squibb/Garvan Institute of Medical Research			obesity
obesity therapy, Cerebrus		5HT agonist; 5HT2C agonist	obesity
obesity therapy, GelTex		lipase inhibitor	obesity
obesity therapy, Magainin			obesity



obesity therapy, Novo Nordisk/ACADIA			obesity
obesity therapy, Novo Nordisk/Boehringer Ingelheim			obesity
obesity therapy, Obesys; obesity therapy, BTG			obesity
obesity therapy, Pharmacia & Upjohn			obesity
obesity therapy, SIDR			obesity
obesity therapy, Trega/Novartis; diabetes therapy, Trega/Novartis			obesity; diabetes
obesity therapy, Tularik/Japan Tobacco			obesity; diabetes
obesity therapy, Tularik/Knoll			obesity
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic; hormone	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly

olmesartan; CS 866	4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester	angiotensin II antagonist	hypertension
ophthalmological, Tanabe	6'-chloro-3'-methylspiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-trione	aldose reductase inhibitor	retinopathy; diabetes
opioid antagonists, NIH		opiate antagonist; peptide; immunosuppressant	addiction; alcoholism; obesity; transplant rejection
oral amylin receptor antagonists, Amylin		amylin antagonist	diabetes
oral insulin mimetics, Insulin Mimetics		insulin mimetic	diabetes
orlistat; orlipastat; tetrahydrolipistatin; THL; Ro 180647; XENICAL	N-formyl-L-leucine [2S-[2alpha(R*),3beta]]-1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester	pancreatic lipase inhibitor	obesity; hyperlipidemia
oxcarbazepine; CGP 47680; KIN 493; GP 47680; TRILEPTAL; TOXECAR	10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide		epilepsy; diabetes; neuropathy
P 06103	4-[3-[(6-amino-9-beta-D-ribofuranosyl-9H-purin-8-yl)thio]-2-oxopropoxy]-benzoic acid 2-methylpropyl ester		hyperlipidemia

P 06139	4-[3-[(4,5-diphenyl-1H-imidazol-2-yl)thio]-2-hydroxypropoxy]-benzoic acid 2-methylpropyl ester	ACAT inhibitor	hyperlipidemia
P 0654	8-[3-[4-(2-methylpropyloxycarbonyl)phenoxy]-2-(R)-hydroxypropyl]adenosine		hyperlipidemia
P 30			diabetes
P 5		calcium channel blocker	hypertension
P 57			obesity
pannorin	4,8,10-trihydroxy-5-methyl-2H-naphtho[1,2-b]pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia
PD 123177; EXP 655	1-[(4-amino-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid	angiotensin II antagonist	hypertension
PD 123319	(S)-1-[[4-(dimethylamino)-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid	angiotensin II antagonist	hypertension
PD 129337	N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-phenylcyclopentyl)methylurea	ACAT inhibitor	hyperlipidemia

PD 132002	[1S-(1R*,2S*,3R*)]-N-(4-morpholinylsulfonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-O-methyl-3-oxo-DL-serinamide	renin inhibitor	hypertension
PD 1323012; PD 132301-2	N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea monohydrochloride	ACAT inhibitor	hyperlipidemia
PD 150304	Unspecified	angiotensin II antagonist	hypertension
PD 156707; PD 156123	alpha-[2-(4-methoxyphenyl)-2-oxo-1-[(3,4,5-trimethoxyphenyl)methyl]ethylidene]1,3-benzodioxole-5-acetic acid sodium salt	endothelin antagonist; endothelin A antagonist	ischemia; reperfusion injury; pulmonary hypertension
pentosan polysulfate sodium; SP 54; PZ 68; CARTROPHEN; LASONIL; ELMIRON; LELONG MOUSSE	(1-4)-beta-D-xylan 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis
PEPTIMER		biotechnology; immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes

perindopril; perindopril erbumine; S 9490; S 94903; SED 9490; MCN A2833109; DW 7950; COVERSYL; ACEON; ACERTIL; COVERENE; COVEREX; COVERSIL	(2S,3aS,7aS)-1-[(2S)- 2-[[[(1S)-1- (ethoxycarbonyl)butyl ]amino]-1- oxopropyl]octahydro- 1-1H-indole-2- carboxylic acid	ACE inhibitor	hypertension; coronary artery disease
phensuccinal	beta- phenylethylamide-2- hydroxysuccinanylic acid	antioxidant	diabetes; kidney disease; retinopathy
phentolamine mesilate; phentolamine mesylate; VASOMAX; Z- MAX; VASOFEM	3-[[[(4,5-dihydro-1H- imidazol-2- yl)methyl](4- methylphenyl)amino] phenol	vasodilator; alpha adrenergic antagonist	sexual dysfunction; hypertension
phosphoenol pyruvate carboxykinase modulators; PEPCK modulators			diabetes
PIC 060 analogs		immunosuppressant; NSAID	psoriasis; dermatitis; diabetes; transplant rejection; rheumatoid arthritis
pimagedine; pimagedine hydrochloride; aminoguanidine; GER 11; YM 585	aminoguanidine		diabetes; kidney disease; retinopathy; atherosclerosis; neuropathy; stroke
pinacidil; P 1134; PINDACIL; PINDAL; PINDAC; THERAPRESS	N-cyano-N'-(4- pyridinyl)-N''-(1,2,2- trimethylpropyl)guani dine	potassium channel blocker	hypertension
PNU 106817		insulin sensitizer	diabetes; obesity

PNU 140975		insulin sensitizer	diabetes; obesity
policosanol; ATEROMIXOL			hyperlipidemia
posatiorelin; RGH 2202	(S)-N-[(6-oxo-2-piperidinyl)carbonyl]-L-leucyl-L-prolinamide	protirelin analogue	cognitive defect; obesity
potassium channel activator, Merck KGaA	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
potassium channel modulators, Phytera/NeuroSearch		potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
PPAR modulators		retinoid	atherosclerosis; obesity
PPAR modulators, metabolic diseases, Ligand/Lilly			diabetes
PPAR-gamma agonist		PPAR agonist	diabetes
pramlintide; tripro-amylin; AC 137; NORMYLIN	lys-cys-asn-thr-ala-thr-cys-ala-thr-gln-arg-leu-ala-asn-phe-leu-val-his-ser-ser-asn-asn-phe-gly-pro-ile-leu-pro-pro-thr-asn-val-gly-ser-asn-thr-tyr-NH <sub>2</sub> , cyclic (2->7)-disulphide	amylin agonist	diabetes

pravastatin; eptastatin; epastatin; CS 514; SQ 31000; RMS 431; LIPOSTAT; MEVALOTIN; PRAVACHOL; PRAVASTATIN; SELECTIN; LIPREVIL; PREVACOL; PRAVASIN; APLACTIN; BRISTACOL	[1S- [1alfa(betaS*,deltaS* ,2alfa,6alfa,8beta(R* ,8aalfa)]- 1,2,6,7,8,8a- hexahydro- beta,delta,6- trihydroxy-2-methyl- 8-(2-methyl-1- oxobutoxy)-1- naphthaleneheptanoic acid	HMG CoA reductase inhibitor	hyperlipidemia; myocardial infarction
probucol; DH 581; DE 3872; LORELCO; PANAVIR; SINLESTAL	4,4'- isopropylidenedithio- bis-2,6-di-t- butylphenol	antioxidant	HIV infection; hyperlipidemia; restenosis
prohormone convertase 2 inhibitors			diabetes
prostanit		vasodilator; prostaglandin agonist	hypertension
PST 2238	(3beta,5beta,14beta)- 21,23-epoxy-24- norchola-20,22-diene- 3,14,17-triol		hypertension
QF 301	2-[2-(N4-O- methoxyphenyl-N1- piperazinyl)ethyl]-1- tetralone	alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension

quinapril; quinapril hydrochloride; CI 906; PD 1094522; ACCUPRIL; CONAN; ACCUPRO; ACUITEL; ACEQUIN; ACCUZIDE; QUINAZIDE	[3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid	ACE inhibitor	hypertension
quinapril + hydrochlorothiazide; hydrochlorothiazide + quinapril; ACCURETIC; ACEQUIDE		ACE inhibitor; diuretic	hypertension
RAGE modulators			diabetes
raloxifene; keoxifene; LY 139481; LY 156758; EVISTA	[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone	antiestrogen; estrogen agonist	osteoporosis; hyperlipidemia; myocardial infarction; cancer
ramipril; HOE 498; ALTACE; TRIATEC; PRAMACE; RAMACE; TRITACE; CARASEL; ACOVIL	(2S,3aS,6aS)-1-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid 1-ethyl ester	ACE inhibitor	hypertension; heart failure
RD 211; (+)-RD 211	(+,-)-2-(dipropylamino)-2,3-dihydro-5-methyl-1H-inden-4-ol	dopamine agonist	hypertension
renin inhibitor, Roche		renin inhibitor; proteinase inhibitor	hypertension
repaglinide; AGEE 623; AGEE 623 ZW; NN 623; NovoNorm; PRANDIN	(S)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid		diabetes



RES 7011; RES 701-1	Gly-Asn-Trp-His-Gly-Thr-Ala-Pro-Asp-Trp-Phe-Phe-Asn-Tyr-Tyr-Trp cyclic (9-1)-peptide		hypertension
riodipine; ryodipine; PP 1466; FORIDONE	4-[2-(difluoromethoxy)phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester	calcium antagonist	hypertension; angina
RL 6134; EQUATEN	unspecified	ACE inhibitor	hypertension
RL 6207; PRENTYL	unspecified	ACE inhibitor	hypertension
RL 6893; SYNECOR		ACE inhibitor	hypertension
Ro 34563		insulin secretagogue	diabetes
RPEP 27		renin inhibitor	hypertension
RS 5773	((2S,3S)-3-acetoxy-8-benzyl-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-1,5-benzothiazepine-4-(5H)-one hydrochloride	calcium antagonist	angina; hypertension
S 12340	8-[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]propyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one		hyperlipidemia
S 18277			diabetes
S 2E	(S)-(+)-4-[[1-[4-(1,1-dimethylethyl)phenyl]-5-oxo-3-pyrrolidinyl]methoxy]benzoic acid		hyperlipidemia

SA 7060	[S-(R*,R*)]-alpha- [[[(3-butoxy-2- hydroxy-3- oxopropyl)(2- methylpropyl)amino] carbonyl]amino]-2- naphthalenepropanoic acid	neutral endopeptidase inhibitor; ACE inhibitor	heart failure; hypertension
SC 103a		aldose reductase inhibitor	diabetes; neuropathy
SC 103b		aldose reductase inhibitor	diabetes; sexual dysfunction
SCA 40	6-bromo-8- (methylamino)- imidazo[1,2- a]pyrazine-2- carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
SCH 39370	[S-(R*,R*)]-N-[N-(1- carboxy-3- phenylpropyl)-L- phenylalanyl]-2- hydroxy-beta-alanine	neutral endopeptidase inhibitor	hypertension
SCH 59498		phosphodiesterase inhibitor; phosphodiesterase I inhibitor; phosphodiesterase V inhibitor	hypertension
screening technology, 5HT1 human neuroreceptors; neuroreceptors, 5- HT1 human		target based screening	obesity; anxiety; depression; migraine; drug design technology
SDZ PGU 693	2-[(4- chlorophenoxy)methy l]-7a-(3,4- dichlorophenyl)tetrah ydropyrrolo[2,1- b]oxazol-5(6H)-one		diabetes

sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
sibutramine hydrochloride monohydrate; BTS 54524; REDUCTIL; MERIDIA	1-(4-chlorophenyl)-N,N-dimethyl-alpha-(2-methylpropyl)cyclobutanemethanamine hydrochloride monohydrate	5HT reuptake inhibitor; noradrenalin reuptake inhibitor	obesity
sibutramine, (S)-; (S)-sibutramine		5HT reuptake inhibitor; noradrenalin reuptake inhibitor	obesity
signal transduction inhibitor, SUGEN/ArQule		signal transduction inhibitor; immunosuppressant	cancer; diabetes; neurological; autoimmune disease
simvastatin; epistatin; synvinolin; velostatin; MK 733; L 654; L 644128; ZOCOR; DENAN; MEDIPO; SIMOVIL; COLEDIS	2,2-dimethylbutanoic acid [1S-[1alpha,3alpha,7beta,8beta,a(2S*,4S*)8beta]]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester	HMG CoA reductase inhibitor	hyperlipidemia
simvastatin analogue, Merck & Co; L 679336	6(R)-(2-(8(S)-(2,2-dimethylbutyryl)oxy)-2(S),6(R)-dimethyl-5(R)-hydroxy-1,2,3,4,4a(R),5,6,7,8,8a(R)-decahydronaphthyl-1(S))ethyl)-4-(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia

simvastatin analogue, Merck & Co	2,2-dimethylbutanoic acid octahydro-3,7-dimethyl-4-hydroxy-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2yl)ethyl)-1-naphthaleny ester	HMG CoA reductase inhibitor	hyperlipidemia
SK 1080; KR 31080	2-butyl-5-methyl-6-(1-oxido-2-pyridinyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazodo[4,5-b]pyridine	angiotensin II antagonist	hypertension
SKP 450; KR 30450	(R)-1-[2-(1,3-dioxolan-2-yl)-2-methyl-6-nitro-2H-1-benzopyran-4-yl]-2-pyrrolidinone	potassium channel activator	hypertension; heart ischemia
SL 910102		angiotensin II antagonist	hypertension
SP 134101			diabetes
spirapril; spirapril hydrochloride; SCH 33844; TI 211950; RENPRESS; SANDOPRIL; RENORMAX; CARDIOPRIL	[8S-[7[R*(R*)]]8R*]-7-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid	ACE inhibitor	hypertension
squalestatin 1; zaragozic acid A; L 694599	[5(2E,4S,6S),7S]-2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-L-erythro-L-glycero-D-altro-7-trideculo-7,4-furanosonic acid 11-acetate 5-(4,6-dimethyl-2-octenoate)	squalene synthetase inhibitor	hyperlipidemia
squalestatins, Reading University		squalene synthetase inhibitor	hyperlipidemia

SR 121463	cis-N-(1,1-dimethylethyl)-4-[[5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy-benzamide (E)-2-butenedioate (1:1)	vasopressin antagonist; diuretic	heart failure; hypertension
SR 146131		cholecystokinin agonist; cholecystokinin A agonist	obesity
staurosporine; (+)-staurosporine; staurosporin; antibiotic 230; AM 2282	(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor	hypertension
succibun	1-[4-N-butylureasulfonyl(phenyl)]pyrrolidin-2,5-dione		diabetes
supersulfated low molecular weight heparin; ssLMWH		heparinoid	thrombosis; hyperlipidemia
symakalim; EMD 57283	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; coronary artery disease; asthma
T 0115		endothelin antagonist	pulmonary hypertension

TAK 536	1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl-2-ethoxy-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist	hypertension
TAK 636		potassium channel activator	hypertension; angina
talinolol; CORDANUM	(+/-)-N-cyclohexyl-N'-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]urea	beta1 adrenergic antagonist; beta adrenergic antagonist	hypertension; myocardial infarction; cardiovascular disease
telmisartan; BIBR 277; BIBR 0277SE; MICARDIS; PRITOR	4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid	angiotensin II antagonist	hypertension
telmisartan + hydrochlorothiazide; hydrochlorothiazide + telmisartan		diuretic; angiotensin II antagonist	hypertension
temocapril; temocapril hydrochloride; CS 622; ESCOL; ACECOL; ACECOR	[2S-[2alpha,6beta(R*)]]-6-[[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid	ACE inhibitor	hypertension
terazosin; A 45975; MY 208; HYTRIN; HEITRIN; VASOMET; SINALFA; BLAVIN; URODIE; HYTRINEX; TERAPROST; ISONTYN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist; vasodilator	benign prostate hypertrophy; hypertension

terlakiren; CP 80794	[R-(R*,S*)]-N-(4-morpholinylcarbonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2-hydroxy-3-(1-methylethoxy)-3-oxopropyl]-S-methyl-L-cysteineamide	renin inhibitor; peptide	hypertension
terpendole C		ACAT inhibitor	hyperlipidemia
terpendole D		ACAT inhibitor	hyperlipidemia
tertatolol; S 2395; SE 2395; ARTEX; ARTENSIL	(+,-)-1-[(3,4-dihydro-2H-1-benzothiopyran-8-yl)oxy]-3-[(1,1-dimethylethyl)amino]-2-propanol	beta adrenergic antagonist	hypertension
thyroid hormone receptor beta agonist, Karo Bio; thyroid hormone receptor beta agonist, Bristol-Myers Squibb			obesity; hyperlipidemia
tienoxolol; UP 78842	2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-5-[(2-thienylcarbonyl)amino]benzoic acid ethyl ester	beta adrenergic antagonist; diuretic	hypertension
tilisolol; N 696; DAIM; SELECAL	4-[3-[(1,1-dimethylethylamino)]-2-hydroxypropoxy]-2-methyl-1(2H)-isoquinolinone	beta adrenergic antagonist; vasodilator	hypertension
tiqueside; beta-tigogenin cellobioside; CP 88818	(3beta,5alpha,25R)-spirostan-3-yl-4-O-beta-D-glucopyranosyl-beta-D-glucopyranoside	cholesterol absorption inhibitor	hyperlipidemia

TMB 8	3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester	calcium antagonist	hypertension
TMP 153	N-[4-(2-chlorophenyl)-6,7-dimethyl-3-quinolinyl]-N'-(2,4-difluorophenyl)urea	ACAT inhibitor	hyperlipidemia
TN 891	(S)-4-(2-hydroxy-3-isopropylaminopropoxy)phenylacetamide		hypertension
torasemide; torsemide; JDL 464; BM 02015; AC 4464; GJ 1090; UNAT; PRESARIL; TORREM; TOREM; ZEMIDE; DEMADEX; TORADIUR; DIURESIX; LUPRAC	N-[[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide	diuretic	hypertension; heart failure
trandolapril; CI 907; RU 44570; RU 570; ODRIK; UDRIK; GOPTEN; TRAPRIL; ODRIC; MAVIK	[2S-[1[R*(R*)],2alpha,3alpha,7abeta]]-1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid	ACE inhibitor; vasodilator	hypertension; heart failure; myocardial infarction
trandolapril + verapamil; verapamil + trandolapril; RU 44570A; TARKA; VERATRON		ACE inhibitor; calcium channel blocker	hypertension



transcription factor regulators, antihypercholesterole mia		transcription factor regulator	hyperlipidemia
troglistazone; CS 045; CI 991; GR 92132X; NOSCAL; ReZulin; ROMOZIN; PRELAY	5-[[4-[(3,4-dihydro-6- hydroxy-2,5,7,8- tetramethyl-2H-1- benzopyran-2- yl)methoxy]phenyl]m ethyl]-2,4- thiazolidinedione	insulin sensitizer	diabetes; gynecological
type II diabetes therapy, Cell Therapeutics			diabetes
U 10483			diabetes
U 37883A	N-cyclohexyl-N'- tricyclo[3.3.1.1 <sup>3,7</sup> ]de c-1-yl-4- morpholinecarboximi damide monohydrochloride	potassium channel blocker	hypertension
U 73482	7,7'-[1,2- ethanediylbis(4,1- piperidinediylmethyle ne)]-bis[4,9- dimethoxy-5H- furo[3,2- g][1]benzopyran-5- one	ACAT inhibitor	hyperlipidemia
U 86192A	2,3-dihydro-2-[[[(3- phenylpropyl)amino] methyl]-7H-1,4- dioxino[2,3-e]indole- 8-carboxylic acid methyl ester	5HT antagonist; 5HT1A antagonist	hypertension

U 88156	[1 alpha(E),4beta]-3-[2-(4-hydroxy-1-methylcyclohexyl)ethenyl]-alpha,alpha-dimethylbenzenepentanol	HMG CoA reductase inhibitor	hyperlipidemia
U 92352	N-cyano-N'-(3,4-dichlorobenzyl)-N''-(4-pyridinyl)guanidine	vasodilator	hypertension
UH 334			hypertension
ULTG 307		beta adrenergic agonist; beta3 adrenergic agonist	obesity
UP 27522	Unspecified	angiotensin II antagonist	hypertension
urapidil; B 66256; BY 05068; EBRANTIL; ALPHA DEPRESSAN	6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; benign prostate hypertrophy; dysuria
UT 15		prostanoid; vasodilator	pulmonary hypertension
UT 26		biotechnology; antisense; oligonucleotide	pulmonary hypertension
V 411; DIAB II		insulin sensitizer	diabetes
vaccine, angiotensin, Proteus; vaccine, hypertension, Proteus		vaccine	hypertension
vaccine, diabetes		vaccine; peptide	diabetes
valsartan; CGP 48933; DIOVAN	N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1-biphenyl]-4-yl]methyl]-L-valine	angiotensin II antagonist	hypertension; heart failure

valsartan + hydrochlorothiazide; hydrochlorothiazide + valsartan; CoDiovan; CO-DIOVAN; DIOVAN HCT; CoTareg; CO-TAREG; DIOVAN-D		angiotensin II antagonist; diuretic	hypertension
vanadeine			diabetes
vasodilator, Ortho	N-(2,3-dihydro-6,7-dimethoxy-1-methyl-3-oxo-4-isoquinolinyl)-N'-2-propenyl-urea	vasodilator	hypertension
verapamil, (S)-; (S)-verapamil; levoverapamil; D 2024	(S)-alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile	calcium channel blocker	hypertension; arrhythmia; angina
veroxan; VUFB 18814		calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease
voglibose; AO 128; A 71100; GLUSTAT; BASEN	3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-D-epi-inositol	alpha glucosidase inhibitor	diabetes
WY 126227; WAY 126227	N-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-2-(trifluoromethyl)-4-quinazolinamine	angiotensin II antagonist	hypertension
Y 20835		calcium antagonist	hypertension
Y 23785	unspecified	ACE inhibitor	hypertension

Y 27632	[4(R)-trans]-4-(1-aminoethyl)-N-4-pyridinylcyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
YM 161511; YM 16151-1	(+)-1,4-dihydro-4-[2-[4-[(2-hydroxy-3-phenoxypropyl)amino]butoxy]-5-nitrophenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester monohydrochloride	calcium antagonist	hypertension; angina
YM 440		insulin sensitizer	diabetes
YM 598	{potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylthioethanesulfonamide}	endothelin A antagonist	hypertension
Z 13752A		ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
Z 15040		dopamine agonist	hypertension
ZD 4522; S 4522		HMG CoA reductase inhibitor	hyperlipidemia
zenarestat; FR 74366; FK 366	3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid	aldose reductase inhibitor	diabetes; retinopathy; neuropathy
ZK 110841	[1R-[1alpha(Z),2beta(1E,3S*),3alpha,5beta]]-7-[5-chloro-2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxycyclopentyl]-5-heptenoic acid	prostanoid; platelet antiaggregant	glaucoma; hypertension; thrombosis

ZK 112566	N'-[(3beta, 8alpha)-13-amino-2,3-dihydro-2,6-dimethyl-ergolin-8-yl]-N,N-dimethylurea	dopamine agonist; dopamine D2 agonist; alpha adrenergic antagonist; alpha2 adrenergic antagonist; vasodilator	hypertension
ZK 118182	[1R-[1alpha(Z),2beta(1E,3S*),3alpha,5alpha]]-[[4-[5-chloro-2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxycyclopentyl]-2-butenyl]oxy]acetic acid	prostanoid; platelet antiaggregant	thrombosis; hypertension
zopolrestat; CP 73850; ALOND	3,4-dihydro-4-oxo-3-[[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid	aldose reductase inhibitor	diabetes; neuropathy; kidney disease

Table 57. Current Candidate Therapeutic Interventions for the Treatment of Anemia

Product Name	Chemical Name	Action	Indication
iron lysozyme glutarate; ABC 1020	Unspecified	Antianemic	anemia
PG 2	Tranditional Asian medicine isolate	Antianemic	anemia; cancer; leukopenia
PG 266	Tranditional Asian medicine isolate	Antianemic	anemia; cancer; leukopenia
PG 349	Tranditional Asian medicine isolate	Antianemic	cancer; anemia
PG 488	Tranditional Asian medicine isolate	Antianemic	cancer; anemia
clotrimazole; BAY 5097; CUTAMYCON; ENSCHENT; FUNGIZID; HAKUSERIN; LOTRIMIN AF; MYCG-HERMAL; MYKO CORDES; TRIGENTAX; CANESTEN; LOTRIMIN	Unspecified	antifungal; imidazole	mycosis; sickle cell anemia; cancer; diarrhea
fructose-1,6-diphosphate; CPC 111; CORDOX	1,6-bis(dihydrogen phosphate) D-fructose	anti-ischemic	heart failure; myocardial infarction; sickle cell anemia; septic shock
SCHAL 1SCA	Unspecified	Antiproliferative agent	sickle cell anemia
CT 15KG	Unspecified	Bursten pathwya inhibitor	anemia
activin	Unspecified	Enzyme antianemic	sickle cell anemia; infertility
transcription factor, erythropoietin	Unspecified	EPO and GM-CSF gene transcription	anemia
erythropoietin mimic, EPO mimic,	Unspecified	EPO mimic; Orally active	anemia
Erythropoietin receptor activators	Unspecified	EPO pathway stimulation	anemia
VG 18563	Oral prodrug of butyrate	Erythropoiesis stimulator	anemia; cancer
erythropoietin modulator	Unspecified	growth factor	anemia

hematopoietic agent, PolyMASC	Unspecified	growth factor	anemia
hematopoietic growth factor mimetics	unspecified	growth factor	cancer; bacterial infection; anemia
HP 367	Unspecified	growth factor	anemia
HP 395	Unspecified	growth factor	anemia
erythropoietin agonists	unspecified	growth factor modulator	anemia
drug delivery system, erythropoietin;	EPO	growth factor; hematopoietic factor	anemia
drug delivery system, oral MACROMOL erythropoietin; erythropoietin MACROMOL; erythropoietin oral; EPO oral	EPO	growth factor; hematopoietic factor	anemia
drug delivery system, ProLease erythropoietin; erythropoietin ProLease; drug delivery system, EPO	EPO	growth factor; hematopoietic factor	anemia
epoetin alfa; recombinant human erythropoietin; KRN 5702; KRN 5701; EPREX; EPOGEN; ERYPO; PROCRIT; ESPO; EPOADE	1-165-erythropoietin (human clone lambdaHEPOFL13 protein moiety) glycoform alpha	growth factor; hematopoietic factor	anemia
epoetin beta; recombinant human erythropoietin; BM 06019; MAROGEN; BECEUMEN; EPOGIN; RECORMON; EPOCH; NEORECORMON	1-165-erythropoietin (human clone lambdaHEPOFL13 protein moiety) glycoform beta	growth factor; hematopoietic factor	anemia
epoetin epsilon; erythropoietin (genetical recombination); SNB 5001; r HuEPO	1-165-erythropoietin (human clone lambdaHEPOFL13 protein moiety), glycoform epsilon	growth factor; hematopoietic factor	anemia

erythropoietin; GA EPO; MDL 104396; HMR 4396	EPO	growth factor; hematopoietic factor	anemia
hemoglobin 1.1; rHb1.1; OPTRO	Hemoglobin	growth factor; hematopoietic factor	anemia
PEG-hemoglobin	polyethylene glycol hemoglobin	growth factor; hematopoietic factor	cancer; anemia
; PEG-EPO; PolyMASC-EPO	polyethylene glycol- erythropoietin	growth factor; hematopoietic factor	anemia
RF 1010	Unspecified	growth factor; hematopoietic factor	anemia
RF 1012	Unspecified	growth factor; hematopoietic factor	anemia
RF 1017	Unspecified	growth factor; hematopoietic factor	anemia
epo-epo fusion protein	EPO recombinant	growth factor; hematopoietic factor; peptide	anemia
novel erythropoiesis stimulating protein; NESP	unspecified	hematopoietic factor; growth factor	anemia
erythropoietin mimic, MYELOS; EPO mimic	EPO mimic unspecified	hematopoietic factor; growth factor; peptide	anemia; neurological
VX 105	Unspecified	Hemoglobin F gene transcription activator	thalassemia; sickle cell anemia
VX 366	2-methyl- propanamide	Hemoglobin F gene transcription activator (analogue of VX105)	thalassemia; sickle cell anemia
tucaresol; BWA 589C; BW 589C80; BW 589C; 589C	4-[(2-formyl-3- hydroxyphenoxy)met hyl]benzoic acid	Hemoglobin stoichiometrically binding to produce high affinity for oxygen	sickle cell anemia; viral infection; HIV infection; cancer; hepatitis
polyclonal antibody, equine antithymocyte; immunoglobulin, equine antithymocyte; LYMPHOGLOBULI N	Unspecified	immunoglobulin; polyclonal antibody	aplastic anemia



lenograstim; granulocyte colony stimulating factor; G- CSF; pluripoietin; NEUTROGIN; GRANOCYTE; EUPROTIN; MYELOSTIM	133-[O-[O-(N-acetyl- alpha-neuraminosyl)- (2-3)-O-beta-D- galactopyranosyl-(1- 3)-2-(acetylamino)-2- deoxy-beta-D- galactopyranosyl]-L- threonine]-colony stimulating factor (human clone 1034)	immunostimulant; growth factor; hematopoietic factor	anemia; HIV infection; cancer; leukopenia
polyclonal antibody, rabbit antithymocyte; immunoglobulin, THYMOGLOBULIN	unspecified	immunosuppressant; immunoglobulin; polyclonal antibody	transplant rejection; aplastic anemia
iron proteinsuccinylate; iron succinyl-protein complex; ITF 282; PERNEXIN; LEGOFER; FERPLEX; FERLATUM; LACTOFERRINA; FERROCUR; FERXAL; HEMO Q	Iron engulfed in succinyl casein shell	Iron supplementation	anemia
ITF 1096	iron-succinyl-albumin	Iron supplementation	anemia
monoclonal antibody, leptin receptor	Unspecified	monoclonal antibody	diabetes; anemia; obesity
sickle cell anemia therapy	Unspecified	oligonucleotide	sickle cell anemia
velaresol; BW 12C79; 12C	5-(2-formyl-3- hydroxyphenoxy)- pentanoic acid	Oxyhemoglobin stabilization	cancer; sickle cell anemia
ribozyme, sickle cell anemia	Unspecified ribozyme	Ribozyme; oligonucleotide	sickle cell anemia
poloxamer 188; CRL 5861; FLOCOR; RheothRx	Unspecified	thrombolytic; fibrinolytic	thrombosis; cytoprotectant; sickle cell anemia
thrombospondin inhibitor, Allelix	Unspecified	thrombospondin inhibitor; peptide; NSAID	inflammation; cancer; sickle cell anemia
anemia therapy	Unspecified	transcription activator	anemia
AN 10; NOVAHEME	Butyric acid	Unspecified	sickle cell anemia; alopecia
EL 532	Unspecified	Unspecified	anemia; cancer

TRIFENS	Unspecified	Unspecified	diarrhea; gastrointestinal disorder; sickle cell anemia; cancer
vaccine, parvovirus B-19; MEDI 491	unspecified	vaccine	anemia
cetiedil; cetiedil citrate; INO 502; STRATENE; CELCIS	alpha-cyclohexyl-3- thiopheneacetic acid 2-(hexahydro-1H- azepin-1-yl)ethyl ester	vasodilator	sickle cell anemia

Table 58. Current Candidate Therapeutic Interventions for the Treatment of Angina

Product Name	Chemical Name	Action	Indication
BW 1139W	Unspecified	5HT antagonist; 5HT1D antagonist	angina
AHR 16303B	1-[4-[3-[4-[bis(4- fluorophenyl)hydroxy methyl]-1- piperidinyl]propoxy]p henyl]-2-methyl-1- propanone ethanedioate (1:1)	5HT antagonist; 5HT2 antagonist	hypertension; angina
LY 215840	[8beta(1S,2R)]-N-(2- hydroxycyclopentyl)- 6-methyl-1-(1- methylethyl)ergoline- 8-carboxamide	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis; angina
N 0840	N-cyclopentyl-9- methyl-9H-purin-6- amine	adenosine antagonist; adenosine A1 antagonist; diuretic	angina
N 0861	endo-(+,-)-N- bicyclo[2.2.1]hept-2- yl-9-methyl-9H- purin-6-amine	adenosine antagonist; adenosine A1 antagonist; vasodilator	arrhythmia; angina
CPC 400; CPC 402; CPC 405; CPC 406	Unspecified	adenosine regulating agent	neuropathy; angina
GP 14683	5-amino-1-(5-amino- 5-deoxy-beta-D- ribofuranosyl)imidazo le-4-N-[(4- chlorophenyl)methyl] carboxamide	adenosine regulating agent	angina

GP 1668; GP 668	5-amino-1-[beta-D-5-phosphoribofuranosyl]-imidazole-1-N-[(4-nitrophenyl)methyl]carboxamide)	adenosine regulating agent	angina; stroke
ledazerol; UCB 22061	2-hydroxy-3-(imidazol-4-ylmethyl)benzyl alcohol	alpha adrenergic agonist	angina
LR B139	Unspecified	angiotensin II antagonist	hypertension; angina
ranolazine; ranolazine hydrochloride; RS 43285; KEG 1295	(+,-)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide	anti-ischemic	angina; peripheral vascular disease
Z 4003	2-[1-[4-(2-methylpropyl)phenyl]ethyl]-4-thiazolidinecarboxylic acid	antioxidant; NSAID	angina; inflammation; emphysema
betaxolol; betaxolol hydrochloride; SL 75212; MCI 144; ABAXON; KERLONE; BETOPTIC; KERLONG; GLAUTAXOL; BERTOCIL; OPTIPRES; BETASEL; BEOF NICOLICH; LOKREN	1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist	glaucoma; hypertension; angina
carvedilol; karvedilol; BM 14190; DQ 2466; KREDEX; COREG; DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC	1-(9H-carbazol-4-yl)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol	beta adrenergic antagonist	hypertension; angina; heart failure

epanolol; ICI 141292; TS 704; VISACOR; VISICOR	N-[2-[[3-(2-cyanophenoxy)-2-hydroxypropyl]amino]ethyl]-4-hydroxybenzencacetamide	beta adrenergic antagonist	angina
esprolol; levo-SL 1050	Unspecified	beta adrenergic antagonist	angina
metoprolol, (S)-; (S)-metoprolol	(2S)-1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist; beta1 adrenergic antagonist	angina; hypertension; arrhythmia
cicloprolol; SL 7517710; SL 75177; SLD 177	(+,-)-1-[4-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist; beta1 adrenergic partial agonist	angina; glaucoma
MAB, 7E3-F(ab')2	Unspecified	monoclonal antibody	angina
MAB, thrombosis; 12D10; CORSEVIN M	Unspecified	monoclonal antibody	thrombosis; septic shock; angina
abciximab; abcirximab; MAb, F(ab')2 fragment platelet; MAb, 7E3; c7E3 FAb; c7E3; ReoPro; CENTORX	Immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhC.gamma.1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3V.kappa.hc.kappa.a.light chain	platelet antiaggregant; monoclonal antibody	thrombosis; restenosis; angina; stroke; myocardial infarction
cilobradine; DKAH 269	3-((1-(2-(3,4-dimethoxyphenyl)ethyl)-3-piperidinyl)methyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one	bradycardic agent	angina
DKAH 3; DKAH 3 CL	Unspecified	bradycardic agent	angina

ivabradine; S 16257; S 16257-2	3-[3-[N-(4,5-dimethoxybenzocyclobutan-1(S)-ylmethyl)-N-methylamino]propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one	bradycardic agent	angina; arrhythmia
zatebradine; ULFS 49	3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-benzazepin-2-one	bradycardic agent	angina; hypertension
ZD 7288; ICI D7288	N-ethyl-1,6-dihydro-1,2-dimethyl-6-(methylimino)-N-phenyl-4-pyrimidineamine monohydrochloride	bradycardic agent	angina
drug delivery system, COER-24 oral verapamil; verapamil COER-24; OROS verapamil; COER-24 verapamil; COVERA-HS; CHRONOVERA; CRONOVERA	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, controlled release diltiazem; diltiazem controlled release; TIAZAC; VIAZEM	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, GEOMATRIX controlled release nifedipine; nifedipine GEOMATRIX	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, OSAT nifedipine; nifedipine sustained release	Unspecified	calcium antagonist	hypertension; angina

drug delivery system, sustained release nifedipine; nifedipine once daily; INDAS nifedipine; NIFENSAR XL; ADALAT SR; UNIDIPINE; NIFELAN; ADALAT OROS	Unspecified	calcium antagonist	angina; hypertension
efonidipine; selefidipine; NZ 105; LANDEL	5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridine-carboxylic acid, 2-[phenyl(phenylmethyl)amino] ethyl ester, P-oxide	calcium antagonist	hypertension; angina; cerebrovascular disease
fantofarone; SR 33557; SR 33700	3,4-dimethoxy-N-methyl-N-[3-[4-[[2-(1-methylethyl)-1-indoliziny]sulfonyl]phenoxylpropyl]benzeneethanamine	calcium antagonist	angina; arrhythmia
flosatidil; SL 851016	[2-(dimethylamino)ethyl][2-[[2-(methylthio)phenyl][3-(trifluoromethyl)phenyl]methyl]amino]-2-oxoethyl]carbamic acid 2-methylpropyl ester	calcium antagonist	angina; hypertension
FPL 62129	4-[3-chloro-6-fluoro-2-(trifluoromethyl)phenyl]-2-(fluoromethyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl) ester	calcium antagonist	hypertension; angina

furmidipine; CRE 319	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl (tetrahydro-2-furanyl)methyl ester	calcium antagonist	hypertension; angina; reperfusion injury
gallopamil; D 600; PROCORUM; CORAPAMIL; ALGOCOR	5-[(3,4-dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile	calcium antagonist	hypertension; angina; arrhythmia
GS 386	3,4-dihydro-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]isoquinoline	calcium antagonist	angina
iganidipine; kirenidipine hydrochloride; NKY 722	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2,2-dimethyl-3-[4-(2-propenyl)-1-piperazinyl]propyl 3,5-pyridinedicarboxylic acid methyl ester	calcium antagonist	hypertension; angina
isradipine; isrodipine; PN 200110; PN 205033; PN 205034; PRESCAL; LOMIR; DynaCirc; VASCAL; ICAZ	4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester	calcium antagonist	hypertension; angina
nilvadipine; nivadipine; FK 235; FR 34235; SKF 102362; CL 287389; NIVADIL; ESCOR	2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl) ester	calcium antagonist	hypertension; angina

nisoldipine; BAY k 5552; SULAR; SYSCOR; BAYMYCARD; CORASOL; CORNEL; NISODIPEN; NISOCOR; ZADIPINA	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2-methylpropyl ester	calcium antagonist	angina; hypertension
ORG 13020	Unspecified	calcium antagonist	angina
PCA 50982	Unspecified	calcium antagonist	hypertension; angina
pranidipine; OPC 13340; ACALAS	(E)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 3-phenyl-2-propenyl ester	calcium antagonist	hypertension; angina
riodipine; ryodipine; PP 1466; FORIDONE	4-[2-(difluoromethoxy)phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester	calcium antagonist	hypertension; angina
RS 5773	((2S,3S)-3-acetoxy-8-benzyl-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-1,5-benzothiazepine-4-(5H)-one hydrochloride	calcium antagonist	angina; hypertension
siratiazem; LR A113	(2S-cis)-3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-[2-[methyl(1-methylethyl)amino]ethyl]-1,5-benzothiazepin-4(5H)-one	calcium antagonist	angina; hypertension



SL 870495; SL 495	N-[2-(2-methylpropoxy)phenyl]-N-[4-[methyl[2-(3-pyridinyl)ethyl]amino]butyl]-3-(trifluoromethyl)benzamide	calcium antagonist	angina
teludipine; taludipine; GR 53992B; GR 53992X	(E)-2-[[[(dimethylamino)methyl]-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium antagonist	hypertension; angina
UK 51656	2-((2-((4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl)methoxy)ethyl)amino)acetamide	calcium antagonist	hypertension; angina
UK 56593	2-[[[(2-amino-1,6-dihydro-6-oxo-4-pyrimidinyl)methoxy]methyl]-4-(2,3-dichlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	angina
YM 161511; YM 16151-1	(+)-1,4-dihydro-4-[2-[4-[(2-hydroxy-3-phenoxypropyl)amino]butoxy]-5-nitrophenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester monohydrochloride	calcium antagonist	hypertension; angina

monatepil; monatepil maleate; monasedin maleate; AJ 2615; AD 2615	(+,-)-N-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)-4-(4-fluorophenyl)-1-piperazinebutanamide	calcium antagonist; alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; angina; hyperlipidemia
BMV 20014	Unspecified	calcium antagonist; alpha adrenergic antagonist; vasodilator	angina
felodipine + metoprolol; metoprolol + felodipine; LOGIMAX	Unspecified	calcium antagonist; beta adrenergic antagonist	hypertension; angina
YM 154301; YM 430	[S-(R*,R*)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylic acid, 4-[(2-hydroxy-3-phenoxypropyl)amino]butyl methyl ester	calcium antagonist; beta adrenergic antagonist	hypertension; angina
CD 349	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-(nitrooxy)propyl 3-(nitrooxy)propyl ester	calcium antagonist; bronchodilator	hypertension; asthma; angina
dopropidil; CERM 4205; ORG 30701	1-[1-[(2-methylpropoxy)methyl]-2-[[1-(1-propynyl)cyclohexyl]oxy]ethyl]pyrrolidine	calcium antagonist; class I antiarrhythmic; class IV antiarrhythmic	angina
benidipine; nakadipine; nacadipine; KW 3049; CONIEL	(R*,R*)-(+,-)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester	calcium antagonist; vasodilator	hypertension; angina

CD 832	(-)-(4R)-2-(nicotinoylamino)ethyl 3-nitrooxypropyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylate	calcium antagonist; vasodilator	angina
clentiazem; clentiazem maleate; TA 3090; LOGNA	(2S-cis)-3-(acetyloxy)-8-chloro-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one	calcium antagonist; vasodilator	hypertension; angina
elgodipine; IQB 875	(+,-)-4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 2-[[[4-fluorophenyl)methyl]methylamino]ethyl 1-methylethyl ester	calcium antagonist; vasodilator	angina; hypertension; heart failure
semotiadil; semotiadil fumarate; SD 3211; DQ 4823; DS 4823	(R)-2-[2-[3-[[2-(1,3-benzodioxol-5-yloxy)ethyl]methylamino]propoxy]-5-methoxyphenyl]-4-methyl-2H-1,4-benzothiazin-3(4H)-one	calcium antagonist; vasodilator	angina; hypertension
felodipine; H 15482; HOE 869; CGH 869; HYDAC; PLENDIL; VASOPINE; SPLENDIL; MUNOBAL; FLODIL	4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist; vasodilator; diuretic	hypertension; angina; heart failure; atherosclerosis
AIT 110	Unspecified	Calcium channel	angina; arrhythmia
AIT 111	Unspecified	Calcium channel	angina; arrhythmia; hypertension

BRL 3287A	(N-(3,4-dimethoxyphenyl)-N-3-(N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino)-propyl)-N'-4-nitrobenzamide hydrochloride	Calcium channel (verapamil derivative)	angina
bepidil; ORG 5730; CERM 1978; CORDIUM; VASCOR; BEPRICOR	1-[2-(N-benzylanilino)-1-(isobutoxymethyl)ethyl]-pyrrolidine	calcium channel blocker	angina
CP 060S	(S)-3-[3-[[2-(1,3-benzodioxol-5-yl)oxy]ethyl]methylamino]propyl]-2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-thiazolidinone (E)-2-butenedioate (1:1)	calcium channel blocker	heart ischemia; angina
verapamil, (S)-; (S)-verapamil; levoverapamil; D 2024	(S)-alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile	calcium channel blocker	hypertension; arrhythmia; angina
mibefradil; mibefradil dihydrochloride; Ro 405967; Ro 405967001; POSICOR; CERATE	methoxyacetic acid, (1S-cis)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester	calcium channel blocker; vasodilator	hypertension; angina; heart failure
bertosamil	3'-isobutyl-7'-isopropylspiro(cyclohexane-1,9'-(3,7)diazabicyclo(3.3.1)nonane)	class I antiarrhythmic; class III antiarrhythmic	arrhythmia; angina
CV 3611	2-O-octadecyl-L-ascorbic acid	free radical scavenger	angina

JTV 806	Unspecified	glycoprotein IIb/IIIa antagonist	angina; restenosis
EMD 122347; YM 028	Unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina; stroke
tirofiban; tirofiban hydrochloride; MK 383; L 700462; AGGRASTAT	N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina
ZD 2486	Unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	angina
eptifibatide; INTEGRILIN; INTEGRILIN	N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide cyclic (1->6)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis; angina; myocardial infarction; restenosis
dalteparin sodium; low molecular weight heparin; heparin, low molecular weight; tedelparin; tedelparine; KABI 2165; K 2165; FR 860; FRAGMIN; FRAGMINE; BOXOL	heparin, sodium salt	heparinoid	thrombosis; coronary artery disease; angina
enoxaparin sodium; low molecular weight heparin; enoxaparin; enoxaparine; PK 10169; RPY 005; RP 54563; LOVENOX; CLEXAN; CLEXANE	heparin sodium salt	heparinoid	thrombosis; angina; stroke; myocardial infarction
pentosan polysulfate sodium; SP 54; PZ 68; CARTROPHEN; LASONIL; ELMIRON; LELONG MOUSSE	(1-4)-beta-D-xylan 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis

BM 121173	4-(2-nitroxyethyl)piperidine	nitrate	angina
BM 121179	trans-2-amino-2-methyl-N-(4-nitroxcyclohexyl)propionamide	nitrate	angina
BM 121200	trans-2-amino-2-methyl-N-(4-nitroxcyclohexylmethyl)propionamide	nitrate	angina
CEDO 8956	trans-1,4-cyclohexanedimethanol dinitrate	nitrate	angina
CRE 652	2-[2-(nitrooxy)ethyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	nitrate	angina
drug delivery system, SODAS isosorbide mononitrate; isosorbide mononitrate SODAS	Unspecified	nitrate	angina
drug delivery system, transdermal isosorbide dinitrate; isosorbide dinitrate transdermal; CR 2471/P	Unspecified	nitrate	angina
drug delivery system, transdermal nitrate; nitrate transdermal delivery system	Unspecified	nitrate	angina
drug delivery system, transdermal nitroglycerin; nitroglycerin transdermal	Unspecified	nitrate	angina
drug delivery system, transdermal nitroglycerin; nitroglycerin transdermal	Unspecified	nitrate	angina

drug delivery system, transdermal nitroglycerin; nitroglycerin, transdermal	Unspecified	nitrate	angina
drug delivery system, transdermal nitroglycerin; nitroglycerin transdermal; OPTIZOR	Unspecified	nitrate	angina; labor inhibition
nitroglycerin TheraDerm-MTX; NITROSYLON; TRINIPATCH; TRINIPLAS; ANGIDERM	drug delivery system, transdermal TheraDerm-MTX nitroglycerin;	nitrate	angina
LA 409	Unspecified	nitrate	angina
PF 9104	Unspecified	nitrate	angina
PF 9404	Unspecified	nitrate	angina; hypertension
SPM 3672; SP/W 3672	N-[2,2-dimethyl-3- (nitrooxy)-1- oxopropyl]-L-cysteine ethyl ester	nitrate	angina
nitroglycerin; glyceryl trinitrate; trinitrin; ANOGESIC	Unspecified	nitrate; cicatrizant; analgesic	skin ulcer; angina; pain
D-isoidide dinitrate; D-IIDN	1,4:3,6-dianhydro-D- iditol dinitrate	nitrate; vasodilator	angina
E 4701	2,3-dihydro-8- hydroxy-7-nitro-1,4- benzodioxin-2- methanol alpha- nitrate	nitrate; vasodilator	angina
sinitrodil; ITF 296	2,3-dihydro-3-[2- (nitrooxy)ethyl]-4H- 1,3-benzoxazin-4-one	nitrate; vasodilator	angina
CAS 1609	Unspecified	nitric oxide donor	angina
cyclosin	Unspecified	nitric oxide donor	angina
darsidomine; marsidomine; C 873754; CAS 754	cis-5-amino-3-(2,6- dimethyl-1- piperidinyl-1,2,3- oxadiazolium inner salt	nitric oxide donor	angina

NO donors	Unspecified	nitric oxide donor	angina
ITF 1129	2,3-dihydro-6-methyl-3-[2-(nitrooxy)ethyl]-4H-1,3-benzoxazin-4-one	nitric oxide donor; nitrate	heart ischemia; angina
FK 409; FR 900409	(3E)-4-ethyl-2-hydroxyimino-5-nitro-3-hexene carboxamide	nitric oxide donor; vasodilator	angina
GEA 3175	Unspecified	nitric oxide donor; vasodilator	angina; hypertension
nitric oxide vasodilators, IVAX	Unspecified	nitric oxide donor; vasodilator	angina; heart failure
pirsdomine; CAS 936; CAS 754	cis-3-(2,6-dimethyl-1-piperidiny)-N-(4-methoxybenzoyl)sydnone imine	nitric oxide donor; vasodilator	angina
SPM 5185	N-[2,2-dimethyl-3-(nitrooxy)-1-oxopropyl]-L-cysteine ethyl ester, ester with N-acetyl-L-alanine	nitric oxide donor; vasodilator	angina
THE 1869	Unspecified	nitric oxide donor; vasodilator	angina
THE CYL358; CYL 358	Unspecified	nitric oxide donor; vasodilator	angina
SPM 4744	2,2-dimethyl-3-(nitrooxy)propanoic acid	nitric oxide donor; vasodilator; nitrate	angina
SIN 1A/CD	(4-morpholinyl)nitrosoamino)acetonitrile	nitric oxide donor; vasodilator; platelet antiaggregant	angina
XR 334 series; XR 334	(Z,Z)-3-[(4-Methoxyphenyl)methylene]-6-(phenylmethylene)-2,5-piperazinedione	PAI inhibitor; thrombolytic	thrombosis; angina
phosphodiesterase I/V inhibitor	Unspecified	phosphodiesterase I inhibitor; phosphodiesterase V inhibitor; phosphodiesterase inhibitor	angina; myocardial infarction



E 4021; ER 21355	1-[4[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidinecarboxylic acid, monosodium salt	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	hypertension; angina; heart failure
IC 351; GF 196960; GG 960	Unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	heart failure; angina; sexual dysfunction; psoriasis
BMV 43351	7-(4-(4-(cyclohexylmethyl)-1-piperazinyl)-4-oxobutoxy)-1,3-dihydro-2H-imidazo(4,5-b)quinolin-2-one	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis; angina
BMS 180448	(3S-trans)-N-(4-chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-guanidine	potassium channel activator	angina
FK 336	2-methyl-N-[2-(nitrooxy)ethyl]-4-thiazolecarboxamide monohydrochloride	potassium channel activator	angina
KC 399	[N-(2-cyanoethyl)-2,2-bisfluoromethyl-6-nitro-2H-1-benzopyran-4-carbothioamide]	potassium channel activator	angina; stroke
TAK 636	Unspecified	potassium channel activator	hypertension; angina
Y 27152	(3S,trans)-N-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N-(phenylmethoxy)acetamide	potassium channel activator	hypertension; angina

nicorandil; SG 75; EMD 36385; U 64417; SIGMART; PERISALOL; DANCOR; IKOREL; ADANCOR; CORDONE; KALIDIL	N-[2-(nitrooxyethyl)-3-pyridinecarboxamide	potassium channel activator; nitrate; vasodilator	angina; cerebrovascular disease; heart failure
DY 9708	[1R-[1 alpha,2(3S*,4R*),6alpha]]-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-[(5-oxo-3,4-diazabicyclo[4.1.0]hept-2-en-2-yl)oxy]-2H-1-benzopyran-6-carbonitrile	potassium channel activator; vasodilator	hypertension; angina
KRN 2391	N-cyano-N'-[2-(nitrooxyethyl)-3-pyridinecarboximide monomethanesulfonate	potassium channel activator; vasodilator	angina
RWJ 29009	(-)-trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-7H-thieno[3,2-b]pyran	potassium channel activator; vasodilator	angina
fasudil; fasudil hydrochloride; AT 877; HA 1077; HA 004; ERIL	hexahydro-1-(5-isoquinolylsulfonyl)-1H-1,4-diazepine	protein kinase inhibitor; protein kinase C inhibitor; vasodilator	brain ischemia; stroke; angina; HIV infection

bivalirudin; BG 8967; HIRULOG	D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycylglycylglycylglycyl-L-asparaginylglycyl-L- $\alpha$ -aspartyl-L-phenylalanyl-L- $\alpha$ -glutamyl-L- $\alpha$ -glutamyl-L-isoleucyl-L-prolyl-L- $\alpha$ -glutamyl-L- $\alpha$ -glutamyl-L-tyrosyl-L-leucine	proteinase inhibitor; hirudin analogue; thrombin inhibitor	thrombosis; angina; myocardial infarction
argatroban; argatrovan; argipidine; argopidine; algipidine; DK 7419; MCI 9038; MD 805; OM 805; GN 1600; NOVASTAN; SLONNON	(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-quinoliny)sulfonyl]amino]pentyl]-4-methyl-2-[piperidinecarboxylic acid	proteinase inhibitor; platelet antiaggregant; thrombin inhibitor	thrombosis; myocardial infarction; ischemia; angina; brain ischemia; thrombocytopenia
inogatran; H 31427; HA 31427	N-[(1R)-2-cyclohexyl-1-[(2S)-2-[(3-guanidinopropyl)carbamoyl]piperidino]carbonyl]ethyl]glycine	proteinase inhibitor; thrombin inhibitor; platelet antiaggregant	angina; myocardial infarction
cariporide; cariporide mesilate; HOE 642; HOE 642A	N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide	sodium/hydrogen exchange inhibitor	arrhythmia; myocardial infarction; angina; restenosis
efegatran; efegatran sulfate; GYKI 14766; LY 294468	N-methyl-D-Phe-Pro-Arg-H	thrombin inhibitor; proteinase inhibitor; peptide	thrombosis; angina; myocardial infarction
nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis
JTV 519	Unspecified	Unspecified	reperfusion injury; angina

teopranitol; KC 046	1,4:3,6-dianhydro-2-deoxy-2-[[3-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl)propyl]amino]-L-iditol-5-nitrate	vasodilator	angina
CAS 754	Unspecified	vasodilator	angina
E 4080	(E)-N-[3-[[2-(3,5-dimethoxyphenyl)ethyl]methylamino]propyl]-4-[4-(1H-imidazol-1-yl)phenyl]-3-butenamide dihydrochloride	vasodilator	angina
KW 3196	5-deoxy-2-O-nitro-5-(4-(pyridin-3-yl)carbonyl piperazin-1-yl)-1,4:3,6-dianhydro-L-iditol	vasodilator	angina
LP 805	8-tert-butyl-6,7-dihydropyrrolo[3,2-e]-5-methylpyrazolo[1,5a]pyrimidine-3-carbonitrile	vasodilator	hypertension; angina
PF 8920	Unspecified	vasodilator	angina
PF 8921	Unspecified	vasodilator	angina
PF 9005	Unspecified	vasodilator	angina
vasodilator	N-(2-(N-hexylamino)ethyl)-5-isoquinolinesulfonamide	vasodilator	angina
propionylcarnitine, L-; propionyl-L-carnitine; levocarnitine propionyl; ST 261; DROMOS	L-3-carboxy-2-(1-oxopropoxy)-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt	vasodilator; cicatrizant	peripheral vascular disease; angina; heart failure; skin ulcer

JTV 506	(3S-trans)-4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)amino]-3,4-dihydro-3-hydroxy-2,2-bis(methoxymethyl)-2H-1-benzopyran-6-carbonitrile	vasodilator; potassium channel activator	angina
---------	--	--	--------

Table 59. Current Candidate Therapeutic Interventions for the Treatment of Arrhythmia

Product Name	Chemical Name	Action	Indication
draflazine; R 75231; R 70380	2-(aminocarbonyl)-N-(4-amino-2,6-dichlorophenyl)-4-[5,5-bis(4-fluorophenyl)pentyl]-1-piperazineacetamide	Adenosine uptake inhibitor	arrhythmia; schistosomiasis
CVT 429	Unspecified	adenosine A1 agonist; adenosine agonist	arrhythmia; heart failure
CVT 609	Unspecified	adenosine A1 agonist; adenosine agonist	arrhythmia; heart failure
CV 1808	2-(phenylamino)adenosine	adenosine agonist	arrhythmia
BN 063	1-cyclopropylisoguanosine	adenosine agonist; adenosine A1 agonist	arrhythmia
CVT 427	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
CVT 510	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
CVT 741	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
DTI 0009	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia
N 0723	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia

adenosine; MEDR 340; SR 96225; MEDR 640; ADENOCOR; ADENOCARD; CARIADEN; ADENOSCAN; KRENOSIN; PALLACOR	9-alpha-D-ribofuranosyl-9H-purin-6-amine	adenosine agonist; vasodilator	arrhythmia; ischemia; reperfusion injury; diagnosis
N 0861	endo-(+,-)-N-bicyclo[2.2.1]hept-2-yl-9-methyl-9H-purin-6-amine	adenosine antagonist; adenosine A1 antagonist; vasodilator	arrhythmia; angina
BW A1433U	4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)benzoic acid	adenosine antagonist; adenosine A3 antagonist	arrhythmia
abanoquil; UK 5204627; UK 52046	2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)-6,7-dimethoxy-4-quinolinamine	alpha adrenergic antagonist; alpha 1 adrenergic antagonist; vasodilator	arrhythmia
A 2545	N-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-2,5-dihydro-2,2,5,5-tetramethyl-1H-pyrrole-3-carboxamide	antiarrhythmic	arrhythmia
amidepin	2-(diethylamino)-N-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)acetamide S,S-dioxide	Antiarrhythmic	arrhythmia
amiodarone; L 3428; SKF 33134A; CORDARONE; CORDARONE X; RYTHMARONE; CARDIORONA; ARRITMIL; ANCARON; AMIORIT; ORTARON	(2-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone	Antiarrhythmic	arrhythmia

AN 132	3-[[2-[bis(1-methylethyl)amino]ethyl]amino]-N-(2,6-dimethylphenyl)propanamide phosphate (1:2)	Antiarrhythmic	arrhythmia
antiarrhythmic, chronic	Unspecified	antiarrhythmic	arrhythmia
Antiarrhythmic chronic	Unspecified	Antiarrhythmic	arrhythmia
Antiarrhythmic	1-[[4-(3-phenoxypropyl)phenyl]methyl]pyrrolidine	Antiarrhythmic	arrhythmia
artilide; artilide fumarate; U 88943E	(R)-N-[4-[4-(dibutylamino)-1-hydroxybutyl]phenyl]methanesulfonamide	Antiarrhythmic	arrhythmia
AWD 160274	Unspecified	Antiarrhythmic	arrhythmia
AWD 23078	Unspecified	Antiarrhythmic	arrhythmia
BRB I28	7-benzyl-7-aza-3-thiabicyclo[3.3.1]nonane hydroperchlorate	Antiarrhythmic	arrhythmia
CK 4000	(S)-N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1-yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide monohydrochloride	Antiarrhythmic	arrhythmia
detajmium bitartrate; TACHMALCOR	(17R,21.alpha.)-4-[3(diethylamino)-2-hydroxypropyl]ajmalinium	Antiarrhythmic	arrhythmia
EO 4711	Unspecified	Antiarrhythmic	arrhythmia

ES 313	[1S-[1R*(R*),2R*,4(1R*,2R*)]]-N-[1-[[[2-hydroxy-4-[[1-(hydroxymethyl)-2-methylbutyl]amino]-1-(2-methylpropyl)-4-oxobutyl]amino]carbonyl]-2-methylpropyl]-alfa-(1-naphthalenylmethyl)-1-naphthalenepropanamide	Antiarrhythmic	arrhythmia
GFA	Unspecified	Antiarrhythmic	arrhythmia
GLG V13	3-[4-(1H-imidazol-1-yl)benzoyl]-7-(1-methylethyl)-3,7-diazabicyclo[3.3.1]nonane diperchlorate	Antiarrhythmic	arrhythmia
GYKI 38233; TYB 3823; B-GYKI 38233; RESTACORIN	2-(2,6-dimethylphenyl)-N,N-dimethylhydrazinecarboximide monohydrochloride	Antiarrhythmic	arrhythmia
H 34552; H 345/52	Unspecified	Antiarrhythmic	arrhythmia
L 702958	(R)-N-[1'-(6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl)-3,4-dihydro-4-oxospiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide	Antiarrhythmic	arrhythmia
L 961121	Unspecified	Antiarrhythmic	arrhythmia
LG 6102	1-[2-[2-methoxy-3-(propylamino)propoxy]phenyl]-3-phenyl-1-propanone hydrochloride	Antiarrhythmic	arrhythmia
M 14157; MD 26	Unspecified	Antiarrhythmic	arrhythmia



NC 1006	N-(azabicyclo[2,2,2]octan-2-yl)methyl, N-(2-indanyl)aniline hydrochloride	Antiarrhythmic	arrhythmia
superoxide dismutase, polyoxyethylene modified; SOD-POE	polyoxyethylene-modified superoxide dismutase	Antiarrhythmic	arrhythmia
RP 58866	1-[2-(3,4-dihydro-2H-1-benzopyran-4-yl)ethyl]-4-(3,4-dimethoxyphenyl)piperidine hydrochloride	Antiarrhythmic	arrhythmia
RS 89497	Unspecified	Antiarrhythmic	arrhythmia
S 711389; S 1389	1-(3,6-dichloro-2-(1-(1H-imidazol-1-yl)ethenyl)phenoxy)-3-(1-methylethyl)amino)-2-propanol	Antiarrhythmic	arrhythmia
SL 1112	Unspecified	Antiarrhythmic	arrhythmia; local anesthesia
solpecainol; EGIS 2936; EGYT 2936	(+,-)-[1R*,2S*(S*)]-2-[(1-methyl-2-phenoxyethyl)amino]-1-phenyl-1,3-propanediol	Antiarrhythmic	arrhythmia
tiracizine; AWD 19166; GS 015; GS 15; BONNECOR	[5-[(dimethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]carbamic acid ethyl ester	Antiarrhythmic	arrhythmia
TN 851; TMC 851	Unspecified	Antiarrhythmic	arrhythmia
Desoxoamiodarone	(2-n-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methane	Antiarrhythmic; amiodarone derivative	arrhythmia
E 047/1	Unspecified	Antiarrhythmic; amiodarone derivative	arrhythmia

ethacizin; NIK 422	[10-[3-(diethylamino)-1-oxopropyl]-10H-phenothiazin-2-yl-carbamic acid, ethyl ester, monohydrochloride	Antiarrhythmic; chemically related to ethmozine	arrhythmia
cibenzoline; cifenline; UP 33901; Ro 227796; CIPRALAN; CIBENOL; EXACOR	2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole	Antiarrhythmic; imidazoline derivative	arrhythmia
glutapyrone	2-(2,6-dimethyl-3,5-diethoxycarbonyl-1,4-dihydropyridine-4-carboxamide)glutaric acid, disodium salt	antioxidant	arrhythmia
ACC 9369	2-[2-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzenepropanoic acid ethyl ester	beta adrenergic antagonist	arrhythmia
drug delivery system, submicron emulsion adaprolol; adaprolol SME; HGP 2; CDDD 2803	4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetic acid, 2-tricyclo[3.3.1.1sup3,7]dec-1-ylethyl ester	beta adrenergic antagonist	arrhythmia; glaucoma
esmolol; ASL 8052; ASL 8123; BREVIBLOC	4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzenepropanoic acid methyl ester	beta adrenergic antagonist	hypertension; arrhythmia
AM 140; AM 0140; D 140	Unspecified	beta adrenergic antagonist; beta1 adrenergic antagonist	glaucoma; arrhythmia
landiolol; ONO 1101; ONOACT	[S-(R*,R*)]-4-[2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]benzenepropanoic acid (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester	beta adrenergic antagonist; beta1 adrenergic antagonist	arrhythmia

metoprolol, (S)-; (S)-metoprolol	(2S)-1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist; beta1 adrenergic antagonist	angina; hypertension; arrhythmia
sotalol; sotalol hydrochloride; MJ 1999; BMY 05763; SOTACOR; SOTALEX; SOTAZIDE; BETAPACE	N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methanesulfonamide	beta adrenergic antagonist; class II antiarrhythmic; class III antiarrhythmic	arrhythmia
dexsotalol; sotalol, (d)-; (+) MJ 1999; BMY 05763	(S)-N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methanesulfonamide	beta adrenergic antagonist; class III antiarrhythmic	arrhythmia
ivabradine; S 16257; S 16257-2	3-[3-[N-(4,5-dimethoxybenzocyclobutan-1(S)-ylmethyl)-N-methylamino]propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one	bradycardic agent	angina; arrhythmia
flapipamil; AQ A39 CL; AG A 39	2-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-2,3-dihydro-5,6-dimethoxy-1H-isoindol-1-one	calcium antagonist	arrhythmia
fantofarone; SR 33557; SR 33700	3,4-dimethoxy-N-methyl-N-[3-[4-[[2-(1-methylethyl)-1-indoliziny]sulfonyl]phenoxy]propyl]benzeneethanamine	calcium antagonist	angina; arrhythmia
gallopamil; D 600; PROCORUM; CORAPAMIL; ALGOCOR	5-[(3,4-dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile	calcium antagonist	hypertension; angina; arrhythmia

KT 362	5-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-oxopropyl]-2,3,4,5-tetrahydro-1,5-benzothiazepine (E)-butenedioate (1:1)	calcium antagonist	arrhythmia
Ro 236152	(+)-cis-3-(acetoxo)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-dimethylamino)ethyl-1-naphtho(1,2b)-1,4-thiazepin-4-(5H)one	calcium antagonist	arrhythmia
EGIS 3966	(E,E)-(+/-)-2-(phenylmethylene)-[3-[bis(1-methylethyl)amino]-2-hydroxypropyl]oxime cyclohexanone (E)-2-butendionate	calcium antagonist; 5HT antagonist	arrhythmia
BRL 32872	N-(3,4-dimethoxyphenyl)-N-[3[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-4-nitrobenzamide	calcium antagonist; class III antiarrhythmic; class IV antiarrhythmic	arrhythmia
AIT 110	Unspecified	Calcium channel	angina; arrhythmia
AIT 111	Unspecified	Calcium channel	angina; arrhythmia; hypertension
verapamil, (S)-; (S)-verapamil; levoverapamil; D 2024	(S)-alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile	calcium channel blocker	hypertension; arrhythmia; angina
EMD 60263	(+)-5-(1-(alpha-ethylimino-3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroquinoline-6-yl)-6-methyl-3,6-dihydro-2H-1,3,4-thiadiazine-2-one	calcium sensitizer	arrhythmia

AFDX 384	N-[2-[2- [(dipropylamino)methyl]-1- piperidinyl]ethyl]-5,6- dihydro-6-oxo-11H- pyrido[2,3- b][1,4]benzodiazepin e-11-carboxamide monomethanesulfonate	cholinergic antagonist; muscarinic antagonist; muscarinic M2 antagonist	arrhythmia; diagnosis
otenzepad; AFDX 116; AFDX 116BS	(+,-)-11-[[2- [(diethylamino)methyl]-1- piperidinyl]acetyl]- 5,11-dihydro-6H- pyrido[2,3- b][1,4]benzodiazepin e-6-one	cholinergic antagonist; muscarinic antagonist; muscarinic M2 antagonist	arrhythmia
acecainide; acecainide hydrochloride; N- acetylprocainamide; NAPA; ASL 601	4-(acetylamino)-N-(2- (diethylamino)ethyl)benzamide	class I antiarrhythmic	arrhythmia
actisomide; SC 36602	(+,-)-cis-4-[(2- diisopropylamino)ethyl]-4,4a,5,6,7,8- hexahydro-1-methyl- 4-phenyl-3H- pyrido[1,2- c]pyrimidin-3-one	class I antiarrhythmic	arrhythmia
barucainide	4-benzyl-1,3-dihydro- 7-[4- (isopropylamino)butoxy]-6-methylfuro[3,4- c]pyridine	class I antiarrhythmic	arrhythmia
berlafenone; bipranolol; GK 23G	1-([1,1'-biphenyl]-2- yloxy)-3-[(1,1- dimethylethyl)amino]- 2-propanol	class I antiarrhythmic	arrhythmia
bidisomide; SC 40230	(+,-)-alpha-[2- [acetyl(1- methylethyl)amino]ethyl]-alpha-(2- chlorophenyl)-1- piperidinebutanamide	class I antiarrhythmic	arrhythmia

CV 6402	2,2'-(2-aminoethyl)imino diethanol bis(butylcarbamate) dihydrochloride	class I antiarrhythmic	arrhythmia
diprafenone; butafenone	(+,-)-1-[2-[3-[(1,1-dimethylpropyl)amino]-2-hydroxypropoxy]phenyl]-3-phenyl-1-propanone	class I antiarrhythmic	arrhythmia
E 0747; E 747; L 29065	6-chloro-2,3-dihydro-1'-[3-(4-hydroxy-1-piperidiny)propyl]-2,2-dimethylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione	class I antiarrhythmic	arrhythmia
E 0747 (-)isomer; E 747 (-)isomer	(-)-6-chloro-2,3-dihydro-1'-[3-(4-hydroxy-1-piperidiny)propyl]-2,2-dimethylspiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione	class I antiarrhythmic	arrhythmia
encainide; MJ 9067; MJ 90671; ENKADE; ENKAID	(+,-)-4-methoxy-N-[2-[2-(1-methyl-2-piperidiny)ethyl]phenyl]benzamide	class I antiarrhythmic	arrhythmia
flecainide; flecainide acetate; R 818; E 0735; DIONDEL; TAMBOCOR; ALMARYTM; FLECAINE; APOCARD; ECRINAL	N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide	class I antiarrhythmic	arrhythmia
indecainide; recainide; LY 135837; DECABID	9-[3-(isopropylamino)propyl]fluorene-9-carboxamide	class I antiarrhythmic	arrhythmia

K 953	3-amino-5'-ethoxy-2'-(3-pyridyl)butyranilide dihydrochloride	class I antiarrhythmic	arrhythmia
LG 6101	1-[3-[2-methoxy-3-[(2-methylpropyl)amino]propoxy]-4-methyl-2-thienyl]-3-phenyl-1-propanone hydrochloride	class I antiarrhythmic	arrhythmia
LNC 834; LNC 409 sulfate	(9S)-10,11-dihydro-6'-methoxycinchonan-3,9-diol sulfate (1:1) salt	class I antiarrhythmic	arrhythmia
modecainide; MJ 14030	(+,-)-4-hydroxy-3-methoxy-N-[2-[2-(1-methyl-2-piperidiny)ethyl]phenyl]benzamide	class I antiarrhythmic	arrhythmia
moracizine; moricizine; ethmosine; ethmozin; etmozin; EN 313; ETHMAZONE; ETHMOZINE	ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate	class I antiarrhythmic	arrhythmia
NS 2	4-diisobutylamino-1,1-diphenyl-1-butanol maleate	class I antiarrhythmic	arrhythmia
ORG 7797	(16 $\alpha$ ,17 $\beta$ )-17-(methylamino)-estra-1,3,5(10)-triene-3,16-diol (Z)-butenedioate (1:1) salt	class I antiarrhythmic	arrhythmia
pilsicainide; pilsicainide hydrochloride; pilzicainide; SUN 1165; SUNRYTHM	N-(2,6-dimethylphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-acetamide	class I antiarrhythmic	arrhythmia
pirmenol; pirmenol hydrochloride; CI 845; PIRMAVAR; PIMENOL	cis-(+,-)-alpha-[3-(2,6-dimethyl-1-piperidiny)propyl]-alpha-phenyl-2-pyridinemethanol	class I antiarrhythmic	arrhythmia

quinacainol; RP 54272; PK 10139	2-(1,1-dimethylethyl)-alpha-[2-(4-piperidiny)ethyl]-4-quinolinemethanol	class I antiarrhythmic	arrhythmia
recainam; WY 42362; WIN 42362	N-(2,6-dimethylphenyl)-N'-[3-[(1-methylethyl)amino]propyl]urea	class I antiarrhythmic	arrhythmia
bertosamil	3'-isobutyl-7'-isopropylspiro(cyclohexane-1,9'-(3,7)diazabicyclo(3.3.1)nonane)	class I antiarrhythmic; class III antiarrhythmic	arrhythmia; angina
levosemotiadil; DQ 4824; DS 4824; SD 3212; SA 3212	(S)-2-[2-[3-[[2-(1,3-benzodioxol-5-yl)oxy]ethyl]methylamino]propoxy]-5-methoxyphenyl]-4-methyl 2H-1,4-benzothiazin-3(4H)-one	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
WIN 57600	Unspecified	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
WIN 61773	Unspecified	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
WIN 65802	Unspecified	class I antiarrhythmic; class III antiarrhythmic	arrhythmia
bisaramil; bisaramil hydrochloride; RGH 2957; YUTAC	4-chlorobenzoic acid syn-3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]non-9-yl ester	class I antiarrhythmic; class IV antiarrhythmic	arrhythmia
ersentilide; CK 3579	N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1-yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide	class II antiarrhythmic; class III antiarrhythmic	arrhythmia



ambasilide; LU 471103	3-(4-aminobenzoyl)-7-benzyl-3,7-diazabicyclo[3.3.1]nonane	class III antiarrhythmic	arrhythmia
AWD 160275	Unspecified	class III antiarrhythmic	arrhythmia
AWD 23111	unspecified	class III antiarrhythmic	arrhythmia
CK 1649C	1-[2-hydroxy-2-[4-[(methylsulfonyl)amino]phenyl]ethyl]-3-methyl-1H-imidazolium chloride	class III antiarrhythmic	arrhythmia
dronedarone; SR 33589	N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]-methanesulfonamide	class III antiarrhythmic	arrhythmia
E 4031	N-[4-[[1-[2-(6-methyl-2-pyridinyl)ethyl]-4-piperidinyl]carbonyl]phenyl]methanesulfonamide dihydrochloride	class III antiarrhythmic	arrhythmia
EGIS 7229	5-chloro-4-[[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]amino]-3(2H)-pyridazinone (E)-2-butenedioate (1:1)	class III antiarrhythmic	arrhythmia
ibutilide; ibutilide fumarate; U 70226; U 70226E; CORVERT	N-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]methanesulfonamide	class III antiarrhythmic	arrhythmia
ipazilide; ipalizide fumarate; WIN 54177; WIN 541774	N-[3-(diethylamino)propyl]-4,5-diphenyl-1H-pyrazole-1-acetamide	class III antiarrhythmic	arrhythmia

L 691121	N-[1'-[2-(5-benzofurazanyl)ethyl]-3,4-dihydro-4-oxospiro[2H-1-benzopyran-2,4'-piperidin]-6-yl]methanesulfonamide monohydrochloride	class III antiarrhythmic	arrhythmia
L 768673	(R)_N-[2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-2,4-bis(trifluoromethyl)benzeneacetamide	class III antiarrhythmic	arrhythmia
nifekalant; MS 551	6-[[2-[(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino]ethyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione monohydrochloride	class III antiarrhythmic	arrhythmia
ORG 20781	unspecified	class III antiarrhythmic	arrhythmia
SB 237376	N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide	class III antiarrhythmic; class IV antiarrhythmic	arrhythmia
KCB 328	1-(2-amino-4-methanesulfonamidophenoxy)-2-[N-(3,4-dimethoxyphenethyl)-N-methylamino]ethanohydrochloride	class III antiarrhythmic; potassium channel blocker	arrhythmia
ITF 1300	Unspecified	heparinoid; class III antiarrhythmic	thrombosis; arrhythmia

selenotifen; BN 52256	4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo[4,5]cyclohepta[1,2-b]selenophen-10-one	histamine antagonist; histamine H1 antagonist	eye disease; asthma; arrhythmia; rhinitis
atrial fibrillation therapy	Unspecified	Ion channel modulator	arrhythmia
ion channel modulators	Unspecified	Ion channel modulator	arrhythmia; asthma
ecdisteron; ecdisten	Unspecified	Membrane stabilization	arrhythmia
mexiletine; KO 1173; MEXITIL	1-methyl-2-(2,6-dimethoxyloxy)ethylamine hydrochloride	Na <sup>+</sup> channel induction of native open state and first step of open channel	neuropathy; arrhythmia; diabetes
5HT4 human neuroreceptor;	Unspecified	neuroreceptor, 5HT4	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
AAP 10	6-L-tyrosinamide-retro-antiarrhythmic peptide (cattle atrium)	peptide	arrhythmia
kappa-conopeptides	Unspecified	peptide; potassium channel blocker	heart ischemia; arrhythmia; gastrointestinal disorder
cloricromen; cloricromene; AD 6; PROENDOTEL	[[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2H-1-benzopyran-7-yl]oxy]acetic acid ethyl ester	platelet antiaggregant; vasodilator	arrhythmia; thrombosis
almokalant; H 234/09	(+,-)-p-[3-[ethyl[3-(propylsulfinyl)propyl]amino]-2-hydroxypropoxy]benz onitrile	Positive inotropic; antiarrhythmic	arrhythmia

pentisomide; penticainide; propisomide; CM 7857; ME 3202; RHYTHMATE	(+,-)-alfa-[2-[bis(1-methylethyl)amino]ethyl]-alfa-(2-methylpropyl)-2-pyridineacetamide	potassium channel activator; class I antiarrhythmic	arrhythmia
AWD 12260; AWD 122-60	6-[[3-(diethylamino)propyl]amino][3,4'bipyridine]-5-carbonitrile	potassium channel blocker	arrhythmia
HMR 1098	unspecified	potassium channel blocker	arrhythmia
HMR 1883	Unspecified	potassium channel blocker	arrhythmia
potassium channel blocker,	Unspecified	potassium channel blocker	arrhythmia
WAY 123398	N-methyl-N-[2-[methyl(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino])benzensulfonamide	potassium channel blocker	arrhythmia
azimilide; azimilide dihydrochloride; azilimide; NE 10064; STEDICOR	1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione	potassium channel blocker; class III antiarrhythmic	ischemia; arrhythmia
dofetilide; UK 68798; XELIDE; TIKOSYN	N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-methanesulfonamide	potassium channel blocker; class III antiarrhythmic	arrhythmia
MK 499; L 706000	unspecified	potassium channel blocker; class III antiarrhythmic	arrhythmia
sematilide; sematilide hydrochloride; CK 1752; RU 752; SH 506; ZK 110516	N-[2-(diethylamino)ethyl]-4-[(methylsulfonyl)amino]benzamide	potassium channel blocker; class III antiarrhythmic	arrhythmia

WAY 123223	N-[4-[2-hydroxy-3-[methyl(2-quinolinylmethyl)amino]propoxy]phenyl]methanesulfonamide	potassium channel blocker; class III antiarrhythmic	arrhythmia
WAY 125971	N-(2-((methyl(3-(4-((methylsulfonyl)amino)phenoxy)propyl)amino)methyl)-6-quinolinyl)methanesulfonamide	potassium channel blocker; class III antiarrhythmic	arrhythmia
KW 3407	5-[[2-(diethylamino)ethyl]amino]-5,11-dihydro-7-methoxy-(1)-benzoxepino-[3,4-b]pyridine fumarate (2:3)	sodium channel blocker	arrhythmia
antiarrhythmic, acute,	unspecified	sodium channel blocker; potassium channel blocker	arrhythmia
cariporide; cariporide mesilate; HOE 642; HOE 642A	N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide	sodium/hydrogen exchange inhibitor	arrhythmia; myocardial infarction; angina; restenosis
KBR 9032; KB-R 9032	N-(aminoiminomethyl)-3,4-dihydro-2,2-dimethyl-4-(1-methylethyl)-3-oxo-2H-1,4-benzoxazine-6-carboxamide monomethanesulfonate	sodium/hydrogen exchange inhibitor; anti-ischemic	arrhythmia; heart ischemia; reperfusion injury
KB 130015	unspecified	thyroid hormone antagonist	arrhythmia
thyroid hormone receptor alpha antagonists	unspecified	thyroid hormone antagonist	arrhythmia

RS 2135	(3aR,12R,12aR,12bS)-12-amino-2,3,3a,4,11,12,12a,12b-octahydro-10-hydroxyisoquino[2,1,8-lma]carbazol-5(1H)-one hydrochloride 1:5 hydrate	vasodilator	arrhythmia
milacainide; xilacainide; Ro 229194	(R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridinyl)propyl]propanamide [S-(R*,R*)]-2,3-dihydroxybutanedioate	vasodilator; sodium channel blocker; class I antiarrhythmic	arrhythmia

Table 60. Current Candidate Therapeutic Interventions for the Treatment of Hypertension

Product Name	Chemical Name	Action	Indication
5-methylurapidil; 5-MU	6-[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3,5-trimethyl-2,4(1H,3H)-pyrimidinedione	5HT agonist; 5HT1A agonist	hypertension
A 74283	Unspecified	5HT agonist; 5HT1A agonist; vasodilator	hypertension
U 86192A	2,3-dihydro-2-[[[3-(phenylpropyl)amino]methyl]-7H-1,4-dioxino[2,3-e]indole-8-carboxylic acid methyl ester	5HT antagonist; 5HT1A antagonist	hypertension
AHR 16303B	1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]phenyl]-2-methyl-1-propanone ethanedioate (1:1)	5HT antagonist; 5HT2 antagonist	hypertension; angina

ketanserin; R 41468; SEREFREV; SUFREXAL; SEREFREX	3-[2-[4-(4-fluorobenzyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolincdione	5HT antagonist; 5HT2 antagonist	hypertension
lidanserin; ZK 33839	(+,-)-4-[3-[3-[4-(p-fluorobenzoyl)piperidino]propoxy]-4-methoxyphenyl]-2-pyrrolidinone	5HT antagonist; 5HT2 antagonist; alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
SUN 9221	2-(4-chlorophenyl)-1,4-dihydro-[1]benzothiopyrano[4,3-c]pyrazol-3(2H)-one 5-oxide	5HT antagonist; 5HT2 antagonist; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension
AB 47	(S)-1-[N-(8-amino-1-carboxyooctyl)-L-alanyl]-L-proline	ACE inhibitor	hypertension
ACE inhibitor	1-(2-((1-carboxy-6-(4-piperidinyl)hexyl)amino)-1-oxopropyl)octahydro-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension
alacepril; DU 1219; CETAPRIL	(S)-N-[1-[3-(acetylthio)-2-methyl-1-oxopropyl]-L-prolyl]-L-phenylalanine	ACE inhibitor	hypertension
benazepril; benazepril hydrochloride; benzazepril; CGS 148247; CIBACEN; LOTENSIN; BRIEM; ZINADRIL; TENSANIL; CIBACENE	[S-(R*,R*)]-3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid	ACE inhibitor	hypertension

captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
ceronapril; ceranapril; SQ 29852	(S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phospinyloxy]-1-oxohexyl]-L-proline	ACE inhibitor	cognitive defect; hypertension; anxiety
cilazapril; Ro 312848; Ro 312848 006; INHIBACE; VASCACE; DYNORM	(1S,9S)-9-[[[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid	ACE inhibitor	hypertension
CV 5975	(R)-3-[(S)-1-carboxy-5-(4-piperidyl)pentyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetic acid	ACE inhibitor	hypertension
delapril; alindapril; CV 3317; REV 6000A; ADECUT; CUPRESSIN; KEDAPRIL; DELAKET	(S)-N-(2,3-dihydro-1H-inden-2-yl)-N-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]glycine	ACE inhibitor	hypertension
drug delivery system, controlled release captopril; captopril	Unspecified	ACE inhibitor	hypertension
drug delivery system, SODAS captopril; captopril SODAS	Unspecified	ACE inhibitor	heart failure; hypertension



DU 1777	(2S,3aS,7aS)-1-(N2-nicotinoyl-L-lysyl-alpha-D-glutamyoctahydro-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension
enalapril; MK 421; INNOVACE; COVERTEN; ENAPREN; RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE	(S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline	ACE inhibitor	hypertension
fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; FUSINORM; FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC	[1[S*(R*)],2alpha.,4b eta]-4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]acetyl]-L-proline	ACE inhibitor	hypertension
fosinoprilat; fosfenopril; fosinoprilic acid; SQ 27519	trans-4-cyclohexyl-1-[[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-L-proline	ACE inhibitor	hypertension
FPL 66564	(R)-2-(3-mercapto-2(S)-methyl-1-oxopropoxy)-3-(methylthio)-propanoic acid	ACE inhibitor	hypertension
hidrapril; LG 32001	(1S,2R)-2-(((hydroxycarbamoyl)methyl)methylcarbamoyle)cyclohexane carboxylic acid	ACE inhibitor	hypertension

imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]-3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid	ACE inhibitor	hypertension; heart failure; diabetes
libenzapril; CGS 16617	[S-(R*,R*)]-3-[(5-amino-1-carboxypentyl)amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid	ACE inhibitor	hypertension
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
moexipril; RS 10085; SPM 925; CI 925; RS 10085197; UNIVASC; FAMPRESS; MOEX; PERDIX; FEMPRESS; PRIMOXIL; FEMIPRESS; FEMPRES	[3S-[2[R*(R*),3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid	ACE inhibitor	hypertension
perindopril; perindopril erbumine; S 9490; S 94903; SED 9490; MCN A2833109; DW 7950; COVERSYL; ACEON; ACERTIL; COVERENE; COVEREX; COVERSIL	(2S,3aS,7aS)-1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension; coronary artery disease; heart failure

perindoprilat; S 9780; S 9490 diacid	[2S-[1[R(R*)],2alfa,3abeta,7abeta]]-1-[2-[(1-carboxybutyl)amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension
quinapril; quinapril hydrochloride; CI 906; PD 1094522; ACCUPRIL; CONAN; ACCUPRO; ACUITEL; ACEQUIN; ACCUZIDE; QUINAZIDE	[3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid	ACE inhibitor	hypertension
ramipril; HOE 498; ALTACE; TRIATEC; PRAMACE; RAMACE; TRITACE; CARASEL; ACOVIL	(2S,3aS,6aS)-1-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid 1-ethyl ester	ACE inhibitor	hypertension; heart failure
RL 6134; EQUATEN	unspecified	ACE inhibitor	hypertension
RL 6207; PRENTYL	unspecified	ACE inhibitor	hypertension
RL 6893; SYNECOR	Unspecified	ACE inhibitor	hypertension
spirapril; spirapril hydrochloride; SCH 33844; TI 211950; RENPRESS; SANDOPRIL; RENORMAX; CARDIOPRIL	[8S-[7[R*(R*)]]8R*]-7-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid	ACE inhibitor	hypertension
temocapril; temocapril hydrochloride; CS 622; ESCOL; ACECOL; ACECOR	[2S-[2alfa,6beta(R*)]]-6-[[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid	ACE inhibitor	hypertension

temocaprilat; temocapril diacid; RS 5139	[2S- [2alpha,6beta(R*)]]- 6-[(1-carboxy-3- phenylpropyl)amino]t etrahydro-5-oxo-2-(2- thienyl)-1,4- thiazepine-4(5H)- acetic acid	ACE inhibitor	hypertension
utibapril; FPL 63547	(S)-2-tert-butyl-4- [(S)-N-[(S)-1- carboxy-3- phenylpropyl]alanyl]- delta2-1,3,4- thiadiazoline-5- carboxylic acid, 4- ethyl ester	ACE inhibitor	hypertension; heart failure
WY 44655	(2S- (1(R*(R*)),2R*))1- (2-(1- (ethoxycarbonyl)-3- phenylpropyl)amino)- 1-oxopropyl)-2,3- dihydro-1H-indole-2- carboxylic acid	ACE inhibitor	hypertension
Y 23785	unspecified	ACE inhibitor	hypertension
zofenopril; SQ 26991; ZOPRACE	[(R*),2alfa,4alfa]-1- [3-(benzoylthio)-2- methyl-1-oxopropyl]- 4-(phenylthio)-L- proline	ACE inhibitor	hypertension; myocardial infarction
zofenoprilat; SQ 26333	(4S)-1-((S)-3- mercapto-2- methylpropionyl)-4- (phenylthio)-L- proline	ACE inhibitor	hypertension
quinapril + diltiazem; diltiazem + quinapril; CI 975	Unspecified	ACE inhibitor; calcium antagonist	hypertension
spirapril + isradipine; isradipine + spirapril; ISPRI	Unspecified	ACE inhibitor; calcium antagonist	hypertension
delapril + manidipine; manidipine + delapril; CHF 1521	Unspecified	ACE inhibitor; calcium channel blocker	hypertension

trandolapril + verapamil; verapamil + trandolapril; RU 44570A; TARKA; VERATRON	Unspecified	ACE inhibitor; calcium channel blocker	hypertension
telmisartan+lacidipine ; lacidipine+telmisartan	Unspecified	ACE inhibitor; calcium channel blocker; angiotensin II antagonist	hypertension
benazepril + hydrochlorothiazide; hydrochlorothiazide + benazepril; CIBADREX; LOTENSIN HCT	Unspecified	ACE inhibitor; diuretic	hypertension
delapril + indapamide; indapamide + delapril; CHF 1513; DELAPRIDE	Unspecified	ACE inhibitor; diuretic	hypertension
fosinopril + hydrochlorothiazide; hydrochlorothiazide + fosinopril; TENSOZIDE; MONOPRIL-HCT; FOSICOMP	Unspecified	ACE inhibitor; diuretic	hypertension; heart failure
lisinopril + hydrochlorothiazide; hydrochlorothiazide + lisinopril; PRINZIDE; PRINIVIL PLUS; CARACE; ZESTORETIC; ACECOMB; ACERCOMP	Unspecified	ACE inhibitor; diuretic	hypertension
moexipril + hydrochlorothiazide; hydrochlorothiazide + moexipril; UNIRETIC; FEMPRESS PLUS	Unspecified	ACE inhibitor; diuretic	hypertension

quinapril + hydrochlorothiazide; hydrochlorothiazide + quinapril; ACCURETIC; ACEQUIDE	Unspecified	ACE inhibitor; diuretic	hypertension
fasidotril; valadotril; alatriopril; BP 1.137	(S)-N-[3-(acetylthio)- 2-(1,3-benzodioxol-5- ylmethyl)-1- oxopropyl]-L-alanine phenylmethyl ester	ACE inhibitor; enkephalinase inhibitor	hypertension
glycopril	N-[(2S)-3- (acetylthio)-2-(1,3- benzodioxol-5- ylmethyl)-1- oxopropyl]glycine phenylmethyl ester	ACE inhibitor; enkephalinase inhibitor	hypertension
BMS 189921	[S-(R*,R*)]- hexahydro-6-[(2- mercapto-1-oxo-3- phenylpropyl)amino]- 2,2-dimethyl-7-oxo- 1H-azepine	ACE inhibitor; matrix metalloproteinase inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
BMS 182657	(S,S)-2-[3-(2- mercapto-3- phenylpropionamide)- 2-oxo-2,3,4,5- tetrahydro-1H-1- benzazepin-1- yl]acetic acid	ACE inhibitor; neutral endopeptidase inhibitor	hypertension
ER 3295	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
mixanpril	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension
sampatrilat; UK 81252	2-[[1-[[[1-carboxy-2- (4- hydroxyphenyl)ethyl] amino]carbonyl]cyclo pentyl]methyl]-N- [N2-(methylsulfonyl)- L-lysyl]-beta-alanine [S-(R*,R*)]-	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure

Z 13752A	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
MDL 100240; MDL 100173 pro	[4S- [4alpha,7alpha(R*),1 2bbeta]]-7-[[2- (acetylthio)-1-oxo-3- phenylpropyl]amino]- 1,2,3,4,6,7,8,12b- octahydro-6-oxo- pyrido[2,1- a][2]benzazepine-4- carboxylic acid	ACE inhibitor; neutral endopeptidase inhibitor; diuretic	heart failure; hypertension
C 111	Gly-Val-Tyr-Pro-His- Lys	ACE inhibitor; peptide	hypertension
C 112	Ile-Arg-Pro-Val-Gln	ACE inhibitor; peptide	hypertension
moveltipril; altiopril calcium; MC 838; LOWPRES	[R-(R*,S*)]-1-[3-[[2- [(cyclohexycarbonyl) amino]-1- oxopropyl]thio]-2- methyl-1-oxopropyl]- L-proline	ACE inhibitor; vasodilator	hypertension
spiraprilat; SCH 33861	(8S)-7-[(S)-N-[(S)-1- carboxy-3- phenylpropyl]alanyl]- 1,4-dithia-7- azaspiro[4.4]nonane- 8-carboxylic acid	ACE inhibitor; vasodilator	hypertension; glaucoma
trandolapril; CI 907; RU 44570; RU 570; ODRIK; UDRIK; GOPTEN; TRAPRIL; ODRIC; MAVIK	[2S- [1[R*(R*)],2alpha,3a alpha,7abeta]]-1-[2- [[1-(ethoxycarbonyl)- 3- phenylpropyl]amino]- 1- oxopropyl]octahydro- 1H-indole-2- carboxylic acid	ACE inhibitor; vasodilator	hypertension; heart failure; myocardial infarction
AGR 529	N-(4-amino-4- oxobutyl)adenosine hydrochloride	Adenosine A1 receptors in fat cells	hypertension; hyperlipidemia
AGR 540	N-(4-amino-4- oxobutyl)adenosine 2',3',5'-tripropanoate	Adenosine A1 receptors in fat cells	hypertension; hyperlipidemia

RPR 100579	Unspecified	adenosine agonist	hypertension; heart failure; hyperlipidemia
antihypertensive	2-hexynyladenosine (2-H-Ado)	adenosine agonist; adenosine A2 agonist	hypertension
antihypertensive	2-octynyladenosine (2-O-Ado)	adenosine agonist; adenosine A2 agonist	hypertension
CGS 21680	4-[2-[[6-amino-9-(N-ethyl-beta-D-ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid	adenosine agonist; adenosine A2 agonist; adenosine A3 agonist	hypertension
CGS 22492	2-[(2-cyclohexylethyl)amino]adenosine	adenosine agonist; vasodilator	hypertension
YT 146	2-(1-octynyl)adenosine	adenosine agonist; vasodilator	hypertension
KS 341; RKS 0341	Unspecified	adenosine antagonist	hypertension
FK 453; FR 113453	[R-(E)]-1-[1-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propenyl]-2-piperidineethanol	adenosine antagonist; adenosine A1 antagonist	hypertension
FK 838	6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazine butyric acid	adenosine antagonist; adenosine A1 antagonist; diuretic	hypertension
CVT 124; BG 9719; ADENTRI	3,7-dihydro-8-(3-oxatricyclo[3.2.1.0 <sup>2,4</sup> ]oct-6-yl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; diuretic; adenosine A1 antagonist	heart failure; hypertension
eplerenone; epoxymexrenone; CGP 30083; SC 66110	(7.alpha.,11.alpha.,17.alpha.)-9,11-epoxy-17-hydroxy-3-oxopregn-4-ene-7,21-dicarboxylic acid .gamma.-lactone methyl ester	aldosterone antagonist	heart failure; hypertension



drug delivery system, transdermal clonidine; clonidine transdermal; M 5041T	Unspecified	alpha adrenergic agonist	hypertension
apraclonidine; p-aminoclonidine; aplonidine; ALO 2145; NC 14; IOPIDINE	2,6-dichloro-N'-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine	alpha adrenergic agonist; alpha2 adrenergic agonist	glaucoma; hypertension
moxonidine; BE 5895; BDF 5895; LY 326869; CYNT; PHYSIOTENS	4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine	alpha adrenergic agonist; alpha2 adrenergic agonist; imidazoline agonist	hypertension; heart failure; diabetes
indoramin; WY 21901; DORALESE; TILTAB; BARATOL; WYDORA; WYPRESIN; VIDORA	N-[1-[2-(1H-indol-3-yl)ethyl]-4-piperidinyl]benzamide	alpha adrenergic antagonist	hypertension; benign prostate hypertrophy
CL 870801	2-methyl-4-chloro-5-((2-(4-(2-methoxyphenyl)piperazinyl-1)ethyl)amino)-3(2H)-pyridazinone hydrochloride	alpha adrenergic antagonist; 5HT agonist; vasodilator	hypertension
alfuzosin; alfuzosin hydrochloride; SL 77499; SL 7749910; ALFOTEN; XATRAL; BENESTAN; BENESTAIN; XATRAL-MAG; DILOTEX; URION; UROXATRAL	N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide	alpha adrenergic antagonist; alpha1 adrenergic antagonist	benign prostate hypertrophy; hypertension
bunazosin; bunazosin hydrochloride; E 643; DE 070; E 1015; DETANTOL; DETANTOL R; ANDANTE	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-butyrylhexahydro-1H-1,4-diazepine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy

CR 2991	Unspecified	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
cyclazosin	Cis-1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)decahydroquinoxaline monohydrochloride	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
dicentrine; d-dicentrine; (+)-dicentrine; eximine; O,N-dimethylitseferine	(S)-6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-5H-benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
doxazosin; UK 33274; UK 3327427; CARDURA; CARDENALIN; SUPRESSIN; CARDURAN; DIBLOCIN; DOXABEN; NORMOTHEN; DEDRALEN; ALFADIL	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	benign prostate hypertrophy; hypertension
drug delivery system, OROS prazosin; prazosin OROS; CP 122991; MINIPRESS XL; ALPRESS LP	Unspecified	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
HSR 175	R-(-)-5-[2[2-(5-fluoro-2-methoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; urinary incontinence
metazosin; metasozin; metazocin; KENOSIN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy; heart failure

QF 301	2-[2-(N4-O-methoxyphenyl-N1-piperazinyl)ethyl]-1-tetralone	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
SGB 1534	3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-2,4(1H,3H)-quinazolinedione monohydrochloride	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
SNAP 5150	N-[3-(4,4-diphenyl-1-piperidiny)propyl]-1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinecarboxamide	alpha adrenergic antagonist; alpha1 adrenergic antagonist	benign prostate hypertrophy; hyperlipidemia; hypertension
urapidil; B 66256; BY 05068; EBRANTIL; ALPHA DEPRESSAN	6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; benign prostate hypertrophy; dysuria
AT 112	2,3-dihydro-2-[(4-phenyl-1-piperazinyl)methyl]imidazo[1,2-c]quinazolin-5(6H)-one	alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	thrombosis; hypertension
terazosin; A 45975; MY 208; HYTRIN; HEITRIN; VASOMET; SINALFA; BLAVIN; URODIE; HYTRINEX; TERAPROST; ISONTYN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist; vasodilator	benign prostate hypertrophy; hypertension
A 65265	Unspecified	alpha adrenergic antagonist; alpha2 adrenergic antagonist	hypertension

amosulalol; YM 09538; LOWGAN	5-[1-hydroxy-2-[[2-(2-methoxyphenoxy)ethyl]amino]ethyl]-2-methylbenzenesulfonamide	alpha adrenergic antagonist; beta adrenergic antagonist	hypertension
brefonalol; BDF 8186	(+,-)-6-[2-[(1,1-dimethyl-3-phenylpropyl)amino]-1-hydroxyethyl]-3,4-dihydrocarbostyrl	alpha adrenergic antagonist; beta adrenergic antagonist	hypertension
N 1518	4-[2-hydroxy-3-[[2-(2-methoxyphenoxy)-1-methylethyl]amino]propoxy]-1(2H)-isoquinolinone	alpha adrenergic antagonist; beta adrenergic antagonist	hypertension
AC 625	Unspecified	amylin antagonist; peptide	hypertension
adrenergic alpha2 human neuroreceptors; neuroreceptors, adrenergic alpha2 human	Unspecified	analgesic	research tool; pain; hypertension; glaucoma
EMD 61650	2-butyl-3,5-dihydro-5-(phenylmethyl)-3-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4H-imidazo[4,5-c]pyridin-4-one	Angiotensin II	hypertension
EMD 66684	2-butyl-4,5-dihydro-4-oxo-3[[[2'-(1H-tetrazol-5-yl)-4-biphenyl]methyl]-3H-imidazo[4,5-C]pyridine-5-(N,N-dimethylacetamide)	Angiotensin II	hypertension
A 81282; ABBOTT 81282	4-[butyl[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-5-pyrimidinecarboxylic acid	angiotensin II antagonist	hypertension

A 81988	Unspecified	angiotensin II antagonist	hypertension
angiotensin II receptor antagonist	Unspecified	angiotensin II antagonist	hypertension
BIBR 363	Unspecified	angiotensin II antagonist	hypertension
BIBS 222	2-[[[4-[[2-butyl-6-[[[(methylamino)carbonyl]pentylamino]-1H-benzimidazol-1-yl]methyl]phenyl]amino]carbonyl]-3,6-dichlorobenzoic acid	angiotensin II antagonist	hypertension
BIBS 39	4'-[[2-n-butyl-6-cyclohexylaminocarbonylamino-benzimidazole-1-yl]methyl]biphenyl]-2-carboxylic acid	angiotensin II antagonist	hypertension
BMS 180560	2-butyl-4-chloro-1-[[1-[2-(1H-tetrazol-5-yl)phenyl]-1H-indol-4-yl]methyl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMIAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
CI 996	2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
DA 2079	Unspecified	angiotensin II antagonist	hypertension

DUP 532	4-(pentafluoroethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
E 4177	4'-[(2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid	angiotensin II antagonist	hypertension
embusartan; BAY 106734	6-butyl-1-[[3-fluoro-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1,2-dihydro-2-oxo-4-pyridinecarboxylic acid methyl ester	angiotensin II antagonist	hypertension
EMD 66397	Unspecified	angiotensin II antagonist	hypertension
eprosartan; eprosartan mesylate; SB 108566; SKF 108566; SKF 108566 J; TEVETEN	(E)-alfa-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl)methylene]-2-thiophenepropanoic acid	angiotensin II antagonist	hypertension
EXP 3174; E 3174	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-imidazole-5-carboxylic acid	angiotensin II antagonist	hypertension
EXP 6155	2-butyl-1-[(4-carboxyphenyl)methyl]-4-chloro-1H-imidazole-5-acetic acid disodium salt	angiotensin II antagonist	hypertension

EXP 6803	2-butyl-1-[[4-[(2-carboxybenzoyl)amino]phenyl)methyl]-4-chloro-1H-imidazole-5-acetic acid alfa-methyl ester monosodium salt	angiotensin II antagonist	hypertension
FK 739; FR 130739	Unspecified	angiotensin II antagonist	hypertension
forasartan; SC 52458	5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(1H-tetrazol-5-ylphenyl)]pyridine	angiotensin II antagonist	hypertension
GA 0056	2-[6-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-quinolinyl]benzoic acid	angiotensin II antagonist	hypertension
HN 65021	2-butyl-4-chloro-1-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-imidazole-5-carboxylic acid 1-(ethoxycarbamoyl)ethyl ester potassium salt	angiotensin II antagonist	hypertension
HR 720; HOE 720	2-butyl-4-(methylthio)-1-[[[2'-[[[(propyl)amino]sulfonyl](1,1'-biphenyl)-4-yl)methyl]-1H-imidazole-5-carboxylic acid dipotassium salt	angiotensin II antagonist	hypertension
ICI D6888	Unspecified	angiotensin II antagonist	hypertension
ICI D7155	Unspecified	angiotensin II antagonist	hypertension

ICI D8731	2-ethyl-4-((2'-(1H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl)-methoxy)quinoline hydrochloride	angiotensin II antagonist	hypertension
irbesartan; SR 47436; BMS 186295; APROVEL; KARVEA; AVAPRO	2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	angiotensin II antagonist	hypertension; kidney disease; heart failure
KRH 594	2-[[[5-ethyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1,3,4-thiadiazol-2(3H)-ylidene]amino]carbonyl]-1-cyclopentene-1-carboxylic acid dipotassium salt	angiotensin II antagonist	hypertension
KT 3671; DA 727; KT 3-671	5,6,7,8-tetrahydro-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4(3H)-cycloheptimidazole	angiotensin II antagonist	hypertension
KW 3433	Unspecified	angiotensin II antagonist	hypertension
L 158978	Unspecified	angiotensin II antagonist	hypertension
L 159282; MK 996	N-[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]-benzamide	angiotensin II antagonist	hypertension
L 159689	N-[3,4-dihydro-4-oxo-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-6-quinazolinyl]-N-pentylbenzamide	angiotensin II antagonist	hypertension



L 161177	2-ethyl-5,7-dimethyl-3-[[2'-(2-oxido-3H-1,2,3,5-oxathiadiazol-4-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine	angiotensin II antagonist	hypertension
L 162154	N-[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]-3-chloro-2-thiophenecarboxamide	angiotensin II antagonist	hypertension
L 162234	[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulphonyl]carbamic acid 1,1-dimethylethyl ester	angiotensin II antagonist	hypertension
L 163017	6-[benzoylamino]-7-methyl-2-propyl-3-[[[2'-(N-(3-methyl-1-butoxy)carbonylaminosulfonyl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine	angiotensin II antagonist	hypertension
L 692429	3-amino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3(R)-yl]-butanamide	angiotensin II antagonist	hypertension

losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
LR B139	Unspecified	angiotensin II antagonist	hypertension; angina
LY 235656	Unspecified	angiotensin II antagonist	hypertension
LY 285434	Unspecified	angiotensin II antagonist	hypertension
LY 301875	(4S)-4-[4-(carboxymethyl)phenoxy]-1-[(2R)-1-oxo-2-[4-[(2-sulfobenzoyl)amino]-1H-imidazol-1-yl]octyl]-L-proline	angiotensin II antagonist	hypertension
LY 302289	Unspecified	angiotensin II antagonist	hypertension
LY 315995	Unspecified	angiotensin II antagonist	hypertension
ME 3221	3-methoxy-2,6-dimethyl-4-[[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl]-4-yl]methoxy]pyridine	angiotensin II antagonist	hypertension
milfasartan; LR B081; LRB 081	2-[[[4-butyl-2-methyl-6-oxo-5-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1(6H)-pyrimidinyl]methyl]-3-thiophenecarboxylic acid methyl ester	angiotensin II antagonist	hypertension

olmesartan; CS 866	4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester	angiotensin II antagonist	hypertension
PD 123177; EXP 655	1-[(4-amino-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid	angiotensin II antagonist	hypertension
PD 123319	(S)-1-[[4-(dimethylamino)-3-methylphenyl]methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid	angiotensin II antagonist	hypertension
PD 150304	(Z)-4-[[2-butyl-5-[[1-butyl-3-[(5-methyl-3-thienyl)methyl]-2,5-dioxo-4-imidazolidinylidene]methyl]-1H-imidazol-1-yl]methyl]benzoic acid	angiotensin II antagonist	hypertension
tipisartan; UP 2696	5-methyl-7-propyl-8-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-[1,2,4-triazolo[1,5-c]pyrimidin-2(3H)-one	angiotensin II antagonist	hypertension

RWJ 46458	2-carbethoxymethylidene-4-methyl-4-ethyl-2-[4-(2'-tetrazolo)-phenyl]benzylpiperidine-6-one	angiotensin II antagonist	hypertension
saprisartan; saprisartan potassium; GR 138950; GR 138950X; GR 138950C	1-[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]benzo[b]furan-5-ylmethyl]-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide	angiotensin II antagonist	hypertension
saralasin; saralasin acetate; aralasin; P 113; P 113 (peptide); SARENIN	1-(N-methylglycine)-5-L-valine-8-L-alanineangiotensin II	angiotensin II antagonist	hypertension; contraception; diagnosis
SC 51316	2,5-dibutyl-2,4-dihydro-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-1,2,4-triazol-3-one	angiotensin II antagonist	hypertension
SK 1080; KR 31080	2-butyl-5-methyl-6-(1-oxido-2-pyridinyl)-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazodo[4,5-b]pyridine	angiotensin II antagonist	hypertension
SL 910102	Unspecified	angiotensin II antagonist	hypertension
TAK 536	1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl-2-ethoxy-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist	hypertension

tasosartan; ANA 756; WAY ANA 756; VERDIA	5,8-dihydro-2,4-dimethyl-8-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-pyrido[2,3-d]pyrimidin-7(6H)-one	angiotensin II antagonist	hypertension
telmisartan; BIBR 277; BIBR 0277SE; MICARDIS; PRITOR	4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid	angiotensin II antagonist	hypertension
U 97018	2-butyl-3,6,7,8,9,11-hexahydro-6,9-dimethyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-6,9-ethano-4H-imidazo[4,5-d]pyridazino[1,2-a]pyridazin-4-one	angiotensin II antagonist	hypertension
UP 27522	5-propyl-6-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol	angiotensin II antagonist	hypertension
UR 7247	3-(1-methylethyl)-1-propyl-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazole-4-carboxylic acid	angiotensin II antagonist	hypertension; heart failure
UR 7280	3-(1,1-dimethylethyl)-1-propyl-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazole-4-carboxylic acid	angiotensin II antagonist	hypertension

valsartan; CGP 48933; DIOVAN	N-(1-oxopentyl)-N-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine	angiotensin II antagonist	hypertension; heart failure
WK 1360	Unspecified	angiotensin II antagonist	hypertension
WY 126227; WAY 126227	N-[[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-2-(trifluoromethyl)-4-quinazolinamine	angiotensin II antagonist	hypertension
YM 31472	Unspecified	angiotensin II antagonist	hypertension
YM 358	2,7-diethyl-5-[(2'-(5-tetrazoyl)biphenyl-4-yl)methyl]-5H-pyrazolo[1,5-b][1,2,4]triazole	angiotensin II antagonist	hypertension; heart failure
irbesartan + hydrochlorothiazide; hydrochlorothiazide + irbesartan; AVALIDE; COAPROVEL; KARVEZIDE	Unspecified	angiotensin II antagonist; diuretic	hypertension; kidney disease
losartan + hydrochlorothiazide; HYZAAR; LOSACOR D	Unspecified	angiotensin II antagonist; diuretic	hypertension
tasosartan + hydrochlorothiazide; hydrochlorothiazide + tasosartan; VERDIA/HCTZ	Unspecified	angiotensin II antagonist; diuretic	hypertension
valsartan + hydrochlorothiazide; hydrochlorothiazide + valsartan; CoDiovan; CO-DIOVAN; DIOVAN HCT; CoTareg; CO-TAREG; DIOVAN-D	Unspecified	angiotensin II antagonist; diuretic	hypertension

candesartan; CV 11974	2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist; imidazole	hypertension
CV 11194; EP 425921A	2-butyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid	angiotensin II antagonist; imidazole	hypertension
LR B087; LRB 087	Unspecified	angiotensin II antagonist; imidazole	hypertension
zolasartan; GR 117289; GR 117289C	1-[[3-bromo-2-[2-(1H-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-2-butyl-4-chloro-1H-imidazole-5-carboxylic acid	angiotensin II antagonist; vasodilator	hypertension
LA 360	Unspecified	anion transport inhibitor	hypertension
AP 539	1-(2-naphthoxyacetyl)piperidin-4-carbonyl-Nalfa-L-arginyl-Nalfa-L-isoleucinyl-Nalfa-L-aspartyl-Nalfa-L-arginyl-Nalfa-L-isoleucinylamide	ANP antagonist	hypertension
antihypertensive	Unspecified	Antihypertensive	hypertension
antihypertensive, ALT 462	4-amino-2,4-dihydro-5-(1-methylethyl)-3H-1,2,4-triazol-3-one hydrazone	Antihypertensive	hypertension
BR 9201	Unspecified	Antihypertensive	hypertension
BW 1045U85	Unspecified	Antihypertensive	hypertension
CKD 705	Unspecified	Antihypertensive	hypertension
erythritol; NIK 242	1,2,3,4-butanetetrol	Antihypertensive	hypertension
IRLS DR09	Unspecified	Antihypertensive	hypertension
IRLS DR12	Unspecified	Antihypertensive	hypertension
IRLS DR33	Unspecified	Antihypertensive	hypertension

LCB 2601	Unspecified	Antihypertensive	hypertension
millisrol; NK 843H; NK 843L; NK 843	Unspecified	Antihypertensive	hypertension; diagnosis
MYD 37	Unspecified	Antihypertensive	hypertension
PST 2238	(3beta,5beta,14beta)- 21,23-epoxy-24- norchola-20,22-diene- 3,14,17-triol	Antihypertensive	hypertension
RES 7011; RES 701- 1	Gly-Asn-Trp-His- Gly-Thr-Ala-Pro- Asp-Trp-Phe-Phe- Asn-Tyr-Tyr-Trp cyclic (9-1)-peptide	Antihypertensive	hypertension
RS 89769	Unspecified	Antihypertensive	hypertension
TN 891	(S)-4-(2-hydroxy-3- isopropylaminopropo xy)phenylacetamide	Antihypertensive	hypertension
UH 334	Unspecified	Antihypertensive	hypertension
antihypertensive	1-((3- methylphenyl)piperaz in-1-yl)-3-(thio(4- acetamido)phenyl)-pr opane	Antihypertensive; central site	hypertension
APCI	Unspecified	atrial peptide clearance receptor inhibitor	hypertension
candoxatril; UK 79300	4-[[[1-[3-[(2,3- dihydro-1H-inden-5- yl)oxy]-2-[(2- methoxyethoxy)meth yl]-3- oxopropyl]cyclopenty l]carbonyl]amino]- cyclohexanecarboxyli c acid	atriopeptidase inhibitor	hypertension; heart failure
candoxatrilat; UK 73967	(alfa,S)-1-[(cis-4- carboxycyclohexyl)ca rbamoyl]-alfa-[(2- methoxyethoxy)meth yl]cyclopentanepropio nic acid	atriopeptidase inhibitor	hypertension
SCH 42945	Unspecified	atriopeptidase inhibitor	hypertension



adimolol; imidolol; MEN 935	1,3-dihydro-1-[3-[[2-hydroxy-3-(1-naphthalenyloxy)propyl]amino]-3-methylbutyl]-2H-benzimidazol-2-one	beta adrenergic antagonist	hypertension
arotinolol; S 596; ALMARL; ANBROTH; ACEMAIL; ALOCHINON; AMOPSOL; AROTINOIL; ASTONIL; LISTERIA	(+,-)-5-[2-[[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]thio]-4-thiazolyl]-2-thiophenecarboxamide	beta adrenergic antagonist	glaucoma; hypertension
betaxolol; betaxolol hydrochloride; SL 75212; MCI 144; ABAXON; KERLONE; BETOPTIC; KERLONG; GLAUTAXOL; BERTOCIL; OPTIPRES; BETASEL; BEOF NICOLICH; LOKREN	1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist	glaucoma; hypertension; angina
bevantolol; bevantolol hydrochloride; CL 775; NC 1400; VANTOL; CALVAN; RANESTOL	(+,-)-1-[(3,4-dimethoxyphenethyl)amino]-3-(m-tolyloxy)-2-propanol	beta adrenergic antagonist	hypertension
bisoprolol; bisoprolol fumarate; EMD 33512; CL 297939; CONCOR; EMCOR; EMCORE; MONOCOR; ISOTEN; SOPROL; DETENSIEL; MAINTATE; ISOBLOC; ZEBETA	1-[(1-methylethyl)amino]-3-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-2-propanol	beta adrenergic antagonist	hypertension; heart failure

bopindolol; LT 31200; SANDONORM	(+,-)-1-[(1,1-dimethylethyl)amino]-3-[(2-methyl-1H-indo-4-yl)oxy]]-2-propanol, benzoate	beta adrenergic antagonist	hypertension
carvedilol; karvedilol; BM 14190; DQ 2466; KREDEX; COREG; DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC	1-(9H-carbazol-4-yl)oxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol	beta adrenergic antagonist	hypertension; angina; heart failure
acetamolol; ICI 72222; AY 27303; AI 27303; BETACOR	2-[2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenoxy]-N-methylacetamide	beta adrenergic antagonist	hypertension
drug delivery system, HALO labetolol; labetolol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, HALO metoprolol; metoprolol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, HALO oxprenolol; oxprenolol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, HALO timolol; timolol HALO	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, MICROPUMP oral controlled release atenolol; atenolol MICROPUMP; ATENAX	Unspecified	beta adrenergic antagonist	hypertension
drug delivery system, transdermal mepindolol; transdermal soft disc, mepindolol; mepindolol B10 TSD	Unspecified	beta adrenergic antagonist	hypertension

esatenolol; atenolol, (S)-; (S)-atenolol; (-)-atenolol	(S)-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide	beta adrenergic antagonist	hypertension
esmolol; ASL 8052; ASL 8123; BREVIBLOC	4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]benzenepropanoic acid methyl ester	beta adrenergic antagonist	hypertension; arrhythmia
levobunolol; W 7000A; AG 901; BETAGAN; VISTAGEN; GOTENSIN; VISTAGAN; LEVOGAN	(-)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2H)-naphthalenone	beta adrenergic antagonist	hypertension; glaucoma
ridazolol; CAS 413	4-chloro-5-[[2-[[3-(2-chlorophenoxy)-2-hydroxypropyl]amino]ethyl]amino]-3(2H)-pyridazinone	beta adrenergic antagonist	hypertension
tertatolol; S 2395; SE 2395; ARTEX; ARTENSIL	(+,-)-1-[(3,4-dihydro-2H-1-benzothiopyran-8-yl)oxy]-3-[(1,1-dimethylethyl)amino]-2-propanol	beta adrenergic antagonist	hypertension
atenolol + lisinopril; lisinopril + atenolol	Unspecified	beta adrenergic antagonist; ACE inhibitor	hypertension
EXP 063	4-[[[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-1H-indol-2-yl]carbonyl]amino]methyl]-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid	beta adrenergic antagonist; angiotensin II antagonist	hypertension

carteolol; OPC 1085; ABBOTT 43326; A 43326; ARTEOPTIC; CARTEOL; CARTROL; ENDAK; MERCATOA; MIKELAN; ORUKALOL; PALSIT; TENALET; TENALIN	5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydroquinolinone	beta adrenergic antagonist; beta adrenergic antagonist	glaucoma; hypertension
metoprolol, (S)-; (S)-metoprolol	(2S)-1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol	beta adrenergic antagonist; beta1 adrenergic antagonist	angina; hypertension; arrhythmia
nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET; LOBIVON	[2R*[R*[R*(S*)]]]-alpha,alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator; vasodilator	hypertension; migraine; heart failure
drug delivery system, HALO sustained release propranolol; propranolol HALO sustained release	Unspecified	beta adrenergic antagonist; beta2 adrenergic antagonist	hypertension
celiprolol; NPB 582; ST 1396; REV 5320A; SELECTOL; CELECTOL	N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethylurea	beta adrenergic antagonist; beta2 adrenergic partial antagonist; vasodilator	hypertension; nephritis
betaxolol + chlortalidone; chlortalidone + betaxolol; KERLEDEX	Unspecified	beta adrenergic antagonist; diuretic	hypertension

bisoprolol + hydrochlorothiazide; hydrochlorothiazide + bisoprolol; EMD 47378; ZIAC; CONCOR PLUS; EMCORECTIC; FONDRIL; MONOZIDE	Unspecified	beta adrenergic antagonist; diuretic	hypertension
tenoxolol; UP 78842	2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-5-[(2-thienylcarbonyl)amino]benzoic acid ethyl ester	beta adrenergic antagonist; diuretic	hypertension
bendacalol; bendacolor; CGS 10078B	[2R*[S*[R*(S*)]]]-alpha,alpha-[iminobis(methylene)]bis[2,3-dihydro-1,4-benzodioxin-2-methanol]	beta adrenergic antagonist; vasodilator	hypertension
tilisolol; N 696; DAIM; SELECAL	4-[3-[(1,1-dimethylethylamino)]-2-hydroxypropoxy]-2-methyl-1(2H)-isoquinolinone	beta adrenergic antagonist; vasodilator	hypertension
TS 702	Unspecified	beta adrenergic antagonist; vasodilator	hypertension
talinolol; CORDANUM	(+/-)-N-cyclohexyl-N'-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]urea	beta1 adrenergic antagonist; beta adrenergic antagonist	hypertension; myocardial infarction; cardiovascular disease
UT 26	Unspecified	biotechnology; antisense; oligonucleotide	pulmonary hypertension
nesiritide; nesiritide citrate; brain natriuretic peptide; BNP; NATRECOR	Brain natriuretic peptide-32	biotechnology; hormone; peptide	heart failure; hypertension

antisense oligonucleotide, angiotensinogen	Unspecified	biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	hypertension
zatebradine; ULFS 49	3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-benzazepin-2-one	bradycardic agent	angina; hypertension
WIN 64338	(S)-[[4-[[2-[[bis(cyclohexylamino)methylene]amino]-3-(2-naphthalenyl)-1-oxopropyl]amino]phenyl]methyl]tributylphosphonium chloride	bradykinin antagonist	hypertension
CP 0364	Unspecified	bradykinin antagonist; NSAID	hypertension; inflammation
AHR 12742	4-(bis(4-fluorophenylmethyl)-7-(3-(4-chlorophenoxy)propyl)piperidine (E)-2-butenedioate	calcium antagonist	hypertension
amlodipine analogue	4-(2,3-dichlorophenyl)-1,4-dihydro-2-[(2-hydroxyethoxy)methyl]-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	hypertension
amlodipine besilate; UK 4834026; NORVASC; ISTIN	2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid, 3-ethyl 5-methyl ester monobenzenesulfonate	calcium antagonist	hypertension

amlodipine, (S)-; (S)-amlodipine; (-)-amlodipine; 1-amlodipine	(S)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid, 3-ethyl 5-methyl ester	calcium antagonist	hypertension
antihypertensive, Kanebo	ethyl isopropyl 4-(benzothiazol-2-yl)benzylphosphonate	calcium antagonist	hypertension
aranidipine; MPC 1304; SAPRESTA; BEC BM; BEC MARUKO; BEC	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid, methyl 2-oxopropyl ester	calcium antagonist	hypertension
azelnidipine; CS 905; RS 9054	(+,-)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-[1-(diphenylmethyl)-3-azetidiny] 5-(1-methylethyl) ester	calcium antagonist	hypertension
belfosdil; SR 7037; BMY 21891	[2-(2-phenoxyethyl)-1,3-propanediyl]bisphosphonic acid tetrabutyl ester	calcium antagonist	hypertension
BN 50394	Unspecified	calcium antagonist	hyperlipidemia; hypertension
calcium antagonist	(6R)-1-(aminocarbonyl)-1,2,3,6-tetrahydro-4-methyl-6-(3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester	calcium antagonist	hypertension

calcium antagonist, Suntory	5-isopropoxyloxycarbonyl-2-chloro-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine	calcium antagonist	hypertension
CGP 28861	Unspecified	calcium antagonist	hypertension
CHF 1978	Unspecified	calcium antagonist	hypertension
cilnidipine; cinaldipine; FRC 8653; SISCARD; CINALONG; ATELEC	(E)-(+,-)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 3-phenyl-2-propenyl ester	calcium antagonist	hypertension
clevudipine	4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl (1-oxobutoxy)methyl ester	calcium antagonist	hypertension
cronidipine; LF 20254	[8-(4-chlorophenyl)-1,4-dioxo-8-azaspiro[4.5]dec-2-yl)methyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate	calcium antagonist	hypertension
darodipine; dazodipine; PY 108068; PY 108; PY 10868; PLIMO	4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium antagonist	hypertension
diltiazem analogue	Unspecified	calcium antagonist	hypertension



drug delivery system, COER-24 oral verapamil; verapamil COER-24; OROS verapamil; COER-24 verapamil; COVERA-HS; CHRONOVERA; CRONOVERA	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, controlled release diltiazem; diltiazem controlled release; TIAZAC; VIAZEM	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, controlled release nifedipine; nifedipine	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, controlled release verapamil; verapamil	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO nifedipine; nifedipine HALO	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO nifedipine; nifedipine HALO	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO sustained release diltiazem; diltiazem HALO sustained release	Unspecified	calcium antagonist	hypertension
drug delivery system, HALO verapamil; verapamil HALO	Unspecified	calcium antagonist	hypertension
drug delivery system, OSAT nifedipine; nifedipine sustained release	Unspecified	calcium antagonist	hypertension; angina
drug delivery system, sustained release diltiazem malate; diltiazem malate sustained release	Unspecified	calcium antagonist	hypertension

drug delivery system, sustained release diltiazem; diltiazem sustained release; DILACOR XR	Unspecified	calcium antagonist	hypertension
drug delivery system, sustained release diltiazem; diltiazem sustained release; DILTELAN; CARDIZEM CD; HERBESSER R; DILZEM OD; TIAZEM SR	Unspecified	calcium antagonist	hypertension
drug delivery system, sustained release nifedipine; nifedipine once daily; INDAS nifedipine; NIFENSAR XL; ADALAT SR; UNIDIPINE; NIFELAN; ADALAT OROS	Unspecified	calcium antagonist	angina; hypertension
efonidipine; selefidipine; NZ 105; LANDEL	5-(5,5-dimethyl-1,3,2- dioxaphosphorinan-2- yl)-1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-3- pyridine-carboxylic acid, 2- [phenyl(phenylmethyl )amino] ethyl ester, P- oxide	calcium antagonist	hypertension; angina; cerebrovascular disease
flosatidil; SL 851016	[2- (dimethylamino)ethyl ][2-[[2- (methylthio)phenyl][[ 3- (trifluoromethyl)phen yl]methyl]amino]-2- oxoethyl]carbamic acid 2-methylpropyl ester	calcium antagonist	angina; hypertension

FPL 62129	4-[3-chloro-6-fluoro-2-(trifluoromethyl)phenyl]-2-(fluoromethyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl) ester	calcium antagonist	hypertension; angina
furmidipine; CRE 319	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl (tetrahydro-2-furanyl)methyl ester	calcium antagonist	hypertension; angina; reperfusion injury
gallopamil; D 600; PROCORUM; CORAPAMIL; ALGOCOR	5-[(3,4-dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile	calcium antagonist	hypertension; angina; arrhythmia
GOE 6070; PD 406070	(+)-2-(N-methyl-N-phenylmethylamino)-ethyl 1,4-dihydro-5-isopropoxy-2-methyl-4-(2-trifluoromethylphenyl)-1,6-naphthyridine-3-carboxylate	calcium antagonist	hypertension
GYKI 46544	Unspecified	calcium antagonist	hypertension
HP 406	1'-[4,4-bis(3-fluorophenyl)butyl]-7-fluoro-2-methylspiro[(2H)-1,4-benzodioxepin-3(5H),4'-piperidine] hydrochloride	calcium antagonist	hypertension

igandipine; krenidipine hydrochloride; NKY 722	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-2,2- dimethyl-3-[4-(2- propenyl)-1- piperazinyl]propyl 3,5- pyridinedicarboxylic acid methyl ester	calcium antagonist	hypertension; angina
isradipine; isrodipine; PN 200110; PN 205033; PN 205034; PRESCAL; LOMIR; DynaCirc; VASCAL; ICAZ	4-(4-benzofurazanyl)- 1,4-dihydro-2,6- dimethyl-3,5- pyridinedicarboxylic acid methyl 1- methylethyl ester	calcium antagonist	hypertension; angina
LCB 2514	Unspecified	calcium antagonist	hypertension
lercanidipine; masnidipine; REC 152375; R 75; TJN 324; ZANIDIP; LERDIP; ZANEDIP; LERCADIP; CARDIOVASC; LERZAM	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)pyridine- 3,5-dicarboxylic acid 2-[(3,3- diphenylpropyl)methy lamino]-1,1- dimethylethyl methyl ester	calcium antagonist	hypertension
leualacin	cyclo(beta-alanyl-4- methyl-2- hydroxypentanoylleuc yl-4-methyl-2- hydroxypentanoyl-N- methylphenylalanyl)	calcium antagonist	hypertension
nilvadipine; nivadipine; FK 235; FR 34235; SKF 102362; CL 287389; NIVADIL; ESCOR	2-cyano-1,4-dihydro- 6-methyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid 3-methyl 5-(1- methylethyl) ester	calcium antagonist	hypertension; angina

nisoldipine; BAY k 5552; SULAR; SYSCOR; BAYMYCARD; CORASOL; CORNEL; NISODIPEN; NISOCOR; ZADIPINA	1,4-dihydro-2,6- dimethyl-4-(2- nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 2- methylpropyl ester	calcium antagonist	angina; hypertension
nitrendipine, (S)-; (S)-nitrendipine	(4S)-1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist	hypertension
nitrendipine; BAY e 5009; BAYOTENSIN; BAYPRESS; NIRAPEL; NITRENDIL; NITRENDIPINA; HYPERDIPINA; HIPERTENOL; PORTIONAL; NELCONIL; RETENCAL	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist	hypertension
NPK 1868	2- [[[(aminocarbonyl)oxy ]methyl]-4-(2,3- dichlorophenyl)-1,4- dihydro-6-methyl-3,5- pyridinedicarboxylic acid dimethyl ester	calcium antagonist	hypertension
olradipine; S 11568; S 12968	(+,-)-2-[[2-(2- aminoethoxy)ethoxy] methyl]-4-(2,3- dichlorophenyl)-1,4- dihydro-6-methyl-3,5- pyridinedicarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	hypertension

OPC 8490	3,4-dihydro-6-[4-(4-oxo-4-phenylbutyl)-1-piperazinyl carbonyl]-2(1H)-quinolinone	calcium antagonist	hypertension
oxodipine; IQB 837	ethyl methyl 1,4-dihydro-2,6-dimethyl-4-[2,3-(methylenedioxy)phenyl]-3,5-pyridinedicarboxylate	calcium antagonist	hypertension
palonidipine; TC 81	(+,-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate	calcium antagonist	hypertension
PCA 50982	Unspecified	calcium antagonist	hypertension; angina
pranidipine; OPC 13340; ACALAS	(E)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 3-phenyl-2-propenyl ester	calcium antagonist	hypertension; angina
riodipine; ryodipine; PP 1466; FORIDONE	4-[2-(difluoromethoxy)phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester	calcium antagonist	hypertension; angina
RS 5773	((2S,3S)-3-acetoxy-8-benzyl-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-1,5-benzothiazepine-4-(5H)-one hydrochloride	calcium antagonist	angina; hypertension

S 12967	(+)-2-[[2-(2-aminoethoxy)ethoxy]methyl]-4-(2,3-dichlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinecarboxylic acid 3-ethyl 5-methyl ester	calcium antagonist	hypertension
siratazem; LR A113	(2S-cis)-3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-[2-[methyl(1-methylethyl)amino]ethyl]-1,5-benzothiazepin-4(5H)-one	calcium antagonist	angina; hypertension
SM 6586	1,4-dihydro-2,6-dimethyl-5-[3-[[methyl(phenylmethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-4-(3-nitrophenyl)-3-pyridinecarboxylic acid methyl ester	calcium antagonist	hypertension
teludipine; taludipine; GR 53992B; GR 53992X	(E)-2-[[[(dimethylamino)methyl]-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium antagonist	hypertension; angina
TMB 8	3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester	calcium antagonist	hypertension

UK 51656	2-((2-((4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl)methoxy)ethyl)amino)acetamide	calcium antagonist	hypertension; angina
vatanidipine; watanidipine; AE 0047; GJ 0956; CALBREN	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid, 2-[4-[4-(diphenylmethyl)-1-piperazinyl]phenyl]ethyl methyl ester	calcium antagonist	hypertension
Y 20835	Unspecified	calcium antagonist	hypertension
YM 161511; YM 16151-1	(+)-1,4-dihydro-4-[2-[4-[(2-hydroxy-3-phenoxypropyl)amino]butoxy]-5-nitrophenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester monohydrochloride	calcium antagonist	hypertension; angina
LU 49938	(2S)-5-[N-methyl-N-(n-hexyl)]amino-2-(3,4,5-trimethoxyphenyl)-2-isopropylvaleronitrile hydrochloride	calcium antagonist; 5HT antagonist	hypertension
amlodipine + benazepril; benazepril + amlodipine; CGP 24267A; LOTREL	Unspecified	calcium antagonist; ACE inhibitor	hypertension
diltiazem malate + enalapril; enalapril + diltiazem malate; TECZEM	Unspecified	calcium antagonist; ACE inhibitor	hypertension
felodipine + enalapril; enalapril + felodipine; LEXXEL	Unspecified	calcium antagonist; ACE inhibitor	hypertension



felodipine + ramipril; ramipril + felodipine; HOE 9869; UNIMAX; TAZKO	Unspecified	calcium antagonist; ACE inhibitor	hypertension
monatepil; monatepil maleate; monasedin maleate; AJ 2615; AD 2615	(+,-)-N-(6,11- dihydrodibenzo[b,c]th iepin-11-yl)-4-(4- fluorophenyl)-1- piperazinebutanamide	calcium antagonist; alpha adrenergic antagonist; alpha 1 adrenergic antagonist	hypertension; angina; hyperlipidemia
felodipine + metoprolol; metoprolol + felodipine; LOGIMAX	Unspecified	calcium antagonist; beta adrenergic antagonist	hypertension; angina
YM 154301; YM 430	[S-(R*,R*)-1,4- dihydro-2,6-dimethyl- 4-(3-nitrophenyl)-3,5- pyridinecarboxylic acid, 4-[(2-hydroxy-3- phenoxypropyl)amino ]butyl methyl ester	calcium antagonist; beta adrenergic antagonist	hypertension; angina
CD 349	1,4-dihydro-2,6- dimethyl-4-(3- nitrophenyl)-3,5- pyridinedicarboxylic acid 2- (nitrooxy)propyl 3- (nitrooxy)propyl ester	calcium antagonist; bronchodilator	hypertension; asthma; angina
AHR 16462B	4-[bis(4- fluorophenyl)methyl]- 1-(2- naphthalenylmethyl)p iperidine hydrochloride	calcium antagonist; vasodilator	hypertension
barnidipine; mepirodipine; YM 09730; YM 097305; YM 730; HYPOCA; OLDECA	[S-(R*,R*)]-1,4- dihydro-2,6-dimethyl- 4-(3-nitrophenyl)-3,5- pyridinedicarboxylic acid methyl 1- (phenylmethyl)-3- pyrrolidinyl ester	calcium antagonist; vasodilator	hypertension; ischemia

benidipine; nakadipine; nacadipine; KW 3049; CONIEL	(R*,R*)-(+,-)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester	calcium antagonist; vasodilator	hypertension; angina
clentiazem; clentiazem maleate; TA 3090; LOGNA	(2S-cis)-3-(acetyloxy)-8-chloro-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one	calcium antagonist; vasodilator	hypertension; angina
elgodipine; IQB 875	(+,-)-4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 2-[[4-(fluorophenyl)methyl]methylamino]ethyl 1-methylethyl ester	calcium antagonist; vasodilator	angina; hypertension; heart failure
lomerizine; KB 2796; TERRANAS TAB; MIGSIS	1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine	calcium antagonist; vasodilator	hypertension; migraine
manidipine; manidipine hydrochloride; CV 4093; CALSLOT; MADIPINE; IPERTEN	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[4-(diphenylmethyl)-1-piperazinyl]ethyl 3,5-pyridinedicarboxylic acid methyl ester	calcium antagonist; vasodilator	hypertension
McN 5691	N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-N,alfa-dimethyl-2-(phenylethynyl)benzenepropanamine	calcium antagonist; vasodilator	hypertension

P 1268	2-(1,2,3,4-tetrahydroisoquinoline-2-yl)ethyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-methoxycarbonylpyridine-3-carboxylate, monohydrochloride	calcium antagonist; vasodilator	hypertension
semotiadil; semotiadil fumarate; SD 3211; DQ 4823; DS 4823	(R)-2-[2-[3-[[2-(1,3-benzodioxol-5-yl)oxy]ethyl]methylamino]propoxy]-5-methoxyphenyl]-4-methyl-2H-1,4-benzothiazin-3(4H)-one	calcium antagonist; vasodilator	angina; hypertension
TJN 220	(1beta)-7-ethoxy-6,6',12-trimethoxy-2,2'-dimethylberbaman	calcium antagonist; vasodilator	hypertension
felodipine; H 15482; HOE 869; CGH 869; HYDAC; PLENDIL; VASOPINE; SPLENDIL; MUNOBAL; FLODIL	4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist; vasodilator; diuretic	hypertension; angina; heart failure; atherosclerosis
drug delivery system, OROS oral controlled release isradipine; isradipine OROS; DynaCirc CR	Unspecified	calcium channel blocker	hypertension
lacidipine; GR 43659; GR 43659X; SN 305; GX 1048; LACIPIL; VIAPRES; LACIREX; MOTENS; CALDINE; MIDOTENS; APONIL; ZASCAL; LACIMEN	(E)-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester	calcium channel blocker	hypertension
P 5	Unspecified	calcium channel blocker	hypertension

RWJ 22726	N-benzyl-N-methyl-aminoethyl 10-(2,3-dichlorophenyl)-3,4,5,6,7,10-hexahydro-8-methyl-1,1-dioxo-2H-thiacycloocteno(3,2-b)pyridine-carboxylate	calcium channel blocker	hypertension
verapamil, (S)-; (S)-verapamil; levoverapamil; D 2024	(S)-alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile	calcium channel blocker	hypertension; arrhythmia; angina
Z 6568	Unspecified	calcium channel blocker	hypertension
meoxan	Unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease
S 2150	(+)-cis-3-acetoxy-8-chloro-2,3-dihydro-2-(4-methoxyphenyl)-5-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-1,5-benzothiazepin-4(5H)-one citrate	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension
veroxan; VUFB 18814	Unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease

ZM 224832	3,5-diamino-N-[2-[[2-[[[(6-bromo-2,3-dihydro-5-hydroxy-1,1-dimethyl-1H-inden-4-yl)methyl]amino]ethyl]methylamino]ethyl]-6-chloropyrazinecarboxamide	calcium channel blocker; diuretic	hypertension
LAS 30538	1-[2-(2,6-dimethylphenoxy)ethyl-alpha,alpha-bis(4-fluorophenyl)-4-piperidinemethanol	calcium channel blocker; vasodilator	hypertension
mibefradil; mibefradil dihydrochloride; Ro 405967; Ro 405967001; POSICOR; CERATE	methoxyacetic acid, (1S-cis)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester	calcium channel blocker; vasodilator	hypertension; angina; heart failure
SQ 33351	[3R-[1(S*),3alpha,4alpha]]-3-(acetyloxy)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-1-(2-pyrrolidinylmethyl)-6-(trifluoromethyl)-2H-1-benzazepin-2-one monohydrochloride	calcium channel blocker; vasodilator	hypertension
SQ 33537	[3R-[1(S*),3alpha,4alpha]]-1,3,4,5-tetrahydro-3-hydroxy-4-(4-methoxyphenyl)-1-(2-pyrrolidinylmethyl)-6-(trifluoromethyl)-2H-1-benzazepin-2-one monohydrochloride	calcium channel blocker; vasodilator	hypertension

DF 100	4-(3,5-dimethyl-1H-pyrazol-1-yl)-2,5-dihydro-1H-pyridazino[4,5-b]indol-1-one hydrazone monohydrochloride	Calcium influx modulator	hypertension
AM 522	Unspecified	cardiac glycoside	hypertension; heart failure
AM 524	Unspecified	cardiac glycoside	heart failure; hypertension
digitoxigenin-PC	Unspecified	cardiac glycoside	heart failure; hypertension
antihypertensive	Unspecified	Catecholamine metabolism	hypertension
JMV 236	N-[(1,1-dimethylethoxy)carbo-nyl]-O-sulfo-L-tyrosyl-L-norleucylglycyl-L-tryptophyl-L-norleucyl-L-alpha-aspartyl-L-phenylalaninamide	cholecystokinin agonist	hypertension
besulpamide; E 3050	1-(4-chloro-3-sulfamoylbenzamido)-2,4,5-trimethylpyridinium hydroxide	diuretic	hypertension
cicletanine; cycletanide; BN 1270; RU 270; WIN 90000; TENSTATEN; JUSTAR	3-(4-chlorophenyl)-1,3-dihydro-6-methylfuro[3,4-c]pyridin-7-ol	diuretic	hypertension
drug delivery system, furosemide; furosemide delivery system; HYAL DI4151	Unspecified	diuretic	hypertension
hattalin	2,3-dibenzylbutane-1,4-diol	diuretic	hypertension

ICI 181037	(R*,R*)-(+,-)-2-[2-[2-(dimethylamino)-1-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-1-hydroxypropyl]phenoxy]acetamide	diuretic	hypertension
ICI 206970	3,5-diamino-N-[2-[N-[2-(3-bromo-5-tert-butyl-2-hydroxybenzylamino)ethyl]-N-methylamino]ethyl]-6-chloropyrazine-2-carboxamide	diuretic	hypertension
ICI 207828	N-(2-(3-bromo-5-tert-butyl-2-hydroxybenzylamino)ethyl)-3-(N-2-(3,5-diamino-6-chloropyrazin-2-ylcarboxamido)ethyl)-N-methylamino)propionamide	diuretic	hypertension
MD 31; M 17055	N-[7-chloro-2,3-dihydro-1-(2-methylbenzoyl)-4(1H)-quinolinylidene]hydroxylamine-O-sulfonic acid potassium salt	diuretic	hypertension
PF 886	Unspecified	diuretic	hypertension
SC 46279	1-(5-amino-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidine-8-yl)-1,2-ethanediol	diuretic	hypertension

torasemide; torsemide; JDL 464; BM 02015; AC 4464; GJ 1090; UNAT; PRESARIL; TORREM; TOREM; ZEMIDE; DEMADEX; TORADIUR; DIURESIX; LUPRAC	N-[[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide	diuretic	hypertension; heart failure
telmisartan + hydrochlorothiazide; hydrochlorothiazide + telmisartan	Unspecified	diuretic; angiotensin II antagonist	hypertension
MCC 134	1-[4-(1H-imidazol-1-yl)benzoyl]-N-methylcyclobutanecarbothioamide	diuretic; potassium channel activator	hypertension
quinelorane; quinelorane hydrochloride; LY 163502	(5aR-trans)-5,5a,6,7,8,9,9a,10-octahydro-6-propylpyrido[2,3-g]quinazolin-2-amine	dopamine agonist	Parkinson disease; hyperprolactinemia; hypertension
RD 211; (+-)-RD 211	2-(dipropylamino)-2,3-dihydro-5-methyl-1H-inden-4-ol	dopamine agonist	hypertension
Z 15040	Unspecified	dopamine agonist	hypertension
A 68930	(1R,3S)-1-aminomethyl-5,6-dihydroxy-3-phenylisochroman	dopamine agonist; dopamine D1 agonist	hypertension; Parkinson disease
SKF-R 106114	ethylcarbamic acid, (R)-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepin-7,8-diyl ester monohydrochloride	dopamine agonist; dopamine D1 agonist	hypertension
Z 1046	((S)-6[[6[[2-(methoxyphenoxy)ethyl]amino]propylamino]5,6,7,8-tetrahydro-1,2-naphtholenediol dihydrochloride	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist; vasodilator	hypertension



E 4010	4-[[[(3-chloro-4-methoxyphenyl)methylamino]-1-(4-hydroxy-1-piperidinyl)-6-phthalazinecarbonitrile monohydrochloride	dopamine agonist; dopamine D1 agonist; phosphodiesterase inhibitor; phosphodiesterase V inhibitor	pulmonary hypertension; sexual dysfunction
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenol)-1H-3-benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
carmoxirole; EMD 45609	3-[4-[3,6-dihydro-4-phenyl-1(2H)-pyridinyl]butyl]-1H-indole-5-carboxylic acid	dopamine agonist; dopamine D2 agonist	hypertension
ZK 112566	N'-[(3beta, 8alpha)-13-amino-2,3-dihydro-2,6-dimethyl-ergolin-8-yl]-N,N-dimethylurea	dopamine agonist; dopamine D2 agonist; alpha adrenergic antagonist; alpha2 adrenergic antagonist; vasodilator	hypertension
fosopamine; SIM 2055; Z 2055	4-[2-(methylamino)ethyl]-1,2-benzenediol 1-(dihydrogenphosphate)	dopamine agonist; vasodilator	hypertension
MDL 43925	Unspecified	dopamine beta monooxygenase inhibitor	hypertension
endothelin A antagonist	Unspecified	endothelin A antagonist; endothelin antagonist	hypertension; kidney disease
FR 139317; FK 139317	N-[N-[N-[(hexahydro-1H-azepin-1-yl)carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-D-alanine	endothelin A antagonist; endothelin antagonist	hypertension; ischemia

SB 209670	(+)-(1S,2R,3S)-3[2-(carboxymethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-propoxyindane-2-carboxylic acid	endothelin A antagonist; endothelin antagonist	kidney disease; hypertension
TAK 044	cyclo[4-oxo-4 (4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl] disodium salt	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; peptide	hypertension; kidney disease; myocardial infarction; brain ischemia
BMS 182874	5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide	endothelin antagonist	hypertension
EMD 94246	N-2,1,3-benzothiadiazol-5-yl-5-(dimethylamino)-1-naphthalenesulfonamide, potassium salt	endothelin antagonist	hypertension
endothelin antagonists	Unspecified	endothelin antagonist	hypertension
J 104132; L 753037	[5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl-5-(1,3-benzeodioxol-5-yl)-7-[(2-carboxypropyl)-4-methoxyphenyl]-6,6-dihydro-5H-cyclopenta[b]pyrindine-6-carboxylic acid	endothelin antagonist	hypertension
T 0115	Unspecified	endothelin antagonist	pulmonary hypertension

PD 156707; PD 156123	alpha-[2-(4-methoxyphenyl)-2-oxo-1-[(3,4,5-trimethoxyphenyl)methyl]ethylidene]1,3-benzodioxole-5-acetic acid sodium salt	endothelin antagonist; endothelin A antagonist	ischemia; reperfusion injury; pulmonary hypertension
SB 247083	Unspecified	endothelin antagonist; endothelin A antagonist	pulmonary hypertension
YM 598	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-2-phenylthioethanesulfonamide	endothelin antagonist; endothelin A antagonist	hypertension
ecadotril; sinorphan; BP 1.02; BAY y 7432; S 049; BP 102	(S)-N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]glycine phenyl methyl ester	enkephalinase inhibitor	hypertension; heart failure; cirrhosis
LY 203647	1-[2-hydroxy-3-propyl-4-[4-[2-[4-(1H-tetrazol-5-yl)butyl]-2H-tetrazol-5-yl]butoxy]phenyl]ethanone	leukotriene D4 antagonist; leukotriene antagonist	hypertension; asthma
omapatrilat; BMS 186716	[4S-[4alpha(R*),7alpha,10beta]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid	matrix metalloproteinase inhibitor; ACE inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
mineralocorticoid antagonists	Unspecified	mineralocorticoid antagonist	hypertension
cardiovascular disease therapy	Unspecified	Myosin motor filaments; actin filaments	hypertension; heart failure
AXC 0216	Unspecified	neuropeptide Y antagonist	obesity; hypertension

AXC 1829	Unspecified	neuropeptide Y antagonist	obesity; hypertension
neuropeptide Y antagonist, Alanex	Unspecified	neuropeptide Y antagonist	obesity; hypertension
SR 120819A	[alpha R-[N[R*(cis)],alpha R*]]-N-[1-[[4-[[[4-[(dimethylamino)methyl]cyclohexyl)methyl]amino]iminomethyl]phenyl]methyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-alpha-[(2-naphthalenylsulfonyl)amino]benzenepropanamide	neuropeptide Y antagonist; neuropeptide Y1 antagonist	hypertension; obesity; eating disorder
SC 3117	N,N'-bis-[2-N-(o-2,6-dichlorobenzyl-L-tyrosyl)aminoethylguanidyl]cystamine	neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypertension
drug delivery system, TheraDerm-MTX transdermal clonidine; clonidine TheraDerm-MTX	Unspecified	Neurotransmitter modulation	hypertension
CGS 24128	N-[3-[1,1'-biphenyl]-4-yl-N-(phosphonomethyl)alaninyl]beta-alanine	neutral endopeptidase inhibitor	hypertension
CGS 24592	N-[3-[1,1'-biphenyl]-4-yl-N-(phosphonomethyl)-L-alaninyl]beta-alanine	neutral endopeptidase inhibitor	hypertension
CGS 25155	[2S-[2R*(trans),9S*]]-1-[[9-[(acetylthio)methyl]decahydro-10-oxo-2-azeciny]carbonyl]-4-hydroxy-L-proline phenylmethyl ester	neutral endopeptidase inhibitor	hypertension

CGS 25462	N-[3-[1,1'-biphenyl]-4-yl-N-[(diphenoxyphosphinyl)methyl]-L-alanyl]-beta-alanine	neutral endopeptidase inhibitor	hypertension
SCH 39370	[S-(R*,R*)]-N-[N-(1-carboxy-3-phenylpropyl)-L-phenylalanyl]-2-hydroxy-beta-alanine	neutral endopeptidase inhibitor	hypertension
SCH 42495	N-[2(S)-acetylthiomethyl-3-(2-methylphenyl)-propanoyl-L-methionine ethyl ester]	neutral endopeptidase inhibitor	hypertension
SQ 29072	7-[[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]amino]heptanoic acid	neutral endopeptidase inhibitor	hypertension
SA 7060	[S-(R*,R*)]-alpha-[[[(3-butoxy-2-hydroxy-3-oxopropyl)(2-methylpropyl)amino]carbonyl]amino]-2-naphthalenepropanoic acid	neutral endopeptidase inhibitor; ACE inhibitor	heart failure; hypertension
SCH 50690	Unspecified	neutral endopeptidase inhibitor; ACE inhibitor	hypertension; heart failure
SQ 28603	N-[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-beta-alanine	neutral endopeptidase inhibitor; diuretic	hypertension
PF 9404	Unspecified	nitrate	angina; hypertension
NCX 900	Unspecified	nitric oxide donor; NSAID	pulmonary hypertension
GEA 3175	Unspecified	nitric oxide donor; vasodilator	angina; hypertension
antihypertensive agent	Unspecified	Noradrenergic release inhibitor	hypertension
LA 213	Unspecified	PAF antagonist; peptide; platelet antiaggregant	hypertension; thrombosis

LA 228	Unspecified	peptide	hypertension
LA 230	Unspecified	peptide	hypertension; hyperlipidemia
LA 231	Unspecified	peptide	hypertension
SNAP 1156	Unspecified	peptide	anxiety; hypertension; obesity; addiction
CGS 19281A	Unspecified	phenylethanolamine N methyl transferase inhibitor	hypertension
KT 2734	2-phenyl-8- ethoxycycloheptimida zole	phosphodiesterase inhibitor	hypertension
SCH 59498	Unspecified	phosphodiesterase inhibitor; phosphodiesterase I inhibitor; phosphodiesterase V inhibitor	hypertension
E 4021; ER 21355	1-[4[(1,3- benzodioxol-5- ylmethyl)amino]-6- chloro-2- quinazolinyl]-4- piperidinecarboxylic acid, monosodium salt	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	hypertension; angina; heart failure
BF 385; GP 385; BF/GP 385; ONO BF11301; ONO 1505	Unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	hypertension; thrombosis
epoprostenol; epoprostenol sodium; prostacyclin; prostaglandin X; prostaglandin I2; vasocyclin; UN 53217A; U 53217; FLOLAN; CYCLO- PROSTIN	(5Z,9alpha,11alpha,1 3E,15S)-6,9-epoxy- 11,15- dihydroxyprosta-5,13- dien-1-oic acid	platelet antiaggregant; vasodilator; prostanoid	pulmonary hypertension; thrombosis

diethylhomospermine; DEHOP; DE 444	N,N'-bis[4-(ethylamino)butyl]-1,4-butanediamine	polyamine analogue	diarrhea; hypertension; cancer; psoriasis; ulcerative colitis
AL 0670	(+)-N-(6-amino-3-pyridyl)-N'-[(1S,2R,4R)-bicyclo[2.2.1]hept-2-yl]-N"-cyanoguanidine	potassium channel activator	hypertension
AL 0671	(1S-endo)-N-(6-amino-3-pyridinyl)-N'-bicyclo[2.2.1]hept-2-yl-N"-cyanoguanidine	potassium channel activator	hyperlipidemia; hypertension
KC 515	N-(2-cyanoethyl)-2,2-bis(fluoromethyl)-6-(pentafluoroethyl)-2H-1-benzopyran-4-carboxamide.	potassium channel activator	hypertension
KP 403	6-cyano-2,2-dimethyl-4-[(N-cyano-acetoimidoyl)amino]-2H-benzo[b]pyran	potassium channel activator	hypertension
KP 4603	Unspecified	potassium channel activator	hypertension
KRN 4884	5-amino-N-[2-(2-chlorophenyl)ethyl]-N'-cyano-3-pyridinecarboximide	potassium channel activator	hypertension
levcromakalim; lemakalim; cromakalim, (-); BRL 38227; BRL 34915; BRL 38226; LEVANEX	(3S,4R)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator	hypertension
NIP 121	trans-(+)-1-(7,8-dihydro-7-hydroxy-6,6-dimethyl-6H-pyrano[2,3-f]-2,1,3-benzoxadiazol-8-yl)-2-piperidinone	potassium channel activator	hypertension

RP 49356	tetrahydro-N-methyl-2-(3-pyridinyl)-2H-thiopyran-2-carbothioamide 1-oxide	potassium channel activator	hypertension
RWJ 26629	trans-(+,-)-1-(6,7-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-5H-thieno[3,2-b]pyran-7-yl)-2-piperidinone	potassium channel activator	hypertension
SKP 450; KR 30450	(R)-1-[2-(1,3-dioxolan-2-yl)-2-methyl-6-nitro-2H-1-benzopyran-4-yl]-2-pyrrolidinone	potassium channel activator	hypertension; heart ischemia
TAK 636	Unspecified	potassium channel activator	hypertension; angina
TCV 295	2-(6-bromo-7-chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine N-oxide	potassium channel activator	hypertension
UR 8218	Unspecified	potassium channel activator	hypertension
UR 8267	Unspecified	potassium channel activator	hypertension
Y 27152	(3S,trans)-N-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N-(phenylmethoxy)acetamide	potassium channel activator	hypertension; angina
CL 891902	Unspecified	potassium channel activator; bronchodilator	asthma; hypertension
emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease



potassium channel activator	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
Ro 316930	2,2-dimethyl-4-(2-pyridinyl)-2H-1-benzopyran-6-carbonitrile N4-oxide	potassium channel activator; bronchodilator	hypertension; asthma
SCA 40	6-bromo-8-(methylamino)-imidazo[1,2-a]pyrazine-2-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma
symakalim; EMD 57283	4-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; coronary artery disease; asthma
UR 8225	1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
YM 934	3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-2H-1,4-benzoxazine N-oxide	potassium channel activator; bronchodilator	hypertension; asthma; urinary incontinence
celikalim; WAY 120491	(3S-trans)-2-[3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-2H-1-benzopyran-4-yl]-2,3-dihydro-1H-isoindol-1-one	potassium channel activator; vasodilator	hypertension

DY 9708	[1R-[1 alpha,2(3S*,4R*),6al pha]]-3,4-dihydro-3- hydroxy-2,2-dimethy l-4-[(5-oxo-3,4- diazabicyclo[4.1.0]he pt-2-en-2-yl)oxy]-2H- 1-benzopyran-6- carbonitrile	potassium channel activator; vasodilator	hypertension; angina
pinacidil; P 1134; PINDACIL; PINDAL; PINDAC; THERAPRESS	N-cyano-N'-(4- pyridinyl)-N''-(1,2,2- trimethylpropyl)guani dine	potassium channel blocker	hypertension
U 37883A	N-cyclohexyl-N'- tricyclo[3.3.1.1 <sup>3,7</sup> ]de c-1-yl-4- morpholinecarboximi damide monohydrochloride	potassium channel blocker	hypertension
CL 115999	(9alfa,11alfa,13E)- 6,9-epoxy-16-ethenyl- 11,16-dihydroxy-5- iodoprost-13-en-1-oic acid methyl ester	prostanoid	hypertension
beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro- 2-hydroxy-1-(3- hydroxy-4-methyl-1- octen-6-ynyl)-1H- cyclopenta[b]benzofu ran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
ZK 110841	[1R- [1alfa(Z),2beta(1E,3S *),3alfa,5beta]]-7-[5- chloro-2-(3- cyclohexyl-3- hydroxy-1-propenyl)- 3- hydroxycyclopenyl]- 5-heptenoic acid	prostanoid; platelet antiaggregant	glaucoma; hypertension; thrombosis

ZK 118182	[1R-[1alpha(Z),2beta(1E,3S*),3alpha,5alpha]]-[[4-[5-chloro-2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxycyclopentyl]-2-butenyl]oxy]acetic acid	prostanoid; platelet antiaggregant	thrombosis; hypertension
UT 15	Unspecified	prostanoid; vasodilator	pulmonary hypertension
alprostadi; lipo-prostaglandin E1; lipo-PGE1; U 10136; PGE1; CAVERJECT; PALUX; LIPL; PROSTIN; EDEX; MUSE	(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid	prostanoid; vasodilator; cicatrizant	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss
Y 27632	[4(R)-trans]-4-(1-aminoethyl)-N-4-pyridinylcyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
staurosporine; (+)-staurosporine; staurosporin; antibiotic 230; AM 2282	(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor	hypertension
SCH 34826	N-[N-[2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-oxo-1-(phenylmethyl)ethyl]-L-phenylalanyl]-beta-alanine	proteinase inhibitor; analgesic	pain; hypertension

A 62198	5-azido-1-cyclohexyl-1,2,5-trideoxy-2-[[[N[N-(2-methyl-1-oxopropyl)-L-phenylalanyl]-L-histidyl]amino-L-arabinitol	proteinase inhibitor; renin inhibitor	hypertension
A 65317	[5S-[5R*[1R*[R*(S*)],2S*]]-N1-[2-[[1-(cyclohexylmethyl)-2-(3-ethyl-2-oxo-5-oxazolidinyl)-2-hydroxyethyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]-N4-[2-[(2-methoxyethoxy)methoxy]ethyl]-N4-methyl-2-(phenylmethyl)butane diamide	proteinase inhibitor; renin inhibitor	hypertension
A 74273	[alphaS-[alphaR*,gammaR*,deltaR*[R*(R*)]]]-gamma-hydroxy-delta-[[2-[2-[4-(methoxymethoxy)-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethoxy]-1-oxohexyl]amino]-alpha-(1-methylethyl)-N-[3-(4-morpholinyl)propyl]cyclohexanehexanamide	proteinase inhibitor; renin inhibitor	hypertension
BW B633C	N-((2Rs,3S)-3-(L-histidyl-L-prolyl-L-phenylalanyl-L-histidyl)-amino-2-hydroxy-5-methylhexyl)-L-valyl-L-isoleucyl-L-phenylalanine methyl ester hemiacetate	proteinase inhibitor; renin inhibitor	hypertension

CG 38560	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
CGP 60536B; CGS 60536	[alphaS-(alphaR*,gammaR*,deltaR*,zetaR*)]-delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)benzenoetanamide	proteinase inhibitor; renin inhibitor	hypertension
CI 992; PD 134672	[1S-(1R*,2S*,3R*)]-N-(4-morpholinylsulfonyl)-L-phenylalanyl-3-(2-amino-4-thiazolyl)-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-L-alaninamide	proteinase inhibitor; renin inhibitor	hypertension
ciprokiren; Ro 449375	[1S-[1R*[R*(R*)],2S*,3R*]]-N-[1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-.alpha.-[[2-[[[1,1-dimethyl-2-(4-morpholinyl)-2-oxoethyl]sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-1H-imidazole-4-propanamide	proteinase inhibitor; renin inhibitor	hypertension

CP 71362	[2R-(2R*,4S*,5S*)]-N-[N2-[6-cyclohexyl-5-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-4-hydroxy-2-(2-methylpropyl)-1-oxohexyl]-L-lysyl]-L-phenylalanine	proteinase inhibitor; renin inhibitor	hypertension
ditckiren; U 71038	[1S-[1R*,2R*,4R*(1R*,2R*)]]-1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-L-phenylalanyl-N-[2-hydroxy-5-methyl-1-(2-methylpropyl)-4-[[[2-methyl-1-[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-N-alpha-methyl-L-histidinamide	proteinase inhibitor; renin inhibitor	hypertension
EMD 56133	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
enalkiren; A 64662	[1S-(1R*,2S*,3R*)]-N-(3-amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-L-histidinamide	proteinase inhibitor; renin inhibitor	hypertension; glaucoma

ES 6864	[S-(R*,S*)]-5-cyclohexyl-2,4,5-trideoxy-N-[2-(4-morpholinyl)ethyl]-4-[[2-[[4-(4-morpholinyl)-2-(1-naphthalenylmethyl)-1,4-dioxobutyl]amino]-1-oxo-3-(4-thiazolyl)propyl]amino]-L-threo-pentonamide	proteinase inhibitor; renin inhibitor	hypertension
ES 8891	5-cyclohexyl-2,4,5-trideoxy-N-hexyl-4-[[N-[3-(1-naphthalenyl)-N-(4-morpholinylacetyl)-L-alanyl]-3-(4-thiazolyl)-L-alanyl]amino]-L-threo-pentonamide	proteinase inhibitor; renin inhibitor	hypertension
FK 906; FR 115906	N-methyl-N-[2(S)-[N-methyl-N-[2-[N-methyl-N-(morpholinocarbonyl)amino]ethyl]carbamoxyloxy]-3-phenylpropionyl]-L-histidine 1(S)-(cyclohexylmethyl)-2(S)-hydroxy-5-methylhexylamide hydrochloride	proteinase inhibitor; renin inhibitor	hypertension
ICI 213878	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
ICI 219623	Unspecified	proteinase inhibitor; renin inhibitor	hypertension

KRI 1314	[alfaR-[alfaR*,betaS*[S*(R* ))]]-alfa-hydroxy- beta-[[3-(1H- imidazol-4-yl)-2-[[4- (4-morpholinyl)-2-(1- naphthalenylmethyl)- 1,4- dioxobutyl]amino]-1- oxopropyl]amino]cycl ohexanebutanoic acid 1-methylethyl ester	proteinase inhibitor; renin inhibitor	hypertension
PD 132002	[1S-(1R*,2S*,3R*)]- N-(4- morpholinylsulfonyl)- L-phenylalanyl-N-[1- (cyclohexylmethyl)- 2,3-dihydroxy-5- methylhexyl]-O- methyl-3-oxo-DL- serinamide	proteinase inhibitor; renin inhibitor	hypertension
remikiren; Ro 425892	[1S- [1R*[R*(R*)],2S*,3R* *]]-N-[1- (cyclohexylmethyl)-3- cyclopropyl-2,3- dihydroxypropyl]- alfa-[[2-[[[(1,1- dimethylethyl)sulfony l]methyl]-1-oxo-3- phenylpropyl]amino]- 1H-imidazole-4- propanamide	proteinase inhibitor; renin inhibitor	hypertension



renin inhibitor	[1S-[1R*,2S*,4S*(1R*,2R*)]-[4-[[[1-(cyclohexylmethyl)-2-hydroxy-4-[(2-methylpropyl)amino]carbonyl]-4-pentenyl]amino]carbonyl]-2-hydroxy-1-(phenylmethyl)-nonenyl]-carbamic acid, 1,1-dimethylethyl ester.	proteinase inhibitor; renin inhibitor	hypertension
renin inhibitor	isopropyl (2R,3S)-3-((N-((2R)-3-(morpholino-carbonyl)-2-(1-naphthylmethyl)propionyl)-L-histidyl)-amino)-4-cyclohexyl-2-hydroxybutyrate	proteinase inhibitor; renin inhibitor	hypertension
RPEP 27	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
S 2864	N-[N-(3-(4-amino-1-piperidinyl-carbonyl)-2(R)-benzylpropionyl)-L-histidinyl]- (2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6(2-pyridyl)-2-hexylamide-acetate	proteinase inhibitor; renin inhibitor	hypertension
SC 45075	[R-(R*,S*)]-N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxypropyl]-L-leucinamide	proteinase inhibitor; renin inhibitor	hypertension

SC 46944	4-morpholinecarboxylic acid, [1S-[1R*[R*(R*)],2S*,3R*]-2-[[1-[[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]amino]carbonyl]-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl ester	proteinase inhibitor; renin inhibitor	hypertension
SC 56525	N2-[2(S)-benzyl-3-(4-methylpiperazin-1-ylsulfonyl)propionyl]-N1-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-2(S)-(2-propynyl)glycinamide	proteinase inhibitor; renin inhibitor	hypertension
SQ 33800	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
SQ 34017	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
U 70714E	(S)-N-[2-[[N-[N-[1-(N-acetyl-1-formyl-L-tryptophyl)-L-prolyl]-L-phenylalanyl]-L-histidyl]amino]-3-phenylpropyl]-L-phenylalanyl-L-valyl-L-tyrosinamide	proteinase inhibitor; renin inhibitor	hypertension

zankiren; zankiren hydrochloride; A 72517;	[1S- [1R*[R*(R*)],2S*,3R *]]-N-[1- (cyclohexylmethyl)- 2,3-dihydroxy-5- methylhexyl]-alfa- [[2-[[[(4-methyl-1- piperazinyl)sulfonyl] methyl]-1-oxo-3- phenylpropyl]amino]- 4- thiazolepropanamide	proteinase inhibitor; renin inhibitor	hypertension
cyclothiazomycin	cyclothiazomycin	proteinase inhibitor; renin inhibitor; antibiotic	hypertension
ES 1005	[1S- [1R*(R*),2R*,4[R*( R*)]]]-N-[4-[[1-[[[(5- amino-6- hydroxyhexyl)amino] carbonyl]-3- methylbutyl]amino]- 2-hydroxy-1-(2- methylpropyl)-4- oxobutyl]-alfa-[[3-(1- naphthalenyl)-2-(1- naphthalenylmethyl)- 1-oxopropyl]amino]- 1H-imidazole-4- propanamide dihydrochloride	proteinase inhibitor; renin inhibitor; peptide	hypertension
terlakiren; CP 80794	[R-(R*,S*)]-N-(4- morpholinylcarbonyl)- L-phenylalanyl-N-[1- (cyclohexylmethyl)-2- hydroxy-3-(1- methylethoxy)-3- oxopropyl]-S-methyl- L-cysteineamide	proteinase inhibitor; renin inhibitor; peptide	hypertension

KB 5246	6-fluoro-5-(4-methyl-1-piperazinyl)-8-oxo-3H,8H-4-oxa-1-thia-9b-azacyclopenta[cd]phenalene-9-carboxylic acid monohydrochloride	quinolone; antibiotic	cancer; pruritis; hypertension; HIV infection; gastrointestinal ulcer; hyperlipidemia; bacterial infection
renin inhibitor	Unspecified	renin inhibitor; proteinase inhibitor	hypertension
U 75875	(1(1S,2S),5(S))-6-cyclohexyl-2,5,6-trideoxy-5-((3-(1H-imidazol-4-yl)-2-((1-naphthalenyloxy)acetyl)amino)-1-oxopropyl)amino)-2-(1-methylethyl)-N-(2-methyl-1-((1-pyridinylmethyl)amino)carbonyl)butyl,-L-idonamide	renin inhibitor; proteinase inhibitor; HIV proteinase inhibitor	hypertension; HIV infection
BIBU 308; DTTX 30	cis-2-[[[2-(hydroxyamino)-2-oxoethyl]methylamino]carbonyl]cyclohexanecarboxylic acid	thromboxane antagonist; platelet antiaggregant	pulmonary hypertension; peripheral vascular disease
terbogrel; BIBV 308 SE	(5E)-6-[3-[[[(cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-5-hexenoic acid	thromboxane antagonist; thromboxane synthase inhibitor	pulmonary hypertension; peripheral vascular disease
AIT 111	unspecified	Unspecified	angina; arrhythmia; hypertension
laennec	human placenta hydrolysate	Unspecified	hypertension; liver disease
S 8666	6,7-dichloro-5-[[[(dimethylamino)sulfonyl]-2,3-dihydro-2-benzofurancarboxylic acid	uricosuric; diuretic	hypertension; gout
vaccine, angiotensin, vaccine, hypertension	Unspecified	vaccine	hypertension

LP 805	8-tert-butyl-6,7-dihydropyrrolo[3,2-e]-5-methylpyrazolo[1,5a]pyrimidine-3-carbonitrile	vasodilator	hypertension; angina
MER A2026A; Mer-A 2026A	2-(10-hydroxy-3,7,9,11,13-pentamethyl-2,5,7,11-tetradecatetraenyl)-6-methoxy-3-methyl-4-pyridinol	vasodilator	hypertension
MER A2026B; Mer-A 2026B	2-(10-hydroxy-3,7,9,11-tetramethyl-2,5,7,11-tridecatetraenyl)-6-methoxy-3-methyl-4-pyridinol	vasodilator	hypertension
metipamide	3-(aminosulfonyl)-4-chlorobenzoic acid 2-methyl-2-phenylhydrazide	vasodilator	hypertension
NY 008	3-octyl-1(3H)-isobenzofuranone	vasodilator	hypertension
U 92352	N-cyano-N'-(3,4-dichlorobenzyl)-N''-(4-pyridinyl)guanidine	vasodilator	hypertension
vasodilator	N-(2,3-dihydro-6,7-dimethoxy-1-methyl-3-oxo-4-isoquinolinyl)-N'-2-propenyl-urea	vasodilator	hypertension
phentolamine mesilate; phentolamine mesylate; VASOMAX; Z-MAX; VASOFEM	3-[[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol	vasodilator; alpha adrenergic antagonist; muscle relaxant	sexual dysfunction; hypertension
prostanit	Unspecified	vasodilator; prostaglandin agonist	hypertension

SKF 105494	O-ethyl-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-5-[1-(carboxymethyl)cyclohexyl]-L-norvalyl-L-arginyl-D-argininamide cyclic (5->1)peptide	vasopressin antagonist	hypertension
OPC 21268	1-[1-[4-(3-acetylaminopropoxy)benzoyl]-4-piperidyl]-3,4-dihydro-2(1H)-quinolinone	vasopressin antagonist; diuretic	hypertension; heart failure
SR 121463	cis-N-(1,1-dimethylethyl)-4-[[5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy-benzamide (E)-2-butenedioate (1:1)	vasopressin antagonist; diuretic	heart failure; hypertension
SR 49059	[2R-[2alpha(S*),3beta]]-1-[[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide	vasopressin antagonist; diuretic	gynecological; cancer; hypertension; heart failure; emesis

Table 61. Current Candidate Therapeutic Interventions for the Treatment of Hypotension

Product Name	Chemical Name	Action	Indication
ICI D4398; ZM 241385	4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol	adenosine antagonist; adenosine A2 antagonist	peripheral vascular disease; hypotension

midodrine; midodrine hydrochloride; A 4020 LINZ; St Peter 224; St 1085; METLIGENE; MIDON; GUTRON; AMATINE; MIDAMINE; ProAmatine; HYPERTAN; MIDRON; NATILDINE; SHUPRASE OHARA	(+,-)-2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide	alpha adrenergic agonist	hypotension; urinary incontinence; sexual dysfunction
M 6434	2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole	alpha adrenergic agonist; alpha1 adrenergic agonist; imidazole	anaphylactic shock; hypotension
atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety
PCA 50941	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)ethyl(tetrahydro-2H-pyran-2-yl)methyl ester	calcium agonist	hypotension; anaphylactic shock
FPL 64176	2,5-dimethyl-4-[2-(phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylic acid methyl ester	Calcium channel activator	hypotension
arginase	Arginase	enzyme depletion of arginine leading to reduction of NO leading to increase in BP	hypotension

neuropeptide Y antagonists	unspecified	neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypotension; obesity; depression
hemoglobin-based scavenger; ENDOGLOBIN-HT; ENDOGLOBIN-CT	unspecified	nitric oxide scavenger	hypotension; cancer
hemoglobin-based therapy	unspecified	nitric oxide scavenger	cancer; hypotension; septic shock
pyridoxylated hemoglobin polyoxyethylene conjugate; PHP-HT; PHP-CT	pyridoxylated hemoglobin	nitric oxide scavenger	cancer; hypotension; septic shock
nitric oxide modulators	unspecified	NSAID	hypotension; cancer; rheumatoid arthritis
BN 50739	6-(2-chlorophenyl)-9-[2-[(3,4-dimethoxyphenyl)thio]-1-thioxoethyl]-7,8,9,10-tetrahydro-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist	hypotension; septic shock; stroke
rocepaftant; BN 50730	6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-9(8H)-carbothioamide	PAF antagonist	hypotension; cytoprotectant; asthma
ARGINON-HT	Arginine-free amino acid product	Peptide induced increase of blood pressure	hypotension



amezinium metilsulfate; amezinium methysulfate; LU 1631; RISUMIC; REGULTON; TENFORTAN; CROVARIL; SUPRATONIN	4-amino-6-methoxy- 1-phenylpyridazinium methyl sulfate	Sympathomimetic	hypotension
INO 4743	unspecified	sympathomimetic	hypotension
INO 5042	unspecified	sympathomimetic	hypotension

Table 62. Current Candidate Therapeutic Interventions for the Treatment of Myocardial Ischemia

Product Name	Chemical Name	Action	Indication
CM 57493	3,6-dihydro-4-[3-(trifluoromethyl)phenyl]-1(2H)-pyridinepropanenitrile	5HT agonist; 5HT1 agonist	ischemia
ITF 1570	Salicylester	5HT1A and bradykinin receptor ligands	peripheral vascular disease; cerebrovascular disease; heart ischemia
adenosine A3 agonists	unspecified	adenosine A3 agonist; anti-ischemic; adenosine agonist	ischemia; myocardial infarction
adenosine agonists	unspecified	adenosine agonist	ischemia
GP 3521	unspecified	adenosine regulating agent	ischemia
adenosine regulating agents, ischemia	unspecified	adenosine regulating agent; anti-ischemic	ischemia
GP 531	5-amino-1-[5-deoxy-5-[phenylmethyl)amino]-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; anti-ischemic	ischemia; thrombosis
acadesine; AICA-riboside; AR 100; GP 1110; GP 11100; ARASINE; PROTARA	5-amino-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; platelet antiaggregant; anti-ischemic	cardiovascular disease; thrombosis; ischemia

mivazerol; UCB 22073	2-hydroxy-3-(1H-imidazol-4-ylmethyl)benzamide	alpha adrenergic agonist; alpha2 adrenergic agonist	ischemia
LY 293558	[3S-(3alpha,4aalpha,6beta,8aalpha)]-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid	AMPA antagonist; glutamate antagonist	heart ischemia; epilepsy
prasterone; dehydroepiandrosterone; DHEA; GL 701; NBI 106; PB 007; ASTENILE; DEANDROS; DIANDRON	(3beta)-3-hydroxyandrost-5-en-17-one	androgen; vaccine adjuvant; hormone replacement therapy; corticosteroid	systemic lupus erythematosus; hormone deficiency; Alzheimer disease; reperfusion injury; ischemia
vascular endothelial growth factor B; AM 133	unspecified	angiogenesis inducer	coronary artery disease; ischemia
Del-1 angiogenic protein based therapies	unspecified	angiogenesis inhibitor; angiogenesis inducer	cancer; ischemia; restenosis
hypoxia therapy	unspecified	antihypoxic	heart ischemia; stroke
AMP deaminase inhibitors	unspecified	anti-ischemic	ischemia
FR 76830	2-methyl-N-(2-(4-morpholinyl)ethyl)-4-(3-nitrophenyl)-6-phenyl-3-pyridinecarboxamide	anti-ischemic	ischemia
TEI 2306	gamma-L-glutamyl-L-cysteine ethyl ester	anti-ischemic	heart ischemia; reperfusion injury
ST 520	(R)-N,N,N-trimethyl-4-oxo-2-(1-oxopropoxy)-4-[(2-sulfoethyl)amino]-1-butanaminium inner salt	Antiischemic agent	ischemia
SM 20550	N-(aminoiminomethyl)-1,4-dimethyl-1H-indole-2-carboxamide monomethanesulfonate	anti-ischemic; sodium/hydrogen exchange inhibitor	heart ischemia; reperfusion injury

delphinidin; ephdine; delphinidol; delfinidol; delphinidine; delphinidin chloride; IDB 1056	3,5,7-trihydroxy-2- (3,4,5- trihydroxyphenyl)-1- benzopyrilium chloride	antioxidant; free radical scavenger	ischemia
LXR 015; LXR 015- 2; ELIREX	Unspecified	apoptosis inhibitor	reperfusion injury; heart ischemia; ischemia
LXR 017	unspecified	apoptosis inhibitor	heart ischemia
LXR 1035	unspecified	apoptosis inhibitor	ischemia; heart ischemia
bak; cell death inhibitor-1; Cdi-1	unspecified	apoptosis inhibitor; chemoprotectant; cytoprotectant; gene	heart ischemia; ischemia; reperfusion injury
MAB, C5 single chain; MAB, complement C5; 5G1.1-SC	unspecified	biotechnology; complement inhibitor; monoclonal antibody; NSAID	inflammation; myocardial infarction; stroke; ischemia
sudismase; superoxide dismutase copper zinc complex; CuZnSOD; OxSODrol	N-acetylsuperoxide dismutase (human clone pS 61-10 copper-zinc subunit protein moiety reduced)	biotechnology; free radical scavenger; NSAID	respiratory disease; ischemia; rheumatoid arthritis; inflammation
F 3226	3-[3-[[2-(3,4- dimethoxyphenyl)eth yl]methylamino]prop yl]-2,3-dihydro-6,7- dimethoxy-4H-1,3- benzoxazin-4-one	calcium antagonist	ischemia
K 201	2,3,4,5-tetrahydro-7- methoxy-4-[1-oxo-3- [4-(phenylmethyl)-1- piperidiny]propyl]- 1,4-benzothiazepine	calcium antagonist	ischemia
KP 840	diethyl 1,4-dihydro 2,6-dimethyl-4-(3- ethynyl phenyl)-3,5- pyridine-dicarboxylic acid	calcium antagonist	ischemia; depression

R 56865	N-[1-[4-(4-fluorophenoxy)-butyl]-4-piperidinyl]-N-methyl-2-benzothiazolamine	calcium antagonist	ischemia
SQ 31486	(3R-cis)-3-(acetyloxy)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-7-(trifluoromethyl)-2H-1-benzazepin-2-one monohydrochloride	calcium antagonist	ischemia
barnidipine; mepirodipine; YM 09730; YM 097305; YM 730; HYPOCA; OLDECA	[S-(R*,R*)]-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-pyrrolidinyl ester	calcium antagonist; vasodilator	hypertension; ischemia
CP 060S	(S)-3-[3-[[2-(1,3-benzodioxol-5-yl)oxy]ethyl]methylamino]propyl]-2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-thiazolidinone (E)-2-butenedioate (1:1)	calcium channel blocker	heart ischemia; angina
DP 16	Acylglycerol derivative of BAPTA	Calcium chelator	epilepsy; stroke; heart ischemia
thiazohalostatin	4,5-dihydro-2-[8-hydroxy-1,3,5-trimethyl-6-oxo-8-(3,4,5-trichloro-1H-pyrrol-2-yl)-7-octenyl]-4-methyl-4-thiazolecarboxylic acid	Calcium overload-induced death inhibition	ischemia
FCE 24265	diethyl-1-,4-dihydro-2,6-dimethyl-4-(3-(1H-imidazol-1-yl)-phenyl)-pyridine-3,5-dicarboxylate	calcium synthetase inhibitor; thromboxane synthetase inhibitor	ischemia

LNF 209	(3beta,5beta,14beta,17beta)-14-amino-3-[[6-deoxy-alfa-L-mannopyranosyl)oxy]androstane-17-carboxylic acid methyl ester hydrochloride	cardiac glycoside	ischemia
R 59494	N-methyl-N-(1-(4-phenoxybutyl)-3-pyrrolidinyl)-2-benzothiazolamine	cardiac glycoside	ischemia
PERFUSOL; MYOSOL	unspecified	chelating agent	trauma; ischemia; reperfusion injury
LY 178002	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylenelene]-4-thiazolidinone	COX inhibitor; 5-lipoxygenase inhibitor; NSAID	inflammation; ischemia
FR 139317; FK 139317	N-[N-[N-[(hexahydro-1H-azepin-1-yl)carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-D-alanine	endothelin A antagonist; endothelin antagonist	hypertension; ischemia
L 749329	4-[1-(1,3-benzodioxol-5-yl)-2-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-oxoethoxy]-3-propylbenzoic acid	endothelin A antagonist; endothelin antagonist	ischemia; reperfusion injury
PD 159433	unspecified	endothelin A antagonist; endothelin antagonist	cardiovascular disease; brain ischemia
TAK 044	cyclo[4-oxo-4 (4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl]disodium salt	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; peptide	hypertension; kidney disease; myocardial infarction; brain ischemia

endothelin antagonist	unspecified	endothelin antagonist	kidney disease; ischemia; inflammatory bowel disease; asthma
PD 156707; PD 156123	alpha-[2-(4-methoxyphenyl)-2-oxo-1-[(3,4,5-trimethoxyphenyl)methyl]ethylidene]1,3-benzodioxole-5-acetic acid sodium salt	endothelin antagonist; endothelin A antagonist	ischemia; reperfusion injury; pulmonary hypertension
TBC 11251; IPI 1251	N-(4-chloro-3-methyl-5-isoxazolyl)-2-[(6-methyl-1,3-benzodioxol-5-yl)acetyl]-3-thiophenesulfonamide	endothelin antagonist; endothelin A antagonist	heart failure; pulmonary obstructive disease; brain ischemia
DCC 9364	unspecified	free radical scavenger	ischemia
disulfiram; CPC 501; ANTABUSE	bis(diethylthiocarbamoyl)disulfide	free radical scavenger	alcoholism; heart ischemia
MDL 73404	3,4-dihydro-6-hydroxy-N,N,N,2,5,7,8-heptamethyl-2H-1-benzopyran-2-ethanaminium 4-methylbenzenesulfonate	free radical scavenger	ischemia
MDL 74270	6-(acetyloxy)-3,4-dihydro-N,N,N,2,5,7,8-heptamethyl-2H-1-benzopyran-2-ethanaminium 4-methylbenzenesulfonate	free radical scavenger	ischemia
pegorgotein; polyethylene glycol superoxide dismutase; PEG-SOD; superoxide dismutase macrogol; WIN 22118; PEG-SOD; DISMUTEC	unspecified	free radical scavenger	ischemia; reperfusion injury

superoxide dismutase, human; hSOD	unspecified	free radical scavenger	heart ischemia; reperfusion injury
YM 21170; Q 1047H-A; Q 1047H-A-A; Q 1047H-A-B	11-hydroxy-4,6,8,10-tetramethyl-2-azabicyclo[10.3.1]hexadeca-8,12,15-triene-3,5,14,16-tetrone stereoisomer	free radical scavenger	heart ischemia
superoxide dismutase B, manganese complex; Mn-SOD-B	unspecified	free radical scavenger; NSAID	ischemia; arthritis
superoxide dismutase manganese complex; hMNSOD	unspecified	free radical scavenger; NSAID; immunosuppressant	ischemia; rheumatoid arthritis; inflammation; reperfusion injury
glycoprotein IIb/IIIa antagonist, P246	unspecified	glycoprotein IIb/IIIa antagonist; peptide; platelet antiaggregant	thrombosis; heart ischemia; stroke
JP 7	unspecified	Hemoglobin allosteric modifier	cancer; surgery; heart ischemia; stroke
ribose; MGI 330	D-ribose	Hemoglobin allosteric modifier	heart ischemia; diagnosis
RSR 13	2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin allosteric modifier	surgery; heart ischemia; stroke
RSR 4	2-[4-[2-[(3,5-dichlorophenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin allosteric modifier	cancer; surgery; heart ischemia; stroke
RSR 46	2-[4-[2-[(2,3-dihydro-1H-inden-5-yl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin allosteric modifier	cancer; surgery; heart ischemia; stroke

monophosphoryl lipid A; TLC 3; RDE; MPL; MPL-C; MPL-S	2-deoxy-6-O-[2-deoxy-2-[[1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-3-O-[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-4-O-phosphono-beta-D-glucopyranosyl]-2-[(3-hydroxy-1-oxotetradecyl)amino]-alpha-D-glucopyranose 3-(3-hydroxytetradecanoate)	immunostimulant; vaccine adjuvant	heart ischemia; bacterial infection; infectious disease; reperfusion injury
soluble complement receptor type 1; sCR1; TP 10; TP 10HD; BRL 55730; YM 55730	unspecified	immunosuppressant; complement inhibitor	respiratory distress syndrome; heart ischemia; transplant rejection
MAb, E/P-selectin, humanized; MAb, SMART E/P-selectin	unspecified	integrin antagonist; biotechnology; monoclonal antibody; E selectin antagonist; P selectin antagonist; cell adhesion inhibitor	respiratory distress syndrome; ischemia; reperfusion injury
GM 1998	unspecified	integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; respiratory distress syndrome; heart ischemia; reperfusion injury
CEN 100	unspecified	integrin antagonist; peptide; P selectin antagonist; cell adhesion inhibitor; NSAID	ischemia; inflammation; reperfusion injury
TBC 427	unspecified	integrin antagonist; selectin antagonist; immunosuppressant; cell adhesion inhibitor	ischemia; psoriasis; respiratory distress syndrome; transplant rejection; reperfusion injury



tirilazad; tirilazad mesylate; trilazad; U 74006F; FREEDOX	21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-alpha-methyl-pregn-1,4,9-(11)-triene-3,20-dione	lazaroid	brain ischemia; stroke; trauma; heart ischemia; kidney disease
H 29051; H 290/51	cis-7-methyl-9-methoxy-5,5a,b,10b-tetrahydroindeno(2,1-6 indole	Lipid peroxidation inhibitor	heart ischemia; reperfusion injury
MAB, 60-3; MAB, CD18/CD11	unspecified	Monoclonal antibody	septic shock; heart ischemia; reperfusion injury
MAB, CD18; R15.7	unspecified	monoclonal antibody	ischemia
MAB, beta2 integrin; LDP 01	unspecified	monoclonal antibody; biotechnology; integrin antagonist; cell adhesion inhibitor	ischemia; reperfusion injury
MAB, P-selectin; CY 1748; CY 1747	unspecified	monoclonal antibody; integrin antagonist; P selectin antagonist; cell adhesion inhibitor	reperfusion injury; ischemia
MAB, CD11b; MAB, m60.1; m60.1; LY 303932	unspecified	monoclonal antibody; NSAID	inflammation; heart ischemia; reperfusion injury
ITF 1129	2,3-dihydro-6-methyl-3-[2-(nitrooxy)ethyl]-4H-1,3-benzoxazin-4-one	nitric oxide donor; nitrate	heart ischemia; angina
ITF 1697	Unspecified	NSAID; peptide	septic shock; inflammation; heart ischemia; inflammatory bowel disease
recombinant PSGL 1, PSGL 1	unspecified	P selectin antagonist; E selectin antagonist; L selectin antagonist; selectin antagonist; NSAID	inflammation; transplant rejection; ischemia; reperfusion injury

BN 50726	6-(2-chlorophenyl)-9-(hexadecylsulfonyl)-7,8,9,10-tetrahydro-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist	ischemia; cytoprotectant
nupafant; nupafant hydrochloride; BB 960; BB 2113	(S)-N-[1-(ethoxymethyl)-3-methylbutyl]-4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]benzenesulfonamide	PAF antagonist	ischemia; reperfusion injury
UR 12670	4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-1-(1-oxo-3,3-diphenylpropyl)-piperidine	PAF antagonist; platelet antiaggregant	kidney disease; ischemia; asthma; pancreatitis
CEN 294	unspecified	peptide; NSAID	inflammation; ischemia; reperfusion injury
kappa-conopeptides	unspecified	peptide; potassium channel blocker	heart ischemia; arrhythmia; gastrointestinal disorder
ER 3826	N-(1-benzyl-4-piperidiny)-4-(N-methyl-N-((E)-3-(4-(methylsulfonyl)phenyl)-2-propenoyl)amino)benzenesulfonamide	phospholipase inhibitor	ischemia
EF 12	unspecified	platelet antiaggregant; antiproliferative agent	heart ischemia; thrombosis; restenosis
aprikalim; RP 52891; APRIM	tetrahydro-N-methyl-2-(3-pyridinyl)-2H-thiopyran-2-carbothioamide 1-oxide	potassium channel activator	heart ischemia

BMS 191095	(3R-trans)-4-[(4-chlorophenyl)(1H-imidazo-2-ylmethyl)amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile	potassium channel activator	ischemia
NS 004; NS 4	1-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-5-(trifluoromethyl)-2H-benzimidazol-2-one	potassium channel activator	ischemia
SKP 450; KR 30450	(R)-1-[2-(1,3-dioxolan-2-yl)-2-methyl-6-nitro-2H-1-benzopyran-4-yl]-2-pyrrolidinone	potassium channel activator	hypertension; heart ischemia
U 89232	trans-N-cyano-N'-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N''-(1,1-dimethylpropyl)-guanidine	potassium channel activator	ischemia
SR 47063	4-(2-cyanoimino-1,2-dihydropyrid-1-yl)-6-nitro-2,2-dimethyl-2H-1-benzopyran	potassium channel activator; bronchodilator	heart ischemia; asthma
azimilide; azimilide dihydrochloride; azilimide; NE 10064; STEDICOR	1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione	potassium channel blocker; class III antiarrhythmic	ischemia; arrhythmia
tedisamil; KC 8857	3',7'-bis(cyclopropylmethyl)spiro[cyclopentane-1,9'-[3,7]diazabicyclo[3.3.1]nonane]	potassium channel blocker; class III antiarrhythmic	heart ischemia

beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
SPC 100271	unspecified	protein kinase inhibitor; protein kinase C inhibitor	ischemia; reperfusion injury
SPC 101591	unspecified	protein kinase inhibitor; protein kinase C inhibitor	cancer; ischemia; reperfusion injury
SPC 100270	unspecified	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	ischemia; transplant rejection; reperfusion injury
SPC 100840	unspecified	protein kinase inhibitor; protein kinase C inhibitor; NSAID	ischemia; psoriasis; cancer; inflammation; reperfusion injury
argatroban; argatrovan; argipidine; argopidine; alipidine; DK 7419; MCI 9038; MD 805; OM 805; GN 1600; NOVASTAN; SLONNON	(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-quinoliny)sulfonyl]amino]pentyl]-4-methyl-2-[piperidinecarboxylic acid	proteinase inhibitor; platelet antiaggregant; thrombin inhibitor	thrombosis; myocardial infarction; ischemia; angina; brain ischemia; thrombocytopenia
Recombinant hemoglobin mutant	unspecified	Recombinant hemoglobin mutant	ischemia
p-38-2 inhibitor	unspecified	signal transduction inhibitor; NSAID	inflammation; ischemia
superoxide dismutase mimetics, SOD mimetics,	unspecified	SOD mimetic	ischemia; reperfusion injury
NO-SOD mimetics, nitrosylated superoxide dismutase mimetics	unspecified	SOD mimetic; nitric oxide donor	asthma; respiratory distress syndrome; ischemia; reperfusion injury
FR 183998	unspecified	sodium/hydrogen exchange inhibitor	heart ischemia

HOE 694	N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(1-piperidinyl)benzamide mesilate	sodium/hydrogen exchange inhibitor	heart ischemia; reperfusion injury
KBR 9032; KB-R 9032	N-(aminoiminomethyl)-3,4-dihydro-2,2-dimethyl-4-(1-methylethyl)-3-oxo-2H-1,4-benzoxazine-6-carboxamide monomethanesulfonate	sodium/hydrogen exchange inhibitor; anti-ischemic	arrhythmia; heart ischemia; reperfusion injury
transforming growth factor beta;	unspecified	TGFbeta receptor pathway; growth factor	brain ischemia; trauma; stroke; neurodegeneration
NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	inflammation; ischemia; cancer; autoimmune disease
hemorrhagic shock therapy	Unspecified	unspecified	cardiovascular disease; ischemia; reperfusion injury
PKH 135	Lipid-colchicine conjugate	Unspecified	cancer; ischemia; reperfusion injury
vascular endothelial growth factor; VEGF; rhVEGF165	unspecified	VEGF, growth factor; cicatrizant	coronary artery disease; ischemia; restenosis; skin ulcer
Ro 315460	4-hydroxy-9H-pyrido[3,4-b]indole-1-carboxaldehyde	xanthine oxidase inhibitor	ischemia; reperfusion injury
torbafylline; HWA 448	7-ethoxymethyl-1-(5-hydroxy-5-methylhexyl)-3-methylxanthine	xanthine; vasodilator	ischemia

Table 63. Current Candidate Therapeutic Interventions for the Treatment of Heart Failure

Product Name	Chemical Name	Action	Indication
docebenone; AA 861	6-(12-hydroxy-5,10-dodecadiynyl)-2,3,5-trimethyl-1,4-benzoquinone	5 lipoxygenase inhibitor	asthma; heart failure

captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
drug delivery system, SODAS captopril; captopril SODAS	Unspecified	ACE inhibitor	heart failure; hypertension
imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]-3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid	ACE inhibitor	hypertension; heart failure; diabetes
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
perindopril; perindopril erbumine; S 9490; S 94903; SED 9490; MCN A2833109; DW 7950; COVERSYL; ACEON; ACERTIL; COVERENE; COVEREX; COVERSIL	(2S,3aS,7aS)-1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid	ACE inhibitor	hypertension; coronary artery disease; heart failure

ramipril; HOE 498; ALTACE; TRIATEC; PRAMACE; RAMACE; TRITACE; CARASEL; ACOVIL	(2S,3aS,6aS)-1-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid 1-ethyl ester	ACE inhibitor	hypertension; heart failure
utibapril; FPL 63547	(S)-2-tert-butyl-4-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]-delta2-1,3,4-thiadiazoline-5-carboxylic acid, 4-ethyl ester	ACE inhibitor	hypertension; heart failure
fosinopril + hydrochlorothiazide; hydrochlorothiazide + fosinopril; TENSOZIDE; MONOPRIL-HCT; FOSICOMP	Unspecified	ACE inhibitor; diuretic	hypertension; heart failure
BMS 189921	[S-(R*,R*)]-hexahydro-6-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-2,2-dimethyl-7-oxo-1H-azepine	ACE inhibitor; matrix metalloproteinase inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
ER 3295	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
sampatrilat; UK 81252	2-[[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]cyclopentyl]methyl]-N-[N2-(methylsulfonyl)-L-lysyl]-beta-alanine [S-(R*,R*)]-	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
Z 13752A	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure

MDL 100240; MDL 100173 pro	[4S-[4alpha,7alpha(R*),12bbeta]]-7-[[2-(acetylthio)-1-oxo-3-phenylpropyl]amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1-a][2]benzazepine-4-carboxylic acid	ACE inhibitor; neutral endopeptidase inhibitor; diuretic	heart failure; hypertension
trandolapril; CI 907; RU 44570; RU 570; ODRIK; UDRIK; GOPTEN; TRAPRIL; ODRIC; MAVIK	[2S-[1[R*(R*)],2alpha,3alpha,7abeta]]-1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid	ACE inhibitor; vasodilator	hypertension; heart failure; myocardial infarction
CVT 429	Unspecified	adenosine A1 agonist; adenosine agonist	arrhythmia; heart failure
CVT 609	Unspecified	adenosine A1 agonist; adenosine agonist	arrhythmia; heart failure
adenosine A1 antagonists	Unspecified	adenosine A1 antagonist; diuretic; adenosine antagonist	heart failure
adenosine A2a agonists	Unspecified	adenosine A2 agonist; adenosine agonist	heart failure
RPR 100579	Unspecified	adenosine agonist	hypertension; heart failure; hyperlipidemia
CVT 427	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
CVT 510	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
CVT 741	Unspecified	adenosine agonist; adenosine A1 agonist	arrhythmia; heart failure
SDZ WAG994; SDZ WAG 994	N-cyclohexyl-2'-0-methyladenosine	adenosine agonist; adenosine A1 agonist	heart failure; hyperlipidemia
WRC 0342	Unspecified	adenosine antagonist	heart failure
WRC 0571	Unspecified	adenosine antagonist	heart failure
HMR 4902	Unspecified	adenosine antagonist; adenosine A1 antagonist	heart failure; kidney disease



KW 3902	8-(noradamantyl-3-yl)-1,3-dipropylxanthine	adenosine antagonist; adenosine A1 antagonist; diuretic	heart failure
CVT 124; BG 9719; ADENTRI	3,7-dihydro-8-(3-oxatricyclo[3.2.1.0 <sup>2,4</sup> ]oct-6-yl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; diuretic; adenosine A1 antagonist	heart failure; hypertension
FR 113453	[R-(E)]-4-hydroxy-1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-5-(1-piperidinyl)-1-penten-3-one	adenosine antagonist; vasodilator; diuretic	heart failure
eplerenone; epoxymexrenone; CGP 30083; SC 66110	(7.alpha.,11.alpha.,17.alpha.)-9,11-epoxy-17-hydroxy-3-oxopregn-4-ene-7,21-dicarboxylic acid .gamma.-lactone methyl ester	aldosterone antagonist	heart failure; hypertension
moxonidine; BE 5895; BDF 5895; LY 326869; CYNT; PHYSIOTENS	4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine	alpha adrenergic agonist; alpha2 adrenergic agonist; imidazoline agonist	hypertension; heart failure; diabetes
metazosin; metasozin; metazocin; KENOSIN	1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)piperazine	alpha adrenergic antagonist; alpha1 adrenergic antagonist	hypertension; glaucoma; benign prostate hypertrophy; heart failure
XB 513	2-amino-1,4-dihydro-4-[2-[[4-[4-(2-methoxyphenyl)-1-piperazinyl]-butyl]sulfinyl]phenyl]-6-methyl-5-nitro-3-pyridinecarboxylic acid methyl ester	alpha adrenergic antagonist; alpha1 adrenergic antagonist; calcium agonist	heart failure

candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMIAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
irbesartan; SR 47436; BMS 186295; APROVEL; KARVEA; AVAPRO	2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	angiotensin II antagonist	hypertension; kidney disease; heart failure
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
UR 7247	3-(1-methylethyl)-1-propyl-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-pyrazole-4-carboxylic acid	angiotensin II antagonist	hypertension; heart failure
valsartan; CGP 48933; DIOVAN	N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1-biphenyl]-4-yl]methyl]-L-valine	angiotensin II antagonist	hypertension; heart failure
YM 358	2,7-diethyl-5-[(2'-(5-tetrazoyl)biphenyl-4-yl)methyl]-5H-pyrazolo[1,5-b][1,2,4]triazole	angiotensin II antagonist	hypertension; heart failure
fructose-1,6-diphosphate; CPC 111; CORDOX	1,6-bis(dihydrogen phosphate) D-fructose	anti-ischemic	heart failure; myocardial infarction; sickle cell anemia; septic shock
apoptosis inhibitors	Unspecified	apoptosis inhibitor	neuropathy; HIV infection; heart failure

cardiovascular disease therapy	Unspecified	apoptosis inhibitor; caspase inhibitor	cardiovascular disease; myocardial infarction; heart failure
OPC 31260	N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzapin-1-yl]carbonyl]phenyl]-2-methylbenzamide	aquaretic; vasopressin antagonist	heart failure
candoxatril; UK 79300	4-[[[1-[3-[(2,3-dihydro-1H-inden-5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]-cyclohexanecarboxylic acid	atriopeptidase inhibitor	hypertension; heart failure
T 0509	(R)-4-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-hydroxyethyl]-1,2-benzenediol	beta adrenergic agonist; beta1 adrenergic agonist	heart failure
xamoterol; ICI 118587; CORWIN; SEPAN	(+,-)-N-[2-[[2-hydroxy-3-(p-hydroxyphenoxy)propyl]amino]ethyl]-4-morpholinecarboxamide	beta adrenergic agonist; beta1 adrenergic agonist; beta adrenergic partial antagonist; beta1 adrenergic partial antagonist	heart failure
BIB 16S	Unspecified	beta adrenergic antagonist	heart failure
bisoprolol; bisoprolol fumarate; EMD 33512; CL 297939; CONCOR; EMCOR; EMCORE; MONOCOR; ISOTEN; SOPROL; DETENSIEL; MAINTATE; ISOBLOC; ZEBETA	1-[(1-methylethyl)amino]-3-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-2-propanol	beta adrenergic antagonist	hypertension; heart failure

carvedilol; karvedilol; BM 14190; DQ 2466; KREDEX; COREG; DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC	1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol	beta adrenergic antagonist	hypertension; angina; heart failure
nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET; LOBIVON	[2R*[R*[R*(S*)]]]-alpha,alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator; vasodilator	hypertension; migraine; heart failure
GI 104313	(S)-2-[2-chloro-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenoxy]-N-[2-[[3-(2-cyanophenoxy)-2-hydroxypropyl]amino]-2-methylpropyl]acetamide	beta adrenergic antagonist; phosphodiesterase inhibitor	heart failure
bucindolol; bucindolol hydrochloride; MJ 131051; BEXTRA	2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]benzonitrile	beta adrenergic antagonist; vasodilator	heart failure; myocardial infarction
drug delivery system, controlled release GEOMATRIX bucindolol; bucindolol GEOMATRIX	Unspecified	beta adrenergic antagonist; vasodilator	heart failure
nesiritide; nesiritide citrate; brain natriuretic peptide; BNP; NATRECOR	Brain natriuretic peptide-32	biotechnology; hormone; peptide	heart failure; hypertension

carperitide; human atrial natriuretic peptide; ANP; HANP; atriopeptin-28 (human); SUN 4936; HANP	1-de-L-leucine-2-de-L-alanine-3-deglycine-4-de-L-proline-5-de-L-arginine-17-L-methionine-atriopeptin-33 (rat)	biotechnology; hormone; peptide; diuretic	heart failure
etanercept; tumor necrosis factor receptor; TNFr; TNR 001; ENBREL	Unspecified	biotechnology; TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease
BAY y 5959	(-)-2-amino-5-cyano-1,4-dihydro-6-methyl-4-(3-phenyl-5-quinolinyl)-3-pyridinecarboxylic acid 1-methylethyl ester	calcium agonist	heart failure
LY 249933	(R)-1,4-dihydro,2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-3-pyridinecarboxylic acid, 1-phenylethyl ester	calcium antagonist	heart failure
SIM 6080	N-[3,3-bis(4-fluorophenyl)propyl]-N,N'-dimethyl-N'-[(3,4,5-trimethoxyphenyl)methyl]-1,2-ethanediamine	calcium antagonist	heart failure
SR 33805	Unspecified	calcium antagonist	heart failure; atherosclerosis
Y 22516	isopropyl 7-(2,6-difluorophenyl)-5-methyl-4,7-dihydropyrazolo-(1,5-a)pyrimidine-6-carboxylate	calcium antagonist	heart failure

elgodipine; IQB 875	(+,-)-4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 2-[[[4-fluorophenyl)methyl]methylamino]ethyl 1-methylethyl ester	calcium antagonist; vasodilator	angina; hypertension; heart failure
felodipine; H 15482; HOE 869; CGH 869; HYDAC; PLENDIL; VASOPINE; SPLENDIL; MUNOBAL; FLODIL	4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester	calcium antagonist; vasodilator; diuretic	hypertension; angina; heart failure; atherosclerosis
mibefradil; mibefradil dihydrochloride; Ro 405967; Ro 405967001; POSICOR; CERATE	methoxyacetic acid, (1S-cis)-2-[2-[[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester	calcium channel blocker; vasodilator	hypertension; angina; heart failure
MCI 154	6-(4-(4-pyridinylamino)phenyl)-4,5-dihydro-3(2H)-pyridazinone monohydrochloride	calcium sensitizer	heart failure
AM 522	Unspecified	cardiac glycoside	hypertension; heart failure
AM 524	Unspecified	cardiac glycoside	heart failure; hypertension
digitalis-like compound 1; DLC-CL3	Unspecified	cardiac glycoside	heart failure
digitoxigenin-PC	Unspecified	cardiac glycoside	heart failure; hypertension
NE 11040	Unspecified	cardiac glycoside	heart failure
acrihellin; D 12316	(3beta,5beta)-5,14-dihydroxy-3-[(3-methyl-1-oxo-2-butenyl)oxy]-19-oxobufa-20,22-dienolide	Cardiac glycoside activity; cardiosteroid	heart failure

acetamide	Unspecified	Cardiac stimulant	heart failure
mildronate; MET 88	2-(2-carboxyethyl)-1,1,1-trimethylhydrazinium, inner salt	Cardiostimulation	heart failure
DAC 7684	Unspecified	cardiotonic	heart failure
P 877692	Unspecified	Cardiotonic	heart failure
UP 10023	Unspecified	Cardiotonic	heart failure
VA 5	6-(2,5-dimethoxyphenyl)-2,3-dihydroimidazo[2,1-b]thiazole	Cardiotonic	heart failure; cancer
GP 2128	1-(3,4-dihydroxyphenyl)-2-[3-(4-carbamoylphenyl)-1-methylpropylamino]ethanol	catecholamine	heart failure
dexrazoxane; razoxane (+), (S); ICRF 187; NSC 169780; ADR529; ICI 59118; CARDIOXANE; EUCARDION; RAZOXIN; ZINECORE; ZINECARD; ANTRAGARD	(+)-(S)-4,4'-propylenedi-2,6-piperazinedione	chemoprotectant; cytoprotectant	cancer; heart failure
ICRF 197	Unspecified	chemoprotectant; cytoprotectant	cancer; heart failure
AQRA 741	11-[[4-[4-(diethylamino)butyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one	cholinergic antagonist; muscarinic antagonist; muscarinic M2 antagonist	heart failure
MCC 135	5-methyl-2-(1-piperazinyl)-benzenesulfonic acid monohydrate	Contractile dysfunction amelioration	heart failure; myocardial infarction

azosemide; PLE 1053; SK 110; LURET; DIART; URETIN	2-chloro-5-(1H-tetrazol-5-yl)-4-[(2-thienylmethyl)amino]benzenesulfonamide	diuretic	heart failure
C 2921	4-(bicyclo[2.2.1]hept-1-ylamino)-N-[(1-methylethyl)amino]carbonyl]-3-pyridinesulfonamide	diuretic	heart failure
JDL 961	4-(cyclooctylamino)-N-[(ethylamino)carbonyl]-3-pyridinesulfonamide	diuretic	heart failure
piretanide; HOE 118; S 734118; ARELIX; ARLIX; TAULIZ; EURELIX; PIRENEX	3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)benzoic acid	diuretic	heart failure
torasemide; torsemide; JDL 464; BM 02015; AC 4464; GJ 1090; UNAT; PRESARIL; TORREM; TOREM; ZEMIDE; DEMADEx; TORADIUR; DIURESIX; LUPRAC	N-[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide	diuretic	hypertension; heart failure
niravoline; niravolin; RU 51599	(1S-trans)-N-[2,3-dihydro-2-(1-pyrrolidinyl)-1H-inden-1-yl]-N-methyl-3-nitrobenzeneacetamide	diuretic; opiate agonist; kappa agonist	trauma; heart failure; cirrhosis
AY 31906	exo-2-amino-4-(bicyclo[2.2.1]hept-2-ylamino)-N-[(1-methylethyl)amino]carbonyl]-5-pyrimidinesulfonamide	diuretic; sulfonyleurea	heart failure



PNU 80873A	Unspecified	diuretic; vasopressin antagonist	heart failure
dopexamine; FPL 60278; FPL 60278AR; CARDURA; DOPACARD	4-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]-1,2-benzenediol	dopamine agonist; beta adrenergic agonist; beta2 adrenergic agonist; vasodilator	heart failure
dobopamine; SB 7506; AF 3104; SKF 100168; INOPAMIL; SCANDINE; ESCANDINE; ERFOLGAN; TRAZYL	2-methylpropanoic acid 4-[2-(methylamino)ethyl]-1,2-phenylene ester	dopamine agonist; dopamine D1 agonist; vasodilator	heart failure; eye disease
fenoldopam prodrug	Unspecified	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	heart failure
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenol)-1H-3-benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
CHF 1035	2-methylpropanoic acid 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester hydrochloride	dopamine agonist; dopamine D2 agonist; alpha adrenergic agonist; alpha2 adrenergic agonist; vasodilator	heart failure
CHF 1255	Unspecified	dopamine agonist; vasodilator	heart failure
docarpamine; TA 8704; TA 870; TANADOPA	carbonic acid (S)-4-[2-[[2-(acetylamino)-4-(methylthio)-1-oxobutyl]amino]ethyl]-1,2-phenylene diethyl ester	dopamine agonist; vasodilator	heart failure
YM 435	(S)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-7,8-isoquinolinediol hydrochloride	dopamine antagonist; dopamine D1 antagonist	heart failure
BMS 193884	Unspecified	endothelin antagonist	heart failure
BMS 207940	Unspecified	endothelin antagonist	heart failure

bosentan; Ro 470203; Ro 470203/039	4-(1,1-dimethylethyl)- N-[6-(2- hydroxyethoxy)-5-(2- methoxyphenoxy)[2,2'- bipyrimidin]-4- yl]benzenesulfonamide	endothelin antagonist	heart failure
TA 0201	(N-(6-(2-(5-bromopyrimidin-2- yloxy)ethoxy)-5-(4- methylphenyl)pyrimidin-4-yl)-4-(2- hydroxy-1,1-dimethyl)benzenesulfonamide sodium salt)	endothelin antagonist	heart failure; myocardial infarction
ZD 1611	Unspecified	endothelin antagonist	heart failure
ZD 2574	Unspecified	endothelin antagonist	heart failure
ZD 4054	Unspecified	endothelin antagonist	heart failure
Ro 485695	2-pyridinyl-carbamic acid, 2-[[5-(2- methoxyphenoxy)-6- [[[4-(1- methylethyl)phenyl]s ulfonyl]amino]-2-(4- morpholinyl)-4- pyrimidinyl]oxy]ethyl ester	endothelin antagonist; endothelin A antagonist	heart failure
TBC 11251; IPI 1251	N-(4-chloro-3- methyl-5-isoxazolyl)- 2-[(6-methyl-1,3- benzodioxol-5- yl)acetyl]-3- thiophenesulfonamide	endothelin antagonist; endothelin A antagonist	heart failure; pulmonary obstructive disease; brain ischemia
ecadotril; sinorphan; BP 1.02; BAY y 7432; S 049; BP 102	(S)-N-[2- [(acetylthio)methyl]- 1-oxo-3- phenylpropyl]glycine phenyl methyl ester	enkephalinase inhibitor	hypertension; heart failure; cirrhosis
ThGRF 129; H 9506; ThGRF 1-29	N-(2-aminoethyl)-1,2- ethanediamine	growth hormone releasing factor analogue	heart failure; hormone deficiency

BU E75; BU-E 75	N-[3-(3,4-difluorophenyl)-3-(2-pyridinyl)propyl]-N'-[3-(1H-imidazol-4-yl)propyl]guanidine	histamine agonist; histamine H2 agonist	heart failure
BU E76; BU-E 76	N-[3-(3,5-difluorophenyl)-3-(2-pyridinyl)propyl]-N'-[3-(1H-imidazol-4-yl)propyl]guanidine	histamine agonist; histamine H2 agonist	heart failure
HE 30582	N-(3-(1H-imidazol-4-yl)propyl)-4-(2-nitro-4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-2-pyridizinyl)phenyl)-1-piperazine carboximidamide	histamine agonist; histamine H2 agonist	heart failure
anaritide; atrial natriuretic factor 4-28; ANF 4-28; atrial natriuretic peptide; anaritide acetate; WY 47663; AURICULIN	N-L-arginyl-8-L-methionine-21a-L-phenylalanine-21b-L-arginine-21c-L-tyrosine-atriopeptin-21 (rat)	hormone; ANP agonist; peptide	heart failure; kidney disease
BM 500430	4,5-dihydro-5-methyl-6-[2-(pyridin-4-yl)-1H-indol-5-yl]-pyridazin-3(2H)-one	Inotropic agent	heart failure
CL 284027	Unspecified	Inotropic agent	heart failure
digitalis-like steroids	Unspecified	Inotropic agent	heart failure
DLC-CL3	digitalis-like compound 2;	Inotropic agent	heart failure
DLC-CL3	digitalis-like compound 3	Inotropic agent	heart failure
GYKI 12735	2-methyl-4-((2-(4-morpholinyl)ethyl)amino-1H-pyrimido(5,4-6)-(1,4) oxazin-7(6H)-one	Inotropic agent	heart failure
KF 15832	6-(4-benzylamino-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone hydrochloride	Inotropic agent	heart failure
LAS 31180	Unspecified	Inotropic agent	heart failure
LAS 31270	Unspecified	Inotropic agent	heart failure

RG 12152	6-(3'-cyano-6'-methyl-2'-oxo-(1H)-pyridin-5'-yl)-1-methyl-2H-pyrido (3,2-b)-1,4-oxazin-3(4H)-one	Inotropic agent	heart failure
RWJ 24517	6-[1-[1-bis(4-fluorophenyl)methyl]piperazin-4-yl]-2-hydroxy-3-propylthiopurine	Inotropic agent	heart failure
UK 66838	6-(4-acetyl-2-methyl-1H-imidazol-1-yl)-8-methyl-2(1H)-quinolinone	Inotropic agent	heart failure
vasotrope	Unspecified	Inotropic agent	heart failure
meribendan; EMD 49931	4,5-dihydro-5-methyl-6-(2-pyrazol-3-yl-5-benzimidazolyl)-3(2H)-pyridazinone	Inotropic agent; cardiotonic	heart failure
omapatrilat; BMS 186716	[4S-[4alpha(R*),7alpha,10abeta]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid	matrix metalloproteinase inhibitor; ACE inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
matrix metalloproteinase inhibitor, coronary heart failure	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor	heart failure
cardiovascular disease therapy	Unspecified	Myosin motor and actin filaments modulation	hypertension; heart failure
SA 7060	[S-(R*,R*)]-alpha-[[[(3-butoxy-2-hydroxy-3-oxopropyl)(2-methylpropyl)amino]carbonyl]amino]-2-naphthalenepropanoic acid	neutral endopeptidase inhibitor; ACE inhibitor	heart failure; hypertension

SCH 50690	Unspecified	neutral endopeptidase inhibitor; ACE inhibitor	hypertension; heart failure
SLV 306	[S-(R*,S*)]-3-[[[1-[2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-acetic acid	neutral endopeptidase inhibitor; diuretic	heart failure
nitric oxide vasodilators	Unspecified	nitric oxide donor; vasodilator	angina; heart failure
VX 745	Unspecified	NSAID; MAP kinase inhibitor; signal transduction inhibitor	inflammation; neurological; heart failure; Crohn disease; asthma
BRL 52656	S(-)-2-(1-pyrrolidinylmethyl)-1-(4-trifluoromethylphenyl)acetylpiperidine hydrochloride	opiate agonist; kappa agonist; diuretic	heart failure
BRL 53114	(-)-1-(4-trifluoromethylphenyl)acetyl-2-(1-pyrrolidinyl)-3,3-dimethylpiperidine hydrochloride	opiate agonist; kappa agonist; diuretic	heart failure
oxytocin antagonist	Unspecified	oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
amrinone; WIN 40680; YM 10310; INOCOR; WINCORAN; VESISTOL; AMCORAL; CARTONIC	5-amino-[3,4'-bipyridin]-6(1H)-one	phosphodiesterase inhibitor	heart failure
BRL 40696	Unspecified	phosphodiesterase inhibitor	heart failure

EMD 53998	6-(3,6-dihydro-6-methyl-2-oxo-2H-1,3,4-thiadiazin-5-yl)-1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydroquinoline	phosphodiesterase inhibitor	heart failure
indolidan; LY 195115	1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one	phosphodiesterase inhibitor	heart failure
N 3601	2-[[[(4,6-dimethylpyridin-2-yl)methylamino]carboxy]-3-[2-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]ethyl]-3-aza-2,3-dihydro-1H-indole	phosphodiesterase inhibitor	heart failure
olprinone; loprinone; E 1020; CORETEC	1,2-dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3-pyridinecarbonitrile	phosphodiesterase inhibitor	heart failure
TZC 5665	4-chloro-2-[3-[[1,1-dimethyl-2[[4(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]amino]ethyl]amino]-2-hydroxypropoxy]benz onitrile, compd. with (Z)-2-butenedioic acid, monoethyl ester, (1:1)	phosphodiesterase inhibitor	heart failure
ZSY 39	4-methyl-5-(4-pyridinyl)-2-thiazolecarboxamide	phosphodiesterase inhibitor	heart failure

EMD 57033; (+)- EMD 53998	(+)-6-(3,6-dihydro-6-methyl-2-oxo-2H-1,3,4-thiadiazin-5-yl)-1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydroquinoline	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
isomazole; LY 175326; EMD 52750	2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
NSP 804	4,5-dihydro-6-[4-[(2-methyl-3-oxo-1-cyclopentenyl)amino]phenyl]-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
NSP 805; TZN 01	4,5-dihydro-5-methyl-6-[4-[(2-methyl-3-oxo-1-cyclopentenyl)amino]phenyl]-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
revizinone; R 801222	(E)-N-cyclohexyl-N-methyl-2-[[[phenyl(1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazolin-7-yl)methylene]amino]oxy]acetamide	phosphodiesterase inhibitor; phosphodiesterase III inhibitor	heart failure
KF 15232	4,5-dihydro-5-methyl-6-[4-[(phenylmethyl)amino]-7-quinazolinyl]-3(2H)-pyridazinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase V inhibitor; vasodilator	heart failure
ORG 10325	N-hydroxy-5,6-dimethoxy-1H-indene-2-carboximidamide monohydrochloride	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor	heart failure

ORG 30029	N-hydroxy-5,6-dimethoxy-benzo[b]thiophene-2-carboximidamide	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor	heart failure
ORG 9731	4-fluoro-N-hydroxy-5,6-dimethoxy-benzo(b)thiophene-2-carboximidamine methyl sulfonic acid	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase IV inhibitor	heart failure
E 4021; ER 21355	1-[4[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidinecarboxylic acid, monosodium salt	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	hypertension; angina; heart failure
IC 351; GF 196960; GG 960	Unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor	heart failure; angina; sexual dysfunction; psoriasis
SKF 95654	4,5-dihydro-6-(4-(1,4-dihydro-4-oxopyridin-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis; heart failure
pimobendan; UDCG 115; UDCG 115A; UDCG 115BS; ACARDI	4,5-dihydro-6-(z-(p-methoxyphenyl)-5-benzimidazolyl)-5-methyl-3-(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	thrombosis; heart failure
simendan	[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	heart failure; thrombosis



levosimendan; OR 1259; SIMDAX	[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator; calcium sensitizer	heart failure; thrombosis
toborinone; OPC 18790	(+,-)-6-[3-[[3,4-dimethoxyphenyl)methyl]amino]-2-hydroxypropoxy ] 2(1H)-quinolinone	phosphodiesterase inhibitor; potassium channel blocker	heart failure
vesnarinone; piperanometozine; OPC 8212; ARKIN-Z; ARKIN	1-(1,2,3,4-tetrahydro-2-oxo-6-quinolyl)-4-veratroylpiperazine	phosphodiesterase inhibitor; potassium channel blocker	heart failure; HIV infection
bemoradan; ORF 22867	7-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2H-1,4-benzoxazin-3(4H)-one	phosphodiesterase inhibitor; vasodilator	heart failure
BW 349U85	6-(1-piperidiny)-2(1H)-quinolinone monohydrochloride	phosphodiesterase inhibitor; vasodilator	heart failure
enoximone; fenoximone; phenoximone; MDL 17043; RMI 17043; PERFAN; PERFLAN; PERFANE	1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-one	phosphodiesterase inhibitor; vasodilator	heart failure
milrinone; WIN 47203; WIN 472032; YM 018; CORATROPE; PRIMACOR; MILRILA	1,6-dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile	phosphodiesterase inhibitor; vasodilator	heart failure
MS 857	4-acetyl-1-methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3(2H)-isoquinolinone	phosphodiesterase inhibitor; vasodilator	heart failure

saterinone; BDF 8634	(+,-)-1,2-dihydro-5-[4-[2-hydroxy-3-[4-(2-methoxy-phenyl)-1-piperazinyl]propoxy]phenyl]-6-methyl-2-oxo-3-pyridinecarbonitrile	phosphodiesterase inhibitor; vasodilator	heart failure
16alpha-gitoxin; gitoxin	Unspecified	Positive inotropic action	heart failure
emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
nicorandil; SG 75; EMD 36385; U 64417; SIGMART; PERISALOL; DANCOR; IKOREL; ADANCOR; CORDONE; KALIDIL	N-[2-(nitrooxy)ethyl]-3-pyridinecarboxamide	potassium channel activator; nitrate; vasodilator	angina; cerebrovascular disease; heart failure
BW 15AU81; BW 15AU; U 62840; 15AU81	[1R-[1alpha(S*),2beta,3alpha,9alpha]]-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-(3-hydroxyoctyl)-1H-benz[f]inden-5-yl]oxy]acetic acid	prostanoid; vasodilator	heart failure
EMD 52297	N-(tert-butoxycarbonyl)-L-phenylalanyl-L-histidyl-(4S-amino-3S-hydroxy-5-cyclohexyl)-pentanecarbonyl)-L-isoleucyl-(2-amidomethyl)-tetrazol	proteinase inhibitor; renin inhibitor	heart failure

BDF 9148	4-[3'-(1-benzhydryl-azetidin-3-oxy)-2'-hydroxylpropoxy]-1H-indole-2-carbonitrile	sodium channel activator	heart failure
BM 20	N-[[4-(cyclooctylamino)pyridin-3-yl]sulfonyl]-N'-ethylthiourea	sulfonylthiourea; diuretic	heart failure
daltroban; BM 13505; SKF 96148	4-[2-[[4-(4-chlorophenyl)sulfonyl]amino]ethyl]benzene acetic acid	thromboxane antagonist; platelet antiaggregant	heart failure; thrombosis
BW A746C	Unspecified	Unspecified	heart failure
CM 3	Unspecified	Unspecified	heart failure
congestive heart failure therapy	Unspecified	Unspecified	heart failure
CK 2289	4-ethyl-1,3-dihydro-5-[4-(1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one	vasodilator	heart failure
FK 664	6-(3,4-dimethoxyphenyl)-1-ethyl-3,4-dihydro-3-methyl-4-[(2,4,6-trimethylphenyl)iminol]-2(1H)-pyrimidinone	vasodilator	heart failure
flosequinan; BTS 49465; MANOPLAX	7-fluoro-1-methyl-3-(methylsulfinyl)-4(1H)-quinolinone	vasodilator	heart failure
HN 10200	2-((3-methoxy-5-methylsulfinyl)-2-thienyl)-1-H-imidazo(4,5-c)pyridine hydrochloride	vasodilator	heart failure
nanterinone; UK 61260; UK 6126027	6-(2,4-dimethyl-1H-imidazol-1-yl)-8-methyl-2(1H)-quinolinone	vasodilator	heart failure
piroximone; MDL 19205	4-ethyl-5-isonicotinoyl-4-imidazolin-2-one	vasodilator	heart failure

prinoxodan; RGW 2938; RG 2938	3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2-(1H)-quinazolinone	vasodilator	heart failure
colforsin dapropate; NKH 477; ADEHL	6-[3-(dimethylamino)propionyl]forskolin	vasodilator; bronchodilator	heart failure; asthma; musculoskeletal disorder
propionylcarnitine, L-; propionyl-L-carnitine; levocarnitine propionyl; ST 261; DROMOS	L-3-carboxy-2-(1-oxopropoxy)-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt	vasodilator; cicatrizant	peripheral vascular disease; angina; heart failure; skin ulcer
VPA 985	N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methylbenzamide	vasopressin antagonist; aquaretic	heart failure
WAY 140288	Unspecified	vasopressin antagonist; aquaretic	heart failure
OPC 21268	1-[1-[4-(3-acetylamino-propoxy)benzoyl]-4-piperidyl]-3,4-dihydro-2(1H)-quinolinone	vasopressin antagonist; diuretic	hypertension; heart failure
SR 121463	cis-N-(1,1-dimethylethyl)-4-[[5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy-benzamide (E)-2-butenedioate (1:1)	vasopressin antagonist; diuretic	heart failure; hypertension

SR 49059	[2R-[2alfa(S*),3beta]]-1-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide	vasopressin antagonist; diuretic	gynecological; cancer; hypertension; heart failure; emesis
vasopressin antagonist	Unspecified	vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
YM 087	N-[1,1'-biphenyl]-2-yl-4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-benzamide	vasopressin antagonist; diuretic	heart failure
YM 471	(Z)-N-[4-[[5-[2-[4-(dimethylamino)-1-piperidinyl]-2-oxoethylidene]-4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-[1,1'biphenyl]-2-carboxamide, monohydrochloride	vasopressin antagonist; diuretic	heart failure

Table 64. Current Candidate Therapeutic Interventions for the Treatment of Thrombosis

Product Name	Chemical Name	Action	Indication
DV 7028	3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-6,7,8,9-tetrahydro-2H-pyrido[1,2-a]-1,3,5-triazine-2,4(3H)-dione maleate	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis

eplivanserin; SR 46349; SR 46349B	(1Z,2E)-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-2-propen-1-one (2E)-2-butenedioate (2:1) salt	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	schizophrenia; insomnia; thrombosis
LY 215840	[8beta(1S,2R)]-N-(2-hydroxycyclopentyl)-6-methyl-1-(1-methylethyl)ergoline-8-carboxamide	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis; angina
MDL 28133A	N-[4-[[1-[2-(4-fluorophenyl)-2-oxoethyl]-4-piperidinyl]carbonyl]phenyl]methanesulfonamide monohydrochloride	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis
S 14280	3-[2-[3-[2-(4-fluorophenyl)-2-oxoethyl]pyrrolidin-1-yl]ethyl]-2,4(1H,3H)-quinazolinedione	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis
sarpogrelate; sarpogrelate hydrochloride; MCI 9042; ANPLAG	butanedioic acid mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	thrombosis
AT 1015	unspecified	5HT antagonist; 5HT2A antagonist; platelet antiaggregant	thrombosis
GP 531	5-amino-1-[5-deoxy-5-[phenylmethyl]amino]-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; anti-ischemic	ischemia; thrombosis
acadesine; AICA-riboside; AR 100; GP 1110; GP 11100; ARASINE; PROTARA	5-amino-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide	adenosine regulating agent; platelet antiaggregant; anti-ischemic	cardiovascular disease; thrombosis; ischemia

AT 112	2,3-dihydro-2-[(4-phenyl-1-piperazinyl)methyl]imidazo[1,2-c]quinazolin-5(6H)-one	alpha adrenergic antagonist; alpha 1 adrenergic antagonist; platelet antiaggregant	thrombosis; hypertension
thrombospondin 1 inhibitor, TSP-1 inhibitor,	unspecified	angiogenesis inhibitor; platelet antiaggregant; radiodiagnostic; contrast medium	cancer; diagnosis; thrombosis
avidinorubicin	unspecified	antibiotic; anthracycline; platelet antiaggregant	thrombosis
placatin A	unspecified	antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
placatin B	unspecified	antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
RP 12986; RG 12986	Recombinant von Willebrand factor fragment	anticoagulant	thrombosis
staphylokinase	Recombinant staphylokinase	anticoagulant	thrombosis
thrombomodulin; MR 33; MB 015	unspecified	Anticoagulant	thrombosis
vascular anticoagulant, natural; VAC, natural	Protein isolated from human placenta	anticoagulant	thrombosis
hirudin, natural	unspecified	antithrombin	thrombosis
polyethylene glycol hirudin; PEG-hirudin; hirudin macrogol	unspecified	antithrombin; platelet antiaggregant	thrombosis
FK 633	N-[4-[4-(aminoiminomethyl)phenoxy]-1-oxobutyl]-L-alpha-aspartyl-L-valine	Antithrombotic	thrombosis
LF 060377	unspecified	antithrombotic	thrombosis
LF 337	unspecified	antithrombotic	thrombosis
LU 208791	unspecified	antithrombotic	thrombosis

M 19791; U 68215	[1R-[1alpha(R*),2beta,3alpha,9alpha]]-[[1-(3-cyclohexyl-3-hydroxypropyl)-2,3,3a,4,9a-hexahydro-2-hydroxy-1H-benz[f]inden-5-yl]oxy]-acetic acid	antithrombotic	thrombosis
protein C	unspecified	antithrombotic	thrombosis
protein C natural, activated; activated protein C, natural; APC	unspecified	antithrombotic	thrombosis
protein C; CTC 111	unspecified	antithrombotic	thrombosis
thrombin receptor inhibitors	unspecified	antithrombotic	thrombosis
thrombomodulin; ART 123	Recombinant Thrombomodulin	antithrombotic	thrombosis
thrombosis therapy	unspecified	antithrombotic	thrombosis
TMD 1105	Deletion mutant of recombinant thrombomodulin	antithrombotic	thrombosis
V 20R	unspecified	antithrombotic	thrombosis
V 21	unspecified	antithrombotic	thrombosis
GS 522	GGTTGGTGTGGTTGG	aptamer; thrombin inhibitor; proteinase inhibitor	thrombosis
nematode anticoagulant protein c2, recombinant; NAPc2; AcAPc2; rNAPc2	unspecified	biotechnology; blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
tick-derived anticoagulant peptide; TAP	unspecified	biotechnology; blood clotting factor Xa inhibitor; peptide; proteinase inhibitor	thrombosis
antistatin; ATS; ghilanten	unspecified	biotechnology; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis



factor Xa inhibitor, leech; FACTOREX	unspecified	biotechnology; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
nematode anticoagulant protein 5, recombinant; rNAP5; NAP5	unspecified	biotechnology; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
TP 9201	N-acetyl-L-cysteinyl- L-asparaginyl-L- prolyl-L- arginylglycyl-L- alpha-aspartyl-O- methyl-L-tyrosyl-L- arginyl-L- cysteinamide cyclic (1-9)-disulfide	biotechnology; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
CX 397	unspecified	biotechnology; hirudin analogue	thrombosis
MAB, AP-1	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, fibrin beta chain plus hirudin; HAF	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, platelet receptor IIb/IIIa + hirudin; HAP; HAP	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, RWR; MAB, alpha2-plasmin	unspecified	biotechnology; monoclonal antibody	thrombosis
MAB, thrombosis; 12D10; CORSEVIN M	unspecified	biotechnology; monoclonal antibody	thrombosis; septic shock; angina
MAB, factor IX; MAB, BC 2; SB 249417	unspecified	biotechnology; monoclonal antibody; blood clotting factor IXa inhibitor	thrombosis
MAB, FAb, 7E3	unspecified	biotechnology; monoclonal antibody; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

MAB, glycoprotein IIb/IIIa; MAB, GP IIb/IIIa	unspecified	biotechnology; monoclonal antibody; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
MAB, glycoprotein IIb/IIIa; YM 337	unspecified	biotechnology; monoclonal antibody; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
MAB, AJvW2; MAB, von Willebrand factor; AJvW2; humanized AJvW2	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	thrombosis
MAB, M735 and P14G11 urokinase conjugate; bispecific antibody, platelet antiaggregant; ATC 3; ATC (3)	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	thrombosis
MAB, platelet, humanized; SMART anti-platelet	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	cardiovascular disease; thrombosis
AAMP-1 derived peptides; cell adhesion peptides	unspecified	biotechnology; peptide	thrombosis
KPI Xa	unspecified	biotechnology; peptide; proteinase inhibitor; thrombolytic; fibrinolytic; serine proteinase inhibitor	thrombosis
D K2P	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
FK2P; U 84793	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
hybrid B; plasminogen activator	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis

monteplase; tissue plasminogen activator, second generation; tPA second generation; E 6010; CLEACTOR	84-L-serineplasminogen activator (human tissue-type protein moiety reduced)	biotechnology; plasminogen activator; thrombolytic	thrombosis
reteplase; tissue plasminogen activator; tPA; BM 06022; RAPILYSIN; RETAVASE; RETEVASE; ECOKINASE	173-L-serine-174-L-tyrosine-175-L-glutamine-173-527-plasminogen activator (human tissue type)	biotechnology; plasminogen activator; thrombolytic	thrombosis; myocardial infarction
tissue plasminogen activator variants; tPA variants	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
tissue plasminogen activator, FK(2)P24; tPA second generation; FK (2)P24	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
BIO-LASE	unspecified	biotechnology; platelet antiaggregant	thrombosis; kidney disease; eye disease
calen; calin; EMD 66800	unspecified	biotechnology; platelet antiaggregant	thrombosis
human von Willebrand fragment	unspecified	biotechnology; platelet antiaggregant	thrombosis
protein C activator	unspecified	biotechnology; platelet antiaggregant	thrombosis
tifacogin; tissue factor pathway inhibitor	N-L-alanyl- blood coagulation factor LACI (human clone lambdaP9 protein moiety reduced)	biotechnology; platelet antiaggregant	thrombosis; septic shock
ectoapyrases	unspecified	biotechnology; platelet antiaggregant; enzyme	thrombosis

abciximab; abcirximab; MAb, F(ab') <sub>2</sub> fragment platelet; MAb, 7E3; c7E3 FAb; c7E3; ReoPro; CENTORX	immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhC.gamma.1 Fab fragment anti- human glycoprotein IIb/IIIa receptor), disulfide with human- mouse monoclonal c7E3 clone p7E3V.kappa.hc.kapp a.light chain	biotechnology; platelet antiaggregant; monoclonal antibody	thrombosis; restenosis; angina; stroke; myocardial infarction
antithrombin III		biotechnology; proteinase inhibitor	thrombosis
KPI 185	unspecified	biotechnology; proteinase inhibitor; peptide; serine proteinase inhibitor; thrombolytic; fibrinolytic	thrombosis
LEX 026	unspecified	biotechnology; proteinase inhibitor; serine proteinase inhibitor	thrombosis; inflammation
lepirudin; HBW 023; REFLUDAN	1-L-leucine-2-L- threonine-63-desulfo- hirudin (hirudo medicinalis isoform HV1)	biotechnology; thrombin inhibitor; proteinase inhibitor	thrombosis; restenosis
BB 10153	unspecified	biotechnology; thrombolytic	thrombosis
hirudin, recombinant	hirudin, recombinant	biotechnology; thrombolytic	thrombosis
hirudin; rHV2-Lys47; rt HV2	unspecified	biotechnology; thrombolytic	thrombosis
LU 52369	unspecified	biotechnology; thrombolytic	thrombosis
plasminogen mutants	unspecified	biotechnology; thrombolytic	thrombosis
hementin; EMD 66777	unspecified	biotechnology; thrombolytic; fibrinolytic; peptide	thrombosis

MAB, bispecific F(ab') <sub>2</sub> fibrin and u-PA + scu-PA; scu-PA/MA-FUI-74F(ab') <sub>2</sub>	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
MAB, bispecific fibrin tissue plasminogen; MAB, bispecific tPA fibrin	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
MAB, chimeric plasminogen activator; K12G2S32	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
MAB, D3-ATF; MAB, thrombosis; MAB, human tissue factor	unspecified	biotechnology; thrombolytic; monoclonal antibody	thrombosis
DSPA; alpha-DSPA; rDSPAalpha1; ZK 152387; SH 576	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
duteplase; tPA; tissue plasminogen activator; SM 9527; PROLYSIS; TIPLAGEN; SOLCLOT	245-L-methionine plasminogen activator (human tissue-type 2-chain form protein moiety)	biotechnology; thrombolytic; plasminogen activator	thrombosis
lanoteplase; novel plasminogen activator; nPA; SUN 9216; BMS 200980	N-[N <sup>2</sup> -(N-glycyl-L-alanyl)-L-arginyl]-117-L-glutamine-245-L-methionine-(1-5)-(87-527)-plasminogen activator (human tissue-type protein moiety)	biotechnology; thrombolytic; plasminogen activator	thrombosis
LY 210825	Unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
nateplase; tissue plasminogen activator; tPA; MMR 701; MILYZER; TEPASE	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
pamiteplase; YM 866; SOLINASE	(1-126)-(209-562)-plasminogen activator [310-glutamic acid] (human tissue-type precursor reduced)	biotechnology; thrombolytic; plasminogen activator	thrombosis

prourokinase; PUK; FCE 26177	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
prourokinase; PUK; rProUK; A 74187; PROLYSE	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis; stroke
saruplase; CG 4509	prouro-(human clone pUK4/pUK18) kinase (enzyme activating)	biotechnology; thrombolytic; plasminogen activator	thrombosis
alteplase; tissue plasminogen activator; tPA; TD 2061; DR 3200; PLASMINER	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tissue plasminogen activator	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tissue plasminogen activator, K2tuPA; tPA, K2tuPA	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tissue plasminogen activator, unglycosylated; rtPA; BM 06021	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis
tPA analogue	unspecified	biotechnology; thrombolytic; plasminogen activator	thrombosis; myocardial infarction
alteplase; tissue plasminogen activator; tPA; ACTIVASE; ACTILYSE; ACTIVACIN; GRTPA	Unspecified	biotechnology; thrombolytic; plasminogen activator; cicatrizant	thrombosis; skin ulcer; stroke
draculin	unspecified	blood clotting factor IXa inhibitor; blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
VM 201	unspecified	blood clotting factor IXa inhibitor; proteinase inhibitor	thrombosis; stroke
factor VIIa inhibitor	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis

factor VIIa inhibitor, injectable; CORSEVIN AS	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
factor VIIa inhibitor, oral, Corvas; CORSEVIN AS	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
factor VIIa inhibitors	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
factor VIIa inhibitors	unspecified	blood clotting factor VIIa inhibitor; proteinase inhibitor	thrombosis
antithrombotic agents	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
DPC 423	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
DX 9065a	[S-(R*,R*)]-7- (aminoiminomethyl)- alpha-[4-[[1-(1- iminomethyl)-3- pyrrolidinyl]oxy]phen yl]-2- naphthalenepropanoic acid monohydrochloride, pentahydrate	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis; stroke; myocardial infarction
factor Xa inhibitor, injectable; CORDECIN AS	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitor; CORDECIN AS	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis

factor Xa inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
factor Xa/thrombin inhibitors	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
JTV 803	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	stroke; myocardial infarction; thrombosis
KFA 1411	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
SH 544; SH 630	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
YM 60828	[[[7-(aminoiminomethyl)- 2-naphthalenyl]methyl][ 4-[[1-(1-iminoethyl)- 4-piperidinyl]oxy]phenyl] amino]sulfonyl]acetic acid dihydrochloride	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
ZD 4927	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis
SR 34006	unspecified	blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis



TA 993	cis-(-)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-1,5-benzothiazepin-4(5H)-one	calcium antagonist; platelet antiaggregant	thrombosis
meoxan	unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease
veroxan; VUFB 18814	unspecified	calcium channel blocker; alpha adrenergic antagonist; alpha1 adrenergic antagonist; platelet antiaggregant	hypertension; thrombosis; eye disease
clinprost; lipoisocarbacyclin; isocarbacyclin methyl ester; TEI 9090	[3aS-[3aalpha,5beta,6alpha(1E,3R*),6aalpha]]-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-2-pentalenepentanoic acid methyl ester	cicatrizant; prostanoid; platelet antiaggregant	thrombosis; skin ulcer; peripheral vascular disease
MRX 408	unspecified	contrast medium; echo contrast medium; thrombolytic	diagnosis; thrombosis
FR 122047	1-[(4,5-bis(4-methoxyphenyl)-2-thiazoyl)carbonyl]-4-methylpiperazine hydrochloride	COX inhibitor; platelet antiaggregant	thrombosis
itazigrel; U 53059	4,5-bis(4-methoxyphenyl)-2-(trifluoromethyl)thiazole	COX inhibitor; platelet antiaggregant	thrombosis

KC 764	(2-methylpyrazolo[1,5-a]pyridin-3-yl)(1,4,5,6-tetrahydro-3-pyridinyl)methanone	COX inhibitor; platelet antiaggregant	thrombosis
trifenagrel; BW 325U	2-[2-(4,5-diphenyl-1H-imidazole-2-yl)phenoxy]-N,N-dimethylethanamine	COX inhibitor; platelet antiaggregant; NSAID	inflammation; thrombosis
ST 681	N-(2-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine mononitrate	COX inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
pamigogrel; KBT 3022; KB 3022; TO 192	2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]-1H-pyrrole-1-acetic acid ethyl ester	COX inhibitor; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease
Ro 462005	4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(3-methoxyphenoxy)-4-pyrimidinyl]-benzenesulphonamide	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; platelet antiaggregant	thrombosis
AC 610612; Ro 610612	unspecified	endothelin antagonist; platelet antiaggregant	thrombosis
PD 145065	(2R)-N-acetyl-2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)glycyl-L-leucyl-L-alpha-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophan disodium salt	endothelin antagonist; platelet antiaggregant	thrombosis
RPR 109891; KLERVAL	Unspecified	fibrinogen antagonist; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

GR 144053	4-[4-[4-(aminoiminomethyl)p-phenyl]-1-piperazinyl]-1-piperidineacetic acid monohydrochloride	fibrinogen antagonist; platelet antiaggregant	thrombosis
GR 233548	Unspecified	fibrinogen antagonist; platelet antiaggregant	thrombosis
UR 12947	unspecified	fibrinogen antagonist; platelet antiaggregant	thrombosis
GR 83895	N-[(6S-amino-5-oxo-8aR-hexahydro-5H-thiazolo[3,2-a]pyridin-3R-yl)-carbonyl]-L-arginyl-L-glycyl-L-aspartyl-L-phenylalanine, cyclic(4--->1)-peptide, monotrifluoroacetate	fibrinogen antagonist; platelet antiaggregant; peptide	thrombosis
bitistatin	unspecified	fibrinogen antagonist; venom; platelet antiaggregant	thrombosis
fibrolase	Agkistrodon conortrix venom metalloproteinase	fibrinolytic; thrombolytic; venom	thrombosis
M4	unspecified	fibrinolytic; thrombolytic; venom	thrombosis
glycoprotein IIb/IIIa antagonist; P246	unspecified	glycoprotein IIb/IIIa antagonist; peptide; platelet antiaggregant	thrombosis; heart ischemia; stroke
C 6822	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
CGH 400	7-amino heptanoyl Gly Asp Phe	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
romafiban	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke

DMP 728	N-[3-(aminomethyl)benzoyl]-D-2-aminobutanoyl-N2-methyl-L-arginylglycyl-L-aspartic acid cyclic (41->1)-peptide monomethanesulfonate	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
DMP 802	3-[[[(5R)-3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-L-alanine	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
EMD 122347; YM 028	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina; stroke
glycoprotein IIb/IIIa antagonist	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
glycoprotein IIb/IIIa inhibitors	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
lamifiban; Ro 449883	(S)-[[1-[2-[[4-(aminoiminomethyl)benzoyl]amino]-3-(4-hydroxyphenyl)-1-oxopropyl]-4-piperidinyl]oxy]acetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
lotrafiban; SB 214857	(S)-7-([4,4'-bipiperidin]-1-ylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

ME 3277	2,2'-[[4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)carbonyl]amino]acetyl]-1,2-phenylene]bis(oxy)]bisacetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
MK 852; L 367073	N-acetyl-L-cysteinyl-L-asparaginyl-(4R)-5,5-dimethyl-4-thiazolidinecarbonyl-4-(aminomethyl)-L-phenylalanylglycyl-L-alpha-aspartyl-L-cysteine, cyclic (1-7)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	stroke; thrombosis
Ro 435054	N-[N-[N-[4-(aminoiminomethyl)benzoyl]-beta-alanyl]-L-alfa-aspartyl]-L-phenylalanine mono(trifluoroacetate)	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
Ro 438857; Ro 43-8857	2,2'-[[4-[[[4-(aminoiminomethyl)benzoyl]methylamino]acetyl]-1,2-phenylene]bis(oxy)]bisacetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
roxifiban; DMP 754	(R)-3-[[[3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-(butoxycarbonyl)-L-alanine methyl ester monoacetate	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
RPR 110173	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

SB 208651	(+,-)-8-[[[4-(aminoiminomethyl)phenyl]methylamino]carbonyl]-2,3,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-1H-1,4-benzodiazepine-2-acetic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 47643	(S)-3-[[8-[[[8-[(aminoiminomethyl)amino]-1-oxooctyl]amino]-4-[[2-(4-methoxyphenyl)ethyl]amino]-4-oxobutanoic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 49992	8-guanadino-octanoyl-Asp-Phe	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 52012A	N-[N-[5-[4-(aminoiminomethyl)phenyl]-1-oxopentyl]-L-alpha-aspartyl]-L-phenylalanine	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SC 54701	(S)-3-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
SDZ GPI562	Unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke
sibrafiban; Ro 483657; RO 483657001; XUBIX; ZUBIX	[S-(Z)]-[[1-[2-[[4-[amino(hydroxyimino)methyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]acetic acid ethyl ester	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

SR 121787	4-[[4-[4- [[[(ethoxycarbonyl)am ino]iminomethyl]phe nyl]-2-thiazolyl] (3- ethoxy-3- oxopropyl)amino]-1- piperidineacetic acid, ethyl ester	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
T 250	(-)-4-[3-(4- (aminoiminomethyl)p henoxy)propyl]-2,3- dioxo-beta-3-py ridinyl-1- piperazinepropanoic acid	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
TAK 029	4-[[[4- (aminoiminomethyl)b enzoyl]amino]acetyl]- 2-oxo-1,3- piperazinnediacetic acid alpha3-methyl ester	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
tirofiban; tirofiban hydrochloride; MK 383; L 700462; AGGRASTAT	N-(butylsulfonyl)-O- [4-(4- piperidinyl)butyl]-L- tyrosine	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina
TRM 147	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
xemilofiban; SC 54684A; SC 54684; CS 551	ethyl 3-[[4-[4- (aminoiminomethyl)p henyl]amino]-1,4- dioxobutyl]amino]-4- pentynoate	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
contortrostatin; CN	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; biotechnology	cancer; thrombosis

teptifibatide; INTEGRILIN; INTEGRELIN	N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide cyclic (1->6)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis; angina; myocardial infarction; restenosis
G 4120	N-(mercaptoacetyl)-D-tyrosyl-L-arginylglycyl-L-alpha-aspartyl-L-cysteine cyclic (1-5)-sulfide S-oxide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis
kistrin	kistrin (Agkistrodon rhodostoma reduced)	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; venom	thrombosis
aprosulate sodium; LW 10082	N,N'-1,3-propanediylbis[4-O-(2,3,4,6-tetra-O-sulfo-beta-D-galactopyranosyl)-D-gluconamide], 2,2',3,3',5,5',6,6'-octakis(hydrogen sulfate) hexadecasodium salt	Heaprin cofactor; serine proteases	thrombosis
dermatan sulfate; chondroitin sulfate B; chondroitinsulfuric acid B; MF 701; DS 435	dermatan, hydrogen sulfate (ester)	heparin cofactor II activator	thrombosis
alpha idosone	unspecified	heparinoid	thrombosis
ardeparin sodium; WY 90493; NORMIFLO	unspecified	heparinoid	thrombosis
bemiparin sodium; HIBOR	unspecified	heparinoid	thrombosis
BF 611	unspecified	heparinoid	thrombosis
C4 CY 216	unspecified	heparinoid	thrombosis
certoparin sodium; ALPHAPARIN	unspecified	heparinoid	thrombosis



dalteparin sodium; low molecular weight heparin; heparin, low molecular weight; tedelparin; tedelparine; KABI 2165; K 2165; FR 860; FRAGMIN; FRAGMINE; BOXOL	heparin, sodium salt	heparinoid	thrombosis; coronary artery disease; angina
danaparoid sodium; danaparoid; glycosamino glycan; ORG 10172; KB 101; ORGARAN; LOMOPARAN; RESTART	unspecified	heparinoid	thrombosis; thrombocytopenia
drug delivery system, BEODAS heparin; heparin BEODAS	unspecified	heparinoid	thrombosis
drug delivery system, LDS microemulsion low molecular weight heparin; heparin, low molecular weight, LDS microemulsion	unspecified	heparinoid	thrombosis
drug delivery system, nanosphere oral heparin; heparin oral; HEPORAL	unspecified	heparinoid	thrombosis
drug delivery system, oral low molecular weight heparin; heparin delivery system	unspecified	heparinoid	thrombosis
drug delivery system, submicron emulsion low molecular weight heparin; low molecular weight heparin SME	unspecified	heparinoid	thrombosis

drug delivery system, transmucosal low molecular weight heparin; heparin, low molecular weight, transmucosal	unspecified	heparinoid	thrombosis
enoxaparin sodium; low molecular weight heparin; enoxaparin; enoxaparine; PK 10169; RPY 005; RP 54563; LOVENOX; CLEXAN; CLEXANE	heparin sodium salt	heparinoid	thrombosis; angina; stroke; myocardial infarction
GM 2000	unspecified	heparinoid	thrombosis; restenosis
heparin sulfate analogue; HHS 5	unspecified	heparinoid	thrombosis
ITF 1331	heparin compound with bis[4- (dibutylamino)butyl] carbonate	heparinoid	thrombosis
ML 009723; CIRICIN	unspecified	heparinoid	thrombosis
nadroparin calcium; low molecular weight heparin; heparin, low molecular weight; CY 216; FRAXIPARIN; FRAXIPARINE; FRAXIPARINA; SELEPARIN	unspecified	heparinoid	thrombosis
naroparcil; LF 90055	p-(p-((5-thio-beta-D- xylopyranosyl)thio)be nzoyl)benzonitrile	heparinoid	thrombosis
parnaparin sodium; parnaparin; low molecular weight heparin; heparin, low molecular weight; LHG 500; FLUXUM; MINIDALTON; LOHEPA	heparin	heparinoid	thrombosis

reviparin sodium; reviparin; low molecular weight heparin; heparin, low molecular weight; LU 47311; CLIVARIN	unspecified	heparinoid	thrombosis
S 5	unspecified	heparinoid	thrombosis
supersulfated low molecular weight heparin; ssLMWH	unspecified	heparinoid	thrombosis; hyperlipidemia
tinzaparin sodium; tinzaparin; low molecular weight heparin; heparin, low molecular weight; LHN 1; LOGIPARIN; INNOHEP	unspecified	heparinoid	thrombosis
ultra low molecular weight heparin; heparin, ultra low molecular weight; CY 222	unspecified	heparinoid	thrombosis
ZYN-LINKER conjugated heparin	unspecified	heparinoid	restenosis; thrombosis
fondaparin sodium; SR 90107; ORG 31540; SR 90107A	methyl O-2-deoxy-6- O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-beta-D- glucopyranuronosyl- (1-4)-O-2-deoxy-3,6- di-O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-2-O-sulfo-alfa-L- idopyranuronosyl-(1- 4)-2-deoxy-2- (sulfoamino)-alfa-D- glucopyranoside 6- (hydrogen sulfate)	heparinoid; blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis; peripheral vascular disease

SanOrg 32701; SR 32701	methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-alpha-D-glucopyranoside 3,6-bis(hydrogen sulfate) undecasodium salt	heparinoid; blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis
ITF 1300	Unspecified	heparinoid; class III antiarrhythmic	thrombosis; arrhythmia
GM 1077; ASTENOSE	unspecified	heparinoid; platelet antiaggregant	thrombosis; restenosis
MDL 28050	N-[N-[N-[N-[N-[1-[N-[1-[N-[N-(3-carboxy-1-oxopropyl)-L-tyrosyl]-L-alfa-glutamyl]-L-prolyl]-L-isoleucyl]-L-prolyl]-L-alfa-glutamyl]-L-alfs-glutamyl]-L-alanyl]-3-D-glutamic acid	hirudin analogue	thrombosis
hirudin peptide analogue; P 79	unspecified	hirudin analogue; peptide; thrombin inhibitor; proteinase inhibitor	thrombosis
antibody-mediated stroke inhibitor	unspecified	immunosuppressant; biotechnology	gynecological; stroke; thrombosis; myocardial infarction
drug delivery system, ANCHOR platelet inhibitor	unspecified	integrin antagonist; cell adhesion inhibitor	thrombosis

PKSI 527	[1(S)-trans]-4-[[2-[[[4-(aminomethyl)cyclohexyl]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]benzeneacetic acid monohydrochloride	kallikrein inhibitor; NSAID	septic shock; inflammation; thrombosis
linsidomine; SIN 1; CORVASAL; CORVATON	3-(4-morpholinyl)sydnone imine	nitric oxide donor; platelet antiaggregant	thrombosis
NCX 4016	2-(acetyloxy)benzoic acid, 2-[(nitrooxy)methyl]phenylester	NSAID; nitric oxide donor; platelet antiaggregant; analgesic	thrombosis; pain
OP 2000	unspecified	oligosaccharide	inflammatory bowel disease; thrombosis
ORG 31550; SR 80027	unspecified	oligosaccharide	thrombosis
SR 123781	unspecified	oligosaccharide	thrombosis
VASOFLUX	unspecified	oligosaccharide; thrombin inhibitor; proteinase inhibitor	thrombosis; myocardial infarction
lexipafant; BB 882; DO 6; GR 167089; ZACUTEX	N-methyl-N[[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-L-leucine ethyl ester	PAF antagonist	thrombosis; endotoxic shock; pancreatitis; eye disease; multiple sclerosis
LA 213	unspecified	PAF antagonist; peptide; platelet antiaggregant	hypertension; thrombosis
dacopafant; RP 48740	(3R)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide	PAF antagonist; platelet antiaggregant	asthma; thrombosis
epiyangambin	(1R,3aR,4S,6aR)-tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-1H,3H-furo[3,4-c]furan	PAF antagonist; platelet antiaggregant	thrombosis
F 1850	unspecified	PAF antagonist; platelet antiaggregant	thrombosis; asthma

ginkgolide B; BN 52021	hexacyclic trilactone	PAF antagonist; platelet antiaggregant	thrombosis; dermatitis; asthma; multiple sclerosis; septic shock
KO 286011	N-[1-(9-ethoxy-6-hydroxy-6-oxido-5,7,11-trioxa-6-phosphaheptacos-1-yl)-4(1H)-pyridinylidene]-N-methylmethanaminium inner salt	PAF antagonist; platelet antiaggregant	thrombosis
L 659989	trans-(+,-)-tetrahydro-2-[3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)furan	PAF antagonist; platelet antiaggregant	asthma; thrombosis
minopafant; E 5880	(R)-1-ethyl-2-[[2-methoxybenzoyl][2-methoxy-3-[[[4-[[[(octadecylamino)carbonyl]oxy]-1-piperidinyl]carbonyl]oxy]propoxy]carbonyl]amino]methyl]pyridinium chloride	PAF antagonist; platelet antiaggregant	thrombosis
R 74654	3-(6-(0-(2R,2S)-(3-heptadecylcarbamoyloxytetrahydropyran-2-yl)methyl)phosphonoxy)hexylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis
R 74717	3-(5-(0-(2S,3S)-(3-heptadecylcarbamoylthiotetrahydropyran-2-yl)methyl)phosphonoxy)pentylthiazolium	PAF antagonist; platelet antiaggregant	asthma; thrombosis

Ro 244736; Ro 24-4736	5-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-2-propynyl]-6(5H)-phenanthridinone	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
SDZ 64412; SDZ 64-412	2,3-dihydro-5-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl]imidazo[2,1-a]isoquinoline monohydrochloride	PAF antagonist; platelet antiaggregant	asthma; thrombosis
SM 12502	(2R-cis)-3,5-dimethyl-2-(3-pyridinyl)-4-thiazolidinone, monohydrochloride	PAF antagonist; platelet antiaggregant	thrombosis
SR 27388	4-[2-[[2-(dimethylamino)ethyl](3-pyridinylmethyl)amino]-4-thiazolyl]-2,6-bis(1,1-dimethylethyl)phenol	PAF antagonist; platelet antiaggregant	thrombosis; asthma; septic shock
UK 74505	4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]-5-[(2-pyridinylamino)carbonyl]-3-pyridinecarboxylic acid ethyl ester	PAF antagonist; platelet antiaggregant	thrombosis; asthma
WEB 2347	6-(2-chlorophenyl)-8,9-dihydro-1-methyl-N,N-dipropyl-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-8-carboxamide	PAF antagonist; platelet antiaggregant	asthma; anaphylactic shock; thrombosis

YM 264	1-(3-methyl-3-phenylbutyl)-4-[[2-(3-pyridinyl)-4-thiazolidinyl]carbonyl]piperazine (E)-2-butenedioate (1:1)	PAF antagonist; platelet antiaggregant	thrombosis; asthma
SDZ 64619	(+,-)-2-[6-methoxy-2-(methylsulfonyl)-3,9-dioxo-4,8-dioxo-2,10-diazaoctacosan-1-yl)-1-methylpyridinium iodide	PAF antagonist; platelet antiaggregant; bronchodilator	thrombosis; asthma
CV 6209	2-(2-acetyl-6-methoxy-3,9-dioxo-4,8-dioxo-2,10-diazaoctacos-1-yl)-1-ethylpyridinium chloride	PAF antagonist; platelet antiaggregant; NSAID	thrombosis; inflammation
UR 11353	2-[[[acetyl[[[tetrahydro-5-(octadecyloxy)-3-furanyl]methoxy]carbonyl]amino]methyl]-1-ethylpyridinium chloride	PAF antagonist; platelet antiaggregant; NSAID	thrombosis; inflammation
XR 334 series; XR 334	(Z,Z)-3-[(4-Methoxyphenyl)methylene]-6-(phenylmethylene)-2,5-piperazinedione	PAI inhibitor; thrombolytic	thrombosis; angina
XR 5118	(Z,Z)-3-[[5-[[2-(dimethylamino)ethyl]thio]-2-thienyl]methylene]-6-(phenylmethylene)-2,5-piperazinedione monohydrochloride	PAI inhibitor; thrombolytic	thrombosis
anticoagulant, Erfurt Medical Academy	D-phenylalanyl-L-prolyl-L-arginine nitrile	peptide	thrombosis
antithrombotic peptides	unspecified	peptide	thrombosis



fibrolase and thrombus targeting peptides; fibrolase and P734	unspecified	peptide	thrombosis
LU 58463	unspecified	peptide	thrombosis
AS 101; METASCAN	unspecified	peptide; contrast medium; radiodiagnostic	diagnosis; thrombosis
GPIIb/IIIa peptide antagonist	unspecified	peptide; platelet antiaggregant	thrombosis
MOL 144	unspecified	peptide; thrombin inhibitor; proteinase inhibitor	thrombosis
MOL 171	unspecified	peptide; thrombin inhibitor; proteinase inhibitor	thrombosis
triflusal; UR 1501; DISGREN; TECNOSAL; TRIFLUX; AFLEN	unspecified	phosphodiesterase inhibitor; COX inhibitor; platelet antiaggregant	thrombosis
NM 702	4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-3(2H)-pyridazinone monohydrochloride	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; phosphodiesterase V inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
cilostazol; OPC 13013; PLETAL; PLETAAL	6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; platelet antiaggregant; vasodilator	thrombosis
BF 385; GP 385; BF/GP 385; ONO BF11301; ONO 1505	unspecified	phosphodiesterase inhibitor; phosphodiesterase V inhibitor; thromboxane synthetase inhibitor; platelet antiaggregant	hypertension; thrombosis

AY 31390	5-bromo-6-[[5-bromo-3-pyridinyl)methyl]amino]-2-methyl-4(1H)-pyrimidinone monohydrobromide	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
BMY 21190	7-[4-(cyclohexylamino)butoxy]-1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
BMY 21638	1,3-dihydro-7-[4-(phenylsulfonyl)butoxy]-2H-imidazo[4,5-b]quinolin-2-one	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
BMY 43351	7-(4-(4-(cyclohexylmethyl)-1-piperazinyl)-4-oxobutoxy)-1,3-dihydro-2H-imidazo(4,5-b)quinolin-2-one	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis; angina
R 69082	unspecified	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis
SKF 95654	4,5-dihydro-6-(4-(1,4-dihydro-4-oxopyridin-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant	thrombosis; heart failure
pimobendan; UDCG 115; UDCG 115A; UDCG 115BS; ACARDI	4,5-dihydro-6-(z-(p-methoxyphenyl)-5-benzimidazolyl)-5-methyl-3-(2H)-pyridazinone	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	thrombosis; heart failure
simendan	[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator	heart failure; thrombosis

levosimendan; OR 1259; SIMDAX	[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile	phosphodiesterase inhibitor; platelet antiaggregant; vasodilator; calcium sensitizer	heart failure; thrombosis
U 73122	1-[6-[[[(17 beta)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]]	phospholipase inhibitor; platelet antiaggregant; NSAID	inflammation; thrombosis
tenecteplase; TNK-tPA; TNK	plasminogen activator (human tissue type), 103-L-asn-117-L-gln-296-L-ala-297-L-ala-298-L-ala-299-L-ala-	plasminogen activator; biotechnology; thrombolytic	thrombosis; myocardial infarction
fu-PA	unspecified	plasminogen activator; thrombolytic	thrombosis
anagrelide; anagrelide hydrochloride; BL 4162A; AGRYLIN; AGRELIN	6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one	platelet antiaggregant	thrombosis; cancer
antiaggregant, Kanebo	4,5-bis(4-methoxyphenyl)-2-(1,5-dimethyl-2-pyrrolyl)thiazole	platelet antiaggregant	thrombosis
anticoagulant	hexadecasodium N,N'-dimethylethylenebis(4-O-beta-D-galactopyranosyl-D-gluconoylamino octasulfate)	platelet antiaggregant	thrombosis
anticoagulant	hexadecasodium trimethylenebis (4-O-beta-galactopyranosyl-D-gluconoylamino octasulfate)	platelet antiaggregant	thrombosis
ARL 67085; FPL 67085; FPL 67085XX	2-(propylthio)-5'-adenylic acid monoanhydride with (dichloromethylene)bis[phosphonic acid]	platelet antiaggregant	thrombosis

aspalatone; asparatone; BK 111	2-(acetyloxy)benzoic acid 2-methyl-4-oxo- 4H-pyran-3-yl ester	platelet antiaggregant	thrombosis
BIBU 251	unspecified	platelet antiaggregant	thrombosis
BIS-TMPP	2,2'-(1-propene-1,3- diyl)bis[3,5,6- trimethylpyrazine]	platelet antiaggregant	thrombosis
BMY 21259	methyl-4-((2,3- dihydro-2-oxo-1H- imidazo(4,5- b)quinolin-7-yl)-oxy) butanoate	platelet antiaggregant	thrombosis
BMY 21260	4-[(2,3-dihydro-2- oxo-1H-imidazo[4,5- b]quinolin-7- yl)oxy]butyric acid	platelet antiaggregant	thrombosis
BP 16	potassium 6-chloro- alpha- cyanopyrazineacetic acid ethyl ester ion(1- )	platelet antiaggregant	thrombosis
C 894095	5-amino-3-(3,3- dimethyl-1,1-dioxido- 4-thiomorpholinyl)- 1,2,3-oxadiazolium chloride	platelet antiaggregant	thrombosis
CK 53	2-[[4-(2- chlorophenyl)-1- piperazinyl]methyl]- 2,6- dihydroimidazo[1,2- c]quinazolin-5(3H)- one	platelet antiaggregant	thrombosis
clopidogrel; clopidogrel bisulfate; SR 25990; SR 25990C; DV 7314; PCR 4099; SR 25990B; SR 25990A; SR 25990D; SR 25990E; PLAVIX; ISCOVER	(S)-alfa-(2- chlorophenyl)-6,7- dihydrothieno[3,2- c]pyridine-5(4H)- acetic acid methyl ester	platelet antiaggregant	thrombosis; stroke; ischemia
CS 747	unspecified	platelet antiaggregant	thrombosis
DHG 1	unspecified	platelet antiaggregant	thrombosis

dicranin	9,12,15-octadecatrien-6-ynoic acid	platelet antiaggregant	thrombosis
drug delivery system, argatroban; argatroban drug delivery system	unspecified	platelet antiaggregant	thrombosis; myocardial infarction
drug delivery system, oral heparin; heparin, oral delivery system	unspecified	platelet antiaggregant	thrombosis
drug delivery system, oral low molecular weight heparin; low molecular weight heparin oral	unspecified	platelet antiaggregant	thrombosis
echicetin	unspecified	platelet antiaggregant	thrombosis
ethyl eicosapentaenoate; ethyl icosapentate; EPA-E; MND 21; EPADEL	ethyl all-cis-5,8,11,14,17-eicosapentaenoate	platelet antiaggregant	thrombosis; hyperlipidemia
fradafiban; BIBU 52	(3S,5S)-5-[(4'-amidino-4-biphenyl)oxymethyl]-2-oxo-3-pyrrolidineacetic acid	platelet antiaggregant	thrombosis
G 619	4-methoxy-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide	platelet antiaggregant	thrombosis
glaucoalyxin A	(7 $\alpha$ ,14R)-7,14-dihydroxy-kaur-16-ene-3,15-dione	platelet antiaggregant	thrombosis
GM 1115	unspecified	platelet antiaggregant	thrombosis; restenosis
GM 1445	unspecified	platelet antiaggregant	thrombosis
GM 9005	unspecified	platelet antiaggregant	thrombosis
GT 12	alpha, alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide	platelet antiaggregant	thrombosis
IBI P05006; IBI-P 05006	2-amino-6-hexylcyclohexanecarboxylic acid	platelet antiaggregant	thrombosis

indobufen; K 3920; IBUSTRIN	(+,-)-2-[p-(1-oxo-2- isoindolinyl)phenyl]b utyric acid	platelet antiaggregant	thrombosis
KK 117	2-hydroxy-1,2,3,3- tetrahydro-3H- pyrano(3,2- f)quinoline-8(7H)-one	platelet antiaggregant	thrombosis
L 367073; MK 0852	N-acetyl-L-cysteinyl- L-asparaginyl-5,5- dimethyl-L-4- thiazolidinecarbonyl- 4-(aminomethyl)-L- phenylalanylglycyl-L- alfa-aspartyl-L- cysteine cyclic (1-7)- disulfide	platelet antiaggregant	thrombosis
L 703014	unspecified	platelet antiaggregant	thrombosis
LF 1351	4-[hydroxy(4- nitrophenyl)methyl]p henyl-beta-D- xylopyranoside	platelet antiaggregant	thrombosis
ME 3229	unspecified	platelet antiaggregant	thrombosis
mycololide B	unspecified	platelet antiaggregant	thrombosis
P1	H-Phe-Gln-Val-Val- Cys(3-nitro-2- pyridinesulfenyl)- Gly-NH <sub>2</sub>	platelet antiaggregant	thrombosis
PI 200	unspecified	platelet antiaggregant	thrombosis
PI 201	unspecified	platelet antiaggregant	thrombosis
RC 3911	2-(diethylamino)-7- hydroxy-4H-1- benzopyran-4-one	platelet antiaggregant	thrombosis
RGDY	unspecified	platelet antiaggregant	thrombosis
SC 52905	unspecified	platelet antiaggregant	thrombosis
SKF 106760	N-acetyl-L-cysteinyl- N <sup>2</sup> -methyl-L- arginylglycyl-L- alpha-aspartyl-3- mercapto-L- valinamide cyclic (1- 5)-disulfide	platelet antiaggregant	thrombosis

thiofedrine	3-[(2-hydroxy-1-methyl-2-phenylethyl)amino]-1-(thien-2-yl)-1-propanone	platelet antiaggregant	thrombosis
trombodipine; thrombodipine; PCA 4230	1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid ethyl 2-(3-oxo-1,2-benzisothiazol-2(3H)-yl)ethyl ester S,S-dioxide	platelet antiaggregant	thrombosis
TY 11223	[1S-[1alpha(R*),2beta,3alpha,7alpha]]-[2-[2,3,3a,6,7,7a-hexahydro]e-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nonadiynyl)-1H-inden-5-yl]ethoxy]acetic acid	platelet antiaggregant	thrombosis
V 20	unspecified	platelet antiaggregant	thrombosis
EF 12	unspecified	platelet antiaggregant; antiproliferative agent	heart ischemia; thrombosis; restenosis
ticlopidine; ticlopidine hydrochloride; 5332 C; 4 C 32; PCR 5332; PICLODIN; PICLONADINE; PROPACALL; TICLID; PANALDINE; ROBETARL; RONDORIN	5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine	platelet antiaggregant; calcium antagonist	stroke; thrombosis
L 734217	[R-(R*,R*)]-3-[[[2-oxo-3-[2-(4-piperidinyl)ethyl]-1-piperidinyl]acetyl]amino-butanoic acid	platelet antiaggregant; fibrinogen antagonist	thrombosis

lefradafiban; BIBU 104; BIBU 104XX	(3S-trans)-5-[[[4'-[imino[(methoxycarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]oxy]methyl]-2-oxo-3-pyrrolidineacetic acid methyl ester	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
MS 180	3,4-dihydro-6-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-2H-1-benzopyran-3-acetic acid ethyl ester monohydrochloride	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
orbofiban; SC 57099B; CS 511	(S)-N-[[[1-[4-(aminoiminomethyl)phenyl]-2-oxo-3-pyrrolidinyl]amino]carbonyl]-beta-alanine ethyl ester	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
RWJ 53308	[S-(R*,S*)]-beta-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
SC 46749	unspecified	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
SR 121566	4-[[4-[4-(aminoiminomethyl)phenyl]-2-thiazolyl](2-carboxyethyl)amino]-1-piperidineacetic acid trihydrochloride	platelet antiaggregant; glycoprotein IIb/IIIa antagonist	thrombosis
platelet adhesion inhibitors	unspecified	platelet antiaggregant; platelet antiaggregant	thrombosis
S 18886	unspecified	platelet antiaggregant; thromboxane antagonist	thrombosis



drug delivery system, MICROPUMP oral controlled release aspirin; aspirin MICROPUMP; ASACARD	unspecified	platelet antiaggregant; thromboxane synthetase inhibitor; analgesic; NSAID	thrombosis; pain; inflammation
cloricromen; cloricromene; AD 6; PROENDOTEL	[[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2H-1-benzopyran-7-yl]oxy]acetic acid ethyl ester	platelet antiaggregant; vasodilator	arrhythmia; thrombosis
vintoperoxol; RGH 2981	(3 $\alpha$ ,16 $\alpha$ )-21-nor-1,14-secoeburnamein-20-ol	platelet antiaggregant; vasodilator; antioxidant	peripheral vascular disease; thrombosis
epoprostenol; epoprostenol sodium; prostacyclin; prostaglandin X; prostaglandin I <sub>2</sub> ; vasocyclin; UN 53217A; U 53217; FLOLAN; CYCLO-PROSTIN	(5Z,9 $\alpha$ ,11 $\alpha$ ,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid	platelet antiaggregant; vasodilator; prostanoid	pulmonary hypertension; thrombosis
triflavin	triflavin (trimeresurus flavoviridis reduced)	platelet antiaggregant; venom	thrombosis
albolabrin	unspecified	platelet antiaggregant; venom; peptide	thrombosis
echistatin	unspecified	platelet antiaggregant; venom; peptide	thrombosis
BMV 42393	2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy] acetic acid	prostaglandin agonist; platelet antiaggregant	hyperlipidemia; thrombosis
SQ 27986	[1S-[1 $\alpha$ ,2 $\beta$ (Z),3 $\alpha$ (1E,3R*),4 $\alpha$ ]]-7-[3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	prostaglandin agonist; platelet antiaggregant	thrombosis

BW 192C86; 192C86	5-(3-carboxypropylthio)-1-(2-cyclohexyl-2-hydroxyethylideneamino)-3-ethyl-hexahydrocyclopenta-(d) imidazol-2(1H)-one	prostaglandin partial agonist; platelet antiaggregant	thrombosis
ataprost; tepoprostenol; ONO 41483; OP 41483	[3aS-[2E,3aalfa,4alfa(1E,3R*),5beta,6aalfa]]-5-[4-(3-cyclopentyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2(1H)-pentalenylidene]penta noic acid	prostanoid; platelet antiaggregant	thrombosis
beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
BMV 45778	unspecified	prostanoid; platelet antiaggregant	thrombosis
ciprostene; ciprostone calcium; U 61431F	[3aS-[2Z,3aalfa,5beta,6alfa(1E,3R*),6aalfa]]-5-[hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-3a-methyl-2(1H)-pentalenylidene]penta noic acid	prostanoid; platelet antiaggregant	thrombosis; restenosis
drug delivery system, lipid microsphere, clinprost; clinprost lipid microsphere; TTC 909; ARTEON	[3aS-[3aalpha,5beta,6alpha(1E,3R*),6aalpha]]-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-2-pentalenepentanoic acid methyl ester	prostanoid; platelet antiaggregant	thrombosis; stroke

maxaprostene; CG 4305	[3aS- [2E,3aalfa,4alfa(1E,3 R*),5beta,6aalfa]]-3- [[4-(3-cyclohexyl-3- hydroxy-1- propenyl)hexahydro- 5-hydroxy-2(1H)- pentalenylidene]meth yl]benzoic acid	prostanoid; platelet antiaggregant	thrombosis
ONO NT012	5(Z)-7- [(1S,2S,3S,5R)-3- (trans-beta- styren)sulfonamido- 6,6- dimethylbicyclo[3.1.1 .]hept-2-yl]-5- heptenoic acid	prostanoid; platelet antiaggregant	thrombosis
ZK 110841	[1R- [1alfa(Z),2beta(1E,3S *),3alfa,5beta]]-7-[5- chloro-2-(3- cyclohexyl-3- hydroxy-1-propenyl)- 3- hydroxycyclopentyl]- 5-heptenoic acid	prostanoid; platelet antiaggregant	glaucoma; hypertension; thrombosis
ZK 118182	[1R- [1alfa(Z),2beta(1E,3S *),3alfa,5alfa]]-[[4- [5-chloro-2-(3- cyclohexyl-3- hydroxy-1-propenyl)- 3- hydroxycyclopentyl]- 2-butenyl]oxy]acetic acid	prostanoid; platelet antiaggregant	thrombosis; hypertension

KP 10614	[3aS-[2(Z),3aalfa,5beta,6alfa(1E,3R*,4R*),6aalfa]]-5-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-4-methyl-1-nonen-6-ynyl)-2-pentalenyl]-4-pentenoic acid	prostanoid; platelet antiaggregant; vasodilator	thrombosis; peripheral vascular disease
taprostene; CG 4203	alpha-((2Z,3aR,4R,5R,6aS)-4-((1E,3S)-3-cyclohexyl-3-hydroxypropenyl)hexahydro-5-hydroxy-2H-cyclopenta(beta)furan-2-ylidene)-meta-toluic acid	prostanoid; platelet antiaggregant; vasodilator	peripheral vascular disease; thrombosis
iloprost; ciloprost; ZK 36374; E 1030; SH 401; ILOMED; ENDOPROST; ILOMEDIN; AIPRO	5-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene]pentanoic acid	prostanoid; platelet antiaggregant; vasodilator; NSAID	peripheral vascular disease; thrombosis; thrombocytopenia; rheumatoid arthritis
alprostadiol; lipo-prostaglandin E1; lipo-PGE1; U 10136; PGE1; CAVERJECT; PALUX; LIPLE; PROSTIN; EDEX; MUSE	(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid	prostanoid; vasodilator; cicatrizant	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss
cicaprost; cicaprost clathrate; ZK 114923; SH 574; SH 490	[3aS-[2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha]]-[2-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl)-2(1H)-pentalenylidene]ethoxy]acetic acid	prostanoid; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease; cancer

protein kinase activators	unspecified	protein kinase activator; protein kinase A activator	asthma; thrombosis
ONO 3307	4-[(aminoiminomethyl)amino]benzoic acid 4-(aminosulfonyl)phenyl ester monomethanesulfonate	proteinase inhibitor	thrombosis
proteinase inhibitors	unspecified	proteinase inhibitor	thrombosis
HMR 2906	unspecified	proteinase inhibitor; blood clotting factor Xa inhibitor	thrombosis
ZK 807191	N-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methylglycine	proteinase inhibitor; blood clotting factor Xa inhibitor	thrombosis
bivalirudin; BG 8967; HIRULOG	D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginyglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl-L-leucine	proteinase inhibitor; hirudin analogue; thrombin inhibitor	thrombosis; angina; myocardial infarction
GL 522	unspecified	proteinase inhibitor; platelet antiaggregant	thrombosis
nafamostat; nafamostat mesylate; nafamostat mesilate; FUT 175; FUTHAN TORII; FUTHAN BANYU	6-amidino-2-naphthyl p-guanidinobenzoate	proteinase inhibitor; platelet antiaggregant	thrombosis; pancreatitis; allergy; anaphylactic shock

SDZ 217766; SDZ 217-766	[3aS-[2(S*),3aalpha,4beta,6beta,7aalpha]]N-[(1,1-dimethylethoxy)carbonyl]-3-(trimethylsilyl)-L-alanyl-N-[4-[(aminoiminomethyl)amino]-1-(hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl)butyl]-L-prolinamide	proteinase inhibitor; platelet antiaggregant; peptide	thrombosis
argatroban; argatrovan; argipidine; argopidine; algipidine; DK 7419; MCI 9038; MD 805; OM 805; GN 1600; NOVASTAN; SLONNON	(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-quinoliny)sulfonyl]amino]pentyl]-4-methyl-2-[piperidinecarboxylic acid	proteinase inhibitor; platelet antiaggregant; thrombin inhibitor	thrombosis; myocardial infarction; ischemia; angina; brain ischemia; thrombocytopenia
proteinase inhibitors, SDR	unspecified	proteinase inhibitor; serine proteinase inhibitor; peptide	thrombosis
BCH 2763	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis
CCI 1004	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis
CL 03135	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis
ORG 37940	N-(carboxymethyl)-3-cyclohexyl-D-alanyl-N-[5-amino-1-(carboxycarbonyl)pentyl]-L-prolinamide	proteinase inhibitor; thrombin inhibitor	thrombosis
PPACK	D-Phe-Pro-Arg-chloromethyl ketone	proteinase inhibitor; thrombin inhibitor	thrombosis
thrombin inhibitor	unspecified	proteinase inhibitor; thrombin inhibitor	thrombosis

SDZ 216744	unspecified	proteinase inhibitor; thrombin inhibitor; platelet antiaggregant	thrombosis
thrombin receptor inhibitors, oral	unspecified	proteinase inhibitor; thrombin inhibitor; platelet antiaggregant	thrombosis
thrombin receptor inhibitors, parenteral	unspecified	proteinase inhibitor; thrombin inhibitor; platelet antiaggregant	thrombosis
AR 69931; AR C69931MX	N-[2- (methylthio)ethyl]-2- [(3,3,3- trifluoropropyl)thio]- 5'-adenylic acid monoanhydride with (dichlorophosphonom ethyl)phosphonic acid	purinoceptor antagonist; platelet antiaggregant	thrombosis; myocardial infarction
purinoceptor 2T antagonists	unspecified	purinoceptor antagonist; platelet antiaggregant	thrombosis
Buthus Martensii Karsch venom; BMK venom; scorpion venom	unspecified	scorpion venom; thrombolytic	thrombosis
ACITIC	[3-[(7-amino-4- chloro-1-oxo-1H-2- benzopyran-3- yl)oxy]propyl]thioure a	serine proteinase inhibitor; proteinase inhibitor	thrombosis
LEX 026 analogues	unspecified	serine proteinase inhibitor; proteinase inhibitor	thrombosis
BIBR 1048	unspecified	thrombin inhibitor	thrombosis
desirudin; desulfatohirudin; hirudindesulfato; hirudin; CGP 39393; REVASC; HIRUDIN	63-desulfohirudin (hirudo medicinalis isoform HV1)	thrombin inhibitor; biotechnology; proteinase inhibitor	thrombosis

CVS 995	N-(1-oxo-2-propylpentyl)-L-alpha-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-tyrosyl-L-leucine	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
DUP 714	(S)-N-acetyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)amino]-1-boronobutyl]-L-prolinamide	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
P 8714	N-acetyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)amino]-1-boronobutyl]-L-prolinamide	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
S 18326	Ac-D-Phe-N-cyclopentylglycine-boroArg	thrombin inhibitor; peptide; proteinase inhibitor	thrombosis
napsagatran; Ro 466240	(S)-N-[N4-[[1-(aminoiminomethyl)-3-piperidinyl]methyl]-N2-(2-naphthalenylsulfonyl)-L-asparaginyl]-N-cyclopropylglycine	thrombin inhibitor; platelet antiaggregant; proteinase inhibitor	thrombosis
3DP 4026	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis



BMS 180742	N2-[N-[N-[N-[1-[N-[1-[N-[N-(3-carboxy-1-oxopropyl)-L-phenylalanyl]-L-alpha-glutamyl]-L-prolyl]-L-isoleucyl]-L-prolyl]-L-alpha-glutamyl]-L-alpha-glutamyl]-L-tyrosyl]-3-cyclohexyl-L-alanyl]-L-glutamine	thrombin inhibitor; proteinase inhibitor	thrombosis
BMV 44621	[S-(R*,R*)]-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-1-(1-oxo-3-phenylpropyl)-2-pyrrolidinecarboxamide	thrombin inhibitor; proteinase inhibitor	thrombosis
CORTHROMBIN	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
CRC 220; CRC 200	[S-(R*,S*)]-4-[[1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinylethyl)amino]-3-[[4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-4-oxobutanoic acid	thrombin inhibitor; proteinase inhibitor	thrombosis
CVS 1123	N-(1-oxo-2-propylpentyl)-L-alpha-aspartyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]-L-prolinamide methyl ester	thrombin inhibitor; proteinase inhibitor	thrombosis
H 376; H 37695; H 376/95	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis

L 374087	N-[(6-amino-2-methyl-3-pyridinyl)methyl]-6-methyl-2-oxo-3-[[[(phenylmethyl)sulfonyl]amino]-1(2H)-pyridineacetamide	thrombin inhibitor; proteinase inhibitor	thrombosis
L 375378	N-[(6-amino-2-methyl-3-pyridinyl)methyl]-6-methyl-2-oxo-3-[(2-phenylethyl)amino]-1(2H)-pyrazineacetamide dihydrochloride	thrombin inhibitor; proteinase inhibitor	thrombosis
LB 30057	(S)-4-[3-(cyclopentylmethylamino)-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]-benzenecarboximide acid hydrazide	thrombin inhibitor; proteinase inhibitor	thrombosis
LY 294291	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
LY 303496	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
MDL 73756	D-Phe-Pro-Arg-CF3	thrombin inhibitor; proteinase inhibitor	thrombosis
melagatran; H 31968	[S-(R*,S*)]-N-[2-[2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidiny]-1-cyclohexyl-2-oxoethyl]glycine	thrombin inhibitor; proteinase inhibitor	thrombosis
MOL 127	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
MOL 376	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis

Ro 091679; Ro 09-1679	[S-(E)]-N2-(3-carboxy-1-oxo-2-propenyl)-L-arginyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-L-leucinamide	thrombin inhibitor; proteinase inhibitor	thrombosis
SDZ MTH958; MTH 958	Boc-D-trimethylsilylalanine-Pro-borolysine	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor, injectable; CORTHTROMBIN	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitor, systemic	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
thrombin inhibitors	unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
V 19	Unspecified	thrombin inhibitor; proteinase inhibitor	thrombosis
efegatran; efegatran sulfate; GYKI 14766; LY 294468	N-methyl-D-Phe-Pro-Arg-H	thrombin inhibitor; proteinase inhibitor; peptide	thrombosis; angina; myocardial infarction
S 17436	Ac-D-Phe-perhydroindole-boroArg	thrombin inhibitor; proteinase inhibitor; peptide	thrombosis
drug delivery system, ANCHOR direct thrombin inhibitor	unspecified	thrombin inhibitor; proteinase inhibitor; serine proteinase inhibitor	thrombosis

UK 156406	[S-(R*,S*)]-1-[3-[3-(aminoiminomethyl)phenyl]-1-oxo-2-[[[(1,2,3,4-tetrahydro-2-methyl-7-isoquinoliny)sulfonylamino]propyl]-1,2,3,6-tetrahydro-4-methyl-2-pyridinecarboxylic acid	thrombin inhibitor; proteinase inhibitor; serine proteinase inhibitor	thrombosis
A 76120	unspecified	thrombolytic	thrombosis; myocardial infarction
anistreplase; acetylated plasminogen streptokinase complex; APSAC; apsaplastase; BRL 26921; EMINASE	anisoylated (human) lys-plasminogen streptokinase	thrombolytic	thrombosis
antithrombotic agents, Actinova	unspecified	thrombolytic	thrombosis
BBNT 12	unspecified	thrombolytic	thrombosis
BRL 54912	unspecified	thrombolytic	thrombosis
drug delivery system, MACROMOL urokinase oral; urokinase MACROMOL urokinase	unspecified	thrombolytic	thrombosis
eliparcil; LF 40212	unspecified	thrombolytic	thrombosis
factor Xa/prothrombinase inhibitors	unspecified	thrombolytic	thrombosis
factor Xai; factor Xa	unspecified	thrombolytic	thrombosis
GM 11001	unspecified	thrombolytic	thrombosis
anasaruplastase; saruplastase, natural; prourokinase; plasminogen pro-activator; proUK; GE 0943; THROMBOLYSE; TOMIZE	unspecified	thrombolytic	thrombosis
nefiparcil; LF 50030	unspecified	thrombolytic	thrombosis

oral factor Xa inhibitors, Cor	unspecified	thrombolytic	thrombosis
RWJ 27755	D-Phe-Pro-Arg-chloromethyl ketone (PPACK)	thrombolytic	thrombosis
saruplase, natural; single chain urokinase plasminogen activator; SCU-PA; SANDOLASE	unspecified	thrombolytic	thrombosis
Thrombosis therapy	unspecified	thrombolytic	thrombosis
tisokinase; tissue plasminogen activator, natural; tPA, natural; AK 124; PLASVATA; HAPASE	unspecified	thrombolytic	thrombosis; stroke
dermatan sulfate, low molecular weight; low molecular weight dermatan sulfate; low molecular weight chondroitin sulfate B; low molecular weight chondroitinsulfuric acid type B; DESMIN 370; DS 435	dermatan, hydrogen sulfate (ester)	thrombolytic; fibrinolytic	thrombosis; restenosis
nattokinase	unspecified	thrombolytic; fibrinolytic	thrombosis
poloxamer 188; CRL 5861; FLOCOR; RheothRx	unspecified	thrombolytic; fibrinolytic	thrombosis; cytoprotectant; sickle cell anemia
hementerin	unspecified	thrombolytic; fibrinolytic; biotechnology	thrombosis
OS 396	(1(S)-trans]-N-(4-acetylphenyl)-alpha-[[[4-(aminomethyl)cyclohexyl]carbonyl]amino]-4-(2-pyridinylmethoxy)benzenepropanamide	thrombolytic; proteinase inhibitor; fibrinolytic	thrombosis

coprinin	2-methoxy-5-methyl-1,4-benzoquinone	thromboxane antagonist; platelet antiaggregant	thrombosis
daltroban; BM 13505; SKF 96148	4-[2-[[4-chlorophenyl)sulfonyl]amino]ethyl]benzene acetic acid	thromboxane antagonist; platelet antiaggregant	heart failure; thrombosis
domitroban; S 1452; S 145; ANBOXAN	(+,-)-[1alfa,2alfa(Z),3beta,4alfa]-7-[3-[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	asthma; rhinitis; thrombosis
F 10171; L 0051	unspecified	thromboxane antagonist; platelet antiaggregant	thrombosis
FR 106881	6-(2S,4R)-1-(4-chlorophenylsulfonyl)-4-(4-chlorophenylsulfonylamino)-pyrrolidine-2-yl-(Z)-5-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
HA 29	2-[(3-methoxyphenyl)methyl]-3,4-dimethylpyrano[2,3-c]pyrazol-6(2H)-one	thromboxane antagonist; platelet antiaggregant	thrombosis
ICI 185282	[2alfa,4alfa,5alfa(Z)]-7-[4-(2-hydroxyphenyl)-2-(trifluoromethyl)-1,3-dioxan-5-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
ICI 192605	[2alfa,4alfa,5alfa(Z)]-6-[2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma

KT 2962; KT 2-962	3-[4-[[4-chlorophenyl)sulfonyl]amino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
KW 3635	(E)-11-(2-(5,6-dimethyl-1-benzimidazolyl)ethylidene)-6,11-dihydrodibenz(b,e)oxepine-2-carboxylic acid sodium salt	thromboxane antagonist; platelet antiaggregant	thrombosis
L 670596	(-)-6,8-difluoro-2,3,4,9-tetrahydro-9-[[4-(methylsulfonyl)phenyl]methyl]-1H-carbazole-1-acetic acid	thromboxane antagonist; platelet antiaggregant	asthma; thrombosis
LCB 2853	4-[[1-[[[4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl]methyl]benzene acetic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	thrombosis
linotroban; HN 11500; CL 871501	[[5-(2-benzenesulfonamidomethyl)-2-thienyl]oxy]acetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
mipitroban; UP 11677	6-chloro-3-[(4-chlorophenyl)methyl]-.beta.,.beta.-dimethyl-3H-imidazo[4,5-b]pyridine-2-butanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
ON 579	4-(2-(4-chlorophenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma

ONO 8809	[1S-[1alfa,2alfa(Z),3beta,4alfa]]-6-[3-[[[(4-bromophenyl)sulfonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-5-hexenoic acid decyl ester	thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
S 17732	unspecified	thromboxane antagonist; platelet antiaggregant	thrombosis
S 17733	unspecified	thromboxane antagonist; platelet antiaggregant	thrombosis
S 19167	6-[[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-3-methyl-1-naphthalenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
SQ 30741	[1S-[1alpha,2alpha(Z),3alpha,4alpha]]-7-[3[[[(1-oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
SQ 33261	[1S-[1alfa,2alfa(Z),3alfa,4alfa]]-6-[3-[[[(phenylamino)carbonyl]hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis



SQ 33552	[1S-[1alfa,2alfa(Z),3alfa,4alfa]]-6-[3-[[[(4-chlorophenyl)amino]carbonyl]hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
SQ 33961	[1S-(exo,exo)]-2-[[3-[4-[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
SQ 35091	[1S-[1alfa,2alfa,3alfa(E),4alfa]]-2-[[3-[[[(phenylamino)carbonyl]hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
sulotroban; BM 13177; SKF 95587	4-[2-(benzenesulfonamido)ethyl]phenoxyacetic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
vapiprost; GR 32191; GR 32191B; SN 309	[1R-[1alfa(Z),2beta,3beta,5alfa]]-7-[5-([1,1'-biphenyl]-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; kidney disease

ZK 151847	(5Z)-(8R,9S,12S)-9-(p-Phenylbenzyloxy)-11-desoxy-12-(p-fluorobenzene sulfonylamino)-13,14,15,16,17,18,19,20-octanor-prost-5-enoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis
ifetroban; ifetroban sodium; BMS 18029102; BMS 180291A; BMS 180291	[1S-(1alfa,2alfa,3alfa,4alfa)]-2-[[3-[4-[(n-pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hepta-2-yl)methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant; cicatrizant	thrombosis; skin ulcer
CGS 22652	(+,-)-gamma-[4-[[[(4-chlorophenyl)sulfonyl]amino]butyl]-3-pyridine]heptanoic acid	thromboxane antagonist; synthase inhibitor; platelet antiaggregant	thrombosis
GR 85305	(E)-6-[3-[2-[[[(4-iodophenyl)sulfonyl]amino]ethyl]phenyl]-6-(3-pyridinyl)-5-hexenoic acid	thromboxane antagonist; synthase inhibitor; platelet antiaggregant	thrombosis
ICI D1542; ZD 1542	[2S-[2alfa,4alfa,5alfa(Z)]]-6-[2-[1-methyl-1-(4-methyl-2-nitrophenoxy)ethyl]-4-(3-pyridinyl)-1,3-dioxan-5-yl]-4-hexenoic acid	thromboxane antagonist; synthetase inhibitor; platelet antiaggregant	thrombosis
thromboxane A2/prostaglandin H2 antagonist; thromboxane A2 synthetase inhibitor, Pfizer.	3-[2-[[[(4-chlorophenyl)sulfonyl]amino]ethyl]-5-(3-pyridinyl)methyl]benzenepropanoic acid	thromboxane antagonist; synthetase inhibitor; prostaglandin antagonist; platelet antiaggregant	thrombosis; restenosis

KDI 792; FK 070; FR 12170	[2S-[2alpha,(Z),4beta]]-6-[4-[(4-chlorophenyl)sulfonylamino]-1-(3-pyridinylmethyl)-2-pyrrolidinyl]-5-hexenoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
TER 930180	4-[1-[[[(4-chlorophenyl)sulfonylamino]methyl]-4-(3-pyridinyl)butyl]benzenepropanoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
ONO 1301; AP 50002; ONO AP 50002	[[[7,8-dihydro-5-[2-[[[(phenyl-3-pyridinylmethylene)amino]oxy]ethyl]1-naphthalenyl]oxy]acetic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
aplaggin	unspecified	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
camonagrel; DEFIBROTIDE	(+,-)-5-(2-imidazol-1-ylethoxy)-1-indancarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
FCE 27262	(E)-5-[[[1-cyclohexyl-2-(1H-imidazol-1-yl)-3-phenylpropylidene]amino]oxypentanoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
isbogrel; CV 4151; A 66900; ANTEXAN	(E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; stroke
KY 063	5-n-hexyloxy-3-(2-(1H-imidazol-1-yl)ethyl indoline-1-propionic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis

ozagrel; ozagrel sodium; OKY 046; DOMENAN; CATACLOT; XANBON; VEGA	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	stroke; thrombosis; asthma; cough
platelet antiaggregant	N-((1H-pyrazol-1-yl)butyl)benzoylamide	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis
rolafagrel; FCE 22178	5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; kidney disease
TEI 5178	[1R-[1 $\alpha$ ,2B(1E,3S*),3 $\alpha$ fa]]-6-[[2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxy-5-oxocyclopentyl]thio]hexanoic acid, methylester	thromboxane synthetase inhibitor; platelet antiaggregant	nephritis; thrombosis
Y 20811	4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethyl-benzoic acid, monosodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; asthma; stroke
satigrel; E 5510	4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid	thromboxane synthetase inhibitor; prostaglandin endoperoxidase inhibitor; platelet antiaggregant	thrombosis
ZT 386	unspecified	thromboxane synthetase inhibitor; thromboxane antagonist; platelet antiaggregant	thrombosis; asthma
tricaprilin; tricaprylin; NOF 005	Octanoic acid, 1,2,3-propanetriyl ester	triglyceride; platelet antiaggregant	thrombosis
vascular anticoagulant; VAC	unspecified	vascular anticoagulant	thrombosis

drotaverine acephyllinate; DEPOGEN	1,2,3,6-tetrahydro- 1,3-dimethyl-2,6- dioxo-7H-purine-7- acetic acid compd. with 1-[(3,4- diethoxyphenyl)meth ylene]-6,7-diethoxy- 1,2,3,4- tetrahydroisoquinolin e (1:1)	vasodilator; antispasmodic	thrombosis; peripheral vascular disease
eptaloprost; eptaprost; ZK 97959	3aS- [2E,3aalfa,4alfa(3R*, 4R*)5beta,6aalfa]-4- (2-hexahydro-5- hydroxy-4-(3- hydroxy-4-methyl- 1,6-nonadiynyl- 2(1H)- pentalenylidene)ethox y-butanedioic acid	vasodilator; prostanoid	thrombosis; peripheral vascular disease; cancer

Table 65. Current Candidate Therapeutic Interventions for the Treatment of Renal Disease, Disorder, or Dysfunction

Product Name	Chemical Name	Action	Indication
captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	1-(3-mercapto-2- methyl-1-oxopropyl)- L-proline	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1- carboxy-3- phenylpropyl)-L- lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease

FK 352	[R-(E)]-1-[1-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propenyl]-2-piperidineacetic acid	adenosine antagonist; adenosine A1 antagonist	kidney disease
HMR 4902	Unspecified	adenosine antagonist; adenosine A1 antagonist	heart failure; kidney disease
midaxifylline; IRFI 117	8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect; depression; kidney disease
ALT 946	Pimagedine derivative	Advanced glycosylated end-products formation inhibitor	diabetes; neuropathy; retinopathy; kidney disease
BST 4001; PYRIDORIN	Vitamin B6 derivative	Advanced glycosylated end-products formation inhibitor	diabetes; kidney disease
pimagedine; pimagedine hydrochloride; aminoguanidine; GER 11; YM 585	Aminoguanidine	Advanced glycosylation end-products inhibition	diabetes; kidney disease; retinopathy; atherosclerosis; neuropathy; stroke
epalrestat; ONO 2235; KINEDAK	(Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid	aldose reductase inhibitor	neuropathy; kidney disease; eye disease; diabetes
zopolrestat; CP 73850; ALOND	3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid	aldose reductase inhibitor	diabetes; neuropathy; kidney disease

candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMIAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
irbesartan; SR 47436; BMS 186295; APROVEL; KARVEA; AVAPRO	2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one	angiotensin II antagonist	hypertension; kidney disease; heart failure
irbesartan + hydrochlorothiazide; hydrochlorothiazide + irbesartan; AVALIDE; COAPROVEL; KARVEZIDE	Unspecified	angiotensin II antagonist; diuretic	hypertension; kidney disease
A 68828	L-arginyl-L-cysteinyl-3-cyclohexyl-L-alanylglycylglycyl-L-arginyl-L-isoleucyl-L-alfa-aspartyl-L-arginyl-L-isoleucyl-L-phenylalanyl-L-arginyl-L-cysteinamide cyclic (2-13)-disulfide	ANP agonist	kidney disease
EXO 226	Unspecified	Antiglycation agent	diabetes; kidney disease
phensuccinal	beta-phenylethylamide-2-hydroxysuccinanylic acid	antioxidant	diabetes; kidney disease; retinopathy
levocarnitine; carnitine, L-; L-carnitine; ST 198; LEVOCARNIL; CARNITENE; CARNITOR	(R)-3-carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide inner salt	Carnitine	cardiovascular disease; kidney disease; septic shock

FPL 63012AR	3-[2-(3-hydroxyphenyl)ethyl]-4-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]-1,2-benzenediol dihydrochloride	dopamine agonist; dopamine D1 agonist	kidney disease
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenol)-1H-3-benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
endothelin A antagonist	Unspecified	endothelin A antagonist; endothelin antagonist	hypertension; kidney disease
SB 209670	(+)-(1S,2R,3S)-3[2-(carboxymethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-propoxyindane-2-carboxylic acid	endothelin A antagonist; endothelin antagonist	kidney disease; hypertension
BQ 123	cyclo(D-alpha-aspartyl-L-prolyl-D-valyl-L-leucyl-D-tryptophyl)	endothelin A antagonist; endothelin antagonist; peptide	kidney disease
TAK 044	cyclo[4-oxo-4 (4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl] disodium salt	endothelin A antagonist; endothelin B antagonist; endothelin antagonist; peptide	hypertension; kidney disease; myocardial infarction; brain ischemia
endothelin antagonist	unspecified	endothelin antagonist	kidney disease
endothelin antagonist	Unspecified	endothelin antagonist	kidney disease; ischemia; inflammatory bowel disease; asthma
SB 234551	Unspecified	endothelin antagonist	kidney disease
VML 588; Ro 611790	Unspecified	endothelin antagonist; endothelin A antagonist	kidney disease; brain ischemia



IxC1-62/47	Unspecified	enzyme degradation of oxalate, reduction in the formation of kidney stones	kidney disease; inflammatory bowel disease; Crohn disease
OPC 15161; NF 1616904	6-(1H-indol-3-ylmethyl)-5-methoxy-3-(2-methylpropyl)-2-(1H)-pyrazinone, 4-oxide	free radical scavenger; NSAID	inflammation; kidney disease
keratinocyte growth factor 2; KGF 2; HG 03400	Protein	growth factor; cicatrizant; chemoprotectant; cytoprotectant	cancer; mucositis; skin ulcer; alopecia; kidney disease
somatropin; human growth hormone; hGH; SJ 0011; SAIZEN; SEROSTIM	Somatotropin (human)	growth hormone	hormone deficiency; Turner syndrome; growth disorder; cachexia; kidney disease
anaritide; atrial natriuretic factor 4-28; ANF 4-28; atrial natriuretic peptide; anaritide acetate; WY 47663; AURICULIN	N-L-arginyl-8-L-methionine-21a-L-phenylalanine-21b-L-arginine-21c-L-tyrosine-atriopeptin-21 (rat)	hormone; ANP agonist; peptide	heart failure; kidney disease
mecasermin; insulin-like growth factor-1; IGF-1; CGP 35126; CEP 079; KW 6151; IGF-1; CEP 151; MYOTROPHIN	Human insulin-like growth factor I	Hormone; growth factor	amyotrophic lateral sclerosis; neuropathy; kidney disease; osteoarthritis
B 2036PEG; PEG-B 2036; TROVERT	Unspecified	Human recombinant growth hormone antagonist	retinopathy; acromegaly; cancer; diabetes; kidney disease
recombinant alpha3 collagen chain; BST 3002	Alpha 3 collagen chain	immunosuppressant	kidney disease
mizoribine; HE 69; BREDININ	5-hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide	immunosuppressant; NSAID	rheumatoid arthritis; transplant rejection; kidney disease

phellodendrine; OB 5	(7S-cis)-5,8,13,13a-tetrahydro-2,11-dihydroxy-3,10-dimethoxy-7-methyl-6H-dibenzo[a,g]quinolizinium	immunosuppressant; NSAID	transplant rejection; inflammation; viral infection; asthma; kidney disease
recombinant alpha3 collagen chain; BST 3003	Alpha 3 collagen chain	Imunosuppressant	kidney disease; systemic lupus erythematosus
tirilazad; tirilazad mesylate; trilazad; U 74006F; FREEDOX	21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-alpha-methyl-pregn-1,4,9-(11)-triene-3,20-dione	lazaroid	brain ischemia; stroke; trauma; heart ischemia; kidney disease
ALT 420	Unspecified	macrophage stimulator	diabetes; neuropathy; retinopathy; kidney disease
macrophage stimulators	Unspecified	macrophage stimulator	diabetes; neuropathy; retinopathy; kidney disease
NEPHROSTAT	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor	kidney disease; diabetes
matrix metalloproteinase inhibitor	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis
MAb, migis-mIgA; Mab, B cell	unspecified	monoclonal antibody	kidney disease
targinine; 546C88; BW 546C88	N5-[imino(methylamino)methyl]-L-ornithine	nitric oxide synthase inhibitor; NSAID	septic shock; arthritis; kidney disease
UR 12670	4-[(2-methyl-1H-imidazo [4,5-c] pyridin-1-yl)methyl]-1-(1-oxo-3,3-diphenylpropyl)-piperidine	PAF antagonist; platelet antiaggregant	kidney disease; ischemia; asthma; pancreatitis
C-peptide analogues		peptide	diabetes; kidney disease

ularitide; urodilatin; urodilatin (human)	l-threonyl-l-alanyl-l-prolyl-l-arginyl-l-seryl-l-leucyl-l-arginyl-l-arginyl l-seryl-l-seryl-l-cysteinyl-l-phenylalanylglycylglycyl-l-arginyl-l-methionyl-l-aspartyl-l-arginyl-l-isoleucylglycyl-l-alanyl-l-glutaminyll-serylglycyl-l-leucylglycyl-l-cysteinyl-l-asparaginyll-seryl-l-phenyalanyl-l-arginyl-l-tyrosine cyclic (11-27) disulfide	peptide	kidney disease
lanthanum carbonate; LAMBDA	Lanthanum carbonate	Phosphate binding	kidney disease
VML 252	High molecular weight, insoluble, polymeric resin	Phosphate binding	kidney disease
sevelamer; GT16-026A; PB 94; RenaGel	2-propen-1-amine, polymer with (chloromethyl)oxirane	Phosphate binding resin	kidney disease
BIO-LASE	unspecified	platelet antiaggregant	thrombosis; kidney disease; eye disease
ALFA 366	Unspecified	platelet antiaggregant	kidney disease; diabetes
ALFA 642	Unspecified	platelet antiaggregant	diabetes; kidney disease
TFC 612; TFC 6122	[1R-[1alpha,2beta(1E,3S*,5R*),3alpha]]-6-[[3-hydroxy-2-(3-hydroxy-5-methyl-1-nonenyl)-5-oxocyclopentyl]thio]-hexanoic acid methyl ester	prostanoid	liver disease; kidney disease

mycophenolate mofetil; RS 61443	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany l)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
LSL 90202	L-lysine monoeicosapentaenoate (1:1)	Renal function improvement in nephrotoxicity associated with cyclosporine	kidney disease
KT 2962; KT 2-962	3-[4-[[4-(4-chlorophenyl)sulfonylamino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
vapiprost; GR 32191; GR 32191B; SN 309	[1R-[1alfa(Z),2beta,3beta,5alfa]]-7-[5-([1,1'-biphenyl]-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; kidney disease
rolafagrel; FCE 22178	5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; kidney disease
TJ 8117	Unspecified	Unspecified	kidney disease
uteroglobin; CC 10	Unspecified	Uteroglobin	respiratory disease; kidney disease
CGP 22979	N-acetyl-L-glutamic acid 5-[2-(5-butyl-2-pyridinyl)hydrazide]	vasodilator	kidney disease
falecalcitriol; flocalcitriol; ST 630; FULSTAN; HORNEL	(1alfa,3beta,5Z,7E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol	vitamin D3 analogue	osteoporosis; kidney disease; hyperparathyroidism; psoriasis

Table 66. Current Candidate Therapeutic Interventions for the Treatment of Nephritis

Product Name	Chemical Name	Action	Indication
melanocortin receptor-1 modulators, Trega Biosciences	unspecified	analgesic; melanocortin agonist; melanocortin MC1 agonist	asthma; pain; nephritis
candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMLAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
celiprolol; NPB 582; ST 1396; REV 5320A; SELECTOL; CELECTOL	N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethylurea	beta adrenergic antagonist; beta2 adrenergic partial antagonist; vasodilator	hypertension; nephritis
recombinant alpha3 collagen chain; BST 3003	unspecified	biotechnology; immunosuppressant	kidney disease; systemic lupus erythematosus
decorin	unspecified	cicatrizant	nephritis; scleroderma
K 76 monocarboxylic acid; K 76C00H; MX 1	6-formyl-3',4',4a',5',6',7',8',8a'-octahydro-4,6,7'-trihydroxy-2',5',5',8a'-tetramethylspiro[benzofuran-2(3H),1'(2'H)-naphthalene]-7-carboxylic acid	complement inhibitor; cicatrizant	atherosclerosis; inflammatory bowel disease
MAB, C5; MAB, complement C5; 5G1.1	unspecified	complement inhibitor; monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus
interleukin-1 antagonist, ImmunoPharmaceutics	unspecified	cytokine antagonist; NSAID	inflammation
actarit; MS 932; MOVER; ORCL	4-(acetylamino)phenylacetic acid	DMARD; immunosuppressant; NSAID	rheumatoid arthritis

SKF-R 105058	ethylcarbamic acid, (R)-6-chloro-1-[4-[[[(ethylamino)carbon yl]oxy]ph enyl]-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diyl ester	dopamine agonist; dopamine D1 agonist; vasodilator	nephritis
OPC 15161; NF 1616904	6-(1H-indol-3-ylmethyl)-5-methoxy-3-(2-methylpropyl)-2-(1H)-pyrazinone, 4-oxide	free radical scavenger; NSAID	inflammation; kidney disease
LJP 394	unspecified	immunosuppressant	systemic lupus erythematosus
MAB, CD40 ligand; 5C8; ANTOVA	unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
SKF 105685	N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dihydrochloride	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
bindarit; AF 2838	2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]-propanoic acid	MCP-1 production inhibition; reduction of mRNA expression	rheumatoid arthritis; nephritis
MAB, gamma interferon, humanized; SMART anti-gamma interferon	unspecified	monoclonal antibody; immunosuppressant	systemic lupus erythematosus; multiple sclerosis
zolimomab aritox; MAB, H65 RTA; MAB, bone marrow-ricin A conjugate; CD5-T lymphocyte immunotoxin; MAB, CD5; XMMLY H65 RTA; XOMAZYME H65; XOMAZYME CD5+; ORTHOZYME CD5+; CD5 Plus	unspecified	monoclonal antibody; immunotoxin; immunosuppressant	transplant rejection

TFC 612; TFC 6122	[1R-[1alpha,2beta(1E,3S*,5R*),3alpha]]-6-[[3-hydroxy-2-(3-hydroxy-5-methyl-1-non-enyl)-5-oxocyclopentyl]thio]-hexanoic acid methyl ester	prostanoid	liver disease; kidney disease
mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany l)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
CV 6504	2,3,5-trimethyl-6-(3-pyridinylmethyl)-2,5-cyclohexadiene-1,4-dione	thromboxane antagonist; 5-lipoxygenase inhibitor	cancer
TEI 5178	[1R-[1alfa,2B(1E,3S*),3alfa]]-6-[[2-(3-cyclohexyl-3-hydroxy-1-propenyl)-3-hydroxy-5-oxocyclopentyl]thio]hexanoic acid, methylester	thromboxane synthetase inhibitor; platelet antiaggregant	nephritis; thrombosis
rolafagrel; FCE 22178	5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; kidney disease
TJ 8014	Lyophilized extracts of 8 Japanese herbal agents	unspecified	nephritis
vaccine, Streptococcus pyogenes; rheumatic fever vaccine	unspecified	vaccine	bacterial infection
MAB, 3E10; vaccine, nephritis	unspecified	vaccine; monoclonal antibody	nephritis

Table 67. Current Candidate Therapeutic Interventions for the Treatment of Restenosis

Product Name	Chemical Name	Action	Indication
Del-1 angiogenic protein based therapies	unspecified	angiogenesis inhibitor; angiogenesis inducer	cancer; ischemia; restenosis
RG 13577	(4-hydroxyphenoxy)acetic acid, polymer with formaldehyde monoammoniate	angiogenesis inhibitor; FGF antagonist	restenosis; multiple sclerosis
antiangiogenesis agent	Unspecified	angiogenesis inhibitor; peptide	cancer; restenosis
candesartan cilexetil; TCV 116; H 21291; BLOPRESS; ATACAND; AMLAS; KENZEN	(+,-)-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-H-benzimidazole-7-carboxylic acid 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl ester	angiotensin II antagonist	hypertension; heart failure; restenosis; kidney disease
PN 271; PN 27,1; AndroCar	unspecified	antibiotic; terpene	cancer; restenosis
CPG 603	unspecified	antioxidant	restenosis
probucol; DH 581; DE 3872; LORELCO; PANAVIR; SINLESTAL	4,4'-isopropylidenedithio-bis-2,6-di-tert-butylphenol	antioxidant	HIV infection; hyperlipidemia; restenosis
CT 8	unspecified	antiproliferative agent	restenosis
CVT 313	2,2'-[[6-[[[(4-methoxyphenyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]imino]bisethanol	antiproliferative agent; cyclin dependent kinase inhibitor	restenosis
antisense oligonucleotide, restenosis	unspecified	antisense; oligonucleotide	restenosis
antisense oligonucleotide, restenosis; TBC 395	unspecified	antisense; oligonucleotide	restenosis



antisense oligonucleotide, smooth muscle cell proliferation; antisense oligonucleotide, SMC proliferation	unspecified	antisense; oligonucleotide	restenosis
drug delivery system, HVJ liposome; drug delivery system, PCNA and cdc2 kinase antisense oligonucleotides	unspecified	antisense; oligonucleotide	restenosis
INX 3280; LR 3280; BW 4003W94; TA 3280	unspecified	antisense; oligonucleotide	restenosis
E2F inhibitors	unspecified	apoptosis inducer; antiproliferative agent	cancer; psoriasis; viral infection; restenosis
RESTENEX	unspecified	calpastatin	restenosis
calpeptin	Benzyloxycarbonyl-leu-norleucinal	calpastatin; peptide	restenosis
inhibitor I	acetyl-leu-leu-norleucinal	calpastatin; peptide	restenosis
CT 1	Sulfated beta dextran monomer	Cationic growth factor binding and inactivator	restenosis
heparinase III; IBT 9302	unspecified	cicatrizant; enzyme	reperfusion injury; restenosis; skin ulcer
fibroblast growth factor, acidic; aFGF	unspecified	cicatrizant; growth factor	skin ulcer; restenosis
pemirolast; pemirolast potassium; BMY 26517; DE 068; BL 5617; PEMILASTON; ALLEGYSAL	9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one	degranulation inhibitor	asthma; conjunctivitis; rhinitis; dermatitis; restenosis
antisense oligonucleotide, platelet derived growth factor; triple helix oligonucleotide, PDGF	unspecified	DNA transcription inhibitor; antisense; oligonucleotide	restenosis

LU 135252; LU 127043; HMR 4005	(S)-alpha-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-beta-methoxy-beta-phenyl benzenepropanoic acid	endothelin A antagonist; endothelin antagonist	restenosis
AZT 1993	1-[1-(3-ethoxyphenyl)propyl]-4,5-dihydro-7-(5-pyrimidinylmethoxy)-1H-benz[g]indazole-3-carboxylic acid sodium salt	endothelin antagonist	restenosis
ABT 627; A 127722; A 147627	[2S-(2alpha,3beta,4alpha)]-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid	endothelin antagonist; endothelin A antagonist	cancer; restenosis; myocardial infarction
fibroblast growth factor receptor inhibitor; FGF receptor inhibitor	unspecified	FGF antagonist; angiogenesis inhibitor	restenosis; cancer
TBC 2573	unspecified	FGF antagonist; NSAID	restenosis; rheumatoid arthritis; retinopathy
epidermal growth factor diphtheria toxin chimeric protein; EGF diphtheria toxin chimeric protein; EGF fusion protein; DAB 389-EGF; DAB 389-EGF	unspecified	fusion toxin	cancer; restenosis; psoriasis
mitotoxin fibroblast growth factor-saporin; mitotoxin, FGF-saporin; PANTARIN	unspecified	fusion toxin	cancer; restenosis; eye disease
cytochalasin B; BioStent	Cytochalasin	G(s)/adenylyl cyclase stimulation	restenosis

JTV 806	unspecified	glycoprotein IIb/IIIa antagonist	angina; restenosis
peptifibatide; INTEGRILIN; INTEGRELIN	N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide cyclic (1->6)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis; angina; myocardial infarction; restenosis
platelet derived growth factor; PDGF	unspecified	growth factor	restenosis
vascular endothelial growth factor; VEGF; rhVEGF165	unspecified	growth factor; cicatrizant	coronary artery disease; ischemia; restenosis; skin ulcer
Tie-2 ligands, Regeneron; angiogenesis ligands, Regeneron	unspecified	growth factor; hematopoietic factor; cicatrizant; angiogenesis inhibitor; angiogenesis inducer	cancer; restenosis; retinopathy; skin ulcer; atherosclerosis; peripheral vascular disease
CL 03405	unspecified	heparinoid	restenosis
GM 1702	unspecified	heparinoid	restenosis
GM 2000	unspecified	heparinoid	thrombosis; restenosis
ZYN-LINKER conjugated heparin	unspecified	heparinoid	restenosis; thrombosis
GM 1077; ASTENOSE	unspecified	heparinoid; platelet antiaggregant	thrombosis; restenosis
tranilast; MK 341; AINTERU; BESSARAL; CLANIST; LIZAMONT; RIZALAST; SYNBERNIA; TEIBLOCK; RIZABEN	2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid	Histamine and leukotriene release inhibitor	asthma; allergy; conjunctivitis; rhinitis; restenosis
K 85; OMACOR	Unspecified	Hypolipemic	hyperlipidemia; restenosis
insulin-like growth factor-1 receptor inhibitor; IGF-1 JB3	unspecified	IGF-1 receptor inhibitor; peptide	restenosis; cancer

SB 223245	(S)-7-[[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid	integrin antagonist; cell adhesion inhibitor	osteoporosis; restenosis; cancer
vitronectin receptor antagonists	unspecified	integrin antagonist; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	osteoporosis; cancer; restenosis
integrin-specific peptides, Integra LifeSciences	unspecified	integrin antagonist; cell adhesion inhibitor; angiogenesis inhibitor	osteoporosis; cancer; restenosis
NE 1405	unspecified	integrin antagonist; oligosaccharide; P selectin antagonist; cell adhesion inhibitor	restenosis; reperfusion injury
antiproliferative agents	Unspecified	Ion transport antiporliferative agent	cancer; restenosis; psoriasis; atherosclerosis
sirolimus; rapamycin; NSC 226080; AY 22989; RAPAMUNE	(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacycloheptriacontine-1,5,11,28,29(4H,6H,31H)-pentone	macrolide; immunosuppressant; antibiotic	transplant rejection; autoimmune disease; restenosis

MAB, thrombin receptor; MAB, restenosis	unspecified	monoclonal antibody	restenosis
MAB, platelet derived growth factor/basic fibroblast growth factor; MAB PDGF/bFGF; SMA PDGF/bFGF	unspecified	monoclonal antibody; biotechnology	cancer; restenosis
MAB, platelet-derived growth factor beta receptor; MAB, PDGFr beta; CDP 860	unspecified	monoclonal antibody; platelet antiaggregant	restenosis
leishmania lipophosphoglycan	leishmania lipophosphoglycan	Monocyte recruitment and infiltration blockade	inflammation; restenosis
MSI 1436	Steroidal compound form dogfish shark	Na <sup>+</sup> /H <sup>+</sup> antiporter modulation	viral infection; restenosis; diabetes; cancer
TAS 301	Unspecified	Neointimal hyperlasia and late vascular constrictive remodeling inhibition	restenosis
drug delivery system, vascular stent NMI 393; NMI 393 vascular stent	unspecified	nitric oxide donor	restenosis
NMI 220	unspecified	nitric oxide donor	restenosis
oligonucleotide inhibitor, human non-muscle myosin IIB	unspecified	oligonucleotide	restenosis
AVI 2221; Resten-NG	unspecified	oligonucleotide; antisense	restenosis
CT 2	Sulfated beta cyclodextran polymer	PDGF, IL-1, bFGF inhibition	restenosis
CT 15A3MG	Unspecified	PDGF, IL-1, bFGF inhibition	restenosis; reperfusion injury
CT 2534	Unspecified	PDGF, IL-1. BFGF inhibition	restenosis; reperfusion injury
somatoprim; PTR 3046	cyclo(Phe-N2-Tyr-D-Trp-Lys-Val-Phe-C3)Thr-NH2	peptide	pancreatitis; cancer; restenosis
GM 1115	unspecified	platelet antiaggregant	thrombosis; restenosis

EF 12	unspecified	platelet antiaggregant; antiproliferative agent	heart ischemia; thrombosis; restenosis
abciximab; abciximab; MAb, F(ab') <sub>2</sub> fragment platelet; MAb, 7E3; c7E3 FAb; c7E3; ReoPro; CENTORX	Immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhC.gamma.1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3V.kappa.hc.kappa.a.light chain	platelet antiaggregant; monoclonal antibody	thrombosis; restenosis; angina; stroke; myocardial infarction
polyclonal antibody, tumor necrosis factor alpha; polyclonal antibody, TNFalpha; CytoTab	unspecified	polyclonal antibody; immunoglobulin; immunosuppressant	septic shock; malaria; restenosis; Crohn disease; graft versus host disease
ciprostene; ciprostone calcium; U 61431F	[3aS-[2Z,3aalfa,5beta,6alfa(1E,3R*),6aalfa]]-5-[hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-3a-methyl-2(1H)-pentalenylidene]penta noic acid	prostanoid; platelet antiaggregant	thrombosis; restenosis
SERP 1	unspecified	proteinase inhibitor; serine proteinase inhibitor	restenosis
mycophenolate mofetil; RS 61443; CellCept	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany 1)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
ribozymes, restenosis, Immusol; RestenASE	unspecified	ribozyme; oligonucleotide	restenosis
ribozymes, restenosis	unspecified	ribozyme; oligonucleotide	restenosis

cariporide; cariporide mesilate; HOE 642; HOE 642A	N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide	sodium/hydrogen exchange inhibitor	arrhythmia; myocardial infarction; angina; restenosis
lanreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSTYL	3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2,7)-disulfide	somatostatin analogue	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
drug delivery system, vascular stent paclitaxel; paclitaxel vascular stent	unspecified	taxane; microtubule assembly promoter	restenosis; cancer
ZYN-LINKER conjugated paclitaxel	unspecified	taxane; microtubule assembly promoter	restenosis; cancer
lepirudin; HBW 023; REFLUDAN	1-L-leucine-2-L-threonine-63-desulfohirudin (hirudo medicinalis isoform HV1)	thrombin inhibitor; proteinase inhibitor	thrombosis; restenosis
dermatan sulfate, low molecular weight; low molecular weight dermatan sulfate; low molecular weight chondroitin sulfate B; low molecular weight chondroitinsulfuric acid type B; DESMIN 370; DS 435	dermatan, hydrogen sulfate (ester)	thrombolytic; fibrinolytic	thrombosis; restenosis
thromboxane A2/prostaglandin H2 antagonist; thromboxane A2 synthetase inhibitor, Pfizer.	3-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-5-(3-pyridinylmethyl)benzenepropanoic acid	thromboxane antagonist; synthetase inhibitor; prostaglandin antagonist; platelet antiaggregant	thrombosis; restenosis
nafagrel; DP 1904	5,6,7,8-tetrahydro-6-(1H-imidazol-1-ylmethyl)-2-naphthalenecarboxylic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; angina; asthma; restenosis

NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	asthma; inflammation; restenosis
AG 1296	6,7-dimethoxy-2-phenyl-quinoxaline	tyrosine kinase inhibitor	restenosis
PD 164199	6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 164771	6-(2,6-dichlorophenyl)-8-methyl-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 166285	6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
KN 1022	4-(6,7-dimethoxy-4-quinazolinyl)-N-(4-nitrophenyl)-1-piperazinecarboxamide	tyrosine kinase inhibitor; PDGF inhibitor	restenosis
CT 3501	Unspecified	Unspecified	cancer; restenosis
PC 1122	Unspecified	Unspecified	restenosis; reperfusion injury

Table 68. Current Candidate Therapeutic Interventions for the Treatment of Peripheral Vascular Disease

Product Name	Chemical Name	Action	Indication
AHR 16303B	1-[4-[3-[4-[bis(4-fluorophenyl)hydroxy methyl]-1-piperidinyl]propoxy]phenyl]-2-methyl-1-propanone ethanedioate (1:1)	5HT antagonist; 5HT2 antagonist	hypertension; angina



ITF 1570	Salicylester derivative	5HT1A and bradykinin antagonist	peripheral vascular disease; cerebrovascular disease; heart ischemia
ICI D4398; ZM 241385	4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol	adenosine antagonist; adenosine A2 antagonist	peripheral vascular disease; hypotension
ZD 9255	Unspecified	adenosine antagonist; adenosine A2 antagonist	peripheral vascular disease
S 170891; S 18149	1,3',4',5-tetrahydro-7'-methyl-spiro[4H-imidazole-4,2'(1'H)-naphthalene]	alpha adrenergic agonist; alpha1 adrenergic agonist; alpha2 adrenergic agonist	peripheral vascular disease
angiopoietin 1	Angiopoietin 1	angiogenesis inducer; growth factor	coronary artery disease; peripheral vascular disease
ranolazine; ranolazine hydrochloride; RS 43285; KEG 1295	(+,-)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide	anti-ischemic	angina; peripheral vascular disease
antisense oligonucleotide, bcl-x	Bcl-x oligonucleotide, Unspecified	antisense oligonucleotide	Peripheral vascular disease
alifedrine; D 13625	[R-(R*,S*)]-1-cyclohexyl-3-[(2-hydroxy-1-methyl-2-phenylethyl)amino]-1-propanone	beta adrenergic agonist; vasodilator	peripheral vascular disease
trafermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; trofermin; KCB 1; CAB 2001; FIBLAST	2-155-fibroblast growth factor, basic (human clone lambda KB7/lambda HFL 1 precursor reduced)	biotechnology; growth factor; cicatrizant	skin ulcer; osteoporosis; stroke; neuropathy; peripheral vascular disease; coronary artery disease

flunarizine; R 14950; FLUZINA; SIBELIUM; ZINASEN; SESNARBO; RIZENA; SINAZINE; HEADACHE; FLORIRATO; DIESPRUDEL	Unspecified	calcium antagonist; vasodilator	peripheral vascular disease; cerebrovascular disease; migraine; epilepsy
elziverine; Ro 224839	1-[(3,4- dimethoxyphenyl)methyl]-6,7-dimethoxy-4- [[4-(2- methoxyphenyl)-1- piperazinyl]methyl]is quinoline	calmodulin antagonist; vasodilator	peripheral vascular disease; cognitive defect
clinprost; lipoisocarbacyclin; isocarbacyclin methyl ester; TEI 9090	[3aS- [3aalpha,5beta,6alpha (1E,3R*),6aalpha]]- 1,3a,4,5,6,6a- hexahydro-5- hydroxy-6-(3- hydroxy-1-octenyl)-2- pentalenepentanoic acid methyl ester	cicatrizant; prostanoid; platelet antiaggregant	thrombosis; skin ulcer; peripheral vascular disease
pamcogrel; KBT 3022; KB 3022; TO 192	2-[4,5-bis(4- methoxyphenyl)-2- thiazolyl]-1H-pyrrole- 1-acetic acid ethyl ester	COX inhibitor; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease
ZD 0892	N-(4- methoxybenzoyl)-L- valyl-N-[(1S)-3,3,3- trifluoro-1-(1- methylethyl)-2- oxopropyl]-L- prolinamide	elastase inhibitor; proteinase inhibitor	peripheral vascular disease
Tie-2 ligands, angiogenesis ligands,	Unspecified	hematopoietic factor; cicatrizant; growth factor; angiogenesis inhibitor; angiogenesis inducer	cancer; restenosis; retinopathy; skin ulcer; atherosclerosis; peripheral vascular disease

fondaparin sodium; SR 90107; ORG 31540; SR 90107A	methyl O-2-deoxy-6- O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-beta-D- glucopyranuronosyl- (1-4)-O-2-deoxy-3,6- di-O-sulfo-2- (sulfoamino)-alfa-D- glucopyranosyl-(1-4)- O-2-O-sulfo-alfa-L- idopyranuronosyl-(1- 4)-2-deoxy-2- (sulfoamino)-alfa-D- glucopyranoside 6- (hydrogen sulfate)	heparinoid; blood clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis; peripheral vascular disease
BAY w 9798	Unspecified	leukocyte adhesion inhibitor; vasodilator	peripheral vascular disease
MAB, AFS 98; AFS 98	Unspecified	monoclonal antibody	peripheral vascular disease
cilostazol; OPC 13013; PLETAL; PLETAAL	6-[4-(1-cyclohexyl- 1H-tetrazol-5- yl)butoxy]-3,4- dihydro-2(1H)- quinolinone	phosphodiesterase inhibitor; phosphodiesterase III inhibitor; platelet antiaggregant; vasodilator	thrombosis
indobufen; K 3920; IBUSTRIN	(+,-)-2-[p-(1-oxo-2- isoindolinyl)phenyl]b utyric acid	platelet antiaggregant	thrombosis
ticlopidine; ticlopidine hydrochloride; 5332 C; 4 C 32; PCR 5332; PICLODIN; PICLONADINE; PROPACALL; TICLID; PANALDINE; ROBETARL; RONDORIN	5-[(2- chlorophenyl)methyl] -4,5,6,7- tetrahydrothieno[3,2- c]pyridine	platelet antiaggregant; calcium antagonist	stroke; thrombosis
vintoperoxol; RGH 2981	(3alpha,16alpha)-21- nor-1,14- secoeburnamein-20-ol	platelet antiaggregant; vasodilator; antioxidant	peripheral vascular disease; thrombosis

BMS 180448	(3S-trans)-N-(4-chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-guanidine	potassium channel activator	angina
emakalim; EMD 56431	(3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease
bimakalim; EMD 52692; SR 44866	2,2-dimethyl-4-(2-oxo-1(2H)-pyridinyl)-2H-1-benzopyran-6-carbonitrile	potassium channel activator; vasodilator; bronchodilator	coronary artery disease; asthma; peripheral vascular disease
drug delivery system, transdermal alprostadil; alprostadil transdermal; prostaglandin E1 transdermal; OT 1404	Unspecified	prostaglandin	peripheral vascular disease
AS 013	(11alpha,13E,15S)-11,15-dihydroxy-9-(1-oxobutoxy)prosta-8,13-dien-1-oic acid butyl ester	prostanoid	peripheral vascular disease
ICI 199456	Unspecified	prostanoid	peripheral vascular disease
ONO 1608	Unspecified	prostanoid	peripheral vascular disease
SI 1702	Unspecified	prostanoid	peripheral vascular disease
limaprost; limeprost; limaprost alfadex; OP 1206; ONO 1206; OPALMON; PRORENAL	(E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-2-heptenoic acid	prostanoid; analgesic	cardiovascular disease; pain

beraprost; TRK 100; RU 55100; ML 1129; MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
ciprostene; ciprostone calcium; U 61431F	[3aS-[2Z,3aalfa,5beta,6alfa(1E,3R*),6aalfa]]-5-[hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-3a-methyl-2(1H)-pentalenylidene]pentanoic acid	prostanoid; platelet antiaggregant	thrombosis; restenosis
KP 10614	[3aS-[2(Z),3aalfa,5beta,6alfa(1E,3R*,4R*),6aalfa]]-5-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-4-methyl-1-nonen-6-ynyl)-2-pentalenyl]-4-pentenoic acid	prostanoid; platelet antiaggregant; vasodilator	thrombosis; peripheral vascular disease
taprostene; CG 4203	alpha-((2Z,3aR,4R,5R,6aS)-4-((1E,3S)-3-cyclohexyl-3-hydroxypropenyl)hexahydro-5-hydroxy-2H-cyclopenta(beta)furan-2-ylidene)-meta-toluic acid	prostanoid; platelet antiaggregant; vasodilator	peripheral vascular disease; thrombosis
iloprost; ciloprost; ZK 36374; E 1030; SH 401; ILOMED; ENDOPROST; ILOMEDIN; AIPRO	5-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene]pentanoic acid	prostanoid; platelet antiaggregant; vasodilator; NSAID	peripheral vascular disease; thrombosis; thrombocytopenia; rheumatoid arthritis

alprostadi; lipo-prostaglandin E1; lipo-PGE1; U 10136; PGE1; CAVERJECT; PALUX; LIPLE; PROSTIN; EDEX; MUSE	(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid	prostanoid; vasodilator; cicatrizant	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss
cicaprost; cicaprost clathrate; ZK 114923; SH 574; SH 490	[3aS-[2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha]]-[2-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl)-2(1H)-pentalenylidene]ethoxy]acetic acid	prostanoid; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease; cancer
BIBU 308; DTTX 30	cis-2-[[[2-(hydroxyamino)-2-oxoethyl]methylamino]carbonyl]cyclohexanecarboxylic acid	thromboxane antagonist; platelet antiaggregant	pulmonary hypertension; peripheral vascular disease
SQ 33961	[1S-(exo,exo)-2-[[3-[4-[[4-cyclohexylbutyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
terbogrel; BIBV 308 SE	(5E)-6-[3-[[[(cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-5-hexenoic acid	thromboxane antagonist; thromboxane synthase inhibitor	pulmonary hypertension; peripheral vascular disease
KDI 792; FK 070; FR 12170	[2S-[2alpha,(Z),4beta]]-6-[4-[[4-chlorophenyl)sulfonyl]amino]-1-(3-pyridinylmethyl)-2-pyrrolidinyl]-5-hexenoic acid	thromboxane antagonist; thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma

vinpocetine; AY 27255; CAVINTON; CERACTON; AIRPACIL; MEDICHILL; NAIKINOL TEISAN; NAIKINOL IWAKI	(3 $\alpha$ ,16 $\alpha$ )-eburnamenine-14-carboxylic acid ethyl ester	vasodilator	peripheral vascular disease; cognitive defect
drotaverine acephyllinate; DEPOGEN	1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purine-7-acetic acid cmpd. with 1-[(3,4-diethoxyphenyl)methylene]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline (1:1)	vasodilator; antispasmodic	thrombosis; peripheral vascular disease
propionylcarnitine, L-; propionyl-L-carnitine; levocarnitine propionyl; ST 261; DROMOS	L-3-carboxy-2-(1-oxopropoxy)-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt	vasodilator; cicatrizant	peripheral vascular disease; angina; heart failure; skin ulcer
calcitonin gene related peptide, $\alpha$ ; CGRP, $\alpha$ ; CGRP, human $\alpha$	H-ala-cys-asp-thr-ala-thr-cys-val-thr-his-arg-leu-ala-gly-leu-leu-ser-arg-ser-gly-gly-val-val-lys-asn-asn-phe-val-pro-thr-asn-val-gly-ser-lys-ala-phe-NH <sub>2</sub>	vasodilator; peptide hormone	peripheral vascular disease; cerebrovascular disease
eptaloprost; eptaprost; ZK 97959	3 $\alpha$ S-[2E,3 $\alpha$ alfa,4 $\alpha$ fa(3R*,4R*)5beta,6 $\alpha$ alfa]-4-(2-hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl-2(1H)-pentalenylidene)ethoxybutanedioic acid	vasodilator; prostanoid	thrombosis; peripheral vascular disease; cancer

pimilprost; SM 10902; SKIPRON	[2R- [2.alpha.,3a.alpha.,4.alpha. lpha.(1E,3S*,5S*),5.b eta.,6a.alpha.]]-[2- [octahydro-5- hydroxy-4-(3- hydroxy-5-methyl-1- nonenyl)-2- pentalenyl]ethoxy]ace tic acid methyl ester	vasodilator; prostanoid; cicatrizant	peripheral vascular disease; skin ulcer
pentoxifylline; oxpentifylline; EBISANIN; SEVSTAN; TRENTAL; TORENTAL	3,7-dimethyl-1-(5- oxo-hexyl)xanthine	xanthine; vasodilator	peripheral vascular disease; stroke; atherosclerosis



Claims

What is claimed is:

1. A method for selecting a treatment for a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune  
5 disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, disorder, or condition, comprising

determining whether cells of said patient contain at least one variance in a gene from a Table herein, wherein the presence or the absence of said at least one variance in said gene is indicative of the effectiveness of said treatment for said  
10 disease, disorder, or condition.

2. The method of claim 1, wherein disease, disorder, or condition is listed in an example or Table herein.

3. The method of claim 1, wherein the presence of said at least one variance is  
15 indicative that said treatment will be effective for said patient.

4. The method of claim 1, wherein the presence of said variance is indicative that said treatment will be ineffective or contra-indicated for said patient.

- 20 5. The method of claim 1, wherein said at least one variance comprises a plurality of variances.

6. The method of claim 5, wherein said plurality of variances comprise a haplotype or haplotypes.

- 25 7. The method of claim 1, wherein said selecting a treatment further comprises identifying a compound differentially active in a patient bearing a form of said gene containing said at least one variance.

8. The method of claim 7, wherein said compound is a compound listed in a  
30 Table herein or that belongs to the same chemical class as a compound listed in a said Table.

9. The method of claim 1, wherein said selecting a treatment further comprises  
35 excluding or eliminating a treatment, wherein said presence or absence of said at least one variance is indicative that said treatment will be ineffective or contra-indicated.

10. The method of claim 1, wherein said treatment comprises a first treatment and a second treatment, said method comprising the steps of:

identifying a said first treatment effective to treat said disease, disorder, or  
5 condition; and

identifying a said second treatment which reduces a deleterious effect or promotes efficacy of said first treatment.

11. The method of claim 1, wherein said selecting a treatment further comprises  
10 selecting a method of administration of a compound effective to treat said disease in a patient, disorder or condition, wherein said presence or absence of said at least one variance is indicative of the appropriate method of administration for said compound.

12. The method of claim 11, wherein said selecting the method of administration  
15 comprises selecting a suitable dosage level or frequency of administration of a compound.

13. The method of claim 1, further comprising determining the level of  
20 expression of said gene or the level of activity of a protein containing a polypeptide expressed from said gene,  
wherein the combination of the determination of the presence or absence of said at least one variance and the determination of the level of activity or the level of expression provides a further indication of the effectiveness of said treatment.

14. The method of claim 1, further comprising determining the at least one of  
25 sex, age, racial origin, ethnic origin, and geographic origin of said patient,  
wherein the combination of the determination of the presence or absence of said at least one variance and the determination of the sex, age, racial origin, ethnic  
30 origin, and geographic origin of said patient provides a further indication of the effectiveness of said treatment.

15. The method of claim 1, wherein said disease, disorder, or condition is  
35 selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central

nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

16. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises amplifying a segment of nucleic acid including at least one of said variances.

17. The method of claim 16, wherein said segment of nucleic acid is 500 nucleotides or less in length.

18. The method of claim 16, wherein said segment of nucleic acid is 100 nucleotides or less in length.

19. The method of claim 16, wherein said segment of nucleic acid is 45 nucleotides or less in length.

20. The method of claim 16, wherein said segment includes a plurality of variances.

21. The method of claim 17, wherein amplification preferentially occurs from one of the two strands of a chromosome.

22. The method of claim 17, wherein said segment of nucleic acid is at least 500 nucleotides in length.

23. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises contacting nucleic acid comprising a variance site with at least one nucleic acid probe, wherein said at least one probe preferentially hybridizes with a nucleic acid sequence including said variance site and containing a complementary base at said variance site under selective hybridization conditions.

24. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises sequencing at least one nucleic acid sequence.

5 25. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises mass spectrometric determination of at least one nucleic acid sequence.

10 26. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises determining the haplotype of a plurality of variances in a gene.

15 27. A method for selecting a method of treatment, comprising  
comparing at least one variance in at least one gene from Tables 1-6, 12-17,  
and 18-23 in a patient suffering from a neurological or psychiatric disease, drug-  
induced disease or toxicity, inflammation or immune disease, endocrine or  
metabolic disease, cardiovascular or renal disease, or proliferative disease or  
condition with a list of variances or haplotypes in said at least one gene indicative of  
the effectiveness of at least one method of treatment.

20 28. The method of claim 27, wherein said list comprises at least 5 variances.

29. The method of claim 27, wherein said at least one variance comprises a plurality of variances.

25 30. The method of claim 27, wherein said list of variances comprises a plurality of variances.

30 31. The method of claim 27, wherein at least one said method of treatment comprises the administration of a compound effective against said disease or condition to a patient.

35 32. The method of claim 31, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics, or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

33. The method of claim 27, wherein the presence or absence of at least one variance or haplotype in said gene is indicative that said treatment will be effective in said patient.

5 34. The method of claim 27, wherein the presence or absence of at least one variance in said gene is indicative that said treatment will be ineffective or contra-indicated.

10 35. The method of claim 27, wherein said treatment is a first treatment and the presence or absence of at least one variance in said gene is indicative that a second treatment will be beneficial to reduce a deleterious effect or promotes efficacy of said first treatment.

15 36. The method of claim 27, wherein said at least one method of treatment is a plurality of methods of treatment.

20 37. The method of claim 36, wherein said selecting comprises determining whether any of said plurality of methods of treatment will be more effective than at least one other of said plurality of methods of treatment.

25 38. The method of claim 27, wherein said disease is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, 30 atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, 35 renal disease, restenosis, and peripheral vascular disease.

39. A method for selecting a method of administration to a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation

or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition for a compound or compounds effective to treat said condition or disease, comprising

5 determining whether at least one variance in a gene from Tables 1-6, 12-17, and 18-23 is present or absent in cells of said patient, wherein said presence or absence of said at least one variance is indicative of an appropriate method of administration for said compound.

10 40. The method of claim 39, wherein said neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition is a disease or condition listed in the Detailed Description, an Example, or a Table herein.

15 41. The method of claim 39, wherein said selecting a method of administration comprises selecting a dosage level or frequency or frequency of administration of said compound.

20 42. The method of claim 39, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics, or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

25 43. The method of claim 39, wherein said disease is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood  
30 dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes  
35 mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia,

angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

44. A method for selecting a patient for administration of a treatment,  
5 comprising

comparing the presence or absence of at least one variance or haplotype in a gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease,  
10 or proliferative disease or condition with a list of variances or haplotypes in said at least one gene, wherein the presence or absence of said at least one variance or haplotype in said cells is indicative that said treatment will be effective, more effective, less effective, ineffective, or contra-indicated in said patient; and

determining whether said patient will receive said treatment based on the  
15 presence or absence of said at least one variance in said cells.

45. The method of claim 44, wherein said list comprises at least 5 variances.

46. The method of claim 44, wherein said method of treatment comprises  
20 administration of a compound effective against said disease or condition.

47. The method of claim 46, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics,  
25 or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

48. A method for identifying the presence or absence of at least one form of a gene from Tables 1-6, 12-17, and 18-23 in cells of an individual, comprising:

30 determining the presence or absence of at least one variance in said gene in said cells.

49. The method of claim 48, wherein said said at least one variance is a plurality of variances.

50. The method of claim 49, wherein said plurality of variances comprises a haplotype.  
35

51. The method of claim 50, wherein said individual suffers from a disease or condition.

52. The method of claim 50, wherein the presence or absence of said at least one variance is indicative of the effectiveness of a therapeutic treatment in a patient having cells containing said at least one variance.

53. The method of claim 50, wherein said determining comprises amplifying a segment of nucleic acid including a site of at least one variance.

54. The method of claim 50, wherein said determining comprises contacting a nucleic acid sequence containing a variance site corresponding to a said variance with a probe which specifically binds under selective binding conditions to a nucleic acid sequence comprising at least one said variance.

55. The method of claim 50, wherein the detection of the presence or absence of said at least one variance comprises sequencing at least one nucleic acid sequence.

56. The method of claim 50, wherein the detection of the presence or absence of said at least one variance comprises mass spectrometric determination of at least one nucleic acid sequence.

57. The method of claim 50, wherein the detection of the presence or absence of said at least one variance comprises determining the haplotype of a plurality of variances in a gene.

58. A pharmaceutical composition comprising  
a compound which has a differential effect in patients having at least one copy of a particular form of an identified gene from Tables 1-6, 12-17, and 18-23;  
and

a pharmaceutically acceptable carrier or excipient or diluent,  
wherein said composition is preferentially effective to treat a patient with cells comprising a form of said gene comprising at least one variance.

59. The method of claim 58, wherein said composition is adapted to be preferentially effective based on the unit dosage, presence of additional active components, complexing of said compound with stabilizing components, or inclusion of components enhancing delivery or slowing excretion of said compound.



60. The composition of claim 58, wherein said compound is deleterious to patients having said at least one copy or in patients not having said at least one copy, but not in both.

5 61. The composition of claim 58, wherein said patient suffers from a disease or condition selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease,  
10 schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation,  
15 psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis,  
20 renal disease, restenosis, and peripheral vascular disease.

62. The pharmaceutical composition of claim 58, wherein said composition is subject to a regulatory restriction or recommendation for use of a diagnostic test determining the presence or absence of at least one variance or haplotype in said  
25 gene.

63. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is subject to a regulatory limitation or recommendation restricting or recommending restriction of the use of said pharmaceutical composition to patients  
30 having at least one copy of a form of a gene comprising at least one variance.

64. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is subject to a regulatory limitation or recommendation indicating said pharmaceutical composition is not to be used in patients having at least one copy of  
35 a form of a gene comprising at least one variance.

65. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is packaged, and the packaging includes a label or insert restricting or

recommending the restriction of the use of said pharmaceutical composition to patients having at least one copy of a form of a gene comprising at least one variance or haplotype.

5        66.     The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is packaged, and said packaging includes a label or insert requiring or recommending the use of a test to determine the presence or absence of at least one variance in cells of a said patient.

10       67.     A nucleic acid probe comprising a nucleic acid sequence 7 to 200 nucleotide bases in length that specifically binds under selective binding conditions to a nucleic acid sequence comprising at least one variance in a gene from Tables 1-6, 12-17, and 18-23, or a sequence complementary thereto or an RNA equivalent.

15       68.     The probe of claim 67, wherein said probe comprises a nucleic acid sequence 500 nucleotide bases or fewer in length.

69.     The probe of claim 67, wherein said nucleic acid sequence is 100 or fewer nucleotide bases in length.

20       70.     The probe of claim 67, wherein said nucleic acid sequence is 25 or fewer nucleotide bases in length.

71.     The probe of claim 67, wherein said probe comprises DNA.

25       72.     The probe of claim 67, wherein said probe comprises DNA and at least one nucleic acid analog.

73.     The probe of claim 67, wherein said probe comprises peptide nucleic acid (PNA).

30       74.     The probe of claim 67, further comprising a detectable label.

75.     The probe of claim 74, wherein said detectable label is a fluorescent label.

35       76.     A method for determining a genotype of an individual, comprising analyzing at least one nucleic acid sequence from cells of said individual using mass spectrometric analysis,

wherein said nucleic acid sequence is a portion of a gene from Tables 1-6, 12-17, and 18-23 or a sequence complementary thereto.

5 77. The method of claim 76, wherein said analyzing a nucleic acid sequence comprises determining the presence or absence of a variance in said gene.

78. The method of claim 76, wherein said analyzing a nucleic acid sequence comprises determining the nucleotide sequence of said at least one nucleic acid sequence.

10 79. The method of claim 76, wherein said at least one nucleic acid sequence is 500 nucleotides or less in length.

15 80. The method of claim 76, wherein said at least one nucleic acid sequence comprises at least one variance site in said gene.

20 81. An isolated, purified or enriched nucleic acid sequence of 15 to 500 nucleotides in length, comprising at least one variance site, wherein said sequence has the base sequence of a portion of an allele of a gene from Tables 1-6, 12-17, and 18-23.

82. The nucleic acid sequence of claim 81, wherein said nucleic acid sequence is 15 to 100 nucleotide bases in length.

25 83. The nucleic acid sequence of claim 81, wherein said nucleic acid sequence is 15 to 25 nucleotide bases in length.

84. A method for determining whether a compound has differential effects on cells containing at least one different form of a gene from Tables 1-6, 12-17, and 18-23, comprising:

30 contacting a first cell and a second cell with said compound, wherein said first cell and said second cell differ in the presence or absence of at least one variance in said gene; and

35 determining whether the responses of said first cell and said second cell to said compound differ, wherein the difference in said response is due to the presence or absence of said at least one variance.

85. The method of claim 84, wherein said at least one variance comprises a haplotype.

86. The method of claim 84, wherein at least one of said first cell and said second cell are contacted *in vivo*.

87. The method of claim 85, wherein at least one of said first cell and said second cell are contacted *in vitro*.

88. The method of claim 87, wherein at least one of said first cell and said second cell is contacted *in vivo* in a plurality of patients suffering from a disease or condition.

89. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition, comprising:

a) determining whether cells of said patient contain a form of a gene from Tables 1-6, 12-17, and 18-23 which comprises at least one variance, wherein the presence or absence of said at least one variance is indicative that a treatment will be effective in said patient; and

b) administering said treatment to said patient.

90. The method of claim 89, wherein said gene is listed in Table 1 or is a gene in a pathway listed in Table 1 herein.

91. The method of claim 89, wherein said disease or condition is a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition listed in the Detailed Description, Examples, or Tables herein.

92. The method of claim 89, wherein said disease is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system

toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

93. The method of claim 89, wherein the presence of said at least one variance is indicative that said treatment will be effective in said patient.

94. The method of claim 93, wherein said treatment comprises the administration of a compound preferentially active for said condition or disease in a said patient having said at least one variance in said gene.

95. The method of claim 94, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics, or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

96. The method of claim 89, wherein the presence of said at least one variance in said gene is indicative of an appropriate dosage or frequency of administration of a compound in said treatment.

97. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition, comprising:

a) comparing the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from said disease or condition with a list of variances in said gene indicative of the effectiveness of at least one method of treatment;

b) selecting a method of treatment from said at least one method of treatment, wherein the presence or absence of at least one of said at least one

variance is indicative that said method of treatment will be effective in said patient;  
and

c) administering said method of treatment to said patient.

5 98. The method of claim 97, wherein said at least one gene comprises a gene listed in Table 1 or comprises a gene in a pathway listed in Table 1 herein.

99. The method of claim 97, wherein said condition or disease is a condition or disease listed in the Detailed Description, Examples, or Tables herein.

10 100. The method of claim 97, further comprising determining the presence or absence of said at least one variance in cells of said patient.

101. The method of claim 97, wherein said at least one variance comprises a  
15 plurality of variances.

102. The method of claim 97, wherein said list of variances comprises a plurality of variances.

20 103. The method of claim 102, wherein said plurality of variances comprises a haplotype or haplotypes.

104. The method of claim 97, wherein said method of treatment comprises the administration of a compound effective against said disease or condition.

25 105. The method of claim 97, wherein said treatment is a first treatment and the presence or absence of at least one variance in said gene is indicative that a second treatment will be beneficial to reduce a deleterious effect or promotes efficacy of said first treatment.

30 106. The method of claim 97, wherein said at least one method of treatment is a plurality of methods of treatment.

35 107. The method of claim 97, wherein said disease or condition is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of

blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis,  
5 atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis,  
10 renal disease, restenosis, and peripheral vascular disease.

108. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative  
15 disease or condition, comprising:

a) comparing the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from said disease or condition with a list of variances in said gene indicative of the effectiveness of at least one method of treatment;

20 b) eliminating a method of treatment from said at least one method of treatment, wherein the presence or absence of at least one of said at least one variance is indicative that said method of treatment will be ineffective or contra-indicated in said patient;

25 c) selecting an alternative method of treatment effective to treat said neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition; and

e. administering said alternative method of treatment to said patient.

30 109. The method of claim 108, further comprising determining the presence or absence of said at least one variance in cells of said patient.

35 110. The method of claim 108, wherein said at least one gene comprises a gene in the acetylcholine pathway; the CNS lipid transport/membrane repair pathway; the prostaglandin, prostacylin and thromboxane pathway, or is a gene involved in Alzheimer's disease neurofibrillary plaque formation or in susceptibility to Alzheimer's disease.

111. The method of claim 108, wherein said disease or condition is a disease or condition listed in the Detailed Description, Examples, or Tables herein.

112. A method for producing a pharmaceutical composition, comprising:

5           a) identifying a compound which has differential activity against a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition in patients having at least one variance in a gene from Tables 1-6, 12-17, and 18-23;

10           b) compounding said pharmaceutical composition by combining said compound and a pharmaceutically acceptable carrier or excipient or diluent in a manner adapted to be preferentially effective in patients having said at least one variance.

113. A method for producing a pharmaceutical agent, comprising:

15           a) identifying a compound which has differential activity against a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition in patients having at least one variance in a gene from Tables 1-6, 12-17, and 18-23; and

20           b) synthesizing said compound in an amount sufficient to provide a pharmaceutical effect in a patient suffering from said neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition.

25           114. A method for determining whether a variance in a gene from Tables 1-6, 12-17, and 18-23 provides variable patient response to a method of treatment for a disease or condition, comprising:

                  determining whether the response of a first patient or set of patients suffering from a neurological or psychiatric disease, drug-induced disease or toxicity,  
30           inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition differs from the response of a second patient or set of patients suffering from said disease or condition;

                  determining whether the presence or absence of at least one variance in said gene differs between said first patient or set of patient and said second patient or set  
35           of patients;



wherein correlation of said presence or absence of at least one variance and the response of said patient to said treatment is indicative that said at least one variance provides variable patient response.

5      115.    The method of claim 114, further comprising identifying at least one variance in a said gene.

116.    The method of claim 114, wherein a plurality of pairwise comparisons of treatment response and the presence or absence of at least one variance are performed for a plurality of patients.

10

117.    The method of claim 114, wherein said determining whether the presence or absence of at least one variance in at least one gene comprises comparing the response of at least one patient homozygous for said at least one variance with at least one patient homozygous for the alternative form of said at least one variance.

15

118.    The method of claim 114, wherein said determining whether the presence or absence of said at least one variance in at least one gene comprises comparing the response of at least one patient heterozygous for said at least one variance with the response of at least one patient homozygous for said at least one variance.

20

119.    The method of claim 114, wherein it is previously known that patient response to said method of treatment is variable.

120.    The method of claim 114, wherein said disease or condition is a disease or condition listed in the Detailed Description, Examples, or Tables herein.

25

121.    The method of claim 114, wherein said disease or condition is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia,

35

adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

5 122. The method of claim 114, wherein said method of treatment comprises administration of a compound effective to treat said disease or condition.

123. A method of treating a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease,  
10 cardiovascular or renal disease, or proliferative disease or condition in a patient, comprising

a) selecting a patient whose cells comprise an allele of a gene from Tables 1-6, 12-17, and 18-23, wherein said allele comprises at least one variance correlated with more effective treatment of said neurological or psychiatric disease, drug-  
15 induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition; and

b) altering the level of activity in cells of said patient of a product said allele, wherein said altering provides a therapeutic effect.  
20

124. A method for determining a method of treatment effective to treat a disease or condition in a sub-population of patients, comprising

altering the level of activity of a product of an allele of a gene from Tables 1-6, 12-17, and 18-23; and

25 determining whether said alteration provides a differential effect related to reducing or alleviating a disease or condition as compared to at least one alternative allele, wherein the presence of a said differential effect is indicative that said altering the level of activity comprises an effective treatment for said disease or condition in said sub-population.  
30

125. A method for performing a clinical trial or study, comprising

selecting or stratifying subjects using a variance or variances or haplotypes from one or more genes specified in Tables 1-6, 12-17, and 18-23.

35 126. The method of claim 125, wherein differential efficacy, tolerance, or safety of a treatment in a subset of patients who have a particular variance, variances, or haplotype in a gene or genes from Tables 1-6, 12-17, and 18-23, comprising

conducting a clinical trial and using a statistical test to assess whether a relationship exists between efficacy, tolerance, or safety with the presence or absence of any of said variances or haplotype in one or more of said genes,

5 wherein results of said clinical trial or study are indicative whether a higher or lower efficacy, tolerance, or safety of said treatment in said subset of patients is associated with any of said variance or variances or haplotype in one or more of said gene.

10 127. The method of claim 125 wherein normal subjects or patients are prospectively stratified by genotype in different genotype-defined groups, including the use of genotype as a enrollment criterion, using a variance, variances or haplotypes from Tables 1-6, 12-17, and 18-23, and subsequently a biological or clinical response variable is compared between the different genotype-defined groups.

15 128. The method of claim 125 wherein the normal subjects or patients in a clinical trial or study are stratified by a biological or clinical response variable in different biologically or clinically-defined groups, and subsequently the frequency of a variance, variances or haplotypes from Tables 1-6, 12-17, and 18-23 is measured in  
20 the different biologically or clinically defined groups.

25 129. The method of claim 127 or 128 where the normal subjects or patients in a clinical trial or study are stratified by at least one demographic characteristic selected from the groups consisting of sex, age, racial origin, ethnic origin, or geographic origin.

130. The method of claim 125, wherein said determining comprises assigning said patient to a group to receive said method of treatment or to a control group.

30 131. A method for determining whether a variance in a gene provides variable patient response to a method of treatment for a disease or condition, comprising:  
determining whether the response of a first patient or set of patients suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or

renal disease, or proliferative disease or condition differs from the response of a second patient or set of patients suffering from said disease or condition;

determining whether the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 differs between said first patient or set of patient and said second patient or set of patients;

wherein correlation of said presence or absence of at least one variance and the response of said patient to said treatment is indicative that said at least one variance provides variable patient response.

132. A method for treating a patient at risk for a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or diagnosed with a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

identifying a said patient and determining the patient's genotype allele status for a gene from Tables 1-6, 12-17, and 18-23;

determining a treatment protocol using the patient's genotype status to provide a prediction of the efficacy and safety of a therapy in light of a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or an associated pathological condition.

133. A method for identifying a patient for participation in a clinical trial of a therapy for the treatment of neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or disorder, comprising

identifying a patient with a disease risk and determining the patient's genotype, allele status for an identified gene from Tables 1-6, 12-17, and 18-23.

134. The method of claim 133, further comprising

determining the patient's allele status and selecting those patients having at least one wild type allele of said gene as candidates likely to develop a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

135. A method for treating a patient at risk for a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

- 5 identifying a patient with a risk for said disease;  
determining the genotypic allele status of the patient for at least one gene from Tables 1-6, 12-17, and 18-23; and  
converting the genotypic allele status into a treatment protocol that comprises a comparison of the genotypic allele status determination with the allele  
10 frequency of a control population, thereby allowing a statistical calculation of the patient's risk for having a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

- 15 136. A method for treating a patient at risk for or diagnosed with having a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising  
identifying a said patient;  
20 determining the gene allele load status of the patient for at least one gene from Tables 1-6, 12-17, and 18-23 and converting the gene allele load status into a treatment protocol that includes a comparison of the allele status determinations with the allele frequency of a control population, thereby allowing a statistical calculation of the patient's risk for having having a neurological or psychiatric disease, drug-  
25 induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

137. A method for improving the safety of candidate therapies associated with having a neurological or psychiatric disease, drug-induced disease or toxicity,  
30 inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising  
comparing the relative safety of the candidate therapeutic intervention in patients having different alleles in one or more than one of the genes listed in Tables 1-6, 12-17, and 18-23, thereby identifying subsets of patients with differing safety of  
35 the candidate therapeutic intervention.

138. A kit for determination of the presence or absence of at least one sequence variance in a gene identified in any of Tables 1-6, 12-17, and 18-23, comprising

at least one probe that preferentially hybridizes with a nucleic acid sequence corresponding to a portion of said gene or at least one primer comprising a nucleic acid sequence corresponding to a portion of said gene or a sequence complementary thereto or both said at least one probe and said at least one primer.

5

139. A method for determining whether there is a genetic component to intersubject variation in a surrogate treatment response, comprising:

10

a. administering said treatment to a group of related normal subjects and a group of unrelated normal subjects;

b. measuring a surrogate pharmacodynamic or pharmacokinetic drug response variable in said subjects;

15

c. performing a statistical test measuring the variation in response in said group of related normal subjects and, separately in said group or unrelated normal subjects;

20

d. comparing the magnitude or pattern of variation in response or both between said groups to determine if the responses of said groups are different, using a predetermined statistical measure of difference,

wherein a difference in response between said groups is indicative that there is a genetic component to intersubject variation in said surrogate treatment response.

25

140. The method of claim 129, wherein the size of the related and unrelated groups is set in order to achieve a predetermined degree of statistical power.

141. A method for evaluating the combined contribution of two or more variances to a surrogate drug response phenotype in subjects, comprising:

30

a. genotyping a set of unrelated subjects participating in a clinical trial or study of a compound for two or more variances to identify subjects with specific genotypes, wherein said two or more specific genotypes define two or more genotype-defined groups;

35

b. administering a drug to subjects with two or more of said specific genotypes;

- c. measuring a surrogate pharmacodynamic or pharmacokinetic drug response variable in said subjects;
- d. performing statistical tests to measure response in said groups separately, wherein said statistical tests provide a measurement of variation in response with each said group;
- e. comparing the magnitude or pattern of variation in response or both between said groups to determine if said groups are different using a predetermined statistical measure of difference.

142. The method of claim 141, wherein said clinical trial or study is a Phase I clinical trial or study.

143. The method of claim 141, wherein said specific genotypes are homozygous genotypes for two variances.

144. The method of claim 141, wherein the comparison is between groups of subjects differing in three or more variances.

145. A method for providing contract research services to a client, comprising:

- a. enrolling subjects in a clinical drug trial or study unit for the purpose of genotyping said subjects in order to assess the contribution of one or more variances or haplotypes to variation in drug response;
- b. genotyping said subjects to determine the status of one or more variances in said subjects;
- c. administering a compound to said subjects and measuring a surrogate drug response variable;
- d. comparing responses between two or more genotype-defined groups of said subjects to determine whether there is a genetic component to the interperson variability in response to said compound; and
- e. reporting the results of said clinical drug trial or study unit to a contracting entity.

146. The method of claim 145, wherein said clinical drug trial or study unit is a Phase I drug trial or study unit.

147. The method of claim 145, wherein at least some of the subjects have disclosed that they are related to each other and said comparing includes comparison of groups of related individuals.

148. The method of claim 147, wherein the related individuals are encouraged to participate by compensation in proportion to the number of their relatives participating.

149. A method for recruiting a clinical trial or study population for studies of the influence of one or more variances or haplotypes on drug response, comprising soliciting subjects to participate in said clinical trial or study; obtaining consent of said subjects for participation in said clinical trial or study;

obtaining additional related subjects for participation in said clinical trial by compensating one or more of the related subjects for said participation at a level based on the number of related subjects participating or based on participation of at least a minimum specified number of related subjects.

from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease



(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number  
**WO 00/50639 A3**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**

(21) International Application Number: **PCT/US00/01392**

(22) International Filing Date: 20 January 2000 (20.01.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/121,047	22 February 1999 (22.02.1999)	US
60/139,440	15 June 1999 (15.06.1999)	US
09/357,743	20 July 1999 (20.07.1999)	US

(71) Applicant (for all designated States except US): **VARIA-GENICS, INC.** [US/US]; 60 Hampshire Street, Cambridge, MA 02139-1562 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **STANTON, Vincent, Jr.** [US/US]; 32 Royal Road, Belmont, MA 02173 (US).

(74) Agent: **AMES, Wesley, B.**; Brobeck, Phleger & Harrison LLP, 12390 El Camino Real, San Diego, CA 92130 (US).

(81) Designated States (*national*): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:

10 May 2002

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE

(57) Abstract: The present disclosure describes the use of genetic variance information for genes involved in gene pathways in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

WO 00/50639 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PL./US 00/01392

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARSHALL ET AL.: "Getting the right drug into the right patient" NATURE BIOTECHNOLOGY, vol. 15, November 1997 (1997-11), pages 1249-1252, XP002178096 page 1249, middle column -page 1250, left-hand column ---	1
X	VUORISTO ET AL.: "Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis" JOURNAL OF HEPATOLOGY, vol. 27, no. 1, July 1997 (1997-07), pages 136-142, XP001024390 page 139, right-hand column -page 141, left-hand column --- -/--	1

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

24 September 2001

Date of mailing of the international search report

09/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

van Klompenburg, W

## INTERNATIONAL SEARCH REPORT

International Application No.

PC/US 00/01392

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ARRANZ ET AL.: "Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine" MOLCECULAR PSYCHIATRY, vol. 3, no. 1, January 1998 (1998-01), pages 61-66, XP001024470 abstract; tables 1-3 page 64, right-hand column -page 65, right-hand column page 61, left-hand column -page 62, left-hand column	1
X	STEEN ET AL.: "The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness" PHARMACOGENETICS, vol. 8, no. 3, June 1998 (1998-06), pages 259-268, XP001024444 abstract; tables 1-3	1

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 145-149

Claims 145-149 relate to methods for providing contract research and methods for recruiting a clinical trial or study population which are considered as methods for doing business under the provisions of Article 17(2)(a)(i) and Rule 39.1(iii), PCT. These methods are therefore excluded from search.

---

Continuation of Box I.2

Claims Nos.: 1-149

The present application relates to gene sequence variations which are useful in selecting suitable treatments of various diseases. The application provides extensive listings and tables relating to human genes, gene sequence variations, diseases and compounds. No individual links are provided between the gene sequence variations and the suitable compound for treating the corresponding disease.

In view of the large number and also the wording of the claims presently on file, which render it difficult, if not impossible, to determine the matter for which protection is sought, the present application fails to comply with the clarity and conciseness requirements of Article 6 PCT (see also Rule 6.1(a) PCT) to such an extent that a meaningful search is impossible. Additionally, present claims 1-149 relate to an extremely large number of possible compounds and methods. In fact, the claims contain so many options and possible combinations of elements from the different tables, that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Independently from the above, because of the large number of elements raising from the various tables, non-unity objections will almost certainly be made when in a later EP regional stage a search is required.

Present claims 58-66 also lack clarity (Article 6 PCT), since they relate to pharmaceutical compositions defined by reference to a desirable characteristic or property, namely having a differential effect in patients having at least one copy of a particular form of an identified gene.

An attempt is made to define the pharmaceutical compositions by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search of the claimed scope impossible.

Claims 89-110, 123, 124, 131, 132, 135, 136, 139, 141-144 relate to methods of treatment of the human body. Normally the search would be based and

## FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

performed on the alleged effects of the compounds. However, considering the shortcomings, especially the lack of conciseness and clarity mentioned above, no search could be performed.

Since for the reasons stated above a complete search was impossible, a limited search for the general principle underlying the first independent claim (claim 1), i.e. a method of selecting a treatment on basis of gene variance, was performed. The many documents retrieved also feature some of the genes mentioned in the many tables of the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.